The task of medicine is to preserve and restore health and to relieve suffering. Understanding pain is essential to both these goals. Because pain is universally understood as a signal of disease, it is the most common symptom that brings a patient to a physician’s attention. The function of the pain sensory system is to protect the body and maintain homeostasis. It does this by detecting, localizing, and identifying tissue-damaging processes. Since different diseases produce characteristic patterns of tissue damage, the quality, time course, and location of a patient’s pain complaint and the location of tenderness provide important diagnostic clues and are used to evaluate the response to treatment. Once this information is obtained, it is the obligation of the physician to provide rapid and effective pain relief.

THE PAIN SENSORY SYSTEM

Pain is an unpleasant sensation localized to a part of the body. It is often described in terms of a penetrating or tissue-destructive process (e.g., stabbing, burning, twisting, tearing, squeezing) and/or of a bodily or emotional reaction (e.g., terrifying, nauseating, sickening). Furthermore, any pain of moderate or higher intensity is accompanied by anxiety and the urge to escape or terminate the feeling. These properties illustrate the duality of pain: it is both sensation and emotion. When acute, pain is characteristically associated with behavioral arousal and a stress response consisting of increased blood pressure, heart rate, pupil diameter, and plasma cortisol levels. In addition, local muscle contraction (e.g., limb flexion, abdominal wall rigidity) is often present.

PERIPHERAL MECHANISMS The Primary Afferent Nociceptor A peripheral nerve consists of the axons of three different types of neurons: primary sensory afferents, motor neurons, and sympathetic postganglionic neurons (Fig. 11-1). The cell bodies of primary afferents are located in the dorsal root ganglia in the vertebral foramina. The primary afferent axon bifurcates to send one process into the spinal cord and the other to innervate tissues. Primary afferents are classified by their diameter, degree of myelination, and conduction velocity. The largest-diameter fibers, A-beta (Aβ), respond maximally to light touch and/or moving stimuli; they are present primarily in nerves that innervate the skin. In normal individuals, the activity of these fibers does not produce pain. There are two other classes of primary afferents: the small-diameter myelinated A-delta (Aδ) and the unmyelinated (C fiber) axons (Fig. 11-1). These fibers are present in nerves to the skin and to deep somatic and visceral structures. Some tissues, such as the cornea, are innervated only by Aδ and C afferents. Most Aδ and C afferents respond maximally only to intense (painful) stimuli and produce the subjective experience of pain when they are electrically stimulated; this defines them as primary afferent nociceptors (pain receptors). The ability to detect painful stimuli is completely ablated when Aδ and C axons are blocked.

Individual primary afferent nociceptors can respond to several different types of noxious stimuli. For example, most nociceptors respond to heating, intense mechanical stimuli such as a pinch, and application of irritating chemicals.

Sensitization When intense, repeated, or prolonged stimuli are applied to damaged or inflamed tissues the threshold for activating primary afferent nociceptors is lowered and the frequency of firing is higher for all stimuli intensities. Inflammatory mediators such as bradykinin, some prostaglandins, and leukotrienes contribute to this process, which is called sensitization. In sensitized tissues normally innocuous stimuli can produce pain. Sensitization is a clinically important process that contributes to tenderness, soreness, and hyperalgesia. A striking example of sensitization is sunburned skin, in which severe pain can be produced by a gentle slap on the back or a warm shower.

Sensitization is of particular importance for pain and tenderness in deep tissues. Viscera are normally relatively insensitive to noxious mechanical and thermal stimuli, although hollow viscera do generate significant discomfort when distended. In contrast, when affected by a disease process with an inflammatory component, deep structures such as joints or hollow visceras characteristically become exquisitely sensitive to mechanical stimulation.

A large proportion of Aδ and C afferents innervating visera are completely insensitive in normal noninjured, noninflamed tissue. That is, they cannot be activated by known mechanical or thermal stimuli and are not spontaneously active. However, in the presence of inflammatory mediators, these afferents become sensitive to mechanical stimuli. Such afferents have been termed silent nociceptors, and their characteristic properties may explain how under pathologic conditions the relatively insensitive deep structures can become the source of severe and debilitating pain and tenderness. Low pH, prostaglandins, leukotrienes, and other inflammatory mediators such as bradykinin play a significant role in sensitization.

Nociceptor-Induced Inflammation One important concept to emerge in recent years is that afferent nociceptors also have a neuroeffector func-

FIGURE 11-1 Components of a typical cutaneous nerve. There are two distinct functional categories of axons: primary afferents with cell bodies in the dorsal root ganglion, and sympathetic postganglionic fibers with cell bodies in the sympathetic ganglion. Primary afferents include those with large-diameter myelinated (Aβ), small-diameter myelinated (Aδ), and unmyelinated (C) axons. All sympathetic postganglionic fibers are unmyelinated.

tion. Most nociceptors contain polypeptide mediators that are released from their peripheral terminals when they are activated (Fig. 11-2). An example is substance P, an 11-amino-acid peptide. Substance P is released from primary afferent nociceptors and has multiple biologic activities. It is a potent vasodilator, degranulates mast cells, is a chemotactant for leukocytes, and increases the production and release of inflammatory mediators. Interestingly, depletion of substance P from joints reduces the severity of experimental arthritis. Primary afferent nociceptors are not simply passive messengers of threats to tissue injury but also play an active role in tissue protection through these neuroeffector functions.

**CENTRAL MECHANISMS • The Spinal Cord and Referred Pain**

The axons of primary afferent nociceptors enter the spinal cord via the dorsal root. They terminate in the dorsal horn of the spinal gray matter (Fig. 11-3). The terminals of primary afferent axons contact spinal neurons that transmit the pain signal to brain sites involved in pain perception. The axon of each primary afferent contacts many spinal neurons, and each spinal neuron receives convergent inputs from many primary afferents. The convergence of sensory inputs to a single spinal pain-transmission neuron is of great importance because it underlies the phenomenon of referred pain. All spinal neurons that receive input from the viscera and deep musculoskeletal structures also receive input from the skin. The convergence patterns are determined by the spinal segment of the dorsal root ganglion that supplies the afferent innervation of a structure. For example, the afferents that supply the central diaphragm are derived from the third and fourth cervical dorsal root ganglia. Primary afferents with cell bodies in these same ganglia supply the skin of the shoulder and lower neck. Thus sensory inputs from both the shoulder skin and the central diaphragm converge on pain-transmission neurons in the third and fourth cervical spinal segments. Because of this convergence and the fact that the spinal neurons are most often activated by inputs from the skin, activity evoked in spinal neurons by input from deep structures is mislocalized by the patient to a place that is roughly coextensive with the region of skin innervated by the same spinal segment. Thus inflammation near the central diaphragm is usually reported as discomfort near the shoulder. This spatial displacement of pain sensation from the site of the injury that produces it is known as referred pain.

**Ascending Pathways for Pain**

A majority of spinal neurons contacted by primary afferent nociceptors send their axons to the contralateral thalamus. These axons form the contralateral spinothalamic tract, which lies in the anterolateral white matter of the spinal cord, the lateral edge of the medulla, and the lateral pons and midbrain. The spinothalamic pathway is crucial for pain sensation in humans. Interruption of this pathway produces permanent deficits in pain and temperature discrimination.

Spinothalamic tract axons ascend to several regions of the thalamus. There is tremendous divergence of the pain signal from these thalamic sites to broad areas of the cerebral cortex that subserve different aspects of the pain experience (Fig. 11-4). One of the thalamic projections is to the somatosensory cortex. This projection mediates the purely sensory aspects of pain, i.e., its location, intensity, and quality. Other thalamic neurons project to cortical regions that are linked to emotional responses, such as the cingulate gyrus and other areas of the frontal lobes. These pathways to the frontal cortex subserve the affective or unpleasant emotional dimension of pain. This affective dimension of pain produces suffering and exerts potent control of behavior. Because of this dimension, fear is a constant companion of pain.

**PAIN MODULATION**

The pain produced by similar injuries is remarkably variable in different situations and in different individuals. For example, athletes have been known to sustain serious fractures with only minor pain, and Beecher’s classic World War II survey revealed that many soldiers in battle were unbothered by injuries that would have produced agonizing pain in civilian patients. Furthermore, even the suggestion of relief can have a significant analgesic effect (placebo).

On the other hand, many patients find even minor injuries (such as venipuncture) frightening and unbearable, and the expectation of pain has been demonstrated to induce pain without a noxious stimulus.

The powerful effect of expectation and other psychological varia-
Neuropathic pains typically have an unusual burning, tingling, or electric shock–like quality and may be triggered by very light touch. These features are rare in other types of pain. On examination, a sensory deficit is characteristically present in the area of the patient’s pain. Hyperpathia is also characteristic of neuropathic pain; patients often complain that the very lightest moving stimuli evoke exquisite pain (allodynia). In this regard it is of clinical interest that a topical preparation of 5% lidocaine in patch form is effective for patients with postherpetic neuralgia who have prominent allodynia.

A variety of mechanisms contribute to neuropathic pain. As with sensitized primary afferent nociceptors, damaged primary afferents, including nociceptors, become highly sensitive to mechanical stimulation and begin to generate impulses in the absence of stimulation. There is evidence that this increased sensitivity and spontaneous activity is due to an increased concentration of sodium channels. Damaged primary afferents may also develop sensitivity to norepinephrine. Interestingly, spinal cord pain-transmission neurons cut off from their normal input may also become spontaneously active. Thus both central and peripheral nervous system hyperactivity contribute to neuropathic pain.

**Symptatically Maintained Pain**

Patients with peripheral nerve injury can develop a severe burning pain (causalgia) in the region innervated by the nerve. The pain typically begins after a delay of hours to days or even weeks. The pain is accompanied by swelling of the extremity, periarticular osteoporosis, and arthritic changes in the distal joints. The pain is dramatically and immediately relieved by blocking the sympathetic innervation of the affected extremity. Damaged primary afferent nociceptors acquire adrenergic sensitivity and can be activated by stimulation of the sympathetic outflow. A similar syndrome called *reflex sympathetic dystrophy* can be produced without obvious nerve damage by a variety of injuries, including fractures of bone, soft tissue trauma, myocardial infarction, and stroke (Chap. 354). Although the pathophysiology of this condition is poorly understood, the pain and the signs of inflammation are rapidly relieved by blocking the sympathetic nervous system. This implies that sympathetic activity can activate undamaged nociceptors when inflammation is present. Signs of sympathetic hyperactivity should be sought in patients with post-traumatic pain and inflammation and no other obvious explanation.

![Diagram of pain transmission system](image)

**TREATMENT**

**ACUTE PAIN**

The ideal treatment for any pain is to remove the cause; thus diagnosis should always precede treatment planning. Sometimes treating the underlying condition does not immediately relieve pain. Furthermore, some conditions are so painful that rapid and effective analgesia is essential (e.g., the postoperative state, burns, trauma, cancer, sickle cell crisis). Analgesic medications are a first line of treatment in these cases, and all practitioners should be familiar with their use.

**Aspirin, Acetaminophen, and Nonsteroidal Anti-Inflammatory Agents (NSAIDS)**

These drugs are considered together because they are used for similar problems and may have a similar mechanism of action (Table 11-1). All these compounds inhibit cyclooxygenase (COX), and, except for acetaminophen, all have anti-inflammatory actions, especially at higher dosages. They are particularly effective for mild to moderate headache and for pain of musculoskeletal origin.

Since they are effective for these common types of pain and are available without prescription, COX inhibitors are by far the most commonly used analgesics. They are absorbed well from the gastrointestinal tract and, with occasional use, side effects are minimal. With chronic use, gastric irritation is a common side effect of aspirin and NSAIDs and is the problem that most frequently limits the dose that can be given. Gastric irritation is most severe with aspirin, which may cause erosion of the gastric mucosa, and because aspirin irreversibly acetylates platelets and thereby interferes with coagulation of the blood, gastrointestinal bleeding is a risk. The NSAIDs are less prob-
There are two major classes of COX: COX-1 is constitutively expressed and COX-2 is induced in the inflammatory state. COX-2-selective drugs have moderate analgesic potency and produce less gastric irritation than the nonselective COX inhibitors. It is not yet clear whether the use of COX-2-selective drugs is associated with a lower risk of nephrotoxicity compared to nonselective NSAIDs. On the other hand, COX-2-selective drugs offer a significant benefit in the management of acute postoperative pain because they do not affect blood coagulation. This is a situation in which the nonselective COX inhibitors would be contraindicated because they impair platelet-mediated blood clotting and are thus associated with increased bleeding at the operative site. A corollary of this is that COX-2 drugs do not provide the same degree of protection from thromboembolic cardiovascular adverse events such as myocardial infarction. In fact, in patients treated for arthritis, those treated with naproxen had significantly fewer adverse thromboembolic events than those treated with rofecoxib, a selective COX-2 inhibitor.

**Opioid Analgesics**

Opioids are the most potent pain-relieving drugs currently available. Furthermore, of all analgesics, they have the broadest range of efficacy, providing the most reliable and effective method for rapid pain relief. Although side effects are common, they are usually not serious except for respiratory depression and can be reversed rapidly with the narcotic antagonist naloxone. The physician should not hesitate to use opioid analgesics in patients with acute severe pain. Table 11-1 lists the most commonly used opioid analgesics.

Opioids produce analgesia by actions in the central nervous system. They activate pain-inhibitory neurons and directly inhibit pain-transmission neurons. Most of the commercially available opioid analgesics act at the same opioid receptor (mu receptor), differing mainly in potency, speed of onset, duration of action, and optimal route of administration. Although the dose-related side effects (sedation, respiratory depression, pruritus, constipation) are similar among the different opioids, some side effects are due to accumulation of nonopioid metabolites that are unique to individual drugs. One striking example of this is normeperidine, a metabolite of meperidine. Normeperidine is a toxic metabolite that is more potent than the parent drug. The most serious side effect is respiratory depression, pruritus, and constipation. Although side effects are common, they are usually not serious except for respiratory depression and can be reversed rapidly with the narcotic antagonist naloxone. The physician should not hesitate to use opioid analgesics in patients with acute severe pain. Table 11-1 lists the most commonly used opioid analgesics.
available. Opioid effects are dose-related, and there is great variability among patients in the doses that relieve pain and produce side effects. Because of this, initiation of therapy requires titration to optimal dose and interval. The most important principle is to provide adequate pain relief. This requires determining whether the drug has adequately relieved the pain and the duration of the relief. The most common error made by physicians in managing severe pain with opioids is to prescribe an inadequate dose. Since many patients are reluctant to complain, this practice leads to needless suffering. In the absence of sedation at the expected time of peak effect, a physician should not hesitate to repeat the initial dose to achieve satisfactory pain relief.

An innovative approach to the problem of achieving adequate pain relief is the use of patient-controlled analgesia (PCA). PCA requires a device that delivers a baseline continuous dose of an opioid drug, and preprogrammed additional doses whenever the patient pushes a button. The device can be programmed to limit the total hourly dose so that overdosing is impossible. The patient can then titrate the dose to the optimal level. This approach is used most extensively for the management of postoperative pain, but there is no reason why it should not be used for any hospitalized patient with persistent severe pain. PCA is also used for short-term home care of patients with intractable pain, such as is caused by metastatic cancer.

Many physicians, nurses, and patients have a certain trepidation about using opioids that is based on an exaggerated fear of addiction. In fact, there is a vanishingly small chance of patients becoming addicted to narcotics as a result of their appropriate medical use.

The availability of new routes of administration has extended the usefulness of opioid analgesics. Most important is the availability of spinal administration. Opioids can be infused through a spinal catheter placed either intrathecally or epidurally. By applying opioids directly to the spinal cord, regional analgesia can be obtained using a relatively low total dose. In this way, side effects as sedation, nausea, and respiratory depression can be minimized. This approach has been used extensively in obstetric procedures and for lower-body postoperative pain. Opioids can also be given intranasally (butorphanol), rectally, and transdermally (fentanyl), thus avoiding the discomfort of frequent injections in patients who cannot be given oral medication. The fentanyl transdermal patch has the advantage of providing fairly steady plasma levels, which maximizes patient comfort.

**OPIOID AND CYCOLOXYGENASE INHIBITOR COMBINATIONS** When used in combination, opioids and COX inhibitors have additive effects. Because a lower dose of each can be used to achieve the same degree of pain relief and their side effects are nonadditive, such combinations can be used to lower the severity of dose-related side effects. Fixed-ratio combinations of an opioid with acetaminophen carry a special risk. Dose escalation as a result of increased severity of pain or decreased opioid effect as a result of tolerance may lead to levels of acetaminophen that are toxic to the liver.

**CHRONIC PAIN**

Managing patients with chronic pain is intellectually and emotionally challenging. The patient’s problem is often difficult to diagnose; such patients are demanding of the physician’s time and often appear emotionally distraught. The traditional medical approach of seeking an obscure organic pathology is usually unhelpful. On the other hand, psychological evaluation and behaviorally based treatment paradigms are frequently helpful, particularly in the setting of a multidisciplinary pain-management center.

There are several factors that can cause, perpetuate, or exacerbate chronic pain. First, of course, the patient may simply have a disease that is characteristically painful for which there is presently no cure. Arthritis, cancer, migraine headaches, fibromyalgia, and diabetic neuropathy are examples of this. Second, there may be secondary perpetuating factors that are initiated by disease and persist after that disease has resolved. Examples include damaged sensory nerves, symptomatic effector activity, and painful reflex muscle contraction. Finally, a variety of psychological conditions can exacerbate or even cause pain.

There are certain areas to which special attention should be paid in the medical history. Because depression is the most common emotional disturbance in patients with chronic pain, patients should be questioned about their mood, appetite, sleep patterns, and daily activity. A simple standardized questionnaire, such as the Beck Depression Inventory, can be a useful screening device. It is important to remember that major depression is a common, treatable, and potentially fatal illness.

Other clues that a significant emotional disturbance is contributing to a patient’s chronic pain complaint include: pain that occurs in multiple unrelated sites; a pattern of recurrent, but separate, pain problems beginning in childhood or adolescence; pain beginning at a time of emotional trauma, such as the loss of a parent or spouse; a history of physical or sexual abuse; and past or present substance abuse.

On examination, special attention should be paid to whether the patient guards the painful area and whether certain movements or postures are avoided because of pain. Discovering a mechanical component to the pain can be useful both diagnostically and therapeutically. Painful areas should be examined for deep tenderness, noting whether this is localized to muscle, ligamentous structures, or joints. Chronic myofascial pain is very common, and in these patients deep palpation may reveal highly localized trigger points that are firm bands or knots in muscle. Relief of the pain following injection of local anesthetic into these trigger points supports the diagnosis. A neuropathic component to the pain is indicated by evidence of nerve damage, such as sensory impairment, exquisitely sensitive skin, weakness and muscle atrophy, or loss of deep tendon reflexes. Evidence suggesting sympathetic nervous system involvement includes the presence of diffuse swelling, changes in skin color and temperature, and hypersensitive skin and joint tenderness compared with the normal side. Relief of the pain with a sympathetic block is diagnostic.

A guiding principle in evaluating patients with chronic pain is to assess both emotional and organic factors before initiating therapy. Addressing these issues together, rather than waiting to address emotional issues after organic causes of pain have been ruled out, improves compliance in part because it assures patients that a psychological evaluation does not mean that the physician is questioning the validity of their complaint. Even when an organic cause for a patient’s pain can be found, it is still wise to look for other factors. For example, a cancer patient with painful bony metastases may have additional pain due to nerve damage and may also be depressed. Optimal therapy requires that each of these factors be looked for and treated.

### Treatment

Once the evaluation process has been completed and the likely causative and exacerbating factors identified, an explicit treatment plan should be developed. An important part of this process is to identify specific and realistic functional goals for therapy, such as getting a good night’s sleep, being able to go shopping, or returning to work.

A multidisciplinary approach that utilizes medications, counseling, physical therapy, nerve blocks, and even surgery may be required to improve the patient’s quality of life. There are also some newer, relatively invasive procedures that can be helpful for some patients with intractable pain. These procedures include implanting intraspinal canulae to deliver morphine or intraspinal electrodes for spinal stimulation. There are no set criteria for predicting which patients will respond to these procedures. They are generally reserved for patients who have not responded to conventional pharmacologic approaches. Referral to a multidisciplinary pain clinic for a full evaluation should precede any of these procedures. Such referrals are clearly not necessary for all chronic pain patients. For some, pharmacologic management alone can often provide adequate relief.

**Antidepressant Medications** The tricyclic antidepressants (TCAs; Table 11-1) are extremely useful for the management of patients with chronic pain. Although developed for the treatment of depression, the...
tricyclics have a spectrum of dose-related biologic activities that include the production of analgesia in a variety of clinical conditions. Although the mechanism is unknown, the analgesic effect of TCAs has a more rapid onset and occurs at a lower dose than is typically required for the treatment of depression. Furthermore, patients with chronic pain who are not depressed obtain pain relief with antidepressants. There is evidence that tricyclic drugs potentiate opioid analgesia, so they are useful adjuncts for the treatment of severe persistent pain such as occurs with malignant tumors. Table 11-2 lists some of the painful conditions that respond to tricyclics. TCAs are of particular value in the management of neuropathic pain such as occurs in diabetic neuropathy and postherpetic neuralgia, for which there are few other therapeutic options.

The TCAs that have been shown to relieve pain have significant side effects (Table 11-1; Chap. 371). Some of these side effects, such as orthostatic hypotension, cardiac conduction delay, memory impairment, constipation, and urinary retention, are particularly problematic in elderly patients, and several are additive to the side effects of opioid analgesics. The serotonin-selective reuptake inhibitors such as fluoxetine (Prozac) have fewer and less serious side effects than TCAs, but they are much less effective for relieving pain. It is of interest that venlafaxine (Effexor), a nontricyclic antidepressant that blocks both serotonin and norepinephrine reuptake, appears to retain most of the pain-relieving effect of TCAs with a side-effect profile more like that of the serotonin-selective reuptake inhibitors. The drug may be particularly useful in patients who cannot tolerate the side effects of tricyclics.

**ANTICONVULSANTS AND ANTIARRHYTHMICS** (Table 11-1) These drugs are useful primarily for patients with neuropathic pain. Phenytoin (Di-lantin) and carbamazepine (Tegretol) were first shown to relieve the pain of trigeminal neuralgia. This pain has a characteristic brief, shooting, electric shock–like quality. In fact, anticonvulsants seem to be of the greatest value in the treatment of this disorder. It is interesting to note that the anticonvulsants of the barbiturate family (for example, phenobarbital) do not appear to be effective in the treatment of trigeminal neuralgia. This is in contrast to the effects of anticonvulsants on the spontaneous activity of damaged primary afferent nociceptors. Although the mechanism is unknown, the analgesic effect of TCAs is explained to the patient. It is also important to point out that some opioid analgesic medications have mixed agonist-antagonist properties (e.g., pentazocine and butorphanol). From a practical standpoint, this means that they may worsen pain by inducing an abstinence syndrome in patients who are physically dependent on other opioid analgesics. With long-term outpatient use of orally administered opioids, it is desirable to use long-acting compounds such as levorphanol, methadone, or sustained-release morphine (Table 11-1). Transdermal fentanyl is another excellent option. The pharmacokinetic profile of these drug preparations enables prolonged pain relief, minimizes side effects such as sedation that are associated with high peak plasma levels, and reduces the likelihood of rebound pain associated with a rapid fall in plasma opioid concentration. Constipation is a virtually universal side effect of opioid use and should be treated expectantly.

It is worth emphasizing that many patients, especially those with chronic pain, seek medical attention primarily because they are suffering and because only physicians can provide the medications required for their relief. A primary responsibility of all physicians is to minimize the physical and emotional discomfort of their patients. Familiarity with pain mechanisms and analgesic medications is an important step toward accomplishing this aim.

**FURTHER READING**


---

**CHEST DISCOMFORT AND PALPITATIONS**

**CHEST DISCOMFORT**

Chest discomfort is one of the most common challenges for clinicians in the office or emergency department. The differential diagnosis includes conditions affecting organs throughout the thorax and abdomen, with prognostic implications that vary from benign to life-threatening (Table 12-1). Failure to recognize potentially serious conditions such as acute ischemic heart disease, aortic dissection, tension pneumothorax, or pulmonary embolism can lead to serious complications, including death. Conversely, overly conservative management of low-risk patients leads to unnecessary hospital admissions, tests, procedures, and anxiety.

**CAUSES OF CHEST DISCOMFORT**

MYOCARDIAL ISCHEMIA AND INJURY (See also Chap. 226) Myocardial ischemia occurs when the oxygen supply to the heart is not sufficient helpful largely for pains that have such a lancinating quality. A new-generation anticonvulsant, gabapentin (Neurontin), is effective for a broad range of neuropathic pains.

**ANTIARRHYTHMIC MEDICATION** The long-term use of opioids is accepted for patients with pain due to malignant disease. Although opioid use for chronic pain of nonmalignant origin is controversial, it is clear that for many such patients opioid analgesics are the best available option. This is understandable since opioids are the most potent and have the broadest range of efficacy of any analgesic medications. Although addiction is rare in patients who first use opioids for pain relief, some degree of tolerance and physical dependence are likely with long-term use. Therefore, before embarking on opioid therapy, other options should be explored, and the limitations and risks of opioids should be explained to the patient. It is also important to point out that some opioid analgesic medications have mixed agonist-antagonist properties (e.g., pentazocine and butorphanol). From a practical standpoint, this means that they may worsen pain by inducing an abstinence syndrome in patients who are physically dependent on other opioid analgesics.

With long-term outpatient use of orally administered opioids, it is desirable to use long-acting compounds such as levorphanol, methadone, or sustained-release morphine (Table 11-1). Transdermal fentanyl is another excellent option. The pharmacokinetic profile of these drug preparations enables prolonged pain relief, minimizes side effects such as sedation that are associated with high peak plasma levels, and reduces the likelihood of rebound pain associated with a rapid fall in plasma opioid concentration. Constipation is a virtually universal side effect of opioid use and should be treated expectantly.

It is worth emphasizing that many patients, especially those with chronic pain, seek medical attention primarily because they are suffering and because only physicians can provide the medications required for their relief. A primary responsibility of all physicians is to minimize the physical and emotional discomfort of their patients. Familiarity with pain mechanisms and analgesic medications is an important step toward accomplishing this aim.

**FURTHER READING**


---

**TABLE 12-1 Differential Diagnoses of Patients Admitted to Hospital with Acute Chest Pain Ruled Not Myocardial Infarction**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastroesophageal disease</td>
<td>42</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
<td></td>
</tr>
<tr>
<td>Esophageal motility disorders</td>
<td></td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td></td>
</tr>
<tr>
<td>Gallstones</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>31</td>
</tr>
<tr>
<td>Chest wall syndromes</td>
<td>28</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>4</td>
</tr>
<tr>
<td>Pleuritis/pneumonia</td>
<td>2</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>2</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>1.5</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>1</td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>1</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>1</td>
</tr>
</tbody>
</table>

* In order of frequency.

Few of us are spared the experience of head pain. As many as 90% of individuals have at least one headache per year. Severe, disabling headache is reported to occur at least annually by 40% of individuals worldwide. A useful classification of the many causes of headache is shown in Table 14-1. Headache is usually a benign symptom, but occasionally it is the manifestation of a serious illness such as brain tumor, subarachnoid hemorrhage, meningitis, or giant cell arteritis. In emergency settings, approximately 5% of patients with headache are found to have a serious underlying neurologic disorder. Therefore, it is imperative that the serious causes of headache be diagnosed rapidly and accurately.

### PAIN-SENSITIVE STRUCTURES OF THE HEAD

Pain usually occurs when peripheral nociceptors are stimulated in response to tissue injury, visceral distension, or other factors (Chap. 11). In such situations, pain perception is a normal physiologic response mediated by a healthy nervous system. Pain can also result when pain-sensitive pathways of the peripheral or central nervous system are damaged or activated inappropriately. Headache may originate from either or both mechanisms. Relatively few cranial structures are pain-sensitive: the scalp, middle meningeal artery, dural sinuses, falx cerebri, and the proximal segments of the large pial arteries. The ventricular ependyma, choroid plexus, pial veins, and much of the brain parenchyma are pain-insensitive. Electrical stimulation of the midbrain in the region of the dorsal raphe has resulted in migraine-like headaches. Thus, whereas most of the brain is insensitive to electrode probing, a site in the midbrain represents a possible source of headache generation. Sensory stimuli from the head are conveyed to the central nervous system via the trigeminal nerves for structures above the tentorium in the anterior and middle fossae of the skull, and via the first three cervical nerves for those in the posterior fossa and the inferior surface of the tentorium.

Headache can occur as the result of (1) distention, traction, or dilation of intracranial or extracranial arteries; (2) traction or displacement of large intracranial veins or their dural envelope; (3) compression, traction, or inflammation of cranial and spinal nerves; (4) spasm, inflammation, or trauma to cranial and cervical muscles; (5) meningeal irritation and raised intracranial pressure; or (6) other possible mechanisms such as activation of brainstem structures.

### GENERAL CLINICAL CONSIDERATIONS

The quality, location, duration, and time course of the headache and the conditions that produce, exacerbate, or relieve it should be carefully reviewed. Ascertaining the quality of cephalic pain is occasionally helpful for diagnosis. Most tension-type headaches are described as tight “bandlike” pain or as dull, deeply located, and aching pain. Jabbing, brief, sharp cephalic pain, often occurring multifocally (ice pick–like pain), is usually benign. A throbbing quality and tight muscles about the head, neck, and shoulder girdle are common nonspecific accompaniments of migraine headaches.

Pain intensity rarely has diagnostic value, although from the patient’s perspective, it is the single aspect of pain that is most important.

### TABLE 14-1 International Headache Society Classification of Headache

<table>
<thead>
<tr>
<th>1. Migraine</th>
<th>7. Headache associated with nonvascular intracranial disorder (cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migraine without aura</td>
<td>Sacroiliitis and other noninfectious inflammatory diseases</td>
</tr>
<tr>
<td>Migraine with aura</td>
<td>Related to intrathecal injections</td>
</tr>
<tr>
<td>Ophthalmoplegic migraine</td>
<td>Intracranial neoplasm</td>
</tr>
<tr>
<td>Retinal migraine</td>
<td>Associated with other intracranial disorder</td>
</tr>
<tr>
<td>Childhood periodic syndromes that may be precursor to or associated with migraine</td>
<td></td>
</tr>
<tr>
<td>Migrainan disorder not fulfilling above criteria</td>
<td></td>
</tr>
<tr>
<td>2. Tension-type headache</td>
<td>8. Headache associated with substances or their withdrawal</td>
</tr>
<tr>
<td>Episodic tension-type headache</td>
<td>Headache induced by acute substance use or exposure</td>
</tr>
<tr>
<td>Chronic tension-type headache</td>
<td>Headache induced by chronic substance use or exposure</td>
</tr>
<tr>
<td>3. Cluster headache and chronic paroxysmal hemicrania</td>
<td>Headache from substance withdrawal (acute use)</td>
</tr>
<tr>
<td>Cluster headache</td>
<td>Headache from substance withdrawal (chronic use)</td>
</tr>
<tr>
<td>Chronic paroxysmal hemicrania</td>
<td>9. Headache associated with noncephalic infection</td>
</tr>
<tr>
<td>4. Miscellaneous headaches not associated with structural lesion</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Idiopathic stabbing headache</td>
<td>Bacterial infection</td>
</tr>
<tr>
<td>External compression headache</td>
<td>Other infection</td>
</tr>
<tr>
<td>Cold stimuli headache</td>
<td></td>
</tr>
<tr>
<td>Benign cough headache</td>
<td></td>
</tr>
<tr>
<td>Benign exertional headache</td>
<td></td>
</tr>
<tr>
<td>Headache associated with sexual activity</td>
<td></td>
</tr>
<tr>
<td>5. Headache associated with head trauma</td>
<td>10. Headache associated with metabolic disorder</td>
</tr>
<tr>
<td>Acute posttraumatic headache</td>
<td>Hypoxia</td>
</tr>
<tr>
<td>Chronic posttraumatic headache</td>
<td>Hypercapnia</td>
</tr>
<tr>
<td>6. Headache associated with vascular disorders</td>
<td>Mixed hypoxia and hypercapnia</td>
</tr>
<tr>
<td>Acute ischemic cerebrovascular disorder</td>
<td>Hypoglycemia</td>
</tr>
<tr>
<td>Intracranial hematoma</td>
<td>Dialysis</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>Other metabolic abnormality</td>
</tr>
<tr>
<td>Unruptured vascular malformation</td>
<td></td>
</tr>
<tr>
<td>Arteritis</td>
<td></td>
</tr>
<tr>
<td>Carotid or vertebral artery pain</td>
<td>11. Headache or facial pain associated with disorder of facial or cranial structures</td>
</tr>
<tr>
<td>Venous thrombosis</td>
<td>Cranial bone</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>Eyes</td>
</tr>
<tr>
<td>Other vascular disorder</td>
<td>Ears</td>
</tr>
<tr>
<td>7. Headache associated with nonvascular intracranial disorder</td>
<td>Nose and sinuses</td>
</tr>
<tr>
<td>High CSF pressure</td>
<td>Teeth, jaws, and related structures</td>
</tr>
<tr>
<td>Low CSF pressure</td>
<td>Temporomandibular joint disease</td>
</tr>
<tr>
<td>Intracranial infection</td>
<td>12. Cranial neuralgias, nerve trunk pain, and deafferentation pain</td>
</tr>
<tr>
<td>Note: CSF, cerebrospinal fluid</td>
<td>Persistent (in contrast to ticlike) pain of cranial nerve origin</td>
</tr>
<tr>
<td></td>
<td>Glossopharyngeal neuralgia</td>
</tr>
<tr>
<td></td>
<td>Nerve intermedium neuralgia</td>
</tr>
<tr>
<td></td>
<td>Superior laryngeal neuralgia</td>
</tr>
<tr>
<td></td>
<td>Occipital neuralgia</td>
</tr>
<tr>
<td></td>
<td>Central causes of head and facial pain other than tic doeloureux</td>
</tr>
<tr>
<td></td>
<td>13. Headache not classifiable</td>
</tr>
</tbody>
</table>
Although meningitis, subarachnoid hemorrhage, and cluster headache produce intense cranial pain, most patients entering emergency departments with the most severe headache of their lives usually have migraine. Contrary to common belief, the headache produced by a brain tumor is not usually distinctive or severe.

Data regarding location of headache may be informative. If the source is an extracranial structure, as in giant cell arteritis, the correspondence with the site of pain is fairly precise. Inflammation of an extracranial artery causes pain and exquisite tenderness localized to the site of the vessel. Lesions of paranasal sinuses, teeth, eyes, and upper cervical vertebrae induce less sharply localized pain, but pain that is still referred in a regional distribution. Intracranial lesions in the posterior fossa cause pain that is usually occipitomastoidal, and supratentorial lesions most often induce frontotemporal pain.

Duration and time-intensity curves of headaches are diagnostically useful. A ruptured aneurysm results in head pain that peaks in an instant, thunderclap-like; much less often, unruptured aneurysms may signal their presence in the same way. Cluster headache attacks reach their peak over 3 to 5 min, remain at maximal levels for about 45 min, and then taper off. Migraine attacks build up over hours, are maintained for several hours to days, and are characteristically relieved by sleep. Sleep disruption and early morning headaches that improve during the day are characteristics of headaches produced by brain tumors or other disorders that produce increased intracranial pressure.

Facial pain must be distinguished from headache. Trigeminal and, less commonly, glossopharyngeal neuralgia are frequent causes of facial pain (Chap. 355). Neuralgias are painful disorders characterized by paroxysmal, fleeting, often electric shock–like episodes that are frequently caused by demyelinating lesions of nerves (the trigeminal or glossopharyngeal nerves in cranial neuralgias). Certain maneuvers characteristically trigger paroxysms of pain. However, the most common cause of facial pain by far is dental; provocation by hot, cold, or sweet foods is typical. The application of a cold stimulus will repeatedly induce dental pain, whereas in neuralgic disorders, are refractory to any dopaminergic agents. How, however, they characteristically trigger paroxysms.
particularly easy to mistake for migraine in that the cardinal symptoms of pounding headache, photophobia, nausea, and vomiting are present. →A detailed discussion of meningitis can be found in Chaps. 360 and 361.

INTRACRANIAL HEMORRHAGE In general, acute, severe headache with stiff neck but without fever suggests subarachnoid hemorrhage. A ruptured aneurysm, arteriovenous malformation, or intraparenchymal hemorrhage may also present with headache alone. Rarely, if the hemorrhage is small or below the foramen magnum, the head CT scan can be normal. Therefore, a lumbar puncture may be required to make the definitive diagnosis of a subarachnoid hemorrhage. →A detailed discussion of intracranial hemorrhage can be found in Chap. 349.

BRAIN TUMOR Approximately 30% of patients with brain tumors consider headache to be their chief complaint. The head pain is usually nondescript—an intermittent deep, dull aching of moderate intensity, which may worsen with exertion or change in position and may be associated with nausea and vomiting. This pattern of symptoms results from migraine far more often than from brain tumor. Headache of brain tumor disturbs sleep in about 10% of patients. Vomiting that precedes the appearance of headache by weeks is highly characteristic of posterior fossa brain tumors. A history of amenorrhea or galactorrhea should lead one to question whether a prolactin-secreting pituitary adenoma (or the poly cystic ovary syndrome) is the source of the headache. Headache arising de novo in a patient with known malignancy suggests either cerebral metastases and/or carcinomatous meningitis. Head pain appearing abruptly after bending, lifting, or coughing can be due to a posterior fossa mass (or a Chiari malformation). →A detailed discussion of brain tumors can be found in Chap. 358.

TEMPORAL ARTERITIS (See also Chaps. 25 and 306) Temporal (giant cell) arteritis is an inflammatory disorder of arteries that frequently involves the extracranial carotid circulation. This is a common disorder of the elderly; its annual incidence is 77:100,000 in individuals aged 50 and older. The average age of onset is 70 years, and women account for 65% of cases. About half of patients with untreated temporal arteritis develop blindness due to involvement of the ophthalmic artery and its branches; indeed, the ischemic optic neuropathy induced by giant cell arteritis is the major cause of rapidly developing bilateral blindness in patients >60 years. Because treatment with glucocorticoids is effective in preventing this complication, prompt recognition of this disorder is important.

Typical presenting symptoms include headache, polymyalgia rheumatica (Chap. 306), jaw claudication, fever, and weight loss. Headache is the dominant symptom and often appears in association with malaise and muscle aches. Head pain may be unilateral or bilateral and is located temporally in 50% of patients but may involve any and all aspects of the cranium. Pain usually appears gradually over a few hours before peak intensity is reached; occasionally, it is explosive in onset. The quality of pain is only seldom throbbing; it is almost invariably described as dull and boring with superimposed episodic ice pick–like lancinating pains similar to the sharp pains that appear in migraine. Most patients can recognize that the origin of their head pain is superficial, external to the skull, rather than originating deep within the cranium (the pain site for migraineurs). Scalp tenderness is present, often to a marked degree; brushing the hair or resting the head on a pillow may be impossible because of pain. Headache is usually worse at night and is often aggravated by exposure to cold. Reddened, tender nodules or red streaking of the skin overlying the temporal arteries may be found in patients with headache, as is tenderness of the temporal or, less commonly, the occipital arteries.

The erythrocyte sedimentation rate (ESR) is often, though not always, elevated; a normal ESR does not exclude giant cell arteritis. A temporal artery biopsy and treatment with prednisone at 80 mg daily for the first 4 to 6 weeks should be initiated when clinical suspicion is high. The prevalence of migraine among the elderly is substantial, considerably higher than that of giant cell arteritis. Migraineurs often report amelioration of their headaches with prednisone, so that one must be cautious about interpreting the therapeutic response.

GLAUCOMA Glaucoma may present with a prostrating headache associated with nausea and vomiting. The history will usually reveal that the headache started with severe eye pain. On physical examination, the eye is often red with a fixed, moderately dilated pupil. →A discussion of glaucoma can be found in Chap. 25.

OTHER CAUSES OF HEADACHE ■ Systemic Illness There is hardly any illness that is never manifested by headache; however, some illnesses are frequently associated with headache. These include infectious mononucleosis, systemic lupus erythematosus, chronic pulmonary failure with hypercapnia (early morning headaches), Hashimoto’s thyroiditis, inflammatory bowel disease, many of the illnesses associated with HIV, and the acute blood pressure elevations that occur in pheochromocytoma and in malignant hypertension. The last two examples are the exceptions to the generalization that hypertension per se is a very uncommon cause of headache; diastolic pressures of at least 120 mmHg are requisite for hypertension to cause headache. Persistent headache and fever are often the manifestations of an acute systemic viral infection; if the neck is supple in such a patient, lumbar puncture may be deferred. Some drugs and drug-withdrawal states, e.g., oral contraceptives, ovulation-promoting medications, and glucocorticoid withdrawal, are also associated with headache in some individuals.

Idiopathic Intracranial Hypertension (Pseudotumor Cerebri) Headache, clinically resembling that of brain tumor, is a common presenting symptom of pseudotumor cerebri, a disorder of raised intracranial pressure probably resulting from impaired cerebrospinal fluid (CSF) absorption by the arachnoid villi. Morning headaches that are worsened by coughing and straining are typical. The pain is sometimes retroocular and worsened by eye movements. Transient visual obscurations and papilledema with enlarged blind spots and loss of peripheral visual fields are additional manifestations. Most patients are young, female, and obese. They often have a history of exposure to provoking agents such as vitamin A and glucocorticoids. →Treatment of idiopathic intracranial hypertension is discussed in Chap. 25.

Cough A male-dominated (4:1) syndrome, cough headache is characterized by transient, severe headache upon coughing, bending, lifting, sneezing, or stooping. Head pain persists for seconds to a few minutes. Many patients date the origins of the syndrome to a lower respiratory infection accompanied by severe coughing or to strenuous weight-lifting programs. Headache is usually diffuse but is localized in about one-third of patients. The incidence of serious intracranial structural anomalies causing this condition is about 25%; the Chiari malformation (Chap. 356) is a common cause. Thus, MRI is indicated for most patients with cough headache. The benign disorder may persist for a few years; it responds dramatically to indomethacin at doses ranging from 50 to 200 mg daily. Approximately half of patients will also show a response to therapeutic lumbar puncture with removal of 40 mL of CSF.

Many patients with migraine note that attacks of headache may be provoked by sustained physical exertion, such as during the third mile of a 5-mile run. Such headaches build up over hours, in contrast to cough headache. The term effort migraine has been used for this syndrome to avoid the ambiguous term exertional headache.

Lumbar Puncture Headache following lumbar puncture usually begins within 48 h but may be delayed for up to 12 days. Its incidence is between 10 and 30%. Head pain is dramatically positional; it begins when the patient sits or stands upright; there is relief upon reclining or with abdominal compression. The longer the patient is upright, the longer the latency before head pain subsides. It is worsened by head shaking and jugular vein compression. The pain is usually a dull ache but may be throbbing; its location is occipitofrontal. Nausea and stiff neck often accompany headache, and occasional patients report blurred vision, photophobia, and vertigo. The symptoms resolve over a few days but may on occasion persist for weeks to months.

Loss of CSF volume decreases the brain’s supportive cushion, so...
TABLE 14-4  Drugs Effective in the Treatment of Tension-Type Headache

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>Tylenol, generic</td>
<td>650 mg PO q4–6h</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Generic</td>
<td>650 mg PO q4–6h</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>Cataflam, generic</td>
<td>(max 200 mg/d)</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>Advil, Motrin, Naprin, generic</td>
<td>400 mg PO q3–4h</td>
</tr>
<tr>
<td>Naproxen sodium</td>
<td>Aleve, Anaprox, generic</td>
<td>220–550 mg bid</td>
</tr>
<tr>
<td><strong>COMBINATION ANALGESICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen, 325 mg, plus butalbital, 50 mg</td>
<td>Phrenilin, generic</td>
<td>1–2 tablets; max 6 per day</td>
</tr>
<tr>
<td>Acetaminophen, 650 mg, plus butalbital, 50 mg</td>
<td>Phrenilin Forte</td>
<td>1 tablet; max 6 per day</td>
</tr>
<tr>
<td>Acetaminophen, 325 mg, plus butalbital, 50 mg, plus caffeine, 40 mg</td>
<td>Fioricet; Esigic, generic</td>
<td>1–2 tablets; max 6 per day</td>
</tr>
<tr>
<td>Acetaminophen, 500 mg, plus butalbital, 50 mg, plus caffeine, 40 mg</td>
<td>Esigicplus</td>
<td>1–2 tablets; max 6 per day</td>
</tr>
<tr>
<td>Aspirin, 325 mg, plus butalbital, 50 mg, plus caffeine, 40 mg</td>
<td>Fiorinal</td>
<td>1–2 tablets; max 6 per day</td>
</tr>
<tr>
<td>Aspirin, 650 mg, plus butalbital, 50 mg</td>
<td>Axotal</td>
<td>1 tablet q4h; max 6 per day</td>
</tr>
<tr>
<td><strong>PROPHYLACTIC MEDICATIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Elavil, generic</td>
<td>10–50 mg at bedtime</td>
</tr>
<tr>
<td>Doxepin</td>
<td>Sinequan, generic</td>
<td>10–75 mg at bedtime</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>Pamelan, generic</td>
<td>25–75 mg at bedtime</td>
</tr>
</tbody>
</table>

that when a patient is upright there is probably dilation and tension placed on the brain’s anchoring structures, the pain-sensitive dural sinuses, resulting in pain. Intracranial hypertension often occurs, but severe lumbar puncture headache may be present even in patients who have normal CSF pressure.

Treatment with intravenous caffeine sodium benzoate given over a few minutes as a 500-mg dose will promptly terminate headache in 75% of patients; a second dose given in 1 h brings the total success rate to 85%. An epidural blood patch accomplished by injection of 15 mL of autologous whole blood rarely fails for those who do not respond to caffeine. The mechanism for these treatment effects is not straightforward. The blood patch has an immediate effect, making it unlikely that scaling off a dural hole with blood clot is its mechanism of action.

**Postconcussion**  Following seemingly trivial head injuries and particularly after rear-end motor vehicle collisions, many patients report varying combinations of headache, dizziness, vertigo, and impaired memory. Anxiety, irritability, and difficulty with concentration are other hallmarks of this syndrome. Symptoms may remit after several weeks or persist for months and even years after the injury. Postconcussion headaches may occur whether or not a person was rendered unconscious by head trauma. Typically, the neurologic examination is normal with the exception of the behavioral abnormalities, and CT or MRI studies are unrevealing. Chronic subdural hematoma may on occasion mimic this disorder. Although the cause of postconcussive headache disorder is not known, it should not in general be viewed as a primary psychological disturbance. It often persists long after the settlement of pending lawsuits. The treatment is symptomatic support. Repeated encouragement that the syndrome eventually remits is important.

**Coital Headache**  This is another male-dominated (4:1) syndrome. Attacks occur periorgasmically, are very abrupt in onset, and subside in a few minutes if coitus is interrupted. These are nearly always benign events and usually occur sporadically; if they persist for hours or are accompanied by vomiting, subarachnoid hemorrhage must be excluded (Chap. 349).

**Principal Clinical Varieties of Recurrent Headache**

There is usually little difficulty in diagnosing the serious types of headaches listed above because of the clues provided by the associated symptoms and signs. It is when headache is chronic, recurrent, and unattended by other important signs of disease that the physician faces a challenging and unique medical problem. The following sections describe a variety of headache types, ranging from the most common (e.g., migraine) to rare causes of recurrent headache.

**Tension-Type Headache**  The term tension-type headache is still commonly used to describe a chronic head pain syndrome characterized by bilateral tight, bandlike discomfort. Patients may report that the head feels as if it is in a vise or that the posterior neck muscles are tight. The pain typically builds slowly, fluctuates in severity, and may persist more or less continuously for many days. Exertion does not usually worsen the headache. The headache may be episodic or chronic (i.e., present >15 days per month). Tension-type headache is common in all age groups, and females tend to predominate. In some patients, anxiety or depression coexist with tension headache.

The pathophysiologic basis of tension-type headache remains unknown. Many investigators believe that periodic tension headache is biologically indistinguishable from migraine, whereas others believe that tension-type headache and migraine are two distinct clinical entities. Abnormalities of cervical and temporal muscle contraction are likely to exist, but the exact nature of the dysfunction has not yet been elucidated.

Relaxation almost always relieves tension-type headaches. Patients should be encouraged to find a means of relaxation, which, for a given individual, could include bed rest, massage, and/or formal biofeedback training. Pharmacologic treatment consists of either simple analgesics and/or muscle relaxants. Ibuprofen and naproxen sodium are useful treatments for most individuals. When simple over-the-counter analgesics such as acetaminophen, aspirin, ibuprofen, and/or other nonsteroidal anti-inflammatory drugs (NSAIDs) alone fail, the addition of butalbital and caffeine (in a combination compound such as Fiorinal, Fioricet) to these analgesics may be effective. A list of commonly used analgesics for tension-type headaches is presented in Table 14-4. For chronic tension-type headache, prophylactic therapy is recommended. Low doses of amitriptyline (10 to 50 mg at bedtime) can provide effective prophylaxis.

**Migraine**  Migraine, the most common cause of headache, affects approximately 15% of women and 6% of men. A useful definition of migraine is a benign and recurring syndrome of headache, nausea, vomiting, and/or other symptoms of neurologic dysfunction in varying admixtures (Table 14-5). Migraine can often be recognized by its activators (red wine, menses, hunger, lack of sleep, glare, estrogen, worry, perfumes, let-down periods) and its deactivators (sleep, pregnancy, exhilaration, triptans). A classification of the many subtypes of migraine, as defined by the International Headache Society, is shown in Table 14-1.

Severe headache attacks, regardless of cause, are more likely to be described as throbbing and associated with vomiting and scalp tenderness. Milder headaches tend to be nondescript—tight, bandlike discomfort often involving the entire head—the profile of tension-type headache.

**Pathogenesis**  **GENETIC BASIS OF MIGRAINE**  Migraine has a definite genetic predisposition. Specific mutations leading to rare causes of vascular headache have been identified (Table 14-6). For example, the MELAS syndrome consists of a mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes and is caused by an A → G point mutation in the mitochondrial gene encoding for tRNA_{A^3}^{N(iso)UR} at nucleotide position 3243. Episodic migraine-like headaches are another
common clinical feature of this syndrome, especially early in the course of the disease. The genetic pattern of mitochondrial disorders is unique, since only mothers transmit mitochondrial DNA. Thus, all children of mothers with MELAS syndrome are affected with the disorder.

Familial hemiplegic migraine (FHM) is characterized by episodes of recurrent hemiparesis or hemiplegia during the aura phase of a migraine headache. Other associated symptoms may include hemianesthesia or paresthesias; hemianopic visual field disturbances; dysphasia; and variable degrees of drowsiness, confusion, and/or coma. In severe attacks, these symptoms can be quite prolonged and persist for days or weeks, but characteristically they last for only 30 to 60 min and are followed by a unilateral throbbing headache.

Approximately 50% of cases of FHM appear to be caused by mutations within theCACNL1A4 gene on chromosome 19, which encodes a P/Q type calcium channel subunit expressed only in the central nervous system. The gene is very large (>300 kb in length) and consists of 47 exons. Four distinct point mutations have been identified within the gene (in five different families) that cosegregate with the clinical diagnosis of FHM. Analysis of haplotypes in the two families with the same mutation suggest that each mutation arose independently rather than representing a founder effect. CACNL1A4 is likely to play a role in calcium-induced neurotransmitter release and/or contraction of smooth muscle. Different mutations within this gene are the cause of two other neurogenic disorders, spinocerebellar ataxia type 6 and episodic ataxia type 2 (Chap. 352).

In a genetic association study, aNcoI polymorphism in the gene encoding theD2 dopamine receptor (DRD2) was overrepresented in a population of patients with migraine with aura compared to a control group of nonmigraineurs, suggesting that susceptibility to migraine with aura is modified by certain DRD2 alleles. In a Sardinian population, a association between different DRD2 alleles and migraine has also been demonstrated. These initial studies suggest that variations in dopamine receptor regulation and/or function may alter susceptibility to migraine since molecular variations within the DRD2 gene have been associated with variations in dopaminergic function. However, since not all individuals with the implicated DRD2 genotypes suffer from migraine with aura, additional genes or factors must also be involved. Migraine is likely to be a complex disorder with polygenic inheritance and a strong environmental component.

**THE VASCULAR THEORY OF MIGRAINE** It was widely held for many years that the headache phase of migrainous attacks was caused by extracranial vasospasms and that the neurologic symptoms were produced by intracranial vasospasm (i.e., the “vascular” hypothesis of migraine). Regional cerebral blood flow studies have shown that in patients with classic migraine there is, during attacks, a modest cortical hypoperfusion that begins in the visual cortex and spreads forward at a rate of 2 to 3 mm/min. The decrease in blood flow averages 25 to 30% (insufficient to explain symptoms on the basis of ischemia) and progresses anteriorly in a wavelike fashion independent of the topography of cerebral arteries. The wave of hypoperfusion persists for 4 to 6 h, appears to follow the convolutions of the cortex, and does not cross the central or lateral sulcus, progressing to the frontal lobe via the insula. Perfusion of subcortical structures is normal. Contralateral neurologic symptoms appear during temporoparietal hypoperfusion; at times, hypoperfusion persists in these regions after symptoms cease. More often, frontal spread continues as the headache phase begins. A few patients with classic migraine show no flow abnormalities; an occasional patient has developed focal ischemia sufficient to cause symptoms. However, focal ischemia does not appear to be necessary for focal symptoms to occur.

The ability of these changes to induce the symptoms of migraine has been questioned. Specifically, the decrease in blood flow that is observed does not appear to be significant enough to cause focal neurologic symptoms. Second, the increase in blood flow per se is not painful, and vasodilatation alone cannot account for the local edema and focal tenderness often observed in migraineurs. Moreover, in migraine without aura, no flow abnormalities are usually seen. Thus, it is unlikely that simple vasocostriction and vasodilatation are the fundamental pathophysiologic abnormalities in migraine. However, it is clear that cerebral blood flow is altered during certain migraine attacks, and these changes may explain some, but clearly not all, of the clinical syndrome of migraine.

**THE NEURONAL THEORY OF MIGRAINE** Fortification spectrum is a migraine aura characterized by a slowly enlarging visual scotoma with luminous edges (see below). It is believed to result from spreading depression, a slowly moving (2 to 3 mm/min), potassium-liberating depression of cortical activity, preceded by a wavefront of increased metabolic activity. Spreading depression can be produced by a variety of experimental stimuli, including hypoxia, mechanical trauma, and the topical application of potassium. These observations suggest that neuronal abnormalities could be the cause of a migraine attack.

Physiologically, electrical stimulation near dorsal raphe neurons in the upper brainstem can result in migraine-like headaches. Blood flow in the pons and midbrain increases focally during migraine headache episodes; this alteration probably results from increased activity of cells in the dorsal raphe and locus coeruleus. There are projections from the dorsal raphe that terminate on cerebral arteries and alter cerebral blood flow. There are also major projections from the dorsal raphe to important visual centers, including the lateral geniculate body, superior colliculus, retina, and visual cortex. These various serotonergic projections may represent the neural substrate for the circulatory and visual characteristics of migraine. The dorsal raphe cells stop firing during deep sleep, and sleep is known to ameliorate migraine; the antimigraine prophylactic drugs also inhibit activity of the dorsal raphe cells through a direct or indirect agonist effect.

### TABLE 14-4 Migraine Genetics

<table>
<thead>
<tr>
<th>Gene (Locus)</th>
<th>Function of Gene</th>
<th>Clinical Syndrome</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>tRNA^Leu(UUR) (mitochondrial)</td>
<td>Unknown</td>
<td>MELAS syndrome</td>
<td>Extremely rare syndrome</td>
</tr>
<tr>
<td>CACNL1A4 (19p13)</td>
<td>P/Q calcium channel regulating neurotransmitter release</td>
<td>Familial hemiplegic migraine (FHM)</td>
<td>Mutations account for approximately 50% of FHM cases</td>
</tr>
<tr>
<td>DRD2 (11q23)</td>
<td>G protein–coupled D2 receptor for dopamine</td>
<td>Migraine</td>
<td>Positive association reported in two independent laboratories</td>
</tr>
</tbody>
</table>

**Note:** MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.
strated that midbrain structures near the dorsal raphe are activated during a migraine attack. In one study of acute migraine, an injection of sumatriptan relieved the headache but did not alter the brainstem changes noted on the PET scan. These data suggest that a “brainstem generator” may be the cause of migraine and that certain antimigraine medications may not interfere with the underlying pathologic process in migraine.

THE TRIGEMINOVASCULAR SYSTEM IN MIGRAINE

Activation of cells in the trigeminal nucleus caudalis in the medulla (a pain-processing center for the head and face region) results in the release of vasoactive neuropeptides, including substance P and calcitonin gene–related peptide, at vascular terminations of the trigeminal nerve. These peptide neurotransmitters have been proposed to induce a sterile inflammation that activates trigeminal nociceptive afferents originating on the vessel wall, further contributing to the production of pain. This provides a potential mechanism for the soft tissue swelling and tenderness of blood vessels that accompany migraine attacks. However, numerous pharmacologic agents that are effective in preventing or reducing inflammation in this animal model (e.g., selective 5-HT<sub>1B</sub> agonists, NK1 antagonists, endothelin antagonists) have failed to demonstrate any clinical efficacy in migraine trials.

5-HYDROXYTRYPTAMINE IN MIGRAINE

Pharmacologic and other data point to the involvement of the neurotransmitter 5-hydroxytryptamine (5-HT; also known as serotonin) in migraine. Approximately 40 years ago, methysergide was found to antagonize certain peripheral actions of 5-HT and was introduced as the first drug capable of preventing migraine attacks. Subsequently, it was found that platelet levels of 5-HT fall consistently at the onset of headache and that drugs that cause 5-HT to be released may trigger migrainous episodes. Such changes in circulating 5-HT levels proved to be pharmacologically trivial, however, and interest in the humoral role of 5-HT in migraine declined.

More recently, interest in the role of 5-HT in migraine has been renewed due to the introduction of the triptan class of antimigraine drugs. The triptans are designed to stimulate selectively a particular subpopulation of 5-HT receptors. At least 14 specific 5-HT receptors exist in humans. The triptans (e.g., naratriptan, rizatriptan, sumatriptan, and zolmitriptan) are potent agonists of 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>1F</sub> receptors and are less potent at 5-HT<sub>1A</sub> and 5-HT<sub>1E</sub> receptors. A growing body of data indicates that the antimigraine efficacy of the triptans relates to their ability to stimulate 5-HT<sub>1B</sub> receptors, which are located on both blood vessels and nerve terminals. Selective 5-HT<sub>1B</sub> receptor agonists have, thus far, failed to demonstrate clinical efficacy in migraine. Triptans that are weak 5-HT<sub>1B</sub> agonists are also effective in migraine; however, only 5-HT<sub>1B</sub> efficacy is currently thought to be essential for antimigraine efficacy.

DOPAMINE IN MIGRAINE

A growing body of biologic, pharmacologic, and genetic data supports a role for dopamine in the pathophysiology of certain subtypes of migraine. Most migraine symptoms can be induced by dopaminergic stimulation. Moreover, there is dopamine receptor hypersensitivity in migraineurs, as demonstrated by the induction of yawning, nausea, vomiting, hypotension, and other symptoms of a migraine attack by dopaminergic agonists at doses that do not affect nonmigraineurs. Conversely, dopamine receptor antagonists are effective therapeutic agents in migraine, especially when given parenterally or concurrently with other antimigraine agents. As noted above, genetic data also suggest that molecular variations within dopamine receptor genes play a modifying role in the pathophysiology of migraine with aura. Therefore, modulation of dopaminergic neurotransmission should be considered in the therapeutic management of migraine.

THE SYMPATHETIC NERVOUS SYSTEM IN MIGRAINE

Alterations occur within the sympathetic nervous system (SNS) of migraineurs before, during, and between migraine attacks. Factors that activate the SNS are also triggers for migraine. Specific examples include environmental changes (e.g., stress, sleep patterns, hormonal shifts, hypoglycemia) and agents that cause release and a secondary depletion of peripheral catecholamines (e.g., tyramine, phenylethylamine, fenfluramine, m-chlorophenylperazine, and reserpine). By contrast, effective therapeutic approaches to migraine share an ability to mimic and/or enhance the effects of norepinephrine in the peripheral SNS. For example, norepinephrine itself, sympathomimetics (e.g., isomethaprine), monoamine oxidase inhibitors (MAOIs), and reuptake blockers alleviate migraine. Dopamine antagonists, prostaglandin synthesis inhibitors, and adenosine antagonists are pharmacologic agents effective in the acute treatment of migraine. These drugs block the negative feedback inhibition or norepinephrine release induced by endogenous dopamine, prostaglandins, and adenosine. Therefore, migraine susceptibility may relate to genetically based variations in the ability to maintain adequate concentrations of certain neurotransmitters within postganglionic sympathetic nerve terminals. This hypothesis has been called the empty neuron theory of migraine.

Clinical Features

MIGRAINE WITHOUT AURA (COMMON MIGRAINE)

In this syndrome no focal neurologic disturbance precedes the recurrent headaches. Migraine without aura is by far the more frequent type of vascular headache. The International Headache Society criteria for migraine include moderate to severe head pain, pulsating quality, unilateral location, aggravation by walking stairs or similar routine activity, attendant nausea and/or vomiting, photophobia and phonophobia, and multiple attacks, each lasting 4 to 72 h.

MIGRAINE WITH AURA (CLASSIC MIGRAINE)

In this syndrome headache is associated with characteristic premonitory sensory, motor, or visual symptoms. Focal neurologic disturbances are more common during headache attacks than as prodromal symptoms. Focal neurologic disturbances without headache or vomiting have come to be known as migraine equivalents or migraine accompaniments and appear to occur more commonly in patients between the ages of 40 and 70 years. The term complicated migraine has generally been used to describe migraine with dramatic transient focal neurologic features or a migraine attack that leaves a persisting residual neurologic deficit.

The most common premonitory symptoms reported by migraineurs are visual, arising from dysfunction of occipital lobe neurons. Scotomas and/or hallucinations occur in about one-third of migraineurs and usually appear in the central portions of the visual fields. A highly characteristic syndrome occurs in about 10% of patients; it usually begins as a small paracentral scotoma, which slowly expands into a “C” shape. Luminous angles appear at the enlarging outer edge, becoming colored as the scintillating scotoma expands and moves toward the periphery of the involved half of the visual field, eventually disappearing over the horizon of peripheral vision. The entire process lasts 20 to 25 min. This phenomenon is pathognomonic for migraine and has never been described in association with a cerebral structural anomaly. It is commonly referred to as a fortification spectrum because the serrated edges of the hallucinated “C” seemed to resemble a fortified town with bastions around it; spectrum is used in the sense of an apparition or spectacle.

BASILAR MIGRAINE

Symptoms referable to a disturbance in brainstem function, such as vertigo, dysarthria, or diplopia, occur as the only neurologic symptoms of the attack in about 25% of patients. A dramatic form of basilar migraine (Bickerstaff’s migraine) occurs primarily in adolescent females. Episodes begin with total blindness accompanied or followed by admixtures of vertigo, ataxia, dysarthria, tinnitus, and distal and perioral paresthesias. In about one-quarter of patients, a confusional state supervenes. The neurologic symptoms usually persist for 20 to 30 min and are generally followed by a throbbing occipital headache. This basilar migraine syndrome is now known also to occur in children and in adults over age 50. An altered sensorium may persist for as long as 5 days and may take the form of confusional states superficially resembling psychotic reactions. Full recovery after the episode is the rule.

CAROTIDDYNIA

The carotiddynia syndrome, sometimes called lower-half headache or facial migraine, is most common among older patients,
with the incidence peaking in the fourth through sixth decades. Pain is usually located at the jaw or neck, although sometimes periorbital or maxillary pain occurs; it may be continuous, deep, dull, and aching, and it becomes pounding or throbbing episodically. There are often superimposed sharp, ice pick–like jabs. Attacks occur one to several times per week, each lasting several minutes to hours. Tenderness and prominent pulsations of the cervical carotid artery and soft tissue swelling overlying the carotid are usually present ipsilateral to the pain; many patients also report throbbing ipsilateral headache concurrent with carotidynia attacks as well as between attacks. Dental trauma is a common precipitant of this syndrome. Carotid artery involvement is accompanied with carotidynia attacks as well as between attacks. Dental trauma is a common precipitant of this syndrome. Carotid artery involvement is accompanied by tenderness at several points on the side most often involved during hemicranial migraine attacks.

**TREATMENT**

**Nonpharmacologic Approaches for All Migraineurs**  Migraine can often be managed to some degree by a variety of nonpharmacologic approaches (Table 14-7). The measures that apply to a given individual should be used routinely since they provide a simple, cost-effective approach to migraine management. Patients with migraine do not encounter more stress than headache-free individuals; overresponsiveness to stress appears to be the issue. Since the stresses of everyday living cannot be eliminated, lessening one’s response to stress by various techniques is helpful for many patients. These include yoga, transcendental meditation, hypnosis, and conditioning techniques such as biofeedback. For most patients, this approach is, at best, an adjunct to pharmacotherapy. Avoidance of migraine trigger factors may also provide significant prophylactic benefits. Unfortunately, these measures are unlikely to prevent all migraine attacks. When these measures fail to prevent an attack, pharmacologic approaches are then needed to abort an attack.

**Pharmacologic Treatment of Acute Migraine**  The mainstay of pharmacologic therapy is the judicious use of one or more of the many drugs that are effective in migraine. The selection of the optimal regimen for a given patient depends on a number of factors, the most important of which is the severity of the attack (Table 14-8). Mild migraine attacks can usually be managed by oral agents; the average efficacy rate is 50 to 70%. Severe migraine attacks may require parenteral therapy. Most drugs effective in the treatment of migraine are members of one of three major pharmacologic classes: anti-inflammatory agents, 5-HT1 agonists, and dopamine antagonists.

Table 14-9 lists specific drugs effective in migraine. In general, an adequate dose of whichever agent is chosen should be used as soon as possible after the onset of an attack. If additional medication is required within 60 min because symptoms return or have not abated, the initial dose should be increased for subsequent attacks. Migraine therapy must be individualized for each patient; a standard approach for all patients is not possible. A therapeutic regimen may need to be constantly refined and personalized until one is identified that provides the patient with rapid, complete, and consistent relief with minimal side effects.

**Nonsteroidal Anti-Inflammatory Agents**  Both the severity and duration of a migraine attack can be reduced significantly by anti-inflammatory agents. Indeed, many undiagnosed migraineurs are self-treated with nonprescription anti-inflammatory agents. The combination of acetaminophen, aspirin, and caffeine (Excedrin Migraine) has been approved for use by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate migraine. The combination of aspirin and metoclopramide has been shown to be equivalent to a single dose of sumatriptan. Major side effects of NSAIDs include dyspepsia and gastrointestinal irritation.

**5-HT1 Agonists**  Oral  Stimulation of 5-HT1 receptors can stop an acute migraine attack. Ergotamine and dihydroergotamine are nonselective receptor agonists, while the series of drugs known as triptans are selective 5-HT1 receptor agonists. A variety of triptans (e.g., naratriptan, rizatriptan, sumatriptan, zolmitriptan, almotriptan, frovatriptan) are now available for the treatment of migraine (Table 14-9). Each of the triptan class of drugs has similar pharmacologic properties but varies slightly in terms of clinical efficacy. Rizatriptan and almotriptan are the fastest acting and most efficacious of the triptans currently available in the United States. Sumatriptan and zolmitriptan have similar rates of efficacy as well as time to onset, whereas naratriptan and frovatriptan are the slowest acting and the least efficacious. Clinical efficacy appears to be related more to the fmax (time to peak plasma level) than to the potency, half-life, or bioavailability (Table 14-10). This observation is in keeping with a significant body of data indicating that faster-acting analgesics are more efficacious than slower-acting agents.

Unfortunately, monotherapy with a selective oral 5-HT1 agonist does not result in rapid, consistent, and complete relief of migraine in all patients. Triptans are not effective in migraine with aura unless given after the aura is completed and the headache initiated. Side effects, although often mild and transient, occur in up to 89% of patients. Moreover, 5-HT1 agonists are contraindicated in individuals with a history of cardiovascular disease. Recurrence of headache is a major limitation of triptan use, and occurs at least occasionally in 40 to 78% of patients.

Ergotamine preparations offer a nonspecific means of stimulating 5-HT1 receptors. A nonnauseating dose of ergotamine should be sought since a dose that provokes nausea is too high and may intensify head pain. Except for a sublingual formulation of ergotamine (Ergo-
more effective relief of a migraine attack than oral formulations, their reported efficacy is only approximately 50 to 60%.

**Parenteral** Parenteral administration of drugs such as dihydroergotamine (DHE-45 Injectable) and sumatriptan (Imitrex SC) is approved by the FDA for the rapid relief of a migraine attack. Peak plasma levels of dihydroergotamine are achieved 3 min after intravenous dosing, 30 min after intramuscular dosing, and 45 min after subcutaneous dosing. If an attack has not already peaked, subcutaneous or intramuscular administration of 1 mg dihydroergotamine suffices for about 80 to 90% of patients. Sumatriptan, 6 mg subcutaneously, is effective in approximately 70 to 80% of patients.

**DOPAMINE ANTAGONISTS** **Oral** Oral dopamine antagonists should be considered as adjunctive therapy in migraine. Drug absorption is impaired during migrainous attacks because of reduced gastrointestinal motility. Delayed absorption occurs in the absence of nausea and is related to the severity of the attack and not its duration. Therefore, when oral NSAIDs and/or triptan agents fail, the addition of a dopamine antagonist such as metoclopramide, 10 mg, should be considered to enhance gastric absorption. In addition, dopamine antagonists decrease nausea/vomiting and restore normal gastric motility.

**Parenteral** Parenteral dopamine antagonists (e.g., chlorpromazine, prochlorperazine, metoclopramide) can also provide significant acute relief of migraine; they can be used in combination with parenteral 5-HT1 agonists. A common intravenous protocol used for the treatment of severe migraine is the administration over 2 min of a mixture of 5 mg of prochlorperazine and 0.5 mg of dihydroergotamine.

**OTHER MEDICATIONS FOR ACUTE MIGRAINE** **Oral** The combination of acetaminophen, dichloralphenazone, and isometheptene (i.e., Midrin, Duradrin, generic), one to two capsules, has been classified by the FDA as “possibly” effective in the treatment of migraine. Since the clinical studies demonstrating the efficacy of this combination analgesic in migraine predated the clinical trial methodologies used with

### TABLE 14-9 Treatment of Acute Migraine

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen, aspirin, caffeine</td>
<td>Excedrin Migraine</td>
<td>Two tablets or caplets q6h (max 8 per day)</td>
</tr>
<tr>
<td><strong>5-HT1 AGONISTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergotamine 1 mg, caffeine 100 mg</td>
<td>Ercaf, Wigraine</td>
<td>One or two tablets at onset, then one tablet q2h (max 2 per day, 10 per week)</td>
</tr>
<tr>
<td>Naratriptan</td>
<td>Amerge, Maxalt</td>
<td>5 to 10 mg tablet at onset; may repeat once after 2 h (max 30 mg/d)</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Imitrex MLT</td>
<td>50 to 100 mg tablet at onset; may repeat after 2 h (max 200 mg/d)</td>
</tr>
<tr>
<td>Zolmitriptan</td>
<td>Zomig, Zomig RapiNe</td>
<td>2.5 mg tablet at onset; may repeat after 2 h (max 10 mg/d)</td>
</tr>
<tr>
<td>Nasal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydroergotamine</td>
<td>Migranal Nasal Spray</td>
<td>Prior to nasal spray, the pump must be primed 4 times; one spray (0.5 mg) is administered followed, in 15 min, by a second spray</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Imitrex Nasal Spray</td>
<td>5 to 20 mg intranasal spray as 4 sprays of 5 mg or a single 20 mg spray (may repeat once after 2 h, not to exceed a dose of 40 mg/d)</td>
</tr>
<tr>
<td>Parenteral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydroergotamine</td>
<td>DHE-45</td>
<td>1 mg IV, IM, or SC at onset and q1h (max 3 mg/d, 6 mg per week)</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Imitrex Injection</td>
<td>6 mg SC at onset (may repeat once after 1 h for max of two doses in 24 h)</td>
</tr>
<tr>
<td><strong>DOPAMINE ANTAGONISTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Reglan, generic</td>
<td>5–10 mg/d</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>Compazine, generic</td>
<td>1–25 mg/d</td>
</tr>
<tr>
<td>Parenteral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>Generic, Reglan, generic</td>
<td>0.1 mg/kg IV at 2 mg/min; max 35 mg/d</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Compazine, generic</td>
<td>10 mg IV</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>10 mg IV</td>
<td></td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen, 325 mg, plus</td>
<td>Midrin, Duradrin</td>
<td>Two capsules at onset followed by 1 capsule q1h (max 5 capsules)</td>
</tr>
<tr>
<td>dichloralphenazone, 100 mg, plus isometheptene, 65 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butorphanol</td>
<td>Stadol</td>
<td>1 mg (1 spray in 1 nostril), may repeat if necessary in 1–2 h</td>
</tr>
<tr>
<td>Parenteral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narcotics</td>
<td>Generic</td>
<td>Multiple preparations and dosages; see Table 11-1.</td>
</tr>
</tbody>
</table>

* Not specifically indicated by the U.S. Food and Drug Administration for migraine.

Note: NSAIDs, nonsteroidal anti-inflammatory drugs; 5-HT, 5-hydroxytryptamine.

---

mar), oral formulations of ergotamine also contain 100 mg caffeine (theoretically to enhance ergotamine absorption and possibly to add additional vasoconstrictor activity). The average oral ergotamine dose for a migraine attack is 2 mg. Since the clinical studies demonstrating the efficacy of ergotamine in migraine predated the clinical trial methodologies used with the triptans, it is difficult to assess the clinical efficacy of ergotamine versus the triptans. In general, ergotamine appears to have a much higher incidence of nausea than triptans, but less headache recurrence.

**Nasal** The fastest acting nonparenteral antimigraine therapies that can be self-administered include nasal formulations of dihydroergotamine (Migranal) or sumatriptan (Imitrex Nasal). The nasal sprays result in substantial blood levels within 30 to 60 min. However, the nasal formulations suffer from inconsistent dosing, poor taste, and variable efficacy. Although in theory the nasal sprays might provide faster and

### TABLE 14-10 Comparative Pharmacology of Oral Triptans

<table>
<thead>
<tr>
<th>Drug and Dose, mg</th>
<th>t_{max}, h</th>
<th>t_{1/2}, h</th>
<th>Bioavailability, %</th>
<th>Clinical Efficacy at 2 h, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rizatriptan, 10</td>
<td>1–2</td>
<td>2–3</td>
<td>45</td>
<td>71</td>
</tr>
<tr>
<td>Zolmitriptan, 2.5</td>
<td>2–3</td>
<td>2–4</td>
<td>66</td>
<td>65</td>
</tr>
<tr>
<td>Sumatriptan, 50</td>
<td>2–3</td>
<td>2–4</td>
<td>68</td>
<td>61</td>
</tr>
<tr>
<td>Naratriptan, 2.5</td>
<td>2–3</td>
<td>5–6</td>
<td>68</td>
<td>45</td>
</tr>
<tr>
<td>Frovatriptan, 2.5</td>
<td>2–3</td>
<td>26</td>
<td>25</td>
<td>43</td>
</tr>
<tr>
<td>Almotriptan, 12.5</td>
<td>2–3</td>
<td>3</td>
<td>70</td>
<td>58</td>
</tr>
</tbody>
</table>

* Data adapted from package inserts approved by the U.S. Food and Drug Administration.
the triptans, it is difficult to assess the clinical efficacy of this symp-
thomimetic compound in comparison to other agents.

Nasal A nasal preparation of butorphanol is available for the treatment of acute pain. As with all narcotics, the use of nasal butorphanol should be limited to a select group of migraineurs, as described below.

Parenteral Narcotics are effective in the acute treatment of migraine. For example, intravenous meperidine (Demerol), 50 to 100 mg, is given frequently in the emergency room. This regimen “works” in the sense that the pain of migraine is eliminated. However, this regimen is clearly suboptimal in patients with recurrent headache for two major reasons. First, narcotics do not treat the underlying headache mechanism; rather, they act at the thalamic level to alter pain sensation. Second, the recurrent use of narcotics can lead to significant problems. In patients taking oral narcotics such as oxycodeone (Percodan) or hy-
drocodone (Vicodin), narcotic addiction can greatly confuse the treat-
ment of migraine. The headache that results from narcotic craving and/or withdrawal can be difficult to distinguish from chronic migraine. Therefore, it is recommended that narcotic use in migraine be limited to patients with severe, but infrequent, headaches that are unresponsive to other pharmacologic approaches.

Prophylactic Treatment of Migraine A substantial number of drugs are now available that have the capacity to stabilize migraine (Table 14-11). The decision of whether to use this approach depends on the frequency of attacks and on how well acute treatment is working. The occurrence of at least three attacks per month could be an indication for this approach. Drugs must be taken daily, and there is usually a lag of at least 2 to 6 weeks before an effect is seen. The drugs that have been approved by the FDA for the prophylactic treatment of migraine include propranolol, timolol, sodium valproate, and meth-
ysergide. In addition, a number of other drugs appear to display pro-
phylactic efficacy. This group of drugs includes amitriptyline, nortrip-
tyline, verapamil, phenelzine, gabapentin, and cyproheptadine. Phenelzine and methysergide are usually reserved for recalcitrant cases because of their serious potential side effects. Phenelzine is an MAOI; therefore, tyramine-containing foods, decongestants, and meperidine are contraindicated. Methysergide may cause retroperitoneal or cardiac valvular fibrosis when it is used, particularly at very low doses. This regimen is used, it is most effective when given 1 to 2 h before an expected

table of contents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Adrenergic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propranolol</td>
<td>Inderal</td>
<td>80–320 mg qd</td>
</tr>
<tr>
<td>Timolol</td>
<td>Inderal LA</td>
<td></td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>Depakote</td>
<td>250 mg bid (max 1000 mg/d)</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Elavil&lt;sup&gt;a&lt;/sup&gt;, generic</td>
<td>10–50 mg qhs</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>Pamelor&lt;sup&gt;a&lt;/sup&gt;, generic</td>
<td>25–75 mg qhs</td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenelzine</td>
<td>Nardil&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15 mg tid</td>
</tr>
<tr>
<td>Serotonergic drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methysergide</td>
<td>Sansert</td>
<td>4–8 mg qd</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>Periactin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4–16 mg qd</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>Calan&lt;sup&gt;a&lt;/sup&gt;</td>
<td>80–480 mg qd</td>
</tr>
<tr>
<td></td>
<td>Isoptin&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Not specifically indicated for migraine by the U.S. Food and Drug Administration.

acceptable side effects, then methysergide or phenelzine can be used. Once effective stabilization is achieved, the drug is continued for 5 to 6 months and then slowly tapered to assess the continued need. Many patients are able to discontinue medication and experience fewer and milder attacks for long periods, suggesting that these drugs may alter the natural history of migraine.

Cluster headache A variety of names have been used for this condition, including “Raeder’s syndrome,” histamine cephalalgia, and sphenopalatine neuralgia. Cluster headache is a distinctive and treat-
able vascular headache syndrome. The episodic type is most common and is characterized by one to three short-lived attacks of periorbital pain per day over a 4- to 8-week period, followed by a pain-free in-
terval that averages 1 year. The chronic form, which may begin de novo or several years after an episodic pattern has become established, is characterized by the absence of sustained periods of remission. Each type may transform into the other. Men are affected seven to eight times more often than women; hereditary factors are usually absent. Although the onset is generally between ages 20 and 50, it may occur as early as the first decade of life. Propranolol and amitriptyline are largely ineffective. Lithium is beneficial for cluster headache and ineffective in migraine. The cluster syndrome is thus clinically, geneti-
cally, and therapeutically different from migraine. Nevertheless, mixed features of the two disorders are occasionally present, suggesting some common elements to their pathogenesis.

Pathogenesis No consistent cerebral blood flow changes accompany attacks of pain. Perhaps the strongest evidence for a central mechanism is the periodicity of attacks; the existence of a central mechanism is also suggested by the observation that autonomic symptoms that accom-
pany the pain are bilateral and are more severe on the painful side. The hypothalamus is probably the site of activation in this disorder. The posterior hypothalamus contains cells that regulate autonomic functions, and the anterior hypothalamus contains cells (in the supra-
chiasmatic nuclei) that constitute the principal circadian pacemaker in mammals. Activation of both is necessary to explain the symptoms of cluster headache. The pacemaker is modulated via serotonergic dorsal raphe projections. It can be concluded tentatively that both migraine and cluster headache result from abnormal serotonergic neurotransmission, albeit at different loci.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-Adrenergic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonidine</td>
<td>Novadur</td>
<td>0.1–0.25 mg qid</td>
</tr>
<tr>
<td>Phenylpropanol</td>
<td>Olprinol</td>
<td>10–20 mg qid</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Elavil&lt;sup&gt;a&lt;/sup&gt;, generic</td>
<td>10–50 mg qhs</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>Pamelor&lt;sup&gt;a&lt;/sup&gt;, generic</td>
<td>25–75 mg qhs</td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenelzine</td>
<td>Nardil&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15 mg tid</td>
</tr>
<tr>
<td>Serotonergic drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methysergide</td>
<td>Sansert</td>
<td>4–8 mg qd</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>Periactin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4–16 mg qd</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>Calan&lt;sup&gt;a&lt;/sup&gt;</td>
<td>80–480 mg qd</td>
</tr>
<tr>
<td></td>
<td>Isoptin&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Not specifically indicated for migraine by the U.S. Food and Drug Administration.

The most satisfactory treatment is the administration of drugs to pre-
vent cluster attacks until the bout is over. Effective prophylactic drugs are prednisone, lithium, methysergide, ergotamine, sodium valproate, and verapamil. Lithium (600 to 900 mg daily) appears to be particu-
larly useful for the chronic form of the disorder. A 10-day course of prednisone, beginning at 60 mg daily for 7 days followed by a rapid taper, may interrupt the pain bout for many patients. When ergotamine is used, it is most effective when given 1 to 2 h before an expected
The importance of back and neck pain in our society is underscored by the following: (1) the cost of back pain in the United States is between $20 and $50 billion annually, (2) back symptoms are the most common cause of disability in patients under 45 years of age, (3) low back pain is the second most common reason for visiting a physician in the United States, and (4) approximately 1% of the U.S. population is chronically disabled because of back pain.

ANATOMY OF THE SPINE

The anterior portion of the spine consists of cylindrical vertebral bodies separated by intervertebral disks and held together by the anterior and posterior longitudinal ligaments. The intervertebral disks are composed of a central gelatinous nucleus pulposus surrounded by a tough cartilaginous ring, the annulus fibrosis; disks are responsible for 25% of spinal column length (Figs. 15-1 and 15-2). The disks are largest in the cervical and lumbar regions where movements of the spine are greatest. The disks are elastic in youth and allow the bony vertebrae to move easily upon each other. Elasticity is lost with age. The function of the anterior spine is to absorb the shock of body movements such as walking and running.

The posterior portion of the spine consists of the vertebral arches and seven processes. Each arch consists of paired cylindrical pedicles anteriorly and paired laminae posteriorly. The vertebral arch gives rise to two transverse processes laterally, one spinous process posteriorly, plus two superior and two inferior articular facets. The functions of the posterior spine are to protect the spinal cord and nerves within the spinal canal and to stabilize the spine by providing sites for the attachment of muscles and ligaments. The contraction of muscles attached to the spinous and transverse processes produces a system of pulleys and levers that results in flexion, extension, and lateral bending movements of the spine.

Nerve root injury (radiculopathy) is a common cause of neck, arm, low back, and leg pain. The nerve roots exit at a level above their respective vertebral bodies in the cervical region (the C7 nerve root exits at the C6-C7 level) and below their respective vertebral bodies in the thoracic and lumbar regions (the T1 nerve root exits at the T1-T2 level). The cervical nerve roots follow a relatively short intraspinal course before exiting. By contrast, because the spinal cord ends at the vertebral L1 or L2 level, the lumbar nerve roots follow a long intraspinal course and can be injured anywhere from the upper lumbar spine to their exit at the intervertebral foramen. For example, it is common for disk herniation at the L4-L5 level to produce compression of the S1 nerve root (Fig. 15-3).

Pain-sensitive structures in the spine include the periosteum of the vertebrae, dura, facet joints, annulus fibrosus of the intervertebral disk, epidural veins, and the posterior longitudinal ligament. The nucleus pulposus of the intervertebral disk is not pain-sensitive under normal circumstances. Pain sensation is conveyed by the sinuvertebral nerve that arises from the spinal nerve at each spine segment and reenters the spinal canal through the intervertebral foramen at the same level. Disease of these diverse pain-sensitive spine structures may explain many cases of back pain without nerve root compression. The lumbar and cervical spine possess the greatest potential for movement and injury.

FURTHER READING

GOADSBY PJ: Serotonin 5-HT 1B/1D receptor agonists in migraine. CNS Drugs 10:271, 1998
LODER E: Safety of sumatriptan in pregnancy. CNS Drugs 17:1, 2003

APPROACH TO THE PATIENT

Types of Back Pain Understanding the type of pain experienced by the patient is the essential first step. Attention is also focused on identification of risk factors for serious underlying diseases.

Local pain is caused by stretching of pain-sensitive structures that compress or irritate sensory nerve endings. The site of the pain is near the affected part of the back.

Pain referred to the back may arise from abdominal or pelvic viscera. The pain is usually described as primarily abdominal or pelvic but is accompanied by back pain and usually unaffected by posture. The patient may occasionally complain of back pain only.

Pain of spine origin may be located in the back or referred to the buttocks or legs. Diseases affecting the upper lumbar spine tend to refer pain to the lumbar region, groin, or anterior thighs. Diseases affecting the lower lumbar spine tend to produce pain referred to the buttocks, posterior thighs, or rarely the calves or feet. Provocative injections into the pain-sensitive structures of the spine may produce leg pain that does not follow a dermatomal distribution. This “sclerotomal” pain may explain instances in which back and leg pain is unaccompanied by evidence of nerve root compression.

Radicular back pain is typically sharp and radiates from the spine to the leg within the territory of a nerve root (see “Lumbar Disk Disease,” below). Coughing, sneezing, or voluntary contraction of abdominal muscles (lifting heavy objects or other activity) may elicit pain in the pain-sensitive structures of the spine. Lumbar radiculopathy is a common cause of neck, arm, low back, and leg pain. Nerve roots exit at a level above their respective vertebral bodies in the cervical region (the C7 nerve root exits at the C6-C7 level) and below their respective vertebral bodies in the thoracic and lumbar regions (the T1 nerve root exits at the T1-T2 level). The cervical nerve roots follow a relatively short intraspinal course before exiting. By contrast, because the spinal cord ends at the vertebral L1 or L2 level, the lumbar nerve roots follow a long intraspinal course and can be injured anywhere from the upper lumbar spine to their exit at the intervertebral foramen. For example, it is common for disk herniation at the L4-L5 level to produce compression of the S1 nerve root (Fig. 15-3).

Pain-sensitive structures in the spine include the periosteum of the vertebrae, dura, facet joints, annulus fibrosus of the intervertebral disk, epidural veins, and the posterior longitudinal ligament. The nucleus pulposus of the intervertebral disk is not pain-sensitive under normal circumstances. Pain sensation is conveyed by the sinuvertebral nerve that arises from the spinal nerve at each spine segment and reenters the spinal canal through the intervertebral foramen at the same level. Disease of these diverse pain-sensitive spine structures may explain many cases of back pain without nerve root compression. The lumbar and cervical spine possess the greatest potential for movement and injury.
Straining at stool may elicit the radiating pain. The pain may increase in postures that stretch the nerves and nerve roots. Sitting stretches the sciatic nerve (L5 and S1 roots) because the nerve passes posterior to the hip. The femoral nerve (L2, L3, and L4 roots) passes anterior to the hip and is not stretched by sitting. The description of the pain alone often fails to distinguish clearly between sclerotomal pain and radiculopathy.

Pain associated with muscle spasm, although of obscure origin, is commonly associated with many spine disorders. The spasms are accompanied by abnormal posture, taut paraspinal muscles, and dull pain.

Back pain at rest or unassociated with specific postures should raise the index of suspicion for an underlying serious cause (e.g., spine tumor, fracture, infection, or referred pain from visceral structures). Knowledge of the circumstances associated with the onset of back pain is important when weighing possible serious underlying causes for the pain. Some patients involved in accidents or work-related injuries may exaggerate their pain for the purpose of compensation or for psychological reasons.

Examination of the Back A physical examination that includes the abdomen and rectum is advisable. Back pain referred from visceral organs may be reproduced during palpation of the abdomen [pancreatitis, abdominal aortic aneurysm (AAA)] or percussion over the costovertebral angles (pyelonephritis, adrenal disease).

The normal spine has a thoracic kyphosis, lumbar lordosis, and cervical lordosis. Exaggeration of these normal alignments may result in hyperkyphosis (lameback) of the thoracic spine or hyperlordosis (swayback) of the lumbar spine. Spasm of lumbar paraspinal muscles results in flattening of the usual lumbar lordosis. Inspection may reveal lateral curvature of the spine (scoliosis) or an asymmetry in the paraspinal muscles, suggesting muscle spasm. Taut paraspinal muscles limit motion of the lumbar spine. Back pain of bony spine origin is often reproduced by palpation or percussion over the spinous process of the affected vertebrae.

Forward bending is frequently limited by paraspinal muscle spasm. Flexion of the hips is normal in patients with lumbar spine disease, but flexion of the lumbar spine is limited and sometimes painful. Lateral bending to the side opposite the injured spinal element may stretch the damaged tissues, worsen pain, and limit motion. Hyperextension of the spine (with the patient prone or standing) is limited when nerve root compression or bony spine disease is present.

Pain from hip disease may resemble the pain of lumbar spine disease. Hip pain can be reproduced by internal and external rotation at the hip with the knee and hip in flexion (Patrick sign) and by tapping the heel with the examiner’s palm while the leg is extended.

With the patient lying flat, passive flexion of the extended leg at the hip stretches the L5 and S1 nerve roots and the sciatic nerve. Passive dorsiflexion of the foot during the maneuver adds to the stretch. While flexion to at least 80° is normally possible without causing pain, tight hamstrings may be a source of pain in some patients. The straight leg–raising (SLR) test is positive if the maneuver reproduces the patient’s usual back or limb pain. Eliciting the SLR sign in the sitting position may help determine if the finding is reproducible. The patient may describe pain in the low back, buttocks, posterior thigh, or lower leg, but the key feature is reproduction of the patient’s usual pain. The crossed SLR sign is positive when flexion of one leg reproduces the pain in the opposite leg or buttocks. The crossed SLR sign is less sensitive but more specific for disk herniation than the SLR sign. The nerve or nerve root lesion is always on the side of the pain. The reverse SLR sign is elicited by standing the patient next to the examination table and passively extending each leg. This maneuver, which stretches the L2-L4 nerve roots and the femoral nerve, is considered positive if the patient’s usual back or limb pain is reproduced.

The neurologic examination includes a search for weakness, muscle atrophy, focal reflex changes, diminished sensation in the legs, and signs of spinal cord injury. The examiner should be alert to the possibility of breakaway weakness, defined as fluctuating levels of strength in one or more muscle groups on examination. The weakness may be due to pain or a combination of pain and underlying true weakness. Breakaway weakness without pain is due to lack of effort. In uncertain cases, electromyography (EMG) can determine whether or not true weakness is present. Findings with specific nerve root lesions are shown in Table 15-1 and are discussed below.

**Laboratory, Imaging, and EMG Studies** Routine laboratory studies such as a complete blood count, erythrocyte sedimentation rate, chem-
**TABLE 15-1** Lumbosacral Radiculopathy—Neurologic Features

<table>
<thead>
<tr>
<th>Nerve Roots</th>
<th>Reflex</th>
<th>Examination Findings</th>
<th>Pain Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>L2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>L3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>L4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Quadriceps (knee)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>L5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>S1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Gastrocnemius/soleus (ankle)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Reverse straight leg-raising sign present—see “Examination of the Back.”
*These muscles receive the majority of innervation from this root.
*Straight leg-raising sign present—see “Examination of the Back.”

**TABLE 15-2** Causes of Low Back and Neck Pain

<table>
<thead>
<tr>
<th>Cause</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital/developmental</td>
<td>Spondylolisthesis and spondylosis&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kyphoscoliosis&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Spina bifida occulta&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tethered spinal cord&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Minor trauma</td>
</tr>
<tr>
<td>Fractures</td>
<td>Minor trauma</td>
</tr>
<tr>
<td>Minor trauma</td>
<td>Strain or sprain</td>
</tr>
<tr>
<td>Whiplash injury&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Intervertebral disk herniation</td>
</tr>
<tr>
<td>Degenerative</td>
<td>Disk-osteophyte complex</td>
</tr>
<tr>
<td>Spinal stenosis with neurogenic claudication&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Internal disk disruption</td>
</tr>
<tr>
<td>Uncooperative joint disease&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Spinal stenosis with neurogenic claudication&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Atlantoaxial joint disease</td>
<td>Atlantoaxial joint disease (e.g., rheumatoid arthritis)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Arthritis</td>
<td>Spondylosis</td>
</tr>
<tr>
<td>Facet or sacroiliac arthropathy</td>
<td>Spondylosis</td>
</tr>
<tr>
<td>Autoimmune (e.g., ankylosing spondylitis, Reiter’s syndrome)</td>
<td>Autoimmune (e.g., ankylosing spondylitis, Reiter’s syndrome)</td>
</tr>
<tr>
<td>Neoplasms—metastatic, hematologic, primary bone tumors</td>
<td>Neoplasms—metastatic, hematologic, primary bone tumors</td>
</tr>
<tr>
<td>Infection/inflammation</td>
<td>Infection/inflammation</td>
</tr>
<tr>
<td>Vertebral osteomyelitis</td>
<td>Vertebral osteomyelitis</td>
</tr>
<tr>
<td>Spinal epidural abscess</td>
<td>Spinal epidural abscess</td>
</tr>
<tr>
<td>Septic disk</td>
<td>Septic disk</td>
</tr>
<tr>
<td>Meningitis</td>
<td>Meningitis</td>
</tr>
<tr>
<td>Lumbar arachnoiditis&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Lumbar arachnoiditis&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Osteoporosis—hyperparathyroidism, immobility</td>
</tr>
<tr>
<td>Osteosclerosis (e.g., Paget’s disease)</td>
<td>Osteosclerosis (e.g., Paget’s disease)</td>
</tr>
</tbody>
</table>

*Low back pain only.
*Neck pain only.

CAUSES OF BACK PAIN (Table 15-2)

**CONGENITAL ANOMALIES OF THE LUMBAR SPINE*** Spondylolisthesis is a bony defect in the pars interarticularis (a segment near the junction of the pedicle with the lamina) of the vertebra; the etiology may be a stress fracture in a congenitally abnormal segment. The defect (usually bilateral) is best visualized on oblique projections in plain x-rays or by CT scan and occurs in the setting of a single injury, repeated minor injuries, or growth.

Spondyloolisthesis is the anterior slippage of the vertebral body, ped-}

icles, and superior articular facets, leaving the posterior elements behind. Spondylolisthesis is associated with spondylosis and degenerative spine disease and occurs more frequently in women. The slippage may be asymptomatic, but may also cause low back pain, nerve root injury (the L5 root most frequently), or symptomatic spinal stenosis. Tenderness may be elicited near the segment that has “slipped” forward (most often L4 on L5 or occasionally L5 on S1). A “step” may be present on deep palpation of the posterior elements of the segment above the spondylolisthetic joint. The trunk may be shortened and the abdomen protruberant as a result of extreme forward displacement of L4 on L5; in severe cases cauda equina syndrome (CES) may occur (see below).

Spina bifida occulta is a failure of closure of one or several vertebral arches posteriorly; the meninges and spinal cord are normal. A dimple or small lipoma may overlie the defect. Most cases are asymptomatic and discovered incidentally during evaluation for back pain.

**Tethered cord syndrome** usually presents as a progressive cauda
equine disorder (see below), although myelopathy may also be the initial manifestation. The patient is often a young adult who complains of perineal or perianal pain, sometimes following minor trauma. Neuroimaging studies reveal a low-lying conus (below L1-L2) and a short and thickened filum terminale.

**TRAUMA** A patient complaining of back pain and inability to move the legs may have a spinal fracture or dislocation and, with fractures above L1, spinal cord compression. Care must be taken to avoid further damage to the spinal cord or nerve roots by immobilizing the back pending results of x-rays.

**Sprains and Strains** The terms low back sprain, strain, or mechanically induced muscle spasm refer to minor, self-limited injuries associated with lifting a heavy object, a fall, or a sudden deceleration such as in an automobile accident. These terms are used loosely and do not clearly describe a specific anatomic lesion. The pain is usually confined to the lower back, and there is no radiation to the buttocks or legs. Patients with paraspinal muscle spasm often assume unusual postures.

**Traumatic Vertebral Fractures** Most traumatic fractures of the lumbar vertebral bodies result from injuries producing anterior wedging or compression. With severe trauma, the patient may sustain a fracture-dislocation or a “burst” fracture involving the vertebral body and posterior elements. Traumatic vertebral fractures are caused by falls from a height (a pars interarticularis fracture of the L5 vertebra is common), sudden deceleration in an automobile accident, or direct injury. Neurolologic impairment is common, and early surgical treatment is indicated.

**LUMBAR DISK DISEASE** This is a common cause of chronic or recurrent low back and leg pain (Fig. 15-4). Disk disease is most likely to occur at the L4-L5 and L5-S1 levels, but upper lumbar levels are involved occasionally. The cause is often unknown; the risk is increased in overweight individuals. Disk herniation is unusual prior to age 20 and is rare in the fibrotic disks of the elderly. Degeneration of the nucleus pulposus and the annulus fibrosus increases with age and may be asymptomatic or painful. The pain may be located in the low back only or referred to the leg, buttock, or hip. A sneeze, cough, or trivial movement may cause the nucleus pulposus to prolapse, pushing the frayed and weakened annulus posteriorly. With severe disk disease, the nucleus may protrude through the annulus (herniation) or become extruded to lie as a free fragment in the spinal canal.

The mechanism by which intervertebral disk injury causes back pain is controversial. The inner annulus fibrosus and nucleus pulposus are normally devoid of innervation. Inflammation and production of proinflammatory cytokines within the protruding or ruptured disk may trigger or perpetuate back pain. Ingrowth of nociceptive (pain) nerve fibers into inner portions of a diseased disk may be responsible for chronic “diskogenic” pain. Nerve root injury (radiculopathy) from disk herniation may be due to compression, inflammation, or both: pathologically, demyelination and axonal loss are usually present. Symptoms of a ruptured disk include back pain, abnormal posture, limitation of spine motion (particularly flexion), or radicular pain. A dermatomal pattern of sensory loss or a reduced or absent deep tendon reflex is more suggestive of a specific root lesion than the pattern of pain. Motor findings (focal weakness, muscle atrophy, or fasciculations) occur less frequently than sensory or reflex changes. Symptoms and signs are usually unilateral, but bilateral involvement does occur with large central disk herniations that compress several nerve roots at the same level. Clinical manifestations of specific nerve root lesions are summarized in Table 15-1. There is evidence to suggest that lumbar disk herniation with a nonprogressive nerve root deficit can be managed nonsurgically. The size of the disk protrusion may naturally decrease over time.

The differential diagnosis includes a variety of serious and treatable conditions, including epidural abscess, hemotoma, or tumor. Fever, constant pain uninfluenced by position, sphincter abnormalities, or signs of spinal cord disease suggest an etiology other than lumbar disk disease. Bilateral absence of ankle reflexes can be a normal finding in old age or a sign of bilateral S1 radiculopathy. An absent deep tendon reflex or focal sensory loss may reflect injury to a nerve root, but other sites of injury along the nerve must also be considered. For example, an absent knee reflex may be due to a femoral neuropathy rather than an L4 nerve root injury. A loss of sensation over the foot and distal lateral calf may result from a peroneal or lateral sciatic neuropathy rather than an L5 nerve root injury. Focal muscle atrophy may reflect a nerve root or peripheral nerve injury, an anterior horn cell disease, or disuse.

An MRI scan or CT-myelogram is necessary to establish the location and type of pathology. Simple MRI yields exquisite views of intraspinal and adjacent soft tissue anatomy. Bony lesions of the lateral recess or intervertebral foramen may be seen with optimal clarity on CT-myelographic studies. The correlation of neuroradiologic findings to symptoms, particularly pain, is not simple. Contrast-enhancing tears in the annulus fibrosus or disk protrusions are widely accepted as common sources of back pain; however, one study found that over half of asymptomatic adults have similar findings. Asymptomatic disk protrusions are also common, and these abnormalities may enhance with contrast. Furthermore, in patients with known disk herniation treated either medically or surgically, persistence of the herniation 10 years later had no relationship to the clinical outcome. MRI findings of disk protrusion, tears in the annulus fibrosus, or contrast enhancement are common incidental findings that by themselves should not dictate management decisions for patients with back pain.

There are four indications for intervertebral disk surgery: (1) progressive motor weakness from nerve root injury demonstrated on clinical examination or EMG, (2) bowel or bladder disturbance or other signs of spinal cord compression, (3) incapacitating nerve root pain despite conservative treatment for at least 4 weeks, and (4) recurrent incapacitating pain despite conservative treatment. The latter two criteria are more subjective and less well established than the others. Surgical treatment should also be considered if the pain and/or neurologic findings do not substantially improve over 4 to 12 weeks.

The usual surgical procedure is a partial hemilaminectomy with excision of the prolapsed disk. Fusion of the involved lumbar segments is considered only if significant spinal instability is present (i.e., degenerative spondylolisthesis or isthmic spondylolysis).

**CES** is an injury of multiple lumbosacral nerve roots within the spinal canal. Low back pain, weakness and areflexia in the lower ex-
tremities, saddle anesthesia, and loss of bladder function may occur. The problem must be distinguished from disorders of the lower spinal cord (conus medullaris syndrome), acute transverse myelitis (Chap. 356), and Guillain-Barré syndrome (Chap. 365). Combined involvement of the conus medullaris and cauda equina can occur. CES is commonly due to a ruptured lumbosacral intervertebral disk, lumbosacral spine fracture, hematoma within the spinal canal (e.g., following lumbar puncture in patients with coagulopathy), compressive tumors, or other mass lesions. Treatment options include surgical decompression, sometimes urgently in an attempt to restore or preserve motor or sphincter function, or palliative radiotherapy or chemotherapy for metastatic tumors.

**DEGENERATIVE CONDITIONS** Lumbar spinal stenosis describes a narrowed lumbar spinal canal. When severe, neurogenic claudication, consisting of back and buttock or leg pain induced by walking or standing and relieved by sitting, can occur. Symptoms in the legs are usually bilateral. Unlike vascular claudication, symptoms are often provoked by standing without walking. Unlike lumbar disk disease, symptoms are usually relieved by sitting. Focal weakness, sensory loss, or reflex changes may occur when spinal stenosis is associated with radiculopathy. Severe neurologic deficits, including paralysis and urinary incontinence, occur rarely. Spinal stenosis can be acquired (75%), congenital, or due to a combination of the two causes. Congenital forms (achondroplasia, idiopathic) are characterized by short, thick pedicles that produce both spinal canal and lateral recess stenosis. Acquired factors that may contribute to spinal stenosis include degenerative diseases (spondylolisthesis, scoliosis), trauma, spine surgery (post laminectomy, fusion), metabolic or endocrine disorders (epidural lipomatosis, osteoporosis, acromegaly, renal osteodystrophy, hypoparathyroidism), and Paget’s disease. MRI or CT-myelography provide the best definition of the abnormal anatomy (Fig. 15-5).

Conservative treatment of symptomatic spinal stenosis includes nonsteroidal anti-inflammatory drugs (NSAIDs), exercise programs, and symptomatic treatment of acute pain exacerbations. Surgical therapy is considered when medical therapy does not relieve pain sufficiently to allow for activities of daily living or when significant focal neurologic signs are present. Between 65 and 80% of properly selected patients treated surgically experience 75% relief of back and leg pain. Up to 25% develop recurrent stenosis at the same spinal level or an adjacent level 5 years after the initial surgery; recurrent symptoms usually respond to a second surgical decompression.

Facet joint hypertrophy can produce unilateral radicular symptoms or signs due to bony compression, that are indistinguishable from disk-related radiculopathy. Patients may exhibit stretch signs, focal motor weakness, hyporeflexia, or dermatomal sensory loss. Hypertrophic superior or inferior facets can often be visualized radiologically. Foraminotomy results in long-term relief of leg and back pain in 80 to 90% of patients.

**ARTHITIS** Spondylosis, or osteoarthritic spine disease, typically occurs in later life and primarily involves the cervical and lumbosacral spine. Patients often complain of back pain that is increased by motion and associated with stiffness or limitation of motion. The relationship between clinical symptoms and radiologic findings is usually not straightforward. Pain may be prominent when x-ray findings are minimal; alternatively, large osteophytes can be seen in asymptomatic patients in middle and later life. Hypertrophied facets and osteophytes may compress nerve roots in the lateral recess or intervertebral foramen. Osteophytes arising from the vertebral body may cause or contribute to central spinal canal stenosis. Loss of intervertebral disk height reduces the vertical dimensions of the intervertebral foramen; the descending pedicle may compress the nerve root exiting at that level. Rarely, osteoarthritic changes in the lumbar spine compress the cauda equina.

**Ankylosing Spondylitis** (See also Chap. 305) This distinctive arthritic spine disease typically presents with the insidious onset of low back and buttock pain. Patients are often males below age 40. Associated features include morning back stiffness, nocturnal pain, pain unrelied by rest, an elevated sedimentation rate, and the histocompatibility antigen HLA-B27. Onset at a young age and back pain improving with exercise is characteristic. Loss of the normal lumbar lordosis and exaggeration of thoracic kyphosis are seen as the disease progresses. Inflammation and erosion of the outer fibers of the annulus fibrosus at the point of contact with the vertebral body are followed by ossification and bony growth that bridges adjacent vertebral bodies and reduces spine mobility in all planes. Radiologic hallmarks are periarticular destructive changes, sclerosis of the sacroiliac joints, and bridging of vertebral bodies to produce the fused “bamboo spine.” Similar restricted movements may accompany Reiter’s syndrome, psoriatic arthritis, and chronic inflammatory bowel disease. Stress fractures through the spontaneously ankylosed posterior bony elements of the rigid, osteoporotic spine may produce focal pain, spinal cord compression, or CES. Atlantoaxial subluxation with spinal cord compression occasionally occurs. Ankylosis of the ribs to the spine and a decrease in the height of the thoracic spine may compromise respiratory function.

**NEOPLASMS** (See also Chap. 358) Back pain is the most common neurologic symptom in patients with systemic cancer and is usually due to vertebral metastases. Metastatic carcinoma (breast, lung, prostate, thyroid, kidney, gastrointestinal tract), multiple myeloma, and non-Hodgkin’s and Hodgkin’s lymphomas frequently involve the spine. Back pain may be the presenting symptom. The pain tends to be constant, dull, unrelieved by rest, and worse at night. In contrast, mechanical low back pain usually improves with rest. Plain x-rays usually, but not always, show destructive lesions in one or several vertebral bodies without disk space involvement. MRI or CT-myelography are the studies of choice when spinal metastasis is suspected. MRI is usually preferred, but the procedure of choice is the study most rapidly available because the patient’s condition may worsen quickly.

**INFECTIONS/INFLAMMATION** *Vertebral osteomyelitis* is usually caused by staphylococci, but other bacteria or the tubercle bacillus (Pott’s disease) may be responsible. A primary source of infection, most often the urinary tract, skin, or lungs, can be identified in 40% of patients. Intravenous drug use is a well-recognized risk factor. Back pain exacerbated by motion and unrelieved by rest, spine tenderness over the involved spine segment, and an elevated erythrocyte sedimentation rate are the most common findings. Fever or an elevated white blood cell count are found in a minority of patients. Plain radiographs may show narrowed disk space with erosion of adjacent vertebrae; however, these diagnostic changes may take weeks or months to appear. MRI and CT are sensitive and specific for osteomyelitis; CT may be
Spinal epidural abscess (Chap. 356) presents with back pain (aggravated by movement or palpation) and fever. Signs of nerve root injury or spinal cord compression may be present. The abscess may track over multiple spinal levels and is best delineated by spine MRI. Lumbar adhesive arachnoiditis with radiculopathy is due to fibrosis following inflammation within the subarachnoid space. The fibrosis results in nerve root adhesions, producing back and leg pain associated with motor, sensory, or reflex changes. Myelography-induced arachnoiditis has become rare with the abandonment of oil-based contrast. Other causes of arachnoiditis include multiple lumbar operations, chronic spinal infections, spinal cord injury, intrathecal hemorrhage, intrathecal injection of glucocorticoids or anesthetics, and foreign bodies. The MRI may show nerve roots that clump together centrally and adhere to the dura peripherally, or loculations of cerebrospinal fluid within the thecal sac. Treatment is often unsatisfactory. Microsurgical lysis of adhesions, dorsal rhizotomy, and dorsal root ganglionectomy have resulted in poor outcomes. Dorsal column stimulation for pain relief has produced varying results. Epidural injections of glucocorticoids have been of limited value.

**METABOLIC CAUSES**

**Osteoporosis and Osteosclerosis** Immobilization or underlying systemic disorders such as osteomalacia, hyperparathyroidism, hyperthyroidism, multiple myeloma, metastatic carcinoma, or glucocorticoid use may accelerate osteoporosis and weaken the vertebral body. The most common cause of traumatic vertebral fractures is postmenopausal (type 1) or senile (type 2) osteoporosis (Chap. 333). Compression fractures occur in up to half of patients with severe osteoporosis, and those who sustain a fracture have a 4.5-fold increased risk for recurrence. The sole manifestation of a compression fracture may be localized aching (often after a trivial injury) that is exacerbated by movement. Other patients experience radicular pain only. Focal tenderness to palpation is common. The clinical context, neurologic signs, and x-ray appearance of the spine establish the diagnosis. When compression fractures are found, treatable risk factors should be sought. Antiresorptive drugs including bisphosphonates (e.g., alendronate), transdermal estrogen, and tamoxifen have been shown to reduce the risk of osteoporotic fractures. Compression fractures above the midthoracic region suggest malignancy; if tumor is suspected, a bone biopsy or diagnostic search for a primary tumor is indicated.

Interventions [percutaneous vertebroplasty (PVP), kyphoplasty] exist for osteoporotic compression fractures associated with debilitating pain. Candidates for PVP should have midline pain, focal tenderness over the spinous process of the affected vertebral body, <80% loss of vertebral body height, and onset of symptoms within the prior 4 months. The technique consists of injection of polymethylmethacrylate, under fluoroscopic guidance, into the affected vertebral body. Rare major complications include extravasation of cement into the epidural space (resulting in myelopathy) or fatal pulmonary embolism from migration of cement into paraspinal veins. Approximately three-quarters of patients who meet selection criteria have reported enhanced quality of life. Relief of pain following PVP has also been reported in patients with vertebral metastases, myeloma, or hemangiomas.

Osteosclerosis (abnormally increased bone density) is readily identifiable on routine x-ray studies (e.g., Paget’s disease) and may or may not produce back pain. Spinal cord or nerve root compression may result from bony encroachment on the spinal canal or intervertebral foramina. Single dual-beam photon absorptiometry or quantitative CT can be used to detect small changes in bone mineral density. —For further discussion of these bone disorders, see Chap. 332–334.

**REFERRED PAIN FROM VISCERAL DISEASE** Diseases of the thorax, abdomen, or pelvis may refer pain to the posterior portion of the spinal segment that innervates the diseased organ. Occasionally, back pain may be the first and only sign. Upper abdominal or pelvic visceral structures generally refer pain to the lower thoracic or upper lumbar region (eighth thoracic to the first and second lumbar vertebrae), lower abdominal diseases to the lumbar region (second to fourth lumbar vertebrae), and pelvic diseases to the sacral region. Local signs (pain with spine palpation, paraspinal muscle spasm) are absent, and minimal or no pain accompanies normal spine movements.

**Low Thoracic or Lumbar Pain with Abdominal Disease** Peptic ulcers or tumors of the posterior wall of the stomach or duodenum typically produce epigastric pain (Chaps. 77 and 274), but midline back or paraspinal pain may occur if retroperitoneal extension is present. Back pain due to peptic ulcer may be precipitated by ingestion of an orange, alcohol, or coffee and relieved by food or antacids. Fatty foods are more likely to induce back pain associated with biliary disease. Diseases of the pancreas produce back pain to the right of the spine (head of the pancreas involved) or to the left (body or tail involved). Pathology in retroperitoneal structures (hemorrhage, tumors, pylonephritis) produces paraspinal pain that radiates to the lower abdomen, groin, or anterior thighs. A mass in the iliohypogastric region often produces unilateral lumbar pain with radiation toward the groin, labia, or testicles. The sudden appearance of lumbar pain in a patient receiving anticoagulants suggests retroperitoneal hemorrhage.

Isolated low back pain occurs in 15 to 20% of patients with a contained rupture of an abdominal aortic aneurysm (AAA). The classic clinical triad of abdominal pain, shock, and back pain in an elderly man occurs in <20% of patients. Two of these three features are present in two-thirds of patients, and hypotension is present in half. The typical patient is an elderly male smoker with back pain. The diagnosis is initially missed in at least one-third of patients because the symptoms and signs can be nonspecific. Common misdiagnoses include nonspecific back pain, diverticulitis, renal colic, sepsis, and myocardial infarction. A careful abdominal examination revealing a pulsatile mass (present in 50 to 75% of patients) is an important physical finding. Patients with suspected AAA should be evaluated with ultrasound, CT, or MRI (Chap. 231).

Inflammatory bowel disorders (colitis, diverticulitis) or cancers of the colon may produce lower abdominal pain, midlumbar back pain, or both. The pain may have a bell-like distribution around the body. A lesion in the transverse or proximal descending colon may refer pain to the middle or left back at the L2-L3 level. Lesions of the sigmoid colon may refer pain to the upper sacral or midline suprapubic regions or left lower quadrant of the abdomen.

**Sacral Pain with Gynecologic and Urologic Disease** Pelvic organs rarely cause low back pain, except for gynecologic disorders involving the uterosacral ligaments. The pain is referred to the sacral region. Endometriosis or cancers of the uterus may invade the uterosacral ligaments; malposition of the uterus may cause uterosacral ligament traction. Pain associated with endometriosis is typically premenstrual and often continues until it merges with menstrual pain. Malposition of the uterus (retroversion, descensus, and prolapse) may produce sacral pain after prolonged standing.

Menstrual pain may be felt in the sacral region. The poorly localized, cramping pain can radiate down the legs. Pain due to neoplastic infiltration of nerves is typically continuous, progressive in severity, and unrelied by rest at night. Less commonly, radiation therapy of pelvic tumors may produce sacral pain from late radiation necrosis of tissue or nerves. Low back pain that radiates into one or both thighs is common in the last weeks of pregnancy.

Urologic sources of lumbosacral back pain include chronic prostatitis, prostate cancer with spinal metastasis, and diseases of the kidney and ureter. Lesions of the bladder and testes do not usually produce back pain. The diagnosis of metastatic prostate carcinoma is established by rectal examination, spine imaging studies (MRI or CT), and measurement of prostate-specific antigen (Chap. 81). Infectious, inflammatory, or neoplastic renal diseases may produce ipsilateral lumbosacral pain, as can renal artery or vein thrombosis. Paraspinal lumbar pain may be a symptom of ureteral obstruction due to nephrolithiasis.
OTHER CAUSES OF BACK PAIN  ■ Postural Back Pain  There is a group of patients with nonspecific CLBP in whom no anatomic or pathologic lesion can be found despite exhaustive investigation. These individuals complain of vague, diffuse back pain with prolonged sitting or standing that is relieved by rest. The physical examination is unrevealing except for “poor posture.” Imaging studies and laboratory evaluations are normal. Exercises to strengthen the paraspinal and abdominal muscles are sometimes therapeutic.

Psychiatric Disease  CLBP may be encountered in patients who seek financial compensation, in malingerers, or in those with concurrent substance abuse, chronic anxiety states, or depression. Many patients with CLBP have a history of psychiatric illness (depression, anxiety, substance abuse) or childhood trauma (physical or sexual abuse) that antedates the onset of back pain. Preoperative psychological assessment has been used to exclude patients with marked psychological impairments; these patients are likely to have a poor surgical outcome.

Unidentified  The cause of low back pain occasionally remains unclear. Some patients have had multiple operations for disk disease but have persistent pain and disability. The original indications for surgery may have been questionable, with back pain only, no definite neurologic signs, or a minor disk bulge noted on CT or MRI. Scoring systems based upon neurologic signs, psychological factors, physiologic studies, and imaging studies have been devised to minimize the likelihood of unsuccessful surgical explorations.

TREATMENT

Acute Low Back Pain  A practical approach to the management of low back pain is to consider acute and chronic presentations separately. ALBP is defined as pain of <3 months duration. Full recovery can be expected in 85% of adults with ALBP unaccompanied by leg pain. Most have purely “mechanical” symptoms—i.e., pain that is aggravated by motion and relieved by rest.

Observational studies have been used to justify a minimalist approach to this problem. These studies share a number of limitations: (1) a true placebo control group is often lacking; (2) patients who consult different provider groups (generalists, orthopedists, neurologists) are assumed to have similar etiologies for their back pain; (3) no information is provided about the details of treatment; and (4) no attempt to tabulate serious causes of ALBP is made.

The algorithms for the treatment of back pain (Fig. 15-6) draw from published guidelines. However, since CPGs are based on incomplete evidence, guidelines should not substitute for clinical judgment.

The initial assessment excludes serious causes of spine pathology that require urgent intervention, including infection, cancer, and trauma. Risks factors for a possible serious underlying cause of back pain include: age >50 years, prior diagnosis of cancer or other serious medical illness, bed rest without relief, duration of pain >1 month, urinary incontinence or recent nocturia, focal leg weakness or numbness, pain radiating into the leg(s) from the back, intravenous drug use, chronic infection (pulmonary or urinary), pain increasing with standing and relieved by sitting, history of spine trauma, and glucocorticoid use. Worrisome signs include unexplained fever, unexplained weight loss, positive SLR sign or reverse SLR sign, crossed SLR sign, percussion tenderness over the spinous or costovertebral angle, an abdominal mass (pulsatile or nonpulsatile), a rectal mass, focal sensory loss (saddle anesthesia or focal limb sensory loss), leg weakness, spasticity, or reflex asymmetry. Laboratory studies are unnecessary unless a serious underlying cause is suspected. Plain spine films are rarely indicated in the first month of symptoms unless a spine fracture is suspected.

Clinical trials have shown no benefit of prolonged (>2 days) bed rest for uncomplicated ALBP. There is evidence that bed rest is also ineffective for patients with sciatica or for acute back pain with findings of nerve root injury. Theoretical advantages of early ambulation for ALBP include maintenance of cardiovascular conditioning, improved disk and cartilage nutrition, improved bone and muscle strength, and increased endorphin levels. A trial examining the effects of a program of early vigorous exercise was negative, but the benefits of less vigorous exercise or other exercise programs are unknown. The early resumption of normal physical activity (without heavy manual labor) is likely to be beneficial. Traction for ALBP is not effective, as shown in well-designed clinical trials that include a “sham” traction control group. Despite this knowledge, in one survey physicians identified strict bed rest for 3 days, trigger point injections (see below), and physical therapy (PT) as beneficial for ALBP. In many instances, the behavior of treating physicians does not reflect the current medical literature.

Proof is lacking to support the treatment of acute back and neck pain with acupuncture, transcutaneous electrical nerve stimulation, massage, ultrasound, diathermy, or electrical stimulation. Cervical collars can be modestly helpful by limiting spontaneous and reflex neck movements that exacerbate pain. Evidence regarding the efficacy of ice or heat is lacking, but these interventions are optional given the lack of negative evidence, low cost, and low risk. Biofeedback has not been studied rigorously. Facet joint, trigger point, and ligament injections are not recommended.

A role for modification of posture has not been validated by rigorous clinical studies. As a practical matter, temporary suspension of activity known to increase mechanical stress on the spine (heavy lifting, prolonged sitting, bending or twisting, straining at stool) may be helpful.

Education is an important part of treatment. Satisfaction and the likelihood of follow-up increase when patients are educated about prognosis, treatment methods, activity modifications, and strategies to prevent future exacerbations. In one study, patients who felt they did not receive an adequate explanation for their symptoms wanted further diagnostic tests. Evidence for the efficacy of structured education programs (“back school”) is inconclusive; in one study, patients attending back school had a shorter duration of sick leave during the initial episode but not during subsequent episodes. Randomized studies of back school for primary prevention of low back injury and pain have failed to demonstrate any benefit.

NSAIDs and acetaminophen are effective over-the-counter agents for ALBP. Muscle relaxants (cyclobenzaprine, methocarbamol) provide short-term (4 to 7 days) benefit, but drowsiness limits daytime use. Opioid analgesics are no more effective than NSAIDs or acetaminophen for initial treatment of ALBP, nor do they increase the likelihood of return to work. Short-term use of opioids in patients unresponsive to or intolerant of acetaminophen or NSAIDs may be helpful. There is no evidence to support the use of oral glucocorticoids or tricyclic antidepressants for ALBP.

Epidural glucocorticoids may occasionally produce short-term pain relief in ALBP and radiculopathy, but proof is lacking for pain relief beyond 1 month. Epidural anesthetics, glucocorticoids, or opioids are not indicated in the initial treatment of ALBP without radiculopathy. Diagnostic nerve root blocks have been advocated to determine if pain originates from a specific nerve root. However, improvement may result even when the nerve root is not responsible for the pain syndrome; this may occur with placebo effects, painful lesions located distally along the peripheral nerve, or anesthesia of the sinuvertebral nerve. Therapeutic nerve root blocks with injection of glucocorticoids and a local anesthetic is an option after conservative measures fail, particularly when temporary relief of pain is necessary.

A short course of spinal manipulation or PT for symptomatic relief of uncomplicated ALBP is an option. A prospective, randomized study comparing PT, chiropractic manipulation, and education interventions for patients with ALBP found modest trends toward benefit with both PT and chiropractic manipulation at 1 year. Costs per year were equivalent in the PT/chiropractic group and ~$280 less for the group treated with education booklet alone. The value of such treatment beyond 1 year is unknown. Similarly, the specific PT or chiropractic protocols that may provide benefit have not been fully defined.
Chronic Low Back Pain  CLBP, defined as pain lasting >12 weeks, accounts for 50% of total back pain costs. Overweight individuals appear to be at particular risk. Other risk factors include: female gender, older age, prior history of back pain, restricted spinal mobility, pain radiating into a leg, high levels of psychological distress, poor self-rated health, minimal physical activity, smoking, job dissatisfaction, and widespread pain. Combinations of these premorbid factors have been used to predict which individuals with ALBP are likely to develop CLBP.

Many conditions that produce CLBP can be identified by a combination of neuroimaging and electrophysiologic studies. Spine MRI or CT-myelography are the techniques of choice but are generally not indicated within the first month after initial evaluation in the absence of risk factors for a serious underlying cause. Imaging studies should be performed only in circumstances where the results are likely to influence surgical or medical treatment.

Diskography provides no additional anatomic information beyond what is available by MRI. Reproduction of the patient’s typical pain with the injection is often used as evidence that a specific disk is the pain generator, but it is not known whether this information has any value in selecting candidates for surgery. There is no proven role for thermography in the assessment of radiculopathy.

The diagnosis of nerve root injury is most secure when the history, examination, results of imaging studies, and the EMG are concordant. The correlation between CT and EMG for localization of nerve root injury is between 65 and 73%. Up to one-third of asymptomatic adults have a disk protrusion detected by CT or MRI scans. Thus, surgical
Neck pain, which usually arises from diseases of the cervical spine and soft tissues of the neck, is common (4.6% of adults in one study). Neck pain arising from the cervical spine is typically precipitated by movements and may be accompanied by focal tenderness and limitation of motion. Pain arising from the brachial plexus, shoulder, or peripheral nerves can be confused with cervical spine disease, but the history and examination usually identify a more distal origin for the pain. Cervical spine trauma, disk disease, or spondylosis may be asymptomatic or painful and can produce a myelopathy, radiculopathy, or both. The nerve roots most commonly affected are C7 and C6. Other causes of neck pain include whiplash injury (usually automobile accidents) causing cervical musculoligamentous strain or strain due to hyperflexion or hyperextension. This diagnosis should not be applied to patients with fractures, disk herniation, head injury, or altered consciousness. One prospective study found that 18% of patients with whiplash injury had persistent injury-related symptoms 2 years after the car accident. These patients were older, had a higher incidence of inclined or rotated head position at impact, greater intensity of initial neck and head pain, greater number of initial symptoms, and more osteoarthritic changes on cervical spine x-rays at baseline compared to patients who ultimately recovered. Severe initial symptoms are associated with a poor long-term outcome.

CERVICAL DISK DISEASE Herniation of a lower cervical disk is a common cause of neck, shoulder, arm, or hand pain. Neck pain (worse with movement), stiffness, and a limited range of motion are the usual manifestations. With nerve root compression, pain may radiate into a shoulder or arm. Extension and lateral rotation of the neck narrows the intervertebral foramen and may reproduce radicular symptoms (Spurling’s sign). In young individuals, acute nerve root compression from a ruptured cervical disk is often due to trauma. Subacute radiculopathy is less likely to be related to a specific traumatic incident and is usually due to a combination of disk disease and spondylosis. Cervical disk herniations are usually posterolateral near the lateral recess and intervertebral foramen. Typical patterns of reflex, sensory, and motor changes that accompany specific cervical nerve root lesions are summarized in Table 15-3; however, (1) overlap in function between adjacent nerve roots is common, (2) symptoms and signs may be evident in only part of the injured nerve root territory, and (3) the location of pain is the most variable of the clinical features.

CERVICAL SPONDYLOSIS Osteoarthritis of the cervical spine may produce neck pain that radiates into the back of the head, shoulders, or arms, or may be the source of headaches in the posterior occipital region (supplied by the C2-C4 nerve roots). Osteophyte formation in the lateral recess or hypertrophic facet joints may produce a monoradiculopathy (Fig. 15-7). Narrowing of the spinal canal by osteophytes, ossification of the posterior longitudinal ligament, or a large central disk may compress the cervical spinal cord. Combinations of radiculopathy and myelopathy also occur. An electrical sensation elicited by neck flexion and radiating down the spine from the neck (Lhermitte’s symptom) usually indicates involvement of the cervical or upper thoracic (T1-T2) spine. When little or no neck pain accompanies the cord compression, the diagnosis may be confused with amyotrophic lateral sclerosis (Chap. 353), multiple sclerosis (Chap. 359), spinal cord tumors, or syringomyelia (Chap. 356). The possibility of treatable cervical spondylitis must be considered even when the patient presents with leg complaints only. In other cases, an unrelated lumbar radiculopathy or polyneuropathy may mask signs of an associated cervical myelopathy. MRI or CT-myelography can define the anatomic abnormalities, and EMG and nerve conduction studies can localize and assess the severity of the nerve root injury.

OTHER CAUSES OF NECK PAIN Rheumatoid arthritis (RA) (Chap. 301) of the cervical apophyseal joints produces neck pain, stiffness, and lim-
surgical intervention is indicated. *Herpes zoster* produces acute posterior occipital or neck pain prior to the outbreak of vesicles. Neoplasms metastatic to the cervical spine, infections (osteomyelitis and epidural abscesses), and metabolic bone diseases may also be the cause of neck pain. Neck pain may also be referred from the heart with coronary artery ischemia (cervical angina syndrome).

**THORACIC OUTLET** The thoracic outlet contains the first rib, the subclavian artery and vein, the brachial plexus, the clavicle, and the lung apex. Injury to these structures may result in postural or movement-induced pain around the shoulder and supraclavicular region. *True neurogenic thoracic outlet syndrome* (TOS) results from compression of the lower trunk of the brachial plexus or ventral rami of the C8 or T1 nerve roots by an anomalous band of tissue connecting an elongate transverse process at C7 with the first rib. Signs include weakness of intrinsic muscles of the hand and diminished sensation on the palmar aspect of the fourth and fifth digits. EMG and nerve conduction studies confirm the diagnosis. Treatment consists of surgical division of the anomalous band. The weakness and wasting of intrinsic hand muscles typically does not improve, but surgery halts the insidious progression of weakness. *Arterial TOS* results from compression of the subclavian artery by a cervical rib; the compression results in poststenotic dilatation of the artery and thrombus formation. Blood pressure is reduced in the affected limb, and signs of emboli may be present in the hand; neurologic signs are absent. Ultrasound can confirm the diagnosis non-invasively. Treatment is with thrombolysis or anticoagulation (with or without embolectomy) and surgical excision of the cervical rib compressing the subclavian artery or vein. *Disputed TOS* includes a large number of patients with chronic arm and shoulder pain of unclear cause. The lack of sensitive and specific findings on physical examination or laboratory markers for this condition frequently results in diagnostic uncertainty. The role of surgery in disputed TOS is controversial. Multidisciplinary pain management is a conservative approach, although treatment is often unsuccessful.

**BRACHIAL PLEXUS AND NERVES** Pain from injury to the brachial plexus or peripheral nerves of the arm can occasionally mimic pain of cervical spine origin. Neoplastic infiltration of the lower trunk of the brachial plexus may produce shoulder pain radiating down the arm, numbness of the fourth and fifth fingers, and weakness of intrinsic hand muscles innervated by the ulnar and median nerves. Postradiation fibrosis (breast carcinoma is the most common setting) may produce similar findings, although pain is less often present. A Pancost tumor of the lung (Chap. 75) is another cause and should be considered, especially when a Horner’s syndrome is present. *Suprascapular neuropathy* may produce severe shoulder pain, weakness, and wasting of the supraspinatus and infraspinatus muscles. *Acute brachial neuritis* is often confused with radiculopathy. It consists of the acute onset of severe shoulder or scapular pain followed over days to weeks by weakness of the proximal arm and shoulder girdle muscles innervated by the upper brachial plexus. The onset is often preceded by an infection or immunization. Complete recovery occurs in 75% of patients after 2 years and in 89% after 3 years. Occasional cases of carpal tunnel syndrome produce pain and paresthesias extending into the forearm, arm, and shoulder resembling a C5 or C6 root lesion. Lesions of the radial or ulnar nerve can mimic a radiculopathy at C7 or C8, respectively. EMG and nerve conduction studies can accurately localize lesions to the nerve roots, brachial plexus, or peripheral nerves. →For further discussion of peripheral nerve disorders, see Chap. 363.

**SHOULDER** Pain from the shoulder can be difficult to distinguish from neck pain. If symptoms and signs of radiculopathy are absent, then the differential diagnosis includes mechanical shoulder pain (tendonitis, bursitis, rotator cuff tear, dislocation, adhesive capsulitis, and cuff impingement under the acromion) and referred pain (subdiaphragmatic irritation, angina, Pancost tumor). Mechanical pain is often worse at night, associated with local shoulder tenderness and aggravated by abduction, internal rotation, or extension of the arm. Pain from shoulder disease may on occasion radiate into the arm or hand, but sensory, motor, and reflex changes are absent.

**TREATMENT**

There are few well-designed clinical trials that address optimal treatment of neck pain. Symptomatic treatment can include the use of analgesic medications and/or a soft cervical collar. Current indications for cervical disk surgery are similar to those for lumbar disk surgery; because of the risk of spinal cord injury with cervical spine disease, an aggressive approach is generally indicated whenever spinal cord injury is threatened. Surgical management of cervical herniated disks usually consists of an anterior approach with discectomy followed by anterior interbody fusion. A simple posterior partial laminectomy with discectomy is an acceptable alternative approach. The risk of subsequent radiculopathy or myelopathy at cervical segments adjacent to the fusion is ~3% per year and 26% per decade. Although this risk is
sometimes portrayed as a late complication of surgery, it may also reflect the natural history of degenerative cervical spine disease. Non-progressive cervical radiculopathy (associated with a focal neurologic deficit) due to a herniated cervical disk may be treated conservatively with a high rate of success. Cervical spondylosis with bony, compressive cervical radiculopathy is generally treated with surgical decompression to forstall the progression of neurologic signs. Cervical spondyotic myelopathy is typically managed with either anterior decompresion and fusion or laminectomy. Outcomes in both surgical groups vary, but late functional deterioration occurs in 20 to 30% of patients; a prospective, controlled study comparing different surgical interventions is needed.

**FURTHER READING**


---

**Section 2 Alterations in Body Temperature**

**FEVER AND HYPERThERMIA**

Charles A. Dinarello, Jeffrey A. Gelfand

Body temperature is controlled by the hypothalamus. Neurons in both the preoptic anterior hypothalamus and the posterior hypothalamus receive two kinds of signals: one from peripheral nerves that reflect warmth/cold receptors and the other from the temperature of the blood bathing the region. These two types of signals are integrated by the thermoregulatory center of the hypothalamus to maintain normal temperature. In a neutral environment, the metabolic rate of humans consistently produces more heat than is necessary to maintain the core body temperature at 37°C.

A normal body temperature is ordinarily maintained, despite environmental variations, because the hypothalamic thermoregulatory center balances the excess heat production derived from metabolic activity in muscle and the liver with heat dissipation from the skin and lungs. According to studies of healthy individuals 18 to 40 years of age, the mean oral temperature is 36.8°C ± 0.4°C (98.2°F ± 0.7°F), with low levels at 6 A.M. and higher levels at 4 to 6 P.M. The maximum normal oral temperature is 37.2°C (98.9°F) at 6 A.M. and 37.7°C (99.9°F) at 4 P.M.; these values define the 99th percentile for healthy individuals. In light of these studies, an *A.M.* temperature of >37.2°C (>99.9°F) or a *P.M.* temperature of >37.7°C (>99.9°F) would define a fever. The normal daily temperature variation is typically 0.5°C (0.9°F). However, in some individuals recovering from a febrile illness, this daily variation can be as great as 1.0°C. During a febrile illness, diurnal variations are usually maintained but at higher levels. Daily temperature swings do not occur in patients with hyperthermia (see below). Rectal temperatures are generally 0.4°C (0.7°F) higher than oral readings. The lower oral readings are probably attributable to mouth breathing, which is a particularly important factor in patients with respiratory infections and rapid breathing. Lower esophageal temperatures closely reflect core temperature. Tympanic membrane (TM) thermometers measure radiant heat energy from the tympanic membrane and nearby ear canal and display that absolute value (unadjusted mode) or a value automatically calculated from the absolute reading on the basis of nomograms relating the radiant temperature measured to actual core temperatures obtained in clinical studies (adjusted mode). These measurements, although convenient, may be more variable than directly determined oral or rectal values. Studies in adults show that readings are lower with unadjusted-mode than with adjusted-mode TM thermometers and that unadjusted-mode TM values are 0.8°C (1.6°F) lower than rectal temperatures.

In women who menstruate, the A.M. temperature is generally lower in the 2 weeks before ovulation; it then rises by about 0.6°C (1°F) with ovulation and remains at that level until menses occur. Seasonal variation in body temperature has been described but may reflect a metabolic change and is not common. Body temperature is elevated in the postprandial state. Pregnancy and endocrinologic dysfunction also affect body temperature. The daily temperature variation appears to be fixed in early childhood; in contrast, elderly individuals can exhibit a reduced ability to develop fever, with only a modest fever even in severe infections.

**FEVER VERSUS HYPERThERMIA**

**Fever** Fever is an elevation of body temperature that exceeds the normal daily variation and occurs in conjunction with an increase in the hypothalamic set point—for example, from 37°C to 39°C. This shift of the set point from “normothermic” to febrile levels very much resembles the resetting of the home thermostat to a higher level in order to raise the ambient temperature in a room. Once the hypothalamic set point is raised, neurons in the vasomotor center are activated and vasoconstriction commences. The individual first notices vasoconstriction in the hands and feet. Shunting of blood away from the periphery to the internal organs essentially decreases heat loss from the skin, and the person feels cold. For most fevers, body temperature increases by 1° to 2°C. Shivering, which increases heat production from the muscles, may begin at this time; however, shivering is not required if heat conservation mechanisms raise blood temperature sufficiently. Heat production from the liver also increases. In humans, behavior (e.g., putting on more clothing or bedding) helps raise body temperature.

The processes of heat conservation (vasoconstriction) and heat production (shivering and increased metabolic activity) continue until the temperature of the blood bathing the hypothalamic neurons matches the new thermostat setting. Once that point is reached, the hypothalamus maintains the temperature at the febrile level by the same mechanisms of heat balance that are operative in the afebrile state. When the hypothalamic set point is again reset downward (due to either a reduction in the concentration of pyrogens or the use of antipyretics), the processes of heat loss through vasodilation and sweating are initiated. Loss of heat by sweating and vasodilation continues until the blood temperature at the hypothalamic level matches the lower setting.

A fever of >41.5°C (>106.7°F) is called *hyperpyrexia*. This extraordinarily high fever can develop in patients with severe infections but most commonly occurs in patients with central nervous system (CNS) hemorrhages. In the preantibiotic era, fever due to a variety of infectious diseases rarely exceeded 106°F, and there has been speculation that this natural “thermal ceiling” is mediated by neuropeptides functioning as central antipyretics.

In some rare cases, the hypothalamic set point is elevated as a result of local trauma, hemorrhage, tumor, or intrinsic hypothalamic malfunction. The term *hypothalamic fever* is sometimes used to describe elevated temperature caused by abnormal hypothalamic function. However, most patients with hypothalamic damage have *subnormal*, not *supranormal*, body temperatures.
SYNCOPE

Syncope is defined as transient loss of consciousness due to reduced cerebral blood flow. Syncope is associated with postural collapse and spontaneous recovery. It may occur suddenly, without warning, or may be preceded by symptoms of faintness (“presyncope”). These include lightheadedness, “dizziness” without true vertigo, a feeling of warmth, diaphoresis, nausea, and visual blurring occasionally proceeding to blindness. Presyncope symptoms vary in duration and may increase in severity until loss of consciousness occurs or may resolve prior to loss of consciousness if the cerebral ischemia is corrected. The differentiation of syncope from seizure is an important, sometimes difficult, diagnostic problem.

Syncope may be benign when it occurs as a result of normal cardiovascular reflex effects on heart rate and vascular tone, or serious when due to a life-threatening arrhythmia. Syncope may occur as a single event or may be recurrent. Recurrent, unexplained syncope, particularly in an individual with structural heart disease, is associated with a high risk of death (40% mortality within 2 years).

PATHOPHYSIOLOGY Syncope results from a sudden impairment of brain metabolism, usually brought about by hypotension with reduction of cerebral blood flow. Several mechanisms subserve circulatory adjustments to the upright posture. Approximately three-fourths of the systemic blood volume is contained in the venous bed, and any interference in venous return may lead to a reduction in cardiac output. Cerebral blood flow may still be maintained as long as systemic arterial vasoconstriction occurs, but when this adjustment fails, serious hypotension, with resultant cerebral underperfusion to less than half of normal, results in syncope. Normally, the pooling of blood in the lower parts of the body is prevented by (1) pressor reflexes that induce constriction of peripheral arterioles and venules, (2) reflex acceleration of the heart by means of aortic and carotid reflexes, and (3) improvement of venous return to the heart by activity of the muscles of the limbs. Tilting a normal person upright on a tilt table causes some blood to accumulate in the lower limbs and diminishes cardiac output slightly; this may be followed by a slight transitory fall in systolic blood pressure. In a patient with defective vasomotor reflexes, however, tilt table testing may produce an abrupt and sustained fall in blood pressure, precipitating a faint.

CAUSES OF SYNCOPE Transiently decreased cerebral blood flow is usually due to one of three general mechanisms: disorders of vascular tone or blood volume, cardiovascular disorders including cardiac arrhythmias, or cerebrovascular disease (Table 20-1). Not infrequently, however, the cause of syncope is multifactorial.

Disorders of Vascular Tone or Blood Volume Disorders of autonomic control of the heart and circulation share common pathophysiologic mechanisms: a cardioinhibitory component (e.g., bradycardia due to increased vagal activity), a vasodepressor component (e.g., inappropriate vasodilatation due to sympathetic withdrawal), or both.

NEUROCARDIOGENIC (VASOVAGAL AND VASODEPRESSOR) SYNCOPE The term neurocardiogenic is generally used to encompass both vasovagal and vasodepressor syncope. Strictly speaking, vasovagal syncope is associated with both sympathetic withdrawal (vasodilatation) and increased parasympathetic activity (bradycardia), whereas vasodepressor syncope is associated with sympathetic withdrawal alone.

These forms of syncope are the common faint that may be experienced by normal persons and account for approximately half of all episodes of syncope. Neurocardiogenic syncope is frequently recurrent and commonly precipitated by a hot or crowded environment, alcohol, extreme fatigue, severe pain, hunger, prolonged standing, and emotional or stressful situations. Episodes are often preceded by a presyncopal prodrome lasting seconds to minutes, and rarely occur in the supine position. The individual is usually sitting or standing and experiences weakness, nausea, diaphoresis, lightheadedness, blurred vision, and often a forceful heart beat with tachycardia followed by cardiac slowing and decreasing blood pressure prior to loss of consciousness. The individual appears pale or ashen; in dark-skinned individuals, the pallor may only be notable in the conjunctivae and lips. Patients with a gradual onset of presyncopal symptoms have time to
protect themselves against injury; in others, syncope occurs suddenly, without warning.

The depth and duration of unconsciousness vary. Sometimes the patient remains partly aware of the surroundings, or there may be complete unresponsiveness. The unconscious patient usually lies motionless with skeletal muscles relaxed, but a few clonic jerks of the limbs and face may occur. Sphincter control is usually maintained, in contrast to a seizure. The pulse may be feeble or apparently absent, the blood pressure low or undetectable, and breathing may be almost imperceptible. The duration of unconsciousness is rarely longer than a few minutes if the conditions that provoke the episode are reversed. Once the patient is placed in a horizontal position, the strength of the pulse improves, color begins to return to the face, breathing becomes quicker and deeper, and consciousness is restored. Some patients may experience a sense of residual weakness after regaining consciousness, and rising too soon may precipitate another faint. Unconsciousness may be prolonged if an individual remains upright, thus it is essential that individuals with vasovagal syncope assume a recumbent position as soon as possible. Although commonly benign, neurocardiogenic syncope can be associated with prolonged asystole and hypotension, resulting in injury.

The syncope often occurs in this setting of increased peripheral sympathetic activity and venous pooling. Under these conditions, vigorous myocardial contraction of a relatively empty left ventricle activates myocardial mechanoreceptors and vagal afferent nerve fibers that inhibit sympathetic activity and increase parasympathetic activity. The resultant vasodilatation and bradycardia induce hypotension and syncope. Although the reflex involving myocardial mechanoreceptors is the mechanism usually accepted as responsible for neurocardiogenic syncope, other reflexes may also be operative. Patients with transplanted (denervated) hearts have experienced cardiovascular responses identical to those present during neurocardiogenic syncope. This should not be possible if the response depends solely on the reflex mechanisms described above, unless the transplanted heart has become reinnervated. Moreover, neurocardiogenic syncope often occurs in response to stimuli (fear, emotional stress, or pain) that may not be associated with venous pooling in the lower extremities, which suggests a cortical component to the reflex. Thus, a variety of afferent and efferent responses may cause neurocardiogenic syncope.

As distinct from the peripheral mechanisms, the central nervous system (CNS) mechanisms responsible for neurocardiogenic syncope are uncertain, but a sudden surge in central serotonin levels may contribute to the sympathetic withdrawal. Endogenous opiates (endorphins) and adenosine are also putative participants in the pathogenesis.

**POSTURAL (ORTHOSTATIC) HYPOTENSION** This occurs in patients who have a chronic defect in, or variable instability of, vasomotor reflexes. Systemic arterial blood pressure falls on assumption of upright posture due to loss of vasoconstriction reflexes in resistance and capacitance vessels of the lower extremities. Although the syncopeal attack differs little from vasodepressor syncope, the effect of posture is critical. Sudden rising from a recumbent position or standing quietly are precipitating circumstances. Orthostatic hypotension may be the cause of syncope in up to 30% of the elderly; polypharmacy with antihypertensive or antidepressant drugs is often a contributor in these patients.

Postural syncope may occur in otherwise normal persons with defective postural reflexes. Patients with idiopathic postural hypotension may be identified by a characteristic response to upright tilt on a table. Initially, the blood pressure diminishes slightly before stabilizing at a lower level. Shortly thereafter, the compensatory reflexes fail and the arterial pressure falls precipitously. The condition is often familial.

Orthostatic hypotension, often accompanied by disturbances in sweating, impotence, and sphincter difficulties, is also a primary feature of autonomic nervous system disorders (Chap. 354). The most common causes of neurogenic orthostatic hypotension are chronic diseases of the peripheral nervous system that involve postganglionic unmyelinated fibers (e.g., diabetic, nutritional, and amyloid polyneuropathy). Much less common are the multiple system atrophies; these are CNS disorders in which orthostatic hypotension is associated with (1) parkinsonism (Shy-Drager syndrome), (2) progressive cerebellar degeneration, or (3) a more variable parkinsonian and cerebellar syndrome (striatonigral degeneration) (Chap. 351). A rare, acute postganglionic dysautonomia may represent a variant of Guillain-Barré syndrome (Chap. 365). There are several additional causes of postural syncope: (1) After physical deconditioning (such as after prolonged illness with reduced muscle tone) or after prolonged weightlessness, as in space flight; (2) after sympathectomy that has abolished vasopressor reflexes; and (3) in patients receiving antihypertensive or vasodilator drugs and those who are hypovolemic because of diuretics, excessive sweating, diarrhea, vomiting, hemorrhage, or adrenal insufficiency.

**CAROTID SINUS HYPERSENSITIVITY** Syncope due to carotid sinus hypersensitivity is precipitated by pressure on the carotid sinus baroreceptors, which are located just cephalad to the bifurcation of the common carotid artery. This typically occurs in the setting of shaving, a tight collar, or turning the head to one side. Carotid sinus hypersensitivity occurs predominantly in men ≥50 years old. Activation of carotid sinus baroreceptors gives rise to impulses carried via the nerve of Hering, a branch of the glossopharyngeal nerve, to the medulla oblongata. These afferent impulses activate efferent sympathetic nerve fibers to the heart and blood vessels, cardiac vagal efferent nerve fibers, or both. In patients with carotid sinus hypersensitivity, these responses may cause sinus arrest or atrioventricular (AV) block (a cardioinhibitory response), vasodilatation (a vasodepressor response), or both (a mixed response). The mechanisms responsible for the syndrome are not clear, and validated diagnostic criteria do not exist; some authorities have questioned its very existence.

**SITUATIONAL SYNOCOPE** A variety of activities, including cough, deglutition, micturition, and defecation, are associated with syncope in susceptible individuals. These syndromes are caused, at least in part, by abnormal autonomic control and may involve a cardioinhibitory response, a vasodepressor response, or both. Cough, micturition, and defecation are associated with maneuvers (such as Valsalva, straining, and coughing) that may contribute to hypotension and syncope by decreasing venous return. Increased intracranial pressure secondary to the increased intrathoracic pressure may also contribute by decreasing cerebral blood flow.

Cough syncope typically occurs in men with chronic bronchitis or chronic obstructive lung disease during or after prolonged coughing fits. Micturition syncope occurs predominantly in middle-aged and older men, particularly those with prostatic hypertrophy and obstruction of the bladder neck; loss of consciousness usually occurs at night during or immediately after voiding. Deglutition syncope and defecation syncope occur in men and women. Deglutition syncope may be associated with esophageal disorders, particularly esophageal spasm. In some individuals, particular foods and carbonated or cold beverages initiate episodes by activating esophageal sensory receptors that trigger reflex sinus bradycardia or AV block. Defecation syncope is probably secondary to a Valsalva maneuver in older individuals with constipation.

**GLOSSOPHARYNGEAL NEURALGIA** Syncope due to glossopharyngeal neuralgia (Chap. 355) is preceded by pain in the oropharynx, tonsillar fossa, or tongue. Loss of consciousness is usually associated with asystole rather than vasodilatation. The mechanism is thought to involve activation of afferent impulses in the glossopharyngeal nerve that terminate in the nucleus solitarius of the medulla and, via collaterals, activate the dorsal motor nucleus of the vagus nerve.

**CARDIOVASCULAR DISORDERS** Cardiac syncope results from a sudden reduction in cardiac output, caused most commonly by a cardiac arrhythmia. In normal individuals, heart rates between 30 and 180 beats/ min do not reduce cerebral blood flow, especially if the person is in
the supine position. As the heart rate decreases, ventricular filling time and stroke volume increase to maintain normal cardiac output. At rates <30 beats/min, stroke volume can no longer increase to compensate adequately for the decreased heart rate. At rates greater than ~180 beats/min, ventricular filling time is inadequate to maintain adequate stroke volume. In either case, cerebral hypoperfusion and syncope may occur. Upright posture; cerebrovascular disease; anemia; loss of atrioventricular synchrony; and coronary, myocardial, or valvular disease all reduce the tolerance to alterations in rate.

Bradyarrhythmias (Chap. 213) may occur as a result of an abnormality of impulse generation (e.g., sinoatrial arrest) or impulse conduction (e.g., AV block). Either may cause syncope if the escape pacemaker rate is insufficient to maintain cardiac output. Syncope due to bradyarrhythmias may occur abruptly, without presyncopal symptoms, and recur several times daily. Patients with sick sinus syndrome may have sinus pauses (>3 s), and those with syncope due to high-degree AV block (Stokes-Adams-Morgagni syndrome) may have evidence of conduction system disease (e.g., prolonged PR interval, bundle branch block). However, the arrhythmia is often transient, and the surface electrocardiogram or continuous electrocardiographic monitor (Holter monitor) taken later may not reveal the abnormality. The bradycardia-tachycardia syndrome is a common form of sinus node dysfunction in which syncope generally occurs as a result of marked sinus pauses, some following termination of paroxysms of atrial tachyarrhythmias. Drugs are a common cause for bradyarrhythmias, particularly in patients with underlying structural heart disease. Digoxin, β-adrenergic receptor antagonists, calcium channel blockers, and many antiarrhythmic drugs may suppress sinoatrial node impulse generation or slow AV nodal conduction.

Syncope due to a tachyarrhythmia (Chap. 214) is usually preceded by palpitation or lightheadedness but may occur abruptly with no warning symptoms. Supraventricular tachyarrhythmias are unlikely to cause syncope in individuals with structurally normal hearts but may if they occur in patients with (1) heart disease that also compromises cardiac output, (2) cerebrovascular disease, (3) a disorder of vascular tone or blood volume, or (4) a rapid ventricular rate. These tachycardias result most commonly from paroxysmal atrial flutter, atrial fibrillation, or reentry involving the AV node or accessory pathways that bypass part or all of the AV conduction system. Patients with the Wolff-Parkinson-White syndrome may experience syncope when a very rapid ventricular rate occurs due to reentry across an accessory AV connection.

In patients with structural heart disease, ventricular tachycardia is a common cause of syncope, particularly in patients with a prior myocardial infarction. Patients with aortic valvular stenosis and hypertrophic obstructive cardiomyopathy are also at risk for ventricular tachycardia. Individuals with abnormalities of ventricular repolarization (prolongation of the QT interval) are at risk to develop polymorphic ventricular tachycardia (torsades de pointes). Those with the inherited form of this syndrome often have a family history of sudden death in young individuals. Genetic markers can identify some patients with familial long-QT syndrome, but the clinical utility of these markers remains unproven. Drugs (i.e., certain antiarrhythmics and erythromycin) and electrolyte disorders (i.e., hypokalemia, hypocalcemia, hypomagnesemia) can prolong the QT interval and predispose to torsades de pointes. Antiarrhythmic medications may precipitate ventricular tachycardia, particularly in patients with structural heart disease.

In addition to arrhythmias, syncope may also occur with a variety of structural cardiovascular disorders. Episodes are usually precipitated when the cardiac output cannot increase to compensate adequately for peripheral vasodilatation. Peripheral vasodilatation may be appropriate, such as following exercise, or may occur due to inappropriate activation of left ventricular mechanoreceptor reflexes, as occurs in aortic stenosis (sometimes called the Marfan syndrome). The most common reason that cardiac output cannot increase is pericardial tamponade, which is a rare cause of syncope. Syncope occurs in up to 10% of patients with massive pulmonary embolism and may occur with exertion in patients with severe primary pulmonary hypertension. The cause is an inability of the right ventricle to provide appropriate cardiac output in the presence of obstruction or increased pulmonary vascular resistance. Loss of consciousness is usually accompanied by other symptoms such as chest pain and dyspnea. Atrial myxoma, a prosthetic valve thrombus, and, rarely, mitral stenosis may impair left ventricular filling, decrease cardiac output, and cause syncope.

Cerebrovascular Disease Cerebrovascular disease alone rarely causes syncope but may lower the threshold for syncope in patients with other causes. The verteobasilar arteries, which supply brainstem structures responsible for maintaining consciousness, are usually involved when cerebrovascular disease causes or contributes to syncope. An exception is the rare patient with tight bilateral carotid stenosis and recurrent syncope, often precipitated by standing or walking. Most patients who experience lightheadedness or syncope due to cerebrovascular disease also have symptoms of focal neurologic ischemia, such as arm or leg weakness, diplopia, ataxia, dysarthria, or sensory disturbances. Basilar artery migraine is a rare disorder that causes syncope in adolescents.

DIFFERENTIAL DIAGNOSIS ■ Anxiety Attacks and the Hyperventilation Syndrome Anxiety, such as occurs in panic attacks, is frequently interpreted as a feeling of faintness or dizziness resembling presyncope. The symptoms are not accompanied by facial pallor and are not relieved by recumbency. The diagnosis is made on the basis of the associated symptoms such as a feeling of impending doom, air hunger, palpitations, and tingling of the fingers and perioral region. Attacks can often be reproduced by hyperventilation, resulting in hypocapnia, alkalosis, increased cerebrovascular resistance, and decreased cerebral blood flow. The release of epinephrine also contributes to the symptoms.

Seizures A seizure may be heralded by an aura, which is caused by a focal seizure discharge and hence has localizing significance (Chap. 348). The aura is usually followed by a rapid return to normal or by a loss of consciousness. Injury from falling is frequent in a seizure and rare in syncope. Since only in generalized seizures are protective reflexes abolished instantaneously. Sustained tonic-clonic movements are characteristic of convulsive seizures but brief clonic, or tonic-clonic, seizure-like activity can accompany fainting episodes. The period of unconsciousness tends to be longer in seizures than in syncope. Urinary incontinence is frequent in seizures and rare in syncope. The return of consciousness is prompt in syncope, slow after a seizure. Mental confusion, headache, and drowsiness are common sequelae of seizures, whereas physical weakness with a clear sensorium characterizes the post-convulsive state. Repeated spells of unconsciousness in a young person at a rate of several per day or month are more suggestive of epilepsy than syncope. See Table 348-7 for a comparison of seizures and syncope.

Hypoglycemia Severe hypoglycemia is usually due to a serious disease such as a tumor of the islets of Langerhans; advanced adrenal, pituitary, or hepatic disease; or to excessive administration of insulin.

Acute Hemorrhage Hemorrhage, usually within the gastrointestinal tract, is an occasional cause of syncope. In the absence of pain and hematemesis, the cause of the weakness, faintness, or even unconsciousness may remain obscure until the passage of a black stool.

Hysterical Fainting The attack is usually unattended by an outward display of anxiety. Lack of change in pulse and blood pressure or color of the skin and mucous membranes distinguish it from the vasodepressor faint.

APPROACH TO THE PATIENT

The diagnosis of syncope is often challenging. The cause may only be apparent at the time of the event, leaving few, if any, clues when the patient returns (as later by the physician. The physician should think first of those causes that constitute a therapeutic emergency. Among them are massive internal hemorrhage or myocardial in-
Figure 20-1 depicts an algorithmic approach to syncope. A careful history is the most important diagnostic tool, both to suggest the correct cause and to exclude important potential causes (Table 20-1). The nature of the events and their time course immediately prior to, during, and after an episode of syncope often provide valuable etiologic clues. Loss of consciousness in particular situations, such as during venipuncture, micturition, or with volume depletion, suggests an abnormality of vascular tone. The position of the patient at the time of the syncopal episode is important; syncope in the supine position is unlikely to be vasovagal and suggests an arrhythmia or a seizure. Syncope due to carotid sinus syndrome may occur when the individual is wearing a shirt with a tight collar, turning the head (turning to look while driving in reverse), or manipulating the neck (as in shaving). The patient’s medications must be noted, including nonprescription drugs or health store supplements, with particular attention to recent changes.

The physical examination should include evaluation of heart rate and blood pressure in the supine, sitting, and standing positions. In patients with unexplained recurrent syncope, an attempt to reproduce an attack may assist in diagnosis. Anxiety attacks induced by hyperventilation can be reproduced readily by having the patient breathe rapidly and deeply for 2 to 3 min. Cough syncope may be reproduced by inducing the Valsalva maneuver. Carotid sinus massage should generally be avoided, even in patients with suspected carotids in situ hypersensitivity; it is a risky procedure that can cause a transient ischemic attack (TIA) or stroke in individuals with carotid atheromas.

**Diagnostic Tests** The choice of diagnostic tests should be guided by the history and the physical examination. Measurements of serum electrolytes, glucose, and the hematocrit are usually indicated. Cardiac enzymes should be evaluated if myocardial ischemia is suspected. Blood and urine toxicology screens may reveal the presence of alcohol or other drugs. In patients with possible adrenocortical insufficiency, plasma aldosterone and mineralocorticoid levels should be obtained.

Although the surface electrocardiogram is unlikely to provide a definitive diagnosis, it may provide clues to the cause of syncope and should be performed in almost all patients. The presence of conduction abnormalities (PR prolongation and bundle branch block) suggests a bradyarrhythmia, whereas pathologic Q waves or prolongation of the QT interval suggests a ventricular tachyarrhythmia. Inpatients should undergo continuous electrocardiographic monitoring; outpatients should wear a Holter monitor for 24 to 48 h. Whenever possible, symptoms should be correlated with the occurrence of arrhythmias. Continuous electrocardiographic monitoring may establish the cause of syncope in as many as 15% of patients. Cardiac event monitors may be useful in patients with infrequent symptoms, particularly in patients with presyncope. The presence of a late potential on a signal-averaged electrocardiogram is associated with increased risk for ventricular tachyarrhythmias in patients with a prior myocardial infarction. Low-voltage (visually inapparent) T wave alternans is also associated with development of sustained ventricular arrhythmias.

**Invasive cardiac electrophysiologic testing** provides diagnostic and prognostic information regarding sinus node function, AV conduction, and supraventricular and ventricular arrhythmias (Chaps. 213 and 214). Prolongation of the sinus node recovery time (t > 1500 ms) is a specific finding (85 to 100%) for diagnosis of sinus node dysfunction but has a low sensitivity; continuous electrocardiographic monitoring is usually more effective for diagnosing this abnormality. Prolongation of the HV interval and conduction block below the His bundle indicate that His-Purkinje disease may be responsible for syncope. Programmed stimulation for ventricular arrhythmias is most useful in patients who have experienced a myocardial infarction; the sensitivity and specificity of this technique is lower in patients with normal hearts or those with heart disease other than coronary artery disease.

**Upright tilt table testing** is indicated for recurrent syncope, a single syncopal episode that caused injury, or a single syncopal event in a “high-risk” setting (pilot, commercial vehicle driver, etc.), whether or not there is a history of preexisting heart disease or prior vasovagal episodes. In susceptible patients, upright tilt at an angle between 60 and 80° for 30 to 60 min induces a vasovagal episode. The protocol can be shortened if upright tilt is combined with administration of drugs that cause venous pooling or increase adrenergic stimulation (isoproterenol, nitroglycerin, ephedrine, or adenosine). The sensitivity and specificity of tilt table testing is difficult to ascertain because of the lack of validated criteria. Moreover, the reflexes responsible for vasovagal syncope can be elicited in most, if not all, individuals given the appropriate stimulus. The reported accuracy of the test ranges from 30 to 80%, depending on the population studied and the techniques used. Whereas the reproducibility of a negative test is 85 to 100%, the reproducibility of a positive tilt table test is only between 62 and 88%.

A variety of other tests may be useful to determine the presence of structural heart disease that may cause syncope. The echocardiogram with Doppler examination detects valvular, myocardial, and pericardial abnormalities. The echocardiogram is the “gold standard” for the diagnosis of hypertrophic cardiomyopathy and atrial myxoma. Cardiac cine magnetic resonance (MR) imaging provides an alternative noninvasive modality that may be useful for patients in whom diagnostic-quality echocardiographic images cannot be obtained. This test is also indicated for patients suspected of having arrhythmogenic right ventricular dysplasia or right ventricular outflow tract ventricular tachycardia. Both are associated

**FIGURE 20-1** Approach to the patient with syncope.
DIZZINESS AND VERTIGO

Dizziness is a common and often vexing symptom. Patients use the term to encompass a variety of sensations, including those that seem to occur in response to changes in posture or head movement (e.g., nystagmus, oscillopsia, or positional vertigo), those that occur in response to visual stimuli (e.g., visual illusions, oscillopsia, or visual snowflakes), and those that occur in response to a variety of other sensory inputs (e.g., auditory, somatosensory, or vestibular). The term is often used to describe a sensation of near-falling or of movement of oneself or the surroundings.

The treatment of syncope is directed toward the underlying cause. This discussion will focus on disorders of autonomic control. Arrhythmias are discussed in Chap. 213 and 214, valvular heart diseases in Chap. 216, and cerebrovascular disorders in Chap. 219.

Certain precautions should be taken regardless of the cause of syncope. At the first sign of symptoms, patients should make every effort to avoid injury should they lose consciousness. Patients with frequent episodes, or those who have experienced syncope without warning symptoms, should avoid situations in which sudden loss of consciousness might result in injury (e.g., climbing ladders, swimming alone, operating heavy machinery, driving). Patients should lower their head to the extent possible and preferably should lie down. Lowering the head by bending at the waist should be avoided because it may further compromise venous return to the heart. When appropriate, family members or other close contacts should be educated as to the problem. This will ensure appropriate therapy and may prevent delivery of inappropriate therapy (chest compressions associated with cardiopulmonary resuscitation) that may inflict trauma.

Patients who have lost consciousness should be placed in a position that maximizes cerebral blood flow, offers protection from trauma, and secures the airway. Whenever possible, the patient should be placed supine with the head turned to the side to prevent aspiration and the tongue from blocking the airway. Assessment of the pulse and direct cardiac auscultation may assist in determining if the episode is associated with a bradyarrhythmia or tachyarrhythmia. Clothing that fits the lower body, rather than just their head, when looking to the side. Those with carotid sinus syndrome should be instructed to avoid clothing and situations that stimulate carotid sinus baroreceptors. They should turn their entire body, rather than just their head, when looking to the side. Those with intractable syncope due to the cardioinhibitory response to carotid sinus stimulation should undergo permanent pacemaker implantation.

Permanent dual-chamber cardiac pacing is effective for patients with frequent episodes of vasovagal syncope and is indicated for those with prolonged asystole associated with vasovagal episodes. Patients in whom vasodilatation contributes to loss of consciousness may also experience symptomatic benefit from permanent pacing. Pacemakers that can be programmed to transiently pace at a high rate (90 to 100 beats/min) after a profound drop in the patient’s intrinsic heart rate are most effective.

Patients with orthostatic hypotension should be instructed to rise slowly and systematically (supine to seated, seated to standing) from the bed or a chair. Movement of the legs prior to rising facilitates venous return from the lower extremities. Whenever possible, medications that aggravate the problem (vasodilators, diuretics, etc.) should be discontinued. Elevation of the head of the bed [20 to 30 cm (8 to 12 in.)] and use of compression stockings may help.

Additional therapeutic modalities include an antigravity or g suit or compression stockings to prevent lower limb blood pooling; salt loading; and a variety of pharmacologic agents including sympathomimetic amines, monamine oxidase inhibitors, beta blockers, and levodopa. The treatment of orthostatic hypotension secondary to central or peripheral disorders of the autonomic nervous system is discussed in Chap. 354.

Glossopharyngeal neuralgia is treated with carbamazepine, which is effective for the syncope as well as for the pain. Patients with carotid sinus syndrome should be instructed to avoid clothing and situations that stimulate carotid sinus baroreceptors. They should turn their entire body, rather than just their head, when looking to the side. Those with intractable syncope due to the cardioinhibitory response to carotid sinus stimulation should undergo permanent pacemaker implantation.

Patients with syncope should be hospitalized when the episode may have resulted from a life-threatening abnormality or if recurrence with significant injury seems likely. These individuals should be admitted to a bed with continuous electrocardiographic monitoring. Patients who are known to have a normal heart and for whom the history strongly suggests vasovagal or situational syncope may be treated as outliers if the episodes are neither frequent nor severe.
individuals with gait disorders caused by peripheral neuropathy, myelopathy, spasticity, parkinsonism, or cerebellar ataxia complain of “dizziness” despite the absence of vertigo or other abnormal cephalic sensations. In this context, the term dizziness is being used to describe disturbed ambulation. There may be mild associated lightheadedness, particularly with impaired sensation from the feet or poor vision; this is known as multiple-sensory-defect dizziness and occurs in elderly individuals who complain of dizziness only when walking. Decreased position sense (secondary to neuropathy or myelopathy) and poor vision (from cataracts or retinal degeneration) create an overreliance on the aging vestibular apparatus. A less precise but sometimes comforting designation to patients is benign disequilibrium of aging. Thus, a careful history is necessary to determine exactly what a patient who states, “Doctor, I’m dizzy,” is experiencing. After eliminating the misleading symptoms or gait disturbance, “dizziness” usually means either faintness (presyncope) or vertigo (an illusory or hallucinatory sense of movement of the body or environment, most often a feeling of spinning). Operationally, after obtaining the history, dizziness may be classified into three categories: (1) faintness, (2) vertigo, and (3) miscellaneous head sensations.

### Faintness
Prior to an actual faint (syncope), there are often prodromal presyncopal symptoms (faintness) reflecting ischemia to a degree insufficient to impair consciousness (see above).

### Vertigo
Vertigo is usually due to a disturbance in the vestibular system. The end organs of this system, situated in the bony labyrinths of the inner ears, consist of the three semicircular canals and the otolithic apparatus (utricle and saccule) on each side. The canals transduce angular acceleration, while the otoliths transduce linear acceleration and the static gravitational forces that provide a sense of head position in space. The neural output of the end organs is conveyed to the vestibular nuclei in the brainstem via the eighth cranial nerves. The principal projections from the vestibular nuclei are to the nuclei of cranial nerves III, IV, and VI; spinal cord; cerebral cortex; and cerebellum. The vestibuloocular reflex (VOR) serves to maintain visual stability during head movement and depends on direct projections from the vestibular nuclei to the sixth cranial nerve (abducens) nuclei in the pons and, via projections from the vestibular nuclei to the third (oculomotor) and fourth (trochlear) cranial nerve nuclei in the midbrain. These connections account for the nystagmus (to-and-fro oscillation of the eyes) that is an almost invariable accompaniment of vestibular dysfunction. The vestibular nerves and nuclei project to areas of the cerebellum (primarily the flocculus and nodulus) that modulate the VOR. The vestibulospinal pathways assist in the maintenance of postural stability. Projections to the cerebral cortex, via the thalamus, provide conscious awareness of head position and movement.

The vestibular system is one of three sensory systems subserving spatial orientation and posture; the other two are the visual system (retina to occipital cortex) and the somatosensory system that conveys peripheral information from skin, joint, and muscle receptors. The three stabilizing systems overlap sufficiently to compensate (partially or completely) for each other’s deficiencies. Vertigo may represent either physiologic stimulation or pathologic dysfunction in any of the three systems.

### Physiologic Vertigo
This occurs in normal individuals when (1) the brain is confronted with a mismatch among the three stabilizing sensory systems; (2) the vestibular system is subjected to unfamiliar head movements to which it is unadapted, such as in seasickness; (3) unusual head/neck positions, such as the extreme extension when painting a ceiling; or (4) following a spin. Intersensory mismatch explains carsickness, height vertigo, and the vertigo of vomiting, but without tinnitus or hearing loss. The most common cause of pathologic vertigo is vestibular dysfunction involving either its end organ (labyrinth), nerve, or central connections. The vertigo is frequently accompanied by nausea, jerk nystagmus, postural unsteadiness, and gait ataxia. Since vertigo increases with rapid head movements, patients tend to hold their heads still.

### Pathologic Vertigo
This results from lesions of the visual, somatosensory, or vestibular systems. Visual vertigo is caused by new or incorrect spectacles or by the sudden onset of an extraocular muscle paresis with diplopia; in either instance, CNS compensation rapidly counteracts the vertigo. Somatosensory vertigo, rare in isolation, is usually due to a peripheral neuropathy or myelopathy that reduces the sensory input necessary for central compensation when there is dysfunction of the vestibular or visual systems.

The most common cause of pathologic vertigo is vestibular dysfunction involving either its end organ (labyrinth), nerve, or central connections. When rotational, the hallucination of movement, whether of environment or self, is directed away from the side of the lesion. The fast phases of nystagmus beat away from the lesion side, and the tendency to fall is toward the side of the lesion, particularly in darkness or with the eyes closed. Under normal circumstances, when the head is straight and mobile, the vestibular end organs generate a tonic resting firing frequency that is equal from the two sides. With any rotational acceleration, the anatomic positions of the semicircular canals on each side necessitate an increased firing rate from one and a commensurate decrease from the other. This change in neural activity is ultimately projected to the cerebral cortex, where it is summed with inputs from the visual and somatosensory systems to produce the appropriate conscious sense of rotational movement. After cessation of movement, the firing frequencies of the two end organs reverse; the side with the initially increased rate decreases, and the other side increases. A sense of rotation in the opposite direction is experienced; since there is no actual head movement, this hallucinatory sensation is physiologic postrotational vertigo.

Any disease state that changes the firing frequency of an end organ, producing unequal neural input to the brainstem and ultimately the cerebral cortex, causes vertigo. The symptom can be conceptualized as the cortex inappropriately interpreting the abnormal neural input as indicating actual head rotation. Transient abnormalities produce short-lived symptoms. With a fixed unilateral deficit, central compensatory mechanisms ultimately diminish the vertigo. Since compensation depends on the plasticity of connections between the vestibular nuclei and the cerebellum, patients with brainstem or cerebellar disease have diminished adaptive capacity, and symptoms may persist indefinitely. Compensation is always inadequate for severe fixed bilateral lesions despite normal cerebellar connections; these patients are permanently symptomatic.

Acute unilateral labyrinthine dysfunction is caused by infection, trauma, and ischemia. Often, no specific etiology is uncovered, and the nonspecific terms acute labyrinthitis, acute peripheral vestibulopathy, or vestibular neuritis are used to describe the event. The vertiginous attacks are brief and leave the patient with mild vertigo for several days. Infection with herpes simplex virus type 1 has been implicated. It is impossible to predict whether a patient recovering from the first bout of vertigo will have recurrent episodes. Labyrinthine ischemia, presumably due to occlusion of the labyrinthe branch of the internal auditory artery, may be the sole manifestation of vertebrobasilar insufficiency (Chap. 349); patients with this syndrome present with the abrupt onset of severe vertigo, nausea, and vomiting, but without tinnitus or hearing loss. Acute bilateral labyrinthine dysfunction is usually the result of toxins such as drugs or alcohol. The most common offending drugs are the angiopticoleptic anticonvulsants that damage the hair cells of the vestibular end organs and may cause a permanent disorder of equilibrium. Recurrent unilateral labyrinthine dysfunction, in association with
signs and symptoms of cochlear disease (progressive hearing loss and tinnitus), is usually due to Ménière’s disease (Chap. 26). When audiometry examinations are absent, the term vestibular neuronitis denotes recurrent monosymptomatic vertigo. TIAs of the posterior cerebral circulation (vertebrobasilar insufficiency) only infrequently cause recurrent vertigo without concomitant motor, sensory, visual, cranial nerve, or cerebellar signs (Chap. 349).

**Positional vertigo** is precipitated by a recumbent head position, either to the right or to the left. Benign paroxysmal positional (or positioning) vertigo (BPPV) of the posterior semicircular canal is particularly common. Although the condition may be due to head trauma, usually no precipitating factors are identified. It generally abates spontaneously after weeks or months. The vertigo and accompanying nystagmus have a distinct pattern of latency, fatigability, and habituation that differs from the less common central positional vertigo (Table 20-2) due to lesions in and around the fourth ventricle. Moreover, the pattern of nystagmus in posterior canal BPPV is distinctive. When supine, with the head turned to the side of the offending ear (bad ear down), the lower eye displays a large-amplitude torsional nystagmus, and the upper eye has a lesser degree of torsion combined with upbeat nystagmus. If the eyes are directed to the upper ear, the vertical nystagmus in the upper eye increases in amplitude. Mild dysequilibrium when upright may also be present.

A *perilymphatic fistula* should be suspected when episodic vertigo is precipitated by Valsalva or exertion, particularly upon a background of a stepwise progressive sensory-neural hearing loss. The condition is usually caused by head trauma or barotrauma or occurs after middle ear surgery.

**Vertigo of Vestibular Nerve Origin** This occurs with diseases that involve the nerve in the petrous bone or the cerebellopontine angle. Although less severe and less frequently paroxysmal, it has many of the characteristics of labyrinthine vertigo. The adjacent auditory division of the eighth cranial nerve is usually affected, which explains the frequent association of vertigo with unilateral tinnitus and hearing loss. The most common cause of eighth cranial nerve dysfunction is a tumor, usually a schwannoma (*acoustic neuroma*) or a meningioma. These tumors grow slowly and produce such a gradual reduction of labyrinthine output that central compensatory mechanisms can prevent or minimize the vertigo; auditory symptoms of hearing loss and tinnitus are the most common manifestations.

**Central Vertigo** Lesions of the brainstem or cerebellum can cause acute vertigo, but associated signs and symptoms usually permit distinction from a labyrinthine etiology (Table 20-2). Occasionally, an acute lesion of the vestibulocerebellum may present with monosymptomatic vertigo indistinguishable from a labyrinthopathy.

Vertigo may be a manifestation of a migraine aura (Chap. 14), but some patients with migraine have episodes of vertigo unassociated with their headaches. Antimigrainous treatment should be considered in such patients with otherwise enigmatic vestibulospinal episodes.

**Vestibular epilepsy**, vertigo secondary to temporal lobe epileptic activity, is rare and almost always intermixed with other epileptic manifestations.

### TABLE 20-2 Benign Paroxysmal Positional Vertigo and Central Positional Vertigo

<table>
<thead>
<tr>
<th>Features</th>
<th>BPPV Central</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latency&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3–40 s None: immediate vertigo and nystagmus</td>
</tr>
<tr>
<td>Fatigability&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Yes No</td>
</tr>
<tr>
<td>Habituation&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Yes No</td>
</tr>
<tr>
<td>Intensity of vertigo&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Severe Mild</td>
</tr>
<tr>
<td>Reproducibility&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Variable Good</td>
</tr>
</tbody>
</table>

<sup>a</sup> Time between attaining head position and onset of symptoms.

<sup>b</sup> Disappearance of symptoms with maintenance of offending position.

<sup>c</sup> Lessening of symptoms with repeated trials.

<sup>d</sup> Likelihood of symptom production during any examination session.

### TABLE 20-3 Differentiation of Peripheral and Central Vertigo

<table>
<thead>
<tr>
<th>Sign or Symptom</th>
<th>Peripheral (Labyrinth)</th>
<th>Central (Brainstem or Cerebellum)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direction of associated nystagmus</td>
<td>Unidirectional; fast phase opposite lesion&lt;sup&gt;†&lt;/sup&gt;</td>
<td>Bidirectional or unidirectional</td>
</tr>
<tr>
<td>Purely horizontal nystagmus without torsional component</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Vertical or purely torsional nystagmus</td>
<td>Never present</td>
<td>May be present</td>
</tr>
<tr>
<td>Visual fixation</td>
<td>Inhibits nystagmus and vertigo</td>
<td>No inhibition</td>
</tr>
<tr>
<td>Severity of vertigo</td>
<td>Marked</td>
<td>Often mild</td>
</tr>
<tr>
<td>Direction of spin</td>
<td>Toward fast phase</td>
<td>Variable</td>
</tr>
<tr>
<td>Direction of fall</td>
<td>Toward slow phase</td>
<td>Variable</td>
</tr>
<tr>
<td>Duration of symptoms</td>
<td>Finite (minutes, days, weeks) but recurrent</td>
<td>May be chronic</td>
</tr>
<tr>
<td>Tinnitus and/or deafness</td>
<td>Often present</td>
<td>Usually absent</td>
</tr>
<tr>
<td>Associated central abnormalities</td>
<td>None</td>
<td>Extremely common</td>
</tr>
<tr>
<td>Common causes</td>
<td>Infection (labyrinthitis), Ménière’s, neuritis, ischemia, trauma, toxin</td>
<td>Vascular, demyelinating, neoplasm</td>
</tr>
</tbody>
</table>

<sup>†</sup> In Ménière’s disease, the direction of the fast phase is variable.

### PSYCHOGENIC VERTIGO

This is usually a concomitant of panic attacks (Chap. 371) or agoraphobia (fear of large open spaces, crowds, or leaving the safety of home) and should be suspected in patients so “incapacitated” by their symptoms that they adopt a prolonged housebound status. Most patients with organic vertigo attempt to function despite their discomfort. Organic vertigo is accompanied by nystagmus; a psychogenic etiology is almost certain when nystagmus is absent during a vertiginous episode.

### Miscellaneous Head Sensations

This designation is used, primarily for purposes of initial classification, to describe dizziness that is neither faintness nor vertigo. Cephalic ischemia or vestibular dysfunction may be of such low intensity that the usual symptomatology is not clearly identified. For example, a small decrease in blood pressure or a slight vestibular imbalance may cause sensations different from distinct faintness or vertigo but that may be identified properly during provocative testing techniques (see below). Other causes of dizziness in this category are hyperventilation syndrome, hypoglycemia, and the somatic symptoms of a clinical depression; these patients should all have normal neurologic examinations and vestibular function tests. Depressed patients often insist that the depression is “secondary” to the dizziness.

### APPROACH TO THE PATIENT

The most important diagnostic tool is a detailed history focused on the meaning of “dizziness” to the patient. Is it faintness (presyncope)? Is there a sensation of spinning? If either of these is affirmed and the neurologic examination is normal, appropriate investigations for the multiple causes of cephalic ischemia or vestibular dysfunction are undertaken.

When the meaning of “dizziness” is uncertain, provocative tests may be helpful. These office procedures simulate either cephalic ischemia or vestibular dysfunction. Cephalic ischemia is obvious if the dizziness is duplicated during maneuvers that produce orthostatic hypotension. Further provocation involves the Valsalva maneuver, which decreases cerebral blood flow and should reproduce ischemic symptoms.

Hyperventilation is the cause of dizziness in many anxious individuals; tingling of the hands and face may be absent. Forced hyperventilation for 1 min is indicated for patients with enigmatic dizziness and normal neurologic examinations.

The simplest provocative test for vestibular dysfunction is rapid rotation and abrupt cessation of movement in a swivel chair. This
always induces vertigo that the patients can compare with their symptomatic dizziness. The intense induced vertigo may be unlike the spontaneous symptoms, but shortly thereafter, when the vertigo has all but subsided, a lightheadedness supervenes that may be identified as “my dizziness.” When this occurs, the dizzy patient, originally classified as suffering from “miscellaneous head sensations,” is now properly diagnosed as having mild vertigo secondary to a vestibulopathy.

Patients with symptoms of positional vertigo should be appropriately tested (Table 20-2). A final provocative and diagnostic vestibular test, requiring the use of Frenzel eyeglasses (self-illuminated goggles with convex lenses that blur out the patient’s vision, but allow the examiner to see the eyes greatly magnified), is vigorous head shaking in the horizontal plane for about 10 s. If nystagmus develops after the shaking stops, even in the absence of vertigo, vestibular dysfunction is demonstrated. The maneuver can then be repeated in the vertical plane. If the provocative tests establish the dizziness as a vestibular symptom, an evaluation of vestibular vertigo is undertaken.

**Evaluation of Patients with Pathologic Vestibular Vertigo**

The evaluation depends on whether a central etiology is suspected (Table 20-3). If so, MR imaging of the head is mandatory. Such an examination is rarely helpful in cases of recurrent monosymptomatic vertigo with a normal neurologic examination. Typical BPPV requires no investigation after the diagnosis is made (Table 20-2).

Vestibular function tests serve to (1) demonstrate an abnormality when the distinction between organic and psychogenic is uncertain, (2) establish the side of the abnormality, and (3) distinguish between peripheral and central etiologies. The standard test is electronystagmography (calorics), where warm and cold water (or air) are applied, in a prescribed fashion, to the tympanic membranes, and the slow-phase velocities of the resultant nystagmus from the two are compared. A velocity decrease from one side indicates hypofunction (“canal paresis”). An inability to induce nystagmus with ice water denotes a “dead labyrinth.” Some institutions have the capability of quantitatively determining various aspects of the VOR using computer-driven rotational chairs and precise oculographic recording of the eye movements.

CNS disease can produce dizzy sensations of all types. Consequently, a neurologic examination is always required even if the history or provocative tests suggest a cardiac, peripheral vestibular, or psychogenic etiology. Any abnormality on the neurologic examination should prompt appropriate neurodiagnostic studies.

### Treatment

Treatment of acute vertigo consists of bed rest (1 to 2 days maximum) and vestibular suppressant drugs such as antihistaminics (meclizine, dimenhydrinate, promethazine), tranquilizers with GABA-ergic effects (diazepam, clonazepam), and glucocorticoids (Table 20-4). If the vertigo persists beyond a few days, most authorities advise ambulation in an attempt to induce central compensatory mechanisms, despite the short-term discomfort to the patient. Chronic vertigo of labyrinthine origin may be treated with a systematized vestibular rehabilitation program to facilitate central compensation.

BPPV is often self-limited but, when persistent, may respond dramatically to specific repositioning exercise programs designed to empty particulate debris from the posterior semicircular canal. One of these exercises, the Epley procedure, is graphically demonstrated, in four languages, on a website for use in both physician’s offices and self-treatment (www.charite.de/ch/neuro/vertigo.html).

Prophylactic measures to prevent recurrent vertigo are variably effective. Antihistamines are commonly utilized but are of limited value. Ménière’s disease may respond to a diuretic or, more effectively, to a very low salt diet (1 g/d). Recurrent episodes of migraine-associated vertigo should be treated with antimigrainous therapy (Chap. 14). There are a variety of inner ear surgical procedures for refractory Ménière’s disease, but these are only rarely necessary.

Helpful websites for both physicians and vertigo patients are: www.iVertigo.net and www.tchain.com.

### Further Reading

KAUFMAN NH, BHATTACHARYA K: Diagnosis and treatment of neurally mediated syncope. The Neurologist 8:175, 2002

### Table 20-4  Treatment of Vertigo

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihistamines</td>
<td></td>
</tr>
<tr>
<td>Meclizine</td>
<td>25–50 mg 3 times/day</td>
</tr>
<tr>
<td>Dimenhydrinate</td>
<td>50 mg 1–2 times/day</td>
</tr>
<tr>
<td>Promethazine</td>
<td>25–50 mg suppository or IM</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>2.5 mg 1–3 times/day</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>0.25 mg 1–3 times/day</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>5 mg IM or 25-mg suppository</td>
</tr>
<tr>
<td>Anticholinergic</td>
<td></td>
</tr>
<tr>
<td>Scopolamine transdermal</td>
<td>Patch</td>
</tr>
<tr>
<td>Sympathomimetics</td>
<td></td>
</tr>
<tr>
<td>Ephedrine</td>
<td>25 mg/d</td>
</tr>
<tr>
<td>Combination preparations</td>
<td></td>
</tr>
<tr>
<td>Ephedrine and promethazine</td>
<td>25 mg/d of each</td>
</tr>
<tr>
<td>Exercise therapy</td>
<td></td>
</tr>
<tr>
<td>Repositioning maneuvers</td>
<td></td>
</tr>
<tr>
<td>Vestibular rehabilitation</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Diuretics or low-salt (1 g/d) diet</td>
<td></td>
</tr>
<tr>
<td>Antimigrainous drugs</td>
<td></td>
</tr>
<tr>
<td>Inner ear surgery</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td></td>
</tr>
</tbody>
</table>

- All listed drugs are U.S. Food and Drug Administration approved, but most are not approved for the treatment of vertigo.
- Usual oral (unless otherwise stated) starting dose in adults; maintenance dose can be reached by a gradual increase.
- For acute vertigo only.
- For motion sickness only.
- For benign paroxysmal positional vertigo.
- For vertigo other than Ménière’s and positional.
- For Ménière’s disease.
- For migraine-associated vertigo (see Chap. 14 for a listing of prophylactic antimigrainous drugs).
- For perilymphatic fistula and refractory cases of Ménière’s disease.
Normal motor function requires integrated muscle activity with appropriate modulation by neuronal activity in the cerebral cortex, basal ganglia, cerebellum, and spinal cord. Symptoms and signs of motor system dysfunction may include weakness, fatigue, myalgias, spasms, cramps, dyskinetic movement, ataxia, imbalance, or disorders in the initiation or planning of movement.

**WEAKNESS**

Weakness is a reduction in normal power of one or more muscles. Limitation in rising from a seated position or combing hair suggests proximal weakness, whereas slapping of the feet while walking or limitation in opening jars suggests distal weakness. Increased fatigability or limitation in function due to pain is often confused with weakness by patients. Increased fatigability is the inability to sustain the performance of an activity that should be normal for a person of the same age, gender, and size.

Paralysis and the suffix “-plegia” indicate weakness that is so severe that it is complete or nearly complete. “Paresis” refers to weakness that is mild or moderate. The prefix “hemi-” refers to one half of the body, “para-” to both legs, and “quadri-” to all four limbs.

**Tone** is the resistance of a muscle to passive stretch. Central nervous system (CNS) abnormalities that cause weakness generally produce spasticity, an increase in tone due to upper motor neuron disease. Spasticity is velocity-dependent, has a sudden release after reaching a maximum (the “clasp-knife” phenomenon), and predominantly affects antigravity muscles (i.e., upper limb flexors and lower limb extensors). Spasticity is distinct from rigidity and paratonia, two other types of increased tone. Rigidity is increased tone that is present throughout the range of motion (a “lead pipe” or “plastic” stiffness) and affects flexors and extensors equally. In some patients, rigidity has a cogwheel quality that is enhanced by voluntary movement of the contralateral limb (reinforcement). Rigidity occurs with certain extrapyramidal disorders such as Parkinson’s disease. Paratonia, also referred to as gegenhalten, is increased tone that varies irregularly in a manner that may seem related to the degree of relaxation, is present throughout the range of motion, and affects flexors and extensors equally. Paratonia usually results from disease of the frontal lobes. Weakness with decreased tone (flaccidity) or normal tone occurs with disorders of the motor unit, that is, a single lower motor neuron and all of the muscle fibers it innervates.

Three basic patterns of weakness can usually be recognized based on the signs summarized in Table 21-1. One results from upper motor neuron pathology, and the other two from disorders of the motor unit (lower motor neuron and myopathic weakness). Fasciculations and early atrophy help to distinguish lower motor neuron (neurogenic) weakness from myopathic weakness. A fasciculation is a visible or palpable twitch within a single muscle due to the spontaneous discharge of one motor unit. Lower motor neuron weakness also produces more prominent hypotonia and greater depression of tendon reflexes than does myopathic weakness.

**PATHOGENESIS**

- **Upper Motor Neuron Weakness**

  This pattern of weakness results from disorders that affect the upper motor neurons or their axons in the cerebral cortex, subcortical white matter, internal capsule, brainstem, or spinal cord (Fig. 21-1). Upper motor neuron lesions produce weakness through decreased activation of the lower motor neurons. In general, distal muscle groups are affected more severely than proximal ones, and axial movements are spared unless the lesion is severe and bilateral. With corticobulbar involvement, weakness is usually observed only in the lower face and tongue; extracocular, upper facial, pharyngeal, and jaw muscles are almost always spared. With bilateral corticobulbar lesions, pseudobulbar palsy often develops, in which dysarthria, dysphagia, dysphonia, and emotional lability accompany bilateral facial weakness. Spasticity accompanies upper motor neuron weakness but may not be present in the acute phase. Upper motor neuron lesions also affect the ability to perform rapid repetitive movements. Such movements are slow and coarse, but normal rhythmicity is maintained. Finger-nose-finger and heel-knee-shin are performed slowly but adequately.

- **Lower Motor Neuron Weakness**

  This pattern results from disorders of cell bodies of lower motor neurons in the brainstem motor nuclei and the anterior horn of the spinal cord, or from dysfunction of the axons of these neurons as they pass to skeletal muscle (Fig. 21-2). Weakness is due to a decrease in the number of motor units that can be activated, through a loss of α motor neurons or disruption of their connections to muscle. With a decreased number of motor units, fewer muscle fibers are activated with full effort and maximum power is reduced. Loss of γ motor neurons does not cause weakness but decreases tension on the muscle spindles, which decreases muscular tone and contributes to less active tendon reflexes on examination. An absent tendon stretch reflex suggests involvement of the spindle afferent fibers.

  When a motor unit becomes diseased, especially in anterior horn cell diseases, it may spontaneously discharge, producing a fasciculation. These isolated small twitches may be seen or felt clinically or recorded by electromyography (EMG). When α motor neurons or their axons degenerate, the denervated muscle fibers spontaneously discharge in a manner that cannot be seen or felt but can be recorded with EMG. These small single muscle fiber discharges are called fibrillation potentials. If lower motor neuron weakness is present, recruitment of motor units is delayed or reduced, with fewer than normal activated at a given discharge frequency. This contrasts with upper motor neuron weakness, in which a normal number of motor units are activated at a given frequency but in which the maximum discharge frequency is decreased.

- **Myopathic Weakness**

  This pattern of weakness is produced by disorders within the motor unit that affect the muscle fibers or the neuromuscular junctions.

  Two types of muscle fibers exist. Type I muscle fibers are rich in mitochondria and oxidative enzymes, produce relatively low force, but have low energy demands that can be supplied by ongoing aerobic metabolism. They produce sustained postural and nonforceful movements. Type II muscle fibers are rich in glycolytic enzymes, can produce relatively high force, but have high energy demands that cannot be supplied for long by ongoing aerobic metabolism. Thus, these units can be activated maximally for only brief periods of time to produce high-force movements.

  For graded voluntary movements, type I muscle fibers are activated earlier in recruitment. For each muscle fiber, if the nerve terminal releases a normal number of acetylcholine molecules presynaptically and a sufficient number of postsynaptic acetylcholine receptors are opened, the end plate reaches threshold and thereby generates an action potential that spreads across the muscle fiber membrane and into the transverse tubular system. This electrical excitation activates intracellular release of calcium that causes contraction of the muscle fibers.
fatigable weakness is suggestive of myasthenia gravis or another neuromuscular junction disease. Furthermore, the number of muscle fibers activated can vary over time, depending on the state of rest of the neuromuscular junctions. Thus, fatigable weakness is suggestive of myasthenia gravis or another neuromuscular junction disease. Some myopathies produce weakness through loss of contractile force of muscle fibers or through relatively selective involvement of the type II muscle fibers. These may not affect the size of individual motor unit action potentials observed with EMG and are detected by a discrepancy between the electrical activity and force of a muscle.

**Integrated Movements** Most purposeful movements require the integrated coordination of many muscle groups. Consider a simple movement, such as grasping a ball. The primary movement is a flexion of the thumb and fingers of one hand, with opposition of the thumb and little finger. This requires the contraction of several muscles, including flexor digitorum superficialis, flexor digitorum profundus, flexor pollicis longus, flexor pollicis brevis, opponens pollicis, and opponens digiti minimi. The prime movers for this action are called agonists. In order for the grasping to be smooth and forceful, the thumb and finger extensors need to relax at the same rate as the flexors contract. The muscles that act in a directly opposing manner to the agonists are antagonists. A secondary action of the thumb and finger flexors is to flex the wrist; because wrist flexion tends to weaken finger flexion if both occur, activation of wrist extensors assists the grasping movement. Muscles that produce such complementary movements are synergists. Finally, the arm needs to be held in a stable position as the grasp occurs, so that the ball is not knocked away before it is secured. Muscles that stabilize the arm position are fixators.

The coordination of activity by agonists, antagonists, synergists, and fixators is regulated by a three-level hierarchy of motor control. The lowest level of control is mediated through segmental reflexes in the spinal cord. These reflexes facilitate agonists and reciprocally inhibit the antagonists. Spinal segments also control rhythmic patterns of movement that involve more than a single pair of agonists and antagonists. For example, the lumbosacral spinal cord contains the basic programming for cyclical stepping movements that involve the synergistic activation of different muscle groups over time. The intermediate level of control is mediated through the descending bulbo-

![Diagram of the corticospinal and bulbospinal upper motor neuron pathways.](image)

**FIGURE 21-1** The corticospinal and bulbospinal upper motor neuron pathways. Upper motor neurons have their cell bodies in layer V of the primary motor cortex (the precentral gyrus, or Brodmann’s area 4) and in the premotor and supplemental motor cortex (area 6). The upper motor neurons in the primary motor cortex are somatotopically organized as illustrated on the right side of the figure. Axons of the upper motor neurons descend through the subcortical white matter and the posterior limb of the internal capsule. Axons of the pyramidal or corticospinal system descend through the brainstem in the cerebral peduncle of the midbrain, the basis pontis, and the medullary pyramids. At the cervico-medullary junction, most pyramidal axons decussate into the contralateral corticospinal tract of the lateral spinal cord, but 10 to 30% remain ipsilateral in the anterior spinal cord. Pyramidal neurons make direct monosynaptic connections with lower motor neurons. They innervate most densely the lower motor neurons of hand muscles and are involved in the execution of learned, fine movements. Corticobulbar neurons are similar to corticospinal neurons but innervate brainstem motor nuclei.

Bulbospinal upper motor neurons influence strength and tone but are not part of the pyramidal system. The descending ventromedial bulbospinal pathways originate in the tectum of the midbrain (tectospinal pathway), the vestibular nuclei (vestibulospinal pathway), and the reticular formation (reticulospinal pathway). These pathways influence axial and proximal muscles and are involved in the maintenance of posture and integrated movements of the limbs and trunk. The descending ventrolateral bulbospinal pathways, which originate predominantly in the red nucleus (rubrospinal pathway), facilitate distal limb muscles. The bulbospinal system is sometimes referred to as the extrapyramidal upper motor neuron system. In all figures, nerve cell bodies and axon terminals are shown, respectively, as closed circles and forks.

Myopathic weakness is produced by a decrease in the number or contractile force of muscle fibers activated within the motor unit. With muscular dystrophies, inflammatory myopathies, or myopathies with muscle fiber necrosis, decreased numbers of muscle fibers survive within many motor units. As demonstrated with EMG, the size of each motor unit action potential is decreased so that motor units must be recruited more rapidly than normal to produce the power necessary for a certain movement. Neuromuscular junction diseases such as myasthenia gravis produce weakness in a similar manner, although the loss of muscle fibers within the motor unit is functional rather than actual. Furthermore, the number of muscle fibers activated can vary over time, depending on the state of rest of the neuromuscular junctions. Thus, fatigable weakness is suggestive of myasthenia gravis or another neuromuscular junction disease. Some myopathies produce weakness through loss of contractile force of muscle fibers or through relatively selective involvement of the type II muscle fibers. These may not affect the size of individual motor unit action potentials observed with EMG and are detected by a discrepancy between the electrical activity and force of a muscle.

**FIGURE 21-2** Lower motor neurons are divided into α and γ types. The larger α motor neurons are more numerous and innervate the extramuscular fibers of the motor unit. Loss of α motor neurons or disruption of their axons produces lower motor neuron weakness. The smaller, less numerous γ motor neurons innervate the intramuscular fibers of the muscle spindle and contribute to normal tone and stretch reflexes. The α motor neuron receives direct excitatory input from corticomotoneurons and primary muscle spindle afferents. The α and γ motor neurons also receive excitatory input from other descending upper motor neuron pathways, segmental sensory inputs, and interneurons. The α motor neuron receives direct inhibition from Renshaw cell interneurons, and other interneurons indirectly inhibit the α and γ motor neurons. A tendon reflex requires the function of all illustrated structures. A tap on a tendon stretches muscle spindles (which are tonically activated by γ motor neurons) and activates the primary spindle afferent neurons. These stimulate the α motor neurons in the spinal cord, producing a brief muscle contraction, which is the familiar tendon reflex.
DISTRIBUTION OF WEAKNESS

<table>
<thead>
<tr>
<th>Hemiparesis</th>
<th>Paraparesis</th>
<th>Quadriparesis</th>
<th>Monoparesis</th>
<th>Distal</th>
<th>Proximal</th>
<th>Restricted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alert</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UMN signs</td>
<td>LMN signs*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortical signs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UMN signs</td>
<td>LMN signs*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMG and NCS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain CT or MRI†</td>
<td>Spinal MRI†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alert</td>
<td></td>
<td>Me</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UMN pattern</td>
<td>LMN pattern</td>
<td>Anterior horn, root, or peripheral nerve disease</td>
<td>Muscle or neuromuscular junction disease</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* or signs of myopathy
† If no abnormality detected, consider myelogram or brain MRI.
‡ If no abnormality detected, consider spinal MRI.

FIGURE 21-3  An algorithm for the initial workup of a patient with weakness. CT, computed tomography; EMG, electromyography; LMN, lower motor neuron; MRI, magnetic resonance imaging; NCS, nerve conduction studies; UMN, upper motor neuron.

spinal pathways, which integrate visual, proprioceptive, and vestibular feedback into the execution of an action. For example, the locomotor center in the midbrain is required to modify the cyclical stepping movements in order that balance be maintained and forward movement occurs. The highest level of control is mediated by the cerebral cortex. Superimposition of this highest level of control is necessary for activities such as walking to be goal-directed. Precise movements that are learned and improved through practice are also initiated and controlled by the motor cortex. Although only the agonists are directly activated, during the course of a complex sequence of actions such as playing the piano, the sequential activation of different groups of agonists for each note or chord is a part of the learned motor program. Further, the execution of these actions also involves input from the basal ganglia and cerebellar hemispheres to facilitate agonists, synergists, and fixators and to inhibit undesired antagonists.

Apraxia is a disorder of planning and initiating a skilled or learned movement (Chap. 23). Unilateral apraxia of the right hand may be due to a lesion of the left frontal lobe (especially anterior or inferior), the left temporoparietal region (especially the supramarginal gyrus), or their connections. Left body apraxia is produced by lesions of these regions in the right hemisphere or by lesions in the corpus callosum that disconnect the right temporoparietal or frontal regions from those on the left. Bilateral apraxia is often due to bilateral frontal lobe lesions or diffuse bilateral hemispheric disease.

Hemiparesis  Hemiparesis results from an upper motor neuron lesion above the midcervical spinal cord; most lesions that produce hemiparesis are located above the foramen magnum. The presence of language disorders, cortical sensory disturbances, cognitive abnormalities, disorders of visual-spatial integration, apraxia, or seizures indicates a cortical lesion. Homonymous visual field defects reflect either a cortical or a subcortical hemispheric lesion. A “pure motor” hemiparesis of the face, arm, and/or leg is due to a small, discrete lesion in the posterior limb of the internal capsule, cerebral peduncle, or upper pons. Some brainstem lesions produce “crossed paralyses,” consisting of ipsilateral cranial nerve signs and contralateral hemiparesis (Chap. 349). The absence of cranial nerve signs or facial weakness suggests that a hemiparesis is due to a lesion in the high cervical spinal cord, especially if associated with ipsilateral loss of proprioception and contralateral loss of pain and temperature sense (the Brown-Séquard syndrome). However, most spinal cord lesions produce quadriparesis or paraparesis.

Acute or episodic hemiparesis usually has a vascular pathogenesis, either ischemia or a primary hemorrhage. Less commonly, hemorrhage may occur into brain tumors or from rupture of normal vessels due to trauma; the trauma may be trivial in patients who are anticoagulated or elderly. Less likely possibilities include a focal inflammatory lesion from multiple sclerosis, abscess, or sarcoidosis. Evaluation begins immediately with a computed tomography (CT) scan of the brain (Fig. 21-3). If CT is normal and an ischemic stroke is unlikely, magnetic resonance imaging (MRI) of the brain or cervical spine may be indicated.

Subacute hemiparesis that evolves over days or weeks has an extensive differential diagnosis. A common cause is subdural hematoma; this readily treatable condition must always be considered, especially in elderly or anticoagulated patients, even in the absence of a history of trauma. Infectious possibilities include cerebral bacterial abscess, fungal granuloma or meningitis, and parasitic infection. Weakness from primary and metastatic neoplasms may evolve over days to weeks. AIDS may present with subacute hemiparesis due to toxoplasmosis or primary CNS lymphoma. Noninfectious inflammatory processes, such as multiple sclerosis or, less commonly, sarcoidosis, are further considerations. If the brain MRI is normal and if cortical and hemispheric signs are not present, MRI of the cervical spine may be required.

Chronic hemiparesis that evolves over months is usually due to a neoplasm, an unruptured arteriovenous malformation, a chronic subdural hematoma, or a degenerative disease. The initial diagnostic test is often an MRI of the brain, especially if the clinical findings suggest brainstem pathology. If MRI of the brain is normal, the possibility of a foramen magnum or high cervical spinal cord lesion should be considered.

Paraparesis  An intraspinal lesion at or below the upper thoracic spinal cord level is most commonly responsible. A sensory level over the trunk identifies the approximate level of the cord lesion. Paraparesis can also result from lesions at other locations that disturb upper motor neurons (especially parasagittal lesions and hydrocephalus) and lower motor neurons (anterior horn cell disorders, cauda equina syndromes, and occasionally peripheral neuropathies). Acute or episodic paraparesis due to spinal cord disease may be difficult to distinguish from disorders affecting lower motor neurons or cerebral hemispheres. Recurrent episodes of paraparesis are often due to multiple sclerosis or to vascular malformations of the spinal cord. With acute spinal cord disease, the upper motor neuron deficit is usually associated with incontinence and a sensory disturbance of the lower limbs that extends rostrally to a level on the trunk; tone is typically flaccid, and tendon reflexes are absent. In such cases, the diagnostic approach begins with an imaging study of the spinal cord (Fig. 21-3). Compressive lesions (particularly epidural tumor, abscess, or
hematoma), spinal cord infarction (propiroception is usually spared), an arteriovenous fistula or other vascular anomaly, and transverse myelitis, among other causes, may be responsible (Chap. 356). Diseases of the cerebral hemispheres that produce acute paraparesis include anterior cerebral artery ischemia (shoulder shrug also affected), superior sagittal sinus or cortical venous thrombosis, and acute hydrocephalus. If upper motor neuron signs are associated with drowsiness, confusion, seizures, or other hemispheric signs but not a sensory level over the trunk, the diagnostic approach starts with an MRI of the brain. Paraparesis is part of the cauda equina syndrome, which may result from trauma to the low back, a midline disk herniation, or intraspinal tumor; although sphincters are affected, hip flexion is often spared, as does sensation over the anterolateral thighs. Rarely, paraparesis is caused by a rapidly evolving peripheral neuropathy such as Guillain-Barré syndrome (Chap. 365) or by a myopathy (Chap. 368). In such cases, electrophysiologic studies are diagnostically helpful and refocus the subsequent evaluation.

Subacute or chronic paraparesis with spasticity is caused by upper motor neuron disease. When there is associated lower limb sensory loss and sphincter involvement, a chronic spinal cord disorder is likely; these are discussed in Chap. 356. The clinical approach begins with an MRI of the spinal cord. If the imaging study is normal and spasticity is present, MRI of the brain may be indicated. If hemispheric signs are present, parasagittal meningioma or chronic hydrocephalus is likely and MRI of the brain is the initial test. In the rare situation when chronic paraparesis is due to lower motor neuron or myopathic etiology, the localization is usually suspected on clinical grounds by the absence of spasticity and confirmed by EMG and nerve conduction tests.

**Quadripareisis or Generalized Weakness** Generalized weakness may be due to disorders of the CNS or of the motor unit. Although the terms quadripareisis and generalized weakness are often used interchangeably, quadripareisis is more often chosen when an upper motor neuron cause is suspected and generalized weakness when a disease of the motor unit is likely. Weakness from CNS disorders is usually associated with changes in consciousness or cognition, with increased muscle tone and muscle stretch reflexes, and with alterations of sensation. Most neuromuscular causes of generalized weakness are associated with normal mental function, diminished muscle tone, and hypoactive muscle stretch reflexes. Exceptions are some causes of acute quadriparesis due to upper motor neuron disorders in which transient hyponatremia is present. The major causes of intermittent weakness are listed in Table 21-2. A patient with generalized fatigability without objective weakness may have the chronic fatigue syndrome (Chap. 370).

**ACUTE QUADRIpareisis** Acute quadripareisis with onset over minutes may result from disorders of upper motor neurons (e.g., axonia, hypotension, brainstem or cervical cord ischemia, trauma, and systemic metabolic abnormalities) or muscle (electrolyte disturbances, certain inborn errors of muscle energy metabolism, toxins, or periodic paralyses). Onset over hours to weeks may, in addition to the above, be due to lower motor neuron disorders. Guillain-Barré syndrome (Chap. 365) is the most common lower motor neuron weakness that progresses over days to 4 weeks; the finding of an elevated protein level in the cerebrospinal fluid is helpful but may be absent early in the course. If stupor or coma is present, the evaluation begins with a CT scan of the brain. If upper motor neuron signs are present but the patient is alert, the initial test is usually an MRI of the cervical cord. If weakness is lower motor neuron, myopathic, or uncertain in origin, the clinical approach begins with blood studies for muscle enzymes and electrolytes and an EMG and nerve conduction study.

**SUBACUTE OR CHRONIC QUADRIpareisis** When quadripareisis due to upper motor neuron disease develops over weeks, months, or years, the distinction among disorders of the cerebral hemispheres, brainstem, and cervical spinal cord is usually possible by clinical criteria alone. The diagnostic approach begins with an MRI of the clinically suspected site of pathology. Lower motor neuron disease usually presents with weakness that is most profound distally, whereas myopathic weakness is typically proximal; the evaluation then begins with EMG and nerve conduction studies.

**Monopareisis** This is usually due to lower motor neuron disease, with or without associated sensory involvement. Upper motor neuron weakness occasionally presents with a monopareisis of distal and nonantigravity muscles. Myopathic weakness is rarely limited to one limb.

**ACUTE MONOPAREISIS** Distinguishing between upper and lower motor neuron disorders may be difficult clinically because tone and reflexes are frequently decreased in both at presentation. If the weakness is predominantly in distal and nonantigravity muscles and not associated with sensory impairment or pain, focal cortical ischemia is likely (Chap. 349); in this setting, diagnostic possibilities are similar to those for acute hemiparesis. Sensory loss and pain usually accompany acute lower motor neuron weakness. The distribution of weakness is commonly localized to a single nerve root or peripheral nerve within one limb but occasionally reflects involvement of the brachial or lumbar-sacral plexus. If lower motor neuron weakness is suspected, or if the pattern of weakness is uncertain, the clinical approach begins with an EMG and nerve conduction study.

**SUBACUTE OR CHRONIC MONOPAREISIS** Weakness with atrophy of one limb that develops over weeks or months is almost always lower motor neuron in origin. If the weakness is associated with numbness, a peripheral nerve or spinal root origin is likely; uncommonly, the brachial or lumbosacral plexus is affected. If numbness is absent, anterior horn cell disease is likely. In either case, an electrodiagnostic study is indicated. If upper rather than lower motor neuron signs are present, a tumor, vascular malformation, or other cortical lesion affecting the precentral gyrus may be responsible. Alternatively, if the leg is affected, a small thoracic cord lesion, often a tumor or multiple sclerosis, may be present. In these situations, the approach begins with an imaging study of the suspicious area.

**Distal Weakness** Involvement of two or four limbs distally suggests lower motor neuron or peripheral nerve disease. Acute distal lower limb weakness occurs occasionally from an acute toxic polyneuropathy or cauda equina syndrome. Distal symmetric weakness usually develops over weeks, months, or years and is due to metabolic, toxic, hereditary, degenerative, or inflammatory diseases of peripheral nerves (Chap. 363). With peripheral nerve disease, weakness is usually less severe than numbness. Anterior horn cell disease may begin distally but is typically asymmetric and is not associated with numbness (Chap. 353). Rarely, myopathies also present with distal weakness (Chap. 368). The first step in evaluation is an electrophysiologic study (Fig. 21-3).

**Proximal Weakness** Proximal weakness of two or four limbs suggests a disorder of muscle or, less commonly, neuromuscular junction or anterior horn cell. Myopathy often produces symmetric weakness of the pelvic or shoulder girdle muscles (Chap. 368). Diseases of the

---

**TABLE 21-2 Causes of Episodic Generalized Weakness**

| 1. Electrolyte disturbances, e.g., hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyponatremia, hypophosphatemia, hypermagnesemia |
| 2. Muscle disorders |
| a. Channelopathies (periodic paralyses) |
| b. Metabolic defects of muscle (impaired carbohydrate or fatty acid utilization; abnormal mitochondrial function) |
| 3. Neuromuscular junction disorders |
| a. Myasthenia gravis |
| b. Lambert-Eaton myasthenic syndrome |
| 4. Central nervous system disorders |
| a. Transient ischemic attacks of the brainstem |
| b. Transient global cerebral ischemia |
| c. Multiple sclerosis |
neuromuscular junction (such as myasthenia gravis) may present with symmetric proximal weakness (Chap. 366), often associated with ptosis, diplopia, or bulbar weakness and fluctuating in severity during the day. Extreme fatigability present in some cases of myasthenia gravis may even suggest episodic weakness, but strength rarely returns fully to normal. The proximal weakness of anterior horn cell disease is most often asymmetric, but may be symmetric if familial (Chap. 353). Nummbers does not occur with any of these diseases. The evaluation usually begins with determination of the serum creatine kinase level and electrophysiologic studies.

**Weakness in a Restricted Distribution**  In some patients, weakness does not fit any of the above patterns. Examples include weakness limited to the extracocular, hemifacial, bulbar, or respiratory muscles. If unilateral, restricted weakness is usually due to lower motor neuron or peripheral nerve disease, such as in a facial palsy (Chap. 355) or an isolated superior oblique muscle paresis (Chap. 25). Relatively symmetric weakness of extraocular or bulbar muscles is usually due to a myopathy (Chap. 367) or neuromuscular junction disorder (Chap. 366). Bilateral facial palsy with areflexia suggests Guillain-Barré syndrome (Chap. 365). Worsening of relatively symmetric weakness with fatigue is characteristic of neuromuscular junction disorders. Asymmetric bulbar weakness is usually due to motor neuron disease. Weakness limited to respiratory muscles is uncommon and is usually due to motor neuron disease, myasthenia gravis, or polymyositis/dermatomyositis (Chap. 369).

**SPASMS AND CRAMPS**

Spontaneous or exercise-related discomfort from muscles is usually benign. However, a number of disorders of the motor system are characteristically painful. *Myalgias* (Chap. 367) are pains that are felt in muscle; the term does not imply an involuntary contraction. *Spasms* and *cramps* refer to episodes of involuntary contraction of one or more muscles. Cramps are usually painful, whereas spasms are not necessarily uncomfortable.

Involuntary contraction of muscle may occur with disorders of the CNS, lower motor neuron, or muscle. Contractions that originate within the CNS and are associated with upper motor neuron signs are usually referred to as spasms and generally affect the flexors or extensors of one or more limbs. Those that originate within the CNS and are not associated with upper motor neuron signs include movement disorders discussed below, as well as the rare stiff-person syndrome and tetanus. Muscle rigidity from active muscle contraction can occur in the malignant hyperthermia syndrome, usually associated with general anesthesia. In the neuroleptic malignant syndrome, muscle rigidity arises from CNS overactivity. Involuntary contractions that originate in the lower motor neurons are usually cramps, occasionally tetany, or rarely neuromyotonia. Spasms that originate in muscle or muscle membrane generally manifest as delayed relaxation after voluntary contraction (myotonia or rarely a contracture). These conditions may be difficult to distinguish clinically but are often well characterized by EMG.

**Stiff-Person Syndrome** This rare syndrome is characterized by slowly progressive muscle stiffness and superimposed spasms. The stiffness commonly begins in the low back and spreads over months up the spine and into the limbs but not into the jaw. The gait becomes stiff, and there is hyperlordosis of the lumbar spine. Spasms are often produced by startled. Emotional stress tends to worsen the stiffness as well as the frequency and severity of spasms. The spontaneous motor activity disappears during sleep. The syndrome is often associated with diabetes mellitus and can be paraneoplastic, accompanying Hodgkin’s lymphoma, small cell cancer of the lung, and breast cancer. Most patients have a serum antibody against glutamic acid decarboxylase, an enzyme responsible for synthesis of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Stiffness results from loss of descending brainstem or segmental spinal inhibitory influences on the lower motor neurons. EMG studies reveal continuous motor unit activity that is similar to voluntary effort with preservation of the silent period to muscle stretch. Stiffness and spasms typically respond partially to treatment with baclofen or benzodiazepines.

**Tetanus** This rare hyperexcitable state results from exposure to tetanus toxin in patients infected with *Clostridium tetani* (Chap. 124). Painful spasms typically begin with jaw closure (trismus) and soon become generalized. EMG studies reveal continuous motor unit activity that is similar to voluntary effort except for loss of the silent period to muscle stretch.

**Cramps** These are the most common type of involuntary muscle contraction. Cramps are a painful contraction of a single muscle that produces a palpable knot within the muscle for seconds to minutes and is relieved by passive stretch of the muscle or spontaneously. EMG studies reveal motor unit activity that has too high a discharge frequency to be voluntary. If cramps are associated with weakness, the weakness is almost always lower motor neuron in origin. When strength is normal, no definable condition is usually found, although dehydration, hypothyroidism, or uremia is occasionally present. If prominent, membrane stabilizing drugs, such as carbamazepine, may provide symptomatic benefit.

**Neuromyotonia (Isaac’s Syndrome)** Neuromyotonia is characterized by muscle stiffness at rest that persists during sleep and by delayed relaxation after voluntary effort. Distal limb muscles are usually affected most severely, but all skeletal muscle may be involved. Gait may be stiff, and close inspection of the muscle reveals undulation of the overlying skin due to continuous muscle fiber contractions (myokymia). The continuous muscle fiber activity generates heat, and excessive sweating is common. EMG studies commonly reveal myokymic discharges, especially in familial cases. Rarely, EMGs record high-frequency neuromyotonic discharges. Autoantibodies against voltage-gated potassium channels have been demonstrated in some cases, and plasma exchange may be effective.

**Myotonia** This is a nonpainful delay in the relaxation of muscle after voluntary activity. Delay in opening the hand after a forceful grip (grip myotonia) is common. These disorders are usually familial and worsen in cold weather. EMG demonstrates a waxing and waning discharge of individual muscle fibers.

**Contracture** A painful inability to relax a muscle after voluntary activity due to energy depletion characterizes certain metabolic disorders with failure of energy production, such as myophosphorylase deficiency (McArdle’s disease). EMG studies reveal electrical silence.

**MOVEMENT DISORDERS**

In these disorders, abnormal movements (or *dyskinesias*) occur due to a disturbance of fluency and speed of voluntary movement or the presence of unintended extra movements. Because they are so distinct from the pyramidal disorders that cause upper motor neuron weakness, movement disorders are often referred to as *extrapyramidal* diseases. Hyperkinetic movement disorders are those in which an excessive amount of spontaneous motor activity is seen or in which abnormal involuntary movements occur. Hypokinetic movement disorders are characterized by *akinesia* or *bradykinesia*, in which purposeful motor activity is absent or reduced (“poverty of movement”).

**PATHOGENESIS** Movement disorders result from disease of the basal ganglia, paired subcortical gray matter structures consisting of the caudate and the putamen (which together are called the striatum), the
internal and external segments of the globus pallidus, the subthalamic nucleus, and the substantia nigra (see Chap. 351).

Parker’s disease the prototypic hypokinetic movement disorder, results from a loss of dopaminergic neurons in the substantia nigra pars compacta. This leads to less excitation of striatal neurons that express the D1 type of dopamine receptors and less inhibition of D2 striatal neurons, both contributing to reduced facilitation of cortically initiated movement. The resting tremor of Parkinson’s disease is less readily explained by this model but may result from effects on cholinergic interneurons in the striatum. Huntington’s disease (Chap. 350), a hyperkinetic movement disorder, may be explained by selective loss of D2 striatal neurons, resulting in disinhibition of cortically initiated movements without normal feedback control. The pathogenesis of hemiballismus is similar—a direct lesion of the glutamatergic neurons in the subthalamic nucleus (usually from a stroke) leads to disinhibition of thalamocortical projections.

Hyperkinetic Movement Disorders Abnormal involuntary movements may be rhythmical or irregular. Those that are rhythmical are termed tremors, with the uncommon exception of palatal and segmental myoclonus. Tremors are divided into three types: rest, postural, and intention tremor. A rest tremor is maximal at rest and becomes less prominent with activity. A gradual onset is characteristic of parkinsonism and is commonly associated with bradykinesia and cogwheel rigidity (Chap. 351). A rest tremor that develops acutely is usually due to toxins [such as exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or dopamine blocking drugs (such as phenothiazines). A postural tremor is maximal while limb posture is actively maintained against gravity; it is lessened by rest and is not markedly enhanced during voluntary movement toward a target. A postural tremor that develops acutely is usually due to toxic or metabolic factors (for example, hyperthyroidism) or stress. The insidious onset of a postural tremor suggests a benign or familial essential tremor. An intention tremor is most prominent during voluntary movement toward a target and is not present during postural maintenance or at rest. It is a sign of cerebellar disease (Chap. 352). Asterixis, which may superficially resemble a tremor, is an intermittent inhibition of muscle contraction that occurs with metabolic encephalopathy (Chap. 257). This leads, for example, to a momentary and repetitive partial flexion of the wrists during attempted sustained wrist extension. Irregular involuntary movements are characterized by their speed and location, and by whether they can be suppressed voluntarily. The slowest are athetosis and dystonia. Athetosis is a slow, writhing, sinuous movement that occurs nearly continuously in distal muscles. Dystonia is a slowly varying but nearly continuous deviation of posture about one or more joints; it may occur in a proximal or distal limb or in axial structures. Dystonia is a more sustained deviation of posture than athetosis, although these two phenomena overlap considerably.

Among the rapid irregular movements, tics are controlled with voluntary effort, while the others are not. Tics often occur repetitively in a single location but are sometimes multifocal. Chorea, hemiballismus, and myoclonus are rapid, irregular jerks that cannot be voluntarily suppressed. Hemiballismus manifests as a sudden and often violent flinging movement of a proximal limb, usually an arm. Hemiballismus usually develops acutely due to infarction of the contralateral subthalamic nucleus but occasionally develops subacutely or chronically due to other lesions of this nucleus.

Chorea is a rapid, jerky, irregular movement that tends to occur in the distal limbs or face but may also occur in proximal limbs and trunk. Acute or subacute onset is usually due to toxins including excess levodopa or dopamine-agonist therapy or, less often, neuroleptics, birth control pills, pregnancy (chorea gravidarum), hyperthyroidism, or the antiphospholipid syndrome. In children, it may be associated with rheumatic fever and, in such cases, is referred to as Sydenham’s chorea. The gradual onset of chorea is typical of degenerative neurologic diseases, such as Huntington’s disease.

Myoclonus is a rapid, brief, irregular movement that is usually multifocal. Myoclonus can occur spontaneously at rest, in response to sensory stimuli, or with voluntary movements. It is a symptom that occurs in a wide variety of metabolic and neurologic disorders. Posthypoxic intention myoclonus is a special myoclonic syndrome that occurs as a sequel to transient cerebral anoxia. Myoclonus may result from lipid storage disease, encephalitis, prion diseases, or metabolic encephalopathies due to respiratory failure, chronic renal failure, hepatic failure, or electrolyte imbalance. Myoclonus is also a feature of certain types of epilepsy (Chap. 348). Palatal and segmental myoclonus are uncommon rhythmical forms of myoclonus that may resemble tremor; they are caused by structural disease of the brainstem or spinal cord at the level of the abnormal movement.

Hypokinetic Movement Disorders These manifest as bradykinesia, with a masked, expressionless facial appearance, loss of associated limb movements during walking, and rigid and en bloc turning. If bradykinesia is associated only with a rest tremor, cogwheel rigidity, or impairment of postural reflexes (especially with a tendency to fall backwards), Parkinson’s disease is likely. If cognitive, language, upper motor neuron, sensory, or autonomic signs are also present, a multisystem degenerative neurologic disease is present.

**Imbalance and Disorders of Gait**

Imbalance is the impaired ability to maintain the intended orientation of the body in space. It is generally manifest as difficulty in maintaining an upright posture while standing or walking; a severe imbalance may also affect the ability to maintain posture while seated. Patients with imbalance commonly complain of a feeling of unsteadiness or dysequilibrium. Whereas imbalance and unsteadiness are synonymous, dysequilibrium implies the additional component of impaired spatial orientation even while lying down. Patients with dysequilibrium commonly also experience vertigo, defined as a hallucination of rotary movement.

**Pathogenesis**

**Imbalance and Limb Ataxia** Imbalance results from disorders of the vestibular, sensory, or cerebellar systems, whereas limb ataxia is produced by disorders of the sensory or cerebellar systems. Asymmetric vestibular sensory input to the brainstem and cerebellum produces asymmetric imbalance, but not limb ataxia. Sensory ataxia is caused by lesions that affect the peripheral sensory fibers; dorsal root ganglia cells; posterior columns of the spinal cord; or lemniscal system in the brainstem, thalamus, or parietal cortex (Chap. 22). Impairment of the proprioceptive sensory feedback to the cerebellum, basal ganglia, and cortex produces sensory ataxia. Sensory ataxia results in imbalance and disturbs the fluency and integration of limb movements that can be partially alleviated by visual feedback. Imbalance with cerebellar ataxia results from disorders of proprioceptive, spinocerebellar, or vestibular sensory input; the integration of these inputs in the brainstem or midline cerebellar vermis or flocculonodular lobe; or the motor output to the spinal neurons that control muscles of the proximal limbs and trunk. Cerebellar limb ataxia results from disorders of the spinocerebellar and corticopontocerebellar inputs, the integration of these inputs in the intermediate and lateral cerebellum, or the output to the spinal neurons (via the red nucleus and rubrospinal tract) or to the cortex. These pathways ensure adequate speed, fluency, and integration of limb movements. The lateral cerebellar hemispheres coordinate a polysynaptic feedback circuit that modulates cortically initiated limb movement.

**Disorders of Gait** Walking is one of the most complicated motor activities. Cylindrical stepping movements produced by the lumbarosacral spinal cord centers are modified by cortical, basal ganglionic, brainstem, and cerebellar influences based on proprioceptive, vestibular, and visual feedback.
**Imbalance**  
A guide to interpretation of imbalance without weakness is presented in Fig. 21-4.

**Imbalance with cerebellar ataxia** typically produces truncal ataxia, which is usually revealed during the process of rising from a chair, assuming the upright stance with the feet together, or performing some other activity while standing. Once a desired position is reached, imbalance may be surprisingly mild. As walking begins, the imbalance recurs. Patients usually learn to lessen the imbalance by walking with the legs widely separated. The imbalance is usually not lateralized; may be accompanied by symmetric nystagmus; and is caused by toxic, metabolic, inflammatory, or neurodegenerative diseases. Asymmetric cerebellar ataxia suggests structural disease from ischemia, tumor, or other mass lesion.

**Cerebellar limb ataxia** is characterized by dysmetria (irregular errors in amplitude and force of movements); intention tremor (acceleration as the target is approached); dystadiadokokinesia (errors in rhythm, velocity or force); and excessive rebound of outstretched arms against a resistance that is suddenly removed. Muscle tone is often modestly reduced; this contributes to the abnormal rebound due to decreased activation of segmental spinal cord reflexes and also to pendular reflexes, i.e., a tendency for a tendon reflex to produce multiple swings to and fro after a single tap. If involvement is asymmetric, lateralized imbalance is common and usually associated with asymmetric nystagmus. —For further discussion of cerebellar diseases, see Chap. 352.

**Imbalance with vestibular dysfunction** is characterized by a consistent tendency to fall to one side. The patient commonly complains of vertigo rather than imbalance, especially if the onset is acute. Acute vertigo associated with lateralized imbalance but no other neurologic signs is often due to disorders of the semicircular canal (Chap. 20); the presence of other neurologic signs suggests brainstem ischemia (Chap. 349) or multiple sclerosis (Chap. 359). When the vestibular dysfunction is peripheral, positional nystagmus and vertigo tend to resolve if a provocative position is maintained (extinction) or repeated (habituation). Lateralized imbalance of gradual onset or persisting for >2 weeks, accompanied by nystagmus, may result from lesions of the semicircular canal or vestibular nerve, brainstem, or cerebellum.

**Imbalance with sensory ataxia** is characterized by marked worsening when visual feedback is removed. The patient can often assume the upright stance with feet together cautiously with eyes open. With eye closure, balance is rapidly lost (positive Romberg sign) in various directions at random. Sensory examination reveals impairment of proprioception at the toes and ankles, usually associated with an even more prominent abnormality of vibratory perception. Prompt evaluation for vitamin B12 deficiency is important, as this disorder is reversible if recognized early. Depression or absence of reflexes points to peripheral nerve disorders. Spasticity with extensor plantar responses suggests posterior column and spinal cord disorders. Rarely, sensory ataxia produces lateralized imbalance. In these cases, the disorder is usually in the parietal lobe or thalamus, but may also be due to an asymmetric sensory neuropathy or posterior column disease.

**Sensory limb ataxia** is similar to cerebellar limb ataxia but is markedly worse when the eyes are closed. Examination also reveals abnormal proprioception and vibratory perception. The approach focuses on localizing the proprioceptive impairment to the peripheral nerves, the posterior columns of the spinal cord, or rarely the parietal lobe.

Other forms of imbalance occur, but the fundamental problem is usually a primary disorder of strength, extrapyramidal function, or cortical initiation of movement, as indicated in Fig. 21-4.

**Abnormal Gait**  
Each of the disorders discussed in this chapter produces a characteristic gait disturbance. If the neurologic examination is normal except for an abnormal gait, diagnosis may be difficult even for the experienced clinician.

**Hemiparetic gait** characterizes spastic hemiparesis. In its most severe form, an abnormal posture of the limbs is produced by spasticity. The arm is adducted and internally rotated, with flexion of the elbow, wrist, and fingers and with extension of the hip, knee, and ankle. Forward swing of the spastic leg during walking requires abduction and circumduction at the hip, often with contralateral tilt of the trunk to prevent the toes catching on the floor as the leg is advanced. In its mildest form, the affected arm is held in a normal position, but swings less than the normal arm. The affected leg is flexed less than the normal leg during its forward swing and is more externally rotated. A hemiparetic gait is a common residual sign of a stroke.

**Paraparetic gait** is a walking pattern in which both legs are moved in a slow, stiff manner with circumduction, similar to the leg movement in a hemiparetic gait. In many patients, the legs tend to cross with each forward swing (“scissoring”). A paraparetic gait is a common sign of spinal cord disease and also occurs in cerebral palsy.

**Steppage gait** is produced by weakness of ankle dorsiflexion. Because of the partial or complete foot drop, the leg must be lifted higher than usual to avoid catching the toe on the floor during the forward swing of the leg. If unilateral, steppage gait is usually due to L5 radiculopathy, sciatic neuropathy, or peroneal neuropathy. If bilateral, it

---

**FIGURE 21-4** An algorithm for evaluation of imbalance without weakness; if weakness is present, see Fig. 21-3.
is the common result of a distal polyneuropathy or lumbosacral polyradiculopathy.

Waddling gait results from proximal lower limb weakness, most often from myopathy but occasionally from neuromuscular junction disease or a proximal symmetric muscular atrophy. With weakness of hip flexion, the trunk is tilted away from the leg that is being moved to lift the hip and provide extra distance between the foot and the floor, and the pelvis is rotated forward to assist with forward motion of the leg. Because pelvic girdle weakness is customarily bilateral, the pelvic lift and rotation alternate from side to side, giving the waddling appearance to the gait.

Parkinsonian gait is characterized by a forward stoop, with modest superficial resemblance that of parkinsonism, in that the posture is stooped and any steps taken are short and shuffling. However, initiation and maintenance of walking are impaired in a different manner. Each movement that is required for walking can usually be performed, if tested in isolation while sitting or lying. However, when asked to step forward while standing, a long pause often occurs before any movement is forward (propulsion) or backward (retropulsion). The postural instability leads to falls (Chap. 351).

Apraxic gait results from bilateral frontal lobe disease with impaired ability to plan and execute sequential movements. This gait superficially resembles that of parkinsonism, in that the posture is stooped and any steps taken are short and shuffling. However, initiation and maintenance of walking are impaired in a different manner. Each movement that is required for walking can usually be performed, if tested in isolation while sitting or lying. However, when asked to step forward while standing, a long pause often occurs before any attempt is made to flex at the hip and advance, as if the patient is “glued to the ground.” Once walking is initiated, it is not maintained, even in an abnormal festinating manner. Rather, after one or several steps are taken, walking is stopped for several seconds or longer. The process is then repeated. Dementia and incontinence may coexist.

Choreoathetotic gait is characterized by an intermittent, irregular movement that disrupts the smooth flow of a normal gait. Flexion or extension movements at the hip are common and unpredictable but readily observed as a pelvic lurch.

Cerebellar ataxic gait is a broad-based gait disorder in which the speed and length of stride varies irregularly from step to step. With midline cerebellar disease, as in alcoholics, posture is erect but the feet are separated; lower limb ataxia is commonly present as well. With disease of the cerebellar hemispheres, limb ataxia and nystagmus are commonly present as well.

Sensory ataxic gait may resemble a cerebellar gait, with its broad-based stance and difficulty with change in position. However, although balance may be maintained with the eyes open, loss of visual input through eye closure results in rapid loss of balance with a fall (positive Romberg sign), unless the physician assists the patient.

Vestibular gait is one in which the patient consistently tends to fall to one side, whether walking or standing. Cranial nerve examination usually demonstrates an asymmetric nystagmus. The possibilities of unilateral sensory ataxia and hemiparesis are excluded by the findings of normal proprioception and strength.

Astasia-abasia is a typical hysterical gait disorder. Although the patient usually has normal coordination of leg movements in bed or while sitting, the patient is unable to stand or walk without assistance. If distracted, stationary balance is sometimes maintained and several steps are taken normally, followed by a dramatic demonstration of imbalance with a lunge toward the examiner’s arms or a nearby bed.

FURTHER READING


22 Numbness, Tingling, and Sensory Loss

Arthur K. Asbury

NORMAL SENSATION

Normal somatic sensation reflects a continuous day and night monitoring process that occupies considerable moment-to-moment nervous system capacity. Little of this activity reaches consciousness under ordinary conditions. In contrast, disordered sensation, particularly if experienced as painful, is alarming and dominates the sufferer’s attention. Abnormalities of sensation, especially if painful, tend to make those suffering seek medical help. The physician must be able to recognize abnormal sensations by how they are described, know their type and likely site of origin, and understand their implications. *For a consideration of pain, see Chap. 11.*

POSITIVE AND NEGATIVE PHENOMENA

Abnormal sensory phenomena may be divided into two categories, positive and negative. The prototype positive phenomenon is tingling (pins-and-needles), and the principal negative phenomenon is numbness. In addition to tingling, positive sensory phenomena include other altered sensations that are described as prickling, bandlike, lightning-like shooting feelings (lancinations), aching, knife-like, twisting, drawing, pulling, tightening, burning, tearing, electrical, or raw feelings. These descriptors are frequently the actual words used by patients. Such sensations are usually experienced as painful, but not necessarily.

Positive phenomena usually result from trains of impulses generated at a site or sites of lowered threshold or heightened excitability along a sensory pathway, either peripheral or central. The nature and severity of an abnormal sensation depend on the number, rate, timing, and distribution of ectopic impulses and the type and function of nervous tissue in which they arise. Because positive phenomena represent excessive activity in sensory pathways, they are not necessarily associated with sensory deficit (loss) upon examination.

Negative phenomena represent loss of sensory function and are characterized by diminished or absent feeling, often experienced as numbness. In contrast to positive phenomena, negative phenomena are accompanied by abnormal findings on sensory examination. In disorders affecting peripheral sensation, it is estimated that at least half the afferent axons innervating a given site are lost or functionless before sensory deficit can be demonstrated by clinical examination. This threshold varies according to how rapidly sensory nerve fibers have lost function. If the rate of loss is slow and chronic, lack of cutaneous feeling may be unnoticed by the patient and difficult to demonstrate on examination, even though few sensory fibers are functioning. Rapidly evolving sensory abnormality usually evokes both positive and negative phenomena that are readily noticed. Subclinical degrees of sensory dysfunction not demonstrable on clinical sensory examination may be revealed by sensory nerve conduction studies or somatosensory evoked potentials (Chap. 359). Sensory symptoms may be either positive or negative, but sensory signs on examination are always a measure of negative phenomena.

TERMINOLOGY

Words used to characterize sensory disturbance are descriptive and have been arrived at mainly by convention. Paresthesia and dysesthesia are general terms used to denote sensory symptoms (positive phenomena) and are usually stated in the plural form. Parasthesias usually refer to tingling or pins-and-needles sensations but may also include a wide variety of other abnormal sensations, ex-
cepting pain. Sometimes “paresthesias” carry the implication that the abnormal sensations are perceived without an apparent stimulus. Dysesthesia is a more general term denoting all types of abnormal sensations, even painful ones, whether a stimulus is evident or not.

While paresthesias and dysesthesias refer to sensations described by patients, another set of terms refers to sensory abnormalities found on examination. These include hypesthesia or hypoesthesia (reduction of cutaneous sensation to a specific type of testing such as pressure, light touch, and warm or cold stimuli); anesthesia (complete absence of skin sensation to the same stimuli plus pinprick); and hypalgasia (referring to reduced pain perception, i.e., nociception, such as the pricking quality elicited by a pin). Hyperesthesia means pain in response to touch. Similarly, allodynia describes the situation in which a nonpainful stimulus, once perceived, is experienced as painful, even excruciating. An example is elicitation of a painful sensation by application of a vibrating tuning fork. Hyperalgnesia denotes severe pain in response to a mildly noxious stimulus, and hyperpathia, a broad term, encompasses all the phenomena described by hyperesthesia, allodynia, and hyperalgnesia. With hyperpathia, the threshold for a sensory stimulus is increased and the perception is delayed, but once felt, is unduly painful.

Disorders of deep sensation, arising from muscle spindles, tendons, and joints, affect proprioception (position sense). Manifestations include imbalance (particularly with eyes closed or in the dark), clumsiness of precision movements, and unsteadiness of gait, which are referred to collectively as sensory ataxia (Chap. 21). Other findings on examination usually, but not invariably, include reduced or absent joint position and vibratory sensibility and absent deep tendon reflexes in the affected limbs. Romberg’s sign is positive, which means that the patient sways or topples when asked to stand with feet close together and eyes closed. In severe states of deafferentation involving deep sensation, the patient cannot walk or stand unaided or even sit unsupported. Continuous, sometimes wormlike involuntary movements, called pseudoathetosis, of the outstretched hands and fingers occur, particularly with eyes closed. Such patients are severely disabled.

ANATOMY OF SENSATION Cutaneous afferent innervation is conveyed by a rich variety of receptors, both naked nerve endings (nociceptors and thermoreceptors) and encapsulated terminals (mechanoreceptors). Each type of receptor has its own set of sensitivities to specific stimuli, size and distinctness of receptive fields, and adaptational qualities. Much of the knowledge about these receptors has come from the development of techniques to study single intact nerve fibers intraneurally in awake, unanesthetized human subjects. It is possible not only to record from single nerve fibers, large or small, but also to stimulate single fibers in isolation. A single impulse, whether elicited by a natural stimulus or evoked by electrical microstimulation, in a large myelinated afferent fiber may be both perceived and localized.

Afferent fibers of all sizes in peripheral nerve trunks traverse the dorsal roots and enter the dorsal horn of the spinal cord (Fig. 22-1). From there the smaller fibers take a different route to the parietal cortex than the larger fibers. The polysynaptic projections of the smaller fibers (unmyelinated and small myelinated), which subserve mainly nociception, temperature sensibility, and touch, cross and ascend in the opposite anterior and lateral columns of the spinal cord, through the brainstem, to the ventral posterolateral (VPL) nucleus of the thalamus, and ultimately project to the postcentral gyrus of the parietal cortex (Chap. 11). This is referred to as the spinothalamic pathway, or anterolateral system. The larger fibers, which subserve tactile and position sense and kinesthesia, project rostrally in the posterior column on the same side of the spinal cord and make their first synapse in the gracile or cuneate nuclei of the lower medulla. The second-order neuron decussates and ascends in the medial lemniscus located medially in the medulla and in the tegmentum of the pons and midbrain and synapses in the VPL nucleus. The third-order neuron projects to parietal cortex; this large fiber system is referred to as the posterior column–medial lemniscal pathway (lemniscal, for short). Note that although the lemniscal and the anterolateral pathways both project up the spinal cord to the thalamus, it is the (crossed) anterolateral pathway that is referred to as the spinothalamic tract, by convention.

Although the fiber types and functions that make up the spinothalamic and lemniscal systems are relatively well known, it has been found that many other fibers, particularly those associated with touch, pressure, and position sense, ascend in a diffusely distributed pattern both ipsilaterally and contralaterally in the anterolateral quadrants of the spinal cord. This explains why an individual with a complete lesion of the posterior columns of the spinal cord may have little sensory deficit on examination.

EXAMINATION OF SENSATION The main components of the sensory examination are tests of primary sensation. These include the sense of pain, touch, vibration, joint position, and thermal sensation, both hot and cold (Table 22-1). Detailed descriptions of how to perform the various tests of the sensory examination can be found in standard texts (see “Bibliography”).

Some general principles pertain. The examiner must depend on patient responses, particularly when testing cutaneous sensation (pin, touch, warm, or cold). This subjective element complicates the interpretation of the sensory examination. Further, some patients are only partially examinable. In a stuporous patient, sensory examination is reduced to observing the briskness of withdrawal in response to a pinch or other noxious stimulus. Comparison of response on one side of the body to the other is essential. In the alert but uncooperative patient, cutaneous sensation may be unexaminable. However, it is usually possible to get some idea of proprioceptive function by noting the patient’s best performance of movements requiring balance and precision. Frequently, patients present with sensory symptoms that do not fit anatomic localization and that are accompanied by either no abnormalities or gross inconsistencies on examination. The examiner should then consider whether the sensory symptoms are a disguised request...
for help with psychological or situational problems. Discretion must be used in pursuing this possibility. Finally, sensory examination of a patient who has no neurologic complaints can be brief and consist of pin, touch, and vibration testing in the hands and feet plus evaluation of stance and gait, including the Romberg maneuver. Evaluation of stance and gait also tests the integrity of motor and cerebellar systems.

**PRIMARY SENSATION** (See Table 22-1)
The sense of pain is usually tested with a clean pin, asking the patient to focus on the pricking or unpleasant quality of the stimulus and not just the pressure or touch sensation elicited. Areas of hyperalgesia should be mapped by proceeding radially from the most hyperalgesic site (Figs. 22-2 and 22-3).

Temperature sensation, to both hot and cold, is probably best tested with water flasks filled with water of the desired temperature, using a thermometer to verify the temperature. This is impractical in most settings. An alternative way to test cold sensation is to touch a metal object, such as a tuning fork at room temperature, to the skin. For testing warm temperatures, the tuning fork or other metal object may be held under warm water of the desired temperature and then used. Both cold and warm should be tested because different receptors respond to each.

Touch is usually tested with a wisp of cotton or a fine camelhair brush. In general, it is better to avoid testing touch on hairy skin because of the profusion of sensory endings that surround each hair follicle.

Joint position testing is a measure of proprioception, one of the most important functions of the sensory system. With the patient keeping eyes closed, joint position is tested in the great toe and in the fingers. If errors are made in recognizing the direction of passive movements of the toe or the finger, more proximal joints should be tested. A test of proximal joint position sense, primarily at the shoulder, is performed by asking the patient to bring the two index fingers together with arms extended and eyes closed. Normal individuals can do this accurately, with errors of a centimeter or less.

The sense of vibration is tested with a tuning fork, preferably a fork at 128 Hz. Vibration is usually tested at bony prominences, beginning distally at the malleoli of the ankles, and at the knuckles. If abnormalities are found, more proximal sites can be examined. Vibratory thresholds at the same site in the patient and the examiner can be compared for control purposes.

**QUANTITATIVE SENSORY TESTING** Effective sensory testing devices have been developed over the past two decades. Quantitative sensory testing is particularly useful for serial evaluation of cutaneous sensation in clinical trials. Threshold testing for touch and vibratory and thermal sensation is the most widely used application.

**CORTICAL SENSATION** The most commonly used tests of cortical function are two-point discrimination, touch localization, and bilateral simultaneous stimulation and tests for graphesthesia and stereognosis. Abnormalities of these sensory tests, in the presence of normal primary sensation in an alert cooperative patient, signify a lesion of the parietal cortex or thalamocortical projections to the parietal lobe. If primary sensation is altered, these cortical discriminative functions will usually be abnormal, too. Comparisons should always be made between analogous sites on the two sides of the body because the deficit with a specific parietal lesion is likely to be hemispatial. Side-to-side comparisons hold true for all cortical sensory testing.

Two-point discrimination is tested by special calipers, the points of which may be set from 2 mm to several centimeters apart and then applied simultaneously to the site to be tested. The pulp of the finger tips is a common site to test; a normal individual can distinguish about 3-mm separation of points there.

**Touch localization** is usually carried out by light pressure for an instant with the examiner’s fingertip, asking the patient, whose eyes are closed, to identify the site of touch with his or her fingertip. Bilateral simultaneous stimulation at analogous sites (e.g., the dorsa of both hands) can be carried out to determine whether the perception of touch is extinguished consistently on one side or the other. The phenomenon is referred to as extinction. Graphesthesia means the capacity to recognize with eyes closed letters or numbers drawn by the examiner’s fingertip on the palm of the hand. Once again, the comparison of one side with the other is of prime importance. Inability to recognize numbers or letters is termed agraphesthesia.

Stereognosis refers to the ability to identify common objects by palpation, recognizing their shape, texture, and size. Common standard objects are the best test objects, such as a marble, a paper clip, or coins. Patients with normal stereognosis should be able to distinguish a dime from a penny and a nickel from a quarter without looking. Patients should only be allowed to feel the object with one hand at a time. If they are unable to identify it in one hand, it should be placed in the other for comparison. Individuals unable to identify common objects and coins in one hand who can do so in the other are said to have astereognosis of the abnormal hand.

**LOCALIZATION OF SENSORY ABNORMALITIES**
Sensory symptoms and signs can result from lesions at almost any level of the nervous system, including parietal cortex, deep white matter, thalamus, brainstem, spinal cord, spinal root, peripheral nerve, and sensory receptor. Noting the distribution and nature of sensory symptoms and signs is the most important way to localize their source. The extent, configuration, symmetry, quality, and severity are the key observations.

Dysesthesias without sensory findings by examination can be difficult to interpret. To illustrate, tingling dysesthesias in an acral distribution (hands and feet) can be systemic in origin, e.g., secondary to hyperventilation, or can be induced by a medication, such as the diuretic acetazolamide. Distal dysesthesias can also be an early event in an evolving polynuropathy or can herald a myelopathy, such as with vitamin B12 deficiency. Sometimes distal dysesthesias have no definable basis. In contrast, dysesthesias that correspond to a particular peripheral nerve territory denote a lesion of that nerve trunk. For instance, dysesthesias restricted to the fifth digit and the adjacent one-half of the fourth finger on one hand reliably point to disorder of the ulnar nerve, most commonly at the elbow.

**NERVE AND ROOT** In focal nerve trunk lesions severe enough to cause a deficit, sensory abnormalities are readily mapped and generally have discrete boundaries (Figs. 22-2 and 22-3). Root lesions, referred to as radicular, are frequently accompanied by deep, aching pain along the

---

### Table 22-1. Testing Primary Sensation

<table>
<thead>
<tr>
<th>Sense</th>
<th>Test Device</th>
<th>Endings Activated</th>
<th>Fiber Size Mediating</th>
<th>Central Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain, Temperature, heat</td>
<td>Pinprick, Warm metal object</td>
<td>Cutaneous nociceptors</td>
<td>Small</td>
<td>SpTh, also D</td>
</tr>
<tr>
<td>Temperature, cold</td>
<td>Cold metal object</td>
<td>Cutaneous thermoreceptors for hot</td>
<td>Small</td>
<td>SpTh</td>
</tr>
<tr>
<td>Touch</td>
<td>Cotton wisp, fine brush</td>
<td>Cutaneous thermoreceptors for cold</td>
<td>Small</td>
<td>SpTh</td>
</tr>
<tr>
<td>Vibration</td>
<td>Tuning fork, 128 Hz</td>
<td>Cutaneous mechanoreceptors, also naked endings</td>
<td>Large and small</td>
<td>Lem, also D and SpTh</td>
</tr>
<tr>
<td>Joint position</td>
<td>Passive movement of specific joints</td>
<td>Joint capsule and tendon endings, muscle spindles</td>
<td>Large</td>
<td>Lem, also D</td>
</tr>
</tbody>
</table>

*Note: D, diffuse ascending projections in ipsilateral and contralateral anterolateral columns; SpTh, spinothalamic projection, contralateral; Lem, posterior column andlemniscal projection, ipsilateral.*
course of the related nerve trunk. With compression of a fifth lumbar (L5) or first sacral (S1) root, as may occur with a ruptured intervertebral disc, sciatica (radicular pain relating to the sciatic nerve trunk) is a frequent manifestation (Chap. 15). With a lesion affecting a single root, sensory deficit in the distribution of that root is often minimal or not demonstrable at all. This is because adjacent root territories overlap extensively.

Polyneuropathies are generally graded, distal, and symmetric in distribution of deficit (Chap. 363). Dysesthesias begin in the toes and ascend symmetrically, followed by numbness. When dysesthesias reach the knees, they have usually also appeared in the fingertips. The process appears to be nerve length–dependent, and the deficit is often described as “stocking-glove” in type. Although most polyneuropathies are pansensory and affect all modalities of sensation, selective sensory dysfunction according to nerve fiber size may occur. In polyneuropathies that affect small nerve fibers selectively, the hallmark is burning, painful dysesthesias with reduced pinprick and thermal sensation but with sparing of proprioception, motor function, and even deep tendon jerks. Touch is variably involved, but when spared, the sensory pattern is referred to as sensory dissociation. Sensory dissociation patterns can be seen with spinal cord lesions (see below) as well as with small fiber neuropathies. In contrast to small fiber polyneuropathies, large fiber polyneuropathies are characterized by position sense deficit, imbalance, absent tendon jerks, and variable motor dysfunction but preservation of most cutaneous sensation. Dysesthesias, if present at all, tend to be tingling or bandlike.
often described in dramatic terms such as “like the flesh is being torn from my limbs” or “as though that side is bathed in acid.”

**CORTEX** With lesions of the parietal lobe involving either the cortex or subjacent white matter, the most prominent symptoms are contralateral hemineglect, hemi-inattention, and a tendency not to use the affected hand and arm. On cortical sensory testing (two-point discrimination, graphesthesia, etc.), abnormalities are often found, but primary sensation is usually intact. Anterior parietal infarction may present as a pseudothalamic syndrome with crossed hemilateral loss of primary sensation from head to toe. Dysesthesias or a sense of numbness may also occur, and rarely, a painful state.

**FOCAL SENSORY SEIZURES** These are generally due to lesions in the area of the postcentral and/or precentral gyrus. The principal symptoms of focal sensory seizures are tingling or numbness or both, but additional, more complex sensations may occur, such as a rushing feeling, a sense of warmth, or a sense of movement without detectable motion. Likely sites of unilateral symptom origin are in the arm or hand, face, leg, or foot, and symptoms often spread as in a Jacksonian march. Duration of seizures is variable; they may be transient, lasting only seconds, or they may persist for an hour or more. Focal motor features, like clonic jerking, can supervene, and seizures often become generalized with loss of consciousness and tonic-clonic jerking. On occasion, symptoms occur in a symmetric bilateral fashion, for instance, in both hands, as a result of involvement of the second sensory area (unilaterally) located in the rolandic area at and just above the Sylvian fissure.

The cerebral cortex of the human brain contains approximately 20 billion neurons spread over an area of 2.5 m². The primary sensory areas provide an obligatory portal for the entry of sensory information into cortical circuitry, whereas the primary motor areas provide a final common pathway for coordinating complex motor acts. The primary sensory and motor areas constitute 10% of the cerebral cortex. The rest is subsumed by unimodal, heteromodal, paralimbic, and limbic sensory and motor areas constitute 10% of the cerebral cortex. The common pathway for coordinating complex motor acts. The primary into cortical circuitry, whereas the

**WERNICKE’S AREA** is to transform sensory inputs into their neural word representations so that these can establish the distributed associations that give the word its meaning. The anterior pole of the language network, known as Broca’s area, includes the posterior part of the inferior frontal gyrus and a surrounding rim of prefrontal heteromodal association cortex and its diseases.

According to current thinking, there are no centers for “hearing words,” “perceiving space,” or “storing memories.” Cognitive and behavioral functions (domains) are coordinated by intersecting large-scale neural networks that contain interconnected cortical and subcortical components. The network approach to higher cerebral function has at least four implications of clinical relevance: (1) a single domain such as language or memory can be disrupted by damage to any one of several areas, as long as these areas belong to the same network; (2) damage confined to a single area can give rise to multiple deficits, involving the functions of all networks that intersect in that region; (3) damage to a network component may give rise to minimal or transient deficits if other parts of the network undergo compensatory reorganization; and (4) individual anatomic sites within a network display a relative (but not absolute) specialization for different behavioral aspects of the relevant function. Five anatomically defined large-scale networks are most relevant to clinical practice: a perisylvian network for language; a parietofrontal network for spatial cognition; an occiptotemporal network for face and object recognition; a limbic network for retentive memory; and a prefrontal network for attention and behavior.

**THE LEFT PERISYLVIAN NETWORK FOR LANGUAGE: APHASIAS AND RELATED CONDITIONS**

Language allows the communication and elaboration of thoughts and experiences by linking them to arbitrary symbols known as words. The neural substrate of language is composed of a distributed network centered in the perisylvian region of the left hemisphere. The posterior pole of this network is known as Wernicke’s area and includes the posterior third of the superior temporal gyrus and a surrounding rim of inferior parietal and midtemporal cortex. An essential function of Wernicke’s area is to transform sensory inputs into their neural word representations so that these can establish the distributed associations that give the word its meaning. The anterior pole of the language network, known as Broca’s area, includes the posterior part of the inferior frontal gyrus and a surrounding rim of prefrontal heteromodal association cortex and its diseases.
cortex. An essential function of this area is to transform neural word representations into their articulatory sequences so that the words can be uttered in the form of spoken language. The sequencing function of Broca’s area also appears to involve the ordering of words into sentences that contain a meaning-appropriate syntax (grammar). Wernicke’s and Broca’s areas are interconnected with each other and with additional perisylvian, temporal, prefrontal, and posterior parietal regions, making up a neural network subserving the various aspects of language function. Damage to any one of these components or to their interconnections can give rise to language disturbances (aphasia). Aphasia should be diagnosed only when there are deficits in the formal aspects of language such as naming, word choice, comprehension, spelling, and syntax. Dysarthria and mutism do not, by themselves, lead to a diagnosis of aphasia. The language network shows a left hemisphere dominance pattern in the vast majority of the population. In approximately 90% of right handers and 60% of left handers, aphasia occurs only after lesions of the left hemisphere. In some individuals no hemispheric dominance for language can be discerned, and in some others (including a small minority of right handers) there is a right hemisphere dominance for language. A language disturbance occurring after a right hemisphere lesion in a right-hander is called crossed aphasia.

CLINICAL EXAMINATION The clinical examination of language should include the assessment of naming, spontaneous speech, comprehension, repetition, reading, and writing. A deficit of naming (anomia) is the single most common finding in aphasic patients. When asked to name common objects (pencil or wristwatch), the patient may fail to come up with the appropriate word, may provide a circumlocutory description of the object (“the thing for writing”), or may come up with the wrong word (paraphasia). If the patient offers an incorrect but legitimate word (“pen” for “pencil”), the naming error is known as a semantic paraphasia; if the word approximates the correct answer but is phonetically inaccurate (“plenti” for “pencil”), it is known as a phonemic paraphasia. Asking the patient to name body parts, geometric shapes, and component parts of objects (lapel of coat, cap of pen) can elicit mild forms of anomia in patients who can otherwise name common objects. In most anomas, the patient cannot retrieve the appropriate name when shown an object but can point to the appropriate object when the name is provided by the examiner. This is known as a one-way (or retrieval-based) naming deficit. A two-way naming deficit exists if the patient can neither provide nor recognize the correct name, indicating the presence of a language comprehension impairment. Spontaneous speech is described as “fluent” if it maintains appropriate output volume, phrase length, and melody or as “nonfluent” if it is sparse, halting, and average utterance length is below four words. The examiner should also note if the speech is paraphasic or circumlocutory; if it shows a relative paucity of substantive nouns and action verbs versus function words (prepositions, conjunctions); and if word order, tenses, suffixes, prefixes, plurals, and possessives are appropriate. Comprehension can be tested by assessing the patient’s ability to follow conversations, by asking yes-no questions (“Can a dog fly?”, “Does it snow in summer?”) or asking the patient to point to appropriate objects (“Where is the source of illumination in this room?”). Statements with embedded clauses or passive voice construction (“If a tiger is eaten by a lion, which animal stays alive?”) help to assess the ability to comprehend complex syntactic structure. Commands to close or open the eyes, stand up, sit down, or roll over should not be used to assess overall comprehension since appropriate responses aimed at such axial movements can be preserved in patients who otherwise have profound comprehension deficits.

Repetition is assessed by asking the patient to repeat single words, short sentences, or strings of words such as “No ifs, ands, or buts.” The testing of repetition with tongue-twisters such as “hippopotamus” or “Irish constabulary” provides a better assessment of dysarthria and paillialia than aphasia. Aphasic patients may have little difficulty with tongue-twisters but have a particularly hard time repeating a string of function words. It is important to make sure that the number of words does not exceed the patient’s attention span. Otherwise, the failure of repetition becomes a reflection of the narrowed attention span rather than an indication of an aphasic deficit. Reading should be assessed for deficits in reading aloud as well as comprehension. Writing is assessed for spelling errors, word order, and grammar. Alexia describes an inability to either read aloud or comprehend single words and simple sentences; agrapphia (or dysgraphia) is used to describe an acquired deficit in the spelling or grammar of written language.

The correspondence between individual deficits of language function and lesion location does not display a rigid one-to-one relationship and should be conceptualized within the context of the distributed network model. Nonetheless, the classification of aphasic patients into specific clinical syndromes helps to determine the most likely anatomic distribution of the underlying neurologic disease and has implications for etiology and prognosis (Table 23-1). Aphasic syndromes can be divided into “central” syndromes, which result from damage to the two epicenters of the language network (Broca’s and Wernicke’s areas), and “disconnection” syndromes, which arise from lesions that interrupt the functional connectivity of these centers with each other and with other components of the language network. The syndromes outlined below are idealizations; pure syndromes occur rarely.

### Table 23-1: Clinical Features of Aphasia and Related Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Comprehension</th>
<th>Repetition of Spoken Language</th>
<th>Naming</th>
<th>Fluency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wernicke’s</td>
<td>Impaired</td>
<td>Impaired</td>
<td>Impaired</td>
<td>Preserved or increased</td>
</tr>
<tr>
<td>Broca’s</td>
<td>Preserved (except for grammar)</td>
<td>Impaired</td>
<td>Impaired</td>
<td>Decreased</td>
</tr>
<tr>
<td>Global</td>
<td>Impaired</td>
<td>Impaired</td>
<td>Impaired</td>
<td>Decreased</td>
</tr>
<tr>
<td>Conduction</td>
<td>Preserved</td>
<td>Impaired</td>
<td>Preserved</td>
<td>Decreased</td>
</tr>
<tr>
<td>Nonfluent (motor)</td>
<td>Preserved</td>
<td>Impaired</td>
<td>Impaired</td>
<td>Decreased</td>
</tr>
<tr>
<td>Fluent (sensory)</td>
<td>Impaired</td>
<td>Preserved</td>
<td>Preserved</td>
<td>Preserved</td>
</tr>
<tr>
<td>Fluent (transcortical)</td>
<td>Impaired</td>
<td>Preserved</td>
<td>Preserved</td>
<td>Preserved</td>
</tr>
<tr>
<td>Isolation</td>
<td>Impaired</td>
<td>Echolalia</td>
<td>Impaired</td>
<td>No purposeful speech</td>
</tr>
<tr>
<td>Anomic</td>
<td>Preserved</td>
<td>Impaired</td>
<td>Preserved</td>
<td>Except for word-finding pauses</td>
</tr>
<tr>
<td>Pure word deafness</td>
<td>Impaired only for spoken language</td>
<td>Impaired</td>
<td>Preserved</td>
<td>Preserved</td>
</tr>
<tr>
<td>Pure alexia</td>
<td>Impaired only for reading</td>
<td>Preserved</td>
<td>Preserved</td>
<td>Preserved</td>
</tr>
</tbody>
</table>

Pure word deafness Involves difficulty in hearing spoken language and understanding speech. Impaired only for speech comprehension

Pure alexia Impaired only for reading

Four examples of clinical syndromes are outlined in Table 23-1: Wernicke’s aphasia, Broca’s aphasia, global aphasia, and transcortical aphasia. Each syndrome is characterized by a specific pattern of language impairment. For example, Wernicke’s aphasia is characterized by fluent speech with frequent paraphasic errors, while Broca’s aphasia is characterized by nonfluent speech with difficulty in naming and motor speech.

Speech contains large numbers of function words (e.g., prepositions, conjunctions) but few substantive nouns or verbs that refer to specific actions. The output is therefore voluminous but uninformative. For example, a patient attempts to describe his wife’s accident: “We don’t need it anymore, she says. And they happened to be in that bag . . .” How could this have happened? How could a thing like this happen . . . So she says we won’t need it anymore . . . I didn’t think we’d use it. And now if I have any problems anybody coming
a month from now, 4 months from now, or 6 months from now, I have a new dentist. Where my two...t w o little pieces of dentist that I
use . . . that I . . . all gone. If she throws the whole thing away . . . visit some friends of hers and she can’t throw them away.”

Gestures and pantomime do not improve communication. The pa-
tient does not seem to realize that his or her language is incomprehen-
sible and may appear angry and impatient when the examiner fails to
decipher the meaning of a severely paraphrastic statement. In some pa-
tients this type of aphasia can be associated with severe agitation and
paranoid behaviors. One area of comprehension that may be preserved
is the ability to follow commands aimed at axial musculature. The
dissociation between the failure to understand simple questions (“What
is your name”) in a patient who rapidly closes his or her eyes, sits up,
or rolls over when asked to do so is characteristic of Wernicke’s apha-
sia and helps to differentiate it from deafness, psychiatric disease, or
malingerers. Patients with Wernicke’s aphasia cannot express their
thoughts in meaningful-appropriate words and cannot decode the mean-
ning of words in any modality of input. This aphasia therefore has
expressive as well as receptive components. Repetition, naming, read-
ing, and writing are also impaired.

The lesion site most commonly associated with Wernicke’s aphasia
is the posterior portion of the language network and tends to involve
at least parts of Wernicke’s area. An embolus to the inferior division
of the middle cerebral artery, and to the posterior temporal or angular
branches in particular, is the most common etiology (Chap. 349). In-
tracerebral hemorrhage, severe head trauma, or neoplasm are other
causes. A coexisting right hemi- or superior quadrantanopia is com-
mon, and mild right nasolabial flattening may be found, but otherwise
the examination is often unrevealing. The paraphasic, neologistic
speech in an agitated patient with an otherwise unremarkable neuro-
logic examination may lead to the suspicion of a primary psychiatric
disorder such as schizophrenia or mania, but the other components
characteristic of acquired aphasia and the absence of prior psychiatric
disease usually settle the issue. Some patients with Wernicke’s aphasia
due to intracerebral hemorrhage or head trauma may improve as the
hemorrhage or the injury heals. In most other patients, prognosis for
recovery is guarded.

Broca’s Aphasia Speech is nonfluent, labored, interrupted by many
word-finding pauses, and usually dysarthric. It is impoverished in
function words but enriched in meaning-appropriate nouns and verbs.
Abnormal word order and the inappropriate deployment of bound mor-
phemes (word endings used to denote tenses, possessives, or plurals)
lead to a characteristic agrammatism. Speech is telegraphic and pithy
but quite informative. In the following passage, a patient with Broca’s
aphasia describes his medical history: “I see . . . the doctor, doctor sent
me . . . Bosson. Go to hospital. Doctor . . . kept me beside. Two,
two days, doctor send me home.”

Output may be reduced to a grunt or single word (“yes” or “no”),
which is emitted with different intonations in an attempt to express
approval or disapproval. In addition to fluency, naming and repetition
are also impaired. Comprehension of spoken language is intact, except
for syntactically difficult sentences with passive voice structure or em-
bedded clauses. Reading comprehension is also preserved, with the
occasional exception of a specific inability to read small grammatical
words such as conjunctions and pronouns. The last two features indi-
cate that Broca’s aphasia is not just an “expressive” or “motor” dis-
order and that it may also involve a comprehension deficit for function
words and syntax. Patients with Broca’s aphasia can be tearful, easily
frustrated, and profoundly depressed. Insight into their condition is
preserved, in contrast to Wernicke’s aphasia. Even when spontaneous
speech is severely dysarthric, the patient may be able to display a
relatively normal articulation of words when singing. This dissociation
has been used to develop specific therapeutic approaches (melodic
intonation therapy) for Broca’s aphasia. Additional neurologic deficits
usually include right facial weakness, hemiparesis or hemiplegia, and
a buccofacial apraxia characterized by an inability to carry out motor
commands involving oropharyngeal and facial musculature (e.g., pa-
tients are unable to demonstrate how to blow out a match or suck
through a straw). Visual fields are intact. The cause is most often
infarction of Broca’s area (the inferior frontal convolution; “B” in Fig.
23-1) and surrounding anterior perisylvian and insular cortex, due to
occlusion of the superior division of the middle cerebral artery (Chap.
349). Mass lesions including tumor, intracerebral hemorrhage, or ab-
sscess may also be responsible. Small lesions confined to the posterior
part of Broca’s area may lead to a nonflaphasic and often reversible
deficit of speech articulation, usually accompanied by mild right facial
weakness. When the cause of Broca’s aphasia is stroke, recovery of
language function generally peaks within 2 to 6 months, after which
time further progress is limited.

Global Aphasia Speech output is nonfluent, and comprehension of
spoken language is severely impaired. Naming, repetition, reading, and
writing are also impaired. This syndrome represents the combined dys-
function of Broca’s and Wernicke’s areas and usually results from
strokes that involve the entire middle cerebral artery distribution in the
left hemisphere. Most patients are initially mute or say a few words,
such as “hi” or “yes.” Related signs include right hemiplegia, hemi-
sensory loss, and homonymous hemianopia. Occasionally, a patient
with a lesion in Wernicke’s area will present with a global aphasia that
soon resolves into Wernicke’s aphasia.

Conduction Aphasia Speech output is fluent but paraphasic, comprehen-
sion of spoken language is intact, and repetition is severely impaired.
Naming and writing are also impaired. Reading aloud is impaired, but
reading comprehension is preserved. The lesion sites spare Broca’s
and Wernicke’s areas but may induce a functional disconnection be-
tween the two so that neural word representations formed in
Wernicke’s area and adjacent regions cannot be conveyed to Broca’s
area for assembly into corresponding articulatory patterns. Occasion-
ally, a Wernicke’s area lesion gives rise to a transient Wernicke’s
aphasia that rapidly resolves into a conduction aphasia. The paraphasic
output in conduction aphasia interferes with the ability to express
meaning, but this deficit is not nearly as severe as the one displayed
by patients with Wernicke’s aphasia. Associated neurologic signs in
conduction aphasia vary according to the primary lesion site.

Nonfluent Transcortical Aphasia (Transcortical Motor Aphasia) The features
are similar to Broca’s aphasia, but repetition is intact and agrammatism
may be less pronounced. The neurologic examination may be other-
wise intact, but a right hemiparesis can also exist. The lesion site
disconnects the intact language network from prefrontal areas of the
brain and usually involves the anterior watershed zone between ante-
rior and middle cerebral artery territories or the supplementary motor
cortex in the territory of the anterior cerebral artery.

Fluent Transcortical Aphasia (Transcortical Sensory Aphasia) Clinical fea-
tures are similar to those of Wernicke’s aphasia, but repetition is intact.
The lesion site disconnects the intact core of the language network
from other temporoparietal association areas. Associated neurologic
findings may include hemianopia. Cerebrovascular lesions (e.g., in-
farctions in the posterior watershed zone) or neoplasms that involve
the temporoparietal cortex posterior to Wernicke’s area are the most
common causes.

Isolation Aphasia This rare syndrome represents a combination of the
two transcortical aphasias. Comprehension is severely impaired, and
there is no purposeful speech output. The patient may parrot fragments
of heard conversations (echolalia), indicating that the neural mecha-
nisms for repetition are at least partially intact. This condition repre-
sents the pathologic function of the language network when it is iso-
lated from other regions of the brain. Broca’s and Wernicke’s areas
tend to be spared, but there is damage to the surrounding frontal, pa-
rietal, and temporal cortex. Lesions are patchy and can be associated
with axonia, carbon monoxide poisoning, or complete watershed zone
infarctions.
Anomic Aphasia  This form of aphasia may be considered the “minimal dysfunction” syndrome of the language network. Articulation, comprehension, and repetition are intact, but confrontation naming, word finding, and spelling are impaired. Speech is enriched in function words but impoverished in substantive nouns and verbs denoting specific actions. Language output is fluent but paraphasic, circumlocutory, and uninformative. The lesion sites can be anywhere within the left hemisphere language network, including the middle and inferior temporal gyri. Anomic aphasia is the single most common language disturbance seen in head trauma, metabolic encephalopathy, and Alzheimer’s disease. The language impairment of Alzheimer’s disease almost always leads to fluent aphasias (e.g., anomic, Wernicke’s, conduction, or fluent transcortical aphasia). The insidious onset and relentless progression of nonfluent language disturbances (Broca’s or nonfluent transcortical aphasia) can be seen in primary progressive aphasia, a degenerative syndrome most commonly associated with focal nonspecific neuronal loss or Pick’s disease.

Pure Word Deafness  This is not a true aphasic syndrome because the language deficit is modality-specific. The most common lesions are either bilateral or left-sided in the superior temporal gyrus. The net effect of the underlying lesion is to interrupt the flow of information from the unimodal auditory association cortex to Wernicke’s area. Patients have no difficulty understanding written language and can express themselves well in spoken or written language. They have no difficulty interpreting and reacting to environmental sounds since primary auditory cortex and subcortical auditory relays are intact. Since auditory information cannot be conveyed to the language network, however, it cannot be decoded into neural word representations and the patient reacts to speech as if it were in an alien tongue that cannot be deciphered. Patients cannot repeat spoken language but have no difficulty naming objects. In time, patients with pure word deafness teach themselves lip reading and may appear to have improved. There may be no additional neurologic findings, but agitated paranoid reactions are frequent in the acute stages. Cerebrovascular lesions are the most frequent cause.

Pure Alexia without Agraphia  This is the visual equivalent of pure word deafness. The lesions (usually a combination of damage to the left occipital cortex and to a posterior sector of the corpus callosum—the splenium) interrupt the flow of visual input into the language network. There is usually a right hemianopia, but the core language network remains unaffected. The patient can understand and produce spoken language, name objects in the left visual hemifield, repeat, and write. However, the patient acts as if illiterate when asked to read even the simplest sentence because the visual information from the written words (presented to the intact left visual hemifield) cannot reach the language network. Objects in the left hemifield may be named accurately because they activate nonvisual associations in the right hemisphere, which, in turn, can access the language network through transcallosal pathways anterior to the splenium. Patients with this syndrome may also lose the ability to name colors, although they can match colors. This is known as a color anomia. The most common etiology of pure alexia is a vascular lesion in the territory of the posterior cerebral artery or an infiltrating neoplasm in the left occipital cortex that involves the optic radiations as well as the crossing fibers of the splenium. Since the posterior cerebral artery also supplies medial temporal components of the limbic system, the patient with pure alexia may also experience an amnesia, but this is usually transient because the limbic lesion is unilateral.

Aphonia  There is an acute onset of severely impaired fluency (often mutism), which cannot be accounted for by corticobulbar, cerebellar, or extrapyramidal dysfunction. Recovery is the rule and involves an intermediate stage of hoarse whispering. Writing, reading, and comprehension are intact, so this is not a true aphasic syndrome. Partial lesions of Broca’s area or subcortical lesions that undercut its connections with other parts of the brain may be present. Occasionally, the lesion site is on the medial aspects of the frontal lobes and may involve the supplementary motor cortex of the left hemisphere.

Apraxia  This generic term designates a complex motor deficit that cannot be attributed to pyramidal, extrapyramidal, cerebellar, or sensory dysfunction and that does not arise from the patient’s failure to understand the nature of the task. The form that is most frequently encountered in clinical practice is known as ideomotor apraxia. Commands to perform a specific motor act (“cough,” “blow out a match”) or to pantomime the use of a common tool (a comb, hammer, straw, or toothbrush) in the absence of the real object cannot be followed. The patient’s ability to comprehend the command is ascertained by demonstrating multiple movements and establishing that the correct one can be recognized. Some patients with this type of apraxia can imitate the appropriate movement (when it is demonstrated by the examiner) and show no impairment when handed the real object, indicating that the sensorimotor mechanisms necessary for the movement are intact. Some forms of ideomotor apraxia represent a disconnection of the language network from pyramidal motor systems: commands to execute complex movements are understood but cannot be conveyed to the appropriate motor areas, even though the relevant motor mechanisms are intact. Buccofacial apraxia involves apraxic deficits in movements of the face and mouth. Limb apraxia encompasses apraxic deficits in movements of the arms and legs. Ideomotor apraxia is almost always caused by lesions in the left hemisphere and is commonly associated with aphasic syndromes, especially Broca’s aphasia and conduction aphasia. Its presence cannot be ascertained in patients with language comprehension deficits. The ability to follow commands aimed at axial musculature (“close the eyes,” “stand up”) is subserved by different pathways and may be intact in otherwise severely aphasic and apraxic patients. Patients with lesions of the anterior corpus callosum can display a special type of ideomotor apraxia confined to the left side of the body. Since the handling of real objects is not impaired, ideomotor apraxia, by itself, causes no major limitation of daily living activities.

Idiational apraxia refers to a deficit in the execution of a goal-directed sequence of movements in patients who have no difficulty executing the individual components of the sequence. For example, when asked to pick up a pen and write, the sequence of uncapping the pen, placing the cap at the opposite end, turning the point towards the writing surface, and writing may be disrupted, and the patient may be seen trying to write with the wrong end of the pen or even with the removed cap. These motor sequencing problems are usually seen in the context of confusional states and dementias rather than focal lesions associated with aphasic conditions. Limb-kinetic apraxia involves a clumsiness in the actual use of tools that cannot be attributed to sensory, pyramidal, extrapyramidal, or cerebellar dysfunction. This condition can emerge in the context of focal premotor cortex lesions or corticobasal ganglionic degeneration.

Gerstmann’s Syndrome  The combination of acalculia (impairment of simple arithmetic), dysgraphia (impaired writing), finger anomia (an inability to name individual fingers such as the index or thumb), and right-left confusion (an inability to tell whether a hand, foot, or arm of the patient or examiner is on the right or left side of the body) is known as Gerstmann’s syndrome. In making this diagnosis it is important to establish that the finger and left-right naming deficits are not part of a more generalized anomia and that the patient is not otherwise aphasic. When Gerstmann’s syndrome is seen in isolation, it is commonly associated with damage to the inferior parietal lobule (especially the angular gyrus) in the left hemisphere.

Aprosodia  Variations of melodic stress and intonation influence the meaning and impact of spoken language. For example, the two statements “He is clever,” “and He is clever?” contain an identical word choice and syntax but convey vastly different messages because of differences in the intonation and stress with which the statements are uttered. This aspect of language is known as prosody. Damage to perisylvian areas in the right hemisphere can interfere with speech prosody and can lead to syndromes of aprosodia. Damage to right hemisphere
HEMISPATIAL NEGLECT

Adaptive orientation to significant events within the extrapersonal space is subserved by a large-scale network containing three major cortical components. The cingulate cortex provides access to a limbic-motivational mapping of the extrapersonal space, the posterior parietal cortex to a sensorimotor representation of salient extrapersonal events, and the frontal eye fields to motor strategies for attentional behaviors (Fig. 23-2). Subcortical components of this network include the striatum and the thalamus. Contralesional hemispatial neglect represents one outcome of damage to any of the cortical or subcortical components of this network. The traditional view that hemispatial neglect always denotes a parietal lobe lesion is inaccurate. In keeping with this anatomic organization, the clinical manifestations of neglect display three behavioral components: sensory events (or their mental representations) within the neglected hemispace have a lesser impact on overall awareness; there is a paucity of exploratory and orienting acts directed toward the neglected hemispace; and the patient behaves as if the neglected hemispace was motivationally devalued.

According to one model of spatial cognition, the right hemisphere directs attention within the entire extrapersonal space, whereas the left hemisphere directs attention mostly within the contralateral right hemispace. Consequently, unilateral left hemisphere lesions do not give rise to much contralesional neglect since the ipsilateral attentional mechanisms of the right hemisphere can compensate for the loss of the contralaterally directed attentional functions of the left hemisphere. Unilateral right hemisphere lesions, however, give rise to severe contralesional left hemispatial neglect because the unaffected left hemisphere does not contain ipsilateral attentional mechanisms. This model is consistent with clinical experience, which shows that contralesional neglect is more common, severe, and lasting after damage to the right hemisphere than after damage to the left hemisphere. Severe neglect for the right hemispace is rare, even in left handers with left hemisphere lesions.

Patients with severe neglect may fail to dress, shave, or groom the left side of the body; may fail to eat food placed on the left side of the tray; and may fail to read the left half of sentences. When the examiner draws a large circle [12 to 15 cm (5 to 6 in.) in diameter] and asks the patient to place the numbers 1 to 12 as if the circle represented the face of a clock, there is a tendency to crowd the numbers on the right side and leave the left side empty. When asked to copy a simple line drawing, the patient fails to copy detail on the left; and when asked to write, there is a tendency to leave an unusually wide margin on the left.

Two bedside tests that are useful in assessing neglect are simultaneous bilateral stimulation and visual target cancellation. In the former, the examiner provides either simultaneous bilateral stimulation in the visual, auditory, and tactile modalities. Following right hemisphere injury, patients who have no difficulty detecting unilateral stimuli on either side experience the bilaterally presented stimulus as coming only from the right. This phenomenon is known as extinction and is a manifestation of the sensory-representational aspect of hemispatial neglect. In the target detection task, targets (e.g., As) are interspersed with foils (e.g., other letters of the alphabet) on a 21.5 to 28.0 cm (8.5 to 11 in.) sheet of paper and the patient is asked to circle all the targets. A failure to detect targets on the left is a manifestation of the exploratory deficit in hemispatial neglect (Fig. 23-3A). Hemianopia, by itself, does not interfere with performance in this task since the patient is free to turn the head and eyes to the left. The normal tendency in target detection tasks is to start from the left upper quadrant and move systematically in horizontal or vertical sweeps. Some patients show a tendency to start the process from the right and proceed in a haphazard fashion. This represents a subtle manifestation of left neglect, even if the patient eventually manages to detect all the appropriate targets. Some patients with neglect may also deny the existence of hemiparesis and may even deny ownership of the paralyzed limb, a condition known as anosognosia.

Cerebrovascular lesions and neoplasms in the right hemisphere are the most common causes of hemispatial neglect. Depending on the site of the lesion, the patient with neglect may also have hemiparesis, hemihypesthesia, and hemianopia on the left, but these are not invariant findings. The majority of patients display considerable improvement of hemispatial neglect, usually within the first several weeks.

BÁLINT'S SYNDROME, SIMULTANAGNOSIA, DRESSING APRAXIA, AND CONSTRUCTION APRAXIA

Bilateral involvement of the network for spatial attention, especially its parietal components, leads to a state of severe spatial disorientation known as Bálint’s syndrome. Bálint’s syndrome involves deficits in the orderly visuomotor scanning of the environment (oculomotor apraxia) and an accurate manual reaching toward visual targets (optic ataxia). The third and most dramatic component of Bálint’s syndrome is known as simultanagnosia and reflects an
be used for the bedside diagnosis of simultanagnosia. In this modification, some of the targets (e.g., As) are made to be much larger than the others [7.5 to 10 cm vs 2.5 cm (3 to 4 in. vs 1 in.) in height], and all targets are embedded among foils. Patients with simultanagnosia display a counterintuitive but characteristic tendency to miss the larger targets (Fig. 23-3B). This occurs because the information needed for the identification of the larger targets cannot be confined to the immediate line of gaze and requires the integration of visual information across a more extensive field of view. The greater difficulty in the detection of the larger targets also indicates that poor acuity is not responsible for the impairment of visual function and that the problem is central rather than peripheral. Bálint’s syndrome results from bilateral dorsal parietal lesions; common settings include watershed infarction between the middle and posterior cerebral artery territories, hypoglycemia, sagittal sinus thrombosis, or atypical forms of Alzheimer’s disease. In patients with Bálint’s syndrome due to stroke, bilateral visual field defects (usually inferior quadrantanopias) are common.

Another manifestation of bilateral (or right-sided) dorsal parietal lobe lesions is dressing apraxia. The patient with this condition is unable to align the body axis with the axis of the garment and can be seen struggling as he or she holds a coat from its bottom or extends his or her arm into a fold of the garment rather than into its sleeve. Lesions that involve the posterior parietal cortex also lead to severe difficulties in copying simple line drawings. This is known as a construction apraxia and is much more severe if the lesion is in the right hemisphere. In some patients with right hemisphere lesions, the drawing difficulties are confined to the left side of the figure and represent a manifestation of hemispatial neglect; in others, there is a more universal deficit in reproducing contours and three-dimensional perspective. Dressing apraxia and construction apraxia represent special instances of a more general disturbance in spatial orientation.

THE OCCIPITOTEMPORAL NETWORK FOR FACE AND OBJECT RECOGNITION: PROSOPAGNOSIA AND OBJECT AGNOSIA

Perceptual information about faces and objects is initially encoded in primary (striate) visual cortex and adjacent (upstream) peristriate visual association areas. This information is subsequently relayed first to the downstream visual association areas of occipitotemporal cortex and then to other heteromodal and paralimbic areas of the cerebral cortex. Bilateral lesions in the fusiform and lingual gyri of occipitotemporal cortex disrupt this process and interfere with the ability of otherwise intact perceptual information to activate the distributed multimodal associations that lead to the recognition of faces and objects. The resultant face and object recognition deficits are known as prosopagnosia and visual object agnosia.

The patient with prosopagnosia cannot recognize familiar faces, including, sometimes, the reflection of his or her own face in the mirror. This is not a perceptual deficit since prosopagnosic patients can easily tell if two faces are identical or not. Furthermore, a prosopagnosic patient who cannot recognize a familiar face by visual inspection alone can use auditory cues to reach appropriate recognition if allowed to listen to the person’s voice. The deficit in prosopagnosia is therefore modality-specific and reflects the existence of a lesion that prevents the activation of otherwise intact multimodal templates by relevant visual input. Damasio has pointed out that the deficit in prosopagnosia

inability to integrate visual information in the center of gaze with more peripheral information. The patient gets stuck on the detail that falls in the center of gaze without attempting to scan the visual environment for additional information. The patient with simultanagnosia “misses the forest for the trees.” Complex visual scenes cannot be grasped in their entirety, leading to severe limitations in the visual identification of objects and scenes. For example, a patient who is shown a table lamp and asked to name the object may look at its circular base and ignore the larger ones. This is a manifestation of simultanagnosia.

A modification of the letter cancellation task described above can-

FIGURE 23-3  A. A 47-year-old man with a large frontoparietal lesion in the right hemisphere was asked to circle all the As. Only targets on the right are circled. This is a manifestation of left hemispatial neglect. B. A 70-year-old woman with a 2-year history of degenerative dementia was able to circle most of the small targets but ignored the larger ones. This is a manifestation of simultanagnosia.
is not limited to the recognition of faces but that it can also extend to the recognition of individual members of larger generic object groups. For example, prosopagnosic patients characteristically have no difficulty with the generic identification of a face as a face or of a car as a car, but they cannot recognize the identity of an individual face or the make of an individual car. This reflects a visual recognition deficit for proprietary features that characterize individual members of an object class. When recognition problems become more generalized and extend to the generic identification of common objects, the condition is known as visual object agnosia. In contrast to prosopagnosic patients, those with object agnosia cannot recognize a face as a face or a car as a car.

It is important to distinguish visual object agnosia from anomaia. The patient with anomaia cannot name the object but can describe its use. In contrast, the patient with visual agnosia is unable either to name a visually presented object or to describe its use. The characteristic lesions in prosopagnosia and visual object agnosia consist of bilateral infarctions in the territory of the posterior cerebral arteries. Associated deficits can include visual field defects (especially superior quadrantanopias) or a centrally based color blindness known as achromatopsia. Rarely, the responsible lesion is unilateral. In such cases, prosopagnosia is associated with lesions in the right hemisphere and object agnosia with lesions in the left.

THE LIMBIC NETWORK FOR MEMORY: AMNESIAS

Limbic and paralimbic areas (such as the hippocampus, amygdala, and entorhinal cortex), the anterior and medial nuclei of the thalamus, the medial and basal parts of the striatum, and the hypothalamus collectively constitute a distributed network known as the limbic system (see Fig. 350-1). The behavioral affiliations of this network include the coordination of emotion, motivation, autonomic tone, and endocrine function. An additional area of specialization for the limbic network, and the one which is of most relevance to clinical practice, is that of declarative (conscious) memory for recent episodes and experiences. A disturbance in this function is known as an amnestic state. In the absence of deficits in motivation, attention, language, or visuospatial function, the clinical diagnosis of a persistent global amnesic state is always associated with bilateral damage to the limbic network, usually within the hippocampal-entorhinal complex or the thalamus.

Although the limbic network is the site of damage for amnestic states, it is almost certainly not the storage site for memories. Memories are stored in widely distributed form throughout the cerebral cortex. The role attributed to the limbic network is to bind these distributed fragments into coherent events and experiences that can sustain conscious recall. Damage to the limbic network does not necessarily destroy memories but interferes with their conscious (declarative) recall in coherent form. The individual fragments of information remain preserved despite the limbic lesions and can sustain what is known as implicit memory. For example, patients with amnestic states can acquire new motor or perceptual skills, even though they may have no conscious knowledge of the experiences that led to the acquisition of these skills.

The memory disturbance in the amnestic state is multimodal and includes retrograde and anterograde components. The retrograde amnesia involves an inability to recall experiences that occurred before the onset of the amnestic state. Relatively recent events are more vulnerable to retrograde amnesia than more remote and more extensively consolidated events. A patient who comes to the emergency room complaining that he cannot remember his identity but who can remember the events of the previous day is almost certainly not suffering from a neurologic cause of memory disturbance. The second and most important component of the amnestic state is the anterograde amnesia, which indicates an inability to store, retain, and recall new knowledge.

Patients with amnestic states cannot remember what they ate a few minutes ago or the details of an important event they may have experienced a few hours ago. In the acute stages, there may also be a tendency to fill in memory gaps with inaccurate, fabricated, and often implausible information. This is known as confabulation. Patients with the amnestic syndrome forget that they forget and tend to deny the existence of a memory problem when questioned.

The patient with an amnestic state is almost always disoriented, especially to time. Accurate temporal orientation and accurate knowledge of current news rule out a major amnestic state. The retrograde component of an amnestic state can be tested with a list of four to five words read aloud by the examiner up to five times or until the patient can immediately repeat the entire list without intervening delay. In the next phase of testing, the patient is allowed to concentrate on the words and to rehearse them internally for 1 min before being asked to recall them. Accurate performance in this phase indicates that the patient is motivated and sufficiently attentive to hold the words online for at least 1 min. The final phase of the testing involves a retention period of 5 to 10 min, during which the patient is engaged in other tasks. Adequate recall at the end of this interval requires offline storage, retention, and retrieval. Amnestic patients fail this phase of the task and may even forget that they were given a list of words to remember. Accurate recognition of the words by multiple choice in a patient who cannot recall them indicates a less severe memory disturbance that affects mostly the retrieval stage of memory. The retrograde component of an amnesia can be assessed with questions related to autobiographical or historical events. The anterograde component of amnestic states is usually much more prominent than the retrograde component. In rare instances, usually associated with temporal lobe epilepsy or benzodiazepine intake, the retrograde component may dominate.

The assessment of memory can be quite challenging. Bedside evaluations may only detect the most severe impairments. Less severe memory impairments, as in the case of patients with temporal lobe epilepsy, mild head injury or early dementia, require quantitative evaluations by neuropsychologists. Confusional states caused by toxic-metabolic encephalopathies and some types of frontal lobe damage interfere with attentional capacity and lead to secondary memory impairments, even in the absence of any limbic lesions. This sort of memory impairment can be differentiated from the amnestic state by the presence of additional impairments in the attention-related tasks described below in the section on the frontal lobes.

Many neurologic diseases can give rise to an amnestic state. These include tumors (of the sphenoid wing, posterior corpus callosum, thalamus, or medial temporal lobe), infarctions (in the territories of the anterior or posterior cerebral arteries), head trauma, herpes simplex encephalitis, Wernicke-Korsakoff encephalopathy, paraneoplastic limbic encephalitis, and degenerative dementias such as Alzheimer’s or Pick’s disease. The one common denominator of all these diseases is that they lead to the bilateral lesions within one or more components in the limbic network, most commonly the hippocampus, entorhinal cortex, the mammillary bodies of the hypothalamus, and the limbic thalamus. Occasionally, unilateral left-sided lesions can give rise to an amnestic state, but the memory disorder tends to be transient. Depending on the nature and distribution of the underlying neurologic disease, the patient may also have visual field deficits, eye movement limitations, or cerebellar findings.

Transient global amnesia is a distinctive syndrome usually seen in late middle age. Patients become acutely disoriented and repeatedly ask who they are, where they are, what they are doing. The spell is characterized by anterograde amnesia (inability to retain new information) and a retrograde amnesia for relatively recent events that occurred before the onset. The syndrome usually resolves within 24 to 48 h and is followed by the filling-in of the period affected by the retrograde amnesia, although there is persistent loss of memory for the events that occurred during the ictus. Recurrences are noted in approximately 20% of patients. Migraine, temporal lobe seizures, and transient ischemic events in the posterior cerebral territory have been postulated as causes of transient global amnesia. The absence of associated neurologic findings may occasionally lead to the incorrect diagnosis of a psychiatric disorder.
Approximately one-third of all the cerebral cortex in the human brain is located in the frontal lobes. The frontal lobes can be subdivided into motor-premotor, dorsolateral prefrontal, medial prefrontal, and orbitofrontal components. The terms frontal lobe syndrome and prefrontal cortex refer only to the last three of these four components. These are the parts of the cerebral cortex that show the greatest phylogenetic expansion in primates and especially in humans. The dorsolateral prefrontal, medial prefrontal, and orbitofrontal areas, and the subcortical structures with which they are interconnected (i.e., the head of the caudate and the dorsomedial nucleus of the thalamus), collectively make up a large-scale network that coordinates exceedingly complex aspects of human cognition and behavior.

The prefrontal network plays an important role in behaviors that require an integration of thought with emotion and motivation. There is no simple formula for summarizing the diverse functional affiliations of the prefrontal network. Its integrity appears important for the simultaneous awareness of context, options, consequences, relevance, and emotional impact so as to allow the formulation of adaptive inferences, decisions, and actions. Damage to this part of the brain impairs mental flexibility, reasoning, hypothesis formation, abstract thinking, foresight, judgment, the (online attentive) holding of information, and the ability to inhibit inappropriate responses. Behaviors impaired by prefrontal cortex lesions, especially those related to the manipulation of mental content, are often referred to as “executive functions.”

Even very large bilateral prefrontal lesions may leave all sensory, motor, and basic cognitive functions intact while leading to isolated but dramatic alterations of personality and behavior. The most common clinical manifestations of damage to the prefrontal network take the form of two relatively distinct syndromes. In the frontal abulia syndrome, the patient shows a loss of initiative, creativity, and curiosity and displays a pervasive emotional blandness and apathy. In the frontal disinhibition syndrome, the patient becomes socially disinhibited and shows severe impairments of judgment, insight, and foresight. The dissociation between intact intellectual function and a total lack of even rudimentary common sense is striking. Despite the preservation of all essential memory functions, the patient cannot learn from experience and continues to display inappropriate behaviors without appearing to feel emotional pain, guilt, or regret when such behaviors repeatedly lead to disastrous consequences. The impairments may emerge only in real-life situations when behavior is under minimal external control and may not be apparent within the structured environment of the medical office. Testing judgment by asking patients what they would do if they detected a fire in a theater or found a stamped and addressed envelope on the road is not very informative since patients who answer these questions wisely in the office may still act very foolishly in the more complex real-life setting. The physician must therefore be prepared to make a diagnosis of frontal lobe disease on the basis of historic information alone even when the office examination of mental state may be quite intact.

The abulia syndrome tends to be associated with damage to the dorsolateral prefrontal cortex, and the disinhibition syndrome with the medial prefrontal or orbitofrontal cortex. These syndromes tend to arise almost exclusively after bilateral lesions, most frequently in the setting of head trauma, stroke, ruptured aneurysms, hydrocephalus, tumors (including metastases, glioblastoma, and falx or olfactory groove meningiomas), or focal degenerative diseases. Unilateral lesions confined to the prefrontal cortex may remain silent until the pathology spreads to the other side. The emergence of developmentally primitive reflexes, also known as frontal release signs, such as grasping (elicited by stroking the palm) and sucking (elicited by stroking the lips) are seen primarily in patients with large structural lesions that extend into the premotor components of the frontal lobes or in the context of metabolic encephalopathies. The vast majority of patients with prefrontal lesions and frontal lobe behavioral syndromes do not display these reflexes.

Damage to the frontal lobe disrupts a variety of attention-related functions including working memory (the transient online holding of information), concentration span, the scanning and retrieval of stored information, the inhibition of immediate but inappropriate responses, and mental flexibility. The capacity for focusing on a trend of thought and the ability to voluntarily shift the focus of attention from one thought or stimulus to another can become impaired. Digit span (which should be seven forward and five reverse) is decreased; the recitation of the months of the year in reverse order (which should take less than 15 s) is slowed; and the fluency in producing words starting with a, f, or s that can be generated in 1 min (normally 12 or more per letter) is diminished even in nonaphasic patients. Characteristically, there is a progressive slowing of performance as the task proceeds; e.g., the patient asked to count backwards by 3s may say “100, 97, 94, . . . 91, . . . 88,” etc., and may not complete the task. In “go–no-go” tasks (where the instruction is to raise the finger upon hearing one tap but to keep it still upon hearing two taps), the patient shows a characteristic inability to keep still in response to the “no go” stimulus; mental flexibility (tested by the ability to shift from one criterion to another in sorting or matching tasks) is impoverished; distractibility by irrelevant stimuli is increased; and there is a pronounced tendency for impersistence and perseveration.

These attentional deficits disrupt the orderly registration and retrieval of new information and lead to secondary memory deficits. Such memory deficits can be differentiated from the primary memory impairments of the amnestic state by showing that they improve when the attentional load of the task is decreased. Working memory (also known as immediate memory) is an attentional function based on the temporary online holding of information. It is closely associated with the integrity of the prefrontal network and the ascending reticular activating system. Retentive memory, on the other hand, depends on the stable (offline) storage of information and is associated with the integrity of the limbic network. The distinction of the underlying neural mechanisms is illustrated by the observation that severely amnestic patients who cannot remember events that occurred a few minutes ago may have intact if not superior working memory capacity as shown in tests of digit span.

Lesions in the caudate nucleus or in the dorsomedial nucleus of the thalamus (subcortical components of the prefrontal network) can also produce a frontal lobe syndrome. This is one reason why the mental state changes associated with degenerative basal ganglia diseases, such as Parkinson’s or Huntington’s disease, may take the form of a frontal lobe syndrome. Because of its widespread connections with other regions of association cortex, one essential computational role of the prefrontal network is to function as an integrator, or “orchestrator,” for other networks. Bilateral multifocal lesions of the cerebral hemispheres, none of which are individually large enough to cause specific cognitive deficits such as aphasia or neglect, can collectively interfere with the connectivity and integrating function of prefrontal cortex. A frontal lobe syndrome is the single most common behavioral profile associated with a variety of bilateral multifocal brain diseases including metabolic encephalopathy, multiple sclerosis, vitamin B12 deficiency, and others. In fact, the vast majority of patients with the clinical diagnosis of a frontal lobe syndrome tend to have lesions that do not involve prefrontal cortex but involve either the subcortical components of the prefrontal network or its connections with other parts of the brain. In order to avoid making a diagnosis of “frontal lobe syndrome” in a patient with no evidence of frontal cortex disease, it is advisable to use the diagnostic term frontal network syndrome, with the understanding that the responsible lesions can lie anywhere within this distributed network.

The patient with frontal lobe disease raises potential dilemmas in differential diagnosis: the abulia and blandness may be misinterpreted as depression, and the disinhibition as idiopathic mania or acting-out. Appropriate intervention may be delayed while a treatable tumor keeps
Disturbed sleep is among the most frequent health complaints physicians encounter. More than one-half of adults in the United States experience at least intermittent sleep disturbances. For most, it is an occasional night of poor sleep or daytime sleepiness. However, at least 15 to 20% of adults report chronic sleep disturbance or misalignment of circadian timing, which can lead to serious impairment of daytime functioning. In addition, such problems may contribute to or exacerbate medical or psychiatric conditions. Thirty years ago, many such complaints were treated with hypnotic medications without further diagnostic evaluation. Since then, a distinct class of sleep and arousal disorders has been identified.

### PHYSIOLOGY OF SLEEP AND WAKEFULNESS

Most adults sleep 7 to 8 h per night, although the timing, duration, and internal structure of sleep vary among healthy individuals and as a function of age. At the extremes, infants and the elderly have frequent interruptions of sleep. In the United States, adults of intermediate age tend to have one consolidated sleep episode per day, although in some cultures sleep may be divided into a midafternoon nap and a shortened night sleep. Two principal systems govern the sleep-wake cycle: one actively generates sleep and sleep-related processes and another times sleep within the 24-h day. Either intrinsic abnormalities in these sys-
orgschs introductory text

**States and Stages of Sleep** States and stages of human sleep are defined on the basis of characteristic patterns in the electroencephalogram (EEG), the electrooculogram (EOG—a measure of eye-movement activity), and the surface electromyogram (EMG) measured on the chin and neck. The continuous recording of this array of electrophysiologic parameters to define sleep and wakefulness is termed polysomnography.

Polysomnographic profiles define two states of sleep: (1) rapid-eye-movement (REM) sleep, and (2) non-rapid-eye-movement (NREM) sleep. NREM sleep is further subdivided into four stages, characterized by increasing arousal threshold and slowing of the cortical EEG. REM sleep is characterized by a low-amplitude, mixed-frequency EEG similar to that of NREM stage 1 sleep. The EOG shows bursts of REM similar to those seen during eyes-open wakefulness. Chin EMG activity is absent, reflecting the brainstem-mediated muscle atonia that is characteristic of that state.

**Organization of Human Sleep** Normal nocturnal sleep in adults displays a consistent organization from night to night (Fig. 24-1). After sleep onset, sleep usually progresses through NREM stages 1 to 4 within 45 to 60 min. Slow-wave sleep (NREM stages 3 and 4) predominates in the first third of the night and comprises 15 to 25% of total nocturnal sleep time in young adults. The percentage of slow-wave sleep is influenced by several factors, most notably age (see below). Prior sleep deprivation increases the rapidity of sleep onset and both the intensity and amount of slow-wave sleep.

The first REM sleep episode usually occurs in the second hour of sleep. More rapid onset of REM sleep in a young adult (particularly if <30 min) may suggest pathology such as endogenous depression, narcolepsy, circadian rhythm disorders, or drug withdrawal. NREM and REM alternate through the night with an average period of 90 to 110 min (the “ultradian” sleep cycle). Overall, REM sleep constitutes 20 to 25% of total sleep, and NREM stages 1 and 2 are 50 to 60%.

Age has a profound impact on sleep state organization (Fig. 24-1). Slow-wave sleep is most intense and prominent during childhood, decreasing sharply at puberty and across the second and third decades of life. After age 30, there is a progressive decline in the amount of slow-wave sleep, and the amplitude of delta EEG activity comprising slow-wave sleep is profoundly reduced. The depth of slow-wave sleep, as measured by the arousal threshold to auditory stimulation, also decreases with age. In the otherwise healthy older person, slow-wave sleep may be completely absent, particularly in males.

A different age profile exists for REM sleep than for slow-wave sleep. In infancy, REM sleep may comprise 50% of total sleep time, and the percentage is inversely proportional to developmental age. The amount of REM sleep falls off sharply over the first postnatal year as a mature REM-NREM cycle develops; thereafter, REM sleep occupies a relatively constant percentage of total sleep time.

**Neuroanatomy of Sleep** Experimental studies in animals have variously implicated the medullary reticular formation, the thalamus, and the basal forebrain in the generation of sleep, while the brainstem reticular formation, the midbrain, the subthalamus, the thalamus, and the basal forebrain have all been suggested to play a role in the generation of wakefulness or EEG arousal.

Current hypotheses suggest that the capacity for sleep and wakefulness generation is distributed along an axial “core” of neurons extending from the brainstem rostrally to the basal forebrain. Complex commingling of neuronal groups occurs at many points along this brainstem–forebrain axis. A cluster of γ-aminobutyric acid (GABA) and galaninergic neurons in the ventrolateral preoptic (VLPO) hypothalamus is selectively activated coincident with sleep onset. These neurons project to and inhibit histaminergic cell groups in the tuberomammillary nucleus that are important to the ascending arousal system, suggesting that the hypothalamic VLPO neurons may play a key executive role in sleep regulation.

Specific regions in the pons are associated with the neurophysiologic correlates of REM sleep. Small lesions in the dorsal pons result in the loss of the descending muscle inhibition normally associated with REM sleep; microinjections of the cholinergic agonist carbachol into the pontine reticular formation appear to produce a state with all of the features of REM sleep. These experimental manipulations are mimicked by pathologic conditions in humans and animals. In narcolepsy, for example, abrupt, complete, or partial paralysis (cataplexy) occurs in response to a variety of stimuli. In dogs with this condition, phystostigmine, a central cholinesterase inhibitor, increases the frequency of cataplectic attacks, while atropine decreases their frequency. Conversely, in REM sleep behavior disorder (see below), patients suffer from incomplete motor inhibition during REM sleep, resulting in involuntary, occasionally violent movement during REM sleep.

**Neurochemistry of Sleep** Early experimental studies that focused on the raphe nuclei of the brainstem appeared to implicate serotonin as the primary sleep-promoting neurotransmitter, while catecholamines were considered to be responsible for wakefulness. Subsequent work has demonstrated that the raphe-serotonin system may facilitate sleep but is not necessary for its expression. Pharmacologic studies of sleep and wakefulness suggest roles for other neurotransmitters as well. Pontine cholinergic neurotransmission is known to play a role in REM sleep generation. The alerting influence of caffeine implicates adenosine, whereas the hypnotic effect of benzodiazepines and barbiturates suggests a role for endogenous ligands of the GABAA receptor complex. A newly characterized neuropeptide, hypocretin (orexin), has recently been implicated in the pathophysiology of narcolepsy (see below), but its role in normal sleep regulation remains to be defined.

A variety of sleep-promoting substances have been identified, although it is not known whether or not they are involved in the endogenous sleep-wake regulatory process. These include prostaglandin D2, delta sleep–inducing peptide, muramyl dipeptide, interleukin 1, fatty acid primary amides, and melatonin. The hypnotic effect of these substances is commonly limited to NREM or slow-wave sleep, although peptides that increase REM sleep have also been reported. Many putative “sleep factors,” including interleukin 1 and prostaglandin D2, are immunologically active as well, suggesting a link between immune function and sleep-wake states.

**Physiology of Circadian Rhythmicity** The sleep-wake cycle is the most evident of the many 24-h rhythms in humans. Prominent daily varia-
of sleep tendency throughout the usual waking day, respectively. Misalignment of the output of the endogenous circadian pacemaker with the desired sleep-wake cycle can, therefore, induce insomnia, decreased alertness, and impaired performance evident in night-shift workers and airline travelers.

**BEHAVIORAL CORRELATES OF SLEEP STATES AND STAGES** Polysomnographic staging of sleep correlates with behavioral changes during specific states and stages. During the transitional state between wakefulness and sleep (stage 1 sleep), subjects may respond to faint auditory or visual signals without “awakening.” Memory incorporation is inhibited at the onset of NREM stage 1 sleep, which may explain why individuals aroused from that transitional sleep stage frequently deny having been asleep. Such transitions may intrude upon behavioral wakefulness after sleep deprivation, notwithstanding attempts to remain continuously awake (see “Shift-Work Sleep Disorder,” below).

Awakenings from REM sleep are associated with recall of vivid dream imagery >80% of the time. The reliability of dream recall increases with REM sleep episodes occurring later in the night. Imagery may also be reported after NREM sleep interruptions, though these typically lack the detail and vividness of REM sleep dreams. The incidence of NREM sleep dream recall can be increased by selective REM sleep deprivation, suggesting that REM sleep and dreaming per se are not inexorably linked.

**PHYSIOLOGIC CORRELATES OF SLEEP STATES AND STAGES** All major physiologic systems are influenced by sleep. Changes in cardiovascular function include a decrease in blood pressure and heart rate during NREM and particularly during slow-wave sleep. During REM sleep, phasic activity (bursts of eye movements) is associated with variability in both blood pressure and heart rate mediated principally by the vagus. Cardiac dysrhythmias may occur selectively during REM sleep. Respiratory function also changes. In comparison to relaxed wakefulness, respiratory rate becomes more regular during NREM sleep (essentially slow-wave sleep) and tonic REM sleep and becomes very irregular during phasic REM sleep. Minute ventilation decreases in NREM sleep out of proportion to the decrease in metabolic rate at sleep onset, resulting in a higher P\(_{\text{CO}_2}\).

Endocrine function also varies with sleep. Slow-wave sleep is associated with secretion of growth hormone, while sleep in general is associated with augmented secretion of prolactin. Sleep has a complex effect on the secretion of luteinizing hormone (LH): during puberty, sleep is associated with increased LH secretion, whereas sleep in the mature woman inhibits LH secretion in the early follicular phase of the menstrual cycle. Sleep onset (and probably slow-wave sleep) is associated with inhibition of thyroid-stimulating hormone and of the adrenocorticotropic hormone–cortisol axis, an effect that is superimposed on the prominent circadian rhythms in the two systems.

The pineal hormone melatonin is secreted predominantly at night in both day- and night-active species, reflecting the direct modulation of pineal activity by the circadian pacemaker through a circuital neural pathway from the SCN to the pineal gland. Melatonin secretion is not dependent upon the occurrence of sleep, persisting in individuals kept awake at night. In addition, exogenous melatonin increases sleepiness and may potentiate sleep when administered to good sleepers attempting to sleep during daylight hours at a time when endogenous melatonin levels are low. The efficacy of melatonin as a sleep-promoting therapy for patients with insomnia is currently not known.

Sleep is also accompanied by alterations of thermoregulatory function. NREM sleep is associated with an attenuation of thermoregulatory responses to either heat or cold stress, and animal studies of thermosensitive neurons in the hypothalamus document an NREM-dependent reduction of the thermoregulatory set-point. REM sleep is associated with complete absence of thermoregulatory responsiveness, potentially resulting in functional poikilothermy. However, the potential adverse impact of this failure of thermoregulation is blunted by inhibition of REM sleep by extreme ambient temperatures.

---

**FIGURE 24-2** Model of the molecular feedback loop at the core of the mammalian circadian clock. The positive element of the feedback loop (**) is the transcriptional activation of the Per1 gene (and probably other clock genes) by a heterodimer of the transcription factors CLOCK and BMAL1 (also called MOP3) bound to an E-box DNA regulatory element. The Per1 transcript and its product, the clock component PER1 protein, accumulate in the cell cytoplasm. As it accumulates, the PER1 protein is recruited into a multiprotein complex thought to contain other circadian clock component protein, TIM, as yet lacking genetic proof of a role in the mammalian circadian oscillator, which averages ~24.2 h in humans, is normally synchronized to the 24-h period of the environmental light-dark cycle. Small differences in circadian period underlie variations in diurnal preference, with the circadian period shorter in morning than in evening types. Entrainment of mammalian circadian rhythms by the light-dark cycle is mediated via the retinohypothalamic tract, a monosynaptic pathway that links specialized, photoreceptive retinal ganglion cells directly to the SCN. Humans are exquisitely sensitive to the resetting effects of light, particularly at the blue end (~460 to 480 nm) of the visible spectrum.

The timing and internal architecture of sleep are directly coupled to the output of the endogenous circadian pacemaker. Paradoxically, the endogenous circadian rhythms of sleep tendency, sleepiness, and REM sleep propensity all peak near the habitual wake time, just after the nadir of the endogenous circadian temperature cycle, whereas the circadian wake propensity rhythm peaks 1 to 3 h before the habitual bedtime. These rhythms are thus timed to oppose the homeostatic decline of sleep tendency during the habitual sleep episode and the rise in melatonin levels at night. In addition, exogenous melatonin increases sleepiness and may potentiate sleep when administered to good sleepers attempting to sleep during daylight hours at a time when endogenous melatonin levels are low. The efficacy of melatonin as a sleep-promoting therapy for patients with insomnia is currently not known.

Sleep is also accompanied by alterations of thermoregulatory function. NREM sleep is associated with an attenuation of thermoregulatory responses to either heat or cold stress, and animal studies of thermosensitive neurons in the hypothalamus document an NREM-dependent reduction of the thermoregulatory set-point. REM sleep is associated with complete absence of thermoregulatory responsiveness, potentially resulting in functional poikilothermy. However, the potential adverse impact of this failure of thermoregulation is blunted by inhibition of REM sleep by extreme ambient temperatures.
**TABLE 24-1 Evaluation of the Patient with the Complaint of Excessive Daytime Somnolence**

<table>
<thead>
<tr>
<th>Findings on History and Physical Examination</th>
<th>Diagnostic Evaluation</th>
<th>Diagnosis</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity, snoring, hypertension</td>
<td>Polysomnography with respiratory monitoring</td>
<td>Obstructive sleep apnea</td>
<td>Continuous positive airway pressure; ENT surgery (e.g., uvulopalatopharyngoplasty); dental appliance; pharmacologic therapy (e.g., protriptyline); weight loss</td>
</tr>
<tr>
<td>Cataplexy, hypnogogic hallucinations, sleep paralysis, family history</td>
<td>Polysomnography with multiple sleep latency testing</td>
<td>Narcolepsy-cataplexy syndrome</td>
<td>Stimulants (e.g., modafinil, methylphenidate); REM-suppressant antidepressants (e.g., protriptyline); genetic counseling</td>
</tr>
<tr>
<td>Restless legs syndrome, disturbed sleep, predisposing medical condition (e.g., anemia or renal failure)</td>
<td>Polysomnography with bilateral anterior tibialis EMG monitoring</td>
<td>Periodic limb movements of sleep</td>
<td>Treatment of predisposing condition, if possible; dopamine agonists (e.g., pramipexole); benzodiazipines (e.g., clonazepam)</td>
</tr>
<tr>
<td>Disturbed sleep, predisposing medical conditions (e.g., asthma) and/or predisposing medical therapies (e.g., theophylline)</td>
<td>Sleep-wake diary recording</td>
<td>Insomnias (see text)</td>
<td>Treatment of predisposing condition and/or change in therapy, if possible; behavioral therapy; short-acting benzodiazepine receptor agonist (e.g., zolpidem)</td>
</tr>
</tbody>
</table>

**Note:** ENT, ears, nose, throat; REM, rapid eye movement; EMG, electromyogram.

**DISORDERS OF SLEEP AND WAKEFULNESS**

**APPROACH TO THE PATIENT**

Patients may seek help from a physician because of one of several symptoms: (1) an acute or chronic inability to sleep adequately at night (insomnia); (2) chronic fatigue, sleepiness, or tiredness during the day; or (3) a behavioral manifestation associated with sleep itself. Complaints of insomnia or excessive daytime sleepiness should be viewed as symptoms (much like fever or pain) of underlying disorders. Knowledge of the differential diagnosis of these presenting complaints is essential to identify the underlying medical disorder. Only then can appropriate treatment, rather than non-specific approaches (e.g., over-the-counter sleeping aids), be applied. Diagnoses of exclusion, such as primary insomnia, should be made only after other diagnoses have been ruled out. Table 24-1 outlines the diagnostic and therapeutic approach to the patient with a complaint of excessive daytime sleepiness.

A careful history is essential. In particular, the duration, severity, and consistency of the symptoms are important. The patient’s estimate of the consequences of reported sleep loss on waking function. Information from a friend or family member can be invaluable; some patients may be unaware of, or will underreport, such potentially embarrassing symptoms as heavy snoring or falling asleep while driving.

Completion by the patient of a day-by-day sleep-work-drug log for at least 2 weeks can help the physician better understand the nature of the complaint. Work times and sleep times (including daytime naps and nocturnal awakenings) as well as drug and alcohol use, including caffeine and hypnotics, should be noted each day. In addition, the sleep times should be recorded.

Polysomnography is necessary for the diagnosis of specific disorders such as narcolepsy and sleep apnea and may be of utility in other settings as well. In addition to the three electrophysiologic variables used to define sleep states and stages, the standard clinical polysomnogram includes measures of respiration (respiratory effort, air flow, and oxygen saturation), anterior tibialis EMG, and electrocardiogram. Evaluation of penile tumescence during nocturnal sleep can also help determine whether the cause of erectile dysfunction in a patient is psychogenic or organic (Chap. 43).

**EVALUATION OF INSOMNIA**

Insomnia is the complaint of inadequate sleep; it can be classified according to the nature of sleep disruption and the duration of the complaint. Insomnia is subdivided into difficulty falling asleep (sleep onset insomnia), frequent or sustained awakenings (sleep maintenance insomnia), early morning awakenings (sleep offset insomnia), or persistent sleepiness despite sleep of adequate duration (nonrestorative sleep). Similarly, the duration of the symptom influences diagnostic and therapeutic considerations. An insomnia complaint lasting one to several nights (within a single episode) is termed transient insomnia and is typically the result of situational stress or a change in sleep schedule or environment (e.g., jet lag). Short-term insomnia lasts from a few days to 3 weeks. Disruption of this duration is usually associated with more protracted stress, such as recovery from surgery or short-term illness. Long-term insomnia, or chronic insomnia, lasts for months or years and, in contrast with short-term insomnia, requires a thorough evaluation of underlying causes (see below). Chronic insomnia is often a waxing and waning disorder, with spontaneous or stressor-induced exacerbations.

An occasional night of poor sleep, typically in the setting of stress or excitement about external events, is both common and without lasting consequences. However, persistent insomnia can lead to impaired daytime function, injury due to accidents, and the development of major depression. In addition, there is emerging evidence that individuals with chronic insomnia have increased utilization of health care resources, even after controlling for co-morbid medical and psychiatric disorders.

All insomnias can be exacerbated and perpetuated by behaviors that are not conducive to initiating or maintaining sleep. Inadequate sleep hygiene is characterized by a behavior pattern prior to sleep or a bedroom environment that is not conducive to sleep. Noise or light in the bedroom can interfere with sleep, as can a bed partner with periodic limb movements during sleep or one who snores loudly. Clocks can heighten the anxiety about the time it has taken to fall asleep. Drugs that act on the central nervous system, large meals, vigorous exercise, or hot showers just before sleep may interfere with sleep onset. Many individuals participate in stressful work-related activities in the evening, producing a state incompatible with sleep onset. In preference to hypnotic medications, patients should be counseled to avoid stressful activities before bed, develop a soporific bedtime ritual, and to prepare and reserve the bedroom environment for sleeping. Consistent, regular rising times should be maintained daily, including weekends.

**PRIMARY INSOMNIA**

- **Insomnia without Identifiable Cause** Many patients with chronic insomnia have no clear, single identifiable underlying cause for their difficulties with sleep. Rather, such patients often have multiple etiologies for their insomnia, which may evolve over the years. Primary insomnia is thus a diagnosis of exclusion, often without a clear underlying single cause. In addition, the chief sleep complaint may change over time, with initial insomnia predominating at one point, and multiple awakenings or nonrestorative sleep occurring at other times. Subsyndromal psychiatric disorders (e.g., anxiety and mood complaints), negative conditioning to the sleep environment...
(psychophysiologic insomnia, see below), amplification of the time spent awake (sleep-state misperception), physiologic hyperarousal, and poor sleep hygiene (see above) may all be present. As these processes may be both causes and consequences of chronic insomnia, many individuals will have a progressive course to their symptoms in which the severity is proportional to the chronicity, and much of the complaint may persist even after effective treatment of the initial inciting etiology. Treatment of primary insomnia is often directed to each of the putative contributing factors: behavior therapies for anxiety and negative conditioning (see below), psychotherapy for mood/ anxiety disorders, an emphasis on maintenance of good sleep hygiene, and intermittent hypnotics for exacerbations of the insomnia.

If insomnia persists after treatment of these contributing factors, empirically, pharmacotherapy is often used on a nightly or intermittent basis. A variety of sedative compounds are used for this purpose. Alcohol and antihistamines are the most commonly used nonprescription sleep aids. The former may help with sleep onset, but is associated with sleep disruption during the night and can escalate into abuse, dependence, and withdrawal in the predisposed individual. Antihistamines may be of benefit when used intermittently, but produce rapid tolerance and have multiple side effects (especially anticholinergic), which limit their use. Benzodiazepine receptor agonists are the most effective and well-tolerated class of medications for insomnia. The broad range of half-lives allows flexibility in the duration of sedative action. Zaleplon (5 to 20 mg), with a half-life of 1 to 2 h, zolpidem (5 to 10 mg) and triazolam (0.125 to 0.25 mg), with half-lives of 2 to 3 h, and temazepam (15 to 30 mg) and lorazepam (0.5 to 2 mg), with half-lives of 6 to 12 h, are the most commonly prescribed agents in this family. Generally, side effects are minimal if the dose is kept low and the serum concentration is minimized during the waking hours (by using the shortest-acting, effective agent). However, with even brief continuous use, rebound insomnia can occur upon discontinuation. There are only limited data supporting sustained efficacy of benzodiazepine receptor agonists; caution should be exercised in long-term use. The likelihood of rebound insomnia and tolerance can be minimized by short durations of treatment, intermittent use, or gradual tapering of the dose. For acute insomnia, nightly use of a benzodiazepine receptor agonist for a maximum of 2 to 4 weeks is advisable. For chronic insomnia, intermittent use is recommended. Benzodiazepine receptor agonists should be avoided, or used very judiciously, in patients with a history of substance abuse. The heterocyclic antidepressants (trazodone, amitriptyline, and doxepin) are the most commonly prescribed alternatives to benzodiazepine receptor agonists due to their lack of abuse potential and lower cost. Trazodone (25 to 100 mg) is used more commonly than the tricylic antidepressants as it has a much shorter half-life (5 to 9 h), has much less anticholinergic activity (sparking patients, particularly the elderly, constipation, urinary retention, and tachycardia), is associated with less weight gain, and is much safer in overdose. The risk of priapism is small (~1 in 10,000).

**Psychophysiological Insomnia** Persistent psychophysiological insomnia is a behavioral disorder in which patients are preoccupied with a perceived inability to sleep adequately at night. The sleep disturbance is often triggered by an emotionally stressful event; however, the poor sleep habits and beliefs about sleep acquired during the stressful period persist long after the initial incident. Such patients become hyperaroused by their own persistent efforts to sleep or the sleep environment, and the insomnia is a conditioned or learned response. They may be able to fall asleep more easily at unscheduled times (when not trying) or outside the home environment. Polysomnographic recording in patients with psychophysiological insomnia reveals an objective sleep disturbance, often with an abnormally long sleep latency; frequent nocturnal awakenings; and an increased amount of stage 1 transitional sleep. Rigorous attention should be paid to sleep hygiene and correction of counterproductive, arousing behaviors before bedtime. Behavioral therapies are the treatment of choice in most patients, with the intermittent use of medications. When patients are awake for >20 min, they should read or perform other relaxing activities to distract themselves from insomnia-related anxiety. In addition, bedtime and wake time should be scheduled to restrict time in bed to be equal to their perceived total sleep time. This will generally produce sleep deprivation, greater sleep drive, and, eventually, better sleep. Time in bed can then be gradually expanded.

**SECONDARY INSOMNIA**

**Transient Situational Insomnia** This typically develops after a change in the sleeping environment (e.g., in an unfamiliar hotel or hospital bed) or before or after a significant life event, such as a change of occupation, loss of a loved one, illness, or anxiety over a deadline or examination. Increased sleep latency, frequent awakenings from sleep, and early morning awakening can all occur. Recovery is generally rapid, usually within a few weeks. Treatment is symptomatic, with intermittent use of hypnotics and resolution of the underlying stress. Altitude insomnia describes a sleep disturbance that is a common consequence of exposure to high altitude. Periodic breathing of the Cheyne-Stokes type occurs during NREM sleep about half the time at high altitude, with restoration of a regular breathing pattern during REM sleep. Both hypoxia and hypocapnia are thought to be involved in the development of periodic breathing. Frequent awakenings and poor quality sleep characterize altitude insomnia, which is generally worst on the first few nights at high altitude but may persist. Treatment with acetazolamide can decrease time spent in periodic breathing and substantially reduce hypoxia during sleep.

**Insomnia Associated with Mental Disorders** Approximately 80% of patients with psychiatric disorders describe sleep complaints. There is considerable heterogeneity, however, in the nature of the sleep disturbance both between conditions and among patients with the same condition. Depression can be associated with sleep onset insomnia, sleep maintenance insomnia, or early morning wakefulness. However, hypersomnia occurs in some depressed patients, especially adolescents and those with either bipolar or seasonal (fall/winter) depression (Chap. 371). Indeed, sleep disturbance is an important vegetative sign of depression and may commence before any mood changes are perceived by the patient. Consistent polysomnographic findings in depression include decreased REM sleep latency, lengthened first REM sleep episode, and shortened first NREM sleep episode; however, these findings are not specific for depression, and the extent of these changes varies with age and symptomatology. Depressed patients also show decreased slow-wave sleep and reduced sleep continuity.

In mania and hypomania, sleep latency is increased and total sleep time can be reduced. Patients with anxiety disorders tend not to show the changes in REM sleep and slow-wave sleep seen in endogenously depressed patients. Chronic alcoholics lack slow-wave sleep, have decreased amounts of REM sleep (as an acute response to alcohol), and have frequent arousals throughout the night. This is associated with impaired daytime alertness. The sleep of chronic alcoholics may remain disturbed for years after discontinuance of alcohol use. Sleep architecture and physiology are disturbed in schizophrenia (with a decreased amount of stage 4 sleep and a lack of augmentation of REM sleep following REM sleep deprivation); chronic schizophrenics often show day-night reversal, sleep fragmentation, and insomnia.

**Insomnia Associated with Neurologic Disorders** A variety of neurologic diseases result in sleep disruption through both indirect, nonspecific mechanisms (e.g., pain in cerebral spondylosis or low back pain) or by impairment of central neural structures involved in the generation and control of sleep itself. For example, dementia from any cause has long been associated with disturbances in the timing of the sleep-wake cycle, often characterized by nocturnal wandering and an exacerbation of symptomatology at night (so-called sundowning). Epilepsy may rarely present as a sleep complaint (Chap. 348). Often the history is of abnormal behavior, at times with convulsive movements during sleep, and the differential diagnosis includes REM sleep behavior disorder, sleep apnea syndrome, and periodic movements of sleep (see above). Diagnosis requires nocturnal EEG recording. Other neurologic diseases associated with abnormal movements, such as...
Parkinson’s disease, hemiballismus, Huntington’s chorea, and Gilles de la Tourette syndrome (Chap. 351), are also associated with disrupted sleep, presumably through secondary mechanisms. However, the abnormal movements themselves are greatly reduced during sleep. Headache syndromes (migraine or cluster headache) may show sleep-associated exacerbations (Chap. 14) by unknown mechanisms.

Fatal familial insomnia is a rare hereditary disorder caused by degeneration of anterior and dorsomedial nuclei of the thalamus. Insomnia is a prominent early symptom. Progressively, the syndrome produces autonomic dysfunction, dysarthria, myoclonus, coma, and death. The pathogenesis is a mutation in the prion gene (Chap. 362).

Insomnia Associated with Other Medical Disorders A number of medical conditions are associated with disruptions of sleep. The association is frequently nonspecific, e.g., that between sleep disruption and chronic pain from rheumatologic disorders. Attention to this association is important in that sleep-associated symptoms are often the presenting complaint. Treatment of the underlying medical disorder or symptom is the most useful approach. Sleep disruption can also result from the inappropriate use of drugs such as glucocorticoids (see below).

One prominent association is between sleep disruption and asthma. In many asthmatics there is a prominent daily variation in airway resistance that results in marked increases in asthmatic symptoms at night, especially during sleep. In addition, treatment with theophylline-based compounds, adrenergic agonists, or glucocorticoids can independently disrupt sleep. When sleep disruption is a side effect of asthma treatment, inhaled glucocorticoids (e.g., beclomethasone) that do not disrupt sleep may provide a useful alternative.

Cardiac ischemia may also be associated with sleep disruption. The ischemia itself may result from increases in sympathetic tone as a result of sleep apnea. Patients may present with complaints of nightmares or vivid, disturbing dreams, with or without awareness of the more classic symptoms of angina or of the sleep disordered breathing. Treatment of the sleep apnea may substantially improve the angina and the nocturnal sleep quality. Paroxysmal nocturnal dyspnea can also occur as a consequence of sleep-associated cardiac ischemia that causes pulmonary congestion exacerbated by the recumbent posture. Chronic obstructive pulmonary disease is also associated with sleep disruption, as is cystic fibrosis, menopause, hyperthyroidism, gastroesophageal reflux, chronic renal failure, and liver failure.

**PERIODIC LIMB MOVEMENT DISORDER** Periodic limb movement disorder, previously known as nocturnal myoclonus, is the principal objective polysomnographic finding in 17% of patients with insomnia and 11% of those with excessive daytime somnolence (Fig. 24-3). It is often unclear whether it is an incidental finding or the cause of disturbed sleep. Stereotyped, 0.5- to 5.0-s extensions of the great toe and dor-
siflexion of the foot recur every 20 to 40 s during NREM sleep, in episodes lasting from minutes to hours. Most such episodes occur during the first half of the night. The disorder occurs in a wide variety of sleep disorders (including narcolepsy, sleep apnea, REM sleep behavior disorder, and various forms of insomnia) and may be associated with frequent arousals and an increased number of sleep-stage transitions. The incidence increases with age: 44% of people over age 65 without a sleep complaint have more than five periodic leg movements per hour of sleep. The pathophysiology is not well understood, though individuals with high spinal transections can exhibit periodic leg movements during sleep, suggesting the existence of a spinal generator. Polysomnography with bilateral surface EMG recording of the anterior tibialis is used to establish the diagnosis. Treatment options include dopaminergic medications or benzodiazepines.

**EVALUATION OF DAYTIME SLEEPINESS** Daytime impairment due to sleep loss may be difficult to quantify for several reasons. First, sleepiness is not necessarily proportional to subjectively assessed sleep deprivation. In obstructive sleep apnea, for example, the repeated brief interruptions of sleep associated with resumption of respiration at the end of apnic episodes result in daytime sleepiness, despite the fact that the patient may be unaware of the sleep fragmentation. Second, subjective descriptions of waking impairment vary from patient to patient. Patients may describe themselves as “sleepy,” “fatigued,” or “tired” and may have a clear sense of the meaning of those terms, while others may use the same terms to describe a completely different condition. Third, sleepiness, particularly when profound, may affect judgment in a manner analogous to ethanol, such that subjective awareness of the condition and the consequent cognitive and motor impairment is reduced. Finally, patients may be reluctant to admit that sleepiness is a problem, both because they are generally unaware of what constitutes normal alertness and because sleepiness is generally viewed pejoratively, ascribed more often to a deficit in motivation than to an inadequately addressed physiologic sleep need.

Specific questioning about the occurrence of sleep episodes during normal waking hours, both intentional and unintentional, can overcome the inconsistencies among subjective characterizations and help to interpret the adverse impact of sleepiness on daytime function. Specific areas to be addressed include the occurrence of inadvertent sleep episodes while driving or in other safety-related settings, sleepiness while at work or school (and the relationship of sleepiness to work and school performance), and the effect of sleepiness on social and family life. Evidence for significant daytime impairment in association either with the diagnosis of a primary sleep disorder, such as narcolepsy or sleep apnea, or with imposed or self-selected sleep-wake schedules (see “Shift-Work Sleep Disorder,” below) raises the question of the physician’s responsibility to notify motor vehicle licensing authorities of the increased risk of sleepiness-related vehicle accidents. As with epilepsy, legal requirements vary from state to state, and existing legal precedents do not provide a consistent interpretation of the balance between the physician’s responsibility and the patient’s right to privacy. At a minimum, physicians should document discussions with the patient regarding the increased risk of operating a vehicle, as well as a recommendation that driving be suspended until successful treatment or schedule modification can be instituted.

The distinction between fatigue and sleepiness can be useful in the differentiation of patients with complaints of fatigue or tiredness in the setting of disorders such as fibromyalgia (Chap. 315), chronic fatigue syndrome (Chap. 370), or endocrine deficiencies such as hypothyroidism (Chap. 320) or Addison’s disease (Chap. 321). While patients with these disorders can typically distinguish their daytime symptoms from the sleepiness that occurs with sleep deprivation, substantial overlap can occur. This is particularly true when the primary disorder also results in chronic sleep disruption (e.g., sleep apnea in hypothyroidism) or in abnormal sleep (e.g., fibromyalgia).

While clinical evaluation of the complaint of excessive sleepiness is usually adequate, objective quantification is sometimes necessary. Assessment of daytime functioning as an index of the adequacy of sleep can be made with the multiple sleep latency test (MSLT), which involves repeated measurement of sleep latency (time to onset of sleep under standardized conditions during a day following quantified nocturnal sleep. The average latency across four to six tests (administered every 2 h across the waking day) provides an objective measure of daytime sleep tendency. Disorders of sleep that result in pathologic daytime somnolence can be reliably distinguished with the MSLT. In addition, the multiple measurements of sleep onset may identify direct transitions from wakefulness to REM sleep that are suggestive of specific pathologic conditions (e.g., narcolepsy).

**NARCOLEPSY** Narcolepsy is both a disorder of the ability to sustain wakefulness voluntarily and a disorder of REM sleep regulation (Table 24-2). The classic “narcolepsy tetrad” consists of excessive daytime somnolence plus three specific symptoms related to an intrusion of REM sleep characteristics (e.g., muscle atonia, vivid dream imagery) into the transition between wakefulness and sleep: (1) sudden weakness or loss of muscle tone without loss of consciousness, often elicited by emotion (cataplexy); (2) hallucinations at sleep onset (hypnogogic hallucinations) or upon awakening (hypnopompic hallucinations); and (3) muscular paralysis upon awakening (sleep paralysis). The severity of cataplexy varies, as patients may have two to three attacks per day or per decade. Some patients with objectively confirmed narcolepsy (see below) may show no evidence of cataplexy. In those with cataplexy, the extent and duration of an attack may also vary, from a transient sagging of the jaw lasting a few seconds to rare cases of flaccid paralysis of the entire voluntary musculature for up to 20 to 30 min. Symptoms of narcolepsy typically begin in the second decade, although the onset ranges from ages 5 to 50. Once established, the disease is chronic without remissions. Secondary forms of narcolepsy have been described (e.g., after head trauma).

Narcolepsy affects about 1 in 4000 people in the United States and appears to have a genetic basis. Recently, several convergent lines of evidence suggest that the hypothalamic neuropeptide hypocretin (orexin) is involved in the pathogenesis of narcolepsy: (1) a mutation in the hypocretin receptor 2 gene has been associated with canine narcolepsy; (2) hypocretin “knockout” mice that are genetically unable to produce this neuropeptide exhibit a phenotype, as assessed by behavioral and electrophysiologic criteria, that is similar to human narcolepsy; and (3) cerebrospinal fluid levels of hypocretin are reduced in most patients who have narcolepsy with cataplexy. The inheritance pattern of narcolepsy in humans is more complex than in the canine model. However, almost all narcoleptics with cataplexy are positive for HLA DQB1*0602 (Chap. 296), suggesting that an autoimmune process may be responsible.

**Diagnosis** The diagnostic criteria continue to be a matter of debate. Certainly, objective verification of excessive daytime somnolence, typically with MSLT mean sleep latencies $<$8 min, is an essential if nonspecific diagnostic feature. Other conditions that cause excessive sleepiness, such as sleep apnea or chronic sleep restriction, must be rigorously excluded. The other objective diagnostic feature of narcolepsy is the presence of REM sleep in at least two of the naps during the MSLT. Abnormal regulation of REM sleep is also manifested by

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Prevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excessive daytime somnolence</td>
<td>100</td>
</tr>
<tr>
<td>Disturbed sleep</td>
<td>87</td>
</tr>
<tr>
<td>Cataplexy</td>
<td>76</td>
</tr>
<tr>
<td>Hypnagogic hallucinations</td>
<td>68</td>
</tr>
<tr>
<td>Sleep paralysis</td>
<td>64</td>
</tr>
<tr>
<td>Memory problems</td>
<td>50</td>
</tr>
</tbody>
</table>

The appearance of REM sleep immediately or within minutes after sleep onset in 50% of narcoleptic patients, a rarity in unaffected individuals, maintains a conventional sleep-wake schedule. The REM-related symptoms of the classic narcolepsy tetrad are variably present. There is increasing evidence that narcoleptics with cataplexy (one-half to two-thirds of patients) may represent a more homogeneous group than those without this symptom. However, a history of cataplexy can be difficult to establish reliably. Hypnagogic and hypnopompic hallucinations and sleep paralysis are often found in narcoleptic individuals and are more common in only one-half of narcoleptics. Nocturnal sleep disturbance is commonly observed in narcolepsy but is also a nonspecific symptom. Similarly, a history of “automatic behavior” during wakefulness (a trancelike state during which simple motor behaviors persist) is not specific for narcolepsy and serves principally to corroborate the presence of daytime somnolence.

**TREATMENT**

The treatment of narcolepsy is symptomatic. Somnolence is treated with wake-promoting therapeutics. Modafinil is now the drug of choice, particularly with fewer side effects than older stimulants and has a long half-life; 200 to 400 mg is given as a single daily dose. Older drugs such as methylphenidate (10 mg bid to 20 mg qid or dextroamphetamine (10 mg bid) are still used as alternatives, particularly in refractory patients.

Treatment of the REM-related phenomena cataplexy, hypnagogic hallucinations, and sleep paralysis requires the potent REM sleep suppression produced by antidepressant medications. The tricyclic antidepressants [e.g., protriptyline (10 to 40 mg/d) and clomipramine (25–50 mg/d)] and the selective serotonin reuptake inhibitors (SSRIs) [e.g., fluoxetine (10 to 20 mg/d)] are commonly used for this purpose. Efficacy of the antidepressants is limited largely by anticholinergic side effects (tricyclics) and by sleep disturbance and sexual dysfunction (SSRIs). Adequate nocturnal sleep time and planned daytime naps (when possible) are important preventative measures.

**SLEEP APNEA SYNDROMES**  Respiratory dysfunction during sleep is a common, serious cause of excessive daytime somnolence as well as of disturbed nocturnal sleep. An estimated 2 to 5 million people in the United States have a reduction or cessation of breathing for 10 to 150 s, from thirty to several hundred times every night during sleep. These episodes may be due to either an occlusion of the airway (obstructive sleep apnea), absence of respiratory effort (central sleep apnea), or a combination of these factors (mixed sleep apnea) (Fig. 24-3). Failure to recognize and treat these conditions appropriately may lead to impairment of daytime alertness; increased risk of sleep-related motor vehicle accidents; hypertension and other serious cardiovascular complications; and increased mortality. Sleep apnea is particularly prevalent in overweight men and in the elderly, yet it is estimated to remain undiagnosed in 80 to 90% of affected individuals. This is unfortunate since effective treatments are available. Readers are referred to Chap. 247 for a comprehensive review of the diagnosis and treatment of patients with these conditions.

**PARASOMNIAS**  The term parasomnia refers to abnormal behaviors that arise from or occur during sleep. A continuum of parasomnias arises from NREM sleep, from brief confusional arousals to sleepwalking and night terrors. The presenting complaint is usually related to the behavior itself, but the parasomnias can disturb sleep continuity or lead to mild impairments in daytime alertness. Only one parasomnia is known to occur in REM sleep, i.e., REM sleep behavior disorder (RBD; see below).

**Sleepwalking (Somnambulism)**  Patients affected by this disorder carry out automatic motor activities that range from simple to complex. Individuals may leave the bed, walk, urinate inappropriately, eat, or exit from the house while remaining only partially aware. Full arousal may be difficult, and some patients may respond to attempted awakening with agitation or even violence. Sleepwalking arises from stage 3 or 4 NREM sleep and is most common in children and adolescents, when these sleep stages are most robust. Episodes are usually isolated but may be recurrent in 1 to 6% of patients. The cause is unknown, though it has a familial basis in roughly one-third of cases.

**Sleep Terrors**  This disorder, also called pavor nocturnus, occurs primarily in young children during the first several hours after sleep onset, in stages 3 and 4 of NREM sleep. The child suddenly screams, exhibiting autonomic arousal with sweating, tachycardia, and hyperventilation. The individual may be difficult to arouse and rarely recalls the episode on awakening in the morning. Recurrent attacks are rare. Parents are usually reassured to learn that the condition is self-limited and benign, and that no specific therapy is indicated. Both sleep terrors and sleepwalking represent abnormalities of arousal. In contrast, nightmares (dream anxiety attacks) occur during REM sleep and cause full arousal, with intact memory for the unpleasant episode.

**REM Sleep Behavior Disorder**  RBD is a rare condition that is distinct from other parasomnias in that it occurs during REM sleep. It primarily afflicts men of middle age or older, many of whom have a history of prior neurologic disease. In fact, over one-third of patients will go on to develop Parkinson’s disease (Chap. 351) within 10 to 20 years. Presenting symptoms consist of agitated or violent behavior during sleep, reported by a bed partner. In contrast to typical somnambulism, injury to patient or bed partner is not uncommon, and, upon awakening, the patient reports vivid, often unpleasant, dream imagery. The principal differential diagnosis is that of nocturnal seizures, which can be excluded with polysomnography. In RBD, seizure activity is absent on the EEG, and disinhibition of the usual motor atonia is observed in the EMG during REM sleep, at times associated with complex motor behaviors. The pathogenesis is unclear, but damage to brainstem areas mediating descending motor inhibition during REM sleep may be responsible. In support of this hypothesis are the remarkable similarities between RBD and the sleep of animals with bilateral lesions of the pontine tegmentum in areas controlling REM sleep motor inhibition. Treatment with clonazepam (0.5 to 1.0 mg qhs) provides sustained improvement in almost all reported cases.

**Sleep Bruxism**  Bruxism is an involuntary, forceful grinding of teeth during sleep that affects 10 to 20% of the population. The patient is usually unaware of the problem. The typical age of onset is 17 to 20 years, and spontaneous remission usually occurs by age 40. Sex distribution appears to be equal. In many cases, the diagnosis is made during dental examination, damage is minor, and no treatment is indicated. In more severe cases, treatment with a rubber tooth guard is necessary to prevent disfiguring tooth injury. Stress management or, in some cases, biofeedback can be useful when bruxism is a manifestation of psychological stress. There are anecdotal reports of benefit using benzodiazepines.

**Sleep Enuresis**  Bedwetting, like sleepwalking and night terrors, is another parasomnia that occurs during sleep in the young. Before age 5 or 6, nocturnal enuresis should probably be considered a normal feature of development. The condition usually improves spontaneously at puberty, has a prevalence in late adolescence of 1 to 3%, and is rare in adulthood. In older patients with enuresis a distinction must be made between primary and secondary enuresis, the latter being defined as bedwetting in patients who have been fully continent for 6 to 12 months. Treatment of primary enuresis is reserved for patients of appropriate age (>5 or 6 years) and consists of bladder training exercises and behavioral therapy. Urologic abnormalities are more common in primary enuresis and must be assessed by urologic examination. Important causes of secondary enuresis include emotional disturbances, urinary tract infections or malformations, cauda equina lesions, epilepsy, sleep apnea, and certain medications. Symptomatic pharmacotherapy is usually accomplished with desmopressin (0.2 mg qhs), oxybutynin chloride (5 to 10 mg qhs) or imipramine (10 to 50 mg qhs).

**Miscellaneous Parasomnias**  Other clinical entities fulfill the definition of a parasomnia in that they occur selectively during sleep and are as-
More than 7 million workers in the United States regularly work at night, either on a permanent or rotating schedule. In addition, each week millions elect to remain awake at night to meet deadlines, drive long distances, or participate in recreational activities, leading to both sleep loss and misalignment of their circadian rhythms with respect to their sleep-wake cycle. Chronic shift workers have higher rates of cardiac, gastrointestinal, and reproductive disorders. Studies of regular night-shift workers indicate that the circadian timing system usually fails to adapt successfully to such inverted schedules. This leads to a misalignment between the desired work-rest schedule and the output of the pacemaker and in disturbed daytime sleep. Sleep deprivation, increased length of time awake prior to work, and misalignment of circadian phase produce decreased alertness and performance, increased reaction time, and increased risk of performance lapses, thereby resulting in greater safety hazards among night workers and other sleep-deprived individuals. Sleep disturbance nearly doubles the risk of a fatal work accident.

Delayed Sleep Phase Syndrome Delayed sleep phase syndrome is characterized by: (1) reported sleep onset and wake times intrinsically later than desired, (2) actual sleep times at nearly the same clock hours daily, and (3) essentially normal all-night polysomnography except for delayed sleep onset. Patients exhibit an abnormally delayed endogenous circadian phase, with the temperature minimum during the constant routine occurring later than normal. This delayed phase could be due to: (1) an abnormally long, genetically determined intrinsic period of the endogenous circadian pacemaker; (2) an abnormally reduced phase-advancing capacity of the pacemaker; or (3) an irregular prior sleep-wake schedule, characterized by frequent nights when the patient chooses to remain awake until past midnight (for social, school, or work reasons). In most cases, it is difficult to distinguish among these factors, since patients with an abnormally long intrinsic period are more likely to “choose” such late-night activities because they are unable to sleep at that time. Patients tend to be young adults. This self-perpetuating condition can persist for years and does not usually respond to attempts to reestablish normal bedtime hours. Treatment methods involving bright-light phototherapy during the morning hours or melatonin administration in the evening hours show promise in these patients, although the relapse rate is high.

Advanced Sleep Phase Syndrome Advanced sleep phase syndrome (ASPS) is the converse of the delayed sleep phase syndrome. Most commonly, this syndrome occurs in older people, 15% of whom report that they cannot sleep past 5 A.M., with twice that number complaining that they wake up too early at least several times per week. Patients with ASPS experience excessive daytime sleepiness during the evening hours, when they have great difficulty remaining awake, even in social settings. Typically, patients awaken from 3 to 5 A.M. each day, often several hours before their desired wake times. In addition to age-related ASPS, an early-onset familial variant of this condition has also been reported. In one such family, autosomal dominant ASPS was due to a missense mutation in a circadian clock component (PER2, as shown in Fig. 24-2) that altered the circadian period. Patients with ASPS may benefit from bright-light phototherapy during the morning hours or melatonin administration in the evening hours, designed to reset the circadian pacemaker to a later hour.

Non-24-Hour Sleep-Wake Disorder This condition can occur when the maximal phase-advancing capacity of the circadian pacemaker is not adequate to accommodate the difference between the 24-h geophysical day and the intrinsic period of the pacemaker in the patient. Alternatively, patients’ self-selected exposure to artificial light may drive the circadian pacemaker to a >24-h schedule. Affected patients are not able to maintain a stable phase relationship between the output of the pacemaker and the 24-h day. Such patients typically present with an incremental pattern of successive delays in sleep onset and wake
times, progressing in and out of phase with local time. When the patient’s endogenous rhythms are out of phase with the local environment, insomnia coexists with excessive daytime sleepiness. Conversely, when the endogenous rhythms are in phase with the local environment, symptoms remit. The intervals between symptomatic periods may last several weeks to several months. Blind individuals unable to perceive light are particularly susceptible to this disorder. Nightly low-dose (0.5 mg) melatonin administration has been reported to improve sleep and, in some cases, even to induce synchronization of the circadian pacemaker.

MEDICAL IMPLICATIONS OF CIRCADIAN RHYTHMICITY Prominent circadian variations have been reported in the incidence of acute myocardial infarction, sudden cardiac death, and stroke, the leading causes of death in the United States. Platelet aggregability is increased after arising in the early morning hours, coincident with the peak incidence of these cardiovascular events. A better understanding of the possible role of circadian rhythmicity in the acute destabilization of a chronic condition such as atherosclerotic disease could improve the understanding of the pathophysiology.

Diagnostic and therapeutic procedures may also be affected by the time of day at which data are collected. Examples include blood pressure, body temperature, the dexamethasone suppression test, and plasma cortisol levels. The timing of chemotherapy administration has been reported to have an effect on the outcome of treatment. Few physicians realize the extent to which routine measures are affected by the time (or sleep/wake state) when the measurement is made.

In addition, both the toxicity and effectiveness of drugs can vary during the day. For example, more than a fivefold difference has been observed in mortality rates following administration of toxic agents to experimental animals at different times of day. Anesthetic agents are particularly sensitive to time-of-day effects. Finally, the physician must be increasingly aware of the public health risks associated with the ever-increasing demands made by the duty-rest-recreation schedules in our round-the-clock society.

FURTHER READING


Section 4 Disorders of the Eyes, Ears, Nose, and Throat

THE HUMAN VISUAL SYSTEM

The visual system provides a supremely efficient means for the rapid assimilation of information from the environment to aid in the guidance of behavior. The act of seeing begins with the capture of images focused by the cornea and lens upon a light-sensitive membrane in the back of the eye, called the retina. The retina is actually part of the brain, banished to the periphery to serve as a transducer for the conversion of patterns of light energy into neuronal signals. Light is absorbed by photopigment in two types of receptors: rods and cones. In the human retina there are 100 million rods and 5 million cones. The rods operate in dim (scotopic) illumination. The cones function under daylight (photopic) conditions. The cone system is specialized for color perception and high spatial resolution. The majority of cones are located within the macula, the portion of the retina serving the central 10° of vision. In the middle of the macula a small pit termed the fovea, packed exclusively with cones, provides best visual acuity.

Photoreceptors hyperpolarize in response to light, activating bipolar, amacrine, and horizontal cells in the inner nuclear layer. After processing of photoreceptor responses by this complex retinal circuit, the flow of sensory information ultimately converges upon a final common pathway: the ganglion cells. These cells translate the visual image impinging upon the retina into a continuously varying barrage of action potentials that propagates along the primary optic pathway to visual centers within the brain. There are a million ganglion cells in each retina, and hence a million fibers in each optic nerve.

Ganglion cell axons sweep along the inner surface of the retina in the nerve fiber layer, exit the eye at the optic disc, and travel through the optic nerve, optic chiasm, and optic tract to reach targets in the brain. The majority of fibers synapse upon cells in the lateral geniculate body, a thalamic relay station. Cells in the lateral geniculate body project in turn to the primary visual cortex. This massive afferent retinogeniculocortical sensory pathway provides the neural substrate for visual perception. Although the lateral geniculate body is the main target of the retina, separate classes of ganglion cells project to other subcortical visual nuclei involved in different functions. Ganglion cells that mediate pupillary constriction and circadian rhythms are light sensitive, owing to a novel visual pigment, melanopsin. Pupil responses are mediated by input to the pretectal olivary nuclei in the midbrain. The pretectal nuclei send their output to the Edinger-Westphal nuclei, which in turn provide parasympathetic innervation to the iris sphincter via an interneuron in the ciliary ganglion. Circadian rhythms are timed by a retinal projection to the suprachiasmatic nucleus. Visual orientation and eye movements are served by retinal input to the superior colliculus. Gaze stabilization and optokinetic reflexes are governed by a group of small retinal targets known collectively as the brainstem accessory optic system.

The eyes must be rotated constantly within their orbits to place and maintain targets of visual interest upon the fovea. This activity, called foveation, or looking, is governed by an elaborate efferent motor system. Each eye is moved by six extraocular muscles, supplied by cranial nerves from the oculomotor (III), trochlear (IV), and abducens (VI) nuclei. Activity in these ocular motor nuclei is coordinated by pontine and midbrain mechanisms for smooth pursuit, saccades, and gaze stabilization during head and body movements. Large regions of the frontal and parietooccipital cortex control these brainstem eye movement centers by providing descending supranuclear input.

CLINICAL ASSESSMENT OF VISUAL FUNCTION

REFRACTIVE STATE In approaching the patient with reduced vision, the first step is to decide whether refractive error is responsible. In emmetropia, parallel rays from infinity are focused perfectly upon the retina. Sadly, this condition is enjoyed by only a minority of the population. In myopia, the globe is too long, and light rays come to a focal point in front of the retina. Near objects can be seen clearly, but distant objects require a diverging lens in front of the eye. In hyperopia, the globe is too short, and hence a converging lens is used to supplement the refractive power of the eye. In astigmatism, the corneal surface is not perfectly spherical, necessitating a cylindrical corrective lens. In recent years it has become possible to correct refractive error with the excimer laser by performing LASIK (laser in situ keratomileusis) to alter the curvature of the cornea.

With the onset of middle age, presbyopia develops as the lens within the eye becomes unable to increase its refractive power to accommodate upon near objects. To compensate for presbyopia, the em-
The human nervous system is the organ of consciousness, cognition, ethics, and behavior; as such, it is the most intricate structure known to exist. One-third of the 35,000 genes encoded in the human genome are expressed in the nervous system. Each mature brain is composed of 100 billion neurons, several million miles of axons and dendrites, and $>10^{15}$ synapses. Neurons exist within a dense parenchyma of multifunctional glial cells that synthesize myelin, preserve homeostasis, and regulate immune responses. Measured against this background of complexity, the achievements of molecular neuroscience have been extraordinary. Advances in cell biology and genetics have provided new tools to explore the pathophysiology of nervous system diseases, clarifying their underlying causes, revealing new unanticipated groupings, and raising realistic hope that novel therapies and prevention strategies will be possible. This chapter reviews selected themes in neurobiology that provide a context for understanding fundamental mechanisms underlying neurologic disorders.

ION CHANNELS AND CHANNELOPATHIES  The resting potential of neurons and the action potentials responsible for impulse conduction are generated by ion currents and ion channels. Most ion channels are gated, meaning that they can transition between conformations that are open or closed to ion conductance. Individual ion channels are distinguished by the specific ions they conduct; by their kinetics; and by whether they directly sense voltage, are linked to receptors for neurotransmitters or other ligands such as neurotrophins, or are activated by second messengers. The diverse characteristics of different ion channels provide a means by which neuronal excitability can be exquisitely modulated at both the cellular and the subcellular levels. Mutations in ion channels—channeledopathies—are responsible for a growing list of human neurologic disorders (Table 345-1). One example is epilepsy, a syndrome of disease characterized by repetitive, synchronous firing of neuronal action potentials. Action potentials are normally generated by the opening of sodium channels and the inward movement of sodium ions down the intracellular concentration gradient. Depolarization of the neuronal membrane opens potassium channels, resulting in outward movement of potassium ions, repolarization, closure of the sodium channel, and hyperpolarization. Sodium or potassium channel subunit genes have long been considered candidate disease genes in inherited epilepsy syndromes, and recently such mutations have been identified (Chap. 348). These mutations appear to alter the normal gating function of these channels, increasing the inherent excitability of neuronal membranes in regions where the abnormal channels are expressed.

Whereas the specific clinical manifestations of channeledopathies are quite variable, one common feature is that manifestations tend to be intermittent or paroxysmal, such as occurs in epilepsy, migraine, ataxia, myotonia, or periodic paralysis. Exceptions are clinically progressive channel disorders such as autosomal dominant hearing impairment. The neurologic channeledopathies identified to date are all uncommon disorders caused by obvious mutations in channel genes. As the full repertoire of human ion channels and related proteins are identified, it is likely that additional channelopathies will be discovered. In addition to rare disorders that result from obvious mutations, it is possible that subtle allelic variations in channel genes or in their pattern of expression might underlie susceptibility to some common forms of epilepsy, migraine, or other disorders.

NEUROTRANSMITTERS AND NEUROTRANSMITTER RECEPTORS  Synaptic neurotransmission is the predominant means by which neurons communicate with each other. Classic neurotransmitters are synthesized in the presynaptic region of the nerve terminal; stored in vesicles; and released into the synaptic cleft, where they bind to receptors on the postsynaptic cell. Secreted neurotransmitters are eliminated by reuptake into the presynaptic neuron (or glia), by diffusion away from the synaptic cleft, and/or by specific inactivation. In addition to the classic neurotransmitters, many neuropeptides have been identified as definite or probable neurotransmitters; these include substance P, neurtensin, enkephalins, β-endorphin, histamine, vasoactive intestinal polypeptide, cholecystokinin, neuropeptide Y, and somatostatin. Peptide neurotransmitters are synthesized in the cell body rather than the nerve terminal and may colocalize with classic neurotransmitters in single neurons. Nitric oxide and carbon monoxide are gases that appear also to function as neurotransmitters, in part by signaling in a retrograde fashion from the postsynaptic to the presynaptic cell.

Neurotransmitters modulate the function of postsynaptic cells by binding to specific neurotransmitter receptors, of which there are two major types. Ionotropic receptors are direct ion channels that open after engagement by the neurotransmitter. Metabotropic receptors interact with G proteins, stimulating production of second messengers and activating protein kinases, which modulate a variety of cellular events. Ionotropic receptors are multiple subunit structures, whereas metabotropic receptors are composed of single subunits only. One important difference between ionotropic and metabotropic receptors is that the kinetics of ionotropic receptor effects are fast (generally $<1$ ms) because neurotransmitter binding directly alters the electrical properties of the postsynaptic cell, whereas metabotropic receptors function over longer time periods. These different properties contribute to the potential for selective and finely modulated signaling by neurotransmitters.

Neurotransmitter systems are perturbed in a large number of clinical disorders, examples of which are highlighted in Table 345-2. One example is the involvement of dopaminergic neurons originating in the substantia nigra of the midbrain and projecting to the striatum...
Amphetamine increases intracellular release of dopamine from vesicles and reverses transport of dopamine through the dopaminergic system. Addictive drugs share the property of increasing dopamine release in the nucleus accumbens. Amphetamine increases intracellular release of dopamine from vesicles and reverses transport of dopamine through the dopaminergic system. Addictive drugs share the property of increasing dopamine release in the nucleus accumbens (Fig. 345-1). Addictive drugs are a major component of addictive behaviors including drug reward. Its key components include the midbrain ventral tegmental area (VTA), median forebrain bundle, and nucleus accumbens. Nicotine increases dopamine release by activating nicotinic acetylcholine receptors on cell bodies and nerve terminals of dopaminergic VTA neurons. Tetrahydrocannabinol, the active ingredient of cannabis, also increases dopamine levels in the nucleus accumbens. Blockade of dopamine in the nucleus accumbens can terminate the rewarding effects of addictive drugs.

<table>
<thead>
<tr>
<th>Neurotransmitter</th>
<th>Anatomy</th>
<th>Clinical Aspects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylcholine (ACh)</td>
<td>Motor neurons in spinal cord → neuromuscular junction</td>
<td>Acetylcholinesterases (nerve gases) Myasthenia gravis (antibodies to ACh receptor) Congenital myasthenic syndromes (mutations in ACh receptor subunits) Lambert-Eaton syndrome (antibodies to Ca channels impair ACh release) Botulism (toxin disrupts ACh release by exocytosis) Alzheimer’s disease (selective cell death) Autosomal dominant frontal lobe epilepsy (mutations in CNS ACh receptor) Parkinson’s disease (tremor)</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Substantia nigra → striatum (nigrostriatal pathway)</td>
<td>Parkinson’s disease (selective cell death) MPTP parkinsonism (toxin transported into neurons) Addiction, behavioral disorders</td>
</tr>
<tr>
<td>Norepinephrine (NE)</td>
<td>Locus coeruleus (pons) → limbic system, hypothalamus, cortex Medulla → locus coeruleus, spinal cord Postganglionic neurons of sympathetic nervous system</td>
<td>Mood disorders (MAOA inhibitors and tricyclics increase NE and improve depression) Anxiety Orthostatic tachycardia syndrome (mutations in NE transporter)</td>
</tr>
<tr>
<td>Serotonin</td>
<td>Pontine raphe nuclei → widespread projections Medulla/pons → dorsal horn of spinal cord</td>
<td>Mood disorders (SSRIs improve depression) Migraine pain pathway Pain pathway</td>
</tr>
<tr>
<td>γ-Aminobutyric acid (GABA)</td>
<td>Major inhibitory neurotransmitter in brain; widespread cortical interneurons and long projection pathways</td>
<td>Stiff person syndrome (antibodies to glutamic acid decarboxylase, the biosynthetic enzyme for GABA) Epilepsy (gabapentin and valproic acid increase GABA)</td>
</tr>
<tr>
<td>Glycine</td>
<td>Major inhibitory neurotransmitter in spinal cord</td>
<td>Spasticity Hyperekplexia (myoclonic startle syndrome) due to mutations in glycine transporter</td>
</tr>
<tr>
<td>Glutamate</td>
<td>Major excitatory neurotransmitter; located throughout CNS, including cortical pyramidal cells</td>
<td>Seizures due to ingestion of domoic acid (a glutamate analogue) Rasmussen’s encephalitis (antibody against glutamate receptor 3) Excitotoxic cell death</td>
</tr>
</tbody>
</table>

Note: CNS, central nervous system; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MAOA, monoamine oxidase A; SSRI, selective serotonin reuptake inhibitor.
are also widespread in glia, creating a syncytium that protects neurons by removing glutamate and potassium from the extracellular environment. Gap junctions consist of membrane-spanning proteins, termed connexins, that pair across adjacent cells. Mechanisms that involve gap junctions have been related to a variety of neurologic disorders. Mutations in connexin 32, a gap junction protein expressed by Schwann cells, are responsible for the X-linked form of Charcot-Marie-Tooth disease (Chap. 364). Mutations in either of two gap junction proteins expressed in the inner ear—connexin 26 and connexin 31—result in autosomal dominant progressive hearing loss (Chap. 26). Gial calcium waves mediated through gap junctions also appear to explain the phenomenon of spreading depression associated with migraine auras and the march of epileptic discharges. Spreading depression is a neural response that follows a variety of different stimuli and is characterized by a circumferentially expanding negative potential that propagates at a characteristic speed of 20 m/s and is associated with an increase in extracellular potassium.

**Signaling Pathways and Gene Transcription**

The fundamental issue of how memory, learning, and thinking are encoded in the nervous system is likely to be clarified by identifying the signaling pathways involved in neuronal differentiation, axon guidance, and synapse formation, and by understanding how these pathways are modulated by experience. Many families of transcription factors, each comprising multiple individual components, are expressed in the nervous system. Elucidation of these signaling pathways has already begun to provide insights into the cause of a variety of neurologic disorders, including inherited disorders of cognition such as X-linked mental retardation. This problem affects approximately 1 in 500 males, and linkage studies in different families suggest that as many as 60 different X-chromosome encoded genes may be responsible. Rett syndrome, a common cause of (dominant) X-linked progressive mental retardation in females, is due to a mutation in a gene (MECP2) encoding a DNA-binding protein involved in transcriptional repression. As the X chromosome comprises only ~3% of germline DNA, then by extrapolation the number of genes that potentially contribute to clinical disorders affecting intelligence in humans must be potentially very large. As discussed below, there is increasing evidence that abnormal gene transcription may play a role in neurodegenerative diseases such as Huntington’s disease in which proteins with polyglutamine expansions bind to and sequester transcription factors. A critical transcription factor for neuronal survival is CREB (cyclic adenosine monophosphate responsive element-binding) protein, which also plays an important role in memory in the hippocampus.

**Myelin** Myelin is the multilayered insulating substance that surrounds axons and speeds impulse conduction by permitting action potentials to jump between naked regions of axons (nodes of Ranvier) and across myelinated segments. A single oligodendrocyte usually ensheaths multiple axons in the central nervous system (CNS), whereas in the peripheral nervous system (PNS) each Schwann cell typically myelinates a single axon. Myelin is a lipid-rich material formed by a spiraling process of the membrane of the myelinating cell around the axon, creating multiple membrane bilayers that are tightly apposed (compartmental myelin) by charged protein interactions. A number of clinically important neurologic disorders are caused by inherited mutations in myelin proteins of the CNS or PNS. Constituents of myelin also have a propensity to be targeted as autoantigens in autoimmune demyelinating disorders (Fig. 345-2).

**Neurotrophic Factors** Neurotrophic factors (Table 345-3) are secreted proteins that modulate neuronal growth, differentiation, repair, and survival; some have additional functions, including roles in neurotransmission and in the synaptic reorganization involved in learning and memory. The neurotrophin (NT) family contains nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT3, and NT4/5. The neurotrophins act at Trk and p75 receptors to promote survival of neurons. Because of their survival-promoting and anti-apoptotic actions in myelin sheaths, the neurotrophins have a propensity to be targeted as autoantigens in autoimmune demyelinating disorders and in other neurologic disorders (Fig. 345-3).
apototic effects, neurotrophic factors are in theory outstanding candidates for therapy of disorders characterized by premature death of neurons such as occurs in amyotrophic lateral sclerosis (ALS) and other degenerative motor neuron disorders. Knockout mice lacking receptors for ciliary neurotrophic factor (CNTF) or BDNF show loss of motor neurons, and experimental motor neuron death can be rescued by treatment with various neurotrophic factors including CNTF and BDNF. However, in phase 3 clinical trials, growth factors were ineffective in human ALS. The growth factor glial-derived neurotrophic factor (BDNF) is important for survival of dopaminergic neurons. It has shown promising neurorestorative effects in experimental models of Parkinson’s disease and in early stage human clinical trials.

STEM CELLS AND TRANSPLANTATION The nervous system is traditionally considered to be a nonmitotic organ, in particular with respect to neurons. These concepts have been challenged by the finding that neural progenitor or stem cells exist in the adult CNS that are capable of differentiation, migration over long distances, and extensive axonal arborization and synapse formation with appropriate targets. These capabilities also indicate that the repertoire of factors required for growth, survival, differentiation, and migration of these cells exists in the mature nervous system. In rodents, neural stem cells, defined as progenitor cells capable of differentiating into mature cells of neural or glial lineage, have been experimentally propagated from fetal CNS and neuroectodermal tissues and also from adult germinal matrix and ependyma regions. Human fetal CNS tissue is also capable of differentiation into cells with neuronal, astrocytic, and oligodendrocytic morphology when cultured in the presence of growth factors. Impressively, such cells could be stably engrafted into mouse CNS tissue, creating neural chimeras. Human adult neural stem cells have been identified in an astrocyte layer adjacent to the lateral ventricles; however, these neurons appeared to be unable to migrate or form connections. Once the repertoire of signals required for cell type specification is better understood, differentiation into specific neural or glial subpopulations can be directed in vitro; such cells could also be engineered to express therapeutic molecules. Another promising approach is to utilize growth factors, such as BDNF, to stimulate endogenous stem cells to proliferate and migrate to areas of neuronal damage. Administration of epidermal growth factor with fibroblast growth factor replenished up to 50% of hippocampal CA1 neurons a month after global ischemia in rats. The new neurons made connections and improved performance in a memory task.

Experimental transplantation of human fetal dopaminergic neurons in patients with Parkinson’s disease has shown that these transplanted cells can survive within the host striatum; however, some patients developed disabling dyskinesias and this approach is no longer in clinical development. Studies of transplantation for patients with Huntington’s disease have also reported encouraging, although very preliminary, results. Oligodendrocyte precursor cells transplanted into mice with a demyelinating disorder effectively migrated in the new environment, interacted with axons, and mediated myelination; such experiments raise hope that similar transplantation strategies may be feasible in human disorders of myelin such as multiple sclerosis. The promise of stem cells for treatment of both neurodegenerative diseases and neural injury is great, but development has been slowed by unresolved concerns over safety (including the theoretical risk of malignant transformation of transplanted cells), ethics (particularly with respect to use of fetal tissue), and efficacy.

In developing brain, the extracellular matrix provides stimulatory and inhibitory signals that promote neuronal migration, neurite outgrowth, and axonal extension. After neuronal damage, reexpression of inhibitory molecules such as chondroitin sulfate proteoglycans may prevent tissue regeneration. Chondroitinase degraded these inhibitory molecules and enhanced axonal regeneration and motor recovery in a rat model of spinal cord injury. Several myelin proteins, specifically Nogo, chondroitin sulfate proteoglycans (OMGP), and myelin-associated glycoprotein (MAG), may also interfere with axon regeneration. Antibodies against Nogo promote regeneration after experimental focal ischemia. Nogo, OMGP, and MAG all bind to the same neural receptor, the Nogo receptor, which mediates its inhibitory function via the p75 neurotrophin receptor signaling.

CELL DEATH—EXCITOTOXICITY AND APOPTOSIS Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors (Fig. 345-3). Compelling evidence for a role of excitotoxicity, especially in ischemic neuronal injury, is derived from experiments in animal models. Experimental models of stroke are associated with increased extracellular concentrations of the excitatory amino acid neurotransmitter glutamate, and neuronal damage is attenuated by dervation of glutamate-containing neurons or the administration of glutamate receptor antagonists. The distribution of cells sensitive to ischemia corresponds closely with that of N-methyl-D-aspartate (NMDA) receptors (except for cerebellar Purkinje cells, which are vulnerable to hypoxia-ischemia but lack NMDA receptors); and competitive and noncompetitive NMDA antagonists are effective in preventing focal ischemia. In global cerebral ischemia, non-NMDA receptors (kainic acid and AMPA) are activated, and antagonists to these receptors are protective. Experimental brain damage induced by hypoglycemia is also attenuated by NMDA antagonists.

Excitotoxicity is not a single event but rather a cascade of cell injury. Excitotoxicity causes influx of calcium into cells, and much of the calcium is sequestered in mitochondria rather than in the cytoplasm. Increased cytoplasmic calcium causes metabolic dysfunction and free radical generation; activates protein kinases, phospholipases, nitric oxide synthase, proteases, and endonucleases; and inhibits protein synthesis. Activation of nitric oxide synthase generates nitric oxide (NO·), which can react with superoxide (O2·−) to generate peroxynitrite (ONOO−), which may play a direct role in neuronal injury. Another critical pathway is activation of poly-ADP-ribose polymerase, which occurs in response to free radical–mediated DNA damage. Experimentally, mice with knockout mutations of neuronal nitric oxide synthase or poly-ADP-ribose polymerase, or those that overexpress superoxide dismutase, are resistant to focal ischemia.

Apoposis, or programmed cell death, plays an important role in both physiologic and pathologic conditions. During embryogenesis, apoptotic pathways operate to destroy neurons that fail to differentiate appropriately or reach their intended targets. There is mounting evidence for an increased rate of apoptotic cell death in a variety of acute and chronic neurologic diseases. Apoptosis is characterized by neuronal shrinkage, chromatin condensation, and DNA fragmentation, whereas necrotic cell death is associated with cytoplasmic and mitochondrial swelling followed by dissolution of the cell membrane. Apoptotic and necrotic cell death can coexist or be sequential events, depending on the severity of the initiating insult. Cellular energy reserves appear to have an important role in these two forms of cell death, with apoptosis favored under conditions in which ATP levels are preserved. Evidence of DNA fragmentation has been found in a number of neurodegenerative disorders, Alzheimer’s disease, Huntington’s disease, and ALS. The best characterized genetic neurologic disorder related to apoptosis is infantile spinal muscular
atrophy (Werdnig-Hoffmann disease), in which two genes thought to be involved in the apoptosis pathways are causative.

Mitochondria are essential in controlling specific apoptosis pathways. The redistribution of cytochrome c, as well as apoptosis-inducing factor (AIF), from mitochondria during apoptosis leads to the activation of a cascade of intracellular proteases known as caspases. Caspase-independent apoptosis occurs after DNA damage, activation of poly-ADP-ribose polymerase, and translocation of AIF into the nucleus. Redistribution of cytochrome c is prevented by overproduction of the apoptotic protein BCL2 and is promoted by the proapoptotic protein BAX. These pathways may be triggered by activation of a large pore in the mitochondrial inner membrane known as the permeability transition pore, although in other circumstances they occur independently. Recent studies suggest that blocking the mitochondrial pore reduces both hypoglycemic and ischemic cell death.

PROTEIN AGGREGATION AND NEURODEGENERATION The possibility that protein aggregation plays a role in the pathogenesis of neurodegenerative diseases is a major focus of current research. Protein aggregation is a major histopathologic hallmark of neurodegenerative diseases. Deposition of β-amyloid is strongly implicated in the pathogenesis of Alzheimer’s disease. Genetic mutations in familial Alzheimer’s disease produce increased amounts of β-amyloid with 42 amino acids, which has an increased propensity to aggregate, as compared to β-amyloid with 40 amino acids. Mutations in genes encoding the microtubule-associated protein tau lead to altered splicing of tau and the production of neurofibrillary tangles in frontotemporal dementia and progressive supranuclear palsy. Familial Parkinson’s disease is associated with mutations in α-synuclein, parkin, and the ubiquitin carboxyl-terminal hydrolase. Parkin, which causes autosomal recessive early-onset Parkinson’s disease, is a ubiquitin ligase. The characteristic histopathologic feature of Parkinson’s disease is the Lewy body, an eosinophilic cytoplasmic inclusion that contains both neurofilaments and α-synuclein. Huntington’s disease and cerebellar degenerations are associated with expansions of polyglutamine repeats in proteins, which aggregate to produce neuronal intranuclear inclusions. Familial ALS is associated with superoxide dismutase mutations and cytoplasmic inclusions containing superoxide dismutase. In autosomal dominant neurophysiologic diabetes insulin, mutations in vasopressin result in abnormal protein processing, accumulation in the endoplasmic reticulum, and cell death (Chap. 319).

The current major scientific question is whether protein aggregates contribute to neuronal death or whether they are merely secondary bystanders. Protein aggregates are usually ubiquinated, which targets them for degradation by the 26S component of the proteosome. An inability to degrade protein aggregates could lead to cellular dysfunction, impaired axonal transport, and cell death by apoptotic mechanisms.

In experimental models of Huntington’s disease and cerebellar degeneration, protein aggregates are not well correlated with neuronal death. A substantial body of evidence suggests that the mutant proteins with polyglutamine expansions in these diseases bind to transcription factors and that this contributes to disease pathogenesis. Agents that upregulate gene transcription are neuroprotective in animal models of these diseases. A number of compounds have been developed to block β-amyloid production and/or aggregation, and these agents are being studied in early clinical trials in humans.

NEUROIMMUNOLOGY The nervous system is traditionally considered to be an immunologically privileged organ, a concept originally derived from observations that tissue grafts implanted in the brain were not rejected efficiently. In this context, immune privilege of the CNS may be maintained by a variety of mechanisms, including the lack of an efficient surveillance function by T cells; the absence of a traditional lymphoid system; limited expression of major histocompatibility complex (MHC) molecules required for T cell recognition of antigen; effects of regulatory cytokines secreted spontaneously or in response to mediators such as NGF, creating an immunosuppressive milieu; and also from expression of fas ligand that can induce apoptosis of fas-expressing immune cells that enter the brain. The blood-brain barrier (BBB) partially isolates the brain from the peripheral environment and contributes to immune privilege. Anatomically, the barrier is created by the presence of impermeable tight junctions between endothelial cells and by a relative absence of transendothelial conduits for the passage of soluble molecules. The BBB serves to preserve CNS homeostasis by excluding neuroactive substances present in the serum, such as neurotransmitters and neurotrophic factors. Because of the BBB, lipid-insoluble molecules must utilize either ion channels or
specific transport systems (for glucose or various amino acids) to gain entry to the CNS. Astrocyte foot processes that encircle the subendothelial basal surface of small blood vessels in the brain contribute to development and maintenance of the BBB.

The concept of immune privilege is at odds with clinical experience that vigorous immune reactions readily occur in the nervous system in response to infections and that autoimmune diseases of the nervous system are relatively common. Although primary (sensitizing) immune responses are not easily generated in the CNS for the reasons outlined above, this is not the case for secondary immune responses. When sensitization to nervous system antigens occurs outside the nervous system (e.g., in a regional lymph node), activated autoreactive T lymphocytes are easily generated, and these cells readily cross the BBB and induce immune-mediated injury. The paradigm for this mechanism of T cell–mediated CNS disease is experimental allergic encephalomyelitis (EAE), a laboratory model for the human autoimmune demyelinating disorders multiple sclerosis and acute disseminated encephalomyelitis; the sequence of events in EAE is illustrated in Fig. 345-4.

Under normal circumstances the BBB is impermeable to antibodies. For autoantibodies to reach the CNS, the BBB must first be disrupted. In inflammatory conditions it is thought that this disruption most often occurs via actions of proinflammatory cytokines elaborated within the brain consequent to interactions between pathogenic T cells and antigen-presenting cells (APCs). In contrast to the BBB, in the PNS the blood-nerve barrier is incomplete. Endothelial tight junctions are lacking, and the capacity of charged molecules, including antibodies, to cross the barrier appears to be greatest in two regions of the PNS: proximally in the spinal roots and distally at neuromuscular junctions. This anatomic feature is likely to contribute to the propensity of antibody-mediated autoimmune disorders of the PNS to target proximal nerves (Guillain-Barré syndrome) or the neuromuscular junction (myasthenia gravis, Eaton-Lambert syndrome).

The major APCs in the CNS are microglial cells and macrophages; both cell types express MHC class 2 molecules as well as co-stimulatory molecules required for antigen presentation. Neurons do not express MHC class 2 molecules; however, some neurons express MHC class 1 proteins, which may be further increased in response to neuronal activity. Neuronal MHC class 1 molecules may function as retrograde postsynaptic signaling molecules that interact with presynaptic CD3 molecules to stabilize active synapses and transsynaptically modulate neuronal function. A role of microglial activation as a contributor to cell death in neurodegenerative and chronic neuroinflammatory diseases is likely and is being actively investigated.

**FURTHER READING**


**346**

**APPROACH TO THE PATIENT WITH NEUROLOGIC DISEASE**

Joseph B. Martin, Daniel H. Lowenstein, Stephen L. Hauser

Neurologic diseases are common and costly. According to one estimate, 180 million Americans suffer from a nervous system disorder, resulting in an annual cost of $634 billion (Table 346-1). Globally, these disorders are responsible for 28% of all years lived with a disability. Most patients with neurologic symptoms seek care from internists and other generalists rather than from neurologists, and this situation is likely to continue as primary care–based health care systems become increasingly prevalent. Because useful therapies now exist for these disorders, a skillful approach to diagnosis is essential. Many errors result from an overreliance on costly neuroimaging procedures and laboratory tests, which, while useful, do not substitute for an adequate history and examination. The proper approach to the patient with a neurologic illness begins with the patient and focuses the clinical problem first in anatomy and then in pathophysiologic terms; only then should a specific diagnosis be entertained. The direct evaluation of the patient also informs the subsequent workup and ensures
that technology is judiciously applied, a correct diagnosis is established in an efficient manner, and treatment is promptly initiated.

THE NEUROLOGIC METHOD

Locate the Lesion(s) The first priority is to identify the region of the nervous system that is likely to be responsible for the symptoms. Can the disorder be mapped to one specific location, is it multifocal, or is a diffuse process present? Are the symptoms restricted to the nervous system, or do they arise in the context of a systemic illness? Is the problem in the central nervous system (CNS), the peripheral nervous system (PNS), or both? If in the CNS, is the cerebral cortex, basal ganglia, brainstem, cerebellum, or spinal cord responsible? Are the pain-sensitive meninges involved? If in the PNS, could the disorder be located in peripheral nerves and, if so, are motor or sensory nerves primarily affected, or is a lesion in the neuromuscular junction or muscle more likely?

The first clues to defining the anatomic area of involvement appear in the history, and the examination is then directed to confirm or rule out these impressions and to clarify uncertainties suggested by the history. A more detailed examination of a particular region of the CNS or PNS is often indicated. For example, the examination of a patient who presents with a history of ascending paresthesias and weakness should be directed toward deciding, among other things, if the location of the lesion is in the spinal cord or peripheral nerves. Focal back pain, a spinal cord sensory level, and incontinence suggest a spinal cord origin, whereas a stocking-glove pattern of sensory loss suggests peripheral nerve damage; areflexia usually indicates peripheral neuropathy but may also be present with spinal shock in acute spinal cord disorders.

Deciding “where the lesion is” accomplishes the task of limiting the possible etiologies to a manageable, finite number. In addition, this strategy safeguards against making tragic errors. Symptoms of recurrent vertigo, diplopia, and nystagmus should not trigger “multiple sclerosis” as an answer (etiology) but “brainstem” or “pons” (location); then a diagnosis of brainstem arteriovenous malformation will not be missed for lack of consideration. Similarly, the combination of optic neuritis and spastic ataxic paraparesis should initially suggest optic nerve and spinal cord disease; multiple sclerosis, CNS syphilis, and vitamin B₁₂ deficiency are treatable disorders that can produce this syndrome. Once the question, “Where is the lesion?” is answered, then the question, “What is the lesion?” can be addressed.

Define the Pathophysiology Clues to the pathophysiology of the disease process may also be present in the history. Primary neuronal (gray matter) disorders may present as early cognitive disturbances, movement disorders, or seizures, whereas white matter involvement produces predominantly “long tract” disorders of motor, sensory, visual, and cerebellar pathways. Progressive and symmetric symptoms often have a metabolic or degenerative origin; in such cases lesions are usually not sharply circumscribed. Thus, a patient with paraparesis and a clear spinal cord sensory level is unlikely to have vitamin B₁₂ deficiency as the explanation. A Lhermitte symptom (electric shock–like sensations evoked by neck flexion) is due to ectopic impulse generation in white matter pathways and occurs with demyelination in the cervical spinal cord. Symptoms that worsen after exposure to heat or exercise may indicate conduction block in demyelinated axons, as occurs in multiple sclerosis. A patient with recurrent episodes of diplopia and dysarthria associated with exercise or fatigue may have a disorder of neuromuscular transmission such as myasthenia gravis. Slowly advancing visual scotoma with luminous edges, termed fortification spectra, indicates spreading cortical depression, typically with migraine.

THE NEUROLOGIC HISTORY As in all other aspects of clinical medicine, attention to the description of the symptoms experienced by the patient and substantiated by family members and others often permits an accurate localization and determination of the probable cause of the complaints, even before the neurologic examination is performed. Furthermore, a careful analysis of the history is a necessary prerequisite for bringing a focus to the neurologic examination that follows. Each complaint should be pursued as far as possible to elucidate the location of the lesion, the likely underlying pathophysiology, and potential etiologies. For example, a patient complains of weakness of the right arm. What are the associated features? Does the patient have difficulty with brushing hair or reaching upward (proximal) or buttoning buttons or opening a twist-top bottle (distal)? Also, negative associations may also be crucial. A patient with a right hemiparesis without a language deficit likely has a lesion (internal capsule, brainstem, or spinal cord) different from that of a patient with a right hemiparesis and aphasia (left hemisphere). Additional features of the history include the following:

1. Temporal course of the illness. It is important to determine the precise time of appearance and rate of progression of the symptoms experienced by the patient. The rapid onset of a neurologic complaint, occurring within seconds or minutes, usually indicates a vascular event, a seizure, or migraine. The onset of sensory symptoms located in one extremity that spread over a few seconds to adjacent portions of that extremity and then to the other regions of the body suggests a seizure. A more gradual onset and less well localized symptoms point to the possibility of a transient ischemic attack (TIA). A similar but slower temporal march of symptoms accompanied by headache, nausea, or visual disturbance suggests migraine. The presence of “positive” sensory symptoms (e.g., tingling or sensations that are difficult to describe) or involuntary motor movements suggests a seizure; in contrast, transient loss of function (negative symptoms) suggests a TIA. A stuttering onset where symptoms appear, stabilize, and then progress over hours or days also suggests cerebrovascular disease; an additional history of transient remission or regression indicates that the process is more likely due to ischemia rather than hemorrhage. A gradual evolution of symptoms over hours or days suggests a toxic, metabolic, infectious, or inflammatory process. Progressing symptoms associated with the systemic manifestations of fever, stiff neck, and altered level of consciousness imply an infectious process. Relapsing and remitting symptoms involving different levels of the nervous system suggest multiple sclerosis or other inflammatory processes; these disorders can occasionally produce new symptoms that are rapidly progressive over hours. Slowly progressive symptoms without remissions are characteristic of neurodegenerative disorders, chronic infections, gradual intoxications, and neoplasms.

2. Patients’ descriptions of the complaint. The same words often mean different things to different patients. “Dizziness” may imply impending syncope, a sense of disequilibrium, or true spinning vertigo. “Numbness” may mean a complete loss of feeling, a positive sensation such as tingling, or paralysis. “Blurred vision” may be used to describe unilateral visual loss, as in transient monocular blindness, or diplopia.

### TABLE 346-1 Impact of Neurologic and Psychiatric Diseases in the U.S.

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Patients, Millions</th>
<th>Cost, Billion $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addiction</td>
<td>17.5</td>
<td>160</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>Blindness/vision loss</td>
<td>13</td>
<td>38.4</td>
</tr>
<tr>
<td>Deafness/hearing loss</td>
<td>28</td>
<td>56</td>
</tr>
<tr>
<td>Depression/mood depressive illness</td>
<td>17.5</td>
<td>47.3</td>
</tr>
<tr>
<td>Developmental disorders</td>
<td>8.6</td>
<td>30</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>2.5</td>
<td>3.5</td>
</tr>
<tr>
<td>Head injury</td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td>0.03</td>
<td>—</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>0.3</td>
<td>2.5</td>
</tr>
<tr>
<td>Pain</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>0.25</td>
<td>5</td>
</tr>
<tr>
<td>Stroke</td>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td>Total</td>
<td>180</td>
<td>634</td>
</tr>
</tbody>
</table>

Source: Modified from Dana Alliance for Brain Initiatives.
The interpretation of the true meaning of the words used by patients to describe symptoms becomes even more complex when there are differences in primary languages and cultures.

3. Corroborating the history by others. It is almost always helpful to obtain additional information from family, friends, or other observers to corroborate or expand the patient’s description. Memory loss, apathy, loss of insight, intoxication, and other factors may impair the patient’s capacity to communicate normally with the examiner or prevent open ness about factors that have contributed to the illness. Episodic loss of consciousness necessitate that details be sought from observers to ascertain precisely what has happened during the event.

4. Family history. Many neurologic disorders have an underlying genetic component. The presence of a Mendelian disorder, such as Huntington’s disease or Charcot-Marie-Tooth neuropathy, is often obvious if family data are available. More detailed questions about family history are often necessary in polygenic disorders such as multiple sclerosis, migraine, and many types of epilepsy. It is important to elicit family history about all illnesses, in addition to neurologic and psychiatric disorders. A familial propensity to hypertension or heart disease is relevant in a patient who presents with a stroke. There are numerous inherited neurologic diseases that are associated with multisystem manifestations that may provide clues to the correct diagnosis (e.g., neurofibromatosis, Wilson’s disease, neuro-ophthalmic syndromes).

5. Medical illnesses. Many neurologic diseases occur in the context of systemic disorders. Diabetes mellitus, hypertension, and abnormalities of blood lipids predispose to cerebrovascular disease. A solitary mass lesion in the brain may be an abscess in a patient with valvular heart disease, a primary hemorrhage in a patient with a coagulopathy, a lymphoma or toxoplasmosis in a patient with AIDS, or a metastasis in a patient with underlying cancer. Patients with malignancy may also present with a paraneoplastic syndrome (Chap. 87) or complications from chemotherapy or radiotherapy. Marfan’s syndrome and related collagen disorders predispose to dissection of the cranial arteries and aneurysmal subarachnoid hemorrhage; the latter may also occur with polycystic kidney disease. A recent onset of asthma suggests the possibility of polyarteritis nodosa. Various neurologic disorders occur with dysthyroid states or other endocrinopathies. It is especially important to look for the presence of systemic diseases in patients with peripheral neuropathy. Most patients with coma in a hospital setting have a metabolic, toxic, or infectious cause.

6. Drug use and abuse and toxin exposure. It is essential to inquire about the history of drug use, both prescribed and illicit. Aminoglycoside antibiotics may exacerbate symptoms of weakness in patients with disorders of neuromuscular transmission, such as myasthenia gravis, and may cause dizziness secondary to otoxicity. Vin- cristine and other antineoplastic drugs can cause peripheral neuropathy, and immunosuppressive agents such as cyclosporine can produce encephalopathy. Excessive vitamin ingestion can lead to disease; for example vitamin A and pseudotumor cerebri, or pyridoxine and peripheral neuropathy. Many patients are unaware that over-thecounter sleeping pills, cold preparations, and diet pills are actually drugs. Alcohol, the most prevalent neurotoxin, is often not recognized as such by patients, and other drugs of abuse such as cocaine and heroin can cause a wide range of neurologic abnormalities. A history of environmental or industrial exposure to neurotoxins may provide an essential clue; consultation with the patient’s co-workers or employer may be required.

7. Formulating an impression of the patient. Use the opportunity while taking the history to form an impression of the patient. Is the information forthcoming, or does it take a circuitous course? Is there evidence of anxiety, depression, hypochondriasis? Are there any clues to deficits in language, memory, insight, or inappropriate behavior? The neurologic assessment begins as soon as the patient comes into the room and the first introduction is made.

THE NEUROLOGIC EXAMINATION The neurologic examination is challenging and complex; it has many components and includes a number of skills that can be mastered only through repeated use of the same techniques on a large number of individuals with and without neurologic disease. Mastery of the complete neurologic examination is usually important only for physicians in neurology and associated specialties. However, knowledge of the basics of the examination, especially those components that are effective in screening for neurologic dysfunction, is essential for all clinicians, especially generalists.

There is no single, universally accepted sequence of the examination that must be followed, but most clinicians begin with assessment of mental status followed by the cranial nerves, motor system, sensory system, coordination, and gait. Whether the examination is basic or comprehensive, it is essential that it be performed in an orderly and systematic fashion to avoid errors and serious omissions. Thus, the best way to learn and gain expertise in the examination is to choose one’s own approach and practice it frequently and do it in the same exact sequence each time.

The detailed description of the neurologic examination that follows describes the more commonly used parts of the examination, with a particular emphasis on the components that are considered most helpful for the assessment of common neurologic problems. Each section also includes a brief description of the minimal examination necessary for adequate screening for abnormalities in a patient who has no symptoms suggesting neurologic dysfunction. A screening examination done in this way can be completed in 3 to 5 min.

Several additional points about the examination are worth noting. First, in recording observations, it is important to describe what is found rather than to apply a poorly defined medical term (e.g., “patient groans to sternal rub” rather than “obtunded”). Second, subtle CNS abnormalities are best detected by carefully comparing a patient’s performance on tasks that require simultaneous activation of both cerebral hemispheres (e.g., eliciting a pronator drift of an outstretched arm with the eyes closed; extinction on one side of bilaterally applied light touch, also with eyes closed; or decreased arm swing or a slight asymmetry when walking). Third, if the patient’s complaint is brought on by some activity, reproduce the activity in the office. If the complaint is of dizziness when the head is turned in one direction, have the patient do this and look for associated signs on examination (e.g., nystagmus or dysmetria). If pain occurs after walking two blocks, have the patient leave the office and walk this distance and immediately return, and repeat the relevant parts of the examination. Finally, the use of tests that are individually tailored to the patient’s problem can be of value in assessing changes over time. Tests of walking a 7.5-m (25-ft) distance (normal, 5 to 6 s; note assistance, if any), repetitive finger or toe tapping (normal, 20 to 25 taps in 5 s), or handwriting are examples.

Mental Status Examination (See also Chaps. 23, 257, and 350)

- The bare minimum: During the interview, look for difficulties with communication and determine whether the patient has recall and insight into recent and past events.

The mental status examination is underway as soon as the physician begins observing and talking with the patient. If the history raises any concern for abnormalities of higher cortical function or if cognitive problems are observed during the interview, then detailed testing of the mental status is indicated. The patient’s ability to understand the language used for the examination, cultural background, educational experience, sensory or motor problems, or co-morbid conditions need to be factored into the applicability of the tests and interpretation of results.

The Folstein mini-mental status examination (MMSE) (Table 350-4) is a standardized screening examination of cognitive function that is extremely easy to administer and takes <10 min to complete. Using age-adjusted values for defining normal performance, the test is ~85% sensitive and 85% specific for a diagnosis that is moderate or severe, especially in educated patients. When there is sufficient time available, the MMSE is one of the best methods for
recognizing the odorant.

Individual elements of the mental status examination can be subdivided into level of consciousness, orientation, speech and language, memory, fund of information, insight and judgment, abstract thought, and calculations.

Level of consciousness is the patient’s relative state of awareness of the self and the environment, and ranges from fully awake to comatose. When the patient is not fully awake, the examiner should describe the responses to the minimum stimulus necessary to elicit a reaction, ranging from verbal commands to a brief, painful stimulus such as a squeeze of the trapezius muscle. Responses that are directed toward the stimulus and signify some degree of intact cerebral function (e.g., opening the eyes and looking at the examiner or reaching to push away a painful stimulus) must be distinguished from reflex responses of a spinal origin (e.g., triple flexion response—flexion at the ankle, knee, and hip in response to a painful stimulus to the foot). Orientation is tested by asking the person to state his or her name, location, and time (day of the week and date); time is usually the first to be affected in a variety of conditions. Speech is assessed by observing articulation, rate, rhythm, and prosody (i.e., the changes in pitch and accentuation of syllable and words). Language is assessed by observing the content of the patient’s verbal and written output, response to spoken commands, and ability to read. A typical testing sequence is to ask the patient to name successively more detailed components of clothing, a watch or a pen; repeat the phrase “No ifs, ands, or buts”; follow a three-step, verbal command; write a sentence; and read and respond to a written command. Memory should be analyzed according to three main time scales: (1) immediate memory can be tested by saying a list of three items and having the patient repeat the list immediately, (2) short-term memory is assessed by asking the patient to recall the same three items 5 and 15 min later, and (3) long-term memory is evaluated by determining how well the patient is able to provide a coherent chronological history of his or her illness or personal events. Fund of information is assessed by asking questions about major historic or current events, with special attention to educational level and life experiences. Abnormalities of insight and judgment are usually detected during the patient interview; a more detailed assessment can be elicited by asking the patient to describe how he or she would respond to situations having a variety of potential outcomes (e.g., “What would you do if you found a wallet on the sidewalk?”). Abstract thought can be tested by asking the patient to describe similarities between various objects or concepts (e.g., apple and orange, desk and chair, poetry and sculpture) or to list items having the same attributes (e.g., a list of four-legged animals). Calculation ability is assessed by having the patient carry out a computation that is appropriate to the patient’s age and education (e.g., serial subtraction of 7 from 100 or 3 from 20; or word problems involving simple arithmetic).

Cranial Nerve Examination (See also Chaps. 25, 26, and 355)

- The bare minimum: Check the fundi, visual fields, pupil size and reactivity, extraocular movements, and facial movements.

The cranial nerves (CN) are best examined in numerical order, except for grouping together CN III, IV, and VI because of their similar function.

CN I (OLFACTORY) Testing is usually omitted unless there is suspicion for inferior frontal lobe disease (e.g., meningioma). With eyes closed, ask the patient to sniff a mild stimulus such as toothpaste or coffee and identify the odorant.

CN II (OPTIC) Check visual acuity (with eyeglasses or contact lens correction) using a Snellen chart or similar tool. Test the visual fields by confrontation, i.e., by comparing the patient’s visual fields to your own. As a screening test, it is usually sufficient to examine the visual fields of both eyes simultaneously; individual eye fields should be examined if there is any reason to suspect a problem of vision by the history or other elements of the examination, or if the screening test reveals an abnormality. Face the patient at a distance of approximately 0.6 to 1.0 m (2 to 3 ft) and place your hands at the periphery of your visual fields in the plane that is equidistant between you and the patient. Instruct the patient to look directly at the center of your face and to indicate when and where he or she sees one of your fingers moving. Beginning with the two inferior quadrants and then the two superior quadrants, move your index finger of the right hand, left hand, or both hands simultaneously and observe whether the patient detects the movements. A single small-amplitude movement of the finger is sufficient for a normal response. Focal perimetry and tangent screen examinations should be used to map out visual field defects fully or to search for subtle abnormalities. Optic fundi should be examined with an ophthalmoscope, and the color, size, and degree of swelling or elevation of the optic disc noted, as well as the color and texture of the retina. The retinal vessels should be checked for size, regularity, arterial-venous nicking at crossing points, hemorrhage, exudates, etc.

CN III, IV, VI (OCULOMOTOR, TROCHLEAR, ABUDUCENS) Describe the size and shape of pupils and reaction to light and accommodation (i.e., as the eyes converge while following your finger as it moves toward the bridge of the nose). To check extraocular movements, ask the patient to keep his or her head still while tracking the movement of the tip of your finger. Move the target slowly in the horizontal and vertical planes; observe any paresis, nystagmus, or abnormalities of smooth pursuit (saccades, oculomotor ataxia, etc.). If necessary, the relative position of the two eyes, both in primary and multidirectional gaze, can be assessed by comparing the reflections of a bright light off both pupils. However, in practice it is typically more useful to determine whether the patient describes diplopia in any direction of gaze; true diplopia should almost always resolve with one eye closed. Horizontal nystagmus is best assessed at 45° and not at extreme lateral gaze (which is uncomfortable for the patient); the target must often be held at the lateral position for at least a few seconds to detect an abnormality.

CN V (TRIGEMINAL) Examine sensation within the three territories of the branches of the trigeminal nerve (opthalmic, maxillary, and mandibular) on each side of the face. As with other parts of the sensory examination, testing of two sensory modalities derived from different anatomic pathways (e.g., light touch and temperature) is sufficient for a screening examination. Testing of other modalities, the corneal reflex, and the motor component of CN V (jaw clench—masseter muscle) is indicated when suggested by the history.

CN VII (FACIAL) Look for facial asymmetry at rest and with spontaneous movements. Test eyebrow elevation, forehead wrinkling, eye closure, smiling, and cheek puff. Look in particular for differences in the lower versus upper facial muscles; weakness of the lower two-thirds of the face with preservation of the upper third suggests an upper motor neuron lesion, whereas weakness of an entire side suggests a lower motor neuron lesion.

CN VIII (VESTIBULOCOCHLEAR) Check the patient’s ability to hear a finger rub or whispered voice with each ear. Further testing for air versus mastoid bone conduction (Rinne) and lateralization of a 512-Hz tuning fork placed at the center of the forehead (Weber) should be done if an abnormality is detected by history or examination. Any suspected problem should be followed up with formal audiometry. →For further discussion of assessing vestibular nerve function in the setting of dizziness or coma, see Chaps. 20 and 257, respectively.

CN IX, X Observe the position and symmetry of the palate and uvula at rest and with phonation (“ahh”). The pharyngeal (“gag”) reflex is evaluated by stimulating the posterior pharyngeal wall on each side with a sterile, blunt object (e.g., tongue blade), but the reflex is often absent in normal individuals.

CN XI Check shoulder shrug (trapezius muscle) and head rotation to each side (sternocleidomastoid) against resistance.
Motor Examination (See also Chap. 21)

- The bare minimum: Look for muscle atrophy and check extremity tone. Assess upper extremity strength by checking for pronator drift and strength of wrist or finger extensors. Tap the biceps, patellar, and Achilles reflexes. Test for lower extremity strength by having the patient walk normally and on heels and toes.

The motor examination includes observations of muscle appearance, tone, strength, and reflexes. Although gait is in part a test of motor function, it is usually evaluated separately at the end of the examination.

APPEARANCE Inspect and palpate muscle groups under good light and with the patient in a comfortable and symmetric position. Check for muscle fasciculations, tenderness, and atrophy or hypertrophy. Involuntary movements may be present at rest (e.g., tics, myoclonus, choreoathetosis), during maintained posture (pill-rolling tremor of the examiner’s hand or fingers or pronation of the forearm, especially if asymmetric), and with voluntary movements (intention tremor of cerebellar disease or familial tremor).

TONE Muscle tone is tested by measuring the resistance to passive movement of a relaxed limb. Patients often have difficulty relaxing during this procedure, so it is useful to distract the patient to minimize active movements. In the upper limbs, tone is assessed by rapid pronation and supination of the forearm and flexion and extension at the wrist. In the lower limbs, while the patient is supine the examiner’s hands are placed behind the knees and rapidly raised; with normal tone the ankles drag along the table surface for a variable distance before rising, whereas increased tone results in an immediate lift of the heel off the surface. Decreased tone is most commonly due to lower motor neuron or peripheral nerve disorders. Increased tone may be evident as spasticity (resistance determined by the angle and velocity of motion; corticospinal tract disease), rigidity (similar resistance in all angles of motion; extrapyramidal disease), or paratonia (fluctuating changes in resistance; frontal lobe pathways or normal difficulty in relaxing). Cogwheel rigidity, in which passive motion elicits jerky interruptions in resistance, is seen in parkinsonism.

STRENGTH Testing for pronator drift is an extremely useful method for screening upper limb weakness. The patient is asked to hold both arms fully extended and parallel to the ground with eyes closed. This position should be maintained for ±10 s; any flexion at the elbow or fingers or pronation of the forearm, especially if asymmetric, is a sign of potential weakness. Muscle strength is further assessed by having the patient exert maximal effort for the particular muscle or muscle group being tested. It is important to isolate the muscles as much as possible, i.e., hold the limb so that only the muscles of interest are active. It is also helpful to palpate accessible muscles as they contract. Grading muscle strength and evaluating the patient’s effort is an art that takes time and practice. Muscle strength is traditionally graded using the following scale:

0 = no movement
1 = flicker or trace of contraction but no associated movement at a joint
2 = movement with gravity eliminated
3 − = movement against gravity but not against resistance
4 − = movement against a mild degree of resistance
4 = movement against moderate resistance
4 + = movement against strong resistance
5 = full power

However, in many cases it is more practical to use the following terms:

Paralysis = no movement
Severe weakness = movement with gravity but not against resistance
Moderate weakness = movement against gravity but not against mild resistance
Mild weakness = movement against moderate resistance
Full strength

Noting the pattern of weakness is as important as assessing the magnitude of weakness. Unilateral or bilateral weakness of the upper limb extensors and lower limb flexors (“pyramidal weakness”) suggests a lesion of the pyramidal tract, bilateral proximal weakness suggests myopathy, and bilateral distal weakness suggests peripheral neuropathy.

REFLEXES Muscle Stretch Reflexes Those that are typically assessed include the biceps (C5, C6), brachioradialis (C5, C6), and triceps (C7, C8) reflexes in the upper limbs and the patellar or quadriceps (L3, L4) and Achilles (S1, S2) reflexes in the lower limbs. The patient should be relaxed and the muscle positioned midway between full contraction and extension. Reflexes may be enhanced by asking the patient to voluntarily contract other, distant muscle groups (Jendrassik maneuver). For example, upper limb reflexes may be reinforced by voluntary teeth-clenching, and the Achilles reflex by hooking the flexed fingers of the two hands together and attempting to pull them apart. For each reflex tested, the two sides should be tested sequentially, and it is important to determine the smallest stimulus required to elicit a reflex rather than the maximum response. Reflexes are graded according to the following scale:

0 = absent
1 = present but diminished
2 = normoactive
3 = exaggerated
4 = clonus

Cutaneous Reflexes The plantar reflex is elicited by stroking, with a nos- tious stimulus such as a tongue blade, the lateral surface of the sole of the foot beginning near the heel and moving across the ball of the foot to the great toe. The normal reflex consists of plantar flexion of the toes. With upper motor neuron lesions above the S1 level of the spinal cord, a paradoxical extension of the toe is observed, associated with fanning and extension of the other toes (termed an extensor plantar response, or Babinski sign). Superficial abdominal reflexes are elicited by gently stroking the abdominal surface near the umbilicus in a diagonal fashion with a sharp object (e.g., the wooden end of a cotton-tipped swab) and observing the movement of the umbilicus. Normally, the umbilicus will pull toward the stimulated quadrant. With upper motor neuron lesions, these reflexes are absent. They are most helpful when there is preservation of the upper (spinal cord level T9) but not lower (T12) abdominal reflexes, indicating a spinal lesion between T9 and T12, or when the response is asymmetric. Other useful cutaneous reflexes include the cremasteric (ipsilateral elevation of the testicle when there is preservation of the upper (spinal cord level T9) but not lower (T12) abdominal reflexes, indicating a spinal lesion between T9 and T12, or when the response is asymmetric. Other useful cutaneous reflexes include the cremasteric (ipsilateral elevation of the testicle following stroking of the medial thigh; mediated by L1 and L2) and anal (contraction of the anal sphincter when the perianal skin is scratched; mediated by S2, S3, S4) reflexes. It is particularly important to test for these reflexes in any patient with suspected injury to the spinal cord or lumbosacral roots.

Primitive Reflexes With disease of the frontal lobe pathways, several primitive reflexes not normally present in the adult may appear. The suck response is elicited by lightly touching the center of the lips, and the root response the corner of the lips, with a tongue blade; the patient will move the lips to suck or root in the direction of the stimulus. The grasp reflex is elicited by touching the palm between the thumb and index finger with the examiner’s fingers; a positive response is a forced grasp of the examiner’s hand. In many instances stroking the back of the hand will lead to its release. The palomental response is contraction of the mentalis muscle (chin) ipsilateral to a scratch stimulus diagonally applied to the palm.

Sensory Examination (See also Chap. 22)

- The bare minimum: Ask whether the patient can feel light touch and the temperature of a cool object in each distal extremity. Check double simultaneous stimulation using light touch on the hands.

Evaluating sensation is usually the most unreliable part of the ex-
Coordination Examination
(See also Chap. 21)

- **The bare minimum:** Observe the patient while walking normally, on the heels and toes, and along a straight line.

Watching the patient walk is the most important part of the neurologic examination. Normal gait requires that multiple systems—including strength, sensation, and coordination—function in a highly integrated fashion. Unexpected abnormalities may be detected that prompt the examiner to return, in more detail, to other aspects of the examination. The patient should be observed while walking and turning normally, walking on the heels, walking on the toes, and walking heel-to-toe along a straight line. The examination may reveal decreased arm swing on one side (corticospinal tract disease), a stooped posture and short-stepped gait (Parkinsonism), a broad-based unstable gait (ataxia), scissoring (spasticity), or a high-stepped, slapping gait (posterior column or peripheral nerve disease), or the patient may appear to be stuck in place (apraxia with frontal lobe disease).

NEUROLOGIC DIAGNOSIS
The clinical data obtained from the history and the examination are interpreted in terms of neuroanatomy and neurophysiology and assembled into one of the known syndromes (see Table 346-2; online). From the syndrome the physician should be able to determine the anatomic localization that best explains the clinical findings, to narrow the list of diagnostic possibilities, and to select the laboratory tests most likely to be informative. The laboratory assessment may include (1) serum electrolytes; complete blood count; and renal, hepatic, endocrine, and immune studies; (2) cerebrospinal fluid examination; (3) focused neuroimaging studies (Chap. 347); or (4) electrophysiologic studies (Chaps. 348 and 363). The anatomic localization, mode of onset and course of illness, other medical data, and laboratory findings are then integrated to establish an etiologic diagnosis.

It should be emphasized that the neurologic examination may be normal even in patients with a serious neurologic disease, such as seizures, chronic meningitis, or a TIA. A comatose patient may arrive with no available history, and in such cases the approach is as described in Chap. 257. In other patients, an inadequate history may be overcome by a succession of examinations from which the course of the illness can be inferred. In perplexing cases it is useful to remember that uncommon presentations of common diseases are more likely than rare etiologies. Thus, even in tertiary care settings, multiple strokes are usually due to emboli and not vasculitis, and dementia with myoclonus is usually Alzheimer’s disease and not a prionopathy or a paraneoplastic disorder. Finally, the most important task of a primary care physician faced with a patient who has a new neurologic complaint is to assess the urgency of referral to a specialist. Here, the imperative is to rapidly identify patients likely to have nervous system infections, acute strokes, and spinal cord compression or other treatable mass lesions and arrange for immediate care.

FURTHER READING
The clinician caring for patients with neurologic symptoms is faced with an expanding number of imaging options, including computerized tomography (CT), CT angiography (CTA), perfusion CT (pCT), magnetic resonance imaging (MRI), MR angiography (MRA), functional MRI (fMRI), MR spectroscopy (MRS), MR neurography, and perfusion MRI (pMRI). In addition, an increasing number of interventional neuroradiologic techniques are available including angiography; embolization and stenting of vascular structures; and spine interventions such as discography, selective nerve root injection, and epidural injections. Recent developments, such as multidetector CT angiography and gadolinium-enhanced MRA, have narrowed the indications for conventional angiography, which is now reserved for patients in whom small-vessel detail is essential for diagnosis or for whom interventional therapies are planned (Table 347-1).

In general, MRI is more sensitive than CT for the detection of lesions affecting the central nervous system (CNS), particularly those of the spinal cord, cranial nerves, and posterior fossa structures. Diffusion MR, a sequence that detects reduction of microscopic motion of water, is the most sensitive technique for detecting acute ischemic stroke and is useful in the detection of encephalitis, abscesses, and prion diseases. CT, however, can be quickly obtained and is widely available, making it a pragmatic choice for the initial evaluation of patients with suspected acute stroke, hemorrhage, and intracranial or spinal trauma. CT is also more sensitive than MRI for visualizing fine osseous detail and is indicated in the initial evaluation of conductive hearing loss as well as lesions affecting the skull base and calvarium.

### Table 347-1 Guidelines for the Use of CT, Ultrasound, and MRI

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommended Technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhage</td>
<td>CT &gt; MR</td>
</tr>
<tr>
<td>Acute parenchymal</td>
<td>MRI</td>
</tr>
<tr>
<td>Subacute/chronic</td>
<td>MRI</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>CT, CTA, lumbar puncture → angiography</td>
</tr>
<tr>
<td>Aneurysm</td>
<td>Angiography &gt; CTA, MRA</td>
</tr>
<tr>
<td>Ischemic infarction</td>
<td>CTA, MRA</td>
</tr>
<tr>
<td>Hemorrhagic infarction</td>
<td>CT</td>
</tr>
<tr>
<td>Bland infarction</td>
<td>MRI &gt; CT</td>
</tr>
<tr>
<td>Carotid or vertebral dissection</td>
<td>MRI/MRA</td>
</tr>
<tr>
<td>Vertebral basilar insufficiency</td>
<td>CTA, MRI/MRA</td>
</tr>
<tr>
<td>Carotid stenosis</td>
<td>CTA &gt; Doppler ultrasound, MRA</td>
</tr>
<tr>
<td>Suspected mass lesion</td>
<td>MRI +/- contrast</td>
</tr>
<tr>
<td>Neoplasms, primary or metastatic</td>
<td>MRI +/- contrast</td>
</tr>
<tr>
<td>Infection/abscess</td>
<td>MRI +/- contrast</td>
</tr>
<tr>
<td>Immunosuppressed with focal findings</td>
<td>MRI</td>
</tr>
<tr>
<td>Vascular malformation</td>
<td>MRI +/- angiography</td>
</tr>
<tr>
<td>White matter disorders</td>
<td>MRI</td>
</tr>
<tr>
<td>Demyelinating disease</td>
<td>MRI</td>
</tr>
<tr>
<td>Dementia</td>
<td>MRI</td>
</tr>
<tr>
<td>Trauma</td>
<td>MRI</td>
</tr>
<tr>
<td>Acute trauma</td>
<td>CT (noncontrast)</td>
</tr>
<tr>
<td>Shear injury/chronic hemorrhage</td>
<td>MRI</td>
</tr>
<tr>
<td>Headache/migraine</td>
<td>CT (noncontrast) / MRI</td>
</tr>
<tr>
<td>Seizure</td>
<td>?CT as screen</td>
</tr>
<tr>
<td>First time, no focal neurologic deficits</td>
<td>MRI with coronal T2W imaging</td>
</tr>
<tr>
<td>Partial complex/refractory</td>
<td>MRI with contrast</td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>MRI with contrast</td>
</tr>
<tr>
<td>Meningeal disease</td>
<td>MRI with contrast</td>
</tr>
</tbody>
</table>

**SPINE**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommended Technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low back pain</td>
<td>MRI or CT after 4 weeks</td>
</tr>
<tr>
<td>No neurologic deficits</td>
<td>MRI or CT after 4 weeks</td>
</tr>
<tr>
<td>With focal deficits</td>
<td>MRI &gt; CT</td>
</tr>
<tr>
<td>Spinal stenosis</td>
<td>MRI or CT</td>
</tr>
<tr>
<td>Cervical spondylosis</td>
<td>MRI or CT or myelography</td>
</tr>
<tr>
<td>Infection</td>
<td>MRI + contrast, CT</td>
</tr>
<tr>
<td>Myelopathy</td>
<td>MRI + contrast, CT</td>
</tr>
<tr>
<td>Arteriovenous malformation</td>
<td>MRI, myelography/angiography</td>
</tr>
</tbody>
</table>

*Note: CT; computed tomography; MRI, magnetic resonance imaging; MRA, MR angiography; CTA, CT angiography; T2W, T2-weighted.*

**Computed Tomography**

**Technique** The CT image is a cross-sectional representation of anatomy created by a computer-generated analysis of the attenuation of x-ray beams passed through a section of the body. As the x-ray beam, collimated to the desired slice width, rotates around the patient, it passes through selected regions in the body. X-rays that are not attenuated by the body are detected by sensitive x-ray detectors aligned 180° from the x-ray tube. A computer calculates a “back projection” image from the 360° x-ray attenuation profile. Greater x-ray attenuation, e.g., as caused by bone, results in areas of high “density,” while soft tissue structures, which have poor attenuation of x-rays, are in lower density. The resolution of an image depends on the radiation dose, the collimation (slice thickness), the field of view, and the matrix size of the display. A modern CT scanner is capable of obtaining sections as thin as 0.5 to 1 mm with submillimeter resolution at a speed of 0.5 to 1 s per section; complete studies of the brain can be completed in 20 to 60 s.

Helical CT is a type of scanner in which continuous CT information is obtained while the patient moves through the x-ray beam. In the helical scan mode, the table moves continuously through the rotating x-ray beam, generating a “helix” of information that can be reformatted into various slice thicknesses. Single or multiple (from 4 to 32) detectors positioned 180 degrees to the x-ray source may result in multiple slices per revolution of the beam around the patient. These “multidetector” scanners have further decreased the time per examination and permit rapid assessment of vascular anatomy as well as perfusion characteristics of brain parenchyma (Figs. 347-1 and 347-2). Advantages of multidetector scanning include shorter scan times, reduced patient and organ motion, and the ability to acquire images dynamically during the infusion of intravenous contrast that can be used to construct CT angiograms of vascular structures and CT perfusion images (Figs. 347-13 and 347-2). CTA images may be processed later for display in three dimensions to yield angiogram-like images (Figs. 347-1C and 347-12). CTA has proven useful in assessing the carotid bifurcation and intracranial arterial and venous anatomy.

Intravenous contrast is often administered prior to or during a CT study to identify vascular structures and to detect defects in the blood-brain barrier (BBB), which are associated with disorders such as tumors, infarcts, and infections. In the normal CNS, only vessels and structures lacking a BBB (e.g., the pituitary gland, choroid plexus, and dura) enhance after contrast administration. The use of iodinated contrast agents carries a risk of allergic reaction and adds additional expense and radiation dose. While helpful in characterizing mass lesions as well as essential for the acquisition of CTA studies, the decision to use contrast material should always be considered carefully.

**Indications** CT is the primary study of choice in the evaluation of acute trauma to the brain and spine, suspected subarachnoid hemorrhage, and conductive hearing loss (Table 347-1). CT is complementary to MR in the evaluation of the skull base, orbit, and osseous structures of the spine. In the spine, CT is useful in evaluating patients with osseous spinal stenosis and spondylolisthesis, but MRI is often preferred in those with neurologic deficits. CT can also be obtained following intrathecal contrast injection to evaluate the intracranial cisterns (CT cisternography) for cerebrospinal fluid (CSF) fistula, as well as the spinal subarachnoid space (CT myelography).

**Complications** CT is safe, fast, and reliable. Radiation exposure is between 3 and 5 cGy per study. Care must be taken to reduce exposure when imaging children. The most frequent complications are associ-
ated with use of intravenous contrast agents. Two broad categories of contrast media, ionic and nonionic, are in use. Although ionic agents are relatively safe and inexpensive, they are associated with a higher incidence of reactions and side effects. As a result, ionic agents have been largely replaced by safer non-ionic compounds (Table 347-2).

**Contrast nephropathy** may result from hemodynamic changes, renal tubular obstruction and cell damage, or immunologic reactions to contrast agents. A rise in serum creatinine of at least 85 μmol/L (1 mg/dL) within 48 h of contrast administration is often used as a definition of contrast nephropathy, although other causes of acute renal failure must be excluded. The prognosis is usually favorable, with serum creatinine levels returning to baseline within 1 to 2 weeks. Risk factors for contrast nephropathy include advanced age, preexisting renal disease, diabetes, dehydration, and high contrast dose. Patients with diabetes and those with mild renal failure should be well hydrated prior to the administration of contrast agents, although careful consideration should be given to alternative imaging techniques, such as MR imaging. Nonionic, low-osmolar media produce fewer abnormalities in renal blood flow and less endothelial cell damage but should still be used carefully in patients at risk (Table 347-3).

Other side effects are rare but include a sensation of warmth throughout the body and a metallic taste during intravenous administration of iodinated contrast media. Anaphylactic reactions to intravenous contrast media, while rare, are the most serious side effects and range from mild hives to bronchospasm, acute anaphylaxis, and death. The pathogenesis of these allergic reactions is not fully understood, but it is thought to include the release of mediators such as histamine, antibody-antigen reactions, and complement activation. Severe allergic reactions occur in ~0.04% of patients receiving nonionic media, sixfold fewer than with ionic media. Risk factors include a history of prior contrast reaction, food allergies to shellfish, and atopy (asthma and hay fever). In such patients, a noncontrast CT or MRI procedure should be considered as an alternative to contrast administration. If iodinated contrast is absolutely required, a nonionic agent should be used in conjunction with pretreatment with glucocorticoids and antihistamines (Table 347-4). Patients with allergic reactions to iodinated contrast material do not usually react to gadolinium-based MR contrast material, although it would be wise to pretreat patients with a prior allergic history to MR contrast administration in a similar fashion.

**MAGNETIC RESONANCE IMAGING**

- **Technique** Magnetic resonance is a complex interaction between hydrogen protons in biologic tissues, a static magnetic field (the magnet), and energy in the form of radiofrequency (RF) waves of a specific frequency introduced by coils placed next to the body part of interest. Spatial localization is achieved by magnetic gradients surrounding the main magnet, which impart slight changes in magnetic field throughout the imaging volume. The energy state of the hydrogen protons is transiently excited by the RF, which is administered at a frequency specific for the field strength of the magnet. This subsequent return to equilibrium energy state (relaxation) of the protons results in a release of RF energy (the echo), which is detected by the coils that delivered the RF pulses. The echo is transformed by Fourier analysis into the information used to form an MR image. The MR image thus consists of a map of the distribution of hydrogen protons, with signal intensity imparted by both density of hydrogen protons as well as differences in the relaxation time (see below) of hydrogen protons on different molecules.

**T1 AND T2 RELAXATION TIMES** The rate of return to equilibrium of perturbed protons is called the relaxation rate. The relaxation rate varies among normal and pathologic tissues. The relaxation rate of a hydrogen proton in a tissue is influenced by local interactions with surrounding molecules and atomic neighbors. Two relaxation rates, T1 and T2, influence the signal intensity of the image. The T1 relaxation time is the time, measured in milliseconds, for 63% of the hydrogen protons to return to their normal equilibrium state, while the T2 relaxation is the time for 63% of the protons to become dephased owing to interactions among nearby protons. The intensity of the signal within various tissues and image contrast can be modulated by altering acquisition parameters, such as the interval between RF pulses (TR) and the time between the RF pulse and the signal reception (TE). So-called T1-weighted (T1W) images are produced by keeping the TR and TE relatively short. T2-weighted (T2W) images are produced by using longer TR and TE times. Fat and subacute hemorrhage have short T1 relaxation rates and a high signal intensity on T1W images. Structures containing more water, such as CSF and edema, have long T1 and T2 relaxation rates, a low signal intensity on T1W images, and a high signal intensity on T2W images (Table 347-5). Gray matter contains 10 to 15% more water than white matter, which accounts for much of its contrast on MRI (Fig. 347-3). T2W images are more sensitive than T1W images to edema, demyelination, infarction, and chronic hemorrhage, while T1-weighted imaging is more sensitive to subacute hemorrhage and fat-containing structures.
FIGURE 347-2 A 49-year-old man with acute neck pain and right hemiparesis. A. Axial noncontrast CT scan demonstrates high density within the right middle cerebral artery (arrow) associated with subtle low density involving the right putamen (arrowheads). B. Mean transit time map calculated from a CT perfusion study obtained with a 40-cc contrast injection during which 45 images were obtained at the same slice location. Prolongation of the mean transit time is visible throughout the right hemisphere (arrows). C. Axial maximum intensity projection from CTA study through the Circle of Willis demonstrates an abrupt occlusion of the proximal right middle cerebral artery (arrow). Reconstitution of flow via collaterals is seen distal to the occlusion, however, the patient sustained a right basal ganglia infarction. D. Sagittal reformation through the right internal carotid artery. Low-density lipid laden plaque (arrows) narrows the lumen of the internal carotid artery (black arrows). The internal jugular vein is shown (white arrows). E. 3D surface CTA images (different patient) demonstrate calcification and narrowing of the right internal carotid artery, consistent with atherosclerotic disease.

Many different MR pulse sequences exist, and each can be obtained in various planes (Figs. 347-3, A, 5). The selection of a proper protocol that will best answer a clinical question depends on an accurate clinical history and indication for the examination. Fluid-attenuated inversion recovery (FLAIR) is a useful pulse sequence that produces T2W images in which the normally high signal intensity of CSF is suppressed.

| TABLE 347-2 Guidelines for Use of Intravenous Contrast in Patients with Impaired Renal Function |
|---|---|
| Serum Creatinine, µmol/L (mg/dL)* | Recommendation |
| <133 (<1.5) | Use either ionic or nonionic at 2 mL/kg to 150 mL total |
| 133–177 (1.5–2.0) | Nonionic; hydrate diabetics 1 mL/kg per hour × 10 h |
| >177 (>2.0) | Consider noncontrast CT or MRI; nonionic contrast if required |
| 177–221 (2.0–2.5) | Nonionic only if required (as above); contraindicated in diabetics |
| >265 (>3.0) | Nonionic IV contrast given only to patients undergoing dialysis within 24 h |

* Risk is greatest in patients with rising creatinine levels.

**Note:** CT, computed tomography; MRI, magnetic resonance imaging.

<table>
<thead>
<tr>
<th>TABLE 347-3 Indications for Use of Nonionic Contrast Media</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prior adverse reaction to contrast media, with the exception of heat, flushing, or an episode of nausea or vomiting</td>
</tr>
<tr>
<td>• Asthma or other serious lung disease</td>
</tr>
<tr>
<td>• History of atopic allergies (pretreatment with steroid/antihistamines recommended)</td>
</tr>
<tr>
<td>• Children under the age of 2 years</td>
</tr>
<tr>
<td>• Renal failure or creatinine &gt;177 µmol/L (&gt;2.0 mg/dL)</td>
</tr>
<tr>
<td>• Cardiac dysfunction, including recent or imminent cardiac decompensation, severe arhythmias, unstable angina pectoris, recent myocardial infarction, and pulmonary hypertension</td>
</tr>
<tr>
<td>• Diabetes</td>
</tr>
<tr>
<td>• Severe debilitation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 347-4 Guidelines for Premedication of Patients with Prior Contrast Allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 h prior to examination: Prednisone, 40 mg PO or methylprednisolone, 32 mg PO</td>
</tr>
<tr>
<td>2 h prior to examination: Prednisone, 40 mg PO or methylprednisolone, 32 mg PO and Cimetidine, 300 mg PO or ranitidine, 150 mg PO</td>
</tr>
<tr>
<td>Immediately prior to examination: Benadryl, 50 mg IV (alternatively, can be given PO 2 h prior to exam)</td>
</tr>
</tbody>
</table>
TABLE 347-5 Some Common Intensities on T1- and T2-Weighted MRI Sequences

<table>
<thead>
<tr>
<th>Image</th>
<th>TR</th>
<th>TE</th>
<th>CSF</th>
<th>Fat</th>
<th>Brain</th>
<th>Edema</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1W</td>
<td>Short</td>
<td>Short</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>T2W</td>
<td>Long</td>
<td>Long</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>High</td>
</tr>
</tbody>
</table>

Note: TR, interval between radiofrequency (RF) pulses; TE, interval between RF pulse and signal reception; CSF, cerebrospinal fluid; T1W and T2W, T1- and T2-weighted.

(FIG. 347-5A). FLAIR images are more sensitive than standard spine echo images for the detection of lesions within or adjacent to CSF. Gradient echo imaging is most sensitive to magnetic susceptibility as seen with blood, calcium, and air, and is indicated in patients with traumatic brain injury. MR images can be generated in sagittal, coronal, axial, or oblique planes without changing the patient’s position. Each plane obtained requires a separate sequence lasting 1 to 10 min. Three-dimensional volumetric imaging is also possible with MRI, resulting in a volume of data that can be reformatted in any orientation on a workstation to highlight certain disease processes.

MR CONTRAST MATERIAL The heavy-metal element gadolinium forms the basis of all currently approved intravenous MR contrast agents. Gadolinium is a paramagnetic substance, which means that it reduces the T1 and T2 relaxation times of nearby water protons, resulting in a high signal on T1W images and a low signal on T2W images (the latter requires a sufficient local concentration, usually in the form of a bolus).

Unlike iodinated contrast agents, the effect of MR contrast agents depends on the presence of local hydrogen protons on which it must act to achieve the desired effect. Gadolinium is chelated to DTPA (diethylenetriaminepentaacetic acid), which allows safe renal excretion. Approximately 0.2 mL/kg body weight is administered intravenously; the cost is ~$60 per dose. Gadolinium-DTPA does not cross the intact BBB but will enhance lesions lacking a BBB (FIG. 347-4A) and areas of the brain that normally are devoid of the BBB. The agent is well tolerated, and severe allergic reactions to gadolinium are rare but have been reported. The adverse reaction rate in patients with a prior history of atopy or asthma is 3.7%; however, the reaction rate increases to 6.3% in those patients with a prior history of unspecified allergic reaction to iodinated contrast. These agents can be administered safely to children as well as adults. Renal failure does not occur.

Complications and Contraindications From the patient’s perspective, an MRI examination can be intimidating, and a higher level of cooperation is required than with CT. The patient lies on a table that is moved into a long, narrow gap within the magnet. Approximately 5% of the population experiences severe claustrophobia in the MR environment. This can be reduced by mild sedation but remains a problem for some. Unlike CT, movement of the patient during an MR sequence distorts all the images; therefore, uncooperative patients should either be sedated for the MR study or scanned with CT. Generally, children under the age of 10 years usually require conscious sedation in order to complete the MR examination without motion degradation.

MRI is considered safe for patients, even at very high field strengths (>3 to 4 T). Serious injuries have been caused, however, by attraction of ferromagnetic objects into the magnet, which act as missiles if brought too close to the magnet. Likewise, ferromagnetic implants, such as aneurysm clips, may torque within the magnet, causing damage to vessels and even death. Metallic foreign bodies in the eye have moved and caused intraocular hemorrhage; screening for ocular metallic fragments is indicated in those with a history of metal work or ocular metallic foreign bodies. Implantated cardiac pacemakers are a contraindication to MRI owing to the risk of induced arrhythmias. All health care personnel and patients must be screened and educated thoroughly to prevent such disasters as the magnet is always “on.” Table 347-6 lists common contraindications for MRI.

MAGNETIC RESONANCE ANGIOGRAPHY On routine spin echo MR sequences, moving protons (e.g., flowing blood, CSF) exhibit complex MR signals that range from high to low signal intensity relative to background stationary tissue. Fast-flowing blood returns no signal (flow void) on routine T1W or T2W spin echo MR images. Slower flowing blood, as occurs in veins or distal to arterial stenoses, may appear high in signal. However, using special pulse sequences called gradient echo sequences, it is possible to increase the signal intensity of moving protons in contrast to the low signal background intensity of stationary tissue. This creates angiography-like images, which can be manipulated in three dimensions to highlight vascular anatomy and relationships.

Two MRA techniques, time-of-flight (TOF) and phase-contrast, are routinely used. TOF, currently the technique used most frequently, relies on the suppression of nonmoving tissue to provide a low-intensity background for the high signal intensity of flowing blood entering the section; arterial or venous structures may be highlighted. A typical TOF angiography sequence results in a series of contiguous thin MR sections (0.9 mm thick), which can be viewed as a stack and manipulated to create an angiographic image data set that can be reformatted.
and viewed in various planes and angles, much like that seen with conventional angiography (Fig. 347-3B). Noncontrast enhanced MRA provides a vascular flow map rather than the anatomic map shown by conventional angiography.

Phase-contrast MRA has a longer acquisition time than TOF MRA, but in addition to providing anatomic information similar to that of TOF imaging, it can be used to reveal the velocity and direction of blood flow in a given vessel. Through the selection of different imaging parameters, differing blood velocities can be highlighted; selective venous and arterial MRA images can thus be obtained. One advantage of phase-contrast MRA is the excellent suppression of high signal intensity background structures.

MRA can also be acquired during infusion of contrast material. Recently, contrast-enhanced MRA has become the standard for extracranial vascular MRA. This technique entails rapid imaging using coronal three-dimensional TOF sequences during a bolus infusion of 15 to 20 mL of gadolinium-DTPA. Proper technique and timing of acquisition relative to bolus arrival are critical for success. Advantages include a reduction in the time of acquisition (1 to 2 min vs. 10 min) and flow-related artifacts.

MRA is lower in spatial resolution compared with conventional film-based angiography, and therefore the detection of small-vessel detail, such as is required in the workup of vasculitis, is problematic. MRA is also less sensitive to slowly flowing blood and thus may not reliably differentiate complete from near-complete occlusions. Motion, either by the patient or by anatomic structures, may distort the MRA images, creating artifacts. These limitations notwithstanding, MRA has proved useful in evaluation of the extracranial carotid and vertebral circulation as well as of larger-caliber intracranial arteries and dural sinuses. It has also proved useful in the noninvasive detection of intracranial aneurysms and vascular malformations.

**ECHO-PLANAR MR IMAGING** Recent improvements in gradients, software, and high-speed computer processors now permit extremely rapid MRI of the brain. With echo-planar MRI (EPI), fast gradients are switched on and off at high speeds to create the information used to form an image. In routine spin echo imaging, images of the brain can be obtained in 5 to 10 min. With EPI, all of the information required for processing an image is accumulated in 50 to 150 ms, and the information for the entire brain is obtained in 1 to 2 min, depending on the degree of resolution required or desired. Fast MRI reduces patient and organ motion, permitting diffusion imaging (Figs. 347-3, 4, 5 and Fig. 349-13), perfusion imaging during contrast infusion fMRI, and kinematic motion studies.

Perfusion and diffusion imaging are EPI techniques that are useful in early detection of ischemic injury of the brain and may be useful together to demonstrate infarcted tissue as well as ischemic but potentially viable tissue at risk of infarction (e.g., the ischemic penumbra). Diffusion-weighted imaging (DWI) assesses microscopic motion of water; restriction of motion appears as relative high signal intensity on diffusion-weighted images. DWI is the most sensitive technique for detection of acute cerebral infarction of \(<7\) days’ duration and is also sensitive to encephalitis and abscess formation, all of which demonstrate reduced diffusion or high signal.

Perfusion MRI involves the acquisition of EPI images during a rapid bolus of contrast material. Relative perfusion abnormalities can be identified. The relative cerebral blood volume, mean transit time,
Images reveal differences in regional glucose activity among normal tissue and cerebral blood flow throughout the image can be calculated within regions of interest. Delay in mean transit time and reduction in cerebral blood volume and cerebral blood flow are typically seen in infarction. Elevated or normal cerebral blood volume in a setting of reduced blood flow may indicate tissue that is at risk of infarction. pMRI imaging can also be used in the assessment of brain tumors where it has been shown to be helpful in differentiating intraxial primary tumors from extraxial tumors or metastasis.

Diffusion tract imaging (DTI) is a special diffusion technique that is capable of demonstrating white matter tracts and their relationship to lesions of the brain. Preferential microscopic motion of water along white matter tracts is detected by diffusion MR, which can also indicate the direction of white matter fiber tracts. This new technique has great potential in the assessment of brain maturation as well as disease entities that undermine the integrity of the white matter architecture.

MR neurography is an MR technique that localizes regions of activity in the brain following task activation. Neuronal activity elicits an increase in the delivery of oxygenated blood flow to a specific region of the brain, resulting in a slight alteration in the balance of oxyhemoglobin and deoxyhemoglobin, which yields a 2 to 3% increase in signal intensity within draining veins. Further work will determine whether these techniques are cost effective or clinically useful, but currently preoperative somatosensory and auditory cortex localization is possible. This technique has proved useful to neuroscientists interested in interrogating the localization of certain brain functions.

MAGNETIC RESONANCE NEUROGRAPHY MR neurography is an MR technique that shows promise in detecting increased signal in irritated, inflamed, or infiltrated nerves. These images are obtained with fat-suppressed fast spin echo imaging or short inversion recovery sequences, and they may indicate nerves that are responsible for pain syndromes more precisely. Irritated or infiltrated nerves will demonstrate high signal on T2W imaging.

POSITRON EMISSION TOMOGRAPHY (PET) PET relies on the detection of positrons emitted during the decay of a radionuclide that has been injected into a patient. The most frequently used moiety is 2-[^18]Ffluoro-2-deoxy-D-glucose (FDG), which is an analogue of glucose and is taken up by cells competitively with 2-deoxyglucose. Multiple images of glucose uptake activity are formed after 45 to 60 min. Images reveal differences in regional glucose activity among normal and pathologic brain structures. A lower activity of FDG in the parietal lobes has been associated with Alzheimer’s disease. FDG PET is used primarily for the detection of extracranial metastatic disease. PET is no longer used primarily for differentiation of tumor from radiation necrosis.

MYELOGRAPHY ■ Technique Myelography involves the intrathecal instillation of specially formulated water-soluble iodinated contrast medium into the lumbar or cervical subarachnoid space. CT scanning is usually performed after myelography (CT myelography) to better demonstrate the spinal cord and roots, which appear as filling defects in the opacified subarachnoid space. Low-dose CT myelography, in which CT is performed after the subarachnoid injection of a small amount of relatively dilute contrast material, has replaced conventional myelography for many indications, thereby reducing exposure to radiation and contrast media. Newer multidetector scanners now obtain CT studies quickly so that reformations in sagittal and coronal planes, equivalent to traditional myelography projections, are now routine.

Indications Myelography has been largely replaced by CT myelography and MRI for diagnosis of diseases of the spinal canal and cord (Table 347-1). Remaining indications for conventional plain film myelography include the evaluation of suspected meningeal or arachnoid cysts and the localization of spinal dural arteriovenous or CSF fistulas. Conventional myelography and CT myelography provide the most precise information in patients with prior spinal fusion and spinal fixation hardware.

Contraindications Myelography is relatively safe; however, it should be performed with caution in any patient with elevated intracranial pressure or a history of allergic reaction to intrathecal contrast media. In patients with a suspected spinal block, MR is the preferred technique. If myelography is necessary, only a small amount of contrast medium should be instilled below the lesion in order to minimize the risk of neurologic deterioration. Lumbar puncture is to be avoided in patients with bleeding disorders, including patients receiving anticoagulant therapy, as well as in those with infections of the soft tissues.

Complications Headache, nausea, and vomiting are the most frequent complications of myelography, occurring in up to 38% of patients. These symptoms are thought to result from neurotoxic effects of the contrast agent, persistent leakage of CSF at the puncture site, or psy-
and removing the catheter while maintaining hemostasis. Therapeutic evaluation of patients with vascular pathology, particularly of smaller disc, which does not accept much more than 1 mL of contrast material. Typically little or no pain is felt during injection of a normal plain film is obtained following the procedure. The risk of cord puncture is greatest in patients with spinal stenosis and perilymph in the inner ear. Puncture of the spinal cord is a rare but serious complication of cervical (C1-2) and high lumbar puncture. The risk of cord puncture is greatest in patients with spinal stenosis or conditions that reduce CSF volume. In these settings, a low-dose lumbar injection followed by thin-section CT or MRI is a safer alternative to cervical puncture. Intrathecal contrast reactions are rare, but aseptic meningitis and encephalopathy may occur. The latter is usually dose-related and associated with contrast entering the intracranial subarachnoid space. Seizures occur following myelography in 0.1 to 0.3% of patients. Risk factors include a preexisting seizure disorder and the use of a total iodine dose of >4500 mg. Other reported symptoms include hyperthermia, hallucinations, depression, and anxiety states. These side effects have been reduced by the development of nonionic, water-soluble contrast agents, as well as by head elevation and generous hydration following myelography.

**SPINE INTERVENTIONS**

**Discography** The evaluation of back pain and radiculopathy may require diagnostic procedures that attempt either to reproduce the patient's pain or relieve it, indicating its correct source. Discography is performed by fluoroscopic placement of a 22- to 25-gauge needle into the intervertebral disc and subsequent injection of 1 to 3 mL of contrast media. The intradiscal pressure is recorded, as is an assessment of the patient's response to the injection of contrast material. Typically little or no pain is felt during injection of a normal disc, which does not accept much more than 1 mL of contrast material, even at pressures as high as 415 to 690 kPa (60 to 100 lb/in²). CT and plain films are obtained following the procedure.

**Selective Nerve Root and Epidural Spinal Injections** Percutaneous selective nerve root and epidural blocks with glucocorticoid and anesthetic mixtures may be both therapeutic as well as diagnostic, especially if a patient's pain is relieved. Typically 1 to 2 mL of an equal mixture of a long-acting glucocorticoid such as betamethasone and a long-acting anesthetic such as bupivacaine 0.75% is instilled under CT or fluoroscopic guidance in the intraspinal epidural space or adjacent to an existing nerve root.

**ANGIOGRAPHY**

**Technique** Catheter angiography is indicated in the evaluation of patients with vascular pathology, particularly of smaller intracranial vessels. However, it carries the greatest risk of morbidity of all diagnostic imaging procedures, owing to the necessity of inserting a catheter into a blood vessel, directing the catheter to the required location, injecting contrast material to visualize the vessel, and removing the catheter while maintaining hemostasis. Therapeutic transcatheter procedures (see below) have become important options for the treatment of some cerebrovascular diseases. The decision to undertake a diagnostic or therapeutic angiographic procedure requires careful assessment of the goals of the investigation and its attendant risks.

To improve tolerance to contrast agents, patients undergoing angiography should be well hydrated before and after the procedure. Since the femoral route is used most commonly, the femoral artery must be compressed after the procedure to prevent a hematoma from developing. The puncture site and distal pulses should be evaluated carefully after the procedure; complications can include thigh hematoma or lower extremity emboli.

**Indications** Table 347-1 lists the indications for conventional angiography. Angiography has been replaced for many indications by CT/CTA or MRI/MRA; however, angiography is still used for evaluating intracranial small-vessel pathology (such as vasculitis), for assessing vascular malformations and aneurysms, and in endovascular therapeutic procedures.

**Complications** A common femoral arterial puncture provides retrograde access via the aorta to the aortic arch and great vessels. The most feared complication of cerebral angiography is stroke. Thrombus can form on or inside the tip of the catheter, and atherosclerotic thrombus or plaque can be dislodged by the catheter or guidewire or by the force of injection and can embolize distally in the cerebral circulation. Risk factors for ischemic complications include limited experience on the part of the angiographer, atherosclerosis, vasospasm, low cardiac output, decreased oxygen-carrying capacity, advanced age, and possibly migraine. The risk of a neurologic complication varies but is ~4% for transient ischemic attack and stroke, 1% for permanent deficit, and <0.1% for death.

Ionic contrast material injected into the cerebral vasculature can be neurotoxic if the BBB is breached, either by an underlying disease or by the injection of hyperosmolar contrast agent. Ionic contrast media are less well tolerated than nonionic media, probably because they can induce changes in cell membrane electrical potentials. Patients with dolichoectasia of the basilar artery can suffer reversible brainstem dysfunction and acute short-term memory loss during angiography, owing to the slow percolation of the contrast material and the consequent prolonged exposure of the brain. Rarely, an intracranial aneurysm rupture during an angiographic contrast injection, causing subarachnoid hemorrhage, perhaps as a result of injection under high pressure.

**Spinal Angiography** Spinal angiography may be indicated to evaluate vascular malformations and tumors and to identify the artery of Adamkiewicz (Chap. 356) prior to aortic aneurysm repair. The procedure is lengthy and requires the use of relatively large volumes of contrast; the incidence of serious complications, including paraparesis, subjective visual blurring, and altered speech, is ~2%. Gadolinium-enhanced MRA has been used successfully in this setting and has promise for replacing diagnostic spinal angiography for some indications.

**INTERVENTIONAL NEUORADIOLOGY** This rapidly developing field is providing new therapeutic options for patients with difficult neurovascular problems. Available procedures include detachable coil therapy for aneurysms, particulate or liquid adhesive embolization of arteriovenous malformations, balloon angioplasty and stenting of arterial stenosis or vasospasm, transarterial or transvenous embolization of dural arteriovenous fistulas, balloon occlusion of carotid-cavernous and vertebral fistulas, endovascular treatment of vein-of-Galen malformations, preoperative embolization of tumors, and thrombolysis of acute arterial or venous thrombosis. Many of these disorders place the patient at high risk of cerebral hemorrhage, stroke, or death.

The highest complication rates are found with the therapies designed to treat the highest-risk diseases. In a large series of surgically difficult intracranial aneurysms treated with detachable balloons, Higashida and colleagues reported a 7.4% incidence of rates and a 9.8% death rate. These figures must be considered in light of the high morbidity and mortality associated with untreated and surgically unap-
proachable aneurysms (Chap. 349). The advent of the electrolytically detachable coil has reduced these rates and ushered in a new era in the treatment of cerebral aneurysms. One recent double-blind trial (ISAT) found a 28% reduction of morbidity and mortality at 1 year among those treated for anterior circulation aneurysm with detachable coils versus neurosurgical clipping. It remains to be determined what the role of coils will be relative to surgical options, but in many centers, coiling of aneurysms has become standard therapy for many aneurysms.

**Section 2 Diseases of the Central Nervous System**

### 348 SEIZURES AND EPILEPSY

Daniel H. Lowenstein

A seizure (from the Latin sacire, “to take possession of”) is a paroxysmal event due to abnormal, excessive, hypersynchronous discharges from an aggregate of central nervous system (CNS) neurons. Depending on the distribution of discharges, this abnormal CNS activity can have various manifestations, ranging from dramatic convulsive activity to experiential phenomena not readily discernible by an observer. Although a variety of factors influence the incidence and prevalence of seizures, ~5 to 10% of the population will have at least one seizure, with the highest incidence occurring in early childhood and late adulthood.

The meaning of the term seizure needs to be carefully distinguished from that of epilepsy. Epilepsy describes a condition in which a person has recurrent seizures due to a chronic, underlying process. This definition implies that a person with a single seizure, or recurrent seizures due to correctable or avoidable circumstances, does not necessarily have epilepsy. Epilepsy refers to a clinical phenomenon rather than a single disease entity, since there are many forms and causes of epilepsy. However, among the many causes of epilepsy there are various epilepsy syndromes in which the clinical and pathologic characteristics are distinctive and suggest a specific underlying etiology.

Using the definition of epilepsy as two or more unprovoked seizures, the incidence of epilepsy is ~0.3 to 0.5% in different populations throughout the world, and the prevalence of epilepsy has been estimated at 5 to 10 persons per 1000.

#### CLASSIFICATION OF SEIZURES

Determining the type of seizure that has occurred is essential for focusing the diagnostic approach on particular etiologies, selecting the appropriate therapy, and providing potentially vital information regarding prognosis. In 1981, the International League Against Epilepsy (ILAE) published a modified version of the International Classification of Epileptic Seizures that has continued to be a useful classification system (Table 348-1). This system is based on the clinical features of seizures and associated electroencephalographic findings. Other potentially distinctive features such as etiology or cellular substrate are not considered in this classification system, although this will undoubtedly change in the future as more is learned about the pathophysiologic mechanisms that underlie specific seizure types.

A fundamental principle is that seizures may be either partial (synonymous with focal) or generalized. Partial seizures are those in which the seizure activity is restricted to discrete areas of the cerebral cortex. Generalized seizures involve diffuse regions of the brain simultaneously. Partial seizures are usually associated with structural abnormalities of the brain. In contrast, generalized seizures may result from cellular, biochemical, or structural abnormalities that have a more widespread distribution.

**PARTIAL SEIZURES** Partial seizures occur within discrete regions of the brain. If consciousness is fully preserved during the seizure, the clinical manifestations are considered relatively simple and the seizure is termed a simple partial seizure. If consciousness is impaired, the symptomatology is more complex and the seizure is termed a complex partial seizure. An important additional subgroup comprises those seizures that begin as partial seizures and then spread diffusely throughout the cortex, i.e., partial seizures with secondary generalization.

**Simple Partial Seizures** Simple partial seizures cause motor, sensory, autonomic, or psychic symptoms without an obvious alteration in consciousness. For example, a patient having a partial motor seizure arising from the right primary motor cortex in the vicinity controlling hand movement will note the onset of involuntary movements of the contralateral, left hand. These movements are typically clonic (i.e., repetitive, flexion/extension movements) at a frequency of ~2 to 3 Hz; pure tonic posturing may be seen as well. Since the cortical region controlling hand movement is immediately adjacent to the region for facial expression, the seizure may also cause abnormal movements of the face synchronously with the movements of the hand. The electroencephalogram (EEG) recorded with scalp electrodes during the seizure (i.e., an ictal EEG) may show abnormal discharges in a very limited region over the appropriate area of cerebral cortex if the seizure focus involves the cerebral convexity. Seizure activity occurring within deeper brain structures is often not recorded by the standard EEG, however, and may require intracranial electrodes for its detection.

Three additional features of partial motor seizures are worth noting. First, in some patients the abnormal motor movements may begin in a very restricted region such as the fingers and gradually progress (over seconds to minutes) to include a larger portion of the extremity. This phenomenon, described by Hughlings Jackson and known as a “Jacksonian march,” represents the spread of seizure activity over a progressively larger region of motor cortex. Second, patients may experience a localized paresis (Todd’s paralysis) for minutes to many hours in the involved region following the seizure. Third, in rare instances the seizure may continue for hours or days. This condition, termed *epilepsia partialis continua*, is often refractory to medical therapy.

Simple partial seizures may also manifest as changes in somatic sensation (e.g., paresthesias), vision (flashing lights or formed hallucinations), equilibrium (sensation of falling or vertigo), or autonomic function (flushing, sweating, piloerection). Simple partial seizures arising from the temporal or frontal cortex may also cause alterations in hearing, olfaction, or higher cortical function (psychic symptoms). This includes the sensation of unusual, intense odors (e.g., burning rubber or kerosene) or sounds (crude or highly complex sounds), or an epigastric sensation that rises from the stomach or chest to the head. Some patients describe odd, internal feelings such as fear, a sense of

---

**Table 348-1 Classification of Seizures**

<table>
<thead>
<tr>
<th>1. Partial seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Simple partial seizures (with motor, sensory, autonomic, or psychic signs)</td>
</tr>
<tr>
<td>b. Complex partial seizures</td>
</tr>
<tr>
<td>c. Partial seizures with secondary generalization</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Primarily generalized seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Absence (petit mal)</td>
</tr>
<tr>
<td>b. Tonic-clonic (grand mal)</td>
</tr>
<tr>
<td>c. Tonic</td>
</tr>
<tr>
<td>d. Atonic</td>
</tr>
<tr>
<td>e. Myoclonic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Unclassified seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Neonatal seizures</td>
</tr>
<tr>
<td>b. Infantile spasms</td>
</tr>
</tbody>
</table>
Impending change, detachment, depersonalization, déjà vu, or illusions that objects are growing smaller (micropsia) or larger (macropsia). When such symptoms precede a complex partial or secondarily generalized seizure, these simple partial seizures serve as a warning, or aura.

**Complex Partial Seizures** Complex partial seizures are characterized by focal seizure activity accompanied by a transient impairment of the patient’s ability to maintain normal contact with the environment. The patient is unable to respond appropriately to visual or verbal commands during the seizure and has impaired recollection or awareness of the ictal phase. The seizures frequently begin with an aura (i.e., a simple partial seizure) that is stereotypic for the patient. The start of the ictal phase is often a sudden behavioral arrest or motionless stare, which marks the onset of the period of amnesia. The behavioral arrest is usually accompanied by automatism, which are involuntary, automatic behaviors that have a wide range of manifestations. Automatisms may consist of very basic behaviors such as chewing, lip smacking, swallowing, or “picking” movements of the hands, or more elaborate behaviors such as a display of emotion or running. The patient is typically confused following the seizure, and the transition to full recovery of consciousness may range from seconds up to an hour. Examination immediately following the seizure may show an anterograde amnesia or, in cases involving the dominant hemisphere, a postictal aphasia.

The routine, interictal (i.e., between seizures) EEG in patients with complex partial seizures is often normal or may show brief discharges termed epileptiform spikes, or sharp waves. Since complex partial seizures can arise from the medial temporal lobe or inferior frontal lobe, i.e., regions distant from the scalp, the EEG recorded during the seizure may be nonlocalizing. However, the seizure focus is often detected using sphenoidal or surgically placed intracranial electrodes.

The range of potential clinical behaviors linked to complex partial seizures is so broad that extreme caution is advised before concluding that stereotypic episodes of bizarre or atypical behavior are not due to seizure activity. In such cases additional, detailed EEG studies may be helpful.

**Partial Seizures with Secondary Generalization** Partial seizures can spread to involve both cerebral hemispheres and produce a generalized seizure, usually of the tonic-clonic variety (discussed below). Secondary generalization is observed frequently following simple partial seizures, especially those with a focus in the frontal lobe, but may also be associated with partial seizures occurring elsewhere in the brain. A partial seizure with secondary generalization is often difficult to distinguish from a primarily generalized tonic-clonic seizure, since bystanders tend to emphasize the more dramatic, generalized convulsive phase of the seizure and overlook the more subtle, focal symptoms present at onset. In some cases, the focal onset of the seizure becomes apparent only when a careful history identifies a preceding aura (i.e., simple partial seizure). Often, however, the focal onset is not clinically evident and may be established only through careful EEG analysis. Nonetheless, distinguishing between these two entities is extremely important, as there may be substantial differences in the evaluation and treatment of partial versus generalized seizure disorders.

**Generalized Seizures** By definition, generalized seizures arise from both cerebral hemispheres simultaneously. However, it is currently impossible to exclude entirely the existence of a focal region of abnormal activity that initiates the seizure prior to rapid secondary generalization. For this reason, generalized seizures may be practically defined as bilateral clinical and electrographic events without any detectable focal onset. Fortunately, several types of generalized seizures have distinctive features that facilitate clinical diagnosis.

**Absence Seizures (Petit Mal)** Absence seizures are characterized by sudden, brief lapses of consciousness without loss of postural control. The seizure typically lasts for only seconds, consciousness returns as suddenly as it was lost, and there is no postictal confusion. Although the brief loss of consciousness may be clinically inapparent or the sole manifestation of the seizure discharge, absence seizures are usually accompanied by subtle, bilateral motor signs such as rapid blinking of the eyelids, chewing movements, or small-amplitude, clonic movements of the hands.

Absence seizures usually begin in childhood (ages 4 to 8) or early adolescence and are the main seizure type in 15 to 20% of children with epilepsy. The seizures can occur hundreds of times per day, but the child may be unaware of or unable to convey their existence. The patient may be constantly piecing together experiences that have been interrupted by the seizures. Since the clinical signs of the seizures are subtle, especially to new parents, it is not surprising that the first clue to absence epilepsy is often unexplained “daydreaming” and a decline in school performance recognized by a teacher.

The electrophysiologic hallmark of typical absence seizures is a generalized, symmetric, 3-Hz spike-and-wave discharge that begins and ends suddenly, superimposed on a normal EEG background. Periods of spike-and-wave discharges lasting more than a few seconds usually correlate with clinical signs, but the EEG often shows many more brief bursts of abnormal cortical activity than were suspected clinically. Hyperventilation tends to provoke these electrographic discharges and even the seizures themselves and is routinely used when recording the EEG.

Typical absence seizures are often associated with generalized, tonic-clonic seizures, but patients usually have no other neurologic problems and respond well to treatment with specific anticonvulsants. Although estimates vary, ~60 to 70% of such patients will have a spontaneous remission during adolescence.

**Atypical Absence Seizures** Atypical absence seizures have features that deviate both clinically and electrophysiologically from typical absence seizures. For example, the lapse of consciousness is usually of longer duration and less abrupt in onset and cessation, and the seizure is accompanied by more obvious motor signs that may include focal or lateralizing features. The EEG shows a generalized, slow spike-and-wave pattern with a frequency of ≤2.5/s, as well as other abnormal activity. Atypical absence seizures are usually associated with diffuse or multifocal structural abnormalities of the brain and therefore may accompany other signs of neurologic dysfunction such as mental retardation. Furthermore, the seizures are less responsive to anticonvulsants compared to typical absence seizures.

**Generalized, Tonic-Clonic Seizures (Grand Mal)** Primarily generalized, tonic-clonic seizures are the main seizure type in ~10% of all persons with epilepsy. They are also the most common seizure type resulting from metabolic derangements and are therefore frequently encountered in many different clinical settings. The seizure usually begins abruptly without warning, although some patients describe vague premonitory symptoms in the hours leading up to the seizure. This prodrome is distinct from the stereotypic auras associated with focal seizures that secondarily generalize. The initial phase of the seizure is usually tonic contraction of muscles throughout the body, accounting for a number of the classic features of the event. Tonic contraction of the muscles of expiration and the larynx at the onset will produce a loud moan or “ictal cry.” Respiration is impaired, secretions pool in the oropharynx, and cyanosis develops. Contraction of the jaw muscles may cause biting of the tongue. A marked enhancement of sympathetic tone leads to increases in heart rate, blood pressure, and pupillary size. After 10 to 20 s, the tonic phase of the seizure typically evolves into the clonic phase, produced by the superimposition of periods of muscle relaxation on the tonic muscle contraction. The periods of relaxation progressively increase until the end of the ictal phase, which usually lasts no more than 1 min. The postictal phase is characterized by unresponsiveness, muscular flaccidity, and excessive salivation that can cause stridorous breathing and partial airway obstruction. Bladder or bowel incontinence may occur at this point. Patients gradually regain consciousness over minutes to hours, and during this transition there is typically a period of postictal confusion. Patients subsequently com-
plain of headache, fatigue, and muscle ache that can last for many hours. The duration of impaired consciousness in the postictal phase can be extremely long, i.e., many hours, in patients with prolonged seizures or underlying CNS diseases such as alcoholic cerebral atrophy.

The EEG during the tonic phase of the seizure shows a progressive increase in generalized low-voltage fast activity, followed by generalized high-amplitude, polyspike discharges. In the clonic phase, the high-amplitude activity is typically interrupted by slow waves to create a spike-and-wave pattern. The postictal EEG shows diffuse slowing that gradually recovers as the patient awakens.

There are many variants of the generalized tonic-clonic seizure, including pure tonic and pure clonic seizures. Brief tonic seizures lasting only a few seconds are especially noteworthy since they are usually associated with specific epileptic syndromes having mixed seizure phenotypes, such as the Lennox-Gastaut syndrome (discussed below).

**Atonic Seizures** Atonic seizures are characterized by sudden loss of postural muscle tone lasting 1 to 2 s. Consciousness is briefly impaired, but there is usually no postictal confusion. A very brief seizure may cause only a quick head drop or nodding movement, while a longer seizure will cause the patient to collapse. This can be extremely dangerous, since there is a substantial risk of direct head injury with the fall. The EEG shows brief, generalized spike-and-wave discharges followed immediately by diffuse slow waves that correlate with the loss of muscle tone. Similar to pure tonic seizures, atonic seizures are usually seen in association with known epileptic syndromes.

**Myoclonic Seizures** Myoclonus is a sudden and brief muscle contraction that may involve one part of the body or the entire body. A normal, common physiologic form of myoclonus is the sudden jerking movement observed while falling asleep. Pathologic myoclonus is most commonly seen in association with metabolic disorders, degenerative CNS diseases, or anoxic brain injury (Chap. 21). Although the distinction from other forms of myoclonus is imprecise, myoclonic seizures are considered to be true epileptic events since they are caused by cortical (versus subcortical or spinal) dysfunction. The EEG may show bilaterally synchronous spike-and-wave discharges synchronized with the myoclonus, although these can be obscured by movement artifact. Myoclonic seizures usually coexist with other forms of generalized seizure disorders but are the predominant feature of juvenile myoclonic epilepsy (discussed below).

**UNCLASSIFIED SEIZURES** Not all seizure types can be classified as partial or generalized. This applies to especially true of seizures that occur in neonates and infants. The distinctive phenotypes of seizures at these early ages likely result, in part, from differences in neuronal function and connectivity in the immature versus mature CNS.

**EPILEPSY SYNDROMES**

Epilepsy syndromes are disorders in which epilepsy is a predominant feature, and there is sufficient evidence (e.g., through clinical, EEG, radiologic, or genetic observations) to suggest a common underlying mechanism. Three important epilepsy syndromes are listed below; additional examples with a known genetic basis are shown in Table 348-2.

**JUVENILE MYOCLONIC EPILEPSY** Juvenile myoclonic epilepsy (JME) is a generalized seizure disorder of unknown cause that appears in early adolescence and is usually characterized by bilateral myoclonic jerks that may be single or repetitive. The myoclonic seizures are most frequent in the morning after awakening and can be provoked by sleep deprivation. Consciousness is preserved unless the myoclonus is especially severe. Many patients also experience generalized tonic-clonic seizures, and up to one-third have absence seizures. The condition is otherwise benign, and although complete remission is uncommon, the seizures respond well to appropriate anticonvulsant medication. There is often a family history of epilepsy, and genetic linkage studies suggest a polygenic cause.

**LENNOX-GASTAUT SYNDROME** Lennox-Gastaut syndrome occurs in children and is defined by the following triad: (1) multiple seizure types (usually including generalized tonic-clonic, atonic, and atypical absence seizures); (2) an EEG showing slow (<3 Hz) spike-and-wave discharges and a variety of other abnormalities; and (3) impaired cognitive function in most but not all cases. Lennox-Gastaut syndrome is associated with CNS disease or dysfunction from a variety of causes, including developmental abnormalities, perinatal hypoxia/ischemia, trauma, infection, and other acquired lesions. The multifactorial nature of this syndrome suggests that it is a nonspecific response of the brain to diffuse neural injury. Unfortunately, many patients have a poor prognosis due to the underlying CNS disease and the physical and psychosocial consequences of severe, poorly controlled epilepsy.

**MESIAL TEMPORAL LOBE EPILEPSY SYNDROME** Mesial temporal lobe epilepsy (MTLE) is the most common syndrome associated with complex partial seizures and is an example of a symptomatic, partial epilepsy with distinctive clinical, electroencephalographic, and pathologic features (Table 348-3). High-resolution magnetic resonance imaging (MRI) can detect the characteristic hippocampal sclerosis that appears to be essential in the pathophysiology of MTLE for many patients (Fig. 348-1). Recognition of this syndrome is especially important because it tends to be refractory to treatment with anticonvulsants but responds extremely well to surgical intervention. Advances in the understanding of basic mechanisms of epilepsy have come through studies of experimental models of MTLE, discussed below.

**THE CAUSES OF SEIZURES AND EPILEPSY**

Seizures are a result of a shift in the normal balance of excitation and inhibition within the CNS. Given the numerous properties that control neuronal excitability, it is not surprising that there are many different ways to perturb this normal balance, and therefore many different causes of both seizures and epilepsy. Three clinical observations emphasize how a variety of factors determine why certain conditions may cause seizures or epilepsy in a given patient.

1. The normal brain is capable of having a seizure under the appropriate circumstances, and there are differences between individuals in the susceptibility or threshold for seizures. For example, seizures may be induced by high fevers in children who are otherwise normal and who never develop other neurologic problems, including epilepsy. However, febrile seizures occur only in a relatively small proportion of children. This implies there are various underlying, endogenous factors that influence the threshold for having a seizure. Some of these factors are clearly genetic, as it has been shown that a family history of epilepsy will influence the likelihood of seizures occurring in otherwise normal individuals. Normal development also plays an important role, since the brain appears to have different seizure thresholds at different maturational stages.

2. There are a variety of conditions that have an extremely high likelihood of resulting in a chronic seizure disorder. One of the best examples of this is severe, penetrating head trauma, which is associated with up to a 50% risk of subsequent epilepsy. The high propensity for severe traumatic brain injury to lead to epilepsy suggests that the injury results in a long-lasting, pathologic change in the CNS that transforms a presumably normal neural network into one that is abnormally hyperexcitable. This process is known as epileptogenesis, and the specific changes that result in a lowered seizure threshold can be considered epileptogenic factors. Other processes associated with epileptogenesis include stroke, infections, and abnormalities of CNS development. Likewise, the genetic abnormalities associated with epilepsy likely involve processes that trigger the appearance of specific sets of epileptogenic factors.

3. Seizures are episodic. Patients with epilepsy have seizures intermittently and, depending on the underlying cause, many patients are completely normal for months or even years between seizures. This implies there are important provocative or precipitating factors that
induce seizures in patients with epilepsy. Similarly, precipitating factors are responsible for causing the single seizure in someone without epilepsy. Precipitants include those due to intrinsic physiologic processes, such as psychological or physical stress, sleep deprivation, or hormonal changes associated with the menstrual cycle. They also include exogenous factors such as exposure to toxic substances and certain medications.

These observations emphasize the concept that the many causes of seizures and epilepsy result from a dynamic interplay between endogenous factors, epileptogenic factors, and precipitating factors. The potential role of each needs to be carefully considered when determining the appropriate management of a patient with seizures. For example, the identification of predisposing factors (e.g., family history of epilepsy) in a patient with febrile seizures may increase the necessity for closer follow-up and a more aggressive diagnostic evaluation. Finding an epileptogenic lesion may help in the estimation of seizure recurrence and duration of therapy. Finally, removal or modification of a precipitating factor may be an effective and safer method for preventing further seizures than the prophylactic use of anticonvulsant drugs.

**CAUSES ACCORDING TO AGE** In practice, it is useful to consider the etiologies of seizures based on the age of the patient, as age is one of the most important factors determining both the incidence and likely causes of seizures or epilepsy (Table 348-4). During the neonatal period and early infancy, potential causes include hypoxic-ischemic encephalopathy, trauma, CNS infection, congenital CNS abnormalities, and metabolic disorders. Babies born to mothers using neurotoxic drugs such as cocaine, heroin, or ethanol are susceptible to drug-withdrawal seizures in the first few days after delivery. Hypoglycemia and hypocalcemia, which can occur as secondary complications of peri-

---

**TABLE 348-2 Examples of Genes Associated with Epilepsy Syndromes***

<table>
<thead>
<tr>
<th>Gene (Locus)</th>
<th>Function of Gene</th>
<th>Clinical Syndrome</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHRNA4 (20q13.2) CHRN B2 (1q21.3)</td>
<td>Nicotinic acetylcholine receptor subunit; mutations cause alterations in Ca&lt;sup&gt;2+&lt;/sup&gt; flux through the receptor; this may reduce amount of GABA release in presynaptic terminals</td>
<td>Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE); childhood onset; brief, nighttime seizures with prominent motor movements; often misdiagnosed as primary sleep disorder</td>
<td>Rare; first identified in a large Australian family; other families found to have mutations in CHRNA2 or CHRN B2, and some families appear to have mutations at other loci</td>
</tr>
<tr>
<td>KCNQ2 (20q13.3) KCNQ3 (8q24)</td>
<td>Voltage-gated potassium channel subunits; mutation in pore regions may cause a 20–40% reduction of potassium currents, which will lead to impaired repolarization</td>
<td>Benign familial neonatal convulsions (BFNC); autosomal dominant inheritance; onset in 1st week of life in infants who are otherwise normal; remission usually within weeks to months; long-term epilepsy in 10–15%</td>
<td>Rare; sequence and functional homology to KCNQ1, mutations of which cause long QT syndrome and a cardiac-auditory syndrome</td>
</tr>
<tr>
<td>SCN1B (19q12.1)</td>
<td>β-subunit of a voltage-gated sodium channel; mutation disrupts disulfide bridge that is crucial for structure of extracellular domain; mutated β-subunit leads to slower sodium channel inactivation</td>
<td>Generalized epilepsy with febrile seizures plus (GEFS+); autosomal dominant inheritance; presents with febrile seizures at median 1 year, which may persist &gt;6 years, then variable seizure types not associated with fever</td>
<td>Incidence uncertain; GEFS+ identified in other families with mutations in other sodium channel subunits (SCN1A and SCN2A) and GABA&lt;sub&gt;α&lt;/sub&gt; receptor subunit (GABRG2); significant phenotypic heterogeneity within same family, including members with febrile seizures only</td>
</tr>
<tr>
<td>LG1 (10q24)</td>
<td>Leucine-rich glioma-inactivated gene; previous evidence for role in gli tumor progression; likely to be involved in nervous system development</td>
<td>Autosomal dominant partial epilepsy with auditory features (ADPEAF); temporal lobe epilepsy with wide range of auditory and other sensory symptoms as major manifestation; age of onset usually between 10 and 25 years</td>
<td>Rare; at least one family with similar syndrome has mutation(s) elsewhere; LG1 mutation is the only known mutation identified in temporal lobe epilepsy and the only non-ion-channel gene mutation known in idiopathic epilepsy</td>
</tr>
<tr>
<td>CSTB (21q22.3)</td>
<td>Cystatin B, a non-caspase cysteine protease inhibitor; normal protein may block neuronal apoptosis by inhibiting caspasess directly or indirectly (via cathepsins), or controlling proteolysis</td>
<td>Progressive myoclonus epilepsy (PME) (Unverricht-Lundborg disease); autosomal recessive inheritance; age of onset between 6–15 years, myoclonic seizures, ataxia, and progressive cognitive decline; brain shows neuronal degeneration</td>
<td>Overall rare, but relatively common in Finland and Western Mediterranean (&gt;1 in 20,000); precise role of cystatin B in human disease unknown, although mice with null mutations of cystatin B have similar syndrome</td>
</tr>
<tr>
<td>EPM2A (6q24)</td>
<td>Laforin, a protein tyrosine phosphatase (PTP); may influence glycolysis metabolism, which is known to be regulated by phosphatases</td>
<td>Progressive myoclonus epilepsy (Lafora’s disease); autosomal recessive inheritance; onset age 6–19 years, death within 10 years; brain degeneration associated with polyglucosan intracellular inclusion bodies in numerous organs</td>
<td>Most common PME in Southern Europe, Middle East, Northern Africa, and Indian subcontinent; genetic heterogeneity; unknown whether seizure phenotype due to degeneration or direct effects of abnormal laforin expression.</td>
</tr>
<tr>
<td>Doublecortin (Xq21-24)</td>
<td>Doublecortin, expressed primarily in frontal lobes; function unknown; potentially an intracellular signalling molecule</td>
<td>Classic lissencephaly associated with severe mental retardation and seizures in males; subcortical band heterotopia with more subtle findings in females (presumably due to random X-inactivation); X-linked dominant</td>
<td>Relatively rare but of uncertain incidence, recent increased ascertainment due to improved imaging techniques; relationship between migration defect and seizure phenotype unknown</td>
</tr>
</tbody>
</table>

---

*The first four syndromes listed in the table (ADNFLE, BFNC, GEFS+, and ADPEAF) are examples of idiopathic generalized epilepsies associated with identified gene mutations. The last three syndromes are examples of the numerous Mendelian disorders in which seizures are one part of the phenotype. Note: GABA, γ-aminobutyric acid.
Febrile seizures usually occur between 3 months and 5 years of age and have a peak incidence between 18 and 24 months. The prevalence is 3 to 5% and even higher in some parts of the world, such as Asia. Patients often have a family history of febrile seizures or epilepsy. Febrile seizures associated with fevers but without evidence of CNS infection or other defined causes. The overall prevalence is 3 to 5% and even higher in some parts of the world, such as Asia. Patients often have a family history of febrile seizures or epilepsy. Febrile seizures usually occur between 3 months and 5 years of age and have a peak incidence between 18 and 24 months. The typical scenario is a child who has a generalized, tonic-clonic seizure during a febrile illness in the setting of a common childhood infection such as otitis media, respiratory infection, or gastroenteritis. The idiopathic or inherited forms of benign neonatal convulsions are also seen during this time period.

The most common seizures arising in late infancy and early childhood are febrile seizures, which are seizures associated with fevers but without evidence of CNS infection or other defined causes. The overall prevalence is 3 to 5% and even higher in some parts of the world, such as Asia. Patients often have a family history of febrile seizures or epilepsy. Febrile seizures usually occur between 3 months and 5 years of age and have a peak incidence between 18 and 24 months. The typical scenario is a child who has a generalized, tonic-clonic seizure during a febrile illness in the setting of a common childhood infection such as otitis media, respiratory infection, or gastroenteritis. The seizure is likely to occur during the rising phase of the temperature curve (i.e., during the first day) rather than well into the course of the illness. A simple febrile seizure is a single, isolated event, brief, and symmetric in appearance. Complex febrile seizures are characterized by repeated seizure activity, duration >15 min, or have focal features. Approximately one-third of patients with febrile seizures will have a recurrence, but <10% have three or more episodes. Recurrences are much more likely when the febrile seizure occurs in the first year of life. Simple febrile seizures are not associated with an increase in the risk of developing epilepsy, while complex febrile seizures have a risk of 2 to 5%; other risk factors include the presence of preexisting neurologic deficits and a family history of nonfebrile seizures.

Childhood marks the age at which many of the well-defined epilepsy syndromes present. Some children who are otherwise normal develop idiopathic, generalized tonic-clonic seizures without other features that fit into specific syndromes. Temporal lobe epilepsy usually presents in childhood and may be related to mesial temporal lobe sclerosis (as part of the MTLE syndrome) or other focal abnormalities such as cortical dysgenesis. Other types of partial seizures, including those with secondary generalization, may be the relatively late manifestation of a developmental disorder, an acquired lesion such as head trauma, CNS infection (especially viral encephalitis), or very rarely a CNS tumor.

The period of adolescence and early adulthood is one of transition during which the idiopathic or genetically based epilepsy syndromes, including JME and juvenile absence epilepsy, become less common, while epilepsies secondary to acquired CNS lesions begin to predominate. Seizures that begin in patients in this age range may be associated with head trauma, CNS infections (including parasitic infections such as cysticercosis), brain tumors, congenital CNS abnormalities, illicit drug use, or alcohol withdrawal.

### Table 348-3 Characteristics of the Mesial Temporal Lobe Epilepsy Syndrome

<table>
<thead>
<tr>
<th>History</th>
<th>Seizures may remit and appear</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history of epilepsy</td>
<td>seizures often intractable</td>
</tr>
<tr>
<td>Early onset</td>
<td>Rare secondarily generalized seizures</td>
</tr>
</tbody>
</table>

### Table 348-4 Causes of Seizures

<table>
<thead>
<tr>
<th>Age</th>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonates (&lt;1 month)</td>
<td>Perinatal hypoxia and ischemia</td>
</tr>
<tr>
<td>Infants and children (&gt;1 mo and &lt;12 years)</td>
<td>Intracranial hemorrhage and trauma</td>
</tr>
<tr>
<td>Adolescents (12–18 years)</td>
<td>Acute CNS infection</td>
</tr>
<tr>
<td>Young adults (18–35 years)</td>
<td>Metabolic disturbances (hypoglycemia, hypocalcemia, hypomagnesemia, pyridoxine deficiency)</td>
</tr>
<tr>
<td>Old adults (&gt;35 years)</td>
<td>Drug withdrawal</td>
</tr>
<tr>
<td></td>
<td>Developmental disorders</td>
</tr>
<tr>
<td></td>
<td>Genetic disorders</td>
</tr>
<tr>
<td></td>
<td>Febrile seizures</td>
</tr>
<tr>
<td></td>
<td>Genetic disorders (metabolic, degenerative, primary epilepsy syndromes)</td>
</tr>
<tr>
<td></td>
<td>CNS infection</td>
</tr>
<tr>
<td></td>
<td>Developmental disorders</td>
</tr>
<tr>
<td></td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
<tr>
<td></td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Genetic disorders</td>
</tr>
<tr>
<td></td>
<td>Infection</td>
</tr>
<tr>
<td></td>
<td>Brain tumor</td>
</tr>
<tr>
<td></td>
<td>Illicit drug use</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
<tr>
<td></td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>Illicit drug use</td>
</tr>
<tr>
<td></td>
<td>Brain tumor</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
<tr>
<td></td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td></td>
<td>Brain tumor</td>
</tr>
<tr>
<td></td>
<td>Alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>Metabolic disturbances (uremia, hepatic failure, electrolyte abnormalities, hypoglycemia)</td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease and other degenerative CNS diseases</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
</tbody>
</table>

**Note:** CNS, central nervous system.
Head trauma is a common cause of epilepsy in adolescents and adults. The head injury can be caused by a variety of mechanisms, and the likelihood of developing epilepsy is strongly correlated with the severity of the injury. A patient with a penetrating head wound, depressed skull fracture, intracranial hemorrhage, or prolonged posttraumatic coma or amnesia has a 40 to 50% risk of developing epilepsy, while a patient with a closed head injury and cerebral contusion has a 5 to 25% risk. Recurrent seizures usually develop within 1 year after head trauma, although intervals of ≥10 years are well known. In controlled studies, mild head injury, defined as a confusion with amnesia or loss of consciousness of <30 min, was found to be associated with only a slightly increased likelihood of epilepsy. Nonetheless, most epileptologists know of patients who have partial seizures within hours or days of a mild head injury and subsequently develop chronic seizures of the same type; such cases may represent rare examples of chronic epilepsy resulting from mild head injury.

The causes of seizures in older adults include cerebrovascular disease, trauma (including subdural hematoma), CNS tumors, and degenerative diseases. Cerebrovascular disease may account for ~50% of new cases of epilepsy in patients older than 65. Acute seizures (i.e., occurring at the time of the stroke) are seen more often with embolic rather than hemorrhagic or thrombotic stroke. Chronic seizures typically appear months to years after the initial event and are associated with all forms of stroke.

Metabolic disturbances such as electrolyte imbalance, hypo- or hyperglycemia, renal failure, and hepatic failure may cause seizures at any age. Similarly, endocrine disorders, hematologic disorders, vascultides, and many other systemic diseases may cause seizures over a broad age range. A wide variety of medications and abused substances are known to precipitate seizures as well (Table 348-5).

**BASIC MECHANISMS**

### MECHANISMS OF SEIZURE INITIATION AND PROPAGATION

Partial seizure activity can begin in a very discrete region of cortex and then spread to neighboring regions, i.e., there is a seizure initiation phase and a seizure propagation phase. The initiation phase is characterized by two concurrent events in an aggregate of neurons: (1) high-frequency bursts of action potentials, and (2) hypersynchronization. The bursting activity is caused by a relatively long-lasting depolarization of the neuronal membrane due to influx of extracellular calcium (Ca^{2+}), which leads to the opening of voltage-dependent sodium (Na^+) channels, influx of Na^+, and generation of repetitive action potentials. This is followed by a hyperpolarizing afterpotential mediated by γ-aminobutyric acid (GABA) receptors or potassium (K^+) channels, depending on the cell type. The synchronized bursts from a sufficient number of neurons result in a so-called spike discharge on the EEG.

Normally, the spread of bursting activity is prevented by intact hyperpolarization and a region of surrounding inhibition created by inhibitory neurons. With sufficient activation there is a recruitment of surrounding neurons via a number of mechanisms. Repetitive discharges lead to the following: (1) an increase in extracellular K^+, which blunts hyperpolarization and depolarizes neighboring neurons; (2) accumulation of Ca^{2+} in presynaptic terminals, leading to enhanced neurotransmitter release; and (3) depolarization-induced activation of the N-methyl-D-aspartate (NMDA) subtype of the excitatory amino acid receptor, which causes Ca^{2+} influx and neuronal activation. The recruitment of a sufficient number of neurons leads to a loss of the surrounding inhibition and propagation of seizure activity into contiguous areas via local cortical connections, and to more distant areas via long commissural pathways such as the corpus callosum. Many factors control neuronal excitability, and that there are many potential mechanisms for altering a neuron’s propensity to have bursting activity. Mechanisms intrinsic to the neuron include changes in the conductance of ion channels, response characteristics of membrane receptors, cytoplasmic buffering, second-messenger systems, and protein expression as determined by gene transcription, translation, and posttranslational modification. Mechanisms extrinsic to the neuron include changes in the amount or type of neurotransmitters present at the synapse, modulation of receptors by extracellular ions and other molecules, and temporal and spatial properties of synaptic and nonsynaptic input. Nonneural cells, such as astrocytes and oligodendrocytes, have an important role in many of these mechanisms as well.

Certain recognized causes of seizures are explained by these mechanisms. For example, accidental ingestion of domoic acid, which is an analogue of glutamate (the principal excitatory neurotransmitter in the brain), causes profound seizures via direct activation of excitatory amino acid receptors throughout the CNS. Penicillin, which can lower the seizure threshold in humans and is a potent convulsant in experimental models, reduces inhibition by antagonizing the effects of GABA at its receptor. The basic mechanisms of other precipitating factors of seizures, such as sleep deprivation, fever, alcohol withdrawal, hypoxia, and infection, are not as well understood but presumably involve analogous perturbations in neuronal excitability. Similarly, the endogenous factors that determine an individual’s seizure threshold may relate to these properties as well.

Knowledge of the mechanisms responsible for initiation and propagation of most generalized seizures (including tonic-clonic, myoclonic, and atonic types) remains rudimentary and reflects the limited understanding of the connectivity of the brain at a systems level. Much more is understood about the origin of generalized spike-and-wave discharges in absence seizures. These appear to be related to oscillatory rhythms normally generated during sleep by circuits connecting the thalamus and cortex. This oscillatory behavior involves an interaction between GABA_A receptors, T-type Ca^{2+} channels, and K^+ channels located within the thalamus. Pharmacologic studies indicate that modulation of these receptors and channels can induce absence seizures, and there is speculation that the genetic forms of absence epilepsy may be associated with mutations of components of this system.

### MECHANISMS OF EPILEPTOGENESIS

Epileptogenesis refers to the transformation of a normal neuronal network into one that is chronically hyperexcitable. There is often a delay of months to years between an initial CNS injury such as trauma, stroke, or infection and the first seizure. The injury appears to initiate a process that gradually lowers the seizure threshold in the affected region until a spontaneous seizure occurs. In many genetic and idiopathic forms of epilepsy, epileptogenesis is presumably determined by developmentally regulated events.

Pathologic studies of the hippocampus from patients with temporal lobe epilepsy have led to the suggestion that some forms of epileptogenesis are related to structural changes in neuronal networks. For example, many patients with MTLE have a highly selective loss of neurons that may contribute to recurrent excitatory neurons within the dentate gyrus. There is also evidence that, in response to the loss of neurons, there is reorganization or “sprouting” of sur-

### TABLE 348-5 Drugs and Other Substances That Can Cause Seizures

<table>
<thead>
<tr>
<th>Antimicrobials/antivirals</th>
<th>Beta-lactam and related compounds</th>
<th>Quinolones</th>
<th>Acyclovir</th>
<th>Isoniazid</th>
<th>Ganciclovir</th>
<th>Anesthetics and analgesics</th>
<th>Meperidine</th>
<th>Tramadol</th>
<th>Local anesthetics</th>
<th>Immuno-modulatory drugs</th>
<th>Cyclosporine</th>
<th>OKT3 (monoclonal antibodies to T cells)</th>
<th>Tacrolimus (FK-506)</th>
<th>Interferons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychotropics</td>
<td>Antidepressants</td>
<td>Antipsychotics</td>
<td>Lithium</td>
<td>Radiographic contrast agents</td>
<td>Theophylline</td>
<td>Sedative-hypnotic drug</td>
<td>withdrawal</td>
<td>Alcohol</td>
<td>Barbital</td>
<td>Benzodiazepines</td>
<td>Drugs of abuse</td>
<td>Amphetamine</td>
<td>Cocaine</td>
<td>Phencyclidine</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Antivirals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cocaine</td>
<td>Methylphenidate</td>
<td>Flumazenil</td>
</tr>
</tbody>
</table>

* In benzodiazepine-dependent patients.
viving neurons in a way that affects the excitability of the network. Some of these changes can be seen in experimental models of prolonged electrical seizures or traumatic brain injury. Thus, an initial injury such as head injury may lead to a very focal, confined region of structural change that causes local hyperexcitability. The local hyperexcitability leads to further structural changes that evolve over time until the focal lesion produces clinically evident seizures. Similar models have also provided strong evidence for long-term alterations in intrinsic, biochemical properties of cells within the network, such as chronic changes in glutamate receptor function.

GENETIC CAUSES OF EPILEPSY The most important recent progress in epilepsy research has been the identification of genetic mutations associated with a variety of epilepsy syndromes (Table 348-2). Although all of the mutations identified to date cause rare forms of epilepsy, their discovery has led to extremely important conceptual advances. For example, it appears that many of the inherited, idiopathic epilepsies (i.e., the relatively “pure” forms of epilepsy in which seizures are the phenotypic abnormality and brain structure and function are otherwise normal) are due to mutations affecting ion channel function. These syndromes are therefore part of the larger group of channelopathies causing paroxysmal disorders such as cardiac arrhythmias, episodic ataxia, periodic weakness, and familial hemiplegic migraine. In contrast, the mutations observed in symptomatic epilepsies (i.e., disorders in which other neurologic abnormalities, such as cognitive impairment, coexist with seizures) are proving to be associated with pathways influencing CNS development or neuronal homeostasis. A current challenge is to identify the multiple susceptibility genes that underlie the more common forms of idiopathic epilepsies.

MECHANISMS OF ACTION OF ANTI-EPILEPTIC DRUGS Antiepileptic drugs appear to act primarily by blocking the initiation or spread of seizures. This occurs through a variety of mechanisms that modify the activity of ion channels or neurotransmitters, and in most cases the drugs have pleiotropic effects. The mechanisms include inhibition of Na+-dependent action potentials in a frequency–dependent manner (e.g., phenytoin, carbamazepine, lamotrigine, topiramate, zonisamide), inhibition of voltage-gated Ca2+ channels (phenytoin), decrease of glutamate release (lamotrigine), potentiation of GABA receptor function (benzodiazepines and barbiturates), and increase in the availability of GABA (valproic acid, gabapentin, tiagabine). The two most effective drugs for absence seizures, ethosuximide and valproic acid, probably act by inhibiting T-type Ca2+ channels in thalamic neurons.

In contrast to the relatively large number of antiepileptic drugs that can attenuate seizure activity, there are currently no drugs known to prevent the formation of a seizure focus following CNS injury. The eventual development of such “antiepileptogenic” drugs will provide an important means of preventing the emergence of epilepsy following injuries such as head trauma, stroke, and CNS infection.

EVALUATION OF THE PATIENT WITH A SEIZURE When a patient presents shortly after a seizure, the first priorities are attention to vital signs, respiratory and cardiovascular support, and treatment of seizures if they resolve (see “Treatment”). Life-threatening conditions such as CNS infection, metabolic derangement, or drug toxicity must be recognized and managed appropriately.

When the patient is not acutely ill, the evaluation will initially focus on whether there is a history of earlier seizures (Fig. 348-2). If this is the first seizure, then the emphasis will be to (1) establish whether the reported episode was a seizure rather than another paroxysmal event, (2) determine the cause of the seizure by identifying risk factors and precipitating events, and (3) decide whether anticonvulsant therapy is required in addition to treatment for any underlying illness.

In the patient with prior seizures or a known history of epilepsy, the evaluation is directed toward (1) identification of the underlying cause and precipitating factors, and (2) determination of the adequacy of the patient’s current therapy.

HISTORY AND EXAMINATION The first goal is to determine whether the event was truly a seizure. An in-depth history is essential, for in many cases the diagnosis of a seizure is based solely on clinical grounds— the examination and laboratory studies are often normal. Questions should be focused on the symptoms before, during, and after the episode in order to discriminate a seizure from other paroxysmal events (see “Differential Diagnosis of Seizures”). Seizures frequently occur out-of-hospital, and the patient may be unaware of the ictal and immediate postictal phases; thus witnesses to the event should be interviewed carefully.

The history should also focus on risk factors and predisposing events. Clues for a predisposition to seizures include a history of febrile seizures, earlier auras or brief seizures not recognized as such, and a family history of seizures. Epileptogenic factors such as prior head trauma, stroke, tumor, or vascular malformation should be identified. In children, a careful assessment of developmental milestones may provide evidence for underlying CNS disease. Precipitating factors such as sleep deprivation, systemic diseases, electrolyte or metabolic derangements, acute infection, drugs that lower the seizure threshold (Table 348-5), or alcohol or illicit drug use should also be identified.

The general physical examination includes a search for signs of infection or systemic illness. Careful examination of the skin may reveal signs of neurocutaneous disorders, such as tuberous sclerosis or neurofibromatosis, or chronic liver or renal disease. A finding of organomegaly may indicate a metabolic storage disease, and limb asymmetry may provide a clue to brain injury early in development. Signs of head trauma and use of alcohol or illicit drugs should be sought. Auscultation of the heart and carotid arteries may identify an abnormality that predisposes to cerebrovascular disease.

All patients require a complete neurologic examination, with particular emphasis on eliciting signs of cerebral hemispheric disease (Chap. 346). Careful assessment of mental status (including memory, language function, and abstract thinking) may suggest lesions in the anterior frontal, parietal, or temporal lobes. Testing of visual fields will help screen for lesions in the optic pathways and occipital lobes. Screening tests of motor function such as pronator drift, deep tendon reflexes, gait, and coordination may suggest lesions in motor (frontal) cortex, and cortical sensory testing (e.g., double simultaneous stimulation) may detect lesions in the parietal cortex.

LABORATORY STUDIES Routine blood studies are indicated to identify the more common metabolic causes of seizures, such as abnormalities in electrolytes, glucose, calcium, or magnesium, and hepatic or renal disease. A screen for toxins in blood and urine should also be obtained from all patients in appropriate risk groups, especially when no clear precipitating factor has been identified. A lumbar puncture is indicated if there is any suspicion of meningitis or encephalitis and is mandatory in all patients infected with HIV, even in the absence of symptoms or signs suggesting infection.

Electroencephalography All patients who have a possible seizure disorder should be evaluated with an EEG as soon as possible. The EEG measures electrical activity of the brain by recording from electrodes placed on the scalp. The potential difference between pairs of electrodes is amplified and displayed on a computer monitor, oscilloscope, or paper. The characteristics of the normal EEG depend on the patient’s age and level of arousal. The recorded activity represents the postsynaptic potentials of vertically oriented pyramidal cells in the cerebral cortex and is characterized by its frequency. In normal awake adults lying quietly with the eyes closed, an 8- to 13-Hz alpha rhythm is seen posteriorly in the EEG, intermixed with a variable amount of generalized faster beta activity (>13 Hz), and it is attenuated when the eyes are opened (Fig. 348-3). During drowsiness, the alpha rhythm is also attenuated; with light sleep, slower activity in the theta (4 to 7 Hz) and delta (<4 Hz) ranges becomes more apparent.

The EEG is best recorded from several different electrode arrangements (montages) in turn, and activating procedures are usually performed in an attempt to provoke abnormalities. Such procedures com-
monly include hyperventilation (for 3 or 4 min), photic stimulation, sleep, and sleep deprivation on the night prior to the recording.

In the evaluation of a patient with suspected epilepsy, the presence of electrographic seizure activity during the clinically evident event, i.e., of abnormal, repetitive, rhythmic activity having an abrupt onset and termination, clearly establishes the diagnosis. The absence of electrographic seizure activity does not exclude a seizure disorder because in such circumstances epileptiform activity is not specific for epilepsy, but it has a much greater prevalence in patients with epilepsy than in normal individuals. However, even in an individual who is known to have epilepsy, the initial routine interictal EEG may be normal up to 60% of the time. Thus, the EEG cannot establish the diagnosis of epilepsy in many cases.

The EEG is also used for classifying seizure disorders and aiding in the selection of anticonvulsant medications. For example, episodic generalized spike-wave activity is usually seen in patients with typical absence epilepsy and may be seen with other generalized epilepsy syndromes. Focal interictal epileptiform discharges would support the diagnosis of a partial seizure disorder such as temporal lobe epilepsy or frontal lobe seizures, depending on the location of the discharges.

The routine scalp-recorded EEG may also be used to assess the prognosis of seizure disorders; in general, a normal EEG implies a better prognosis, whereas an abnormal background or sharp waves. The presence of epileptiform activity suggests a poor outlook. Unfortunately, the EEG has not proved to be useful in predicting which patients with predisposing conditions, such as head injury or brain tumor, will go on to develop epilepsy, because in such circumstances epileptiform activity is commonly encountered regardless of whether seizures occur.

**Brain Imaging** Almost all patients with new-onset seizures should have a brain imaging study to determine whether there is an underlying structural abnormality that is responsible. The only potential exception to this rule is children who have an unambiguous history and examination suggestive of a benign, generalized seizure disorder such as absence epilepsy. MRI has been shown to be superior to computed tomography (CT) for the detection of cerebral lesions associated with epilepsy. In some cases MRI will identify lesions such as tumors, vascular malformations, or other pathologies that need immediate therapy. The use of newer MRI methods, such as fluid-attenuated inversion recovery (FLAIR), has increased the sensitivity for detection of abnormalities.

FIGURE 348-2  Evaluation of the adult patient with a seizure. CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; EEG, electroencephalogram; CNS, central nervous system.
of cortical architecture, including hippocampal atrophy associated with mesial temporal sclerosis, and abnormalities of cortical neuronal migration. In such cases the findings may not lead to immediate therapy, but they do provide an explanation for the patient’s seizures and point to the need for chronic anticonvulsant therapy or possible surgical resection.

In the patient with a suspected CNS infection or mass lesion, CT scanning should be performed emergently when MRI is not immediately available. Otherwise, it is usually appropriate to obtain an MRI study within a few days of the initial evaluation. Functional imaging procedures such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are also used to evaluate certain patients with medically refractory seizures (discussed below).

**Differential Diagnosis of Seizures**

Disorders that may mimic seizures are listed in Table 348-6. In most cases seizures can be distinguished from other conditions by meticulous attention to the history and relevant laboratory studies. On occasion, additional studies, such as video-EEG monitoring, sleep studies, tilt table analysis, or cardiac electrophysiology, may be required to reach a correct diagnosis. Two of the more common nonepileptic syndromes in the differential diagnosis are detailed below.

**Syncope** (See also Chap. 20) The diagnostic dilemma encountered most frequently is the distinction between a generalized seizure and syncope. Observations by the patient and bystanders that can help discriminate between the two are listed in Table 348-7. Characteristics of a seizure include the presence of an aura, cyanosis, unconsciousness, motor manifestations lasting >30 s, postictal disorientation, muscle soreness, and sleepiness. In contrast, a syncope episode is more likely if the event was provoked by acute pain or anxiety or occurred immediately after arising from the lying or sitting position. Patients with syncope often describe a stereotyped transition from consciousness to unconsciousness that includes tiredness, sweating, nausea, and tunneling of vision, and they experience a relatively brief loss of consciousness. Headache or incontinence usually suggests a seizure but may on occasion also occur with syncope. A brief period (i.e., 1 to 10 s) of convulsive motor activity is frequently seen immediately at the onset of a syncopal episode, especially if the patient remains in an upright posture after fainting (e.g., in a dentist’s chair) and therefore has a sustained decrease in cerebral perfusion. Rarely, a syncope episode can induce a full tonic-clonic seizure. In such cases the evaluation must focus on both the cause of the syncopal event as well as the possibility that the patient has a propensity for recurrent seizures.

**Psychogenic Seizures** Psychogenic seizures are nonepileptic behaviors that resemble seizures. They are often part of a conversion reaction precipitated by underlying psychological distress. Certain behaviors, such as side-to-side turning of the head, asymmetric and large-amplitude shaking movements of the limbs, twitching of all four extremities without loss of consciousness, and pelvic thrusting are more commonly associated with psychogenic rather than epileptic seizures. Psychogenic seizures often last longer than epileptic seizures and may wax and wane over minutes to hours. However, the distinction is sometimes difficult on clinical grounds alone, and there are many examples of diagnostic errors made by experienced epileptologists. This is especially true for psychogenic seizures that resemble complex partial seizures, since the behavioral manifestations of complex partial seizures (especially of frontal lobe origin) can be extremely unusual, and in both cases the routine surface EEG may be normal. Video-EEG monitoring is often useful when historic features are nondiagnostic. Generalized tonic-clonic seizures always produce marked EEG abnormalities during and after the seizure. For suspected complex partial seizures of temporal lobe origin, the use of additional electrodes beyond the standard scalp locations (e.g., sphenoidal electrodes) may be required to localize a seizure focus. Measurement of serum prolactin levels may also help to discriminate between organic and psychogenic seizures, since most generalized seizures and many complex partial

**Table 348-6 Differential Diagnosis of Seizures**

<table>
<thead>
<tr>
<th>Syncope</th>
<th>Basilar artery TIAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasovagal syncope</td>
<td>Sleep disorders</td>
</tr>
<tr>
<td>Cardiac arrhythmia</td>
<td>Narcolepsy/cataplexy</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>Benign sleep myoclonus</td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>Movement disorders</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>Tics</td>
</tr>
<tr>
<td>Psychological disorders</td>
<td>Nonepileptic myoclonus</td>
</tr>
<tr>
<td>Psychogenic seizures</td>
<td>Paroxysmal choreoathesism</td>
</tr>
<tr>
<td>Hyperventilation</td>
<td>Special considerations in children</td>
</tr>
<tr>
<td>Panic attack</td>
<td>Breath-holding spells</td>
</tr>
<tr>
<td>Metabolic disturbances</td>
<td>Migraine with recurrent abdominal pain and cyclic vomiting</td>
</tr>
<tr>
<td>Alcoholic blackouts</td>
<td>Benign paroxysmal vertigo</td>
</tr>
<tr>
<td>Delirium tremens</td>
<td>Apnea</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>Night terrors</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Sleepwalking</td>
</tr>
<tr>
<td>Psychoactive drugs (e.g., hallucinogens)</td>
<td></td>
</tr>
<tr>
<td>Migraine</td>
<td>Confusional migraine</td>
</tr>
<tr>
<td>Confusional migraine</td>
<td>Basilar migraine</td>
</tr>
</tbody>
</table>

**Figure 348-3**

A. A normal EEG showing a posteriorly situated 9-Hz alpha rhythm that attenuates with eye opening. B. Onset of a tonic seizure showing generalized repetitive sharp activity with synchronous onset over both hemispheres. C. Burst of repetitive spikes in the right temporal region during a clinical spell suggestive of a complex partial seizure. D. Generalized 3-Hz spike-wave activity occurring synchronously over both hemispheres during an absence seizure. Horizontal calibration: 1 s; vertical calibration: 200 μV in A and C, 400 μV in B, and 750 μV in D. Electrode placements are indicated at the left of each panel in accord with the international 10-20 system. A; earlobe; C; central; F, frontal; Fp, frontal polar; P, parietal; T, temporal; O, occipital. Right-sided placements are indicated by even numbers, left-sided placements by odd numbers, and midline placements by Z. [From MJ Aminoff (ed): Electrodiagnosis in Clinical Neurology, 4th ed. New York, Churchill Livingstone, 1999.]
seizures are accompanied by rises in serum prolactin (during the immediate 30-min postictal period), whereas psychogenic seizures are not. The diagnosis of psychogenic seizures does not exclude a concurrent diagnosis of epilepsy, since the two often coexist.

**TREATMENT**

Therapy for a patient with a seizure disorder is almost always multimodal and includes treatment of underlying conditions that cause or contribute to the seizures, avoidance of precipitating factors, suppression of recurrent seizures by prophylactic therapy with antiepileptic medications or surgery, and addressing a variety of psychological and social issues. Treatment plans must be individualized, given the many different types and causes of seizures as well as the differences in efficacy and toxicity of antiepileptic medications for each patient. In almost all cases a neurologist with experience in the treatment of epilepsy should design and oversee implementation of the treatment strategy. Furthermore, patients with refractory epilepsy or those who require polypharmacy with antiepileptic drugs should remain under the regular care of a neurologist.

**TREATMENT OF UNDERLYING CONDITIONS** If the sole cause of a seizure is a metabolic disturbance such as an abnormality of serum electrolytes or glucose, then treatment is aimed at reversing the metabolic problem and preventing its recurrence. Therapy with antiepileptic drugs is usually unnecessary unless the metabolic disorder cannot be corrected promptly and the patient is at risk of having further seizures. If the apparent cause of a seizure was a medication (e.g., theophylline) or illicit drug use (e.g., cocaine), then appropriate therapy is avoidance of the drug; there is usually no need for antiepileptic medications unless subsequent seizures occur in the absence of these precipitants.

Seizures caused by a structural CNS lesion such as a brain tumor, vascular malformation, or brain abscess may not recur after appropriate treatment of the underlying lesion. However, despite removal of the structural lesion, there is a risk that the seizure focus will remain in the surrounding tissue or develop de novo as a result of gliosis and other processes induced by surgery, radiation, or other therapies. Most patients are therefore maintained on an antiepileptic medication for at least 1 year, and an attempt is made to withdraw medications only if the patient has been completely seizure-free. If seizures are refractory to medication, the patient may benefit from surgical removal of the epileptic brain region (see below).

**AVOIDANCE OF PRECIPITATING FACTORS** Unfortunately, little is known about the specific factors that determine precisely when a seizure will occur in a patient with epilepsy. Some patients can identify particular situations that appear to lower their seizure threshold; these situations should be avoided. For example, a patient who has seizures in the setting of sleep deprivation should obviously be advised to maintain a normal sleep schedule. Many patients note an association between alcohol intake and seizures, and they should be encouraged to modify their drinking habits accordingly. There are also relatively rare cases of patients with seizures that are induced by highly specific stimuli such as a video game monitor, music, or an individual’s voice (“reflex epilepsy”). If there is an association between stress and seizures, stress reduction techniques such as physical exercise, meditation, or counseling may be helpful.

**Antiepileptic Drug Therapy** Antiepileptic drug therapy is the mainstay of treatment for most patients with epilepsy. The overall goal is to completely prevent seizures without causing any untoward side effects, preferably with a single medication and a dosing schedule that is easy for the patient to follow. Seizure classification is an important element in designing the treatment plan, since some antiepileptic drugs have different activities against various seizure types. However, there is considerable overlap between many antiepileptic drugs, such that the choice of therapy is often determined more by specific needs of the patient, especially the patient’s assessment of side effects.

**WHEN TO INITIATE ANTIETEPILEPTIC DRUG THERAPY** Antiepileptic drug therapy should be started in any patient with recurrent seizures of unknown etiology or a known cause that cannot be reversed. Whether to initiate therapy in a patient with a single seizure is controversial. Patients with a single seizure due to an identified lesion such as a CNS tumor, infection, or trauma, in which there is strong evidence that the lesion is epileptogenic, should be treated. The risk of seizure recurrence in a patient with an apparently unprovoked or idiopathic seizure is uncertain, with estimates ranging from 31 to 71% in the first 12 months after the initial seizure. This uncertainty arises from differences in the underlying seizure types and etiologies in various published epidemiologic studies. Generally accepted risk factors associated with recurrent seizures include the following: (1) an abnormal neurologic examination, (2) seizures presenting as status epilepticus, (3) postictal Todd’s paralysis, (4) a strong family history of seizures, or (5) an abnormal EEG. Most patients with one or more of these risk factors should be treated. Issues such as employment or driving may influence the decision whether or not to start medications as well. For example, a patient with a single, idiopathic seizure whose job depends on driving may prefer taking antiepileptic drugs rather than risk a seizure recurrence and the potential loss of driving privileges.

**SELECTION OF ANTIETEPILEPTIC DRUGS** Antiepileptic drugs available in the United States are shown in Table 348-8, and the main pharmacologic characteristics of commonly used drugs are listed in Table 348-9. Older medications such as phenytoin, valproic acid, carbamazepine, and ethosuximide are generally used as first-line therapy for most seizure disorders since, overall, they are as effective as recently marketed drugs and significantly less expensive. Most of the new drugs that have become available in the past decade are used as add-on or alternative therapy.

In addition to efficacy, factors influencing the choice of an initial medication include the convenience of dosing (e.g., once daily versus three or four times daily) and potential side effects. Almost all of the commonly used antiepileptic drugs can cause similar, dose-related side effects such as sedation, ataxia, and diplopia. Close follow-up is required to ensure these are promptly recognized and reversed. Most of the drugs can also cause idiosyncratic toxicity such as rash, bone marrow suppression, or hepatotoxicity. Although rare, these side effects should be considered during drug selection, and patients require laboratory tests (e.g., complete blood count and liver function tests) prior to the institution of a drug (to establish baseline values) and during initial dosing and titration of the agent.

### TABLE 348-7 Features That Distinguish Generalized Tonic-Clonic Seizure from Syncope

<table>
<thead>
<tr>
<th>Features</th>
<th>Seizure</th>
<th>Syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate precipitating factors</td>
<td>Usually none</td>
<td>Emotional stress, Valsalva, orthostatic hypotension, cardiac etiologies</td>
</tr>
<tr>
<td>Premonitory symptoms</td>
<td>None or aura (e.g., odd odor)</td>
<td>Tiredness, nausea, diaphoresis, tunneling of vision</td>
</tr>
<tr>
<td>Posture at onset</td>
<td>Variable</td>
<td>Usually erect</td>
</tr>
<tr>
<td>Transition to unconsiousness</td>
<td>Often immediate</td>
<td>Gradual over seconds*</td>
</tr>
<tr>
<td>Duration of unconsciousness</td>
<td>Minutes</td>
<td>Seconds</td>
</tr>
<tr>
<td>Duration of tonic or clonic movements</td>
<td>30–60 s</td>
<td>Never more than 15 s</td>
</tr>
<tr>
<td>Facial appearance during event</td>
<td>Cyanosis, frothing at mouth</td>
<td>Pallor</td>
</tr>
<tr>
<td>Disorientation and sleepiness</td>
<td>Many minutes to hours</td>
<td>&lt;5 min</td>
</tr>
<tr>
<td>Aching of muscles after event</td>
<td>Often</td>
<td>Sometimes</td>
</tr>
<tr>
<td>Biting of tongue</td>
<td>Sometimes</td>
<td>Rarely</td>
</tr>
<tr>
<td>Incontinence</td>
<td>Sometimes</td>
<td>Sometimes</td>
</tr>
<tr>
<td>Headache</td>
<td>Sometimes</td>
<td>Rarely</td>
</tr>
</tbody>
</table>

* May be sudden with certain cardiac arrhythmias.
Antiepileptic Drug Selection for Partial Seizures

Carbamazepine, phenytoin, or lamotrigine is currently the initial drug of choice for the treatment of partial seizures, including those that secondarily generalize. Overall they have very similar efficacy, but differences in pharmacokinetics and toxicity are the main determinants for use in a given patient. Phenytoin has a relatively long half-life and offers the advantage of once or twice daily dosing compared to two or three times daily dosing for carbamazepine (although a more expensive, extended-release form of carbamazepine is now available) and lamotrigine. An advantage of carbamazepine is that its metabolism follows first-order pharmacokinetics, and the relationship between drug dose, serum levels, and toxicity is linear. By contrast, phenytoin shows properties of saturation kinetics, such that small increases in phenytoin doses above a standard maintenance dose can precipitate marked side effects. This is one of the main causes of acute phenytoin toxicity. Long-term use of phenytoin is associated with untoward cosmetic effects (e.g., hirsutism, coarsening of facial features, and gingival hypertrophy), and effects on bone metabolism, so it is often avoided in young patients who are likely to require the drug for many years. Carbamazepine can cause leukopenia, aplastic anemia, or hepatotoxicity and would therefore be contraindicated in patients with predispositions to these problems. A major concern with lamotrigine is the occurrence of skin rash during the initiation of therapy. This can be extremely severe and lead to Stevens-Johnson syndrome if unrecognized and if the medication is not discontinued immediately. This risk can be reduced by slow introduction and titration. Lamotrigine must be started slowly when used as add-on therapy with valproic acid, since valproic acid can inhibit its metabolism, thereby substantially prolonging its half-life.

Valproic acid is an effective alternative for some patients with partial seizures, especially when the seizures secondarily generalize. Gastrointestinal side effects are fewer when using the valproate semisodium formulation (Depakote). Valproic acid also rarely causes reversible bone marrow suppression and hepatotoxicity, and laboratory testing is required to monitor toxicity. This drug should generally be avoided in patients with preexisting bone marrow or liver disease. Irreversible, fatal hepatic failure appearing as an idiosyncratic rather than dose-related side effect is a relatively rare complication; its risk is highest in children <2 years old, especially those taking other antiepileptic drugs or with inborn errors of metabolism.

Topiramate, tiagabine, levetiracetam, zonisamide, gabapentin, and oxcarbazepine are additional drugs currently used for the treatment of partial seizures with or without secondary generalization. Until recently, phenobarbital and other barbiturate compounds were commonly used as first-line therapy for many forms of epilepsy. However, the barbiturates frequently cause sedation in adults, hyperactivity in children, and other more subtle cognitive changes; thus, their use should be limited to situations in which no other suitable treatment alternatives exist.

Antiepileptic Drug Selection for Generalized Seizures

Valproic acid is currently considered the best initial choice for the treatment of primarily generalized, tonic-clonic seizures. Lamotrigine, followed by carbamazepine and phenytoin, are suitable alternatives. Valproic acid is also particularly effective in absence, myoclonic, and tonic seizures and is therefore the drug of choice in patients with generalized epilepsy syndromes having mixed seizure types. Importantly, both carbamazepine and phenytoin can worsen certain types of generalized seizures, including absence, myoclonic, tonic, and atonic seizures. Ethosuximide is a particularly effective drug for the treatment of unaccompanied absence seizures, but it is not useful for tonic-clonic or partial seizures. Ethosuximide rarely causes bone marrow suppression, so that periodic monitoring of blood cell counts is required. Although approved for use in partial seizure disorders, lamotrigine appears to be effective in epilepsy syndromes with mixed, generalized seizure types such as JME and Lennox-Gastaut syndrome. Topiramate, zonisamide, and felbamate may have similar broad efficacy. Clinical trials are underway to establish the usefulness of levetiracetam in generalized seizure syndromes.

**INITIATION AND MONITORING OF THERAPY**

Because the response to any antiepileptic drug is unpredictable, patients should be carefully educated about the approach to therapy. The goal is to prevent seizures and minimize the side effects of therapy; determination of the optimal dose is often a matter of trial and error. This process may take months or longer if the baseline seizure frequency is low. Most anticonvulsant drugs need to be introduced relatively slowly to minimize side effects, and patients should expect that minor side effects such as mild sedation, slight changes in cognition, or imbalance will typically resolve within a few days. Starting doses are usually the lowest value listed under the dosage column in Table 348-9. Subsequent increases should be made only after achieving a steady state with the previous dose (i.e., after an interval of five or more half-lives).

Monitoring of serum antiepileptic drug levels can be very useful for establishing the initial dosing schedule. However, the published therapeutic ranges of serum drug concentrations are only an approximate guide for determining the proper dose for a given patient. The key determinants are the clinical measures of seizure frequency and presence of side effects, not the laboratory values. Conventional assays of serum drug levels measure the total drug (i.e., both free and protein-bound). However, it is the concentration of free drug that reflects extracellular levels in the brain and correlates best with efficacy. Thus, patients with decreased levels of serum proteins (e.g., decreased serum albumin due to impaired liver or renal function) may have an increased ratio of free to bound drug, yet the concentration of free drug may be adequate for seizure control. These patients may have a “subtherapeutic” drug level, but the dose should be changed only if seizures remain uncontrolled, not just to achieve a “therapeutic” level. It is also useful to monitor free drug levels in such patients. In practice, other than during the initiation or modification of therapy, monitoring of antiepileptic drug levels is most useful for documenting compliance.

If seizures continue despite gradual increases to the maximum tolerated dose and documented compliance, then it becomes necessary to switch to another antiepileptic drug. This is usually done by maintaining the patient on the first drug while a second drug is added. The dose of the second drug should be adjusted to decrease seizure frequency without causing toxicity. Once this is achieved, the first drug can be gradually withdrawn (usually over weeks unless there is significant toxicity). The dose of the second drug is then further optimized based on seizure response and side effects. Monotherapy should be the goal whenever possible.

**WHEN TO DISCONTINUE THERAPY**

Overall, about 70% of children and 60% of adults who have their seizures completely controlled with antiepileptic drugs or with inborn errors of metabolism would be considered by the initiation or modification of therapy, monitoring of antiepileptic drug levels is most useful for documenting compliance.

### Table 348-8 Selection of Antiepileptic Drugs

<table>
<thead>
<tr>
<th>Primary Generalized Tonic-Clonic</th>
<th>Partial&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Absence</th>
<th>Atypical Absence, Myoclonic, Atonic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-Line</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Carbamazepine</td>
<td>Valproic acid Ethosuximide</td>
<td>Valproic acid</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Phenytoin</td>
<td>Lamotrigine Clonazepam</td>
<td>Lamotrigine</td>
</tr>
<tr>
<td><strong>Alternatives</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Topiramate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Levetiracetam&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Lamotrigine</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Tiagabine&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Zonisamide&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Topiramate&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Felbamate</td>
<td>Zonisamide&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Gabapentin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Clonazepam</td>
</tr>
<tr>
<td>Primidone</td>
<td>Phenobarbital</td>
<td>Primidone</td>
<td>Felbamate</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td></td>
<td>Phenobarbital</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Includes simple partial, complex partial, and secondarily generalized seizures.

<sup>b</sup> As adjunctive therapy.
## TABLE 348-9 Dosage and Adverse Effects of Commonly Used Antiepileptic Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Principal Uses</th>
<th>Typical Dose; Dose Interval</th>
<th>Half-Life</th>
<th>Therapeutic Range</th>
<th>Adverse Effects</th>
<th>Drug Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin</td>
<td>Dilantin</td>
<td>Tonic-clonic (grand mal) Focal-onset</td>
<td>300–400 mg/d (3–6 mg/kg, adult; 4–8 mg/kg, child); qd-bid</td>
<td>24 h (wide variation, dose-dependent)</td>
<td>10–20 μg/mL</td>
<td>Dizziness, Diplopia, Ataxia, Incoordination, Confusion</td>
<td>Gum hyperplasia, Lymphadenopathy, Hirsutism, Osteomalacia, Facial coarsening, Skin rash</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Tegretol, Carbatrol</td>
<td>Tonic-clonic Focal-onset</td>
<td>600–1800 mg/d (15–35 mg/kg, child); bid-qid</td>
<td>10–17 h</td>
<td>6–12 μg/mL</td>
<td>Ataxia, Dizziness, Diplopia, Vertigo</td>
<td>Aplastic anemia, Leukopenia, Gastrointestinal irritation, Hepatotoxicity, Hyponatremia</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Depakene, Depakote</td>
<td>Absence, Atypical absence, Myoclonic Focal-onset</td>
<td>750–2000 mg/d (20–60 mg/kg); bid-qid</td>
<td>15 h</td>
<td>50–150 μg/mL</td>
<td>Ataxia, Sedation, Tremor</td>
<td>Hepatotoxicity, Thrombocytopenia, Gastrointestinal irritation, Weight gain, Transient alopecia, Hyperammonemia</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Lamictal</td>
<td>Focal-onset, Tonic-clonic Atypical absence, Myoclonic Lennox-Gastaut syndrome</td>
<td>150–500 mg/d; bid</td>
<td>25 h, 14 h (with enzyme-inducers)</td>
<td>59 h (with valproic acid)</td>
<td>Not established, Dizziness, Diplopia, Sedation, Ataxia, Headache</td>
<td>Skin rash, Stevens-Johnson syndrome,</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td>Zarontin</td>
<td>Absence (petit mal)</td>
<td>750–1250 mg/d (20–40 mg/kg); qd-bid</td>
<td>60 h, adult 30 h, child</td>
<td>40–100 μg/mL</td>
<td>Ataxia, Lethargy, Headache</td>
<td>Gastrointestinal irritation, Skin rash, Bone marrow suppression</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>Neurontin</td>
<td>Focal-onset</td>
<td>900–2400 mg/d; tid-qid</td>
<td>5–9 h</td>
<td>Not established</td>
<td>Sedation, Dizziness, Ataxia, Fatigue</td>
<td>Gastrointestinal irritation, Weight gain, Edema</td>
</tr>
<tr>
<td>Topiramate</td>
<td>Topamax</td>
<td>Focal-onset, Tonic-clonic Lennox-Gastaut syndrome</td>
<td>200–400 mg/d; bid</td>
<td>20–30 h</td>
<td>Not established</td>
<td>Psychomotor slowing, Sedation, Speech or language problems, Fatigue, Paresthesias</td>
<td>Renal stones (avoid use with other carbonic anhydrase inhibitors), Weight loss</td>
</tr>
<tr>
<td>Tiagabine</td>
<td>Gabitril</td>
<td>Focal-onset</td>
<td>32–56 mg/d; bid-qid</td>
<td>7–9 h</td>
<td>Not established</td>
<td>Confusion, Sedation, Depression, Dizziness, Speech or language problems, Paresthesias, Psychosis</td>
<td>Gastrointestinal irritation</td>
</tr>
</tbody>
</table>

(continued)
leptic drugs can eventually discontinue therapy. The following patient profile yields the greatest chance of remaining seizure-free after drug withdrawal: (1) complete medical control of seizures for 1 to 5 years; (2) single seizure type, either partial or generalized; (3) normal neurologic examination, including intelligence; and (4) normal EEG. The appropriate seizure-free interval is unknown and undoubtedly varies for different forms of epilepsy. However, it seems reasonable to attempt withdrawal of therapy after 2 years in a patient who meets all of the above criteria, is motivated to discontinue the medication, and clearly understands the potential risks and benefits. In most cases it is preferable to reduce the dose of the drug gradually over 2 to 3 months. Most recurrences occur in the first 3 months after discontinuing therapy, and patients should be advised to avoid potentially dangerous situations such as driving or swimming during this period.

**TREATMENT OF REFRACTORY EPILEPSY** Approximately one-third of patients with epilepsy do not respond to treatment with a single antiepileptic drug, and it becomes necessary to try a combination of drugs to control seizures. Patients who have focal epilepsy related to an underlying structural lesion or those with multiple seizure types and developmental delay are particularly likely to require multiple drugs. There are currently no clear guidelines for rational polypharmacy, although in theory a combination of drugs with different mechanisms of action may be most useful. In most cases the initial combination therapy combines first-line drugs, i.e., carbamazepine, phenytoin, valproic acid, and lamotrigine. If these drugs are unsuccessful, then the addition of a newer drug such as topiramate or levetiracetam is indicated. Patients with myoclonic seizures resistant to valproic acid may benefit from the addition of phenobarbital, and those with absence seizures may respond to a combination of valproic acid and ethosuximide. The same principles concerning the monitoring of therapeutic response, toxicity, and serum levels for monotherapy apply to polypharmacy, and potential drug interactions need to be recognized. If there is no improvement, a third drug can be added while the first two are maintained. If there is a response, the less effective or less well-tolerated of the first two drugs should be gradually withdrawn.

**Surgical Treatment of Refractory Epilepsy** Approximately 20% of patients with epilepsy are resistant to medical therapy despite efforts to find an effective combination of antiepileptic drugs. For some, surgery can be extremely effective in substantially reducing seizure frequency and even providing complete seizure control. Understanding the potential value of surgery is especially important when, at the time of diagnosis, a patient has an epilepsy syndrome that is considered likely to be drug-resistant. Rather than submitting the patient to years of unsuccessful medical therapy and the psychosocial trauma and increased mortality involved.
associated with ongoing seizures, the patient should have an efficient but relatively brief attempt at medical therapy and then be referred for surgical evaluation.

The most common surgical procedure for patients with temporal lobe epilepsy involves resection of the anteromedial temporal lobe (temporal lobectomy) or a more limited removal of the underlying hippocampus and amygdala (amygdalohippocampectomy). Focal seizures arising from extratemporal regions may be abolished by a focal neocortical resection with precise removal of an identified lesion (lesionectomy). When the cortical region cannot be removed, multiple subpial transection, which disrupts intracortical connections, is sometimes used to prevent seizure spread. Hemispherectomy or multilobar resection is useful for some patients with severe seizures due to hemispheric abnormalities such as hemimegalencephaly or other dysplastic abnormalities, and corpus callosotomy has been shown to be effective for disabling tonic or atomic seizures, usually when they are part of a mixed-seizure syndrome (e.g., Lennox-Gastaut syndrome).

Presurgical evaluation is designed to identify the functional and structural basis of the patient’s seizure disorder. Inpatient video-EEG monitoring is used to define the anatomic location of the seizure focus and to correlate the abnormal electrophysiologic activity with behavioral manifestations of the seizure. Routine scalp or scalp-sphenoidal recordings are usually sufficient for localization, and advances in neuroimaging have made the use of invasive electrophysiologic monitoring such as implanted depth electrodes or subdural electrodes less common. A high-resolution MRI scan is routinely used to identify structural lesions. Functional imaging studies such as SPECT and PET are adjunctive tests that may help verify the localization of an apparent epileptogenic region. Once the presumed location of the seizure onset is identified, additional studies, including neuropsychological testing and the intracarotid amobarital test (Wada test) may be used to assess language and memory localization and to determine the possible functional consequences of surgical removal of the epileptogenic region. In some cases, the exact extent of the resection to be undertaken is determined by performing cortical mapping at the time of the surgical procedure, allowing for a tailored resection. This involves electrocorticographic recordings made with electrodes on the surface of the brain to identify the extent of epileptiform disturbances. If the region to be resected is within or near brain regions suspected of having sensorimotor or language function, electrical cortical stimulation mapping is performed in the awake patient to determine the function of cortical regions in question in order to avoid resection of so-called eloquent cortex, and thereby minimize postsurgical deficits.

Advances in presurgical evaluation and microsurgical techniques have led to a steady increase in the success of epilepsy surgery. Clinically significant complications of surgery are <5%, and the use of functional mapping procedures has markedly reduced the neurologic sequelae due to removal or sectioning of brain tissue. For example, about 70% of patients treated with temporal lobectomy will become seizure-free, and another 15 to 25% will have at least a 90% reduction in seizure frequency. Marked improvement is also usually seen in patients treated with hemispherectomy for catastrophic seizure disorders due to large hemispheric abnormalities. Postoperatively, patients generally need to remain on antiepileptic drug therapy, but the marked reduction of seizures following surgery can have a very beneficial effect on quality of life.

Vagus Nerve Stimulation (VNS) VNS is a new treatment option for patients with medically refractory epilepsy who are not candidates for resective brain surgery. The procedure involves placement of a bipolar electrode on the midcervical portion of the left vagus nerve. The electrode is connected to a small, subcutaneous generator located in the infraclavicular region, and the generator is programmed to deliver intermittent electrical pulses to the vagus nerve. Unlike medications, there may be a delay between the initiation of VNS and the appearance of antiseizure effects. The precise mechanism of action of VNS is unknown, although experimental studies have shown that stimulation of vagal nuclei leads to widespread activation of cortical and subcortical pathways and an associated increased seizure threshold. In practice, the efficacy of VNS appears to be no greater than recently introduced anticonvulsant medications. Adverse effects of the surgery are rare, and stimulation-induced side effects, including transient hoarseness, cough, and dyspnea, are usually mild and well tolerated.

**Status Epilepticus** Status epilepticus refers to continuous seizures or repetitive, discrete seizures with impaired consciousness in the interictal period. The duration of seizure activity sufficient to meet the definition of status epilepticus has traditionally been specified as 15 to 30 min. However, a more practical definition is to consider status epilepticus as a situation in which the duration of seizures prompts the acute use of anticonvulsant therapy, typically when seizures last beyond 5 min.

Status epilepticus is an emergency and must be treated immediately, since cardiorespiratory dysfunction, hyperthermia, and metabolic derangements can develop as a consequence of prolonged seizures, and these can lead to irreversible neuronal injury. Furthermore, CNS injury can occur even when the patient is paralyzed with neuromuscular blockade but continues to have electrographic seizures. The most common causes of status epilepticus are anticonvulsant withdrawal or noncompliance, metabolic disturbances, drug toxicity, CNS infection, CNS tumors, refractory epilepsy, and head trauma.

Generalized status epilepticus is obvious when the patient is having overt convulsions. However, after 30 to 45 min of uninterrupted seizures, the signs may become increasingly subtle. Patients may have mild clonic movements of only the fingers, or fine, rapid movements of the eyes. There may be paroxysmal episodes of tachycardia, hypertension, and pupillary dilation. In such cases, the EEG may be the only method of establishing the diagnosis. Thus, if the patient stops having overt seizures, yet remains comatose, an EEG should be performed to rule out ongoing status epilepticus.

The first step in the management of a patient in status epilepticus is to attend to any acute cardiorespiratory problems or hyperthermia, perform a brief medical and neurologic examination, establish venous access, and send samples for laboratory studies to identify metabolic abnormalities. Anticonvulsant therapy should then begin without delay; a treatment approach is shown in Fig. 348-4.

**Beyond Seizures: Other Management Issues**

**Interictal Behavior** The adverse effects of epilepsy often go beyond the occurrence of clinical seizures, and the extent of these effects depends largely upon the etiology of the seizure disorder, the degree to which the seizures are controlled, and the presence of side effects from antiepileptic therapy. Many patients with epilepsy are completely normal between seizures and able to live highly successful and productive lives. In contrast, patients with seizures secondary to developmental abnormalities or acquired brain injury may have impaired cognitive function and other neurologic deficits. Frequent interictal EEG abnormalities have been shown to be associated with subtle dysfunction of memory and attention. Patients with many seizures, especially those emanating from the temporal lobe, often note an impairment of short-term memory that may progress over time.

Patients with epilepsy are at risk of developing a variety of psychiatric problems including depression, anxiety, and psychosis. This risk varies considerably depending on many factors, including the etiology, frequency, and severity of seizures and the patient’s age and previous history. Depression occurs in ~20% of patients, and the incidence of suicide is higher in epileptic patients than in the general population. Depression should be treated through counseling or medication. The selective serotonin reuptake inhibitors typically have no effect on seizures, while the tricyclic antidepressants may lower the seizure threshold. Anxiety can appear as a manifestation of a seizure, and anxious or psychiatric behavior can sometimes be observed as part of a postictal delirium. Postictal psychosis is a rare phenomenon that typically occurs after a period of increased seizure frequency. There
is usually a brief lucid interval lasting up to a week, followed by days to weeks of agitated, psychotic behavior. The psychosis will usually resolve spontaneously but may require treatment with antipsychotic or anxiolytic medications.

There is ongoing controversy as to whether some patients with epilepsy (especially temporal lobe epilepsy) have a stereotypical “interictal personality.” The predominant view is that the unusual or abnormal personality traits observed in such patients are, in most cases, not due to epilepsy but result from an underlying structural brain lesion, the effects of antiepileptic drugs, or psychosocial factors related to suffering from a chronic disease.

**Mortality of Epilepsy**  
Patients with epilepsy have a risk of death that is roughly two to three times greater than expected in a matched population without epilepsy. Most of the increased mortality is due to the underlying etiology of epilepsy, e.g., tumors or strokes in older adults. However, a significant number of patients die from accidents, status epilepticus, and a syndrome known as *sudden unexpected death in epileptic patients* (SUDEP), which usually affects young people with convulsive seizures and tends to occur at night. The cause of SUDEP is unknown; it may result from brainstem-mediated effects of seizures on cardiac rhythms or pulmonary function.

**Psychosocial Issues**  
There continues to be a cultural stigma about epilepsy, although it is slowly declining in societies with effective health education programs. Many patients with epilepsy harbor fears, such as the fear of becoming mentally retarded or dying during a seizure. These issues need to be carefully addressed by educating the patient about epilepsy and by ensuring that family members, teachers, fellow employees, and other associates are equally well informed. The Epilepsy Foundation of America (1-800-EFA-1000) is a patient advocacy organization and a useful source of educational material.

**Employment and Driving**  
Many patients with epilepsy face difficulty in obtaining or maintaining employment, even when their seizures are well controlled. Federal and state legislation is designed to prevent employers from discriminating against patients with epilepsy, and patients should be encouraged to understand and claim their legal rights. Patients in these circumstances also benefit greatly from the assistance of health providers who act as strong patient advocates.

Loss of driving privileges is one of the most disruptive social consequences of epilepsy. Physicians should be very clear about local regulations concerning driving and epilepsy, since the laws vary considerably among states and countries. In all cases, it is the physician’s responsibility to warn patients of the danger imposed on themselves and others while driving if their seizures are uncontrolled (unless the seizures are not associated with impairment of consciousness or motor control). In general, most states allow patients to drive after a seizure-free interval (on or off medications) between 3 months and 2 years.

**SPECIAL ISSUES RELATED TO WOMEN AND EPILEPSY**

**Catamenial Epilepsy**  
Some women experience a marked increase in seizure frequency around the time of menses. This is thought to reflect either the effects of estrogen and progesterone on neuronal excitability or changes in antiepileptic drug levels due to altered protein binding. Acetazolamide (250 to 500 mg/d) may be effective as adjunctive therapy in some cases when started 7 to 10 days prior to the onset of menses and continued until bleeding stops. Some patients may benefit from increases in antiepileptic drug dosages during this time or from control of the menstrual cycle through the use of oral contraceptives. Natural progestins may be of benefit to a subset of women.

**Pregnancy**  
Most women with epilepsy who become pregnant will have an uncomplicated gestation and deliver a normal baby. However, epilepsy poses some important risks to a pregnancy. Seizure frequency during pregnancy will remain unchanged in ~50% of women, increase in 30%, and decrease in 20%. Changes in seizure frequency are attributed to endocrine effects on the CNS, variations in antiepileptic drug pharmacokinetics (such as acceleration of hepatic drug metabolism or effects on plasma protein binding), and changes in medication compliance. It is useful to see patients at frequent intervals during pregnancy and monitor serum antiepileptic drug levels. Measurement of the unbound drug concentrations may be useful if there is an increase in seizure frequency or worsening of side effects of antiepileptic drugs.

The overall incidence of fetal abnormalities in children born to mothers with epilepsy is 5 to 6%, compared to 2 to 3% in healthy women. Part of the higher incidence is due to teratogenic effects of antiepileptic drugs, and the risk increases with the number of medications used (e.g., 10% risk of malformations with three drugs). A syndrome comprising facial dysmorphism, cleft lip, cleft palate, cardiac defects, digital hypoplasia, and nail dysplasia was originally ascribed to phenytoin therapy, but it is now known to occur with other first-line antiepileptic drugs (i.e., valproic acid and carbamazepine) as well. Also, valproic acid and carbamazepine are associated with a 1 to 2% incidence of neural tube defects compared with a baseline of 0.5 to 1%. Littie is currently known about the safety of newer drugs.

Since the potential harm of uncontrolled seizures on the mother and fetus is considered greater than the teratogenic effects of antiepileptic drugs, it is currently recommended that pregnant women be maintained on effective drug therapy. When possible, it seems prudent to have the patient on monotherapy at the lowest effective dose, especially during the first trimester. Patients should also take folate (1

---

**FIGURE 348-4**  
Pharmacologic treatment of generalized tonic-clonic status epilepticus in adults. IV, intravenous; PE, phenytoin equivalents. The horizontal bars indicate the approximate duration of drug infusions.
to 4 mg/d), since the antifolate effects of anticonvulsants are thought to play a role in the development of neural tube defects, although the benefits of this treatment remain unproven in this setting.

Enzyme-inducing drugs such as phenytoin, phenobarbital, and primidone cause a transient and reversible deficiency of vitamin K—dependent clotting factors in ~50% of newborn infants. Although neonatal hemorrhage is uncommon, the mother should be treated with oral vitamin K (20 mg daily) in the last 2 weeks of pregnancy, and the infant should receive vitamin K (1 mg) at birth.

**Contraception** Special care should be taken when prescribing antiepileptic medications for women who are taking oral contraceptive agents. Drugs such as carbamazepine, phenytoin, phenobarbital, and topiramate can significantly antagonize the effects of oral contraceptives via enzyme induction and other mechanisms. Patients should be advised to consider alternative forms of contraception, or their contraceptive medications should be modified to offset the effects of the antiepileptic medications.

**Breast Feeding** Antiepileptic medications are excreted into breast milk to a variable degree. The ratio of drug concentration in breast milk relative to serum is ~80% for ethosuximide, 40 to 60% for phenobarbital, 40% for carbamazepine, 15% for phenytoin, and 5% for valproic acid. Given the overall benefits of breast feeding and the lack of evidence for long-term harm to the infant by being exposed to antiepileptic drugs, mothers with epilepsy can be encouraged to breast feed. This should be reconsidered, however, if there is any evidence of drug effects on the infant, such as lethargy or poor feeding.

**Acknowledgment**

The editors acknowledge the contributions of Michael J. Aminoff to this chapter in earlier editions of Harrison’s.

**Further Reading**


---

**Cerebrovascular Diseases**

Wade S. Smith, S. Claiborne Johnston, J. Donald Easton

Cerebrovascular diseases include some of the most common and devastating disorders: ischemic stroke, hemorrhagic stroke, and cerebrovascular anomalies such as intracranial aneurysms and arteriovenous malformations (AVMs). They cause ~200,000 deaths each year in the United States and are a major cause of disability. The incidence of cerebrovascular diseases increases with age, and the number of strokes is projected to increase as the elderly population grows, with a doubling in stroke deaths in the United States by 2030. Most cerebrovascular disorders are manifest by the abrupt onset of a focal neurologic deficit, as if the patient was “struck by the hand of God.” A stroke, or cerebrovascular accident, is defined by this abrupt onset of a neurologic deficit that is attributable to a focal vascular cause. Thus, the definition of stroke is clear, and laboratory studies including brain imaging are used to support the diagnosis. The clinical manifestations of stroke are highly variable because of the complex anatomy of the brain and its vasculature. Cerebral ischemia is caused by a reduction in blood flow that lasts longer than several seconds. Neurologic symptoms are manifest within seconds because neurons lack glycogen, so energy failure is rapid. When blood flow is quickly restored, brain tissue can recover fully and the patient’s symptoms are only transient: this is called a transient ischemic attack (TIA). Typically the neurologic signs and symptoms of a TIA last for 5 to 15 min but, by definition, must last <24 h. If the cessation of flow lasts for more than a few minutes, infarction or death of brain tissue results. Stroke has occurred if the neurologic signs and symptoms last for >24 h. A generalized reduction in cerebral blood flow due to systemic hypotension (e.g., cardiac arrhythmia, myocardial infarction, or hemorrhagic shock) usually produces syncope (Chap. 20). If low cerebral blood flow persists for a longer duration, then infarction in the border zones between the major cerebral artery distributions may develop. In more severe instances, global hypoxia-ischemia causes widespread brain injury; the constellation of cognitive sequelae that ensue is called hypoxic-ischemic encephalopathy (Chap. 258). Focal ischemia or infarction, on the other hand, is usually caused by thrombosis of the cerebral vessels themselves or by emboli from a proximal arterial source or the heart. Cerebral hemorrhage produces neurologic symptoms by producing a mass effect on neural structures or from the toxic effects of blood itself.
is the goal of thrombolytic therapy and newer therapies under investigation.

The complex processes that are involved in focal cerebral infarction are summarized in Fig. 349-2. Cellular death occurs via two distinct pathways: (1) a necrotic pathway in which cellular cytoskeletal breakdown is rapid, due principally to energy failure of the cell; and (2) an apoptotic pathway in which cells become programmed to die. Ischemia produces necrosis by starving neurons of glucose which in turn results in failure of mitochondria to produce ATP. Without ATP, membrane ion pumps stop functioning and neurons depolarize, allowing intracellular calcium to rise. Cellular depolarization also causes glutamate release from synaptic terminals; excess extracellular glutamate produces neurotoxicity by agonizing postsynaptic glutamate receptors that increase neuronal calcium influx. Free radicals are produced by membrane lipid degradation and mitochondrial dysfunction. Free radicals cause catalytic destruction of membranes and likely damage other vital functions of cells. Lesser degrees of ischemia, as are seen within the ischemic penumbra, favor apoptotic cellular death causing cells to die days to weeks later. There are no clinically proven strategies that alter these ischemic cascades despite extensive clinical study. It is clear, however, that fever dramatically worsens ischemia, as does hyperglycemia [glucose > 11.1 to 16.7 mmol/L (200 to 300 mg/dL)], so it is reasonable to suppress fever and prevent hyperglycemia as much as possible. Hypothermia and other neuroprotective strategies are subjects of continuing clinical research.

### ISCHEMIC STROKE

**PATHOPHYSIOLOGY OF ISCHEMIC STROKE**

Acute occlusion of an intracranial vessel causes reduction in blood flow to the brain region it supplies. The magnitude of flow reduction is a function of collateral blood flow and this depends on individual vascular anatomy and the site of occlusion. A fall in cerebral blood flow to zero causes death of brain tissue within 4 to 10 min; values <16 to 18 mL/100 g tissue per min cause infarction within an hour; and values <20 mL/100 g tissue per min cause ischemia without infarction unless prolonged for several hours or days. If blood flow is restored prior to a significant amount of cell death, the patient may experience only transient symptoms, i.e., a TIA. Tissue surrounding the core region of infarction is ischemic but reversibly dysfunctional and is referred to as the ischemic penumbra. The penumbra may be imaged by using perfusion-diffusion imaging with MRI (see below and Fig. 349-13). The ischemic penumbra will eventually infarct if no change in flow occurs, and hence saving the ischemic penumbra
**TABLE 349-1  Clinical Management of Acute Stroke**

<table>
<thead>
<tr>
<th>New onset of neurologic deficit: Stroke or TIA?</th>
<th>Differential diagnosis of new focal deficit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure with postictal Todd’s paresis</td>
<td>Stroke or TIA</td>
</tr>
<tr>
<td>Tumor</td>
<td>Migraine</td>
</tr>
<tr>
<td>Metabolic encephalopathy</td>
<td>Fever/infection and old stroke</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>Hypercalcemia</td>
</tr>
<tr>
<td>Hepatic encephalopathy</td>
<td></td>
</tr>
</tbody>
</table>

**Initial assessment and management**

| ABCs, serum glucose                           | Noncontrast head CT                         |
| Hemorrhage                                    | Tumor or other CNS process                  |
| Medical and surgical management               | Treat as indicated                          |
| Normal or hypodense area consistent with acute ischemic stroke | Admit patient to appropriate level of care depending on concomitant medical problems and airway |

**Subsequent hospital management**

| Establish cause of stroke and risk factors     | Plan for secondary prophylaxis (drugs, risk factor modifications) |
| Plan for discharge, including prescriptions for risk factor reduction, including when to institute antihypertensive treatment, and antithrombotic medication prophylaxis | Obtain physical, occupational, and speech therapy consultation and social work as appropriate |
| Provide nutrition                              |                                            |

**Note:** ABCs, airway management, breathing, cardiac status; CNS, central nervous system; CT, computed tomography; TIA, transient ischemic attack.

**MEDICAL SUPPORT** When cerebral infarction occurs, the immediate goal is to optimize cerebral perfusion in the surrounding ischemic penumbra. Attention is also directed toward preventing the common complications of bedridden patients—infecations (pneumonia, urinary tract, and skin) and deep venous thrombosis (DVT) with pulmonary embolism. Many physicians use pneumatic compression stockings to prevent DVT; subcutaneous heparin appears to be safe as well.

Because collateral blood flow within the ischemic brain is blood pressure dependent, there is controversy about whether blood pressure should be lowered acutely. Blood pressure should be lowered if there is malignant hypertension (Chap. 230) or concomitant myocardial ischemia or if blood pressure is >185/110 mmHg and thrombolytic therapy is anticipated. When faced with the competing demands of myocardium and brain, lowering the heart rate with a β1-adrenergic blocker (such as esmolol or labetalol) can be a first step to decrease cardiac work and maintain blood pressure. Fever is detrimental and should be treated with antipyretics. Serum glucose should be monitored and kept at <11.1 mmol/L (200 mg/dL).

Between 5 and 10% of patients develop enough cerebral edema to cause obtundation or brain herniation. Edema peaks on the second or third day but can cause mass effect for ~10 days. The larger the infarct, the greater the likelihood that clinically significant edema will develop. Special vigilance is warranted for patients with cerebellar infarction. Even small amounts of cerebellar edema can acutely increase intracranial pressure (ICP) in the posterior fossa or directly compress the brainstem. The resulting brainstem compression can result in coma and respiratory arrest and require emergency surgical decompression. Water restriction and intravenous mannitol may be used to raise the serum osmolarity, but hypovolemia should be avoided as this may contribute to hypotension and worsening infarction. Trials are under way to test the clinical benefits of craniotomy and temporary removal of part of the skull (hemispherectomy) for large hemispheric infarcts with marked cerebral edema.

**THROMBOLYSIS** The National Institute of Neurological Disorders and Stroke (NINDS) recombinant tPA (rtPA) Stroke Study showed a clear benefit for intravenous rtPA in selected patients with acute stroke. The NINDS study used intravenous rtPA (0.9 mg/kg to a 90-mg max; 10% as a bolus, then the remainder over 60 min) vs. placebo in patients with ischemic stroke within 3 h of onset. Half of the patients were treated within 90 min. Symptomatic intracerebral hemorrhage occurred in 6.4% of patients on rtPA and 0.6% on placebo. There was a nonsignificant 4% reduction in mortality in patients on rtPA (21% on placebo and 17% on rtPA); there was a significant 12% absolute increase in the number of patients with only minimal disability (32% on placebo and 44% on rtPA.) Thus, despite an increased incidence of symptomatic intracerebral hemorrhage, treatment with intravenous rtPA within 3 h of the onset of ischemic stroke improved clinical outcome.

Results of other trials of rtPA have been negative, perhaps because of the dose of rtPA and timing of its delivery. The European Cooperative Acute Stroke Study (ECASS) I used a higher dose of rtPA (1.2 mg/kg), and ECASS-II tested the NINDS dose of rtPA (0.9 mg/kg; maximum dose, 90 mg) but allowed patients to receive drug up to the sixth hour. No significant benefit was found, but improvement was found in post hoc analyses. ATLANTIS tested the NINDS dosing of rtPA between 3 and 5 h and found no benefit. Three major trials using streptokinase reported increased mortality for patients receiving streptokinase. Early administration of the fibrinolytic agent anconid appears to improve outcomes for patients with acute ischemic stroke; although the drug has not been approved for clinical use, its efficacy provides further evidence that thrombolytics should have a role in treatment of acute ischemic stroke.

Because of the marked differences in trial design, including drug and dose used, time to thrombolysis, and severity of stroke, the precise efficacy of intravenous thrombolytics for acute ischemic stroke remains unclear. The risk of intracranial hemorrhage appears to rise with larger strokes, longer times from onset of symptoms, and higher doses of rtPA administered. The established dose of 0.9 mg/kg administered intravenously within 3 h of stroke onset appears safe. Many hospitals have developed expert stroke teams to facilitate this treatment. The drug is now approved in the United States, Canada, and Europe for acute stroke when given within 3 h from the time the stroke symptoms began, and efforts should be made to give it as early in this 3-h window as possible. The time of stroke onset is defined as the time the patient’s symptoms began or the time the patient was last seen as normal. A patient who awakenis with stroke has the onset defined as when they went to bed. Table 349-2 summarizes eligibility criteria and instructions for administration of rtPA.

There is growing interest in using thrombolytics via an intraarterial route to increase the concentration of drug at the clot and minimize systemic bleeding complications. The Prolyse in Acute Cerebral Thrombolysis (PROACT) II trial found benefit for intraarterial pro-urokinase for acute middle cerebral artery (MCA) occlusions up to the sixth hour following onset of stroke. Intraarterial treatment of basilar artery occlusions may also be beneficial for selected patients. Intraarterial administration of a thrombolytic agent for acute ischemic stroke is not approved by the U.S. Food and Drug Administration (FDA); however, many stroke centers offer this treatment based on these data.

**ANTIPLATELET AGENTS** Aspirin is the only antiplatelet agent that has been approved by the U.S. Food and Drug Administration (FDA) for acute ischemic stroke. Recent large trials, the International Stroke Trial (IST) and the Chinese Acute Stroke Trial (CAST), found that the use of aspirin within 48 h of stroke onset reduced both stroke recurrence risk and mortality minimally. Among 19,435 patients in IST, those allocated to aspirin, 300 mg/d, had slightly fewer deaths within 14 days (9.0 vs. 9.4%), signif-
### Table 349-2: Administration of Intravenous Recombinant Tissue Plasminogen Activator (rtPA) for Acute Ischemic Stroke

<table>
<thead>
<tr>
<th>Indication</th>
<th>Contraindication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical diagnosis of stroke</td>
<td>Sustained BP &gt; 185/110 despite</td>
</tr>
<tr>
<td>Onset of symptoms to time of drug administration ≤ 3 h</td>
<td>treatment</td>
</tr>
<tr>
<td>CT scan showing no hemorrhage or edema of &gt;1 of the MCA territory</td>
<td>Platelets &lt; 100,000;</td>
</tr>
<tr>
<td>Age ≥ 18 years</td>
<td>HCT &lt; 25%; glucose &lt; 50 or &gt; 400 mg/dL;</td>
</tr>
<tr>
<td>Consent by patient or surrogate</td>
<td>Use of heparin within 48 h and prolonged PTT, or elevated INR</td>
</tr>
<tr>
<td></td>
<td>Rapidly improving symptoms</td>
</tr>
<tr>
<td></td>
<td>Prior stroke or head injury within 3 months; prior intracranial hemorrhage</td>
</tr>
<tr>
<td></td>
<td>Major surgery in preceding 14 days</td>
</tr>
<tr>
<td></td>
<td>Minor stroke symptoms</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal bleeding in preceding 21 days</td>
</tr>
<tr>
<td></td>
<td>Recent myocardial infarction</td>
</tr>
<tr>
<td></td>
<td>Coma or stupor</td>
</tr>
</tbody>
</table>

**Administration of rtPA**

- Intravenous access with two peripheral IV lines (avoid arterial or central line placement)
- Review eligibility for rtPA
- Administer 0.9 mg/kg intravenously (maximum 90 mg) IV as 10% of total dose by bolus, followed by remainder of total dose over 1 h
- Frequent cuff blood pressure monitoring
- No other antithrombotic treatment for 24 h
- For decline in neurologic status or uncontrolled blood pressure, stop infusion, give cryoprecipitate, and reimage brain emergently
- Avoid urethral catheterization for ≥ 2 h

---

**Note:** rtPA is indicated for patients who present < 3 h after the onset of symptoms of ischemic stroke. It is contraindicated in patients with a history of recent stroke, intracranial hemorrhage, or uncontrolled hypertension.care.

---

**Deficits**

- Deficits will progress over several hours to 1 to 2 days. Some physicians heparinize all patients with recent mild ischemic stroke in order to prevent some of this worsening, but this practice is discouraged. The bleeding complication rate for 7 days of heparin is about 10%, with a serious bleed rate of ~2%. Clearly the value of this approach must be clarified. Heparinization is generally accomplished by beginning an infusion without bolus and is monitored to maintain the activated partial thromboplastin time (PTT) at approximately twice normal.

**Neuroprotection**

Neuroprotection is the concept of providing a treatment that prolongs the brain’s tolerance to ischemia. Hypothermia is a powerful neuroprotective treatment in patients with cardiac arrest, but it has not been adequately studied in patients with stroke. Drugs that block the excitatory amino acid pathways have been shown to protect neurons and glia in animals, but despite multiple clinical trials, they have not yet been proven to be beneficial in humans. Even so, interest in neuroprotection continues because of the potential for agents to have limited risk, even when administered in the pre-hospital setting or in conjunction with thrombolytic agents.

**Stroke Centers and Rehabilitation**

Patient care in comprehensive stroke units followed by rehabilitation services improves neurologic outcomes and reduces mortality. Use of clinical pathways and staff dedicated to the stroke patient can improve care. Stroke teams that provide emergency 24-h evaluation of acute stroke patients for acute medical management and consideration of thrombolysis are important.

Proper rehabilitation of the stroke patient includes early physical, occupational, and speech therapy. It is directed toward educating the patient and family about the patient’s neurologic deficit, preventing the complications of immobility (e.g., pneumonia, DVT and pulmonary embolism, pressure sores of the skin, and muscle contractures), and providing encouragement and instruction in overcoming the deficit. The goal of rehabilitation is to return the patient to home and to maximize recovery by providing a safe, progressive regimen suited to the individual patient. Additionally, the use of restraint therapy has been shown to improve hemiparesis following stroke, even years following the stroke, suggesting that physical therapy can recruit unused neural pathways. This finding suggests that the human nervous system is more adaptable than originally thought and has stimulated active research into physical and pharmacologic strategies that can enhance long-term neural recovery.

**Etiology of Ischemic Stroke**

Although the initial management of acute ischemic stroke often does not depend on the etiology, establishing a cause is essential in reducing the risk of recurrence. The clinical presentation and examination findings often establish the cause of stroke or narrow the possibilities to a few. Judicious use of laboratory testing and imaging studies completes the initial evaluation. Nevertheless, nearly 30% of strokes remain unexplained despite extensive evaluation.

**Clinical Examination**

- Clinical examination should be focused on the peripheral and cerebral vascular system (carotid auscultation for bruits, blood pressure, and pressure comparison between arms), the heart (dysrhythmia, murmurs, extremities (peripheral emboli)), and retina (effects of hypertension and cholesterol emboli (Hollenhorst plaques)). A complete neurologic examination is performed to localize the site of stroke. An imaging study of the brain is nearly always performed and is required for patients being considered for thrombolysis. A chest x-ray, electrocardiogram (EGC), urinalysis, complete blood count, erythrocyte sedimentation rate, serum electrolytes, blood urea nitrogen, creatinine, blood sugar, serologic test for syphilis, serum lipid profile, prothrombin time, and PTT are often useful and should be considered in all patients. An ECG may demonstrate conduction abnormalities and arrhythmias or reveal evidence of recent myocardial infarction (MI).

**Cardioembolic Stroke**

Cardioembolism is responsible for ~20% of all ischemic strokes. Stroke caused by heart disease is primarily due to embolism of thrombotic material forming on the atrial or ventricular base of text.
A few pertinent aspects are highlighted here.

Nonrheumatic atrial fibrillation is the most common cause of cerebral embolism overall. The presumed stroke mechanism is thrombus formation in the fibrillating atrium or atrial appendage, with subsequent embolization. Patients with atrial fibrillation have an average annual risk of stroke of ~5%. The risk varies according to the presence of certain risk factors, including older age, hypertension, poor left ventricular function, prior cardioembolism, diabetes, and thyrotoxicosis. Patients younger than 60 with none of these risk factors have an annual risk for stroke of ~0.5%, while those with most of the factors have a rate of ~15% per year. Left atrial enlargement and congestive heart failure are additional risk factors for formation of atrial thrombi. Rheumatic heart disease usually causes ischemic stroke when there is prominent mitral stenosis or atrial fibrillation. Guidelines for the use of warfarin and aspirin for secondary prevention are based on risk factors (Table 349-4).

Recent MI may be a source of emboli, especially when transmural and involving the anteroapical ventricular wall, and prophylactic anticoagulation following MI has been shown to reduce stroke risk. Mitral valve prolapse is not usually a source of emboli unless the prolapse is severe.

Paradoxical embolization occurs when venous thrombi migrate to the arterial circulation, usually via a patent foramen ovale or atrial septal defect. Bubble-contrast echocardiography (intravenous injection of agitated saline coupled with either transthoracic or transesophageal echocardiography) can demonstrate a cardiac right-to-left shunt, revealing the conduit for paradoxical embolization. Alternatively, a right-to-left shunt is implied if immediately following intravenous injection of agitated saline, high-intensity transients are observed during transcranial Doppler insonation of the MCA. Both techniques are highly sensitive for detection of right-to-left shunts. Besides venous clot, fat and tumor emboli, bacterial endocarditis, intravenous air, and amniotic fluid emboli associated with delivery may occasionally be responsible for paradoxical embolization. The importance of right-to-left shunt as a cause of stroke is debated, particularly because such shunts occur in ~15% of the general population. Some studies have suggested that the risk is only elevated in the presence of a coexisting atrial septal aneurysm. The presence of a venous source of emboli, most commonly a deep venous thrombus, may provide confirmation of the importance of a right-to-left shunt in a particular case.

Bacterial endocarditis can cause valvular vegetations that can give rise to multiple septic emboli (Chap. 109). The appearance of multifocal symptoms and signs in a patient with stroke makes bacterial endocarditis more likely. Infarcts of microscopic size occur, and large septic infarcts may evolve into brain abscesses or cause hemorrhage into the infract, which generally precludes use of anticoagulation or thrombolytics. Myocytic aneurysms caused by septic emboli give rise to SAH or intracerebral hemorrhage.

**Artery-to-Artery Embolic Stroke** Thrombus formation on atherosclerotic plaques may embolize to intracranial arteries producing an artery-to-artery embolic stroke. Alternatively, a diseased vessel may acutely thrombose; the resulting blockage causes stroke by producing ischemia within the region of brain it supplied. Unlike the myocardial vessels, artery-to-artery embolism appears to be the dominant vascular mech-

---

**TABLE 349-3 Causes of Ischemic Stroke**

<table>
<thead>
<tr>
<th>Common Causes</th>
<th>Uncommon Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis</td>
<td>Hypercoagulable disorders</td>
</tr>
<tr>
<td>Lacunar stroke (small vessel)</td>
<td>Protein C deficiency</td>
</tr>
<tr>
<td>Large vessel thrombosis</td>
<td>Protein S deficiency</td>
</tr>
<tr>
<td>Embolic occlusion</td>
<td>Antithrombin III deficiency</td>
</tr>
<tr>
<td>Artery-to-artery</td>
<td>Antiphospholipid syndrome</td>
</tr>
<tr>
<td>Carotid bifurcation</td>
<td>Factor V Leiden mutation*</td>
</tr>
<tr>
<td>Aortic arch</td>
<td>Prothrombin G20210 mutation*</td>
</tr>
<tr>
<td>Arterial dissection</td>
<td>Systemic malignancy</td>
</tr>
<tr>
<td>Cardiogenic</td>
<td>Sickle cell anemia</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>β-Thalassemia</td>
</tr>
<tr>
<td>Mural thrombus</td>
<td>Homocysteinemia</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>Thrombotic thrombocytopenic</td>
</tr>
<tr>
<td>Dilated cardiomyopathy</td>
<td>Purpura</td>
</tr>
<tr>
<td>Valvular lesions</td>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>Mitral stenosis</td>
<td>Systemic lupus erythematous</td>
</tr>
<tr>
<td>Mechanical valve</td>
<td>Dysproteinemias</td>
</tr>
<tr>
<td>Bacterial endocarditis</td>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td>Paradoxical embolus</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>Artrial septal defect</td>
<td>Oral contraceptives</td>
</tr>
<tr>
<td>Patent foramen ovale</td>
<td>Venous sinus thrombosis*</td>
</tr>
<tr>
<td>Atrial septal aneurysm</td>
<td>Fibromuscular dysplasia</td>
</tr>
<tr>
<td>Spontaneous echo</td>
<td>Vasculitis</td>
</tr>
<tr>
<td>contrast</td>
<td>Systemic vasculitis (PAN, Wegner’s, Takayasu’s, giant cell arthritis) Primary CNS vasculitis Meningitis (syphilis, tuberculosis, fungal, bacterial, zoster Cardiogenic Mitral valve calcification Atrial myxoma Intracardiac tumor Marantic endocarditis Libman-Sacks endocarditis Subarachnoid hemorrhage vasospasm Drugs: cocaine, amphetamine Moyamoya disease Eclampsia</td>
</tr>
</tbody>
</table>

* Chiefly cause venous sinus thrombosis.  
* May be associated with any hypercoagulable disorder.

**TABLE 349-4 Consensus Recommendation for Antithrombotic Prophylaxis in Atrial Fibrillation**

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk Factors</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≤65</td>
<td>≥1</td>
<td>Warfarin INR 2–3</td>
</tr>
<tr>
<td>Age 65–75</td>
<td>≥1</td>
<td>Aspirin or no treatment</td>
</tr>
<tr>
<td>Age &gt;75</td>
<td>0</td>
<td>Warfarin INR 2–3 or aspirin</td>
</tr>
</tbody>
</table>

* Risk factors include previous transient ischemic attack or stroke, hypertension, heart failure, diabetes, clinical coronary artery disease, mitral stenosis, prosthetic heart valves, or thyrotoxicosis.

**Source:** Modified from GW Albers et al: Antithrombotic therapy in atrial fibrillation. Chest 119:194S, 2001; with permission.
anism causing ischemia rather than thrombosis. The most common source of embolism is the carotid bifurcation, but any diseased vessel may be a source, including the aortic arch and common carotid, internal carotid, vertebral, and basilar arteries. Carotid bifurcation atherosclerosis is the most common source of artery-to-artery embolus, and specific treatments have proven efficacy in reducing risk.

**CAROTID ATHEROSCLEROSIS** Atherosclerosis within the carotid artery occurs most frequently within the common carotid bifurcation and proximal internal carotid artery. Additionally, the carotid siphon (portion within the cavernous sinus) is also vulnerable to atherosclerosis. Male gender, older age, smoking, hypertension, diabetes, and hypercholesterolemia are risk factors for carotid disease, as they are for stroke in general (Table 349-5). Carotid atherosclerosis produces an estimated 5% of ischemic stroke, and the risk of stroke rises the higher the degree of carotid narrowing. Further discussion of the pathogenesis of atherosclerosis, see Chap. 224.

Carotid disease can be classified by whether the stenosis is symptomatic or asymptomatic and by the degree of stenosis (percent narrowing of the narrowest segment compared to a more distal internal carotid segment). Symptomatic carotid disease implies that the patient has experienced a stroke or TIA within the vascular distribution of the artery, and it is associated with a greater risk of subsequent stroke than asymptomatic stenosis, in which the patient is symptom free and the stenosis is detected through screening. Greater degrees of arterial narrowing are generally associated with a greater risk of stroke.

### Risk Factors for Stroke

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Relative Risk</th>
<th>Relative Risk Reduction with Treatment</th>
<th>Number Needed to Treat*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>2–5</td>
<td>38%</td>
<td>100–300</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1.8–2.9</td>
<td>68% warfarin, 21% aspirin</td>
<td>20–83</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.8–6</td>
<td>No proven effect</td>
<td>12</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.8</td>
<td>50% at 1 year, baseline risk at 5 years post cessation</td>
<td>77</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1.8–2.6</td>
<td>10–29%</td>
<td>85</td>
</tr>
<tr>
<td>Asymptomatic carotid stenosis</td>
<td>2.0</td>
<td>53%</td>
<td>N/A</td>
</tr>
<tr>
<td>Symptomatic carotid stenosis</td>
<td>2.0</td>
<td>65% at 2 years</td>
<td>12</td>
</tr>
<tr>
<td>Symptomatic carotid stenosis (70–99%)</td>
<td>2.0</td>
<td>29% at 5 years</td>
<td>N/A</td>
</tr>
<tr>
<td>Symptomatic carotid stenosis (50–69%)</td>
<td>2.0</td>
<td>29% at 5 years</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Number needed to treat to prevent one stroke annually. Prevention of other cardiovascular outcomes is not considered here.

Note: N/A, not applicable.

### TREATMENT

**Surgical Therapy** Surgery for atherosclerotic occlusive disease is largely limited to carotid endarterectomy for plaques located at the origin of the internal carotid artery in the neck.

Symptomatic carotid stenosis was studied in the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST). Both showed a substantial benefit for surgery in patients with a stenosis of >70%. In NASCET, the average cumulative ipsilateral stroke risk at 2 years was 26% for patients treated medically and 9% for those receiving the same medical treatment plus a carotid endarterectomy. This 17% absolute reduction in the surgical group is a 65% relative risk reduction favoring surgery (Table 349-5). NASCET also showed a significant benefit for patients with 50 to 70% stenosis, although less robust. ECST found harm for patients with stenosis in the 0 to 30% range treated surgically.

A patient’s risk of stroke and possible benefit from surgery are related to the presence of retinal versus hemispheric symptoms, degree of arterial stenosis, extent of associated medical conditions, institutional morbidity and mortality, and other factors. A patient with multiple atherosclerosis risk factors, symptomatic hemispheric ischemia, high-grade stenosis in the appropriate internal carotid artery, and an institutional perioperative morbidity and mortality rate of ≥6% generally should undergo carotid endarterectomy. If the perioperative stroke rate is >6% for any particular surgeon, however, the benefits of carotid endarterectomy are questionable.

The indications for surgical treatment of asymptomatic carotid disease have been clarified by the results of the Asymptomatic Carotid Atherosclerosis Study (ACAS), which randomized patients with ≥60% stenosis to medical treatment with aspirin or the same medical treatment plus carotid endarterectomy. The surgical group had a risk over 5 years for ipsilateral stroke (and any perioperative stroke or death) of 5.1%, compared to a risk in the medical group of 11%.

This demonstrates a 53% relative risk reduction, the absolute risk reduction is only 5.9% over 5 years, or 1.2% annually (Table 349-5). The perioperative complication rate was higher in women, so they received only a 17% relative risk reduction over 5 years. Nearly half of the strokes in the surgery group were caused by preoperative angiograms.

The natural history of asymptomatic stenosis is an ~2% per year stroke rate, while symptomatic patients experience a 13% per year risk of stroke. Whether to recommend carotid revascularization for an asymptomatic patient remains controversial and depends on many factors including patient preference, age, and comorbidities. Medical therapy for reduction of atherosclerosis risk factors, including statins and aspirin, is generally recommended for patients with asymptomatic carotid stenosis. As with atrial fibrillation, it is imperative to counsel the patient about TIAs so their therapy can be revised if they become symptomatic.

Balloon angioplasty coupled with stenting is being used with increasing frequency to open stenotic carotid arteries and maintain their patency. This method has not yet been compared prospectively with endarterectomy, except in high-risk patients where one small trial suggested less morbidity with stenting compared with endarterectomy. Concern exists about distal embolization of plaque during vessel dilation, and many new devices designed to prevent distal embolization are undergoing clinical trials. Extracranial to intracranial (EC-IC) bypass surgery has been proven ineffective for atherosclerotic stenoses that are inaccessible to conventional carotid endarterectomy. However, using more functional techniques [positron emission tomography (PET) imaging] to select patients who may benefit from EC-IC bypass is currently being studied.

**OTHER CAUSES OF ARTERY-TO-ARTERY EMBOLIC STROKE** Intracranial atherosclerosis produces stroke either by an embolic mechanism or by in-situ thrombosis of a diseased vessel and is more common in patients of Asian and African-American descent. It is estimated that following a stroke or TIA from intracranial atherosclerosis the risk of a second stroke is ~15% per year. There is no proven superior treatment for stroke prevention in this disorder. Warfarin sodium and aspirin are being compared in a U.S. based prospective trial. Many neurointerventional centers are using intracranial angioplasty coupled with intracranial stenting, but this has not been compared with antithrombotic strategies for stroke prevention.

**Dissection** of the internal carotid or vertebral arteries or even vessels beyond the circle of Willis is a common source of embolic stroke in young (age <60 years) patients. The dissection is usually painful and precedes the stroke by several hours or days. Intracranial dissections rarely cause hemorrhage because of the tough adventitia of these vessels. Intracranial dissections, on the other hand, may produce SAH because the adventitia of intracranial vessels is thin and pseudoaneu-
syndromes may form, requiring treatment to prevent rerupture. The cause of dissection is usually unknown and recurrence is rare. Ehlers-Danlos type IV, Marfan’s disease, cystic medial necrosis, and fibromuscular dysplasia are associated with dissections. Trauma (usually a motor vehicle accident or a sports injury) can cause carotid and vertebral artery dissections. Spinal manipulative therapy is independently associated with vertebral artery dissection and stroke. Most dissections heal spontaneously, and stroke or TIA is uncommon beyond 2 weeks. Although there are no trials comparing anticoagulation to antiplatelet agents, many physicians treat with anticoagulants for 3 to 6 months then convert to antiplatelet therapy after demonstration of vascular recanalization.

Small-Vessel Stroke  The term lacunar infarction refers to infarction following atherothrombotic or lipohyalinotic occlusion of a small artery (30 to 300 µm) in the brain. The term small-vessel stroke denotes occlusion of such a small penetrating artery and is now the preferred term. Small-vessel strokes account for ~20% of all strokes.

PATHOPHYSIOLOGY  The MCA stem, the arteries comprising the circle of Willis (A1 segment, anterior and posterior communicating arteries, and P1 segment), and the basilar and vertebral arteries all give rise to 30- to 300-µm branches that penetrate the deep gray and white matter of the cerebrum or brainstem (Fig. 349-3). Each of these small branches can occlude either by atherothrombotic disease at its origin or by the development of lipohyalinotic thickening. Thrombosis of these vessels causes small infarcts that are referred to as lacunes (Latin for “lake” of fluid noted at autopsy). They range in size from 3 mm to 2 cm. Hypertension and age are the principal risk factors.

CLINICAL MANIFESTATIONS  The most common lacunar syndromes are the following: (1) Pure motor hemiparesis from an infarct in the posterior limb of the internal capsule or basis pontis; the face, arm, and leg are almost always involved; (2) pure sensory stroke from an infarct in the ventrolateral thalamus; (3) ataxic hemiparesis from an infarct in the base of thepons; (4) dysarthria and a clumsy hand or arm due to infarction in the base of the pons or in the genu of the internal capsule; and (5) pure motor hemiparesis with “motor (Broca’s) aphasia” due to thrombotic occlusion of a lenticulostriate branch supplying the genu and anterior limb of the internal capsule and adjacent white matter of the corona radiata.

Transient symptoms (small vessel TIAs) may herald a small-vessel infarct; they may occur several times a day and last only a few minutes. Recovery from a small-vessel stroke often begins within hours or days, and over weeks or months may be nearly complete; in some cases, however, there is severe permanent disability. Often, institution of combined antithrombotic treatments does not prevent eventual stroke in “stuttering lacunes.”

A large-vessel source (either thrombosis or embolism) may manifest initially as a lacunar syndrome with small-vessel infarction. Therefore, the search for embolic sources (carotid and heart) should not be completely abandoned in the evaluation of these patients. Secondary prevention of lacunar stroke involves risk factor modification, specifically reduction in blood pressure (see “Primary and Secondary Prevention,” below).

LESS COMMON CAUSES OF STROKE  (Table 349-3) Hypercoagulable disorders (Chap. 53) primarily cause increased risk of venous thrombosis and therefore may cause venous sinus thrombosis. Protein S deficiency and homocysteinemia may cause arterial thromboses as well. Systemic lupus erythematosus with Liebman-Sacks endocarditis can be a cause of embolic stroke. These conditions overlap with the antiphospholipid syndrome, which probably requires long-term anticoagulation to prevent further stroke.

Venous sinus thrombosis of the lateral or sagittal sinus or of small cortical veins (cortical vein thrombosis) occurs as a complication of pregnancy and the postpartum period, sepsis, and intracranial infections (meningitis). It is also seen with increased incidence in patients with laboratory-confirmed thrombophilia (Table 349-3) including polycythemia, sickle cell anemia, proteins C and S deficiency, factor V Leiden mutation (resistance to activated protein C), antithrombin III deficiency, homocysteinemia, and the prothrombin G20210 mutation. Women who take oral contraceptives and have the prothrombin G20210 mutation may be at high risk for sinus thrombosis. Patients present with headache, focal neurologic signs (especially paraparesis), and seizures. Often, CT imaging is normal unless an intracranial venous hemorrhage has occurred, but the venous sinus occlusion is readily visualized using magnetic resonance (MR) venography or conventional x-ray angiography. With greater degrees of sinus thrombosis, the patient may develop signs of increased ICP and coma. Intravenous heparin, regardless of the presence of intracranial hemorrhage, has been shown to reduce morbidity and mortality, and the long-term outcome is generally good. Heparin prevents further thrombosis and reduces venous hypertension and ischemia. If an underlying hypercoagulable state is not found, many physicians treat with warfarin sodium for 3 to 6 months then convert to aspirin, depending on the degree of resolution of the venous sinus thrombus. Anticoagulation is often continued indefinitely if thrombophilia is diagnosed.

Fibromuscular dysplasia affects the cervical arteries and occurs mainly in women. The carotid or vertebral arteries show multiple rings of segmental narrowing alternating with dilatation. Occlusion is usually incomplete. The process is often asymptomatic but occasionally is associated with an audible bruit, TIAs, or stroke. The cause and natural history of fibromuscular dysplasia is unknown (Chap. 232). TIA or stroke generally occurs only when the artery is severely narrowed or occluded. Anticoagulation or antiplatelet therapy may be helpful.

Temporal (giant cell) arteritis (Chap. 306) is a relatively common affliction of elderly persons in which the external carotid system, particularly the temporal arteries, becomes the site of a subacute granu-
lomatous inflammation with giant cells. Occlusion of posterior ciliary arteries derived from the ophthalmic artery results in blindness in one or both eyes and can be prevented with glucocorticoids. It rarely causes stroke as the internal carotid artery is usually not inflamed. Idiopathic giant cell arteritis involving the great vessels arising from the aortic arch (Takayasu’s arteritis) may cause carotid or vertebral thrombosis; it is rare in the western hemisphere.

Necrotizing (or granulomatous) arteritis, occurring alone or in association with generalized polyarteritis nodosa or Wegener’s granulomatosis, involves the distal small branches (<2 mm diameter) of the main intracranial arteries and produces small ischemic infarcts in the brain, optic nerve, and spinal cord. The cerebrospinal fluid often shows pleocytosis, and the protein level is elevated. Primary central nervous system vasculitis is rare; small or medium-sized vessels are usually affected. Brain biopsy or high-resolution conventional x-ray angiography is usually required to make the diagnosis. Patients with any form of vasculitis may present with insidious progression of combined white and gray matter infarctions, prominent headache, and cognitive decline. Aggressive immunosuppression with glucocorticoids, and often cyclophosphamide, is usually necessary to prevent progression. Depending upon the duration of the disease, many patients can make an excellent recovery.

Drugs, in particular amphetamines and perhaps cocaine, may cause stroke on the basis of acute hypertension and drug-induced vasculitis. Abstinence appears to be the best treatment, as no data exist on use of any treatment. Phenylpropanolamine has been linked with intracranial hemorrhage as has cocaine, perhaps related to a drug-induced vasculitis. Arteritis can also occur as a consequence of bacterial, tuberculous, and syphilitic meningitis.

Moyamoya disease is a poorly understood occlusive disease involving large intracranial arteries, especially the distal internal carotid artery and the stem of the middle and anterior cerebral arteries. Vasculitis is absent. The lenticulostriate arteries develop a rich collateral circulation around the occlusive lesion, which gives the impression of a “puff of smoke” (moyamoya in Japanese) on conventional x-ray angiography. Other collaterals include transdural anastomoses between the cortical surface branches of the meningeal and scalp arteries. The disease occurs mainly in Asian children or young adults, but the appearance may be identical in adults who have atherosclerosis. The etiology of the childhood form is unknown. Because of the occurrence of intracranial hemorrhage from rupture of the transdural and pial anastomotic channels, anticoagulation is risky. Breakdown of dilated lenticulostriate arteries may produce parenchymal hemorrhage, and progressive occlusion of large surface arteries can occur, producing large-artery distribution strokes. Bypass of extracranial carotid arteries to the dura or MCAs may prevent stroke and hemorrhage.

Reversible posterior leukoencephalopathy can occur in head injury, migraine, sympathomimetic drug use, eclampsia, and the postpartum period. The etiology is unclear but likely involves widespread cerebral segmental vasoconstriction. Patients complain of headache and manifest fluctuating neurologic symptoms and signs, especially visual symptoms. Sometimes cerebral infarction ensues. Conventional x-ray angiography is the only means of establishing the diagnosis, but because angiography itself can cause spasm of vessels, even the existence of this vascular entity is debated.

Binswanger’s disease (chronic progressive subcortical encephalopathy) is a rare condition in which infarction of the subcortical white matter occurs subacutely. CT or MRI scans detect periventricular white matter infarcts and gliosis. There is lipohyalinosis in the small arteries of the deep white matter, as in hypertension. There are usually associated lacunar infarcts. Binswanger’s disease may represent a type of border zone ischemic infarction in the deep white matter between the penetrating arteries of the circle of Willis and of the cortex. The pathophysiologic basis of the disease is unclear, but it typically occurs in older adults with severe long-standing hypertension.

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an inherited disorder that presents as small-vessel strokes, progressive dementia, and extensive symmetric white matter changes visualized by MRI. Approximately 40% of patients have migraine with aura, often manifest as transient motor or sensory deficits. Onset is usually in the fourth or fifth decade of life. This autosomal dominant condition is caused by one of several mutations in Notch-3, a member of a highly conserved gene family characterized by epidermal growth factor repeats in its extracellular domain. CADASIL is the only monogenic ischemic stroke syndrome so far described. Genetic testing is available.

TRANSIENT ISCHEMIC ATTACKS TIAs are episodes of stroke symptoms that last only briefly; the current definition of duration is <24 h, but the average duration of a TIA is ~12 min. The causes of TIA are similar to all causes of stroke, but because TIAs may herald stroke they are an important risk factor that should be considered separately. TIAs may arise from emboli to the brain or from in situ thrombosis of an intracranial vessel. With a TIA, the occluded blood vessel reopens and neurologic function is restored. However, infarcts of the brain do occur in 15 to 40% of TIAs even though neurologic signs and symptoms are absent.

In addition to the stroke syndromes discussed below, there are a few specific TIA symptoms that should receive special notice. Am. aurosis fugax, or transient monocular blindness, occurs from emboli to the central retina of one eye. This may indicate carotid stenosis as the cause or local ophthalmic artery disease. The risk of stroke after a TIA is ~10% in the first 3 months, with most events occurring in the first 2 days. Therefore, urgent evaluation and treatment are justified. Since etiologies for stroke and TIA are identical, evaluation for TIA should parallel that of stroke (Tables 349-1 and 349-3). The improvement characteristic of TIA is a contraindication to thrombolysis. Acute antiplatelet therapy has not been tested specifically after TIA but is likely to be effective and is recommended. No large-scale trial has evaluated acute anticoagulation after TIA, a setting in which the risk of hemorrhage may be lower.

RISK FACTORS FOR ISCHEMIC STROKE Identification and control of modifiable risk factors is the best strategy to reduce the burden of stroke, as the total number of strokes could be reduced substantially by these means (Table 349-5).

PRIMARY AND SECONDARY PREVENTION General Principles A number of medical and surgical interventions, as well as lifestyle modifications, are available for preventing stroke. Some of these can be widely applied because of their low cost and minimal risk; others are expensive and carry substantial risk but may be valuable for selected high-risk patients.

Evaluation of a patient’s clinical risk profile can help determine which preventive treatments to offer. In addition to known risk factors for ischemic stroke (above), certain clinical characteristics also contribute to an increased risk of stroke (Table 349-5). NASCET found that even in patients with the same degree of carotid artery stenosis, specifically 70 to 99%, nine prospectively selected risk factors predicted the risk of vascular outcomes in the medically treated patients. The overall risk of stroke was much greater in a high-risk group (those with more than six risk factors) than in a low-risk group (those with fewer than six risk factors). Fully 39% of patients in the high-risk group treated medically experienced an ipsilateral stroke within 2 years. The rate for the low-risk group was less than half that but was still 17%.

Atherosclerosis Risk Factors The relationship of various factors to the risk of atherosclerosis is described in Chap. 225. Older age, family history of thrombotic stroke, diabetes mellitus, hypertension, tobacco smoking, abnormal blood cholesterol [particularly, low high-density lipoprotein (HDL) and/or low high-density lipoprotein (LDL), and other factors are either proven or probable risk factors for ischemic stroke, largely by their link to atherosclerosis. Risk of second stroke is strongly influenced by prior stroke or TIA, depending on cause.
Many cardiac conditions predispose to stroke, including atrial fibrillation and recent MI. Oral contraceptives may increase stroke risk, and certain inherited and acquired hypercoagulable states predispose to stroke. Hypertension is the most significant of the risk factors; in general, all hypertension should be treated. The presence of known cerebrovascular disease is not a contraindication to treatment aimed at achieving normotension. Also, the value of treating systolic hypertension in older patients has been clearly established. Lowering blood pressure to levels below those traditionally defining hypertension appears to reduce the risk of stroke even further. Data are particularly strong in support of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Several trials have confirmed that statin drugs reduce the risk of stroke even in patients without elevated LDL or low HDL. Although studies specifically targeting prevention of second stroke are still underway, results for patients with cardiovascular risk factors or dyslipidemia have been compelling, with a 20 to 30% relative risk reduction for stroke. Therefore, a statin should be considered in all patients with stroke. Hypertension is the most significant of the risk factors; in general, all hypertension should be treated. The presence of known cerebrovascular disease is not a contraindication to treatment aimed at achieving normotension. Also, the value of treating systolic hypertension in older patients has been clearly established. Lowering blood pressure to levels below those traditionally defining hypertension appears to reduce the risk of stroke even further. Data are particularly strong in support of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Antiplatelet Agents Platelet antiaggregation agents can prevent atherothrombotic events, including TIA and stroke, by inhibiting the formation of intraarterial platelet aggregates. These can form on diseased arteries, induce thrombus formation, and occlude the artery or embolize into the distal circulation. Aspirin, clopidogrel, and the combination of aspirin plus extended-release dipyridamole are the antiplatelet agents most commonly used for this purpose. Ticlopidine has been largely abandoned because of its adverse effects.

Aspirin is the most widely studied antiplatelet agent. Aspirin acetylates platelet cyclooxygenase, which irreversibly inhibits the formation in platelets of thromboxane A2, a platelet aggregating and vasoconstricting prostaglandin. This effect is permanent and lasts for the usual 8-day life of the platelet. Paradoxically, aspirin also inhibits the formation in endothelial cells of prostacyclin, an antiaggregating and vasodilating prostaglandin. This effect is transient. As soon as aspirin is cleared from the blood, the nucleated endothelial cells again produce prostacyclin. Aspirin in low doses given once daily inhibits the production of thromboxane A2 in platelets without substantially inhibiting prostacyclin formation. The FDA recommends 50 to 325 mg of aspirin daily for stroke prevention.

Ticlopidine and clopidogrel block the ADP receptor on platelets and thus prevent the cascade resulting in activation of the glycoprotein IIb/IIIa receptor that leads to fibrinogen binding to the platelet and consequent platelet aggregation. Ticlopidine is more effective than aspirin; however, it has the disadvantage of causing diarrhea, skin rash, a low incidence of neutropenia, and thrombotic thrombocytopenic purpura. Clopidogrel is not associated with these important side effects. However, the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) trial, which led to FDA approval, found that it was only marginally more effective than aspirin in reducing risk of stroke. Studies of clopidogrel in combination with aspirin are in progress in both cerebrovascular and cardiovascular patients.

Dipyridamole is an antiplatelet agent that inhibits the uptake of adenosine by a variety of cells, including those of the vascular endothelium. The accumulated adenosine is an inhibitor of aggregation. At least in part through its effects on platelet and vessel wall phosphodiesterases, dipyridamole also potentiates the antiaggregatory effects of prostacyclin and nitric oxide produced by the endothelium and acts by inhibiting platelet phosphodiesterase, which is responsible for the breakdown of cyclic AMP. The resulting elevation in cyclic AMP inhibits aggregation of platelets. Dipyridamole has a controversial history in stroke prevention. The European Stroke Prevention Study-2 showed efficacy of both 50 mg daily of aspirin and extended-release dipyridamole in preventing stroke, and a significantly better risk reduction when the two agents were combined. A combination capsule of extended-release dipyridamole and aspirin is approved for prevention of stroke.

Many large clinical trials have demonstrated clearly that most antiplatelet agents reduce the risk of all important vascular atherothrombotic events (i.e., ischemic stroke, MI, and death due to all vascular causes) in patients at risk for these events. The overall relative reduction in risk of nonfatal stroke is about 25 to 30% and of all vascular events is about 25%. The absolute reduction varies considerably depending on the particular patient’s risk. Individuals at very low risk for stroke seem to experience the same relative reduction, but their risk may be so low that the “benefit” is meaningless. On the other hand, individuals with a 10 to 15% risk of vascular events per year experience a reduction in risk of about 7.5 to 11%.

Aspirin is inexpensive, can be given in low doses, and could be recommended for all adults to prevent both stroke and MI. However, it causes epigastric discomfort, gastric ulceration, and gastrointestinal hemorrhage, which may be asymptomatic or life-threatening. Consequently, not every 40- or 50-year-old should be advised to take aspirin regularly because the risk of atherothrombotic stroke is extremely low and is outweighed by the risk of adverse side effects. Conversely, every patient who has experienced an atherothrombotic stroke or TIA and has no contraindication should be taking an antiplatelet agent regularly because the average annual risk of another stroke is 8 to 10%; another few percent will experience a MI or vascular death. Clearly, the likelihood of benefit far outweighs the risks of treatment.

The choice of antiplatelet agent and dose must balance the risk of stroke, the expected benefit, and the risk and cost of treatment. However, there are no definitive data, and opinions vary. Many authorities believe low-dose (30 to 75 mg daily) and high-dose (650 to 1300 mg daily) aspirin are about equally effective. Some advocate very low doses to avoid adverse effects, and still others advocate very high doses to be sure the benefit is maximal. Most physicians in North America recommend 81 to 325 mg daily, while most Europeans recommend 50 to 100 mg. Similarly, the choice of aspirin, clopidogrel, or dipyridamole plus aspirin must balance the fact that the latter are more effective than aspirin but the cost is higher.

Anticoagulation Therapy and Noncardiogenic Stroke There are few data to support the use of long-term warfarin for preventing atherothrombotic stroke, either intracranially or extracranially. The WARSS study found no benefit of warfarin sodium (INR, 2 to 3) over aspirin, 325 mg, for secondary prevention of stroke but did find a slightly higher bleeding rate in the warfarin group. A prospective trial is ongoing to study warfarin versus aspirin in secondary stroke prevention for intracranial atherosclerosis.

Anticoagulation Therapy and Embolic Stroke Several trials have shown that anticoagulation (INR range, 2 to 3) in patients with chronic nonvalvular (nonrheumatic) atrial fibrillation prevents cerebral embolism and is safe. For primary prevention and for patients who have experienced stroke or TIA, anticoagulation with warfarin reduces the risk by about 67% which clearly outweighs the 1% risk per year of a major bleeding complication.

The decision to use anticoagulation for primary prevention is based primarily on risk factors (Table 349–4). The presence of any risk factor tips the balance in favor of anticoagulation.

Because of the high annual stroke risk in untreated rheumatic heart disease, primary prophylaxis against stroke has not been studied in a double-blind fashion. These patients generally receive long-term anticoagulation.

Anticoagulation also reduces the risk of embolism in acute MI. Most clinicians recommend a 3-month course of anticoagulation when there is anterior Q-wave infarction, substantial left ventricular dysfunction, congestive heart failure, mural thrombosis, or atrial fibrillation. Warfarin is recommended long-term if atrial fibrillation persists. Warfarin is currently being studied in patients with congestive heart failure.

Thromboembolism is one of the most serious complications of
prosthetic heart valve implantation. Anticoagulation has been proven effective for preventing strokes in this situation, while antiplatelet therapy alone has not. However, coupled with warfarin anticoagulation, aspirin adds substantial benefit. A greater degree of anticoagulation (INR of 3 to 4, depending on valve type) is recommended for some patients with prosthetic heart valves.

If the embolic source cannot be eliminated, anticoagulation should in most cases be continued indefinitely. Many neurologists recommend combining antiplatelet agents with anticoagulants for patients who “fail” one form of therapy (i.e., have another stroke or TIA). This empirical approach subjects the patient to an increased bleeding risk.

Other Causes of Stroke CAROTID DISEASE Surgical or endovascular repair of carotid atherosclerosis is preferred over medical therapy for symptomatic carotid artery disease (see section above). Anticoagulation has not been directly compared with antiplatelet therapy for carotid disease.

DURAL SINUS THROMBOSIS Limited evidence exists to support short-term usage of anticoagulants, regardless of the presence of intracranial hemorrhage for venous infarction following sinus thrombosis.

STROKE SYNDROMES A careful history and neurologic examination can often localize the region of brain dysfunction; if this region corresponds to a particular arterial distribution, the possible causes responsible for the syndrome can be narrowed. This is of particular importance when the patient presents with a TIA and a normal examination. For example, if a patient develops language loss and a right homonymous hemianopia, a search for causes of left middle cerebral emboli should be performed. A finding of an isolated stenosis of the right internal carotid artery in that patient, for example, suggests an asymptomatic carotid stenosis, and the search for other causes of stroke should continue. The following sections describe the clinical findings of cerebral ischemia associated with cerebral vascular territories depicted in Figs. 349-3 through 349-11. Stroke syndromes are divided into: (1) large-vessel stroke within the anterior circulation, (2) large-vessel stroke within the posterior circulation, and (3) small-vessel disease of either vascular bed.

Stroke Within the Anterior Circulation The internal carotid artery and its branches comprise the anterior circulation of the brain. These vessels can be occluded by intrinsic disease of the vessel (e.g., atherosclerosis or dissection) or by embolic occlusion from a proximal source as discussed above. Occlusion of each major intracranial vessel has distinct clinical manifestations.

MIDDLE CEREBRAL ARTERY Occlusion of the proximal MCA or one of its major branches is most often due to an embolus (artery-to-artery, cardiac, or of unknown source) rather than intracranial atherothrombosis. Atherosclerosis of the proximal MCA may cause distal emboli to the middle cerebral territory or, less commonly, may produce low-flow TIAs. Collateral formation via leptomeningeal vessels often prevents MCA stenosis from becoming symptomatic.

The cortical branches of the MCA supply the lateral surface of the hemisphere except for (1) the frontal pole and a strip along the superomedial border of the frontal and parietal lobes supplied by the ACA, and (2) the lower temporal and occipital pole convolutions supplied by the PCA (Figs. 349-4, 349-6, and 349-7).

The proximal MCA (M1 segment) gives rise to penetrating branches (termed lenticulostriate arteries) that supply the putamen, outer globus pallidus, posterior limb of the internal capsule, the adjacent corona radiata, and most of the caudate nucleus. In the sylvian fissure, the MCA in most patients divides into superior and inferior divisions (M2 branches). Branches of the inferior division supply the inferior parietal and temporal cortex, and those from the superior division supply the frontal and superior parietal cortex (Fig. 349-5). If the entire MCA is occluded at its origin (blocking both its penetrating and cortical branches) and the distal collaterals are limited, the clinical findings are contralateral hemiplegia, hemianesthesia, homonymous hemianopia, and a day or two of gaze preference to the ipsilateral side. Dysarthria is common because of facial weakness.
When the dominant hemisphere is involved, global aphasia is present also, and when the nondominant hemisphere is affected, anosognosia, constructional apraxia, and neglect are found (Chap. 23).

Complete MCA syndromes occur most often when an embolus occludes the stem of the artery. Cortical collateral blood flow and differing arterial configurations are probably responsible for the development of many partial syndromes. Partial syndromes may also be due to emboli that enter the proximal MCA without complete occlusion, occlude distal MCA branches, or fragment and move distally.

Partial syndromes due to embolic occlusion of a single branch include hand, or arm and hand, weakness alone (brachial syndrome) or facial weakness with nonfuent (Broca) aphasia (Chap. 23), with or without arm weakness (frontal opercular syndrome). A combination of sensory disturbance, motor weakness, and nonfuent aphasia suggests that an embolus has occluded the proximal superior division and infarcted large portions of the frontal and parietal cortices (Fig. 349-5). If a fluent (Wernicke’s) aphasia occurs without weakness, the inferior division of the MCA supplying the posterior part (temporal cortex) of the dominant hemisphere is probably involved. Jargon speech and an inability to comprehend written and spoken language are prominent features, often accompanied by a contralateral, homonymous superior quadrantanopia. Hemineglect or spatial agnosia without weak-ness indicates that the inferior division of the MCA in the nondominant hemisphere is involved.

Occlusion of a lenticulostriate vessel produces small-vessel (lacunar) stroke within the internal capsule. This produces pure motor paresis of vertical eye movement, skew deviation, sluggish pupillary responses to light, and when the nondominant hemisphere is affected, anosognosia, constructional apraxia, and neglect are found (Chap. 23).

Anterior cerebral artery

The ACA is divided into two segments: the precommmunal (A1) circle of Willis, or stem, which connects the internal carotid artery to the anterior communicating artery, and the postcommunal (A2) segment distal to the anterior communicating artery (Figs. 349-3 and 349-7). The A1 segment gives rise to several deep penetrating branches that supply the anterior limb of the internal capsule, the anterior perforate substance, amygdala, anterior hypothalamus, and the inferior part of the head of the caudate nucleus (Fig. 349-4).

Occlusion of the proximal ACA is usually well tolerated because of collateral flow through the anterior communicating artery and collaterals through the MCA and PCA. Occlusion of a single A2 segment results in the contralateral symptoms noted in Fig. 349-6. If both A2 segments arise from a single anterior cerebral stem (contralateral A1arterial occlusion syndrome). Lacunar infarction affecting the globus pallidus and putamen often has few clinical signs, but parkinsonism and hemiballismus have been reported.

**Signs and symptoms: Structures involved**

Paralysis of opposite foot and leg: Motor leg area

A lesser degree of paresis of opposite arm: Arm area of cortex or fibers descending to corona radiata

Cortical sensory loss over toes, foot, and leg: Sensory area for foot and leg

Urinary incontinence: Sensory areas in paracentral lobule

Abulia (akinetic mutism), slowness, delay, intermittent interruption, lack of spontaneity, whispering, reflex distraction to sights and sounds: Uncertain localization—probably cerebellar gyrus and medial inferior portion of frontal, parietal, and temporal lobes

Impairment of gait and stance (gait apraxia): Frontal cortex near leg motor area

dyspraxia of left limbs, tactile aphasia in left limbs: Corpus callosum

**Part XV Neurologic Disorders**

2382

**FIGURE 349-6** Diagram of a cerebral hemisphere, medial aspect, showing the branches and distribution of the anterior cerebral artery and the principal regions of cerebral localization. (Courtesy of CM Fisher, MD.)

**Signs and symptoms: Structures involved**

Paralysis of opposite foot and leg: Motor leg area

A lesser degree of paresis of opposite arm: Arm area of cortex or fibers descending to corona radiata

Cortical sensory loss over toes, foot, and leg: Sensory area for foot and leg

Urinary incontinence: Sensory areas in paracentral lobule

Abulia (akinetic mutism), slowness, delay, intermittent interruption, lack of spontaneity, whispering, reflex distraction to sights and sounds: Uncertain localization—probably cerebellar gyrus and medial inferior portion of frontal, parietal, and temporal lobes

**FIGURE 349-7** Inferior aspect of the brain with the branches and distribution of the posterior cerebral artery and the principal anatomic structures shown. (Courtesy of CM Fisher, MD.)

**Signs and symptoms: Structures involved**

Peripheral territory (see also Fig. 349-11). Homonymous hemianopia (often upper quadrantic): Calcarine cortex or optic radiation nearby. Bilateral homonymous hemianopia, cortical blindness, awareness or denial of blindness; tactile naming, achromatopia (color blindness); failure to see to-and-fro movements, inability to perceive objects not centrally located, apraxia of ocular movements, inability to count or enumerate objects, tendency to run into things that the patient sees and tries to avoid: Bilateral occipital lobe with possibly the parietal lobe involved. Verbal dyslexia without agraphia, color anoma: Dominant calcarine lesion and posterior part of corpus callosum. Memory defect: Hippocampal lesion bilaterally or on the dominant side only. Topographic disorientation and prosopagnosia: Usually with lesions of nondominant calcarine, and lingual gyus. Simultanagnosia, hemisensory neglect: Domiant visual cortex, contralateral hemisphere. Uniformed visual hallucinations, peduncular hallucinosis, metamorphopsia, teleopsia, illusory visual spread, palinopsia, distortion of outlines, central photopsia: Calcarine cortex. Complex hallucinations: Usually nondominant hemisphere.

Central territory, Thalamic syndrome: sensory loss (all modalities), spontaneous pain and dysesthesias, choreathetosis, intention tremor, spasms of hand, mild hemiparesis: Posteroventral nucleus of thalamus; involvement of the adjacent subthalamic body or its afferent tracts. Thalamoperforate syndrome: crossed cerebellar ataxia with ipsilateral third nerve palsy (Claude’s syndrome): Dentatothalamus tract and issuing third nerve. Weber’s syndrome: third nerve palsy and contralateral hemiplegia: Third nerve and cerebral peduncle. Contralateral hemiplegia: Cerebral peduncle. Paralysis or paresis of vertical eye movement, skew deviation, sluggish pupillary responses to light, slight miosis and ptosis (retraction nystagmus and “tucking” of the eyelids may be associated): Spponuclear fibers to third nerve, interstitial nucleus of Cajal, nucleus of Darkschewitsch, and posterior commissure. Contralateral rhythmic, ataxic action tremor, rhythmic postural or “holding” tremor (rubral tremor): Dentatothalamic tract (?).
This artery arises from the internal carotid artery and supplies the posterior limb of the internal capsule and the white matter posterolateral to it, through which pass some of the geniculocalcarine fibers (Figs. 349-4 and 349-7). The complete syndrome of anterior choroidal artery occlusion consists of contralateral hemiplegia, hemianesthesia (hypesthesia), and homonymous hemianopia. However, because this territory is also supplied by penetrating vessels of the proximal MCA and the posterior communicating and posterior choroidal arteries, minimal deficits may occur, and patients frequently recover substantially. Anterior choroidal strokes are usually the result of in situ thrombosis of the vessel, and the vessel is particularly vulnerable to iatrogenic occlusion during surgical clipping of aneurysms arising from the internal carotid artery.

**INTERNAL CAROTID ARTERY** The clinical picture of internal carotid occlusion varies depending on whether the cause of ischemia is propagated thrombus, embolism, or low flow. The cortex supplied by the MCA territory is affected most often. With a competent circle of Willis, occlusion may go unnoticed. If the thrombus propagates up the internal carotid artery into the MCA or embolizes it, symptoms are identical to proximal MCA occlusion (see above). Sometimes there is massive infarction of the entire deep white matter and cortical surface. When the origins of both the ACA and MCA are occluded at the top of the carotid artery, abulia or stupor occurs with hemiplegia, hemianenes-
2. Lateral midpontine syndrome (short circumferential artery)

COMMON CAROTID ARTERY

fainter and may disappear when occlusion is imminent. Occurs at the time of cerebral TIA or infarction.

Infarction of the ophthalmic artery or central retinal arteries in most cases, these symptoms last only a few minutes. Rarely, ischemia, and aphasia or anosognosia. When the PCA arises from the internal carotid artery (a configuration called a fetal posterior cerebral artery), it may also become occluded and give rise to symptoms referable to its peripheral territory (Figs. 349-6 and 349-7).

In addition to supplying the ipsilateral brain, the internal carotid artery perfuses the optic nerve and retina via the ophthalmic artery. In about 25% of symptomatic internal carotid disease, recurrent transient monocular blindness (amaurosis fugax) warns of the lesion. Patients typically describe a horizontal shade that sweeps down or up across the field of vision. They may also complain that their vision was blurred in that eye or that the upper or lower half of vision disappeared. In most cases, these symptoms last only a few minutes. Rarely, ischemia or infarction of the ophthalmic artery or central retinal arteries occurs at the time of cerebral TIA or infarction.

A high-pitched prolonged carotid bruit fading into diastole is often associated with tightly stenotic lesions. As the stenosis grows tighter and flow distal to the stenosis becomes reduced, the bruit becomes fainter and may disappear when occlusion is imminent.

COMMON CAROTID ARTERY All symptoms and signs of internal carotid occlusion may also be present with occlusion of the common carotid artery. Bilateral common carotid artery occlusions at their origin may occur in Takayasu’s arteritis (Chap. 306).

Stroke Within the Posterior Circulation The posterior circulation is composed of the paired vertebral arteries, the basilar artery, and the paired posterior cerebral arteries. The vertebral arteries join to form the basilar artery at the pontomedullary junction. The basilar artery divides into two posterior cerebral arteries in the interpeduncular fossa (Fig. 349-3). These major arteries give rise to long and short circumferential branches and to smaller deep penetrating branches that supply the cerebellum, medulla, pons, midbrain, thalamus, thalamus, hippocampus, and medial temporal and occipital lobes. Occlusion of each vessel produces its own distinctive syndrome.

POSTERIOR CEREBRAL ARTERY In 75% of cases, both PCAs arise from the bifurcation of the basilar artery; in 20%, one has its origin from the ipsilateral internal carotid artery via the posterior communicating artery; in 5%, both originate from the respective ipsilateral internal carotid arteries (Fig. 349-3). The precommunal, or P1, segment of the true posterior cerebral artery is atretic in such cases.

PCA syndromes usually result from atheroma formation or emboli that lodge at the top of the basilar artery; posterior circulation disease may also be caused by dissection of either vertebral artery and fibromuscular dysplasia.

Two clinical syndromes are commonly observed with occlusion of the PCA: (1) P1 syndrome: midbrain, subthalamic, andthalamic signs, which are due to disease of the proximal P1 segment of the PCA or its penetrating branches (thalamogeniculate, Percheron, and posterior choroidal arteries); and (2) P2 syndrome: cortical temporal and occipital lobe signs, due to occlusion of the P2 segment distal to the junction of the PCA with the posterior communicating artery.

P1 Syndromes Infarction usually occurs in the ipsilateral subthalamus and medial thalamus and in the ipsilateral cerebral peduncle and midbrain (Fig. 349-7). A third nerve palsy with contralateral ataxia (Claude’s syndrome) or with contralateral hemiplegia (Weber’s syndrome) may result. The ataxia indicates involvement of the red nucleus or dentatorubrothalamic tract; the hemiplegia is localized to the cerebral peduncle. If the subthalamic nucleus is involved, contralateral
hemiballismus may occur. Occlusion of the artery of Percheron produces paresis of upward gaze and drowsiness, and often abulia. Extensive infarction in the midbrain and subthalamus occurring with bilateral proximal PCA occlusion presents as coma, unreactive pupils, bilateral pyramidal signs, and decerebrate rigidity.

Occlusion of the penetrating branches of thalamic and thalamogeniculate arteries produces less extensive thalamic and thalamocapsular lacunar syndromes. The thalamic Dejerine-Roussy syndrome consists of contralateral hemisensory loss followed later by an agonizing, seeing or burning pain in the affected areas. It is persistent and responds poorly to analgesics. Anticonvulsants (carbamazepine or gabapentin) or tricyclic antidepressants may be beneficial.

P2 Syndromes (See also Fig. 349-7) Occlusion of the distal PCA causes infarction of the medial temporal and occipital lobes. Contralateral homonymous hemianopia with macula sparing is the usual manifestation. Occasionally, only the upper quadrant of visual field is involved. If the visual association areas are spared and only the calcarine cortex is involved, the patient may be aware of visual defects. Medial temporal lobe and hippocampal involvement may cause an acute disturbance in memory, particularly if it occurs in the dominant hemisphere. The defect usually clears because memory has bilateral representation. If the dominant hemisphere is affected and the infarct extends to involve the splenium of the corpus callosum, the patient may demonstrate alexia without agraphia. Visual agnosia for faces, objects, mathematical symbols, and colors and anoma with paraphasic errors (amnestic aphasia) may also occur in this setting even without callosal involvement. Occlusion of the posterior cerebral artery can produce peduncular hallucinosis (visual hallucinations of brightly colored scenes and objects).

Bilateral infarction in the distal PCs produces cortical blindness (blindness with preserved pupillary light reaction). The patient is often unaware of the blindness or may even deny it (Anton’s syndrome). Tiny islands of vision may persist, and the patient may report that vision fluctuates as images are captured in the preserved portions. Rarely, only peripheral vision is lost and central vision is spared, resulting in “gun-barrel” vision. Bilateral visual association area lesions may result in Balint’s syndrome, a disorder of the orderly visual scanning of the environment (Chap. 23), usually resulting from infarcts secondary to low flow in the “watershed” between the distal posterior and middle cerebral artery territories, as occurs after cardiac arrest. Patients may experience persistence of a visual image for several minutes despite gazeing at another scene (palinopsia). Embolic occlusion of the top of the basilar artery can produce any or all of the central or peripheral territory symptoms. The hallmark is the sudden onset of bilateral signs, including ptoisis, pupillary asymmetry or lack of reaction to light, and somnolence.

**VERTEBRAL AND POSTERIOR INFERIOR CEREBELLAR ARTERIES** The vertebral artery, which arises from the innominate artery on the right and the subclavian artery on the left, consists of four segments. The first (V1) extends from its origin to its entrance into the sixth or fifth transverse vertebral foramen. The second segment (V2) traverses the vertebral foramina from C6 to C2. The third (V3) passes through the transverse foramen and circles around the arch of the atlas to pierce the dura at the foramen magnum. The fourth (V4) segment courses upward to join the other vertebral artery to form the basilar artery; only the fourth segment gives rise to branches that supply the brainstem and cerebellum. The posterior inferior cerebellar artery (PICA) in its proximal segment supplies the lateral medulla and, in its distal branches, the inferior surface of the cerebellum.

Atherothrombotic lesions have a predilection for V1 and V4 segments of the vertebral artery. The first segment may become diseased at the origin of the vessel and may produce posterior circulation emboli; collateral flow from the contralateral vertebral artery or the ascending cervical, thyrocervical, or occipital arteries is usually sufficient to prevent low-flow TIAs or stroke. When one vertebral artery is atretic and an atherothrombotic lesion threatens the origin of the other, the collateral circulation, which may also include retrograde flow down the basilar artery, is often insufficient (Figs. 349-3 and 349-7). In this setting, low-flow TIAs may occur, consisting of syncope, vertigo, and alternating hemiplegia; this state also sets the stage for thrombosis. Disease of the distal fourth segment of the vertebral artery can promote thrombus formation manifest as embolism or with propagation as basilar artery thrombosis. Stenosis proximal to the origin of the posterior inferior cerebellar artery can threaten the lateral medulla and posterior inferior surface of the cerebellum.

If the subclavian artery is occluded proximal to the origin of the vertebral artery, there is a reversal in the direction of blood flow in the ipsilateral vertebral artery. Exercise of the ipsilateral arm may increase demand on vertebral flow, producing posterior circulation TIAs, or “subclavian steal.” Although atheromatous disease rarely narrows the second and third segments of the vertebral artery, this region is subject to dissection, fibromuscular dysplasia, and, rarely, encroachment by osteophytic spurs within the vertebral foramina.

Emolic occlusion or thrombosis of a V4 segment causes ischemia of the lateral medulla. The constellation of vertigo, numbness of the ipsilateral face and contralateral limbs, diplopia, hoarseness, dysarthria, dysphagia, and ipsilateral Horner’s syndrome is called the lateral medullary (or Wallenberg’s) syndrome (Fig. 349-8). Most cases result from ipsilateral vertebral artery occlusion; in the remainder, PICA occlusion is responsible. Occlusion of the medullary penetrating branches of the vertebral artery or PICA results in partial syndromes. Hemiparesis is not a feature of vertebral artery occlusion.

Rarely, a medial medullary syndrome occurs with infarction of the pyramid and contralateral hemisareosis of the arm and leg, sparing the face. If the medial lemniscus and emerging hypoglossal nerve fibers are involved, contralateral loss of joint position sense and ipsilateral tongue weakness occur.

Cerebellar infarction with edema can lead to sudden respiratory arrest due to raised ICP in the posterior fossa. Drowsiness, Babinski signs, dysarthria, and bifacial weakness may be absent, or present only briefly, before respiratory arrest ensues. Gait unsteadiness, headache, dizziness, nausea, and vomiting may be the only early symptoms and signs and should arouse suspicion of this impending complication, which may require neurosurgical decompression, often with an excellent outcome. Separating these symptoms from those of viral labyrinthitis can be a challenge, but headache, neck stiffness, and unilateral dysmetria favor stroke.

**BASILAR ARTERY** Branches of the basilar artery supply the base of the pons and superior cerebellum and fall into three groups: (1) paramedian, 7 to 10 in number, which supply a wedge of pons on either side of the midline; (2) short circumferential, 5 to 7 in number, which supply the lateral two-thirds of the pons and middle and superior cerebellar peduncles; and (3) bilateral long circumferential (superior cerebellar and anterior inferior cerebellar arteries), which course around the pons to supply the cerebellar hemispheres.

Atheromatous lesions can occur anywhere along the basilar trunk but are most frequent in the proximal basilar and distal vertebral segments. Typically, lesions occlude either the proximal basilar and or both vertebral arteries. The clinical picture varies depending on the availability of retrograde collateral flow from the posterior communicating arteries. Rarely, dissection of a vertebral artery may involve the basilar artery and, depending on the location of true and false lumen, may produce multiple penetrating artery strokes.

Although atherothrombosis occasionally occludes the distal portion of the basilar artery, emboli from the heart or proximal vertebral or basilar segments are more commonly responsible for “top of the basilar” syndromes.

Because the brainstem contains many structures in close apposition, a diversity of clinical syndromes may emerge with ischemia, reflecting involvement of the corticospinal and corticobulbar tracts, ascending sensory tracts, and cranial nerve nuclei (Figs. 349-9, 349-10, and 349-11).
The symptoms of transient ischemia or infarction in the territory of the basilar artery often do not indicate whether the basilar artery itself or one of its branches is diseased, yet this distinction has important implications for therapy. The picture of complete basilar occlusion, however, is easy to recognize as a constellation of bilateral long tract signs (sensory and motor) with signs of cranial nerve and cerebellar dysfunction. A “locked-in” state of preserved consciousness with quadriplegia and cranial nerve signs suggests complete pontine and lower midbrain infarction. The therapeutic goal is to identify impending basilar occlusion before devastating infarction occurs. A series of TIAs and a slowly progressive, fluctuating stroke are extremely significant as they often herald an atherothrombotic occlusion of the distal vertebral or proximal basilar artery.

TIAs in the proximal basilar distribution may produce dizziness (often described by patients as “swimming,” “swaying,” “moving,” “unsteadiness” or “light-headedness”). Other symptoms that warn of basilar thrombosis include diplopia, dysarthria, facial or circumoral numbness, and hemisensory symptoms. In general, symptoms of basilar branch TIAs affect one side of the brainstem, whereas symptoms of basilar artery TIAs usually affect both sides, though a “herald” hemiparesis has been emphasized as an initial symptom of basilar occlusion. Most often TIAs, whether due to impending occlusion of the basilar artery or a basilar branch, are short-lived (5 to 30 min) and repetitive, occurring several times a day. The pattern suggests intermittent reduction of flow. Many neurologists treat with heparin to prevent clot propagation.

Atherothrombotic occlusion of the basilar artery with infarction usually causes bilateral brainstem signs. A gaze paresis or internuclear ophthalmoplegia associated with ipsilateral hemiparesis may be the only manifestation of bilateral brainstem ischemia. More often, unequivocal signs of bilateral pontine disease are present. Complete basilar thrombosis carries a high mortality.

Occlusion of a branch of the basilar artery usually causes unilateral symptoms and signs involving motor, sensory, and cranial nerves. As long as symptoms remain unilateral, concern over impending basilar occlusion should be reduced.

Occlusion of the superior cerebellar artery results in severe ipsilateral cerebellar ataxia, nausea and vomiting, dysarthria, and contralateral loss of pain and temperature sensation over the extremities, body, and face (spino- and trigeminothalamic tract). Partial deafness, ataxic tremor of the ipsilateral upper extremity, Horner’s syndrome, and palatal myoclonus may occur rarely. Partial syndromes occur frequently (Fig. 349-11). With large strokes, swelling and mass effects may compress the midbrain or produce hydrocephalus; these symptoms may evolve rapidly. Neurosurgical intervention may be lifesaving in such cases.

Occlusion of the anterior inferior cerebellar artery produces variable degrees of infarction because the size of this artery and the territory it supplies vary inversely with those of the PICA. The principal symptoms include: (1) ipsilateral deafness, facial weakness, vertigo, nausea and vomiting, nystagmus, tinnitus, cerebellar ataxia, Horner’s syndrome, and paresis of conjugate lateral gaze; and (2) contralateral loss of pain and temperature sensation. An occlusion close to the origin of the artery may cause corticospinal tract signs (Fig. 349-9).

Occlusion of one of the short circumferential branches of the basilar artery affects the lateral two-thirds of the pons and middle or superior cerebellar peduncle, whereas occlusion of one of the paramedian branches affects a wedge-shaped area on either side of the medial pons (Figs. 349-9 through 349-11).

**IMAGING STUDIES** (See also Chap. 347)  
**Computed Tomographic Scans**  
CT radiographic images identify or exclude hemorrhage as the cause of stroke, and they identify extraparenchymal hemorrhages, neoplasms, abscesses, and other conditions masquerading as stroke. Scans obtained in the first several hours after an infarction generally show no abnormality, and the infarct may not be seen reliably for 24 to 48 h. CT may fail to show small ischemic strokes in the posterior fossa because of bone artifact; small infarcts on the cortical surface may also be missed.

Contrast-enhanced CT scans add specificity by showing contrast enhancement of subacute infarcts and allow visualization of venous structures. Coupled with newer generation scanners, CT angiography (CTA) can be performed with administration of intravenous iohodinated contrast allowing visualization of the cervical and intracranial arteries. Carotid disease and intracranial vascular occlusions are readily identified with this method (Fig. 349-12). After an intravenous bolus of contrast, deficits in brain perfusion produced by vascular occlusion can also be demonstrated (Fig. 349-12 C). CT imaging is also sensitive for detecting subarachnoid hemorrhage, and CTA can readily identify intracranial aneurysms (see below). Because of its speed and wide availability, noncontrast head CT is the imaging modality of choice in patients with acute stroke (Fig. 349-1), and CTA and CT perfusion imaging may also be useful and convenient adjuncts.

**Magnetic Resonance Imaging (MRI)**  
MRI reliably documents the extent and location of infarction in all areas of the brain, including the posterior fossa and cortical surface. It also identifies intracranial hemorrhage and other abnormalities but is less sensitive than CT for detecting acute blood. MRI scanners with magnets of higher field strength produce more reliable and precise images. Diffusion-weighted imaging is more sensitive for early brain infarction than standard MR sequences (Fig. 349-13), as is FLAIR (fluid-attenuated inversion recovery) imaging (Chap. 347). Using intravenous administration of gadolinium contrast, MR perfusion studies can be performed. Brain regions showing poor perfusion but no abnormality on diffusion are considered equivalent to the ischemic penumbra (see “Pathophysiol-
Cerebral angiography coupled with endovascular techniques for cerebral angiography carries risks of arterial damage, groin hemorrhage, embolic stroke, and renal failure from contrast nephropathy, so it should be reserved for situations where less invasive means are inadequate. Ultrasound Techniques Stenosis at the origin of the internal carotid artery can be identified and quantified reliably by ultrasonography that combines a B-mode ultrasound image with a Doppler ultrasound assessment of flow velocity (“duplex” ultrasound). Transcranial Doppler (TCD) assessment of middle, anterior, and posterior cerebral artery flow and of vertebrobasilar flow is also useful. This latter technique can detect stenotic lesions in the large intracranial arteries because such lesions increase systolic flow velocity. In many cases, MR angiography combined with carotid and transcranial ultrasound studies eliminates the need for conventional x-ray angiography in evaluating vascular stenosis. Alternatively, CT angiography of the entire head and neck can be performed during the initial imaging of acute stroke. Because this images the entire arterial system relevant to stroke, with the exception of the heart, much of the clinician’s stroke workup can be completed with one imaging study.

Perfusion Techniques Both xenon techniques (principally xenon-CT) and PET can quantify cerebral blood flow. These tools are generally used for research (Chap. 347) but can be useful for determining the significance of arterial stenosis and planning for revascularization surgery. Single photon emission tomography (SPECT), CT perfusion, and MR perfusion techniques report relative cerebral blood flow. Since CT imaging is used as the initial imaging modality for acute stroke, many centers now combine both CT angiography and CT perfusion imaging together with the noncontrast CT scan. CT perfusion imaging increases the sensitivity and improves accuracy in imaging ischemic brain. Alternatively, MR perfusion can be combined with MR diffusion imaging to identify the ischemic penumbra as the mismatch between these two imaging sequences (Fig. 349-13). The ability to image the ischemic penumbra allows more judicious selection of patients who may or may not benefit from acute interventions such as thrombolysis or investigational neuroprotective strategies.

INTRACRANIAL HEMORRHAGE

Hemorrhages are classified by their location and the underlying vascular pathology. Bleeding into subdural and epidural spaces is principally produced by trauma (Chap. 357). Intraparenchymal, intraventricular, and subarachnoid hemorrhage will be considered here.

DIAGNOSIS Intracranial hemorrhage is often discovered on noncontrast CT imaging of the brain during the acute evaluation of stroke. Since CT is more sensitive than routine MRI for acute blood, CT imaging is the preferred method for acute stroke evaluation (Fig. 349-1). The location of the hemorrhage narrows the differential diagnosis to a few entities. Table 349-6 lists the causes and anatomic spaces involved in hemorrhages.

EMERGENCY MANAGEMENT Close attention should be paid to airway management since a reduction in the level of consciousness is common. The initial blood pressure should be maintained until the results of the CT scan are reviewed. Patients with acute SAH should have blood pressure lowered to a normal range with nonvasodilating agents such as nicardipine, labetalol, or esmolol. Patients with cerebellar hemorrhages or with depressed mental status and radiographic evidence of hydrocephalus should undergo urgent neurosurgical evaluation. Based on the clinical examination and CT findings, further imaging studies may be necessary, including MRI or conventional x-ray angiography. Stuporous or comatose patients generally are treated presumptively for elevated ICP, with tracheal intubation and hyperventilation, mannitol administration, and elevation of the head of the bed while surgical consultation is obtained (Chap. 258).

SUBARACHNOID HEMORRHAGE Excluding head trauma, the most common cause of SAH is rupture of a saccular aneurysm. Other causes
include bleeding from a vascular anomaly and extension into the subarachnoid space from a primary intracerebral hemorrhage. Some idiopathic SAHs are localized to the perimesencephalic cisterns and are benign; they probably have a venous or capillary source, and angiography is unrevealing.

**Saccular ("Berry") Aneurysm** Autopsy and angiography studies have found that about 2% of adults harbor intracranial aneurysms, for a prevalence of 4 million persons in the United States; the aneurysm will rupture, producing SAH, in 25,000 to 30,000 cases per year. For patients who arrive alive at hospital, the mortality rate over the next month is about 45%. Of those who survive, more than half are left with major neurologic deficits as a result of the initial hemorrhage, cerebral vasospasm with infarction, or hydrocephalus. If the patient survives but the aneurysm is not obliterated, the rate of rebleeding is about 20% in the first 2 weeks and about 3% per year afterwards. Given these alarming figures, the major therapeutic emphasis is on preventing the predictable early complications of the SAH.

Unruptured, asymptomatic aneurysms are much less dangerous than a recently ruptured aneurysm. The annual risk of rupture for aneurysms <10 mm in size is ~0.1%, and for aneurysms ≥10 mm in size is ~0.5 to 1%; the surgical morbidity far exceeds these percentages. As more data become available, a true risk-benefit analysis for treating these aneurysms will result.

Giant aneurysms, those >2.5 cm in diameter, occur at the same sites (see below) as small aneurysms and account for 5% of cases. The three most common locations are the terminal internal carotid artery, MCA bifurcation, and top of the basilar artery. Their risk of rupture is about 6% in the first year after identification and may remain high indefinitely. They often cause symptoms by compressing the adjacent brain or cranial nerves.

Mycotic aneurysms are usually located distal to the first bifurcation of major arteries of the circle of Willis. Most result from infected emboli due to bacterial endocarditis causing septic degeneration of arteries and subsequent dilatation and rupture. Whether these lesions should be sought and repaired prior to rupture, or left to heal spontaneously, is controversial.

**PATHOPHYSIOLOGY** Saccular aneurysms occur at the bifurcations of the large to medium-sized intracranial arteries; rupture is into the subarachnoid space in the basal cisterns and often into the parenchyma of the adjacent brain. Approximately 85% of aneurysms occur in the anterior circulation, mostly on the circle of Willis. About 20% of patients have multiple aneurysms, many at mirror sites bilaterally. As an aneurysm develops, it typically forms a neck with a dome. The length of the neck and the size of the dome vary greatly and are factors that are important in planning neurosurgical obliteration or endovascular embolization. The arterial internal elastic lamina disappears at the base of the neck. The media thins, and connective tissue replaces smooth-muscle cells. At the site of rupture (most often the dome) the wall thins, and the tear that allows bleeding is often no more than 0.5 mm long. Aneurysm size and site are important in predicting risk of rupture. Those >7 mm in diameter and those at the top of the basilar artery and at the origin of the posterior communicating artery are at greater risk of rupture.

**CLINICAL MANIFESTATIONS** Most unruptured intracranial aneurysms are completely asymptomatic. Symptoms are usually due to rupture and resultant SAH. At the moment of aneurysmal rupture with major SAH, the ICP suddenly rises. This may account for the sudden transient loss of consciousness that occurs in nearly half of patients. Sudden loss of consciousness may be preceded by a brief moment of excruciating headache, but most patients first complain of headache upon regaining consciousness. In 10% of cases, aneurysmal bleeding is severe enough to cause loss of consciousness for several days. In about 45% of cases, severe headache associated with exertion is the presenting complaint. The patient often calls the headache “the worst headache of my life.” Occasionally these ruptures may present as headache of only moderate intensity or as a change in the patient’s usual headache pattern. The headache is usually generalized, often with neck stiffness, and vomiting is common.

Although sudden headache in the absence of focal neurologic symptoms is the hallmark of aneurysmal rupture, focal neurologic deficits may occur. Anterior communicating artery or MCA bifurcation aneurysms may rupture into the adjacent brain or subdural space and form a hematoma large enough to produce mass effect. The common deficits that result include hemiparesis, aphasia, and abulia.

Occasionally, prodromal symptoms suggest the location of a progressively enlarging unruptured aneurysm. A third cranial nerve palsy, particularly when associated with papillary dilation, loss of ipsilateral (but retained contralateral) light reflex, and focal pain above or behind the eye, may occur with an expanding aneurysm at the junction of the posterior communicating artery and the internal carotid artery. A sixth nerve palsy may indicate an aneurysm in the cavernous sinus, and visual field defects can occur with an expanding suprachiasmatic carotid or anterior cerebral artery aneurysm. Occipital and posterior cerebral pain may signal a posterior inferior cerebellar artery or anterior inferior cerebellar artery aneurysm. Pain in or behind the eye and in the low temple can occur with an expanding MCA aneurysm. Thunderclap headache is a variant of migraine that simulates a SAH. Before concluding that a patient with sudden, severe headache has thunderclap migraine, a definitive workup for aneurysm or other intracranial pathology is required.

Aneurysms can undergo small ruptures and leaks of blood into the subarachnoid space, so-called sentinel bleeds. Sudden unexplained headache at any location should raise suspicion of SAH and be investigated, because a major hemorrhage may be imminent.
DELAYED NEUROLOGIC DEFICITS  There are four major causes of delayed neurologic deficits: rerupture, hydrocephalus, vasospasm, and hyponatremia.

1. Rerupture. The incidence of rerupture of an untreated aneurysm in the first month following SAH is ~30%, with the peak in the first 7 days. Rerupture is associated with a 60% mortality and poor outcome. Early treatment eliminates this risk.

2. Hydrocephalus. Acute hydrocephalus can cause stupor and coma. More often, subacute hydrocephalus develops over a few days or weeks and causes progressive drowsiness or slowed mentation (abulia) with incontinence. Hydrocephalus is differentiated from cerebral vasospasm with a CT scan, TCD ultrasound, or conventional x-ray angiography. Hydrocephalus may clear spontaneously or require temporary ventricular drainage. Chronic hydrocephalus may develop weeks or months after SAH and manifest as gait difficulty, incontinence, or impaired mentation. Subtle signs may be a lack of initiative in conversation or a failure to recover independence.

3. Vasospasm. Narrowing of the arteries at the base of the brain following SAH causes symptoms of ischemia and infarction in ~30% of patients and is the major cause of delayed morbidity and death. Signs of ischemia appear 4 to 14 days after the hemorrhage, most often at 7 days. The severity and distribution of vasospasm determine whether infarction will occur.

   Delayed vasospasm is believed to result from direct effects of clotted blood and its breakdown products on the artery. In general, the more blood that surrounds the arteries, the greater the chance of symptomatic vasospasm. Spasm of major arteries produces symptoms referable to the appropriate vascular territory (see “Stroke Syndromes,” above). All of these focal symptoms may present abruptly, fluctuate, or develop over a few days. In most cases, focal spasm is preceded by a decline in mental status.

   Vasospasm can be detected reliably with conventional x-ray angiography, but this invasive procedure is expensive and carries risk of stroke and other complications. TCD ultrasound is based on the principle that the velocity of blood flow within an artery will rise as the lumen diameter is narrowed. By directing the probe along the MCA and proximal ACA, carotid terminus, vertebral, and basilar arteries on a daily or every-other-day basis, vasospasm can be reliably detected and treatments initiated to prevent cerebral ischemia (see below). CT angiography is another method that can reliably detect vasospasm.

   Severe cerebral edema in patients with infarction from vasospasm may increase the ICP enough to reduce cerebral perfusion pressure. Treatment is with mannitol and hyperventilation (Chap. 258).

4. Hyponatremia. Hyponatremia may be profound and develop quickly in the first 2 weeks following SAH. It usually results from inappropriate secretion of vasopressin (Chap. 319) and secretion of atrial and brain natriuretic factors, which produce a natriuresis. This “cerebral salt-wasting syndrome” clears over the course of 1 to 2 weeks and, in the setting of SAH, should not be treated with free-water restriction as this may increase the risk of stroke (see below).

LABORATORY EVALUATION AND IMAGING  (Fig. 349-14) The hallmark of aneurysmal rupture is blood in the cerebrospinal fluid (CSF). More than 95% of cases have enough blood to be visualized on a high-quality noncontrast CT scan obtained within 72 h. If the scan fails to establish the diagnosis of SAH and no mass lesion or obstructive hydrocephalus is found, a lumbar puncture should be performed to establish the presence of subarachnoid blood. Lysis of the red blood cells and subsequent conversion of hemoglobin to bilirubin stains the spinal fluid yellow within 6 to 12 h of SAH. This xanthochromic spinal fluid peaks in intensity at 48 h and lasts for 1 to 4 weeks, depending on the amount of subarachnoid blood.

   The extent and location of subarachnoid blood on noncontrast CT scan help locate the underlying aneurysm, identify the cause of any neurologic deficit, and predict delayed vasospasm. A high incidence of symptomatic vasospasm in the MCA and ACA has been found when early CT scans show subarachnoid clots >5 × 3 mm in the basal cisterns or layers of blood >1 mm thick in the cerebral fissures. CT scans less reliably predict vasospasm in the vertebral, basilar, or posterior cerebral arteries.

   Lumbar puncture prior to an imaging procedure is indicated only if a CT scan is not available at the time of the suspected SAH. Once the diagnosis of hemorrhage from a ruptured saccular aneurysm is suspected, four-vessel conventional x-ray angiography (both carotids and both vertebrais) is generally performed to localize and define the anatomic details of the aneurysm and to determine if other unruptured aneurysms exist (Fig. 349-14). CT angiography is an alternative method for locating the aneurysm and may be sufficient to plan definitive therapy. At some centers, the ruptured aneurysm can be treated using endovascular techniques at the time of the initial angiogram (see below).

   The ECG frequently shows ST-segment and T-wave changes similar to those associated with cardiac ischemia. Prolonged QRS complex, increased QT interval, and prominent “peaked” or deeply inverted symmetric T waves are usually secondary to the intracranial hemorrhage. There is evidence that structural myocardial lesions produced by circulating catecholamines may occur after SAH, causing reversible cardiomyopathy sufficient to cause shock or congestive heart failure. Serious ventricular dysrhythmias are unusual. Close monitoring (daily or twice daily) of electrolytes is important because hyponatremia can occur precipitously during the first 2 weeks following SAH (see above).

TREATMENT  Early aneurysm repair prevents rerupture and allows the safe application of techniques to improve blood flow (e.g., induced hypertension and hypervolemia) should symptomatic vasospasm develop. An aneurysm can be “clipped” by a neurosurgeon or “coiled” by a neurinterventional radiologist. Surgical repair involves placing a metal clip across the aneurysm neck, thereby immediately eliminating the risk of
rebleeding. This approach requires craniotomy and brain retraction, which is associated with neurologic morbidity. The newer endovascular technique involves placing platinum coils within the aneurysm via a catheter that is passed from the femoral artery. The aneurysm is packed tightly to enhance thrombosis and over time is walled-off from the circulation (Fig. 349-14). The only prospective randomized trial of surgery versus endovascular treatment for ruptured aneurysm, the International Study of Aneurysm Treatment (ISAT), was terminated early when 24% of patients treated with endovascular therapy were dead or dependent at 1 year compared to 31% treated with surgery, a 23% relative reduction. However, some aneurysms have a morphology that is not amenable to coiling, and only a few endovascular centers are available worldwide. Thus, surgery remains an important treatment option.

The medical management of SAH centers on protecting the airway, managing blood pressure before and after aneurysm treatment, preventing rebleeding prior to treatment, managing vasospasm, treating hydrocephalus, treating hyponatremia, and preventing pulmonary embolus.

Intracranial hypertension following aneurysmal rupture occurs secondary to subarachnoid blood, parenchymal hematoma, acute hydrocephalus, or loss of vascular autoregulation. Patients who are stuporous should undergo emergent ventriculostomy to prevent cerebral ischemia from high ICP. Medical therapies designed to combat raised ICP (e.g., mild hyperventilation, mannitol, and sedation) can also be used as needed (Chap. 258). High ICP refractory to treatment is a poor prognostic sign.

Prior to definitive treatment of the ruptured aneurysm, care is required to maintain adequate cerebral perfusion pressure while avoiding excessive elevation of arterial pressure. Occasionally an intracranial hematoma causing neurologic deterioration requires removal. Because rebleeding is common, all patients who are not candidates for early aneurysm repair are put on bed rest in a quiet room and are given stool softeners to prevent straining. If headache or neck pain is severe, mild sedation and analgesia are prescribed. Extreme sedation is avoided because it can obscure changes in neurologic status. Adequate hydration is necessary to avoid a decrease in blood volume predisposing to brain ischemia.

Seizures are uncommon at the onset of aneurysmal rupture. The quivering, jerking, and extensor posturing that often accompany loss of consciousness are probably related to the sharp rise in ICP or, perhaps, acute generalized vasospasm. However, phenytoin is often given as prophylactic therapy since a seizure may promote rebleeding.

Glucocorticoids may help reduce the head and neck ache caused by the irritative effect of the subarachnoid blood. There is no good evidence that they reduce cerebral edema, are neuroprotective, or reduce vascular injury, and their routine use therefore is not recommended.

Antifibrinolytic agents are not routinely prescribed but may be considered in patients in whom aneurysm treatment cannot proceed immediately. They are associated with a reduced incidence of aneurysmal rerupture but are also associated with an increased incidence of delayed cerebral infarction and DVT.

Vasospasm remains the leading cause of morbidity and mortality following aneurysmal SAH and treatment of the aneurysm. Treatment with the calcium channel antagonist nimodipine (60 mg orally every 4 h) improves outcome, perhaps by preventing ischemic injury rather than reducing the risk of vasospasm. Nimodipine can cause significant hypotension in some patients, which may worsen cerebral ischemia in patients with vasospasm. Symptomatic cerebral vasospasm can also be treated by increasing the cerebral perfusion pressure by raising mean arterial pressure through plasma volume expansion and the judicious use of vasopressor agents, usually phenylephrine or dopamine. Raised perfusion pressure has been associated with clinical improvement in many patients, but high arterial pressure may promote rebleeding in unprotected aneurysms. Treatment with induced hypertension and hypervolemia generally requires monitoring of arterial and central venous pressures. Volume expansion helps prevent hypotension, augments cardiac output, and reduces blood viscosity by reducing the hematocrit. This method is called “triple-H” (hypertension, hemodilution, and hypervolemic) therapy.

If symptomatic vasospasm persists despite optimal medical therapy, intraarterial vasodilators and percutaneous transluminal angioplasty are considered. Vasodilatation following angioplasty appears to be permanent, allowing triple-H therapy to be tapered sooner. The pharmacologic vasodilators (verapamil and nicardipine) do not last more than 8 to 24 h, and therefore multiple treatments may be required until the subarachnoid blood is reabsorbed.

Acute hydrocephalus can cause stupor or coma. It may clear spontaneously or require temporary ventricular drainage. When chronic hydrocephalus develops, ventricular shunting is the treatment of choice.

Free-water restriction is contraindicated in patients with SAH at risk for vasospasm because hypovolemia and hypotension may occur and precipitate cerebral ischemia. Many patients continue to experience a decline in serum sodium despite receiving parenteral fluids containing normal saline. Frequently, supplemental oral salt coupled with normal saline will mitigate hyponatremia, but often patients also require hypertonic saline. Care must be taken not to correct serum sodium too quickly in patients with marked hyponatremia of several days’ duration, as central pontine myelinolysis (Chap. 258) may occur.

All patients should have pneumatic compression stockings applied to prevent pulmonary embolism. Systemic heparin is contraindicated in patients with ruptured and untreated aneurysms; it is a relative contraindication following craniotomy, and it may delay thrombosis of a coiled aneurysm.

**Intraparenchymal Hemorrhage** Intraparenchymal hemorrhage is the most common type of intracranial hemorrhage. It accounts for about 10% of all strokes and is associated with a 50% case fatality rate. Incidence rates are particularly high in Asians and African Americans. Hypertension, trauma, and cerebral amyloid angiopathy cause the majority of these hemorrhages. Advanced age and heavy alcohol consumption increase the risk, and cocaine use is one of the most important causes in the young.

**Hypertensive Intraparenchymal Hemorrhage** Hypertensive intraparenchymal hemorrhage (hypertensive hemorrhage or hypertensive intracerebral hemorrhage) usually results from spontaneous rupture of a small penetrating artery deep in the brain. The most common sites are the basal ganglia (putamen, thalamus, and adjacent deep white matter), deep cerebellum, andpons. When hemorrhages occur in other brain areas or in nonhypertensive patients, greater consideration should be given to hemorrhagic disorders, neoplasms, vascular malformations, and other causes. The small arteries in these areas seem most prone to hypertension-induced vascular injury. The hemorrhage may be small or a large clot may form and compress adjacent tissue, causing herniation and death. Blood may dissect into the ventricular system, which substantially increases morbidity and may cause hydrocephalus.

Most hypertensive intraparenchymal hemorrhages develop over 30 to 90 min, whereas those associated with anticoagulant therapy may evolve for as long as 24 to 48 h. Within 48 h macrophages begin to phagocytize the hemorrhage at its outer surface. After 1 to 6 months, the hemorrhage is generally resolved to a slitlike orange cavity lined with glial scar and hemosiderin-laden macrophages.

**Clinical Manifestations** Although not particularly associated with exertion, intracerebral hemorrhages almost always occur while the patient is awake and sometimes when stressed. The hemorrhage generally presents as the abrupt onset of focal neurologic deficit. Seizures are uncommon. The focal deficit typically worsens steadily over 30 to 90 min and is associated with a diminishing level of consciousness and signs of increased ICP, such as headache and vomiting.

The putamen is the most common site for hypertensive hemorrhage, and the adjacent internal capsule is invariably damaged (Fig.
Contralateral hemiparesis is therefore the sentinel sign. When mild, the face sags on one side over 5 to 30 min, speech becomes slurred, the arm and leg gradually weaken, and the eyes deviate away from the side of the hemiparesis. The paralysis may worsen until the affected limbs become flaccid or extend rigidly. When hemorrhages are large, drowsiness gives way to stupor as signs of upper brainstem compression appear. Coma ensues, accompanied by deep, irregular, or intermittent respiration, a dilated and fixed ipsilateral pupil, and decerebrate rigidity. In milder cases, edema in adjacent brain tissue may cause progressive deterioration over 12 to 72 h.

Thalamic hemorrhages also produce a contralateral hemiplegia or hemiparesis from pressure on, or dissection into, the adjacent internal capsule. A prominent sensory deficit involving all modalities is usually present. Aphasia, often with preserved verbal repetition, may occur after hemorrhage into the dominant thalamus, and apraxia or mutism occurs in some cases of nondominant hemorrhage. There may also be a homonymous visual field defect. Thalamic hemorrhages cause several typical ocular disturbances by virtue of extension medially into the upper midbrain. These include deviation of the eyes downward and inward so that they appear to be looking at the nose, unequal pupils with absence of light reaction, skew deviation with the eye opposite the hemorrhage displaced downward and medially, ipsilateral Horner’s syndrome, absence of convergence, paralysis of vertical gaze, and retraction nystagmus. Patients may later develop a chronic, contralateral pain syndrome (Déjerine-Roussy syndrome).

In pontine hemorrhages, deep coma with quadriplegia usually occurs over a few minutes. There is often prominent decerebrate rigidity and “pin-point” (1 mm) pupils that react to light. There is impairment of reflex horizontal eye movements evoked by head turning (doll’s head or oculocephalic maneuver) or by irrigation of the ears with ice water (Chap. 257). Hyperpnea, severe hypertension, and hyperhidrosis are common. Death often occurs within a few hours, but small hemorrhages are compatible with survival.

Cerebellar hemorrhages usually develop over several hours and are characterized by occipital headache, repeated vomiting, and ataxia of gait. In mild cases there may be no other neurologic signs other than gait ataxia. Dizziness or vertigo may be prominent. There is often paresis of conjugate lateral gaze toward the side of the hemorrhage, forced deviation of the eyes to the opposite side, or an ipsilateral sixth nerve palsy. Less frequent ocular signs include blepharospasm, involuntary closure of one eye, ocular bobbing, and skew deviation. Dysarthria and dysphagia may occur. As the hours pass, the patient often becomes stuporous and then comatose from brainstem compression or obstructive hydrocephalus; immediate surgical evacuation before brainstem compression occurs may be lifesaving. Hydrocephalus from fourth ventricle compression can be relieved by external ventricular drainage, but definitive hematoma evacuation is essential for survival. If the deep cerebellar nuclei are spared, full recovery is common.

Lobar Hemorrhage Symptoms and signs appear over several minutes. Most lobar hemorrhages are small and cause a restricted clinical syndrome that simulates an embolus to an artery supplying one lobe. For example, the major neurologic deficit with an occipital hemorrhage is hemianopia; with a left temporal hemorrhage, aphasia and delirium; with a parietal hemorrhage, hemisensory loss; and with frontal hemorrhage, arm weakness. Large hemorrhages may be associated with stupor or coma if they compress the thalamus or midbrain. Most patients with lobar hemorrhages have focal headaches, and more than half vomit or are drowsy. Stiff neck and seizures are uncommon.

Other Causes of Intracerebral Hemorrhage Cerebral amyloid angiopathy is a disease of the elderly in which arteriolar degeneration occurs and amyloid is deposited in the walls of the cerebral arteries. Amyloid angiopathy causes both single and recurrent lobar hemorrhages and is probably the most common cause of lobar hemorrhage in the elderly. It accounts for some intracranial hemorrhages associated with intravenous thrombolysis given for MI. This disorder can be suspected in patients who present with multiple hemorrhages (and infarcts) over several months or years, or in patients with “micro-bleeds” seen on brain MRI sequences sensitive for hemosiderin, but it is definitively diagnosed by demonstration of Congo red staining of amyloid in cerebral vessels. There is no specific therapy.

Cocaine is a frequent cause of stroke in young (age < 45) patients. Intracerebral hemorrhage, ischemic stroke, and SAH are all associated with cocaine use. Angiographic findings vary from completely normal arteries to large-vessel occlusion or stenosis, vasospasm, or changes consistent with vasculitis. The mechanism of cocaine-related stroke is not known, but cocaine enhances sympathetic activity causing acute, sometimes severe, hypertension, and this may lead to hemorrhage. Slightly more than half of cocaine-related intracranial hemorrhages are intracerebral, and the rest are subarachnoid. In cases of SAH, a saccular aneurysm is usually identified. Presumably, acute hypertension causes aneurysmal rupture. Head injury often causes intracranial bleeding. The common sites are intracerebral (especially temporal and inferior frontal lobes) and into the subarachnoid, subdural, and epidural spaces. Trauma must be considered in any patient with an unexplained acute neurologic deficit (hemiparesis, stupor, or confusion), particularly if the deficit occurred in the context of a fall (Chap. 357).

Intracranial hemorrhage associated with anticoagulant therapy can occur at any location; they are often lobar or subdural. Anticoagulant-related intracerebral hemorrhages may evolve slowly, over 24 to 48 h. Coagulopathy should be reversed with fresh-frozen plasma or factor replacement and vitamin K to limit the volume of hemorrhage. When intracerebral hemorrhage is associated with thrombocytopenia (platelet count < 50,000/μL), transfusion of fresh platelets is indicated. Intracerebral hemorrhage associated with hematologic disorders (leukemia, aplastic anemia, thrombocytopenic purpura) can occur at any site and may present as multiple intracerebral hemorrhages. Skin and mucous membrane bleeding is usually evident and offers a diagnostic clue.

Hemorrhage into a brain tumor may be the first manifestation of neoplasia. Choriocarcinoma, malignant melanoma, renal cell carcinoma, and bronchogenic carcinoma are among the most common metastatic tumors associated with intracerebral hemorrhage. Glioblastoma multiforme in adults and medulloblastoma in children may also have areas of intracerebral hemorrhage.
coma. Focal or lateralizing neurologic signs, either transitory or permanent, may occur but are infrequent and therefore suggest some other vascular disease (hemorrhage, embolism, or atherothrombosis). There are retinal hemorrhages, exudates, papilledema (hypertensive retinopathy), and evidence of renal and cardiac disease. In most cases ICP and CSF protein levels are elevated. The hypertension may be essential or due to chronic renal disease, acute glomerulonephritis, acute toxemia of pregnancy, pheochromocytoma, or other causes. Lowering the blood pressure reverses the process, but stroke can occur, especially if blood pressure is lowered too rapidly. Neuroradiologic examination reveals multifocal to diffuse cerebral edema and hemorrhage of various sizes from petechial to massive. Microscopically, there are necrosis of arterioles, minute cerebral infarcts, and hemorrhages. The term hypertensive encephalopathy should be reserved for this syndrome and not for chronic recurrent headaches, dizziness, recurrent TIAs, or small strokes that often occur in association with high blood pressure.

Primary intraventricular hemorrhage is rare. It usually begins within the substance of the brain and dissects into the ventricular system without leaving signs of intraparenchymal hemorrhage. Alternatively, bleeding can arise from peripendymal veins. Vasculitis, usually polyarteritis nodosa or lupus erythematosus, can produce hemorrhage into any region of the central nervous system; most hemorrhages are associated with hypertension, but the arteritis itself may cause bleeding by disrupting the vessel wall. Sepsis can cause small petechial hemorrhages throughout the cerebral white matter. Moya-moya disease, mainly an occlusive arterial disease that causes ischemic symptoms, may on occasion produce intraparenchymal hemorrhage, particularly in the young. Hemorrhages into the spinal cord are usually the result of an AVM or metastatic tumor. Epidural spinal hemorrhage produces a rapidly evolving syndrome of spinal cord or nerve root compression (Chap. 356). Spinal hemorrhages usually present with sudden back pain and some manifestation of myelopathy.

Laboratory and Imaging Evaluation The CT scan reliably detects acute focal hemorrhages in the supratentorial space. Small pontine hemorrhages may not be identified because of motion and bone-induced artifact that obscure structures in the posterior fossa. After the first 2 weeks, x-ray attenuation values of clotted blood diminish until they become isodense with surrounding brain. Mass effect and edema may remain. In some cases, a surrounding rim of contrast enhancement appears after 2 to 4 weeks and may persist for months. MRI, though more sensitive for delineating posterior fossa lesions, is generally not necessary in most instances. Images of flowing blood on MRI scan may identify AVMs as the cause of the hemorrhage. MRI, CT angiography, and conventional x-ray angiography are used when the cause of intracranial hemorrhage is uncertain, particularly if the patient is young or not hypertensive and the hematoma is not in one of the four usual sites for hypertensive hemorrhage. For example, hemorrhage into the temporal lobe suggests rupture of a MCA saccular aneurysm.

Since patients typically have focal neurologic signs and obtundation, and often show signs of increased ICP, a lumbar puncture should be avoided as it may induce cerebral herniation.

**TREATMENT**

**Acute Management** Nearly 50% of patients with a hypertensive intracerebral hemorrhage die, but others may have a good to complete recovery if they survive the initial hemorrhage. The volume and location of the hematoma determine the prognosis. In general, supratentorial hematomas with volumes <30 mL have a good prognosis; 30 to 60 mL, an intermediate prognosis; and >60 mL, a poor prognosis during initial hospitalization. Extension into the ventricular system worsens the prognosis. Except in patients who are on therapeutic anticoagulation or who have a bleeding disorder, little can be done about the hemorrhage itself. Hematomas may expand for several hours following the initial hemorrhage, so treating severe hypertension seems reasonable to prevent hematoma progression.

Evacuation of the hematoma is usually not helpful, except in cerebellar hemorrhages. For cerebellar hemorrhages, a neurosurgeon should be consulted immediately to assist with the evaluation; most cerebellar hematomas >3 cm in diameter will require surgical evacuation. If the patient is alert without focal brainstem signs and if the hematoma is <1 cm in diameter, surgical removal is usually unnecessary. Patients with hematomas between 1 and 3 cm require careful observation for signs of impaired consciousness and precipitous respiratory failure.

Tissue surrounding hematomas is displaced and compressed but not necessarily infarcted. Hence, in survivors, major improvement commonly occurs as the hematoma is reabsorbed and the adjacent tissue regains its function. Careful management of the patient during the acute phase of the hemorrhage can lead to considerable recovery.

Surprisingly, despite large intraparenchymal hematomas, ICP is often not elevated. However, if the hematoma causes marked midline shift of structures with consequent obtundation, coma, or hydrocephalus, osmotic agents coupled with induced hyperventilation can be instituted to lower ICP (Chap. 258). These maneuvers will provide enough time to place a ventriculostomy or ICP monitor. Once ICP is recorded, further hyperventilation and osmotic therapy can be tailored to the individual patient. For example, if ICP is found to be high, CSF can be drained from the ventricular space and osmotic therapy continued; persistent or progressive elevation in ICP may prompt surgical evacuation of the clot or withdrawal of support. Alternately, if ICP is normal or only mildly elevated, induced hyperventilation can be reversed and osmotic therapy tapered. Since hyperventilation may actually produce ischemia by cerebral vasoconstriction, induced hyperventilation should be limited to acute resuscitation of the patient with presumptive high ICP and eliminated once other treatments (osmotic therapy or surgical treatments) have been instituted. Glucocorticoids are not helpful for the edema from intracerebral hematoma.

**Prevention** Hypertension is the leading cause of primary intracerebral hemorrhage. Prevention is aimed at reducing hypertension, excessive alcohol use, and use of illicit drugs such as cocaine and amphetamines.

**VASCULAR ANOMALIES**

Vascular anomalies can be divided into congenital vascular malformations and acquired vascular lesions.

**CONGENITAL VASCULAR MALFORMATIONS** True arteriovenous malformations, venous anomalies, and capillary telangiectasias are lesions that usually remain clinically silent through life. Although most AVMs are congenital, cases of acquired lesions have been reported.

True AVMs are congenital shunts between the arterial and venous systems that may present as headache, seizures, and intracranial hemorrhage. AVMs consist of a tangle of abnormal vessels across the cortical surface or deep within the brain substance. AVMs vary in size from a small blemish a few millimeters in diameter to a large mass of tortuous channels composing an arteriovenous shunt of sufficient magnitude to raise cardiac output. The blood vessels forming the tangle interposed between arteries and veins are usually abnormally thin and do not have a normal structure. AVMs occur in all parts of the cerebral hemispheres, brainstem, and spinal cord, but the largest ones are most frequently in the posterior half of the hemispheres, commonly forming a wedge-shaped lesion extending from the cortex to the ventricle.

Although the lesion is present from birth, bleeding or other symptoms are most common between the ages of 10 and 30, occasionally as late as the fifties. AVMs are more frequent in men, and rare familial cases have been described.

Headache (without bleeding) may be hemicranial and throbbing, like migraine, or diffuse. Focal seizures, with or without generalization, occur in about 30% of cases. Half of AVMs become evident as intracerebral hemorrhages. In most, the hemorrhage is mainly intraparenchymal with extension into the subarachnoid space in some cases. Blood is usually not deposited in the basal cisterns, and symp-
tomato cerebral vasospasm is rare. The risk of rerupture is about 18% per year and is particular high in the first few weeks. Hemorrhages may be massive, leading to death, or may be as small as 1 cm in diameter, leading to minor focal symptoms or no deficit. The AVM may be large enough to steal blood away from adjacent normal brain tissue or to increase venous pressure significantly to produce venous ischemia locally and in remote areas of the brain. This is seen most often with large AVMs in the territory of the MCA.

Large AVMs of the anterior circulation may be associated with a systolic and diastolic bruit (sometimes self-audible) over the eye, forehead, or neck and a bounding carotid pulse. Headache at the onset of AVM rupture is not generally as explosive as with aneurysmal rupture. MRI is better than CT for diagnosis, although contrast CT scanning sometimes detects calcification of the AVM.

Surgical treatment of symptomatic AVMs, often with preoperative embolization to reduce operative bleeding, is usually indicated for accessible lesions. Stereotactic radiation, an alternative to surgery, can produce a slow sclerosis of arterial channels over 2 to 3 years.

Patients with asymptomatic AVMs have about a 2% per year risk for hemorrhage. Several angiographic features of the AVM can be used to help predict future bleeding risk. Paradoxically, smaller lesions seem to have a higher hemorrhage rate. The mortality rate with each bleed is about 15%. Given this natural history, surgical treatment is probably indicated for most AVMs that can be treated with reasonable surgical risk.

Venous anomalies are the result of development of anomalous cerebral, cerebellar, or brainstem drainage. These structures, unlike AVMs, are functional venous channels. They are of little clinical significance and should be ignored if found incidentally on brain imaging studies. Surgical resection of these anomalies may result in venous infarction and hemorrhage. Venous anomalies may be associated with cavernous malformations (see below), which do carry some bleeding risk. If resection of a cavernous malformation is attempted, the venous anomaly should not be disturbed.

Capillary telangiectasias are true capillary malformations that often form extensive vascular networks through an otherwise normal brain structure. The pons and deep cerebral white matter are typical locations, and these capillary malformations can be seen in patients with hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber) syndrome. If bleeding does occur, it rarely produces mass effect or significant symptoms. No treatment options exist.

ACQUIRED VASCULAR LESIONS Cavernous angiomas are tufts of capillary sinusoids that form within the deep hemispheric white matter and brainstem with no normal intervening neural structures. The pathogenesis is unclear. Familial cavernous angiomas have been mapped to several different chromosomal loci; the gene responsible for the 7q-linked form encodes a protein that interacts with a member of the RAS family of GTPases. Cavernous angiomas are typically <1 cm in diameter and are often associated with a venous anomaly. Bleeding is usually of small volume, causing slight mass effect only. The bleeding risk for single cavernous malformations is 0.7 to 1.5% per year and may be higher for patients with prior clinical hemorrhage or multiple malformations. Seizures may occur if the malformation is located near the cerebral cortex. Surgical resection eliminates bleeding risk and may reduce seizure risk, but it is reserved for those malformations that form near the brain surface. Radiation treatment has not been shown to be of benefit.

Dural arteriovenous fistulas are acquired connections usually from a dural artery to a dural sinus. Patients may complain of a pulse-synchronous cephalic bruit (“pulsatile tinnitus”) and headache. Depending on the magnitude of the shunt, venous pressures may rise high enough to cause cortical ischemia or venous hypertension and hemorrhage. Surgical and endovascular techniques are usually curative. These fistulas may form because of trauma, but most are idiopathic. There is an association between fistulas and dural sinus thrombosis. Fistulas have been observed to appear months to years following venous sinus thrombosis, suggesting that angiogenesis factors elaborated from the thrombotic process may cause these anomalous connections to form. Alternatively, dural arteriovenous fistulas can produce venous sinus occlusion over time, perhaps from the high pressure and high flow through a venous structure.

FURTHER READING


PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033, 2001


Dementia results from disorders of cerebral neuronal circuits and is a result of the total quantity of neuronal loss combined with the specific location of such loss (Chap. 23). Episodic memory requires the dorso-medial nucleus of the thalamus (damaged in Korsakoff’s syndrome due to thiamine deficiency) and the medial temporal lobes. Unilateral temporal lobe lesions produce mild to moderate amnesia for either verbal or nonverbal material, while bilateral lesions produce a severe anterograde learning disorder, i.e., an inability to store new memories, often with retained ability to recall old ones.

The components of the medial temporal lobe memory system include the hippocampus and adjacent cortex, including the entorhinal, perirhinal, and parahippocampal regions (Fig. 350-1). This includes a circular pathway of neurons from the entorhinal cortex to the dentate gyrus, CA3 and CA1 neurons of the hippocampus to the subiculum, and back to the entorhinal cortex; this pathway is heavily damaged in Alzheimer’s disease (AD). This system is fast, has limited capacity, and performs a crucial function at the time of learning and establishing declarative memory and semantic associations. Its role continues after learning during a lengthy period of reorganization and consolidation, whereby memory stored in neocortex eventually becomes independent of the medial temporal lobe memory system. This process, by which the burden of long-term (permanent) memory storage is gradually assumed by neocortex, ensures that the medial temporal lobe system is constantly available for the acquisition of new information.

Functional imaging studies indicate that learning and memory involve many of the same regions of the cortex that process sensory information and control motor output. The forms of perceptual and motor learning that can occur without conscious recollections are mediated in part by contractions and expansions of representations in the sensory and motor cortex. One study, for example, has shown that the cortical representation of the fingers of the left hand of musical string players is larger than that in controls, suggesting that the representation of different parts of the body in the primary somatosensory cortex of humans depends on use and changes to conform to the current needs and experiences of the individual. Discrete cortical regions exist in the anterior temporal lobes in which object knowledge (such as words related to color, animals, tools, or action) is organized as a distributed system. Here the attributes of an object are stored close to the regions of the cortex that mediate perception of those attributes.

Procedural (implicit) memory appears to involve centers outside the hippocampus such as amygdala, basal ganglia, cerebellum, and sensory cortex. Different frontal regions are activated for different kinds of memory storage. Functional magnetic resonance imaging (MRI) studies show that the magnitude of focal activation in left prefrontal-temporal regions and right prefrontal-bilateral parahippocampal regions predicts how well verbal or visual stimuli, respectively, will be remembered.

**FUNCTIONAL ANATOMY OF THE DEMENTIAS**

Dementia results from disorders of cerebral neuronal circuits and is a result of the total quantity of neuronal loss combined with the specific location of such loss (Chap. 23). Episodic memory requires the dorso-medial nucleus of the thalamus (damaged in Korsakoff’s syndrome due to thiamine deficiency) and the medial temporal lobes.

**FIGURE 350-1** The principal connections of the hippocampus. Afferent connections (red arrows) from the cingulate gyrus (cortical association fibers) and amygdala converge on the entorhinal cortex (part of the parahippocampal gyrus) and connect with the hippocampus via a polysynaptic circuit (black arrows) from dentate to CA3, CA1, and subiculum neurons with output back to the entorhinal cortex. Efferent connections (broken arrows) are principally via the fornix to the anterior nucleus of the thalamus, septal nucleus, and mammillary body.
The cholinergic system plays an important role in memory, and anticholinergic agents such as atropine and scopolamine interfere with memory. Choline acetyltransferase (the enzyme catalyzing the formation of acetylcholine) and cholinergic receptors are known to be deficient in the cortex of patients with AD. The brains of AD patients show severe neuronal loss in the nucleus basalis of Meynert, the major source of cholinergic input to the cerebral cortex. These findings form the basis for the use of cholinesterase inhibitors in the treatment of AD, with benefits thought to arise from increased available levels of acetylcholine. Behavior and mood are modulated by noradrenergic, serotonergic, and dopaminergic pathways, and norepinephrine has been shown to be reduced in the brainstem locus coeruleus in AD. Neurotrophins (Chap. 345) are also postulated to play a role in memory in part by preserving cholinergic neurons. Long-term potentiation (LTP), which refers to a long-lasting enhancement of synaptic transmission resulting from repetitive stimulation of excitatory synapses, is presumed to be involved in memory acquisition and storage. LTP occurs in the hippocampus and is mediated by N-methyl-D-aspartate (NMDA) receptors as well as cyclic AMP-responsive element-binding (CREB) protein. Dementias have anatomically specific patterns of neuronal degeneration, which dictate the clinical symptomatology. AD begins in the entorhinal cortex, spreads to the hippocampus, then moves to posterior temporal and parietal neocortex and eventually causes a relatively diffuse degeneration throughout the cerebral cortex. Multi-infarct dementia is associated with focal damage in a random patchwork of cortical regions. Diffuse white matter damage may disrupt intracerebral connections and cause dementia syndromes similar to those associated with leukodystrophies, multiple sclerosis, andBinswanger’s disease (see below). Subcortical structures including the caudate, putamen, thalamus, and substantia nigra also modulate cognition and behavior in ways that are not yet well understood. AD primarily presents as memory loss and is often associated with aphasia or other disturbance of language. In contrast, patients with frontal lobe or subcortical dementias such as frontotemporal dementia (FTD) or Huntington’s disease are less likely to begin with memory and language problems and more likely to have difficulties with attention, judgment, awareness, and behavior. Lesions of specific cortical-subcortical pathways will have important effects on behavior (Chap. 23). The dorsolateral prefrontal cortex has connections with the dorsolateral caudate, globus pallidus, and thalamus. Lesions of these pathways result in poor organization and planning, decreased cognitive flexibility, and impaired judgment. The lateral orbital frontal cortex connects with the ventromedial caudate, globus pallidus, and thalamus. Lesions of these connections cause irritability, impulsiveness, and distractibility. The anterior cingulate cortex connects with the nucleus accumbens, globus pallidus, and thalamus. Interruption of these connections produces apathy and poverty of speech or even akinetic mutism.

THE CAUSES OF DEMENTIA
The many causes of dementia are listed in Table 350-1. The frequency of each condition depends on the age group under study, the access of the group to medical care, the country of origin, and perhaps racial or ethnic background. AD is the most common cause of dementia in western countries, representing more than half of demented patients. Vascular disease is the second most common cause of dementia in the United States, representing 10 to 20%. In populations with limited access to medical care, where vascular risk factors are undertreated, the prevalence of vascular dementia can be much higher. Dementia associated with Parkinson’s disease is the next most common category, and in many instances these patients suffer from dementia with Lewy bodies (DLB). Chronic intoxications including those resulting from alcohol and prescription drugs are an important, often treatable cause of dementia. Other disorders listed in the table are uncommon but important because many are reversible. The classification of dementing illnesses into two broad groups of reversible and irreversible disorders is a useful approach to the differential diagnosis of dementia. In a study of 1000 persons attending a memory disorders clinic, 19% had a potentially reversible cause of the cognitive impairment and 23% had a potentially reversible concomitant condition. The three most common potentially reversible diagnoses were depression, hydrocephalus, and alcohol dependence. The single strongest risk factor for dementia is increasing age. The prevalence of disabling memory loss increases with each decade over age 50 and is associated most often with the microscopic changes of AD at autopsy. Slow accumulation of mutations in neuronal mitochondria is also hypothesized to contribute to the increasing prevalence of dementia with age. Nonetheless, some centenarians have

### Table 350-1 Differential Diagnosis of Dementia

<table>
<thead>
<tr>
<th>MOST COMMON CAUSES OF DEMENTIA</th>
<th>LESS COMMON CAUSES OF DEMENTIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease</td>
<td>Toxic disorders</td>
</tr>
<tr>
<td>Vascular dementia</td>
<td>Alcoholism</td>
</tr>
<tr>
<td>Multi-infarct</td>
<td>Drug, medication, and narcotic poisoning</td>
</tr>
<tr>
<td>Diffuse white matter disease (Binswanger’s)</td>
<td>Heavy metal intoxication</td>
</tr>
<tr>
<td></td>
<td>Nicotine toxics</td>
</tr>
<tr>
<td></td>
<td>Psychiatric</td>
</tr>
<tr>
<td></td>
<td>Depression (pseudodementia)</td>
</tr>
<tr>
<td></td>
<td>Schizophrenia</td>
</tr>
<tr>
<td></td>
<td>Conversion reaction</td>
</tr>
<tr>
<td></td>
<td>Degenerative disorders</td>
</tr>
<tr>
<td></td>
<td>Huntington’s disease</td>
</tr>
<tr>
<td></td>
<td>Pick’s disease</td>
</tr>
<tr>
<td></td>
<td>Dementia with Lewy bodies</td>
</tr>
<tr>
<td></td>
<td>Progressive supranuclear palsy</td>
</tr>
<tr>
<td></td>
<td>Richardson syndrome</td>
</tr>
<tr>
<td></td>
<td>Multisystem degeneration (Shy-Drager syndrome)</td>
</tr>
<tr>
<td></td>
<td>Hereditary ataxias (some forms)</td>
</tr>
<tr>
<td></td>
<td>Motor neuron disease [amyotrophic lateral sclerosis (ALS); some forms]</td>
</tr>
<tr>
<td></td>
<td>Frontotemporal dementia</td>
</tr>
<tr>
<td></td>
<td>Cortical basal degeneration</td>
</tr>
<tr>
<td></td>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td></td>
<td>Adult Down’s syndrome with Alzheimer’s disease</td>
</tr>
<tr>
<td></td>
<td>ALS–Parkinson’s–Dementia complex of Guam</td>
</tr>
<tr>
<td></td>
<td>Miscellaneous</td>
</tr>
<tr>
<td></td>
<td>Vasculitis</td>
</tr>
<tr>
<td></td>
<td>CADASIL</td>
</tr>
<tr>
<td></td>
<td>Acute intermittent porphyria</td>
</tr>
<tr>
<td></td>
<td>Recurrent nonconvulsive seizures</td>
</tr>
<tr>
<td></td>
<td>Additional conditions in children or adolescents</td>
</tr>
<tr>
<td></td>
<td>Hallervorden-Spatz disease</td>
</tr>
<tr>
<td></td>
<td>Subacute sclerosing panencephalitis</td>
</tr>
<tr>
<td></td>
<td>Metabolic disorders (e.g., Wilson’s and Leigh’s diseases, leukodystrophies, lipid storage diseases, mitochondrial mutations)</td>
</tr>
</tbody>
</table>

* Potentially reversible dementia.
The major degenerative dementias include AD, FTD and related disorders, DLB, and prion disorders including Creutzfeldt-Jakob disease (CJD). These disorders are all associated with the abnormal aggregation of a specific protein: ApoE4 in AD, tau in FTD, α-synuclein in DLB, and PrP in CJD.

### APPROACH TO THE PATIENT

(Tables 350-1 and 350-2) Three major issues should be kept in the forefront: (1) What is the most accurate diagnosis? (2) Is there a treatable or reversible component to the dementia? (3) Can the physician help to alleviate the burden on caregivers? The major degenerative dementias can usually be distinguished by the initial symptoms; neuropsychological, neuropsychiatric, and neurologic findings; and neuroimaging features (Table 350-3).

#### History
The history should focus on the onset, duration, and tempo of progression of the dementia. An acute or subacute onset of confusion may represent delirium and should trigger the search for intoxication, infection, or metabolic derangement. An elderly person with slowly progressive memory loss over several years is likely to suffer from AD. Nearly 75% of AD patients begin with initial symptoms; neuropsychological, neuropsychiatric, and neurologic findings; and neuroimaging features (Table 350-3).

#### Treatment

**AD**
- Memory loss
- Episodic memory loss
- Initially normal
- Initially normal
- Entorhinal and hippocampal atrophy
- Cortical and/or subcortical infarctions, confluent white matter disease

**Vascular**
- Often sudden; variable initial symptoms; aphasia, falls, focal weakness
- Frontal/executive cognitive slowing; can spare memory
- Apathy, delusions, anxiety
- Usually motor slowing, spasticity; can be normal
- Frontal and/or temporal atrophy; spares posterior parietal lobe

**FTD**
- Apathy; reduced judgment/insight/speech/language; hyperorality
- Frontal/executive, language; spares drawing
- Apathy, disinhibition, hyperorality, euphoria, depression
- Vertical gaze palsy, axial rigidity, dystonia, alien hand (due to PSP/CBD overlap)
- Frontal and/or temporal atrophy; spares posterior parietal lobe

**DLB**
- Visual hallucinations, REM-sleep disorder, delirium, Capgras syndrome, parkinsonism
- Drawing and frontal/executive; spares memory; delirium prone
- Visual hallucinations, depression, sleep disorder, delusions
- Parkinsonism
- Posterior parietal; hippocampi larger than in AD

**Prion**
- Dementia, mood changes, anxiety, movement disorder
- Variable, frontal/executive, focal cortical, memory
- Depression, anxiety
- Myoclonus, rigidity, parkinsonism
- Cortical ribboning and basal ganglia hyperintensities on diffusion/flare MRI

### TABLE 350-2 Evaluation of the Patient with Dementia

<table>
<thead>
<tr>
<th>Routine Evaluation</th>
<th>Optional Focused Tests</th>
<th>Occasionally Helpful Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>HIV</td>
<td>EEG</td>
</tr>
<tr>
<td>Physical examination</td>
<td>Chest x-ray</td>
<td>Parathyroid function</td>
</tr>
<tr>
<td>Laboratory tests</td>
<td>Lumbar puncture</td>
<td>Adrenal function</td>
</tr>
<tr>
<td>Thyroid function (TSH)</td>
<td>Liver function</td>
<td>Urine heavy metals</td>
</tr>
<tr>
<td>Complete blood count</td>
<td>Urine toxin screen</td>
<td>RBC sedimentation rate</td>
</tr>
<tr>
<td>Electrolytes</td>
<td>Psychometric testing</td>
<td>Brain biopsy</td>
</tr>
<tr>
<td>VDRL</td>
<td>Apolipoprotein E</td>
<td>SPECT</td>
</tr>
<tr>
<td>CT/MRI</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Diagnostic Categories

<table>
<thead>
<tr>
<th>Reversible Causes</th>
<th>Irreversible/Degenerative Dementias</th>
<th>Psychiatric Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothyroidism</td>
<td>Examples</td>
<td>Examples</td>
</tr>
<tr>
<td>Thiamine deficiency</td>
<td>Examples</td>
<td>Depression</td>
</tr>
<tr>
<td>Vitamin B12 deficiency</td>
<td>Frontotemporal dementia</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Normal-pressure hydrocephalus</td>
<td>Huntington’s</td>
<td>Conversion reaction</td>
</tr>
<tr>
<td>Chronic infection</td>
<td>Examples</td>
<td>Drug side effects</td>
</tr>
<tr>
<td>Brain tumor</td>
<td>Examples</td>
<td>Drug side effects</td>
</tr>
<tr>
<td>Drug intoxication</td>
<td></td>
<td>Drug side effects</td>
</tr>
</tbody>
</table>

### Associated Treatable Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>Depression</td>
</tr>
<tr>
<td>Seizures</td>
<td>Seizures</td>
</tr>
<tr>
<td>Insomnia</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Agitation</td>
<td>Agitation</td>
</tr>
<tr>
<td>Caregiver “burnout”</td>
<td>Caregiver “burnout”</td>
</tr>
</tbody>
</table>

Note: AD, Alzheimer’s disease; FTD, frontotemporal dementia; PSP, progressive supranuclear palsy; CBD, cortical basal degeneration; DLB, dementia with Lewy bodies; MRI, magnetic resonance imaging.
tension, atrial fibrillation, peripheral vascular disease, and diabetes. In patients suffering from cerebrovascular disease it can be difficult to determine whether the dementia is due to AD, multi-infarct dementia, or a mixture of the two. Rapid progression of the dementia in association with motor rigidity and myoclonus suggests a prion disease. Seizures may indicate strokes or neoplasm. Gait disturbance is commonly seen with multi-infarct dementia, Parkinson’s disease, or normal-pressure hydrocephalus. Multiple sex partners or intravenous drug use should trigger a search for a central nervous system (CNS) infection, especially in persons with HIV. A history of recurrent head trauma could indicate chronic subdural hematoma, dementia pugilistica, or normal-pressure hydrocephalus. Alcoholism may suggest malnutrition and thiamine deficiency. A removable history of gastric surgery may result in loss of intrinsic factor and vitamin B₁₂ deficiency. Certain occupations such as working in a battery or chemical factory might indicate heavy metal intoxication. A careful review of medications, especially of sedatives and tranquilizers, may raise the issue of chronic drug intoxication. A family history of dementia is found in Huntington’s disease, familial AD, or familial FTD. Depressive signs such as insomnia or weight loss are often seen with pseudodementia due to depression, which can also be caused by the recent death of a loved one.

**Physical and Neurologic Examination** A thorough examination is essential to document the dementia, look for other signs of nervous system involvement, and search for clues of a systemic disease that might be responsible for the cognitive disorder. AD does not affect motor systems until late in the course. In contrast, FTD patients often develop axial rigidity, supranuclear gaze palsy, or features of amyotrophic lateral sclerosis (ALS). In DLB, initial symptoms may be the new onset of a parkinsonian syndrome (resting tremor, cogwheel rigidity, bradykinesia, and festinating gait) with the dementia following later, or vice-versa. Corticobasal degeneration (CBD) is associated with dystonia and alien hand (unilateral involuntary movements of the upper limb resembling purposeful actions) and with asymmetric motor deficits or myoclonus. A presentation with unexplained falls, axial rigidity, and gaze deficits suggests progressive supranuclear palsy (PSP). CJD is suggested by diffuse rigidity, an akinetic state, and myoclonus.

Hemiparesis or other focal neurologic deficits may occur in multi-infarct dementia or brain tumor. Dementia with a myelopathy and peripheral neuropathy suggests vitamin B₁₂ deficiency. A peripheral neuropathy could also indicate an underlying vitamin deficiency or heavy metal intoxication. Dry cool skin, hair loss, and bradycardia suggest hypothyroidism. Confusion associated with repetitive stereotyped movements may indicate ongoing seizure activity. Hearing impairment or visual loss may produce confusion and disorientation misinterpreted as dementia. Such sensory deficits are common in the elderly.

**Cognitive and Neuropsychiatric Examination** Brief screening tools such as the mini-mental status examination (MMSE) help to confirm the presence of cognitive impairment and to follow the progression of dementia (Table 350-4). The MMSE is an easily administered 30-point test of cognitive function and contains tests of orientation, working and episodic memory, language comprehension, naming, and copying. In most patients with MCI and some with clinically apparent AD, the MMSE may be normal and a more rigorous set of neuropsychological tests will be required. Additionally, when the etiology for the dementia syndrome remains in doubt, a specially tailored evaluation should be performed that includes tasks of working and episodic memory, frontal executive tasks, language, visuospatial function, and perception. In AD the deficits involve episodic memory, category generation (“name as many animals as you can in one minute”), and visuoconstructive ability. Deficits in verbal or visual episodic memory are often the first neuropsychological abnormalities seen with AD, and tasks that require the patient to recall a long list of words or pictures after a predetermined delay will demonstrate deficits in most AD patients. In FTD the earliest deficits often involve frontal executive function or language (speech or naming). DLB patients have more severe deficits in visuospatial function but do better on episodic memory tasks than do patients with AD. Patients with vascular dementia often demonstrate a mixture of frontal executive and visuospatial deficits. In delirium, deficits tend to occur in the areas of attention, working memory, and frontal tasks.

A functional assessment should also be performed. The physician should determine the day-to-day impact of the disorder on the patient’s memory, community affairs, hobbies, judgment, dressing, and eating. Knowledge of the patient’s day-to-day function will help to organize a therapeutic approach with the family.

Neuropsychiatric assessment is important for diagnosis, prognosis, and treatment. In the early stages of AD mild depressive features, social withdrawal, and denial of illness are the most prominent psychiatric changes. However, patients often maintain their social skills into the middle stages of the illness when delusions, agitation, and sleep disturbance become more common. In FTD dramatic personality change, apathy, overeating, repetitive compulsions, disinhibition, euphoria, and loss of empathy are common. DLB shows visual hallucinations, delusions related to personal identity, and day-to-day fluctuation. Vascular dementia can present with psychiatric symptoms such as depression, delusions, disinhibition, or apathy.

**Laboratory Tests** The choice of laboratory tests in the evaluation of dementia is not straightforward. A reversible or treatable cause must not be missed, yet no single etiology is common; thus a screen must employ multiple tests, each of which has a low yield. Cost/benefit ratios are difficult to assess, and many laboratory screening algorithms for dementia discourage multiple tests. Nevertheless, even a test with only a 1 to 2% positive rate is probably worth undertaking if the alternative is missing a treatable cause of dementia. The algorithm in Table 350-2 lists most screening tests for dementia. Recently the American Academy of Neurology recommended the routine measurement of thyroid function tests, a vitamin B₁₂ level, and a neuroimaging study [computed tomography (CT) or MRI].

Neuroimaging studies will identify primary and secondary ne-
The cognitive changes with AD tend to follow susceptibility genes has provided a foundation for rapid progress in understanding cerebral blood vessels. The identification of four different susceptibility genes, such as APOE, has suggested a genetic basis for AD, even though the exact genetic mechanisms are not fully understood. Recent advances in genetic research have shown that there is a strong familial component to AD, with an autosomal dominant inheritance pattern in some cases. The identification of these susceptibility genes has provided a framework for future drug development and preventive strategies.

Cognitive problems begin to interfere with daily activities, such as standardized memory tasks, the disease is defined as MCI. Slowly, the disease progresses, and activities of daily living are affected. The disease may go unrecognized or be ascribed to aging or other factors. In the early stages of the disease, the memory loss begins to affect day-to-day activities or falls to <1.5 standard deviations from normal on standardized memory tests, the disease is defined as MCI. Slowly, the cognitive problems begin to interfere with daily activities, such as keeping track of finances, following instructions on the job, driving, shopping, and housekeeping. Some patients are unaware of these difficulties (anosognosia), while others have considerable insight. Change of environment may be bewildering, and the patient may become lost on walks or while driving an automobile. In the middle stages of the disease, the patient is unable to work, is easily lost and confused, and requires daily supervision. Social graces, routine behavior, and superficial conversation may be surprisingly retained. Language becomes impaired: first naming, then comprehension, and finally fluency. In some patients, aphasia is an early and prominent feature. Word-finding difficulties and circumlocution may be a problem even when formal testing demonstrates intact naming and fluency. Apraxia emerges and patients have trouble carrying out sequential motor tasks. Visuospatial deficits begin to interfere with dressing, eating, solving simple puzzles, and copying geometric figures. Patients may be unable to perform simple calculations or tell time.

In the late stages of the disease, some persons remain ambulatory but wander aimlessly. Loss of judgment, reason, and cognitive abilities occurs. Delusions are common, usually simple in quality, involving delusions of theft, infidelity, or misidentification. Approximately 10% of AD patients develop the Capgras syndrome, believing that a caregiver has been replaced by an impostor. In contrast to DLB, the Capgras syndrome is an early feature, indicating that AD patients may also have a tendency to develop the syndrome later in the course of the illness. Loss of inhibitions and aggression may alternate with passivity and withdrawal. Sleep-wake patterns are prone to disruption, and nighttime wandering becomes disturbing to the household. Some patients develop a shuffling gait, with generalized muscle rigidity associated with slowness and awkwardness of movement. Patients often look parkinsonian (Chap. 351) but rarely have tremor. In end-stage AD, patients become rigid, mute, incontinent, and bedridden. Help may be needed with the simplest tasks, such as eating, dressing, and toilet function. Hyperactive tendon reflexes may be noted. Myoclonic jerks (sudden brief contractions of various muscles or the whole body) may occur spontaneously or in response to physical or auditory stimulation. Myoclonus raises the possibility of a prion disease (Chap. 362), but the course of AD is much more prolonged. Generalized seizures may also occur. Often, death results from malnutrition, secondary infections, pulmonary emboli, or heart disease. The typical duration of AD is 8 to 10 years, but the course can range from 1 to 25 years. For unknown reasons, some AD patients show a steady downhill decline in function, while others have prolonged plateaus without major deterioration.

Diagnosis Early in the disease course, other etiologies of dementia should be excluded (see above). Neuroimaging studies (CT and MRI) do not show a single specific pattern with AD and may be normal early in the course of the disease. As AD progresses, diffuse cortical atrophy becomes apparent, and MRI scans show atrophy of the hippocampus (Fig. 350-2A, B). Functional imaging studies in AD reveal hypoperfusion or hypometabolism in the posterior temporal-parietal cortex (Fig. 350-2C, D). The EEG is normal or shows nonspecific slowing. Routine spinal fluid examination is also normal. The use of blood Apo E genotyping is discussed under “Genetic Considerations” below.

The cognitive changes with AD tend to follow a characteristic pattern, beginning with memory impairment and spreading to language and visuospatial deficits. However, approximately 10% of AD patients present with nonmemory complaints such as word-finding, organizational, or navigational difficulty. In the early stages of the disease, the memory loss may go unrecognized or may be ascribed to benign forgetfulness. Once the memory loss begins to affect day-to-day activities or falls to <1.5 standard deviations from normal on standardized memory tasks, the disease is defined as MCI. Slowly, the cognitive problems begin to interfere with daily activities, such as

Specific Dementias

Alzheimer’s Disease AD is the most common cause of dementia in western countries. Approximately 10% of all persons over the age of 70 have significant memory loss, and in more than half the cause is AD. AD can occur, however, in any decade of adulthood. The annual cost of caring for a single AD patient in an advanced stage of the disease is estimated at $50,000. The disease also exacts a heavy economic toll (Fig. 350-2A). A clinical diagnosis of AD, reached after results on laboratory tests, and an MRI or CT scan showing only diffuse atrophy (Fig. 350-2B), is the best available diagnostic tool. Functional imaging studies in AD reveal hypoperfusion or hypometabolism in the posterior temporal-parietal cortex (Fig. 350-2C, D). The EEG is normal or shows nonspecific slowing. Routine spinal fluid examination is also normal. The use of blood Apo E genotyping is discussed under “Genetic Considerations” below.

Clinical Manifestations The cognitive changes with AD tend to follow a characteristic pattern, beginning with memory impairment and spreading to language and visuospatial deficits. However, approximately 10% of AD patients present with nonmemory complaints such as word-finding, organizational, or navigational difficulty. In the early stages of the disease, the memory loss may go unrecognized or may be ascribed to benign forgetfulness. Once the memory loss begins to affect day-to-day activities or falls to <1.5 standard deviations from normal on standardized memory tasks, the disease is defined as MCI. Slowly, the cognitive problems begin to interfere with daily activities, such as

Epidemiology The most important risk factors for AD are old age and a positive family history. The frequency of AD increases with each decade of adult life, reaching 20 to 40% of the population over the age of 85. A positive family history of dementia suggests a genetic cause of AD. Female gender may also be a risk factor independent of the genetic factors (see below). Some AD patients have a history of head trauma with concussion, but this appears to be a relatively minor risk factor. AD is more common in groups with lower educat-
tional attainment, but education influences test-taking ability, and it is clear that AD can affect persons of all intellectual levels. One study found that the capacity to express complex written language in early adulthood correlated with a decreased risk for AD. Numerous environmental factors, including aluminum, mercury, and viruses, have been proposed as causes of AD, but none has been demonstrated to play a significant role. Several studies suggest that the use of nonsteroidal anti-inflammatory agents is associated with a decreased risk of AD, but this has not been confirmed in large prospective studies. Vascular disease does not seem to be a direct cause of AD, but amyloid angiopathy can lead to ischaemic infarctions or hemorrhages. Elevated homocysteine and cholesterol levels, hypertension, and insufficient exercise are all being explored as potential risk factors for AD.

Pathology The most severe pathology is usually found in the hippocampus, temporal cortex, and nucleus basalis of Meynert (lateral septum). The most important microscopic findings are neuritic “senile” plaques and NFTs. These lesions accumulate in small numbers during normal aging of the brain but occur in excess in AD. Neuritic plaques contain a central core that includes Aβ amyloid, proteoglycans, Apo e4, α, anti-chymotrypsin, and other proteins. Aβ amyloid is a protein of 39 to 42 amino acids that is derived proteolytically from a larger transmembrane protein, amyloid precursor protein (APP), which has neurotrophic and neuroprotective activity. The normal function of Aβ amyloid is unknown. Soluble amyloid fibrils may represent the initial pathologic event in AD leading to formation of neuritic plaques. The plaque core is surrounded by the debris of degenerating neurons, microglia, and macrophages. The accumulation of Aβ amyloid in cerebral arterioles, termed amyloid angiopathy, may lead to cerebral lobar hemorrhages. NFTs are silver-staining, twisted neurofilaments in neuronal cytoplasm that represent abnormally phosphorylated tau protein and appear as paired helical filaments by electron microscopy. Tau is a microtubule-associated protein that may function to assemble and stabilize the microtubules that convey cell organelles, glycoproteins, and other important materials through the neuron.

A hyperphosphorylated state of tau impairs its capacity to bind to microtubules. AD is also associated with decreased levels of several proteins and neurotransmitters in the cerebral cortex, especially acetylcholine, its synthetic enzyme choline acetyltransferase, and nicotinic cholinergic receptors. Reduction of acetylcholine may result from degeneration of cholinergic neurons in the nucleus basalis of Meynert that project to many areas of the cortex. There is also reduction in norepinephrine levels in brainstem nuclei such as the locus coeruleus.

GENETIC CONSIDERATIONS Several genes have been found to play important roles in the pathogenesis of at least some cases of AD. The first to be identified was the APP gene on chromosome 21. Point mutations in APP produce early-onset, autosomal dominant AD. APP is a membrane-spanning protein that is subsequently processed into smaller units, including Aβ amyloid that is deposited in neuritic plaques. Aβ peptide results from cleavage of APP by β- and γ-secretases (Fig. 350-3). Only very rare families with AD-producing APP mutations have been identified. However, adults with trisomy 21 (Down’s syndrome) who survive beyond age 40 consistently develop a progressive dementia superimposed upon their baseline mental retardation and accompanied by typical neuropathologic changes of AD. Presumably the extra dose of the APP gene on chromosome 21 is the initiating cause of AD in adult Down’s syndrome and results in an excess of cerebral amyloid.

Investigation of large families with multigenerational familial AD led to the discovery of two additional AD genes, termed the presenilins. Presenilin-1 (PS-1) is on chromosome 14 and encodes a protein called S182. Mutations in this gene cause an early-onset AD (onset before age 60 and often before age 50) transmitted in an autosomal dominant, highly penetrant fashion. More than 50 different mutations have been found in the PS-1 gene in families from a wide range of ethnic backgrounds. Presenilin-2 (PS-2) is on chromosome 1 and encodes a protein called STM2. The two genes (PS-1 and PS-2) are highly homologous and encode similar proteins that at first appeared to have seven transmembrane domains (hence the designation STM), but subsequent studies have suggested eight such domains with a ninth submembrane region. Both S182 and STM2 are cytoplasmic neuronal proteins that are widely expressed throughout the nervous system. They are homologous to a cell-trafficking protein, sel 12, found in the nematode Coenorhabditis elegans. Patients with mutations in these genes have elevated plasma levels of Aβ1-42 amyloid, suggesting a possible link between the presenilins and APP. There is evidence that PS-1 is involved in the cleavage of APP at the γ-secretase site, and mutations in either gene (PS-1 or PS-2) may disturb this function. Mutations in PS-1 have thus far proved to be the most common cause of early-onset familial AD, representing 40 to 70% of this relatively rare syndrome. Mutations in PS-1 tend to produce AD with an earlier age of onset (mean onset, 45 years) and a shorter, more rapidly pro-

![Image](https://example.com/image1.png)

**FIGURE 350-2** Alzheimer’s disease. Axial T1-weighted MR images through the midbrain of a normal 86-year-old athletic individual (A) and a 72-year-old male (B) with Alzheimer’s disease. Note that both individuals have prominent sulci and slight dilatation of the lateral ventricles. However, there is a reduction in the volume of the hippocampus of the patient with Alzheimer’s disease (arrows) compared with that of the normal–age hippocampus of the older individual. Fluorodeoxyglucose positron emission tomographic scans of a normal control (C) and a patient with Alzheimer’s disease (D). Note that the patient with Alzheimer’s disease has decreased activity in the parietal lobes bilaterally (arrows), a typical finding in this condition. (Images courtesy of TF Budinger, University of California.)
An additional candidate genes have been described on chromosomes 12 (α2-macroglobulin) and 10.

AD cannot be cured, and no highly effective drug exists. The focus is on judicious use of cholinesterase inhibitor drugs; symptomatic management of behavioral problems; and building rapport with the patient, family members, and other caregivers.

Tacrine (tetrahydroaminoacridine), donepezil, rivastigmine, and galantamine are approved by the U.S. Food and Drug Administration (FDA) for treatment of AD. Their pharmacologic action is presumed to be inhibition of cholinesterase, with a resulting increase in cerebral levels of acetylcholine. Controlled studies indicate that cholinesterase inhibitors improve caregiver ratings of patients’ functioning and decrease the rate of decline in cognitive test scores over periods of up to 3 years. The average patient on an anticholinesterase compound maintains his or her MMSE score at 1 year, whereas a placebo-treated patient declines two to three points over the same time period. Nevertheless, these compounds are only modestly efficacious and offer little or no benefit in the late stages of AD. Tacrine is expensive and may cause hepatotoxicity, thus it is rarely used. Donepezil avoids liver toxicity and can be administered once daily (5 to 10 mg), offering an advantage over the other cholinesterase inhibitors.

In a prospective observational study, the use of estrogen-replacement therapy appeared to protect—by ~50%—against development of AD in women. This study appeared to confirm the results of two earlier case-controlled studies. However, a prospective placebo-controlled study of a combined estrogen-progesterone therapy for asymptomatic postmenopausal women appeared to increase the prevalence of dementia. This study has markedly dampened enthusiasm for hormone treatments for the prevention of dementia. Additionally, no benefit has been found in the treatment of established AD with estrogen.

In patients with moderately advanced AD, a prospective trial of the antioxidants selegiline (Chap. 351), α-tocopherol (vitamin E), or both slowed institutionalization and progression to death. Because vitamin E has less potential for toxicity than selegiline and is inexpensive, the doses used in this study of 1000 IU twice daily are offered to many patients with AD. However, the beneficial effects of vitamin E are likely to be small.

A controlled trial of an extract of Ginkgo biloba found modest improvement in cognitive function in subjects with AD and vascular dementia. This study requires confirmation before Ginkgo biloba is considered an effective treatment for dementia because there was a high subject dropout rate and no improvement on a clinician’s judgment scale.

One study of AD subjects in the mid-stages of disease showed a slowing of progression over a 28-week course in patients treated with memantine, an NMDA receptor antagonist.

There has been considerable enthusiasm for a strategy involving vaccination against the Aβ protein. This approach was highly effective in mouse models of AD; amyloid deposits were effectively cleared, and cognitive decline was arrested. The mechanism appears to involve generation of antibodies against Aβ, which cross the blood-brain barrier and eliminate neuritic plaques. Unfortunately, in human trials this approach led to life-threatening meningoencephalitis in some vaccinated individuals. Modifications of the vaccine approach are under development.

Several retrospective studies have suggested that nonsteroidal anti-inflammatory agents and statins (HMG-CoA reductase inhibitors) may protect against dementia. Controlled prospective studies are under way. Other prospective studies designed to lower serum homocysteine levels are in progress, based upon epidemiologic studies that revealed an association of elevated homocysteine levels with dementia progression.

Mild to moderate depression, common in the early stages of AD, may respond to antidepressant or cholinesterase inhibitors. Selective serotonin reuptake inhibitors (SSRIs) are commonly used due to their
low anticholinergic side effects. Generalized seizures should be treated with an appropriate anticonvulsant, such as phenytoin or carbamazepine. For management of behavioral disturbances and suggestions for caregivers, see “General Symptomatic Treatment of the Patient with Dementia,” below.

VASCULAR DEMENTIA Dementia associated with cerebrovascular disease can be divided into two general categories: multi-infarct dementia and diffuse white matter disease (also called subcortical arteriosclerotic encephalopathy, orBinswanger’s disease). Cerebrovascular disease appears to be a more common cause of dementia in Asia than in Europe and North America. Individuals who have had several strokes may develop chronic cognitive deficits, commonly called multi-infarct dementia. The strokes may be large or small (sometimes lacunar) and usually involve several different brain regions. The occurrence of dementia appears to depend partly on the total volume of damaged cortex, but it is also more common in individuals with left-hemisphere lesions, independent of any language disturbance. Patients typically report a history of discrete episodes of sudden neurologic deterioration. Many multi-infarct dementia patients have a history of hypertension, diabetes, coronary artery disease, or other manifestations of widespread atherosclerosis. Physical examination usually shows focal neurologic deficits such as hemiparesis, a unilateral Babinski reflex, a visual field defect, or pseudobulbar palsy. The recurrent strokes result in a stepwise progression of disease. Neuroimaging studies show multiple areas of infarction. Thus, the history and neuroimaging findings differentiate this condition from AD. However, both AD and multiple infarctions are common and sometimes occur together. With normal aging, there is also an accumulation of amyloid in cerebral blood vessels, leading to a condition called cerebral amyloid angiopathy of aging (not associated with dementia), which predisposes older persons to hemorrhagic lobar stroke. AD patients with amyloid angiopathy may be at increased risk of cerebral infarction.

Some individuals with dementia are discovered on MRI to have bilateral subcortical white matter abnormalities, termed diffuse white matter disease (or leukoaraiosis), often occurring in association with lacunar infarctions (Fig. 350-4). The dementia may be insidious in onset and progress slowly, features that distinguish it from multi-infarct dementia, although other patients can show a stepwise deterioration more typical of multi-infarct dementia. Early symptoms are mild confusion, apathy, changes in personality, depression, psychosis, and memory or executive deficits. Marked difficulties in judgment and orientation and dependence on others for daily activities develop later. Euphoria, elation, depression, or aggressive behaviors are common. Both pyramidal and cerebellar signs may be present in the same patient. A gait disorder appears in at least half of affected patients. With advanced disease, urinary incontinence and dysarthria with or without other pseudobulbar features (e.g., dysphagia, emotional lability) are frequent. Seizures and myoclonic jerks appear in a minority of patients. This disorder is a microangiopathy due to occlusive disease of small penetrating cerebral arteries and arterioles. The patients usually, but not always, have a history of hypertension, but any disease causing stenosis of small cerebral vessels may be the critical underlying factor. The term Binswanger’s disease should be used with caution, because it does not really identify a single entity.

A dominantly inherited form of diffuse white matter disease is known as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Clinically there is a progressive dementia developing in the fifth to seventh decades in multiple family members who may also have a history of migraine and recurrent stroke without hypertension. Skin biopsy may show characteristic dense bodies in the media of arterioles. The disease is caused by mutations in the notch 3 gene, and there is a commercially available genetic test. The frequency of this disorder is unknown, and there are no known treatments. Mitochondrial disorders can present with stroke-like episodes and can selectively injure basal ganglia or cortex. Many such patients show other findings suggestive of a neurologic or systemic disorder such as ophthalmoplegia, retinal degeneration, deafness, myopathy, neuropathy, or diabetes. Diagnosis is difficult, but serum, and especially CSF, levels of lactate and pyruvate may be abnormal, and biopsy of affected tissue is often diagnostic.

Treatment of vascular dementia must be focused on the underlying causes, such as hypertension, atherosclerosis, and diabetes. Recovery of lost cognitive function is not likely to occur, although fluctuations with periods of improvement are common. Anticholinesterase compounds appear to be useful, as in AD (see above).

FRONTOTEMPORAL DEMENTIA AND RELATED DISORDERS Frontotemporal dementia FT Dementia FT D often begins between 50 and 70 years of age, and in this age group its prevalence may approach that of AD. Men and women are equally affected. Unlike AD, behavioral symptoms often predominate in the early stages of FTD. FTD can be sporadic or familial. The clinical heterogeneity is remarkable; patients demonstrate combinations of disinhibition, dementia, apraxia, parkinsonism, and motor neuron disease. In many families with an autosomal dominant pattern of inheritance, mutations in the tau gene on chromosome 17 have been found; in others, the dementia has been linked to 17 but does not involve tau. In still other families, chromosomes 3 and 9 have been linked to FTD.

Early symptoms are divided between cognitive, behavioral, and sometimes motor abnormalities, reflecting degeneration of the anterior frontal and temporal regions, basal ganglia, and motor neurons. Cognitive presentations typically spare memory and involve planning, judgment, or language. Poor business decisions, difficulty organizing work plans, and speech and language deficits emerge. Insight into the disorder is often severely impaired. Common behavioral deficits associated with FTD include apathy, disinhibition, weight gain, food fetishes, compulsions, and euphoria.

Findings at the bedside are dictated by the anatomic localization of the disorder. Asymmetric left frontal cases present with nonfluent aphasias, while left anterior temporal degeneration is characterized by loss of words and concepts related to language (semantic dementia). Nonfluent patients quickly progress to mutism, while those with semantic dementia develop features of visual agnosia, losing the ability to recognize faces, objects, and words (Chap. 23). Copying, calculating, and navigation often remain normal into later in the illness. These left hemisphere presentations of FTD have been called primary pro-

FIGURE 350-4 Diffuse white matter disease (Binswanger’s disease). Axial T2-weighted MR image through the lateral ventricles reveals multiple areas of abnormal high signal intensity involving the periventricular white matter as well as the corona radiata and lentiform nuclei (arrows). While seen in some individuals with normal cognition, this appearance is more pronounced in patients with dementia of a vascular etiology.
Progressive aphasia. In contrast, right frontal or temporal cases show profound alterations in social conduct with loss of empathy, disinhibition, and antisocial behaviors predominating. Memory and visuospatial skills are relatively spared in most FTD patients. There is a striking overlap between FTD and PSP, CBD, and motor neuron disease; ophthalmoplegia, dystonia, swallowing symptoms, and fasciculations are common at presentation of FTD or emerge during the course of the illness.

The anatomic hallmark of FTD is a marked atrophy of the temporal and/or frontal lobes, which can be visualized by neuroimaging studies (Figs. 350-5 and 350-6). The atrophy is sometimes remarkably asymmetric. A variety of pathologies have been associated with the clinical syndrome. The most consistent microscopic findings include gliosis and neuronal loss, and many cases show swollen or ballooned neurons containing cytoplasmic inclusions that in the majority of cases stain for tau. These aggregates sometimes resemble those found in PSP and CBD; tau is accepted as playing a major role in the pathogenesis of all three conditions. A toxic gain of function related to tau underlies the pathogenesis of many familial cases and is presumed to play a role in sporadic cases as well. Finally, many patients show no cellular inclusions, and the pathology remains bland with frontal and temporal gliosis, vascular changes, and neuronal loss the only evidence for disease. Nearly 80% of FTD patients show involvement of the basal ganglia at autopsy, and 15% go on to develop motor neuron disease, indicating the multisystem nature of this illness. Depletion of serotonergic and glutamatergic neurons is present in many patients. In contrast to AD, the cholinergic system is relatively spared in FTD.

Pick’s disease was historically described as a progressive degenerative disorder of the anterior frontal and temporal neocortex accompanied by intracellular inclusions (Pick’s bodies) that stain positive with silver (argyrophilic) and tau. Many of the NFT-positive inclusions in FTD cases, however, are not labeled with silver stains. Although the nomenclature for these patients has remained controversial, the term FTD is increasingly used for all patients with frontotemporal degenerations, whereas Pick’s disease is used to classify pathologically the subset of FTD cases that show Pick’s bodies at autopsy.

The burden on caregivers of FTD patients is extremely high. Treatment is symptomatic, and there are currently no therapies known to slow progression or improve cognitive symptoms. Many of the behaviors that accompany FTD such as depression, hyperorality, compulsions, and irritability can be ameliorated with serotonin-modifying antidepressants. The co-association with motor disorders necessitates the careful use antipsychotics, which can exacerbate this problem.

Progressive Supranuclear Palsy PSP is a degenerative disease that usually begins with falls and a vertical supranuclear gaze paresis and progresses to symmetric rigidity and dementia. A stiff, unstable posture with hyperextension of the neck and slow gait with frequent falls is characteristic. Early in the disease, patients have difficulty with downgaze and lose vertical optokinetic nystagmus on downward movement of a target. Although patients have very limited voluntary eye movements, oculocephalic reflexes (doll’s head maneuver) are retained; thus, the eye movement disorder is supranuclear. Frequent unexplained and sometimes spectacular falls are common secondary to a combination of axial rigidity, inability to look down, and bad judgment. The dementia is similar to FTD with apathy, frontal/executive dysfunction, poor judgment, slowed thought processes, impaired verbal fluency, and difficulty with sequential actions and with shifting from one task to another. These cognitive deficits are usually evident at the time of presentation and often precede the motor syndrome.

PSP is often confused with Parkinson’s disease. Dementia does occur in ~20% of Parkinson’s disease patients, often secondary to DLB. Furthermore, the behavioral syndromes seen with DLB differ from those of PSP (see below). The occurrence of dementia in Parkinson’s disease is more likely with increasing age, increasing severity of extrapyramidal signs, a long duration of disease, and the presence of depression. Cortical atrophy is usually present on brain imaging studies. Neuropathologically, there may be Alzheimer changes in the cortex (amyloid plaques and NFTs), neuronal Lewy body inclusions in both the substantia nigra and the cortex, or no specific microscopic changes other than gliosis and neuronal loss.

CT and MRI show atrophy of the frontal lobes, diffuse symmetrical loss of basal ganglia and thalamus, and thinning of the corpus callosum. SSD is regarded as the definitive diagnostic criterion for PSP, however, the sensitivity and specificity are not high. In neuroimaging studies, the base of the brain is often atrophic compared to other degenerative dementias. The oculomotor component of the clinical syndrome is not as prominent as in other parkinsonian syndromes. Careful evaluation may reveal hypometric saccades, decreased smooth pursuit, impaired optokinetic nystagmus, and a reduction in the size of the vertical and horizontal ocular movements. Eye movements can be abnormal in the normal elderly population, however, when these movements are abnormal in the young or middle-aged, a more serious condition should be considered. Patients with PSP are highly susceptible to neuroleptics and may develop severe extrapyramidal side effects when prescribed antipsychotics.

Cortical Basal Degeneration CBD is a slowly progressive dementing illness that typically presents with a unilateral onset with rigidity, dystonia, and apraxia of one arm and hand, sometimes called the “alien hand.” Eventually the condition becomes bilateral and includes dystonia, slow gait, action tremor, and dementia.

Dementia with Lewy Bodies This syndrome is characterized by visual hallucinations, parkinsonism, fluctuating alertness, and falls. Dementia can precede or follow the appearance of parkinsonism. DLB may present in a patient with longstanding Parkinson’s disease without cognitive impairment who slowly develops dementia associated with visual hallucinations, parkinsonism, and fluctuating alertness. In other patients the dementia and neuropsychiatric syndrome precede the parkinsonism. DLB patients are highly susceptible to metabolic perturbations, and in some the first manifestation of illness is a delirium.
often precipitated by an infection or other systemic disturbance. A delirium induced by L-dopa, prescribed for parkinsonian symptoms attributed to Parkinson’s disease, may be the initial clue that the correct diagnosis is DLB. Even without an underlying precipitant, fluctuations can be marked in DLB patients, with the occurrence of episodic confusion admixed with lucid intervals. However, despite the fluctuating pattern, the clinical features persist over a long period of time, unlike delirium, which resolves following correction of the underlying precipitant. Cognitively, DLB patients tend to have relatively better memory, but more severe visuospatial deficits, than individuals with AD.

The key neuropathologic feature is the presence of Lewy bodies throughout the cortex, amygdala, cingulated cortex, and substantia nigra. Lewy bodies are intraneuronal cytoplasmic inclusions that stain with periodic acid–Schiff (PAS) and ubiquitin. They are composed of straight neurofilaments 7 to 20 nm long with surrounding amorphous material. They are recognized by antibodies against phosphorylated and nonphosphorylated neurofilament proteins, ubiquitin, and a presynaptic protein called α-synuclein. Lewy bodies are traditionally found in the substantia nigra of patients with idiopathic Parkinson’s disease. A profound cholinergic deficit is present in many patients with DLB and may be a factor responsible for the fluctuations and visual hallucinations present in these patients. In patients without other pathologic features, the condition is referred to as diffuse Lewy body disease. In patients whose brains also contain excessive amounts of amyloid plaques and NFTs, the condition is called the Lewy body variant of AD. The quantity of Lewy bodies required to establish the diagnosis is not agreed on, but a definite diagnosis requires pathologic confirmation. At autopsy, 10 to 30% of demented patients show cortical Lewy bodies. Due to the overlap with AD and the cholinergic deficit in DLB, anticholinesterase compounds may be helpful. Exercise programs are also helpful to maximize the motor function of these patients. Antidepressants are often necessary to treat depressive syndromes that accompany DLB. Atypical antipsychotics in low doses are sometimes needed to alleviate psychosis, although even low doses can increase extrapyramidal syndromes, which rarely may be life-threatening. As noted above, patients with DLB are extremely sensitive to dopaminergic medications, which must be carefully titrated; tolerability may be improved by concomitant use of cholinesterase inhibitors.

**OTHER CAUSES OF DEMENTIA** Huntington’s disease (HD) (Chap. 351) is an autosomal dominant, degenerative brain disorder. A DNA repeat expansion (CAG repeat) of the gene encoding huntingtin on chromosome 4 forms the basis of a diagnostic blood test for the disease gene. The clinical hallmarks of the disease are chorea, behavioral disturbance, and a frontal/executive disorder. Onset is usually in the fourth or fifth decade, but there is a wide range in age of onset, from childhood to >70 years. Memory is frequently not impaired until late in the disease, but attention, judgment, awareness, and executive functions may be seriously deficient at an early stage. Depression, apathy, social withdrawal, irritability, and intermittent disinhibition are common. Delusions and obsessive-compulsive behavior may occur. The disease duration is typically about 15 years but is quite variable. There is no specific treatment, but the adventitious movements and behavioral changes may partially respond to phenothiazines, haloperidol, or benzodiazepines. Asymptomatic adult children at risk for HD should receive careful genetic counseling prior to DNA testing, because a positive result may have serious emotional and social consequences.

**Normal-pressure hydrocephalus (NPH)** is a relatively uncommon syndrome consisting of an abnormal gait (ataxic or apractic), dementia (usually mild to moderate), and urinary incontinence. Historically, many individuals who have been treated as having NPH have suffered from other dementias, particularly AD, multi-infarct dementia, and DLB. Neuroimaging findings in NPH are those of a communicating hydrocephalus with a patent aqueduct of Sylvius (Fig. 350-7). In many cases periventricular edema is present. Lumbar puncture findings include an opening pressure in the high-normal range and normal CSF protein, sugar concentrations, and cell count. NPH is presumed to be caused by obstruction to normal flow of CSF over the cerebral convexity and delayed absorption into the venous system. The indolent nature of the process results in enlarged lateral ventricles but relatively little increase in CSF pressure. There is presumably stretching and distortion of white matter tracts in the corona radiata, but the exact physiologic cause of the clinical syndrome is unclear. Some patients have a history of conditions producing scarring of the basilar meninges (blocking upward flow of CSF) such as previous meningitis, subarachnoid hemorrhage, or head trauma. Others with longstanding but asymptomatic congenital hydrocephalus may have an adult-onset deterioration in gait or memory that is confused with NPH; in these patients, the aqueduct of Sylvius is small, in contrast to patients with NPH. Unlike in AD, the NPH patient has an early and prominent gait disturbance and no evidence of cortical or hippocampal atrophy on neuroimaging studies. A number of attempts have been made to use various special studies to improve the diagnosis of NPH and predict the success of ventricular shunting. These include radionuclide cisternography (showing a delay in CSF absorption over the convexity) and various attempts to monitor and alter CSF flow dynamics. None has proved to be specific or consistently useful. There is sometimes a transient improvement in gait or cognition following lumbar puncture (or serial punctures) with removal of ≥30 mL of CSF, but this finding is not a reliable predictor of post-shunt improvement. Approximately 30 to 50% of patients identified by careful diagnosis as having NPH will show improvement with a ventricular shunting procedure. Gait may improve more than memory. Transient, short-lasting improvement is common. Patients should be carefully selected for this operation, because subdural hematoma and infection are known complications.
Prion diseases such as CJD are rapidly progressive disorders associated with dementia, focal cortical signs, rigidity, and myoclonus. The rapidity of progression seen with CJD is uncommon in AD so that distinction between the two disorders is usually straightforward. CBD and DLB progress more rapidly than AD and are associated with prominent disorders of movement and so are more likely to be mistaken for CJD. Abnormal periodic EEG discharges and cortical and basal ganglia abnormalities on diffusion-weighted MRI are unique diagnostic features of CJD. **Prion diseases are discussed in detail in Chap. 362.**

Dementia can accompany chronic alcoholism (Chap. 372). This may be a result of associated malnutrition, especially of B vitamins and particularly thiamine. However, other as yet poorly defined aspects of chronic alcohol ingestion may also produce cerebral damage. A rare syndrome of dementia and seizures with degeneration of the corpus callosum has been reported primarily in male Italian drinkers of red wine (Marchiafava-Bignami disease).

Thiamine (vitamin B	extsubscript{1}) deficiency causes Wernicke’s encephalopathy (Chap. 258). The clinical presentation is a malnourished individual (frequently but not necessarily alcoholic) with confusion, ataxia, and diplopia from ophthalmoplegia. Thiamine deficiency damages the thalamus, mammillary bodies, midline cerebellum, periaqueductal gray matter of the midbrain, and peripheral nerves. Damage to the dorsal-medial thalamic regions correlates most closely with memory loss. Prompt administration of parenteral thiamine may reverse the disease if given in the first few days of symptom onset. However, prolonged untreated thiamine deficiency can result in an irreversible dementia/amnestic syndrome known as Korsakoff’s syndrome. Here, the patient is unable to recall new information despite normal immediate memory, attention span, and level of consciousness. Memory for new events is seriously impaired, whereas memory of knowledge prior to the illness is relatively intact. Patients are easily confused, disoriented, and incapable of recalling new information for more than a brief interval. Superficially, they may be conversant, entertaining, able to perform simple tasks, and follow immediate commands. Confabulation is common, although not always present, and may result in obviously erroneous statements and elaborations. There is no specific treatment because the previous thiamine deficiency has produced irreversible damage to the medial thalamic nuclei and mammillary bodies. Mammillary body atrophy may be visible on high-resolution MRI (Fig. 258-6).

Vitamin B	extsubscript{12} deficiency, as can occur in pernicious anemia, causes a macrocytic anemia and may also damage the nervous system (Chaps. 92 and 356). Neurologically it most commonly produces a spinal cord syndrome (myelopathy) affecting the posterior columns (loss of position and vibratory sense) and corticospinal tracts (hyperactive tendon reflexes with Babinski responses); it also damages peripheral nerves, resulting in sensory loss with depressed tendon reflexes. Damage to cerebral myelinated fibers may also cause dementia. The mechanism of neurologic damage is unclear but may be related to a deficiency of S-adenosylmethionine (required for methylation of myelin phospholipids) due to reduced methionine synthase activity or accumulation of methylmalonate, homocysteine, and propionate, providing abnormal substrates for fatty acid synthesis in myelin. The neurologic signs of vitamin B	extsubscript{12} deficiency are usually associated with macrocytic anemia, but on occasion may occur in its absence. Treatment with parenteral vitamin B	extsubscript{12} stops progression of the disease if instituted promptly, but reversal of advanced nervous system damage will not occur.

Deficiency of nicotinic acid (pellagra) is associated with sun-exposed skin rash, glossitis, and angular stomatitis (Chap. 61). Severe dietary deficiency of nicotinic acid along with other B vitamins such as pyridoxine may result in spastic paraparesis, peripheral neuropathy, fatigue, irritability, and dementia. This syndrome has been seen in prisoner-of-war and concentration camps. Low serum folate levels appear to be a rough index of malnutrition, but isolated folate deficiency has not been proved to be a specific cause of dementia.

Infections of the CNS usually cause delirium and other acute neurologic syndromes (Chap. 258). However, some chronic CNS infections, particularly those associated with chronic meningitis (Chap. 361), may produce a dementing illness. The possibility of chronic infectious meningitis should be suspected in patients presenting with a dementia or behavioral syndrome who also have headache, meningismus, cranial neuropathy, and/or radiculopathy. Between 20 and 30% of patients in the advanced stages of infection with HIV become demented (Chap. 173). Cardinal features include psychomotor retardation, apathy, and impaired memory. This may result from secondary opportunistic infections but can also be caused by direct infection of CNS neurons with HIV. Neurosyphilis (Chap. 153) was a common cause of dementia in the preantibiotic era; it is now uncommon but can still be encountered in patients with multiple sex partners. Characteristic CSF changes consist of pleocytosis, increased protein, and a positive Venereal Disease Research Laboratory (VDRL) test. Primary and metastatic neoplasms of the CNS (Chap. 358) usually produce focal neurologic findings and seizures rather than dementia. However, if tumor growth begins in the frontal or temporal lobes, the initial manifestations may be memory loss or behavioral changes. A paraneoplastic syndrome of dementia associated with occult carcinoma (often small cell lung cancer) is termed limbic encephalitis (Chap. 87). In this syndrome, confusion, agitation, seizures, poor memory, movement disorders, and dementia occur in association with sensory neuropathy.

A nonconvulsive seizure disorder may underlie a syndrome of confusion, clouding of consciousness, and garbled speech. Psychiatric disease is often suspected, but an EEG demonstrates the seizure discharges. If recurrent or persistent, the condition may be termed complex partial status epilepticus. The cognitive disturbance often responds to anticonvulsant therapy. The etiology may be previous small strokes or head trauma; some cases are idiopathic.

It is important to recognize systemic diseases that indirectly affect the brain and produce chronic confusion or dementia. Such conditions include hypothyroidism; vasculitis; and hepatic, renal, or pulmonary disease. Hepatic encephalopathy may begin with irritability and confusion and slowly progress to agitation, lethargy, and coma (Chap. 258).

Isolated vasculitis of the CNS (CNS granulomatous vasculitis) (Chaps. 306 and 349) occasionally causes a chronic encephalopathy with confusion, disorientation, and clouding of consciousness. Headache is common, and strokes and cranial neuropathies may occur. Brain imaging studies may be normal or nonspecifically abnormal. CSF studies reveal a mild pleocytosis or elevation in the protein level. Cerebral angiography often shows multifocal stenosis and narrowing of vessels. A few patients have only small-vessel disease that is not revealed on angiography. The angiographic appearance is nonspecific and may be mimicked by atherosclerosis, infection, or other causes of vascular disease. Brain or meningeal biopsy demonstrates abnormal arteries with endothelial cell proliferation and infiltrates of mononuclear cells. The prognosis is often poor; however, the disorder may remit spontaneously. Some patients respond to glucocorticoids or chemotherapy.

**Chronic metal exposure** may produce a dementing syndrome. The key to diagnosis is to elicit a history of exposure at work, home, or even as a consequence of a medical procedure such as dialysis. Chronic lead poisoning may present as fatigue, depression, and confusion and may be associated with episodic abdominal pain and peripheral neuropathy. Inadequately fired glazed pottery has been reported as a cause. Gray lead lines appear in the gums. There is usually an anemia with basophilic stippling of red cells. The clinical presentation can resemble that of acute intermittent porphyria, including elevated levels of urine porphyrins as a result of the inhibition of δ-aminolevulinic acid dehydrase. The treatment is chelation therapy with agents such as ethylenediamine tetraacetic acid (EDTA). Chronic mercury poisoning produces dementia, peripheral neuropathy, ataxia, and tremulousness that may progress to choreoathetosis. Chronic arsenic intoxication can produce confusion and memory loss associated with nausea, weight
loss, peripheral neuropathy, pigmentation and scaling of the skin, and transverse white lines of the fingernails (Mee’s lines). Treatment is chelation therapy with dimercaprol (BAL). Aluminum poisoning has been best documented with the dialysis dementia syndrome in which water used during renal dialysis was contaminated with excessive amounts of aluminum. A progressive encephalopathy ensued, associated with confusion, aphasia, memory loss, agitation, and, later, lethargy and stupor. Speech arrest and myoclonic jerks were common and associated with severe and generalized EEG changes. The condition has been eliminated by the use of deionized water for dialysis.

**Recurrence head trauma** in professional boxers may lead to dementia, sometimes called the “punch drunk” syndrome or dementia pugilistica. The symptoms can be progressive, beginning late in a boxer’s career and eventually leading to dementia. In young men, the duration correlates with the length of the boxing career and number of bouts. Early on, a personality change associated with social instability and sometimes paranoia and delusions occurs. Later, memory loss progresses to full dementia, often associated with parkinsonian signs and ataxia or intention tremor. At autopsy, the cerebral cortex may show changes similar to those in AD, although NFTs are usually more prominent than amyloid plaques (which are usually diffuse rather than neuritic). There may also be loss of neurons in the substantia nigra. Chronic subdural hematoma (Chap. 357) is also occasionally associated with dementia, often in the context of underlying cortical atrophy from conditions such as AD or Huntington’s disease. In these latter cases, evacuation of the subdural hematoma will not alter the underlying degenerative process.

**Transient global amnesia (TGA)** is characterized by the sudden onset of a severe episodic memory deficit, usually occurring in persons over age 50. Often, the memory loss occurs in the setting of an emotional stimulus or physical exertion. During the attack the individual is alert and communicative, general cognition seems intact, and there are no other neurologic signs or symptoms. The patient may seem confused and repeatedly ask about present events. The ability to form new memories returns after a period of hours, and the individual returns to normal with no recall for the period of the attack. Frequently no cause is determined, but cerebrovascular disease, epilepsy (7% in one study), migraine, or cardiac arrhythmia have all been implicated. A Mayo Clinic review of 277 patients with TGA found a past history of migraine in 14% and cerebrovascular disease in 11%, but these conditions were not temporally related to the TGA episodes. Approximately one-quarter of the patients had recurrent attacks, but they were not at increased risk for subsequent stroke. Rare instances of permanent memory loss after sudden onset have been reported, usually representing ischemic infarction of the hippocampi or medial thalamic nuclei bilaterally.

The ALS/parkinsonian/dementia complex of Guam is a rare degenerative disease that has occurred in the Chamorro natives on the island of Guam. Any combination of parkinsonian features, dementia, and motor neuron disease may occur. The most characteristic pathologic features are the presence of NFTs in degenerating neurons of the cortex and substantia nigra and loss of motor neurons in the spinal cord. Epidemiologic evidence supports a possible environmental cause, such as exposure to a neurotoxin with a long latency period. One interesting but unproven candidate neurotoxin occurs in the seed of the false palm tree, which Guamanians traditionally used to make flour. The ALS syndrome is decreasing in frequency on Guam, but a dementing illness with rigidity continues to be seen.

Rarely adult-onset leukodystrophies, neuronal storage diseases, and other genetic disorders can cause dementia late in life. Adult metachromatic leukodystrophy (arylsulfatase A deficiency) can present as a dementia associated with large frontal white matter lesions. Adult presentations of adrenoleukodystrophy have been reported, and in these cases involvement of the spinal cord and posterior white matter is common. This is diagnosed with measurement of medium- and long-chain fatty acids (Chap. 356). The neuronal ceroidlipofuscinoses are a genetically heterogeneous group of disorders associated with oculonous, seizures, and progressive dementia. Diagnosis is made by finding curvilinear inclusions within white blood cells or neuronal tissue.

**Psychogenic amnesia** for personally important memories is common, although whether this results from deliberate avoidance of unpleasant memories or from unconscious repression is currently unknown. The event-specific amnesia is more likely to occur after violent crimes such as homicide of a close relative or friend or sexual abuse. It may also develop in association with drug or alcohol intoxication and sometimes with schizophrenia. More prolonged psychogenic amnesia occurs in fugue states that also commonly follow severe emotional stress. The patient with a fugue state suffers from a sudden loss of personal identity and may be found wandering far from home. In contrast to organic amnesia, fugue states are associated with amnesia for personal identity and events closely associated with the personal past. At the same time, memory for other recent events and the ability to learn and use new information are preserved. The episodes usually last hours or days and occasionally weeks or months while the patient takes on a new identity. On recovery, there is a residual amnesia for the period of the fugue. Very rarely, selective loss of autobiographical information represents a focal injury in the brain areas involved with these functions.

**Psychiatric diseases** may mimic dementia. Severely depressed individuals may appear demented, a phenomenon called pseudodementia. Memory and language are usually intact when carefully tested in depressed persons, and a significant memory disturbance usually suggests an underlying dementia, even if the patient is depressed. The patient with pseudodementia may feel confused and unable to accomplish routine tasks. Vegetative symptoms are common, such as insomnia, lack of energy, poor appetite, and concern with bowel function. The onset is often abrupt, and the psychosocial milieu may suggest prominent reasons for depression. Such patients respond to treatment of the depression. Schizophrenia is usually not difficult to distinguish from dementia, but occasionally the distinction can be problematic. Schizophrenia usually has a much earlier age of onset (second and third decades) than most dementing illnesses and is associated with intact memory. The delusions and hallucinations of schizophrenia are usually more complex and bizarre than those of dementia. Some chronic schizophrenics develop an unexplained progressive dementia late in life that is not related to AD. Conversely, FTD, HD, vascular dementia, DLB, AD, or leuoencephalopathy can begin with schizophrenia-like features, leading to the misdiagnosis of a psychiatric condition. The later age of onset, presence of significant deficits on cognitive testing, and neuroimaging findings point toward a degenerative condition. Memory loss may also be part of a conversion reaction. In this situation, patients commonly complain bitterly of memory loss, but careful cognitive testing either does not confirm the deficits or demonstrates inconsistent or unusual patterns of cognitive problems. The patient’s behavior and “wrong” answers to questions often indicate that he or she understands the question and knows the correct answer.

Clouding of cognition by chronic drug or medication use, often prescribed by physicians, is an important cause of dementia. Sedatives, tranquilizers, and analgesics used to treat insomnia, pain, anxiety, or agitation may cause confusion, memory loss, and lethargy, especially in the elderly. Discontinuation of the offending medication often improves mentation.

**GENERAL SYMPTOMATIC TREATMENT OF THE PATIENT WITH DEMENTIA**

The major goals of management are to treat any correctable causes of the dementia and to provide comfort and support to the patient and caregivers. Removal of sedating or cognition-imparing drugs and medications is often beneficial. If the patient is depressed rather than demented, the depression should be vigorously treated. Patients with depression who also have dementia may also be depressed, and that portion of their condition may respond to antidepressant therapy. Antidepressants that are low in cognitive side effects, such as SSRIs (Chap. 371), are ad-
visable when treatment is necessary. Anticonvulsants are used to control seizures.

Agitation, hallucinations, delusions, and confusion are difficult to treat. These behavioral problems represent major causes for nursing home placement and institutionalization. Before treating these behaviors with medications, a thorough search for potentially modifiable environmental or metabolic factors should be sought. Hunger, lack of exercise, toothache, constipation, urinary tract infection, or drug toxicity all represent easily correctable factors that can be treated without psychoactive drugs. Medications that may calm agitation and insomnia without worsening dementia include low-dose haloperidol (0.5 to 2 mg), trazodone, buspirone, or propranolol. The new antipsychotics including risperidone, olanzapine, and quetiapine are increasingly used for patients with difficult behaviors. When patients do not respond it is usually a mistake to advance to higher doses or to use anticholinergics or sedatives (such as barbiturates or benzodiazepines).

The few controlled studies comparing drugs with behavioral intervention in the treatment of agitation suggest that both approaches are effective. However, careful, daily, nondrug behavior management is not always available, rendering medication necessary. Sometimes, apathy, visual hallucinations, and other psychiatric symptoms respond to the cholinesterase inhibitors, obviating the need for other therapies.

A proactive strategy has been shown to reduce the occurrence of delirium in hospitalized patients. This includes frequent orientation, cognitive activities, sleep-enhancement measures, vision and hearing aids, and correction of dehydration.

Nondrug behavior therapy has an important place in the management of dementia. The primary goal is to make the demented patient’s life comfortable, uncomplicated, and safe. Memory aids such as notebooks, lists, and posted daily reminders are frequently helpful. It is also useful to stress familiar routines, short-term tasks, walks, and simple physical exercises. For many demented patients, the memory for facts is worse than that for routine activities, and they still may be able to take part in remembered physical activities such as walking, bowling, dancing, and golf. Demented patients usually object to losing control over familiar tasks such as driving, cooking, and handling finances. Attempts to help or take over may be greeted with complaints, depression, or anger. Hostile responses on the part of the caretaker are useless and sometimes harmful. Explanation, reassurance, distraction, and calm statements are more productive responses in this setting. Eventually, tasks such as finances and driving must be assumed by others, and the patient will conform and adjust. Safety is an important issue that includes not only driving but the environment of the kitchen, bathroom, and sleeping area. These areas need to be monitored, supervised, and made as safe as possible. A move to a retirement home, assisted-living center, or nursing home can initially increase confusion and agitation. Repeated reassurance, reorientation, and careful introduction to the new personnel will help to smooth the process. Provision of activities that are known to be enjoyable to the patient can be of considerable benefit. Attention should also be paid to frustration and depression in family members and caregivers. Caregiver guilt and burn-out are common, often resulting in nursing home placement of the patient. Family members often feel overwhelmed and helpless and may vent their frustrations on the patient, each other, and health care providers. Caregivers should be encouraged to take advantage of day-care facilities and respite breaks. Education and counseling about dementia are important. Local and national support groups, such as the Alzheimer’s Disease and Related Disorders Association, can be of considerable help.

**FURTHER READING**


---

**PARKINSON’S DISEASE AND OTHER MOVEMENT DISORDERS**

**Mahlon R. DeLong, Jorge L. Juncos**

**PARKINSON’S DISEASE**

Parkinson’s disease (PD) is the most common example of a family of neurodegenerative disorders characterized by a neuronal accumulation of the presynaptic protein α-synuclein and by variable degrees of parkinsonism, defined as a paucity and slowness of movement (bradykinesia), tremor at rest, rigidity, shuffling gait, and flexed posture. Nearly all forms of parkinsonism result from a reduction of dopaminergic transmission within the basal ganglia. Sporadic and idiopathic PD account for ~75% of all cases of parkinsonism; the remaining 25% result from genetically defined etiologies and other causes including other neurodegenerative disorders, cerebrovascular disease, and drugs.

**Epidemiology** PD affects ~1 million individuals in the United States (~1% of those >55 years). Its peak age of onset is in the 60s (range is 35 to 85 years), and the course of the illness ranges between 10 and 25 years. Familial clusters of autosomal dominant and recessive forms of PD comprise ~5% of cases (Table 351-1). These are characterized by an earlier age of onset (typically before age 50 years) and a longer course than the more typical “sporadic” PD. Although most patients with PD appear to have no strong genetic determinant, epidemiologic evidence points to a complex interaction between genetic vulnerability and environmental factors (Fig. 351-1). Risk factors include a positive family history, male gender, head injury, exposure to pesticides, consumption of well water, and rural living. Factors linked to a reduced incidence of PD include coffee drinking, smoking, use of nonsteroidal anti-inflammatory drugs, and estrogen replacement in postmenopausal women.

**Clinical Features** A diagnosis of PD can be made with some confidence in patients who present with at least two of the three cardinal signs—rest tremor, rigidity, and bradykinesia. Tremor is particularly important, as it is present in 85% of patients with true PD; a diagnosis of PD is particularly difficult when tremor is absent. A unilateral and gradual onset of symptoms further supports the diagnosis. Masked facies, decreased eye blinking, stooped posture, and decreased arm swing complete the early picture. The onset may also be heralded by

---

**TABLE 351-1 Familial Parkinson’s Disease**

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARK1</td>
<td>α-Synuclein</td>
<td>AD</td>
</tr>
<tr>
<td>PARK2</td>
<td>Parkin</td>
<td>AR</td>
</tr>
<tr>
<td>PARK4</td>
<td>α-Synuclein triplication</td>
<td>AD</td>
</tr>
<tr>
<td>PARK5</td>
<td>UCHL1</td>
<td>AD</td>
</tr>
<tr>
<td>PARK7</td>
<td>DJ-1</td>
<td>AR</td>
</tr>
<tr>
<td>PARK3.4,6,8,9</td>
<td>Unknown</td>
<td>AD and AR mutations</td>
</tr>
<tr>
<td>PARK10</td>
<td>Unknown</td>
<td>Late-onset susceptibility gene</td>
</tr>
</tbody>
</table>
vague feelings of weakness and fatigue, incoordination, aching, and discomfort.

**Motor Features**  The most disabling feature of PD is bradykinesia, which interferes with all aspects of daily living such as walking, rising from a chair, turning in bed, dressing. Fine motor control is also impaired as evidenced by decreased manual dexterity and handwriting (micrographia). Soft speech (hypophonia) and sialorrhea are other troubling manifestations of (bulbar) bradykinesia. Rest tremor, at a frequency of 4 to 6 Hz, typically appears unilaterally, first distally, involving the digits and wrist where it may have a “pill-rolling” character. Tremor usually spreads proximally, ipsilaterally, and occasionally to the leg before crossing to the other side after a year or more. It may appear later in the lips, tongue, and jaw but spares the head. Rigidity is felt as a uniform resistance to passive movement about a joint throughout the full range of motion, giving rise to a characteristic “plastic” quality. Brief, regular interruptions of resistance during passive movement, corresponding to subclinical tremor, may give rise to a “cogwheeling” sensation. Dystonia involving the distal arm or leg may occur early in the disease, unrelated to treatment, especially in younger patients. It can also be provoked by antiparkinsonian drug therapy.

Gait disturbance with shuffling short steps and a tendency to turn en bloc is a prominent feature of PD. Festinating gait, a classic parkinsonian sign, results from the combination of flexed posture and loss of postural reflexes, which cause the patient to accelerate in an effort to “catch up” with the body’s center of gravity. Freezing of gait, a feature of more advanced PD, occurs commonly at the onset of locomotion (start hesitation), when attempting to change direction or turn around, and upon entering a narrow space such as a doorway.

Abnormalities of balance and posture tend to increase in prominence as the disease progresses. Flexion of the head, stooping and tilting of the upper trunk, and a tendency to hold the arm in a flexed posture while walking are common, as are changes in the posture of the fingers and hands. Postural instability is one of the most disabling features of advanced PD, contributing to falls and injuries and leading to major morbidity and mortality. Significant postural instability and falls in the first years of the illness, however, strongly suggest a diagnosis other than PD.

**Non-Motor Features**  Non-motor aspects of PD include depression and anxiety, cognitive impairment, sleep disturbances, sensory abnormalities and pain, loss of smell (anosmia), and disturbances of autonomic function. Together they may contribute as much to the burden of the disease as the more obvious motor abnormalities. Some of these (e.g., anosmia, depression, and sleep disorders) may be present long before the onset of motor signs. The physiologic basis of the non-motor signs and symptoms are explained in part by widespread involvement of brainstem, olfactory, thalamic, and cortical structures, as discussed below.

Sensory symptoms most often manifest as a distressing sensation of inner restlessness presumed to be a form of akathisia. Aching pain and discomfort in the extremities can be a prominent presenting symptom or develop when antiparkinson medications are wearing off. Other patients develop a subjective shortness of breath in the absence of any underlying cardiorespiratory pathology.

Sleep disorders are common in PD. Daytime drowsiness and frequent napping are typical signs of sleep disruption. Factors that disrupt sleep include nighttime reemergence of bradykinesia and rigidity, with difficulty turning in bed, as well as tremor and involuntary movements (e.g., myoclonic jerks or periodic leg movements). Restless legs and rapid eye movement–behavioral disorder (RBD) are present in considerable numbers of patients, often preceding the onset of PD. Vivid dreams and hallucinations related to dopaminomimetic therapy may also contribute to sleep disruption. Finally, sleep apnea and other sleep disturbances can occur.

Autonomic dysfunction can produce diverse manifestations, including orthostatic hypotension, constipation, urinary urgency and frequency, excessive sweating, and seborrhea. Orthostatic hypotension is present in many patients resulting from sympathetic denervation of the heart or as a side effect of dopaminomimetic therapy. This rarely leads to syncope unless the patient has developed true autonomic failure or has an unrelated cardiac problem. Drenching sweats may occur in advanced PD, often related to wearing off of medication.

**Neuropsychiatric Symptoms**  Changes in mood, cognition, and behavior are common accompaniments of the later stages of PD and may be the direct result of PD or its comorbid pathologies [e.g., Alzheimer’s disease (AD), cortical dementia with Lewy bodies (DLB)], or occur as a side effect of its pharmacotherapy.

Depression affects approximately half of patients with PD and can occur at any phase of the illness. It is often difficult to diagnose due to the overlap between the somatic and vegetative symptoms of PD and depression. As a consequence, depression often goes unrecognized and untreated. There is compelling evidence that depression in PD is an intrinsic part of the illness and not simply a reaction to disability. Recognizing even mild depression is particularly important since it can account for otherwise unexplained worsening parkinsonian motor symptoms, new somatic symptoms, and sleep disruption. Depression can also be induced or aggravated iatrogenically by antiparkinsonian and psychotropic agents used to treat other symptoms. Finally, other causes for depressive symptoms and refractory depression should always be considered, including hypothryoidism, hypogonadism, and vitamin B12 deficiency.

Anxiety disorders in PD can appear in isolation or as an accompaniment of depression or progressive cognitive impairment. They can also be due to an akathisia equivalent mediated by “dopamine hunger” due to undertreatment of motor symptoms. The development of drug-induced motor fluctuations can compound the problem by precipitating fluxes in anxiety during the off periods that mimic panic attacks.

---

![Possible cascade of pathogenic events leading to neuronal cell death in Parkinson's disease.](image-url)
Cognitive abnormalities affect many patients with PD. Most are mild to moderate in severity. Difficulties with complex tasks, long-term planning, and memorizing or retrieving new information are common. Although some of these symptoms represent bradyphrenia (the cognitive equivalent of bradykinesia), it is now clear that the dysfunction also includes working memory, attention, mental flexibility, visuospatial function, word fluency, and executive functions. Iatrogenic contributors include the indiscriminate use of amantadine or psychotropic, anticholinergic, and dopaminimmetic medications. Depression and intercurrent medical illnesses, such as urinary tract or other infections, are reversible causes of cognitive symptoms in PD. Whether these nonmenting abnormalities form a continuum with the dementias that affect a subset of patients in later stages of the disease is unknown. The incidence of dementia in PD may be as high as six times that in age-matched controls. The presence of significant cognitive impairment may limit therapeutic options and contribute more to overall disability than the motor symptoms in PD. Predictors of dementia include late age of onset, akinetic rigid phenotype, presence of severe depression, persistent hallucinations, and advanced stages of disease. In most instances accumulating amyloid and α-synuclein pathologies in the frontal lobes, basal forebrain, hippocampus, and amygdala account for the progression of symptoms (see “Pathology,” below).

Psychotic symptoms affect 6 to 40% of patients with PD, depending on the age and prevalence of dementia in the population surveyed. Early symptoms include formed visual hallucinations (usually people and animals) with retained insight. Although depression and dementia are the most important risk factors for psychotic symptoms in PD, the symptoms are often triggered by drug therapy and are dose-dependent. Dopaminimmetics, anticholinergics, amantadine, and selegiline are the chief offenders. Delusions are more disturbing than hallucinations because they place an even heavier burden on the family and caregivers. The prodrome to these psychotic symptoms includes subtle erratic behaviors with temperamental and sometimes unreasonable outbursts.

**Differential Diagnosis** The differential diagnosis of parkinsonian syndromes requires a careful history and physical examination (Table 351-2). Neuroimaging with magnetic resonance imaging (MRI) is useful to rule out disorders such as normal pressure hydrocephalus, vascular disease, or mass lesions. Positron emission tomography (PET) is helpful in confirming suspected atypical forms (see “Corticobasal Degeneration,” below). Essential tremor (ET) is sometimes confused with rest tremor in PD, but the absence of other signs of parkinsonism and the bilaterality, higher frequency (8 to 10 Hz), and postural dependency of ET plus significant relief with even a small amount of alcohol help differentiate this from the rest tremor of PD. In individuals under 40 it is important to rule out Wilson’s disease (Chap. 339). In younger individuals Huntington’s disease (HD) sometimes presents with prominent parkinsonian features. Although parkinsonian features are often present in AD, they are greatly outweighed by the cognitive and behavioral disturbances. In DLB, the parkinsonian features are compounded by the early appearance of hallucinations and disturbances in arousal and behavior. Parkinsonism may also develop following exposure to certain neurotoxins such as carbon monoxide or manganese.

The differentiation of sporadic PD from atypical parkinsonism (see below) is the most difficult task, since early in their course these atypical forms often meet diagnostic criteria for PD. Accordingly, it is important not to settle on a definite diagnosis at the first visit. The development of early imbalance and falls suggests progressive supranuclear palsy (PSP); early urinary incontinence, orthostatic hypotension, and dysarthria suggest multiple system atrophy (MSA). The

<table>
<thead>
<tr>
<th>PRIMARY PARKINSONISM</th>
<th>SECONDARY PARKINSONISM</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Familial (“primary”) PD (rare; see Table 351-1)</td>
<td>I. Repeated head trauma (“dementia pugilistica” with parkinsonian features)</td>
</tr>
<tr>
<td>II. Idiopathic (“sporadic”) PD (most common form)</td>
<td>II. Infectious and postinfectious diseases</td>
</tr>
<tr>
<td>Phenotype may be influenced by vulnerability genes and environmental factors</td>
<td>A. Postencephalitic PD</td>
</tr>
<tr>
<td>III. Other neurodegenerative disorders</td>
<td>B. Neurosyphilis</td>
</tr>
<tr>
<td>A. Disorders associated with α-synuclein pathology</td>
<td>III. Metabolic conditions</td>
</tr>
<tr>
<td>1. Multiple systems atrophies (glial and neuronal inclusions)</td>
<td>A. Hypoparathyroidism or pseudohypoparathyroidism with basal ganglia calcifications</td>
</tr>
<tr>
<td>a. Striatonigral degeneration</td>
<td>B. Non-Wilsonian hepatolenticular degeneration</td>
</tr>
<tr>
<td>b. Olivopontocerebellar atrophy</td>
<td>IV. Drugs</td>
</tr>
<tr>
<td>c. Shy-Drager syndrome</td>
<td>A. Neuroleptics (typical antipsychotics)</td>
</tr>
<tr>
<td>d. Motor neuron disease with PD features</td>
<td>B. Selected atypical antipsychotics (see text)</td>
</tr>
<tr>
<td>2. Dementia with Lewy bodies (cortical and brainstem neuronal inclusions)</td>
<td>C. Antiemetics (e.g., compazine, metoclopramide)</td>
</tr>
<tr>
<td>B. Disorders associated with primary tau pathology (“taupathies”)</td>
<td>D. Dopamine-depleting agents (reserpine, tetrabenazine)</td>
</tr>
<tr>
<td>1. Progressive supranuclear palsy</td>
<td>E. α-Methylldopa</td>
</tr>
<tr>
<td>2. Corticobasal degeneration</td>
<td>F. Lithium carbonate</td>
</tr>
<tr>
<td>3. Frontotemporal dementia</td>
<td>G. Valproic acid</td>
</tr>
<tr>
<td>C. Disorders associated with primary amyloid pathology (“amyloidopathies”)</td>
<td>H. Fluoxetine</td>
</tr>
<tr>
<td>1. Alzheimer’s disease with parkinsonism</td>
<td>V. Toxins</td>
</tr>
<tr>
<td>IV. Genetically mediated disorders with occasional parkinsonian features</td>
<td>A. 1-Methyl-1,2,4,6 tetrahydropyridine (MPTP)</td>
</tr>
<tr>
<td>A. Wilson’s disease</td>
<td>B. Manganese</td>
</tr>
<tr>
<td>B. Hallervorden-Spatz disease</td>
<td>C. Cyanide</td>
</tr>
<tr>
<td>C. Chédiak-Higashi disease</td>
<td>D. Methanol</td>
</tr>
<tr>
<td>D. SCA-3 spinocerebellar ataxia</td>
<td>E. Carbon monoxide</td>
</tr>
<tr>
<td>E. X-linked dystonia-parkinsonism (DYT3)</td>
<td>F. Carbon disulfide</td>
</tr>
<tr>
<td>F. Fragile X premutation associated ataxia-tremor-parkinsonism syndrome</td>
<td>G. N-hexane</td>
</tr>
<tr>
<td>G. Huntington’s disease (Westphalt variant)</td>
<td></td>
</tr>
<tr>
<td>H. Prion disease</td>
<td></td>
</tr>
<tr>
<td>V. Miscellaneous acquired conditions</td>
<td></td>
</tr>
<tr>
<td>A. Vascular parkinsonism</td>
<td></td>
</tr>
<tr>
<td>B. Normal pressure hydrocephalus</td>
<td></td>
</tr>
<tr>
<td>C. Catatonia</td>
<td></td>
</tr>
<tr>
<td>D. Cerebral Palsy</td>
<td></td>
</tr>
</tbody>
</table>

*Note: PD, Parkinson’s disease.*
early appearance of drug-induced hallucinations strongly favors the diagnosis of DLB. As a rule the different forms of atypical parkinsonism can be reliably differentiated from sporadic PD within the first 3 to 4 years.

**Pathology** Gross pathologic examination of the brain in PD reveals mild frontal atrophy with loss of the normal dark melanin pigment of the midbrain. Microscopically there is degeneration of the dopaminergic cells with the presence of Lewy bodies (LBs) in the remaining neurons and processes of the substantia nigra pars compacta (SNpc), other brainstem nuclei, and regions such as the medial temporal, limbic, and frontal cortices. LBs have a high concentration of α-synuclein and are the pathologic hallmark of the disorder. Mutations in the α-synuclein gene can cause familial PD by promoting the formation of α-synuclein-positive filaments that aggregate into LBs and Lewy neurites (Fig. 351-2). This pathology may begin in the anterior olfactory nuclei and lower brainstem (glossopharyngeal and vagal nerve nuclei), with ascending brainstem involvement of the locus coeruleus, n. gigantocellularis, and the raphe, before extending to the magnocellular nuclei of the basal forebrain, the central nucleus of the amygdala, and the SNpc. Involvement of these nuclei may play a role in the non-motor (e.g., autonomic, sleep, emotional, and cognitive) and refractory motor aspects (e.g., postural instability, gait, and bulbar disturbances) of PD.

The biochemical consequence of dopaminergic cell loss in the SNpc is gradual denervation of the striatum, the main target projection for the SNpc neurons. Other target regions of these neurons include the intralaminar and parafascicular nuclei of the thalamus, the globus pallidus, and the subthalamic nucleus (STN). Dopamine denervation of the striatum leads to many of the motor symptoms of PD. Symptoms develop when striatal dopamine depletion reaches 50 to 70% of normal. Pharmacologic restoration of dopamine transmission is the basis for symptomatic drug treatment of PD.

**GENETIC CONSIDERATIONS** Although >90% of cases of idiopathic PD appear to be sporadic, increasing evidence indicates that genetic factors play an important role in many forms PD. Much of this evidence comes from studies of the concordance rates for PD among monozygotic and dizygotic twins. These studies suggest that heredity plays an important role in cases with age of onset <50 years and a less important role in older patients. Four genes have been clearly linked to familial forms of PD (Table 351-1), and a number of other candidate genes or genetic loci have been identified as possibly causative of PD. Among the former, PARK1 and PARK5 lead to an autosomal dominant form of PD with atypical features such as early age of onset and rapid progression of symptoms. PARK1 encodes α-synuclein, leading to its abnormal aggregation. PARK2 and PARK7 lead to autosomal recessive disorders also with atypical features, including juvenile forms of parkinsonism. PARK2 encodes parkin, an E3 ubiquitin protein ligase. Mutations in parkin appear to be the major cause of autosomal recessive PD. Remarkably, PARK5 codes for the ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), another component of the ubiquitin proteosomal system. Because ubiquitination of proteins targets them for degradation in the proteosome, these findings suggest that abnormal proteosomal processing is important in the pathogenesis of PD. Other mutations with yet-to-be identified genes include PARK10, a late-onset PD susceptibility gene. All these mutations are thought to affect α-synuclein or its biochemical processing, either directly or indirectly. The identification of these and other mutations are proving invaluable in refining the correlation between genotypes and phenotypes, in generating animal models to study pathogenesis, and in identifying target pathways for possible therapeutic intervention.

**Pathogenesis** (Fig. 351-1) In PD dopaminergic and other cells die due to a combination of factors including: (1) genetic vulnerability, (2) oxidative stress, (3) proteosomal dysfunction, and (4) environmental factors, most of which have yet to be identified.

Oxidative stress appears to play an important role in the sporadic forms of PD. Endogenous sources of oxidative stress include the free-radicals produced by the metabolism of dopamine and melanin. Additional stress may come from defects in mitochondrial complex I of the oxidative phosphorylation chain in patients with PD. This defect has been detected in platelets and muscle and in postmortem tissue from the substantia nigra. Several toxins have been shown to cause oxidative toxicity and dopamine cell death in animal models of PD, further strengthening the above hypothesis. The most important of these are MPTP, a meperidine derivative, and rotenone, a commonly used insecticide. Both cause oxidative damage by inhibiting complex I. In vitro, oxidative stress can lead to aggregation of α-synuclein and proteosomal dysfunction. Proteosomal system abnormalities have also been described in the substantia nigra from sporadic cases of PD. The other factors of the selective dopamine neuron degeneration in PD are microglial activation, low-grade inflammation, and apoptosis, each a potential target for therapeutic intervention.

**TREATMENT**

**General Considerations** The goals of therapy in PD are to maintain function and quality of life and to avoid drug-induced complications. Bradykinesia, tremor, rigidity, and abnormal posture respond well to symptomatic therapy early in the course of the illness. In contrast, cognitive symptoms, hypophonia, autonomic dysfunction, and balance difficulties respond poorly. Primary motor disability in PD is often aggravated by secondary disability resulting from physical deconditioning following a sedentary lifestyle. Prevention of secondary disability requires a consistent program of physical activity, thus regular activity is strongly encouraged. Remaining mentally active is probably equally important.

A current priority is to move beyond symptom control to neuroprotective therapies. Unfortunately, no such therapy is yet available, although selegiline (deprenyl) may, in addition to a mild symptomatic effect, have a neuroprotective function. High doses of coenzyme Q10 and intrastratal infusion of neurotrophic factors show promise in early clinical trials. Animal studies have shown that exercise can promote neuroprotection against neurotoxins.
Initiation of Therapy  From a practical standpoint, dopaminomimetic therapy should be initiated as soon as the patient’s symptoms begin to interfere with quality of life. The ideal agent for initiation of symptomatic therapy depends on the age and cognitive status of the patient and, to a lesser extent, the patient’s clinical type and finances. The choices consist of either a levodopa preparation or a dopamine agonist. Controlled studies support the view that, in early PD, dopamine agonists and, to a lesser extent, the patient’s clinical type and finances. The ideal agent for initiation of symptoms. It significantly improves motor symptoms and increases quality of life and independence. The aim of all dopaminomimetic strategies is to restore dopamine transmission in the striatum. This is accomplished by stimulating postsynaptic receptors (directly with dopamine agonists), increasing dopamine precursor availability (levodopa), blocking the metabolism of levodopa in the periphery and in the brain, and blocking the catabolism of dopamine at the presynaptic terminal.

DOPAMINE AGONISTS  Dopamine agonists readily cross the blood-brain barrier and act directly on postsynaptic dopamine receptors (primarily D2 type). Compared to levodopa, they are longer acting and thus provide a more uniform stimulation of dopamine receptors. They are effective as monotherapeutic agents and as adjuncts to carbidopa/levodopa therapy. They can also be used in combination with anticholinergics and amantadine. Table 351-3 provides a guide to the doses and uses of these agents.

Available agents include two ergot alkaloids, pergolide and bromocriptine, and two non-ergot alkaloids, pramipexole and ropinirole. Apomorphine has been available for subcutaneous infusion and injection in Europe and Canada for many years and will soon become available in the United States as “rescue therapy” to help control motor

| TABLE 351-3  Guide to the Use of Levodopa Formulations and Dopamine Agonists in Parkinson’s Disease |
|---------------------------------------------------|---------------------------------|--------------------|----------------|-----------------|-----------------|
| **LD Dose** | **Available** | **Initial Dose** | **Other Considerations** |
| **Equivalency, mg** | **Strengths, mg** | | | |
| Carbidopa/levodopa (Typical Initial Strength) | | | | |
| Carbidopa/levodopa IR 25/100 | → | 100 | 10/100 | 25/100; 0.5 tab tid | Target dose = 3–6 25/100 tabs/d |
| Carbidopa/levodopa CR 50/200 | → | 150 | 25/100 | 25/250; one tab bid to tid | Increased bioavailability with food; splitting the tablet negates the CR property |
| Carbidopa/levodopa/entacapone 25/100/200 | → | 120 | 12.5/50/200 | 25/100/200; one tab bid to tid | Do not split tablets |

| Approximate Target Doses | | | | |
| **Available** | **As Monotherapy, mg/d** | | | |
| **Strenghts, mg** | | | As Adjuncts to LD, mg/d | Other Considerations |
| Non-ergot alkaloids | | | | |
| Ropinirole 5 | 0.25, 0.5, 1, 2, 3, 4, 5 | 0.25 tid | 12–24 | 6–16 | Hepatic metabolism; potential drug-drug interactions |
| | | | | Occasionally associated with “sleep attacks” |
| Pramipexole 1 | 0.125, 0.25, 1, 1.5 | 0.125 tid | 1.5–4.5 | 0.375–3.0 | Renal metabolism; dose adjustments needed in renal insufficiency |
| | | | | Occasionally associated with “sleep attacks” |
| Ergot alkaloids | | | | |
| Pergolide 1 | 0.05, 0.25, 1.0 | 0.05 tid | 1.5–6 | 0.3–3 | Rare reports of valvular heart disease; fewer reports of sleep attacks compared to non-ergots |
| | | | | Rare reports of sleep attacks not well studied |
| Bromocriptine 2 | 2.5, 5.0 | 1.25 bid to tid | 7.5–15 | 3.75–7.5 | Relative incidence of sleep attacks not well studied |

* Equivalency doses are approximations based on clinical experience and may not correlate with the relative in vitro binding properties of these compounds.

Note: LD, levodopa (with carbidopa); IR, immediate release; CR, controlled release; DA, dopamine agonist. Carbidopa/levodopa/entacapone, Stalevo.
fluctuations (“off” spells) in patients with moderate to advanced disease. These agents are particularly effective in treating bradykinesia and gait disturbances, but they are less effective in treating tremor. Side effects include nausea, postural hypotension, psychiatric symptoms, daytime sedation, and occasional sleep attacks. These can be managed using the above strategies and, in severe cases, through the introduction of peripheral dopamine blockers such as domperidone (not available in the United States) or short courses of trimethobenzamide or dronabinol until the symptoms subside. Patients need to be warned against the potential for sleep attacks, which can occur without warning and have resulted in traffic accidents. This phenomenon has been most often associated with agonists and less so with carbidopa/levodopa. Pergolide has recently been shown to be associated with valvular disease. When used as adjuncts to levodopa therapy these agents can aggravate dyskinesias if the doses of carbidopa/levodopa are not adjusted accordingly, and they are more expensive than carbidopa/levodopa, which is now available in generic form.

**CARBIDOPA/LEVDOPA FORMULATIONS** Carbidopa/levodopa is available in regular, immediate release (IR) formulations (Sinemet, Atamet and others; 10/100 mg, 25/100 mg, and 25/250 mg), controlled release (CR) formulations (Sinemet CR 25/100 mg, 50/200 mg), and more recently as Stalevo (Table 351-3). The latter combines IR carbidopa/levodopa with 200 mg of entacapone (see below). In most individuals, at least 75 mg/d of carbidopa is necessary to block peripheral levodopa decarboxylation into dopamine and thus symptoms of nausea and orthostasis often associated with the initiation of levodopa. Initial target doses of these medications are summarized in the table. Individualized and gradual escalation of these doses is recommended. Initiation of dosing at mealtimes will reduce the incidence and severity of nausea. As patients develop tolerance to nausea and other side effects, these medications can be administered on an empty stomach, which generally leads to a more brisk and predictable absorption.

**LEVODOPA AUGMENTATION** Selegiline is a selective and irreversible monoamine oxidase (MAO) B inhibitor with a weak symptomatic effect when used as monotherapy or as an adjunct to carbidopa/levodopa. Typically, selegiline is used as initial therapy or is added to alleviate tremor or levodopa-associated wearing-off. The usual dose is 5 mg with breakfast and lunch. At this dose there is no need for dietary restrictions, as is the case with non-selective and MAO-A inhibitors. A significant side-effect of selegiline is insomnia. Older individuals, and those with significant cardiac abnormalities, may benefit from doses as low as 2.5 mg/d. The potential role of selegiline (or desmethylselegiline) as neuroprotective therapy remains controversial.

The catechol O-methyltransferase (COMT) inhibitors entacapone and tolcapone offer yet another strategy to augment the effects of levodopa. Entacapone is preferred to tolcapone because of the low but potentially serious incidence of hepatic and hematologic side effects of the latter. When used in conjunction with carbidopa/levodopa, these agents increase the area under the curve of plasma levodopa by >30%. They alleviate wearing-off symptoms and increase by 1 to 2 h the time a patient remains “on” (i.e., well medicated) during the day. The more common side effects are gastrointestinal and hyperdopaminergic, including increased dyskinesias that may require reductions in the dose of carbidopa/levodopa. The dose of entacapone is 200 mg coadministered with each dose of carbidopa/levodopa. The dose of tolcapone is 50 to 200 mg tid.

Anticholinergics and amantadine are appropriate adjuncts to dopaminomimetic therapy. Anticholinergics are particularly useful for controlling rest tremor and dystonia, and amantadine can reduce drug-induced dyskinesias by up to 70%. The mechanisms of action of amantadine are unknown, although there is evidence it has both anticholinergic and dopaminomimetic properties. Recently amantadine has been shown to have weak glutamate antagonist properties, a mechanism thought responsible for reducing drug-induced dyskinesias. The side-effects of amantadine are nausea, headaches, edema, erythema, and livedo reticularis. In older patients, it may aggravate confusion and psychosis. Doses need to be adjusted in patients with renal failure.

**Therapy of Non-Motor Symptoms** Patients with frequent nighttime awakenings due to nocturnal akinesia or tremor can be treated with supplemental doses of carbidopa/levodopa at night. A bedtime dose of dopamine agonists helps restless leg symptoms and urinary urgency. Treatment of other bladder symptoms will improve sleep for many elderly patients. Depression typically responds to antidepressants [e.g., tricyclics, selective serotonin reuptake inhibitors (SSRIs)]. The combination of SSRIs and selegiline carries an exceedingly low risk of a hypoperforomeric syndrome (delirium with myoclonus and hyperpyrexia). Electroconvulsive therapy (ECT) is highly effective in drug-refractory cases or in patients intolerant of oral antidepressants. There are several reports indicating that ECT, in addition, has short-term benefit for parkinsonian motor symptoms.

In patients with psychotic symptoms or confusion, anticholinergics and amantadine should be eliminated first. In severe cases not responding to the above approach, some dopaminomimetics may have to be reduced or eliminated. Further drug simplification and dose reductions should proceed in the following order: selegiline, nocturnal doses of dopamine agonists, Sinemet CR, daytime doses of dopamine agonists, and finally, daytime doses of carbidopa/levodopa. If the patient improves after only a modest reduction of antiparkinsonian therapy, the overall impact on the parkinsonian motor symptoms will be negligible.

If in the process parkinsonian symptoms worsen, most specialists initiate treatment with an atypical antipsychotic with a low incidence of extrapyramidal side effects rather than continuing to lower dopaminomimetic therapy. Quetiapine is recommended first because, although not as well studied in PD as clozapine, it has proved to be effective in open-label studies and lacks the small risk of agranulocytosis associated with clozapine. Typical doses of quetiapine are 12.5 to 100 mg/d, and for clozapine 12.5 to 100 mg/d. Both are dosed at night to promote sleep and minimize daytime sedation and orthostasis. Other atypical antipsychotics, such as risperidone and olanzapine, are not well tolerated by most patients with PD because they are associated with dose-dependent parkinsonism. Early evidence suggests that the use of acetylcysteine and levetiracetam may be well tolerated and capable of treating hallucinations and delusions in patients with PD and dementia.

Given the complexity of the above polypharmacy, the management of non-motor symptoms is best carried out in an interdisciplinary setting, coordinated by a neurologist who specializes in PD together with a psychiatrist and the patient’s primary care physician.

**Neuroprotective Therapy** Reducing the progression of PD through neuroprotective or restorative therapy is a major focus of research. Epidemiologic studies suggest that the chronic use of nonsteroidal anti-inflammatory agents or the use of estrogen replacement in postmenopausal women may delay or prevent the onset of PD through yet unclear mechanisms. From a pharmacologic standpoint, current strategies involve interrupting the cascade of biochemical events that leads to death of dopaminergic cells (Fig. 351-2). The first such clinical trial in PD was the large multicenter DATATOP study in which selegeline monotherapy delayed the need for levodopa therapy by 9 to 12 months in newly diagnosed patients. Most evidence indicates that this delay was due to a mild symptomatic effect of selegeline. Long-term follow-up of the DATATOP cohort revealed that patients who remained on selegeline for 7 years experienced slower motor decline compared to those who were changed to placebo after 5 years. The 7-year patient group was more likely to develop dyskinesias but less likely to develop freezing gait. Finally, the metabolite of selegeline, desmethylselegiline, has been shown in laboratory studies to have powerful neuroprotective effects, possibly through interactions of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and other cellular protective (antiapoptotic) factors. Clinical trials to test this agent are under way.
In a recent trial, coenzyme Q10, an antioxidant and a cofactor of complex I of the mitochondrial oxidative chain, appeared to delay progression of early disability in PD. Other potentially neuroprotective agents under investigation are acetyl-levo-carnitine and creatine monohydrate. A large controlled study of the antilutamigentic agent riluzole (Chap. 353) was prematurely discontinued after a futility analysis revealed little effect on progression of symptoms. Dopamine agonists are also under investigation as putative agents to slow disease progression in PD, based on their potential antioxidant properties resulting in part from their ability in vitro to decrease dopamine turnover, scavenging free radicals, and interfere with proapoptotic cell signals. Other promising agents include nitric oxide synthetase inhibitors, anti-apoptotic agents such as Jun N-terminal kinase inhibitors, and the antibacterial minocycline. Minocycline can inhibit microglial activation in vitro and interrupt apoptosis by inhibiting caspase 1 and 3, which are involved in the enzymatic processing of α-synuclein.

**Surgical Treatments**

Over the past decade there has been a renaissance in the surgical treatment of PD and other movement disorders. Although both pallidotomy and thalamotomy were performed widely in the 1950s, the introduction of levodopa in the 1960s led to the virtual abandonment of surgery. The resurgence in the use of surgery has been motivated by the fact that after 5 years of treatment, many patients develop significant drug-induced motor fluctuations and dyskinesias. Second, advances in understanding of the functional organization of the basal ganglia and the pathophysiologic basis of parkinsonism have provided a clearer rationale for the effectiveness of these procedures and guidance for targeting specific structures (Fig. 351-3). The demonstration, in animal models of PD, that ablation of the STN (subthalamotomy) resulted in a dramatic reduction in all of the cardinal features of parkinsonism was a critical finding.

The selection of suitable patients for surgery is most important, since in general patients with atypical Parkinson’s do not have a favorable response. The major indications for surgery are (1) a diagnosis of idiopathic PD, (2) a clear response to levodopa, (3) significant intractable symptoms of PD, and/or (4) drug-induced dyskinesias and wearing-off. Contraindications to surgery include atypical forms of PD, cognitive impairment, major psychiatric illness, substantial medical comorbidities, and advanced age (a relative factor). Signs and symptoms not responding to levodopa, such as postural instability and falling, hypophonia, micrographia, drooling, and autonomic dysfunction, are unlikely to benefit from surgery. As a rule of thumb, the benefits from surgery are unlikely to exceed the benefits of antiparkinson medication. In general, the decision for surgery should be made by a movement disorder neurologist who is part of a team including a neurosurgeon trained in functional neurosurgery, a psychiatrist, a neuropsychologist, and trained technicians.

**ABLATION VERSUS DEEP BRAIN STIMULATION (DBS)**

The use of ablation (e.g., pallidotomy or thalamotomy) has decreased greatly since the introduction of DBS and is generally reserved for individuals who for medical or economic reasons cannot have DBS. Major advantages of DBS are that it is somewhat less invasive and more reversible than ablation, and in addition may be adjusted to best effect following implantation. Although the choice between the STN and the internal segment of the globus pallidus for DBS has shifted toward the STN, the data to support this are lacking. Several clinical trials are now under way to compare these two targets. The available evidence suggests that both are effective for all the cardinal features of PD as well as for dyskinesias and motor fluctuations. Unilateral stimulation is appropriate for patients with asymmetric disease, although bilateral surgery is generally necessary for patients with more advanced disease and for those with significant bilateral manifestations. Reductions in drug dosages appear to be easier with STN than globus pallidus procedures.

The mechanism of action of DBS remains controversial. Since clinically it appears that ablation and stimulation of a given target have a similar effect, it has been assumed that stimulation caused a functional blockade. It is likely, however, that multiple factors are involved. The basis for improvement may be the replacement of abnormal neural activity by a more tolerable pattern of activity. Following ablation or DBS, the remaining motor systems in the brainstem, thalamus, and cortex are able to compensate more effectively for the abnormal activity associated with the parkinsonian state. Whatever the mechanism, it is clear that these approaches can offer impressive results in properly selected patients.

**NEUROTRANSPANTATION AND OTHER SURGICAL APPROACHES**

Despite highly encouraging open-label pilot studies of fetal cell transplantation, this approach has suffered considerable disappointment with the recent publication of the results from two large, well-controlled clinical trials. The first, using sham surgery, showed only modest benefit in patients under 60 and no benefit in those over 60. An unexpected complication in a number of patients was the development of symptomatic dyskinesias, occurring off medication. The second study has shown similar findings with regard to benefit and the development of dyskinesias. A puzzling feature of these studies is the apparent successful grafting observed by PET and autopsy. Because of these disappointing results, the considerable obstacles to obtaining sufficient fetal tissue, and opposition to the use of fetal tissue on ethical grounds, this approach is now viewed as purely investigational. It is hoped that these issues can be addressed with the development of other strategies to enhance dopaminergic cell function (e.g., carotid body cells; stem cells; encapsulated and genetically engineered cells capable of producing levodopa, dopamine, and/or trophic factors). The favorable response from direct infusion of glial cell–derived neurotrophic factor (GDNF) to the putamen in a small number of patients with PD has raised hopes that this approach, or the use of gene-transfer of trophic factors such as GDNF, will succeed. Preliminary studies in primate models of PD have been encouraging in this regard.

**DEMENTIA IN PARKINSON’S DISEASE**

As noted above, the incidence of dementia in PD may be as high as six times that in the general non-PD population. Approximately a quarter of patients will develop de-
mentia of the Alzheimer type simply due to the overlap of these two common age-related disorders. Pathologically, the incidence of AD-type findings in postmortem tissue from patients dying with PD is as high as 40%. Conversely, 25% of AD patients have at least mild clinical parkinsonian features such as rigidity and bradykinesia, and >60% have coexistent α-synuclein pathology in the cortex. Patients with PD-dementia (PDD) typically have the akinetic/rigid form of the disorder where tremor is less prominent than in idiopathic PD. The course of PDD is more rapid and the management is more difficult than in PD due to the high incidence of cognitive side effects from antiparkinsonian therapy, particularly anticholinergics and amantadine. Central dopaminergic toxicity can present in many ways, ranging from sleep disruption with daytime sleepiness, personality changes, depression, and emotional dullness, episodic confusion, hallucinations, and disruptive behaviors.

DLB is an increasingly recognized form of dementia with prominent parkinsonian features. The dementia may precede or follow the parkinsonian syndrome. In patients presenting with parkinsonian features, the dementia is often heralded by levodopa-induced sedation, myoclonus, and hallucinations. Early on, the phenotype can be indistinguishable from PD. Features that help differentiate this entity from PD include the presence of an action rather than a rest tremor, a rapidly fading response to levodopa, and rapidly fluctuating, spontaneous, and drug-induced problems with arousal. Another feature of DLB is the higher incidence of neuropsychiatric symptoms than in idiopathic PD. These symptoms include apathy, personality changes, depression, fixed delusions, and hallucinations. Finally, patients with DLB exhibit a heightened sensitivity to drug-induced parkinsonism (DIP) when exposed to any dopamine blocker. The progression of symptoms in DLB is intermediate between the PD and PD/AD overlap. →DLB is discussed in detail in Chap. 350.

OTHER PARKINSONIAN DISORDERS

PARKINSONIAN DISORDERS ASSOCIATED WITH ABNORMAL METABOLISM OF α-SYNUCLEIN (α-SYNUCLEINOPATHIES) • Multiple System Atrophy MSA represents a sporadic group of disorders characterized by varying degrees of parkinsonism and cerebellar, corticospinal, and autonomic dysfunction. The average age of onset is 50 years (earlier than in PD), and the median survival 6 to 9 years. The clinical presentation is highly varied and may begin with any of the above clinical signs. The unifying pathologic hallmark is the presence of α-synuclein-positive inclusions located in various brain regions.

CLINICAL PHENOTYPES With disease progression, 90% percent of patients exhibit parkinsonian signs, 80% signs of autonomic failure, and a similarly high percentage exhibit upper motor neuron signs. Tremor is common but, unlike in PD, this and other parkinsonian signs are more likely to present symmetrically. Parkinsonian symptoms are typically poorly responsive to dopaminergic therapy, although some patients may respond favorably for years. Drug-induced dyskinesias typically involve the face and neck rather than the trunk and limbs, as is the case in PD. Corticospinal signs consist of spasticity, involving the legs more than the arms, and pseudobulbar palsy. This aspect of the illness may mimic primary lateral sclerosis with lower motor neurons being occasionally involved. A few patients develop myoclonus.

Signs of autonomic failure include orthostatic hypotension, leg swelling not due to drug therapy, changes in sweating patterns, and autonomic storms with diaphoresis and flushing. Orthostatic hypotension can present with dizziness, faintness, or syncope. Once patients are successfully treated for syncope, they often develop fatigue and lassitude. This is due in part to chronic tissue hypoperfusion caused by marginal blood pressures while sitting or standing. More aggressive management of the blood pressure is warranted but not always successful. Urinary symptoms include urgency, retention, and incontinence. In men impotence is one of the earliest and most prominent signs. The autonomic dysfunction can precede or follow the development of other neurologic signs by several years. Dementia may not be as frequent as in PD.

The clinical phenotype of MSA can fall into one of three broad categories, termed striatonigral degeneration (SND), olivopontocerebellar atrophy (OPCA), and progressive autonomic failure (PAF), either without parkinsonism or with parkinsonism (Shy-Drager syndrome). Patients presenting with a relatively pure form of akinetic rigid parkinsonism and a limited response to levodopa are designated as SND. The diagnosis is difficult. Individuals with other signs such as ataxia, upper motor neuron and corticobulbar involvement, myoclonus, oculomotor abnormalities, peripheral neuropathy, and deafness fit into the category of OPCA. This phenotype is notably heterogeneous, with sporadic and hereditary forms. The sporadic forms are more likely to form part of the spectrum referred to in this section, with the hereditary forms usually representing one of the spinocerebellar ataxias (Chap. 352). Finally, a diagnosis of Shy-Drager syndrome is justified when the parkinsonian features are associated with prominent signs of autonomic dysfunction. Although the above categories remain clinically useful, it should be noted that as disease progresses, there tends to be more clinical and pathologic overlap than separation between these entities.

The spectrum of disease in MSA is determined by the location and density of the LB pathology. For instance, in PD the LBs are confined to neurons in the brainstem, and in DLB to the brainstem, cortex, and hippocampus. In MSA these deposits take the form of glial α-synuclein-positive intracytoplasmic inclusions in the substantia nigra, putamen, inferior olives, pontine nuclei, pigmented nuclei of the brainstem, the intermediolateral nucleus of the spinal cord, and the cerebellum. In addition in MSA there are myelin degeneration and oligodendroglia containing argyrophilic glial cytoplasmic inclusions that are immunoreactive for ubiquitin and α-synuclein. Similar inclusions can be found in neuronal cell bodies and processes. Several diagnostic tests help differentiate MSA from PD and other parkinsonian syndromes. In OPCA, brain MRI reveals prominent atrophy of the cerebellum, pons, and olivary eminence of the medulla. In SND, prominent volume loss and T2-weighted image hyperintensity in the putamen, globus pallidus, and white matter may be present. Electrodiagnostic studies may reveal rectal sphincter abnormalities with signs of degeneration with reinnervation due to anterior horn cell loss. Commercially available genetic tests are available for many of the spinocerebellar ataxias (Chap. 352) that present with features that overlap OPCA.

TREATMENT

Early in the course of the illness parkinsonian features may respond to dopaminomimetic agents. These have to be used with caution due to their tendency to provoke orthostatic hypotension. →Treatment of orthostatic hypotension and other autonomic symptoms is discussed in Chap. 354.

PARKINSONIAN DISORDERS ASSOCIATED WITH ABNORMALITIES OF TAU METABOLISM (TAUOPATHIES) As in the synucleinopathies, the discovery that a group of familial and sporadic disorders with pathology involving the microtubule-associated protein tau has helped classify a group of disorders characterized by atypical parkinsonism and dementia. In the less common familial forms, mutations in the tau gene have been linked to rare forms of parkinsonism and to frontotemporal dementia, another tauopathy discussed in Chap. 350. This discussion will focus on two entities that typically present with movement disorders. The first, PSP, has not been linked to mutations in the tau gene but is associated with overrepresentation of the H1 tau gene haplotype. These and other findings support the view that abnormal processing of tau may be directly linked to the pathogenesis of sporadic and familial tauopathies.

Progressive Supranuclear Palsy This is a sporadic neurodegenerative disorder of unknown etiology associated with tau pathology. It presents in the sixth to seventh decades and progresses faster than PD, with
death in 5 to 10 years. Risk factors include head trauma, vascular disease, psychiatric exposure to benzyl-tetrahydroisoquinolines (TIQ, reticuline), and beta-carbolines (reports from the West Indies).

PSP is characterized by akinesic rigid parkinsonism, dizziness, unsteadiness, slowness, falls, and pseudobulbar dysarthria. Tremor is distinctly uncommon. Supranuclear eye movement abnormalities affecting downgaze occur first, followed by variable limitations of upward and horizontal eye movement. Because the vestibular ocular reflex (“doll’s eyes” maneuver) and the Bell’s reflex (elevation and abduction of eyes on attempted lid closure) are intact, these abnormalities are termed supranuclear. Neurologic examination often reveals prominent stare and furrowed brow, axial (especially nuchal) and proximal distal limb rigidity and dystonia, as well as upper motor neuron and occasional cerebellar signs. Virtually all patients develop frontal-type cognitive dysfunction (Chap. 350), and a significant number may develop dementia with distinct subcortical features (e.g., abulia, mental inflexibility, and defects in memory retrieval). Brain MRI reveals midbrain atrophy (superior colliculus), and PET studies show symmetric frontal and striatal hypometabolism. Although some response may occur to levodopa and other antiparkinson medications, especially early in the course, treatment is generally not highly effective. The diagnosis is made on clinical grounds.

Pathologically, PSP is characterized by deposition of neurofibrillary tangles histochemically positive for tau (mostly 4-repeat tau) and made on clinical grounds. The deposits are associated with varying degrees of degeneration in the brainstem, basal ganglia, and cerebellum. There is loss of dopamine and dopamine receptors due to intrinsic striatal damage. This is thought to account for the poor response to therapy.

Corticobasal Degeneration (CBD) CBD, another sporadic tauopathy, is less common and has a broader range of clinical presentations than PSP. As with most atypical forms of parkinsonism, it begins insidiously in the sixth to seventh decades with varying degrees of asymmetric progressive apraxia, rigidity, dystonia, bradykinesia, and myoclonic jerks with or without cortical sensory loss. Alien limb phenomena is a characteristic sign present in many cases. The disorder progresses to become bilateral over 2 to 5 years, leading to total incapacity with, ultimately, paraplegia in flexion. A significant number of cases present with frontotemporal dementia or progressive aphasia, followed by asymmetric cortical sensory signs, including abnormalities of graphesthesia and astereognosis (Chap. 350). Brain MRI reveals focal cortical loss in the contralateral superior frontal and parietal lobes with corresponding hypometabolic changes on PET scan, as well as hyperintense signal abnormalities in white matter and sometimes atrophy of the corpus callosum. Treatment is largely ineffective.

Grossly, CBD is a focal cortical degenerative process with asymmetric pathology and volume loss in the parietal and frontal regions. Most of the damage is in the dorsal peri-Rolandic, superior frontal, and superior parietal cortices, whereas cases with aphasia show abnormalities in the per-Sylvian regions. Histologically, gliosis and swollen (ballooned) achromatic neurons and neuronal loss are present in these cortical regions as well as in the nigra, caudate, putamen, and thalamus. Recent clinicopathologic evidence indicates the syndrome can occur in the absence of basal ganglia or nigral degeneration.

SECONDARY PARKINSONISM ■ Drug-Induced Parkinsonism DIP closely resembles PD except for the tremor, which is generally (but not always) less prominent. It is commonly due to neuroleptics, some atypical antipsychotics, lithium carbonate, or antiemetic agents (especially metochlopramide). Less common causes include valproic acid and, more recently, fluoxetine. DIP can be induced as well by the chronic administration of antihypertensive agents such as reserpine and alpha-methyldopa. Exposure to manganese, carbon monoxide or disulfides, cyanide, and methanol can also lead to a parkinsonian state. The severity of the parkinsonian symptoms usually correlates with the dose or exposure to a medication or toxin. If due to medication, the symp-

toms tend to disappear within days to weeks after stopping the offending agent but may be permanent. Patients with permanent symptoms may have been in the process of developing parkinsonism. DIP may respond to anticholinergic agents, amantadine, and levodopa.

Vascular Parkinsonism The concept of vascular or atherosclerotic parkinsonism remains a topic of controversy. Generally, patients with vascular parkinsonism exhibit an akinesic-rigid syndrome with short mincing steps without tremor. Most have neurologic signs distinguishable from those associated with PD, including upper motor neuron signs, pseudobulbar palsy, or dementia. A poor response to levodopa therapy is characteristic. Imaging studies are heterogeneous and may reveal basal ganglia lacunes or multiple infarcts. The hypertensive and diabetic microangiopathy and diffuse white matter disease (Chap. 349) typically present with patchy, confluent or diffuse white matter in the centrum semiovale. Other causes of microangiopathy can also rarely be a cause. The premortem diagnosis of these disorders is difficult to make with certainty, given the absence of disease markers.

TREMOR Tremor is defined as an “approximately rhythmic and roughly sinusoidal movement of variable amplitude and frequency” (Elble and Koller). Not all tremors are abnormal; most are involuntary with occasional voluntary tremors occurring in malingering. Individuals with conversion disorders may show partial control over their tremor symptom. Physiologic tremor is a normal high-frequency, low-amplitude tremor notable only during hyperadrenergic states. Parkinsonian rest tremor is discussed above. Cerebellar kinetic tremor is discussed in Chaps. 21 and 352. Kinetic tremors can be postural, action, or both. Postural tremor is most prominent when the arms are held in front of the chest. Action or intention tremor is most notable when reaching to a target. Most tremor disorders have a predominant tremor type and a variable representation of other tremor types.

ESSENTIAL TREMOR ET is perhaps the most common movement disorder, affecting 5 to 10 million adults and a few children in the United States. It is characterized by a 6- to 12-Hz postural and kinetic tremor affecting the arms in almost all cases. In order of decreasing frequency, other body parts that can also be involved include the head (titubation), legs, the larynx (voice tremor), and the trunk. Diagnosis is made on clinical grounds. An autosomal dominant inheritance pattern is likely; thus a positive family history is very helpful, as is a history of partial response to alcohol consumption. Drugs that can aggravate any tremor include valproic acid, lithium, β-adrenergic agonists, methylxanthines, thyroxin, glucocorticoids, tricyclic antidepressants, and serotonin reuptake blockers. Withdrawal from drugs associated with tolerance, or medical conditions such as thyrotoxicosis and other enhanced adrenergic states, can amplify physiologic tremor, mimic pathologic tremors, or aggravate ET.

Compared to PD, symptoms of ET are generally bilateral from onset and the course slower. A small subset of patients has comorbid PD. ET can nonetheless be associated with significant disability, depending on amplitude of the tremor and the body region involved. Anxiety disorders are comorbid in a significant number of cases, and, as in all movement disorders, symptoms and signs worsen during emotional and physiologic stress. There is no consensus with respect to any pathology associated with ET, and diagnostic imaging of the brain is normal.

<table>
<thead>
<tr>
<th>TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no cure for ET, but symptoms can be managed adequately with pharmacologic interventions in ~50% of cases and with surgical interventions in 80% of patients. Primidone and propranolol are the first-line treatments for ET; both have shown efficacy in double-blind, placebo-controlled studies. Primidone (50 to 750 mg/d) is often highly effective. The starting dose should be 25 mg (one-half of a 50-mg tab) at bedtime, with slowly increasing doses to minimize sedation. Propranolol (40 to 320 mg/d) is better tolerated but no more effective and is contraindicated in patients with asthma, bradycardia, and some car-</td>
</tr>
</tbody>
</table>
HYPERKINETIC DISORDERS

Hyperkinetic movement disorders (Chap. 21) encompass a wide variety of involuntary movements, which may occur in isolation or in combination. Hyperkinesias have a wide spectrum of severity ranging from subtle restlessness to the violent movements of hemiballismus and the highly complex and emotionally laden vocal tics and coprolalia in Tourette syndrome.

HEMIBALLISMUS/HEMICHOREA Hemiballismus, a dramatic disorder, is typically acute in onset and ranges from mild chorea to the wild flinging movements of ballism. Hemiballismus may be viewed as a large-amplitude, violent form of chorea affecting the proximal more than the distal limbs. The most common cause is a lesion of the subthalamic nucleus, most often a hypertensive lacunar stroke (Fig. 351–4). Other cerebral lesions associated with hemiballismus and hemichorea include cortical, thalamic, and basal ganglia infarcts or lesions and demyelinating disease. Medical management of hemiballismus consists of supportive care to avoid injuries, exhaustion, and dehydration. The condition is difficult to treat pharmacologically but the drugs most consistently beneficial are tetrabenazine (not available in the United States), haloperidol, propranolol, phenytoin, clonazepam, and baclofen. Although hemiballismus was once thought to carry a poor prognosis, with proper treatment there is a high likelihood of survival and improvement over weeks to months. In intractable cases, pallidotomy or thalamotomy can be highly effective.

HUNTINGTON'S DISEASE HD is a fatal autosomal dominant disorder characterized by progressive motor, emotional, and cognitive dysfunction. Onset is typically between the ages of 35 and 45 years (range 3 to 70). HD occurs worldwide, with a prevalence of 10 cases per 100,000. It is caused by mutations in the Huntington’s gene on the short arm of chromosome 4, specifically an expanding and unstable polyglutamine repeat (CAG) in its coding sequence. The gene encodes the highly conserved cytoplasmic protein huntingtin, which is present in all neurons.

Clinical Features A clinical diagnosis of HD can be made readily in cases with a positive family history and an insidious onset of chorea with variable degrees of dementia and emotional symptoms. The term chorea (“dance”) refers to arrhythmic involuntary movements that are typically sudden and brief and that seem to flow from one part of the body to another. When combined with slower writhing movements or dystonic posturing, the term choreoathetosis is often used. Examples of other involuntary movements that may be confused with chorea include myoclonus and tics. Myoclonic jerks are lightning fast but lack the rhythmic flow of activity seen in chorea. While patients with myoclonic jerks commonly lose motor control and drop objects, this rarely happens with chorea or tics. Unlike chorea and myoclonus, motor tics can be readily suppressed voluntarily.

The clinical course of HD can last 15 to 20 years. In the early stages the chorea is focal and segmental (i.e., increased blinking, grimacing) but progresses to involve multiple body parts. The chorea typically peaks within 10 years and is gradually replaced by bradykinesia, rigidity, and dystonia. In 6 to 10% of cases HD may present with a parkinsonian syndrome rather than with chorea (Westphalt variant). The latter cases typically have an early onset (e.g., < 20 years). The behavioral and cognitive disturbances characteristic of HD most often account for the burden of the patient’s disability and most of the hardship to the family. Approximately one-third develop dysthymia or an affective disorder; one-third an intermittent explosive disorder; and the remaining third substance-abuse problems, sexual dysfunction, antisocial personality traits, or schizophreniaforms. Depression with suicidal tendencies is not uncommon. Even the minority who may not manifest behavioral problems ultimately succumb to dementia.

The diagnosis of HD is confirmed with genetic testing, which is also helpful in the differential diagnosis of chorea of unknown etiology and in cases of atypical dementia or psychosis. Genetic testing is also used for genetic counseling in adults but is usually not necessary in symptomatic individuals if there is genetic or pathologic confirmation of HD in other family members. Other conditions important in the differential diagnosis of HD include so-called senile chorea occurring in older individuals, benign hereditary chorea in younger individuals, and neuroacanthocytosis, a progressive autosomal recessive degeneration of the basal ganglia associated with acanthocytosis of red cells in the peripheral smear and normal plasma lipoproteins. Ancillary diagnostice measures include MRI to determine if there is caudate atrophy. Other diagnostic measures may be helpful in atypical cases without a clear family history and in cases where the genetic testing results are indeterminate. These tests include PET, which typically reveals decreased striatal metabolic activity before atrophy is apparent, and neuropsychologic testing.

Pathology and Pathophysiology The neuropathology of HD consists of widespread cerebral atrophy with prominent involvement of the striatum and cerebral cortex. Neuronal loss and gliosis are maximal in the caudate initially, with lesser involvement of the cortex and other subcortical structures. Although the mechanism of cell death in HD remains unclear, there is now experimental evidence to support the hypothesis that abnormal glutamatergic transmission with excitotoxicity of striatal cells bearing glutamate receptors plays a role.

| TREATMENT | Treatment should involve a multidisciplinary team that can provide social, medical, neuropsychiatric, and genetic guidance to patients and families throughout the course of the illness. Although dopamine blockers are moderately effective for chorea, they may aggravate bradykinesia and dystonia. Atypical antipsychotics such as clozapine, risperidone, and olanzapine are better tolerated but may not be as effective. |

FIGURE 351–4 Schematic diagram of the basal ganglia–thalamiccortical circuitry in hemiballismus, a surrogate in this case for other hyperkinetic movement disorders. As in Fig. 351–3, inhibitory connections are shown as black arrows and excitatory connections as red arrows. In hemiballismus the sudden loss of activity in STN neurons or their connections results in the loss of the normal thalamic inhibition by basal ganglia outflow, leading to poorly modulated and excessive thalamic activation of cortex. Clinically the patient exhibits abnormal contralateral choreiform movements. Dopamine antagonists help reduce the violence of the movements by decreasing neuronal activity in the direct pathway and increasing it in the indirect pathway, elevating neuronal activity in GPi/SNr. Paradoxically, surgical lesions of GPi/SNr are also beneficial, suggesting that abnormalities in neuronal discharge patterns are a major factor as well. D, direct pathway; I, indirect pathway; GPe, external segment of the globus pallidus; GPi, internal segment of the globus pallidus; SNr, substantia nigra, pars reticulata; SNc, substantia nigra, pars compacta; STN, subthalamic nucleus; VA/VL, ventral anterior and ventral lateral thalami; CM, centromedian nucleus; PPN, pedunculopontine nucleus. (Courtesy of T Wichmann, MD, Emory University School of Medicine.)
Dystonia - Clinical Features

**Dystonia** is a syndrome consisting of involuntary muscular contractions that result in twisting and repetitive movements and/or abnormal postures. Dystonia comprises a large and heterogeneous group of disorders. Although dystonia is one of the more common movement disorders, it is also one of the most frequently under- and misdiagnosed due to its highly variable presentations. The prevalence is not certain because of underreporting but probably exceeds 300,000 cases in the United States, a prevalence equal to that of multiple sclerosis.

Co-contraction of agonist and antagonist muscles is a fundamental feature of dystonia, distinguishing it from chorea, tics, and other dyskinesias. Also, unlike other hyperkinetic movement disorders, dystonia is characteristically present during attempted voluntary movement (so-called action dystonia). It is also associated with "overflow," the abnormal spread of activation to muscles other than those required for the intended movement. As with most movement disorders, dystonia is exacerbated by stress and fatigue. A unique feature of dystonia is that it can often be attenuated by sensory (tactile or proprioceptive) input (so-called sensory tricks). For instance, in patients with torticollis, stepping on the floor or rubbing the head can reduce the neck twist. The twisting movements or abnormal postures. Another common feature of primary dystonia is the presence of dystonic tremor, which may appear in a form resembling essential tremor or as a succession of rapid dystonic movements.

The dystonias can be classified according to: (1) age of onset (childhood vs. adult), (2) region of the body involved, and (3) etiology. Using an etiologic scheme, similar to that used for PD, the dystonias may be divided into primary, secondary, dystonia-plus syndromes, and hereditary degenerative disorders.

**Primary Dystonia**

Primary dystonia includes syndromes in which dystonia is the only clinical manifestation of the disease (other than tremor), and no pathologic changes are evident. Primary dystonia is often inherited and a number of genes have been identified. The major childhood disorder in this group is idiopathic torsion dystonia (ITD), or Oppenheim’s dystonia. Sporadic adult-onset focal dystonias are the most common forms of primary dystonia.

**Oppenheim’s Dystonia**

ITD dystonia is an autosomal dominant hereditary disorder affecting primarily Ashkenazi Jewish families (up to 90% of all cases of dystonia) but also present in non-Jewish families. The gene is located on chromosome 9q34 and results in a loss of glutamic acid in the protein Torsin A. The penetrance is about 30%. Families with ITD dystonia may exhibit either generalized or focal dystonia. The age of onset is typically in childhood for generalized and later for focal dystonia. The first signs of dystonia generally occur in the foot during walking or in the arms during voluntary movement. Dystonia later occurs at rest, leading to postural abnormalities. It usually spreads to the arm on the same side before spreading to the other side of the body. The age of onset is typically later in cases in which the symptoms begin in the arm or neck. In late-onset ITD the dystonia tends to remain focal, in contrast to early-onset forms that usually become generalized.

**Focal Dystonias**

The most common forms of dystonia are the focal dystonias, which present primarily in adults. These may affect (1) the eyelids, causing them to close involuntarily (blepharospasm); (2) the neck and shoulders (cervical dystonia), causing the neck to twist to the side (torticollis), forward (anterocollis), or backward (retrocollis); (3) the lower face and jaw or a syndrome causing the jaw to move incessantly (oromandibular dystonia); and (4) the larynx (spasmodic dysphonia), causing the voice to have a strained and discontinuous quality due to involuntary closing of the vocal cords with phonation. The combination of lower facial and jaw dystonia (Meige’s syndrome) is not uncommon. Another type of task-specific focal dystonia affects the hand and forearm in specific activities such as handwriting (writer’s cramp), typing, or playing a musical instrument (musician’s cramp). Dystonia can, in fact, occur in almost any situation involving repetitive activities of the hand or other body parts. The focal dystonias are still often misdiagnosed as psychiatric or orthopedic problems.

The role of hereditary and environmental factors in adult-onset focal dystonia is not well understood. There is now mounting evidence that in some cases dystonia can develop from peripheral factors such as trauma to peripheral nerves. In addition to peripheral injury, discrete cerebral lesions, typically involving the basal ganglia but also the thalamus, cortex, or brainstem, can cause unilateral dystonia. The most frequent cause is a cerebral infarction but trauma, tumor, and other lesions may be accountable. In the case of infarction, the onset of dystonia is typically delayed by weeks to months as the associated hemiparesis clears.

**Secondary Dystonias**

Secondary dystonias are largely due to drugs and other environmental factors. The drug-induced phenomena include levodopa-induced dystonia as well as acute and tardive dystonia associated with dopamine receptor blockers (see “Drug-Induced Movement Disorders,” below). External factors producing dystonia include cerebral palsy (athetoid form), cerebral trauma, peripheral nerve injury, cerebral hypoxia, some infectious and postinfectious states, and toxic exposure to manganese, cyanide, and 3-nitropropionic acid.

**Dystonia-Plus Syndromes**

Two types of dystonia-plus syndromes deserve mention—dopamine-responsive dystonia (DRD) and myoclonic dystonia. DRD is a dominantly inherited disorder associated with mutations in the gene for cyclohydrolase I (GTPCH), the rate-limiting enzyme in the synthesis of the tyrosine hydroxylase cofactor tetrahydrobiopterin. Tyrosine hydroxylase is the rate-limiting enzyme for dopamine synthesis. DRD typically presents in childhood beginning in the legs and spreading to the arms. Marked diurnal fluctuations are common. In the typical case a child aged between 4 and 8 develops a stiff-legged gait that worsens as the day progresses but improves dramatically on awakening from sleep. Some patients exhibit parkinsonism and signs of spasticity. In late-onset cases the presentation may consist of parkinsonism instead of dystonia. Patients have an excellent response to levodopa and a non-progressive course. DRD may be misdiagnosed as “athetoid” cerebral palsy, “spastic” paraplegia, or parkinsonism. Although rare, DRD is so responsive to levodopa that many feel that a trial of levodopa is warranted in all cases of dystonia.

The hereditary syndrome of myoclonic dystonia (also called hereditary dystonia with lightning jerks) is not always easily distinguished from primary dystonia or heredity essential myoclonus. It is distinguished not only by its character but also by its responsiveness to alcohol.

The hereditary degenerative diseases that may manifest dystonia typically present with more prominent parkinsonian features and include Wilson’s disease, HD, PD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), the Lubag form of dystonia-parkinsonism (DYT3), Leigh’s disease, and other mitochondrial encephalopathies.

**Pathophysiology**

There is now considerable evidence for a loss of inhibition at multiple levels in the central nervous system (CNS), in-
Treatment of dystonia is for the most part symptomatic except in the rare instances such as Wilson’s disease (Chap. 339) or DRD, where known mechanisms are present and specific therapies are available. The available treatments include physical and emotional support, physical therapy and neurorehabilitation, drugs, and surgery. The importance of education and supportive care must be recognized. Sensory retraining in humans with focal dystonias has resulted in a substantial recovery of function in some patients. Patients with generalized dystonia benefit from a team approach in a specialized center.

Pharmacotherapy

Anticholinergic drugs are the most effective forms of treatment for generalized primary dystonia. Trihexyphenidyl is most commonly used. Doses ≥120 mg/d in children may be necessary, with a usual range of 20 to 50 mg/d. Adults can rarely tolerate these high doses. The limiting factors include constipation, dry mouth, blurred vision, and urinary retention as well as impaired short-term memory, confusion, and hallucinations. Benzodiazepines, including clonazepam or diazepam, are also effective for dystonia, alone or in combination with anticholinergics. Dosages are raised slowly until benefits are obtained or side effects, including sedation, ataxia, and confusion, prevent further escalation. Baclofen, a drug similar to the naturally occurring neurotransmitter γ-aminobutyric acid (GABA), is also effective for treating both focal and generalized dystonia. Relatively high doses are required (60 to 100 mg); however, side effects are often limiting. A baclofen pump for intrathecal infusion may be helpful for such cases. Dystonia involving the legs and trunk is most responsive to this form of therapy. Unfortunately, sustained benefits are not the rule and complications are not infrequent. Dopaminergic drugs are occasionally beneficial in both generalized and focal dystonias, but the most dramatic effects are seen in individuals with DRD, who experience a dramatic and sustained improvement with even a small dose of levodopa. Paradoxically, a fair percentage of patients with generalized dystonia (and cranio-cervical dystonia) respond to dopaminergic antagonists, such as haloperidol or pimozide. Sometimes the combination of tetrabenazine, pimozide, and trihexyphenidyl is effective.

Botulinum Toxin

Although the focal dystonias are generally poorly responsive to drugs, they often respond dramatically to botulinum toxin injected into the affected muscle groups. Botulinum toxin can also be used in generalized dystonia for the occasional treatment of focal problems. Botulinum toxin acts by blocking the release of acetylcholine at the neuromuscular junction, resulting in dose-dependent weakness. Repeated injections are required every 2 to 5 months. Botulinum toxin serotypes A and B are now available, providing an alternative should resistance develop to either serotype.

Surgical Approaches

Prior to the introduction of botulinum toxin, peripheral denervation procedures, such as dorsal or anterior cervical rhizotomy and selective peripheral denervation, were commonly performed, primarily for the treatment of cervical dystonia. These are now performed far less frequently, generally in patients with cervical dystonia who fail botulinum toxin injections. Stereotactic surgery is used primarily for severe generalized dystonia unresponsive to other treatments. In recent years following the success in PD, pallidotomy and DBS of the pallidum are being used with promising results. The best candidates for surgery appear to be individuals with primary (DYT1) dystonia. Patients with secondary forms of dystonia are less likely to benefit. Bilateral surgery is usually necessary to obtain control of axial dystonia.
which appears most frequently in a generalized form in children and in a focal form (e.g., blepharospasm, torticollis, or oromandibular dystonia) in adults. These movements can be readily treated with the per- enteral administration of anticholinergics (benzotropine or diphenhy- dramine) or benzodiazepines (lorazepam or diazepam). Other acute movement disorders include dyskinesias, stereotypic behaviors, and tics after exposure to CNS stimulants such as methylphenidate, dextroamphetamine, and pemoline.

Subacute Prob-ably the most common of these reactions is neuroleptic-induced akathisia, a state of motor restlessness with a feeling of restlessness and a need to move, which tends to alleviate the symptoms temporarily. Therapy consists of removing the offending agent(s). When this is not possible, symptoms can be ameliorated with benzodi- azepines, anticholinergics, beta blockers, and, in some cases, dopa-mine agonists.

Tardive Tardive movement disorders such as TD are primarily due to chronic exposure to central dopamine blockers. The movements are most often choreatic, affecting first the mouth, lips, and tongue and later the trunk and limbs. In a fully developed case there can be head nodding, pelvic rocking, and fine movements of the fingers and toes. The diaphragm is affected rarely, producing respiratory distress. Other tardive syndromes include tardive dystonia, which generally presents with more axial than appendicular involvement; tardive akathisia; tar- dive tics; and even tardive tremor.

Approximately one-third of patients with TD remit within 3 months of stopping neuroleptic therapy, and in most patients the movements will gradually remit within 5 years. Patients at risk of permanent TD include the elderly, the edentulous, and those with underlying organic cerebral dysfunction. Patients with affective illnesses appear more likely to develop TD than patients with schizophrenia. Since treatment of TD is most often unsatisfactory and frustrating for both patient and physician, it is critical that typical antipsychotics be used judiciously and that, once started, their continued need be reassessed periodically. Abrupt drug cessation may result in “withdrawal dyskinesias,” which presage the development of frank TD.

### Treatment

Atypical antipsychotics (clozapine, risperidone, olanzapine, quetia- pine, ziprasidone, and aripiprazole) significantly lower the risk of TD compared to typical antipsychotics. Accordingly, if withdrawal of the offending antipsychotic is not possible, replacing traditional with atypical antipsychotics should be tried. Furthermore, it appears that atypical antipsychotics can successfully block the dyskinesias themselves. Elimination of stimulants and anticholinergics will also alleviate dys- kinesias. In refractory cases, choreatic TD can be treated with the catecholamine depleters reserpine and tetrabenazine. Reserpine should be started at 0.125 mg/d and escalated slowly as needed up to 6 mg/d. Tetrabenazine should be started at 12.5 mg/d and gradually increased as necessary up to 200 mg/d. The elderly are less likely to tolerate the dose-dependent sedation and orthostatic hypotension associated with these drugs. Approximately 15% of patients on cate- cholamine depleters develop depression with chronic use of reserpine. Another strategy employs GABAergic medications such as baclofen (40 to 80 mg/d), clonazepam (1 to 8 mg/d), or valproic acid (750 to 3,000 mg/d). The latter strategy is particularly helpful in patients with tardive dystonia, which may also benefit from anticholinergic therapy and botulinum toxin injections.

### Neuroleptic Malignant Syndrome (NMS)

This serious complication of neuroleptic medications occurs in 1 to 2% of treated individuals; the mortality rate is as high as 20%. Muscle rigidity with myonecrosis; an altered mental status resembling catatonia; and autonomic dysfunction with hyperthermia, tachycardia, and a labile blood pressure constitute the princi- pal manifestations. Symptoms typically evolve subacutely over several days and usually occur in the first few weeks following initial exposure to the drug, but can develop anytime. NMS can also be precipitated by the abrupt withdrawal of antiparkinson medications.

### Further Reading


### TABLE 352-1. Etiology of Cerebellar Ataxia

<table>
<thead>
<tr>
<th>Symmetric and Progressive Signs</th>
<th>Focal and Ipsilateral Cerebellar Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute (Hours to Days)</strong></td>
<td><strong>Subacute (Days to Weeks)</strong></td>
</tr>
<tr>
<td>Intoxication: alcohol, lithium, diphenylhydantoin, barbiturates (positive history and toxicology screen)</td>
<td>Intoxication: mercury, solvents, gasoline, glue, cytotoxic chemotherapeutic drugs</td>
</tr>
<tr>
<td>Acute viral cerebellitis (CSF supportive of acute viral infection)</td>
<td>Alcoholic-nutritional (vitamin B&lt;sub&gt;1&lt;/sub&gt; and B&lt;sub&gt;12&lt;/sub&gt; deficiency)</td>
</tr>
<tr>
<td>Postinfection syndrome</td>
<td>Lyme disease</td>
</tr>
</tbody>
</table>

**Paraneoplastic Syndromes**

- Anti-glutamate antibodies
- Paraneoplastic cerebellar ataxia
- Anti-Hu
- Anti-Yo
- Anti-Ri
- Anti-PM/Scl

**Neurologic Syndromes**

- Tabes dorsalis
- Meningovascular syphilis
- Mucopolysaccharidosis
- Charcot-Marie-Tooth disease
- Mitochondrial encephalomyopathy

**Malignancies**

- Hodgkin’s lymphoma
- Non-Hodgkin’s lymphoma
- Breast cancer
- Ovarian cancer
- Small cell lung cancer

**Vascular Syndromes**

- Cerebrovascular disease
- Trauma
- Malignancy
- Aneurysm

**Infectious Syndromes**

- Viral: varicella, poliovirus, coxsackievirus, echovirus, Epstein-Barr virus
- Bacterial: meningitis, encephalitis
- Parasitic: toxoplasmosis, cysticercosis
- Fungal: candidiasis, aspergillosis

**Autoimmune Syndromes**

- Devic’s syndrome
- GBS

**Metabolic Syndromes**

- Neurodegeneration with brain iron accumulation (NBIA)
- Wilson’s disease
- Niemann-Pick disease
- Gaucher’s disease

**Degenerative Syndromes**

- Spinocerebellar ataxias (SCAs)
- Friedreich’s ataxia
- Huntington’s disease
- Alzheimer’s disease

**Achilles’ Heel**

- Many syndromes overlap
- Clinical presentation may vary widely
- Genetic testing may be necessary

**THE INHERITED ATAXIAS**

These may show autosomal dominant, autosomal recessive, or maternal (mitochondrial) modes of inheritance. A genomic classification (Table 352-2) has now largely superseded previous ones based on clinical expression alone.

Although the clinical manifestations and neuropathologic findings of cerebellar disease dominate the clinical picture, there may also be characteristic changes in the basal ganglia, brainstem, spinal cord, optic nerves, retina, and peripheral nerves. In large families with dominantly inherited ataxias, many gradations are observed from purely cerebellar manifestations to mixed cerebellar and brainstem disorders, cerebellar and basal ganglia syndromes, and spinal cord or peripheral nerve disease. Rarely, dementia is present as well. The clinical picture may be homogeneous within a family with dominantly inherited ataxia, but sometimes most affected family members show one characteristic syndrome, while one or several members have an entirely different phenotype.

**AUTOSOMAL DOMINANT ATAXIAS**

The autosomal spinocerebellar ataxias (SCAs) include SCA type 1 through SCA23, dentatorubropallidoluysian atrophy (DRPLA), and episodic ataxia (EA) types 1 and 2 (Table 352-2). SCA1, SCA2, SCA3 [Machado-Joseph disease (MJD)], SCA6, SCA7, and SCA17 are caused by CAG triplet repeat expansions in different genes. SCA8 is due to an untranslated CTG repeat expansion, SCA12 is linked to an untranslated CAG repeat, and SCA10 is caused by an untranslated pentanucleotide repeat. The clinical phenotypes of these SCAs overlap. The genotype has become the “gold standard” for diagnosis and classification. CAG encodes glutamine, and these expanded CAG triplet repeat expansions result in expanded polyglutamine proteins, termed ataxins, that produce a toxic gain of function with autosomal dominant inheritance. Although the phenotype is variable for any given disease gene, a pattern of neuronal loss with gliosis is produced that is relatively unique for each ataxia. Immunohistochemical and biochemical studies have shown cytoplasmic (SCA2), neuronal (SCA1, MJD, SCA7), and nucleolar (SCA7) accumulation of the...
<table>
<thead>
<tr>
<th>Name</th>
<th>Locus</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SCA1</strong> (autosomal dominant type 1)</td>
<td>6p22-p23 with CAG repeats (exonic)</td>
<td>Ataxia with ophthalmoplegias, pyramidal and extrapyramidal findings</td>
</tr>
<tr>
<td><strong>SCA2</strong> (autosomal dominant type 2)</td>
<td>12q23-q24.1 with CAG repeats (exonic)</td>
<td>Ataxia with slow saccades and minimal pyramidal and extrapyramidal findings</td>
</tr>
<tr>
<td>Machado-Joseph disease/SCA3 (autosomal dominant type 3)</td>
<td>14q24.3-q32 with CAG repeats (exonic)</td>
<td>Ataxia with ophthalmoplegias and variable pyramidal, extrapyramidal, and ataxia</td>
</tr>
<tr>
<td><strong>SCA4</strong> (autosomal dominant type 4)</td>
<td>16q24-ter</td>
<td>Ataxia with normal eye movements, sensory axonal neuropathy, and pyramidal signs</td>
</tr>
<tr>
<td><strong>SCA5</strong> (autosomal dominant type 5)</td>
<td>Centromeric region of chromosome II</td>
<td>Ataxia and dystonia</td>
</tr>
<tr>
<td><strong>SCA6</strong> (autosomal dominant type 6)</td>
<td>1p31.3-q21.4 with CAG repeats (exonic)</td>
<td>Ataxia and dystonia, nystagmus, mild proprioceptive sensory loss</td>
</tr>
<tr>
<td><strong>SCA7</strong> (autosomal dominant type 7)</td>
<td>3p14.1-p21.1 with CAG repeats (exonic)</td>
<td>Ophthalmoplegias, visual loss, ataxia, dystonia, extensor plantar response, pigmentary retinal degeneration</td>
</tr>
<tr>
<td><strong>SCA8</strong> (autosomal dominant type 8)</td>
<td>13q21 with CTG repeats; noncoding</td>
<td>Gait ataxia, dystonia, nystagmus, leg spasticity, and reduced vibratory sensation</td>
</tr>
<tr>
<td><strong>SCA9</strong> (autosomal dominant type 9)</td>
<td>22q; ATTCT repeat; noncoding</td>
<td>Gait ataxia, dystonia, nystagmus; partial complex and generalized motor seizures; polymyopathy</td>
</tr>
<tr>
<td><strong>SCA10</strong> (autosomal dominant type 10)</td>
<td>15q14-q21.3 by linkage</td>
<td>Slowly progressive gait and extremity ataxia, dystonia, vertical nystagmus, hyperreflexia</td>
</tr>
<tr>
<td><strong>SCA11</strong> (autosomal dominant type 11)</td>
<td>1q41-q21.3 by linkage</td>
<td>Tremor, decreased movement, increased reflexes, dystonia, ataxia, dysautonomia, dementia, dystonia</td>
</tr>
<tr>
<td><strong>SCA12</strong> (autosomal dominant type 12)</td>
<td>7p21.3-p15.1</td>
<td>Mutation unknown</td>
</tr>
<tr>
<td><strong>SCA13</strong> (autosomal dominant type 13)</td>
<td>Mutation unknown in 1 family; other known loci</td>
<td>Gait and extremity ataxia, dystasia</td>
</tr>
<tr>
<td><strong>SCA14</strong> (autosomal dominant type 14)</td>
<td>8q22.1-24.1</td>
<td>Mutation unknown; pure cerebellar ataxia and head tremor, gait ataxia, and dystasia; horizontal gaze–evoked nystagmus</td>
</tr>
<tr>
<td><strong>SCA15</strong> (autosomal dominant type 15)</td>
<td>Ataxia, extrapyramidal features of akinesia, rigidity, tremor, cognitive defect</td>
<td>Ataxia, choreoathetosis, dystonia, seizures, myoclonus, dementia</td>
</tr>
<tr>
<td><strong>SCA16</strong> (autosomal dominant type 16)</td>
<td>6p27; CAG expansion in the TATA-binding protein (TBP) gene</td>
<td>Ataxia, areflexia, extensor plantar responses, position sense deficits, cardiomyopathy, diabetes mellitus, scoliosis, foot deformities; defective iron transport from mitochondria</td>
</tr>
<tr>
<td><strong>SCA17</strong> (autosomal dominant type 17)</td>
<td>7q22-q32</td>
<td>Same as phenotype that maps to 9q but associated with vitamin E deficiency</td>
</tr>
<tr>
<td><strong>SCA18</strong> (autosomal dominant type 18)</td>
<td>1p21-q21</td>
<td>Childhood onset of ataxia, spasticity, dystonia, distal muscle wasting, foot deformity, retinal striations, ptosis, ophthalmoplegias, pigmentary retinal degeneration, cardiomyopathy, diabetes mellitus, deafness, heart block, increased CSF protein, ataxia</td>
</tr>
<tr>
<td><strong>SCA19</strong> (autosomal dominant type 19)</td>
<td>12p12-ter with CAG repeats (exonic)</td>
<td>Myoclonic epilepsy, ragged red fiber myopathy, ataxia</td>
</tr>
<tr>
<td><strong>SCA20</strong> (assigned but not yet published)</td>
<td>9q13-q21.1 with intronic GAA repeats</td>
<td>Myoclonic epilepsy, ragged red fiber myopathy, ataxia</td>
</tr>
<tr>
<td><strong>SCA21</strong> ( autosomal dominant type 21)</td>
<td>Mutation unknown in 1 family; other known loci were excluded</td>
<td>—</td>
</tr>
<tr>
<td><strong>SCA22</strong> (assigned but not yet published)</td>
<td>13q21 with CTG repeats; noncoding</td>
<td>Ataxia, choreoathetosis, dystonia, seizures, myoclonus, dementia</td>
</tr>
<tr>
<td><strong>Dentatorubropallidoluysian atrophy (autosomal dominant)</strong></td>
<td>12p12-ter with CAG repeats (exonic)</td>
<td>Ataxia, areflexia, extensor plantar responses, position sense deficits, cardiomyopathy, diabetes mellitus, scoliosis, foot deformities; defective iron transport from mitochondria</td>
</tr>
<tr>
<td><strong>Friedreich’s ataxia (autosomal recessive)</strong></td>
<td>6p21-q21</td>
<td>Same as phenotype that maps to 9q but associated with vitamin E deficiency</td>
</tr>
<tr>
<td><strong>Friedreich’s ataxia (autosomal recessive)</strong></td>
<td>8q13.1-q13.3; (α-TTP deficiency)</td>
<td>Childhood onset of ataxia, spasticity, dystonia, distal muscle wasting, foot deformity, retinal striations, ptosis, ophthalmoplegias, pigmentary retinal degeneration, cardiomyopathy, diabetes mellitus, deafness, heart block, increased CSF protein, ataxia</td>
</tr>
<tr>
<td><strong>Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)</strong></td>
<td>Chromosome 13; SACS gene; loss of Sacsin peptide activity</td>
<td>Myoclonic epilepsy, ragged red fiber myopathy, ataxia</td>
</tr>
<tr>
<td><strong>Kearns-Sayre syndrome (sporadic)</strong></td>
<td>mtDNA deletion and duplication mutations</td>
<td>Myoclonic epilepsy, ragged red fiber myopathy, ataxia</td>
</tr>
<tr>
<td><strong>Myoclonic epilepsy and ragged red fiber syndrome (MERRF) (maternal inheritance)</strong></td>
<td>Mutation in mtDNA of the tRNA&lt;sub&gt;lys&lt;/sub&gt; at 8344; also mutation at 8356</td>
<td>Headache, stroke, lactic acidosis, ataxia</td>
</tr>
<tr>
<td><strong>Mitochondrial encephalopathy, lactic acidosis, and stroke syndrome (MELAS) (maternal inheritance)</strong></td>
<td>tRNA&lt;sub&gt;lys&lt;/sub&gt; mutation at 3243; also at 3271 and 3252</td>
<td>Obtundation, hypotonia, cranial nerve deficits, respiratory failure, hypertensive signals on T2-weighted MRI in basal ganglia, cerebellum, or brainstem; ataxia</td>
</tr>
<tr>
<td><strong>Leigh’s disease: subacute necrotizing encephalopathy (maternal inheritance or autosomal recessive)</strong></td>
<td>tRNA&lt;sub&gt;lys&lt;/sub&gt; mutation at 3243; also at 3271 and 3252</td>
<td>Episodic ataxia for minutes; provoked by startle or exercise; with facial and hand myokymia; cerebellar signs are not progressive; responds to phenytoin</td>
</tr>
<tr>
<td><strong>Episodic ataxia, type 1 (EA-1) (autosomal dominant)</strong></td>
<td>tRNA&lt;sub&gt;lys&lt;/sub&gt; mutation at 3243; also at 3271 and 3252</td>
<td>Episodic ataxia for days; provoked by stress, fatigue; with down-gaze nystagmus; cerebellar atrophy results; progressive cerebellar signs; responds to acetazolamide</td>
</tr>
<tr>
<td><strong>Episodic ataxia, type 2 (EA-2) (autosomal dominant)</strong></td>
<td>11q22-23; ATM gene for regulation of cell cycle; mitotic signal transduction and meiotic recombination</td>
<td>Telangiectasia, ataxia, dystasia, pulmonary infections, neoplasms of lymphatic system; IgA and IgG deficiencies; diabetes mellitus, breast cancer</td>
</tr>
</tbody>
</table>
specific mutant polyglutamine containing ataxin proteins. Expanded polyglutamine ataxins with more than 40 glutamines are potentially toxic to neurons for a variety of reasons including the following: high levels of gene expression for the mutant polyglutamine ataxin in affected neurons; conformational change of the aggregated protein to a β-pleated structure; abnormal transport of the ataxin into the nucleus (SCA1, MJD, SCA7); binding to other polyglutamine proteins, including the TATA-binding transcription protein and the CREB-binding protein, impairing their functions; altering the efficiency of the ubiquitin-proteosome system of protein turnover; and inducing neuronal apoptosis. An earlier age of onset (anticipation) and more aggressive disease in subsequent generations are due to further expansion of the CAG triplet repeat and increased polyglutamine number in the mutant ataxin. The most common disorders are discussed below.

**SCA1**  SCA1 was previously referred to as olivopontocerebellar atrophy, but genomic data have shown that that entity represents several different genotypes with overlapping clinical features.

**SYMPTOMS AND SIGNS**  SCA1 is characterized by the development in early or middle adult life of progressive cerebellar ataxia of the trunk and limbs, impairment of equilibrium and gait, slowness of voluntary movements, scanning speech, nystagmoid eye movements, and oscillatory tremor of the head and trunk. Dysarthria, dysphagia, and ocu-lomotor and facial palsies may also occur. Extrapyramidal symptoms include rigidity, an immobile face, and parkinsonian tremor. The reflexes are usually normal, but knee and ankle jerks may be lost, and extensor plantar responses may occur. Dementia may be noted but is usually mild. Impairment of sphincter function is common, with urinary and sometimes fecal incontinence. Cerebellar and brainstem atrophy are evident on MRI (Fig. 352-1).

Marked shrinkage of the ventral half of the pons, disappearance of the olivary eminence on the ventral surface of the medulla, and atrophy of the cerebellum are evident on gross postmortem inspection of the brain. Variable loss of Purkinje cells, reduced numbers of cells in the molecular and granular layer, demyelination of the middle cerebellar peduncle and the cerebellar hemispheres, and severe loss of cells in the pontine nuclei and olives are found on histologic examination. Degenerative changes in the striatum, especially the putamen, and loss of the pigmented cells of the substantia nigra may be found in cases with extrapyramidal features. More widespread degeneration in the central nervous system (CNS), including involvement of the posterior columns and the spinocerebellar fibers, is often present.

**GENETIC CONSIDERATIONS**  SCA1 encodes a gene product, called ataxin-1, which is a novel protein of unknown function. The mutant allele has 40 CAG repeats located within the coding region, whereas alleles from unaffected individuals have ≤36 repeats. A few patients with 38 to 40 CAG repeats have been described. There is a direct correlation between a larger number of repeats and a younger age of onset for SCA1. Juvenile patients have higher numbers of repeats, and anticipation is present in subsequent generations. Transgenic mice carrying SCA1 developed ataxia and Purkinje cell pathology. Nuclear localization, but not aggregation, of ataxin-1 appears to be required for cell death initiated by the mutant protein.

**SCA2**  Another clinical phenotype, SCA2, has been described in Cubans. These patients probably are descendants of a common ancestor, and the population may be the largest homogeneous group of patients with ataxia yet described. The age of onset ranges from 2 to 65 years, and there is considerable clinical variability within families. Although neuropathologic and clinical findings are compatible with a diagnosis of SCA1, including slow saccadic eye movements, ataxia, dysarthria, parkinsonian rigidity, optic disk pallor, mild spasticity, and retinal degeneration, SCA2 is a unique form of cerebellar degenerative disease.

**GENETIC CONSIDERATIONS**  The gene in SCA2 families also contains CAG repeat expansions coding for a polyglutamine-containing protein, ataxin-2. Normal alleles contain 15 to 32 repeats; mutant alleles have 35 to 77 repeats.

**Machado-Joseph Disease/SCA3**  MJD was first described among the Portuguese and their descendants in New England and California. Subsequently, MJD has been found in families from Portugal, Australia, Brazil, Canada, China, England, France, India, Israel, Italy, Japan, Spain, Taiwan, and the United States. In most populations, it is the most common autosomal dominant ataxia.

**SYMPTOMS AND SIGNS**  MJD has been classified into three clinical types. In type I MJD (amyotrophic lateral sclerosis-parkinsonism-dystonia type), neurologic deficits appear in the first two decades and involve weakness and spasticity of extremities, especially the legs, often with dystonia of the face, neck, trunk, and extremities. Patellar and ankle clonus are common, as are extensor plantar responses. The gait is slow and stiff, with a slightly broadened base and lurching from side to side; this gait results from spasticity, not true ataxia. There is no truncal

---

**TABLE 352-2**

<table>
<thead>
<tr>
<th>Name</th>
<th>Locus</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infantile-onset spinocerebellar ataxia of Nikali et al (autosomal recessive)</td>
<td>10q23.3-q24.1</td>
<td>Infantile ataxia, sensory neuropathy; atethosis, hearing deficit, ophthalmodystopia, optic atrophy; primary hypogonadism in females</td>
</tr>
<tr>
<td>Hypoceruloplasminemia with ataxia and dysarthria (autosomal recessive)</td>
<td>Ceruloplasmin gene; 3q23-q25 (trp 858 ter)</td>
<td>Gait ataxia and dysarthria; hyperreflexia; cerebellar atrophy by MRI; iron deposition in cerebellum, basal ganglia, thalamus, and liver; onset in the 4th decade</td>
</tr>
<tr>
<td>Spinocerebellar ataxia with neuropathy (SCAN1) (autosomal recessive)</td>
<td>Tryosyl-DNA phosphodiesterase-1 (TDP-1) 14q31-q32</td>
<td>Onset in 2nd decade; gait ataxia, dysarthria, seizures, cerebellar vermis atrophy on MRI, dysmetria</td>
</tr>
</tbody>
</table>

**Abbreviations:** MRI, magnetic resonance imaging; CSF, cerebrospinal fluid.
titubation. Pharyngeal weakness and spasticity cause difficulty with speech and swallowing. Of note is the prominence of horizontal and vertical nystagmus, loss of fast saccadic eye movements, hypermetric and hypometric saccades, and impairment of upward vertical gaze. Facial fasciculations, facial myokymia, lingual fasciculations without atrophy, ophthalmoparesis, and ocular prominence are common early manifestations.

In type II MJD (ataxic type), true cerebellar deficits of dystasia and gait and extremity ataxia begin in the second to fourth decades along with corticospinal and extrapyramidal deficits of spasticity, rigidity, and dystonia. Type II is the most common form of MJD. Ophthalmoparesis, upward vertical gaze deficits, and facial and lingual fasciculations are also present. Type II MJD can be distinguished from the clinically similar disorders SCA1 and SCA2.

Type III MJD (ataxic-amyotrophic type) presents in the fifth to the seventh decades with a pancerebellar disorder that includes dystasia and gait and extremity ataxia. Distal sensory loss involving pain, touch, vibration, and position senses and distal atrophy are prominent, indicating the presence of peripheral neuropathy. The deep tendon reflexes are depressed to absent, and there are no corticospinal or extrapyramidal findings.

The mean age of onset of symptoms in MJD is 25 years. Neurologic deficits invariably progress and lead to death from debilitation within 15 years of onset, especially in patients with types I and II disease. Usually, patients retain full intellectual function.

The major pathologic findings are variable loss of neurons and glial replacement in the corpus striatum and severe loss of neurons in the pars compacta of the substantia nigra. A moderate loss of neurons occurs in the dentate nucleus of the cerebellum and in the red nucleus Purkinje cell loss and granule cell loss occur in the cerebellar cortex. Cell loss also occurs in the dentate nucleus and in the cranial nerve motor nuclei. Sparing of the inferior olives distinguishes MJD from other dominantly inherited ataxias.

**GENETIC CONSIDERATIONS**

The gene for MJD maps to 14q24.3-q32. Unstable CAG repeat expansions are present in the MJD gene coding for a polyglutamine-containing protein named ataxin-3, or MJD-ataxin. An earlier age of onset is associated with longer repeat lengths. Alleles from normal individuals have between 12 and 37 CAG repeats. Polyglutamine-containing aggregates of ataxin-3 (MJD-ataxin) have been described in neuronal nuclei undergoing degeneration.

**SCA6** Genomic screening for CAG repeats in other families with autosomal dominant ataxia and vibratory and proprioceptive sensory loss have yielded another locus. Of interest is that different mutations in the same gene for the α4 voltage-dependent calcium channel subunit (CACNA1A; also referred to as the CACNA1A gene) at 19p13 result in different clinical disorders. CAG repeat expansions (21 to 27 in patients; 4 to 16 triplets in normal individuals) result in late-onset progressive ataxia with cerebellar degeneration. Missense mutations in this gene result in familial hemiplegic migraine. Nonsense mutations resulting in termination of protein synthesis of the gene product yield hereditary paroxysmal cerebellar ataxia or EA. Some patients with familial hemiplegic migraine develop progressive ataxia and also have cerebellar atrophy.

**SCA7** This disorder is distinguished from all other SCAs by the presence of retinal pigmentary degeneration. The visual abnormalities first appear as blue-yellow color blindness and proceed to frank visual loss with macular degeneration. In almost all other respects, SCA7 resembles several other SCAs in which ataxia is accompanied by various noncerebellar findings, including ophthalmoparesis and extensor plantar responses. The genetic defect is an expanded CAG repeat in the SCA7 gene. The expanded repeat size in SCA7 is highly variable. Consistent with this, the severity of clinical findings varies from essentially asymptomatic to mild late-onset symptoms to severe, aggressive disease in childhood with rapid progression. Marked anticipation has been recorded, especially with paternal transmission. The disease protein, ataxin-7, forms aggregates in nuclei of affected neurons, as has also been described for SCA1 and SCA3/MJD.

**SCA8** This form of ataxia is caused by a CTG repeat expansion in an untranslated region of a gene on chromosome 13q21. There is marked maternal bias in transmission, perhaps reflecting contractions of the repeat during spermatogenesis. The mutation is not fully penetrant. Symptoms include slowly progressive dystasia and gait ataxia beginning at ~40 years of age with a range between 20 and 65 years. Other features include nystagmus, leg spasticity, and reduced vibratory sensation. Severely affected individuals are nonambulatory by the fourth to sixth decades. MRI shows cerebellar atrophy. The mechanism of disease may involve a dominant “toxic” effect occurring at the RNA level, as occurs in myotonic dystrophy.

**Dentatorubropallidoluysian Atrophy (DRPLA)** DRPLA has a variable presentation that may include progressive ataxia, choreoathetosis, dystonia, seizures, myoclonus, and dementia. DRPLA is due to unstable CAG triplet repeats in the open reading frame of a gene named atrophin located on chromosome 12p12-ter. Larger expansions are found in patients with earlier onset. The number of repeats is 49 in patients with DRPLA and ≤26 in normal individuals. Anticipation occurs in successive generations, with earlier onset of disease in association with an increasing CAG repeat number in children who inherit the disease from their father. One well-characterized family in North Carolina has a phenotypic variant known as the Haw River syndrome, now recognized to be due to the DRPLA mutation.

**Episodic Ataxia** EA types 1 and 2 are two rare dominantly inherited disorders that have been mapped to chromosomes 12p (a potassium channel gene) for type 1 and 19p for type 2. Patients with EA-1 have brief episodes of ataxia with myokymia and nystagmus that last only minutes. Startle, sudden change in posture, and exercise can induce episodic acetazolamide or anticonvulsants may be therapeutic. Patients with EA-2 have episodes of ataxia with nystagmus that can last for hours or days. Stress, exercise, or excessive fatigue may be precipitants. Acetazolamide may be therapeutic and can reverse the relative intracellular alkalosis detected by magnetic resonance spectroscopy. Stop codon, nonsense mutations causing EA-2 have been found in the CACNA1A gene, encoding the α1β voltage-dependent calcium channel subunit (see “SCA6,” above).

**AUTOSOMAL RECESSIVE ATAXIAS** Friedrich’s Ataxia This is the most common form of inherited ataxia, comprising one-half of all hereditary ataxias. It can occur in a classic form or in association with a genetically determined vitamin E deficiency syndrome; the two forms are clinically indistinguishable.

**SYMPTOMS AND SIGNS** Friedrich’s ataxia presents before 25 years of age with progressive staggering gait, frequent falling, and titubation. The lower extremities are more severely involved than the upper ones. Dysarthria occasionally is the presenting symptom; rarely, progressive scoliosis, foot deformity, nystagmus, or cardiopathy is the initial sign.

The neurologic examination reveals nystagmus, loss of fast saccadic eye movements, truncal titubation, dysarthria, dysmetria, and ataxia of trunk and limb movements. Extensor plantar responses (with normal tone in trunk and extremities), absence of deep tendon reflexes, and weakness (greater distally than proximally) are usually found. Loss of vibratory and proprioceptive sensation occurs. The median age of death is 35 years. Women have a significantly better prognosis than men.

Cardiac involvement occurs in 90% of patients. Cardiomegaly, symmetric hypertrophy, murmurs, and conduction defects are reported. Moderate mental retardation or psychiatric syndromes are present in a small percentage of patients. A high incidence of diabetes mellitus (20%) is found and is associated with insulin resistance and pancreatic β-cell dysfunction. Musculoskeletal deformities are com-
Abetalipoproteinemia is caused by mutations in the gene for the vitamin E transfer protein (VLDL) have been delineated. These are abetalipoproteinemia and ataxia, demonstrating spinal cord atrophy.

Focal degeneration of nerves and cardiac ganglia. Subintimal or medial deposition of periodic acid-Schiff (PAS)-positive material, myocytolysis with unusual pleomorphic nuclei, and focal degeneration of nerves and cardiac ganglia.

**GENETIC CONSIDERATIONS**

The classic form of Friedreich’s ataxia has been mapped to 9q13-q21.1, and the mutant gene, *frataxin*, contains expanded GAA triplet repeats in the first intron. There is homozygosity for expanded GAA repeats in >95% of patients. Normal persons have 7 to 22 GAA repeats, and patients have 200 to 900 GAA repeats. A more varied clinical syndrome has been described in compound heterozygotes who have one copy of the GAA expansion and the other copy a point mutation in the *frataxin* gene. When the point mutation is located in the region of the gene that encodes the amino-terminal half of frataxin, the phenotype is milder, often consisting of a spastic gait, retained or exaggerated reflexes, no dysarthria, and mild or absent ataxia.

Patients with Friedreich’s ataxia have undetectable or extremely low levels of *frataxin* mRNA, as compared with carriers and unrelated individuals; thus, disease appears to be caused by a loss of expression of the frataxin protein. Frataxin is a mitochondrial protein involved in iron homeostasis. Mitochondrial iron accumulation due to loss of the iron transporter coded by the mutant *frataxin* gene results in oxidized intramitochondrial iron. Excess oxidized iron results in turn in the oxidation of cellular components and irreversible cell injury.

Two forms of hereditary ataxia associated with abnormalities in the interactions of vitamin E (α-tocopherol) with very low density lipoprotein (VLDL) have been delineated. These are abetalipoproteinemia (Bassen-Kornzweig syndrome) and ataxia with vitamin E deficiency (AVED). Abetalipoproteinemia is caused by mutations in the gene coding for the larger subunit of the microsomal triglyceride transfer protein (MTP). Defects in MTP result in impairment of formation and secretion of VLDL in liver. This defect results in a deficiency of delivery of vitamin E to tissues, including the central and peripheral nervous system, as VLDL is the transport molecule for vitamin E and other fat-soluble substitutes. AVED is due to mutations in the gene for α-tocopherol transfer protein (α-TTP). These patients have an impaired ability to bind vitamin E into the VLDL produced and secreted by the liver, resulting in a deficiency of vitamin E in peripheral tissues. Hence, either absence of VLDL (abetalipoproteinemia) or impaired binding of vitamin E to VLDL (AVED) causes an ataxic syndrome. Once again, a genotype classification has proved to be essential in sorting out the various forms of the Friedreich’s disease syndrome, which may be clinically indistinguishable.

**Ataxia Telangiectasia**

**SYMPTOMS AND SIGNS**

Patients with ataxia telangiectasia (AT) present in the first decade of life with progressive telangiectatic lesions associated with deficits in cerebellar function and nystagmus. The neurologic manifestations correspond to those in Friedreich’s disease, which should be included in the differential diagnosis. Truncal and limb ataxia, dysarthria, extensor plantar responses, myoclonic jerks, areflexia, and distal sensory deficits may develop. There is a high incidence of recurrent pulmonary infections and neoplasms of the lymphatic and reticuloendothelial system in patients with AT. Thymic hypoplasia with cellular and humoral (IgA and IgG2) immunodeficiencies, premature aging, and endocrine disorders such as type 1 diabetes mellitus are described. There is an increased incidence of lymphomas, Hodgkin’s disease, acute leukemias of the T cell type, and breast cancer.

The most striking neuropathologic changes include loss of Purkinje, granule, and basket cells in the cerebellar cortex as well as of neurons in the deep cerebellar nuclei. The inferior olives of the medulla may also have neuronal loss. There is a loss of anterior horn neurons in the spinal cord and of dorsal root ganglion cells associated with posterior column spinal cord demyelination. A poorly developed or absent thymus gland is the most consistent defect of the lymphoid system.

**GENETIC CONSIDERATIONS**

The gene for AT (the *ATM* gene) encodes a protein that is similar to several yeast and mammalian phosphatidylinositols-3'-kinases involved in mitogen signal transduction, meiotic recombination, and cell cycle control. Defective DNA repair in AT fibroblasts exposed to ultraviolet light has been demonstrated. The discovery of *ATM* will make possible the identification of heterozygotes who are at risk for cancer (e.g., breast cancer) and permit early diagnosis.

**Mitochondrial Ataxias**

Spinocerebellar syndromes have been identified with mutations in mitochondrial DNA (mtDNA). Thirty pathogenic mtDNA point mutations and 60 different types of mtDNA deletions are known, several of which cause or are associated with ataxia (Chap. 368).

**TREATMENT**

The most important goal in management of patients with ataxia is to identify treatable disease entities. Mass lesions must be recognized promptly and treated appropriately. Paraneoplastic disorders can often be identified by the clinical patterns of disease that they produce, measurement of specific autoantibodies, and uncovering the primary cancer; these disorders are often refractory to therapy, but some patients improve following removal of the tumor or immunotherapy (Chap. 87). Ataxia with anti-gliadin antibodies and gluten-sensitive enteropathy may improve with a gluten-free diet. Malabsorption syndromes leading to vitamin E deficiency may lead to ataxia. The vitamin E deficiency form of Friedreich’s ataxia must be considered, and serum vitamin E levels measured. Vitamin E therapy is indicated for these
AMYOTROPHIC LATERAL SCLEROSIS

AMYOTROPHIC LATERAL SCLEROSIS (ALS) is the most common form of progressive motor neuron disease. It is a prime example of a neurodegenerative disease and is arguably the most devastating of the neurodegenerative disorders.

Pathology The pathologic hallmark of motor neuron degenerative disorders is death of lower motor neurons (consisting of anterior horn cells in the spinal cord and their brainstem homologues innervating bulbar muscles) and upper, or corticospinal, motor neurons (originating in layer five of the motor cortex and descending via the pyramidal tract to synapse with lower motor neurons, either directly or indirectly via interneurons) (Chap. 21). Although at its onset ALS may involve selective loss of function of only upper or lower motor neurons, it ultimately causes progressive loss of both categories of motor neurons. Indeed, in the absence of clear involvement of both motor neuron types, the diagnosis of ALS is questionable.

Other motor neuron diseases involve only particular subsets of motor neurons (Tables 353-1 and 353-2). Thus, in bulbar palsy and spinal muscular atrophy (SMA; also called progressive muscular atrophy), the lower motor neurons of brainstem and spinal cord, respectively, are most severely involved. By contrast, pseudobulbar palsy, primary lateral sclerosis (PLS), and familial spastic paraplegia (FSP) affect only upper motor neurons innervating the brainstem and spinal cord.

In each of these diseases, the affected motor neurons undergo shrinkage, often with accumulation of the pigment lipid (lipofuscin) that normally develops in these cells with advancing age. In ALS, the motor neuron cytoskeleton is typically affected early in the illness. Focal enlargements are frequent in proximal motor axons; ultrastructurally, these “spheroids” are composed of accumulations of neurofilaments. Also seen is proliferation of astroglia and microglia, the inevitable accompaniment of all degenerative processes in the central nervous system (CNS).

The death of the peripheral motor neurons in the brainstem and spinal cord leads to denervation and consequent atrophy of the corresponding muscle fibers. Histochemical and electrophysiologic evidence indicates that in the early phases of the illness denervated muscle can be reinnervated by sprouting of nearby distal motor nerve terminals, although reinnervation in this disease is considerably less extensive than in most other disorders affecting motor neurons (e.g., poliomyelitis, peripheral neuropathy). As denervation progresses, muscle atrophy is readily recognized in muscle biopsies and on clinical examination. This is the basis for the term amyotrophy. The loss of cortical motor neurons results in thinning of the corticospinal tracts that travel via the internal capsule (Fig. 353-1) and brainstem to the lateral and anterior white matter columns of the spinal cord. The loss of fibers in the lateral columns and resulting fibrillary gliosis impart a particular firmness (lateral sclerosis). A remarkable feature of the disease is the selectivity of neuronal cell death. By light microscopy, the entire sensory apparatus, the regulatory mechanisms for the control and coordination of movement, and the components of the brain that are needed for cognitive processes, remain intact. However, immunostaining indicates that neurons bearing ubiquitin, a marker for degeneration, are also detected in nonmotor systems. Moreover, studies of glucose metabolism in the illness also indicate that there is neuronal dysfunction outside of the motor system. Within the motor system, there is some selectivity of involvement. Thus, motor neurons required for ocular motility remain unaffected, as do the parasympathetic neurons in the sacral spinal cord (the nucleus of Onufrowicz, or Onuf) that innervate the sphincters of the bowel and bladder.

Clinical Manifestations The manifestations of ALS are somewhat variable depending on whether corticospinal neurons or lower motor neurons in the brainstem and spinal cord are more prominently involved. With lower motor neuron dysfunction and early denervation, typically the first evidence of the disease is insidiously developing asymmetric weakness, usually first evident distally in one of the limbs. A detailed history often discloses recent development of cramping with volitional movements, typically in the early hours of the morning (e.g., while stretching in bed). Weakness caused by denervation is associated with progressive wasting and atrophy of muscles and, particularly early in the illness, spontaneous twitching of motor units, or fasciculations. In the hands, a preponderance of extensor over flexor weakness is common. When the initial denervation involves bulbar rather than limb muscles, the problem at onset is difficulty with chewing, swallowing, and movements of the face and tongue. Early involvement of the muscles of respiration may lead to death before the disease is far advanced elsewhere. With prominent corticospinal involvement, there is hyperactivity of the muscle-stretch reflexes (tendon jerks) and, often, spastic resistance to passive movements of the affected limbs. Patients with significant reflex hyperactivity complain of muscle stiffness often out of proportion to weakness. Degeneration of the corticobulbar projections innervating the brainstem results in dysarthria and exaggeration of the motor expressions of emotion. The latter leads to involuntary excess in weeping or laughing (so-called pseudobulbar affect).

Virtually any muscle group may be the first to show signs of disease, but, as time passes, more and more muscles become involved until ultimately the disorder takes on a symmetric distribution in all regions. The motor characteristics of ALS that, regardless of whether the initial disease involves upper or lower motor neurons, both will eventually be implicated. Even in the late stages of the illness, sensory, bowel...
and bladder, and cognitive functions are preserved. Even when there is severe brainstem disease, oculocutaneous atrophy is spared until the very late stages of the illness. Dementia is not a component of sporadic ALS. In some families, ALS is co-inherited with frontotemporal dementia, characterized by early behavioral abnormalities with prominent behavioral features indicative of frontal lobe dysfunction.

A committee of the World Federation of Neurology has established diagnostic guidelines for ALS. Essential for the diagnosis is simultaneous upper and lower motor neuron involvement with progressive weakness, and the exclusion of all alternative diagnoses. The disorder is ranked as “definite” ALS when three or four of the following are involved: bulbar, cervical, thoracic, and lumbosacral motor neurons. When two sites are involved, the diagnosis is “probable,” and when only one site is implicated, the diagnosis is “possible.” An exception is made for those who have progressive upper and lower motor neuron signs at only one site and a mutation in the gene encoding superoxide dismutase (SOD1; below).

Epidemiology The illness is relentlessly progressive, leading to death from respiratory paralysis; the median survival is from 3 to 5 years. There are very rare reports of stabilization or even regression of ALS. In most societies there is an incidence of 1 to 3 per 100,000 and a prevalence of 3 to 5 per 100,000. Several endemic foci of higher prevalence exist in the western Pacific (e.g., in specific regions of Guam or Papua New Guinea). In the United States and Europe, males are somewhat more frequently affected than females. While ALS is overwhelmingly a sporadic disorder, some 5 to 10% of cases are inherited as an autosomal dominant trait.

Familial ALS Several forms of selective motor neuron disease are inheritable (Table 353-3). Two involve both corticospinal and lower motor neurons. The most common is familial ALS (FALS). Apart from its inheritance as an autosomal dominant trait, it is clinically indistinguishable from sporadic ALS. Genetic studies have identified mutations in the gene encoding the cytosolic, copper- and zinc-binding enzyme SOD1 as the cause of one form of FALS. However, this accounts for only 20% of inherited cases of ALS. Rare mutations in other genes are also clearly implicated in ALS-like diseases. Thus, a familial, predominantly lower motor neuron disease with bulbar predominance has been ascribed to mutations in the gene encoding the cellular motor protein dynactin. Another familial, adult-onset disorder that may mimic aspects of ALS is Kennedy’s syndrome; as described below, this arises from distinctive mutations in the androgen receptor. Genetic

---

**TABLE 353-1** Etiology and Investigation of Motor Neuron Disorders

<table>
<thead>
<tr>
<th>Diagnostic Category</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural lesions</td>
<td>MRI scan of head (including foramen magnum), cervical spine*</td>
</tr>
<tr>
<td>Parasagittal or foramen magnum tumors</td>
<td></td>
</tr>
<tr>
<td>Cervical spondylosis</td>
<td></td>
</tr>
<tr>
<td>Chiari malformation or syrinx</td>
<td></td>
</tr>
<tr>
<td>Spinal cord arteriovenous malformation</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td></td>
</tr>
<tr>
<td>Bacterial—tetanus, Lyme</td>
<td></td>
</tr>
<tr>
<td>Viral—poliomyelitis, herpes zoster</td>
<td></td>
</tr>
<tr>
<td>Retroviral myelopathy</td>
<td></td>
</tr>
<tr>
<td>Intoxications, physical agents</td>
<td></td>
</tr>
<tr>
<td>Toxins—lead, aluminum, others</td>
<td></td>
</tr>
<tr>
<td>Drugs—strychnine, phenytoin</td>
<td></td>
</tr>
<tr>
<td>Electric shock, x-irradiation</td>
<td></td>
</tr>
<tr>
<td>Immunologic mechanisms</td>
<td></td>
</tr>
<tr>
<td>Plasma cell dyscrasias</td>
<td></td>
</tr>
<tr>
<td>Autoimmune polyradiculoneuropathy</td>
<td></td>
</tr>
<tr>
<td>Motor neuropathy with conduction block</td>
<td></td>
</tr>
<tr>
<td>Paraneoplastic</td>
<td></td>
</tr>
<tr>
<td>Paracarcinomatous/lymphoma</td>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td></td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td></td>
</tr>
<tr>
<td>Deficiency of folate, vitamin B₁₂, vitamin E</td>
<td></td>
</tr>
<tr>
<td>Malabsorption</td>
<td></td>
</tr>
<tr>
<td>Mitochondrial dysfunction</td>
<td></td>
</tr>
<tr>
<td>Hereditary biochemical disorders</td>
<td></td>
</tr>
<tr>
<td>Superoxide dismutase 1 gene mutation</td>
<td></td>
</tr>
<tr>
<td>Androgen receptor defect (Kennedy’s disease)</td>
<td></td>
</tr>
<tr>
<td>Hexosaminidase deficiency</td>
<td></td>
</tr>
<tr>
<td>Infantile (α-glucosidase deficiency/Pompe’s disease)</td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td></td>
</tr>
<tr>
<td>Hyperglycinuria</td>
<td></td>
</tr>
<tr>
<td>Methylcrotonylglycinuria</td>
<td></td>
</tr>
</tbody>
</table>

* Denotes studies that should be obtained in all cases.

**TABLE 353-2** Sporadic Motor Neuron Diseases

**CHRONIC**

- Upper and lower motor neurons
- Amyotrophic lateral sclerosis
- Predominantly upper motor neurons
- Primary lateral sclerosis
- Predominantly lower motor neurons
- Multifocal motor neuropathy with conduction block
- Motor neuropathy with paraproteinemia or cancer
- Motor-predominant peripheral neuropathies
- Other
  - Associated with other degenerative disorders
  - Secondary motor neuron disorders (see Table 353-1)

**ACUTE**

- Poliomyelitis
- Herpes zoster
- Coxsackie virus

---

**FIGURE 353-1** Amyotrophic lateral sclerosis. Axial T2-weighted MRI scan through the lateral ventricles of the brain reveals abnormal high signal intensity within the corticospinal tracts (arrows). This MRI feature represents an increase in water content in myelin tracts undergoing Wallerian degeneration secondary to cortical motor neuronal loss. This finding is commonly present in ALS, but can also be seen in AIDS-related encephalopathy, infarction, or other disease processes that produce corticospinal neuronal loss in a symmetric fashion.
analyses are also beginning to illuminate the pathogenesis of some childhood-onset motor neuron diseases. For example, a slowly disabling degenerative, predominantly upper motor neuron disease that starts in the first decade is caused by mutations in a gene that expresses a novel signaling molecule with properties of a guanine-exchange factor, termed alsin. In other instances, chromosomal locations for motor neuron diseases, but not the causative genes themselves, have been identified. Typical FALS has been genetically mapped to chromosomes 16 and 20 in several families, and a juvenile-onset, dominantly inherited form of ALS has been mapped to the long arm of chromosome 9.

**Differential Diagnosis** Because ALS is currently untreatable, it is imperative that potentially remediable causes of motor neuron dysfunction be excluded (Table 353-1). This is particularly true in cases that are atypical by virtue of (1) restriction to either upper or lower motor neurons, (2) involvement of neurons other than motor neurons, and (3) evidence of motor neuronal conduction block on electrophysiologic testing. Compression of the cervical spinal cord or cervicomedullary junction from tumors in the cervical regions or at the foramen magnum or from cervical spondylosis with osteophytes projecting into the vertebral canal can produce weakness, wasting, and fasciculations in the upper limbs and spasticity in the legs, closely resembling ALS. The absence of cranial nerve involvement may be helpful in differentiation, although some foramen magnum lesions may compress the twelfth cranial (hypoglossal) nerve, with resulting paralysis of the tongue. Absence of pain or of sensory changes, normal bowel and bladder function, normal roentgenographic studies of the spine, and normal cerebrospinal fluid (CSF) all favor ALS. Where doubt exists, magnetic resonance imaging (MRI) scans and contrast myelography should be performed to visualize the cervical spinal cord.

Another important entity in the differential diagnosis of ALS is *multifocal motor neuropathy with conduction block* (MMCB), discussed below. A diffuse, lower motor axonal neuropathy mimicking ALS sometimes evolves in association with hematopoietic disorders such as lymphoma. In this clinical setting, the presence of an M-component in serum should prompt consideration of a bone marrow biopsy. Lyme disease (Chap. 157) may also cause an axonal, lower motor neuropathy.

Other treatable disorders that occasionally mimic ALS are chronic lead poisoning and thyrotoxicosis. These disorders may be suggested by the patient’s social or occupational history or by unusual clinical features. When the family history is positive, disorders involving the genes encoding cytosolic SOD1, hexosaminidase A, or α-glucosidase deficiency must be excluded (Chap. 340). These are readily identified by appropriate laboratory tests. Benign fasciculations are occasionally a source of concern because on inspection they resemble the fascicular twitches that accompany motor neuron degeneration. The absence of weakness, atrophy, or denervation phenomena on electrophysiologic examination usually excludes ALS or other serious neurologic disease. Patients who have recovered from poliomyelitis may experience a delayed deterioration of motor neurons that presents clinically with progressive weakness, atrophy, and fasciculations. Its cause is unknown, but it is thought to reflect sublethal prior injury to motor neurons by poliovirus (Chap. 175).

Rarely, ALS develops concurrently with features indicative of more widespread neurodegeneration. Thus, one infrequently encounters otherwise typical ALS patients with a parkinsonian movement disorder or dementia. It remains unclear whether this reflects the unlikely simultaneous occurrence of two disorders or a primary defect triggering two forms of neurodegeneration. The latter is suggested by the observation that multisystem neurodegenerative diseases may be inherited. For example, prominent amyotrophy has been described as a dominantly inherited disorder in individuals with bizarre behavior and a movement disorder suggestive of parkinsonism; many such cases have now been ascribed to mutations that alter the expression of tau protein in brain (Chap. 350). In other cases, ALS develops simultaneously with a striking frontotemporal dementia. These disorders may be dominantly co-inherited; in some families, this trait is linked to a locus on chromosome 9q, although the underlying genetic defect is not established.

**Pathogenesis** The cause of sporadic ALS is not well defined. Several mechanisms that impair motor neuron viability have been elucidated in mice and rats induced to develop motor neuron disease by SOD1 transgenes with ALS-associated mutations. It is evident that excitotoxic neurotransmitters such as glutamate participate in the death of motor neurons in ALS. This may be a consequence of diminished uptake of synaptic glutamate by an astroglial glutamate transporter, EAAT2. It is striking that one cellular defense against such excitotoxicity is the enzyme SOD1, which detoxifies the free radical superoxide anion (Chap. 345). Because SOD1 is mutated in some familial cases of ALS, it may be that glutamate excitotoxicity and ALS result from free radical accumulations in motor neurons. Precisely why the SOD1 mutation is toxic to motor neurons is not established, although it is clear the effect is not simply loss of normal scavenging of the superoxide anion. The mutant protein is conformationally unstable and prone to aberrant catalytic reactions. In turn, these features lead to aggregation of SOD1 protein, impairment of axonal transport, reduced production of ATP and other perturbations of mitochondrial function, activation of cyclo-oxygenase within the ALS spinal cord, and ultimately induction of cell death via pathways that are at least partially

**TABLE 353-1 Genetic Motor Neuron Diseases**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Locus</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Upper and lower motor neurons (familial ALS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Autosomal dominant</td>
<td>2p</td>
<td>Dynactin</td>
</tr>
<tr>
<td></td>
<td>21q</td>
<td>Superoxide dismutase</td>
</tr>
<tr>
<td></td>
<td>22q</td>
<td>Neurofilament heavy subunit</td>
</tr>
<tr>
<td></td>
<td>9q</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>16q</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>20q</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>X</td>
<td>Unknow</td>
</tr>
<tr>
<td>B. Autosomal recessive (juvenile)</td>
<td>2q</td>
<td>Alsin</td>
</tr>
<tr>
<td>C. Mitochondrial</td>
<td>15q</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytochrome c oxidase</td>
</tr>
<tr>
<td>II. Lower motor neurons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Spinal muscular atrophies</td>
<td>5q</td>
<td>Survival motor neuron protein</td>
</tr>
<tr>
<td>B. X-linked spinobulbar muscular atrophy</td>
<td>Xq</td>
<td>Androgen receptor</td>
</tr>
<tr>
<td>C. Gax, gangliosidosis</td>
<td>15q</td>
<td>Hexosaminidase A</td>
</tr>
<tr>
<td></td>
<td>5q</td>
<td>Hexosaminidase B</td>
</tr>
<tr>
<td></td>
<td>5q</td>
<td>Μ₃₆ activator protein</td>
</tr>
<tr>
<td>III. Upper motor neurons/selected FSPs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Autosomal dominant</td>
<td>2p</td>
<td>Spastin</td>
</tr>
<tr>
<td></td>
<td>2q</td>
<td>Mitochondrial heat shock protein</td>
</tr>
<tr>
<td></td>
<td>12q</td>
<td>Kinesin heavy chain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KIF5A</td>
</tr>
<tr>
<td>B. Autosomal recessive</td>
<td>14q</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>16q</td>
<td>Paraplegin</td>
</tr>
<tr>
<td>C. X-linked</td>
<td>Xq21</td>
<td>Proteolipid protein</td>
</tr>
<tr>
<td></td>
<td>Xq28</td>
<td>L1 CAM</td>
</tr>
<tr>
<td>D. Adrenomyeloneuropathy</td>
<td>Xq21</td>
<td>Adreno leukodystrophy protein</td>
</tr>
<tr>
<td>IV. ALS-plus syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. ALS with frontotemporal dementia</td>
<td>9q</td>
<td>Unknown</td>
</tr>
<tr>
<td>B. Amyotrophy with behavioral disorder and parkinsonian features</td>
<td>17q</td>
<td>Tau protein</td>
</tr>
</tbody>
</table>

Note: ALS, amyotrophic lateral sclerosis; FSP, familial spastic paraplegia.
SELECTED LOWER MOTOR NEURON DISORDERS

In these motor neuron diseases, the peripheral motor neurons are affected without evidence of involvement of the corticospinal motor system (Tables 353-1 to 353-3).

X-Linked Spinobulbar Muscular Atrophy (Kennedy's Disease)  This is an X-linked lower motor neuron disorder in which progressive weakness and wasting of limb and bulbar muscles begins in males in mid-adult life and is conjoined with androgen insensitivity manifested by gynecomastia and reduced fertility (Chap. 325). In addition to gynecomastia, which may be subtle, two findings distinguishing this disorder from ALS are the absence of signs of pyramidal tract disease (spasticity) and the presence of a subtle sensory neuropathy in some patients. The underlying molecular defect is an expanded trinucleotide repeat (CAG) in the first exon of the androgen receptor gene on the X chromosome. DNA testing is available. An inverse correlation appears to exist between the number of CAG repeats and the age of onset of the disease.

SELECTED DISORDERS OF THE UPPER MOTOR NEURON

Primary Lateral Sclerosis  This exceedingly rare disorder arises sporadically in adults in mid- to late life. Clinically PLS is characterized by progressive spastic weakness of the limbs, preceded or followed by spastic dysarthria and dysphagia, indicating combined involvement of the corticospinal and corticobulbar tracts. Fasciculations, atrophy, and sensory changes are absent; neither electromyography nor muscle biopsy shows denervation. On neuropathologic examination there is selective loss of the large pyramidal cells in the precentral gyrus and degeneration of the corticospinal and corticobulbar projections. The peripheral motor neurons and other neuronal systems are spared. The course of PLS is variable; while long-term survival is documented, the course may be as aggressive as in ALS, with ~3-year survival from onset to death. Early in its course, PLS raises the question of multiple sclerosis or other demyelinating diseases such as adrenoleukodystrophy as diag-

Adult Tay-Sach's Disease  Several reports have described adult-onset, predominantly lower motor neuropathies arising from deficiency of the enzyme β-hexosaminidase (hex A). These tend to be distinguishable from ALS because they are known to be slowly progressive, dystarthisia and radiographically evident cerebellar atrophy may be prominent. In rare cases, spasticity may also be present, although it is generally absent (Chap. 340).

Spinal Muscular Atrophy  The SMAs are a family of selective lower motor neuron diseases of early onset. Despite some genetic variability (largely in age of onset), the defect in the majority of families with SMA maps to a locus on chromosome 5 encoding a putative motor neuron survival protein (SMN, for survival motor neuron) that is important in the formation and trafficking of RNA complexes across the nuclear membrane. Neuropathologically these disorders are characterized by extensive loss of large motor neurons; muscle biopsy reveals evidence of denervation atrophy. Several clinical forms exist.

Infantile SMA  (SMA I, Werdnig-Hoffmann Disease) has the earliest onset and most rapidly fatal course. In some instances it is apparent even before birth, as indicated by decreased fetal movements late in the third trimester. Though alert, afflicted infants are weak and floppy (hypoactive) and have generalized hypotonicity. Death generally ensues within the first year of life. Chronic childhood SMA (SMA II) begins later in childhood and evolves with a more slowly progressive course. Juvenile SMA (SMA III, Kugelberg-Welander disease) manifests during late childhood and runs a slow, indolent course. Unlike most devastating diseases, in this chronic disorder weakness is greatest in the proximal muscles; indeed, the pattern of clinical weakness can suggest a primary myopathy such as limb-girdle dystrophy. Electrophysiologic and muscle biopsy evidence of denervation distinguish SMA III from the myopathic syndromes.

Multifocal Motor Neuropathy with Conduction Block  In this disorder lower motor neuron function is regionally and chronically disrupted by remarkably focal blocks in conduction. Many cases have elevated serum titers of mono- and polycyclonal antibodies to ganglioside GM1; it is hypothesized that the antibodies produce selective, focal, paranodal demyelination of motor neurons. MMCB is not typically associated with corticospinal signs. In contrast with ALS, MMCB may respond dramatically to therapy such as intravenous immunoglobulin or chemotherapy; it is thus imperative that MMCB be excluded when considering a diagnosis of ALS.

Other Forms of Lower Motor Neuron Disease  In individual families, other syndromes characterized by selective lower motor neuron dysfunction in an SMA-like pattern have been described. There are rare X-linked and autosomal dominant forms of apparent SMA. There is an ALS variant of juvenile onset, the Fazio-Londe syndrome, that involves mainly the musculature innervated by the brainstem. A component of lower motor neuron dysfunction is also found in degenerative disorders such as Machado-Joseph disease and the related olivopontocerebellar degenerations (Chap. 352).

No treatment addresses the underlying pathologic process in ALS. The drug riluzole (100 mg/d) was approved for ALS because it produces a modest lengthening of survival. In one trial, the survival rate at 18 months with riluzole was similar to placebo at 15 months. The mechanism of this effect is not known with certainty; riluzole may reduce excitotoxicity by diminishing glutamate release. Riluzole is generally well tolerated; nausea, dizziness, weight loss, and elevated liver enzymes occur occasionally. Several agents have failed in clinical trials in human ALS including brain-derived neurotrophic factor, glial-derived neurotrophic factor, the anti-glutamate compound topiramate, and creatine. The latter was somewhat surprising as creatine was proven to be beneficial in transgenic ALS mice, perhaps by augmenting intracellular ATP stores. Insulin-like growth factor 1 (IGF-1) produced inconsistent results in ALS patients and is undergoing further clinical trials. The finding that cyclo-oxygenase activity is enhanced in the spinal cords of ALS mice led to a preclinical study of the COX-2 inhibitor, celecoxib, which significantly increased life span in that model. As a consequence, celecoxib is currently being tested in human ALS. Analogously, because minocycline produces a modest benefit in ALS mice, presumably by inhibiting late stages of the apoptotic cascade, it is now being tested in a multicenter ALS trial.

In the absence of a primary therapy for ALS, a variety of rehabilitative aids may substantially assist ALS patients. Foot-drop splints facilitate ambulation by obviating the need for excessive hip flexion and by preventing tripping on a floppy foot. Finger extension splints can potentiate grip. Respiratory support may be life-sustaining. For patients electing against long-term ventilation by tracheostomy, positive-pressure ventilation by mouth or nose provides transient (several weeks) relief from hypercarbia and hypoxia. Also extremely beneficial for some patients is a respiratory device (In-exsufflator or Cough Assist Device) that produces an artificial cough. This is highly effective in clearing airways and preventing aspiration pneumonia. When bulbar disease prevents normal chewing and swallowing, gastrostomy is uniformly helpful, restoring normal nutrition and hydration. Fortunately, an increasing variety of speech synthesizers are now available to augment communication and maybe effective for telephone use.

In contrast to ALS, several of the disorders (Tables 353-1 and 353-3) that bear some clinical resemblance to ALS are treatable. For this reason, a careful search for causes of secondary motor neuron disease is warranted.
Disorders of the Autonomic Nervous System

The autonomic nervous system (ANS) innervates the entire neuraxis and permeates all organ systems. It regulates blood pressure (BP), heart rate, sleep, and bladder and bowel function. It operates in the background, so that its full importance becomes recognized only when ANS function is compromised, resulting in dysautonomia. Hypothalamic disorders that cause disturbances in homeostasis are discussed in Chaps. 16 and 318.

ANATOMIC ORGANIZATION The activity of the autonomic nervous system is regulated by central neurons responsive to diverse afferent inputs. After central integration of afferent information, autonomic outflow is adjusted to permit the functioning of the major organ systems in accordance with the needs of the organism as a whole. Connections between the cerebral cortex and the autonomic centers in the brainstem coordinate autonomic outflow with higher mental functions.

The preganglionic neurons of the parasympathetic nervous system leave the central nervous system (CNS) in the third, seventh, ninth, and tenth cranial nerves as well as the second and third sacral nerves, while the preganglionic neurons of the sympathetic nervous system exit the spinal cord between the first thoracic and the second lumbar segments (Fig. 354-1). The postganglionic neurons, located in ganglia outside the CNS, give rise to the postganglionic autonomic nerves that innervate organs and tissues throughout the body. Responses to sympathetic and parasympathetic stimulation are frequently antagonistic (Table 354-1), reflecting highly coordinated interactions within the CNS: the resultant changes in parasympathetic and sympathetic activity provide more precise control of autonomic responses than could be achieved by the modulation of a single system.

Acetylcholine (ACh) is the preganglionic neurotransmitter for both divisions of the ANS as well as the postganglionic neurotransmitter of the parasympathetic nerves. Norepinephrine (NE) is the neurotransmitter of the postganglionic sympathetic nerves, except for cholinergic nerves innervating the eccrine sweat glands and perhaps some blood vessels supplying skeletal muscle.

CLINICAL EVALUATION Classification Disorders of the ANS may result from pathology of either the CNS or the peripheral nervous system (PNS) (Table 354-2). Signs and symptoms may result from interruption of the afferent limb, CNS processing centers, or efferent limb of reflex arcs controlling autonomic responses. For example, a lesion of the medulla produced by a posterior fossa tumor can impair BP responses to postural changes and result in orthostatic hypotension (OH). OH can also be caused by lesions of the spinal cord or peripheral vasomotor nerve fibers (e.g., diabetic autonomic neuropathy). The site of reflex interruption is usually established by the clinical context in which the dysautonomia arises, combined with judicious use of ANS testing and neuroimaging studies. Important elements of the clinical context include the presence or absence of CNS signs (pathophysiology and prognosis differ), association with sensory or motor polyneuropathy, family history, and pathologic findings. Some syndromes do not fit easily into any classification scheme.

Symptoms of Autonomic Dysfunction Clinical manifestations result from a loss of function (e.g., impaired baroreflexes leading to OH), overactivity (e.g., hyperhidrosis, tachycardia), or loss of regulation (e.g., autonomic storms, autonomic dysreflexia) of autonomic circuits. The disorder may be widespread or regional in distribution.
An autonomic history focuses on systemic functions (BP, heart rate, sleep, thermoregulation) and individual organ systems (pupils, bowel, bladder, sexual function). More formal assessment is possible using a standardized instrument such as the autonomic symptom profile. It is also important to recognize the modulating effects of age and gender. For instance, OH commonly results in lightheadedness in the young, whereas cognitive slowing is much more important in the elderly. Specific symptoms of orthostatic intolerance are quite diverse (Table 354-3). Autonomic symptoms may vary dramatically, reflecting the dynamic nature of autonomic control over homeostatic function. For example, OH might be manifest only in the early morning, following a namic nature of autonomic control over homeostatic function. For ex-
3). Autonomic symptoms may vary dramatically, reflecting the dy-
cific symptoms of orthostatic intolerance are quite diverse (Table 354-
whereas cognitive slowing is much more important in the elderly. Spe-
also important to recognize the modulating effects of age and gender.

### TABLE 354-1 Functional Consequences of Normal ANS Activation

<table>
<thead>
<tr>
<th>Sympathetic</th>
<th>Parasympathetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate</td>
<td>Increased</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Increased</td>
</tr>
<tr>
<td>Bladder</td>
<td>Increased sphincter tone</td>
</tr>
<tr>
<td>Bowel motility</td>
<td>Decreased motility</td>
</tr>
<tr>
<td>Lung</td>
<td>Bronchodilation</td>
</tr>
<tr>
<td>Sweat glands</td>
<td>Sweating</td>
</tr>
<tr>
<td>Pupils</td>
<td>Dilation</td>
</tr>
<tr>
<td>Adrenal glands</td>
<td>Catecholamine release</td>
</tr>
<tr>
<td>Sexual function</td>
<td>Ejaculation, orgasm</td>
</tr>
<tr>
<td>Lacrimal glands</td>
<td>—</td>
</tr>
<tr>
<td>Parotid glands</td>
<td>—</td>
</tr>
</tbody>
</table>

**Note:** BP, blood pressure; HR, heart rate.


**TABLE 354-3 Symptoms of Orthostatic Intolerance**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lightheadedness (dizziness)</td>
<td>88%</td>
</tr>
<tr>
<td>Weakness or tiredness</td>
<td>72%</td>
</tr>
<tr>
<td>Cognitive difficulty (thinking/concentrating)</td>
<td>47%</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>47%</td>
</tr>
<tr>
<td>Tremulousness</td>
<td>38%</td>
</tr>
<tr>
<td>Vertigo</td>
<td>37%</td>
</tr>
<tr>
<td>Pallor</td>
<td>31%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>29%</td>
</tr>
<tr>
<td>Palpitations</td>
<td>26%</td>
</tr>
<tr>
<td>Clammy feeling</td>
<td>19%</td>
</tr>
<tr>
<td>Nausea</td>
<td>18%</td>
</tr>
</tbody>
</table>

**Source:** From Low et al.

meal, or with exercise, depending upon the regional vascular bed affected by dysautonomia.

Early symptoms may be overlooked. Impotence, although not specific for autonomic failure, often heralds autonomic failure in men and may precede other symptoms by years (Chap. 43). A decrease in the frequency of spontaneous early morning erections may occur months before loss of nocturnal penile tumescence and development of total impotence. Bladder dysfunction may appear early in men and women, particularly in those with CNS involvement. Brain and spinal cord disease above the level of the lumbar spine results first in urinary frequency and small bladder volumes, and eventually in incontinence (upper motor neuron or spastic bladder). Disease of PNS autonomic nerve fibers to and from the bladder results in large bladder volumes, urinary frequency, and overflow incontinence (lower motor neuron bladder or flaccid bladder). Measurement of bladder volume (postvoid residual) is a useful bedside test for distinguishing between upper and lower motor neuron bladder dysfunction in the early stages of dysautonomia. Gastrointestinal autonomic dysfunction typically presents as severe constipation. Diarrhea occurs occasionally (as in diabetes mellitus) due to rapid transit of contents or uncoordinated small-bowel motor activity, or on an osmotic basis from bacterial overgrowth associated with small-bowel stasis. Impaired glandular secretory function may cause difficulty with food intake due to decreased salivation or with eye irritation due to decreased lacrimation. Occasionally, temperature elevation and vasodilation can result from anhidrosis because sweating is normally important for heat dissipation (Chap. 16).

OH (also called “postural hypotension”) is perhaps the most disabling feature of autonomic dysfunction. The prevalence of OH is relatively high, especially when OH associated with aging is included (Table 354-4). OH can cause a variety of symptoms including dimming or loss of vision, lightheadedness, diaphoresis, diminished hearing, pallor, and weakness. Syncope results when the drop in BP impairs cerebral perfusion. Other manifestations of impaired baroreflexes are supine hypertension, a heart rate that is fixed regardless of posture, postprandial hypotension, and an excessively high nocturnal BP. Many patients with OH have a preceding diagnosis of hypertension, reflecting the great importance of baroreflexes in maintaining postural and supine normotension. The most common causes of OH are not neurologic in origin; these must be distinguished from the neurogenic causes. →Neurocardiogenic and cardiac syncopese are considered in Chap. 20.

**APPROACH TO THE PATIENT**

The first step in the evaluation of symptomatic OH is the exclusion of treatable causes. The history should include a review of medications that may cause OH (e.g., diuretics, antihypertensives, antidepressants, phenothiazines, ethanol, narcotics, insulin, barbiturates, and calcium channel blocking agents). However, the precipitation of OH by medications may also be the first sign of an underlying autonomic disorder. The history may reveal an underlying cause for symptoms (e.g., diabetes, Parkinson’s disease) or specific underlying mechanisms (e.g., cardiac pump failure, reduced intravascular volume). The relationship of symptoms to meals (splanchnic pooling), standing on awakening in the morning (intravascular volume depletion), ambient warming (vasodilatation), or exercise (muscle arteriolar vasodilatation) should be sought.

Physical examination includes measurement of supine and standing pulse and BP. OH is defined as a sustained drop in systolic (≥20 mmHg) or diastolic (≥10 mmHg) BP within 3 min of standing up. In nonneurogenic causes of OH (such as hypovolemia), the BP drop is accompanied by a compensatory increase in heart rate of >15 beats/min. An important clinical clue that the patient has neurogenic OH is the aggravation or precipitation of OH by autonomic stressors (such as a meal, hot tub/hot bath, and exercise). Neurologic evaluation should include a mental status examination (to exclude neurodegenerative disorders), cranial nerve examination (impaired downgaze is found with progressive supranuclear palsy), abnormal pupils (Horner’s or Adie’s pupils), motor examination (Parkinson’s disease and parkinsonian syndromes), and sensory examination (polyneuropathies). In patients without a clear initial diagnosis, follow-up neurologic examinations and repeat laboratory evaluations over 1 to 2 years may reveal an evolution of findings that enables a specific diagnosis to be made.

Disorders of autonomic function should be considered in patients with symptoms of altered sweating (hyperhidrosis or hypohidrosis), gastroparesis (bloating, nausea, vomiting of old food), constipation, impotence, or bladder dysfunction (urinary frequency, hesitancy, or incontinence).

**Autonomic Testing** Autonomic function tests (Table 354-5) are helpful when the history and physical examination findings are inconclusive, when detection of subclinical involvement is important to evaluate the extent and severity of abnormalities, or to follow the course of an autonomic disorder or its response to therapy.

**HEART RATE VARIATION WITH DEEP BREATHING** This is a test of parasympathetic influence on cardiovascular function. Results are influenced by the subject’s posture, rate and depth of respiration (6 breaths per minute and a forced vital capacity (FVC) >1.5 L are optimal), age, medications, and hypocapnea. Interpretation of results requires comparison of test data with results from normal individuals collected under the same test conditions. For example, the lower limit of normal heart rate variation with deep breathing

| Table 354-4 Prevalence of Orthostatic Hypotension in Different Disorders |
|-----------------------------|---------------------|
| Disorder                    | Prevalence          |
| Aging                       | 14–20%              |
| Diabetic neuropathy         | 10%                 |
| Other autonomic neuropathies| 10–50 per 100,000   |
| Multiple system atrophy     | 5–15 per 100,000    |
| Pure autonomic failure      | 10–30 per 100,000   |

**Source:** From Low et al.

**TABLE 354-5 Neural Pathways Underlying Some Standardized Autonomic Tests**

<table>
<thead>
<tr>
<th>Test Evaluated</th>
<th>Procedure</th>
<th>Autonomic Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRBD Valsalva ratio</td>
<td>6 deep breaths/min Expiratory pressure, 40 mmHg for 10–15 s</td>
<td>Cardiovascular function Cardiovascular function</td>
</tr>
<tr>
<td>QSART</td>
<td>Axon-reflex test 4 limb sites</td>
<td>Postganglionic sudomotor function</td>
</tr>
<tr>
<td>BP&lt;sub&gt;n&lt;/sub&gt; to VM</td>
<td>BP&lt;sub&gt;n&lt;/sub&gt; response to VM</td>
<td>Adrenergic sudomotor function baroreflex adrenergic control of vaginal and vasomotor function</td>
</tr>
<tr>
<td>HUT</td>
<td>BP&lt;sub&gt;n&lt;/sub&gt; and heart rate response to HUT</td>
<td>Adrenergic and cardiovascular responses to HUT</td>
</tr>
</tbody>
</table>

**Note:** HRBD, heart rate response to deep breathing; BP<sub>n</sub>, beat-to-beat blood pressure; QSART, quantitative sudomotor axon-reflex test; VM, Valsalva maneuver; HUT, head-up tilt.
in persons <20 years is >15 to 20 beats/min, but for persons over age 60 it is 5 to 8 beats/min. Heart rate variation with deep breathing (respiratory sinus arrhythmia) is abolished by the administration of atropine.

**VALSALVA RESPONSE** This response (Table 354-5) assesses integrity of the baroreflex control of heart rate (parasympathetic) and BP (adrenergic). The response is obtained with the subject supine. A constant expiratory pressure of 40 mmHg is maintained for 15 s while measuring changes in heart rate and beat-to-beat BP. There are four phases of BP and heart rate response to the Valsalva maneuver. Phases I and III are mechanical and related to changes in intrathoracic and intraabdominal pressure. In early phase II, reduced venous return results in a fall in stroke volume and BP, counteracted by a combination of reflex tachycardia and increased total peripheral resistance. Increased total peripheral resistance arrests the BP drop ~5 to 8 s after the onset of the maneuver. Late phase II begins with a progressive rise in BP to or above baseline. Venous return and cardiac output return to normal in phase IV. Persistent peripheral arteriolar vasoconstriction and increased cardiac adrenergic tone results in a temporary BP overshoot and phase IV bradycardia (mediated by the baroreceptor reflex).

Autonomic function during the Valsalva maneuver can be measured using beat-to-beat blood pressure or heart rate changes. The Valsalva ratio is defined as the maximum phase II tachycardia divided by the minimum phase IV bradycardia. The ratio reflects cardiovascular function.

**SUDOMOTOR FUNCTION** Sweating is induced by release of ACh from sympathetic postganglionic fibers. The quantitative sudomotor axon reflex test (QSART) is a measure of regional autonomic function mediated by ACh-induced sweating. A reduced or absent response indicates a lesion of the postganglionic sudomotor axon. For example, sweating may be reduced in the legs as a result of peripheral neuropathy (e.g., in diabetes) before other signs of autonomic dysfunction emerge. The thermoregulatory sweat test (TST) is a qualitative measure of regional sweat production in response to an elevation of body temperature. An indicator powder placed on the anterior body surface changes color with sweat production during temperature elevation. The pattern of color changes is a measure of regional sweat secretion. Combining TST and QSART results will determine the site of the lesion. A postganglionic lesion is present if both QSART and TST show absent sweating. In a preganglionic lesion, QSART is intact but TST shows anhidrosis. Measurement of galvanic skin responses in the limbs after an induced electrical potential is another qualitative test for detecting the presence or absence of sweating.

**ORTHOSTATIC BP RECORDINGS** Beat-to-beat BP measurements determined in supine, 70° tilt, and tilt-back positions are useful to quantify orthostatic failure of BP control. It is important to allow a 20-min period of supine rest before assessing changes in BP during tilting. The BP change combined with heart rate monitoring can be useful for the evaluation of patients with suspected OH or unexplained syncope or to detect vagally mediated syncope.

**PHARMACOLOGIC TESTS** Pharmacologic assessments can help localize an autonomic defect to the CNS or the PNS. A useful method to evaluate the systemic adrenergic response is the measurement of plasma NE, first with the patient supine and then after standing for 5 min. Supine values are reduced in postganglionic disorders (such as autonomic neuropathy or pure autonomic failure) and may fail to increase in preganglionic or postganglionic disorders (e.g., multiple system atrophy).

Administration of tyramine (releases NE from postganglionic terminals) and phenylephrine (denervation supersensitivity—directly acting α1-agonist) is often used to evaluate postganglionic adrenergic function. In a postganglionic lesion, the response to tyramine is reduced and there is an excessive response to subthreshold doses of phenylephrine. Other strategies include ganglionic blockade with trimethaphan (greater fall in resulting BP with a preganglionic lesion) or administration of arginine vasopressin (to evaluate afferent central pathways).

**SPECIFIC SYNDROMES OF ANS DYSFUNCTION** Multiple system atrophy (MSA) is an uncommon entity that comprises autonomic failure (OH and/or a neurogenic bladder are required for diagnosis) combined with either striatogniral degeneration (Shy-Drager syndrome) or sporadic olivopontocerebellar atrophy (Chap. 351). The parkinsonism is usually unassociated with rest tremor and is not responsive to levodopa. Levodopa-induced dyskinesia is also uncommon. Autonomic function tests can usually differentiate MSA from Parkinson’s disease in that the severity and distribution of autonomic failure is more severe and generalized in MSA. Cardiac postganglionic adrenergic innervation, measured as labeled metaiodobenzylguanidine (MIBG) uptake on single photon emission computed tomography or fluorodopamine on positron emission tomography (PET), is markedly impaired in the dysautonomia of Parkinson’s disease but is normal in MSA.

MSA generally progresses relentlessly to death 7 to 10 years after onset. Neuropathologic changes include primary neuronal degeneration with loss of neurons and glia in many CNS regions, including the brainstem, the cerebellum, the striatum, and the intermediolateral cell column of the thoracolumbar spinal cord.

**Spinal Cord** Spinal cord lesions from any cause may result in focal autonomic deficits or autonomic hyperreflexia. Spinal cord transection or hemisection may be attended by autonomic hyperreflexia affecting bowel, bladder, sexual, temperature-regulation, or cardiovascular functions. Dangerous increases or decreases in body temperature may result from inability to experience the sensory accompaniments of heat or cold exposure below the level of the injury. Quadriplegic patients exhibit both supine hypertension and OH after upward tilting. Markedly increased autonomic discharge can be elicited by bladder pressure or stimulation of the skin or muscles; suprapubic palpation of the bladder, a distended bladder, catheter insertion, catheter obstruction, or urinary infection are common and correctable precipitants. This phenomenon, termed autonomic dysreflexia, affects 85% of patients with a traumatic spinal cord lesion above the C6 level. In patients with supine hypertension, BP can be lowered by tilting the head upward. Vasodilator drugs may be used to treat acute elevations in BP. Clonidine is used prophylactically to reduce the hypertension resulting from bladder stimulation. Sudden, dramatic increases in BP can lead to intracranial hemorrhage and death.

**Peripheral Nerve and Neuromuscular Junction Disorders** Peripheral neuropathies (Chap. 363) are the most common cause of chronic autonomic insufficiency. Neuropathies that affect small myelinated and unmyelinated fibers of the sympathetic and parasympathetic nerves occur in diabetes mellitus, amyloidosis, chronic alcoholism, porphyria, and Guillain-Barré syndrome. Neuromuscular junction disorders include botulism and Lambert-Eaton syndrome.

**DIABETES MELLITUS** Autonomic neuropathy typically begins ~10 years after the onset of diabetes (Chap. 323) and slowly progresses. The earliest autonomic abnormalities, typically asymptomatic, consist of vagal disturbances, which can be detected as reduced heart rate variation with deep breathing, and loss of distal sudomotor function, detected by QSART. Loss of small myelinated and unmyelinated nerve fibers in the splanchnic distribution, carotid sinus, and vagus nerves is characteristic. In advanced disease, widespread enteric neuropathy can cause profound disturbances in gut motility (gastroparesis), nausea and vomiting, malnutrition, achlorhydria, and bowel incontinence. Other symptoms can include impotence, urinary incontinence, pupillary abnormalities, and OH. Typical symptoms and signs of hypoglycemia may fail to appear because damage to the sympathetic innervation of the adrenal gland can result in a lack of epinephrine
release. Insulin increases flow through arteriovenous shunts and may also aggravate OH. Autonomic dysfunction may lengthen the QT interval, increasing the risk of sudden death due to cardiac arrhythmia. There is postganglionic cardiac denervation with some proximal segments showing increased uptake of labeled hydroxyephedrine, indicative of hyperadrenergic innervation, on PET scanning. This finding is of interest in that these areas could be potentially arrhythmogenic. Hyperglycemia appears to be a direct risk factor for autonomic involvement in diabetes. Biochemical and pharmacologic studies in diabetic neuropathy are compatible with autonomic failure localized to the PNS. Supine plasma NE levels can be reduced, and a minority of patients experience a phase of hyperadrenergic autonomic function characterized by exaggerated orthostatic pressor responsiveness.

**AMYLOIDOSIS** Autonomic neuropathy occurs in both sporadic and familial forms of amyloidosis (Chap. 310). The AL (immunoglobulin light chain) type is associated with primary amyloidosis or amyloidosis secondary to multiple myeloma. The ATTR type, with transthyretin as the primary protein component, is responsible for the most common form of inherited amyloidosis. Although patients usually present with a distal painful neuropathy accompanied by sensory loss, autonomic insufficiency can precede the development of the polynuropathy or occur in isolation. Death is usually due to cardiac or renal impairment. Postmortem studies reveal amyloid deposition in many organs, including two sites that contribute to autonomic failure: intraneuronal blood vessels and autonomic ganglia. Pathologic examination reveals a loss of unmyelinated and myelinated nerve fibers.

**ALCOHOLIC NEUROPATHY** Abnormalities in parasympathetic vagal and efferent sympathetic function are usually mild in individuals with alcoholic neuropathy. Pathologic changes can be demonstrated in the parasympathetic (vagus) and sympathetic fibers and in ganglia. OH is usually due to brainstem involvement. Impotence is a major problem, but concurrent gonadal hormone abnormalities may obscure the parasympathetic component. Clinical symptoms of autonomic failure generally appear when the polynuropathy is severe and there is usually coexisting Wernicke’s encephalopathy (Chap. 258). Autonomic involvement may contribute to the high mortality rates associated with alcoholism (Chap. 372).

**PORPHYRIA** Although each of the porphyrias can cause autonomic dysfunction, the condition is most extensively documented in the acute intermittent type (Chap. 337). Autonomic symptoms include tachycardia, sweating, urinary retention, and hypertension, or, less commonly, hypotension. Other prominent symptoms include anxiety, abdominal pain, nausea, and vomiting. Abnormal autonomic function can occur both during acute attacks and during remissions. Elevated catecholamine levels during acute attacks correlate with the degree of tachycardia and hypertension that are present.

**GUILLAIN-BARRÉ SYNDROME** BP fluctuations and arrhythmias can be severe (Chap. 365). It is estimated that 2 to 10% of patients seriously ill with Guillain-Barré syndrome suffer fatal cardiovascular collapse. Gastrointestinal autonomic involvement is common. Abnormal sweating, sphincter disturbance, and pupillary dysfunction also occur. Demyelination has been described in the vagus and glossopharyngeal nerves, the sympathetic chain, and the white rami communicantes. The presence of autonomic involvement is not clearly related to the severity of motor or sensory involvement.

**AUTOIMMUNE AUTONOMIC NEUROPATHY** The development of serologic testing for the ganglionic ACh receptor (A3 AChR) autoantibody, which is a putative effector of autoimmune dysautonomia, now allows definition of the entity of autoimmune autonomic neuropathy (AAN). This disorder presents as the subsacute development of autonomic failure with OH, enteric neuropathy (gastroparesis, ileus, constipation/diarrhea), and cholinergic failure; the latter consists of loss of sweating, sicca complex, and a tonic pupil. In general, the antibody titer correlates with the severity of autonomic failure. Symptoms of cholinergic failure are also predictive of a high antibody titer. Onset of the neuropathy follows a viral infection in approximately half of cases. Some patients appear to respond to immunotherapy. The spectrum of AAN is broader than originally thought, and some antibody-positive cases have an inidious onset and slow progression with a pure autonomic feature (see below) phenotype. An experimental autonomic neuropathy has recently been produced by immunization of rabbits with this receptor.

AAN can have a paraneoplastic basis (Chap. 87). The clinical features of the autonomic neuropathy may be indistinguishable from the nonparaneoplastic form, or a coexisting paraneoplastic syndrome, such as cerebellar involvement or dementia, may be present (Tables 87-2 and 87-3). The neoplasm may be truly occult, possibly suppressed by the autoantibody.

**BOTULISM** Botulinum toxin binds presynaptically to cholinergic nerve terminals and, after uptake into the cytosol, blocks ACh release. Manifestations consist of motor paralysis and autonomic disturbances that include blurred vision, dry mouth, nausea, unreactive or sluggishly reactive pupils, constipation, and urinary retention (Chap. 125).

**Pure Autonomic Failure (PAF)** This sporadic syndrome consists of postural hypotension, impotence, bladder dysfunction, and defective sweating. The disorder begins in the middle decades and occurs in women more often than men. The symptoms can be disabling, but the disease does not shorten life span. The clinical and pharmacologic characteristics suggest primary involvement of postganglionic sympathetic neurons. There is a severe reduction in the density of neurons within sympathetic ganglia that results in low supine plasma NE levels and noradrenergic supersensitivity. Recent studies have questioned the specificity of PAF as a distinct clinical entity. Some cases are gangliosidic antibody–positive and thus represent a type of AAN. Between 10 and 15% of cases evolve into MSA.

**Postural Orthostatic Tachycardia Syndrome (POTS)** This syndrome is characterized by symptomatic orthostatic intolerance (not OH) and by either an increase in heart rate to >120 beats/min or an increase of 30 beats/min with standing that subsides on sitting or lying down. Women are affected approximately five times more often than men, and most develop the syndrome between the ages of 15 and 50 years. Approximately half of affected patients report an antecedent viral infection. Syncopeal symptoms (lightheadedness, weakness, blurred vision) combined with those of autonomic overactivity (palpitations, tremulousness, nausea) are common. Recurrent unexplained episodes of dysautonomia and fatigue also occur. The pathogenesis is unclear in most cases; hypovolemia, venous pooling, impaired brainstem regulation, or β-receptor supersensitivity may play a role. In one affected individual, a mutation in the NE transporter, which resulted in impaired NE clearance from synapses, was responsible. Some cases are due to an underlying limited autonomic neuropathy. Although ~80% of patients improve, only one-quarter eventually resume their usual daily activities (including exercise and sports). Expansion of fluid volume and postural training (see “Treatment”) are initial approaches to treatment. When these approaches are inadequate, midodrine, fludrocortisone, phenobarbital, beta blockers, and clonidine have been used with some success.

**Inherited Disorders** There are five known hereditary sensory and autonomic neuropathies (HSAN I–V). The most important ones are HSAN I and HSAN III (Riley-Day syndrome; familial dysautonomia). HSAN I is dominantly inherited and often presents as a distal small-fiber neuropathy (burning feet syndrome). The responsible gene, on chromosome 9q, is designated *SPTLC1*. SPTLC is an important enzyme in the regulation of ceramide. Cells from HSAN I patients affected by mutation of *SPTLC1* produce higher-than-normal levels of glucosyl ceramide, perhaps triggering apoptosis.

HSAN III, an autosomal recessive disorder of infants and children that occurs among Ashkenazi Jews, is much less prevalent than HSAN I. It is characterized by decreased sweating, hyperhidrosis, reduced sensitivity to pain, areflexia, absent fungiform papillae on the tongue, and labile BP may be present. Episodic abdominal crises and fever are common. Patho-
logic examination of nerves reveals a loss of small myelinated and unmyelinated nerve fibers. The defective gene, named IKBKAP, is also located on the long arm of chromosome 9. Pathogenic mutations may prevent normal transcription of important molecules in neural development.

**Primary Hyperhidrosis** This syndrome presents with excess sweating of the palms of the hands and soles of the feet. The disorder affects 0.6 to 1.0% of the population; the etiology is unclear but there may be a genetic component. While not dangerous, the condition can be socially embarrassing (e.g., shaking hands) or disabling (e.g., inability to write without soiling the paper). Onset of symptoms is usually in adolescence; the condition tends to improve with age. Topical antiperspirants are occasionally helpful. More useful are potent anticholinergic drugs such as glycopyrrrolate, 1 to 2 mg tid. T2 ganglionectomy or sympathectomy is successful in >90% of patients with palmar hyperhidrosis. The advent of endoscopic transaxillary T2 sympathectomy has lowered the complication rate of the procedure. The most common postoperative complication is compensatory hyperhidrosis, which improves spontaneously over months; other potential complications include recurrent hyperhidrosis (16%), Horner’s syndrome (<2%), gustatory sweating, wound infection, hemithorax, and intercostal neuralgia. Local injection of botulinum toxin has also been used to block cholinergic, postganglionic sympathetic fibers to sweat glands in patients with palmar hyperhidrosis. This approach is limited by the need for repetitive injections (the effect usually lasts 4 months before waning), pain with injection, the high cost of botulinum toxin, and the possibility of temporary intrinsic hand muscle weakness. Tap water iontophoresis has been successful for some patients.

**Miscellaneous** Other conditions associated with autonomic failure include infections, poisoning (organophosphates), malignancy, and aging. Disorders of the hypothalamus can affect autonomic function and produce abnormalities in temperature control, satiety, sexual function, and circadian rhythms (Chap. 318).

**Reflex Sympathetic Dystrophy and Causalgia** The failure to identify a primary role of the ANS in the pathogenesis of these disorders has resulted in a change of nomenclature. Complex regional pain syndrome (CRPS) types I and II are now used in place of reflex sympathetic dystrophy (RSD) and causalgia, respectively.

CRPS type I is a regional pain syndrome that usually develops after tissue trauma. Examples of associated trauma include myocardial infarction, minor shoulder or limb injury, and stroke. Alloodynia (the perception of a nonpainful stimulus as painful), hyperpathia (an exaggerated pain response to a painful stimulus), and spontaneous pain occur. The symptoms are unrelated to the severity of the initial trauma and are not confined to the distribution of a single peripheral nerve. CRPS type II is a regional pain syndrome that develops after injury to a peripheral nerve, usually a major nerve trunk. Spontaneous pain initially develops within the territory of the affected nerve but eventually may spread outside the nerve distribution.

Pain is the primary clinical feature of CRPS. Vasomotor dysfunction, sudomotor abnormalities, or focal edema may occur alone or in combination but must be present for diagnosis. Limb pain syndromes that do not meet these criteria are best classified as “limb pain—not otherwise specified.” In CRPS, localized sweating (increased resting sweat output) and changes in blood flow may produce temperature differences between affected and unaffected limbs.

CRPS type I (RSD) has classically been divided into three clinical phases but is now considered to be more variable. Phase I consists of pain and swelling in the distal extremity occurring within weeks to 3 months after the precipitating event. The pain is diffuse, spontaneous, and either burning, throbbing, or aching in quality. The involved extremity is warm and edematous, and the joints are tender. Increased sweating and hair growth develop. In phase II (3 to 6 months after onset), thin, shiny, cool skin appears. After an additional 3 to 6 months (phase III), atrophy of the skin and subcutaneous tissue plus flexion contractures complete the clinical picture.

The natural history of typical CRPS may be more benign than reflected in the literature. A variety of surgical and medical treatments have been developed, with conflicting reports of efficacy. Clinical trials suggest that early mobilization with physical therapy or a brief course of glucocorticoids may be helpful for CRPS type I. Other medical treatments include the use of adrenergic blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers, phentolamine, opioids, and calcitonin. Stellate ganglion blockade is a commonly used invasive therapeutic technique that often provides temporary pain relief, but the efficacy of repetitive blocks is uncertain.

### TREATMENT

Management of autonomic failure is aimed at specific treatment of the cause and alleviation of symptoms. Of particular importance is the removal of drugs or amelioration of underlying conditions that cause or aggravate the autonomic symptom. For instance, OH can be caused or aggravated by angiotensin-converting enzyme inhibitors, calcium channel blocking agents, tricyclic antidepressants, levodopa, alcohol, or insulin.

**Patient Education** OH can be asymptomatic or symptomatic. Neurogenic OH requires treatment, but only a minority of patients require pharmacologic treatment. All patients should be taught the mechanisms of postural normotension (volume status, resistance and capacitance bed, autoregulation) and the nature of orthostatic stressors (time of day and the influence of meals, heat, standing, and exercise). Patients should learn to recognize orthostatic symptoms early in their evolution (especially subtle cognitive symptoms, weakness, and fatigue) and to modify activities that provoke episodes. Other helpful measures may include keeping a BP log, dietary education (salt/fluids), monitoring urine volume and sodium excretion, or recognizing medications and situations to avoid. Learning physical countermeasures that reduce standing OH, practicing postural and resistance training, and learning to manage worsening OH in specific situations and at specific times are helpful measures.

**Symptomatic Treatment** Nonpharmacologic approaches are summarized in Table 354-6. Adequate intake of salt and fluids to produce a voiding volume between 1.5 to 2.5 L of urine (containing >170 meq of Na⁺) each 24 h is essential. Sleeping with the head of the bed elevated will minimize the effects of supine nocturnal hypertension. Prolonged recumbency should be avoided when possible. Patients are advised to sit with legs dangling over the edge of the bed for several minutes before attempting to stand in the morning; other postural stresses should be similarly approached in a gradual manner. Physical countermeasures that can reduce OH include leg-crossing, with maintained contraction of leg muscles for 30 s. Such maneuvers compress leg veins and increase systemic resistance. Compressive garments such as compression stockings and abdominal binders may be helpful; some patients find these uncomfortable. Anemia should be corrected, if necessary, with erythropoietin, administered subcutaneously at doses of 25 to 75 U/kg three times per week. The hematocrit increases after 2 to 6 weeks. A weekly maintenance dose is usually necessary. The increased intravascular volume that accompanies the rise in hematocrit can exacerbate supine hypertension.

If these measures are not sufficient, drug treatment might be nec-

<table>
<thead>
<tr>
<th>TABLE 354-6 Initial Treatment of Orthostatic Hypotension (OH)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient education:</strong> mechanisms and stressors of OH</td>
</tr>
<tr>
<td><strong>High-salt diet (10–20 g/d)</strong></td>
</tr>
<tr>
<td><strong>High-fluid intake (2 L/D)</strong></td>
</tr>
<tr>
<td><strong>Elevate head of bed 10 cm (4 in.)</strong></td>
</tr>
<tr>
<td><strong>Maintain postural stimuli</strong></td>
</tr>
<tr>
<td><strong>Learn physical countermeasures</strong></td>
</tr>
<tr>
<td><strong>Compression garments</strong></td>
</tr>
<tr>
<td><strong>Correct anemia</strong></td>
</tr>
</tbody>
</table>


neous. Midodrine is effective but can aggravate supine hypertension at higher doses. The drug is a directly acting α1-agonist that does not cross the blood-brain barrier. It has a duration of action of 2 to 4 h. The usual dose is 5 to 10 mg orally tid, but some patients respond best to a decremental dose (e.g., 15 mg on awakening, 10 mg at noon, and 5 mg in the afternoon). Midodrine should not be taken after 6 P.M. Side effects include pruritus, uncomfortable piloerection, and supine hypertension. Pyridostigmine appears to improve OH without aggravating supine hypertension by enhancing ganglionic transmission (maximal when orthostatic, minimal supine). Fludrocortisone will reduce OH, but it aggravates supine hypertension. At doses between 0.1 mg/d and 0.3 mg bid orally, it enhances renal sodium conservation and increases the sensitivity of arterioles to NE. Susceptible patients may develop fluid overload, congestive heart failure, supine hypertension, or hypokalemia. Potassium supplements are often necessary with chronic administration of fludrocortisone. Sustained elevations of supine BP >180/110 mmHg should be avoided.

Postprandial OH may respond to several measures. Frequent, small, low-carbohydrate meals may diminish splanchnic shunting of blood after meals and reduce postprandial OH. Prostaglandin inhibitors (ibuprofen or indomethacin) taken with meals or midodrine (10 mg with the meal) can be helpful. The somatostatin analogue octreotide can be useful in the treatment of postprandial syncope by inhibiting the release of gastrointestinal peptides that have vasodilator and hypertensive effects. The subcutaneous dose ranges from 25 μg bid to 100 to 200 μg tid.

The patient should be taught to self-treat transient worsening of OH. Drinking two 250-mL (8-oz) glasses of water can raise standing BP 20 to 30 mmHg for about 2 h, beginning ~20 min after the fluid load. The patient can increase intake of salt and fluids (bouillon treatment), increase use of physical countermaneuvers, temporarily resort to a full-body stocking (compression pressure 30 to 40 mmHg), or increase the dose of midodrine. Supine hypertension (>180/110 mmHg) can be self-treated by avoiding the supine position and reducing fludrocortisone. A daily glass of wine, if requested by the patient, can be taken shortly before bedtime. If these simple measures are not adequate, drugs to be considered include oral hydralazine (25 mg qhs), oral procardia (10 mg qhs), or a nitroglycerin patch.

ACKNOWLEDGMENT

In the previous edition, Lewis Landsberg and James B. Young contributed the section on the anatomic organization of the autonomic nervous system.

FURTHER READING


Symptoms and signs of cranial nerve pathology are common in internal medicine. They often develop in the context of a widespread neurologic disturbance, and in such situations cranial nerve involvement may represent the initial manifestation of the illness. In other disorders, involvement is largely restricted to one or several cranial nerves; these distinctive disorders are reviewed in this chapter. Disorders of ocular movement are discussed in Chap. 25; disorders of smell, taste, and hearing in Chap. 26; and vertigo and disorders of vestibular function in Chap. 20.

FACIAL PAIN OR NUMBNESS

ANATOMIC CONSIDERATIONS The trigeminal (fifth cranial) nerve supplies sensation to the skin of the face and anterior half of the head (Fig. 355-1). Its motor part innervates the masseter and pterygoid masticatory muscles.

TRIGEMINAL NEURALGIA (TIC DOULOUREUX) ■ Clinical Manifestations Trigeminal neuralgia is characterized by excruciating paroxysms of pain in the lips, gums, cheek, or chin and, very rarely, in the distribution of the ophthalmic division of the fifth nerve. The pain seldom lasts more than a few seconds or a minute or two but may be so intense that the patient winces, hence the term tic. The paroxysms, experienced as single jabs or clusters, tend to recur frequently, both day and night, for several weeks at a time. They may occur spontaneously or with movements of affected areas evoked by speaking, chewing, or smiling. Another characteristic feature is the presence of trigger zones, typically on the face, lips, or tongue, that provoke attacks; patients may report that tactile stimuli—e.g., washing the face, brushing the teeth, or exposure to a draft of air—generate excruciating pain. An essential feature of trigeminal neuralgia is that objective signs of sensory loss cannot be demonstrated on examination.

Trigeminal neuralgia is relatively common, with an estimated annual incidence of 4.5 per 100,000 individuals. Middle-aged and elderly persons are affected primarily, and ~60% of cases occur in women. Onset is typically sudden, and bouts tend to persist for weeks or months before remitting spontaneously. Remissions may be longlasting, but in most patients the disorder ultimately recurs.

Pathophysiology Symptoms result from ectopic generation of action potentials in pain-sensitive afferent fibers of the fifth cranial nerve root just before it enters the lateral surface of the pons. Compression or other pathology in the nerve leads to demyelination of large myelinated fibers that do not themselves carry pain sensation but become hyperexcitable and electrically coupled with smaller unmyelinated or poorly myelinated pain fibers in close proximity; this may explain why tactile stimuli, conveyed via the large myelinated fibers, can stimulate paroxysms of pain. Compression of the trigeminal nerve root by a blood vessel, most often the superior cerebellar artery or on occasion a tortuous vein, is the source of trigeminal neuralgia in a substantial
proportion of patients. In cases of vascular compression, age-related brain sagging and increased vascular thickness and tortuosity may explain the prevalence of trigeminal neuralgia in later life.

**Differential Diagnosis** Trigeminal neuralgia must be distinguished from other causes of face and head pain (Chap. 14) and from pain arising from diseases of the jaw, teeth, or sinuses. Pain from migraine or cluster headache tends to be deep seated and steady, unlike the superficial stabbing quality of trigeminal neuralgia; rarely, cluster headache is associated with trigeminal neuralgia, a syndrome known as *cluster tic*. In temporal arteritis, superficial facial pain is present but is not typically shock-like, the patient frequently complains of myalgias and other systemic symptoms and an elevated erythrocyte sedimentation rate (ESR) is usually present (Chap. 306). When trigeminal neuralgia develops in a young adult or is bilateral, multiple sclerosis is a key consideration, and in such cases the cause is a demyelinating plaque at the root entry zone of the fifth nerve in the pons; often, evidence of facial sensory loss can be found on careful examination. Cases that are secondary to mass lesions—such as aneurysms, neurofibromas, or meningiomas—also usually produce objective signs of sensory loss in the trigeminal nerve distribution (trigeminal neuropathy, see below).

**Laboratory Evaluation** An ESR is indicated if temporal arteritis is suspected. In typical cases of trigeminal neuralgia, neuroimaging studies are not necessary.

### **TREATMENT**

Drug therapy with carbamazepine is effective in ~50 to 75% of patients. Carbamazepine should be started as a single daily dose of 100 mg taken with food, and increased gradually (by 100 mg daily every 1 to 2 days) until substantial (>50%) pain relief is achieved. Most patients require a maintenance dose of 200 mg qid. Doses >1200 mg daily provide no additional benefit. Dizziness, imbalance, sedation, and rare cases of agranulocytosis are the most significant side effects of carbamazepine. If treatment is effective, it is usually continued for approximately 1 month and then tapered as tolerated. If carbamazepine is not well tolerated or is ineffective, phenytoin, 300 to 400 mg daily, can be tried. Baclofen may also be administered, either alone or in combination with carbamazepine or phenytoin. The initial dose is 5 to 10 mg tid, gradually increasing as needed to 20 mg qid.

If drug treatment fails, surgical therapy should be offered. The most widely applied procedure creates a heat lesion of the trigeminal (gasserian) ganglion or nerve, a method termed *radiofrequency thermal rhizotomy*. Injection of glycerol in Meckel’s cave is a method preferred by some surgeons. Either procedure produces short-term relief in >95% of patients; however, long-term studies indicate that pain recurs in a substantial percentage of treated patients. Complications are infrequent in experienced hands. These procedures result in partial numbness of the face and carry a risk of corneal denervation with secondary keratitis when used for first-division trigeminal neuralgia.

A third treatment, microvascular decompression, requires a suboccipital craniotomy. This procedure has a >70% efficacy rate and a low rate of pain recurrence in respondents; in a small number of cases, there is perioperative damage to the eighth or seventh nerve. High-resolution magnetic resonance angiography may be useful preoperatively to visualize the relationships between the fifth cranial nerve root and nearby blood vessels.

**TRIGEMINAL NEUROPATHY** A variety of diseases may affect the trigeminal nerve (Table 355-1). Most present with sensory loss on the face or with weakness of the jaw muscles. Deviation of the jaw on opening indicates weakness of the pterygoids on the side to which the jaw deviates. Some cases are due to Sjögren’s syndrome or a collagen-vascular disease such as systemic lupus erythematosus, scleroderma, or mixed connective tissue disease. Among infectious causes, herpes zoster and leprosy should be considered. Tumors of the middle cranial fossa (meningiomas), of the trigeminal nerve (schwannomas), or of the base of the skull (metastatic tumors) may cause a combination of motor and sensory signs. Lesions in the cavernous sinus can affect the first and second divisions of the trigeminal nerve, and lesions of the superior orbital fissure can affect the first (ophthalmic) division; the accompanying corneal anesthesia increases the risk of ulceration (neurokeratitis).

Loss of sensation over the chin (mental neuropathy) can be the only manifestation of systemic malignancy. Rarely, an idiopathic form of trigeminal neuropathy is observed. It is characterized by numbness and paresthesia, sometimes bilaterally, with loss of sensation in the territory of the trigeminal nerve but without weakness of the jaw. Gradual recovery is the rule. Tonic spasm of the masticatory muscles, known as *trismus*, is symptomatic of tetanus (Chap. 124) or may occur in patients treated with phenothiazine drugs.

### **FACIAL WEAKNESS**

**ANATOMIC CONSIDERATIONS** (Fig. 355-2) The seventh cranial nerve supplies all the muscles concerned with facial expression. The sensory component is small (the nervus intermedius); it conveys taste sensation from the anterior two-thirds of the tongue and probably cutaneous impulses from the anterior wall of the external auditory canal. The motor nucleus of the seventh nerve lies anterior and lateral to the abducens nucleus. After leaving the pons, the seventh nerve enters the internal auditory meatus with the acoustic nerve. The nerve continues its course in its own bony channel, the facial canal, and exits from the brain. The motor nucleus of the seventh nerve gives rise to two divisions: the motor (VII n.) and the parasympathetic (VII n.) divisions.

The motor division gives rise to distinct branches: the *facial* and the *glossopharyngeal* nerves. The *facial* nerve innervates all muscles of facial expression except the orbicularis oris and the buccal muscles, which are innervated by the *glossopharyngeal* nerve. The motor division of the facial nerve contains five nuclei: the *motor* nucleus of the fifth nerve (VII n.), the *supranuclear* motor nucleus, the *motor* nucleus of the seventh nerve, the *motor* nucleus of the ninth nerve, and the *motor* nucleus of the eleventh nerve. The motor nucleus of the seventh nerve is located in the pontine tegmentum, just lateral to the vertical obex. After leaving the pons, the seventh nerve enters the internal auditory meatus with the acoustic nerve. The nerve continues its course in its own bony channel, the facial canal, and exits from the brain.
The most common form of facial paralysis is Bell's palsy. This condition typically affects one side of the face, often beginning in adulthood. The cause is unknown, but viruses, such as the herpes simplex virus, have been implicated. Symptoms include weakness or paralysis of the muscles around the eye, mouth, and ear, causing difficulty with facial expression, taste sensation, and hearing.

### Clinical Manifestations
- Onset is typically gradual or abrupt, with unilateral weakness or paralysis.
- facial diplegia occurs in Guillain-Barré syndrome (Chap. 365) and in facial myokymia.
- Other cranial nerve palsies may be present, especially of the trigeminal nerve.

### Pathophysiology
- The condition is characterized by axonal degeneration and Wallerian degeneration.
- There is a delay in recovery, and some cases may have complete or incomplete resolution.

### Differential Diagnosis
- Other causes of facial palsy include Bell's palsy, Ramsay Hunt syndrome, and Ramsay Hunt syndrome.
- Other causes include trauma, tumors, and infections.

### Treatment
- Symptomatic treatment includes rest, anti-inflammatory drugs, and topical corticosteroids.
- Acyclovir may be used for suspected viral causes.
- Surgical intervention may be considered for severe cases.

---

**Laboratory Evaluation**
- Electromyography and nerve conduction studies can help confirm the diagnosis.
- MRI of the skull may be used to rule out tumors or aneurysms.
- Blood tests for diabetes mellitus and Lyme disease may be ordered.

---

**Hemifacial Spasm**
- A rare condition characterized by involuntary twitching of the face.
- Causes include vascular compression, acoustic neuromas, or inflammatory processes.
- Treatment options include local injections of botulinum toxin, surgical procedures, and medications such as carbamazepine or baclofen.

---

**Facial Hemiatrophy**
- A congenital disorder characterized by asymmetry of the face.
- It is often associated with other congenital anomalies and is believed to result from a developmental abnormality of the facial nerve.
years and is slowly progressive. In its advanced form, the affected side of the face is gaunt, and the skin is thin, wrinkled, and rather brown. The facial hair may turn white and fall out, and the sebaceous glands become atrophic. The muscles and bones are not involved as a rule. Sometimes the atrophy becomes bilateral. The condition is a form of lipodystrophy. Treatment is cosmetic, consisting of transplantation of skin and subcutaneous fat.

**OTHER CRANIAL NERVE DISORDERS**

**GLOSSOPHARYNGEAL NEURALGIA** This form of neuralgia involves the ninth (glossopharyngeal) and sometimes portions of the tenth (vagus) cranial nerves. It resembles trigeminal neuralgia in many respects but is much less common. The pain is intense and paroxysmal; it originates on one side of the throat, approximately in the tonsillar fossa. In some cases the pain is localized in the ear or may radiate from the throat to the ear because of involvement of the tympanic branch of the glossopharyngeal nerve. Spasms of pain may be initiated by swallowing or coughing. There is no demonstrable motor or sensory deficit; the glossopharyngeal nerve supplies taste sensation to the posterior third of the tongue and is slowly progressive. In its advanced form, the affected side, as well as of the "curtain movement" of the lateral wall of the pharynx, whereby the faucial pillars move medially as the palate rises in saying "ah." The voice is hoarse and slightly nasal, and the vocal cord lies immobile midway between abduction and adduction. Loss of sensation at the external auditory meatus and the posterior pinna may also be present.

The pharyngeal branches of both vagal nerves may be affected in diphtheria; the voice has a nasal quality, and regurgitation of liquids through the nose occurs during the act of swallowing.

The vagus nerve may be involved at the meningeal level by neoplastic and infectious processes and within the medulla by tumors, vascular lesions (e.g., the lateral medullary syndrome), and motor neuron disease. This nerve may be involved by infection with herpes zoster virus. Polymyositis and dermatomyositis, which cause hoarseness and dysphagia by direct involvement of laryngeal and pharyngeal muscles, may be confused with diseases of the vagus nerves. Also, dysphagia is a symptom in some patients with myotonic dystrophy. —See Chap. 33 for discussion of nonneurologic forms of dysphagia.

The recurrent laryngeal nerves, especially the left, are most often damaged as a result of intrathoracic disease. Aneurysm of the aortic arch, an enlarged left atrium, and tumors of the mediatinum and bronchi are much more frequent causes of an isolated vocal cord palsy than are intracranial disorders. However, a substantial number of cases of recurrent laryngeal palsy remain idiopathic.

When confronted with a case of laryngeal palsy, the physician must attempt to determine the site of the lesion. If it is intramedullary, there are usually other signs, such as ipsilateral cerebellar dysfunction, loss of pain and temperature sensation over the ipsilateral face and contralateral arm and leg, and an ipsilateral Horner syndrome. If the lesion is extramedullary, the glossopharyngeal and spinal accessory nerves are frequently involved (jugular foramen syndrome). If it is extracranial in the posterior laterocondylar or retroparotid space, there may be a combination of ninth, tenth, eleventh, and twelfth cranial nerve palsies and a Horner syndrome (Table 355-2). If there is no sensory loss over the palate and pharynx and no palatal weakness or dysphagia, the lesion is below the origin of the pharyngeal branches, which leave the vagus nerve high in the cervical region; the usual site of disease is then the mediatinum.

### NECK WEAKNESS
Isolated involvement of the accessory (eleventh cranial) nerve supplies the ipsilateral muscles of the tongue. The nucleus of the nerve or its fibers of exit may be involved by intramedullary lesions such as tumor, poliomyelitis, or most often motor neuron disease. Lesions of the basilar meninges and the occipital bones (platybasia, invagination of occipital condyles, Paget’s disease) may compress the nerve in its extramedullary course or in the hypoglossal canal. Isolated lesions of unknown cause can occur. Atrophy and fasciculation of the tongue develop weeks to months after interruption of the nerve.

### MULTIPLE CRANIAL NERVE PALSYSES
Several cranial nerves may be affected by the same disease process. In this situation, the main clinical problem is to determine whether the lesion lies within the brainstem or outside it. Lesions that lie on the surface of the brainstem are characterized by involvement of adjacent cranial nerves (often occurring in succession) and late and rather slight involvement of the long sensory and motor pathways and segmental structures lying within the brainstem. The opposite is true of primary lesions within the brainstem. The extramedullary lesion is more likely
to cause bone erosion or enlargement of the foramen of exit of cranial nerves. The intramedullary lesion involving cranial nerves often produces a crossed sensory or motor paralysis (cranial nerve signs on one side of the body and tract signs on the opposite side).

Involvement of multiple cranial nerves outside the brainstem is frequently the result of diabetes or trauma, localized infections such as herpes zoster, infectious and noninfectious (especially carcinomatous) causes of meningitis (Chap. 361), granulomatous diseases such as Wegener’s granulomatosis, Behçet’s disease, enlarging saccular aneurysms, or tumors. Among the tumors, nasopharyngeal cancers, lymphomas, neurofibromas, meningiomas, chordomas, cholesteatomas, carcinomas, and sarcomas have all been observed to involve a succession of lower cranial nerves. Owing to their anatomic relationships, the multiple cranial nerve palsies form a number of distinctive syndromes, listed in Table 355-2. Sarcoidosis is the cause of some cases of multiple cranial neuropathy, and chronic glandular tuberculosis is the cause of a few others. Platytasia, basilar invasion of the skull, and the adult Chiari malformation are additional causes. A purely motor disorder without atrophy always raises the question of myasthenia gravis (Chap. 366). As noted above, Guillain-Barré syndrome commonly affects the facial nerves bilaterally. In the Fisher variant of the Guillain-Barré syndrome, oculomotor paresis occurs with ataxia and areflexia in the limbs (Chap. 365). Wernicke encephalopathy can cause a severe ophthalmoplegia combined with other brainstem signs.

The cavernous sinus syndrome (Fig. 355-3) is a distinctive and frequently life-threatening disorder. It often presents as orbital or facial pain; orbital swelling and chemosis due to occlusion of the ophthalmic veins; fever; oculomotor neuropathy affecting the third, fourth, and sixth cranial nerves; and trigeminal neuropathy affecting the ophthalmic (V1) and occasionally the maxillary (V2) divisions of the trigeminal nerve. Cavernous sinus thrombosis, often secondary to infection from orbital cellulitis (frequently Staphylococcus aureus), a cutaneous source on the face, or sinusitis (especially with mucormycosis in diabetic patients), is the most frequent cause; other etiologies include aneurysm of the carotid artery, a carotid-cavernous fistula (orbital bruit may be present), meningioma, nasopharyngeal carcinoma, other tumors, or an idiopathic granulomatous disorder (Tolosa-Hunt syndrome). The two cavernous sinuses directly communicate via intercavernous channels, thus involvement on one side may extend to become bilateral. Early diagnosis is essential, especially when due to infection, and treatment depends upon the underlying etiology. In infectious cases, prompt administration of broad-spectrum antibiotics, drainage of any abscess cavities, and identification of the offending organism is essential. Anticoagulant therapy may benefit cases of primary thrombosis. Repair or occlusion of the carotid artery may be required for treatment of fistulas or aneurysms. The Tolosa-Hunt syndrome generally responds to glucocorticoids.

An idiopathic form of multiple cranial nerve involvement on one or both sides of the face is occasionally seen. The syndrome consists of a subacute onset of boring facial pain, followed by paralysis of motor cranial nerves. The clinical features overlap those of the Tolosa-Hunt syndrome and appear to be due to idiopathic inflammation of the dura mater, which may be visualized by MRI. The syndrome is frequently responsive to glucocorticoids.

ACKNOWLEDGMENT
The authors acknowledge the contributions of Dr. Joseph B. Martin to this chapter in previous editions.

FURTHER READING
Carpenter MB. Core Text of Neuroanatomy, 2d ed. Baltimore, Williams & Wilkins, 1978
The spinal cord has 31 segments, each defined by an exiting ventral motor root and entering dorsal sensory root. During embryologic development, growth of the cord lags behind that of the vertebral column, and in the adult the spinal cord (conus segments) ends at approximately the first lumbar vertebral body. The lower spinal nerves take an increasingly downward course to exit via intervertebral foramina. The first seven pairs of cervical spinal nerves exit above the same-numbered vertebral bodies, whereas all the subsequent nerves exit below the same-numbered vertebral bodies; this situation is due to the presence of eight cervical spinal cord segments but only seven cervical vertebrae. The relationship between spinal cord segments and the corresponding vertebral bodies is shown in Table 356-2. These relationships assume particular importance for localization of lesions that cause spinal cord compression; a T10 spinal cord level, for example, indicates involvement of the cord adjacent to the seventh or eighth thoracic vertebral body. In addition, at every level the main ascending and descending tracts are somatotopically organized with a laminated distribution that reflects the origin or destination of nerve fibers.

**Level of the Lesion** (Fig. 356-1) The presence of a horizontally defined level below which sensory, motor, and/or autonomic function is impaired is a hallmark of spinal cord disease. A sensory level is sought by asking the patient to identify a pinprick or cold stimulus (i.e., a dry tuning fork after immersion in cold water) applied to the low back and sequentially moved upward to the neck on each side. The presence of a sensory level indicates damage to the spinothalamic tract, but the lesion is located one to two segments above the perceived level of a unilateral spinal cord lesion and at the level of the lesion when bilateral. That is the result of the ascent of second-order sensory fibers, which originate in the dorsal horn, proceed to cross anterior to the central canal, and join the opposite spinothalamic tract. Lesions that transect the descending corticospinal and other motor tracts cause paraplegia or quadriplegia, with increased muscle tone, exaggerated deep tendon reflexes, and extensor plantar signs (the upper motor neuron syndrome). Such lesions also typically produce autonomic disturbances consisting of disturbed sweating and bladder, bowel, and sexual dysfunction.

The uppermost level of a spinal cord lesion can also be localized by attention to the *segmental signs* corresponding to disturbed motor or sensory innervation by an individual cord segment. A band of altered sensation (hyperalgesia or hyperpathia) at the upper end of the sensory disturbance, fasciculations or atrophy in muscles innervated by one or several segments, or a diminished or absent deep tendon reflex may be noted. These signs also occur with focal root or peripheral nerve disorders; thus, segmental signs are most useful when they occur with signs of long tract damage. With severe and acute transverse lesions, the limbs initially may be flaccid rather than spastic. This state of “spinal shock” lasts for several days, rarely for weeks, and should not be mistaken for extensive damage to many segments of the cord or for a polyneuropathy.

The main features of transverse damage at each level of the spinal cord are summarized below.

**CERVICAL CORD** Extensive lesions near the junction of the cervical cord and medulla are usually fatal owing to involvement of adjacent medullary vasomotor and respiratory centers. Upper cervical cord lesions produce quadriplegia and weakness of the diaphragm. Breathing is possible only by use of accessory muscles of respiration. Lesions at C4-C5 produce quadriplegia; at C5-C6, there is loss of power and reflexes in the biceps; at C7 weakness is found in finger and wrist extensors and triceps; and at C8, finger and wrist flexion are impaired. A Horner’s syndrome (miosis, ptosis, and facial hypohidrosis) may accompany a cervical cord lesion at any level.

**THORACIC CORD** Lesions here are localized by the sensory level on the trunk and midline back pain if it accompanies the syndrome. The sensory dermatomes of the body are shown in Fig. 22-2; useful markers are the nipples (T4) and umbilicus (T10). Leg weakness and disturbances of bladder and bowel function accompany the paralysis. Lesions at T9-T10 paralyze the lower, but not the upper, abdominal muscles, resulting in upward movement of the umbilicus when the abdominal wall contracts (Beevor’s sign).

**LUMBAR CORD** The lumbar and sacral cord segments are small and are situated behind the T12 to L1 vertebrae. Lesions at L2-L4 paralyze flexion andadduction of the thigh, weaken leg extension at the knee, and abolish the patellar reflex. Lesions at L5-S1 paralyze movements of the foot and ankle, flexion at the knee, and extension of the thigh, and abolish the ankle jerk (S1).

**SACRAL CORD/CONUS MEDULLARIS** The conus medullaris is the tapered caudal termination of the spinal cord, comprising the lower sacral and single coccygeal segments. The conus syndrome is distinctive, consisting of bilateral saddle anesthesia (S3-S5), prominent bladder and bowel dysfunction (urinary retention and incontinence with lax anal tone), and impotence. The bulbocavernosus (S2-S4) and anal (S4-S5) reflexes are absent (Chap. 346). Muscle strength is largely preserved. Lesions of the conus must be distinguished from those

---

**TABLE 356-1** Some Treatable Spinal Cord Disorders

| Compressive | Epidural, intradural, or intramedullary neoplasm | Epidural abscess | Epidural hemorrhage | Cervical spondylosis | Herniated disc | Posttraumatic compression by fractured or displaced vertebra or hemorrhage | Vascular | Arteriovenous malformation | Antiphospholipid syndrome and other hypercoagulable states | Inflammatory | Multiple sclerosis including neuromyelitis optica | Transverse myelitis | Sarcoidosis | Infectious | Viral: VZV, HSV-1 and -2, CMV, HIV, HTLV-I, others | Bacterial and mycobacterial: *Borrelia, Listeria, syphilis, others* | Parasitic: *schistosomiasis, toxoplasmosis* | Developmental | Syringomyelia | Meningomyelocele | Tethered cord syndrome | Metabolic | Vitamin B₁₂ deficiency (subacute combined degeneration) | Adrenomyeloneuropathy |

Note: VZV, varicella-zoster virus; HSV, herpes simplex virus; CMV, cytomegalovirus; HTLV, human T cell lymphotropic virus.

---

**TABLE 356-2** Spinal Cord Levels Relative to the Vertebral Bodies

<table>
<thead>
<tr>
<th>Spinal Cord Level</th>
<th>Corresponding Vertebral Body</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper cervical</td>
<td>Same as cord level</td>
</tr>
<tr>
<td>Lower cervical</td>
<td>1 level higher</td>
</tr>
<tr>
<td>Upper thoracic</td>
<td>2 levels higher</td>
</tr>
<tr>
<td>Lower thoracic</td>
<td>2 to 3 levels higher</td>
</tr>
<tr>
<td>Lumbar</td>
<td>T10-T12</td>
</tr>
<tr>
<td>Sacral</td>
<td>T12-L1</td>
</tr>
<tr>
<td>Coccygeal</td>
<td>L1</td>
</tr>
</tbody>
</table>

**356 Diseases of the Spinal Cord** 2439
of the cauda equina, the cluster of nerve roots derived from the lower cord. Cauda equina lesions are characterized by low back or radicular pain, asymmetric leg weakness and sensory loss, variable areflexia in the lower extremities, and relative sparing of bowel and bladder function. Mass lesions in the lower spinal canal often produce a mixed clinical picture in which elements of both cauda equina and conus medullaris syndromes coexist; the typical cause is an ependymoma in that region. Cauda equina syndromes are discussed in Chap. 15.

Special Patterns of Spinal Cord Disease The location of the major ascending and descending pathways of the spinal cord are shown in Fig. 356-1. Most fiber tracts— including the posterior columns and the spino cerebellar and pyramidal tracts— are situated on the side of the body that is innervated. Afferent fibers mediating pain and temperature sensation ascend the spinothalamic tract contralateral to the side they supply. The anatomic relationships of these various fiber tracts produce characteristic clinical syndromes that provide clues to the underlying disease process.

BROWN-SEQUARD HEMICORD SYNDROME This consists of ipsilateral weakness (corticospinal tract) and loss of joint position and vibratory sense (posterior column), with contralateral loss of pain and temperature sense (spinthalamic tract) or one or two levels below the lesion. Segmental signs, such as radicular pain, muscle atrophy, or loss of a deep tendon reflex, are unilateral. This classical syndrome is rare, and partial forms are more commonly encountered.

CENTRAL CORD SYNDROME The central cord syndrome results from damage to the gray matter nerve cells and crossing spinothalamic tracts near the central canal. In the cervical cord, the central cord syndrome produces arm weakness out of proportion to leg weakness and a “disassociated” sensory loss signifying a loss of pain and temperature sense in a cape distribution over the shoulders, lower neck, and upper trunk in contrast to intact light touch, joint position, and vibration sense in these regions. Trauma, syringomyelia, tumors, and anterior spinal artery ischemia are main causes.

ANTERIOR SPINAL ARTERY SYNDROME Infarction of the cord is generally the result of occlusion or diminished flow in this artery. The result is extensive bilateral tissue destruction that spares the posterior columns. All spinal cord functions—motor, sensory, and autonomic—are lost below the level of the lesion, with the striking exception of retained vibration and position sensation.

LESIONS OF THE FORAMEN MAGNUM Partial lesions in this area interrupt decussating pyramidal tract fibers destined for the legs, which cross below those of the arms, resulting in a “crural paresis” of the lower limbs. Compressive lesions near the foramen magnum may produce weakness of the ipsilateral shoulder and arm followed by weakness of the ipsilateral leg, then the contralateral leg, and finally the contralateral arm (an “around the clock” pattern that may begin in any of the four limbs). There is typically suboccipital pain spreading to the neck and shoulders.

INTRAMEDULLARY AND EXTRAMEDULLARY SYNDROMES It is useful to differentiate intramedullary processes, arising within the substance of the cord, from extramedullary ones that compress the spinal cord or its vascular supply. The differentiating features are only relative and serve as rough guides to clinical decision making. With extramedullary lesions, radicular pain is often prominent, and there are early sacral sensory loss (lateral spinothalamic tract) and spastic weakness in the legs (corticospinal tract); this is due to the superficial location of the leg fibers in the corticospinal tract. Intramedullary lesions tend to produce poorly localized burning pain rather than radicular pain and spare sensation in the perineal and sacral areas (“sacral sparing”) reflecting the laminated configuration of the spinothalamic tract with these fibers outermost; corticospinal tract signs appear later. Regarding extramedullary lesions, a further distinction is made between extradural and intradural masses, as the former are generally malignant and the latter benign (neurofibroma being the common cause); for this reason, a long duration of symptoms favors an intradural origin.

ACUTE AND SUBACUTE SPINAL CORD DISEASES

The initial symptom is often focal neck or back pain, followed by various combinations of paresthesias, sensory loss, motor weakness, and sphincter disturbance evolving over hours to several days. There may be mild sensory symptoms only or a devastating functional transection of the cord. Partial forms may selectively involve the posterior columns, anterior spinothalamic tracts, or one hemicord. Paresthesias or numbness may begin in the feet and ascend either symmetrically or asymmetrically, earlier in one leg than in the other; these symptoms may initially raise a question of Guillain-Barré syndrome, but involvement of the trunk with a sharply demarcated spinal cord level indicates the myelopathic nature of the process. In severe cases, areflexia indicating spinal shock may be present, but hyperreflexia soon supervenes; persistent areflexic paralysis indicates necrosis over multiple segments of the spinal cord.

APPROACH TO THE PATIENT

Distinguishing Compressive from Noncompressive Myelopathy The first priority is to identify a treatable mass lesion. The common causes in this category are tumor, epidural abscess or hematoma, herniated disc, or other vertebreal pathology. Epidural compression due to malignancy or abscess often causes warning signs of neck or back pain, bladder disturbances, and sensory symptoms that precede the development of paralysis. Spinal subluxation, hemorrhage, and noncompressive etiologies such as infection are more likely to produce myelopathy without antecedent symptoms. Magnetic res-
onance imaging (MRI) with contrast of the clinically suspected level of pathology is the initial diagnostic procedure; in some cases it is appropriate to image the entire spine (cervical through sacral regions) to search for additional, clinically silent, lesions. Once compressive lesions have been excluded, noncompressive causes of acute myelopathy that are intrinsic to the cord are considered: primarily vascular, inflammatory, and infectious etiologies.

COMPRESSIVE MYELOPATHIES ■ Neoplastic Spinal Cord Compression In adults, most neoplasms are epidural in origin, resulting from metastases to the adjacent spinal bones. The propensity of solid tumors to metastasize to the vertebral column probably reflects the high percentage of bone marrow located in the axial skeleton. Almost any malignant tumor can metastasize to the spinal column, with breast, lung, prostate, kidney, lymphoma, and plasma cell dyscrasias being particularly frequent. The thoracic cord is most commonly involved; exceptions are metastases from prostate and ovarian cancer, which occur disproportionately in the sacral and lumbar vertebrae, perhaps resulting from spread through Batson’s plexus, a network of veins along the anterior epidural space. Retroperitoneal neoplasms (especially lymphomas or sarcomas) enter the spinal canal through the intervertebral foramina; they produce radicular pain and other signs of root involvement prior to cord compression.

Pain is the initial symptom; it may be either aching and localized or sharp and radiating in quality. The pain typically worsens with movement, coughing, or sneezing and characteristically awakens patients at night. A recent onset of persistent back pain, particularly if in the thoracic spine (which is uncommonly involved by spondylosis), should prompt consideration of vertebral metastasis. Rarely, pain is mild or absent. Pain typically precedes signs of cord compression by weeks or even months. However, once cord compression occurs, it usually advances rapidly. Plain radiographs of the spine and radionuclide bone scans have only a limited role in diagnosis because they do not identify 15 to 20% of metastatic vertebral lesions and fail to detect paravertebral masses that reach the epidural space through the intervertebral foramina. MRI provides excellent anatomic resolution of the site and extent of spinal tumors (Fig. 356-2); MRI has largely replaced computed tomography (CT) and myelography in the diagnosis of epidural masses. MRI can often distinguish between malignant lesions and other masses—epidural abscess, tuberculosis, or epidural hemorrhage, among others—that present in a similar fashion. Vertebral metastases are usually hypointense relative to a normal bone marrow signal on T1-weighted MRI scans; after the administration of gadolinium, contrast enhancement may “normalize” the appearance of the tumor by increasing its intensity to that of normal bone marrow. Infections of the spinal column (osteomyelitis and related disorders) are distinctive in that, unlike tumor, they may cross the disk space.

It is important to convey to the radiologist an estimate of the urgency of the imaging procedure requested. If signs of spinal cord involvement are present, imaging should be obtained promptly. If there are radicular symptoms but no evidence of myelopathy, it is usually safe, if necessary, to defer imaging for 24 to 48 h. With back or neck pain only, imaging studies may be obtained within a few days. Up to 40% of patients who present with symptomatic disease at one level are found to have asymptomatic epidural disease elsewhere; thus, the length of the spine should be imaged when epidural malignancy is in question.

Management includes glucocorticoids to reduce cord edema, local radiotherapy (initiated as early as possible) to the symptomatic lesion, and specific therapy for the underlying tumor type. Glucocorticoids (dexamethasone, 40 mg daily) can be administered before the imaging study if the clinical suspicion is strong and continued at a lower dose (20 mg daily in divided doses) until radiotherapy (a total of 3000 cGy administered in 15 daily fractions) is completed. Radiotherapy appears to be as effective as surgery, even for classically radioresistant metastases. Biopsy of the epidural mass is unnecessary in patients with known preexisting cancer, but the procedure may be indicated if a history of underlying cancer is lacking. Surgery, either decompression or vertebral body resection, should be considered when signs of cord compression worsen despite radiotherapy, when the maximum tolerated dose of radiotherapy has been delivered previously to the site, or when a vertebral compression fracture contributes to cord compression. A good response to radiotherapy can be expected in individuals who are ambulatory at presentation; new weakness is prevented, and some recovery of motor function occurs in approximately half of treated patients. Fixed motor deficits—paraplegia or quadriplegia—once established for >12 h, do not usually improve, and beyond 48 h the prognosis for substantial motor recovery is poor.

In contrast to tumors of the epidural space, most intradural mass lesions are slow-growing and benign. Meningiomas and neurofibromas account for most of these lesions, with occasional cases representing chordoma, lipoma, dermoid, or sarcoma (Chap. 358). Meningiomas (Fig. 356-3) are often located posterior to the thoracic cord or near the foramen magnum, although they can arise from the meninges anywhere along the spinal canal. Neurofibromas are benign tumors of the nerve sheath that typically arise near the posterior root; when multiple, neurofibromatosis is the likely etiology. Symptoms usually begin with radicular sensory symptoms followed by an asymmetric, progressive spinal cord syndrome. Therapy is by surgical resection.

Primary intramedullary tumors of the spinal cord are uncommon. They typically present as central cord or hemispheric syndromes, often in the cervical region; there may be poorly localized burning pain in the extremities and sparing of sacral sensation. In adults, most of these lesions are ependymomas, hemangioblastomas, or low-grade astrocytomas (Fig. 356-4). Complete resection of an intramedullary ependymoma is often possible with microsurgical techniques. Debunking of an intramedullary astrocytoma can also be helpful, as these are often slowly growing lesions; the value of adjunctive radiotherapy is uncertain. Secondary (metastatic) intramedullary tumors are seen on most oncology services (Chap. 358).

**Spinal Epidural Abscess** Spinal epidural abscess presents as a clinical triad of pain, fever, and rapidly progressive weakness. Prompt recognition of this distinctive and treatable process will in most cases prevent permanent sequelae. Aching pain is almost always present, either over the spine or in a radicular pattern. The duration of pain prior to presentation is generally ≤2 weeks but may on occasion be several weeks or even months. However, once cord compression occurs, it usually advances rapidly. Plain radiographs of the spine and radionuclide bone scans have only a limited role in diagnosis because they do not identify 15 to 20% of metastatic vertebral lesions and fail to detect paravertebral masses that reach the epidural space through the intervertebral foramina. MRI provides excellent anatomic resolution of the site and extent of spinal tumors (Fig. 356-2); MRI has largely replaced computed tomography (CT) and myelography in the diagnosis of epidural masses. MRI can often distinguish between malignant lesions and other masses—epidural abscess, tuberculosis, or epidural hemorrhage, among others—that present in a similar fashion. Vertebral metastases are usually hypointense relative to a normal bone marrow signal on T1-weighted MRI scans; after the administration of gadolinium, contrast enhancement may “normalize” the appearance of the tumor by increasing its intensity to that of normal bone marrow. Infections of the spinal column (osteomyelitis and related disorders) are distinctive in that, unlike tumor, they may cross the disk space.

It is important to convey to the radiologist an estimate of the urgency of the imaging procedure requested. If signs of spinal cord involvement are present, imaging should be obtained promptly. If there are radicular symptoms but no evidence of myelopathy, it is usually safe, if necessary, to defer imaging for 24 to 48 h. With back or neck pain only, imaging studies may be obtained within a few days. Up to 40% of patients who present with symptomatic disease at one level are found to have asymptomatic epidural disease elsewhere; thus, the length of the spine should be imaged when epidural malignancy is in question.

Management includes glucocorticoids to reduce cord edema, local radiotherapy (initiated as early as possible) to the symptomatic lesion, and specific therapy for the underlying tumor type. Glucocorticoids (dexamethasone, 40 mg daily) can be administered before the imaging study if the clinical suspicion is strong and continued at a lower dose (20 mg daily in divided doses) until radiotherapy (a total of 3000 cGy administered in 15 daily fractions) is completed. Radiotherapy appears to be as effective as surgery, even for classically radioresistant metastases. Biopsy of the epidural mass is unnecessary in patients with known preexisting cancer, but the procedure may be indicated if a history of underlying cancer is lacking. Surgery, either decompression or vertebral body resection, should be considered when signs of cord compression worsen despite radiotherapy, when the maximum tolerated dose of radiotherapy has been delivered previously to the site, or when a vertebral compression fracture contributes to cord compression. A good response to radiotherapy can be expected in individuals who are ambulatory at presentation; new weakness is prevented, and some recovery of motor function occurs in approximately half of treated patients. Fixed motor deficits—paraplegia or quadriplegia—once established for >12 h, do not usually improve, and beyond 48 h the prognosis for substantial motor recovery is poor.

In contrast to tumors of the epidural space, most intradural mass lesions are slow-growing and benign. Meningiomas and neurofibromas account for most of these lesions, with occasional cases representing chordoma, lipoma, dermoid, or sarcoma (Chap. 358). Meningiomas (Fig. 356-3) are often located posterior to the thoracic cord or near the foramen magnum, although they can arise from the meninges anywhere along the spinal canal. Neurofibromas are benign tumors of the nerve sheath that typically arise near the posterior root; when multiple, neurofibromatosis is the likely etiology. Symptoms usually begin with radicular sensory symptoms followed by an asymmetric, progressive spinal cord syndrome. Therapy is by surgical resection.

Primary intramedullary tumors of the spinal cord are uncommon. They typically present as central cord or hemispheric syndromes, often in the cervical region; there may be poorly localized burning pain in the extremities and sparing of sacral sensation. In adults, most of these lesions are ependymomas, hemangioblastomas, or low-grade astrocytomas (Fig. 356-4). Complete resection of an intramedullary ependymoma is often possible with microsurgical techniques. Debunking of an intramedullary astrocytoma can also be helpful, as these are often slowly growing lesions; the value of adjunctive radiotherapy is uncertain. Secondary (metastatic) intramedullary tumors are seen on most oncology services (Chap. 358).

Spinal Epidural Abscess Spinal epidural abscess presents as a clinical triad of pain, fever, and rapidly progressive weakness. Prompt recognition of this distinctive and treatable process will in most cases prevent permanent sequelae. Aching pain is almost always present, either over the spine or in a radicular pattern. The duration of pain prior to presentation is generally ≤2 weeks but may on occasion be several weeks or even months.
months or longer. Fever is usual, accompanied by an elevated white blood cell count and sedimentation rate. As the abscess expands, further spinal cord damage results from venous congestion and thrombosis in the epidural space. Once weakness and other signs of myelopathy appear, progression may be rapid. A more chronic granulomatous form of abscess is also known.

Risk factors include an impaired immune status (diabetes mellitus, renal failure, alcoholism, malignancy), intravenous drug abuse, and infections of the skin or other tissues. Two-thirds of epidural infections result from hematogenous spread from the skin (furunculosis), soft tissue (pharyngeal or dental abscesses), or deep viscera (bacterial endocarditis). One-third result from direct extension of a local infection to the subdural space; examples of local predisposing conditions are carditis). One-third result from direct extension of a local infection to the subdural space; examples of local predisposing conditions are vertebral osteomyelitis; decubitus ulcers; or iatrogenic complications (e.g., hematoma from an adjacent vertebral source remains an important cause in the underdeveloped world. MRI scans (Fig. 356-5) localize the abscess and exclude other causes of myelopathy. Lumbar puncture is not required but may be indicated if encephalopathy or other clinical signs raise the question of associated meningitis, a feature that is found in <25% of cases. In such situations, the level of the puncture should be planned to minimize the risk of inducing meningitis by passage of the needle through infected tissue, or herniation from decompression below an area of obstruction to the flow of cerebrospinal fluid (CSF). A high cervical tap is often the safest approach. CSF abnormalities in subdural abscess consist of pleocytosis with a preponderance of polymorphonuclear cells, an elevated protein level, and a reduced glucose level, but the responsible organism is not cultured unless there is an associated meningitis. Blood cultures are positive in <25% of cases.

**TREATMENT**

Treatment is by decompressive laminectomy with debridement combined with long-term antibiotic treatment. Surgical evacuation prevents development of paralysis and may improve or reverse paralysis in evolution, but it is unlikely to improve deficits of more than several days duration. Antibiotics should be started empirically before surgery and then modified on the basis of culture results; medication is continued for at least 4 weeks. If surgery is contraindicated or if there is a fixed paraplegia or quadriplegia that is unlikely to improve following surgery, long-term administration of systemic and oral antibiotics can be used; in such cases, the choice of antibiotics may be guided by results of blood cultures. However, paralysis may develop or progress during antibiotic therapy; thus, initial surgical management remains the treatment of choice unless the abscess is very limited in size and causes no neurologic signs.

**Epidural Hematoma** Hemorrhage into the epidural (or subdural) space causes an acute onset of focal or radicular pain followed by variable signs of a spinal cord or conus medullaris disorder. Therapeutic anticoagulation, trauma, tumor, or blood dyscrasias are predisposing conditions. Rare cases complicate lumbar puncture or epidural anesthesia, sometimes in association with use of low-molecular-weight heparin. MRI and CT confirm the clinical suspicion and can delineate the extent of the bleeding. Extrinsic spinal cord compression from any cause is an urgent condition, and appropriate treatment consists of prompt reversal of any underlying clotting disorder and surgical decompression. Surgery may be followed by substantial recovery, especially in patients with some preservation of motor function preoperatively. Because of...
the risk of hemorrhage, lumbar puncture should be avoided whenever possible in patients with thrombocytopenia or other coagulopathies.

**Hematomyelia** Hemorrhage into the substance of the spinal cord is a rare result of trauma, intraparenchymal vascular malformation (see below), vasculitis due to polyarteritis nodosa or systemic lupus erythematosus (SLE), bleeding disorders, or a spinal cord neoplasm. Hematomyelia presents as an acute painful transverse myelopathy. With large lesions, extension into the subarachnoid space may occur, resulting in subarachnoid hemorrhage (Chap. 349). Diagnosis is made by MRI. Therapy is supportive, and surgical intervention is generally not useful. An exception is hematomyelia due to an underlying vascular malformation, in which selective spinal angiography may be indicated, followed by surgery to evacuate the clot and remove the underlying vascular lesion.

**NONCOMPRESSIVE MYELOPATHIES** Acute transverse myelopathies (ATM) are rapidly progressive spinal cord syndromes with limb weakness, incontinence, and bilateral sensory loss accompanied by a sensory level and not due to cord compression. The time from onset to maximum symptoms is often hours or a few days, but some cases progress more slowly, over several weeks. Five general causes of ATM need to be considered: spinal cord infarction; systemic disorders including SLE and sarcoidosis; infectious (especially viral) causes; demyelinating diseases such as multiple sclerosis or neuromyelitis optica; and idiopathic transverse myelitis. The evaluation begins with a lumbar puncture and a search for systemic disease that may underlie the myelopathy (Table 356-3).

**Spinal Cord Infarction** The cord is supplied by three arteries that course vertically over its surface: a single anterior spinal artery and paired posterior spinal arteries. At each segment, paired penetrating vessels branch from the anterior spinal artery to supply the anterior two-thirds of the spinal cord; the posterior spinal arteries, which often become less distinct below the midthoracic level, supply the posterior columns. Rostrally, the spinal arteries arise from the vertebral arteries. During embryogenesis, arterial feeders arise at each segmental level, but most involute before birth; generally, between three and eight major feeders remain, arising from the vertebral, subclavian, intercostal (from the aorta), iliac, and sacral arteries. In addition to the vertebral arteries, anterior spinal artery feeders arise at C6, at an upper thoracic level, and, most consistently, at T11-L2 (artery of Adamkiewicz).

Spinal cord ischemia can occur at any level; however, the presence of the artery of Adamkiewicz creates a watershed of marginal blood flow in the upper-thoracic segments. With systemic hypotension, cord infarction occurs at the level of greatest ischemic risk, often T3-T4, and also at boundary zones between the anterior and posterior spinal artery territories. The latter may result in an acute—or more commonly progressive—syndrome of weakness and spasticity with little sensory change, superficially resembling amyotrophic lateral sclerosis (ALS).

Acute infarction in the territory of the anterior spinal artery produces paraplegia or quadriplegia, dissociated sensory loss affecting pain and temperature sense but sparing vibration and position sense, and loss of sphincter control. Onset may be sudden and dramatic but more typically is progressive over minutes or a few hours, quite unlike stroke in the cerebral hemispheres. Sharp midline or radiating back pain localized to the area of ischemia is frequent. Partial infarction of one anterior hemiscord (hemiplegia or monoplegia and crossed pain and temperature loss) may also occur. Areflexia due to spinal shock is often present initially; with time, hyperreflexia and spasticity appear. Infarction in the territory of the posterior spinal arteries, resulting in loss of posterior column function, also occurs and may be underrecognized as a cause of obscure loss of position and vibration sense.

Spinal cord infarction is associated with aortic atherosclerosis, dissecting aortic aneurysm (chest or back pain with diminished pulses in legs), or hypotension from any cause. Cardiogenic emboli; vasculitis related to collagen vascular disease, particularly SLE and the anti-phospholipid antibody syndrome (see below); and surgical interruption of aortic aneurysms are other causative conditions. Occasional cases develop by an unknown mechanism that leads to embolism of nucleus pulposus material into spinal vessels. In a substantial number of cases, no cause can be found, and thromboembolism in arterial feeders is suspected. The MRI may not demonstrate limited infarctions of the cord but is more often abnormal at the affected level.

Therapy is directed at treatment of any predisposing condition. In cord infarction due to presumed thromboembolism, acute anticoagulation is probably not indicated, with the exception of the unusual transient ischemic attack or incomplete infarction with a stuttering or progressive course. The antiphospholipid antibody syndrome is treated with anticoagulation, as described in Chap. 300.

### Immune-Mediated Diseases

ATM occurs in ~1% of patients with SLE (Chap. 300) and may appear as the presenting manifestation of SLE. In some patients the ATM may be preceded or followed by optic neuritis (neuromyelitis optica; Chap. 359). Antiphospholipid antibodies are present in nearly two-thirds of patients with SLE-associated ATM. CSF is usually normal or shows a lymphocytic pleocytosis; oligoclonal bands are generally negative. Possible responses to glucocorticoids and/or cyclophosphamide have been reported. Other immune-mediated disorders associated with ATM include Sjögren’s syndrome (Chap. 304), mixed connective tissue disease (Chap. 303), Behçet’s syndrome (Chap. 307), and vasculitis with perinuclear antineutrophil cytoplasmic (p-ANCA) antibodies (Chap. 306).

Another important consideration is sarcoid myelopathy (Chap. 309), in which a large edematous swelling of the spinal cord may mimic tumor; there is almost always enhancement of the lesion and the adjacent surface of the cord. The CSF profile consists of variable lymphocytic pleocytosis, and oligoclonal bands are present in one-third of cases. The diagnosis of sarcoid affecting the spinal cord is particularly difficult when systemic manifestations of sarcoid are meager or absent (50% of cases) or when other neurologic manifestations of the disease—such as cranial neuropathy, hypothalamic involvement, or meningal enhancement visualized by MRI—are lacking. Whenever neuromyelitis is considered, a careful slit-lamp examination of the eye to search for uveitis, chest x-ray and CT to assess pulmonary involvement and mediastinal lymphadenopathy, serum angiotensin-converting enzyme (positive in only one-quarter of cases), serum calcium, and a gallium scan may be indicated. Initial treatment is with

---

**TABLE 356-3 Evaluation of Acute Transverse Myelopathy**

| 1. | MRI of spinal cord with and without contrast (exclude compressive causes). |
| 2. | CSF studies: Cell count, protein, glucose, IgG index/synthesis rate, oligoclonal bands, VDRL; Gram’s stain, acid-fast bacilli, and India ink stains; PCR for VZV, HSV-2, HSV-1, EBV, CMV, HHV-6, enteroviruses, HIV; antibody for HTLV-I, B. burgdorferi, M. pneumoniae, and Chlamydia pneumoniae; viral, bacterial, mycobacterial, and fungal cultures. |
| 3. | Blood studies for infection: HIV; RPR; IgG and IgM enterovirus antibody; IgM mumps, measles, rubella, group B arbovirus, Brucella melitensis, Chlamydia psittaci, Bartonella henselae, schistosomal antibody; cultures for B. melitensis. Also consider nasal/pharyngeal/anal cultures for enteroviruses; stool O&P for Schistosoma ova. |
| 4. | Immune-mediated disorders: ESR; ANA; ENA; dsDNA; rheumatoid factor; anti-SSA; anti-SSB, complement levels, antiphospholipid and anticardiolipin antibodies; p-ANCA; antinuclear and antithyroglobulin antibodies; if Sjögren syndrome suspected, Schirmer test, salivary gland scintigraphy, and salivary/lacrimal gland biopsy. |
| 5. | Sarcoïdosis: Serum angiotensin-converting enzyme; serum Ca; 24 hour urine Ca; chest x-ray; chest CT; total body gallium scan; lymph node biopsy. |
| 6. | Demyelinating disease: Brain MRI scan, evoked potentials. |
| 7. | Vascular causes: CT myelogram; spinal angiogram. |

**Note:** VDRL, Venereal Disease Research Laboratory; PCR, polymerase chain reaction; VZV, varicella-zoster virus; HHV, human herpes virus; RPR, rapid plasma reagin (test); O&P, ova and parasites; ESR, erythrocyte sedimentation rate; ANA, antinuclear antibodies; ENA, epithelial neutrophil-activity (protein).
oral glucocorticoids; immunosuppressant drugs are used for resistant cases.

Recurrent episodes of myelitis are usually due to an immune-mediated disease such as SLE or sarcoid, a demyelinating disease, or infection with herpes simplex virus (HSV) type 2 (below).

**Infectious and Parainfectious Myelitis**  Many viruses have been associated with an acute myelitis that is due to direct infection of the spinal cord. Herpes zoster is the most common viral cause of acute myelitis; HSV types 1 and 2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), and rubies viruses are other well-described etiologies. HSV-2 can produce a distinctive syndrome of recurrent sacral myelitis in association with outbreaks of genital herpes which mimics multiple sclerosis (MS). Poliomyelitis is the prototypic virus that produces acute infection of the spinal cord. In some cases it may be appropriate to begin specific therapy based upon the suspicion that a particular viral agent might be responsible for myelitis, pending laboratory confirmation. Herpes zoster, HSV, and EBV myelitis are treated with acyclovir (10 mg/kg tid for 10 to 14 days); CMV with ganciclovir (5 mg/kg IV bid) plus foscarin (60 mg/kg IV tid) or with cidofovir (5 mg/kg per week for 2 weeks).

Bacterial and mycobacterial etiologies are less common than viral causes. Almost any pathogenic species may be responsible, including *Listeria monocytogenes*, *Burrelia burgdorferi* (Lyme disease), and *Treponema pallidum* (syphilis). Mycoplasma pneumoniae may be underrecognized as a cause of ATM.

Schistosomiasis (Chap. 203) is an important cause of parasitic myelitis in endemic areas. The myelitis is intensely inflammatory and granulomatous in nature, caused by a local response to tissue-digesting enzymes from the ova of the parasite. Toxoplasmosis (Chap. 198) can occasionally cause a focal myelopathy, and this diagnosis should be considered, particularly in patients with AIDS.

Other cases of myelitis, termed postinfectious myelitis, or postvaccinal myelitis, follow an infection or vaccination. Many infectious agents have been implicated, including influenza, measles, varicella, rubella, and mumps. As in the related disorder, acute disseminated encephalomyelitis (Chap. 359), postinfectious transverse myelitis often begins as the patient appears to be recovering from the infection, but an infectious agent cannot be isolated from the nervous system or spinal fluid. These features suggest that the myelitis represents an autoimmune disorder triggered by infection and is not due to direct infection of the spinal cord.

**Demyelinating Diseases**  Multiple sclerosis (Chap. 359) may present as ATM, particularly in individuals of Asian or African ancestry. In Caucasians, MS rarely causes ATM (e.g., transverse myelitis with acute bilateral signs) but is a common cause of acute partial myelopathy. Unlike infectious and parainfectious ATM, MS-associated ATM is usually not associated with fever, rash, or other manifestations of an antecedent infection. Neuromyelitis optica (Devic’s disease; Chap. 359) is a demyelinating syndrome related to MS that presents as ATM associated with optic neuritis; the optic neuritis is often bilateral and may precede or follow the myelitis by weeks or months. A neuro-myelitis optica syndrome is also associated with SLE (see above) and other immune-mediated diseases, and with the antiphospholipid syndrome.

MRI findings in MS-associated ATM consist of mild swelling and edema of the cord and diffuse or multifocal areas of abnormal signal on T2-weighted sequences, often extending over several cord segments. Contrast enhancement, indicating disruption in the blood-brain barrier associated with inflammation, is present in acute cases. A brain MRI should be obtained to assess the likelihood that the myelitis represents an initial attack of MS. A normal scan indicates that the risk of evolution to MS is low—less than 10% over 5 years; by contrast, the finding of multiple periventricular T2-bright lesions indicates a risk of >50%. The CSF may be normal, but more often there is a mild pleocytosis, occasionally up to several hundred mononuclear cells per microliter. CSF protein levels are normal or at most mildly elevated; oligoclonal banding is a variable finding but, when present, implicates MS.

There are no adequate trials of therapy for MS-associated ATM. Intravenous methylprednisolone (500 mg qd for 3 days) followed by oral prednisone (1 mg/kg per day for several weeks, then gradual taper) is the initial treatment of choice; a course of plasma exchange may be tried if glucocorticoids are ineffective.

**Idiopathic Transverse Myelitis**  In approximately one-quarter of cases of ATM, no underlying cause can be identified. Some will later manifest additional symptoms of a systemic immune-mediated disease such as SLE or a demyelinating disorder. In cases associated with inflammation (e.g., contrast enhancement of the lesion by spinal MRI or CSF pleocytosis) but not evidence of infection, glucocorticoids and plasma exchange are the first and second options, as for demyelinating causes (above).

**CHRONIC MYELOPATHIES**

**SPONDYLITIC MYELOPATHY**  Spondylitic myelopathy is one of the most common causes of gait difficulty in the elderly. Neck and shoulder pain with stiffness are early symptoms; impingement of bone and soft tissue overgrowth on nerve roots results in radicular arm pain, most often in a C5 or C6 distribution. Compression of the cervical cord produces a slowly progressive spastic paraparesis, at times asymmetric, and often accompanied by paresthesias in the feet and hands. Vibratory sense is diminished in the legs, and occasionally there is a sensory level for vibration on the upper thorax. In some cases coughing or straining produces leg weakness or radiating arm or shoulder pain. Dermatomal sensory loss in the arms, atrophy of intrinsic hand muscles, increased deep tendon reflexes in the legs, and extensor plantar responses are common. Urinary urgency or incontinence occurs in advanced cases. A tendon reflex in the arms is often diminished at some level; the biceps is most often affected (C5-C6). In individual cases, radicular, myelopathic, or combined signs may predominate. The diagnosis should be considered in cases of progressive cervical myelopathy, paresthesias of the feet and hands, or wasting of the hands.

Diagnosis is best made by MRI. Extrinsinc cord compression is appreciated on axial views, and T2-weighted sequences may reveal areas of high signal intensity within the cord adjacent to the site of compression. Definitive therapy consists of surgical relief of the compression. Posterior laminectomy or an anterior approach with resection of the protruded disc material may be required. A cervical collar may be very helpful in milder cases. →Cervical spondylitis and related degenerative diseases of the spine are discussed in Chap. 15.

**VASCULAR MALFORMATIONS**  Although uncommon, vascular malformations of the cord are important lesions because they represent a treatable cause of progressive myelopathy. Arteriovenous malformations (AVMs) are most often located posteriorly, within the dura or along the surface of the cord, at or below the midthoracic level. The typical presentation is a middle-aged man with a progressive myelopathy. The myelopathy may worsen slowly or rapidly or may have periods of apparent remission with superimposed worsenings, resembling MS. Acute deterioration due to hemorrhage into the spinal cord or subarachnoid space may also occur. At presentation, most patients have sensory, motor, and bladder disturbances. The motor disorder may predominate and produce a mixture of upper and lower motor neuron signs, simulating amyotrophic lateral sclerosis (ALS). Pain, either dysesthesias or radicular pain, is also common. Other symptoms suggestive of AVM include intermittent claudication (symptoms that appear with exercise and are relieved by rest), or symptoms that change with posture, menses, or fever. A rare AVM syndrome presents as a progressive thoracic myelopathy with paraparesis developing over weeks or several months, associated with abnormally thick, hyalinized vessels (Foix-Alajouanine syndrome).

Spinal AVMs are infrequent but should be sought at rest and after exercise. High-resolution MRI with contrast administration detects most AVMs (Fig. 356-6). A small number of AVMs not detected by
The classic presentation is of a central cord syndrome with associated sensory loss and areflexic weakness in the upper limbs. The sensory deficit consists of loss of pain and temperature sensation with sparing of touch and vibration which is "suspended" over the nape of the neck, shoulders, and upper arms in a cape distribution or is in the hands. Most cases begin asymmetrically with unilateral sensory loss in the hands and unappreciated burns. Muscle wasting in the lower neck, shoulders, arms, and hands with asymmetric or absent reflexes reflects extension of the cavity to the anterior horns. As the lesion enlarges, spasticity and weakness of the legs, bladder and bowel dysfunction, and, in some cases, a Horner’s syndrome appear. Thoracic kyphoscoliosis is a frequent additional finding. Some patients develop facial numbness and sensory loss from damage to the descending tract of the trigeminal nerve (C2 level or above). With Chiari malformations, cough headache, and neck, arm, or facial pain are common. Extension of the syrinx into the medulla, syringobulbia, may present as palatal or vocal cord paralysis, dysarthria, horizontal or vertical nystagmus, episodic dizziness, and/or tongue weakness.

MRI scans accurately identify developmental and acquired syrinx cavities and their associated spinal cord enlargement (Fig. 356-7). MRI scans of the brain and the entire spinal cord should be obtained to delineate the full longitudinal extent of the syrinx, assess posterior fossa structures, and determine whether hydrocephalus is present. If a Chiari malformation is not found, a contrast-enhanced MRI scan should be obtained to search for abnormal enhancement from an associated spinal cord tumor.

**TREATMENT**

Treatment is generally unsatisfactory. Syringomyelia associated with tonsillar herniation is treated with posterior fossa decompression, generally consisting of suboccipital craniectomy, upper cervical laminectomy, and placement of a dural graft. If obstruction of fourth ventricular outflow is present, flow may be reestablished by enlargement of the opening. If the syrinx cavity is large, some surgeons recommend direct decompression of the fluid cavity, but the added benefit of this procedure is uncertain, and morbidity may occur. With Chiari malformations, shunting of hydrocephalus should generally precede any attempt to correct the syrinx. Surgery may stabilize the neurologic deficit; some patients have improvement postoperatively. Syringomyelia secondary to trauma or infection is treated with a decompression and drainage procedure in which a small shunt is inserted between the syrinx cavity and the subarachnoid space. Syringomyelia due to

**RETROVIRUS-ASSOCIATED MYELOPATHIES** The myelopathy associated with the human T cell lymphotropic virus type I (HTLV-I), formerly called tropical spastic paraparesis, presents as a slowly progressive spastic paraparesis with variable sensory and bladder disturbance. The myelopathy typically implicates a thoracic level. Approximately half of patients have back or leg pain. The signs may be asymmetric, often lacking a well-defined sensory level; the only sign in the arms is hyperreflexia. The onset is generally insidious, and the tempo of progression is variable, but most patients are nonambulatory within 10 years of onset. This presentation may resemble primary progressive MS or a thoracic AVM. Diagnosis is made by demonstration of HTLV-I-specific antibody in serum by enzyme-linked immunosorbent assay (ELISA), confirmed by radioimmunoprecipitation or western blot analysis. There is no effective treatment, but symptomatic therapy for spasticity and bladder symptoms may be helpful. —**HTLV-I infections of the nervous system are discussed in Chap. 173.**

A progressive myelopathy may also occur in AIDS, characterized by vacuolar degeneration of the posterior and lateral tracts resembling subacute combined degeneration (see below).

**SYRINGOMYELIA** Syringomyelia is a developmental, slowly enlarging cavitary expansion of the cervical cord that produce progressive myelopathy. Symptoms begin insidiously in adolescence or early adulthood, progress irregularly, and may undergo spontaneous arrest for several years; most patients acquire a cervical-thoracic scoliosis. More than half of all cases are associated with Chiari type 1 malformations in which the cerebellar tonsils protrude through the foramen magnum and into the cervical spinal canal. The pathophysiology of the syrinx is controversial. Some interference with the normal flow of CSF seems likely. Acquired cavitations of the cord are also termed syrinx cavities; these may follow trauma, myelitis, chronic arachnoiditis due to tuberculosis and other etiologies, or necrotic spinal cord tumors.

---

**FIGURE 356-6** Arteriovenous malformation. Sagittal MR scans of the thoracic spinal cord; T2 fast spin-echo technique (left) and T1 post-contrast image (right). On the T2-weighted image (left), abnormally high signal intensity is noted in the central aspect of the spinal cord (arrowheads). Numerous punctate flow voids indent the dorsal and ventral spinal cord (arrow). These represent the abnormally dilated venous plexus supplied by a dural arteriovenous fistula. After contrast administration (right), multiple, serpentine, enhancing veins (arrows) on the ventral and dorsal aspect of the thoracic spinal cord are visualized, diagnostic of arteriovenous fistula. This patient was a 54-year-old man with a 4-year history of progressive paraparesis.

**FIGURE 356-7** MRI of a syringomyelia associated with a Chiari malformation. Sagittal T1-weighted image through the cervical and upper thoracic spine demonstrates descent of the cerebellar tonsils and vermis below the level of the foramen magnum (black arrows). Within the substance of the cervical and thoracic spinal cord, a CSF collection dilates the central canal (white arrows).
an intramedullary spinal cord tumor is managed by resection of the tumor, if feasible; decompression of the cyst cavity may produce temporary relief, but recurrence is common.

**MULTIPLE SCLEROSIS** Spinal cord involvement is common in MS. It may develop acutely as an exacerbation in a patient with known MS or appear as the presenting manifestation of the disease (see above). Chronic progressive myelopathy is the most frequent cause of disability in both primary progressive and secondary progressive forms of MS. Involvement is typically asymmetric, producing motor, sensory, and bladder/bowel disturbances. Diagnosis is facilitated by identification of earlier attacks that may not be initially recalled by the patient; by MRI, CSF and evoked response testing; and by exclusion of other conditions. The diagnosis may be particularly difficult to establish in patients with primary progressive MS. Therapy with interferon β or glatiramer acetate is indicated for patients with coexisting relapses of MS. [MS is discussed in Chap. 359.]

**SUBACUTE COMBINED DEGENERATION (VITAMIN B12 DEFICIENCY)** This treatable myelopathy presents with parasthesias in the hands and feet, early loss of vibration and position sensation, and a progressive spastic and ataxic weakness. Loss of reflexes due to a superimposed peripheral neuropathy, present in many patients, is an important diagnostic clue. Optic atrophy and irritability and other mental changes may be prominent in advanced cases and on occasion are the presenting symptoms (megaloblastic madness). The myelopathy of subacute combined degeneration tends to be diffuse rather than focal; signs are generally symmetric and reflect predominant involvement of the posterior and lateral tracts, including Romberg’s sign. The diagnosis is confirmed by the finding of macrocytic red cells, a low serum B12 concentration, elevated levels of homocysteine and methylmalonic acid in uncertain cases, and a positive Schilling test (Chap. 61).

**TABES DORSALIS** The classic syndromes of tabes dorsalis and meningovascular syphilis of the spinal cord are rare but must be considered in the differential diagnosis of spinal cord disorders. The most common symptoms of tabes are characteristic fleeting and repetitive lancinating pains, which occur primarily in the legs and less commonly in the back, thorax, abdomen, arms, and face. Ataxia of the legs and gait due to loss of position sense occurs in half of patients. Parasthesias, bladder disturbances, and acute abdominal pain with vomiting (visceral crisis) occur in 15 to 30% of the patients. The cardinal signs of tabes are loss of reflexes in the legs, impaired position and vibratory sense, Romberg’s sign, and bilateral Argyll Robertson pupils, which fail to constrict to light but react with accommodation. In the modern era, diabetic polyradiculopathy simulates tabes.

**FAMILIAL SPASTIC PARAPLEGIA** (Chap. 353) Some cases of progressive myelopathy are genetic in origin. More than 20 different loci have been identified, including autosomal dominant, autosomal recessive, and X-linked forms. Most patients present with progressive spasticity and weakness in the legs; the syndrome is usually but not always symmetric. Sensory symptoms and signs are usually absent or mild. Sphincter disturbances may be present. In some families in which the condition is referred to as “complicated” familial spastic paraplegia, additional neurologic signs, e.g., nystagmus, ataxia, or optic atrophy, occur. Onset may be as early as the first year of life or as late as middle adulthood. The causative mutations responsible for several forms of familial spastic paraplegia are now known (Table 353-3). No therapies are currently available.

**ADRENOMYELONEUROPATHY** This X-linked disorder, a variant of adrenoleukodystrophy, most commonly presents as a progressive spastic paraparesis beginning in early adulthood; some patients also have a mild peripheral neuropathy. Affected males usually have a history of adrenal insufficiency beginning in childhood.

**OTHER CHRONIC MYELOPATHIES** Primary lateral sclerosis (Chap. 353) is a degenerative disorder characterized by progressive spasticity with weakness, often accompanied by dysarthria and dysphonia. Sensory function is spared. The disorder resembles ALS, but there is no evidence of a lower motor neuron disturbance. Toxic causes of spastic myelopathy include (1) lathyrism due to ingestion of chick peas containing the excitotoxin β-N-oxalylaminoalanine (BOAA) and seen primarily in the undeveloped world, and (2) nitrous oxide inhalation producing a myelopathy identical to subacute combined degeneration. SLE (Chap. 300), Sjögren’s syndrome (Chap. 304), and sarcoid (Chap. 309), as mentioned above, have all been associated with progressive myelopathy, which may involve the cord even without evidence of overt systemic disease. Cancer-related causes include chronic paraneoplastic myelopathy (Chap. 87) or radiation injury (Chap. 358); metastases to the cord are probably more common than either of these. Finally, as in ATM, in some patients the etiology of a chronic myelopathy may not be determined initially. A cause can often be identified through periodic reassessment. [Traumatic spinal cord lesions are discussed in Chap. 357.]

**MEDICAL REHABILITATION OF SPINAL CORD DISORDERS** The prospects for recovery from an acute spinal cord lesion fade after ~6 months. There are currently no effective means to promote repair of injured spinal cord tissue; promising experimental approaches include the use of factors that influence reinnervation by axons of the corticospinal tract, nerve graft bridges that promote reinnervation across spinal cord lesions, and the local injection of stem cells. The disability associated with irreversible spinal cord damage is determined primarily by the level of the lesion and by whether the disturbance in function is complete or incomplete (Table 356-4). Even a complete high cervical cord lesion may be compatible with a productive life. Development of a rehabilitation plan framed by realistic expectations, and attention to the neurologic, medical, and psychological complications that commonly arise, are primary goals of treatment.

Many of the usual symptoms associated with medical illnesses, especially somatic and visceral pain, may be lacking because of the destruction ofafferent pain pathways. Unexplained fever, worsening of spasticity, or deterioration in neurologic function should prompt a search for infection, thrombophlebitis, or an intraabdominal pathology; these etiologies are far more likely to be responsible than primary neurologic events such as meningitis, secondary syringomyelia, or chronic arachnoiditis. The loss of normal thermoregulation and in ability to maintain normal body temperature can produce recurrent fever (quadruplegic fever), although most episodes of fever are due to infection of the primary tract, lung, skin, or bone.

Bladder dysfunction generally results from loss of supraspinal innervation of the detrusor muscle of the bladder wall and the sphincter

---

**TABLE 356-4 Expected Neurologic Function Following Complete Cord Lesions**

<table>
<thead>
<tr>
<th>Level</th>
<th>Self-Care</th>
<th>Transfers</th>
<th>Maximum Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td>High quadriplegia (C1-C4)</td>
<td>Dependent on others; requires respiratory support</td>
<td>Dependent on others</td>
<td>Motorized wheelchair</td>
</tr>
<tr>
<td>Low quadriplegia (C5-C8)</td>
<td>Partially independent with adaptive equipment</td>
<td>May be dependent or independent</td>
<td>May use manual wheelchair, drive an automobile with adaptive equipment</td>
</tr>
<tr>
<td>Paraplegia (below T1)</td>
<td>Independent</td>
<td>Independent</td>
<td>Ambulates short distances with aids</td>
</tr>
</tbody>
</table>

CONCUSSION AND OTHER HEAD INJURIES
Allan H. Ropper

Almost 10 million head injuries occur annually in the United States, about 20% of which are serious enough to cause brain damage. Among men under 35 years, accidents, usually motor vehicle collisions, are the chief cause of death, and >70% of these involve head injury. Furthermore, minor head injuries are so common that almost all physicians will be called upon to provide immediate care or to see patients who are suffering from various sequelae.

Medical personnel caring for head injury patients should be aware that (1) spinal injury often accompanies head injury, and care must be taken to prevent compression of the spinal cord due to instability of the spinal column; (2) intoxication is an important accompaniment of that (1) spinal injury often accompanies head injury, and care must be taken to prevent compression of the spinal cord due to instability of the spinal column; (2) intoxication is an important accompaniment of trauma due to asymptomatic colonization is extremely common and is generally not treated. Prophylaxis with antibiotics or antivertigo may be indicated in cases of persistent paralysis, anticoagulation should probably be continued for 3 months.

Prophylaxis against decubitus ulcers should involve frequent changes in position in a chair or bed, the use of special mattresses, and cushioning of areas where pressure sores often develop, such as the sacral prominence and heels. Early treatment of ulcers with careful cleansing, surgical or enzyme debridement of necrotic tissue, and appropriate dressing and drainage may prevent infection of adjacent soft tissue or bone.

Spasticity (Chap. 21) is aided by stretching exercises to maintain mobility of joints. Drug treatment is effective but may result in reduced function, as some patients depend upon spasticity as an aid to stand, transfer, or walk. Baclofen (15 to 240 mg/d in divided doses) is the most effective drug; it acts by facilitating GABA-mediated inhibition of motor reflex arcs. Diazepam acts by a similar mechanism and is useful for leg spasms that interrupt sleep (2 to 4 mg at bedtime). For nonambulatory patients, the direct muscle inhibitor dantrolene (25 to 100 mg qid) may be used, but it is potentially hepatotoxic. In severe cases, intrathecal baclofen administered via an implanted pump, botulinum toxin injections, or dorsal rhizotomy may be required to control spasticity.

A dramatic paroxysmal autonomic hyperreflexia may occur following lesions above the major splanchnic sympathetic outflow at T6. Headache, flushing, and diaphoresis above the level of the lesion, and hypertension with bradycardia or tachycardia, are the major symptoms. The trigger is typically a noxious stimulus—for example, bladder or bowel distention, a urinary tract infection, or a decubitus ulcer—below the level of the cord lesion. Treatment consists of removal of offending stimuli; ganglionic blocking agents (mecamylamine, 2.5 to 5 mg) or other short-acting antihypertensive drugs are useful in some patients.

Attention to these details allows longevity and a productive life for patients with myelopathy.

FURTHER READING
Kalb RG: Getting the spinal cord to think for itself. Arch Neurol 60:805, 2003
on later testing, a bizarre effect, forgetting one’s own name, or a persistent anterograde deficit that is excessive in comparison with the degree of injury. —For further discussion of amnesia, see Chap. 23.

A single, uncomplicated head injury only infrequently produces permanent neurobehavioral changes in patients who are free of pre-existing psychiatric problems and substance abuse. These minor problems in memory and concentration may have an anatomic correlate in small shearing or other microscopic lesions (see below).

**CONTUSION, BRAIN HEMORRHAGE, AND AXONAL SHEARING LESIONS** A surface bruise of the brain, or contusion, consists of varying degrees of petechial hemorrhage, edema, and tissue destruction. Contusions and deeper hemorraghes result from mechanical forces that displace the hemispheres forcefully relative to the skull by deceleration of the brain against the inner skull, either under a point of impact (coup lesion) or, as the brain swings back, in the antipolar area (contrecoup lesion). Trauma sufficient to cause prolonged unconsciousness usually produces some degree of contusion. Blunt impact, as from an automobile dashboard or from falling forward while drunk, typically causes contusions on the orbital surfaces of the frontal lobes and the anterior and basal portions of the temporal lobes. With lateral forces the contusions are situated on the lateral convexity of the hemispheres. In both instances there may be contrecoup contusions on the opposite side of the impact. The clinical signs are determined by the location and size of the contusion; a hemiparesis or gaze preference is fairly typical. Large bilateral contusions produce coma with extensor posturing. Contusions limited to the frontal lobes cause an abulic-tactum state, and those in the temporal lobe may cause an aggressive, combative, or delirious syndrome, described below.

Contusions are visible on CT and MRI scans, appearing early as inhomogeneous hyperdensities on CT and as hyperintensities on MRI; the signal changes reflect small scattered areas of cortical and subcortical blood and localized brain edema (Fig. 357-1); there is also some degree of subarachnoid bleeding, which may be detected by scans or lumbar puncture. Subacutely, contusions acquire a surrounding contrast enhancement that may be mistaken for tumor or abscess. Giall and macrophage reactions may result in scarred, hemosiderin-stained depressions on the surface (plaques jaunes) that are the main source of posttraumatic epilepsy.

Torsion or shearing forces in the brain can cause basal ganglial and other deep hematomas independent of surface damage. Large single hemorrhages after minor trauma may be associated with a bleeding diathesis or cerebrovascular amyloidosis in the elderly. For unexplained reasons, deep cerebral hemorraghes may not develop until several days after severe injury. Sudden neurologic deterioration in a comatose patient or a sudden rise in intracranial pressure (ICP) should therefore prompt investigation with a CT scan.

Another type of deep white matter lesion consists of widespread acute disruption, or shearing, of axons at the time of impact. Most characteristic are small areas of tissue disruption in the corpus callosum and dorsolateral pons. The presence of widespread axonal damage of both hemispheres, a state called diffuse axonal injury, explains persistent coma and the vegetative state, but small ischemic-hemorrhagic lesions in the midbrain and thalamus are as often the cause. Only severe shearing lesions that contain blood are visualized by CT, usually in the corpus callosum and centrum semiovale (Fig. 357-2); however, within days of the injury, MRI scan demonstrates such lesions throughout the white matter with the use of special imaging sequences.

**SKULL FRACTURES** A blow to the skull causes a fracture if the elastic tolerance of the bone is exceeded. Intracranial lesions accompany two-thirds of skull fractures, and the presence of a skull fracture increases manifold the chances of an underlying subdural or epidural hematoma. Consequently, fractures are primarily markers of the site and severity of injury. They provide pathways for entry of bacteria (meningitis) or air (pneumocephalus) to the cerebrospinal fluid (CSF) and for leakage of CSF out through the dura.

Linear fractures, which are most often associated with subdural or epidural hematomas, account for 80% of all skull fractures. They are usually oriented from the point of impact toward the base of the skull. Basilar skull fractures are often extensions of adjacent fractures over the convexity of the skull but may occur independently owing to stresses on the floor of the middle cranial fossa or occiput. They are located parallel to the petrous bone or along the sphenoid bone toward the sella turcica and ethmoidal groove. Although most are uncomplicated, basilar skull fractures can cause CSF leakage, pneumocephalus, and cavernous-carotid fistulas. Hemotympanum (blood behind the tympanic membrane), delayed ecchymosis over the mastoid process (Battle’s sign), or periorbital ecchymosis (“raccoon sign”) all signify fracture of the base of the skull. Because routine x-ray examination may fail to disclose basilar fractures, they should be suspected if these clinical signs are present. CSF may leak through the cribriform plate or the adjacent sinus and manifest as a watery discharge from the nose (CSF rhinorrhea). Persistent rhinorrhea and recurrent meningitis are indications for surgical repair of torn dura underlying the fracture. The precise site of the leak is often difficult to determine, but useful diagnostic tests include the instillation of water-soluble contrast into the CSF followed by CT with the patient in various positions, and injection of radionuclidean compounds or fluorescein into the CSF with an assessment of uptake of these compounds by absorptive nasal pledgets. The site of an intermittent leak is rarely delineated, and most resolve spontaneously. Sellar fractures, even ones associated with serious neuroendocrine dysfunction, are sometimes radiologically occult. Fractures of the dorum sella may cause sixth or seventh nerve palsies or optic nerve damage. An air-fluid level in the sphenoid sinus suggests a fracture of the sellar floor.

Petrous bone fractures, especially those oriented along the long axis of the bone, may be associated with facial palsy, disruption of ear ossicles, and CSF otorrhea. Transverse petrous fractures are less com-
or hours after injury. Up to one-third of patients have a lucid interval immediately by CT or MRI scan and evacuated when appropriate. Acute Subdural Hematoma be life threatening, it is imperative that hemorrhages be identified immediately because epidural hematomas as often occur as the sole manifestation of injury, whereas subdural hematomas and are therefore more treacherous. They occur in up to 10% of severe head injury cases and are less often associated with underlying cortical damage than are subdural hematomas. Most patients are unconscious when first seen. A "lucid interval" of several minutes to hours before coma supervenes is most characteristic of epidural hemorrhage, but it is still uncommon, and epidural hemorrhage by no means is the only cause of this temporal sequence of events.

Cranial Nerve Injuries The cranial nerves likely to be injured with head trauma include the olfactory, optic, oculomotor, and trochlear nerves; the first and second branches of the trigeminal nerve; and the facial and auditory nerves. Anosmia and an apparent loss of taste (actually a loss of perception of aromatic flavors, with elementary tastes retained) occur in ~10% of persons with serious head injuries, particularly after falls on the back of the head. This sequela results from displacement of the brain and shearing of the olfactory nerve filaments and may occur in the absence of a fracture. Recovery is the rule, leaving residual hyposmia, but if bilateral anosmia persists for several months, the prognosis is poor. Partial optic nerve injuries from closed trauma result in blurring of vision, central or paracentral scotomas, or sector defects. Direct orbital injury may cause short-lived blurred vision for close objects and pupillary paralysis because of reversible iridoplegia. Diplopia limited to downward gaze and corrected when the head is tilted away from the affected eye indicates trochlear nerve damage. It occurs as an isolated problem after minor injury and can develop after a delay of several days. Direct facial nerve injury by a basal fracture is present immediately in 3% of severe injuries; it may also be delayed 5 to 7 days. Fractures through the petrous bone, particularly the less common transverse type, are liable to produce this injury. Delayed facial palsy, the mechanism of which is unknown, has a good prognosis. Injury to the eighth cranial nerve from a fracture of the petrous bone causes loss of hearing, vertigo, and nystagmus immediately after injury. Deafness from nerve injury must be distinguished from that due to rupture of the eardrum, blood in the middle ear, or disruption of the ossicles from fracture through the middle ear. A high-tone hearing loss occurs with direct cochlear concussion.

Seizures Convulsions are surprisingly uncommon immediately after a head injury, but a brief period of tonic extensor posturing or a few clonic movements of the limbs just after the moment of impact may occur. However, the superficial cortical scars that evolve from contusions are highly epileptogenic and may later manifest as seizures, even after many years (Chap. 348). The severity of injury determines the risk of future seizures. It has been estimated that 17% of individuals with brain contusion, subdural hematoma, or prolonged loss of consciousness will develop a seizure disorder and that this risk extends for an indefinite period of time, whereas the risk is only 2% after mild injury. The majority of convulsions in the latter group occur within 5 years of injury.

Subdural and Epidural Hematomas Hemorrhages beneath the dura (subdural) or between the dura and skull (epidural) may be associated with contusions and other injuries, making it difficult to determine their relative contribution to the clinical state. However, subdural and epidural hematomas as often occur as the sole manifestation of injury, and each has characteristic clinical and radiologic features. Because the mass effect and the rise in ICP caused by these hematomas may be life threatening, it is imperative that hemorrhages be identified immediately by CT or MRI scan and evacuated when appropriate. Acute Subdural Hematoma These lesions become symptomatic minutes or hours after injury. Up to one-third of patients have a lucid interval before coma supervenes, but most are drowsy or comatose from the moment of injury. Direct cranial trauma is not required for acute subdural hemorrhage to occur; acceleration forces alone, as from whiplash, are adequate, especially in the elderly and those taking anticoagulant medications. A unilateral headache and slightly enlarged pupil on the same side are frequently but not invariably found. Stupor or coma, a hemiparesis, and unilateral pupillary enlargement are the signs of larger hematomas. In an acutely deteriorating patient with diminished alertness and with pupillary enlargement, burr (drainage) holes or an emergency craniotomy are appropriate. Small subdural hematomas may be asymptomatic and usually do not require evacuation. A subacute syndrome due to subdural hematoma occurs days to weeks after injury with drowsiness, headache, confusion, or mild hemiparesis; it is seen in alcoholics and in the elderly. Subdural hematomas appear as crescentic collections over the convexity of the hemisphere and are located over the frontotemporal region, less often in the inferior middle fossa or over the occipital poles (Fig. 357-3).

Interhemispheric, posterior fossa, or bilateral convexity hematomas are less common and are difficult to diagnose clinically, although drowsiness and the signs expected for each region can be detected (Chap. 23). Larger hematomas are primarily venous in origin, though additional arterial bleeding sites are often found; a few large hematomas, when explored surgically, have an exclusively arterial cause.

Epidural Hematoma (Fig. 357-4) These evolve more rapidly than subdural hematomas and are therefore more treacherous. They occur in up to 10% of severe head injury cases and are less often associated with underlying cortical damage than are subdural hematomas. Most patients are unconscious when first seen. A "lucid interval" of several minutes to hours before coma supervenes is most characteristic of epidural hemorrhage, but it is still uncommon, and epidural hemorrhage by no means is the only cause of this temporal sequence of events.

Chronic Subdural Hematoma A history of trauma may or may not be elicited; 20 to 30% of patients recall no head injury, particularly the elderly and those with bleeding diatheses. The causative injury may be trivial and is often forgotten because it was remote. Headache (common but not invariable), slowed thinking, change in personality, a seizure, or a mild hemiparesis emerges weeks or months afterwards. The headache may fluctuate in severity, sometimes with position changes. Many chronic subdural hematomas are bilateral and produce perplexing clinical syndromes. The initial clinical impression is of a stroke, brain tumor, drug intoxication, depression, or a dementing illness because drowsiness, inattentiveness, and incoherence of thought are more prominent than focal signs such as hemiparesis. Patients with undetected small bilateral subdural hematomas seem to have a low tolerance for surgery, anesthesia, and drugs that depress the nervous system, remaining drowsy or confused for long periods postoperatively. Occasionally a chronic hematoma causes brief episodes of hemiparesis or aphasia that are indistinguishable from transient ischemic attacks.

Skull x-rays are usually normal except for a shift of the calcified pineal body to one side or an occasional unexpected fracture. In long-standing cases the irregular calcification of membranes that surround the collection may be appreciated. CT performed soon after injury (without contrast infusion) shows a low-density mass over the convexity of the hemisphere (Fig. 357-5), but between 2 to 6 weeks after the initial bleeding the hemorrhage appears isodense compared to adjacent brain. Bilateral chronic hematomas may fail to be detected because of the absence of lateral tissue shifts; this circumstance is suggested by a "hypernornon" CT scan with fullness of the cortical sulci and small ventricles in an older patient. CT with contrast demonstrates the vascular fibrous capsule surrounding the hemorrhage. MRI reliably identifies either a subacute or chronic hematoma. Chronic subdural hematomas can expand gradually and clinically resemble tumors of the brain.

Clinical observation and serial imaging are reasonable in patients with few symptoms and small chronic subdural collections. Treatment with glucocorticoids alone is sufficient in some larger hematomas, but surgical evacuation is more often successful. The fibrous membranes...
that grow from the dura and encapsulate the region require surgical resection to prevent recurrent fluid accumulation. Small hematomas are largely resorbed, leaving only the organizing membranes.

**CLINICAL SYNDROMES AND TREATMENT OF HEAD INJURY**

**MINOR INJURY** The patient who is fully alert and attentive after head injury but who has one or more symptoms of headache, faintness, nausea, a single episode of emesis, difficulty with concentration, or slight blurring of vision has a good prognosis with little risk of subsequent deterioration. Such patients have usually sustained a concussion and are expected to have a brief amnestic period. Children and young adults are particularly prone to drowsiness, vomiting, and irritability, which is sometimes delayed for several hours after apparently minor injuries. Occasionally, vasovagal syncope follows several minutes to an hour after the injury and may cause undue concern. Constant generalized or frontal headache is common in the days following trauma; it may be migrainous (throbbing and hemicranial) in nature. After several hours of observation, patients with this category of injury may be accompanied home and observed by a family member or friend. Most patients with this syndrome do not have a skull fracture on x-ray or hemorrhage on CT. The decision to perform these tests therefore depends largely on clinical signs suggesting that the impact was severe (e.g., prolonged concussion, periorbita l or mastoid hematoma, repeated vomiting, apparent fracture), on the seriousness of other bodily injuries, and on the degree of surveillance that can be anticipated at home. Persistent severe headache and repeated vomiting in the context of normal alertness and no focal neurologic signs are usually benign, but radiologic studies should be obtained and observation in the hospital is justified.

**INJURY OF INTERMEDIATE SEVERITY** Patients who are not comatose but who have persistent confusion, behavioral changes, subnormal alertness, extreme dizziness, or focal neurologic signs such as hemiparesis should be admitted to the hospital and soon thereafter have a CT scan. Usually a contusion or hematoma is found. The clinical syndromes most common in this group, in addition to postconcussive drowsiness, headache, dizziness, and vomiting, include (1) delirium with a disinclination to be examined or moved, expletive speech, and resistance if disturbed (anterior temporal lobe contusions); (2) a quiet, disinterested, slowed mental state (abulia) with dull facial appearance and irascibility (inferior frontal and frontopolar contusions); (3) a focal deficit such as aphasia or mild hemiparesis (due to subdural hematoma or convexit y contusion, or, less often but frequently missed, carotid artery dissection); (4) confusion with inattentiveness, poor performance on simple mental tasks, and fluctuating or slightly erroneous orientation (associated with several types of injuries, including the first two described above as well as medial frontal contusions and interhemispheric subdural hematoma); (5) repetitive vomiting, nystagmus, drowsiness, and unsteadiness (usually from labyrin thine concussion, but occasionally due to a posterior fossa subdural hematoma or vertebral artery dissection); and (6) diabetes insipidus (damage to the median eminence or pituitary stalk). It should be emphasized that intermediate-grade injuries are often complicated by drug or alcohol intoxication.

Clinical observation is necessary to detect increasing drowsiness, change in respiratory pattern, or pupillary enlargement and to ensure restriction of free water (unless there is diabetes insipidus). Most patients in this category improve over several days. During the first week, the state of alertness, memory, and other cognitive functions often fluctuates, and irascibility or agitation is common. Behavioral changes are worse at night, as with many other encephalopathies, and may be treated with small doses of antipsychotic medications. Subtle abnormalities of attention, intellect, spontaneity, and memory tend to return to normal weeks or months after the injury, sometimes surprisingly abruptly; persistent problems in cognition are discussed below.

**SEVERE INJURY** Patients who are comatose from the onset require immediate neurologic attention and resuscitation. After intubation, with care taken to avoid deforming the cervical spine, the depth of coma, pupillary size and reactivity, limb movements, and Babinski responses are assessed. As soon as vital functions permit and cervical spine x-rays and a CT scan have been obtained, the patient should be transported to a critical care unit where ICP can be monitored, and where the systemic complications that follow severe brain injury can be treated. The finding of an epidural or subdural hematoma or large intracerebral hemorrhage is an indication for prompt surgery and intracranial decompression in otherwise salvageable patients. →Management of raised ICP is discussed in Chap. 258.

**PROGNOSIS** In severe head injury, eye opening, the best motor response of the limbs, and verbal output have been found to be roughly predictive of outcome; these are summarized using the “Glasgow Coma Scale” (Table 357-1). Over 85% of patients with aggregate scores of 3 or 4 die within 24 h. However, a number of patients with slightly higher scores and a poor initial prognosis, including a few without pupillary light responses, survive, suggesting that an initially
aggressive approach is justified in most patients. Patients <20 years, particularly children, may make remarkable recoveries after having grave early neurologic signs. In one large study of severe head injury, 55% of children had a good outcome at 1 year, compared with 21% of adults. Older age, increased ICP, hypoxia and hypotension, and CT scan evidence of compression of the cisterns surrounding the brain-stem and shift of midline structures are all poor prognostic signs. Delayed evacuation of large intracerebral hemorrhages is associated with a poor prognosis. Carrier status for the apolipoprotein E-4 allele is also associated with poor recovery following traumatic brain injury.

**POSTCONCUSSION SYNDROME**

A structural basis has been sought for the posttraumatic nervous instability termed the postconcussion syndrome, which consists of fatigue, dizziness, headache, and difficulty in concentration after mild or moderate injury. Most instances are difficult to distinguish from asthena and depression. Based largely on experimental models, some investigators believe that subtle axonal shearings lesions or yet undefined biochemical alterations account for the cognitive symptoms even when the findings are normal on brain imaging, evoked potentials, and electroencephalogram. In moderate and severe trauma, neuropsychological changes such as difficulty with attention, memory, and other cognitive deficits are undoubtedly present, sometimes severe, but many deficits identified in formal testing are not important for daily functioning. Test scores tend to improve rapidly during the first 6 months after injury, then more slowly for years.

Treatment of the various symptoms of the postconcussive syndrome first requires a symptomatic approach to identify and treat depression and loss of energy, sleeplessness, anxiety, persistent headache, and dizziness. Often, reassurance and treatment directed at anxious depression and sleep problems are all that are required. Care is taken to avoid prolonged use of drugs that produce dependence. Vestibular exercises (Chap. 26) and small doses of vestibular suppressants such as phenergan are helpful when dizziness is the main problem. Patients who after minor or moderate injury report difficulty with memory or with complex cognitive tasks at work may also be reassured that these problems usually improve over 6 to 12 months. It is helpful in this group to obtain focused, serial, and quantified neuropsychological testing in order to adjust the work environment to the patient’s current abilities and to document improvement. Whether cognitive exercises are useful is uncertain, but patients certainly report them to be helpful. Previously energetic individuals are usually found to have the best recoveries. In patients with persistent symptoms, the possibility of malingering exists. Physicians should be aware that symptoms tend to persist when litigation regarding the injury is prolonged.

In the absence of adequate data, a common sense approach has been taken to deciding when an athlete who has suffered a concussion should resume athletic activities. Generally, it is advisable to avoid contact sports for several days at least, and for weeks after a second concussion or if there are protracted neurologic symptoms (Table 357-2). These guidelines are designed to avoid an extremely rare complication of recurrent head injury, termed the *second impact syndrome*, in which devastating cerebral swelling follows a minor head injury superimposed upon a recent concussion. There is some evidence that repeated concussions in football and soccer players are associated with mild but cumulative cognitive deficits.

**FURTHER READING**


---

**TABLE 357-1 Glasgow Coma Scale for Head Injury**

<table>
<thead>
<tr>
<th>Eye opening (E)</th>
<th>Verbal response (V)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous</td>
<td>Oriented</td>
</tr>
<tr>
<td>To loud voice</td>
<td>Inappropriate words</td>
</tr>
<tr>
<td>To pain</td>
<td>Nil</td>
</tr>
<tr>
<td>Nil</td>
<td>Incomprehensible sounds</td>
</tr>
<tr>
<td>Best motor response (M)</td>
<td></td>
</tr>
<tr>
<td>Obeyes</td>
<td>Nil</td>
</tr>
<tr>
<td>Localizes</td>
<td></td>
</tr>
<tr>
<td>Withdraws (flexion)</td>
<td></td>
</tr>
<tr>
<td>Abnormal flexion</td>
<td></td>
</tr>
<tr>
<td>posturing</td>
<td></td>
</tr>
<tr>
<td>Extension posturing</td>
<td>2</td>
</tr>
<tr>
<td>Nil</td>
<td>1</td>
</tr>
</tbody>
</table>

**Note:** Coma score = E + M + V. Patients scoring 3 or 4 have an 85 percent chance of dying or remaining vegetative, while scores above 11 indicate only a 5 to 10 percent likelihood of death or vegetative state and 85 percent chance of moderate disability or good recovery. Intermediate scores correlate with proportional chances of recovery.

**TABLE 357-2 Guidelines for Management of Concussion in Sports**

**SEVERITY OF CONCUSSION**

**Grade 1:** Transient confusion, no loss of consciousness (LOC), all symptoms resolve within 15 min.

**Grade 2:** Transient confusion, no LOC, but concussive symptoms or mental status abnormalities persist longer than 15 min.

**Grade 3:** Any LOC, either brief (seconds) or prolonged (minutes).

**ON-SITE EVALUATION**

1. Mental status testing
   a. Orientation—time, place, person, circumstances of injury
   b. Concentration—digits backward, months of year in reverse order
   c. Memory—names of teams, details of contest, recent events, recall of three words and objects at 0 and 5 min
2. Finger-nose-finger with eyes open and closed
3. Pupillary symmetry and reaction
4. Romberg and tandem gait
5. Provocative testing—40-yard sprint, 5 push ups, 5 sit ups, 5 knee bends (development of dizziness, headaches, or other symptoms is abnormal)

**MANAGEMENT GUIDELINES**

**Grade 1:** Remove from contest. Examine immediately and at 5 min intervals. May return to contest if exam clears within 15 min. A second grade 1 concussion eliminates player for 1 week, with return contingent upon normal neurologic assessment at rest and with exercise.

**Grade 2:** Remove from contest, cannot return for at least 1 week. Examine at frequent intervals on sideline. Formal neurologic exam the next day. If headache or other symptoms persist for 1 week or longer, CT or MRI scan is indicated. After 1 full asymptomatic week, repeat neurologic assessment at rest and with exercise before cleared to resume play. A second grade 2 concussion eliminates player for at least 2 weeks following complete resolution of symptoms.

**Grade 3:** Transport by ambulance to emergency department if still unconscious or worrisome signs are present; cervical spine stabilization may be indicated. Neurologic exam and, when indicated, CT or MRI scan will guide subsequent management. Hospital admission indicated when signs of pathology are present or if mental status remains abnormal. If findings are normal at the time of the initial medical evaluation, the athlete may be sent home, but daily exams as an outpatient are indicated. A brief (LOC for seconds) grade 3 concussion eliminates player for 1 week, and a prolonged (LOC for minutes) grade 3 concussion for 2 weeks, following complete resolution of symptoms. A second grade 3 concussion should eliminate player from sports for at least 1 month following resolution. Any abnormality on CT or MRI scans should result in termination of the season for the athlete, and return to play at any future time should be discouraged.

**Note:** CT, computed tomography; MRI, magnetic resonance imaging.

Malignant primary tumors of the central nervous system (CNS) occur in ~16,500 individuals and account for an estimated 13,000 deaths in the United States annually, a mortality rate of 6 per 100,000. An approximately equal number of benign tumors of the CNS are diagnosed, with a much lower mortality rate. Glial tumors account for 50 to 60% of primary brain tumors, meningiomas for 25%, schwannomas for 10%, and all other CNS tumors for the remainder.

Primary brain tumors (including gliomas and meningiomas) account for an estimated 14% of all malignancies in the United States annually, a mortality rate of 6 per 100,000. An approximately equal number of benign tumors of the CNS are diagnosed, with a much lower mortality rate. Glial tumors account for 50 to 60% of primary brain tumors, meningiomas for 25%, schwannomas for 10%, and all other CNS tumors for the remainder.

Brain and vertebral metastases from systemic cancer are more prevalent than primary CNS tumors. About 15% of patients who die of cancer (80,000 individuals each year in the United States) have symptomatic brain metastases; an additional 5% suffer spinal cord involvement. Brain and spinal metastases therefore pose a major problem in the management of systemic cancer.

**BRAIN TUMORS**

**APPROACH TO THE PATIENT**

**Clinical Features**

Brain tumors usually present with one of three syndromes: (1) subacute progression of a focal neurologic deficit; (2) seizure; or (3) nonfocal neurologic disorder such as headache, dementia, personality change, or gait disorder. The absence of systemic symptoms such as malaise, weight loss, anorexia, or fever suggests a metastatic rather than a primary brain tumor.

Progressive focal neurologic deficits result from compression of neurons and white matter tracts by expanding tumor and surrounding edema. Less commonly, a brain tumor presents with a sudden stroke-like onset of a focal neurologic deficit. Although this presentation may be caused by hemorrhage into the tumor, often no hemorrhage can be demonstrated and the mechanism is obscure. Tumors frequently associated with hemorrhage include high-grade gliomas and metastatic melanoma and choriocarcinoma.

Seizures may result from disruption of cortical circuits. Tumors that invade or compress the cerebral cortex, even small meningiomas, are more likely to be associated with seizures than subcortical neoplasms. Nonfocal neurologic dysfunction usually reflects increased intracranial pressure (ICP), hydrocephalus, or diffuse tumor spread. Tumors in some areas of the brain may produce behavioral disorders; for example, frontal lobe tumors may present with personality change, dementia, or depression.

Headache may result from focal irritation or displacement of pain-sensitive structures (Chap. 14) or from a generalized increase in ICP. A headache that worsens rather than abates with recumbency is suggestive of a mass lesion. Headaches from increased ICP are usually holocephalic and episodic, occurring more than once a day. They typically develop rapidly over several minutes, persist for 20 to 40 min, and subside quickly. They may awaken the patient from a sound sleep, generally 60 to 90 min after retiring, or may be precipitated by coughing, sneezing, or straining. Vomiting may occur with severe headaches. As elevated ICP becomes sustained, the headache becomes continuous but varying in intensity. Elevated ICP may cause papilledema (Chap. 25), although it is often not present in infants or patients >55 years.

The Karnofsky performance scale is useful in assessing and predicting survival. Where possible, patients should be isolated from stimuli that may increase ICP. Anticonvulsants are used prophylactically; phenytoin, carbamazepine, and valproic acid are equally effective (Chap. 348). If the tumor is subcortical in location, prophylactic anticonvulsants are unnecessary.

**Laboratory Examination**

Primary brain tumors typically do not produce serologic abnormalities such as an elevated sedimentation rate or tumor-specific antigens associated with systemic cancers. In contrast, metastases to the nervous system, depending on the type and extent of the primary tumor, may be associated with systemic signs of malignancy (Chap. 66). Lumbar puncture may precipitate brain herniation in patients with mass lesions and should be performed only in patients with suspected CNS infection or meningeal metastasis. Findings in the cerebrospinal fluid (CSF) of patients with primary and metastatic nervous system tumors may include raised opening pressure, elevated protein level, and a mild lymphocytic pleocytosis. The CSF rarely contains malignant cells, with the important exceptions of leptomeningeal metastases, primary CNS lymphoma, and primitive neuroectodermal tumors, including medulloblastoma.

**Neuroradiology**

Computed tomography (CT) and magnetic resonance imaging (MRI) can reveal mass effect and contrast enhancement. Mass effect reflects the volume of neoplastic tissue as well as surrounding edema. Brain tumors typically produce a vasogenic pattern of edema, with accumulation of excess water in white matter. Contrast enhancement reflects a breakdown of the blood-brain barrier within the tumor, permitting leakage of contrast agent. Low-grade gliomas typically do not exhibit contrast enhancement.

Positron emission tomography (PET) and single-photon emission tomography (SPECT) have ancillary roles in the imaging of brain tumors, primarily in distinguishing tumor recurrence from tissue necrosis that can occur after irradiation (see below). Electroencephalography (EEG) has a role in the evaluation of patients with seizures. Functional imaging with PET, MRI, or magnetoencephalography may be of use in surgical or radiosurgical planning to define the anatomic relationship of the tumor to critical brain regions such as the primary motor or language cortex.

**TREATMENT**

**Symptomatic**

Glucocorticoids decrease the volume of edema surrounding brain tumors and improve neurologic function; dexamethasone (12 to 20 mg/d in divided doses orally or intravenously) is used because it has relatively little mineralocorticoid activity.

Tumors that involve the cerebral cortex or hippocampus may produce epilepsy. Anticonvulsants are therefore used therapeutically and prophylactically; phenytoin, carbamazepine, and valproic acid are equally effective (Chap. 348). If the tumor is subcortical in location, prophylactic anticonvulsants are unnecessary.

Gliomas and primary CNS lymphomas are associated with an increased risk for deep vein thrombosis and pulmonary embolism, probably because these tumors secrete procoagulant factors into the systemic circulation. Even though hemorrhage within gliomas is a frequent histopathologic finding, patients appear to be at no increased risk for symptomatic intracranial bleeding following treatment with an anticoagulant. Prophylaxis with low-dose subcutaneous heparin should be considered for patients with brain tumors who have lower limb immobility, which places them at risk for deep venous thrombosis.

**PRIMARY BRAIN TUMORS**

**Etiology**

Exposure to ionizing radiation is the only well-documented environmental risk factor for the development of gliomas. A number of hereditary syndromes are associated with an increased risk of brain tumors (Table 358-1). Genes that contribute to the development of brain tumors, as well as other malignancies, fall into two general classes, tumor-suppressor genes and proto-oncogenes (Chap. 68). Whereas germ-line mutations of tumor-suppressor genes are rare, somatic mutations are almost invariably found in malignant tumors, including brain tumors. Likewise, the activation of proto-oncogenes occurs frequently in brain tumors. Moreover, cytogenetic analysis often reveals characteristic changes. In astrocytic tumors, DNA is com-
The particular constellation of genetic alterations varies among individual gliomas, even those that are histologically indistinguishable. Moreover, gliomas are genetically unstable. Genetic abnormalities tend to accumulate with time, and these changes correspond with an increasingly malignant phenotype. There are at least two genetic routes for the development of malignant glioma (Fig. 358-1). One route involves the progression, generally over years, from a low-grade astrocytoma with deletions of chromosome 17 and inactivation of the p53 gene to a malignant glioma with additional chromosomal alterations. The second route is characterized by the de novo appearance of a malignant glioma with amplification of the EGFR gene and an intact p53 gene. In both pathways, inactivation of the PTEN gene as a result of the loss of chromosome 10 occurs frequently.

ASTROCYTOMAS Tumors with astrocytic cytologic features are the most common primary intracranial neoplasms (Fig. 358-2). The most widely used histologic grading system is the World Health Organization tiered grading system. Grade I is reserved for special histologic variants of astrocytoma that have an excellent prognosis after surgical excision. These include juvenile pilocytic astrocytoma, subependymal giant cell astrocytoma (which occurs in patients with tuberous sclerosis), and pleomorphic xanthoastrocytoma. At the other extreme is grade IV, glioblastoma multiforme, a clinically aggressive tumor. Astrocytoma (grade II) and anaplastic astrocytoma (grade III) are intermediate in their histologic and clinical manifestations. The histologic features associated with higher grade are hypercellularity, nuclear and cytoplasmic atypia, endothelial proliferation, mitotic activity, and necrosis. Endothelial proliferation and necrosis are predictors of aggressive behavior.

A limitation of all grading schemes, especially when applied to a single biopsy, is that astrocytic tumors are histologically variable from region to region, and their histopathology may change with time. It is common for low-grade astrocytomas to progress over time to a higher histopathologic grade and a more aggressive clinical course.

Quantitative measures of mitotic activity also correlate with prognosis. The proliferation index can be determined by immunohistochemical staining with antibodies to the proliferating cell nuclear antigen (PCNA) or with a monoclonal antibody termed Ki-67, which recognizes a histone protein expressed in proliferating but not quiescent cells. These measures provide estimates of DNA synthesis and correlate with malignant clinical behavior of the tumor.

The overall prognosis is poor. In a representative Finnish population, the median survival was 93.5 months for patients with grade I or II astrocytomas, 12.4 months for patients with grade III (anaplastic astrocytoma), and 5.1 months for patients with grade IV (glioblastoma) tumors. In the United States, the median survival of patients with high-grade brain tumors is ~12 months. Clinical features that correlate with poor prognosis include age >65 and a poor functional status, as defined by the Karnofsky performance scale.

### TABLE 358-1 Hereditary Syndromes Associated with Brain Tumors

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene (Locus)</th>
<th>Gene Product (Function)</th>
<th>Nervous System Neoplasms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurofibromatosis type 1 (von Recklinghausen’s Disease)</td>
<td>NFI (17q)</td>
<td>Neurofibromin (GTPase activating protein)</td>
<td>Neuroma, schwannoma, meningioma, optic glioma</td>
</tr>
<tr>
<td>Neurofibromatosis type 2</td>
<td>NFA (22q)</td>
<td>Merlin (cytoskeletal protein)</td>
<td>Schwannoma, glioma, epidermoidoma, meningioma</td>
</tr>
<tr>
<td>Tuberculous sclerosis</td>
<td>TSC1 (9q)</td>
<td>Hamartin (unknown function)</td>
<td>Astrocytoma</td>
</tr>
<tr>
<td>von Hippel-Lindau</td>
<td>TSC2 (16p)</td>
<td>Tuberin (GTPase activating protein)</td>
<td>Hemangioblastoma of retina, cerebellum and spinal cord; pheochromocytoma</td>
</tr>
<tr>
<td>Li-Fraumeni</td>
<td>VHL (3p)</td>
<td>pVHL (modulator of cellular hypoxic response)</td>
<td>Malignant glioma</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>RB1 (13q)</td>
<td>RB (cell cycle regulator)</td>
<td>Retinoblastoma, pineoblastoma, malignant glioma</td>
</tr>
<tr>
<td>Turcot</td>
<td>APC (5q)</td>
<td>APC (cell adhesion)</td>
<td>Medulloblastoma, malignant glioma</td>
</tr>
<tr>
<td>Gorlin (basal cell nevus syndrome)</td>
<td>PTCH1 (9q) (patched)</td>
<td>PTH (developmental regulator)</td>
<td>Medulloblastoma</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia 1 (Werner syndrome)</td>
<td>MEN1 (11q13)</td>
<td>Menin (cofactor for transcription)</td>
<td>Pituitary adenoma, malignant schwannoma</td>
</tr>
</tbody>
</table>

* Genetic testing possible.

**Low-Grade Astrocytoma** Low-grade astrocytomas are more common in children than adults. Pilocytic astrocytoma, named for its characteristic spindle-shaped cells, is the most common childhood brain tumor. It frequently occurs in the cerebellum. Typically, this tumor is cystic and well demarcated from adjacent brain. Complete surgical excision usually produces long-term, disease-free survival.

The optimal management of grade II astrocytomas, termed fibril-
lary astrocytomas, is controversial. For patients who are symptomatic from mass effect or poorly controlled epilepsy, surgical excision can relieve symptoms. For patients who are asymptomatic or minimally symptomatic at presentation, a diagnostic biopsy should be performed and, when surgically feasible, the tumor may be resected. The indications for postoperative radiation therapy are uncertain. In many centers, when only a biopsy or partial resection is possible, postoperative external beam radiation therapy is administered, whereas it is not used if a gross total tumor resection can be achieved. Other centers reserve radiation therapy for tumor recurrence or progression, at which time the tumor may display a more malignant phenotype. No role for chemotherapy in the management of low-grade astrocytoma has been defined.

High-Grade Astrocytoma The large majority of astrocytomas arising in adults are high grade, supratentorial, and do not have a clearly defined margin. Neoplastic cells migrate away from the main tumor mass and infiltrate adjacent brain, often tracking along white matter pathways. Imaging studies do not indicate the full extent of the tumor. These tumors are eventually fatal, although prolonged survival occurs in a few patients. Longer survival correlates with younger age, better performance status, and greater extent of surgical resection. Late in their course, gliomas, especially those located in the posterior fossa, can metastasize along CSF pathways to the spine. Metastases outside the CNS are rare.

High-grade astrocytomas are managed with glucocorticoids, surgery, radiation therapy, and chemotherapy. Dexamethasone is generally administered at the time of diagnosis and continued for the duration of radiation therapy. After completion of radiation therapy, dexamethasone is tapered to the lowest tolerated dose.

Because astrocytomas infiltrate adjacent normal brain, total surgical excision is not possible. Surgery is indicated to obtain tissue for pathologic diagnosis and to control mass effect. Moreover, retrospective studies indicate that the extent of tumor resection correlates with survival, at least in younger patients. Therefore, accessible astrocytomas are resected aggressively in patients <65 years old who are in good general medical condition.

Postoperative radiation therapy prolongs survival and improves quality of life, although the duration of benefit is only a few months. Treated with dexamethasone alone following surgery, the mean survival of patients <65 years with glioblastoma is 7 to 9 months. Survival is prolonged to 11 to 13 months with radiation therapy. Focal brain irradiation is less toxic and is as effective as whole-brain radiation for primary glial tumors. Radiation is generally administered to the tumor mass, as defined by contrast enhancement on a CT or MRI scan, plus a 3- to 4-cm margin. A total dose of 5000 to 7000 cGy is administered in 25 to 35 equal fractions, 5 days per week.

The roles of stereotactic radiosurgery and interstitial brachytherapy in glioma treatment are uncertain. Stereotactic radiosurgery is the administration of a focused high dose of radiation to a precisely defined volume of tissue in a single treatment. Stereotactic radiosurgery can potentially achieve tumor ablation within the treated volume. A major limitation of stereotactic radiosurgery is that it can be used for only relatively small tumors, generally <4 cm in maximum diameter. Interstitial brachytherapy, the implantation of radioactive material into the tumor mass, is generally reserved for tumor recurrence because of its associated toxicity—particularly, necrosis of adjacent brain tissue.

Chemotherapy is marginally effective and is often used as an adjuvant therapy following surgery and radiation therapy. Nitrosoureas, including carmustine (BCNU) and lomustine (CCNU), are the most effective available agents. Since a typical glioma infiltrates normal brain where the blood-brain barrier is relatively intact, lipid-soluble agents such as the nitrosoureas, which cross the blood-brain barrier, may reach more malignant cells than water-soluble agents. Temozolomide is an orally administered alkylating agent, has activity against gliomas, and is generally better tolerated than the nitrosoureas. Experimental approaches include intraarterial infusion of chemotherapy, the implantation of chemotherapy-releasing wafers or injection of chemotherapeutic agents into the tumor resection cavity, and administration of chemotherapy after disruption of the blood-brain barrier.

Gliomatosis cerebri is a rare form of astrocytoma in which there is diffuse infiltration of the brain by malignant astrocytes without a focal enhancing mass. It generally presents as a multifocal CNS syndrome or a more generalized disorder including dementia, personality change, or seizures. Neuroimaging studies are often nonspecific, and biopsy is required to establish the diagnosis. Gliomatosis cerebri is treated with whole-brain radiation therapy and, in selected patients, with radiation to the entire neuroaxis and systemic chemotherapy.

Oligodendrogliomas Oligodendrogliomas, which comprise about 15% of gliomas in adults, have a more benign course and are more responsive to cytotoxic treatment than astrocytomas. Five-year survival is >50%, and 10-year survival is 25 to 34%.

Oligodendrogliomas occur chiefly in supratentorial locations; in adults, ~30% contain areas of calcification (Fig. 358–3). Many gliomas contain mixtures of cells with astrocytic and oligodendrogial features. If this mixed histology is prominent, the tumor is termed a mixed glioma or an oligoastrocytoma. The greater the oligodendrogial component, the more benign the clinical course. As a rule, oligodendrogliomas are less infiltrative than astrocytomas, permitting more complete surgical excision. Histologic features of mitoses, necrosis, and nuclear atypia are associated with a more aggressive clinical course. If these features are prominent, the tumor is termed an anaplastic oligodendroglioma.

Surgery, at minimum a stereotactic biopsy, is necessary to establish a diagnosis. Many oligodendrogliomas are amenable to gross total surgical resection. In addition, oligodendrogliomas may respond dramatically to systemic combination chemotherapy with procarbazine, lomustine, and vincristine (PCV). Oligodendrogliomas with deletions of chromosome 1p always respond to PCV, but only ~25% of oligodendrogliomas lacking 1p deletion respond to chemotherapy. The simultaneous deletion of 1p and 19q predicts a durable response to chemotherapy (>31 months on average) and survival >10 years. Many centers therefore use 1p deletion as an indication for adjuvant or neo-adjuvant chemotherapy and reserve external beam irradiation for tumor recurrence.

Ependymomas In adults ependymomas are typically located in the spinal canal, especially in the lumbosacral region. They typically arise
from the filum terminale of the spinal cord and have a myxopapillary histology, with a papillary arrangement of cells and mucin production. In children, ependymomas occur within the ventricles, most often the fourth ventricle, and have a different histology, typically with ependymal rosettes. Ependymomas with histologic signs of malignancy, including cellular atypia, frequent mitotic figures, or a high labeling index virtually always recur after surgical resection. Imaging with CT or MRI scans reveals ependymomas as uniformly enhancing masses that are relatively well demarcated from adjacent neural tissue. Ependymomas may metastasize via CSF pathways; brain tumor metastases that spread to the spinal cord by this means are termed drop metastases.

Following the gross total excision of an ependymoma, the prognosis is excellent. The 5-year disease-free survival is >80%. However, many ependymomas cannot be totally excised, and postoperative focal external beam radiation or stereotaxic radiosurgery is used. Whether focal radiation is adequate or whether the entire neuraxis needs to be irradiated is not known.

GERMINOMAS These tumors most commonly present during the second decade of life, generally at sites within or adjacent to the third ventricle, including the pineal region. Germinomas are the most frequent variety of germ cell tumor, a tumor type arising in midline structures and including teratoma, yolk sac tumor (endodermal sinus tumor), embryonal carcinoma, and choriocarcinoma. Germinomas of the CNS may be benign but are more often aggressive and invasive. Due to their location, patients frequently present with hypothalamic-pituitary dysfunction including diabetes insipidus, visual field deficits, disturbances of memory or mood, or hydrocephalus (Chap. 318). Neuroimaging demonstrates germinomas to be uniformly enhancing masses that may not have well-defined borders. The treatment of choice is complete surgical resection. For unresectable tumors, a stereotactic biopsy is performed for diagnosis, and focal radiation is the primary therapy. When the extent of disease or very young age precludes radiotherapy as primary treatment, platinum-based chemotherapy may decrease tumor size and facilitate subsequent radiation therapy of residual disease or recurrent tumor. Prognosis depends on the histology and surgical resectability of the tumor. Germinomas are generally radiosensitive and chemosensitive. Five year survival is >85%.

MEDULLOBLASTOMAS AND PRIMITIVE NEUROECTODERMAL TUMORS (PNET) These highly cellular malignant tumors are thought to arise from neural precursor cells. Medulloblastomas of the posterior fossa are the most frequent malignant brain tumor of children. PNET is a term applied to tumors histologically indistinguishable from medulloblastoma but occurring either in adults or supratentorially in children. In adults, >50% present in the posterior fossa. These tumors frequently disseminate along CSF pathways.

If possible, these tumors should be surgically excised, although outcome is not related to the extent of surgery. In adults, surgical excision of a PNET should be followed by chemotherapy and irradiation of the entire neuraxis, with a boost in radiation dose to the primary tumor. If the tumor is not disseminated at presentation, the prognosis is generally favorable. Aggressive treatment can result in prolonged survival, although half of adult patients relapse within 5 years of treatment.

CNS LYMPHOMA Primary CNS Lymphoma These are high-grade B cell malignancies that present within the neuraxis without evidence of systemic lymphoma. They occur most frequently in immunocompromised individuals, specifically organ transplant recipients or patients with AIDS (Chap. 173). In immunocompromised patients, CNS lymphomas are invariably associated with Epstein-Barr virus infection of the tumor cells.

In immunocompetent patients, neuroimaging studies most often reveal a uniformly enhancing mass lesion. In immunocompromised patients, primary CNS lymphoma is likely to be multicentric and exhibit ring enhancement or to arise in the meninges (Fig. 358-4). Stereotactic needle biopsy can be used to establish the diagnosis. Leptomeningeal involvement is present in ~15% of patients at presentation and in 50% at some time during the course of the illness. Moreover, the disease extends to the eyes in up to 15% of patients. Therefore, a slit-lamp examination and, if indicated, anterior chamber paracentesis or vitreous biopsy is necessary to define radiation ports.

The prognosis of primary CNS lymphoma is poor compared to histologically similar lymphoma occurring outside the CNS. Many patients experience a dramatic clinical and radiographic response to glucocorticoids; however, relapse almost invariably occurs within weeks. The mainstay of definitive therapy is chemotherapy including high-dose methotrexate. This is followed in patients <60 years with whole-brain irradiation. Whole-brain irradiation is postponed as long as possible in patients >60 because of the risk of dementia as a manifestation of late-delayed radiation toxicity. Consolidation therapy is with high-dose cytarabine. Intraarterial chemotherapy with or without blood-brain barrier disruption is an alternative. Intrathecal chemotherapy with methotrexate can be added if leptomeningeal disease is present. Despite aggressive therapy, >90% of patients develop recurrent CNS disease. Historically, the survival of immunocompetent patients with CNS lymphoma has been ~18 months but is now longer with the use of systemic chemotherapy. In organ transplant recipients, reversal of the immunosuppressed state can improve outcome. Survival with AIDS-related primary CNS lymphoma is very poor, generally ≤3 months; pretreatment performance status, the degree of immunosuppression, and the extent of CNS dissemination at diagnosis all appear to influence outcome.

Secondary CNS Lymphoma Secondary CNS lymphoma is a manifestation of systemic disease and almost always occurs in adults with progressive B cell lymphoma or B cell leukemia who have tumor involvement of bone, bone marrow, testes, or the cranial sinuses. Leptomeningeal lymphoma is usually detectable with contrast-enhanced CT or gado-

![FIGURE 358-3 Oligodendroglioma. A. Noncontrast CT scan reveals a calcified mass involving the left temporal lobe (arrows) associated with mild mass effect but little edema. B. An MR T2-weighted image demonstrates a heterogeneous mass with hypointense signal (black arrows) surrounded by a zone of higher signal intensity (white arrows), consistent with a calcified temporal lobe mass. The tumor extends into the left medial temporal lobe and compresses the midbrain.](image-url)
linium-enhanced MRI of the brain and spine or by CSF examination. Treatment consists of systemic chemotherapy, intrathecal chemotherapy, and CNS irradiation. It is usually possible to suppress the leptomeningeal disease effectively, although the overall prognosis is determined by the course of the systemic lymphoma.

PITUITARY ADENOMAS  See Chap. 318.

MENINGIOMAS Meningiomas are derived from mesoderm, probably from cells giving rise to the arachnoid granulations. These tumors are usually benign and attached to the dura. They may invade the skull but only infrequently invade the brain. Meningiomas most often occur along the sagittal sinus, over the cerebral convexities, in the cerebellar-pontine angle, and along the dorsum of the spinal cord. They are more frequent in women than men, with a peak incidence in middle age.

Meningiomas may be found incidentally on a CT or MRI scan or may present with a focal seizure, a slowly progressive neurologic deficit, or symptoms of raised ICP. The radiologic image of a dural-based, extraaxial mass with dense, uniform contrast enhancement is essentially diagnostic, although a dural metastasis must also be considered (Fig. 358-5). A meningioma may have a “dural tail,” a streak of dural enhancement flanking the main tumor mass; however, this finding may also be present with other dural tumors.

Total surgical resection of benign meningiomas is curative. If a total resection cannot be achieved, local external beam radiotherapy or stereotaxic radiosurgery reduces the recurrence rate to <10%. For meningiomas that are not surgically accessible, targeted radiosurgery or heavy particle radiation should be considered. Small asymptomatic meningiomas incidentally discovered in older patients can safely be followed radiologically; these tumors grow at an average rate of ~0.24 cm in diameter per year and only rarely become symptomatic.

Rare meningiomas invade the brain or have histologic evidence of malignancy such as nuclear pleomorphism and cellular atypia. A high mitotic index is also predictive of aggressive behavior. Hemangiopericytoma, although not strictly a meningioma, is a meningeval tumor with an especially aggressive behavior. Meningiomas with features of aggressiveness and hemangiopericytomas, even if totally excised by gross inspection, frequently recur and should receive postoperative radiotherapy. Chemotherapy has no proven benefit.

SCHWANNOMAS These tumors are also called neuromas, neurinomas, or neurolemmomas. They arise from Schwann cells of nerve roots, most frequently in the eighth cranial nerve (vestibular schwannoma, formerly termed acoustic schwannoma). The fifth cranial nerve is the second most frequent site; however, schwannomas may arise from any cranial or spinal root except the optic and olfactory nerves, which are myelinated by oligodendroglia rather than Schwann cells. NF type 2 (see below) strongly predisposes to vestibular schwannoma. Schwannomas of spinal nerve roots also occur in patients with NF type 2 as well as patients with NF type 1.

Eighth nerve schwannomas typically arise from the vestibular division of the nerve. They are densely and uniformly enhancing neoplasms on MRI (Fig. 358-6). Vestibular schwannomas enlarge the internal auditory canal, an imaging feature that helps distinguish them from other cerebellopontine angle masses. Because the vestibular system adapts to slow destruction of the eighth nerve, vestibular schwannomas characteristically present as progressive unilateral hearing loss rather than dizziness or other vestibular symptoms. Unexplained unilateral hearing loss merits evaluation with audiometry and either brainstem auditory evoked potentials or an MRI scan (Chap. 26). As
a vestibular schwannoma grows, it can compress the cerebellum, pons, or facial nerve. With rare exceptions schwannomas are histologically and clinically benign.

Whenever possible, schwannomas should be surgically excised. When the tumors are small, it is usually possible to preserve hearing in the involved ear. In the case of large tumors, the patient is usually deaf at presentation; nonetheless, surgery is indicated to prevent further compression of posterior fossa structures. Stereotactic radiosurgery is also effective treatment for schwannoma and has a complication rate equivalent to that of surgery.

OTHER BENIGN BRAIN TUMORS Epidermoid tumors are cystic tumors with proliferative epidermal cells at the periphery and more mature epidermal cells towards the center of the cyst. The mature cells desquamate into the liquid center of the cyst. Epidermoid tumors are thought to arise from embryonic epidermal rests within the cranium. They occur extraaxially near the midline, in the middle cranial fossa, the suprasellar region, or the cerebellopontine angle. These well-demarcated lesions are amenable to complete surgical excision. Postoperative radiation therapy is unnecessary.

Dermoid cysts are thought to arise from embryonic rests of skin tissue trapped within the CNS during closure of the neural tube. The most frequent locations are in the midline supratentorially or at the cerebellopontine angle. Histologically, they are composed of all elements of the dermis, including epidermis, hair follicles, and sweat glands; they frequently calcify. Treatment is surgical excision.

Craniopharyngiomas are thought to arise from remnants of Rathke’s pouch, the mesodermal structure from which the anterior pituitary gland is derived (Chap. 318). Craniopharyngiomas typically present as suprasellar masses. Histologically, craniopharyngiomas resemble epidermoid tumors; they are usually cystic, and in adults 80% are calcified. Because of their location, they may present as growth failure in children, endocrine dysfunction in adults, or visual loss in either age group. Treatment is surgical excision; postoperative external beam radiation or stereotactic radiosurgery is added if total surgical removal cannot be achieved.

Colloid cysts are benign tumors of unknown cellular origin that occur within the third ventricle and can obstruct CSF flow. Rare benign primary brain tumors include neurocytomas, subependymomas, and pleomorphic xanthoastrocytomas. Surgical excision of these neoplasms is the primary treatment and can be curative.

NEUROCUTANEOUS SYNDROMES
This group of genetic disorders, also known as the phakomatoses, produces a variety of developmental abnormalities of skin along with an increased risk of nervous system tumors (Table 358-1). These disorders are inherited as autosomal dominant conditions with variable penetrance.

NEUROFIBROMATOSIS TYPE 1 (VON RECKLINGHAUSEN’S DISEASE) NF1 is characterized by cutaneous neurofibromas,pigmented lesions of the skin called café au lait spots, freckling in non-sun-exposed areas such as the axilla, hamartomas of the iris termed Lisch nodules, and pseu
deoarthrosis of the tibia. Neurofibromas are benign peripheral nerve tumors composed of proliferating Schwann cells and fibroblasts. They present as multiple, palpable, rubbery, cutaneous tumors. They are generally asymptomatic; however, if they grow in an enclosed space, e.g., the intravertebral foramen, they may produce a compressive radiculopathy or neuropathy. Avascular stenosis with hydrocephalus, scoliosis, short stature, hypertension, epilepsy, and mental retardation may also occur.

Patients with NF1 are at increased risk of developing nervous system neoplasms, including plexiform neurofibromas, optic pathway gliomas, ependymomas, meningiomas, astrocytomas, and pheochromocytomas. Neurofibromas may undergo secondary malignant degeneration and become sarcomatous.

Mutation of the NF1 gene on chromosome 17 causes von Recklinghausen’s disease. The NF1 gene is a tumor-suppressor gene; it encodes a protein, neurofibromin, which modulates signal transduction through the ras GTPase pathway.

NEUROFIBROMATOSIS TYPE 2 NF2 is characterized by the development of bilateral vestibular schwannomas in >90% of individuals who inherit the gene. Patients with NF2 also have a predisposition for the development of meningiomas, gliomas, and schwannomas of cranial and spinal nerves. In addition, a characteristic type of cataract, juvenile posterior subcapsular lenticular opacity, occurs in NF2. Multiple café au lait spots and peripheral neurofibromas occur rarely.

In patients with NF2, vestibular schwannomas usually present with progressive unilateral deafness early in the third decade of life. Bilateral vestibular schwannomas are generally detectable by MRI at that time (Fig. 358-6). Surgical management is designed to treat the underlying tumor and preserve hearing as long as possible.

This syndrome is caused by mutation of the NF2 gene on chromosome 22q; NF2 encodes a protein called neurofibromin 2, schwannomin, or merlin, with homology to a family of cytoskeletal proteins that includes moesin, ezrin, and radixin.

TUBEROUS SCLEROSIS (BOURNEVILLE’S DISEASE) Tuberous sclerosis is characterized by cutaneous lesions, seizures, and mental retardation. The cutaneous lesions include adenoma sebaceum (facial angiofibromas), ash leaf–shaped hypopigmented macules (best seen under ultraviolet illumination with a Wood’s lamp), shagreen patches (yellowish thickenings of the skin over the lumbosacral region of the back), and depigmented nevi. On neuroimaging studies, the presence of subependymal nodules, which may be calcified, is characteristic. Patients inheriting the tuberous sclerosis gene are at increased risk of developing ependymomas and childhood astrocytomas, of which >90% are subependymal giant cell astrocytomas. These are benign neoplasms that may develop in the retina or along the border of the lateral ventricles. They may obstruct the foramen of Monro and produce hydrocephalus. Rhabdomyomas of the myocardium and angiomyomas of the kidney, liver, adrenals, and pancreas may also occur.

TREATMENT Treatment is symptomatic. Anticonvulsants for seizures, shunting for hydrocephalus, and behavioral and educational strategies for mental retardation are the mainstays of management. Severely affected individuals generally die before age 30.

Mutations at both 9q(TSC-1) and 16p(TSC-2) are associated with tuberous sclerosis. The mutated genes encode tuberins, proteins that modulate the GTPase activity of other cellular proteins.
Small metastases often enhance uniformly. Larger metastases typically produce ring enhancement surrounding a central mass of non-enhancing necrotic tissue that develops as the metastasis outgrows its blood supply. Metastases are surrounded by variable amounts of edema. Blood products may also be seen, reflecting hemorrhage of abnormal tumor vessels. The radiologic appearance of a brain metastasis is not specific. The differential diagnosis of ring-enhancement lesions includes brain abscess, radiation necrosis, toxoplasmosis, granulomas (tuberculosis, sarcoidosis), demyelinating lesions, primary brain tumors, primary CNS lymphoma, stroke, hemorrhage, and trauma. Contrast-enhanced CT scanning is less sensitive than MRI for the detection of brain metastases. Cytologic examination of the CSF is not indicated, since intraparenchymal brain metastases almost never shed cells into the CSF. Measuring CSF levels of tumor markers such as carcinoembryonic antigen (CEA) is rarely helpful in management.

**VON HIPPEL–LINDAU SYNDROME** This syndrome consists of retinal, cerebellar, and spinal hemangioblastomas, which are slowly growing cystic tumors. Hypernephromas, renal cell carcinoma, pheochromocytoma, and benign cysts of the kidneys, pancreas, epididymis, or liver may also occur. Erythropoietin production by hemangioblastomas may result in polycythemia. The von Hippel–Lindau (VHL) gene on chromosome 3p is a tumor suppressor that encodes a protein with multiple functions, including mediating signal transduction in response to cellular hypoxia.

**TUMORS METASTATIC TO BRAIN**

**MECHANISMS OF BRAIN METASTASES** The large majority of brain metastases disseminate by hematogenous spread. The anatomic distribution of brain metastases generally parallels regional cerebral blood flow, with a predilection for the gray matter–white matter junction and for the border zone between middle cerebral and posterior cerebral artery distributions. The lung is the most common origin of brain metastases; both primary lung cancer (adenocarcinoma and small cell lung cancer) and cancers metastatic to the lung can metastasize to the brain. Breast cancer (especially ductal carcinoma) has a propensity to metastasize to the cerebellum and the posterior pituitary gland. Moreover, breast cancer that metastasizes to bone tends not to metastasize to the brain. Other common origins of brain metastases are gastrointestinal malignancies, and melanoma (Table 358-2). Certain less common tumors have a special propensity to metastasize to brain, including germ cell tumors and thyroid cancer. By contrast, prostate cancer, ovarian cancer, and Hodgkin’s disease rarely metastasize to the brain.

**EVALUATION OF METASTASES FROM KNOWN CANCER** On MRI scans brain metastases typically appear as well-demarcated, approximately spherical lesions that are hypointense or isointense relative to brain on T1-weighted images and bright on T2-weighted images. They invariably enhance with gadolinium, reflecting extravasation of gadolinium through tumor vessels that lack a blood-tumor barrier (Fig. 358-7).

<table>
<thead>
<tr>
<th>Site of Primary Tumor</th>
<th>Brain Metastases, %</th>
<th>Leptomeningeal Metastases, %</th>
<th>Spinal Cord Compression, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>40</td>
<td>24</td>
<td>18</td>
</tr>
<tr>
<td>Breast</td>
<td>19</td>
<td>41</td>
<td>24</td>
</tr>
<tr>
<td>Melanoma</td>
<td>10</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>7</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Genitourinary tract</td>
<td>7</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>Other</td>
<td>17</td>
<td>10</td>
<td>30</td>
</tr>
</tbody>
</table>

**TREATMENT**

Once a systemic cancer metastasizes to the brain it is, with rare exception, incurable. Therapy is therefore palliative, designed to prevent disability and suffering and, if possible, to prolong life. Published outcome studies have focused on survival as the primary end point, leaving questions regarding quality of life unanswered. There is, however, widespread agreement that glucocorticoids, anticonvulsants, and radiation therapy improve the quality of life for many patients. The roles of surgery and chemotherapy are less well established.

**General Measures** Glucocorticoids frequently ameliorate symptoms of brain metastases. Improvement is often dramatic, occurs within 24 h, and is sustained with continued administration, although the toxicity of glucocorticoids is cumulative. Therefore, if possible, a more definitive therapy for metastases should be instituted to permit withdrawal of glucocorticoid therapy. One-third of patients with brain metastases have one or more seizures. Anticonvulsants are used empirically for seizure prophylaxis when supratentorial metastases are present.

**Specific Measures** Radiation therapy is the primary treatment for brain metastases. Since multiple microscopic deposits of tu-
mor cells throughout the brain are likely to be present in addition to metastases visualized by neuroimaging studies, whole-brain irradiation is usually used. Its benefit has been established in controlled studies, but no clear dose response has been shown. Usually, 30 to 37.5 Gy is administered in 10 to 15 fractions; an additional dose (“boost”) of focal irradiation to a single or large metastasis may also be administered. Stereotaxic radiosurgery is of benefit in patients with four or fewer metastases demonstrable by MRI.

**SURGERY**

Up to 40% of patients with brain metastases have only a single tumor mass identified by CT. Accessible single metastases are usually surgically excised as a palliative measure. If the systemic disease is under control, gross resection of a single brain lesion has been demonstrated to improve survival and minimize disability. Survival appears to be improved if surgery is followed by whole-brain irradiation.

**CHEMOTHERAPY**

Brain metastases of certain tumors, including breast cancer, small cell lung cancer, and germ cell tumors, are often responsive to systemic chemotherapy. Although metastases frequently do not respond as well as the primary tumor, dramatic responses to systemic chemotherapy or hormonal therapy may occur in some cases. In patients who are neurologically stable, two to four cycles of systemic chemotherapy may be administered initially to reduce tumor mass and render the residual tumor more amenable to radiation therapy. Even if a complete radiologic remission is achieved from chemotherapy, whole-brain irradiation should then be administered.

**EXPERIMENTAL THERAPIES**

These include gene therapy, immunotherapy, intraarterial chemotherapy, and chemotherapy administered following osmotic disruption of the blood-brain barrier.

**LEPTOMENINGEAL METASTASES**

Leptomeningeal metastases are also called carcinomatous meningitis, meningeal carcinomatosis, and, in the cases of specific tumors, leukemic meningitis or lymphomatous meningitis. Clinical evidence of leptomeningeal metastases is present in 8% of patients with metastatic solid tumors; at necropsy, the prevalence is as high as 19%. Among solid tumors, adenocarcinomas of the breast, lung, and gastrointestinal tract and melanoma are the most common cause of leptomeningeal metastases (Table 358-2). In one-quarter of patients the systemic cancer is under control; thus effective control of leptomeningeal disease can improve the quality and duration of life.

Cancer usually metastasizes to the meninges via the bloodstream. Alternatively, a superficially located parenchymal brain metastasis may shed cells directly into the subarachnoid space. Some tumors, including squamous cell carcinoma of the skin and some non-Hodgkin’s lymphomas, have a propensity to grow along peripheral nerves and may seed the meninges by that route.

**CLINICAL FEATURES**

Leptomeningeal metastases present with signs and symptoms at multiple levels of the nervous system, most often in a setting of known systemic malignancy. Encephalopathy is frequent, and cranial neuropathy or spinal radiculopathy from nodular nerve root compression is characteristic. Hydrocephalus results from obstruction of CSF outflow. Focal neurologic deficits from coexisting intraparenchymal metastases may occur.

**LABORATORY EVALUATION**

Leptomeningeal metastases are diagnosed by cytologic demonstration of malignant cells in the CSF, by MRI demonstration of nodular tumor deposits in the meninges or diffuse meningeal enhancement (Fig. 358-8), or by meningeal biopsy. CSF findings are usually those of an inflammatory meningitis, consisting of lymphocytic pleocytosis, elevated protein levels, and normal or low CSF glucose. A complete MRI examination of the neuraxis may demonstrate hydrocephalus due to obstruction of CSF pathways and identify nodular meningeal metastases.

**TREATMENT**

In selected patients, intrathecal chemotherapy or focal external beam radiotherapy to sites of nodular leptomeningeal disease is employed. Although the prognosis of leptomeningeal metastases is poor, ~20% of patients treated aggressively for leptomeningeal metastases can expect a response of ≥6 months. Intrathecal therapy exposes meningeal tumor implants to high concentrations of chemotherapy with minimal systemic toxicity. Methotrexate can be safely administered intrathecally and is effective against leptomeningeal metastases from a variety of solid tumors and lymphoma; cytarabine and thiotepa are alternative agents. Intrathecal chemotherapy may be administered either by repeated lumbar puncture or through an indwelling Ommaya reservoir, which consists of a catheter in one lateral ventricle attached to a reservoir implanted under the scalp. If there is a question of patency of CSF pathways, a radionuclide flow study through the reservoir may be performed.

Large, nodular deposits of tumor on the meninges or along nerve roots are unlikely to respond to intrathecal chemotherapy, as the barrier to diffusion is too great. Therefore, external beam radiation is employed. Hydrocephalus is treated with a ventriculoperitoneal shunt, although seeding of the peritoneum by tumor is a risk.

**MALIGNANT SPINAL CORD COMPRESSION**

Spinal cord compression from solid tumor metastases usually results from expansion of a vertebral metastasis into the epidural space. Primary tumors that frequently metastasize to bone include lung, breast, and prostate cancer. Back pain is usually the first symptom and is prominent at presentation in 90% of patients. The pain is typically dull, aching, and may be associated with localized tenderness. If a nerve root is compressed, radicular pain is also present. The thoracic cord is most often affected. Weakness, sensory loss, and autonomic dysfunction (urinary urgency and incontinence, fecal incontinence, and sexual impotence in men) are the hallmarks of spinal cord compression. Once signs of spinal cord compression appear, they tend to progress rapidly. It is thus essential to recognize and treat this serious complication of malignancy promptly in order to prevent irreversible neurologic deficits. Diagnosis and management are discussed in Chap. 356.

**METASTASES TO THE PERIPHERAL NERVOUS SYSTEM**

Systemic cancer may compress or invade peripheral nerves. Compression of the brachial plexus may occur by direct extension of Pancoast’s tumors (cancer of the apex of the lung) or by extension of local lymph node metastases of breast or lung cancer or lymphoma. The
lumbosacral plexus may be compressed by the retroperitoneal spread of prostate or ovarian cancer or lymphoma. Skull metastases may compress cranial nerve branches as they pass through the skull, and pituitary metastases may extend into the cavernous sinus. The epineurium generally provides an effective barrier to invasion of the peripheral nerves by solid tumors, but certain tumors characteristically invade and spread along peripheral nerves. Squamous cell carcinoma of the skin may spread along the trigeminal nerve and extend intracranially. Non-Hodgkin’s lymphoma may be neurotrophic and cause polymyalgia or a syndrome resembling mononeuropathy multiplex. Focal external beam irradiation may reduce pain, prevent irreversible loss of peripheral nerve function, and possibly restore function.

In patients with cancer who have brachial or lumbosacral plexopathy, it may be difficult to distinguish tumor invasion from radiation injury. High radiation dose or the presence of myokymia (rippling contractions of muscle) suggests radiation injury, whereas pain suggests tumor. Radiographic imaging studies may be equivocal, and surgical exploration is sometimes required.

**COMPLICATIONS OF THERAPY**

**RADIATION TOXICITY** The nervous system is vulnerable to injury by therapeutic radiation. Histologically, there is demyelination, degeneration of small arterioles, and eventually brain infarction and necrosis.

Acute radiation injury occurs during or immediately after therapy. It is rarely seen with current protocols of external beam radiation but may occur after stereotaxic radiosurgery. Manifestations include headache, sleepiness, and worsening of preexisting neurologic deficits.

Early delayed radiation injury occurs within 4 months of therapy. It is associated with an increased white matter T2 signal on MRI scans. In children, the somnolence syndrome is a common form of early delayed radiation injury in which somnolence and ataxia develop after whole-brain irradiation. Irradiation of the cervical spine may cause Lhermitte’s phenomenon, an electricity-like sensation evoked by neck flexion. Acute and early delayed radiation injury are self-limited and glucocorticoid-responsive disorders that do not appear to increase the risk of late radiation injury.

Late delayed radiation injury produces permanent damage to the nervous system. It occurs >4 months (generally 8 to 24 months) after completion of therapy; onset 15 years after therapy has been described. After whole-brain irradiation, progressive dementia can occur, sometimes accompanied by gait apraxia. White matter signal abnormalities are present on MRI studies (Fig. 358-9). Following focal brain irradiation, radiation necrosis occurs within the radiation field producing a contrast-enhancing (frequently ring-enhancing) mass. MRI or CT scans are often unable to distinguish radiation necrosis from recurrent tumor, but PET or SPECT scans may demonstrate that glucose metabolism is increased in tumor tissue but decreased in radiation necrosis. Magnetic resonance spectroscopy may demonstrate a high lactate concentration with relatively low choline concentration in areas of necrosis. Biopsy is frequently required to establish the correct diagnosis. Peripheral nerves, including the brachial and lumbosacral plexuses, may also develop late delayed radiation injury.

If untreated, radiation necrosis of the CNS may act as an expanding mass lesion, although it may resolve spontaneously or after treatment with glucocorticoids. Progressive radiation necrosis is best treated with surgical resection if the patient has a life expectancy of at least 6 months and a Karnofsky performance score >70. There are anecdotal reports that anticoagulation with heparin or warfarin may be beneficial. Radiation injury also accelerates the development of atherosclerosis in large arteries, but an increase in the risk of stroke becomes significant only years after radiation treatment.

Endocrine dysfunction frequently follows exposure of the hypothalamus or pituitary gland to therapeutic radiation. Growth hormone is the pituitary hormone most sensitive to radiation therapy, and thyroid-stimulating hormone is the least sensitive; ACTH, prolactin, and the gonadotropins have an intermediate sensitivity. Development of a second neoplasm is another risk of therapeutic radiation that generally occurs many years after radiation exposure. Depending on the irradiated field, the risk of gliomas, meningiomas, sarcomas, and thyroid cancer is increased.

**COMPLICATIONS OF CHEMOTHERAPY** Chemotherapy regimens used to treat primary brain tumors have generally included a nitrosourea and are well tolerated. Infrequently, nitrosoureas and other drugs used to treat CNS neoplasms cause altered mental states (e.g., confusion, depression), ataxia, and seizures. Chemotherapy for systemic malignancy is a more frequent cause of nervous system toxicity. Cisplatin commonly produces tinnitus and high-frequency bilateral hearing loss, especially in younger patients. At cumulative doses, >450 mg/m², cisplatin can produce a symmetric, large-fiber axonal neuropathy that is predominantly sensorineural; paclitaxel (Taxol) produces a similar picture. Fluorouracil and high-dose cytarabine can cause cerebellar dysfunction that resolves after discontinuation of therapy. Vincristine, which is commonly used to treat lymphoma, may cause an acute ileus and is frequently associated with development of a progressive distal, symmetric sensory-motor neuropathy with foot drop and paresthesia.

**FIGURE 358-9** Radiation injury. **A.** Late-delayed radiation injury 1 year after whole-brain radiation (5500 cGy). T2-weighted MR image at the level of the temporal lobes reveals high signal intensity abnormality in periventricular white matter (arrows). **B** and **C.** Focal radiation necrosis 3 years after radiotherapy (7000 cGy) for carcinoma of the nasopharynx. Axial T2-weighted MRI (**B**) demonstrates a mass in the right frontal lobe with surrounding vasogenic edema. Abnormal signal changes are also present on the left. T1-weighted postcontrast MRI (**C**) reveals a heterogeneously enhancing mass in the right cingulate gyrus.
Demyelinating disorders are characterized by inflammation and selective destruction of central nervous system (CNS) myelin. The peripheral nervous system (PNS) is spared, and most patients have no evidence of an associated systemic illness.

**MULTIPLE SCLEROSIS**

Multiple sclerosis (MS) is characterized by a triad of inflammation, demyelination, and gliosis (scarring); the course can be relapsing-remitting or progressive. Lesions of MS are typically disseminated in time and location. MS affects ~350,000 Americans and 1.1 million individuals worldwide. In western societies, MS is second only to trauma as a cause of neurologic disability in early to middle adulthood. Manifestations of MS vary from a benign illness to a rapidly evolving and incapacitating disease requiring profound life-style adjustments.

**PATHOGENESIS**

**Anatomy**

These lesions (plaques) vary in size from 1 or 2 mm to several centimeters. Acute MS lesions are characterized by perivenular cuffing with inflammatory mononuclear cells, predominantly T cells and macrophages, which also infiltrate the surrounding white matter. At sites of inflammation, the blood-brain barrier (BBB) is disrupted but, unlike vasculitis, the vessel wall is preserved. In more than half of cases, myelin-specific autoantibodies promote demyelination and stimulate macrophages and microglial cells (bone marrow–derived CNS phagocytes) that scavenge the myelin debris. As lesions evolve, astrocytes proliferate (gliosis). Surviving oligodendrocytes or those that differentiate from precursor cells may partially remyelinate the surviving naked axons, producing so-called shadow plaques. Ultrastructural studies of MS lesions suggest that fundamentally different underlying pathologies may exist in different patients. Heterogeneity has been observed in terms of: (1) whether the inflammatory cell infiltrate is associated with deposition of antibody and activation of complement, and (2) whether the target of the immunopathologic process is the myelin sheath itself or the cell body of the oligodendrocyte. Although sparing of axons is typical of MS, partial or total axonal destruction can also occur. Indirect evidence suggests that axonal loss is a major cause of irreversible neurologic disability in MS.

**Physiology**

Nerve conduction in myelinated axons occurs in a saltatory manner, with the nerve impulse jumping from one node of Ranvier to the next without depolarization of the axonal membrane underlying the myelin sheath between nodes (Fig. 359-1). This produces considerably faster conduction velocities (~70 m/s) than the slow velocities (~1 m/s) produced by continuous propagation in unmyelinated nerves. Conduction block occurs when the nerve impulse is unable to traverse the demyelinated segment. This can happen when the resting axon membrane becomes hyperpolarized due to the exposure of voltage-dependent potassium channels that are normally buried underneath the myelin sheath. A temporary conduction block often follows a demyelinating event before the sodium channels (originally concentrated at the nodes) have had a chance to redistribute themselves along the naked axon (Fig. 359-1). This redistribution ultimately allows the continuous propagation of nerve action potentials through the demyelinated segment but, before this happens, the leakage currents are too large for the nerve impulse to jump the intermediate distance and conduction fails. On occasion, conduction block is incomplete, affecting, for example, high- but not low-frequency volleys of impulses. Variable conduction block can occur with raised body temperature or metabolic alterations and may explain clinical fluctuations (typical of MS) that vary from hour to hour or in association with fever or exercise. Conduction slowing occurs when the demyelinated segments support only (slow) continuous nerve impulse propagation.

**Epidemiology**

MS is approximately twice as common in women as in men. The age of onset is typically between 20 and 40 years (slightly later in men than in women). Rarely, it can begin as early as 2 years of age or as late as the eighth decade. The highest known prevalence for MS (250 per 100,000) occurs in the Orkney islands, located north of Scotland, and similarly high rates are found throughout northern Europe, the northern United States, and Canada. By contrast, the prevalence is low in Japan (2 per 100,000), in other parts of Asia, in equatorial Africa, and in the Middle East. In general, prevalence increases with increasing distance from the equator, although certain exceptions are notable. Thus, the incidence of MS in the Eskimo population of Alaska is rare compared to the incidence in Caucasians living at similar latitudes. Similarly, native South Africans have a markedly lower prevalence compared to South Africans of European descent who live in the same geographic area. However, distinctive migration patterns of certain populations may artifically suggest a relationship between MS and climate. Thus, when Scandinavians migrated to the United States or when the Scots migrated to New Zealand, they tended to migrate preferentially to places (e.g., the northern United States or southern New Zealand) with similar climates to their native lands. Such considerations point to potential genetic mechanisms (see below) rather than to an influence of temperate climate per se.

**CHANGES IN INCIDENCE/PREVALENCE**

Studies from the United States, Europe, Australia, and the Middle East suggest that the prevalence of MS may be increasing, although improved methods of diagnosis may account for the apparent change. Other reports suggest that individuals who move from an area of high prevalence to one of low prevalence (or vice versa) before the age of 15 years adopt the risk of MS in their
new environment, whereas if they move after this age, they retain the risk of their native land. The reliability of these observations is uncertain, although, if correct, they would suggest an environmental factor in the pathogenesis of MS.

**REPORTED CLUSTERS** Clusters of MS cases are occasionally reported. Often these apparent epidemics cannot be distinguished easily from chance occurrences, although some reports (e.g., the clustering of MS cases in the Faeroe Islands after British occupation during World War II) are more convincing than others. Such clustering, however, seems to be rare.

**The Relationship of MS to Trauma and Stress** The existing evidence does not support any association of trauma with either MS onset or exacerbation. Similarly, a relationship between stress and either onset or exacerbation of MS has not been established, although this area is not easily studied because of difficulties in quantifying stress.

**GENETIC CONSIDERATIONS** A genetic susceptibility to MS exists, as evidenced by the following observations:

1. The prevalence of MS differs among ethnic groups residing in the same environment.
2. First-, second-, and third-degree relatives of MS patients are at increased risk for the disease. Siblings of affected individuals have a lifetime risk of 2 to 5%, whereas the risk to parents or children of affected individuals is somewhat lower.
3. Twin studies demonstrate concordance rates of 25 to 30% in monozygotic twins compared to only 2 to 5% in dizygotic twins (similar to the risk in non-twin siblings).

The inheritance of MS cannot be explained by a simple genetic model. Susceptibility is probably polygenic, with each gene contributing a relatively small amount to the overall risk. It is also likely that genetic heterogeneity (different susceptibilities among individuals) also exists. The major histocompatibility complex (MHC) on chromosome 6p21 (encoding proteins involved in presenting peptide antigens to T cells) is the most important MS susceptibility region identified to date. MS susceptibility is associated with the class II region of the MHC, specifically with the DR2 (DRB1*1501) allele and its corresponding haplotype. Other genetic regions implicated in MS susceptibility are located on chromosomal regions 19q35 and 17q13.

**Immunology** An autoimmune cause for MS is supported by the laboratory model of experimental allergic encephalomyelitis (EAE) and by studies of the immune system in MS patients.

**AUTOACTIVE T LYMPHOCYTES** Myelin basic protein (MBP) is an important T cell antigen in EAE and probably also in human MS. Activated MBP-reactive T cells are often found in the blood or cerebrospinal fluid (CSF) of MS patients and, occasionally also, in MS lesions. Moreover, DR2 may influence the autoimmune response because it binds with high affinity to a fragment of MBP (spanning amino acids 89 to 96), stimulating T cell responses to this self-protein.

**AUTOANTIBODIES** Autoantibodies, directed against myelin antigens such as myelin oligodendrocyte glycoprotein (MOG), probably act in concert with a pathogenic T cell response to cause the demyelinating lesions in many patients. Recent evidence suggests that the presence of anti MOG antibodies in the serum of patients with a clinically isolated syndrome (CIS) is highly predictive of the development of MS in the future. Also, evidence of an abnormal humoral immune response is present in the CSF of MS patients. Membrane attack complexes (from complement-mediated antibody damage) can be detected in CSF, and elevated CSF immunoglobulin (synthesized locally) is characteristic of MS. Oligoclonal antibody (derived from expansion of a selected group of plasma cells) is present in most cases. Oligoclonal immunoglobulin is also detected in other chronic inflammatory conditions, including infections, and thus is not specific to MS. The pattern of banding is unique to each individual, and attempts to identify the targets of these antibodies have been unsuccessful.

**CYTOKINES** (Chap. 295) The proinflammatory T<sub>H</sub>1 cytokines such as interleukin (IL) 2, tumor necrosis factor (TNF-α), and interferon (IFN)-γ are thought to be central to MS pathogenesis and some (e.g., TNF-α and IFN-γ) may directly injure oligodendrocytes or the myelin membranes. Nevertheless, the notion of an isolated T<sub>H</sub>1 imbalance causing MS is probably simplistic. The presence of autoantibodies in MS suggests that regulatory T<sub>H</sub>2 cytokines (including IL-4, -5, and -10) may also play a pathogenic role. Moreover, T<sub>H</sub>1-based therapies have often proved to be unhelpful or, in the case of certain TNF-α inhibitors, harmful to patients.

**TRIGGERS** Magnetic resonance imaging (MRI) has demonstrated bursts of disease activity 7 to 10 times more frequently than is clinically apparent. This finding indicates that there is a large reservoir of subclinical disease activity in MS, especially during the early stages of the disease. The triggers causing these bursts are unknown, although the fact that patients may experience relapses after nonspecific upper respiratory infections suggests that either molecular mimicry between viruses and myelin antigens or viral superantigens activating pathogenic T cells may play a role in MS pathogenesis. (Chap. 299).

**Microbiology** As noted above, epidemiologic evidence supports the role of an environmental exposure in MS. MS risk also correlates with high socioeconomic status, which may reflect improved sanitation and delayed initial exposures to infectious agents. By analogy, some viral infections (e.g., poliomyelitis and measles viruses) produce neurologic sequelae more frequently when the age of initial infection is delayed. The best studied experimental model of virus-induced demyelinating disease is infection with Theiler virus, a murine coronavirus similar to measles, which produces a chronic oligodendrocyte infection with multifocal perivascular lymphocytic infiltration and demyelination, closely resembling lesions of MS.

High antibody titers against many viruses have been reported in serum and CSF of MS patients, including measles, herpes simplex, varicella, rubella, Epstein-Barr, and influenza C and some parainfluenza strains. Numerous viruses and bacteria (or their genomic sequences) have been recovered from MS tissues and fluids. Most recent human herpes virus type 6 (HHV-6) and Chlamydia pneumoniae have been implicated, although a causal role for any infectious agent in MS remains unproven.

**CLINICAL MANIFESTATIONS** The onset of MS may be abrupt or insidious. Symptoms may be severe or seem trivial, since a patient may not seek medical attention for months or years. Indeed, at autopsy some individuals who were asymptomatic during life will be found, unexpectedly, to have MS. In other cases an MRI scan obtained for an unrelated reason may show evidence of asymptomatic MS. Symptoms of MS are extremely varied and depend upon the location of lesions within the CNS (Table 359-1). Examination generally reveals evidence of neurologic dysfunction, often in asymptomatic locations. For example, a patient may present with symptoms in one leg and signs in both.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Percent of Cases</th>
<th>Symptom</th>
<th>Percent of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensory loss</td>
<td>37</td>
<td>Lhermitte</td>
<td>3</td>
</tr>
<tr>
<td>Optic neuritis</td>
<td>36</td>
<td>Pain</td>
<td>3</td>
</tr>
<tr>
<td>Weakness</td>
<td>35</td>
<td>Dementia</td>
<td>2</td>
</tr>
<tr>
<td>Paresthesias</td>
<td>24</td>
<td>Visual loss</td>
<td>2</td>
</tr>
<tr>
<td>Diplopia</td>
<td>15</td>
<td>Facial palsy</td>
<td>1</td>
</tr>
<tr>
<td>Ataxia</td>
<td>11</td>
<td>Impotence</td>
<td>1</td>
</tr>
<tr>
<td>Vertigo</td>
<td>6</td>
<td>Myokymia</td>
<td>1</td>
</tr>
<tr>
<td>Paroxysmal attacks</td>
<td>4</td>
<td>Epilepsy</td>
<td>1</td>
</tr>
<tr>
<td>Bladder</td>
<td>4</td>
<td>Falling</td>
<td>1</td>
</tr>
</tbody>
</table>

**Source:** Alter WB Matthews et al, McAlpine’s Multiple Sclerosis, New York, Churchill Livingstone, 1991.
Weakness of the limbs may manifest as loss of strength or dexterity, fatigue, or a disturbance of gait. Exercise-induced weakness is a characteristic symptom of MS. The weakness is of the upper motor neuron type (Chap. 20) and is frequently accompanied by other pyramidal signs such as spasticity, hyperreflexia and Babinski signs. Occasionally, a tendon reflex may be lost (simulating a lower motor neuron lesion) if a MS lesion disrupts the afferent reflex fibers in the spinal cord.

Spasticity (Chap. 21) is often associated with spontaneous and movement-induced muscle spasms. More than 30% of MS patients have moderate to severe spasticity, especially in the legs. It is often accompanied by painful spasms and can interfere with a patient’s ability to ambulate or work or with self-care. Occasionally, spasticity may provide nonvolitional support for the body weight during ambulation. In these cases, treatment of spasticity may actually do more harm than good.

Optic neuritis (ON) generally presents as diminished visual acuity, dimness, or decreased color perception (desaturation) in the central field of vision. These symptoms may be mild or may progress to severe visual loss. Rarely, there is complete loss of light perception. Visual symptoms are generally monocular but may occur bilaterally. Periorbital pain (aggravated by eye movement) often precedes or accompanies the visual loss. An afferent pupillary defect (Chap. 25) may be found. Funduscopic examination may be normal or reveal optic disc swelling (papillitis). Pallor of the optic disc (optic atrophy) commonly follows ON. Uveitis is rare and should raise the possibility of alternative diagnoses. \( ON \) is discussed in detail in Chap. 25.

Visual blurring in MS may result from ON or diplopia. Visual blurring that resolves when either eye is covered is due to diplopia.

Diplopia may result from internuclear ophthalmoplegia (INO) or from palsy of the sixth cranial nerve (rarely the third or fourth). An INO consists of impaired adduction of one eye due to a lesion in the ipsilateral medial longitudinal fasciculus (Chap. 25). Prominent nystagmus is often observed in the abducting eye, along with a small skew deviation. A bilateral INO is particularly suggestive of MS. Other common gaze disturbances in MS include: (1) a horizontal gaze palsy, (2) a “one and a half” syndrome (horizontal gaze palsy plus an INO), and (3) acquired pendular nystagmus.

Sensory symptoms are varied and include both paresthesias (e.g., tingling, prickling sensations, formations, “pins and needles,” or painful burning) and hypesthesia (e.g., reduced sensation, numbness or a “dead” feeling). Unpleasant sensations (e.g., feelings that body parts are swollen, wet, raw, or tightly wrapped) are also common. Sensory impairment of the trunk and legs below a horizontal line on the torso (a sensory level) suggests that the spinal cord is the origin of the sensory disturbance. It is often accompanied by a bandlike sensation of tightness around the torso. Pain is a common symptom of MS, experienced by >50% of patients. Pain can occur anywhere on the body and can change locations over time.

Ataxia usually manifests as cerebellar tremors (Chap. 21). Ataxia may also involve the head and trunk or the voice, producing a characteristic cerebellar dysarthria (scanning speech). The true extent of cerebellar involvement may be difficult to determine in an individual patient, because motor and sensory deficits can affect coordination and weakness may interfere with coordination testing.

Bladder and bowel dysfunction arise from different causes and frequently different types of dysfunction coexist. During normal reflex voiding, relaxation of the bladder sphincter (\( \alpha \)-adrenergic innervation) is coordinated with contraction of the detrusor muscle in the bladder wall (mucosal cholinergic innervation). Stoppage of the urinary stream is accomplished with a coordinated sphincter contraction and detrusor relaxation. Bladder-stretch (during filling) activates this reflex, which is inhibited by supraspinal (voluntary) input. Symptoms of bladder dysfunction are present in >90% of MS patients and, in a third, dysfunction results in weekly or more frequent episodes of incontinence.

Detrusor hyperreflexia, due to impairment of suprasegmental inhibition, causes urinary frequency, urgency, nocturia, and uncontrolled bladder-emptying. Detrusor sphincter dysynergia, due to loss of synchronization between detrusor and sphincter muscles, causes difficulty in initiating and/or stopping the urinary stream, thereby producing hesitancy. It can also lead to urinary retention, large postvoid residual volumes, overflow incontinence, and recurrent infection.

Constipation occurs in >30% of patients. Fecal urgency or bowel incontinence is less common (15%) but can be socially debilitating. Cognitive dysfunction can include memory loss, impaired attention, difficulties in problem-solving, slowed information processing, and problems shifting between cognitive tasks. Euphoria (elevated mood) was once thought to be characteristic of MS but is actually uncommon, occurring in <20% of patients. Cognitive dysfunction sufficient to impair activities of daily living also occurs but is rare.

Depression, experienced by 50 to 60% of patients, can be reactive, endogenous, or part of the illness itself and can contribute to fatigue. Suicide in MS patients is 7.5-fold more common than in age-matched controls.

Fatigue is experienced by 90% of patients and is moderate or severe in half. Symptoms include generalized motor weakness, limited ability to concentrate, extreme lassitude, loss of energy, decreased endurance, and an overwhelming sense of exhaustion that requires the patient to rest or fall asleep. Fatigue (either alone or with other symptoms) is the most common reason for work-related disability in MS. Fatigue can be exacerbated by elevated temperatures, by depression, by expending exceptional effort to accomplish basic activities of daily living, or by sleep disturbances (e.g., from frequent nocturnal awakenings to urinate). MS-related fatigue may be maximum during mid-afternoon or continuous throughout the day, and it is often difficult to treat.

Sexual dysfunction is common in MS. Men report impotence, less desire, impaired genital sensation, impaired ejaculation, and inability to achieve/maintain an erection. Women report genital numbness, diminished orgasmic response, decreased libido, unpleasant sensations during intercourse, and diminished vaginal lubrication. Adductor spasticity (in women) can also interfere with intercourse, and urinary incontinence (in either men or women) can be problematic.

Facial weakness due to a lesion in the intraparenchymal pathway of the seventh cranial nerve may resemble idiopathic Bell’s palsy. However, unlike Bell’s palsy, facial weakness in MS is generally not associated with ipsilateral loss of taste sensation or retroauricular pain (Chap. 355).

Vertigo may appear suddenly and resemble acute labyrinthitis. A brainstem rather than end-organ origin is suggested by the presence of coexisting trigeminal or facial nerve involvement; vertical nystagmus; or nystagmus that has no latency to onset, no direction reversal, and doesn’t fatigue (Chap. 20). Hearing loss may also occur in MS but is uncommon.

Ancillary Symptoms Heat sensitivity refers to neurologic symptoms produced by an elevation of the body’s core temperature. For example, transient unilateral visual blurring or loss may occur during a hot shower or with physical exercise (Uhthoff’s symptom). It is common for MS symptoms to worsen transiently, sometimes dramatically, during febrile illnesses (see pseudoxacerbation, below). Such heat-related symptoms probably result from transient conduction block (see above).

Lhermitte’s symptom is the electric shock–like sensation (evoked by neck flexion or other movement) that radiates down the back into the legs. Rarely, it radiates into the arms. It is generally self-limited but may persist for years. Lhermitte’s symptom can also occur with other disorders of the cervical spine (e.g., cervical spondylitis).

Paroxysmal symptoms are distinguished by their brief duration (30 s to 2 min), high frequency (5 to 40 episodes per day), lack of any alteration of consciousness or change in background electroencephalographic activity, and a self-limited course (generally lasting weeks to months). They may be precipitated by hyperventilation or movement. These syndromes include Lhermitte’s symptom; tonic con-
Trigeminal neuralgia can occur when the demyelinating lesion involves the root entry (or exit) zone of the fifth, seventh, and ninth cranial nerve, respectively. *Trigeminal neuralgia* (tic douloureux) is a very brief lancinating facial pain often triggered by an afferent input from the face or teeth. Most cases of trigeminal neuralgia are not MS-related. However, the occurrence of atypical features (Chap. 359) such as the onset before age 50 years, bilateral symptoms, objective sensory loss, or nonparoxysmal pain should raise concerns that a symptomatic cause such as MS is responsible.

*Facial myokymia* consists of either persistent rapid flickering contractions of the facial musculature (especially the lower portion of the orbicularis oculus) or a contraction that slowly spreads across the face. It results from lesions of the corticobulbar tracts or brainstem course of the facial nerve.

**Disease Course**  
Four clinical types of MS have been described (Fig. 359–2):

1. *Relapsing/remitting MS* (RRMS) accounts for 85% of MS cases at onset and is characterized by discrete attacks that generally result from lesions of the corticobulbar tracts or brainstem course of the facial nerve. It results from demyelinating plaques, and spreading ephatically to adjacent white matter tracts.

2. *Secondary progressive MS* (SPMS) always begins as RRMS (Fig. 359–2B). At some point, however, the RRMS clinical course changes so that the patient experiences a steady deterioration in function unassociated with acute attacks (which may continue or cease during the progressive phase). SPMS produces a greater amount of fixed neurologic disability than RRMS. Approximately 50% of patients with RRMS will have developed SPMS after 15 years, and longer follow-up points indicate that the great majority of RRMS ultimately evolves into SPMS. Thus, SPMS appears to represent a late-stage of the same underlying illness as RRMS.

3. *Primary progressive MS* (PPMS) accounts for ~15% of cases. These patients do not experience attacks but only a steady functional decline from disease onset (Fig. 359–2C). Compared to RRMS, the clinical course of multiple sclerosis (MS). A. Relapsing/remitting MS. B. Secondary progressive MS. C. Primary progressive MS. D. Progressive/relapping MS.

4. *Progressive/relapping MS* (PRMS) overlaps PPMS and SPMS and accounts for ~5% of MS patients. Like patients with PPMS, these patients experience a steady deterioration in their condition from disease onset. However, like SPMS patients, they experience occasional attacks superimposed upon their progressive course (Fig. 359–2D). The early stages of RPMS are indistinguishable from those of PPMS (i.e., until the first clinical attack).

**Diagnosis**  
There is no definitive diagnostic test for MS. Diagnostic criteria for clinically definite MS require documentation of two or more episodes of symptoms and two or more signs that reflect pathology in anatomically noncontiguous white matter tracts of the CNS (Table 359–2). Symptoms must last for >24 h and occur as distinct episodes that are separated by a month or more. At least one of the two required signs must be present on neurologic examination. The second may be documented by certain abnormal paraclinical tests such as MRI or evoked potentials (EPs). In patients who experience gradual progression of disability for ≥6 months without superimposed relapses, documentation of intrathecal IgG and visual EP testing may be used to support the diagnosis.

**Diagnosing Multiple Sclerosis**  
There is no definitive diagnostic test for MS. Diagnostic criteria for clinically definite MS require documentation of two or more episodes of symptoms and two or more signs that reflect pathology in anatomically noncontiguous white matter tracts of the CNS (Table 359–2). Symptoms must last for >24 h and occur as distinct episodes that are separated by a month or more. At least one of the two required signs must be present on neurologic examination. The second may be documented by certain abnormal paraclinical tests such as MRI or evoked potentials (EPs). In patients who experience gradual progression of disability for ≥6 months without superimposed relapses, documentation of intrathecal IgG and visual EP testing may be used to support the diagnosis.

**Diagnostic Testing**  
**MRI** has revolutionized the diagnosis and management of MS (Fig. 359–3); characteristic abnormalities are found in >95% of patients. An increase in vascular permeability from a breakdown of the BBB is detected by leakage of intravenous gadolinium (Gd) into the parenchyma. Such leakage occurs early in the development of an MS lesion and serves as a useful marker of inflammation. Gd-enhancement persists for up to 3 months, and the residual MS plaque remains visible indefinitely as a focal area of hyperintensity (a lesion) on spin-echo (T2-weighted) and proton-density images. Lesions are frequently oriented perpendicular to the underlying white matter tracts, usually including (a) pyramidal pathways, (b) cerebellar pathways, (c) medial longitudinal fasciculus, (d) optic nerve, and (e) posterior columns.

**TABLE 359–2 Diagnostic Criteria for MS**

1. Examination must reveal objective abnormalities of the CNS.
2. Involvement must reflect predominantly disease of white matter tracts, usually including (a) pyramidal pathways, (b) cerebellar pathways, (c) medial longitudinal fasciculus, (d) optic nerve, and (e) posterior columns.
3. Examination or history must implicate involvement of two or more areas of the CNS.
4. MRI may be used to document a second lesion when only one site of abnormality has been demonstrable on examination. A confirmatory MRI must have either four lesions involving the white matter or three lesions if one is periventricular in location. Acceptable lesions must be ≥3 mm in diameter. For patients older than 50 years, two of the following criteria must also be met: (a) lesion size ≥5 mm, (b) lesions adjacent to the bodies of the lateral ventricles, and (c) lesion(s) present in the posterior fossa.
5. Evoked response testing may be used to document a second lesion not evident on clinical examination.
6. The clinical pattern must consist of (a) two or more separate episodes of worsening involving different sites of the CNS, each lasting at least 24 h and occurring at least 1 month apart, or (b) gradual or stepwise progression over at least 6 months if accompanied by increased IgG synthesis or two or more oligoclonal bands. MRI may be used to document dissemination in time if a new T2 lesion or a Gd-enhancing lesion is seen 3 or more months after a clinically isolated syndrome.
7. The patient’s neurologic condition could not better be attributed to another disease.

**Diagnostic Categories**

1. *Definite MS*: All five criteria fulfilled.
2. *Probable MS*: All five criteria fulfilled except (a) only one objective abnormality despite two symptomatic episodes or (b) only one symptomatic episode despite two or more objective abnormalities.
3. *At risk for MS*: Criteria 1, 2, 3, and 5 fulfilled; patient has only one symptomatic episode and one objective abnormality.

**Note:** CNS, central nervous system; MRI, magnetic resonance imaging; Gd, gadolinium.
ventricular surface, corresponding to the pathologic pattern of perivenous demyelination (Dawson’s fingers). Lesions are multifocal within the brain, brainstem, and spinal cord. Lesions in the anterior corpus callosum are helpful diagnostically because this site is usually spared in cerebrovascular disease. Different criteria for the use of MRI in the diagnosis of MS have been proposed (Table 359-2).

The total volume of T2-weighted signal abnormalities (the “burden of disease”) shows a significant (albeit weak) correlation with clinical disability. Approximately one-third of T2-weighted lesions appear as hypointense lesions (black holes) on T1-weighted imaging. Black holes may be a better marker of irreversible demyelination and axonal loss than T2 hyperintensities, although even this measure depends upon the timing of the image acquisition (e.g., most acute Gd-enhancing T2 lesions are T1 dark).

Newer MRI measures such as brain atrophy, magnetization transfer ratio (MTR) imaging and proton magnetic resonance spectroscopic imaging (MRSI) may ultimately serve as surrogate markers of clinical disability. For example, MRSI can quantitate molecules such as N-acetyl aspartate (NAA), which is a marker of axonal integrity, and MTR may be able to distinguish demyelination from edema.

Evoked Potentials EP testing assesses function in afferent (visual, auditory, and somatosensory) or efferent (motor) CNS pathways. EPs use computer averaging to measure CNS electric potentials evoked by repetitive stimulation of selected peripheral nerves or of the brain. These tests provide the most information when the pathways studied are clinically uninvolved. For example, in a patient with a remitting and relapsing spinal cord syndrome with sensory deficits in the legs, an abnormal somatosensory EP following posterior tibial nerve stimulation provides little new information. By contrast, an abnormal visual EP in this circumstance would permit a diagnosis of clinically definite MS (Table 359-2). Abnormalities on one or more EP modalities occur in 80 to 90% of MS patients. EP abnormalities are not specific to MS, although a marked delay in the latency of a specific EP component (as opposed to a reduced amplitude) is suggestive of demyelination.

Cerebrospinal Fluid CSF abnormalities found in MS include a monoclonal cell pleocytosis and an increased level of intrathecally synthesized IgG. The total CSF protein is usually normal or slightly elevated. Various formulas distinguish intrathecally synthesized IgG from IgG that may have entered the CNS passively from the serum. One formula (the CSF IgG index) expresses the ratio of IgG to albumin in the CSF divided by the same ratio in the serum. A more complicated formula, the IgG synthesis rate, makes certain assumptions but uses the same serum and CSF IgG and albumin measurements to calculate the rate of CNS IgG synthesis. The measurement of oligoclonal banding (OCB) in the CSF also assesses intrathecal production of IgG. OCBs are detected by agarose gel electrophoresis. Two or more OCBs are found in 75 to 90% of patients with MS. OCBs may be absent at the onset of MS, and in individual patients the number of bands present may increase with time. It is important that paired serum samples be studied to exclude a peripheral (i.e., non-CNS) origin of any OCBs detected in the CSF.

A mild CSF pleocytosis (>5 cells/μL) is present in ~25% of cases, usually in young patients with RRMS. A pleocytosis of >75 cells/μL, the presence of polymorphonuclear leukocytes, or a protein concentration of >1.0 g/L (>100 mg/dL) in CSF should raise concern that the patient may not have MS.

DIFFERENTIAL DIAGNOSIS No single clinical sign or test is diagnostic of MS. The diagnosis is readily made in a young adult with relapsing and remitting symptoms involving different areas of CNS white matter. The possibility of an alternative diagnosis should always be considered (Table 359-3), particularly when (1) symptoms are localized exclusively to the posterior fossa, cranio-cervical junction, or spinal cord; (2) the patient is <15 or >60 years of age; (3) the clinical course is progressive from onset; (4) the patient has never experienced visual, sensory, or bladder symptoms; or (5) laboratory findings (e.g., MRI, CSF, or EPs) are atypical. Similarly, uncommon or rare symptoms in
MS after 10 years is 70 to 80%. Conversely, with a normal brain MRI, the likelihood of developing MS is <20%. Similarly, two or more Gd-enhancing lesions at baseline are highly predictive of future MS, as is the appearance of either new T2-weighted lesions or new Gd enhancement ≥3 months after the episode. Typical abnormalities on EP testing and CSF examination provide similar prognostic information, although these relationships are not as well characterized.

Mortality as a direct consequence of MS is uncommon, although it has been estimated that the 25-year survival is only 85% of expected. Death can occur during an acute MS attack, although this is distinctly rare. More commonly, death occurs as a complication of MS (e.g., pneumonia in a debilitated individual). Death also results from suicide.

**Effect of Pregnancy** Pregnant MS patients experience fewer attacks than expected during gestation (especially in the last trimester) but more attacks than expected in the first 3 months post-partum. When considering the pregnancy year as a whole (i.e., 9 months pregnancy plus 3 months post-partum), the overall disease course is unaffected. Decisions about childbirth should thus be made based upon (1) the mother’s physical state, (2) her ability to care for the child, and (3) the availability of social support. Disease-modifying therapy is generally discontinued during pregnancy, although the actual risk from the interferons and glatiramer acetate (see below) appears to be quite low.

**TREATMENT**

Current therapy for MS can be divided into several categories: (1) treatment of acute attacks as they occur; (2) treatment with disease-modifying agents that reduce the biological activity of MS, and (3) symptomatic therapy. Treatments that promote remyelination or neural repair do not currently exist but would be highly desirable.

The Kurtzke Expanded Disability Status Score (EDSS) is a measure of neurologic impairment in MS (Table 359-4). The EDSS provides a useful snapshot of the disease status of a patient at a given time and a composite picture of the disease course over time. Most patients with EDSS scores <3.5 have RRMS, walk normally, and are not disabled; by contrast, patients with EDSS scores >5.5 have progressive MS (SPMS or PPMs) and are gait-impaired and occupationally disabled.

**Acute Attacks or Initial Demyelinating Episodes** When patients experience an acute deterioration, it is important to consider whether this change reflects new disease activity or a “pseudoexacerbation” resulting from an increase in ambient temperature, fever, or an infection. In such instances, glucocorticoid treatment is inappropriate. Glucocorticoids are used to manage either first attacks or acute exacerbations. They provide short-term clinical benefit by reducing the severity and shortening the duration of attacks. Whether treatment provides any long-term benefit on the course of the illness is less clear. As a result, mild attacks are often not treated. Physical and occupational therapy can help with mobility and manual dexterity.

Glucocorticoid treatment is administered as intravenous methylprednisolone, 500 to 1000 mg/d for 3 to 5 days, either without a taper or followed by a course of oral prednisone beginning at a dose of 60 to 80 mg/d and gradually tapered over 2 weeks. Outpatient treatment is usually possible. If intravenous therapy is unavailable or inconvenient, oral glucocorticoids can be substituted.

Side effects of short-term glucocorticoid therapy include fluid retention, potassium loss, weight gain, gastric disturbances, acne, and emotional lability. Concurrent use of a low-salt, potassium-rich diet and avoidance of potassium-wasting diuretics is advisable. Lithium carbonate (300 mg orally bid) may help to manage emotional lability and insomnia associated with glucocorticoid therapy. Patients with a history of peptic ulcer disease may require cimetidine (400 mg bid) or ranitidine (150 mg bid).

Plasma exchange (7 exchanges: 54 mL/kg or 1.1 plasma volumes per exchange, every other day for 14 days) may benefit patients with fulminant attacks of demyelination (not only MS) that are unresponsive to glucocorticoids. However, because the cost is high, and the evidence of efficacy is preliminary, plasma exchange should be considered only in selected cases.

### TABLE 359-3 Disorders that Can Mimic MS

<table>
<thead>
<tr>
<th>Disorder/Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute disseminated encephalomyelitis (ADEM)</td>
</tr>
<tr>
<td>Antiphospholipid antibody syndrome</td>
</tr>
<tr>
<td>Behcet’s disease</td>
</tr>
<tr>
<td>Cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL)</td>
</tr>
<tr>
<td>Congenital leukodystrophies (e.g., adrenoleukodystrophy, metachromatic leukodystrophy)</td>
</tr>
<tr>
<td>Human immunodeficiency virus (HIV) infection</td>
</tr>
<tr>
<td>Ischemic optic neuropathy (arteritic and nonarteritic)</td>
</tr>
<tr>
<td>Lyme disease</td>
</tr>
<tr>
<td>Mitochondrial encephalopathy with lactic acidosis and stroke (MELAS)</td>
</tr>
<tr>
<td>Neoplasms (e.g., lymphoma, glioma, meningo)</td>
</tr>
<tr>
<td>Sarcoïd</td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
</tr>
<tr>
<td>Stroke and ischemic cerebrovascular disease</td>
</tr>
<tr>
<td>Syphilis</td>
</tr>
<tr>
<td>Systemic lupus erythematosus and related collagen vascular disorders</td>
</tr>
<tr>
<td>Tropical spastic paraparesis (HTLV I/II infection)</td>
</tr>
<tr>
<td>Vascular malformations (especially spinal dural AV fistulas)</td>
</tr>
<tr>
<td>Vasculitis (primary CNS or other)</td>
</tr>
</tbody>
</table>

Note: HTLV, human T cell leukemia/lymphoma virus; AV, arteriovenous; CNS, central nervous system.
**TABLE 359-4  Scoring Systems for MS**

**KURTZKE EXPANDED DISABILITY STATUS SCORE (EDSS)**

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>Normal neurologic exam [all grade 0 in functional status (FS)]</td>
</tr>
<tr>
<td>1.0</td>
<td>No disability, minimal signs in one FS (i.e., grade 1)</td>
</tr>
<tr>
<td>1.5</td>
<td>No disability, minimal signs in more than one FS (more than one grade 1)</td>
</tr>
<tr>
<td>2.0</td>
<td>Minimal disability in one FS (one grade 2, others 0 or 1)</td>
</tr>
<tr>
<td>2.5</td>
<td>Minimal disability in two FS (two grade 2, others 0 or 1)</td>
</tr>
<tr>
<td>3.0</td>
<td>Moderately severe disability in one FS (one grade 3, others 0 or 1) or mild disability in three or four FS (three/four grade 2, others 0 or 1) though fully ambulatory</td>
</tr>
<tr>
<td>3.5</td>
<td>Fully ambulatory but with moderate disability in one FS (one grade 3) and one or two FS grade 2; or two FS grade 3; or five FS grade 2 (others 0 or 1)</td>
</tr>
<tr>
<td>4.0</td>
<td>Ambulatory without aid or rest for ( \geq 500 ) m</td>
</tr>
<tr>
<td>4.5</td>
<td>Ambulatory without aid or rest for ( \geq 300 ) m</td>
</tr>
<tr>
<td>5.0</td>
<td>Ambulatory without aid or rest for ( \geq 200 ) m</td>
</tr>
<tr>
<td>5.5</td>
<td>Ambulatory without aid or rest for ( \geq 100 ) m</td>
</tr>
<tr>
<td>6.0</td>
<td>Unilateral assistance required to walk about 100 m with or without resting</td>
</tr>
<tr>
<td>6.5</td>
<td>Constant bilateral assistance required to walk about 20 m without resting</td>
</tr>
<tr>
<td>7.0</td>
<td>Unable to walk beyond about 5 m even with aid; essentially restricted to wheelchair; wheels self and transfers alone</td>
</tr>
<tr>
<td>7.5</td>
<td>Unable to take more than a few steps; restricted to wheelchair; may need aid to transfer</td>
</tr>
<tr>
<td>8.0</td>
<td>Essentially restricted to bed or chair or perambulated in wheelchair, but out of bed most of day; retains many self-care functions; generally has effective use of arms</td>
</tr>
<tr>
<td>8.5</td>
<td>Essentially restricted to bed much of the day; has some effective use of arms(s); retains some self-care functions</td>
</tr>
<tr>
<td>9.0</td>
<td>Helpless bed patient; can communicate and eat</td>
</tr>
<tr>
<td>9.5</td>
<td>Totally helpless bed patient; unable to communicate or eat</td>
</tr>
<tr>
<td>10.0</td>
<td>Death due to MS</td>
</tr>
</tbody>
</table>

**FUNCTIONAL STATUS (FS) SCORE**

A. Pyramidal functions

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Abnormal signs without disability</td>
</tr>
<tr>
<td>2</td>
<td>Minimal disability</td>
</tr>
<tr>
<td>3</td>
<td>Mild or moderate paraparesis or hemiparesis, or severe monoparesis</td>
</tr>
<tr>
<td>4</td>
<td>Marked paraparesis or hemiparesis, moderate quadriparesis, or monoplegia</td>
</tr>
<tr>
<td>5</td>
<td>Paraplegia, hemiplegia, or marked quadriparesis</td>
</tr>
<tr>
<td>6</td>
<td>Quadriplegia</td>
</tr>
</tbody>
</table>

B. Cerebellar functions

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Abnormal signs without disability</td>
</tr>
<tr>
<td>2</td>
<td>Mild ataxia</td>
</tr>
<tr>
<td>3</td>
<td>Moderate truncal or limb ataxia</td>
</tr>
<tr>
<td>4</td>
<td>Severe ataxia all limbs</td>
</tr>
<tr>
<td>5</td>
<td>Unable to perform coordinated movements due to ataxia</td>
</tr>
</tbody>
</table>

C. Brainstem functions

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Signs only</td>
</tr>
<tr>
<td>2</td>
<td>Moderate nystagmus or other mild disability</td>
</tr>
<tr>
<td>3</td>
<td>Severe nystagmus, marked extracranial weakness, or moderate disability of other cranial nerves</td>
</tr>
<tr>
<td>4</td>
<td>Marked dysarthria or other marked disability</td>
</tr>
<tr>
<td>5</td>
<td>Inability to swallow or speak</td>
</tr>
</tbody>
</table>

D. Sensory functions

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Vibration or figure-writing decrease only, in 1 or 2 limbs</td>
</tr>
<tr>
<td>2</td>
<td>Mild decrease in touch or pain or position sense, and/or moderate decrease in vibration in 1 or 2 limbs, or vibratory decrease alone in 3 or 4 limbs</td>
</tr>
<tr>
<td>3</td>
<td>Moderate decrease in touch or pain or position sense, and/or essentially lost vibration in 1 or 2 limbs, or mild decrease in touch or pain, and/or moderate decrease in all proprioceptive tests in 3 or 4 limbs</td>
</tr>
<tr>
<td>4</td>
<td>Marked decrease in touch or pain or loss of proprioception, alone or combined, in 1 or 2 limbs or moderate decrease in touch or pain and/or severe proprioceptive decrease in more than 2 limbs</td>
</tr>
</tbody>
</table>


**Disease-Modifying Therapies for Relapsing Forms of MS (RRMS SPMS with Exacerbations)**

Four such agents are approved in the United States: (1) IFN-β1a (Avonex), (2) IFN-β1a (Rebif); (3) IFN-β1b (Betaseron); and (4) glatiramer acetate (Copaxone). Each of these treatments is also used in SPMS patients who still experience attacks, because SPMS can be difficult to distinguish from RRMS and the clinical trials suggest that such patients also derive therapeutic benefit. In Phase III clinical trials, recipients of IFNβ1b, IFNβ1a, and glatiramer acetate experienced ~30% fewer clinical exacerbations and fewer new MRI lesions compared to placebo recipients. Mitoxantrone (Novantrone), an immune suppressant, has also been approved in the United States, although, because of its potential toxicity, it is generally reserved for patients with progressive disability who have failed other treatments.

**INTERFERON β AND GLATIRAMERE ACETATE**

IFN-β is a class I interferon originally identified by its antiviral properties. Efficacy in MS, however, probably results from immunomodulatory properties including: (1) downregulating expression of MHC molecules on antigen-presentation cells; (2) inhibiting proinflammatory and increasing regulatory cytokine levels; (3) inhibition of T cell proliferation; and (4) limiting the trafficking of inflammatory cells in the CNS. Glatiramer acetate is a synthetic, random polypeptide composed of four amino acids (L-glutamic acid, L-lysine, L-alanine, and L-tyrosine). Its mechanism of action may include: (1) induction of antigen-specific suppressor T cells; (2) binding to MHC molecules, thereby displacing bound MBP; or (3) altering the balance between proinflammatory and regulatory cytokines.

IFN-β reduces the attack rate (whether measured clinically or by MRI) in MS patients. It also improves disease severity measures such as EDSS progression and MRI-documented disease burden. The efficacy of IFN-β in SPMS patients is less convincing than the efficacy

---

**Note:** The table is a key to the rating system for evaluating neurologic impairment in MS, a condition associated with chronic inflammation and demyelination of the central nervous system. The EDSS, or Expanded Disability Status Scale, is a widely used tool to assess the worsening of clinical disability in MS patients.
in RRMS patients. IFN-β should be considered in patients with either RRMS or SPMS with superimposed relapses. In patients with SPMS but without relapses, efficacy has not been established. Higher IFN-β doses appear to have slightly greater efficacy but are also more likely to induce neutralizing antibodies, which may reduce the clinical benefit (see below).

Glatiramer acetate also reduces the attack rate (whether measured clinically or by MRI) in RRMS. Glatiramer acetate may also benefit disease severity measures, although this is less well established than for the relapse rate. Therefore, glatiramer acetate should be considered in RRMS patients. However, its usefulness in progressive disease is entirely unknown.

The long-term efficacy of these treatments remains largely unknown. For the interferons, clear-cut beneficial effects in reducing the relapse rate and, more substantially, in reducing CNS inflammation inferred by MRI have not been matched by similar success in treating patients with progressive symptoms (see below). This discordance has led to a reconsideration of the MS disease process as having two separate phases: inflammatory and neurodegenerative. In this model, the former leads to attacks and the latter to progression. It is likely that a gradual loss of axons underlies progressive MS symptoms, and this process could hypothetically result from loss of trophic influences provided by intact myelin. If true, then an MS attack early in the course might lead to a progressive symptom many years later. Because of this possibility, many experts currently believe that very early treatment with a disease-modifying drug is appropriate for most MS patients. It is reasonable to delay initiating treatment in patients with (1) normal neurologic exams; (2) a single attack or a low attack frequency; and (3) a low burden of disease as assessed by brain MRI. Untreated patients need to be followed closely with periodic brain MRI scans; the need for therapy is reassessed if the scans reveal evidence of ongoing, subclinical disease.

Most treated patients with relapsing forms of MS receive IFN-β as first-line therapy. Regardless of which agent is chosen first, treatment should probably be altered in patients who continue to have frequent attacks or progressive disability (Fig. 359-4). The value of combination therapy is unknown.

IFN-β1a (Avonex), 30 µg, is administered by intramuscular injection once every week. IFN-β1a (Rebif), 44 µg, is administered by subcutaneous injection three times per week. IFN-β1b (Betaseron), 250 µg, is administered by subcutaneous injection every other day. Glatiramer acetate, 20 mg, is administered by subcutaneous injection every day. Common side effects of IFN-β therapy include flu-like symptoms (e.g., fevers, chills, and myalgias) and mild abnormalities on routine laboratory evaluation (e.g., elevated liver function tests or lymphopenia). Rarely, more severe hepatotoxicity may occur. Subcutaneous IFN-β also causes reactions at the injection site (e.g., pain, redness, induration, or, rarely, skin necrosis). Side effects can usually be managed with concomitant nonsteroidal anti-inflammatory medications and with the use of an auto-injector. Depression, increased spasticity, and cognitive changes have been reported, although these symptoms can also be due to the underlying disease. In any event, side effects to IFN-β therapy usually subside with time.

Approximately 2 to 10% of IFN-β1a (Avonex) recipients, 15 to 25% of IFN-β1a (Rebif) recipients, and 30 to 40% of IFN-β1b (Betaseron) recipients develop neutralizing antibodies to IFN-β, which may disappear over time. Some evidence suggests that neutralizing antibodies reduce efficacy, especially for MRI outcomes. The current clinical data, however, are quite conflicted. Moreover, there are few situations where measurement of antibodies is necessary. Thus, for a patient doing well on therapy, the presence of antibodies should not matter. Conversely, for a patient doing poorly on therapy, alternative...
treatment should be considered, even if there are no detectable antibodies.

Injection site reactions also occur with glatiramer acetate but are less severe than with IFN-β1b. Approximately 15% of patients experience one or more episodes of flushing, chest tightness, dyspnea, palpitations, and anxiety after injection. This systemic reaction is unpredictable, brief (duration <1 h), and tends not to recur.

MITOXANTRONE HYDROCHLORIDE Mitoxantrone (Novantrone), an antineoplastic action by (1) intercalating into DNA and producing both strand breaks and intersand cross-links, (2) interfering with RNA synthesis and, (3) inhibiting topoisomerase II (involved in DNA repair). The U.S. Food and Drug Administration (FDA) approved mitoxantrone on the basis of a single (relatively small) phase III clinical trial in Europe, in addition to an even smaller phase II study completed earlier. Mitoxantrone received (from the FDA) the broadest indication of any current treatment for MS. Thus, mitoxantrone is indicated for use in SPMS, in PRMS, and in patients with worsening RRMS (defined as patients whose neurologic status remains significantly abnormal between MS attacks). Despite this broad indication, however, the data supporting its efficacy are weaker than for other approved therapies.

Mitoxantrone can produce cardiac problems (e.g., cardiomyopathy, reduced left ventricular ejection fraction, and irreversible congestive heart failure). As a result, a cumulative dose >140 mg/m² is not recommended. At currently approved doses (12 mg/m² every 3 months), the maximum duration of therapy can be only 2 to 3 years. Furthermore, >40% of women will experience amenorrhea, which may be permanent. Finally, there is risk of acute leukemia, and this complication has already been reported in several mitoxantrone-treated MS patients.

Given these risks, mitoxantrone should not be used as a first-line agent in either RRMS or relapsing MS. It is reasonable to consider mitoxantrone in selected patients with a progressive course who have failed other approved therapies.

Disease-Modifying Therapies for SPMS without Relapses High-dose IFN-β probably has a beneficial effect in patients with SPMS who are still experiencing acute relapses. IFN-β is probably ineffective in patients with SPMS who are not having acute attacks.

Although mitoxantrone has been approved for patients with progressive MS, this is not the population studied in the pivotal trial. Therefore no evidence-based recommendation can be made with regard to its use in this setting.

PPMS No currently available therapies have shown any promise for treating PPMS at this time. A phase III clinical trial of glatiramer acetate in PPMS was recently stopped because of an apparent lack of efficacy. A trial of mitoxantrone in PPMS is in progress.

Off-Label Treatment Options for RRMS and SPMS Azathioprine (2 to 3 mg/kg body weight) has been used primarily in SPMS. Meta-analysis of published trials suggests that azathioprine is marginally effective at lowering relapse rates, although a benefit on disability progression has not been demonstrated. Methotrexate (7.5 to 20 mg/week) was shown in one study to slow the progression of upper extremity dysfunction in SPMS. Because of the possibility of developing irreversible liver damage, some experts recommend a blind liver biopsy after 2 years of therapy.

Cyclophosphamide (700 mg/m², every other month) may be helpful for treatment-refractory patients who are (1) otherwise in good health, (2) ambulatory, and (3) <40 years of age. Because cyclophosphamide can be used for periods in excess of 3 years, it may be preferable to mitoxantrone in these circumstances.

Intravenous immunoglobulin (IVIg), administered in monthly pulses (up to 1 g/kg) for up to 2 years, appears to reduce annual exacerbation rates. However, its use is limited because of its high cost, questions about optimal dose, and uncertainty about its effect on long-term disability outcome.

Methylprednisolone administered in one study as monthly high-dose intravenous pulses, reduced disability progression (see above).

Other Therapeutic Claims Many purported treatments for MS have never been subjected to scientific scrutiny. These include dietary therapies (e.g., the Swank diet in addition to others), megadose vitamins, calcium citrate, bee stings, cow colostrum, hyperbaric oxygen, probiotics (a combination of histamine and caffeine), chelation, acupuncture, acupuncture, various Chinese herbal remedies, and removal of mercury amalgam tooth fillings, among many others. Patients should avoid costly or potentially hazardous unproven treatments. Many such treatments lack biologic plausibility. For example, no reliable case of mercury poisoning resembling typical MS has ever been described.

Although potential roles for human herpes virus 6 and/or chlamydia have been suggested for MS, these reports are unconfirmed, and treatment with antiviral agents or antibiotics is not currently appropriate.

Symptomatic Therapy Potassium channel blockers (e.g., 4-aminopyridine, 10 to 40 mg/d; and 3,4-di-aminopyridine, 40 to 80 mg/d) may be helpful for weakness, especially for heat-sensitive symptoms. At high doses they may cause seizures. These agents are not FDA-approved but can be obtained from compounding pharmacies around the United States. Ataxia/tremor is often intractable. Clonazepam, 1.5 to 20 mg/d; myosin, 50 to 250 mg/d; propranolol, 40 to 200 mg/d; or oندansetron, 8 to 16 mg/d may help. Wrist-weights occasionally reduce tremor in the arm or hand. Thalamotomy or deep brain stimulation has been tried with mixed success.

Spasticity and spasms may improve with physical therapy, regular exercise, and stretching. Avoidance of triggers (e.g., infections, fecal impactions, bed sores) is extremely important. Effective medications include lioresal (20 to 120 mg/d), diazepam (2 to 40 mg/d), tizanidine (8 to 32 mg/d), dantrolene (25 to 400 mg/d), and cyclobenzaprine hydrochloride (10 to 60 mg/d). For severe spasticity, a lioresal pump (delivering medication directly into the CSF) can provide substantial relief.

Pain is treated with anticonvulsants (carbamazepine, 100 to 1000 mg/d; phenytoin, 300 to 600 mg/d; or gabapentin, 300 to 3600 mg/d), antidepressants (amitriptyline, 25 to 150 mg/d; nortryptiline, 25 to 150 mg/d; desipramine, 100 to 300 mg/d; or venlafaxine, 75 to 225 mg/d), or antiarrhythmic agents (mexiletine, 300 to 900 mg/d). If these approaches fail, patients should be referred to a comprehensive pain management program.

Bladder dysfunction management is best guided by urodynamics. Evening fluid restriction or frequent voluntary voiding may help detrusor hyperreflexia. If these methods fail, propanolone bromide (10 to 15 mg/d), oxybutin (5 to 15 mg/d), hyoscine sulfate (0.5 to 0.75 mg/d), or tolteridine (2 to 4 mg/d) may help. Coadministration of pseudoephedrine (30 to 60 mg) is sometimes beneficial.

Detrusor/osphyncter dyssynergy may respond to phenoxybenzamine (10 to 20 mg/d) or terazosin hydrochloride (1 to 20 mg/d). Loss of reflex bladder wall contraction may respond to bethanecol (30 to 150 mg/d). However, both conditions often require catheterization.

Urinary tract infections should be treated promptly. Patients with large postvoid residual urine volumes are predisposed to infections. Prevention by urine acidification (with cranberry juice or vitamin C) inhibits some bacteria. Prophylactic administration of antibiotics is sometimes necessary but may lead to colonization by resistant organisms. Intermittent catheterization may help to prevent recurrent infections.

Treatment of constipation includes high-fiber diets and fluids. Natural or other laxatives may help. Fecal incontinence may respond to a reduction in dietary fiber.
Promising experimental therapies include maintaining erections. 100 mg sildenafil (50 to 200 mg) taken 1 to 2 h before sex is now the standard treatment for erectile dysfunction, and bladder/bowel dysfunction may also help. Sildenafil (50 to 200 mg) can be combined with low-dose anticonvulsants (acetazolamide, 200 to 600 mg/d; carbamazepine, 50 to 400 mg/d; phenytoin, 50 to 300 mg/d; or gabapentin, 600 to 1800 mg/d). Heat sensitivity may respond to heat-avoidance, air conditioning, or cooling garments. Sexual dysfunction may be helped by lubricants to aid in genital stimulation and sexual arousal. Management of pain, spasticity, and bowel/bladder dysfunction may also help. Sildenafil (50 to 100 mg) taken 1 to 2 h before sex is now the standard treatment for maintaining erections.

Promising experimental therapies include: (1) combination therapies; (2) higher-dose IFN-β than currently prescribed; (3) monoclonal antibodies against α4-integrin to prevent adhesion of lymphocytes to endothelial surfaces, against CD52 to induce global lymphocyte depletion, or against CD20 to deplete B cells selectively; (4) use of statins as immunomodulators; (5) estriol to induce a pregnancy-like state; (6) bone marrow transplants; and (7) schwann cell transplants.

CLINICAL VARIANTS OF MS Neuromyelitis optica (NMO), or Devic’s syndrome, consists of separate attacks of acute ON and myelitis. ON may be unilateral or bilateral and precede or follow an attack of myelitis by days, months, or years. In contrast to MS, patients with NMO do not experience brainstem, cerebellar, and cognitive involvement, and the brain MRI is typically normal. A focal enhancing region of swelling and cavitation, extending over three or more spinal cord segments, is typically seen on MRI. Histopathology of these lesions may reveal areas of necrosis and thickening of blood vessel walls. NMO, which is uncommon in Caucasians compared with Asians and Africans, is best understood as a syndrome with diverse causes. Some patients have a systemic autoimmune disorder, often systemic lupus erythematosus, Sjögren’s syndrome, p-ANCA (perinuclear antineutrophil cytoplasmic antibody) associated vasculitis, or mixed connective tissue disease. In others, onset may be associated with acute infection with varicella-zoster virus or HIV. More frequently, however, NMO is idiopathic and probably represents an MS variant.

Occasional patients present with apparent NMO but have periventricular MRI changes indicating typical MS. Furthermore, in the MS disease model EAE, immunization with peptides of MOG can produce an NMO-like disorder. Disease-modifying therapies for MS have not been rigorously studied in NMO. Acute attacks are usually treated with high-dose glucocorticoids as for MS exacerbations (see above). Because of the possibility that NMO is antibody-mediated, plasma exchange has also been used empirically for acute episodes that fail to respond to glucocorticoids. Immunosuppressants or interferons are sometimes used in the hope that further relapses will be prevented.

Acute MS (Marburg’s variant) is a fulminant demyelinating process that progresses to death within 1 to 2 years. Typically, there are no remissions. Diagnosis is established by biopsy or at autopsy, revealing widespread demyelination, axonal loss, edema, and macrophage infiltration. Discrete plaques may also be seen. Recent evidence strongly supports an antibody-mediated process in the demyelinating lesions. Marburg’s variant does not seem to follow infection or vaccination, and it is unclear whether this syndrome represents an extreme form of MS or another disease altogether. No controlled trials of therapy exist; high-dose glucocorticoids, plasma exchange, and cyclophosphamide have been tried, with uncertain benefit.

ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM) ADEM has a monophasic course and is frequently associated with antecedent immunization (postvaccinal encephalomyelitis) or infection (postinfectious encephalomyelitis). The hallmark of ADEM is the presence of widely scattered small foci of periventricular inflammation and demyelination. In its most explosive form, acute hemorrhagic leukoencephalitis of Weston Hurst, the lesions are vasculitic and hemorrhagic, and the clinical course is devastating.

Postvaccinal encephalomyelitis may follow the administration of smallpox and certain rabies vaccines. Postinfectious encephalomyelitis is most frequently associated with the viral exanthems of childhood. Infection with measles virus is the most common antecedent (1 in 1000 cases). Worldwide, measles encephalomyelitis is still common, although use of the live measles vaccine has dramatically reduced its incidence in developed countries. An ADEM-like illness rarely follows vaccination with live measles vaccine (1 to 2 in 10^6 immunizations). ADEM is now most frequently associated with varicella (chickenpox) infections (1 in 4000 to 10,000 cases). It may also follow infection with rubella, mumps, influenza, parainfluenza, and infectious mononucleosis viruses and with Mycoplasma. Some patients may have a nonspecific upper respiratory infection or no known antecedent illness.

An autoimmune response to MBP can be detected in the CSF from many patients with ADEM. This response has been most clearly established after rabies vaccination and infection with measles virus. With measles infection, the induction of immune responses to a variety of CNS antigens may occur, but only the response to MBP correlates with the development of ADEM. Many cases of postvaccinal encephalomyelitis may result from sensitization with brain material that contaminates the viral vaccines. Attempts to demonstrate direct viral invasion of the CNS have been unsuccessful.

CLINICAL MANIFESTATIONS In severe cases, onset is abrupt, and progression rapid (hours to days). In postinfectious ADEM, the neurologic syndrome generally begins late in the course of the viral illness as the exanthem is fading. Fever reappears, and headache, meningismus, and lethargy progressing to coma may develop. Seizures are common. Signs of disseminated neurologic disease are consistently present (e.g., hemiparesis or quadriparesis, extensor plantar responses, lost or hyperactive tendon reflexes, sensory loss and brainstem involvement). In ADEM due to chickenpox, cerebellar involvement is often conspicuous. CSF protein is modestly elevated (0.5 to 1.5 g/L [50 to 150 mg/dL]). Lymphocytic pleocytosis, generally 200 cells/μL, occurs in 80% of patients. Occasional patients have higher counts or a mixed polymorphonuclear-lymphocytic pattern during the initial days of the illness. Persistent CSF oligoclonal banding has been reported. MRI may reveal extensive gadolinium enhancement of white matter in brain and spinal cord.

DIAGNOSIS The diagnosis is easily established when there is a history of recent vaccination or exanthematous illness. In severe cases with predominantly cerebral involvement, acute encephalitis due to infection with herpes simplex or other viruses may be difficult to exclude. The simultaneous onset of disseminated symptoms and signs is common in ADEM and rare in MS. Similarly, meningismus, drowsiness or coma, or seizures suggest ADEM rather than MS. Unlike in MS, in ADEM optic nerve involvement is generally bilateral and transverse myelopathy complete. MRI findings that may support a diagnosis of ADEM include extensive and relatively symmetric white matter abnormalities and Gd enhancement of all abnormal areas, indicating active disease and a monophasic course.
Initial treatment is with high-dose glucocorticoids as for exacerbations of MS (see above). Patients who fail to respond may benefit from a course of plasma exchange or intravenous immunoglobulin. The prognosis reflects the severity of the underlying acute illness. Measles encephalomyelitis is associated with a mortality rate of 5 to 20%, and most survivors have permanent neurologic sequelae. Children who recover may have persistent seizures and behavioral and learning disorders.

**TREATMENT**

**MENINGITIS, ENCEPHALITIS, BRAIN ABDUCSS, AND EMPYEMA**

Karen L. Roos, Kenneth L. Tyler

Acute infections of the nervous system are among the most important problems in medicine because early recognition, efficient decision-making, and rapid institution of therapy can be lifesaving. These distinct clinical syndromes include acute bacterial meningitis, viral meningitis, encephalitis, focal infections such as brain abscess and subdural empyema, and infectious thrombophlebitis. Each may present with a nonspecific prodrome of fever and headache, which in a previously healthy individual may initially be thought to be benign, until (with the exception of viral meningitis) altered consciousness, focal neurologic signs, or seizures appear. Key goals of early management are to emergently distinguish between these conditions, identify the responsible pathogen, and initiate appropriate antimicrobial therapy.

**APPROACH TO THE PATIENT**

(Fig. 360-1) The first task is to identify whether an infection predominantly involves the subarachnoid space (“meningitis”) or whether there is evidence of either generalized or focal involvement of brain tissue in the cerebral hemispheres, cerebellum, or brainstem. When brain tissue is directly injured by a viral infection the disease is referred to as “encephalitis,” whereas focal bacterial, fungal, or parasitic infections involving brain tissue are classified as either “cerebritis” or “abscess,” depending on the presence or absence of a capsule.

Nuchal rigidity is the pathognomonic sign of meningeal irritation and is present when the neck resists passive flexion. Kernig’s and Brudzinski’s signs are also classic signs of meningeal irritation. Kernig’s sign is elicited with the patient in the supine position. The thigh is flexed on the abdomen, with the knee flexed; attempts to passively extend the knee elicit pain when meningeal irritation is present. Brudzinski’s sign is elicited with the patient in the supine position and is positive when passive flexion of the neck results in spontaneous flexion of the hips and knees. Although commonly tested on physical examinations, the sensitivity and specificity of Kernig’s and Brudzinski’s signs are uncertain. Both may be absent or reduced in very young or elderly patients, immunocompromised individuals, or patients with a severely depressed mental status. The high prevalence of cervical spine disease in older individuals may result in false-positive tests for nuchal rigidity.

Initial management can be guided by several considerations: (1) Empirical therapy should be initiated promptly whenever bacterial meningitis is a significant diagnostic consideration. (2) All patients who have had recent head trauma, are immunocompromised, have known malignant lesions or central nervous system (CNS) neoplasms, or have focal neurologic findings including papilledema or a depressed level of consciousness should undergo computed tomography (CT) or magnetic resonance imaging (MRI) of the brain prior to lumbar puncture (LP). In these cases empirical antibiotic therapy should not be delayed pending test results but should be administered prior to neuroimaging and LP. (3) A significantly depressed mental status (e.g., somnolence, coma), seizures, or focal neurologic deficits only rarely occur in viral (“aseptic”) meningitis; patients with these symptoms should be hospitalized for further evaluation and treated empirically for bacterial and viral meningitis. (4) Immunocompetent patients with a normal level of consciousness, no prior antimicrobial treatment, and a cerebrospinal fluid (CSF) profile consistent with viral meningitis (lymphocytic pleocytosis and a normal glucose concentration) can often be treated as outpatients, if appropriate contact and monitoring can be ensured. Failure of a patient with suspected viral meningitis to improve within 48 h should prompt a reevaluation including follow-up neurologic and general medical examination and repeat imaging and laboratory studies, often including a second LP.

**ACUTE BACTERIAL Meningitis**

**DEFINITION** Bacterial meningitis is an acute purulent infection within the subarachnoid space. It is associated with a CNS inflammatory reaction that may result in decreased consciousness, seizures, raised intracranial pressure (ICP), and stroke. The meninges, the subarachnoid space, and the brain parenchyma are all frequently involved in the inflammatory reaction (meningoencephalitis).

**EPIDEMIOLOGY** Bacterial meningitis is the most common form of suppurative CNS infection, with an annual incidence in the United States of > 2.5 cases/100,000 population. The epidemiology of bacterial meningitis has changed significantly in recent years, reflecting a dramatic decline in the incidence of meningitis due to Haemophilus influenzae, and a smaller decline in that due to Neisseria meningitidis, following the introduction and increasingly widespread use of vaccines for both these organisms. Currently, the organisms most commonly responsible for community-acquired bacterial meningitis are Streptococcus pneumoniae (~50%), N. meningitidis (~25%), group B streptococci (~15%), and Listeria monocytogenes (~10%). H. influenzae now accounts for < 10% of cases of bacterial meningitis in most series.

**ETIOLOGY** S. pneumoniae (Chap. 121) is the most common cause of meningitis in adults > 20 years of age, accounting for nearly half the reported cases (1.1 per 100,000 persons per year). There are a number of predisposing conditions that increase the risk of pneumococcal meningitis, the most important of which is pneumococcal pneumonia. Additional risk factors include coexisting acute or chronic pneumococcal sinusitis or otitis media, alcoholism, diabetes, splenectomy, hypogammaglobulinemia, complement deficiency, and head trauma with basal skull fracture and CSF rhinorrhea. Mortality remains ~ 20% despite antibiotic therapy.

N. meningitidis (Chap. 127) accounts for 25% of all cases of bacterial meningitis (0.6 cases per 100,000 persons per year) and for up to 60% of cases in children and young adults between the ages of 2 and 20. The presence of petechial or purpuric skin lesions can provide an important clue to the diagnosis of meningococcal infection. In some patients the disease is fulminant, progressing to death within hours of symptom onset. Infection may be initiated by nasopharyngeal colo-
Group B streptococcus, or *S. agalactiae*, was previously responsible for meningitis predominantly in neonates, but it has been reported with increasing frequency in individuals >50 years of age, particularly those with underlying diseases.

*L. monocytogenes* (Chap. 123) has become an increasingly important cause of meningitis in neonates (<1 month of age), pregnant women, individuals >60 years, and immunocompromised individuals of all ages. Infection is acquired by ingesting foods contaminated by *Listeria*. Foodborne human listerial infection has been reported from contaminated coleslaw, milk, soft cheeses, and several types of “ready-to-eat” foods including delicatessen meat and uncooked hotdogs.

The frequency of *H. influenzae* type b meningitis in children has declined dramatically since the introduction of the Hib conjugate vaccine, although rare cases of Hib meningitis in vaccinated children have been reported. More frequently, *H. influenzae* causes meningitis in unvaccinated children and adults.

Staphylococcus aureus and coagulase-negative staphylococci (Chap. 120) are important causes of meningitis that follows invasive neurosurgical procedures, particularly shunting procedures for hydrocephalus, or that occurs as a complication of the use of subcutaneous Omaya reservoirs for administration of intrathecal chemotherapy.

**PATHOPHYSIOLOGY** The most common bacteria that cause meningitis, *S. pneumoniae* and *N. meningitidis*, initially colonize the nasopharynx by attaching to nasopharyngeal epithelial cells. Bacteria are transported across epithelial cells in membrane-bound vacuoles to the intravascular space or invade the intravascular space by creating separations in the apical tight junctions of columnar epithelial cells. Once in the bloodstream, bacteria are able to avoid phagocytosis by neutrophils and classic complement-mediated bactericidal activity because of the presence of a polysaccharide capsule. Bloodborne bacteria can reach the intraventricular choroid plexus, directly infect choroid plexus epithelial cells, and gain access to the CSF. Some bacteria, such as *S. pneumoniae*, can adhere to cerebral capillary endothelial cells and subsequently migrate through or between these cells to reach the CSF. Bacteria are able to multiply rapidly within CSF because of the absence of effective host immune defenses. Normal CSF contains few white blood cells (WBCs) and relatively small amounts of complement proteins and immunoglobulins. The paucity of the latter two prevents effective opsonization of bacteria, an essential prerequisite for bacterial phagocytosis by neutrophils. Phagocytosis of bacteria is further impaired by the fluid nature of CSF, which is less conducive to phagocytosis than a solid tissue substrate.

A critical event in the pathogenesis of bacterial meningitis is the inflammatory reaction induced by the invading bacteria. Many of the neurologic manifestations and complications of bacterial meningitis result from the immune response to the invading pathogen rather than from direct bacteria-induced tissue injury. As a result, neurologic injury can progress even after the CSF has been sterilized by antibiotic therapy.
The lysis of bacteria with the subsequent release of cell-wall components into the subarachnoid space is the initial step in the induction of the inflammatory response and the formation of a purulent exudate in the subarachnoid space (Fig. 360-2). Bacterial cell-wall components, such as the lipopolysaccharide (LPS) molecules of gram-negative bacteria and teichoic acid and peptidoglycans of *S. pneumoniae*, induce meningeal inflammation by stimulating the production of inflammatory cytokines and chemokines by microglia, astrocytes, monocytes, microvascular endothelial cells, and CSF leukocytes. In experimental models of meningitis, cytokines including tumor necrosis factor (TNF) and interleukin (IL) 1 are present in CSF within 1 to 2 h of intracisternal inoculation of LPS. This cytokine response is quickly followed by an increase in CSF protein concentration and leukocytosis. Chemokines (cytokines that induce chemotactic migration in leukocytes) and a variety of other proinflammatory cytokines are also produced and secreted by leukocytes and tissue cells that are stimulated by IL-1 and TNF. In addition, bacteremia and the inflammatory cytokines induce the production of excitatory amino acids, reactive oxygen and nitrogen species (free oxygen radicals, nitric oxide, and peroxynitrite), and other mediators that can induce death of brain cells.

Much of the pathophysiology of bacterial meningitis is a direct consequence of elevated levels of CSF cytokines and chemokines. TNF and IL-1 act synergistically to increase the permeability of the blood-brain barrier, resulting in induction of vasogenic edema and the leakage of serum proteins into the subarachnoid space (Fig. 360-2). The subarachnoid exudate of proteinaceous material and leukocytes obstructs the flow of CSF through the ventricular system and diminishes the resorptive capacity of the arachnoid granulations in the dural sinuses, leading to obstructive and communicating hydrocephalus and concomitant interstitial edema.

Inflammatory cytokines upregulate the expression of selectins on cerebral capillary endothelial cells and leukocytes, promoting leukocyte adherence to vascular endothelial cells and subsequent migration into the CSF. The adherence of leukocytes to capillary endothelial cells increases the permeability of blood vessels, allowing for the leakage of plasma proteins into the CSF, which adds to the inflammatory exudate. Neutrophil degranulation results in the release of toxic metabolites that contribute to cytotoxic edema, cell injury, and death. Contrary to previous beliefs, CSF leukocytes probably do little to contribute to the clearance of CSF bacterial infection.

During the very early stages of meningitis there is an increase in cerebral blood flow, soon followed by a decrease in cerebral blood flow and a loss of cerebrovascular autoregulation (Chap. 258). Narrowing of the large arteries at the base of the brain due to encroachment by the purulent exudate in the subarachnoid space and infiltration of the arterial wall by inflammatory cells with intimal thickening (vasculitis) also occur and may result in ischemia and infarction, obstruction of branches of the middle cerebral artery by thrombosis, thrombosis of the major cerebral venous sinuses, and thrombophlebitis of the cerebral cortical veins. The combination of interstitial, vasogenic, and cytotoxic edema leads to raised ICP and coma. Cerebral herniation usually results from the effects of cerebral edema, either focal or generalized; hydrocephalus and dural sinus or cortical vein thrombosis may also play a role.

**FIGURE 360-18** (Continued)

**CLINICAL PRESENTATION** Meningitis can present as either an acute fulminant illness that progresses rapidly in a few hours or as a subacute infection that progressively worsens over several days. The classic clinical triad of meningitis is fever, headache, and nuchal rigidity (“stiff neck”). Each of these signs and symptoms occurs in >90% of cases. Alteration in mental status occurs in >75% of patients and can vary from lethargy to coma. Nausea, vomiting, and photophobia are also common complaints.

Seizures occur as part of the initial presentation of bacterial meningitis or during the course of the illness in 20 to 40% of patients. Focal seizures are usually due to focal arterial ischemia or infarction, cortical venous thrombosis with hemorrhage, or focal edema. Generalized seizure activity and status epilepticus may be due to hypotremia, cerebral anoxia, or, less commonly, the toxic effects of antimicrobial agents such as high-dose penicillin.

Raised ICP is an expected complication of bacterial meningitis and is the major cause of obtundation and coma in this disease. More than 90% of patients will have a CSF opening pressure >180 mmH2O, and 20% have opening pressures >400 mmH2O. Signs of increased ICP include a deteriorating or reduced level of consciousness, papilledema, dilated poorly reactive pupils, sixth nerve palsies, decerebrate posturing, and the Cushing reflex (bradycardia, hypertension, and irregular respirations). The most disastrous complication of increased ICP is cerebral herniation. The incidence of herniation in patients with bacterial meningitis has been reported to occur in as few as 1% to as many as 8% of cases.

Specific clinical features may provide clues to the diagnosis of
individual organisms and are discussed in more detail in specific chapters devoted to individual pathogens. The most important of these clues is the rash of meningococcemia, which begins as a diffuse erythematous maculopapular rash resembling a viral exanthem, but the skin lesions of meningococcemia rapidly become petechial. Petechiae are found on the trunk and lower extremities, in the mucous membranes and conjunctiva, and occasionally on the palms and soles.

**DIAGNOSIS** When bacterial meningitis is suspected, blood cultures should be immediately obtained and empirical antimicrobial therapy initiated without delay. The diagnosis of bacterial meningitis is made by examination of the CSF (Table 360-1). The need to obtain neuroradiographic studies (CT or MRI) prior to LP requires clinical judgment. In an immunocompetent patient with no known history of recent head trauma, a normal level of consciousness, and no evidence of papilledema or focal neurologic deficits, it is safe to perform LP without prior neuroradiographic studies. If LP is delayed in order to obtain neuroimaging studies, empirical antibiotic therapy should be initiated after blood cultures are obtained. Antibiotic therapy initiated a few hours prior to LP will not significantly alter the CSF WBC count or glucose concentration, nor is it likely to prevent visualization of organisms by Gram’s stain.

The classic CSF abnormalities in bacterial meningitis (Table 360-1) are: (1) polymorphonuclear (PMN) leukocytosis (>100 cells/µL in 90%), (2) decreased glucose concentration (<2.2 mmol/L (<40 mg/dL) and/or CSF/serum glucose ratio of <0.4 in <60%), (3) increased protein concentration (>0.45 g/L (>45 mg/dL) in 90%), and (4) increased opening pressure (>180 mmH₂O in 90%). CSF bacterial cultures are positive in >80% of patients, and CSF Gram’s stain demonstrates organisms in >60%.

CSF glucose concentrations <2.2 mmol/L (<40 mg/dL) are abnormal, and a CSF glucose concentration of zero can be seen in bacterial meningitis. Use of the CSF/serum glucose ratio corrects for hyperglycemia that may mask a relative decrease in the CSF glucose concentration. The CSF glucose concentration is low when the CSF/serum glucose ratio is <0.6. A CSF/serum glucose ratio <0.4 is highly suggestive of bacterial meningitis but may also be seen in other conditions, including fungal, tuberculous, and carcinomatous meningitis. It takes from 30 min to several hours for CSF glucose concentration to reach equilibrium with blood glucose concentrations; therefore, administration of 50 mL of 50% glucose (D50) prior to LP, as commonly occurs in emergency room settings, is unlikely to alter CSF glucose concentration significantly unless more than a few hours have elapsed between glucose administration and LP.

The latex agglutination (LA) test for the detection of bacterial antigens of *S. pneumoniae*, *N. meningitidis*, *H. influenzae* type b, group B streptococcus, and *Escherichia coli* K1 strains in the CSF is very useful for making a rapid diagnosis of bacterial meningitis, especially in patients who have been pre-treated with antibiotics and in whom CSF Gram’s stain and culture are negative. The CSF LA test has a specificity of 95 to 100% for *S. pneumoniae* and *N. meningitidis*, so a positive test is virtually diagnostic of bacterial meningitis caused by these organisms. However, the sensitivity of the CSF LA test is only 70 to 100% for detection of *S. pneumoniae* and 33 to 70% for detection of *N. meningitidis* antigens, so a negative test does not exclude infection by these organisms. The Limulus amebocyte lysate assay is a rapid diagnostic test for the detection of gram-negative endotoxin in CSF, and thus for making a diagnosis of gram-negative bacterial meningitis. The test has a specificity of 85 to 100% and a sensitivity approaching 100%. Thus, a positive Limulus amebocyte lysate assay occurs in virtually all patients with gram-negative bacterial meningitis, but false-positives may occur. CSF polymerase chain

---

**FIGURE 360-2** The pathophysiology of the neurologic complications of bacterial meningitis. SAS, subarachnoid space; CSF, cerebrospinal fluid.

---

**TABLE 360-1** Cerebrospinal Fluid (CSF) Abnormalities in Bacterial Meningitis

<table>
<thead>
<tr>
<th>Test</th>
<th>Abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening pressure</td>
<td>&gt;180 mmH₂O</td>
</tr>
<tr>
<td>White blood cells</td>
<td>10 to 10,000/µL; neutrophils predominate</td>
</tr>
<tr>
<td>Red blood cells</td>
<td>Absent in nontraumatic tap</td>
</tr>
<tr>
<td>Glucose</td>
<td>&lt;2.2 mmol/L (&lt;40 mg/dL)</td>
</tr>
<tr>
<td>CSF/serum glucose ratio</td>
<td>&lt;0.4</td>
</tr>
<tr>
<td>Protein</td>
<td>&gt;0.45 g/L (&gt;45 mg/dL)</td>
</tr>
<tr>
<td>Gram’s stain</td>
<td>Positive in &gt;60%</td>
</tr>
<tr>
<td>Culture</td>
<td>Positive in &gt;80%</td>
</tr>
<tr>
<td>Latex agglutination</td>
<td>May be positive in patients with meningitis due to <em>S. pneumoniae</em>, <em>N. meningitidis</em>, <em>H. influenzae</em> type b, <em>E. coli</em>, group B streptococcus</td>
</tr>
<tr>
<td>Limulus lysates</td>
<td>Positive in cases of gram-negative meningitis</td>
</tr>
<tr>
<td>PCR for bacterial DNA</td>
<td>Research test</td>
</tr>
</tbody>
</table>

*Note: PCR, polymerase chain reaction.*
reaction (PCR) tests are not as useful in the diagnosis of bacterial meningitis as they are in the diagnosis of viral CNS infections. A CSF PCR test has been developed for detecting DNA from bacteria in CSF, but its sensitivity and specificity need to be better characterized before its role in diagnosis can be defined.

Almost all patients with bacterial meningitis will have neuroimaging studies performed during the course of their illness. MRI is preferred over CT because of its superiority in demonstrating areas of cerebral edema and ischemia. In patients with bacterial meningitis, diffuse meningeal enhancement is often seen after the administration of gadolinium. Meningeal enhancement is not diagnostic of meningitis but occurs in any CNS disease associated with increased blood–brain barrier permeability.

Petechial skin lesions, if present, should be biopsied. The rash of meningococcemia results from the dermal seeding of organisms with vascular endothelial damage, and biopsy may reveal the organism on Gram’s stain.

**Differential Diagnosis**

Viral meningoencephalitis, and particularly herpes simplex virus (HSV) encephalitis, can mimic the clinical presentation of bacterial meningitis (see “Encephalitis,” below). HSV encephalitis typically presents with headache, fever, altered consciousness, focal neurologic deficits (e.g., dysphasia, hemiparesis), and focal or generalized seizures. The findings on CSF studies, neuroimaging, and electroencephalogram (EEG) distinguish HSV encephalitis from bacterial meningitis. The typical CSF profile with viral CNS infections is a lymphocytic pleocytosis with a normal glucose concentration, in contrast to PMN pleocytosis and hypoglycorrhachia characteristic of bacterial meningitis. MRI abnormalities (other than meningeal enhancement) are not seen in uncomplicated bacterial meningitis. By contrast, in HSV encephalitis parenchymal changes, especially in orbitofrontal and medial temporal lobes, are usually found. Some patients with HSV encephalitis have a distinctive periodic pattern on EEG (see below).

Rickettsial disease can resemble bacterial meningitis (Chap. 158). Rocky Mountain spotted fever (RMSF) is transmitted by a tick bite and caused by the bacteria *Rickettsia rickettsii*. The disease may present acutely with high fever, prostration, myalgia, headache, and nausea and vomiting. Most patients develop a characteristic rash within 96 h of the onset of symptoms. The rash is initially a diffuse erythematous maculopapular rash that may be difficult to distinguish from that of meningococcemia. It progresses to a petechial rash, then to a purpuric rash, and, if untreated, to skin necrosis or gangrene. The color of the lesions changes from bright red to very dark red, then yellowish-green to black. The rash typically begins in the wrist and ankles, and then spreads distally and proximally within a matter of a few hours and involves the palms and soles. Diagnosis is made by immunofluorescent staining of skin biopsy specimens.

Focal suppurative CNS infections (see below), including subdural and epidural empyema and brain abscess, should also be considered, especially when focal neurologic findings are present. MRI should be performed promptly in all patients with suspected meningitis who have focal features, both to detect the intracranial infection and to search for associated areas of infection in the sinuses or mastoid bones.

A number of noninfectious CNS disorders can mimic bacterial meningitis. Subarachnoid hemorrhage (SAH; Chap. 349) is generally the major consideration. Other possibilities include chemical meningitis due to rupture of tumor contents into the CSF (e.g., from a cystic glioma, craniopharyngioma epidermoid or dermoid cyst); drug-induced hypersensitivity meningitis; carcinomatous or lymphomatous meningitis; meningitis associated with inflammatory disorders such as sarcoid, systemic lupus erythematosus (SLE), and Behçet disease; pitiuitary apoplexy; and uveomeningitic syndromes (Vogt-Koyanagi-Harada syndrome).

Subacute involving meningitis (Chap. 361) may on occasion be considered in the differential diagnosis of acute meningitis. The principal causes include *Mycobacterium tuberculosis* (Chap. 150), *Cryptococcus neoformans* (Chap. 186), *Histoplasma capsulatum* (Chap. 248), *Coccidioides immitis* (Chap. 184), and *Treponema pallidum* (Chap. 153).

**Empirical Antimicrobial Therapy**

Bacterial meningitis is a medical emergency. The goal is to begin antibiotic therapy within 60 min of a patient’s arrival in the emergency room. Empirical antimicrobial therapy is initiated in patients with suspected bacterial meningitis before the results of CSF Gram’s stain and culture are known. *S. pneumoniae* (Chap. 119) and *N. meningitidis* (Chap. 127) are the most common etiologic organisms of community-acquired bacterial meningitis. Due to the emergence of penicillin- and cephalosporin-resistant *S. pneumoniae*, empirical therapy of community-acquired bacterial meningitis in children and adults should include a third-generation cephalosporin (e.g., ceftriaxone or cefotaxime) and vancomycin. Ceftriaxone or cefotaxime provide good coverage for susceptible *S. pneumoniae*, group B streptococci, and *H. influenzae* and adequate coverage for *N. meningitidis*. Cefepime is a broad-spectrum fourth-generation cephalosporin with in vitro activity similar to that of cefotaxime or ceftriaxone against *S. pneumoniae* and *N. meningitidis* and greater activity against *Enterobacter* spp. and *P. aeruginosa*. In clinical trials, cefepime has been demonstrated to be equivalent to cefotaxime in the treatment of penicillin-sensitive pneumococcal and meningococcal meningitis, but its efficacy in bacterial meningitis caused by penicillin- and cephalosporin-resistant pneumococcal organisms, *Enterobacter* spp., and *P. aeruginosa* has not been established. Ampicillin should be added to the empirical regimen for coverage of *L. monocytogenes* in individuals <3 months of age, those >55, or those with suspected impaired cell-mediated immunity because of chronic illness, organ transplantation, pregnancy, malignancies, or immunosuppressive therapy. In hospital-acquired meningi-
gits, and particularly meningitis following neurosurgical procedures, staphylococci and gram-negative organisms including *P. aeruginosa* are the most common etiologic organisms. In these patients, empirical therapy should include a combination of vancomycin and cefazidime. Cefazidime should be substituted for ceftriaxone or cefotaxime in neurosurgical patients and in neurotic patients, as cefazidime is the only cephalosporin with adequate activity against CNS infection with *P. aeruginosa*. Meropenem is a carbapenem antibiotic that is highly active in vitro against *L. monocytogenes*, has been demonstrated to be effective in cases of meningitis caused by *P. aeruginosa*, and shows good activity against penicillin-resistant pneumococci. In experimental pneumococcal meningitis, meropenem was comparable to ceftriaxone and inferior to vancomycin in sterilizing CSF cultures. The number of patients with bacterial meningitis enrolled in clinical trials of meropenem has not been sufficient to definitively assess the efficacy of this antibiotic.

**Specific Antimicrobial Therapy (Table 360-3)**

Although ceftriaxone and cefotaxime provide adequate empirical coverage for *N. meningitidis*, penicillin G remains the antibiotic of choice for meningococcal meningitis caused by susceptible strains. Isolates of *N. meningitidis* with moderate resistance to penicillin have been identified, but patients infected with these strains have still been successfully treated with penicillin. CSF isolates of *N. meningitidis* should be tested for penicillin and ampicillin susceptibility, and if resistance is found, cefotaxime or ceftriaxone should be substituted for penicillin. A 7-day course of intravenous antibiotic therapy is adequate for uncomplicated meningococcal meningitis. The index case and all close contacts should receive chemoprophylaxis with a 2-day regimen of rifampin (600 mg every 12 h for 2 days in adults and 10 mg/kg every 12 h for 2 days in children > 1 year). Rifampin is not recommended in pregnant women. Alternatively, adults can be treated with one dose of ciprofloxacin (750 mg), one dose of azithromycin (500 mg), or one intramuscular dose of ceftriaxone (250 mg). Close contacts are defined as those individuals who have had contact with oropharyngeal secretions either through kissing or by sharing toys, beverages, or cigarettes.

**Pneumococcal Meningitis**

Antimicrobial therapy of pneumococcal meningitis is initiated with a cephalosporin (ceftriaxone, cefotaxime, or cefepime) and vancomycin. All CSF isolates of *S. pneumoniae* should be tested for sensitivity to penicillin and the cephalosporins. Once the results of antimicrobial susceptibility tests are known, therapy can be modified accordingly (Table 360-3). For *S. pneumoniae* meningitis, an isolate of *S. pneumoniae* is considered to be susceptible to penicillin with a minimal inhibitory concentration (MIC) < 0.06 μg/mL, to have intermediate resistance when the MIC is 0.1 to 1.0 μg/mL, and to be highly resistant when the MIC > 1.0 μg/mL. Isolates of *S. pneumoniae* that have cephalosporin MICs ≤ 0.5 μg/mL are considered sensitive to the cephalosporins (cefotaxime, ceftriaxone, cefepime). Those with MICs of 1 μg/mL are considered to have intermediate resistance, and those with MICs ≥ 2 μg/mL are considered resistant. For meningitis due to pneumococci with cefotaxime or ceftriaxone MICs ≥ 0.5 μg/mL, treatment with cefotaxime or ceftriaxone is usually adequate. If the MIC > 1 μg/mL, vancomycin is the antibiotic of choice. Rifampin can be added to vancomycin for its synergistic effect but is inadequate as monotherapy because resistance develops rapidly when it is used alone.

Patients with *S. pneumoniae* meningitis should have a repeat LP performed 24 to 36 h after the initiation of antimicrobial therapy to document sterilization of the CSF. Failure to sterilize the CSF after 24 to 36 h of antibiotic therapy should be considered presumptive evidence of antibiotic resistance. Patients with penicillin- and cephalosporin-resistant strains of *S. pneumoniae* who do not respond to intravenous vancomycin alone may benefit from the addition of intraventricular vancomycin. The intraventricular route of administration is preferred over the intrathecal route because adequate concentrations of vancomycin in the cerebral ventricles are not always achieved with intrathecal administration. A 2-week course of intravenous antimicrobial therapy is recommended for pneumococcal meningitis.

**L. monocytogenes Meningitis**

Meningitis due to this organism is treated with ampicillin for at least 3 weeks (Table 360-3). Gentamicin is often added (2 mg/kg loading dose, then 5.1 mg/kg per day given every 8 h and adjusted for serum levels and renal function). The combination of trimethoprim [10 to 20 (mg/kg)/d] and sulfamethoxazole [50 to 100 (mg/kg)/d] given every 6 h may provide an alternative in penicillin-allergic patients.

**Staphylococcal Meningitis**

Meningitis due to susceptible strains of *S. aureus* or coagulase-negative staphylococci is treated with nafcillin (Table 360-3). Vancomycin is the drug of choice for methicillin-resistant staphylococci and for patients allergic to penicillin. In these patients, the CSF should be monitored during therapy. If the CSF is not sterilized after 48 h of intravenous vancomycin therapy, then either intrathecal or intraventricular vancomycin, 20 mg once daily, can be added.

**Gram-Negative Bacillary Meningitis**

The third-generation cephalosporins, cefotaxime, ceftriaxone, and cefazidime, are equally efficacious for the treatment of gram-negative bacillary meningitis, with the exception of meningitis due to *P. aeruginosa*, which should be treated with cefazidime (Table 360-3). A 3-week course of intravenous antibiotic therapy is recommended for meningitis due to gram-negative bacilli.

**Adjuvant Therapy**

The release of bacterial cell-wall components by bactericidal antibiotics leads to the production of the inflammatory cytokines IL-1 and TNF in the subarachnoid space. Dexamethasone exerts its beneficial effect by inhibiting the synthesis of IL-1 and TNF at the level of mRNA, decreasing CSF outflow resistance, and stabilizing the blood-brain barrier. The rationale for giving dexamethasone 20 min before antibiotic therapy is that dexamethasone inhibits the production of TNF by macrophages and microglia only if it is administered before these cells are activated by endotoxin. Dexamethasone does not alter TNF production once it has been induced. The results of clinical trials of dexamethasone therapy in children, predominantly with meningitis due to *H. influenzae* and *S. pneumoniae*, have demonstrated its efficacy in decreasing meningeal inflammation and neurologic sequelae such as the incidence of sensorineural hearing loss.

A prospective European trial of adjunctive therapy for acute bacterial meningitis in 301 adults found that dexamethasone reduced the number of unfavorable outcomes (15% vs. 25%, p = .03) including death (7% vs. 15%, p = .04). The benefits were most striking in patients with pneumococcal meningitis. Dexamethasone (10 mg intra-

---

**TABLE 360-3** Antimicrobial Therapy of CNS Bacterial Infections Based on Pathogen

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Neisseria meningitidis</em></td>
<td>Penicillin G or Ampicillin</td>
</tr>
<tr>
<td>Penicillin-sensitive</td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td>Penicillin-resistant</td>
<td></td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>Penicillin G</td>
</tr>
<tr>
<td>Penicillin-sensitive</td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td>Penicillin-intermediate</td>
<td><em>(Ceftriaxone or cefotaxime)</em> +</td>
</tr>
<tr>
<td>Penicillin-resistant</td>
<td>Vancomycin</td>
</tr>
<tr>
<td>Gram-negative bacilli (except</td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td></td>
</tr>
<tr>
<td><em>Staphylococci spp.</em></td>
<td>Cefazidime</td>
</tr>
<tr>
<td>Methicillin-sensitive</td>
<td>Nafcillin</td>
</tr>
<tr>
<td>Methicillin-resistant</td>
<td>Vancomycin</td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em></td>
<td>Ampicillin + gentamicin</td>
</tr>
<tr>
<td><em>Hemophilus influenzae</em></td>
<td><em>(Ceftriaxone or cefotaxime)</em></td>
</tr>
<tr>
<td><em>Streptococcus agalactiae</em></td>
<td>Penicillin G or ampicillin</td>
</tr>
<tr>
<td><em>Bacteroides fragilis</em></td>
<td>Metronidazole</td>
</tr>
<tr>
<td><em>Fusobacterium spp.</em></td>
<td>Metronidazole</td>
</tr>
</tbody>
</table>

* Doses are as indicated in Table 360-2.
venously) was administered 15 to 20 min before the first dose of an antimicrobial agent, and the same dose was repeated every 6 h for 4 days. These results were confirmed in a second trial of dexamethasone in adults with pneumococcal meningitis. Therapy with dexamethasone should ideally be started 20 min before, or not later than concurrent with, the first dose of antibiotics. It is unlikely to be of significant benefit if started >6 h after antimicrobial therapy has been initiated. Dexamethasone may decrease the penetration of vancomycin into CSF, and it delays the sterilization of CSF in experimental models of S. pneumoniae meningitis. As a result, its potential benefit should be carefully weighed when vancomycin is the antibiotic of choice. Alternatively, vancomycin can be administered by the intraventricular route.

**Increased Intracranial Pressure**

Emergency treatment of increased ICP includes elevation of the patient’s head to 30 to 45°, intubation and hyperventilation (P\(_{\text{aCO}_2}\) 25 to 30 mmHg), and mannitol. Patients with increased ICP should be managed in an intensive care unit; accurate ICP measurements are best obtained with an ICP monitoring device.

——Treatment of increased intracranial pressure is discussed in detail in Chap. 258.

**PROGNOSIS**

Mortality is 3 to 7% for meningitis caused by H. influenzae, N. meningitidis, or group B streptococci; 15% for that due to L. monocytogenes; and 20% for S. pneumoniae. In general, the risk of death from bacterial meningitis increases with (1) decreased level of consciousness on admission, (2) onset of seizures within 24 h of admission, (3) signs of increased ICP, (4) young age (infancy) and age >50, (5) the presence of comorbid conditions including shock and/or the need for mechanical ventilation, and (6) delay in the initiation of treatment. Decreased CSF glucose concentration [<2.2 mmol/L (<40 mg/dL)] and markedly increased CSF protein concentration [>3 g/L (>300 mg/dL)] have been predictive of increased mortality and poorer outcomes in some series. Moderate or severe sequelae occur in ~25% of survivors, although the exact incidence varies with the infecting organism. Common sequelae include decreased intellectual function, memory impairment, seizures, hearing loss and dizziness, and gait disturbances.

**ACUTE VIRAL MENINGITIS**

**CLINICAL MANIFESTATIONS**

Viral meningitis presents as fever, headache, and meningeal irritation coupled with an inflammatory CSF profile (see below). Fever may be accompanied by malaise, myalgia, anorexia, nausea and vomiting, abdominal pain, and/or diarrhea. It is not uncommon to see a mild degree of lethargy or drowsiness. The presence of more profound alterations in consciousness, such as stupor, coma, or marked confusion, should prompt consideration of alternative diagnoses. Similarly, seizures or other focal neurologic signs or symptoms suggest involvement of the brain parenchyma and do not occur in uncomplicated viral meningitis. The headache associated with viral meningitis is usually frontal or retroorbital and often associated with photophobia and pain on moving the eyes. Nuchal rigidity is present in most cases but may be mild and present only near the limit of neck anteflexion. Evidence of severe meningeal irritation, such as Kernig’s and Brudzinski’s signs, is generally absent.

**ETIOLOGY**

Enteroviruses account for 75 to 90% of aseptic meningitis cases in most series (Table 360-4). Viruses belonging to the Enterovirus genus are members of the family Picornaviridae and include the coxsackieviruses, echoviruses, polioviruses, and human enteroviruses 68 to 71. Using a variety of diagnostic techniques including CSF PCR tests, culture, and serology, a specific viral cause can be found in 75 to 90% of cases of viral meningitis. CSF cultures are positive in 30 to 70% of patients, the frequency of isolation depending on the specific viral agent. Approximately two-thirds of culture-negative cases of aseptic meningitis have a specific viral etiology identified by CSF PCR testing (see below).

**EPIDEMIOLOGY**

The exact incidence of viral meningitis in the United States is impossible to determine since most cases go unreported to public health authorities, although a reasonable estimate would be ~75,000 cases per year. In temperate climates, there is a substantial increase in cases during the summer and early fall months, reflecting the seasonal predominance of enterovirus and arthropod-borne encephalitis virus (“arbovirus”) infections, with a peak monthly incidence of about 1 reported case per 100,000 population. The dramatic seasonal predilections of some viruses causing meningitis provide a valuable clue to diagnosis (Table 360-5).

**LABORATORY DIAGNOSIS**

**CSF Examination**

The most important laboratory test in the diagnosis of viral meningitis is examination of the CSF. The typical profile is a lymphocytic pleocytosis (25 to 500 cells/μL) or a normal or slightly elevated protein concentration (0.2 to 0.8 g/L (20 to 80 mg/dL)), a normal glucose concentration, and a normal or mildly elevated opening pressure (100 to 350 mmH\(_2\)O). Organisms are not seen on Gram’s or acid-fast stained smears or india ink preparations of CSF. Rarely, PMNs may predominate in the first 48 h of illness, especially in patients with infections due to echovirus 9, West Nile virus or Eastern equine encephalitis virus, or mumps. Recent studies suggest that in some patients with West Nile virus infection, PMN pleocytosis can persist for up to a week before shifting to a lymphocytic pleocytosis. Despite these exceptions, the presence of a CSF PMN pleocytosis in a patient with suspected viral meningitis should always prompt consideration of an alternative diagnosis including bacterial meningitis or parameningeal infections. The total CSF cell count in viral meningitis is typically 25 to 500/μL, although cell counts of several thousand per microliter are occasionally seen, especially with infections due to lymphocytic choriomeningitis virus (LCMV) and mumps virus. The CSF glucose concentration is typically normal in viral infections, although it may be decreased in 10 to 30% of cases due to mumps as well as in cases due to LCMV. Rare instances of decreased CSF glucose concentration occur in cases of meningitis due to echoviruses and other enteroviruses, HSV type 2, and varicella-zoster virus (VZV). As a rule, a lymphocytic pleocytosis with a low glucose concentration should suggest fungal, listerial, or tuberculous meningitis or noninfectious disorders (e.g., sarcoid, neoplastic meningitis).

A number of tests measuring levels of various CSF proteins, enzymes, and mediators, including C-reactive protein, lactic acid, lactate dehydrogenase, neopterin, quinolinate, IL-1β, IL-6, soluble IL-2 receptor, β₂-microglobulin, and TNF, have been proposed as potential markers of viral meningitis.

**TABLE 360-4 Viruses Causing Acute Meningitis and Acute Encephalitis**

<table>
<thead>
<tr>
<th>Common</th>
<th>Less Common</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enteroviruses</td>
<td>HSV-1</td>
<td>Adenoviruses</td>
</tr>
<tr>
<td>Arboviruses</td>
<td>LCMV</td>
<td>CMV</td>
</tr>
<tr>
<td>HIV</td>
<td>VZV</td>
<td>EBV</td>
</tr>
<tr>
<td>HSV-2</td>
<td></td>
<td>Influenza A, B, parainfluenza, mumps, rubella</td>
</tr>
</tbody>
</table>

**ACUTE ENCEPHALITIS**

<table>
<thead>
<tr>
<th>Arboviruses</th>
<th>CMV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enteroviruses</td>
<td>EBV</td>
</tr>
<tr>
<td>HSV-1</td>
<td>HIV</td>
</tr>
<tr>
<td></td>
<td>Adenoviruses, CTFV, hepatitis C, influenza A, LCMV, parainfluenza, rubella, rotavirus, rubella</td>
</tr>
</tbody>
</table>

**TABLE 360-5 Seasonal Prevalence of Viruses Commonly Causing Meningitis**

<table>
<thead>
<tr>
<th>Summer/Early Fall</th>
<th>Fall/Winter</th>
<th>Winter/Spring</th>
<th>Nonsesonal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arboviruses</td>
<td>LCMV</td>
<td>Mumps</td>
<td>HSV</td>
</tr>
<tr>
<td>Enteroviruses</td>
<td></td>
<td></td>
<td>HIV</td>
</tr>
</tbody>
</table>

**Note:** Abbreviations are as in Table 360-4.
Other Sources for Viral Isolation

Enteroviral epidemics. It also occurs in some asymptomatic individuals during enteroviral infection; it may result from residual shedding from a previous enteroviral infection for several weeks. The presence of enterovirus in stool is not diagnostic and may result from residual shedding from a previous enteroviral infection; it also occurs in some asymptomatic individuals during enteroviral epidemiology.

Polymersase Chain Reaction Amplification of Viral Nucleic Acid

Amplification of viral-specific DNA or RNA from CSF using PCR amplification has become the single most important method for diagnosing CNS viral infections. In both enteroviral and HSV infections of the CNS, PCR has become the diagnostic procedure of choice and is substantially more sensitive than viral cultures. HSV PCR has also been an important diagnostic test in patients with recurrent episodes of “aseptic” meningitis, many of whom have amplifiable HSV DNA in CSF despite negative viral cultures. HSV PCR is also used routinely to diagnose CNS viral infections caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV), and VZV.

CSF Culture

The overall results of CSF culture for the diagnosis of viral infection are disappointing, presumably because of the generally low concentration of infectious virus present and the need to customize isolation procedures for individual viruses. For viral isolation, 2 mL of CSF should be cultured promptly to the microbiology laboratory, where it should be refrigerated and processed as speedily as possible.

Other Sources for Viral Isolation

Viruses may also be isolated from sites and body fluids other than CSF, including throat, stool, blood, and urine. Enteroviruses and adenoviruses may be found in feaces; arboviruses, some enteroviruses, and LCMV, in blood; mumps and CMV, in urine; and enteroviruses, mumps, and adenoviruses, in throat washings. During enteroviral infections, viral shedding in stool may persist for several weeks. The presence of enterovirus in stool is not diagnostic and may result from residual shedding from a previous enteroviral infection; it also occurs in some asymptomatic individuals during enteroviral epidemics.

Serologic Studies

For some viruses, including many arboviruses such as West Nile virus (WNV), serologic studies remain a crucial diagnostic tool. Serum serologic studies are less useful for viruses such as HSV, VZV, CMV, and EBV for which the prevalence of antibody seropositivity in the general population is high. Diagnosis of acute viral infection can be made by documenting seroconversion between acute-phase and convalescent sera (typically obtained after 2 to 4 weeks) or by demonstrating the presence of virus-specific IgM antibodies. Documentation of intrathecal synthesis of virus-specific antibodies, as shown by an increased IgG index or the presence of IgM antibodies in CSF, is often significantly more useful than serum serology alone and can provide presumptive evidence of CNS infection. Although serum and CSF IgM antibodies generally persist for only a few months after acute infection, there are exceptions to this rule. For example, WNV IgM has been shown to persist in some patients for >1 year following acute infection. Unfortunately, the delay between onset of infection and the generation by the host of a virus-specific antibody response often means that serologic data are useful mainly for the retrospective establishment of a specific diagnosis, rather than in urgent diagnosis or management.

Agarose electrophoresis or isoelectric focusing of CSF γ-globulins may reveal the presence of oligoclonal bands. These bands have been found in association with a number of viral infections, including infections with HIV, human T cell lymphotrophic virus (HTLV) type I, VZV, mumps, subacute sclerosing panencephalitis (SSPE), and progressive rubella panencephalitis. The associated antibodies are often directed against viral proteins. The finding of oligoclonal bands may be of some diagnostic utility, since typically they are not seen with arboviruses, enteroviruses, or HSV infections. Oligoclonal bands are also encountered in certain noninfectious neurologic diseases (e.g., multiple sclerosis) and may be found in nonviral infections (e.g., syphilis, Lyme borreliosis).

Other Laboratory Studies

All patients with suspected viral meningitis should have a complete blood count and differential; liver function tests; and measurement of the erythrocyte sedimentation rate (ESR), blood urea nitrogen (BUN), and plasma levels of electrolytes, glucose, creatinine, creatine kinase, aldolase, amylase, and lipase. Abnormalities in specific test results may suggest particular etiologic diagnoses. MRI, CT, EEG, evoked response studies, electromyography (EMG), and nerve conduction studies are not necessary in most cases. They are best used selectively when atypical presentations or unusual features present diagnostic problems.

Differential Diagnosis

The most important issue in the differential diagnosis is the exclusion of nonviral causes that can mimic viral meningitis. The major categories of disease that should always be considered and excluded are (1) bacterial meningitis and other infectious meningitides (e.g., Mycoplasma, Listeria, Brucella, Coxiella, and Rickettsia); (2) parameningeal infections or partially treated bacterial meningitis; (3) nonviral infectious meningitides where cultures may be negative (e.g., fungal, tuberculotic, parasitic, or syphilitic disease); (4) neoplastic meningitis; and (5) meningitis secondary to noninfectious inflammatory diseases such as sarcoid, Behçet’s disease, and the uveomeningitic syndromes.

Specific viral etiologies

Enteroviruses (Chap. 175) are the most common cause of viral meningitis (>75% of cases in which a specific etiology can be identified) and should be considered the most likely cause of viral meningitis when a typical case occurs in the summer months, especially in a child (<15 years). However, despite their summer predominance, sporadic cases of enteroviral CNS infection are seen year-round. The physical examination should include a careful search for exanthemata, hand-foot-mouth disease, herpangina, pylorodynia, myopericarditis, and hemorrhagic conjunctivitis, which may be stigmata of enterovirus infections. PCR amplification of enteroviral RNA from CSF has become the diagnostic procedure of choice for these infections.

Arbovirus infections (Chap. 180) typically occur in the summer months, may have clear circumscribed geographic localization, and occur in both endemic and epidemic form, all factors reflecting the ecology of their transmission through infected insect vectors (Fig. 360-2; Tables 360-5 and 360-6). Arboviral meningitis should be considered when clusters of meningitis cases occur in a restricted geographic region during the summer or early fall. WNV infection should be suspected when bird deaths precede clusters of human cases of meningitis or encephalitis in an area known to harbor the virus. A history of tick exposure or travel or residence in the appropriate geographic area should suggest the possibility of Colorado tick fever virus or Powassan virus infection, although nonviral diseases producing meningitis (e.g.,
Lyme disease) or headache with meningismus (e.g., RMSF) may also present this way.

**HSV-2 meningitis** (Chap. 163) occurs in ~25% of women and 11% of men at the time of an initial (primary) episode of genital herpes. Of these patients, 20% go on to have recurrent attacks of meningitis. In some series, HSV-2 has been the most important cause of aseptic meningitis in adults, especially women, and overall it is probably second only to enteroviruses as a cause of viral meningitis. Although HSV-2 can be cultured from CSF during a first episode of meningitis, cultures are invariably negative during recurrent episodes of HSV-2 meningitis. Diagnosis depends on amplification of HSV-2 DNA from CSF by PCR. Almost all cases of recurrent HSV meningitis are due to HSV-2, although rare cases due to HSV-1 have been reported. Most cases of benign recurrent lymphocytic meningitis, including cases previously diagnosed as “Mollaret’s meningitis,” appear to be due to HSV. Genital lesions may not be present, and most patients give no history of genital herpes. CSF cultures are negative, although HSV DNA can be amplified from CSF by PCR during attacks of meningitis but not during symptom-free intervals.

**VZV meningitis** should be suspected in the presence of concurrent chickenpox or shingles. However, it is important to recognize that in some series up to 40% of VZV meningitis cases have been reported to occur in the absence of rash. The frequency of VZV as a cause of meningitis is extremely variable, ranging from as low as 3% to as high as 20% in different series. In addition to meningitis, encephalitis (see below), and shingles (see below), VZV can also produce acute cerebellar ataxia. This typically occurs in children and presents with the abrupt onset of limb and truncal ataxia. A similar syndrome occurs less commonly in association with EBV and enteroviral infection. PCR has rapidly become a major tool in the diagnosis of VZV CNS infections. In patients with negative CSF PCR results, the diagnosis of VZV CNS infection can be made by the demonstration of VZV-specific intrathecal antibody synthesis and/or the presence of VZV CSF IgM antibodies, or by positive CSF cultures.

**EBV infections** may also produce aseptic meningitis, with or without accompanying evidence of the infectious mononucleosis syndrome. The diagnosis may be suggested by the finding of atypical lymphocytes in the CSF or an atypical lymphocytosis in peripheral blood. The demonstration of IgM antibody to viral capsid antigen (VCA), or antibody to the diffuse (D) component of early antigen (EA) in the absence of or preceding detectable antibody to nuclear antigen (EBNA), are indicative of acute EBV infection. EBV is almost never cultured from CSF, but EBV DNA can be amplified from CSF in some patients with EBV-associated CNS infections. HIV-infected patients with primary CNS lymphoma may have a positive CSF PCR for EBV DNA even in the absence of meningoencephalitis.

**HIV meningitis** should be suspected in any patient with known or identified risk factors for HIV infection. Aseptic meningitis is a common manifestation of primary exposure to HIV and occurs in 5 to 10% of cases. In some patients, seroconversion may be delayed for several months; however, detection of the presence of HIV genome by PCR or p24 protein establishes the diagnosis. HIV can be cultured from CSF in some patients. Cranial nerve palsies, most commonly involving cranial nerves V, VII, or VIII, are more common in HIV meningitis than in other viral infections. For further discussion of HIV infection, see Chap. 173.

**Mumps** (Chap. 178) should be considered when meningitis occurs in the late winter or early spring, especially in males (male/female ratio 3:1). With the widespread use of the live attenuated mumps vaccine in the United States since 1967, the incidence of mumps meningitis has fallen by >95%. Rare cases of mumps vaccine–associated meningitis have been reported, but they are not usually seen after vaccination with the attenuated Jeryl-Lynn strain of virus used in the United States. The presence of orchitis, oophoritis, parotitis, pancreatitis, or elevations in serum lipase and amylase are suggestive but can be found with other viruses, and the absence does not exclude the diagnosis. Clinical meningitis occurs in 5% of patients with parotitis, but only 50% of patients with meningitis have associated parotitis.

Mumps infection confers lifelong immunity, so a documented history of previous infection excludes this diagnosis. The presence of hypoglycorrhachia, found in 10 to 30% of patients, may be an additional diagnostic clue, once other causes have been excluded (see above). Up to 25% of patients may have a PMN-predominant CSF pleocytosis, and CSF abnormalities may persist for months. Diagnosis is typically made by isolation of virus from CSF and/or demonstration of seroconversion between acute-phase and convalescent sera.

**LCMV infection** (Chap. 180) should be considered when aseptic meningitis occurs in the late fall or winter, and in individuals with a history of exposure to house mice (Mus musculus), pet or laboratory rodents (e.g., hamsters), or their excreta. Some patients have an associated rash, pulmonary infiltrates, alopecia, parotitis, orchitis, or myopericarditis. Laboratory clues to the diagnosis of LCMV, in addition to the clinical findings noted above, may include the presence of leukopenia, thrombocytopenia, or abnormal liver function tests. Some cases present with a marked CSF pleocytosis (>1000 cells/µL) and hypoglycorrhachia (~30%).
of meningitis and other neurologic complications associated with poliovirus, mumps, and measles infection. A live attenuated VZV vaccine (Varivax) is available in the United States. Clinical studies indicate an effectiveness rate of 70 to 90% for this vaccine, but a booster may be required to maintain immunity. An inactivated varicella vaccine is available for transplant recipients.

**PROGNOSIS** In adults, the prognosis for full recovery from viral meningitis is excellent. Rare patients complain of persisting headache, mild mental impairment, incoordination, or generalized asthenia for weeks to months. The outcome in infants and neonates (<1 year) is less certain; intellectual impairment, learning disabilities, hearing loss, and other lasting sequelae have been reported in some studies.

**VIRAL ENCEPHALITIS**

**DEFINITION** In contrast to viral meningitis, where the infectious process and associated inflammatory response are limited largely to the meninges, in encephalitis the brain parenchyma is also involved. Many patients with encephalitis also have evidence of associated meningitis (meningoencephalitis) and, in some cases, involvement of the spinal cord or nerve roots (encephalomyelitis, encephalomyeloradiculitis).

**CLINICAL MANIFESTATIONS** In addition to the acute febrile illness with evidence of meningeal involvement characteristic of meningitis, the patient with encephalitis commonly has confusion, behavioral abnormalities, an altered level of consciousness, and evidence of either focal or diffuse neurologic signs and symptoms. Any degree of altered consciousness may occur, ranging from mild lethargy to deep coma. Patients with encephalitis may have hallucinations, agitation, personality change, behavioral disorders, and, at times, a frankly psychotic state. Focal or generalized seizures occur in many patients with severe encephalitis. Virtually every possible type of focal neurologic disturbance has been reported in viral encephalitis; the signs and symptoms reflect the sites of infection and inflammation. The most commonly encountered focal findings are aphasia, ataxia, hemiparesis (with hyperactive tendon reflexes and extensor plantar responses), involuntary movements (e.g., myoclonic jerks, tremor), and cranial nerve deficits (e.g., ocular palsies, facial weakness). Involvement of the hypothalamic-pituitary axis may result in temperature dysregulation, diabetes insipidus, or the development of SIADH. Despite the clear neuropathologic evidence that viruses differ in the regions of the CNS they injure, it is often impossible to distinguish reliably on clinical grounds alone one type of viral encephalitis (e.g., that caused by HSV) from others (see “Differential Diagnosis,” below).

**ETIOLOGY** In the United States, there are ~20,000 reported cases of encephalitis per year; the actual number is likely to be significantly higher. Hundreds of viruses are capable of causing encephalitis, although only a limited subset is responsible for most cases in which a specific cause is identified (Table 360-4). The same organisms responsible for aseptic meningitis are also responsible for encephalitis, although their relative frequencies differ. The most important viruses causing sporadic cases of encephalitis in immunocompetent adults are HSV-1 (Fig. 360-3), VZV and, less commonly, enteroviruses. Epidemics of encephalitis are caused by arboviruses, which belong to several different viral taxonomic groups including *Alphaviruses* (e.g., Eastern equine encephalitis virus, Western equine encephalitis virus), *Flaviviruses* (e.g., WNV, St. Louis encephalitis virus, Powassan virus), and *Bunyaviruses* (e.g., California encephalitis virus serogroup, LaCrosse virus). Historically, the largest number of cases of arbovirus encephalitis in the United States has been due to St. Louis encephalitis virus and the California encephalitis virus serogroup. However, in 2002, WNV produced the largest epidemic of encephalitis ever recorded in the United States, with 4,156 cases and 284 deaths. New causes of viral encephalitis are constantly appearing, as evidenced by the recent outbreak of 257 cases of encephalitis with a 40% mortality rate in Malaysia caused by Nipah virus, a new member of the Paramyxovirus family.

**LABORATORY DIAGNOSIS**

**CSF Examination** CSF examination should be performed in all patients with suspected viral encephalitis unless contraindicated by the presence of severely increased ICP. The characteristic CSF profile is indistinguishable from that of viral meningitis and consists of a lymphocytic pleocytosis, a mildly elevated protein concentration, and a normal glucose concentration. A CSF pleocytosis (>5 cells/μL) occurs in >95% of patients with documented viral encephalitis. In rare cases, a pleocytosis may be absent on the initial LP but present on subsequent LPs. Patients who are severely immunocompromised by HIV infection, glucocorticoid or other immunosuppressant drugs, chemotherapy, or lymphoreticular malignancies may fail to mount a CSF inflammatory response. CSF cell counts exceed 500/μL in only about 10% of patients with encephalitis. Infections with certain arboviruses (e.g., Eastern equine encephalitis or California encephalitis viruses), mumps, and LCMV may occasionally result in cell counts >1000/μL, but this degree of pleocytosis should suggest the possibility of nonviral infections or other inflammatory processes. Atypical lymphocytes in the CSF may be seen in EBV infection and less commonly with other viruses, including CMV, HSV, and enteroviruses. The presence of substantial numbers of PMNs after the first 48 h should prompt consideration of bacterial infection, leptospiriosis, amebic infection, and noninfectious processes such as acute hemorrhagic leukoencephalitis. PMN pleocytosis that can persist for up to a week has also been reported in cases of WNV encephalitis. Large numbers of CSF PMNs may be present in patients with viral encephalitis due to Eastern equine encephalitis virus, echovirus 9, and, more rarely, other enteroviruses. About 20% of patients with encephalitis will have a significant number of red blood cells (>500/μL) in the CSF in a nontraumatic tap. The pathologic correlate of this finding may be a hemorrhagic encephalitis of the type seen with HSV, Colorado tick fever virus, and occasionally California encephalitis virus. A decreased CSF glucose concentration is distinctly unusual in viral encephalitis and should suggest the possibility of bacterial, fungal, tuberculous, parasitic, leptospiral, syphilitic, sarcoïd, or neoplastic meningitis. Rare patients with mumps, LCMV, or advanced HSV encephalitis may have low CSF glucose concentrations.

**CSF PCR** CSF PCR has become the primary diagnostic test for CNS infections caused by CMV, EBV, VZV and enteroviruses (see “Viral Meningitis,” above). The sensitivity and specificity of CSF PCRs vary with the virus being tested. Recent studies with HSV encephalitis indicate that the sensitivity (~98%) and specificity (~94%) of CSF PCR...
equal or exceed those of brain biopsy. It is important to recognize that CSF HSV PCR results need to be interpreted after considering the likelihood of disease in the patient being tested, the timing of the test in relationship to onset of symptoms, and the prior use of antiviral therapy. A negative HSV CSF PCR test performed in a patient with a high likelihood of HSV encephalitis based on clinical and laboratory tests significantly reduces the likelihood of HSV encephalitis but does not exclude it. There have been several recent reports of initially negative CSF HSV PCR tests that were obtained early (<72 h) following symptom onset, that became positive when repeated 1 to 3 days later. The frequency of positive CSF HSV PCR in patients with herpes encephalitis also decreases as a function of the duration of illness, with only ~20% of cases remaining positive after ≥14 days. PCR results are generally not affected by ≤1 week of antiviral therapy. In one study 98% of CSF specimens remained PCR-positive during the first week of initiation of antiviral therapy, but the numbers fell to ~50% by 8 to 14 days and to ~21% by >15 days after initiation of therapy.

The sensitivity and specificity of CSF PCR tests for viruses other than herpes simplex have not been definitively characterized. Enteroviral CSF PCR appears to have a sensitivity and specificity of >95%. The specificity of EBV CSF PCR has not been established, and apparent false-positive results can occur in patients with CNS lymphoma and in patients with inflammatory CSF specimens. In patients with CNS infection due to VZV, CSF antibody and PCR studies should be considered complementary, as several cases with positive serologies and negative PCR studies have been reported. In the case of WNV infection, CSF PCR is considerably less sensitive (~70% sensitivity) than detection of WNV specific CSF IgM in diagnosis of WNV encephalitis.

**CSF Culture** Attempts to culture viruses from the CSF in cases of encephalitis are often disappointing. Cultures are invariably negative in cases of HSV-1 encephalitis.

**Serologic Studies and Antigen Detection** The basic approach to the serodiagnosis of viral encephalitis is identical to that discussed earlier for viral meningitis. In patients with HSV encephalitis, both antibodies to HSV-1 glycoproteins and glycoprotein antigens have been detected in the CSF. Optimal detection of both HSV antibodies and antigen typically occurs after the first week of illness, limiting the utility of these tests in acute disease. Nonetheless, CSF HSV antibody testing may be of value in selected patients whose illness is >1 week in duration and who are CSF PCR-negative for HSV. Demonstration of WNV IgM antibodies is diagnostic of WNV encephalitis, as IgM antibodies do not cross the blood-brain barrier and their presence in CSF is therefore indicative of intrathecal synthesis.

**MRI, CT, EEG** Patients with suspected encephalitis almost invariably undergo neuroimaging studies and often EEG. These tests help identify or exclude alternative diagnoses and assist in the differentiation between a focal, as opposed to a diffuse, encephalitic process. Focal findings in a patient with encephalitis should always raise the possibility of HSV encephalitis. Examples of focal findings include: (1) areas of increased signal intensity in the frontotemporal, cingulate, or insular regions of the brain on T2-weighted, fluid-attenuated inversion recovery (FLAIR), or diffusion-weighted MRI images (Fig. 360-3); (2) temporoparietal areas of low absorption, mass effect, and contrast enhancement on CT; or (3) periodic focal temporal lobe spikes on a background of slow or low-amplitude (“flattened”) activity on EEG. Approximately 10% of patients with PCR-documented HSV encephalitis will have a normal MRI, although nearly 90% will have abnormalities in the temporal lobe. CT is less sensitive than MRI and is normal in up to 33% of patients. The addition of FLAIR and diffusion-weighted images to the standard MRI sequences enhances sensitivity. EEG abnormalities occur in >90% of PCR-documented cases of HSV encephalitis; they typically involve the temporal lobes but are often nonspecific. Some patients with HSV encephalitis have a distinctive EEG pattern consisting of periodic, stereotyped, sharp-and-slow complexes originating in one or both temporal lobes and repeating at regular intervals of 2 to 3 s. The periodic complexes are typically noted between the second and the fifteenth day of the illness and are present in two-thirds of pathologically proven cases of HSV encephalitis.

Significant MRI abnormalities are found in only ~30% of patients with WNV encephalitis, a frequency significantly less than that of HSV encephalitis. When present, abnormalities often involve deep brain structures including the thalamus, basal ganglia, and brainstem rather than the cortex. Patients with VZV encephalitis may show areas of hemorrhagic infarction reflecting the tendency of this virus to produce a CNS vasculopathy rather than a true encephalitis.

**Brain Biopsy** Brain biopsy is now generally reserved for patients in whom CSF PCR studies fail to lead to a specific diagnosis, who have focal abnormalities on MRI, and who continue to show progressive clinical deterioration despite treatment with acyclovir and supportive therapy. The isolation of HSV from brain tissue obtained at biopsy was once considered the “gold standard” for the diagnosis of HSV encephalitis, although with the advent of CSF PCR tests for HSV it is rarely necessary to perform brain biopsy for this purpose. The need for brain biopsy to diagnose other forms of viral encephalitis has also declined greatly with the widespread availability of CSF PCR diagnostic tests for EBV, CMV, VZV, and enteroviruses. When biopsy is performed, the tissue is cultured for virus and examined histopathologically and ultrastructurally. Tissue should be taken from a site that appears to be significantly involved on the basis of clinical and laboratory criteria. Although brain biopsy is not an innocuous procedure, the mortality rate is low (<0.2%) and serious complications occur in only 0.5 to 2.0% of cases. Potential morbidity, in addition to that related to general anesthesia, includes local bleeding and edema, the development of a seizure focus, and wound dehiscence or infection.

**Differential Diagnosis** Some of the most common illnesses masquerading as viral encephalitis, as identified in multicenter clinical trials using brain biopsy as a diagnostic standard, were vascular diseases; abscess and empyema; fungal, parasitic, ricketsial, and tuberculous infections; tumors; Reye’s syndrome; toxic encephalopathy; subdural hematoma; and SLE. Acute disseminated encephalomyelitis (ADEM), limbic encephalitis, prion diseases, and Hashimoto’s encephalopathy are additional considerations.

Differential diagnoses include acute central nervous system infection due to VZV, CSF antibody and PCR studies should be considered complementary, as several cases with positive serologies and negative PCR studies have been reported. In the case of WNV infection, CSF PCR is considerably less sensitive (~70% sensitivity) than detection of WNV specific CSF IgM in diagnosis of WNV encephalitis.
beinfectedbyflaviviruses (WNV, Japanese encephalitis virus), HSV, inentbrainstem signs, symptoms orneuroimaging abnormalities may todagnosis. Patients withrapidly progressive encephalitis andprom-
listhestediagnosis, and anegativetest dramatically reducethelike-
roimaging studies, or EEG. Thediagnostic procedure of choicein these
lucinations, anosmia, unusual or bizarre behavior or personality alter-
ations, or memory disturbance. HSV encephalitis should always be suspected in patients with focal findings on clinical examination, neu-
roimaging studies, or EEG. Thediagnostic procedure of choice in these
patients is CSF PCR analysis for HSV. A positive CSF PCR estab-
ishes the diagnosis, and a negative test dramatically reduces the like-
lihood of HSV encephalitis (see above).

The anatomic distribution of lesions may provide an additional clue
to diagnosis. Patients with rapidly progressive encephalitis and prom-
inent brainstem signs, symptoms or neuroimaging abnormalities may beinfected by flaviviruses (WNV, Japanese encephalitis virus), HSV, rabies or L. monocytogenes. Significant involvement of deep gray mat-
ter structures including the basal ganglia and thalamus should also sug-
gest possible flavivirus infection. These patients may present clinic-
cally with prominent movement disorders (tremor, myoclonus) or Parkin-
son’s disease-like features. Patients with WNV infection can also present with acute poliomyelitis-like areflexic paralysis, as can patients infected with enterovirus 71 and less common other enter-
oviruses. Despite an aggressive World Health Organization poliovirus eradicative initiative, cases of wild-type polio-virus-induced poliomy-
elitis continue to be reported in at least seven countries worldwide:
Egypt, Somalia, Niger, Nigeria, India, Pakistan, and Afghanistan. Rare cases continue to occur in the United States in nonvaccinated individ-
uals exposed to vaccine strains of virus that have reverted to virulence.
A recent outbreak of poliomyelitis on Hispaniola (the Dominican Re-
public and Haiti) has been attributed to vaccine strain-derived viruses that have reverted to virulence after apparently recombining with other circulating enteroviruses. Acute ascending paralysis resembling Guil-
lain-Barré syndrome but associated with CSF pleocytosis can occur with HIV infection, rabies, and WNV infection. Epidemiologic factors may provide important clues. Particular at-
tention should be paid to the season of the year (Table 360-5); the age of the patient (Table 360-6); the geographic location and travel history (Table 360-6); and possible exposure to animal bites or scratches, ro-
dents, and ticks. Although transmission from the bite of an infected dog remains the most common cause of rabies worldwide, in the United States very few cases of dog rabies occur, and the most com-
mon risk factor is exposure to bats—although a clear history of a bite or scratch is often lacking. The classic clinical presentation of enceph-
italic (furious) rabies is of fever and autonomic hyperactivity with fluctuating mental status. Phobic spasms of the larynx, pharynx, neck muscles, and diaphragm can be triggered by attempts to swallow water (hydrophobia) or by inspiration (aerophobia). Patients may also present with paralytic (dumb) rabies characterized by acute ascending paralysis. Patients with rabies have a CSF lymphocytic pleocytosis and may show areas of increased T2 signal abnormality in the brain-
stem, hippocampus, and hypothalamus. Diagnosis can be made by finding rabies virus antigen in brain tissue or in the neural innervation of hair follicles at the nape of the neck. PCR amplification of viral nucleic acid from CSF and saliva or tear may also enable diagnosis. Serology is frequently negative in both serum and CSF in the first week after onset of infection, which limits its acute diagnostic utility.

No specific therapy is available, and cases are almost invariably fatal, with isolated survivors having devastating neurologic sequelae.

Morbidity and Mortality Weekly Reports provides regular infor-
mation about the prevalence of particular viruses causing encephalitis by season and region of the country. State public health authorities provide another valuable resource concerning isolation of particular agents in individual regions. Deaths in crows and other corvid birds in the local area have preceded human infection by WNV during out-
breaks in the United States. Details of the occurrence of WNV in mosquitos, birds, horses, and humans can be found on the Centers for Disease Control and Prevention (CDC) and U.S. Geological Survey (USGS) websites (and http://westnilemaps.usgs.gov/).

**TREATMENT**

Specific antiviral therapy should be initiated when appropriate. Vital functions, including respiration and blood pressure, should be moni-
tored continuously and supported as required. In the initial stages of encephalitis, many patients will require care in an intensive care unit. Basic management and supportive therapy should include careful mon-
itoring of ICP, fluid restriction and avoidance of hypotonic intravenous solutions, and suppression of fever. Seizures should be treated with standard anticonvulsant regimens, and prophylactic therapy should be considered in view of the high frequency of seizures in severe cases of encephalitis. As with all seriously ill, immobilized patients with altered levels of consciousness, encephalitis patients are at risk for aspiration pneumonia, stasis ulcers and decubiti, contractures, deep venous thrombosis and its complications, and infections of indwelling lines and catheters.

Acyclovir is of benefit in the treatment of HSV and should be started empirically in patients with suspected viral encephalitis while awaiting viral diagnostic studies. Treatment should be discontinued in patients found not to have HSV encephalitis, with the possible exception of patients with severe encephalitis due to VZV or EBV. HSV, VZV, and EBV all encode an enzyme, deoxyxymyridine (thymidine) kinase, that phosphorylates acyclovir to produce acyclovir-5’-mon-
ophosphate. Host cell enzymes then phosphorylate this compound to form a triphosphate derivative. It is the triphosphate that acts as an antiviral agent by inhibiting viral DNA polymerase and by causing premature termination of nascent viral DNA chains. The specificity of action depends on the fact that uninfected cells do not phosphorylate significant amounts of acyclovir to acyclovir-5’-monophosphate. A second level of specificity is provided by the fact that the acyclovir triphosphate is a more potent inhibitor of viral DNA polymerase than of the analogous host cell enzymes.

Adults should receive a dose of 10 mg/kg of acyclovir intra-
venously every 8 h (30 mg/kg per day total dose) for a minimum of 14 days. Although no studies directly addressing this issue are yet available, repeating the CSF PCR after completion of acyclovir ther-
apy should be considered. Patients with a persisting positive CSF PCR for HSV after completing a standard course of acyclovir therapy should be treated for an additional 7 days, followed by a repeat CSF PCR test. Neonatal HSV CNS infection is less responsive to acyclovir therapy than HSV encephalitis in adults; it is recommended that ne-
onates with HSV encephalitis receive 20 mg/kg of acyclovir every 8 h (60 mg/kg per day total dose) for a minimum of 21 days.

Prior to intravenous administration, acyclovir should be diluted to a concentration ≤7 mg/mL. (A 70-kg person would receive a dose of 700 mg, which would be diluted in a volume of 100 mL.) Each dose should be infused slowly over 1 h rather than by rapid or bolus infu-
sion, to minimize the risk of renal dysfunction. Care should be taken to avoid extravasation or intramuscular or subcutaneous administra-
tion. The alkaline pH of acyclovir can cause local inflammation and phlebitis (9%). Dose adjustment is required in patients with impaired renal glomerular filtration. Penetration into CSF is excellent, with aver-
age drug levels ~50% of serum levels. Complications of therapy include elevations in BUN and creatinine levels (5%), thrombocyto-
penia (6%), gastrointestinal toxicity (nausea, vomiting, diarrhea) (7%),
and neurotoxicity (lethargy or obtundation, disorientation, confusion, agitation, hallucinations, tremors, seizures) (1%). Acyclovir resistance may be mediated by changes in either the viral deoxyxypirimidine kinase or DNA polymerase. To date, acyclovir-resistant isolates have not been a significant clinical problem in immunocompetent individuals. However, there have been reports of clinically virulent acyclovir-resistant HSV isolates from sites outside the CNS in immunocompromised individuals, including those with AIDS.

Oral antiviral drugs with efficacy against HSV, VZV, and EBV, including acyclovir, famciclovir, and valacyclovir, have not been evaluated in the treatment of encephalitis either as primary therapy or as supplemental therapy following completion of a course of parenteral acyclovir. An NIAID/NIH-sponsored phase III trial of supplemental oral acyclovir therapy (2 g qid for 3 months) following the initial 14- to 21-day course of therapy with parenteral acyclovir has recently been initiated by the Collaborative Antiviral Study Group (CASS) in patients with HSE encephalitis (CASS 204); it may help clarify the role of extended oral antiviral therapy.

Both ganciclovir and foscarinet have been shown to be effective in the treatment of CMV-related CNS infections. These drugs are often used in combination. Cidofovir (see below) may provide an alternative in patients who fail to respond to ganciclovir and foscarinet, although data concerning its use in CMV CNS infections are extremely limited.

Ganciclovir is a synthetic nucleoside analogue of 2’-deoxyguanosine. The drug is preferentially phosphorylated by virus-induced cellular kinases. Ganciclovir triphosphate acts as a competitive inhibitor of the CMV DNA polymerase, and its incorporation into nascent viral DNA results in premature chain termination. Following intravenous administration, CSF concentrations of ganciclovir are 25 to 70% of coincident plasma levels. The usual dose for treatment of severe neurologic illnesses is 5 mg/kg every 12 h given intravenously at a constant rate over 1 h. Induction therapy is followed by maintenance therapy of 5 mg/kg every day for an indefinite period. Induction therapy should be continued until patients show a decline in CSF pleocytosis and a reduction in CSF CMV DNA copy number on quantitative PCR testing (where available). Doses should be adjusted in patients with renal insufficiency. Treatment is often limited by the development of granulocytopenia and thrombocytopenia (20 to 25%), which may require reduction in or discontinuation of therapy. Gastrointestinal side effects including nausea, vomiting, diarrhea, and abdominal pain occur in ~20% of patients. Some patients treated with ganciclovir for CMV retinitis have developed retinal detachment, but the causal relationship to ganciclovir treatment is unclear.

Foscarinet is a pyrophosphate analogue that inhibits viral DNA polymerase by binding to the pyrophosphate-binding site. Following intravenous infusion, CSF concentrations range from 15 to 100% of coincident plasma levels. The usual dose for serious CMV-related neurologic illness is 60 mg/kg every 8 h administered by constant infusion over 1 h. Induction therapy for 14 to 21 days is followed by maintenance therapy (60 to 120 mg/kg per day). Induction therapy may need to be extended in patients who fail to show a decline in CSF pleocytosis and a reduction in CSF CMV DNA copy number on quantitative PCR tests (where available). Approximately one-third of patients develop renal impairment during treatment, which is reversible following discontinuation of therapy in most, but not all, cases. This is often associated with elevations in serum creatinine and proteinuria and is less frequent in patients who are adequately hydrated. Many patients experience fatigue and nausea. Reduction in serum calcium, magnesium, and potassium occur in ~15% of patients and may be associated with tetany, cardiac rhythm disturbances, or seizures.

Cidofovir is a nucleotide analogue that is effective in treating CMV retinitis and equivalent or better than ganciclovir in some experimental models of murine CMV encephalitis, although data concerning its efficacy in human CMV CNS disease are limited. The usual dose is 5 mg/kg intravenously once weekly for 2 weeks, then biweekly for 2 or more additional doses, depending on its prophylactic or therapeutic role. Patients must be prehydrated with normal saline (e.g., 1 L over 1 to 2 h) prior to each dose and treated with probenecid (e.g., 1 g 3 h before cidofovir and 1 g 2 and 8 h after cidofovir). Nephrotoxicity is common; the dose should be reduced if renal function deteriorates.

Intravenous ribavarin (15 to 25 mg/kg per day in divided doses given every 8 h) has been reported to be of benefit in isolated cases of severe encephalitis due to California encephalitis (LaCrosse) virus. Ribavarin might be of benefit for the rare patients, typically infants or young children, with severe adenovirus or rotavirus encephalitis and in patients with encephalitis due to LCMV or other arenaviruses. However, clinical trials are lacking. Hemolysis, with resulting anemia, has been the major side effect limiting therapy.

No specific antiviral therapy of proven efficacy is currently available for treatment of WNV encephalitis. Small groups of patients have been treated with interferon α, ribavirin, and IV Ig preparations of non-U.S. origin containing high titer anti-WNV antibody. Evidence is insufficient to establish efficacy of any of these therapies.

**SEQUELAE**

There is considerable variation in the incidence and severity of sequelae in patients surviving viral encephalitis. In the case of Eastern equine encephalitis virus infection, nearly 80% of survivors have severe neurologic sequelae. At the other extreme are infections due to EBV, California encephalitis virus, and Venezuelan equine encephalitis virus, where severe sequelae are unusual. For example, ~5 to 15% of children infected with LaCrosse virus have a residual seizure disorder, and 1% have persistent hemiparesis. Detailed information about sequelae in patients with HSV encephalitis treated with acyclovir are available from the NIAID-CASS trials. Of 32 acyclovir-treated patients, 26 survived (81%). Of the 26 survivors, 12 (46%) had no or only minor sequelae, 3 (12%) were moderately impaired (gainfully employed but not functioning at their previous level), and 11 (42%) were severely impaired (requiring continuous supportive care). The incidence and severity of sequelae were directly related to the age of the patient and the level of consciousness at the time of initiation of therapy. Patients with severe neurologic impairment (Glasgow coma score 6) at initiation of therapy either died or survived with severe sequelae. Young patients (<30 years) with good neurologic function at initiation of therapy did substantially better (100% survival, 62% with no or mild sequelae) compared with their older counterparts (>30 years): (64% survival, 57% no or mild sequelae). Some recent studies using quantitative CSF PCR tests for HSV indicate that clinical outcome following treatment also correlates with the amount of HSV DNA present in CSF at the time of presentation. Many patients with WNV infection have acute sequelae including cognitive impairment; weakness; and hyper- or hypo-kinetin movement disorders including tremor, myoclonus, and parkinsonism. Improvement in these symptoms may occur over the subsequent 6 to 12 months, although detailed clinical studies of the duration and severity of WNV sequelae are still lacking.

**SUBACUTE MENINGITIS**

**CLINICAL MANIFESTATIONS**

Patients with subacute meningitis typically have an unrelenting headache, stiff neck, low-grade fever, and lethargy for days to several weeks before they present for evaluation. Cranial nerve abnormalities and night sweats may be present. This syndrome overlaps that of chronic meningitis discussed in detail in Chap. 361.

**ETOLOGY**

Common causative organisms include *M. tuberculosis*, *C. neoformans*, *H. capsulatum*, *C. immitis*, and *T. pallidum*. Initial infection with *M. tuberculosis* is acquired by inhalation of aerosolized droplet nuclei. Tuberculous meningitis in adults does not develop acutely from hematogenous spread of tubercle bacilli to the meninges. Rather, millet seed–size (miliary) tubercles form in the parenchyma of the brain during hematogenous dissemination of tubercle bacilli in the course of primary infection. These tubercles enlarge and are usually caseating. The propensity for a caseating lesion to produce meningitis is determined by its clonality to the SAS and the rate at which fibrous encapsulation develops. Subependymal caseous foci cause meningitis via discharge of bacilli and tuberculous antigens into the SAS.
cobacterial antigens produce an intense inflammatory reaction that leads to the production of a thick exudate that fills the basilar cisterns and surrounds the cranial nerves and major blood vessels at the base of the brain.

Fungal infections are typically acquired by the inhalation of airborne fungal spores. The initial pulmonary infection may be asymptomatic or present with fever, cough, sputum production, and chest pain. The pulmonary infection is often self-limited. A localized pulmonary fungal infection can then remain dormant in the lungs until there is an abnormality in cell-mediated immunity that allows the fungus to reactivate and disseminate to the CNS. The most common pathogen causing fungal meningitis is *C. neoformans*. This fungus is found worldwide in soil and bird excreta. *H. capsulatum* is endemic to the Ohio and Mississippi River valleys of the central United States and to parts of Central and South America. *C. immitis* is endemic to the desert areas of the southwest United States, northern Mexico, and Argentina.

Syphilis is a sexually transmitted disease that is manifest by the appearance of a painless chancre at the site of inoculation. *T. pallidum* invades the CNS early in the course of syphilis. Cranial nerves VII and VIII are most frequently involved.

**LABORATORY DIAGNOSIS** The classic CSF abnormalities in tuberculous meningitis are as follows: (1) elevated opening pressure, (2) lymphocytic pleocytosis (10 to 500 cells/µL), (3) elevated protein concentration in the range of 1 to 5 g/L (10 to 500 mg/dL), and (4) decreased glucose concentration in the range of 1.1 to 2.2 mmol/L (20 to 40 mg/dL). The combination of unrelenting headache, stiff neck, fatigue, night sweats, and fever with a CSF lymphocytic pleocytosis and a mildly decreased glucose concentration is highly suspicious for tuberculous meningitis. The last tube of fluid collected at LP is the best tube to send for a smear for acid-fast bacilli (AFB). If there is a pellicle in the CSF or a cobweb-like clot on the surface of the fluid, AFB can best be demonstrated in a smear of the clot or pellicle. Positive smears are typically reported in only 10 to 40% of cases of tuberculous meningitis in adults. Cultures of CSF take 4 to 8 weeks to identify the organism and are positive in ~50% of adults. Culture remains the “gold standard” to make the diagnosis of tuberculous meningitis. PCR for the detection of *M. tuberculosis* DNA has a sensitivity of 70 to 80% but at the present time is limited by a high rate of false-positive results.

The characteristic CSF abnormalities in fungal meningitis are a mononuclear or lymphocytic pleocytosis, an increased protein concentration, and a decreased glucose concentration. There may be eosinophils in the CSF in *C. immitis* meningitis. Large volumes of CSF are often required to demonstrate the organism on India ink smear or grow the organism in culture. If spinal fluid examined by LP on two separate occasions fails to yield an organism, CSF should be obtained by high-cervical or cisternal puncture.

The cryptococcal polysaccharide antigen test is a highly sensitive and specific test for cryptococcal meningitis. A reactive CSF cryptococcal antigen test establishes the diagnosis. The detection of the *his-toplasma* polysaccharide antigen in CSF establishes the diagnosis of a fungal meningitis but is not specific for meningitis due to *H. capsulatum*. It may be falsely positive in coccidiodial meningitis. The CSF complement fixation antibody test is reported to have a specificity of 100% and a sensitivity of 75% for coccidiodial meningitis.

The diagnosis of syphilitic meningitis is made when a reactive serum treponemal test (fluorescent treponemal antibody, absorbed [FTA-ABS] or microhemagglutination- *T. pallidum* [MHA-TP]) is associated with a CSF lymphocytic or mononuclear pleocytosis and an elevated protein concentration, or when the CSF VDRL is positive. A reactive CSF-FTA-ABS is not definitive evidence of neurosyphilis. The CSF-FTA-ABS can be falsely positive from asymptomatic nonbuboesyphilis. A negative CSF VDRL does not rule out neurosyphilis. A negative CSF FTA-ABS or MHA-TP rules out neurosyphilis.

Empirical therapy of tuberculous meningitis is often initiated on the basis of a high index of suspicion without adequate laboratory support. Initial therapy is a combination of isoniazid (300 mg/d), rifampin (10 mg/kg per day), pyrazinamide (30 mg/kg per day divided doses), ethambutol (15 to 25 mg/kg per day in divided doses), and pyridoxine (50 mg/d). If the clinical response is good, pyrazinamide and ethambutol can be discontinued after 8 weeks and isoniazid and rifampin continued alone for the next 6 to 12 months. A 6-month course of therapy is acceptable, but therapy should be prolonged for 9 to 12 months in patients who have an inadequate resolution of symptoms of meningitis or who have positive mycobacterial cultures of CSF during the course of therapy. Dexamethasone therapy is recommended for patients who develop hydrocephalus.

Meningitis due to *C. neoformans* is treated with amphotericin B (0.7 mg/kg per day) and fluconazole (100 mg/kg per day in four divided doses) for 2 weeks, followed by an 8- to 10-week course of fluconazole (400 to 800 mg/d). If the CSF culture is sterile after 10 weeks of acute therapy, the dose of fluconazole is decreased to 200 mg/d for 6 months to a year. Patients with HIV infection may require indefinite maintenance therapy. Meningitis due to *H. capsulatum* is treated with amphotericin B (0.7 to 1.0 mg/kg per day) for 4 to 12 weeks followed by itraconazole (400 mg/d). Therapy with amphotericin B is not discontinued until fungal cultures are sterile. After completing a course of amphotericin B, maintenance therapy with itraconazole is initiated and continued for at least 6 months to a year. *C. immitis* meningitis is treated with intravenous amphotericin B (0.5 to 0.7 mg/kg per day) for ≥4 weeks until CSF fungal cultures are negative. Intrathecal amphotericin B may be required to eradicate the infection. Lifelong therapy with fluconazole is recommended to prevent relapse. Ambisome (4 mg/kg per day) or amphotericin B lipid complex (5 mg/kg per day) can be substituted for amphotericin B in patients who have or who develop significant renal dysfunction. The most common complication of fungal meningitis is hydrocephalus. Patients who develop hydrocephalus should receive a CSF diversion device. A ventriculostomy can be used until CSF fungal cultures are sterile, at which time the ventriculostomy is replaced by a ventriculoperitoneal shunt.

Syphilitic meningitis is treated with aqueous penicillin G in a dose of 3 to 4 million units intravenously every 4 h for 10 to 14 days. An alternative regimen is 2.4 million units of procaine penicillin G intramuscularly daily with 500 mg of oral probenecid four times daily for 10 to 14 days. Either regimen is followed with 2.4 million units of benzathine penicillin G intramuscularly once a week for 3 weeks. The standard criterion for treatment success is reappearance of the CSF. The CSF should be reexamined at 6-month intervals for 2 years. The cell count is expected to normalize within 12 months, and the VDRL titer to decrease by two dilutions or revert to nonreactive within 2 years of completion of therapy. Failure of the CSF pleocytosis to resolve or an increase in the CSF VDRL titer by two or more dilutions requires re-treatment.

**CHRONIC ENCEPHALITIS**

**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY** Clinical Features and Pathology Progressive multifocal leukoencephalopathy (PML) is a progressive disorder characterized pathologically by multifocal areas of demyelination of varying size distributed throughout the CNS. In addition to demyelination, there are characteristic cytologic alterations in both astrocytes and oligodendrocytes. Astrocytes are tremendously enlarged and contain hyperchromatic, deformed, and bizarre nuclei and frequent mitotic figures. Oligodendrocytes have enlarged, densely staining nuclei that contain viral inclusions formed by crystalline arrays of JC virus particles. Patients often present with visual deficits (45%), typically a homonymous hemianopia, and mental impairment (38%) (dementia, confusion, personality change). Motor weakness may not be present early but eventually occurs in 75% of cases.

Almost all patients have an underlying immunosuppressive disorder. Prior to the HIV epidemic, common associated diseases included
lymphoproliferative disorders, immune deficiency states, myeloproliferative disease, and chronic infectious or granulomatous diseases. More than 60% of currently diagnosed PML cases occur in patients with AIDS. Conversely, it has been estimated that nearly 1% of AIDS patients will develop PML. The basic features of AIDS-associated and non-AIDS-associated PML are identical.

**Diagnostic Studies**  
MRI reveals multifocal asymmetric, coalescing white matter lesions located periventricularly, in the centrum semiovale, in the parietal-occipital region, and in the cerebellum. These lesions have increased T2 and decreased T1 signal, are generally nonenhancing or show only minimal peripheral enhancement, and are not associated with edema or mass effect. CT scans, which are less sensitive than MRI for the diagnosis of PML, often show hypodense nonenhancing white matter lesions.

The CSF is typically normal, although mild elevation in protein and/or IgG may be found. Pleocytosis occurs in <25% of cases, is predominantly mononuclear, and rarely exceeds 25 cells/μL. PCR amplification of JC virus DNA from CSF has become an important diagnostic tool. CSF PCR for JC virus DNA has high specificity, but sensitivity has varied among studies. Rare cases of positive CSF PCR for JC virus DNA in the absence of clinical or radiographic evidence of PML have been described in HIV-infected patients. It remains to be established whether these results are false positives or indicate preclinical PML.

A positive CSF PCR for JC virus DNA in association with typical MRI lesions in the appropriate clinical setting is diagnostic of PML. Patients with negative CSF PCR studies may require brain biopsy for definitive diagnosis; JC virus antigen and nucleic acid can be detected by immunocytochemistry, in situ hybridization, or PCR amplification. Detection of JC virus antigen or genomic material should be considered diagnostic of PML only if accompanied by characteristic pathologic changes, since both antigen and genomic material have been found in the brains of normal patients.

### Treatment

No effective therapy is available. Recent trials in HIV-associated PML failed to show benefit from either cytarabine or cidofovir. Some patients with HIV-associated PML have shown dramatic clinical improvement associated with improvement in their immune status following institution of highly active antiretroviral therapy.

**Subacute sclerosing panencephalitis**  
SSPE is a rare progressive demyelinating disease of the CNS associated with a chronic infection of brain tissue with measles virus. Most patients give a history of primary measles infection at an early age (2 years), which is followed after a latent interval of 6 to 8 years by the development of insidious intellectual decline and mood and personality changes. Typical signs of a CNS viral infection, including fever and headache, do not occur. Focal and/or generalized seizures, myoclonus, ataxia, and visual disturbances occur as the disease progresses. The EEG shows a characteristic periodic pattern with bursts every 3 to 8 s of high-voltage, sharp slow waves, followed by periods of attenuated (“flat”) background. The CSF is acellular with a normal or mildly elevated protein level and a markedly elevated \( \gamma \)-globulin level (>20% of total CSF protein). CSF antimeasles antibody levels are invariably elevated, and oligoclonal antimeasles antibodies are often present. CT and MRI show evidence of multifocal white matter lesions and generalized atrophy. Measles virus can be cultured from brain tissue, and viral genome can be detected by in situ hybridization or PCR amplification. Treatment with isoprinosine (Inosiplex) (100 mg/kg per day), alone or in combination with intrathecal or intraventricular interferon, has been reported to prolong survival and produce clinical improvement in some patients but has never been subjected to a controlled clinical trial.

**Progressive rubella panencephalitis**  
This is an extremely rare disorder that primarily affects males with congenital rubella syndrome, although isolated cases have been reported following childhood rubella. After a latent period of 8 to 19 years, patients develop progressive neurologic deterioration. The manifestations are similar to those seen in SSPE. CSF shows a mild lymphocytic pleocytosis, slightly elevated protein level, markedly increased \( \gamma \)-globulin, and rubella virus-specific oligoclonal bands. No therapy is available.

**Brain abscess**

**Definition**  
A brain abscess is a focal, suppurative infection within the brain parenchyma, typically surrounded by a vascularized capsule. The term *cerebritis* is often employed to describe a nonencapsulated brain abscess.

**Epidemiology**  
A bacterial brain abscess is a relatively uncommon intracranial infection, with an incidence of ~1 in 100,000 persons per year. Predisposing conditions include otitis media and mastoiditis, paranasal sinusitis, pyogenic infections in the chest or other body sites, penetrating head trauma or neurosurgical procedures, and dental infections. In most modern series, an increasing proportion of brain abscesses are not caused by classic pyogenic bacteria, but rather by fungi and parasites including *Toxoplasma gondii*, *Aspergillus spp.*, *Nocardia spp.*, *Mycobacteria spp.*, and *C. neoformans*. These organisms are almost exclusively restricted to immunocompromised hosts with underlying HIV infection, organ transplantation, cancer, or immunosuppressive therapy. In Latin America and in immigrants from Latin America, the most common cause of brain abscess is *Taenia solium* (neurocysticercosis). In India and the Far East, mycobacterial infection (tuberculoma) remains a major cause of focal CNS mass lesions.

**Etiology**  
A brain abscess may develop (1) by direct spread from a contiguous cranial site of infection, such as paranasal sinusitis, otitis media, mastoiditis, or dental infection; (2) following head trauma or a neurosurgical procedure; or (3) as a result of hematogenous spread from a remote site of infection. In up to 25% of cases no obvious primary source of infection is apparent (cryptogenic brain abscess).

Up to one-third of brain abscesses are associated with otitis media and mastoiditis, often with an associated cholesteatoma. Otogenic brain abscesses occur predominantly in the temporal lobe (55% to 75%) and cerebellum (20% to 30%). In some series up to 90% of cerebellar abscesses are otogenic. Common organisms include streptococci, *Bacteroides spp.*, *P. aeruginosa*, and Enterobacteriaceae. Abscesses that develop as a result of direct spread of infection from the frontal, ethmoidal, or sphenoidal sinuses and those that occur due to dental infections are usually located in the frontal lobes. Approximately 10% of brain abscesses are associated with paranasal sinusitis, and this association is particularly strong in young males in their second and third decades of life. The most common pathogens in brain abscesses associated with paranasal sinusitis are *Strep. pneumoniae* (especially *S. milleri*), *Haemophilus spp.*, *Bacteroides spp.*, *Pseudomonas spp.*, and *S. aureus*. Dental infections are associated with ~2% of brain abscesses, although it is often suggested that many “cryptogenic” abscesses are in fact due to dental infections. The most common pathogens in this setting are streptococci, staphylococci, and *Bacteroides* and *Fusobacterium* spp.

Hematogenous abscesses account for ~25% of brain abscesses. These abscesses show a predilection for the territory of the middle cerebral artery (i.e., posterior frontal or parietal lobes). Hematogenous abscesses are often located at the junction of the gray and white matter and are often poorly encapsulated. Not surprisingly, hematogenous abscesses are often multiple, and multiple abscesses often have a hematogenous origin. The microbiology of these hematogenous abscesses is dependent on the primary source of infection. For example, brain abscesses that develop as a complication of infective endocarditis are often due to viridans streptococci or *S. aureus*. Abscesses associated with pyogenic lung infections such as lung abscess or bronchiectasis are often due to *Strep. pneumoniae*, *Staphylococci*, *Bacteroides* or *Fusobacterium* spp. Enterobacteriaceae and *P. aeruginosa* are important causes of abscesses associated with urinary sepsis. Abscesses that follow penetrating head trauma or neurosurgical procedures are fre-
frequently due to *Staphylococci*, *Enterobacteriaceae*, and *Pseudomonas* species. Congenital cardiac malformations that produce a right-to-left shunt, such as tetralogy of Fallot, patent ductus arteriosus, and atrial and ventricular septal defects, allow bloodstream bacteria to bypass the pulmonary capillary bed and reach the brain. Similar phenomena can occur with pulmonary arteriovenous malformations. The decreased arterial oxygenation and saturation from the right-to-left shunt and polycythemia may cause focal areas of cerebral ischemia, thus providing a nidus for microorganisms that bypassed the pulmonary circulation to multiply and form an abscess. *Streptococci* are the most common pathogens in this setting.

**PATHOGENESIS AND HISTOPATHOLOGY** The intact brain parenchyma is relatively resistant to infection; preexisting brain ischemia, necrosis, or hypoxia appears to be a prerequisite for effective bacterial invasion. Once infection is established, brain abscess frequently evolves through a series of stages, influenced by the nature of the infecting organism and by the immunocompetence of the host. The early cerebritis stage (days 1 to 3) is characterized by a perivascular infiltration of inflammatory cells, which surround a central core of coagulative necrosis. Marked edema surrounds the lesion at this stage. In the late cerebritis stage (days 4 to 9), pus formation leads to enlargement of the necrotic center, which is surrounded at its border by an inflammatory infiltrate of macrophages and fibroblasts. A thin capsule of fibroblasts and reticular fibers gradually develops, and the surrounding area of cerebral edema becomes more distinct than in the previous stage. The third stage, early capsule formation (days 10 to 13), is characterized by the formation of a capsule that is better developed on the cortical than on the ventricular side of the lesion. This stage correlates with the appearance of a ring-enhancing capsule on neuroimaging studies. The final stage, late capsule formation (day 14 and beyond), is defined by a well-formed necrotic center surrounded by a dense collagenous capsule. The surrounding area of cerebral edema has regressed, but marked gliosis with large numbers of reactive astrocytes has developed outside the capsule. This gliotic process may contribute to the development of seizures as a sequel of brain abscesses.

**CLINICAL PRESENTATION** A brain abscess typically presents as an expanding intracranial mass lesion, rather than as an infectious process. Although the evolution of signs and symptoms is extremely variable, ranging from hours to weeks or even months, most patients present to the hospital 11 to 12 days following onset of symptoms. The classic clinical triad of headache, fever, and a focal neurologic deficit is present in <50% of cases. The most common symptom in patients with a brain abscess is headache, occurring in >75% of patients. The headache is often characterized as a constant, dull, aching sensation, either hemicranial or generalized, and it becomes progressively more severe and refractory to therapy. Fever is present in only 50% of patients at the time of diagnosis, and its absence should not exclude the diagnosis. The new onset of focal or generalized seizure activity is a presenting sign in 15 to 35% of patients. Focal neurologic deficits including hemiparesis, aphasia, or visual field defects are part of the initial presentation in >60% of patients.

The clinical presentation of a brain abscess depends on its location, the nature of the primary infection if present, and on the level of the ICP. Hemiparesis is the most common localizing sign of a frontal lobe abscess. A temporal lobe abscess may present with a disturbance of language (dysphasia) or an upper homonymous quadrantanopia. Nystagmus and ataxia are signs of a cerebellar abscess. Signs of raised ICP—papilledema, nausea and vomiting, and drowsiness or confusion—can be the dominant presentation of some abscesses, particularly those in the cerebellum. Meningismus is not present unless the abscess has ruptured into the ventricle or the infection has spread to the subarachnoid space.

**DIAGNOSIS** Diagnosis is made by neuroimaging studies. MRI (Fig. 360-4) is better than CT for demonstrating abscesses in the early (cerebritis) stages and is superior to CT for identifying abscesses in the posterior fossa. A mature brain abscess appears on CT as a focal area of hypodensity surrounded by ring enhancement. The CT and MRI appearance, particularly of the capsule, may be altered by treatment with glucocorticoids. The distinction between a brain abscess and other focal lesions such as tumors may be facilitated with diffusion-weighted imaging (DWI) sequences in which brain abscesses typically show increased signal and low apparent diffusion coefficient.

**TREATMENT** Optimal therapy of brain abscesses involves a combination of high-dose parenteral antibiotics and neurosurgical drainage. Empirical therapy of community-acquired brain abscess in an immunocompetent patient typically includes a third-generation cephalosporin (e.g., cefotaxime or ceftriaxone) and metronidazole (see Table 360-2 for antibiotic dosages). In patients with penetrating head trauma or recent neurosurgical procedures, treatment should include ceftazidime as the
third-generation cephalosporin to enhance coverage of *Pseudomonas* spp. and vancomycin for coverage of staphylococci. Meropenem plus vancomycin also provides good coverage in this setting.

Aspiration and drainage of the abscess under stereotactic guidance are beneficial for both diagnosis and therapy. Empirical antibiotic coverage should be modified based on the results of Gram’s stain and culture of the abscess contents. Complete excision of a bacterial abscess via craniotomy or craniectomy is generally reserved for multiloculated abscesses or those in which stereotactic aspiration is unsuccessful.

Medical therapy alone is not optimal for treatment of brain abscess and should be reserved for patients whose abscesses are neurosurgically inaccessible, for patients with small nonencapsulated abscesses (cerebritis), and patients whose condition is too tenuous to allow performance of a neurosurgical procedure. All patients should receive a minimum of 6 to 8 weeks of parenteral antibiotic therapy. The role, if any, of supplemental oral antibiotic therapy following completion of a standard course of parenteral therapy has never been adequately studied.

Patients should also receive prophylactic anticonvulsant therapy because of the high risk of seizures. Anticonvulsant therapy is continued for at least 3 months after resolution of the abscess, and decisions regarding withdrawal are then based on the EEG. If the EEG is abnormal, anticonvulsant therapy should be continued. If the EEG is normal, anticonvulsant therapy can be slowly withdrawn, with close follow-up and repeat EEG after the medication has been discontinued.

Glucocorticoids should not be given routinely to patients with brain abscesses. Intravenous dexamethasone therapy (10 mg every 6 h) is usually reserved for patients with substantial periabscess edema and associated mass effect and increased ICP. Dexamethasone should be tapered as rapidly as possible to avoid delaying the natural process of encapsulation of the abscess.

Serial MRI or CT scans should be obtained on a monthly or twice-monthly basis to document resolution of the abscess. More frequent studies (e.g., weekly) are probably warranted in the subset of patients who are receiving antibiotic therapy alone. A small amount of enhancement may remain for months after the abscess has been successfully treated.

**PROGNOSIS** The mortality of brain abscess has declined in parallel with the development of enhanced neuroimaging techniques, improved neurosurgical procedures for stereotactic aspiration, and improved antibiotics. In modern series the mortality is typically <15%. Significant sequelae including seizures, persisting weakness, aphasia, or mental impairment occur in ≥20% of survivors.

**NONBACTERIAL CAUSES OF INFECTIOUS FOCAL CNS LESIONS**

**ETIOLOGY** Neurocysticercosis is the most common parasitic disease of the CNS worldwide. Humans acquire cystercerosis by the ingestion of food contaminated with the eggs of the parasite *T. solium*. Eggs are contained in undercooked pork or in drinking water or other foods contaminated with human feces. *T. gondii* is a parasite that is acquired from the ingestion of undercooked meat and from handling cat feces.

**CLINICAL PRESENTATION** The most common manifestation of neurocysticercosis is new-onset partial seizures with or without secondary generalization. Cysticerci may develop in the brain parenchyma and cause seizures or focal neurologic deficits. When present in the subarachnoid or ventricular spaces, cysticerci can produce increased ICP by interference with CSF flow. Spinal cysticerci can mimic the presentation of intraspinal tumors. When the cysticerci first lodge in the brain, they frequently cause little in the way of an inflammatory response. As the cysticercal cyst degenerates, it elicits an inflammatory response that may present clinically as a seizure. Eventually the cyst dies, a process that may take several years, and is typically associated with resolution of the inflammatory response and often abatement of seizures.

Primary *toxoplasma* infection is often asymptomatic. However, during this phase parasites may spread to the CNS, where they become latent. Reactivation of CNS infection is almost exclusively associated with immunocompromised hosts, particularly those with HIV infection. During this phase patients present with headache, fever, seizures, and focal neurologic deficits.

**DIAGNOSIS** The lesions of neurocysticercosis are readily visualized by MRI or CT scans. Parenchymal brain calcifications are the most common finding. The scolex can often be visualized on MRI. A very early sign of cyst death is hypointensity of the vesicular fluid on T2-weighted images when compared with CSF. MRI findings consist of multiple lesions in the deep white matter, the thalamus, and basal ganglia and at the gray-white junction in the cerebral hemispheres. With contrast administration, the majority of the lesions enhance in a ringed, nodular, or homogeneous pattern and are surrounded by edema.

In the presence of the characteristic neuroimaging abnormalities of this parasitic infection, serum anti-*T. gondii* antibodies should be obtained; if positive, the patient should be treated.

**TREATMENT**

Anticonvulsant therapy is initiated when the patient with neurocysticercosis presents with a seizure. There is controversy about whether or not antihelminthic therapy should be given to all patients. Such therapy does not necessarily reduce the risk of seizure recurrence, but the control of seizures is easier after treatment with cysticidal drugs than when the disease is untreated. Albendazole and praziquantel are used in the treatment of neurocysticercosis. Approximately 85% of parenchymal cysts are destroyed by a single course of albendazole and ~75% are destroyed by a single course of praziquantel. The dose of albendazole is 15 mg/kg per day in two doses for 8 days. The dose of praziquantel is 50 mg/kg per day for 15 days, although a number of other dosage regimens are also frequently cited. Antiepileptic therapy can be stopped once the follow-up CT scan shows resolution of the lesion. Long-term antiepileptic therapy is recommended when seizures occur after resolution of edema and resorption or calcification of the degenerating cyst.

CNS toxoplasmosis is treated with a combination of sulfadiazine, 1.5 to 2.0 g orally qid, plus pyrimethamine, 100 mg orally to load then 75 to 100 mg orally qd, plus folinic acid, 10 to 15 mg orally qd. Folinic acid is added to the regimen to prevent megaloblastic anemia. Therapy is continued until there is no evidence of active disease on neuroimaging studies, which typically takes at least 6 weeks, and then the dose of sulfadiazine is reduced to 2 to 4 g/d and pyrimethamine to 50 mg/d. Clindamycin plus pyrimethamine is an alternative therapy for patients who cannot tolerate sulfadiazine, but the combination of pyrimethamine and sulfadiazine is more effective.

**SUBDURAL EMPYEMA**

A subdural empyema (SDE) is a collection of pus between the dura and arachnoid membranes (Fig. 360-5).

**EPIDEMIOLOGY** SDE is a rare disorder that accounts for 15 to 25% of focal suppurative CNS infections. Sinusitis is the most common predisposing condition and typically involves the frontal sinuses, either alone or in combination with the ethmoid and maxillary sinuses. Sinusitis-associated empyema has a striking predilection for young males, possibly reflecting sex-related differences in sinus anatomy and development. It has been suggested that SDE may complicate 1 to 2% of cases of frontal sinusitis severe enough to require hospitalization. As a consequence of this epidemiology, SDE shows an ~3:1 male: female predominance, with 70% of cases occurring in the second and third decades of life. SDE may also develop as a complication of head trauma or neurosurgery. Secondary infection of a subdural effusion may also result in empyema, although secondary infection of hematomas, in the absence of a prior neurosurgical procedure, is rare.

**ETIOLOGY** Aerobic and anaerobic streptococci, staphylococci, Enterobacteriaceae, and anaerobic bacteria are the most common causative
organisms of sinusitis-associated SDE. Staphylococci and gram-negative bacilli are often the etiologic organisms when SDE follows neurosurgical procedures or head trauma. Up to one-third of cases are culture-negative, possibly reflecting difficulty in obtaining adequate anaerobic cultures.

PATHOPHYSIOLOGY Sinusitis-associated SDE develops as a result of either retrograde spread of infection from septic thrombophlebitis of the mucosal veins draining the sinuses or contiguous spread of infection to the brain from osteomyelitis in the posterior wall of the frontal or other sinuses. SDE may also develop from direct introduction of bacteria into the subdural space as a complication of a neurosurgical procedure. The evolution of SDE can be extremely rapid because the subdural space is a large compartment that offers few mechanical barriers to the spread of infection. In patients with sinusitis-associated SDE, suppurative changes typically begin in the upper and anterior portions of one cerebral hemisphere and then extend posteriorly. SDE is often associated with other intracranial infections including epidural empyema (40%), cortical thrombophlebitis (35%), and intracranial abscess or cerebritis (>25%). Cortical venous infarction produces necrosis of underlying cerebral cortex and subcortical white matter, with focal neurologic deficits and seizures (see below).

CLINICAL PRESENTATION A patient with SDE typically presents with fever and a progressively worsening headache. The diagnosis of SDE should always be suspected in a patient with known sinusitis who presents with new CNS signs or symptoms. Patients with underlying sinusitis frequently have symptoms related to this infection. As the infection progresses, focal neurologic deficits, seizures, nuchal rigidity, and signs of increased ICP commonly occur. Headache is the most common complaint at the time of presentation; initially it is localized to the side of the subdural infection but then becomes more severe and generalized. Contralateral hemiparesis or hemiplegia is the most common focal neurologic deficit and can occur from the direct effects of the SDE on the cortex or as a consequence of venous infarction. Seizures begin as partial motor seizures that then become secondarily generalized. Seizures may be due to the direct irritative effect of the SDE on the underlying cortex or result from cortical venous infarction (see above). In untreated SDE, the increasing mass effect and increase in ICP cause progressive deterioration in consciousness, leading ultimately to coma.

DIAGNOSIS MRI (Fig. 360-6) is superior to CT in identifying SDE and any associated intracranial infections. The administration of gadolinium greatly improves diagnosis by enhancing the rim of the empyema and allowing the empyema to be clearly delineated from the underlying brain parenchyma. Cranial MRI is also extremely valuable in identifying sinusitis, other focal CNS infections, cortical venous infarction, cerebral edema, and cerebritis. CT may show a crescent-shaped hypodense lesion over one or both hemispheres or in the interhemispheric fissure. Frequently the degree of mass effect, exemplified by midline shift, ventricular compression, and sulcal effacement, is far out of proportion to the mass of the SDE.

CSF examination should be avoided in patients with known or suspected SDE as it adds no useful information and is associated with the risk of cerebral herniation.

DIFFERENTIAL DIAGNOSIS The differential diagnosis of the combination of headache, fever, focal neurologic signs, and seizure activity that progresses rapidly to an altered level of consciousness includes subdural hematoma, bacterial meningitis, viral encephalitis, brain abscess, superior sagittal sinus thrombosis, and acute disseminated encephalomyelitis. The presence of nuchal rigidity is unusual with brain abscess or epidural empyema and should suggest the possibility of SDE when associated with significant focal neurologic signs and fever. Patients with bacterial meningitis also have nuchal rigidity but do not typically have focal deficits of the severity seen with SDE.

PROGNOSIS Prognosis is influenced by the level of consciousness of the patient at the time of hospital presentation, the size of the empyema, and the speed with which therapy is instituted. Long-term neurologic sequelae, which include seizures and hemiparesis, occur in up to 50% of cases.

FIGURE 360-6 Subdural empyema. There is marked enhancement of the dura and leptomeninges (A, B, straight arrows) along the left medial hemisphere. The pus is hypointense on T1-weighted images (A, B), but markedly hyperintense on the proton density–weighted (C, curved arrow) image. (Courtesy of Joseph Lurito, MD.)
Cranial epidural abscess is a collection of pus between the dura and the inner table of the skull (Fig. 360-7).

ETIOLOGY AND PATHOPHYSIOLOGY Epidural abscess is less common than either brain abscess or SDE and accounts for <2% of focal suppurative CNS infections. A cranial epidural abscess develops as a complication of a craniotomy or compound skull fracture or as a result of spread of infection from the frontal sinuses, middle ear, mastoid, or orbit. An epidural abscess may develop contiguous to an area of osteomyelitis, when craniotomy is complicated by infection of the wound or bone flap, or as a result of direct infection of the epidural space. Infection in the frontal sinus, middle ear, mastoid, or orbit can reach the epidural space through retrograde spread of infection from septic thrombophlebitis in the emissary veins that drain these areas or by way of direct spread of infection through areas of osteomyelitis. Unlike the subdural space, the epidural space is really a potential rather than an actual compartment. The dura is normally tightly adherent to the inner skull table, and infection must dissect the dura away from the skull table as it spreads. As a result, epidural abscesses are often smaller than SDEs. Cranial epidural abscesses, unlike brain abscesses, only rarely result from hematogenous spread of infection from extracranial primary sites. The bacteriology of a cranial epidural abscess is similar to that of SDE (see above). The etiologic organisms of an epidural abscess that arises from frontal sinusitis, middle ear infections, or mastoiditis are usually streptococci or anaerobic organisms. Staphylococci or gram-negative organisms are the usual cause of an epidural abscess that develops as a complication of craniotomy or compound skull fracture.

CLINICAL PRESENTATION Patients present with fever (60%), headache (40%), nuchal rigidity (35%), seizures (10%), and focal deficits (5%). Periorbital edema and Potts puffy tumor, reflecting underlying associated frontal bone osteomyelitis, are present in ~40%. In patients with a recent neurosurgical procedure, wound infection is invariably present, but other symptoms may be subtle and can include altered mental status (45%), fever (35%), and headache (20%). The diagnosis should also be considered when fever and headache follow recent head trauma or occur in the setting of frontal sinusitis, mastoiditis, or otitis media.

DIAGNOSIS Cranial MRI is the procedure of choice to demonstrate a cranial epidural abscess. The sensitivity of CT is limited by the presence of signal artifacts arising from the bone of the inner skull table. The CT appearance of an epidural empyema is that of a lens or crescent-shaped hypodense extraaxial lesion. On MRI, an epidural empyema appears as a lentiform or crescent-shaped fluid collection that is hyperintense compared to CSF on T2-weighted images. On T1-weighted images, the fluid collection has a signal intensity that is intermediate between that of brain tissue and CSF. Following the administration of gadolinium, a significant enhancement of the dura is seen on T1-weighted images. In distinction to subdural empyema, signs of mass effect or other parenchymal abnormalities are uncommon.

TREATMENT Immediate neurosurgical drainage is indicated. Empirical antimicrobial therapy, pending the results of Gram’s stain and culture of the purulent material obtained at surgery, should include a combination of a third-generation cephalosporin, nafcillin or vancomycin, and metronidazole (Table 360-2). Ceftazidime should be substituted for ceftriaxone or cefotaxime in neurological patients. Meropenem and vancomycin also provide effective empirical therapy in postneurosurgical cases. When the organism has been identified, antimicrobial therapy can be modified accordingly. Antibiotics should be continued for at least 3 weeks after surgical drainage.

PROGNOSIS Mortality is <5% in modern series, and full recovery is the rule in most survivors.

SUPPURATIVE THROMBOPHLEBITIS

DEFINITION Suppurative intracranial thrombophlebitis is septic venous thrombosis of cortical veins and sinuses. This may occur as a complication of bacterial meningitis; SDE; epidural abscess; or infection in the skin of the face, parasinal sinuses, middle ear, or mastoid.

ANATOMY AND PATHOPHYSIOLOGY The cerebral veins and venous sinuses have no valves; therefore, blood within them can flow in either direction. The superior sagittal sinus is the largest of the venous sinuses (Fig. 360-8). It receives blood from the frontal, parietal, and occipital superior cerebral veins and the diploic veins, which communicate with the meningeal veins. Bacterial meningitis is a common predisposing condition for septic thrombosis of the superior sagittal sinus. The diploic veins, which drain into the superior sagittal sinus, provide a route for the spread of infection from the meninges, especially in cases where there is purulent exudate near areas of the superior sagittal sinus. Infection can also spread to the superior sagittal sinus from nearby SDE or epidural abscess. Dehydration from vomiting, hypercoagulable states, and immunologic abnormalities, including the presence of circulating antiphospholipid antibodies, also contribute to cerebral venous sinus thrombosis. Thrombosis may extend from one sinus to another, and often at autopsy thrombi of different histologic ages can be detected in several sinuses. Thrombosis of the superior sagittal sinus is often associated with thrombosis of superior cortical veins and small parenchymal hemorrhages.

The superior sagittal sinus drains into the transverse sinuses (Fig. 360-8). The transverse sinuses also receive venous drainage from small veins from both the middle ear and mastoid cells. The transverse sinus becomes the sigmoid sinus before draining into the internal jugular vein. Septic transverse/sigmoid sinus thrombosis can be a complica-
tion of acute and chronic otitis media or mastoiditis. Infection spreads from the mastoid air cells to the transverse sinus via the emissary veins or by direct invasion. The cavernous sinuses are inferior to the superior sagittal sinus at the base of the skull. The cavernous sinuses receive blood from the facial veins via the superior and inferior ophthalmic veins. Bacteria in the facial veins enter the cavernous sinus via these veins. Bacteria in the sphenoid and ethmoid sinuses can spread to the cavernous sinuses via the small emissary veins. The sphenoid and ethmoid sinuses are the most common sites of primary infection resulting in septic cavernous sinus thrombosis.

**CLINICAL MANIFESTATIONS**  Septic thrombosis of the superior sagittal sinus presents with headache, fever, nausea and vomiting, confusion, and focal or generalized seizures. There may be a rapid development of stupor and coma. Weakness of the lower extremities with bilateral Babinski signs or hemiparesis is often present. When superior sagittal sinus thrombosis occurs as a complication of bacterial meningitis, nuchal rigidity and Kernig’s and Brudzinski’s signs may be present.

The oculomotor nerve, the trochlear nerve, the abducens nerve, the ophthalmic and maxillary branches of the trigeminal nerve, and the internal carotid artery all pass through the cavernous sinus (Fig. 355-3). The symptoms of septic cavernous sinus thrombosis are fever, headache, frontal and retroorbital pain, and diplopia. The classic signs are ptosis, proptosis, chemosis, and extraocular dysmotility due to deficits of cranial nerves III, IV, and VI; hyperesthesia of the ophthalmic and maxillary divisions of the fifth cranial nerve and a decreased corneal reflex may be detected. There may be evidence of dilated, tortuous retinal veins and papilledema.

Headache and earache are the most frequent symptoms of transverse sinus thrombosis. A transverse sinus thrombosis may also present with otitis media, sixth nerve palsy, and retroorbital or facial pain (Gradinego’s syndrome). Sigmoid sinus and internal jugular vein thrombosis may present with neck pain.

**DIAGNOSIS**  The diagnosis of septic venous sinus thrombosis is suggested by an absent flow void within the affected venous sinus on MRI and confirmed by magnetic resonance venography or the venous phase of cerebral angiography. The diagnosis of thrombophlebitis of intracerebral and meningeal veins is suggested by the presence of intracerebral hemorrhage but requires cerebral angiography for definitive diagnosis.

**TREATMENT**  Septic venous sinus thrombosis is usually treated with antibiotics and hydration. The choice of antimicrobial therapy is based on the bacteria responsible for the predisposing or associated condition. Optimal duration of therapy is unknown, but antibiotics are usually continued for 6 weeks or until there is radiographic evidence of resolution of thrombosis. Anticoagulation with dose-adjusted heparin has been reported to be beneficial in patients with aseptic venous sinus thrombosis; it is also used in the treatment of septic venous sinus thrombosis complicating bacterial meningitis. The presence of a small intracerebral hemorrhage from septic thrombophlebitis is not an absolute contraindication to heparin therapy. Successful management of aseptic venous sinus thrombosis has been reported with urokinase therapy and with a combination of intrathrombus recombinant tissue plasminogen activator (rtPA) and intravenous heparin, but the efficacy of these therapies in septic venous sinus thrombosis is unknown.


**CLINICAL PATHOPHYSIOLOGY**  Neurologic manifestations of chronic meningitis (Table 361-1) are determined by the anatomic location of the infection and its consequences. Persistent headache with or without stiff neck, and hydrocephalus, cranial neuropathies, radiculopathies, and cognitive or personality changes are the cardinal features. These can occur alone or in combination. When they appear in combination, widespread dissemination of the inflammatory process along CSF pathways has occurred. In some cases, the presence of an underlying systemic illness points to a specific agent or class of agents as the probable cause. The diagnosis of chronic meningitis is usually made when the clinical presentation prompts the astute physician to examine the CSF for signs of inflammation. CSF is produced by the choroid plexus of the cerebral ventricles, exits through narrow foramina into the subarachnoid space surrounding the brain and spinal cord, circulates around the base of the brain and over the cerebral hemispheres, and is resorbed by arachnoid villi projecting into the superior sagittal sinus. CSF flow provides a pathway for rapid spread of infectious and malignant processes over the brain, spinal cord, and cranial and spinal nerve roots. Spread from the subarachnoid space into brain parenchyma may occur via the arachnoid cuffs that surround blood vessels that penetrate brain tissue (Virchow-Robin spaces).

**Intracranial Meningitis**  Nociceptive fibers of the meninges (Chap. 14) are stimulated by the inflammatory process, resulting in headache or
neck or back pain. Obstruction of CSF pathways at foramina or arachnoid villi may produce hydrocephalus and symptoms of raised intracranial pressure (ICP), including headache, vomiting, apathy or drowsiness, gait instability, papilledema, visual loss, impaired upgaze, or palsies of the sixth cranial nerve (CN) (Chap. 258). Cognitive and behavioral changes during the course of chronic meningitis may also result from vascular damage, which may similarly produce seizures, stroke, or myelopathy. Inflammatory deposits seeded via the CSF circulation are often prominent around the brainstem and cranial nerves and along the undersurface of the frontal and temporal lobes. Such cases, termed basal meningitis, often present as multiple cranial neuropathies, with visual loss (CN II), facial weakness (CN VII), hearing loss (CN VIII), diplopia (CNs III, IV, and VI), sensory or motor abnormalities of the cranial nerves (CNs IX, X, and XII), decreased constriction (CN I), or facial sensory loss and masseter weakness (CN V).

Spinal Meningitis Injury may occur to motor and sensory roots as they traverse the subarachnoid space and penetrate the meninges. These cases present as multiple radiculopathies with combinations of radicular pain, sensory loss, motor weakness, and sphincter dysfunction. Meningeal inflammation can encircle the cord, resulting in myelopathy. Patients with slowly progressive involvement of multiple cranial nerves and/or spinal nerve roots are likely to have chronic meningitis. Electrophysiologic testing (emergonography, nerve conduction studies, and evoked response testing) may be helpful in determining whether there is involvement of cranial and spinal nerve roots.

Systemic Manifestations In some patients, evidence of systemic disease provides clues to the underlying cause of chronic meningitis. A careful history and physical examination are essential before embarking on a diagnostic workup, which may be costly, prolonged, and associated with risk from invasive procedures. A complete history of travel, sexual practice, and exposure to infectious agents should be sought. Infectious causes are often associated with fever, malaise, anorexia, and signs of localized or disseminated infection outside the nervous system. Infectious causes are of major concern in the immunosuppressed patient, especially in patients with AIDS, in whom chronic meningitis may present without headache or fever. Noninfectious inflammatory disorders often produce systemic manifestations, but meningitis may be the initial manifestation. Carcinomatous meningitis may or may not be accompanied by clinical evidence of the primary neoplasm.

**APPROACH TO THE PATIENT**

The occurrence of chronic headache, hydrocephalus, cranial neuropathy, radiculopathy, and/or cognitive decline in a patient should prompt consideration of a lumbar puncture for evidence of meningial inflammation. On occasion the diagnosis is made when an imaging study [computed tomography (CT) or magnetic resonance imaging (MRI)] shows contrast enhancement of the meninges, always abnormal with the exception of dural enhancement after lumbar puncture, neurosurgical procedures, or spontaneous CSF leakage. Once chronic meningitis is confirmed by CSF examination, effort is focused on identifying the cause (Tables 361-2 and 361-3) by (1) further analysis of the CSF, (2) diagnosis of an underlying systemic infection or noninfectious inflammatory condition, or (3) pathologic examination of meningeal biopsy specimens.

Two clinical forms of chronic meningitis exist. In the first, the symptoms are chronic and persistent, whereas in the second there are recurrent, discrete episodes of illness. In the latter group, all symptoms, signs, and CSF parameters of meningeal inflammation resolve completely between episodes without specific therapy. In such patients, the likely etiologies include infection with herpes simplex virus (HSV) type 2; chemical meningitis due to leakage into CSF of contents from an epidermoid tumor, craniopharyngioma, or cholesteatoma; primary inflammatory conditions, including Vogt-Koyanagi-Harada syndrome, Behçet’s syndrome (Chap. 307), Mollaret’s meningitis, and systemic lupus erythematosus (SLE; Chap. 300); and drug hypersensitivity with repeated administration of the offending agent.

The epidemiologic history is of considerable importance and may provide direction for selection of laboratory studies. Pertinent features include a history of tuberculosis or exposure to a likely case; past travel to areas endemic for fungal infections (the San Joaquin Valley in California and southwestern states for coccidioidomycosis, midwestern states for histoplasmosis, southeastern states for blastomycosis); travel to the Mediterranean region or ingestion of imported unpasteurized dairy products (Brucella); time spent in areas endemic for Lyme disease (e.g., Connecticut, New York, Massachusetts); exposure to sexually transmitted disease (syphilis); exposure of an immunocompromised host to pigeons and their droppings (Cryptococcus); gardening (Sporothrix schenckii); ingestion of poorly cooked meat or contact with a household cat (Toxoplasma gondii); residence in Thailand or Japan (Gnathostoma spinigerum) or the South Pacific (Angiostrongylus cantonensis); rural residence and raccoon exposure (Beylisasarcas procyonis); and residence in Latin America, the Philippines, or Southeast Asia when eosinophilic meningitis is present (Taenia solium).

The presence of focal cerebral signs in a patient with chronic meningitis suggests the possibility of a brain abscess or other parameningeal infection; identification of a potential source of infection (chronic draining ear, sinusitis, right-to-left cardiac pulmonary shunt, chronic pleuropulmonary infection) supports this diagnosis. In some cases, diagnosis may be established by recognition and biopsy of unusual skin lesions (Behçet’s syndrome, cryptococcosis, blastomycosis, SLE, Lyme disease, intravenous drug use, sporotrichosis, trypanosomiasis) or enlarged lymph nodes (lymphoma, tuberculosis, sarcoid, infection with HIV, secondary syphilis, or Whipple’s disease). A careful ophthalmologic examination may reveal uveitis [Vogt-Koyanagi-Harada syndrome, sarcoid, or central nervous system (CNS) lymphoma], keratoconjunctivitis sicca (Sjögren’s syndrome), or iridocyclitis (Behçet’s syndrome) and is essential to assess visual loss from hydrocephalus. Aphthous oral lesions, genital ulcers, and hypopyon suggest Behçet’s syndrome. Hepatosplenomegaly suggests lymphoma, sarcoid, tuberculosis, or brucellosis. Herpetic lesions in the genital area or on the thighs suggest HSV-2 infection. A breast nodule, a suspicious pigmented skin lesion, focal bone pain, or an abdominal mass directs attention to possible carcinomatous meningitis.

**Imaging** Once the clinical syndrome is recognized as a potential manifestation of chronic meningitis, proper analysis of the CSF is essential. However, if the possibility of raised ICP exists, a brain imaging study should be performed before lumbar puncture. If ICP is elevated because of a mass lesion, brain swelling, or a block in ventricular CSF outflow (obstructive hydrocephalus), then lumbar puncture carries the potential risk of brain herniation. Obstructive hydrocephalus usually requires direct ventricular drainage of CSF. In patients with open CSF flow pathways, elevated ICP can occur due to impaired resorption of CSF by arachnoid villi. In such patients, lumbar puncture is usually safe, but repetitive or continuous lumbar drainage may be necessary to prevent relatively sudden death from raised ICP. In some patients, especially with cryptococcal meningitis, life-threatening levels of ICP can occur without visible hydrocephalus on brain imaging.

Contrast-enhanced MRI or CT studies of the brain and spinal cord can identify meningeal enhancement, parameningeal infections (including brain abscess), encasement of the spinal cord (malignancy or inflammation and infection), or nodular deposits on the meninges or nerve roots (malignancy or sarcoidosis) (Fig. 361-1). Imaging studies are also useful to localize areas of meningeal disease prior to meningeal biopsy.
### TABLE 361-2 Infectious Causes of Chronic Meningitis

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>CSF Formula</th>
<th>Helpful Diagnostic Tests</th>
<th>Risk Factors and Systemic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COMMON BACTERIAL CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partially treated suppurative meningitis</td>
<td>Mononuclear or mixed mononuclear- polymorphonuclear cells</td>
<td>CSF culture and Gram stain</td>
<td>History consistent with acute bacterial meningitis and incomplete treatment</td>
</tr>
<tr>
<td>Parameningeal infection</td>
<td>Mononuclear or mixed polymorphonuclear- mononuclear cells</td>
<td>Contrast-enhanced CT or MRI to detect parenchymal, subdural, epidural, or sinus infection</td>
<td>Otitis media, pleuropulmonary infection, right-to-left cardiopulmonary shunt for brain abscess; focal neurologic signs; neck, back, ear, or sinus tenderness</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
<td>Mononuclear cells except polymorphonuclear cells in early infection (commonly &lt;500 WBC/μL); low CSF glucose; high protein Mononuclear cells; elevated protein</td>
<td>Tuberculin skin test may be negative; AFB culture of CSF (sputum, urine, gastric contents if indicated); tuberculostearic acid detection in CSF; identify tubercle bacillus on acid-fast stain of CSF or protein pellicle; PCR</td>
<td>Exposure history; previous tuberculous illness; immunosuppressed or AIDS; young children; fever, meningismus, night sweats, miliary TB on X-ray or liver biopsy; stroke due to arteritis</td>
</tr>
<tr>
<td>Lyme disease (Bannwarth’s syndrome)</td>
<td><em>Borrelia burgdorferi</em></td>
<td>Serum Lyme antibody titer; Western blot confirmation; (patients with syphilis may have false-positive Lyme titer)</td>
<td>History of tick bite or appropriate exposure history; erythema chronicum migrans skin rash; arthritis, radiculopathy, Bell’s palsy, meningocencephalitis—multiple sclerosis-like syndrome</td>
</tr>
<tr>
<td>Syphilis (secondary, tertiary)</td>
<td><em>Treponema pallidum</em></td>
<td>CSF VDRL; serum VDRL (or RPR); fluorescent treponemal antibody-absorbed (FTA) or MHA-TP; serum VDRL may be negative in tertiary syphilis</td>
<td>Appropriate exposure history; HIV seropositive individuals at increased risk of aggressive infection; “dementia”; cerebral infarction due to endarteritis</td>
</tr>
<tr>
<td><strong>UNCOMMON BACTERIAL CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Actinomyces</em></td>
<td>Polymorphonuclear cells</td>
<td>Anaerobic culture</td>
<td>Parameningeal abscess or sinus tract (oral or dental focus); pneumonitis</td>
</tr>
<tr>
<td><em>Nocardia</em></td>
<td>Polymorphonuclear; occasionally mononuclear cells; often low glucose Mononuclear cells (rarely polymorphonuclear); elevated protein; often low glucose</td>
<td>Isolation may require weeks; weakly acid fast</td>
<td>Associated brain abscess may be present</td>
</tr>
<tr>
<td><em>Brucella</em></td>
<td>Mononuclear cells</td>
<td>CSF antibody detection; serum antibody detection</td>
<td>Intake of unpasteurized dairy products; exposure to goats, sheep, cows; fever, arthralgia, myalgia, vertebral osteomyelitis</td>
</tr>
<tr>
<td>Whipple’s disease</td>
<td><em>Tropherema whippleii</em></td>
<td>Biopsy of small bowel or lymph node; CSF PCR for <em>T. whipplei</em>; brain and meningeal biopsy (with PAS stain and EM examination)</td>
<td>Diarrhea, weight loss, arthralgias, fever; dementia, ataxia, paresis, ophthalmoplegia, oculomotor dysfunction</td>
</tr>
<tr>
<td><strong>RARE BACTERIAL CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptospirosis (occasionally if left untreated may last 3–4 weeks)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FUNGAL CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Cryptococcus neoformans</em></td>
<td>Mononuclear cells; count not elevated in some patients with AIDS</td>
<td>India ink or fungal wet mount of CSF (budding yeast); blood and urine cultures; antigen detection in CSF</td>
<td>AIDS and immune suppression; pigeon exposure; skin and other organ involvement due to disseminated infection</td>
</tr>
<tr>
<td><em>Coccidioides immitis</em></td>
<td>Mononuclear cells (sometimes 10–20% eosinophils); often low glucose</td>
<td>Antibody detection in CSF and serum</td>
<td>Exposure history—southwestern US; increased virulence in dark-skinned races</td>
</tr>
<tr>
<td><em>Candida sp.</em></td>
<td>Polymorphonuclear or mononuclear</td>
<td>Fungal stain and culture of CSF</td>
<td>IV drug abuse; post surgery; prolonged intravenous therapy; disseminated candidiasis</td>
</tr>
<tr>
<td><em>Histoplasma capsulatum</em></td>
<td>Mononuclear cells; low glucose</td>
<td>Fungal stain and culture of large volumes of CSF; antigen detection in CSF, serum, and urine; antibody detection in serum, CSF</td>
<td>Exposure history—Ohio and central Mississippi River Valley; AIDS; mucosal lesions</td>
</tr>
<tr>
<td><em>Blastomyces dermatitidis</em></td>
<td>Mononuclear cells</td>
<td>Fungal stain and culture of CSF; biopsy and culture of skin, lung lesions; antibody detection in serum</td>
<td>Midwestern and Southeastern USA; usually systemic infection; abscesses, draining sinus, ulcers</td>
</tr>
<tr>
<td><em>Aspergillus sp.</em></td>
<td>Mononuclear or polymorphonuclear cells</td>
<td>CSF culture</td>
<td>Sinusitis; granulocytopenia or immunosuppression</td>
</tr>
<tr>
<td><em>Sporothrix schenckii</em></td>
<td>Mononuclear cells</td>
<td>Antibody detection in CSF and serum; CSF culture</td>
<td>Traumatic inoculation; IV drug use; ulcerated skin lesion</td>
</tr>
<tr>
<td><strong>RARE FUNGAL CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Xylohypha</em> (formerly Cladosporium) trichoides and other dark-walled (demateaceous) fungi such as Curvularia, Drechslera, Mucor, Pseudallescheria boydii*</td>
<td></td>
<td></td>
<td>(continued)</td>
</tr>
<tr>
<td>Causative Agent</td>
<td>CSF Formula</td>
<td>Helpful Diagnostic Tests</td>
<td>Risk Factors and Systemic Manifestations</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
<td>--------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td><strong>PROTOZOA CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxoplasma gondii</td>
<td>Mononuclear cells</td>
<td>Biopsy or response to empirical therapy in clinically appropriate context (including presence of antibody in serum)</td>
<td>Usually with intracerebral abscesses common in HIV seropositive patients</td>
</tr>
<tr>
<td>Trypanosomiasis</td>
<td>Mononuclear cells, elevated protein</td>
<td>Elevated CSF IgM; identification of trypanosomes in CSF and blood smear</td>
<td>Endemic in Africa; chancr, lymphadenopathy; prominent sleep disorder</td>
</tr>
</tbody>
</table>

**RARE PROTOZOA CAUSES**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>CSF Formula</th>
<th>Helpful Diagnostic Tests</th>
<th>Risk Factors and Systemic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acanthamoeba sp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trychomonas vaginalis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxoplasma gondii</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROTOZOA CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cysticercosis (infection with cysts of Taenia solium)</td>
<td>Mononuclear cells; may have eosinophils; glucose level may be low</td>
<td>Indirect hemagglutination assay in CSF; ELISA immunoblotting in serum</td>
<td>Usually with multiple cysts in basal meninges and hydrocephalus; cerebral cysts, muscle calcification</td>
</tr>
<tr>
<td>Gnathostoma spinigerum</td>
<td>Eosinophils, mononuclear cells</td>
<td>Peripheral eosinophilia</td>
<td>History of eating raw fish; common in Thailand and Japan; subarachnoid hemorrhage; painful radiculopathy</td>
</tr>
<tr>
<td>Angiostrongylus cantonensis</td>
<td>Eosinophils, mononuclear cells</td>
<td>Recovery of worms from CSF</td>
<td>History of eating raw shellfish; common in tropical Pacific regions; often benign</td>
</tr>
<tr>
<td>Baylisascaris procyonis (raccoon ascariid)</td>
<td>Eosinophils, mononuclear cells</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RARE HELMINTHIC CAUSES**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>CSF Formula</th>
<th>Helpful Diagnostic Tests</th>
<th>Risk Factors and Systemic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baylisascaris procyonis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trypanosoma rhodesiense</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trypanosoma gambiense</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T. rhodesiense</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RARE HELMINTHIC CAUSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cysticercosis (infection with cysts of Taenia solium)</td>
<td>Mononuclear cells; may have eosinophils; glucose level may be low</td>
<td>Indirect hemagglutination assay in CSF; ELISA immunoblotting in serum</td>
<td>Usually with multiple cysts in basal meninges and hydrocephalus; cerebral cysts, muscle calcification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELISA immunoblotting in serum</td>
<td>History of eating raw fish; common in Thailand and Japan; subarachnoid hemorrhage; painful radiculopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peripheral eosinophilia</td>
<td>History of eating raw shellfish; common in tropical Pacific regions; often benign</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recovery of worms from CSF</td>
<td></td>
</tr>
</tbody>
</table>

**VIRAL CAUSES**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>CSF Formula</th>
<th>Helpful Diagnostic Tests</th>
<th>Risk Factors and Systemic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mumps</td>
<td>Mononuclear cells</td>
<td>Antibody in serum</td>
<td>No prior mumps or immunization; may produce meningoencephalitis; may persist for 3–4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Contact with rodent or their excreta; may persist for 3–4 weeks</td>
</tr>
<tr>
<td>Lymphocytic choriomeningitis</td>
<td>Mononuclear cells; may have low glucose</td>
<td>Mononuclear cells</td>
<td>Viral isolation from CSF</td>
</tr>
<tr>
<td>Echovirus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV (acute retroviral syndrome)</td>
<td>Mononuclear cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>p24 antigen in serum and CSF; high level of HIV viremia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes simplex (HSV)</td>
<td>Mononuclear cells</td>
<td>PCR for HSV DNA; CSF antibody</td>
<td>Recurrent meningitis due to HSV-2 (rarely HSV-1) often associated with genital recurrences</td>
</tr>
</tbody>
</table>

**Abbreviations:** AFB, acid-fast bacillus; CSF, cerebrospinal fluid; CT, computed tomography; ELISA, enzyme-linked immunosorbent assay; EM, electron microscopy; FTA, fluorescent treponemal antibody absorption test; MHA-TP, microhemagglutination assay; T. pallidum, MRI, magnetic resonance imaging; PAS, periodic acid–Schiff; PCR, polymerase chain reaction; RPR, rapid plasma reagin test; TB, tuberculosis; VDRL, Venereal Disease Research Laboratories test.

### Cerebrospinal Fluid Analysis

The CSF pressure should be measured and samples sent for bacterial culture, cell count and differential, Gram’s stain, and measurement of glucose and protein. In cases without a known cause, CSF should be sent for the Venereal Disease Research Laboratories (VDRL) test, acid-fast bacillus (AFB) stain and culture, wet mount for fungus and parasites, India ink preparation and culture, culture for fastidious bacteria and fungi, assays for cryptococcal antigen and oligoclonal immunoglobulin bands, and cytology. Other specific CSF or blood tests and cultures (Tables 361-2 and 361-3) should be ordered as indicated on the basis of the history, physical examination, or preliminary CSF results (i.e., eosinophilic, mononuclear, or polymorphonuclear meningitis). Rapid diagnosis may be facilitated by serologic tests and polymerase chain reaction (PCR) testing to identify DNA sequences in the CSF that are specific for the suspected pathogen.

In most categories of chronic (not recurrent) meningitis, mononuclear cells predominate after 3 weeks of illness, the principal considerations are Nocardia asteroides, Actinomyces israelii, Brucella, Mycobacterium tuberculosis (5 to 10% of early cases only), various fungi (Blastomyces dermatitidis, Candida albicans, Histoplasma capsulatum, Aspergillus species, Pseudallescheria boydii, Cladophialaphora bantiana), and noninfectious causes (SLE, exogenous chemical meningitis). When eosinophils predominate or are present in limited numbers in a primarily mononuclear cell response in the CSF, the differential diagnosis includes parasitic diseases (A. cantonensis, G. spinigerum, B. procyonis, or Toxocara canis infection, cysticercosis, schistosomiasis, echinococcal disease, T. gondii infection), fungal infections (6 to 20% eosinophils along with a predominantly lymphocyte pleocytosis, particularly with coccidiodal meningitis), neoplastic disease (lymphoma, leukemia, metastatic carcinoma), or other inflammatory processes (sarcoïdosis, hyper-eosinophilic syndrome).

It is often necessary to broaden the number of diagnostic tests if the initial workup does not reveal the cause. In addition, repeated samples of large volumes of CSF may be required to diagnose certain infectious and malignant causes of chronic meningitis. For instance, lymphomatous or carcinomatous meningitis may be di-
Table 361-3  Noninfectious Causes of Chronic Meningitis

<table>
<thead>
<tr>
<th>Causative Agents</th>
<th>CSF Formula</th>
<th>Helpful Diagnostic Tests</th>
<th>Risk Factors and Systemic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignancy</td>
<td>Mononuclear cells, elevated protein, low glucose</td>
<td>Repeated cytologic examination of large volumes of CSF; CSF exam by polarizing microscopy; clonal lymphocyte markers; deposits on nerve roots or meninges seen on myelogram or contrast-enhanced MRI; meningeal biopsy</td>
<td>Metastatic cancer of breast, lung, stomach, or pancreas; melanoma, lymphoma, leukemia; meningeal gliomatosis; meningeal sarcoma; cerebral dysgerminoma; meningeal melanoma or B cell lymphoma</td>
</tr>
<tr>
<td>Chemical compounds (may cause recurrent meningitis)</td>
<td>Mononuclear or PMNs, low glucose, elevated protein; xanthochromia from subarachnoid hemorrhage in week prior to presentation with “meningitis”</td>
<td>Contrast-enhanced CT scan or MRI; Cerebral angiogram to detect aneurysm</td>
<td>History of recent injection into the subarachnoid space; history of sudden onset of headache; recent resection of acoustic neuraoma or craniopharyngioma; epidermoid tumor of brain or spine, sometimes with dermoid sinus tract; pituitary apoplexy</td>
</tr>
<tr>
<td>Primary inflammation</td>
<td>Mononuclear cells; elevated protein; often low glucose</td>
<td>Serum and CSF angiotensin-converting enzyme levels; biopsy of extraneural affected tissues or brain lesion/meningeal biopsy</td>
<td>CN palsies, especially of CN VII; hypothalamic dysfunction, especially diabetes insipidus; abnormal chest radiograph; peripheral neuropathy or myopathy</td>
</tr>
<tr>
<td>CNS sarcoidosis</td>
<td>Mononuclear cells</td>
<td>Angiography or meningeal biopsy</td>
<td>Recurrent meningoencephalitis with uveitis, retinal detachment, alopecia, lightening of eyebrows and lashes, dysacousia, cataracts, glaucoma</td>
</tr>
<tr>
<td>Vogt-Koyanagi-Harada syndrome (recurrent meningitis)</td>
<td>Mononuclear cells</td>
<td>Anti-DNA antibody, antinuclear antibodies</td>
<td>Subacute dementia; multiple cerebral infarctions; recent zoster ophthalmicus</td>
</tr>
<tr>
<td>Isolated granulomatous angiitis of the nervous system</td>
<td>Mononuclear cells, elevated protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>Mononuclear or PMNs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behçet’s syndrome (recurrent meningitis)</td>
<td>Mononuclear or PMNs, elevated protein</td>
<td>PCr for herpes; MR/CT to rule out epidermoid tumor or dural cyst</td>
<td>Oral and genital aphthous ulcers; iridocyclitis; retinal hemorrhages; pathergic lesions at site of skin puncture</td>
</tr>
<tr>
<td>Chronic benign lymphocytic meningitis</td>
<td>Mononuclear cells</td>
<td></td>
<td>Recovery in 2–6 months, diagnosis by exclusion</td>
</tr>
<tr>
<td>Mollaret’s meningitis (recurrent meningitis)</td>
<td>Large endothelial cells and PMNs in first hours, followed by mononuclear cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug hypersensitivity</td>
<td>PMNs; occasionally mononuclear cells or eosinophils</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wegener’s granulomatosis</td>
<td>Mononuclear cells</td>
<td>Chest and sinus radiographs; urinalysis; ANCA antibodies in serum</td>
<td>Associated sinus, pulmonary, or renal lesions; CN palsies; skin lesions; peripheral neuropathy</td>
</tr>
</tbody>
</table>

Other: multiple sclerosis, Sjögren’s syndrome, neonatal onset multisystemic inflammatory disease (NOMID), and rarer forms of vasculitis (e.g., Cogan’s syndrome)

Abbreviations: ANCA, anti-neutrophil cytoplasmic antibodies; CN, cranial nerve; CSF, cerebrospinal fluid; CT, computed tomography; HSV, herpes simplex virus; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; PMNs, polymorphonuclear cells.

Meningeal Biopsy  A diagnostic meningeal biopsy should be strongly considered in patients who are severely disabled, who need chronic ventricular decompression, or whose illness is progressing rapidly. The activities of the surgeon, pathologist, microbiologist, and cytologist should be coordinated so that a large enough sample is obtained and the appropriate cultures and histologic and molecular studies, including electron microscopic and PCR studies, are performed. The diagnostic yield of meningeal biopsy can be increased by targeting regions that enhance with contrast on MRI or CT. With current microsurgical techniques, most areas of the basal meninges can be accessed for biopsy via a limited craniotomy. In a series from the Mayo Clinic reported by Cheng et al., MRI demonstrated meningeal enhancement in 47% of patients undergoing meningeal biopsy. Biopsy of an enhancing region was diagnostic in 80% of cases; biopsy of nonenhancing regions was diagnostic in only 9%; sarcoid (31%) and metastatic adenocarcinoma (25%) were the most common conditions identified.

Malignancy  The diagnosis of meningeal malignancy may require large volumes of CSF for culture of sediment. If standard lumbar puncture is unrewarding, a cervical cisternal tap to sample CSF near to the basal meninges may be fruitful.

Laboratory Investigation  In addition to the CSF examination, an attempt should be made to uncover pertinent underlying illnesses. Tuberculin skin test, chest radiograph, urine analysis and culture, blood count and differential, renal and liver function tests, alkaline phosphatase, sedimentation rate, antinuclear antibody, anti-Ro and anti-La antibody, and serum angiotensin-converting enzyme level are often indicated. Liver or bone marrow biopsy may be diagnostic in some cases of miillary tuberculosis, disseminated fungal infection, sarcoidosis, or metastatic malignancy. Abnormalities discovered on chest radiograph or chest CT can be pursued by bronchoscopy or transthoracic needle biopsy.
Prions are infectious proteins that cause degeneration of the central nervous system (CNS). Prion diseases are disorders of protein conformation, the most common of which is the Creutzfeldt-Jakob disease (CJD). CJD typically presents with dementia and myoclonus, is relentlessly progressive, and generally causes death within a year of onset. Most CJD patients are between 50 and 75 years of age; however, patients as young as 17 years and as old as 83 years may be affected. The average age of onset is 60 years. CJD typically presents with dementia and myoclonus, is relentlessly progressive, and generally causes death within a year of onset. Most CJD patients are between 50 and 75 years of age; however, patients as young as 17 years and as old as 83 years may be affected. The average age of onset is 60 years.

Prions are infectious proteins that cause degeneration of the central nervous system (CNS). Prion diseases are disorders of protein conformation, the most common of which is called Creutzfeldt-Jakob disease (CJD). CJD typically presents with dementia and myoclonus, is relentlessly progressive, and generally causes death within a year of onset. Most CJD patients are between 50 and 75 years of age; however, patients as young as 17 years and as old as 83 years have been recorded.

In mammals, prions reproduce by binding to the normal, cellular isoform of the prion protein (PrPC) and stimulating conversion of PrPC into the disease-causing isoform (PrPSc). PrPSc is rich in α-helix and has little β-structure, while PrPSc has less α-helix and a high amount of β-structure (Fig. 362-1). This α-to-β structural transition in the prion protein (PrP) is the fundamental event underlying prion diseases (Table 362-1).

Four new concepts have emerged from studies of prions: (1) Prions are the only known infectious pathogens that are devoid of nucleic acid; all other infectious agents possess genomes composed of either RNA or DNA that direct the synthesis of their progeny. (2) Prion diseases may be manifest as infectious, genetic, and sporadic disorders; no other group of illnesses with a single etiology presents with such a wide spectrum of clinical manifestations. (3) Prion diseases result from the accumulation of PrPSc, the conformation of which differs substantially from that of its precursor PrPC. (4) PrPSc can exist in a variety of different conformations, each of which seems to specify a particular disease phenotype. How a specific conformation of a PrPSc molecule is imparted to PrPSc during prion replication to produce nascent PrPSc with the same conformation is unknown. Additionally, it is...
The sporadic form of CJD is the most common prion disorder in humans. Sporadic CJD (sCJD) accounts for ~85% of all cases of human prion disease, while inherited prion diseases account for 10 to 15% of all cases (Table 362-2). Familial CJD (fCJD), Gerstmann-Straussler-Scheinker (GSS) disease, and exotonic ungulate encephalopathy are all thought to occur after the consumption of prion-infected foodstuffs. The BSE epidemic emerged in Britain in the late 1980s and was shown to be due to industrial cannibalism. Whether BSE began as a sporadic case of BSE in a cow or started with scrapie in sheep is unknown. The origin of chronic wasting disease (CWD), a prion disease endemic in deer and elk in regions of North America, is uncertain.

**EPIDEMIOLOGY** CJD is found throughout the world. The incidence of sCJD is approximately one case per million population. Although many geographic clusters of CJD have been reported, each has been shown to segregate with a PrP gene mutation. Attempts to identify common exposure to some etiologic agent have been unsuccessful for both the sporadic and familial cases. Ingestion of scrapie-infected sheep or goat meat as a cause of CJD in humans has not been demonstrated by epidemiologic studies, although speculation about this potential route of inoculation continues. Of particular interest are deer hunters who develop CJD, because up to 90% of culled deer in some game herds have been shown to harbor CWD prions. Studies with Syrian hamsters demonstrate that oral infection with prions can occur, but the process is inefficient compared to intracerebral inoculation.

**PATHOGENESIS** The human prion diseases were initially classified as neurodegenerative disorders of unknown etiology on the basis of pathologic changes being confined to the CNS. With the transmission of kuru and CJD to apes, investigators began to view these diseases as infectious CNS illnesses caused by slow viruses. Even though the familial nature of a subset of CJD cases was well described, the significance of this observation became more obscure with the transmission of CJD to animals. Eventually, the meaning of heritable CJD became

**SPECTRUM OF PRION DISEASES** The sporadic form of CJD is the most common prion disorder in humans. Sporadic CJD (sCJD) accounts for ~85% of all cases of human prion disease, while inherited prion diseases account for 10 to 15% of all cases (Table 362-2). Familial CJD (fCJD), Gerstmann-Straussler-Scheinker (GSS) disease, and exotonic ungulate encephalopathy are all thought to occur after the consumption of prion-infected foodstuffs. The BSE epidemic emerged in Britain in the late 1980s and was shown to be due to industrial cannibalism. Whether BSE began as a sporadic case of BSE in a cow or started with scrapie in sheep is unknown. The origin of chronic wasting disease (CWD), a prion disease endemic in deer and elk in regions of North America, is uncertain.

**TABLE 362-2** The Prion Diseases

<table>
<thead>
<tr>
<th>Disease</th>
<th>Host</th>
<th>Mechanism of Pathogenesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>Fore people</td>
<td>Infection through ritualistic cannibalism</td>
</tr>
<tr>
<td>iCJD</td>
<td>Humans</td>
<td>Infection from prion-contaminated hGH, dura mater grafts, etc.</td>
</tr>
<tr>
<td>vCJD</td>
<td>Humans</td>
<td>Infection from bovine prions</td>
</tr>
<tr>
<td>icCJD</td>
<td>Humans</td>
<td>Germ-line mutations in PRNP</td>
</tr>
<tr>
<td>GSS</td>
<td>Humans</td>
<td>Germ-line mutations in PRNP</td>
</tr>
<tr>
<td>FFI</td>
<td>Humans</td>
<td>Germ-line mutation in PRNP</td>
</tr>
<tr>
<td>sCJD</td>
<td>Humans</td>
<td>Somatic mutation or spontaneous conversion of PrP&lt;sup&gt;c&lt;/sup&gt; into PrP&lt;sup&gt;Sc&lt;/sup&gt;?</td>
</tr>
<tr>
<td>sFI</td>
<td>Humans</td>
<td>Somatic mutation or spontaneous conversion of PrP&lt;sup&gt;c&lt;/sup&gt; into PrP&lt;sup&gt;Sc&lt;/sup&gt;?</td>
</tr>
<tr>
<td>Animal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scapie</td>
<td>Sheep</td>
<td>Infection in genetically susceptible sheep</td>
</tr>
<tr>
<td>BSE</td>
<td>Cattle</td>
<td>Infection with prion-contaminated MBM</td>
</tr>
<tr>
<td>TME</td>
<td>Mink</td>
<td>Infection with prions from sheep or cattle</td>
</tr>
<tr>
<td>CWD</td>
<td>Mule deer, elk</td>
<td>Unknown</td>
</tr>
<tr>
<td>FSE</td>
<td>Cats</td>
<td>Infection with prion-contaminated beef</td>
</tr>
<tr>
<td>Exotic ungulate encephalopathy</td>
<td>Greater kudu, nyala, or oxyx</td>
<td>Infection with prion-contaminated MBM</td>
</tr>
</tbody>
</table>

**TABLE 362-1** Glossary of Prion Terminology

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prion</td>
<td>Proteinaceous infectious particle that lacks nucleic acid. Prions are composed largely, if not entirely, of PrP&lt;sup&gt;c&lt;/sup&gt; molecules. They can cause scrapie in animals and related neurodegenerative diseases of humans such as Creutzfeldt-Jakob disease (CJD).</td>
</tr>
<tr>
<td>PrP&lt;sup&gt;Sc&lt;/sup&gt;</td>
<td>Disease-causing isoform of the prion protein. This protein is the only identifiable macromolecule in purified preparations of scrapie prions.</td>
</tr>
<tr>
<td>PrP&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Cellular isoform of the prion protein. PrP&lt;sup&gt;c&lt;/sup&gt; is the precursor of PrP&lt;sup&gt;Sc&lt;/sup&gt;.</td>
</tr>
<tr>
<td>PrP 27-30</td>
<td>A fragment of PrP&lt;sup&gt;c&lt;/sup&gt;, generated by truncation of the NH&lt;sub&gt;2&lt;/sub&gt;-terminus by limited digestion with proteinase K. PrP 27-30 retains prion infectivity and polymerizes into amyloid.</td>
</tr>
<tr>
<td>PRNP</td>
<td>PrP gene located on human chromosome 20.</td>
</tr>
<tr>
<td>Prion rod</td>
<td>An aggregate of prions composed largely of PrP 27-30 molecules. Created by detergent extraction and limited proteolysis of PrP&lt;sup&gt;c&lt;/sup&gt;. Morphologically and histochemically indistinguishable from many amyloids.</td>
</tr>
<tr>
<td>PrP amyloid</td>
<td>Amyloid containing PrP in the brains of animals or humans with prion disease; often accumulates as plaques.</td>
</tr>
</tbody>
</table>
clear with the discovery of mutations in the PrP gene of these patients. The prion concept explains how a disease can manifest as a heritable as well as an infectious illness. Moreover, the hallmark of all prion diseases, whether sporadic, dominantly inherited, or acquired by infection, is that they involve the aberrant metabolism of PrP.

A major feature that distinguishes prions from viruses is the finding that both PrP isoforms are encoded by a chromosomal gene. In humans, the PrP gene is designated PRNP and is located on the short arm of chromosome 20. Limited proteolysis of PrPSc produces a smaller, protease-resistant molecule of ~142 amino acids designated PrP 27-30; PrPSc is completely hydrolyzed under the same conditions (Fig. 362-2). In the presence of detergent, PrP 27-30 polymerizes into amyloid. Prion rods formed by limited proteolysis and detergent extraction are indistinguishable from the filaments that aggregate to form PrP amyloid plaques in the CNS. Both the rods and the PrP amyloid filaments found in brain tissue exhibit similar ultrastructural morphology and green-gold birefringence after staining with Congo red dye.

### Prion Strains

The existence of prion strains raised the question of how heritable biologic information can be deciphered in a molecule other than nucleic acid. Various strains of prions have been defined by incubation times and the distribution of neuronal vacuolation. Subsequently, the patterns of PrPSc deposition were found to correlate with vacuolation profiles, and these patterns were also used in their characterization.

Persuasive evidence that strain-specific information is deciphered in the tertiary structure of PrPSc comes from transmission of two different inherited human prion diseases to mice expressing a chimeric human-mouse PrP transgene. In FFI, the protease-resistant fragment of PrPSc after deglycosylation has a molecular mass of 19 kDa, whereas in fCJD and most sporadic prion diseases, it is 21 kDa (Table 362-3). This difference in molecular mass was shown to be due to different sites of proteolytic cleavage at the NH2 termini of the two human PrPSc molecules, reflecting different tertiary structures. These distinct conformations were not unexpected because the amino acid sequences of the PrPs differ.

Extracts from the brains of patients with FFI transmitted disease into mice expressing a chimeric human-mouse PrP transgene and induced formation of the 19-kDa PrPSc, whereas brain extracts from fCJD and sCJD patients produced the 21-kDa PrPSc in mice expressing the same transgene. On second passage, these differences were maintained, demonstrating that chimeric PrPSc can exist in two different conformations based on the sizes of the protease-resistant fragments, even though the amino acid sequence of PrPSc is invariant.

This analysis was extended when patients with sporadic fatal insomnia (sFI) were identified. Although they did not carry a PRNP gene mutation, the patients demonstrated a clinical and pathologic phenotype that was indistinguishable from that of patients with FFI. Furthermore, 19-kDa PrPSc was found in their brains, and on passage of prion disease to mice expressing a chimeric human-mouse PrP transgene, 19-kDa PrPSc was also found. These findings indicate that the disease phenotype is dictated by the conformation of PrPSc and not the amino acid sequence. PrPSc acts as a template for the conversion of PrPSc into nascent PrPSc. On the passage of prions into mice expressing a chimeric hamster-mouse PrP transgene, a change in the conformation of PrPSc was accompanied by the emergence of a new strain of prions.

### Species Barrier

Studies on the role of the primary and tertiary structures of PrP in the transmission of prion disease have given new insights into the pathogenesis of these maladies. The amino acid sequence of PrP encodes the species of the prion, and the prion derives its PrPSc sequence from the last mammal in which it was passed. While the primary structure of PrP is likely to be the most important or even sole determinant of the tertiary structure of PrPSc, PrPSc seems to function as a template in determining the tertiary structure of nascent PrPSc molecules as they are formed from PrPSc. In turn, prion diversity appears to be encoded in the conformation of PrPSc and thus, prion strains seem to represent different conformers of PrPSc.

In general, transmission of prion disease from one species to another is inefficient, in that not all intracebrally inoculated animals develop disease, and those that fall ill do so only after long incubation times that can approach the natural life span of the animal. This "spe-

### Prion Diseases

The existence of prion strains raised the question of how heritable biologic information can be deciphered in a molecule other than nucleic acid. Various strains of prions have been defined by incubation times and the distribution of neuronal vacuolation. Subsequently, the patterns of PrPSc deposition were found to correlate with vacuolation profiles, and these patterns were also used in their characterization.

Persuasive evidence that strain-specific information is deciphered in the tertiary structure of PrPSc comes from transmission of two different inherited human prion diseases to mice expressing a chimeric human-mouse PrP transgene. In FFI, the protease-resistant fragment of PrPSc after deglycosylation has a molecular mass of 19 kDa, whereas in fCJD and most sporadic prion diseases, it is 21 kDa (Table 362-3). This difference in molecular mass was shown to be due to different sites of proteolytic cleavage at the NH2 termini of the two human PrPSc molecules, reflecting different tertiary structures. These distinct conformations were not unexpected because the amino acid sequences of the PrPs differ.

Extracts from the brains of patients with FFI transmitted disease into mice expressing a chimeric human-mouse PrP transgene and induced formation of the 19-kDa PrPSc, whereas brain extracts from fCJD and sCJD patients produced the 21-kDa PrPSc in mice expressing the same transgene. On second passage, these differences were maintained, demonstrating that chimeric PrPSc can exist in two different conformations based on the sizes of the protease-resistant fragments, even though the amino acid sequence of PrPSc is invariant.

This analysis was extended when patients with sporadic fatal insomnia (sFI) were identified. Although they did not carry a PRNP gene mutation, the patients demonstrated a clinical and pathologic phenotype that was indistinguishable from that of patients with FFI. Furthermore, 19-kDa PrPSc was found in their brains, and on passage of prion disease to mice expressing a chimeric human-mouse PrP transgene, 19-kDa PrPSc was also found. These findings indicate that the disease phenotype is dictated by the conformation of PrPSc and not the amino acid sequence. PrPSc acts as a template for the conversion of PrPSc into nascent PrPSc. On the passage of prions into mice expressing a chimeric hamster-mouse PrP transgene, a change in the conformation of PrPSc was accompanied by the emergence of a new strain of prions.

### Species Barrier

Studies on the role of the primary and tertiary structures of PrP in the transmission of prion disease have given new insights into the pathogenesis of these maladies. The amino acid sequence of PrP encodes the species of the prion, and the prion derives its PrPSc sequence from the last mammal in which it was passed. While the primary structure of PrP is likely to be the most important or even sole determinant of the tertiary structure of PrPSc, PrPSc seems to function as a template in determining the tertiary structure of nascent PrPSc molecules as they are formed from PrPSc. In turn, prion diversity appears to be encoded in the conformation of PrPSc and thus, prion strains seem to represent different conformers of PrPSc.

In general, transmission of prion disease from one species to another is inefficient, in that not all intracebrally inoculated animals develop disease, and those that fall ill do so only after long incubation times that can approach the natural life span of the animal. This "spe-

### Prion Diseases

The existence of prion strains raised the question of how heritable biologic information can be deciphered in a molecule other than nucleic acid. Various strains of prions have been defined by incubation times and the distribution of neuronal vacuolation. Subsequently, the patterns of PrPSc deposition were found to correlate with vacuolation profiles, and these patterns were also used in their characterization.

Persuasive evidence that strain-specific information is deciphered in the tertiary structure of PrPSc comes from transmission of two different inherited human prion diseases to mice expressing a chimeric human-mouse PrP transgene. In FFI, the protease-resistant fragment of PrPSc after deglycosylation has a molecular mass of 19 kDa, whereas in fCJD and most sporadic prion diseases, it is 21 kDa (Table 362-3). This difference in molecular mass was shown to be due to different sites of proteolytic cleavage at the NH2 termini of the two human PrPSc molecules, reflecting different tertiary structures. These distinct conformations were not unexpected because the amino acid sequences of the PrPs differ.

Extracts from the brains of patients with FFI transmitted disease into mice expressing a chimeric human-mouse PrP transgene and induced formation of the 19-kDa PrPSc, whereas brain extracts from fCJD and sCJD patients produced the 21-kDa PrPSc in mice expressing the same transgene. On second passage, these differences were maintained, demonstrating that chimeric PrPSc can exist in two different conformations based on the sizes of the protease-resistant fragments, even though the amino acid sequence of PrPSc is invariant.

This analysis was extended when patients with sporadic fatal insomnia (sFI) were identified. Although they did not carry a PRNP gene mutation, the patients demonstrated a clinical and pathologic phenotype that was indistinguishable from that of patients with FFI. Furthermore, 19-kDa PrPSc was found in their brains, and on passage of prion disease to mice expressing a chimeric human-mouse PrP transgene, 19-kDa PrPSc was also found. These findings indicate that the disease phenotype is dictated by the conformation of PrPSc and not the amino acid sequence. PrPSc acts as a template for the conversion of PrPSc into nascent PrPSc. On the passage of prions into mice expressing a chimeric hamster-mouse PrP transgene, a change in the conformation of PrPSc was accompanied by the emergence of a new strain of prions.

### Species Barrier

Studies on the role of the primary and tertiary structures of PrP in the transmission of prion disease have given new insights into the pathogenesis of these maladies. The amino acid sequence of PrP encodes the species of the prion, and the prion derives its PrPSc sequence from the last mammal in which it was passed. While the primary structure of PrP is likely to be the most important or even sole determinant of the tertiary structure of PrPSc, PrPSc seems to function as a template in determining the tertiary structure of nascent PrPSc molecules as they are formed from PrPSc. In turn, prion diversity appears to be encoded in the conformation of PrPSc and thus, prion strains seem to represent different conformers of PrPSc.

In general, transmission of prion disease from one species to another is inefficient, in that not all intracebrally inoculated animals develop disease, and those that fall ill do so only after long incubation times that can approach the natural life span of the animal. This "spe-
PrPSc may be present at very low levels in some normal cells, where it performs some important, as yet unknown, function. The level of PrPSc in such cells is hypothesized to be sufficiently low to be not detected by bioassay. In some altered metabolic states, the cellular mechanisms for clearing PrPSc might become compromised and the rate of PrPSc formation would then begin to exceed the capacity of the cell to clear it. The third possible mechanism is attractive since it suggests PrPSc is not simply a misfolded protein, as proposed for the first and second mechanisms, but that it is an alternatively folded molecule with a function.

More than 30 different mutations resulting in nonconservative substitutions in the human PRNP gene have been found to segregate with inherited human prion diseases. Missense mutations and expansions in the octapeptide repeat region of the gene are responsible for familial forms of prion disease. Five different mutations of the PRNP gene have been linked genetically to heritable prion disease.

Although phenotypes may vary dramatically within families, specific phenotypes tend to be observed with certain mutations. A clinical phenotype indistinguishable from typical sCJD is usually seen with substitutions at codons 180, 183, 200, 208, 210, and 232. Substitutions at codons 102, 105, 117, 198, and 217 are associated with the GSS variant of prion disease. The normal human PrP sequence contains five repeats of an eight-amino-acid sequence. Insertions from two to nine extra octapeptides frequently cause variable phenotypes ranging from a condition indistinguishable from sCJD to a slowly progressive dementia of illness of many years’ duration. A mutation at codon 178 resulting in substitution of asparagine for aspartic acid produces FFI if a methionine is encoded at the polymorphic 129 residue on the same allele. Typical CJD is seen if a valine is encoded at position 129 of the same allele.

**Human PRNP Gene Polymorphisms**

Polymorphisms influence the susceptibility to sporadic, inherited, and infective forms of prion disease. The methionine/valine polymorphism at position 129 not only modulates the age of onset of some inherited prion diseases but can also determine the clinical phenotype. The finding that homozygosity at codon 129 predisposes to sCJD supports a model of prion production that favors PrP interactions between homologous proteins.

Substitution of the basic residue lysine at position 218 in mouse PrP produced dominant-negative inhibition of prion replication in transgenic mice. This same lysine at position 219 in human PrP has been found in 12% of the Japanese population, and this group appears to be resistant to prion disease. Dominant-negative inhibition of prion replication was also found with substitution of the basic residue arginine at position 171; sheep with arginine are resistant to scrapie prions but are susceptible to BSE prions that were inoculated intracerebrally.

**Infectious Prion Diseases**

**Iatrogenic CJD**

Accidental transmission of CJD to humans appears to have occurred with corneal transplantation, contaminated electroencephalogram (EEG) electrode implantation, and surgical procedures. Corneas from donors with apparently healthy recipients who developed CJD after prolonged incubation periods. The same improperly decontaminated EEG electrodes that caused CJD in two young patients with intractable epilepsy caused CJD in a chimpanzee 18 months after their experimental implantation.

Surgical procedures may have resulted in accidental inoculation of patients with prions during their operations, presumably because some instrument or apparatus in the operating theater became contaminated when a CJD patient underwent surgery. Although the epidemiology of these studies is highly suggestive, no proof for such episodes exists.

**Dura Mater Grafts**

More than 120 cases of CJD after implantation of dura mater grafts have been recorded. All of the grafts were thought to have been acquired from a single manufacturer whose preparative procedures were inadequate to inactivate human prions. One case of CJD occurred after repair of an ear drum perforation with a pericardium graft.

**Human Growth Hormone and Pituitary Gonadotropin Therapy**

The possibility of transmission of CJD from contaminated human growth hormone (hGH) preparations derived from human pituitaries has been raised by the occurrence of fatal cerebellar disorders with dementia in >120 patients ranging in age from 10 to 41 years. These patients received injections of hGH every 2 to 4 days for 4 to 12 years. If it is assumed that these patients developed CJD from injections of prion-contaminated hGH preparations, the possible incubation periods range from 4 to 30 years. Even though several investigations argue for the efficacy of inactivating prions in hGH fractions prepared from human pituitaries with 6 M urea, it seems doubtful that such protocols will be used for purifying hGH because recombinant hGH is available. Four cases of CJD have occurred in women receiving human pituitary gonadotropin.

**Variant CJD**

The restricted geographic occurrence and chronology of vCJD raised the possibility that BSE prions have been transmitted to humans through the consumption of tainted beef. More than 140 cases of vCJD have occurred, with >90% of these in Britain. Because the number of vCJD cases is still small, it is not possible to decide if we are at the beginning of a prion disease epidemic in Europe, similar to those seen for BSE and kuru, or if the number of vCJD cases will remain small. What is certain is that prion-tainted meat should be prevented from entering the human food supply.

The most compelling evidence that vCJD is caused by BSE prions was obtained from experiments in mice expressing the bovine PrP transgene. Both BSE and vCJD prions were efficiently transmitted to these transgenic mice and with similar incubation periods. In contrast to sCJD prions, vCJD prions did not transmit disease efficiently to mice expressing a chimeric human-mouse PrP transgene. Earlier studies with nontransgenic mice suggested that vCJD and BSE might be derived from the same source because both inocula transmitted disease with similar but very long incubation periods.

Attempts to determine the origin of BSE and vCJD prions have relied on passaging studies in mice, some of which are described above, as well as studies of the conformation and glycosylation of PrPSc. One scenario suggests that a particular conformation of bovine PrPSc was selected for heat resistance during the rendering process and was then reselected multiple times as cattle infected by ingesting prion-contaminated meat and bone meal (MBM) were slaughtered and their offal rendered into more MBM.

**Neuropathology**

Frequently, the brains of patients with CJD have no recognizable abnormalities on gross examination. Patients who survive for several years have variable degrees of cerebral atrophy.

On light microscopy, the pathologic hallmarks of CJD are spongiform degeneration and astrocytic gliosis. The lack of an inflammatory response in CJD and other prion diseases is an important pathologic feature of these degenerative disorders. Spongiform degeneration is characterized by many 1- to 5-μm vacuoles in the neuropil between
nerve cell bodies. Generally, the spongiform changes occur in the cerebral cortex, putamen, caudate nucleus, thalamus, and molecular layer of the cerebellum. Astrocytic gliosis is a constant but nonspecific feature of prion diseases. Widespread proliferation of fibrous astrocytes is found throughout the gray matter of brains infected with CJD prions. Astrocytic processes filled with glial filaments form extensive networks.

Amyloid plaques have been found in ~10% of CJD cases. Purified CJD prions from humans and animals exhibit the ultrastructural and histochemical characteristics of amyloid when treated with detergents during limited proteolysis. In first passage from some human Japanese CJD cases, amyloid plaques have been found in mouse brains. These plaques stain with antiserum raised against PrP.

The amyloid plaques of GSS disease are morphologically distinct from those seen in kuru or scrapie. GSS plaques consist of a central dense core of amyloid surrounded by smaller globules of amyloid. Ultrastructurally, they consist of a radiating fibrillar network of amyloid fibrils, with scant or no neuritic degeneration. The plaques can be distributed throughout the brain but are most frequently found in the cerebellum. They are often located adjacent to blood vessels. Congophilic angiopathy has been noted in some cases of GSS disease.

In vCJD, a characteristic feature is the presence of “floral plaques.” These are composed of a central core of PrP amyloid, surrounded by vacuoles in a pattern suggesting petals on a flower.

**CLINICAL FEATURES**

Nonspecific prodromal symptoms occur in about a third of patients with CJD and may include fatigue, sleep disturbance, weight loss, headache, malaise, and ill-defined pain. Most patients with CJD present with deficits in higher cortical function. These deficits almost always progress over weeks or months to a state of profound dementia characterized by memory loss, impaired judgment, and a decline in virtually all aspects of intellectual function. A few patients present with either visual impairment or cerebellar gait and coordination deficits. Frequently, the cerebellar deficits are rapidly followed by progressive dementia. Visual problems often begin with blurred vision and diminished acuity, rapidly followed by dementia.

Other symptoms and signs include extrapyramidal dysfunction manifested as rigidity, masklike facies, or choreoathetoid movements; pyramidal signs (usually mild); seizures (usually major motor) and, less commonly, hypesthesia; supranuclear gaze palsy; optic atrophy; and vegetative signs such as changes in weight, temperature, sweating, and menstruation.

**Myoclonus**

Most patients (~90%) with CJD exhibit myoclonus that appears at various times throughout the illness. Unlike other involuntary movements, myoclonus persists during sleep. Startle myoclonus elicited by loud sounds or bright lights is frequent. It is important to stress that myoclonus is neither specific nor confined to CJD. Dementia with myoclonus can also be due to Alzheimer’s disease (AD) (Chap. 350), to cryptococcal encephalitis (Chap. 186), or to the myoclonic epilepsy disorder Unverricht-Lundborg disease (Chap. 348).

**Clinical Course**

In documented cases of accidental transmission of CJD to humans, an incubation period of 1.5 to 2.0 years preceded the development of clinical disease. In other cases, incubation periods of up to 30 years have been suggested. Most patients with CJD live 6 to 12 months after the onset of clinical signs and symptoms, whereas some live for up to 5 years.

**DIAGNOSIS**

The constellation of dementia, myoclonus, and periodic electrical bursts in an afibrile 60-year-old patient generally indicates CJD. Clinical abnormalities in CJD are confined to the CNS. Fever, elevated sedimentation rate, leukocytosis in blood, or a pleocytosis in cerebrospinal fluid (CSF) should alert the physician to another etiology to explain the patient’s CNS dysfunction.

Variations in the typical course appear in inherited and transmitted forms of the disease. FCDJ has an earlier mean age of onset than sCJD. In GSS disease, ataxia is usually a prominent and presenting feature, with dementia occurring late in the disease course. GSS disease typically presents earlier than CJD (mean age, 43 years) and is typically more slowly progressive than CJD; death usually occurs within 5 years of onset. FFI is characterized by insomnia and dysautonomia; dementia occurs only in the terminal phase of the illness. Rare sporadic cases have been identified. vCJD has an unusual clinical course, with a prominent psychiatric prodrome that may include visual hallucinations and early ataxia, while frank dementia is usually a late sign of vCJD.

**DIFFERENTIAL DIAGNOSIS**

Many conditions may mimic CJD superficially. AD is occasionally accompanied by myoclonus but is usually distinguished by its protracted course and lack of motor and visual dysfunction.

Intracranial vasculitides (Chap. 306) may produce nearly all of the symptoms and signs associated with CJD, sometimes without systemic abnormalities. Myoclonus is exceptional with cerebral vasculitis, but focal seizures may confound the picture; furthermore, myoclonus is often absent in the early stages of CJD. Stepwise change in deficits, prominent headache, abnormal CSF, and focal magnetic resonance imaging (MRI) or angiographic abnormalities all favor vasculitis.

Neurosyphilis (Chap. 153) may present with dementia and myoclonus that progresses in a relatively rapid fashion but is easily distinguished from CJD by CSF findings, as is cryptococcal meningocerebral encephalitis. A diffuse intracranial tumor (gliomatosis cerebri; Chap. 358) may occasionally be confused with CJD. In rare cases of CNS neoplasia, neuroimaging studies are normal and there are no signs of increased intracranial pressure; however, CSF protein is usually elevated. Adult onset leukodystrophies (cereoid lipofuscinosisis; Chap. 350) and myoclonic epilepsy with Lafora bodies (Chap. 348) may be responsible for dementia, myoclonus, and ataxia; but the less acute courses and prominent seizures distinguish them from CJD. A number of diseases that may simulate CJD are easily distinguished by the clinical setting in which they occur. These diseases include anoxic encephalopathy, subacute sclerosing panencephalitis, progressive tuberoencephalitis, herpes simplex encephalitis (in immunocompromised patients), dialysis dementia, uremia, and hepatic encephalopathy. When CJD begins atypically, it may for a short time resemble other disorders such as Parkinson’s disease, progressive supranuclear palsy (Chap. 351), or progressive multifocal leukoencephalopathy (Chap. 360).

Certain drug intoxications, particularly lithium and bismuth, may produce encephalopathy and myoclonus. The rare condition known as Hashimoto’s encephalopathy, which presents with a subacute progressive encephalopathy and myoclonus with periodic triphasic complexes on the EEG, should be excluded in every case of suspected CJD. It is diagnosed by the finding of high titers of antithyroglobulin or antithyroid peroxidase (antimicrosomal) antibodies in the blood, and improves with glucocorticoid therapy. Unlike CJD, fluctuations in severity typically occur in Hashimoto’s encephalopathy.

The AIDS dementia complex (Chap. 173) may occasionally imitate CJD in onset, early course, physical signs, computed tomography (CT) findings, and lack of abnormalities on routine CSF studies. The few such patients without manifestations of systemic immunodeficiency (<10%) should be questioned about risk factors and should have serum antibodies to HIV determined.

**LABORATORY TESTS**

The only specific diagnostic tests for CJD and other human prion diseases measure PrPSc. The most widely used method involves limited proteolysis that generates PrP 27-30, which is detected by immunoblotting after denaturation. The conformation-dependent immunoblot assay (CDA) is based on immunoreactive epitopes that are exposed in PrPSc but buried in PrP. The CDA is extremely sensitive and quantitative and is likely to find wide application in both the post- and antemortem detection of prions in humans. The diagnosis of CJD can be established by brain biopsy if PrPSc is detected. If no attempt is made to measure PrPSc, but the constellation of pathologic changes frequently found in CJD is seen in a brain biopsy, then the diagnosis is reasonably secure (see “Neuropathology,” above). Because PrPSc is
not uniformly distributed throughout the CNS, the apparent absence of PrPSc in a limited sample such as a biopsy does not rule out prion disease. At autopsy, sufficient brain samples should be taken for both PrPSc immunoassay, preferably by the CDI, and immunohistochemistry of tissue sections.

Whether an antemortem test can be developed using the CDI to detect protease-sensitive forms of PrPSc in blood is uncertain. Another possibility is such a test based on PrPSc formation in muscle. PrPSc accumulation seems to be restricted to the hindlimb muscles in mice but is more widespread in hamsters. Whether muscles in humans and livestock can be identified in which PrPSc accumulates consistently remains to be established.

To establish the diagnosis of either CJD or familial prion disease, sequencing the PRNP gene must be performed. Finding the wild-type PRNP gene sequence permits the diagnosis of scJD if there is no history to suggest exposure to an exogenous source of prions. The identification of a mutation in the PRNP gene sequence that encodes a nonconservative amino acid substitution argues for familial prion disease.

CT may be normal or show cortical atrophy. The MRI scan may show a subtle increased intensity in the basal ganglia with T2- or diffusion-weighted imaging, but this finding is neither sensitive nor specific enough to make a diagnosis.

CSF is nearly always normal but may show minimal protein elevation. Although the stress protein 14-3-3 is elevated in the CSF of some patients with CJD, similar elevations of 14-3-3 are found in patients with herpes simplex virus encephalitis, multi-infarct dementia, and stroke. In AD, 14-3-3 is generally not elevated. In the serum of some patients with CJD, the S-100 protein is elevated, but as with 14-3-3, this elevation is not specific.

The EEG is often useful in the diagnosis of CJD. During the early phase of CJD, the EEG is usually normal or shows only scattered theta activity. In most advanced cases, repetitive, high-voltage, triphasic, and polyphasic sharp discharges are seen, but in many cases their presence is transient. The presence of these stereotyped periodic bursts of <200 ms duration, occurring every 1 to 2 s, makes the diagnosis of CJD very likely. These discharges are frequently but not always symmetric; there may be a one-sided predominance in amplitude. As CJD progresses, normal background rhythms become fragmentary and slow.

**CARE OF CJD PATIENTS** Although CJD should not be considered either a contagious or communicable disease, it is transmissible. The risk of accidental inoculation by aerosols is very small; nonetheless, procedures producing aerosols should be performed in certified biosafety cabinets. Biosafety level 2 practices, containment equipment, and facilities are recommended by the Centers for Disease Control and Prevention and the National Institutes of Health. The primary problem in caring for patients with CJD is the inadvertent infection of health care workers by needle and stab wounds. The transmission of prions through the air has never been documented. Electroencephalographic and electromyographic needles should not be reused after studies on patients with CJD have been performed.

There is no reason for pathologists or morgue dieners to resist performing autopsies on patients whose clinical diagnosis was CJD. Standard microbiologic practices outlined here, along with specific recommendations for decontamination, seem to be adequate precautions for the care of patients with CJD and the handling of infected specimens.

**DECONTAMINATION OF CJD PRIONS** Prions are extremely resistant to common inactivation procedures, and there is some disagreement about the optimal conditions for sterilization. Some investigators recommend treating CJD-contaminated materials once with 1 N NaOH at room temperature, but we believe this procedure may be inadequate for sterilization. Autoclaving at 132°C for 5 h or treatment with 2 N NaOH for several hours is recommended for sterilization of prions. The term “sterilization” implies complete destruction of prions; any residual infectivity can be hazardous.

**PREVENTION AND THERAPEUTICS** There is no known effective therapy for preventing or treating CJD. The finding that phenothiazines and acridines inhibit PrPSc formation in cultured cells led to clinical studies of quinacrine in CJD patients. Although quinacrine seems to slow the rate of decline in some CJD patients, no cure of the disease has been observed. In mice, the results of quinacrine treatment are mixed: Some investigators report treatment is ineffective, while others find that quinacrine prolongs the lives of prion-infected mice compared to untreated animals.

Like the acridines, anti-PrP antibodies have been shown to eliminate PrPSc from cultured cells. Additionally, such antibodies in mice either administered by injection or produced from a transgene have been shown to prevent prion disease when prions are introduced by a peripheral route, such as intraperitoneal inoculation. Unfortunately, the antibiotics were ineffective in mice inoculated intracerebrally with prions. Several drugs delay the onset of disease in animals inoculated intracerebrally with prions if the drugs are given around the time of the inoculation.

Structure-based drug design predicated on dominant-negative inhibition of prion formation has produced several promising compounds. Modified quinacrine compounds that are more potent than the parent drug have been found. Whether improving the efficacy of such small molecules will provide general methods for developing novel therapeutics for other neurodegenerative disorders, including AD and Parkinson’s disease, as well as amyotrophic lateral sclerosis (ALS), remains to be established.

Financial Disclosure: SBP has a financial interest in InPro Biotechnology, Inc.

**FURTHER READING**


---

**Section 3 Nerve and Muscle Disorders**

**Approach to the Patient with Peripheral Neuropathy**

Arthur K. Asbury

Peripheral neuropathy is a general term indicating peripheral nerve disorders of any cause; the manifestations of neuropathy may be so diverse that it is difficult for the physician to know where to begin and how to proceed.

The clinical and electrodiagnostic (EDX) approach to evaluation and management of a neuropathic disorder is summarized in Fig. 363-1. The EDX approach consists of electrophysiologic examination of nerve and muscle, including nerve conduction studies and electromyography. It is part of the evaluation of any neuropathy and is considered to be an extension of the neurologic examination. Using this
Ulnar Neuropathy

Complete ulnar paralysis results in a characteristic amination. Eventually weakness and atrophy of the abductor pollicis brevis (thenar eminence) become evident. The principal treatment of carpal tunnel syndrome is surgical section of the carpal ligament to relieve entrapment.

Carpal Tunnel Syndrome

The median nerve in the carpal tunnel lies in close quarters with nine tendons. Entrapment of the nerve at the wrist (carpal tunnel syndrome) is usually due to excessive use of the wrist but on occasion may be secondary to tendovaginitis with arthritis or local infiltration, e.g., by a thickening of connective tissue as in acromegaly or by deposit of amyloid or by one of the mucopolysaccharidoses. Other systemic diseases associated with carpal tunnel syndrome are hypothyroidism, rheumatoid arthritis, and diabetes mellitus, but underlying diseases account for only a small fraction of all cases. The main symptoms of carpal tunnel syndrome are nocturnal paresthesias of thumb, index, and middle fingers. With worsening, numbness occurs in that distribution and is demonstrable by pin examination. Eventually weakness and atrophy of the abductor pollicis brevis (thenar eminence) become evident. The principal treatment of carpal tunnel syndrome is surgical section of the carpal ligament to relieve entrapment.

FIGURE 363-1  Approach to the evaluation of peripheral neuropathies. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; EDX, electrodiagnostic studies; GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin. For management and treatment considerations, see relevant sections of this chapter or of the two succeeding chapters on immune-mediated and on genetically determined neuropathies.
Tarsal Tunnel Syndrome  The distal tibial nerve, along with several tendons and the posterior tibial artery, lies in the tarsal tunnel just posterior to the medial malleolus. Because of its superficial site, the distal tibial nerve is subject to compression or to direct trauma. Causes include sprain or fracture of the ankle, ill-fitting footwear, posttraumatic fibrosis, cysts or ganglia adjacent to the nerve, arthritis, and tenosynovitis. Characteristic symptoms are pain in the ankle and the sole of the foot with paresthesias, particularly while walking. On examination, the tibial nerve trunk in the tarsal tunnel is usually tender to palpation, sensory deficit should be demonstrable on the sole of the foot, and weakness of the toe plantar-flexor muscles may be noted. EDX examination and also nerve block using local anesthetic are useful in establishing the diagnosis. Definitive treatment is extensive surgical decompression of the tibial nerve in the tarsal tunnel. Tarsal tunnel syndrome, in terms of its pathophysiology and management, is similar to carpal tunnel syndrome but is much less common (Table 363-1).

Cranial Mononeuropathy  Mononeuropathy affecting individual cranial nerves is a large subject and is dealt with separately in Chap. 355.

**POLYNEUROPATHY**  The prototypical picture of polyneuropathy occurs with acquired toxic or metabolic neuropathic states. The first symptoms tend to be sensory and consist of tingling, pricking, burning, or bandlike dysesthesias in the balls of the feet or tips of the toes, or in a general distribution over the soles (Chap. 22). Symptoms and findings are usually symmetric and graded distally and often precede objective motor or sensory signs.

With progression, dysesthesias spread up the lower legs. Paresthesia loss is usually found over both feet, ankle jerks are lost, and weakness of dorsiflexion of the toes, best demonstrated in the great toe, is present. In some instances, the process begins with weakness in the feet, without preceding sensory symptoms. As worsening occurs, sensory loss moves centripetally in a graded “stocking” fashion, and the patient may complain that the feet have a numb or “wooden” feeling or may say “I feel as though I’m walking on stumps.” Patients have difficulty walking on their heels during examination, and their feet may slap while walking. Later, the knee jerk reflex disappears and foot drop becomes more apparent. By the time sensory disturbance...
has reached the upper shin, dysesthesias are usually noticed in the tips of the fingers. The degree of spontaneous pain varies but is often considerable. Light stimuli to hypesthetic areas, once perceived, may be experienced as extremely uncomfortable (hyperpathia). Unsteadiness of gait may be out of proportion to muscle weakness because of proprioceptive loss.

Worsening is more severe in the legs than in the arms and proceeds in a centripetal, symmetrically graded manner with ponsensory loss, areflexia, and muscle atrophy; motor weakness is usually greater in the extensor muscles than in corresponding flexor groups. When the sensory disturbance reaches the elbows and mid-thighs, a tent-shaped area of hypesthesia may often be demonstrated on the lower abdomen. This area will grow broader, and its apex will extend rostrally toward the sternum as the neuropathy worsens. By this time, patients generally cannot stand or walk or hold objects in their hands.

Overall, nerve fibers are affected according to axon length, without regard to root or nerve trunk distribution—hence the aptness of the term stocking-glove to describe the pattern of sensory deficit. In general, the motor deficit is also graded, distal, and symmetric.

Although polyneuropathy connotes a widespread symmetric process, usually distal and graded, polyneuropathies are quite diverse because of the variability of tempo, severity, mix of sensory and motor features, and presence or absence of positive symptoms. For instance, a patient with a subacute, severely dysesthetic sensory polyneuropathy and areflexia who is in the early phases of thallium intoxication bears little similarity to the patient with a 40-year history of insidiously progressive clumsiness of gait whose findings are foot drop, lower leg atrophy, pes cavus, and minimal asymptomatic distal sensory deficit, all due to a hereditary polyneuropathy (Chap. 364). These two patients fall at opposite ends of the spectrum of polyneuropathy.

The classification of peripheral neuropathies has become increasingly complex as the capacity to discriminate new subgroups and identify new associations with toxins and systemic disorders improves. The important features of each major grouping of polyneuropathies are summarized in Tables 363-2, and key aspects of specific polyneuropathies are given in Tables 363-3 to Table 363-6.

**Mononeuropathy Multiplex** (Multifocal Neuropathy) Mononeuropathy multiplex refers to simultaneous or sequential involvement of individual noncontiguous nerve trunks, either partially or completely, evolving over days to years. Since the disease process underlyng mononeuropathy multiplex affects peripheral nerves in a multifocal and random fashion, progression of the disease favors the neurologic deficit becoming less patchy and multifocal and more confluent and symmetric. As a result, some patients present with what appears to be a distinct symmetric neuropathy. Attention to the pattern of early symptoms is therefore important in making the judgment that a particular neuropathy is indeed a mononeuropathy multiplex and not a polyneuropathy.

### TABLE 363-2 Major Types of Polyneuropathy

<table>
<thead>
<tr>
<th>Type of Polyneuropathy</th>
<th>Evolution</th>
<th>Causes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axonal Acute</td>
<td>Days to weeks</td>
<td>Porphyria</td>
<td>See Table 363-3; also Chap. 337</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Massive intoxications (arsenic; inhalants)</td>
<td>See Table 363-4</td>
</tr>
<tr>
<td>Subacute</td>
<td>Weeks to months</td>
<td>Guillain-Barré syndrome—axonal form</td>
<td>See Chap. 365</td>
</tr>
<tr>
<td>Chronic</td>
<td>Months to years</td>
<td>Mostly toxic or metabolic polyneuropathies; see Tables 363-3 and 363-4</td>
<td>Treatment involves eliminating the toxins or treating the associated systemic disorder</td>
</tr>
<tr>
<td>Demyelinating Acute</td>
<td>Days to weeks</td>
<td>&lt;5 years, consider toxic/metabolic causes; &gt;5 years, consider hereditary basis, also diabetic and dysproteinemic causes</td>
<td>See Tables 363-3 and 363-4; also Chap. 364 on hereditary neuropathy</td>
</tr>
<tr>
<td>Subacute</td>
<td>Weeks to months</td>
<td>Almost all are the common form of Guillain-Barré syndrome; see Chap. 365</td>
<td>Rare possibilities include diphtheritic polyneuritis or buckthorn berry intoxication</td>
</tr>
<tr>
<td>Chronic</td>
<td>Months to years</td>
<td>Mostly relapsing form of CIDP (see Chap. 365)</td>
<td>Rarely, toxins mentioned above plus aurothioglucose and taxol (see Table 363-3)</td>
</tr>
</tbody>
</table>

Note: CIDP, chronic inflammatory demyelinating polyneuropathy.
<table>
<thead>
<tr>
<th>Systemic Disease (Occurrence)</th>
<th>Axonal(^a)</th>
<th>Demyelinating(^b)</th>
<th>Sensory vs. Motor(^c)</th>
<th>Autonomic(^d)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus (common)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>±</td>
</tr>
<tr>
<td>Uremia (sometimes)</td>
<td>±</td>
<td>+</td>
<td>±</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Porphyria (3 types) (rare)</td>
<td>+</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Hypoglycemia (rare)</td>
<td>±</td>
<td>+</td>
<td>±</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Vitamin deficiency, excluding B(_{12}) (sometimes)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Vitamin B(_{12}) deficiency (sometimes)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Critical illness (sepsis) (common)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>±</td>
<td>−</td>
</tr>
<tr>
<td>Chronic liver disease (sometimes)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Primary biliary cirrhosis (rare)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Primary systemic amyloidosis (rare)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Hypothyroidism (rare)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Chronic obstructive lung disease (rare)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td>Acromegaly (rare)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Malabsorption (sprue, celiac disease) (sometimes)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Carcinoma (sensory) (rare)</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Carcinoma (sensorimotor) (sometimes)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Carcinoma (late) (common)</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Carcinoma (demyelinating) (sometimes)</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>±</td>
<td>+</td>
</tr>
<tr>
<td>HIV infection (sometimes)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lyme disease (sometimes)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lymphoma, including Hodgkin’s (sometimes)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td>Polycythemia vera (rare)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Multiple myeloma, lytic type (sometimes)</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Multiple myeloma, osteosclerotic(^e) (sometimes)</td>
<td>−</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>MGUS(^f) (sometimes):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgA</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>IgG</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>IgM</td>
<td>−</td>
<td>−</td>
<td>±</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Cryoglobulinemia (rare)</td>
<td>−</td>
<td>±</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

\(^a\) +, Usually; ±, sometimes; −, rare, if ever.

\(^b\) S, sensory; M, motor; SM, sensorimotor.

\(^c\) See Table 363-5

\(^d\) May be proximal > distal and may have atypical proximal sensory deficits

\(^e\) Some cases associated with POEMS syndrome (polynuropathy, organomegaly, endocrinopathy, M proteins, and skin changes; see Chap. 330).

\(^f\) Monoclonal gammopathy of undetermined significance.
### Polyneuropathy Associated with Drugs and Environmental Toxins

<table>
<thead>
<tr>
<th>DRUGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone (antiarrhythmic)</td>
</tr>
<tr>
<td>Aurothioglucose (antirheumatic)</td>
</tr>
<tr>
<td>Cisplatin (antineoplastic)</td>
</tr>
<tr>
<td>Dapsone (dermatologic agent, e.g., for leprosy)</td>
</tr>
<tr>
<td>Disulfiram (antialcoholism agent)</td>
</tr>
<tr>
<td>Hydralazine (antihypertensive)</td>
</tr>
<tr>
<td>Isoniazid</td>
</tr>
<tr>
<td>Metronidazole (antiprotozoal)</td>
</tr>
<tr>
<td>Misonidazole (radiosensitizer)</td>
</tr>
<tr>
<td>Nitrofurantoin (urinary antiseptic)</td>
</tr>
<tr>
<td>Nucleoside analogues (ddC, ddl, d4T) (antiretroviral agents)</td>
</tr>
<tr>
<td>Phenytoin (anticonvulsant)</td>
</tr>
<tr>
<td>Pyridoxine (vitamin)</td>
</tr>
<tr>
<td>Statins (HMG CoA reductase inhibitors)</td>
</tr>
<tr>
<td>Suramin (antineoplastic)</td>
</tr>
<tr>
<td>Taxol (antineoplastic)</td>
</tr>
<tr>
<td>Vincristine (antineoplastic)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOXINS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acrylamide (flocculant; grouting agent)</td>
</tr>
<tr>
<td>Arsenic (herbicide; insecticide)</td>
</tr>
<tr>
<td>Diphtheria toxin</td>
</tr>
<tr>
<td>γ-Diketone hexacarbons (solvents)</td>
</tr>
<tr>
<td>Inorganic lead</td>
</tr>
<tr>
<td>Organophosphates</td>
</tr>
<tr>
<td>Thallium (rat poison)</td>
</tr>
</tbody>
</table>

**Note:** CNS, central nervous system; GBS, Guillain-Barré syndrome.

### TABLE 363-4 Polyneuropathy Associated with Drugs and Environmental Toxins

<table>
<thead>
<tr>
<th>Axonal&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Demyelinating&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute</strong></td>
<td><strong>Subacute</strong></td>
</tr>
<tr>
<td><strong>Comment</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> +, Usually; ±, sometimes; −, rare, if ever.

<sup>b</sup> S, sensory; M, motor; SM, sensorimotor.

<sup>c</sup> The following drugs and environmental toxins are also neurotoxic, mainly to the peripheral nervous system:

Drugs: Allopurinol, amitriptyline, chloramphenicol, colchicine, ethambutol, flecainide, indomethacin, lithium, nitrous oxide, perhexiline maleate, podophyllin, sodium cyanate, thalidomide, 1-tryptophan.

Environmental toxins: Allyl chloride, buckthorn berry, carbon disulfide, diglycols (either ethylene or propylene), dimethylaminoproprionitrile (DMAPN), ethylene oxide, metallic mercury, methyl bromide, polychlorinated biphenyls, styrene, trichlorethylene, vacor.

**Note:** CNS, central nervous system; GBS, Guillain-Barré syndrome.
by tapping along the course of the nerve trunk); and for pain elicited by stretching of the nerve trunk. In leprosus neuritis, fusiform thickening of nerve trunks is frequent, and beading of nerve trunks may be encountered in amyloid polyneuropathy. In genetically determined hypertrophic neuropathies, uniform thickening of all nerve trunks may occur, often to the diameter of one's little finger.

Most neuropathies involve nerve fibers of all sizes, but damage is sometimes restricted either to large or to small fibers. In a polynévropathy affecting mainly small fibers, diminished pinprick and temperature sensation, often with painful, burning dysesthesias, will predominate, along with autonomic dysfunction, but with relative sparing of motor power, balance, and tendon jerks. Some cases of amyloid and distal diabetic polyneuropathies fall into this category. In contrast, large-fiber polyneuropathy is characterized by areflexia, sensory ataxia, relatively minor cutaneous sensory deficit (even though distal dysesthesias are common), and variable degrees of motor dysfunction, sometimes severe.

For patients with polynévropathy or mononeuropathies multiplex, standard tests should include a complete blood count and measurement of erythrocyte sedimentation rate, urinalysis, chest x-ray or chest computed tomography (CT) scan, postprandial blood glucose determination, and serum protein electrophoresis. Further tests are dictated by the combined results of the history and the physical and EDX examination (Fig. 363-1).

**Electrodiagnosis** EDX studies are an essential part of the evaluation of neuropathies and also of myopathies and neuromuscular junction disorders. Such studies indeed are critical in helping to distinguish between these three categories of disease. The EDX examination ordinarily comprises electromyography (EMG) and nerve conduction studies (NCSs). EMG involves recording for electrical potentials from a needle electrode in muscle both at rest and during voluntary contraction of the muscle. Resulting electromyographic patterns are displayed on an oscilloscope screen for analysis. EMG is generally most useful for distinguishing between and among myopathic and neurodegenerative disorders. Myopathic disorders are marked by small, short-duration, polyphasic muscle action potentials recruited in excessive numbers for a given degree of voluntary muscle contraction. Other patterns characteristic of specific muscle abnormalities can also be observed, such as myotonia (high-frequency discharges that wax and wane).

By contrast, EMG findings in neuropathic disorders are those of muscle denervation. Specifically, denervation features a decrease in the number of motor units activated by maximal effort to contract muscle but an increase in the rate of firing of those remaining motor units. In long-standing muscle denervation (months or years), motor unit potentials become large and polyphasic. This occurs as a result of collateral reinnervation of nearby denervated muscle fibers by axonal sprouts from surviving motor axons. In brief, when motor axons die back, their motor fiber domains are taken over by intact neighboring axons. Other EMG features that favor denervation include fibrillations (random, unregulated firing of individual denervated muscle fibers), fasciculations (random, spontaneous firing of motor units, which in chronic states can be markedly enlarged and polyphasic), positive sharp waves, and complex repetitive discharges (Fig. 363-2).

NCSs are carried out by stimulating motor or sensory nerves electrically at two or more sites and recording from either the muscle innervated, for motor nerves (Fig. 363-3), or from yet another site on the stimulated nerve trunk, for sensory nerves. From the data recorded, the velocity of conduction and other informative characteristics of the recorded waveforms can be determined. When a disorder of the neuromuscular junction is suspected, other more specialized techniques are used, including muscle response to repetitive stimulation of nerve and single-fiber EMG. Detailed discussion of the full range of EDX techniques and their application, use, and interpretation may be found in several recent monographs listed in the references.

It is generally not possible to distinguish between axonal and demyelinating disorders by clinical examination alone; here EDX analysis is particularly useful. EDX features of demyelination are slowing of nerve conduction velocity (NCV), dispersion of evoked compound action potentials, conduction block (major decrease in amplitude of muscle compound action potentials on proximal stimulation of the nerve, as compared to distal stimulation), and marked prolongation of distal latencies. In contrast, axonal neuropathies are characterized by a reduction in amplitude of evoked compound action potentials with relative preservation of NCV. The distinction between a primarily demyelinating neuropathy and an axonal neuropathy is crucial because of the differing approaches to diagnosis and management.

EDX studies also help to determine the presence or absence of a sensory involvement when that is not clear by clinical examination alone. It provides information about the distribution of subclinical findings, thus sharpening the diagnostic focus. Other issues that may be clarified by the electrodiagnostician include:

1. The distinction between disorders primary to nerve or to muscle (neuropathy versus myopathy)
2. The distinction between root or plexus involvement and more distal nerve trunk involvement
3. The distinction between generalized polyneuropathic processes and widespread multifocal nerve trunk involvement
4. The distinction between upper and lower motor neuron weakness
5. The distinction, in a given generalized polyneuropathic process, between primary demyelinating neuropathy and primary axonal degeneration
6. The assessment, in both primary axonal and demyelinating neuropathies, of features bearing on the nature, activity, and likely prognosis of the neuropathy, particularly the extent of primary or secondary axonal degeneration
7. The assessment, in mononeuropathies, of the site of the lesion and its major effect on nerve fibers, especially the distinction between demyelinating conduction block and wallerian degeneration
8. The characterization of disorders of the neuromuscular junction
9. The identification, often in muscle of normal bulk and strength, of important features such as chronic partial denervation, fasciculations, and myotonia
10. The analysis of cramp, and its distinction from physiologic contracture

If in a particular instance of progressive polynévropathy of subacute or chronic evolution the EDX findings are those of an axonopathy, a long list of metabolic states and exogenous toxins comes under consideration (Tables 363-3 and 363-4). If the course is protracted over several years, it raises the likelihood of a hereditary neu-
growth factor; MAG, myelin-associated glycoprotein; SCLC, small-cell lung carcinoma.

Abbreviations

nerve-damaged muscle at rest.

and positive sharp waves.

B (myopathic disorders).

duration, polyphasic motor unit action potential such as is commonly encountered in neuropathy in these patients, only about one-half can be shown to have nation. Although ischemia should be suspected as the basis of multifocal motor neuropathy, see Chap. 365.

If the clinical features indicate mononeuropathy multiplex, the EDX question is whether the process is primarily axonal or demyelinating. Almost one-third of all adults with the clinical syndrome of mononeuropathy multiplex have a clear-cut picture of a demyelinating disorder, often with focci of persistent conduction block on EDX examination. Multifocal demyelinating neuropathy may represent part of the spectrum of chronic inflammatory demyelinating polyneuropathy (CIDP) or, if multifocal and only motor, would fit into the related category of multifocal motor neuropathy. For further discussion of the management of multifocal motor neuropathy, see Chap. 365.

The remaining two-thirds of patients with mononeuropathy multiplex have a picture of patchy axonal involvement by EDX examination. Although ischemia should be suspected as the basis of neuropathy in these patients, only about one-half can be shown to have disease of the vasa nervorum, usually vasculitis. Management of those with proven vasculitis of vasa nervorum is often the same as treatment for systemic vasculitis (Chaps. 306 and 365). If the cause of mononeuropathy multiplex remains undiagnosed even on follow-up, management should be conservative. In many patients the disease will stabilize or reverse, at least partially.

Mononeuropathy multiplex syndrome may also be seen as a manifestation of leprosy, sarcoidosis, certain types of amyloidosis, hyperesinophilia syndrome, cryoglobulinemia, neuroAIDS, and multifocal types of diabetic neuropathy.

Nerve Biopsy The sural nerve at the ankle is the preferred site for cutaneous nerve biopsy. There are few indications to employ this invasive technique. The main one is in asymmetric and multifocal neu-

In the management of multifocal motor neuropathy, the approach is entirely different. If the clinical features indicate mononeuropathy multiplex, the EDX question is whether the process is primarily axonal or demyelinating. Almost one-third of all adults with the clinical syndrome of mononeuropathy multiplex have a clear-cut picture of a demyelinating disorder, often with focci of persistent conduction block on EDX examination. Multifocal demyelinating neuropathy may represent part of the spectrum of chronic inflammatory demyelinating polyneuropathy (CIDP) or, if multifocal and only motor, would fit into the related category of multifocal motor neuropathy. For further discussion of the management of multifocal motor neuropathy, see Chap. 365.

The remaining two-thirds of patients with mononeuropathy multiplex have a picture of patchy axonal involvement by EDX examination. Although ischemia should be suspected as the basis of neuropathy in these patients, only about one-half can be shown to have disease of the vasa nervorum, usually vasculitis. Management of those with proven vasculitis of vasa nervorum is often the same as treatment for systemic vasculitis (Chaps. 306 and 365). If the cause of mononeuropathy multiplex remains undiagnosed even on follow-up, management should be conservative. In many patients the disease will stabilize or reverse, at least partially.

Mononeuropathy multiplex syndrome may also be seen as a manifestation of leprosy, sarcoidosis, certain types of amyloidosis, hyperesinophilia syndrome, cryoglobulinemia, neuroAIDS, and multifocal types of diabetic neuropathy.

Nerve Biopsy The sural nerve at the ankle is the preferred site for cutaneous nerve biopsy. There are few indications to employ this invasive technique. The main one is in asymmetric and multifocal neu-

In the management of multifocal motor neuropathy, the approach is entirely different. If the clinical features indicate mononeuropathy multiplex, the EDX question is whether the process is primarily axonal or demyelinating. Almost one-third of all adults with the clinical syndrome of mononeuropathy multiplex have a clear-cut picture of a demyelinating disorder, often with focci of persistent conduction block on EDX examination. Multifocal demyelinating neuropathy may represent part of the spectrum of chronic inflammatory demyelinating polyneuropathy (CIDP) or, if multifocal and only motor, would fit into the related category of multifocal motor neuropathy. For further discussion of the management of multifocal motor neuropathy, see Chap. 365.

The remaining two-thirds of patients with mononeuropathy multiplex have a picture of patchy axonal involvement by EDX examination. Although ischemia should be suspected as the basis of neuropathy in these patients, only about one-half can be shown to have disease of the vasa nervorum, usually vasculitis. Management of those with proven vasculitis of vasa nervorum is often the same as treatment for systemic vasculitis (Chaps. 306 and 365). If the cause of mononeuropathy multiplex remains undiagnosed even on follow-up, management should be conservative. In many patients the disease will stabilize or reverse, at least partially.

Mononeuropathy multiplex syndrome may also be seen as a manifestation of leprosy, sarcoidosis, certain types of amyloidosis, hyperesinophilia syndrome, cryoglobulinemia, neuroAIDS, and multifocal types of diabetic neuropathy.

Nerve Biopsy The sural nerve at the ankle is the preferred site for cutaneous nerve biopsy. There are few indications to employ this invasive technique. The main one is in asymmetric and multifocal neu-
Neuropathies producing a clinical picture of mononeuropathy multiplex, the basis of which is still unclear after other laboratory investigations are complete. Diagnostic considerations include vasculitis, multifocal demyelinating neuropathies, amyloidosis, leprosy, and occasionally sarcoidosis. Nerve biopsy is also helpful when one or more cutaneous nerves are palpably enlarged. Another clinical application is in establishing the diagnosis in some genetically determined childhood disorders such as metachromatic leukodystrophy, Krabbe’s disease, giant axonal neuropathy, and infantile neuroaxonal dystrophy. In all of these recessively inherited diseases, both the central nervous system and the peripheral nervous system are affected. There is a tendency to carry out sural nerve biopsy in distal symmetric polyneuropathies of subacute or chronic evolution. This practice is discouraged because its yield is low and not worth the risk of wound infection, poor healing, or persistent pain. Nerve biopsy in this situation may be useful as part of an approved research protocol when the biopsy will provide crucial information not otherwise obtainable.

**SPECIAL CATEGORIES OF NEUROPATHY** Some neuropathies require individual description because of their importance or distinctiveness.

**Diabetic Neuropathies** The neuropathies of diabetes mellitus are classified in Table 363-5. A limitation of this classification is that most patients do not fit neatly into any single category but instead have overlapping clinical features of several. For instance, many diabetic patients with distal, primarily sensory polyneuropathy can also be shown to have autonomic dysfunction, usually in the form of vaso-motor disturbance in the limbs and abnormalities of sweating. Similarly, patients who develop a proximal motor syndrome often have dysautonomic features (including sexual impotence in males) and some degree of distal sensory polyneuropathy. To compound matters, such patients appear at risk of developing a cranial mononeuropathy. Pain is a frequent feature of diabetic neuropathies (Table 363-5) but is variable in incidence and degree.

Neuropathies occur in the setting of long-standing hyperglycemia, the principal manifestation of the group of metabolic disorders comprising diabetes mellitus. By far the most common neuropathies related to diabetes mellitus are the diffuse sensory and autonomic types (categories 1 and 2 under “Symmetric” in Table 363-5). Sensory and autonomic polyneuropathy, chronic and indolent in evolution, may first be noticed in the third to fifth decades in patients with juvenile-onset diabetes but tend to occur after age 50 in patients with adult-onset diabetes. Focal and multifocal types of neuropathy are less common but quite dramatic (categories 1, 2, and 3 under “Asymmetric” in Table 363-5). They rarely occur before the age of 45 and are usually subacute or acute in onset. Cranial mononeuropathies are mainly isolated sixth or third nerve palsies. The latter spares the pupil in three-fourths of cases, and some local pain or headache occurs in one-half. Truncal (thoracolumbar) neuropathy is painful, involves one or more intercostal or lumbar nerves unilaterally, and frequently coexists with asymmetric proximal motor neuropathy in the legs. In asymmetric proximal motor neuropathy (diabetic amyotrophy), the most evident features are weakened muscles innervated by the femoral and obturator nerves (quadriceps femoris, ilioptsoas, adductor magnus) and ipsilateral loss of the knee jerk reflex. Sensory deficit is minor, but pain in the hip and anterior thigh may be prominent. In all these multifocal and focal neuropathies, the pain usually subsides within weeks to a year, and function is usually partly or completely recovered. The same is true for symmetric proximal motor neuropathy (category 3 under “Symmetric” in Table 363-5).

Focal and multifocal diabetic neuropathies are considered to be ischemic in origin; ischemia may also underlie symmetric polyneuropathies, which are also thought to involve an abnormality of nerve metabolism.

Management of diabetic neuropathies is directed toward optimal glycemic control and symptomatic pain suppression. In the long-term Diabetes Control and Complications Trial, patients who controlled their diabetes meticulously showed significantly less neuropathy. The role of aldose reductase inhibitors in preventing or reversing diabetic complications, including neuropathy, remains unclear. Entrapment neuropathies are frequently amenable to surgical decompression.

**Neuropathies with HIV Infection** Neuropathies are common in infection with HIV, but different types of neuropathy are seen according to the stage of the disease. GBS or CIDP (Chap. 365) are the neuropathies likely to occur following conversion to seropositivity and during the asymptomatic phase of HIV infection. Treatment is the same as for HIV-negative patients. In later, symptomatic stages, mononeuritis multiplex, axonal in nature, can occur; the course is typically subacute or chronic. In some cases, vasculitis of the vasa nervorum has been demonstrated.

A common neuropathy is a distal, symmetric, mainly sensory polyneuropathy, which evolves slowly in the late symptomatic stages of HIV infection and frequently coexists with symptomatic encephalopathy and myelopathy (Table 363-3; Chap. 173). The incidence of late-stage neurologic disorders, including sensory polyneuropathy, appears to be diminishing for HIV-positive individuals on effective highly active antiretroviral therapy (HAART) programs. Sensory polyneuropathy of late-stage HIV infection must be distinguished from toxic polyneuropathy that may result from the use of nucleoside analogue treatment (Table 363-4). At times, nucleoside analogues may precipitate a rapidly evolving, severe polyneuropathy with concurrent lactic acidemia. Clinically the neuropathy can be mistaken for GBS. Also in the late stages, a severe, destructive, subacute, asymmetric polyradioucopathy involving the cauda equina may be seen; it is caused by infection of the nerve roots with cytomegalovirus. Ganciclovir, started early, can arrest the disorder.

**Herpes Zoster** This is a sensory neuritis due to infection with varicella-zoster virus (VZV) and is characterized by acute inflammation of one or more dorsal root ganglia. Lancinating pain and hyperalgesia over the skin surface supplied by the affected roots occur for 3 to 4 days, followed by the appearance in the same segment of a herpetic eruption characterized by painful raised blisters on reddened bases. Pain usually subsides in a few weeks. If the inflammatory process spreads to involve related motor roots, segmental motor weakness and wasting appear. Paralysis of the ocular motor nerves may occur in conjunction with involvement of the ophthalmic division of the trigeminal ganglion (ophthalmoplegic zoster). Facial paralysis may occur with involvement of the geniculate ganglion and herpetic eruption on the ipsilateral tympanic membrane or external ear canal (Ramsay Hunt syndrome).

In a small proportion of patients, neuropathic pain persists in the dermatomal distribution of the affected ganglia. This pain, known as *postherpetic neuralgia*, is intense, burning, hyperpathic, and unreleasant; it often dominates the lives of those affected. Advancing age is a risk factor for this outcome. In some patients, blunting of the pain to tolerable levels is achieved by use of anticonvulsants such as carbamazepine or gabapentin or a tricyclic antidepressant such as desipramine or nortriptyline. Recent investigations suggest that postherpetic neuralgia reflects active persistent VZV infection of the ganglion, and that it may respond to intravenous antiviral treatment (Chap. 164).

**Leprous Neuritis** This is a major worldwide cause of neuropathy. *Mycobacterium leprae* organisms readily invade Schwann cells in cutaneous nerve twigs, particularly those associated with unmyelinated nerve fibers. *M. leprae* thrives best in the coolest tissues in the body.
Two major forms of lepromatous leprosy are recognized, tuberculoid and lepromatous, which actually represent the ends of a spectrum of disease, the middle of which is called borderline (dimorphous) leprosy (patchy and multifocal involvement of skin and nerve). The treatment of a given case depends on where it falls in this spectrum (Chap. 151). Tuberculoid (high-resistance) leprosy consists of a single patch of hypesthetic or anesthetic skin in any location. The skin patch is frequently thickened, reddened, or hypopigmented. Few or no M. leprae bacilli may be demonstrated. If a superficially placed nerve trunk, typically a cutaneous nerve, courses just beneath the area of affected skin, it may be engulphed in the inflammatory reaction, resulting in an associated mononeuropathy. Such a nerve may be palpably enlarged and beaded. Lepromatous (low-resistance) leprosy is marked by immunologic tolerance; numerous bacilli; and widespread skin thickening, cutaneous anesthetic, and anhidrosis, which spare only the warmest parts of the body, notably the axilla, the groin, and beneath the scalp hair. Motor signs (focal weakness and atrophy) result from damage to mixed nerves lying close to the skin, particularly the median, ulnar, peroneal, and facial nerves.

**SPECIAL NEUROPATHIC PRESENTATIONS** Some disorders selectively affect the peripheral nervous system, limiting dysfunction to specific systems or sites, such as motor nerves, brachial plexus, or the autonomic nervous system.

**Autonomic Neuropathy** The autonomic nervous system regulates the visceral organs and vegetative functions (Chap. 354). Many pharmacologic agents modify specific autonomic functions, but autonomic neuropathy (dysautonomia) with structural changes in pre- and post-ganglionic neurons can also occur. Usually autonomic neuropathy is a manifestation of a more generalized polyneuropathy, as in diabetic neuropathy, GBS, and alcoholic polyneuropathy, but occasionally syndromes of pure pandysautonomia are encountered. Symptoms of dysautonomia are mainly negative (i.e., loss of function) and include postural hypotension with faintness or syncope, anhidrosis, hypothermia, bladder atony, obstipation, dry mouth and dry eyes from failure of salivary and lacrimal glands to secrete, blurring of vision from lack of pupillary and ciliary regulation, and sexual impotence in males. Positive phenomena (hyperfunction) may also occur and include episodic hypertension, diarrhea, hyperhidrosis, and either tachycardia or bradycardia. Management is symptomatic and also directed at the underlying cause, if it can be identified.

**Pure Motor Neuropathy** Disorders affecting any level of the motor unit—anterior horn cell, motor axon, or neuromuscular junction—can result in a purely lower motor syndrome without sensory disturbance. Distinguishing anterior horn cell disorders (motor neuroopathies) from motor axonopathies may be difficult clinically because they share manifestations (weakness, muscle denervation atrophy, hypo- or areflexia, fasciculations). EDX examination may also fail to localize the primary site of the lesion (neuropathic versus motor neuropathic) unless the lesion is demyelinating in nature, in which case it is by definition neuropathic.

Examples of motor neuropathies include the lower-motor form of amyotrophic lateral sclerosis, poliomyelitis, hereditary spinal muscular atrophies, and adult variant of hexosaminidase A deficiency (Chap. 353). Motor neuropathies may be seen with lead or dapsone intoxication, occasionally with porphyria, and also with multifocal motor neuropathy. The latter is a chronic asymmetric disorder of middle age associated with persistent conduction block on EDX examination, and often high titers of antiganglioside antibodies (particularly anti-GM1) (Chap. 365). Neuromuscular junction disorders (e.g., Lambert-Eaton myasthenic syndrome, tick bite paralysis, other types of toxic neuromuscular blockade) are purely motor and can be recognized and localized electrodiagnostically (Chap. 366). Some motor-sensory polyneuropathies have predominant motor symptoms and signs, such as hereditary motor-sensory neuropathies, GBS, and CIDP, but the subclinical sensory component is readily demonstrated electrodiagnostically or by quantitative sensory testing.

**Pure Sensory Neuropathy** Clinical presentations involving primary sensation only (Table 363-6; Chap. 22) are common. Manifestations may (1) reflect mainly large afferent fiber involvement with deficits of vibratory and proprioceptive sense, areflexia, and sensory ataxia with or without tingling dysesthesias; (2) reflect mainly small afferent fiber involvement with numbness and cutaneous hyposthesia to pin-prick and temperature stimuli, often with painful, burning dysesthesias; or (3) be pan sensory, with both large- and small-fiber manifestations. The pattern of distribution, although variable, is often distal and symmetric, particularly for large-fiber neuropathies.

The most severe and widespread of these pure sensory syndromes exhibit low-resistance or no resistance, indicating irreversible lesions of nerve cell bodies in dorsal root and trigeminal ganglia. These are referred to as sensory neuropathies. With sensory neurotoxins, moderate doses lead to potentially reversible neuropathy, but high doses appear to cause irreversible neuropathy.

**Plexopathy** This term refers to disorders of either the brachial or the lumbosacral plexus. Lesions of the brachial plexus are characterized by motor and sensory signs different from those expected in either mononeuropathies of the upper limb or polyneuropathies. The usual causes are direct trauma to the plexus, idiopathic brachial neuritis (also called neuralgic amyotrophy; Chap. 15), cervical rib or band, infiltration by malignant tumor, or prior radiation therapy. When the upper parts of the brachial plexus, arising from cervical roots 5 through 7, are affected, weakness and atrophy of shoulder girdle and upper arm muscles occur. Injuries to the lower brachial plexus, arising from the eighth cervical and first thoracic roots, produce distal arm weakness, atrophy, and focal sensory deficit in the forearm and hand. In general, idiopathic brachial neuritis, irradiation with >60 Gy (6000 rad), and particular types of trauma (arm jerked downward) result in damage to the upper portions of the brachial plexus. In contrast, infiltration by malignant tumor, cervical rib or band, and certain other types of trauma (arm jerked upward) cause damage to the lower brachial plexus. Lumbosacral plexopathies are less common; they may be due to trauma, including intraoperative damage, retroperitoneal hemorrhage, idiopathic plexitis, or malignant tumor infiltration or may occur in association with long-standing diabetes mellitus.

**Cold Effects** Cold exerts direct deleterious effects on peripheral nerve, independent of ischemia. Cold injury to nerve occurs after prolonged exposure, usually of a limb, to moderately low temperatures, as with immersion of the feet in seawater; actual freezing of tissue is not required. Axonal degeneration of myelinated fibers is the pathologic expression of cold injury. Frequently, limbs affected by cold injury to nerve show sensory deficit and dysesthesias, cutaneous vasomotor instability, pain, and marked sensitivity to minimal cold exposure, which may persist for years. The pathophysiology of these phenomena is uncertain.

**Trophic Changes** The array of observable changes in completely denervated muscle, bone, and skin, including hair and nails, is well known, if incompletely understood. It is unclear what portion of the changes is due purely to denervation versus what is due to disuse, immobility, lack of weight bearing, and particularly recurrent, unnoticed, painless trauma. Considerable evidence favors the view that ulceration of skin, poor healing, tissue resorption, neurogenic arthropathy, and mutilation are the result of repeated unheeded injury to insensitive parts. This sequence of events is avoidable with proper attention to and care of the insensitive parts by both patient and physician.

**RECOVERY FROM NEUROPATHY** In contrast to axons in the central nervous system, peripheral nerve fibers have an excellent ability to regenerate under proper circumstances. The process of regeneration following axonal degeneration may take from 2 months to more than a year, depending on the severity of the neuropathy and the length of regeneration required. Regeneration can take place when the cause of the neuropathy has been eliminated, such as removal from contact with a
neurotoxic substance or correction of an abnormal metabolic state. A
deficit secondary to demyelination may recover rapidly, since intact
axons may remyelinate in just a few weeks. For example, a patient
with GBS, in whom demyelination but no secondary axonal
degeneration has occurred, may recover to normal strength from
bedfastness and paralysis of arms and legs in as little as 3 to 4 weeks.

**PERIPHERAL NERVE TUMORS**

These tumors are mostly benign and can
arise on any nerve trunk or twig. Although peripheral nerve tumors
can occur anywhere in the body, including the spinal roots and
cauda equina, many are subcutaneous in location and present as a soft
swelling, sometimes with a purplish discoloration of the skin. Two
major categories of peripheral nerve tumors are recognized: neurilemmoma
(schwannoma) and neurofibroma. Neurilemmomas are usually solitary
and grow in the nerve sheath, rendering the tumor relatively easy to
dissect free. In contrast, neurofibromas tend to be multiple, grow in
the endoneurial substance, which renders them difficult to dissect, may
undergo malignant changes, and are the hallmark of von Reckling-
hausen’s neurofibromatosis (NF1) (Chap. 358).

---

### CHARCOT-MARIE-TOOTH DISEASE AND OTHER INHERITED NEUROPATHIES

**Phillip F. Chance, Thomas D. Bird**

#### CHARCOT-MARIE-TOOTH DISEASE

**GENERAL CLINICAL FEATURES**

Charcot-Marie-Tooth (CMT) neuropathy comprises a heterogeneous group of inherited peripheral nerve diseases (Table 364-1). Transmission is most frequently autosomal dominant but may also be autosomal recessive or X-linked. An estimated 1 in 2500 persons has a form of CMT, making it one of the most frequently encountered inherited neurologic syndromes.

The neuropathy of CMT affects both motor and sensory nerves. Typical features consist of distal muscle weakness and atrophy, impaired sensation, and absent or hypoactive deep tendon reflexes. Common signs and symptoms are related to muscle weakness, initially involving the feet and legs and later progressing to the hands and forearms. A history of an abnormal high-stepped (steppage) gait with frequent tripping and falling is frequently elicited. Complaints related to foot deformity (pes cavus, or high-arched feet) result from atrophy of intrinsic muscles of the feet. Despite the involvement of sensory nerves in CMT, complaints of limb pain or sensory disturbances are unusual.

Onset is most often during the first or second decade of life, although presentation in mid-adult life is not unusual. The variation in clinical presentation is exceptionally wide, ranging from individuals whose only clinical finding is pes cavus and minimal or no distal muscle weakness to those with severe distal atrophy and marked hand and foot deformity. However, it is unusual for patients with CMT to lose ambulation. There are no therapies that can prevent the onset or delay progression of disability associated with CMT. Patients frequently benefit from physical therapy, use of ankle-foot orthoses (AFOs) to alleviate foot drop, and, in some cases, surgical procedures to the foot. Surgery should be undertaken only when pain or difficulty walking due to severe foot deformity cannot be managed by more conservative means.

#### CLASSIFICATION BY PHENOTYPE

A widely accepted classification system distinguishes demyelinating forms of CMT (also designated as CMT type 1, or CMT1) from those due to axonal degeneration (CMT type 2, or CMT2). Individuals with CMT1 have electrophysiologic findings of reduced motor and sensory nerve conduction velocities (NCVs; typically <38 to 40 m/s) and pathologic findings of hypertrophic demyelinating neuropathy (“onion bulbs”). By contrast, in CMT2 there is relative preservation of the myelin sheath and these individuals have normal or near-normal NCVs. CMT3 refers to Déjerine-Sottas disease.

#### Table 364-1

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMT1A</td>
<td>17p11.2-p12</td>
<td>PMP22</td>
</tr>
<tr>
<td>CMT1B</td>
<td>1q22-q23</td>
<td>P0</td>
</tr>
<tr>
<td>CMT1C</td>
<td>16p12-p13</td>
<td>SIMPLE</td>
</tr>
<tr>
<td>CMT1D</td>
<td>10q21-q22</td>
<td>EGR2</td>
</tr>
<tr>
<td>CMTX</td>
<td>Xq13.1</td>
<td>CX32</td>
</tr>
<tr>
<td>CMT4A</td>
<td>8q13-q21</td>
<td>GDAP1</td>
</tr>
<tr>
<td>CMT4B1</td>
<td>11q22</td>
<td>MTMR2</td>
</tr>
<tr>
<td>CMT4B2</td>
<td>11p15</td>
<td>SFB2</td>
</tr>
<tr>
<td>CMT4D (HMSN-Lom)</td>
<td>8q24</td>
<td>NDRG1</td>
</tr>
<tr>
<td>CMT4F</td>
<td>19q13</td>
<td>PRX</td>
</tr>
</tbody>
</table>

#### DéJERINE-SOTTAS

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSS</td>
<td>17p11.2-p12</td>
<td>PMP22</td>
</tr>
<tr>
<td>1q22-q23</td>
<td>P0</td>
<td>AD</td>
</tr>
<tr>
<td>10q21-q22</td>
<td>EGR2</td>
<td>AD/AR</td>
</tr>
<tr>
<td>19q13</td>
<td>PRX</td>
<td>AD</td>
</tr>
</tbody>
</table>

#### CONGENITAL HYPOMYELINATION

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHN</td>
<td>1q22-23</td>
<td>P0</td>
</tr>
<tr>
<td>10q21-q22</td>
<td>EGR2</td>
<td>AR/AD</td>
</tr>
</tbody>
</table>

#### HEREDITARY NEUROPATHY WITH PRESSURE PALSIES

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>HNPP</td>
<td>17p11.2-p12</td>
<td>PMP22</td>
</tr>
</tbody>
</table>

**Abbreviations:** PMP22, peripheral myelin protein 22; P0, myelin protein zero; SIMPLE, small integral membrane protein of late endosome; Cx32, connexin32; EGR2 (Krox-20) early growth response gene 2; GDAP1, ganglioside-induced differentiation-associated protein-1; MTMR2, myotubularin-related protein-2; SFB2, SET binding factor 2; NDRG1, N-myel downstream regulated gene 1; PRX, perixxin; KIF1B, kinesin family member 1B; RAB7, Ras-associated protein 7; GARS, Glycerol-3-phosphate synthase; NEFL, neurofilament, light polypeptide; LMNA, lamin A.

---

**FURTHER READING**


Stewart JD: Focal Peripheral Neuropathies, 3d ed. Philadelphia, Lippincott Williams & Wilkins, 1999

(DSD; see below), CMT4 to autosomal recessive forms of CMT, and CMTX to X-linked varieties.

An alternative classification system designates these disorders as hereditary motor and sensory neuropathies (HMSN); HMSN refers to CMT1, HMSNII to CMT2, HMSNIII to DSD, and HMSNIV to Refsum disease (see below).

**APPROACH TO THE PATIENT**

A clinical diagnosis of an inherited peripheral neuropathy consistent with a form of CMT (CMT1 or CMT2) should be established prior to undertaking specific genetic tests. Other causes of peripheral neuropathy (e.g., diabetes mellitus, alcoholism, heavy metal poisoning, immune neuropathies) should also be considered and, if necessary, ruled out. An environmental exposure may affect multiple family members, thereby potentially mimicking a hereditary illness. CMT is usually a chronic, slowly progressive condition. One should be suspicious of cases that seem to have a rapid course of deterioration. As noted above, the neurologic findings show great variability in patients with CMT; mild pes cavus and depressed deep tendon reflexes may be the only signs of disease.

Although symptoms related to sensory disturbances are uncommon in CMT, a careful sensory examination is nonetheless essential. In patients who have no objective signs of sensory impairment and no evidence of sensory nerve dysfunction on electrophysiologic studies, alternative diagnoses including primary motor system disorders (e.g., distal spinal muscle atrophy, juvenile amyotrophic lateral sclerosis) should be considered.

The pediatrician is of paramount importance in the diagnosis of CMT. Examination of multiple family members, particularly parents, for subtle signs of neuropathy may help to establish a diagnosis. If possible, it is also important to obtain NCVs and an electromyogram (EMG) from all at-risk family members.

**GENETIC CONSIDERATIONS**

**CMT Neuropathy Type 1A (CMT1A)**

Approximately three-quarters of pedigrees with autosomal dominant CMT1A demonstrate linkage to chromosome 17p11.2-12 (CMT1A) and are associated with a tandem 1.5-megabase (Mb) DNA duplication. The duplication is usually inherited as a stable Mendelian trait; however, it may also arise as a de novo event. The de novo duplication is responsible for many sporadic cases of CMT1 and may also account for some cases previously thought to occur on the basis of an autosomal recessive mode of inheritance. When present as a de novo event, the duplication results more commonly from an error in spermatogenesis; however, ~10% of de novo cases have been found to result from an error in oogenesis.

The critical gene for CMT1A is peripheral myelin protein-22 (PMP22), which is expressed in Schwann cells. The PMP22 gene encodes a 160-amino-acid protein localized to the compact portion of peripheral nerve myelin; it contains four putative transmembrane domains and is highly conserved in evolution. The level of expression of PMP22 is crucial for proper myelination of peripheral nerves. The neuropathy in patients with the duplication results from the presence of three copies of PMP22 leading to increased expression at this locus. In rare cases, patients heterozygous for the CMT1A duplication have been identified, and in some cases these individuals exhibit a more severe phenotype than their heterozygous siblings or parents. As discussed below, monosomic underexpression of PMP22 results in hereditary neuropathy with liability to pressure palsies (HNPP).

Rare CMT1A pedigrees that are linked to chromosome 17p11.2-p12, yet lack the duplication, may harbor missense mutations within the PMP22 gene.

DNA testing for CMT1A (including the duplication and sequencing to detect point mutations in PMP22) is available and now an accepted part of the evaluation of patients with suspected hereditary neuropathies (see below).

**CMT Neuropathy Type 1B (CMT1B)**

CMT1B is less common than CMT1A; it results from mutations in the human myelin protein zero gene (MPZ, or P0), which maps to chromosome 1q22-q23. P0 is the major structural protein component of peripheral nervous system myelin (quantitatively 50% by weight) and represents ~10% of total Schwann cell mRNA. P0 is a member of the immunoglobulin gene superfamily of cell adhesion molecules and localizes to the compact portion of peripheral nerve myelin. P0 protein consists of 248 amino acids and contains an intracellular and a glycosylated extracellular domain with a single transmembrane segment. Many different point mutations in the P0 gene have been found in patients with CMT1B, and these mutations predominately map to the extracellular domain of its gene product.

At the clinical level it is not possible to differentiate patients with CMT1A from those with CMT1B. Molecular genetic testing is available.

**Déjerine-Sottas Disease (CMT3)**

Patients who never ambulate (or lose the ability to ambulate in infancy or childhood) are sometimes diagnosed as DSD (also called HMSNIII) or congenital hypomyelinating neuropathy (CHN). These disorders are severe, infantile- or childhood-onset, hypertrophic demyelinating polyneuropathies. NCVs are substantially slowed (typically 10 m/s), and elevations in the cerebrospinal fluid (CSF) protein level are typically present. The clinical features of DSD and CHN overlap those of severe CMT1, and for this reason the continued clinical separation of CMT1 and DSD/CHN is perhaps unwarranted. Many cases of DSD or CHN appear to be sporadic, occurring in the absence of a family history of neuropathy.

Molecular genetic studies indicate that DSD and CHN may be associated with point mutations in the P0 or the PMP22 genes, although pedigrees have been described that lack mutations in either the P0, PMP22, or Cx32 gene (see below). Most DSD mutations identified to date appear to function as dominant genetic traits.

**Hereditary Neuropathy with Liability to Pressure Palsies**

HNPP (also called tomaculous neuropathy) is an autosomal dominant disorder that produces an episodic, recurrent demyelinating neuropathy. HNPP typically develops during adolescence and may cause attacks of numbness, muscular weakness, and atrophy. Peroneal palsies, carpal tunnel syndrome, and other entrapment neuropathies are manifestations of HNPP. Motor and sensory NCVs are mildly reduced in affected patients as well as in asymptomatic gene carriers. Pathologic changes observed in HNPP include segmental demyelination and tomacula, or sausage-like, formations in peripheral nerves. Due to overlap of clinical features between HNPP and CMT1, some HNPP patients may be misdiagnosed as having CMT1. Approximately 10% of patients with HNPP present with a brachial neuropathy, which is typically painless. Rare patients with HNPP have been found by magnetic resonance imaging (MRI) to have central nervous system (CNS) demyelination. The HNPP locus maps to chromosome 17p11.2-p12 and is associated with a 1.5-Mb deletion. The duplicated CMT1A chromosome (described earlier) and the deleted HNPP chromosome are the reciprocal products of unequal crossing-over during meiosis. In the case of HNPP, loss of a copy of the PMP22 gene and underexpression of this critical myelin gene lead to demyelination. Most HNPP patients have the associated chromosome 17 deletion; however, rare patients with HNPP have been found to have point mutations in the PMP22 gene. Molecular genetic testing is clinically available.

Treatment for HNPP is largely supportive. Surgical decompression of nerves has been proposed but is controversial. There is some evidence that surgical repair of carpal tunnel syndrome in HNPP is of little benefit and that transposition of the ulnar nerve at the elbow may produce poor results because the nerves are especially sensitive to manipulation and minor trauma.

**CMT Neuropathy Type 2**

CMT2 is less common than CMT1 and, in general, has a later age of onset, produces less involvement of the intrinsic muscles of the hands, and lacks palpably enlarged nerves. Extensive demyelination with “onion bulb” formation is not present in CMT2. Motor NCVs are normal or only slightly reduced in affected
persons. The CMT2A locus maps to chromosome 1p35-p36, and in one pedigree a mutation in KIF1B, an axonal motor protein, was found. Limb ulceration is a notable feature of CMT2B. CMT2B maps to chromosome 3q13-q22 and results from mutations in the RAB7 gene, a member of the Rab family of ras-related GTPases that function in intracellular membrane trafficking. Further genetic heterogeneity within CMT2 is evidenced by the identification of kindreds with the features of axonal neuropathy, weakness of the diaphragm, and vocal cord paralysis. Such pedigrees carry the designation of CMT2C, which has been mapped to chromosome 1q23-q24. Yet another form of CMT2, designated CMT2D, maps to chromosome 17q14 and results from mutations in the glycy1 RNA synthetase gene (GARS). In a large Russian pedigree having an autosomal dominant axonopathy, a CMT2 gene was mapped to chromosome 8p21 (and designated CMT2E), and a mutation was found in the neurofilament-light (NEFL) gene.

Additionally, certain P0, or connexin32 (Cx32, see below) mutations have been found to be the underlying genetic defect in a subset of patients with CMT1 or CMTX who were initially thought to have CMT2 because of only mild slowing of NCVs. With these exceptions, DNA testing is not widely available for any form of CMT2.

X-linked CMT Neuropathy The clinical features of X-linked CMT disease (CMTX) include demyelinating neuropathy, absence of male-to-male transmission, and an earlier age of onset and faster rate of progression in males. NCVs vary widely in CMTX from nearly normal to moderately slowed. CMTX accounts for ~10% of all patients thought to have a form of demyelinating CMT (i.e., CMT1). CMTX should be suspected when the commonly associated chromosome 17 duplication is not present and there is no history of father-to-son transmission of the neuropathy.

The gene for CMTX maps to chromosome Xq13-q21 and results from point mutations in the Cx32 gene. Cx32 encodes a major component of gap junctions and is structurally similar to PMP22, as both of these proteins contain four putative transmembrane domains in similar orientation. Unlike PMP22 and P0, which are present in compact myelin, Cx32 is located at uncompacted folds of Schwann cell cytoplasm around the nodes of Ranvier and at Schmidt-Lanterman incisures. This localization suggests a role for gap junctions composed of Cx32 in providing a pathway for the transfer of ions and nutrients around and across the myelin sheath of peripheral nerves. Mutations in the Cx32 protein have been suggested to alter its cellular localization and its trafficking and interfere with cell-to-cell communication. Over 200 different mutations in the Cx32 gene have been described in patients with CMTX, and the distribution pattern of these mutations suggests that all parts of the Cx32 protein are functionally important. DNA testing is available.

Rare Forms of CMT Mutations in the putative zinc finger domain of the early growth response 2 gene (EGR2, or Krox-20) or in the small integral membrane protein of the lysosome/late endosome (SIMPLE) gene have been found in CMT1 families that were found to be negative for the CMT1A duplication, as well as for mutations in PMP22, P0, or Cx32. EGR2 mutations have also been reported in CHN. EGR2 acts as a direct transactivator of myelination genes in differentiating Schwann cells. SIMPLE has been proposed to play a role in myelin protein degradation and turnover. Mutations have also been found in periaxin (PRX), an important structural myelin protein, in demyelinating forms of neuropathy clinically diagnosed as CMT1 or DSD. DNA testing is available for EGR2 and PRX.

Rare families with autosomal recessive motor and sensory neuropathy have been reported, particularly Tunisian families with parental consanguinity. Both demyelinating and axonal types of neuropathy have been described and given the designation CMT4. One form of autosomal recessive demyelinating neuropathy, CMT4A, has been mapped to chromosome 11q13-q21 and is associated with mutations in the ganglioside-induced differentiation-associated protein (GDAP1). CMT4B is characterized by focally folded myelin sheaths and maps to chromosome 11q23. CMT4B is caused by mutations in the myotubularin-related protein-2 (MTMR2), which is thought to be a transcriptional regulator. Additional loci for other rare forms of CMT4 have been found, and in some cases causal genes are known (Table 364-1).

Genetic Evaluation of CMT and HNPP An approach for evaluating a patient suspected of having an inherited peripheral neuropathy is presented in Fig. 364-1. If the proband has evidence for CMT1, determination of NCVs is a useful screening tool for parents and other at-risk family members. The CMT1 gene is penetrant in early life, and correct disease status can probably be determined by age 5 by screening with NCVs. However, if a proband’s nerve conduction is normal or only mildly prolonged, the diagnosis may be CMT2. In this case the screening examination will need to focus on determination of motor unit amplitudes and other electrical signs of denervation. Rare patients have been found to have point mutations in either P0 or Cx32, resulting in very mild demyelination and misclassification as CMT2.

Most CMT1 and CMT2 pedigrees have autosomal dominant inheritance. In pedigrees lacking male-to-male transmission and whenever males are more severely affected than females and have an earlier onset, CMTX should be suspected. Determination of autosomal dominant versus X-linked CMT is important as the genetic counseling for these two modes of inheritance is different. For any form of autosomal dominant CMT, the likelihood of an affected parent (of either sex) having an affected child is 50% for each pregnancy, regardless of the sex of the child. For CMTX, all daughters of an affected father will inherit the gene, and none of the sons will be affected. For a woman with CMTX, there is a 50% likelihood that her children will be affected regardless of their sex.

Sporadic cases in males can be especially difficult to evaluate, as the neuropathy could be nongenetic or the pattern of inheritance could be autosomal dominant, X-linked, or even autosomal recessive. Sporadic cases may also represent de novo duplications (CMT1A) or de novo deletions (HNPP). False paternity is another explanation for apparent sporadic CMT or HNPP.

Molecular genetic testing is currently available for the DNA duplication (or deletion) associated with CMT1A or HNPP and for point mutations in the PMP22, P0, EGR2, PRX, and Cx32 genes associated with other forms of CMT1 and CMTX.
CHEMOTHERAPY IN PATIENTS WITH CMT  Chemotherapeutic agents known to affect peripheral nerves should be used with great caution in patients with inherited neuropathies, and in the case of vincristine, total avoidance is strongly advised. A number of reports have documented the serious consequences of vincristine treatment administered in standard oncologic dosages in patients with CMT, including CMT1A and CMT2. The complications ranged from the precipitation of severe neuropathies in clinically asymptomatic at-risk individuals, induction of marked worsening in previously symptomatic patients, and even death due to respiratory collapse.

OTHER INHERITED NEUROPATHIES

HEREDITARY SENSORY NEUROPATHIES  Hereditary sensory neuropathies (HSNs) are a heterogeneous group of disorders affecting sensory nerves. The most common form of HSN, HSN type I, is an autosomal degenerative disorder of sensory and motor neurons. Phenotypically, distal sensory loss, distal muscle wasting and weakness, and variable neural deafness are observed. The disease involves progressive loss of dorsal root ganglion cells and axons in peripheral nerves. Age of onset is the second decade of life or later. The HSN-I locus maps to chromosome 9q22.1-q22.3 and results from mutations in the serine palmitoyltransferase (SPTLC1) gene. Because of the presence of muscular weakness in some patients with HSN, this disorder may be clinically confused with CMT.

FAMILIAL AMYLOID NEUROPATHY  Familial amyloid polyneuropathy (FAP) is an autosomal dominant disorder that classically presents as progressive sensory peripheral neuropathy, with early involvement of the autonomic nervous system and an associated cardiomyopathy. Postmortem studies have shown extensive amyloid deposition in multiple organs throughout the body. Transthyretin (TTR) is the most common constituent amyloid fibril protein deposited in FAP. Several different point mutations in the TTR gene have been described in TTR-related FAP, and DNA testing for these mutations is clinically available. 

AMYLOIDOSIS IS DISCUSSED IN Chap. 310.

REFSUM DISEASE  This autosomal recessive disorder is characterized by a progressive sensorimotor demyelinating polyneuropathy, associated with cerebellar ataxia and retinitis pigmentosa. Neural deafness, cardiomyopathy, cataracts, and ichthyosis are additional features. Onset is in late childhood or early adulthood. Patients often complain of night blindness as the earliest symptom. The CSF protein is typically elevated. Diagnosis is made by demonstration of elevated levels of phytanic acid (a 20-carbon branched-chain fatty acid) in the serum and urine. The disorder appears to be due to a deficiency of a peroxysomal enzyme, phytanic acid oxidase, responsible for alpha oxidation of phytanic acid. Therapy, consisting of avoidance of dietary sources of phytanic acid and plasmapheresis in some cases, is partially effective.

FURTHER READING


GUILLAIN-BARRÉ SYNDROME AND OTHER IMMUNE-MEDIATED NEUROPATHIES

GUILLAIN-BARRÉ SYNDROME

Guillain-Barré syndrome (GBS) is an acute, frequently severe, and fulminant polyradiculoneuropathy that is autoimmune in nature. It occurs year-round at a rate of about one case per million per month, or ~3500 cases per year in the United States and Canada. Males and females are equally at risk, and in western countries adults are more frequently affected than children.

Clinical Manifestations  GBS manifests as rapidly evolving areflexic motor paralysis with or without sensory disturbance. The usual pattern is an ascending paralysis that may be first noticed as rubbery legs. Weakness typically evolves over hours to a few days and is frequently accompanied by tingling dysesthesias in the extremities. The legs are usually more affected than the arms, and facial diparesis is present in 50% of affected individuals. The lower cranial nerves are also frequently involved, causing bulbar weakness and difficulty with handling secretions and maintaining an airway. Most patients require hospitalization, and almost 30% require ventilatory assistance at some time during the illness. Fever and constitutional symptoms are absent at the onset, and, if present, cast doubt on the diagnosis. Deep tendon reflexes usually disappear within the first few days of onset. Cutaneous sensory deficits, e.g., loss of pain and temperature sensation, are usually relatively mild, but functions subserved by large sensory fibers, such as deep tendon reflexes and proprioception, are more severely affected. Bladder dysfunction may occur in severe cases but is usually transient. If bladder dysfunction is a prominent feature and comes early in the course, possibilities other than GBS should be considered, particularly spinal cord disease. Once clinical worsening stops and the patient reaches a plateau, further progression is unlikely.

FAMILIAL AMYLOID NEUROPATHY

Familial amyloid polyneuropathy (FAP) is an autosomal dominant disorder that classically presents as progressive sensory peripheral neuropathy, with early involvement of the autonomic nervous system and an associated cardiomyopathy. Postmortem studies have shown extensive amyloid deposition in multiple organs throughout the body. Transthyretin (TTR) is the most common constituent amyloid fibril protein deposited in FAP. Several different point mutations in the TTR gene have been described in TTR-related FAP, and DNA testing for these mutations is clinically available. 

AMYLOIDOSIS IS DISCUSSED IN Chap. 310.

REFSUM DISEASE  This autosomal recessive disorder is characterized by a progressive sensorimotor demyelinating polyneuropathy, associated with cerebellar ataxia and retinitis pigmentosa. Neural deafness, cardiomyopathy, cataracts, and ichthyosis are additional features. Onset is in late childhood or early adulthood. Patients often complain of night blindness as the earliest symptom. The CSF protein is typically elevated. Diagnosis is made by demonstration of elevated levels of phytanic acid (a 20-carbon branched-chain fatty acid) in the serum and urine. The disorder appears to be due to a deficiency of a peroxysomal enzyme, phytanic acid oxidase, responsible for alpha oxidation of phytanic acid. Therapy, consisting of avoidance of dietary sources of phytanic acid and plasmapheresis in some cases, is partially effective.

FURTHER READING


GUILLAIN-BARRÉ SYNDROME AND OTHER IMMUNE-MEDIATED NEUROPATHIES

GUILLAIN-BARRÉ SYNDROME

Guillain-Barré syndrome (GBS) is an acute, frequently severe, and fulminant polyradiculoneuropathy that is autoimmune in nature. It occurs year-round at a rate of about one case per million per month, or ~3500 cases per year in the United States and Canada. Males and females are equally at risk, and in western countries adults are more frequently affected than children.

Clinical Manifestations  GBS manifests as rapidly evolving areflexic motor paralysis with or without sensory disturbance. The usual pattern is an ascending paralysis that may be first noticed as rubbery legs. Weakness typically evolves over hours to a few days and is frequently accompanied by tingling dysesthesias in the extremities. The legs are usually more affected than the arms, and facial diparesis is present in 50% of affected individuals. The lower cranial nerves are also frequently involved, causing bulbar weakness and difficulty with handling secretions and maintaining an airway. Most patients require hospitalization, and almost 30% require ventilatory assistance at some time during the illness. Fever and constitutional symptoms are absent at the onset, and, if present, cast doubt on the diagnosis. Deep tendon reflexes usually disappear within the first few days of onset. Cutaneous sensory deficits, e.g., loss of pain and temperature sensation, are usually relatively mild, but functions subserved by large sensory fibers, such as deep tendon reflexes and proprioception, are more severely affected. Bladder dysfunction may occur in severe cases but is usually transient. If bladder dysfunction is a prominent feature and comes early in the course, possibilities other than GBS should be considered, particularly spinal cord disease. Once clinical worsening stops and the patient reaches a plateau, further progression is unlikely.

In severe cases of GBS requiring critical care management, autonomic involvement is common. Usual features are loss of vasomotor control with wide fluctuation in blood pressure, postural hypotension, and cardiac dysrhythmias. These features require close monitoring and management and can be fatal. Pain is another common feature of GBS; several types are encountered. Most common is deep aching pain in weakened muscles, which patients liken to having overexercised the previous day. Other pains in GBS include back pain involving the entire spine and sometimes dysesthetic pain in the extremities as a manifestation of sensory nerve fiber involvement. These pains are self-limited and should be treated with standard analgesics.

Several subtypes of GBS are now recognized, as determined primarily by electrodiagnostic and pathologic distinctions (Table 365-1). A range of limited or regional GBS syndromes may be encountered, although uncommonly. These include (1) the Miller Fisher syndrome (Table 365-1 and see “Immunopathogenesis,” below); (2) pure sensory forms; (3) ophthalmoplegia with anti-GQ1b antibodies (see “Immunopathogenesis,” below) as part of severe motor-sensory GBS; (4) GBS with severe bulbar and facial paralysis, sometimes associated with antecedent cytomegalovirus (CMV) infection and anti-GM2 antibodies; and (5) acute panhypoadonutism.

Antecedent Events  Some 75% of cases of GBS are preceded 1 to 3 weeks by an acute infectious process, usually respiratory or gastrointestinal. Culture and seroepidemiologic techniques show that 20 to 30% of all cases occurring in North America, Europe, and Australia are preceded by infection or reinfection with Campylobacter jejuni. A similar proportion is preceded by a human herpes virus infection, often CMV or Epstein-Barr virus. Other viruses and also Mycoplasma pneu-
**TABLE 365-1**  Types of Guillain-Barré Syndrome (GBS)

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Features</th>
<th>Electrodiagnosis</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute inflammatory demyelinating polyneuropathy (AIDP)</td>
<td>Adults affected more than children; 90% of cases in western world; recovery rapid; anti-GM1 antibodies (&lt;50%)</td>
<td>Demyelinating</td>
<td>First attack on Schwann cell surface; widespread myelin damage, macrophage activation, and lymphocytic infiltration; variable secondary axonal damage</td>
</tr>
<tr>
<td>Acute motor axonal neuropathy (AMAN)</td>
<td>Children and young adults; prevalent in China and Mexico; may be seasonal; recovery rapid; anti-GD1a antibodies</td>
<td>Axonal</td>
<td>First attack at motor nodes of Ranvier; macrophage activation, few lymphocytes, frequent periaxial macrophages; extent of axonal damage highly variable</td>
</tr>
<tr>
<td>Acute motor sensory axonal neuropathy (AMSAN)</td>
<td>Mostly adults; uncommon; recovery slow, often incomplete; closely related to AMAN</td>
<td>Axonal</td>
<td>Same as AMAN, but also affects sensory nerves and roots; axonal damage usually severe</td>
</tr>
<tr>
<td>M. Fisher syndrome (MFS)</td>
<td>Adults and children; uncommon; ophthalmoplegia, ataxia, and areflexia; anti-GQ1b antibodies (90%)</td>
<td>Demyelinating</td>
<td>Few cases examined; resembles AIDP</td>
</tr>
</tbody>
</table>

**Immunopathogenesis**  Several lines of evidence support an autoimmune basis for acute inflammatory demyelinating polyneuropathy (AIDP), the most common and best studied type of GBS; the concept extends to all of the subtypes of GBS (Table 365-1).

It is likely that both cellular and humoral immune mechanisms contribute to tissue damage in AIDP. T cell activation is suggested by the finding that elevated levels of cytokines and cytokine receptors are present in serum [interleukin (IL) 2, soluble IL-2 receptor] and in cerebrospinal fluid (CSF) (IL-6, tumor necrosis factor α, interferon-γ). AIDP is also closely analogous to an experimental T cell–mediated immunopathology designated experimental allergic neuritis (EAN); EAN is induced in laboratory animals by immune sensitization against protein fragments derived from peripheral nerve proteins, and in particular against the P2 protein. Based on analogy to EAN, it was initially thought that AIDP was likely to be primarily a T cell–mediated disorder; however, abundant data now suggest that autoantibodies directed against nonprotein determinants may be central to many cases.

Circumstantial evidence suggests that all GBS results from immune responses to nonself antigens (infectious agents, vaccines) that misdirect to host nerve tissue through a resemblance-of-epitope (molecular mimicry) mechanism (Fig. 365-1) (Chap. 299). The neural targets are likely to be glycoconjugates, specifically gangliosides (Table 365-2, Fig. 365-2). Gangliosides are complex glycosphingolipids that contain one or more sialic acid residues; various gangliosides participate in cell–cell interactions (including those between axons and glia), modulation of receptors, and regulation of growth. They are typically exposed on the plasma membrane of cells, rendering them susceptible to an antibody-mediated attack. Gangliosides and other glycoconjugates are present in large quantity in human nervous tissues and in key sites, such as nodes of Ranvier. Antiganglioside antibodies, most frequently to GM1, are common in GBS (20 to 50% of cases), particularly in those preceded by *C. jejuni* infection. Furthermore, isolates of *C. jejuni* from stool cultures of patients with GBS have surface glycolipid structures that antigenically cross react with gangliosides, including GM1, concentrated in human nerves. Another line of evidence is derived from experience in Europe with parenteral use of purified bovine brain gangliosides for treatment of various neuropathic disorders. Between 5 and 15 days after injection some recipients developed acute motor axonal GBS with high titers of anti-GM1 antibodies that recognized epitopes at nodes of Ranvier and motor endplates.

Particularly noteworthy is the Miller Fisher syndrome (MFS), which presents as rapidly evolving ataxia and areflexia of limbs without weakness, and ophthalmoplegia often with pupillary paralysis. The MFS variant accounts for ~5% of all GBS cases. Anti-GQ1b IgG antibodies are found in >90% of patients with MFS (Tables 365-1 and 365-2; Fig. 365-2), and titers of IgG are highest early in the course. Anti-GQ1b antibodies are not found in other forms of GBS unless there is extraocular motor nerve involvement. Extraocular motor nerves are enriched in GQ1b ganglioside receptors; those other forms of GBS (Table 365-1 and 365-2), particularly those preceded by *C. jejuni* infection. Furthermore, isolates of *C. jejuni* from stool cultures of patients with GBS have surface glycolipid structures that antigenically cross react with gangliosides, including GM1, concentrated in human nerves. Another line of evidence is derived from experience in Europe with parenteral use of purified bovine brain gangliosides for treatment of various neuropathic disorders. Between 5 and 15 days after injection some recipients developed acute motor axonal GBS with high titers of anti-GM1 antibodies that recognized epitopes at nodes of Ranvier and motor endplates. Partic

**FIGURE 365-1**  Postulated immunopathogenesis of GBS associated with *C. jejuni* infection. B cells recognize glycoconjugates on *C. jejuni* (triangles) that cross-react with ganglioside present on Schwann cell surface and subjacent peripheral nerve myelin. Some B cells, activated via a T cell–independent mechanism, secrete primarily IgM (not shown). Other B cells (upper left side) are activated via a partially T cell–dependent route and secrete primarily IgG; T cell help is provided by CD4 cells activated locally by fragments of *C. jejuni* proteins that are presented on the surface of antigen-presenting cells (APC). A critical event in the development of GBS is the escape of activated B cells from Peger’s patches into regional lymph nodes. Activated T cells probably also function to assist in opening of the blood–nerve barrier, facilitating penetration of pathogenic autoantibodies. The earliest changes in myelin (right) consist of edema between myelin lamellae and vesicular disruption (shown as circular blebs) of the outermost myelin layers. These effects are associated with activation of the C3a-C5 membrane attack complex and probably mediated by calcium entry; it is possible that the macrophage cytokine tumor necrosis factor (TNF) also participates in myelin damage. B, B cell; MHC II, class II major histocompatibility complex molecule; TCR, T cell receptor; A, axon.
osides in comparison to limb nerves. Further, a monoclonal anti-GQ1b antibody raised against \textit{C. jejuni} isolated from a patient with MFS blocked neuromuscular transmission experimentally.

Taken together, these observations provide strong but still inconclusive evidence that autoantibodies play an important pathogenic role in GBS. Although anti-ganglioside antibodies have been studied most intensely, other antigenic targets may also be important. One recent report identified IgG antibodies against Schwann cells and neurons (nerve growth cone region) in some GBS cases. Proof that these antibodies are pathogenic requires that they be capable of mediating disease following direct passive transfer to naïve hosts; this has not yet been demonstrated, although a case of apparent maternal-fetal transplacental transfer of GBS has been described.

**Pathophysiology** In the demyelinating forms of GBS, the basis for flaccid paralysis and sensory disturbance is conduction block. This finding, demonstrable electrophysiologically, implies that the axonal connections remain intact. Hence, recovery can take place rapidly as remyelination occurs. In severe cases of demyelinating GBS, secondary axonal degeneration usually occurs; its extent can be estimated electrophysiologically. More secondary axonal degeneration correlates with a slower rate of recovery and a greater degree of residual disability. When a primary axonal pattern is encountered electrophysiologically, the implication is that axons have degenerated and become disconnected from their targets, specifically the neuromuscular junctions, and must therefore regenerate for recovery to take place. In motor axonal cases in which recovery is rapid, the lesion is thought to be localized to preterminal motor branches, allowing regeneration and reinnervation to take place quickly.

**Laboratory Features** CSF findings are distinctive, consisting of an elevated CSF protein level (1 to 10 g/L [100 to 1000 mg/dL]) without accompanying pleocytosis. The CSF is often normal when symptoms have been present for \(<48\) h; by the end of the first week the level of protein is usually elevated. A transient increase in the CSF white cell count (10 to 100/\mu\text{L}) occurs on occasion in otherwise typical GBS; however, a sustained CSF pleocytosis suggests an alternative diagnosis (viral myelitis) or a concurrent diagnosis (unrecognized HIV infection; Chap. 173). Electrodagnostic features are mild or absent in the early stages of GBS and lag behind the clinical evolution. In cases with demyelination (Table 365-1), prolonged distal latencies, conduction velocity slowing, evidence of conduction block, and temporal dispersion of compound action potential are the usual features. In cases with primary axonal pathology, the principal electrophagnostic finding is reduced amplitude of compound action potentials without conduction slowing or prolongation of distal latencies.

**Diagnosis** GBS is a descriptive entity. The diagnosis is made by recognizing the pattern of rapidly evolving paralysis with areflexia, absence of fever or other systemic symptoms, and characteristic antecedent events (Table 365-3). Other disorders that may enter into the

### Table 365-2 Principal Anti-Glycolipid Antibodies Implicated in Immune Neuropathies

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Antibody Target</th>
<th>Usual Isotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE IMMUNE NEUROPATHIES (GUILLAIN BARRÉ SYNDROMES)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute inflammatory demyelinating polyneuropathy (AIDP)</td>
<td>No clear patterns</td>
<td>IgG (polyclonal)</td>
</tr>
<tr>
<td>Acute motor axonal neuropathy (AMAN)</td>
<td>GD1a, GM1, GM1b, Ga1NAc–GD1a (&lt;50% for any)</td>
<td>IgG (polyclonal)</td>
</tr>
<tr>
<td>Miller Fisher Syndrome (MFS)</td>
<td>QG1b (&gt;90%)</td>
<td>IgG (polyclonal)</td>
</tr>
<tr>
<td>Acute pharyngeal cervicobrachial neuropathy (APCBN)</td>
<td>GT1a (? Most)</td>
<td>IgG (polyclonal)</td>
</tr>
<tr>
<td><strong>CHRONIC IMMUNE NEUROPATHIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic inflammatory demyelinating polyneuropathy CIDP (75%)</td>
<td>Neural binding sites</td>
<td>IgG, IgA (monoclonal)</td>
</tr>
<tr>
<td>CIDP (MGUS associated) (25%)</td>
<td>SPGP, SGLPG (on MAG)</td>
<td>IgG (polyclonal)</td>
</tr>
<tr>
<td>Chronic sensory &gt; motor neuropathy</td>
<td>Uncertain (50%)</td>
<td>IgM (monoclonal)</td>
</tr>
<tr>
<td>Multifocal motor neuropathy (MMN)</td>
<td>GM1, Ga1NAc–GD1a, others (25–50%)</td>
<td>IgM (polyclonal, monoclonal)</td>
</tr>
<tr>
<td>Chronic sensory axonal neuropathy</td>
<td>GD1b, GQ1b and other b-series gangliosides</td>
<td>IgM (monoclonal)</td>
</tr>
</tbody>
</table>

**Note:** MGUS, monoclonal gammopathy of undetermined significance; MAG, myelin-associated glycoprotein.

**Source:** Modified from HJ Willison, N Yuki: Brain 125:2591, 2002.

**TABLE 365-3 Diagnostic Criteria for Guillain-Barre Syndrome**

**REQUIRED**
1. Progressive weakness of 2 or more limbs due to neuropathy
2. Areflexia
3. Disease course \(<4\) weeks
4. Exclusion of other causes [e.g., vasculitis (polyarteritis nodosa, systemic lupus erythematosus, Churg-Strauss syndrome), toxins (organophosphates, lead), botulism, diphtheria, porphyria, localized spinal cord or cauda equina syndrome]

**SUPPORTIVE**
1. Relatively symmetric weakness
2. Mild sensory involvement
3. Facial nerve or other cranial nerve involvement
4. Absence of fever
5. Typical CSF profile (acellular, increase in protein level)
6. Electrophysiologic evidence of demyelination

*Excluding M. Fisher and other variant syndromes.

**Source:** Modified from AK Asbury, DR Cornblath: Ann Neurol 27:S21, 1990.

**Figure 365-2** Glycolipids implicated as antigens in immune-mediated neuropathies. (Modified from HJ Willison, N Yuki: Brain 125:2591, 2002.)
differential diagnosis include acute myelopathies (especially with prolonged back pain and sphincter disturbances); botulism (pupillary reactivity loss early); diphtheria (early oropharyngeal disturbances); Lyme polyradiculitis and other tick-born paralyses; porphyria (abdominal pain, seizures, psychosis); vasculitic neuropathy (check erythrocyte sedimentation rate, described below); poliomyelitis (fever and meningismus common); CMV polyradiculitis (in immunocompromised patients); critical illness neuropathy; neuromuscular disorders such as myasthenia gravis; or poisonings with organophosphates, thallium, or arsenic. Laboratory tests are helpful primarily to exclude mimics of GBS. Electrodiagnostic features may be minimal, and the CSF protein level may not rise until the end of the first week. If the diagnosis is strongly suspected, treatment should be initiated without waiting for evolution of the characteristic electrodiagnostic and CSF findings to occur. GBS patients with risk factors for HIV or with CSF pleocytosis should have a serologic test for HIV.

**TREATMENT**

In the vast majority of patients with GBS, treatment should be initiated as soon after diagnosis as possible. Each day counts; ~2 weeks after the first motor symptoms, immunotherapy is no longer effective. Either high-dose intravenous immune globulin (IVIg) or plasmapheresis can be initiated, as they are equally effective (Table 365-4). A combination of the two therapies is not significantly better than either alone. IVIg is often the initial therapy chosen because of its ease of administration and good safety record. IVIg is administered as five daily infusions for a total dose of 2 g/kg body weight. There is some evidence that GBS autoantibodies are neutralized by anti-idiotypic antibodies present in IVIg preparations, perhaps accounting for the therapeutic effect. A course of plasmapheresis, consisting of ~40 to 50 mL/kg plasma exchange (PE) four times over a week, is usually employed. In patients who are treated early in the course of GBS and improve, relapse may occur in the second or third week. Brief retreatment with the original therapy is usually effective. Glucocorticoids have not been found to be effective in GBS. Occasional patients with very mild forms of GBS, especially those who appear to have already reached a plateau when initially seen, may be managed conservatively without IVIg or plasma exchange.

In the worsening phase of GBS, most patients require monitoring in a critical care setting, with particular attention to vital capacity, cardiovascular status, and chest physiotherapy. As noted, ~30% of patients with GBS require ventilatory assistance, sometimes for prolonged periods of time (several weeks or longer). Frequent turning and assiduous skin care are important, as are daily range-of-motion exercises to avoid joint contractures, and daily reassurance as to the generally good outlook for recovery.

**Prognosis and Recovery**

Approximately 85% of patients with GBS achieve a full functional recovery within several months to a year, although minor findings on examination (such as areflexia) may persist. The mortality rate is <5% in optimal settings; death usually results from secondary pulmonary complications. The outlook is worst in patients with severe proximal motor and sensory axonal damage. Such axonal damage may be either primary or secondary in nature (see “Pathophysiology,” above), but in either case successful regeneration cannot occur. Other factors that worsen the outlook for recovery are advanced age, a fulminant or severe attack, and a delay in the onset of treatment. Between 5 to 10% of patients with typical GBS have one or more late relapses; such cases are then classified as chronic inflammatory demyelinating polyneuropathy (CIDP).

**CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY**

CIDP is distinguished from GBS by its chronic course. In other respects, this neuropathy shares many features with GBS, including elevated CSF protein levels and the electrodiagnostic findings of acquired demyelination. Most cases occur in adults, and males are affected slightly more often than females. The incidence of CIDP is lower than that of GBS, but due to the protracted course the prevalence is greater.

**Clinical Manifestations**

Onset is usually gradual, sometimes subacute; in a few, the initial attack is indistinguishable from that of GBS. Symptoms are both motor and sensory in most cases. Weakness of the limbs is usually symmetric but can be strikingly asymmetric. There is considerable variability from case to case. Some patients experience a

<table>
<thead>
<tr>
<th>Trial/Site</th>
<th>Reference</th>
<th>No. Patients (N)/Follow Up (FU)/End Points</th>
<th>Results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>GBS Study Group: USA/Canada (18 centers)</td>
<td>Neurology 35:1096, 1985</td>
<td>N = 245 FU = 6 months PE vs. none</td>
<td>1. % improved 1 grade at 4 weeks 2. Days to improve 1 grade 3. Days to reach grade 2</td>
<td>1. 59% (PE) vs. 39% (none) p &lt; .001 2. 19 days (PE) vs. 40 days (none) p &lt; .001 3. 53 days (PE) vs. 85 days (none) p &lt; .001</td>
</tr>
<tr>
<td>French Coop. Group on PE in GBS; France/Switzerland (28 centers)</td>
<td>Ann Neurol 22:753, 1987; Ann Neurol 32:94, 1992</td>
<td>N = 220 FU = 1 year PE vs. none; Albumin vs. FFP in PE arm</td>
<td>1. Days to walk with assistance 2. Days to positive Δ score 3. Albumin vs. FFP</td>
<td>1. 30 days (PE) vs. 44 days (none) p &lt; .01 2. 4 days (PE) vs. 12 days (none) p &lt; .001 3. No significant difference</td>
</tr>
<tr>
<td>Dutch GB Study Group: The Netherlands (15 centers)</td>
<td>Engl J Med 326:1123, 1992</td>
<td>N = 150 FU = 6 months IVlg vs. PE</td>
<td>1. % improved 1 grade at 4 weeks 2. Days to reach grade 2 1. % improved 1 grade at 4 weeks 2. Secondary end points: days to reach grade 2; days to off-respirator; disability at 48 weeks</td>
<td>1. 53% (IVlg) vs. 34% (PE) p = .024 2. 55 days (IVlg) vs. 70 days (PE) p = .07</td>
</tr>
<tr>
<td>Plasma Exchange/ Sandoglobulin GBS Trial (38 centers in 11 countries)</td>
<td>Lancet 349:225, 1997</td>
<td>N = 329 FU = 48 weeks IVlg vs. PE vs. both (3 arms)</td>
<td>1. % improved 1 grade at 4 weeks 2. Days to reach grade 2</td>
<td>1. 53% (IVlg) vs. 34% (PE) p = .024 2. 55 days (IVlg) vs. 70 days (PE) p = .07</td>
</tr>
</tbody>
</table>

**Abbreviations:** PE, plasma exchange; IVlg, high dose intravenous immunoglobulin; FFP, fresh-frozen plasma

**Note:** All studies except the French Coop. Group used the London grade scale: 0, healthy; 1, minor symptoms/signs; 2, walk 5 m unassisted; 3, walk 5 m with assistance; 4, bed/chairbound; 5, requiring assisted respiration; 6, dead.
chronic progressive course, whereas others, usually younger patients, have a relapsing and remitting course. Some have only motor findings, and a small proportion present with a relatively pure syndrome of sensory ataxia. Tremor occurs in ~10% and may become more prominent during periods of subacute worsening or improvement. A small proportion have cranial nerve findings, including external ophthalmoplegia. CIDP tends to ameliorate over time with treatment; the result is that many years after onset nearly 75% of patients have reasonable functional status. Death from CIDP is uncommon.

**Diagnosis** The diagnosis rests on characteristic clinical, CSF, and electroneurophysiologic findings. The CSF is usually acellular with an elevated protein level, sometimes several times normal. Electroneurodiagnostically, variable degrees of conduction slowing, prolonged distal latencies, temporal dispersion of compound action potentials, and conduction block are the principal features. In particular, the presence of conduction block is a certain sign of an acquired demyelinating process. Evidence of axonal loss, presumably secondary to demyelination, is present in >50% of patients. Serum protein electrophoresis with immunofixation is indicated to search for monoclonal gammopathy and associated conditions (see “Monoclonal Gammopathy of Undetermined Significance,” below). In all patients with presumptive CIDP, it is also reasonable to exclude collagen vascular disease (especially systemic lupus erythematosus), chronic hepatitis, HIV infection, and diabetes mellitus.

**Pathogenesis** Although there is evidence of immune activation in CIDP, the precise mechanisms of pathogenesis are unknown. Biopsy typically reveals little inflammation and onion-bulb changes (imbricated layers of attenuated Schwann cell processes surrounding an axon) that result from recurrent demyelination and remyelination. The response to therapy suggests that CIDP is immune-mediated; interestingly, CIDP responds to glucocorticoids (see below), whereas GBS does not. Passive transfer of demyelination into experimental animals was recently accomplished using IgG purified from the serum of some patients with CIDP, lending support for a humoral autoimmune pathogenesis. Although the target antigen or antigens in CIDP have not yet been identified, one recent study implicated the myelin protein Po as a potential autoantigen in some patients. Approximately 25% of patients with clinical features of CIDP also have a monoclonal gammopathy of undetermined significance (MGUS). Cases associated with monoclonal IgA or IgG usually respond to treatment as favorably as cases without a monoclonal gammopathy. Patients with IgM monoclonal gammopathy tend to have more sensory findings, a more protracted course, and may have a less satisfactory response to treatment, although this is an area of controversy.

**TREATMENT**

Most authorities initiate treatment for CIDP when progression is rapid or walking is compromised. If the disorder is mild, management can be expectant, awaiting spontaneous remission. Controlled studies have shown that high-dose IVIg, PE, and glucocorticoids are all more effective than placebo. Initial therapy is usually either IVIg or PE, which appear to be equally effective. IVIg is administered as 0.4 g/kg body weight daily for 5 days; most patients require periodic re-treatment at ~6-week intervals. PE is initiated at two to three treatments per week for 6 weeks; periodic re-treatment may also be required. Treatment with oral glucocorticoids is another option (60 to 80 mg prednisone daily for 1 to 2 months, followed by a gradual dose reduction of 10 mg per month as tolerated), but long-term adverse effects including bone demineralization, gastrointestinal bleeding, and cushingoid changes are problematic. Approximately one-half of patients with CIDP fail to respond adequately to the initial therapy chosen; a different treatment should then be tried. Patients who fail therapy with IVIg, PE, and glucocorticoids may benefit from treatment with immunosuppressive agents such as azathioprine, methotrexate, cyclosporine, and cyclophosphamide, either alone or as adjunctive therapy. Use of these therapies requires periodic reassessment of their risks and benefits.

**MULTIFOCAL MOTOR NEUROPATHY**

Multifocal motor neuropathy (MMN) is a distinctive but uncommon neuropathy that presents as a slowly progressive motor weakness and atrophy evolving over years in the distribution of selected nerve trunks, associated with sites of persistent focal motor conduction block in the same nerve trunks. Sensory fibers are relatively spared. The arms are affected more frequently than the legs, and >75% of all patients are male. Some cases have been confused with lower motor neuron forms of amyotrophic lateral sclerosis (Chap. 353). Approximately 50% of patients present with high titers of polyclonal IgM antibody to the ganglioside GM1. It is uncertain how this finding relates to the discrete foci of persistent motor conduction block, but high concentrations of GM1 gangliosides are normal constituents of nodes of Ranvier in peripheral nerve fibers. Pathology reveals demyelination and mild inflammatory changes at the sites of conduction block.

Most patients with MMN respond to high-dose IVIg (dosages as for CIDP, above) and some refractory patients have responded to cyclophosphamide. Glucocorticoids and PE are not effective.

**NEUROPATHIES WITH MONOCLONAL GAMMOPATHY**

**MULTIPLE MYELOMA** Clinically overt polyneuropathy occurs in ~5% of patients with the commonly encountered type of multiple myeloma, which exhibits either lytic or diffuse osteoporotic bone lesions. These neuropathies are sensorimotor, are usually mild but may be severe, and generally do not reverse with successful suppression of the myeloma. In most cases, electrodiagnostic and pathologic features are consistent with a process of axonal degeneration.

In contrast, myeloma with osteosclerotic features, although representing only 3% of all myelomas, is associated with polyneuropathy in one-half of cases. These neuropathies, which may also occur with solitary plasmacytoma, are distinct because they (1) are usually demyelinating in nature; (2) often respond to radiation therapy or removal of the primary lesion; (3) are associated with different monoclonal proteins and light chains (almost always lambda as opposed to primarily kappa in the lytic type of multiple myeloma); and (4) may occur in association with other systemic findings including thickening of the skin, hyperpigmentation, hypertrichosis, organomegaly, endocrinopathy, anasarca, and clubbing of fingers. These are features of the POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes). The pathogenesis of this uncommon syndrome and the explanation for its association with lambda light chains are unknown. Treatment of the neuropathy is best directed at the osteosclerotic myeloma using surgery, radiotherapy, or chemotherapy, as indicated.

Neuropathies are also encountered in other systemic conditions with gammopathy including Waldenström’s macroglobulinemia, primary systemic amyloidosis, and cryoglobulinemic states (mixed essential cryoglobulinemia, some cases of hepatitis C).

**MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE** Chronic polyneuropathies occurring in association with MGUS are usually associated with the immunoglobulin isotypes IgG, IgA, and IgM. From a clinical standpoint, many of these patients are indistinguishable from patients with CIDP without monoclonal gammopathy (see “Chronic Inflammatory Demyelinating Polyneuropathy,” above), and their response to immunosuppressive agents is also similar. An exception is the syndrome of IgM kappa monoclonal gammopathy associated with an indolent, longstanding, sometimes static sensory neuropathy, frequently with tremor and sensory ataxia. Most patients are male and over age 50. In the majority, the monoclonal IgM immunoglobulin binds to a normal peripheral nerve constituent, myelin-associated glycoprotein (MAG), found in the paranodal regions of Schwann cells. Binding appears to be specific for a polysaccharide epitope that is also found in other normal peripheral nerve myelin glycoproteins, P0 and PMP22, and also in other normal nerve-related glycosphingolipids (Fig. 365-1). In the MAG-positive cases, IgM paraprotein is incor-
porated into the myelin sheaths of affected patients and widens the spacing of the myelin lamellae, thus producing a distinctive ultrastructural pattern. Demyelination and remyelination are the hallmarks of the lesions. The chronic demyelinating neuropathy appears to result from a destabilization of myelin metabolism rather than activation of an immune response. Therapy with chlorambucil or cyclophosphamide often results in improvement of the neuropathy associated with a prolonged reduction in the levels in the circulating paraprotein; chronic use of these alkylating agents is associated with significant risks (Chap. 70). In a small proportion of patients, MGUS will in time evolve into frankly malignant conditions, such as multiple myeloma (Chap. 98) or lymphoma (Chap. 97).

**VASCULITIC NEUROPATHY**

Peripheral nerve involvement is common in polyarteritis nodosa (PAN), appearing in half of all cases clinically and in 100% of cases at postmortem studies (Chap. 306). The most common pattern is multifocal (asymmetric) motor-sensory neuropathy (mononeuropathy multiplex) due to ischemic lesions of nerve trunks and roots; however, some cases of vasculitic neuropathy present as a distal, symmetric motor-sensory neuropathy. Symptoms of neuropathy are a common presenting complaint in patients with PAN. The electrodiagnostic findings are those of an axonal process. Small- to medium-sized arteries of the vasa nervorum, particularly the epi neural vessels, are affected in PAN, resulting in a widespread ischemic neuropathy. A high frequency of neuropathy is also present in allergic angiitis and granulomatosis (Churg-Strauss syndrome).

Systemic vasculitis should always be considered when a subacute or chronically evolving mononeuropathy multiplex occurs in conjunction with constitutional symptoms (fever, anorexia, weight loss, loss of energy, malaise, and nonspecific pains). Diagnosis of suspected vasculitic neuropathy is made by a combined nerve and muscle biopsy, with serial section or skip-serial techniques (Chap. 363).

Approximately one-third of biopsy-proven cases of vasculitic neuropathy are “nonsystemic” in that the vasculitis appears to affect only peripheral nerve. Constitutional symptoms are absent, and the course is more indolent than that of PAN. The erythrocyte sedimentation rate may be elevated, but other tests for systemic disease are negative. Nevertheless, clinically silent involvement of other organs is likely, and vasculitis is frequently found in muscle biopsies at the same time as nerve.

Vasculitic neuropathy may also be seen as part of the vasculitis syndrome occurring in the course of other connective tissue disorders. The most frequent is rheumatoid arthritis, but ischemic neuropathy due to involvement of vasa nervorum may also occur in mixed cryoglobulinemia, Sjögren’s syndrome, Wegener’s granulomatosis, hypersensitivity angiitis (Chap. 306), and progressive systemic sclerosis (Chap. 303). Management of these neuropathies, including the “nonsystemic” vasculitic neuropathy, consists of treatment of the underlying condition as well as the aggressive use of glucocorticoids and other immunosuppressants, usually cyclophosphamide.

**ANTI-HU PARANEOPLASTIC NEUROPATHY**

This uncommon immune-mediated disorder manifests as a sensory neuropathy, i.e., selective damage to dorsal root ganglia. The onset is often asymmetric with dysesthesias and sensory loss in the limbs that soon progress to affect all limbs, the torso, and face. Marked sensory ataxia, pseudoarthrosis, and inability to walk, stand, or even sit unsupported are frequent features and are secondary to the extensive deafferentation. Subacute sensory neuropathy is often idiopathic, but ~25% of cases are paraneoplastic, primarily related to lung cancer, and most of those are small-cell lung cancer (SCLC) (Chap. 87). The target antigens are a family of RNA binding proteins (HuD, HuC, and Hel-N1) that in normal tissues are only expressed by neurons. The same proteins are usually expressed by SCLC, triggering in some patients an immune response characterized by antibodies and cytotoxic T cells that cross-react with the Hu proteins of the dorsal root ganglion neurons, resulting in immune-mediated neuronal destruction. An encephalomyelitis may accompany the sensory neuropathy and presumably has the same pathogenesis. Neurologic symptoms usually precede, by 1 year on average, the identification of SCLC. The sensory neuropathy runs its course in a few weeks or months and stabilizes, leaving the patient disabled. Most cases are unresponsible to treatment with glucocorticoids, IVlg, PE, or immunosuppressant drugs.

**FURTHER READING**


---

**366 MYASTHENIA GRAVIS AND OTHER DISEASES OF THE NEUROMUSCULAR JUNCTION**

Daniel B. Drachman

Myasthenia gravis (MG) is a neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is a decrease in the number of available acetylcholine receptors (AChRs) at neuromuscular junctions due to an antibody-mediated autoimmune attack. Treatment now available for MG is highly effective, although a specific cure has remained elusive.

**PATHOPHYSIOLOGY**

In the neuromuscular junction (Fig. 366-1), acetylcholine (ACh) is synthesized in the motor nerve terminal and stored in vesicles (quanta). When an action potential travels down a motor nerve and reaches the nerve terminal, ACh from 150 to 200 vesicles is released and combines with AChRs that are densely packed at the peaks of postsynaptic folds. The structure of the AChR has been fully elucidated; it consists of five subunits (2α, 1β, 1δ, and 1γ or e) arranged around a central pore. When ACh combines with the binding sites on the AChR, the channel in the AChR opens, permitting the rapid entry of cations, chiefly sodium, which produces depolarization at the end-plate region of the muscle fiber. If the depolarization is sufficiently large, it initiates an action potential that is propagated along the muscle fiber, triggering muscle contraction. This process is rapidly terminated by hydrolysis of ACh by acetylcholinesterase (AChE), which is present within the synaptic folds, and by diffusion of ACh away from the receptor.

In MG, the fundamental defect is a decrease in the number of available AChRs at the postsynaptic muscle membrane. In addition, the postsynaptic folds are flattened, or “simplified.” These changes result in decreased efficiency of neuromuscular transmission. Therefore, although ACh is released normally, it produces small end-plate potentials that may fail to trigger muscle action potentials. Failure of transmission at many neuromuscular junctions results in weakness of muscle contraction.

The amount of ACh released per impulse normally declines on repeated activity (termed presynaptic rundown). In the myasthenic patient, the decreased efficiency of neuromuscular transmission combined with the normal rundown results in the activation of fewer and fewer muscle fibers by successive nerve impulses and hence increasing weakness, or myasthenic fatigue. This mechanism also accounts for...
AChRs, acetylcholinesterase. See text for description of normal neuromuscular transmission. The MG junction show a normal nerve terminal; a reduced number of AChRs (stippling); flattened, simplified postsynaptic folds; and a widened synaptic space.

**Anticholinesterase Test**

Drugs that inhibit the enzyme AChE allow ACh to interact repeatedly with the limited number of AChRs, producing improvement in the strength of myasthenic muscles. Edrophonium is used most commonly for diagnostic testing because of the rapid onset (30 s) and short duration (about 5 min) of its effect. An objective endpoint must be selected to evaluate the effect of edrophonium. The examiner should focus on one or more unequivocally weak muscle groups and evaluate their strength objectively. For example, weakness of extraocular muscles, impairment of speech, or the length of time that the patient can maintain the arms in forward abduction may be useful measures. An initial dose of 2 mg of edrophonium is given intravenously. If definite improvement occurs, the test is considered positive and is terminated. If there is no change, the patient is given an additional 8 mg intravenously. The dose is administered in two parts because some patients react to edrophonium with unpleasant side effects such as nausea, diarrhea, salivation, fasciculations, and rarely with severe symptoms of syncope or bradycardia. Atropine (0.6 mg) should be drawn up in a syringe, ready for intravenous administration if these symptoms become troublesome.

False-positive tests occur in occasional patients with other neurologic disorders, such as amyotrophic lateral sclerosis, and in placebo reactors. False-negative or equivocal tests may also occur. In some cases it is helpful to use a longer-acting drug such as neostigmine (15 mg given orally), since this permits more time for detailed evaluation.

**Diagnosis and Evaluation** (Table 366-1) The diagnosis is suspected on the basis of weakness and fatigability in the typical distribution described above, without loss of reflexes or impairment of sensation or other neurologic function. The suspected diagnosis should always be confirmed definitively before treatment is undertaken; this is essential because (1) other treatable conditions may closely resemble MG, and (2) the treatment of MG may involve surgery and the prolonged use of drugs with adverse side effects.

### Table 366-1 Diagnosis of Myasthenia Gravis (MG)

<table>
<thead>
<tr>
<th>History</th>
<th>Weakness in characteristic distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diplopia, ptosis, weakness</td>
<td>Fluctuation and fatigue: worse with repeated activity, improved by rest</td>
</tr>
</tbody>
</table>

**Laboratory testing**

- Anti-AChR radioimmunoassay: ~85% positive in generalized MG; 50% in ocular MG; definite diagnosis if positive; negative result does not exclude MG, ~40% of AChR antibody-negative patients with generalized MG have anti-MuSK antibodies.
- Edrophonium chloride (Tension) 2 mg + 8 mg IV; highly probable diagnosis if unequivocally positive.
- Repetitive nerve stimulation; decrement of >15% at 3 Hz: highly probable.
- Single-fiber electromyography: blocking and jitter, with normal fiber density; confirmatory, but not specific.
- For ocular or cranial MG: exclude intracranial lesions by CT or MRI.

**Note:** AChR, acetylcholine receptor; CT, computed tomography; MRI, magnetic resonance imaging; MuSK, muscle specific tyrosine kinase.

of strength. In virtually all instances, it is desirable to carry out further testing to establish the diagnosis of MG definitively.

**Electrodiagnostic Testing** Repetitive nerve stimulation often provides helpful diagnostic evidence of MG. Anti-AChE medication is stopped 6 to 24 h before testing. It is best to test weak muscles or proximal muscle groups. Electric shocks are delivered at a rate of two or three per second to the appropriate nerves, and action potentials are recorded from the muscles. In normal individuals, the amplitude of the evoked muscle action potentials does not change at these rates of stimulation. However, in myasthenic patients there is a rapid reduction in the amplitude of the evoked responses of >10 to 15%. As a further test, a single dose of edrophonium may be given to prevent or diminish this decremental reaction.

**Antiacetylcholine Receptor Antibody** As noted above, anti-AChR antibodies are detectable in the serum of ~85% of all myasthenic patients but in only about 50% of patients with weakness confined to the ocular muscles. The presence of anti-AChR antibodies is virtually diagnostic of MG, but a negative test does not exclude the disease. The measured level of anti-AChR antibody does not correspond well with the severity of MG in different patients. However, in an individual patient, a treatment-induced fall in the antibody level often correlates with clinical improvement. Recently, antibodies to muscle-specific kinase (MuSK) have been found to be present in about 40% of AChR antibody-negative patients with generalized MG, and their presence is a useful diagnostic test in these patients. MuSK antibodies are not present in ACHR antibody-positive patients or in patients with MG limited to ocular muscles. The role of these antibodies in the pathogenesis of MG is as yet uncertain. MuSK is known to participate in clustering of AChRs at neuromuscular junctions during development.

**Inherited Myasthenic Syndromes** The congenital myasthenic syndromes (CMS) comprise a heterogeneous group of disorders of the neuromuscular junction that are not autoimmune but rather are due to genetic mutations in which virtually any component of the neuromuscular junction may be affected. Alterations in function of the presynaptic nerve terminal or in the various subunits of the AChR or AChE have been identified in the various forms of CMS. These disorders share many of the clinical features of autoimmune MG, including weakness and fatigability of skeletal muscles, in some cases involving extraocular muscles (EOMs), lids, and proximal muscles, similar to the distribution in autoimmune MG. CMS should be suspected when symptoms of myasthenia have begun in infancy or childhood and AChR antibody tests are consistently negative. Features of four of the most common forms of CMS are summarized in Table 366-2. Although clinical features and electrodiagnostic and pharmacologic tests may suggest the correct diagnosis, sophisticated electrophysiologic and molecular analysis are required for precise elucidation of the defect; this may lead to helpful treatment as well as genetic counseling. In the forms that involve the AChR, a wide variety of mutations have been identified in each of the subunits, but the ε subunit is affected in ~75% of these cases. In most of the recessively inherited forms of CMS, the mutations are heteroallelic; that is, different mutations affect each of the two alleles are present.

**Differential Diagnosis** Other conditions that cause weakness of the cranial and/or somatic musculature include the nonautoimmune CMS discussed above, drug-induced myasthenia, Lambert-Eaton myasthenic syndrome (LEMS), neuroasthenia, hyperthyroidism, botulism, intracranial mass lesions, and progressive external ophthalmoplegia. Treatment with penicillamine (used for scleroderma or rheumatoid arthritis) may result in true MG, but the weakness is usually mild, and recovery occurs within weeks or months after discontinuing its use. Aminoglycoside antibiotics or procainamide can cause exacerbation of weakness in myasthenic patients; very large doses can cause neuromuscular weakness in normal individuals.

LEMS is a presynaptic disorder of the neuromuscular junction that can cause weakness similar to that of MG. The proximal muscles of the lower limbs are most commonly affected, but other muscles may be involved as well. Cranial nerve findings, including ptosis of the eyelids and diplopia, occur in up to 70% of patients and resemble features of MG. However, the two conditions are readily distinguished, since patients with LEMS have depressed or absent reflexes, show autonomic changes such as dry mouth and impotence, and show decremental rather than decremental responses on repetitive nerve stimulation. LEMS is caused by autoantibodies directed against P/Q type calcium channels at the motor nerve terminals, which can be detected in ~85% of LEMS patients by radioimmunoassay. These autoantibodies result in impaired release of Ach from nerve terminals. A majority of patients with this syndrome have an associated malignancy, most commonly small-cell carcinoma of the lung, which is thought to trigger the autoimmune response. The diagnosis of LEMS may signal the presence of the tumor long before it would otherwise be detected, permitting early removal. Treatment of the neuromuscular disorder involves plasmapheresis and immunosuppression, as for MG, 3,4-Diaminopyridine (3-DAP) and pyridostigmine may be symptomatically
helpful in LEMS. 3,4-DAP acts by blocking potassium channels, which results in prolonged depolarization of the motor nerve terminals and thereby enhances ACh release. Pyridostigmine prolongs the action of ACh, allowing repeated interactions with AChRs.

Neurasthenia is the historic term for a myasthenia-like fatigue syndrome without an organic basis. These patients may present with subjective symptoms of weakness and fatigue, but muscle testing usually reveals the “jerky release” or “give-away weakness” characteristic of nonorganic disorders; the complaint of fatigue in these patients means tiredness or apathy rather than decreasing muscle power on repeated effort. Hyperthyroidism is readily diagnosed or excluded by tests of thyroid function, which should be carried out routinely in patients with suspected MG. Abnormalities of thyroid function (hyper- or hypothyroidism) may increase myasthenic weakness. Botulism can cause myasthenic-like weakness, but the pupils are often dilated, and repetitive nerve stimulation gives an incremental response. Diplopia that mimics the symptoms of MG may occasionally be due to an intracranial mass lesion that compresses nerves to the EOMs (e.g., sphenoid ridge meningioma), but magnetic resonance imaging (MRI) of the head and orbits usually reveals the lesion.

Progressive external ophthalmoplegia is a rare condition resulting in weakness of the EOMs, which may be accompanied by weakness of the proximal muscles of the limbs and other systemic features. Most patients with this condition have mitochondrial disorders that can be detected on muscle biopsy (Chap. 368).

Search for Associated Conditions (Table 366-3) Myasthenic patients have an increased incidence of several associated disorders. Thymic abnormalities occur in ~75% of patients, as noted above. Neoplastic change (thymoma) may produce enlargement of the thymus, which is detected by computed tomography (CT) or MRI scanning of the anterior mediastinum. A thymic shadow on CT scan may normally be present through young adulthood, but enlargement of the thymus in a patient >40 years old is highly suspicious of thymoma. Hyperthyroidism occurs in 3 to 5% of patients and may aggravate the myasthenic weakness. Tests of thyroid function should be obtained. Because of the association of MG with other autoimmune disorders, blood tests for rheumatoid factor and antinuclear antibodies should be carried out in all patients. Chronic infection of any kind can exacerbate MG and should be sought carefully. Finally, measurements of ventilatory function are valuable because of the frequency and seriousness of respiratory impairment in myasthenic patients.

Because of the side effects of glucocorticoids and other immunosuppressive agents used in the treatment of MG, a thorough medical investigation should be undertaken, searching specifically for evidence of chronic or latent infection (such as tuberculosis or hepatitis), hypertension, diabetes, renal impairment, and glaucoma.

**TABLE 366-3** Disorders Associated with Myasthenia Gravis and Recommended Laboratory Tests

<table>
<thead>
<tr>
<th>Associated disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disorders of the thymus: thymoma, hyperplasia</td>
</tr>
<tr>
<td>Other autoimmune disorders: Hashimoto’s thyroiditis, Graves’ disease, rheumatoid arthritis, lupus erythematosus, skin disorders, family history of autoimmune disorder</td>
</tr>
<tr>
<td>Disorders or circumstances that may exacerbate myasthenia gravis: hypothyroidism or hyperthyroidism, occult infection, medical treatment for other conditions (aminoglycoside antibiotics, quinine, antiarrhythmic agents)</td>
</tr>
<tr>
<td>Disorders that may interfere with therapy: tuberculosis, diabetes, peptic ulcer, gastrointestinal bleeding, renal disease, hypertension, asthma, osteoporosis, obesity</td>
</tr>
</tbody>
</table>

**Recommended laboratory tests or procedures**

- CT or MRI of mediastinum
- Tests for lupus erythematosus, antinuclear antibody, rheumatoid factor, antithyroid antibodies
- Thyroid-function tests
- PPD skin test
- Chest radiography
- Fasting blood glucose measurement
- Pulmonary-function tests
- Bone densitometry in older patients

**Note:** CT, computed tomography; MRI, magnetic resonance imaging; PPD, purified protein derivative.


**TABLE 366-3** Disorders Associated with Myasthenia Gravis

<table>
<thead>
<tr>
<th>Associated disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disorders of the thymus: thymoma, hyperplasia</td>
</tr>
<tr>
<td>Other autoimmune disorders: Hashimoto’s thyroiditis, Graves’ disease, rheumatoid arthritis, lupus erythematosus, skin disorders, family history of autoimmune disorder</td>
</tr>
<tr>
<td>Disorders or circumstances that may exacerbate myasthenia gravis: hypothyroidism or hyperthyroidism, occult infection, medical treatment for other conditions (aminoglycoside antibiotics, quinine, antiarrhythmic agents)</td>
</tr>
<tr>
<td>Disorders that may interfere with therapy: tuberculosis, diabetes, peptic ulcer, gastrointestinal bleeding, renal disease, hypertension, asthma, osteoporosis, obesity</td>
</tr>
</tbody>
</table>

**Recommended laboratory tests or procedures**

- CT or MRI of mediastinum
- Tests for lupus erythematosus, antinuclear antibody, rheumatoid factor, antithyroid antibodies
- Thyroid-function tests
- PPD skin test
- Chest radiography
- Fasting blood glucose measurement
- Pulmonary-function tests
- Bone densitometry in older patients

**Note:** CT, computed tomography; MRI, magnetic resonance imaging; PPD, purified protein derivative.

This approach. Fractory patients and administered only in a facility fully familiar with cyclophosphamide. This procedure should be reserved for truly re-

They express the enzyme aldehydedehydrogenase, which hydrolyzes tem. At high doses, cyclophosphamide eliminates mature lympho-

lasting (possibly permanent) benefit by "rebooting" the immune systems. Agents, a course of high-dose cyclophosphamide may induce long-

pheresis should be undertaken. For the intermediate term, glucocorticoids and cyclosporine generally produce clinical improvement within a period of 1 to 3 months. The beneficial effects of azathioprine and mycophenolate mofetil usually begin after many months (up to a year), but these drugs have advantages for the long-term treatment of patients with MG. For the occasional patient with MG that is genuinely refractory to optimal treatment with conventional immunosuppressive agents, a course of high-dose cyclophosphamide may induce long-

This dose is maintained for 1 to 3 months and then is gradually modi-

ified to an alternate-day regimen over the course of an additional 1 to 3 months; the goal is to reduce the dose on the "off day" to zero or to a minimal level. Generally, patients begin to improve within a few weeks after reaching the maximum dose, and improvement continues to progress for months or years. The prednisone dosage may gradually be reduced, but usually months or years may be needed to determine the minimum effective dose, and close monitoring is required. Few patients are able to do without immunosuppressive agents entirely. Patients on long-term glucocorticoid therapy must be followed carefully to prevent or treat adverse side effects. The most common errors in glucocorticoid treatment of myasthenic patients include (1) insufficient persistence—improvement may be delayed and gradual; (2) tapering too rapid, or excessive tapering of dosage; and (3) lack of attention to prevention and treatment of side effects. —The management of patients treated with glucocorticoids is discussed in Chap. 321.

Other immunosuppressive drugs Azathioprine, cyclosporine, myco-

phenolate mofetil, or occasionally cyclophosphamide is effective in many patients, either alone or in combination with glucocorticoid ther-

apy. Azathioprine has been the most widely used of these drugs be-

cause of its relative safety in most patients and long track record. Its therapeutic effect may add to that of glucocorticoids and/or allow the glucocorticoid dose to be reduced. However, up to 10% of patients are unable to tolerate azathioprine because of idiosyncratic reactions consisting of flulike symptoms of fever and malaise, bone marrow depression, or abnormalities of liver function. An initial dose of 50 mg/ d should be used to test for adverse side effects. If this dose is tolerated, it is increased gradually until the white blood count falls to ~3000 to 4000/μL. In patients who are receiving glucocorticoids concurrently, leukocytosis precludes the use of this measure. A reduction of the lymphocyte count to <1000/μL and/or an increase of the mean corpuscular volume of red blood cells may be used as indications of adequacy of azathioprine dosage. The typical dosage range is 2 to 3 mg/kg total body weight. The beneficial effect of azathioprine takes at least 3 to 6 months to begin and even longer to peak. In patients taking azathioprine, allopurinol should never be used to treat hyper-

uricemia, because the two drugs share a common degradation pathway; the result may be severe bone marrow depression due to increased effects of the azathioprine.

Cyclosporine is approximately as effective as azathioprine and is being 

used increasingly in the management of MG. Its beneficial effect appears more rapidly than that of azathioprine. It may be used alone but is usually used as an adjunct to glucocorticoids to permit reduction of the glucocorticoid dose. The usual dose of cyclosporine is 4 to 5 mg/kg per day, given in two equally divided doses (to minimize side effects). Side effects of cyclosporine include hypertension and nephrotoxicity, which must be closely monitored. "Trough" blood levels of cyclosporine are measured 12 h after the evening dose. The therapeutic range, as measured by radioimmunoassay, is 150 to 200 ng/L.

Mycophenolate mofetil is also useful in the treatment of MG. A dose of 1 g to 1.5 g bid is recommended. Its mechanism of action involves inhibition of purine synthesis by the de novo pathway. Since lymphocytes lack the alternative salvage pathway that is present in all other cells, mycophenolate inhibits proliferation of lymphocytes but not proliferation of other cells. It does not kill or eliminate preexisting autoreactive lymphocytes, and therefore clinical improvement may be delayed for many months to a year, until the preexisting autoreactive lymphocytes die spontaneously. The advantage of mycophenolate lies in its relative lack of adverse side effects, with only occasional production of diarrhea and rare development of leukopenia. This drug may become the choice for long-term treatment of myasthenic patients. Unfortunately, the present cost of mycophenolate may be prohibitively high.

Cyclophosphamide is reserved for occasional patients refractory to the other drugs (see above for discussion of high-dose cyclophospha-

mide treatment).
Plasmapheresis and Intravenous Immunoglobulin

Plasmapheresis has been used therapeutically in MG. Plasma, which contains the pathogenic antibodies, is mechanically separated from the blood cells, which are returned to the patient. A course of five exchanges (3 to 4 L per exchange) is generally administered over a 2-week period. Plasmapheresis produces a short-term reduction in anti-AChR antibodies, with clinical improvement in many patients. It is useful as a temporary expedient in seriously affected patients or to improve the patient’s condition prior to surgery (e.g., thymectomy).

The indications for the use of IVIg are the same as those for plasma exchange: to produce rapid improvement to help the patient through a difficult period of myasthenic weakness or prior to surgery. This treatment has the advantages of not requiring special equipment or large-bore venous access. The usual dose is 2 g/kg, which is typically administered over 5 days (400 mg/kg per day). If tolerated, the course of IVIg can be shortened to administer the entire dose over a 3-day period. Improvement occurs in about 70% of patients, beginning during treatment, or within 4 to 5 days thereafter, and continuing for weeks to months. The mechanism of action of IVIg is not known; the treatment has no consistent effect on the measurable amount of circulating AChR antibody. Adverse reactions are generally not serious but include headache, fluid overload, and rarely aseptic meningitis or renal shutdown. IVIg should rarely be used as a long-term treatment in place of rationally managed immunosuppressive therapy. Unfortunately, there is a growing tendency for physicians unfamiliar with immunosuppressive treatments to rely on repeated IVIg infusions, which are inconvenient, usually produce only intermittent benefit, and are costly. The intermediate and long-term treatment of myasthenic patients requires other methods of therapy outlined earlier in this chapter.

Management of Myasthenic Crisis

Myasthenic crisis is defined as an exacerbation of weakness sufficient to endanger life; it usually consists of respiratory failure caused by diaphragmatic and intercostal muscle weakness. Crisis rarely occurs in properly managed patients. Treatment should be carried out in an intensive care unit staffed with physicians experienced in the management of MG, respiratory insufficiency, infectious disease, and fluid and electrolyte therapy. The possibility that the deterioration could be due to excessive anticholinesterase medication (“cholinergic crisis”) is best excluded by temporarily stopping anticholinesterase drugs. The most common cause of crisis is intercurrent infection. This should be treated immediately, because the mechanical and immunologic defenses of the patient can be assumed to be compromised. The myasthenic patient with fever and early infection should be treated like other immunocompromised patients. Early and effective antibiotic therapy, respiratory assistance, and pulmonary physiotherapy are essentials of the treatment program. As discussed above, plasmapheresis or IVIg is frequently helpful in hastening recovery.

**PATIENT ASSESSMENT**

In order to evaluate the effectiveness of treatment as well as drug-induced side effects, it is important to assess the patient’s clinical status at baseline and on repeated interval examinations in a systematic manner. Because of the variability of symptoms of MG, the interval history as well as findings on examination must be taken into account. The most useful clinical tests include forward arm abduction time (up to a full 5 min), forced vital capacity, range of eye movements, and time to development of ptosis on upward gaze. Manual muscle testing or, preferably, quantitative dynamometry of limb muscles, especially proximal muscles, is also important. An interval form can provide a succinct summary of the patient’s status and a guide to treatment results; an abbreviated form is shown in Fig. 366-3. A progressive reduction in the patient’s AChR antibody level also provides clinically valuable confirmation of the effectiveness of treatment; conversely, a rise in AChR antibody levels during tapering of immunosuppressive medication may predict clinical exacerbation. For reliable quantitative measurement of AChR antibody levels, it is best to compare antibody levels from prior frozen serum aliquots with current serum samples in simultaneously run assays.

**FURTHER READING**


Skeletal muscle diseases, or myopathies, are disorders with structural changes or functional impairment of muscle. These conditions can be differentiated from other diseases of the motor unit (e.g., lower motor neuron or neuromuscular junction pathologies) by characteristic clinical and laboratory findings. Myasthenia gravis and related disorders are discussed in Chap. 366; muscular dystrophies and inherited, metabolic, and toxic myopathies in Chap. 368; inflammatory muscle diseases and inclusion body myositis in Chap. 369.

**CLINICAL FEATURES**

**Muscle Weakness** Symptoms of muscle weakness can be either intermittent or persistent. Disorders causing **intermittent weakness** (Fig. 367-1) include myasthenia gravis, periodic paralyses (hypokalemic, hyperkalemic, and paramyotonia congenita), and metabolic energy deficiencies of glycolysis (especially myophosphorylase deficiency) and fatty acid utilization (carnitine palmitoyltransferase deficiency). The states of energy deficiency cause activity-related muscle breakdown accompanied by myoglobinuria, appearing as light-brown- to dark-brown-colored urine. Most muscle disorders cause **persistent weakness** (Fig. 367-2). In the majority of these, including most types of muscular dystrophy, polymyositis, and dermatomyositis, the proximal muscles are weaker than the distal, and the facial muscles are spared, a pattern referred to as **limb-girdle**. The differential diagnosis is more restricted for other patterns of weakness. Facial weakness (difficulty with eye closure and impaired smile) and scapular winging (Fig. 367-3) are characteristic of facioscapulohumeral dystrophy. Facial and distal limb weakness associated with hand grip myotonia is virtually diagnostic of myotonic dystrophy. When other cranial nerve muscles are weak, causing ptosis and extraocular muscle weakness without diplopia, the most important disorders to consider include oculopharyngeal muscular dystrophy, mitochondrial myopathies, or myotubular myopathy. A pathognomonic pattern exclusive to inclusion body myositis includes loss of strength in both proximal and distal muscles, hand grip weakness, and wasting of quadriceps muscles. Less frequently, but important diagnostically, is the presence of a dropped head syndrome indicative of selective neck extensor muscle weakness. The most common neuromuscular diseases causing this pattern of weakness include myasthenia gravis, polymyositis, and amyotrophic lateral sclerosis. A final pattern, recognized because of preferential distal extremity weakness, is typical of a unique category of muscular dystrophy, the distal myopathies (Chap. 368).

It is important to examine functional capabilities to help disclose certain patterns of weakness (Table 367-1). The Gowers’ sign (Fig. 367-4) is particularly useful. Observing the gait of an individual may disclose a lordotic posture caused by combined trunk and hip weakness, frequently exaggerated by toe walking (Fig. 367-5). A waddling gait is caused by the inability of weak hip muscles to prevent hip drop or hip dip. Hyperextension of the knee (genu recurvatum or back-kneeling) is characteristic of quadriceps muscle weakness; and a step-over gait, due to footdrop, accompanies distal weakness.

Any disorder causing muscle weakness may be accompanied by **fatigue**, referring to an inability to maintain or sustain a force (pathologic fatigability). This condition must be differentiated from asthenia, a type of fatigue caused by excess tiredness or lack of energy. Associated symptoms may help differentiate asthenia and pathologic fatigability. Asthenia is often accompanied by a tendency to avoid physical activities, complaints of daytime sleepiness, necessity for frequent naps, and difficulty concentrating on activities such as reading. There may be feelings of overwhelming stress and depression. Thus, asthenia is not a myopathy. In contrast, pathologic fatigability occurs in disorders of neuromuscular transmission and in disorders altering energy production, including defects in glycolysis, lipid metabolism, or mitochondrial energy production. Pathologic fatigability also occurs in chronic myopathies because of difficulty accomplishing a task with less muscle. Pathologic fatigability is accompanied by abnormal clinical or laboratory findings. Fatigue without those supportive features almost never indicates a primary muscle disease.

**Muscle Pain (Myalgias), Cramps, and Stiffness** Muscle pain can be associated with cramps, spasms, contractures, and stiffness (Chap. 21). In distinction, true myalgia (muscle aching), which can be localized or generalized, may be accompanied by weakness, tenderness to palpation, or swelling. Certain drugs cause true myalgia (Table 367-2).

There are two painful muscle conditions of particular importance, neither of which is associated with muscle weakness. **Fibromyalgia** is a common, yet poorly understood type of myofascial pain syndrome.
Persistent Weakness

Patterns of Weakness on Neurologic Exam

- Proximal > distal
  - PM; DM: muscular dystrophies
- Ptosis, EOM
  - OPMD; mitochondrial myopathy; myotubular myopathy
- Facial and scapular winging
  - FSHD
- Facial, distal, quadriceps; handgrip myotonia
  - Myotonic muscular dystrophy
- Proximal & distal (hand grip), & quadriceps
  - IBM
- Distal
  - Distal myopathy
- Dropped head
  - MG; PM; ALS

Myopathic EMG confirms muscle disease and excludes ALS
Repetitive nerve stimulation indicates MG
CK elevation supports myopathy

May need DNA testing for further distinction of inherited myopathies

Muscle biopsy will help distinguish many disorders

FIGURE 367-2
Diagnostic evaluation of persistent weakness. Examination reveals one of seven patterns of weakness. The pattern of weakness in combination with the laboratory evaluation leads to a diagnosis. EOM, extracocular muscle; OPMD, oculopharyngeal muscular dystrophy; FSHD, facioscapulohumeral muscular dystrophy; IBM, inclusion body myositis; DM, dermatomyositis; PM, polymyositis; MG, myasthenia gravis; ALS, amyotrophic lateral sclerosis; CK, creatine kinase.

Patients complain of severe muscle pain and tenderness and have specific painful trigger points, sleep disturbances, and easy fatigability. Serum creatine kinase (CK) and erythrocyte sedimentation rate (ESR) are normal (Chap. 315). Polymyalgia rheumatica occurs mainly in patients >50 years and is characterized by stiffness and pain in the shoulders, lower back, hips, and thighs (Chap. 306). The ESR is elevated, while serum CK, electromyography (EMG), and muscle biopsy are normal. Temporal arteritis, an inflammatory disorder of medium- and large-sized arteries, usually involving one or more branches of the carotid artery, may accompany polymyalgia rheumatica. Vision is threatened due to ischemic optic neuritis. Glucocorticoids can relieve the myalgias and protect against visual loss.

Localized muscle pain is most often traumatic. A common cause of sudden abrupt-onset pain is a ruptured tendon, which leaves the muscle belly appearing rounded and shorter in appearance compared to the normal side. The biceps brachii and Achilles tendons are particularly vulnerable to rupture. Infection or neoplastic infiltration of the muscle is a rare cause of localized muscle pain.

A muscle cramp or spasm is a painful, involuntary, localized, muscle contraction with a visible or palpable hardening of the muscle. Cramps are abrupt in onset, short in duration, and may cause abnormal posturing of the joint. The EMG shows firing of motor units, reflecting an origin from spontaneous neural discharge. Muscle cramps often occur in neurogenic disorders, especially motor neuron disease (Chap. 353), radiculopathies, and polynuropathies (Chap. 363), but are not a feature of most primary muscle diseases. Duchenne muscular dystrophy (Chap. 368) is an exception since calf muscle complaints are a common complaint. Muscle cramps are also common during pregnancy.

A muscle contracture is different from a muscle cramp. In both conditions, the muscle becomes hard, but a contracture is associated with energy failure in glycolytic disorders. The muscle is unable to relax after an active muscle contraction. The EMG shows electrical silence. Confusion is created because contracture also refers to a muscle that cannot be passively stretched to its proper length (fixed contracture) because of fibrosis. In some muscle disorders, especially Emery-Dreifuss muscular dystrophy and Bethlem myopathy (Chap.

<table>
<thead>
<tr>
<th>Functional Impairment</th>
<th>Muscle Weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inability to forcibly close eyes</td>
<td>Upper facial muscles</td>
</tr>
<tr>
<td>Impaired pucker</td>
<td>Lower facial muscles</td>
</tr>
<tr>
<td>Inability to raise head from prone position</td>
<td>Neck extensor muscles</td>
</tr>
<tr>
<td>Inability to raise head from supine position</td>
<td>Neck flexor muscles</td>
</tr>
<tr>
<td>Inability to raise arms above head</td>
<td>Proximal arm muscles (may be only scapular stabilizing muscles)</td>
</tr>
<tr>
<td>Inability to walk without hyperextending knee (backkneeing or genu recurvatum)</td>
<td>Knee extensor muscles</td>
</tr>
<tr>
<td>Inability to walk with heels touching the floor (toe walking)</td>
<td>Shortening of the Achilles tendon</td>
</tr>
<tr>
<td>Inability to lift foot while walking (steppage gait or footdrop)</td>
<td>Anterior compartment of leg</td>
</tr>
<tr>
<td>Inability to walk without a waddling gait</td>
<td>Hip muscles</td>
</tr>
<tr>
<td>Inability to get up from the floor without climbing up the extremities (Gowers’ sign)</td>
<td>Hip muscles</td>
</tr>
<tr>
<td>Inability to get up from a chair without using arms</td>
<td>Hip muscles</td>
</tr>
</tbody>
</table>

FIGURE 367-3
Facioscapulohumeral dystrophy with prominent scapular winging.
fixed contractures occur early and represent distinctive features of the disease.

Muscle stiffness can refer to different phenomena. Some patients with inflammation of joints and periarticular surfaces feel stiff. This condition is different from the disorders of hyperexcitable motor nerves causing stiff or rigid muscles (Chap. 21). In stiff-person syndrome spontaneous discharges of the motor neurons of the spinal cord cause involuntary muscle contractions mainly involving the axial (trunk) and proximal lower extremity muscles. The gait becomes stiff and labored, with hyperlordosis of the lumbar spine. Superimposed episodic muscle spasms are precipitated by sudden movements, unexpected noises, and emotional upset. The muscles relax during sleep. Serum antiluminal acid dehydrogenase antibodies are present in approximately two-thirds of cases. In neuromyotonia (Isaac’s syndrome) there is hyperexcitability of the peripheral nerves manifesting as continuous muscle fiber activity. Myokymia (continuous undulations of muscle) and impaired muscle relaxation are the result. Muscles of the leg are stiff, and the constant contractions of the muscle cause increased sweating of the extremities. This peripheral nerve hyperexcitability is antibody-mediated, targeted against voltage-gated potassium channels. The site of origin of the spontaneous nerve discharges is principally in the distal portion of the motor nerves.

Myotonia is a condition of prolonged muscle contraction followed by slow muscle relaxation. It always follows muscle activation, usually voluntary, but may be elicited by mechanical stimulation (percussion myotonia) of the muscle. Myotonia typically causes difficulty in releasing objects after a firm grasp. In myotonic muscular dystrophy, weakness accompanies myotonia. Myotonia also occurs with myotonia congenita (a chloride channel disorder), but in this condition muscle weakness is not prominent. Paramyotonia congenita (a sodium channel disorder more closely aligned with hyperkalemic periodic paralysis) is named for a paradoxical phenomenon whereby the prolonged muscle contraction, with features virtually indistinguishable from myotonia, is exacerbated by repeated muscle contractions (Chap. 368). In hypokalemic periodic paralysis, myotonia of the eyelids may be present but limb muscles are usually spared.

Muscle Enlargement and Atrophy In most myopathies muscle tissue is replaced by fat and connective tissue, but the size of the muscle is usually not affected. However, in Duchenne and Becker muscular dystrophies, enlarged calf muscles are typical. In the patients with these forms of dystrophy, the enlargement represents true muscle hypertrophy; hence the term “pseudohypertrophy” should be avoided when referring to these patients. The calf muscles remain very strong even late in the course of these disorders. Muscle enlargement can also result from infiltration by sarcoid granulomas, amyloid deposits, bacterial and parasitic infections, and focal myositis.

### Table 367-2 Drugs That Cause True Myalgia

<table>
<thead>
<tr>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statins</td>
</tr>
<tr>
<td>Gemfibrozil</td>
</tr>
<tr>
<td>Vincristine</td>
</tr>
<tr>
<td>Zidovudine</td>
</tr>
<tr>
<td>Cyclosporine</td>
</tr>
<tr>
<td>Gold</td>
</tr>
<tr>
<td>Danazol</td>
</tr>
<tr>
<td>Cimetidine</td>
</tr>
<tr>
<td>Methadone</td>
</tr>
</tbody>
</table>

* 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
A limited battery of tests can be used to evaluate a suspected myopathy. Nearly all patients require serum enzyme level measurements and electrodiagnostic studies as screening tools to differentiate muscle disorders from other motor unit diseases. The other tests described—DNA studies, the forearm exercise test, and muscle biopsy—are used to diagnose specific types of myopathies.

**Serum Enzymes** CK is the preferred muscle enzyme to measure in the evaluation of myopathies. Damage to muscle causes the CK to leak from the muscle fiber to the serum. The MM isoenzyme predominates in skeletal muscle, while CK-MB is the marker for cardiac muscle. Serum CK can be elevated in normal individuals without provocation, presumably on a genetic basis or after strenuous activity, minor trauma (including the EMG needle), a prolonged muscle cramp, or a generalized seizure. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactic dehydrogenase (LDH) are enzymes sharing an origin in both muscle and liver. Problems arise when the levels of these enzymes are found to be elevated in a routine screening battery, leading to the erroneous assumption that liver disease is present when in fact muscle could be the cause. An elevated gamma-glutamyl transferase (GGT) helps to establish a liver origin since this enzyme is not found in muscle. Aldolase is often thought to be a muscle-specific enzyme but is also present in liver.

**Electrodiagnostic Studies** EMG, repetitive nerve stimulation, and nerve conduction studies (Chap. 363) are essential methods for evaluation of the patient with suspected muscle disease. In combination they provide the information necessary to differentiate myopathies from neuromyopathies and neuromuscular junction diseases. Certain features of the EMG will point to an acquired, inflammatory muscle disorder (e.g., irritability on needle placement) versus a long-standing myopathic disorder (lack of irritability) that is more suggestive of a dystrophic process. Both inflammatory and noninflammatory myopathies share findings characterized by excessively recruited (too many) compound muscle action potentials for the degree of effort expended. This degree of recruitment is necessary to compensate for loss of muscle fibers related to the underlying process. The EMG can also be invaluable in helping to choose an appropriately affected muscle to sample for biopsy. The EMG can be used to fully characterize suspected involuntary activity seen during the examination, such as myokymia and myotonia.

**DNA Analysis** Advances in molecular diagnosis have evolved over the past decade and now serve as important tools for diagnosis. Certain muscle disorders can be definitively diagnosed by DNA analysis; these are fully discussed in Chap. 368. Nevertheless, important limitations need to be mentioned in seeking a molecular diagnosis. For example, in some disorders, such as Duchenne and Becker dystrophies, two-thirds of patients have deletion- or duplication-mutations that are easy to detect, while the remainder have point mutations that are much more difficult to find. For patients without identifiable gene defects, the muscle biopsy remains the main diagnostic tool.

**Forearm Exercise Test** In myopathies with intermittent symptoms, and especially those associated with myoglobinuria, there may be a defect in glycolysis. Many variations of the forearm exercise test exist. For safety, the test should not be performed under ischemic conditions to avoid an unnecessary insult to the muscle, causing rhabdomyolysis. The test is performed by placing a small indwelling catheter into an antecubital vein. A baseline blood sample is obtained for lactic acid and ammonia. The forearm muscles are exercised by asking the patient to vigorously squeeze a sphygmomanometer bulb for 1 min. Blood is then obtained at intervals of 1, 2, 4, 6, and 10 min for comparison with the baseline sample. Normal controls must be established for each laboratory. A three- to fourfold rise in lactic acid is typical. The simultaneous measurement of ammonia serves as a control, since it should also rise with exercise. In patients with myophosphorylase deficiency or other glycolytic defects (Chap. 368), the lactic acid rise will be absent or below normal, while the rise in ammonia will reach control values. If there is lack of effort, neither lactic acid nor ammonia will rise. Patients with selective failure to increase ammonia may have myoadenylate deaminase deficiency. This condition has been reported to be a cause of myoglobinuria, but deficiency of this enzyme in asymptomatic individuals makes interpretation controversial.

**Muscle Biopsy** Muscle biopsy analysis is an important step in establishing the final diagnosis of suspected myopathy. The microscopic evaluation uses a combination of techniques—histochemistry, immunocytochemistry with a battery of antibodies, and electron microscopy. Not all techniques need to be used on every case. A specific diagnosis can be established in many disorders. A combination of stains to identify mononuclear cells (polymyositis), complement (dermatomyositis), and amyloid (inclusion body myositis) helps to distinguish the inflammatory myopathies. Mitochondrial and metabolic (e.g., myophosphorylase and acid maltase deficiencies) myopathies demonstrate distinctive histochemical and electron-microscopic profiles. A battery of antibodies is available for the identification of missing components of the dystrophin-glycoprotein complex and related proteins to help diagnose specific types of muscular dystrophies. In addition, the congenital myopathies have distinctive histologic features essential for diagnosis.

**FURTHER READING**


VERNINO S, LENNON VA: Ion channel and striatal antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 26: 70, 2002

**368 MUSCULAR DYSTROPHIES AND OTHER MUSCLE DISEASES**

Robert H. Brown, Jr., Jerry R. Mendell

The muscle disorders discussed in this chapter include diseases that cause acute, subacute, and chronic muscle weakness. Some cause pain in addition to or instead of weakness. Dermatomyositis and polymyositis are discussed in Chap. 369.

**HEREDITARY MYOPATHIES**

Muscular dystrophy refers to a group of hereditary progressive diseases each with unique phenotypic and genetic features (Table 368-1).

**DUCHENNE MUSCULAR DYSTROPHY** This X-linked recessive disorder, sometimes also called pseudohypertrophic muscular dystrophy, has an incidence of ~30 per 100,000 live-born males.

**Clinical Features** Duchenne dystrophy is present at birth, but the disorder usually becomes apparent between ages 3 and 5. The boys fall frequently and have difficulty keeping up with friends when playing. Running, jumping, and hopping are invariably abnormal. By age 5, muscle weakness is obvious by muscle testing. On getting up from the floor, the patient uses his hands to climb up himself [Gowers’ maneou-
ver (Fig. 367-4)]. Contractures of the heel cords and iliobial bands become apparent by age 6, when toe walking is associated with a lordotic posture. Loss of muscle strength is progressive, with predilection for proximal limb muscles and the neck flexors; leg involvement is more severe than arm involvement. Between ages 8 and 10 walking may require the use of braces; joint contractures and limitations of hip flexion, knee, elbow, and wrist extension are made worse by prolonged sitting. By age 12, most patients are wheelchair dependent. Contractures become fixed, and a progressive scoliosis often develops that may be associated with pain. The chest deformity with scoliosis impairs pulmonary function, which is already diminished by muscle weakness. By age 16 to 18, patients are predisposed to serious, sometimes fatal pulmonary infections. Other causes of death include aspiration of food and acute gastric dilation.

A cardiac cause of death is uncommon despite the presence of a cardiomyopathy in almost all patients. Congestive heart failure seldom occurs except with severe stress such as pneumonia. Cardiac arrhythmias are rare. The typical electrocardiogram (ECG) shows an increase net RS in lead V1; deep, narrow Q waves in the precordial leads; and tall right precordial R waves in V1. Intellectual impairment in Duchenne dystrophy is common; the average intelligence quotient (IQ) is approximately one standard deviation below the mean. Impairment of intellectual function appears to be nonprogressive and affects verbal ability more than performance.

**Laboratory Features** Serum creatine kinase (CK) levels are invariably elevated to between 20 and 100 times normal. The levels are abnormal at birth but decline late in the disease because of inactivity and loss of muscle mass. Electromyography (EMG) demonstrates features typical of myopathy. The muscle biopsy shows muscle fibers of varying size as well as small groups of necrotic and regenerating fibers. Connective tissue and fat replace lost muscle fibers. A definitive diagnosis of Duchenne dystrophy can be established on the basis of dystrophin deficiency in a biopsy of muscle tissue or mutation analysis on peripheral blood leukocytes as discussed below.

---

**TABLE 368-1 Progressive Muscular Dystrophies**

<table>
<thead>
<tr>
<th>Type</th>
<th>Inheritance</th>
<th>Defective Gene/Protein</th>
<th>Onset Age</th>
<th>Clinical Features</th>
<th>Other Organ Systems Involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duchenne</td>
<td>XR</td>
<td>Dystrophin</td>
<td>Before 5 years</td>
<td>Progressive weakness of girdle muscles Unable to walk after age 12</td>
<td>Cardiomyopathy Mental impairment</td>
</tr>
<tr>
<td>Becker</td>
<td>XR</td>
<td>Dystrophin</td>
<td>Early childhood to adult</td>
<td>Progressive weakness of girdle muscles Able to walk after age 15</td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>Limb-girdle</td>
<td>AD/AR</td>
<td>Several (Tables 368-2, 368-3)</td>
<td>Early childhood to early adult</td>
<td>Slow progressive weakness of shoulder and hip girdle muscles</td>
<td>± Cardiomyopathy</td>
</tr>
<tr>
<td>Emery-Dreifuss</td>
<td>XR/AD</td>
<td>Emerin/Lamins A/C</td>
<td>Childhood to adult</td>
<td>Elbow contractures, humeral and peroneal weakness</td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>Congenital</td>
<td>AR</td>
<td>Several</td>
<td>At birth or within first few months</td>
<td>Hypotonia, contractures, delayed milestones</td>
<td>CNS abnormalities (hypomyelination, malformation)</td>
</tr>
<tr>
<td>Myotonic (+ DM1, DM2)</td>
<td>AD</td>
<td>DM1: Expansion CTG repeat DM2: Expansion CCTG repeat</td>
<td>Usually 2d decade May be infancy if mother affected (DM1 only)</td>
<td>Slowly progressive weakness of face, shoulder girdle, and foot dorsiflexion</td>
<td>Cardiac conduction defects Mental impairment</td>
</tr>
<tr>
<td>Facioscapulohumeral</td>
<td>AD</td>
<td>Deletion, distal 4q</td>
<td>Before 20</td>
<td>Slowly progressive weakness of face, shoulder girdle, and foot dorsiflexion</td>
<td>Cataracts Frontal baldness Gonadal atrophy</td>
</tr>
<tr>
<td>Oculopharyngeal</td>
<td>AD</td>
<td>Expansion, poly-A RNA binding protein</td>
<td>5th to 6th decade</td>
<td>Slowly progressive weakness of extraocular, pharyngeal, and limb muscles</td>
<td>Deafness Coats’ (eye) disease</td>
</tr>
</tbody>
</table>

---

* Two forms of myotonic dystrophy, DM1 and DM2, have been identified. Many features overlap (see text).

**Abbreviations:** XR, X-linked recessive; AD, autosomal dominant; AR, autosomal recessive; CNS, central nervous system.
Pathogenesis  Dystrophin is part of a large complex of sarcomemlal proteins and glycoproteins (Fig. 368-1). Dystrophin binds to F-actin at its amino terminus and to β-dystroglycan at the carboxyl terminus. β-Dystroglycan complexes to α-dystroglycan, which binds to laminin in the extracellular matrix (ECM). Laminin has a heterotrimetric molecular structure arranged in the shape of a cross with one heavy chain and two light chains, β1 and γ1. The laminin heavy chain of skeletal muscle is designated laminin α2. Collagen proteins IV and VI are also found in the ECM. Like β-dystroglycan, the transmembrane sarcoglycan proteins also bind to dystrophin; these five proteins (designated α-through ε-sarcoglycan) complex tightly with each other. More recently, other membrane proteins implicated in muscular dystrophy have been found to be loosely affiliated with constituents of the dystrophin complex. These include caveolin-3, α7 integrin, and collagen VI.

The dystrophin-glycoprotein complex appears to confer stability to the sarcolemma, although the function of each individual component of the complex is incompletely understood. Deficiency of one member of the complex may cause abnormalities in other components. For example, a primary deficiency of dystrophin (Duchenne dystrophy) may lead to secondary loss of the sarcoglycans and dystroglycan. The primary loss of a single sarcoglycan (see “Limb-Girdle Muscular Dystrophy,” below) results in a secondary loss of other sarcoglycans in the membrane without uniformly affecting dystrophin. In either instance, disruption of the dystrophin-glycoprotein complexes weakens the sarcolemma, causing membrane tears and a cascade of events leading to muscle fiber necrosis. This sequence of events occurs repeatedly during the life of a patient with muscular dystrophy.

TREATMENT

Glucocorticoids, administered as prednisone in a dose of 0.75 mg/kg per day, significantly slow progression of Duchenne dystrophy for up to 3 years. Some patients cannot tolerate glucocorticoid therapy; weight gain in particular represents a significant deterrent for some boys.

BECKER MUSCULAR DYSTROPHY  This less severe form of X-linked recessive muscular dystrophy results from allelic defects of the same gene responsible for Duchenne dystrophy. Becker muscular dystrophy is approximately 10 times less frequent than Duchenne, with an incidence of about 3 per 100,000 live-born males.

Clinical Features  The pattern of muscle wasting in Becker muscular dystrophy closely resembles that seen in Duchenne. Proximal muscles, especially of the lower extremities, are prominently involved. As the disease progresses, weakness becomes more generalized. Significant facial muscle weakness is not a feature. Hypertrophy of muscles, particularly in the calves, is an early and prominent finding.

Most patients with Becker dystrophy first experience difficulties between ages 5 and 15 years, although onset in the third or fourth decade or even later can occur. By definition, patients with Becker dystrophy walk beyond age 15, while patients with Duchenne dystrophy are typically in a wheelchair by the age of 12. Patients with Becker dystrophy have a reduced life expectancy, but most survive into the fourth or fifth decade.

Mental retardation may occur in Becker dystrophy, but it is not as common as in Duchenne. Cardiac involvement occurs in Becker dystrophy and may result in heart failure.

Laboratory Features  Serum CK levels, results of EMG, and muscle biopsy findings closely resemble those in Duchenne dystrophy. The diagnosis of Becker muscular dystrophy requires western blot analysis of muscle biopsy samples demonstrating a reduced amount or abnormal size of dystrophin. Mutation analysis of DNA from peripheral blood leukocytes reveals deletions or duplications of the dystrophin gene in 65% of patients with Becker dystrophy, approximately the same percentage as in Duchenne dystrophy. In both Becker and Duchenne dystrophies, the size of the DNA deletion does not predict clinical severity; however, in ~95% of patients with Becker dystrophy, the DNA deletion does not alter the translational reading frame of messenger RNA. These “in-frame” mutations allow for production of some dystrophin, which accounts for the presence of altered rather than absent dystrophin on western blot analysis.

The use of glucocorticoids has not been adequately studied in Becker dystrophy.

LIMB-GIRDLE MUSCULAR DYSTROPHY  The syndrome of limb-girdle muscular dystrophy (LGMD) represents more than one disorder. Both males and females are affected, with onset ranging from late in the first decade to the fourth decade. The LGMDs typically manifest with progressive weakness of pelvic and shoulder girdle musculature. Respiratory insufficiency from weakness of the diaphragm may occur, as may cardiomyopathy. Unlike Duchenne dystrophy, intellectual function is unaffected.

A systematic classification of LGMD is based on autosomal dominant (LGMD1) and autosomal recessive (LGMD2) inheritance. Superimposed on the backbone of LGMD1 and LGMD2, the classification employs a sequential alphabetical lettering system (LGMD1A, LGMD2A, etc.). Disorders receive letters in the order in which they are found to have chromosomal linkage. This results in an ever-expanding list of conditions. Presently there are 5 autosomal dominant and 10 autosomal recessive disorders, summarized in Tables 368-2 and 368-3. None of the conditions is as common as the dystrophinopathies; however, prevalence data for the LGMDs have not been systematically gathered for any large heterogeneous population. In referral-based clinical populations, the sarcoglycan deficiencies (LGMD2C, 2D, 2E, 2F) and dysferlinopathies (LGMD2B) have emerged as the most common disorders. Some small group analyses predict that calpain-3 deficiency (LGMD2A) and Fukutin-related protein (FKRP) deficiency (LGMD2I) may rival others for prevalence.

EMERY-DREIFFUSS MUSCULAR DYSTROPHY  There are two genetically distinct forms of Emery-Dreifuss muscular dystrophy (EDMD). One is...
inherited as an X-linked disorder, while the other is autosomal dominant. The latter is classified under the rubric of LGMD1B, but clinically the conditions are closely related.

**Clinical Features** Prominent contractures can be recognized in early childhood and teenage years, often preceding muscle weakness. The contractures persist throughout the course of the disease and are present at the elbows and neck. Muscle weakness affects humeral and peroneal muscles at first and later spreads to a limb-girdle distribution. The cardiomyopathy is potentially life threatening and may result in sudden death. A spectrum of atrial rhythm and conduction defects includes atrial fibrillation and paralysis and atrioventricular heart block. Some patients have a dilated cardiomyopathy. Female carriers of the X-linked variant may have cardiac manifestations that become clinically significant.

**Laboratory Features** Serum CK may be elevated two-to tenfold. EMG is myopathic. Muscle biopsy shows nonspecific dystrophic features. ECGs demonstrate atrial and atrioventricular rhythm disturbances.

**GENETIC CONSIDERATIONS** X-linked EDMD arises from defects in the emerin gene encoding a nuclear envelope protein. The autosomal dominant disease is caused by mutations of the LMNA gene on chromosome 1q21.2 encoding the lamin proteins A and C. These proteins are alternatively spliced products of the LMNA gene that are essential components of the filamentous network underlying the inner nuclear membrane. Loss of structural integrity of the nuclear envelope from defects in emerin or lamin A/C accounts for overlapping phenotypes.

**TREATMENT** Supportive care should be offered for neuromuscular disability, including ambulatory aids, if necessary. Stretching of contractures is typically the conditions are closely related.

**Clinical Features** The clinical expression of myotonic dystrophy varies widely and involves many systems other than muscle. Affected patients have a typical "hatchet-faced" appearance due to temporalis, masseter, and facial muscle atrophy and weakness. Frontal baldness is characteristic of men with the disease. Neck muscles, including flexors and sternocleidomastoids, and distal limb muscles are involved early. Weakness of wrist extensors, finger extenders, and intrinsic hand muscles impairs function. Ankle dorsiflexor weakness may cause footdrop. Proximal muscles remain stronger throughout the course, although preferential atrophy and weakness of quadriceps muscles occur in many patients. Palatal, pharyngeal, and tongue involvement produce a dysarthric speech, nasal voice, and swallowing problems. Some patients have diaphragm and intercostal muscle weakness, resulting in respiratory insufficiency.

Myotonia, which usually appears by age 5, is demonstrable by percussion of the thenar eminence, the tongue, and wrist extensor muscles. Myotonia causes a slow relaxation of hand grip after a forced voluntary closure. Advanced muscle wasting makes myotonia more difficult to detect.

Cardiac disturbances occur commonly in patients with DM1. ECG abnormalities include first-degree heart block and more extensive conduction system involvement. Complete heart block and sudden death can occur. Congestive heart failure occurs infrequently but may result from cor pulmonale secondary to respiratory failure. Mitral valve prolapse also occurs commonly. Other associated features include intellectual impairment, hypersomnia, posterior subcapsular cataracts, gonadal atrophy, insulin resistance, and decreased esophageal and colonic motility.

Congenital myotonic dystrophy is a more severe form of DM1 and occurs in ~25% of infants of affected mothers. It is characterized by severe facial and bulbar weakness, transient neonatal respiratory insufficiency, and mental retardation.

DM2, or PROMM, has a distinct pattern of muscle weakness affecting mainly proximal muscles. Other features of the disease overlap with DM1, including cataracts, testicular atrophy, insulin resistance, constipation, hypersomnia, and cognitive defects. Cardiac conduction defects occur but are less common, and the hatchet face and frontal baldness are less consistent features. A very striking difference is the failure to clearly identify a congenital form of DM2.

**Laboratory Features** The diagnosis of myotonic dystrophy can usually be made on the basis of clinical findings. Serum CK levels may be normal or mildly elevated. EMG evidence of myotonia is present in most cases. Muscle biopsy shows muscle atrophy, which selectively involves type 1 fibers in 50% of cases. Typically, increased numbers of central nuclei can be seen. Necrosis of muscle fibers and increased connective tissue, common in other muscular dystrophies, do not usually occur in myotonic dystrophy.

**GENETIC CONSIDERATIONS** DM1 and DM2 are both autosomal dominant disorders. New mutations do not appear to contribute to the pool of affected individuals. DM1 is transmitted by an intronic mutation consisting of an unstable expansion of a CAG trinucleotide repeat in a serine-threonine protein kinase gene (named DMPK) on chromosome 19q13.3. An increase in the severity of the disease phenotype in successive generations (genetic anticipation) is accompanied by an increase in the number of trinucleotide repeats. A similar type of mutation has been identified in fragile X syndrome (Chap. 56). The

---

**TABLE 368-2 Autosomal Dominant Limb-Girdle Muscular Dystrophies (LGMDs)**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical Features</th>
<th>Laboratory Features</th>
<th>Locus or Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>LGMD1A</td>
<td>Onset 3d to 4th decade</td>
<td>Serum CK 2 × normal</td>
<td>Myotilin</td>
</tr>
<tr>
<td></td>
<td>Muscle weakness affects distal limb</td>
<td>EMG mixed myopathy/neuropathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>muscles, vocal cords, and pharyngeal</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>muscles</td>
<td>Serum CK 3–5 × normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Onset 1st or 2d decade</td>
<td>NCS normal</td>
<td>Lamin A/C</td>
</tr>
<tr>
<td></td>
<td>Proximal lower limb weakness</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and cardiomyopathy with conduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>defects</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Some cases indistinguishable from</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emery-Dreifuss muscular dystrophy with</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>joint contractures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGMD1B</td>
<td>Onset in early childhood</td>
<td>Serum CK 4–25 × normal</td>
<td>Caveolin-3</td>
</tr>
<tr>
<td></td>
<td>Proximal weakness</td>
<td>normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gowers’ sign, calf hypertrophy</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exercise-related muscle cramps</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Onset 3d to 5th decade</td>
<td>Serum CK 2–4 × normal</td>
<td>Linked to</td>
</tr>
<tr>
<td></td>
<td>Proximal muscle weakness</td>
<td>normal</td>
<td>chromosome 7q</td>
</tr>
<tr>
<td></td>
<td>Cardiomyopathy and arhythmias</td>
<td>NCS normal</td>
<td>Gene unidentified</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td>LGMD1C</td>
<td>Childhood onset</td>
<td>Serum CK normally</td>
<td>Linked to</td>
</tr>
<tr>
<td></td>
<td>Proximal muscle weakness</td>
<td>normal</td>
<td>chromosome 6q23</td>
</tr>
<tr>
<td>LGMD1D</td>
<td>Onset at 3 to 5th decade</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proximal muscle weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGMD1E</td>
<td>Onset in early childhood</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proximal weakness</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CK, creatine kinase; NCS, nerve conduction studies; EMG, electromyography.

---

**MYOTONIC DYSTROPHY** Myotonic dystrophy is also known as dystrophia myotonica (DM). The condition is composed of at least two clinical disorders with overlapping phenotypes and distinct molecular genetic defects: myotonic dystrophy type 1 (DM1), the classic disease originally described by Steinert, and myotonic dystrophy type 2 (DM2), also called proximal myotonic myopathy (PROMM).
detachment, also occurs. Laboratory Features

FACIOSCAPULOHUMERAL (FSH) MUSCULAR DYSTROPHY This form of muscular dystrophy has a prevalence of ~1 in 20,000. It is distinct from a similar disorder known as scapuloperoneal dystrophy.

Clinical Features The condition typically has an onset in childhood or young adulthood. In most cases, facial weakness is the initial manifestation, appearing as an inability to smile, whistle, or fully close the eyes. Weakness of the shoulder girdles, rather than the facial muscles, usually brings the patient to medical attention. Loss of scapular stabilizer muscles makes arm elevation difficult. Scapular winging (Fig. 367-3) becomes apparent with attempts at abduction and forward movement of the arms. Biceps and triceps muscles may be severely affected, with relative sparing of the deltoid muscles. Weakness is invariably worse for wrist extension than for wrist flexion, and weakness of the anterior compartment muscles of the legs may lead to footdrop.

In most patients, the weakness remains restricted to facial, upper extremity, and distal lower extremity muscles. In 20% of patients, weakness progresses to involve the pelvic girdle muscles, and severe functional impairment and possible wheelchair dependency result.

Characteristically, patients with FSH dystrophy do not have involvement of other organ systems, although labile hypertension is common, and there is an increased incidence of nerve deafness. Coats' disease, a disorder consisting of telangiectasia, exudation, and retinal detachment, also occurs.

Laboratory Features The serum CK level may be normal or mildly elevated. EMG usually indicates a myopathic pattern. The muscle biopsy shows nonspecific features of a myopathy. A prominent inflammatory infiltrate, which is often multifocal in distribution, is present in some biopsy samples. The cause or significance of this finding is unknown.

GENETIC CONSIDERATIONS An autosomal dominant inheritance pattern with almost complete penetrance has been established, but each family member should be examined for the presence of the disease, since ~30% of those affected are unaware of involvement. FSH dystrophy is caused by deletions of tandem 3.3-kb repeats at 4q35. The deletion reduces the number of repeats to a fragment of <35 kb in most patients. This mutation results in an overexpression of upstream genes and a loss of DNA binding of a multigene complex mediating transcriptional repression of 4q35 genes. The mutation permits carrier detection and prenatal diagnosis. Most sporadic cases represent new mutations.

TREATMENT No specific treatment is available; ankle-foot orthoses are helpful for footdrop. Scapular stabilization procedures improve scapular winging but may not improve function.

OCULOUPHARYNGEAL DYSTROPHY This form of muscular dystrophy represents one of several disorders characterized by progressive external ophthalmoplegia, which consists of slowly progressive ptosis and limitation of eye movements with sparing of pupillary reactions for light and accommodation. Patients usually do not complain of diplopia, in contrast to patients having conditions with a more acute onset of ocular muscle weakness (e.g., myasthenia gravis).

### Table 368-3 Autosomal Recessive Limb-Girdle Muscular Dystrophies (LGMDs)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical Features</th>
<th>Laboratory Features</th>
<th>Locus or Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>LGMD2A</td>
<td>Onset 1st or 2d decade</td>
<td>Serum CK 3–15 × normal</td>
<td>Calpain-3</td>
</tr>
<tr>
<td></td>
<td>Tight heel cords</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contractures at elbows, wrists, and fingers; rigid spine in some</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proximal and distal weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGMD2B</td>
<td>Onset 2d or 3d decade</td>
<td>Serum CK 3–100 × normal</td>
<td>Dysferlin</td>
</tr>
<tr>
<td></td>
<td>Proximal muscle weakness at onset, later</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>distal (ca) muscles affected</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miyoshi myopathy is variant of LGMD2B</td>
<td>Inflammation on</td>
<td></td>
</tr>
<tr>
<td></td>
<td>with call muscles affected at onset</td>
<td>muscle biopsy may</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>simulate polymyositis</td>
<td></td>
</tr>
<tr>
<td>LGMD2C–F</td>
<td>Onset in childhood to teenage yrs</td>
<td>Serum CK 5–100 × normal</td>
<td>γ, α, β, δ</td>
</tr>
<tr>
<td></td>
<td>Clinical condition similar to Duchenne and Becker muscular dystrophies</td>
<td>NCS normal</td>
<td>sarcoglycans</td>
</tr>
<tr>
<td></td>
<td>Cardiomyopathy uncommon</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cognitive function normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGMD2G</td>
<td>Onset age 10 to 15</td>
<td>Serum CK 3–17 × normal</td>
<td>Telethonin</td>
</tr>
<tr>
<td></td>
<td>Proximal and distal muscle weakness</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td>LGMD2H</td>
<td>Onset 1st to 3d decade</td>
<td>Serum CK 2–25 × normal</td>
<td>TRIM32 gene</td>
</tr>
<tr>
<td></td>
<td>Proximal muscle weakness</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td>LGMD2I</td>
<td>Onset 1st to 3d decade</td>
<td>Serum CK 10–30 × normal</td>
<td>Fukutin-related</td>
</tr>
<tr>
<td></td>
<td>Clinical condition similar to Duchenne or Becker dystrophies</td>
<td>NCS normal</td>
<td>protein</td>
</tr>
<tr>
<td></td>
<td>Cardiomyopathy (some not all)</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cognitive function normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGMD2J*</td>
<td>Onset 1st to 3d decade</td>
<td>Serum CK 1.5–2 × normal</td>
<td>Titin</td>
</tr>
<tr>
<td></td>
<td>Proximal lower limb weakness</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild distal weakness</td>
<td>EMG myopathic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Progressive weakness causes loss of ambulation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Triatal muscular dystrophy is a form of titin deficiency with only distal muscle weakness (see Table 368-4).

** Abbreviations: CK, creatine kinase; NCS, nerve conduction studies; EMG, electromyography.
TABLE 368-4  Distal Myopathies

<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical Features</th>
<th>Laboratory Features</th>
<th>Locus/Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Welander distal myopathy</strong></td>
<td>Onset in fifth decade</td>
<td>Serum CK 2–3 × normal</td>
<td>AD inheritance</td>
</tr>
<tr>
<td></td>
<td>Weakness begins in hands</td>
<td>EMG myopathic</td>
<td>Linked to</td>
</tr>
<tr>
<td></td>
<td>Slow progression with spread to distal lower extremities</td>
<td>NCS normal</td>
<td>chromosome</td>
</tr>
<tr>
<td></td>
<td>Lifespan normal</td>
<td>Muscle biopsy shows dystrophic features</td>
<td>2p13</td>
</tr>
<tr>
<td><strong>Tibial Muscular dystrophy</strong></td>
<td>Onset 4th to 6th decade</td>
<td>Serum CK 2–4 × normal</td>
<td>AD inheritance</td>
</tr>
<tr>
<td><em>(Markesbery/Griggs/Udd)</em></td>
<td>Distal lower extremity weakness (tibial distribution)</td>
<td>EMG myopathic</td>
<td>Titin</td>
</tr>
<tr>
<td></td>
<td>Upper extremities usually normal</td>
<td>NCS normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lifespan normal</td>
<td>Muscle biopsy shows dystrophic features</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Onset 2d to 3d decade</td>
<td>Titin absent in M-line of muscle</td>
<td></td>
</tr>
<tr>
<td><strong>Nonanka distal myopathy</strong></td>
<td>Onset 2d to 3d decade</td>
<td>Serum CK 3–10 × normal</td>
<td>AR</td>
</tr>
<tr>
<td><em>(distal myopathy with rimmed vacuoles)</em></td>
<td>Lower extremity distal weakness</td>
<td>EMG myopathic</td>
<td>Allelic to</td>
</tr>
<tr>
<td></td>
<td>Mild distal upper limb weakness may be present early</td>
<td>NCS normal</td>
<td>hereditary</td>
</tr>
<tr>
<td></td>
<td>Progression to other muscles sparing quadriiceps</td>
<td>Dystrophic features on muscle</td>
<td>inclusion body</td>
</tr>
<tr>
<td></td>
<td>Ambulation may be lost in 10–15 years</td>
<td>biopsy plus rimmed vacuoles 15–19-nm filaments within</td>
<td>myopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vacuoles</td>
<td>GNE gene:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>UDP-N-acetylglucosamine</td>
</tr>
<tr>
<td><strong>Miyoshi myopathy</strong></td>
<td>Onset 2d to 3d decade</td>
<td>Serum CK 20–100 × normal</td>
<td>AR</td>
</tr>
<tr>
<td></td>
<td>Lower extremity weakness in posterior compartment muscles</td>
<td>EMG myopathic</td>
<td>Allelic to</td>
</tr>
<tr>
<td></td>
<td>Progression leads to weakness in other muscle groups</td>
<td>NCS normal</td>
<td>LGMD2B (see</td>
</tr>
<tr>
<td></td>
<td>Ambulation lost after 10–15 years in about one-third of cases</td>
<td>Muscle biopsy shows nonspecific</td>
<td>Table 368–3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dystrophic features</td>
<td>Dysferlin</td>
</tr>
</tbody>
</table>

Abbreviations: CK, creatine kinase; AD, autosomal dominant; AR, autosomal recessive; EMG, electromyography; NCS, nerve conduction studies.

Clinical Features  Oculopharyngeal muscular dystrophy has a late onset; it usually presents with ptosis and/or dysphagia in the fourth to sixth decade. The extraocular muscle impairment is less prominent in the early phase but may be severe later. The swallowing problem may become debilitating and result in pooling of secretions and repeated episodes of aspiration. Mild weakness of the neck and extremities also occurs.

Laboratory Features  The serum CK level may be two to three times normal. Myopathic EMG findings are typical. On biopsy, muscle fibers are found to contain vacuoles, which by electron microscopy are shown to contain membranous whorls, accumulation of glycogen, and other nonspecific debris related to lysosomes. A distinct feature of oculopharyngeal dystrophy is the presence of tubular filaments, 8.5 nm in diameter, in muscle cell nuclei.

GENETIC CONSIDERATIONS  Oculopharyngeal dystrophy has an autosomal dominant inheritance pattern with complete penetrance. The incidence is high in French-Canadians and in Spanish-American families of the southwestern United States. Large kindreds of Italian and of eastern European Jewish descent have been reported. The molecular defect in oculopharyngeal muscular dystrophy is a subtle expansion of a modest polyaninerepeat tract in a poly-RNA binding protein (PABP2) in muscle.

TREATMENT  Dysphagia can cause inanition, making oculopharyngeal muscular dystrophy a potentially life-threatening disease. Cricopharyngeal myotomy may improve swallowing, although it does not prevent aspiration. Eyelid crutches can improve vision in patients in whom ptosis obstructs vision; candidates for ptosis surgery must be carefully selected—those with severe facial weakness are not suitable.

DISTAL MYOPATHIES  A group of muscle diseases, the distal myopathies, are notable for their preferential distal distribution of muscle weakness in contrast to most muscle conditions associated with proximal weakness. The major distal myopathies are summarized in Table 368-4.

Clinical Features  Two of the conditions, Welander distal myopathy and tibial muscular dystrophy, are late-onset disorders, usually manifesting after age 40. Nonanka distal myopathy and Miyoshi myopathy are distinguished by their early onset in the late teens or twenties. Only Welander disease begins in the hands; all others start in the lower limbs. Miyoshi myopathy is unique in that gastrocnemius muscles are preferentially affected at onset. A clinical feature that makes all of these disorders confusing is that proximal muscles can be affected as the disorders progress (less so for Welander disease than others), perhaps diminishing the entire concept of the distal myopathy. In contrast to many genetic muscle diseases, the distal myopathies are for the most part limited to skeletal muscle.

Laboratory Features  Serum CK is particularly helpful in diagnosing Miyoshi myopathy since it is very elevated. In the other conditions serum CK is only slightly increased. EMGs are myopathic. Muscle biopsy shows nonspecific dystrophic features. In Nonanka distal myopathy rimmed vacuoles, which contain 15- to 19-nm filaments, are common findings. Immune staining for gene product can be helpful in demonstrating titin abnormalities in tibial muscular dystrophy and reduced dysferlin in Miyoshi myopathy.

GENETIC CONSIDERATIONS  Welander and tibial muscular dystrophy are inherited as autosomal dominant disorders, while Nonanka and Miyoshi myopathies are autosomal recessive conditions. The affected genes and their gene products are listed in Table 368–4. The gene for Welander disease awaits identification.

TREATMENT  Occupational therapy is offered for loss of hand function; ankle-foot orthoses can support distal lower limb muscles.

CONGENITAL MYOPATHIES  These rare disorders are distinguished from muscular dystrophies by the presence of specific histochemical and structural abnormalities in muscle. Although primarily disorders of infancy or childhood, three forms that may present in adulthood are described here: central core disease, nemaline (rod) myopathy, and centronuclear (myotubular) myopathy. Other types, such as minicore myopathy (multi-minicore disease), fingerprint body myopathy, and sarcotubular myopathy, are not discussed.

CENTRAL CORE DISEASE  Patients with central core disease may have decreased fetal movements and breech presentation. Hypotonia and delay
Three distinct variants of centronuclear myopathy occur. A neonatal form, also known as myotubular myopathy, presents with severe hypotonia and weakness at birth. The late infancy—early childhood form presents with delayed motor milestones. Later, difficulty with running and stair climbing becomes apparent. A marfanoid, slender body habitus, long narrow face, and high-arched palate are typical. Scoliosis and clubbed feet may also be present. Most patients exhibit progressive weakness, some requiring wheelchairs. Progressive external ophthalmoplegia with ptosis and varying degrees of extraocular muscle impairment are characteristic of both the neonatal and the late-infantile forms. A third variant, the late childhood—adult form, has an onset in the second or third decade. Patients have full extraocular muscle movements and rarely exhibit ptosis. There is mild, nonprogressive limb weakness and no associated skeletal abnormalities.

Normal or slightly elevated CK levels occur in each of the forms. EMG studies often give distinctive results, showing positive sharp waves and fibrillation potentials, complex and repetitive discharges, and rarely myotonic discharges. Muscle biopsy specimens in longitudinal section demonstrate rows of central nuclei, often surrounded by Z disk streaming. In transverse sections, central nuclei are found in 25 to 80% of muscle fibers.

A gene for the neonatal form of centronuclear myopathy has been localized to Xq28; this gene encodes myotubulin, a protein tyrosine phosphatase. Missense, frameshift, and splice-site mutations predict loss of myotubulin function in affected individuals. Carrier identification and prenatal diagnosis are possible. The inheritance pattern for the late infancy—early childhood disorder is autosomal recessive, and for the late childhood—adult form is probably autosomal dominant. No specific treatment is available.

### DISORDERS OF MUSCLE ENERGY METABOLISM

There are two principal sources of energy for skeletal muscle—fatty acids and glucose. Abnormalities in either glucose or lipid utilization can be associated with distinct clinical presentations that can range from an acute, painful syndrome with rhabdomyolysis and myoglobinuria to a chronic, progressive muscle weakness simulating muscular dystrophy.

#### GLYCOGEN STORAGE AND GLYCOLYTIC DEFECTS

<table>
<thead>
<tr>
<th>Disorders of Glycogen Storage Causing Progressive Weakness</th>
<th>ACID MALTASE DEFICIENCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Three clinical forms of acid maltase deficiency (type II glycogenosis) can be distinguished. The infantile form is the most common, with onset of symptoms in the first 3 months of life. Infants develop severe muscle weakness, cardiomegaly, hepatomegaly, and respiratory insufficiency. Glycogen accumulation in motor neurons of the spinal cord and brainstem contributes to muscle weakness. Death usually occurs by 1 year of age. In the childhood form, the picture resembles muscular dystrophy. Delayed motor milestones result from proximal limb muscle weakness and involvement of respiratory muscles. The heart may be involved, but the liver and brain are unaffected. The adult form begins in the third or fourth decade. Respiratory failure and diaphragmatic weakness are often initial manifestations, heralding progressive proximal muscle weakness. The heart and liver are not involved.</td>
<td></td>
</tr>
<tr>
<td>In all forms of acid maltase deficiency, the serum CK level is 2 to 10 times normal. EMG examination demonstrates a myopathic pattern, but other features are especially distinctive, including myotonic discharges, trains of fibrillation and positive waves, and complex repetitive discharges. EMG discharges are very prominent in the lumbar-sacral paraspinal muscles. The muscle biopsy shows vacuoles containing glycogen and the lysosomal enzyme acid phosphatase. Electron microscopy reveals membrane-bound and free tissue glycogen. Definitive diagnosis is established by enzyme determination in muscle. Acid maltase deficiency is inherited as an autosomal recessive disorder caused by mutations of the acid maltase gene. Recombinant human α-glucosidase infused intravenously is well tolerated. Clinical benefits in the infantile disease include reduced heart size, improved muscle tone, and longer life.</td>
<td></td>
</tr>
</tbody>
</table>

#### OTHER GLYCOGEN STORAGE DISEASES WITH PROGRESSIVE WEAKNESS

In debranching enzyme deficiency (type III glycogenosis), a slowly progressive form of muscle weakness can develop after puberty. Rarely, myoglobinuria may occur. Patients are usually diagnosed in infancy, however, because of hypotonia and delayed motor milestones, hepatomegaly, growth retardation, and hypoglycemia. Branching enzyme...
deficiency (type IV: glycogenosis) is a rare and fatal glycogen storage disease characterized by failure to thrive and hepatomegaly. Hypotonia and muscle wasting may be present, but the skeletal muscle manifestations are minor compared to liver failure.

**Disorders of Glycolysis Causing Exercise Intolerance** Five glycolytic defects are associated with recurrent myoglobinuria: myophosphorylase deficiency (type V glycogenosis), phosphofructokinase deficiency (type VII glycogenosis), phosphoglycerate kinase deficiency (type IX glycogenosis), phosphoglycerate mutase deficiency (type X glycogenosis), and lactate dehydrogenase deficiency (glycogenosis type XI). Myophosphorylase deficiency, also known as McArdle’s disease, is by far the most common of the glycolytic defects associated with exercise intolerance. These five glycolytic defects result in a common failure to support energy production at the initiation of exercise, although the exact site of energy failure remains controversial.

Clinical muscle manifestations in these five conditions usually begin in adolescence. Symptoms are precipitated by brief bursts of high-intensity exercise, such as running or lifting heavy objects. A history of myalgia and muscle stiffness usually precedes the intensely painful muscle contractures, which may be followed by myoglobinuria. Acute renal failure accompanies significant pigmenturia. Exercise tolerance can be enhanced by a slow induction phase (warm-up) or brief periods of rest, allowing for the start of the “second-wind” phenomenon (switching to utilization of fatty acids).

Certain features help distinguish some enzyme defects. Varying degrees of hemolytic anemia accompany deficiencies of both phosphofructokinase (mild) and phosphoglycerate kinase (severe). In phosphoglycerate kinase deficiency, the usual clinical presentation is a seizure disorder associated with mental retardation; exercise intolerance is an infrequent manifestation.

In all of these conditions, the serum CK levels fluctuate wildly and may be elevated even during symptom-free periods. CK levels >100 times normal are expected, accompanying myoglobinuria. All patients with suspected glycolytic defects leading to exercise intolerance should undergo a forearm exercise test (Chap. 367). An impaired rise in venous lactate is highly indicative of a glycolytic defect. In lactate dehydrogenase deficiency, venous levels of lactate do not increase, but pyruvate rises to normal. A definitive diagnosis of glycolytic disease is made by muscle biopsy.

Myophosphorylase deficiency, phosphofructokinase deficiency, and phosphoglycerate mutase deficiency are inherited as autosomal recessive disorders. Phosphoglycerate kinase deficiency is X-linked recessive. Mutations can be found in the respective genes encoding the abnormal proteins in each of these disorders.

Training may enhance the second-wind phenomenon, but attempts to raise blood glucose or to modify these disorders through diet have not proved beneficial.

**LIPID AS AN ENERGY SOURCE AND ASSOCIATED DEFECTS** Lipid is an important muscle energy source during rest and during prolonged, submaximal exercise. Fatty acids are derived from circulating very low density lipoprotein (VLDL) in the blood or from triglycerides stored in muscle fibers. Oxidation of fatty acids occurs in the mitochondria. To enter the mitochondria, a fatty acid must first be converted to an “activated fatty acid,” acyl-CoA. The acyl-CoA must be linked with carnitine by the enzyme carnitine palmitoyltransferase (CPT) I for transport into the mitochondria. CPT I is present on the inner side of the outer mitochondrial membrane. Carnitine is removed by CPT II, an enzyme attached to the inside of the inner mitochondrial membrane, allowing transport of acyl-CoA into the mitochondrial matrix for β-oxidation.

**Carnitine Palmitoyltransferase Deficiency** CPT II deficiency is the most common recognizable cause of recurrent myoglobinuria, more common than the glycolytic defects. Onset is usually in the teenage years or early twenties. Muscle pain and myoglobinuria occur after prolonged exercise. Strength is normal between attacks. Fasting predisposes to the development of symptoms. In contrast to disorders caused by defects in glycolysis, in which muscle cramps follow short, intense bursts of exercise, the muscle pain in CPT II deficiency does not occur until the limits of utilization have been exceeded and muscle breakdown has already begun. Episodes of rhabdomyolysis may produce severe weakness. In young children and newborns, CPT II deficiency can present with a very severe clinical picture including hypoketotic hypoglycemia, cardiomyopathy, liver failure, and sudden death.

Serum CK levels and EMG findings are both usually normal between episodes. A normal rise of venous lactate during forearm exercise distinguishes this condition from glycolytic defects, especially myophosphorylase deficiency. Muscle biopsy does not show lipid accumulation and is usually normal between attacks. The diagnosis requires direct measurement of muscle CPT II levels. CPT II deficiency is much more common in men than women (5:1); nevertheless, all evidence indicates autosomal recessive inheritance. A mutation in the gene for CPT II (chromosome 1p36) causes the disease in some individuals. It has been suggested that frequent meals and a low-fat, high-carbohydrate diet can prolong exercise tolerance. Others suggest substituting medium-chain triglycerides in the diet. Neither approach has proved beneficial.

**Myoadenylate Deaminase Deficiency** The muscle enzyme myoadenylate deaminase converts adenosine 5’-monophosphate (5’-AMP) to inosine monophosphate (IMP) with liberation of ammonia. Myoadenylate deaminase may play a role in regulating adenosine triphosphate (ATP) levels in muscles. Most individuals with myoadenylate deaminase deficiency have no symptoms. There have been a few reports of patients with this disorder who have exercise-exacerbated myalgia and myoglobinuria. Many questions have been raised about the clinical effects of myoadenylate deaminase deficiency, and, specifically, its relationship to exertional myalgia and fatigability, but there is no consensus.

**MITOCHONDRIAL MYOPATHIES**

In 1972, Olson and colleagues recognized that muscle fibers with significant numbers of abnormal mitochondria could be highlighted with the modified trichrome stain; the term ragged red fibers was coined. By electron microscopy, the mitochondria in ragged red fibers are enlarged and often bizarrely shaped and have crystalline inclusions. Since that seminal observation, the understanding of these disorders of muscle and other tissues has expanded (Chap. 56).

Mitochondria play a key role in energy production. Oxidation of the major nutrients derived from carbohydrate, fat, and protein leads to the generation of reducing equivalents. The latter are transported through the respiratory chain in the process known as oxidative phosphorylation. The energy generated by the oxidation-reduction reactions of the respiratory chain is stored in an electrochemical gradient coupled to ATP synthesis.

A novel feature of mitochondria is their genetic composition. Each mitochondrion possesses a DNA genome that is distinct from that of the nuclear DNA. Human mitochondrial DNA (mtDNA) consists of a double-strand, circular molecule comprising 16,569 base pairs. It codes for 22 transfer RNAs, 2 ribosomal RNAs, and 13 polypeptides of the respiratory chain enzymes. The genetics of mitochondrial diseases differ from the genetics of chromosomal disorders. The DNA of mitochondria is directly inherited from the cytoplasm of the gametes, mainly from the oocyte. The sperm contributes very little of its mitochondria to the offspring at the time of fertilization. Thus, mitochondrial genes are derived almost exclusively from the mother, accounting for maternal inheritance of some mitochondrial disorders.

Patients with mitochondrial disorders have clinical manifestations that fall into three groups: chronic progressive external ophthalmoplegia (CPEO), skeletal muscle—central nervous system syndromes, and pure myopathy simulating muscular dystrophy.

**PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA SYNDROMES WITH RAGGED RED FIBERS** The single most common sign of a mitochondrial myopathy is CPEO, occurring in >50% of all mitochondrial myopathies. Varying degrees of ptosis and weakness of extraocular muscles are seen,
usually in the absence of diplopia, a point of distinction from disorders with fluctuating eye weakness (e.g., myasthenia gravis).

KEARNS-SAYRE SYNDROME (KSS) KSS is a widespread multisystem disorder with a defined triad of clinical findings: onset before age 20, CPEO, and pigmentary retinopathy plus one or more of the following features: complete heart block, cerebrospinal fluid protein > 1.0 g/L (100 mg/dL), or cerebellar ataxia. Some patients with CPEO and ragged red fibers may not fulfill all of the criteria for KSS. The cardiac disease includes syncopal attacks and cardiac arrest related to the abnormalities in the cardiac conduction system: prolonged intraventricular conduction time, bundle branch block, and complete atrioventricular block. Death attributed to heart block occurs in about 20% of the patients. Varying degrees of progressive limb muscle weakness and easy fatigability affect activities of daily living. Endocrine abnormalities are common including gonadal dysfunction in both sexes with delayed puberty, short stature, and infertility. Diabetes mellitus is a cardinal sign of mitochondrial disorders and is estimated to occur in 13% of KSS patients. Other less common endocrine disorders include thyroid disease, hyperaldosteronism, Addison’s disease, and hypoparathyroidism. Both mental retardation and dementia are common accompaniments to this disorder. Serum CK levels are normal or slightly elevated. Serum lactate and pyruvate levels may be elevated. EMG is myopathic. Nerve conduction studies may be abnormal related to an associated neuropathy. Muscle biopsies reveal ragged red fibers, highlighted in oxidative enzyme stains, many showing defects in cytochrome oxidase. By electron microscopy increased numbers of mitochondria often appear enlarged with paracrystalline inclinations.

KSS is a sporadic disorder. The disease is caused by single mtDNA deletions presumed to arise spontaneously in the ovum or zygote. The most common deletion, occurring in about one-third of patients, removes 4977 bp of contiguous mtDNA. Monitoring for cardiac conduction defects is critical. Prophylactic pacemaker implantation is indicated when electrocardiograms demonstrate a bifascicular block. In KSS no benefit has been shown for supplementary therapies, including multivitamins or coenzyme Q10. Of all the proposed options, exercise might be the most applicable but must be approached cautiously because of defects in the cardiac conduction system.

AUTOSOMAL DOMINANT PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA This condition is caused by nuclear DNA mutations affecting mtDNA copy number and integrity and is thus inherited in a Mendelian fashion. Onset is usually after puberty. Fatigue, exercise intolerance, and complaints of muscle weakness are typical. Some patients notice swallowing problems. The neurologic examination confirms the ptosis and ophthalmoplegia, usually asymmetric in distribution. A sensorineural hearing loss may be encountered. Mild facial, neck flexor, and proximal weakness are typical. Rarely, respiratory muscles may be progressively affected and may be the direct cause of death. Serum CK is normal or mildly elevated. The resting lactates are normal or slightly elevated but may rise excessively after exercise. Spinal fluid protein is normal. The EMG is myopathic, and nerve conduction studies are usually normal. Ragged red fibers are prominently displayed in the muscle biopsy. Southern blots of muscle reveal a normal mtDNA band at 16.6 kb and several additional mtDNA deletion bands with genomes varying from 0.5 to 10 kb.

This autosomal dominant form of CPEO has been linked to loci on three chromosomes: 4q35, 10q24, and 15q22-26. In the chromosome 4q–related form of disease, mutations of the gene encoding the heart and skeletal muscle–specific isoform of the adenine nucleotide translocator 1 (ANT1) gene are found. This highly abundant mitochondrial protein forms a homodimeric inner mitochondrial channel of mitochondrial integrity. In the cases mapped to chromosome 15q, a mutation affects the gene encoding mtDNA polymerase (POLG), an enzyme important in mtDNA replication.

Exercise may improve function but will depend on patients’ ability to participate.

AUTOSOMAL RECESSIVE CARDIOMYOPATHY AND OPHTHALMOPLEGIA (ARCO) ARCO is a rare mitochondrial disorder clinically important because of an associated life-threatening cardiomyopathy. CPEO is the initial manifestation, occurring between ages 8 and 10. Exercise intolerance and fatigue follow the early symptoms, accompanied by palpitations and chest pain. Examination reveals extraocular muscle weakness, ptosis, facial weakness, reduced muscle bulk, and limb weakness, greater in proximal muscles. A dilated cardiomyopathy is typical, and some patients have conduction system involvement. Death from congestive heart failure occurs as early as age 13. Serum lactate is normal at rest but increases with mild exercise. Serum CK is increased by two- to fourfold. EMG is normal or myopathic. Muscle biopsies demonstrate typical ragged red fibers. Multiple mtDNA deletions are seen on Southern blots of muscle. Echocardiograms show reduced ejection fraction. Conduction block is seen on electrocardiograms. The disease is inherited as an autosomal recessive disorder. The gene has not been identified. Heart failure may require orthotopic cardiac transplantation. Cardiac pacemakers are appropriate for patients with heart block.

mtDNA SKELETAL MUSCLE–CENTRAL NERVOUS SYSTEM SYNDROMES ■ Myoclonic Epilepsy with Ragged Red Fibers (MERRF) The onset of MERRF is variable, ranging from late childhood to middle adult life. Characteristic features include myoclonic epilepsy, cerebellar ataxia, and progressive muscle weakness. The seizure disorder is an integral part of the disease and may be the initial symptom. Cerebellar ataxia precedes or accompanies epilepsy. It is slowly progressive, affects both trunk and limbs, and impairs gait and extremity functions. The third major feature of the disease is muscle weakness in a limb-girdle distribution. Other more variable features include dementia, peripheral neuropathy, optic atrophy, hearing loss, and diabetes mellitus.

Serum CK levels are normal or slightly increased. The serum lactate may be elevated. EMG is myopathic, and in some patients nerve conduction studies show the neuropathy. The electroencephalogram is abnormal, corroborating clinical findings of epilepsy. Typical ragged red fibers are seen on muscle biopsy. MERRF is caused by maternally inherited point mutations of mitochondrial transfer RNA (tRNA) genes. The most common mutation found in 80% of MERRF patients is an A to G substitution at nucleotide 8344 of tRNA lysine (A8344G in tRNA(lys)3). Other tRNA mutations include base-pair substitutions T8356C and G8363A. Only supportive treatment is possible, with special attention to epilepsy.

MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES (MELAS) MELAS is the most common mitochondrial encephalomyopathy. The term stroke-like is appropriate because the cerebral lesions do not conform to a strictly vascular distribution. The onset in the majority of patients is before age 20. Seizures, usually partial motor or generalized, are common and may represent the first clearly recognizable sign of disease. The cerebral insults that resemble strokes cause hemiparesis, hemianopia, and cortical blindness. A presumptive stroke occurring before age 40 should place this mitochondrial encephalomyopathy high in the differential diagnosis. Associated conditions include hearing loss, diabetes mellitus, hypothalamic pituitary dysfunction causing growth hormone deficiency, hypothyroidism, and absence of secondary sexual characteristics. In its full expression MELAS leads to dementia, a bedridden state, and a fatal outcome. Serum lactate acidosis is typically elevated. The spinal fluid protein is also increased but is usually <1.0 g/L (100 mg/dL). Muscle biopsies show ragged red fibers. Neuroimaging demonstrates basal ganglia calcification in a high percentage of cases. Focal lesions that mimic infarction are present predominantly in the occipital and parietal lobes. Strict vascular territories are not respected, and cerebral angiography fails to demonstrate lesions of the major cerebral blood vessels.
MELAS is caused by maternally inherited point mutations of mitochondrial tRNA genes. Most of the tRNA mutations are lethal, accounting for the paucity of multigeneration families with this syndrome. The A3243G point mutation in tRNA<sub>Leu</sub>(UUR) is the most common, occurring in ∼80% of MELAS cases. About 10% of MELAS patients have other mutations of the tRNA<sub>Leu</sub>(UUR) gene including 3252G, 3256T, 3271C, and 3291C. Other tRNA gene mutations have also been reported in MELAS including G583A tRNA<sub>Phe</sub>, G1642A tRNA<sub>Ala</sub>, G4332A tRNA<sub>Glu</sub>, and T8316C tRNA<sub>Lys</sub>. Mutations have also been reported in mtDNA polypeptide-coding genes. Two mutations were found in the ND5 subunit of complex I of the respiratory chain. A missense mutation has been reported to mtDNA position 9957 in the gene for subunit III of cytochrome C oxidase. No specific treatment is available. Supportive treatment is essential for the stroke-like episodes, seizures, and endocrinopathies.

**PURE MYOPATHY SYNDROMES**  Muscle weakness and fatigue can be the predominant manifestations of mtDNA mutations. When the condition affects exclusively muscle (pure myopathy), the disorder becomes difficult to recognize.

**Mitochondrial DNA Depletion Myopathy**  This disorder, clinically indistinguishable from muscular dystrophy, usually presents in the neonatal period with weakness, hypotonia, and delayed motor milestones. Some cases are rapidly fatal, with death before age 2. A milder form affects patients at a slightly later age. These patients have slowly evolving proximal muscle weakness simulating Duchenne muscular dystrophy. In some, seizures and cardiomyopathy may be present. Serum CK can reach levels of 20 to 30 times normal. Resting lactates vary from normal to mildly elevated. The EMG is myopathic, and ragged red fibers are seen on muscle biopsy. The mtDNA depletion syndrome is inherited as an autosomal recessive condition. Mutations have been identified in the TK2 gene on chromosome 16q22 encoding thymidine kinase-2. The affected gene controls the supply of deoxyribonucleotides used for the synthesis of mtDNA. No specific treatment is available. Supportive care follows the approaches outlined for muscular dystrophy.

**DISORDERS OF MUSCLE MEMBRANE EXCITABILITY**  Muscle membrane excitability is affected in a group of disorders referred to as channelopathies. The heart may also be involved, resulting in life-threatening complications (Table 368-5).

**CALCULUM CHANNEL DISORDERS OF MUSCLE**

### Hyperkalemic Periodic Paralysis (HyperKPP)

Onset occurs at adolescence. Men are more often affected because of decreased penetrance in women. Episodic weakness with onset after age 25 is almost never due to periodic paralyses with the exception of thyrotoxic periodic paralysis (see below). Attacks are often provoked by meals high in carbohydrates or sodium and may accompany rest following prolonged exercise. Weakness usually affects proximal limb muscles more than distal. Ocular and bulbar muscles are less likely to be affected. Respiratory muscles are usually spared but when they are involved, the condition may prove fatal. Weakness may take as long as 24 h to resolve. Life-threatening cardiac arrhythmias related to hypokalemia may occur during attacks. Myotonia, if present, is confined to the eyelids. As a late complication, patients commonly develop severe, disabling proximal lower extremity weakness.

Attacks of thyrotoxic periodic paralysis resemble those of primary hypoKPP. Despite a higher incidence of thyrotoxicosis in women, men, particularly those of Asian descent, are more likely to manifest this complication. Attacks abate with treatment of the underlying thyroid condition.

A low serum potassium level during an attack, excluding secondary causes, establishes the diagnosis. Interattack muscle biopsies show the presence of single or multiple centrally placed vacuoles. Provocative tests with glucose and insulin to establish a diagnosis are usually not necessary and are potentially hazardous. HypoKPP is inherited as an autosomal dominant disorder with incomplete penetrance. Mutations in the voltage-sensitive, skeletal muscle calcium channel (Fig. 368-2) cause the disease.

The acute paralysis improves after the administration of potassium. Muscle strength and electrocardiogram should be monitored. Oral KCl (0.2 to 0.4 mmol/kg) should be given every 30 min. Only rarely is intravenous therapy necessary (e.g., swallowing problems or vomiting present). Administration of potassium in glucose or saline, which may further lower potassium, should be avoided. Mannitol is the preferred vehicle for administration of intravenous potassium. The long-term goal of therapy is to avoid attacks. This may reduce late-onset, fixed weakness. Patients should be made aware of the importance of a low-carbohydrate, low-sodium diet and consequences of intense exercise. Prophylactic administration of acetazolamide (125 to 1000 mg/d in divided doses) reduces or may abolish attacks. Paradoxically, the potassium is lowered, but this is offset by the beneficial effect of metabolic acidosis. If attacks persist on acetazolamide, oral KCl should be added. Some patients require treatment with triamterene (25 to 100 mg/d) or spironolactone (25 to 100 mg/d).

**SODIUM CHANNEL DISORDERS OF MUSCLE**

Table 368-5 provides a comparison of periodic paralysis and non-dystrophic myotonia. This table shows the differences in clinical features and laboratory findings among these disorders.

### TABLE 368-5  Clinical Features of Periodic Paralysis and Nondystrophic Myotonias

<table>
<thead>
<tr>
<th>Feature</th>
<th>Calcium Channel</th>
<th>Sodium Channel</th>
<th>Paralympathy Congenita</th>
<th>Potassium Channel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mode of inheritance</td>
<td>AD</td>
<td>AD</td>
<td>AD</td>
<td>AD</td>
</tr>
<tr>
<td>Age of onset</td>
<td>AD</td>
<td>Hyperkalemic</td>
<td>No</td>
<td>Early childhood</td>
</tr>
<tr>
<td>Myotonia</td>
<td>Adolescence</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Episodic weakness</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Frequency of attacks of weakness</td>
<td>Yes</td>
<td>No change</td>
<td>Increased myotonia, then weakness</td>
<td>Yes</td>
</tr>
<tr>
<td>Duration of attacks of weakness</td>
<td>Daily to yearly</td>
<td>No</td>
<td>Increased myotonia</td>
<td>Yes</td>
</tr>
<tr>
<td>Serum K⁺ level during attacks of weakness</td>
<td>2–12 h</td>
<td>No change</td>
<td>Increased myotonia</td>
<td>Yes</td>
</tr>
<tr>
<td>Effect of K⁺ loading</td>
<td>No change</td>
<td>No change</td>
<td>Increased myotonia, then weakness</td>
<td>Yes</td>
</tr>
<tr>
<td>Effect of muscle cooling</td>
<td>Fixed weakness</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; PP, periodic paralysis.

---

**Notes:**

- May be paradoxical in paramyotonia congenita.
- Dystrophic features and cardiac arrhythmias are distinguishing features (see text).
an attack. The EMG will often demonstrate myotonia during and between attacks. The muscle biopsy shows vacuoles that are smaller, less numerous, and more peripheral compared to the hypokalemic form. Provocative tests by administration of potassium can induce weakness but are usually not necessary to establish the diagnosis. HyperKPP and potassium-aggravated myotonia are inherited as autosomal dominant disorders. Mutations of the voltage-gated sodium channel SCN4A (Fig. 368-3) cause these conditions. For patients with frequent attacks acetazolamide (125 to 100 mg/d) is helpful.

**Paramyotonia Congenita** In paramyotonia congenita (PC) the attacks of weakness are cold-induced or occur spontaneously and are mild. Myotonia is a prominent feature but worsens with muscle activity (paradoxic myotonia). This is in contrast to classic myotonia in which exercise alleviates the condition. Attacks of weakness are seldom severe enough to require emergency room treatment. Over time patients develop interattack weakness as they do in other forms of periodic paralysis. PC is usually associated with normokalemia or hyperkalemia. Other features are similar to those of hyperKPP. PC is inherited as an autosomal dominant condition; voltage-gated sodium channel mutations (Fig. 368-3) are responsible. Patients with PC seldom seek treatment during attacks. Oral administration of glucose or other carbohydrates hastens recovery. Since interattack weakness may develop after repeated episodes, prophylactic treatment is usually indicated. Thiazide diuretics (e.g., chlorothiazide 250 to 1000 mg/d) and mexiletine (slowly increase dose from 450 mg/d) are reported to be helpful. Patients should be advised to increase carbohydrates in their diet.

**POTASSIUM CHANNEL DISORDERS**

**Andersen’s Syndrome** This rare disease is characterized by episodic weakness, cardiac arrhythmias, and dysmorphic features (short stature, scoliosis, clinodactyly, hypertelorism, small or prominent low set ears, micrognathia, and broad forehead). The cardiac arrhythmias are potentially serious and life threatening. They include long QT, ventricular ectopy, bidirectional ventricular arrhythmias, and tachycardia. For many years the classification of this disorder was uncertain because episodes of weakness are associated with elevated, normal, or reduced levels of potassium during an attack. In addition, the potassium levels differ among kindreds but are consistent within a family. Inheritance is autosomal dominant, with incomplete penetrance and variable expressivity. The disease is caused by mutations of the inwardly rectifying potassium channel (KIR) gene. The treatment is similar to that for other forms of periodic paralysis and must include cardiac monitoring. The episodes of weakness may differ between patients because of potassium variability. Acetazolamide will decrease the attack frequency and severity.

**CHLORIDE CHANNEL DISORDERS** Two forms of this disorder, autosomal dominant (Thomsen’s disease) and autosomal recessive (Becker’s disease) are related to the same gene abnormality. Symptoms are noted in infancy and early childhood. The severity lessens in the third to fourth decade. Myotonia is worsened by cold and improved by activity. The gait may appear slow and labored at first but improves with walking. In Thomsen’s disease muscle strength is normal, but in Becker’s, which is usually more severe, there may be muscle weakness. Muscle hypertrophy is usually present. Myotonia is prominently displayed by EMG recordings. Serum CK is normal or mildly elevated. The muscle biopsy shows hypertrophied fibers. The disease is inherited as dominant or recessive and is caused by mutations of the chloride channel gene (Fig. 368-3). Many patients will not require treatment and learn that the symptoms improve with activity. Medications that can be used to decrease myotonia include quinine, phenytoin, and mexiletine.

**ENDOCRINE AND METABOLIC MYOPATHIES**

Many endocrine disorders cause weakness. Muscle fatigue is more common than true weakness. The cause of weakness in these disorders is not well defined. It is not even clear that weakness results from...
disease of muscle as opposed to another part of the motor unit, since the serum CK level is often normal (except in hypothyroidism) and the muscle histology is characterized by atrophy rather than destruction of muscle fibers. Nearly all endocrine myopathies respond to treatment.

THYROID DISORDERS (See also Chap. 320) Abnormalities of thyroid function can cause a wide array of muscle disorders. These conditions relate to the important role of thyroid hormones in regulating the metabolism of carbohydrates and lipids as well as the rate of protein synthesis and enzyme production. Thyroid hormones also stimulate calorigenesis in muscle, increase muscle demand for vitamins, and enhance muscle sensitivity to circulating catecholamines.

Hypothyroidism Patients with hypothyroidism have frequent muscle complaints, and proximal muscle weakness occurs in about one-third of them. Muscle cramps, pain, and stiffness are common. Features of slow muscle contraction and relaxation occur in 25% of patients, and the relaxation phase of muscle stretch reflexes is characteristically prolonged. The serum CK level is often elevated (up to 10 times normal), even when there is minimal clinical evidence of muscle disease. Hoffer’s syndrome results in prominent muscle enlargement and weakness with muscle stiffness. The cause of muscle enlargement has not been determined, and muscle biopsy shows no distinctive morphologic abnormalities.

Hyperthyroidism Patients who are thyrotoxic commonly have proximal muscle weakness and atrophy on examination, but they rarely complain of the deficit. Muscle stretch reflexes are preserved and often brisk. Bulbar, respiratory, and even esophageal muscles may occasionally be affected, causing dysphagia, dysphonia, and aspiration. When bulbar involvement occurs, it is usually accompanied by chronic proximal limb weakness, but occasionally it presents in the absence of generalized thyrotoxic myopathy. Other neuromuscular disorders occur in association with hyperthyroidism, including hypokalemic, myasthenia gravis, and a progressive ocular myopathy associated with proptosis (Graves’ ophthalmopathy). Serum CK levels are not elevated in thyrotoxic myopathy. The muscle histology usually shows only atrophy of muscle fibers.

PARATHYROID DISORDERS (See also Chap. 332) Hyperparathyroidism Muscle weakness is an integral part of primary and secondary hyperparathyroidism. Proximal muscle weakness, muscle wasting, and brisk muscle stretch reflexes are the main features of this endocrinopathy. Serum CK levels are usually normal or slightly elevated. Serum calcium and phosphorus levels show no correlation with the clinical neuromuscular manifestations. Muscle biopsies show only varying degrees of atrophy without muscle fiber degeneration.

Hypoparathyroidism An overt myopathy due to hypocalcemia rarely occurs. Neuromuscular symptoms are usually related to localized or generalized tetany. Serum CK levels may be increased secondary to muscle damage from sustained tetany. Hyporeflexia or areflexia is usually present and contrasts with the hyperreflexia in hyperparathyroidism.

ADRENAL DISORDERS (See also Chap. 321) Conditions associated with glucocorticoid excess cause a myopathy; in fact, steroid myopathy is the most commonly diagnosed endocrine muscle disease. Glucocorticoid excess, either endogenous or exogenous (see “Toxic Myopathies,” below), produces various degrees of proximal limb weakness. Muscle wasting may be striking. A cushingoid appearance usually accompanies clinical signs of myopathy. Histologic sections demonstrate muscle fiber atrophy rather than degeneration or necrosis of muscle fibers. Adrenal insufficiency commonly causes muscle fatigue. The degree of weakness may be difficult to assess but is typically mild. In primary hyperaldosteronism (Conn’s syndrome), neuromuscular complications are due to potassium depletion. The clinical picture is one of persistent muscle weakness. Long-standing hyperaldosteronism may lead to proximal limb weakness and wasting. Serum CK levels may be elevated, and a muscle biopsy may demonstrate degenerating fibers, some with vacuoles. These changes relate to hypokalemia and are not a direct effect of aldosterone on skeletal muscle.

PITUITARY DISORDERS (See also Chap. 318) Patients with acromegaly usually have mild proximal weakness without muscle atrophy. Muscles often appear enlarged but exhibit decreased force generation. The duration of acromegaly, rather than the serum growth hormone levels, correlates with the degree of myopathy.

DIABETES MELLITUS (See also Chap. 323) Neuromuscular complications of diabetes mellitus are most often related to neuropathy, with cranial and peripheral nerve palsies or distal sensorimotor polyneuropathy. Diabetic amyotrophy is a clumsy term since the condition represents a neuropathy affecting the proximal major nerve trunks and lumbosacral plexus. More appropriate terms for this disorder include diabetic proximal neuropathy and lumbosacral radiculoplexus neuropathy.

The only notable myopathy of diabetes mellitus is ischemic infarction of thigh muscles. This condition occurs in patients with poorly controlled diabetes and presents with abrupt onset of pain, tenderness, and edema of one thigh. The area of muscle infarction is hard and indurated. The muscles most often affected include the vastus lateralis, thigh adductors, and biceps femoris. Computed tomography or magnetic resonance imaging can demonstrate focal abnormalities in the affected muscle. Diagnosis by imaging is preferable to muscle biopsy, if possible.

VITAMIN DEFICIENCY Vitamin D deficiency ( Chap. 61 ) due to either decreased intake, decreased absorption, or impaired vitamin D metabolism (as occurs in renal disease) may lead to chronic muscle weakness. Pain reflects the underlying bone disease (osteomalacia). Vitamin E deficiency may result from malabsorption. Clinical manifestations include ataxic neuropathy due to loss of proprioception and myopathy with proximal weakness. Progressive external ophthalmoplegia is a distinctive finding. It has not been established that deficiency of other vitamins causes a myopathy.

MYOPATHIES OF SYSTEMIC ILLNESS Systemic illnesses such as chronic respiratory, cardiac, or hepatic failure are frequently associated with severe muscle wasting and complaints of weakness. Fatigue is usually a more significant problem than weakness, which is typically mild.

Myopathy may be a manifestation of chronic renal failure, independent of the better known uremic polyneuropathy. Abnormalities of calcium and phosphorus homeostasis and bone metabolism in chronic renal failure result from a reduction in 1,25-dihydroxyvitamin D, leading to decreased intestinal absorption of calcium. Hypocalcemia, further accentuated by hyperphosphatemia due to decreased renal phosphate clearance, leads to secondary hyperparathyroidism. Renal osteodystrophy results from the compensatory hyperparathyroidism, which leads to osteomalacia from reduced calcium availability and to osteitis fibrosa from the parathyroid hormone excess. The clinical picture of the myopathy of chronic renal failure is identical to that of primary hyperparathyroidism and osteomalacia. There is proximal limb weakness with bone pain.

Gangrenous calcification represents a separate, rare, and sometimes fatal complication of chronic renal failure. In this condition, widespread arterial calcification occurs and results in ischemia. Extensive skin necrosis may occur, along with painful myopathy and even myoglobinuria.

TOXIC MYOPATHIES Toxic myopathies are relatively uncommon in clinical practice with the exception of those caused by the cholesterol-lowering agents and glucocorticoids. Others impact practice to a lesser degree but are important to consider in specific situations. Table 368-6 provides a comprehensive list of toxic myopathies with their distinguishing features.

MYOPATHY FROM LIPID-LOWERING AGENTS All classes of lipid-lowering agents have been implicated in muscle toxicity including fibrates (clo-
GLUCOCORTICOID-RELATED MYOPATHIES Glucocorticoid myopathy occurs with chronic treatment or as “acute quadriplegic” myopathy secondary to high-dose, intravenous glucocorticoids. Chronic administration produces proximal weakness accompanied by cushingoid manifestations, which can be quite debilitating; the chronic use of prednisone at a daily dose of ≥30 mg/d is most often associated with toxicity. Patients taking fluorinated glucocorticoids (triamcinolone, betamethasone, dexamethasone) appear to be at especially high risk for myopathy. Patients receiving high-dose, intravenous glucocorticoids for status asthmaticus, chronic obstructive pulmonary disease or other indications may develop severe generalized weakness. Involvement of the diaphragm and intercostal muscles causes respiratory failure and requires ventilatory support. In this setting, the use of glucocorticoids in combination with nondepolarizing neuromuscular blocking agents to further decrease airway resistance is particularly likely to lead to this complication. In chronic steroid myopathy the serum CK is usually normal. Serum potassium may be low. The muscle biopsy in chronic cases shows preferential type 2 muscle fiber atrophy; this is not reflected in the EMG, which is usually normal. In acute cases with quadriplegic myopathy the muscle biopsy is abnormal, showing a distinctive loss of thick filaments by electron microscopy. By light microscopy there is focal loss of ATPase staining in central or paracentral areas of the muscle fiber. Calpain stains show diffusely reactive atrophic fibers. Withdrawal of glucocorticoids will improve the chronic myopathy. In acute quadriplegic myopathy, recovery is slow. Patients require supportive care and rehabilitation.

MYOPATHY OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS Patients may receive nondepolarizing neuromuscular blocking agents because of life-threatening airway resistance. Acute quadriplegic myopathy may result, with or without glucocorticoid use. The clinical features are identical to acute quadriplegic myopathy secondary to glucocorticoids.

DRUG-INDUCED MITOCHONDRIAL MYOPATHY Zidovudine, used in the treatment of HIV infection, is a thymidine analogue that inhibits viral replication by interrupting reverse transcriptase. Myopathy is a well-established complication of this agent. Patients present with myalgias, muscle weakness, and atrophy affecting the thigh and calf muscles. The complication occurs in about 17% of patients treated with doses of 1200 mg/d for 6 months. The introduction of protease inhibitors for treatment of HIV infection has led to lower doses of zidovudine therapy and a decreased incidence of myopathy. Serum CK is elevated and EMG is myopathic. Muscle biopsy shows ragged red fibers with minimal inflammation; the lack of inflammation serves to distinguish zidovudine toxicity from HIV-related myopathy. If the myopathy is thought to be drug related the medication should be stopped or the dosage reduced.

DRUGS OF ABUSE AND RELATED MYOPATHIES Myotoxicity is a potential consequence of addiction to alcohol and illicit drugs. Ethanol is one of the most commonly abused substances with potential to damage muscle. Other potential toxins include cocaine, heroin, and amphetamines. The most deleterious reactions occur from overdosing leading to coma and seizures, causing rhabdomyolysis, myoglobinuria, and renal failure. Direct toxicity can occur from cocaine, heroin, and amphetamines causing muscle breakdown and varying degrees of weakness. The effects of alcohol are more controversial. Direct muscle damage is less certain, since toxicity usually occurs in the setting of poor nutrition and possible contributing factors such as hypokalemia and hypophosphatemia. Alcoholics are also prone to neuropathy and a variety of central nervous system disorders (Chap. 372).

Focal myopathies from self-administration of meperidine, heroin, and pentazocine can cause pain, swelling, muscle necrosis, and hemorrhage. The cause is multifactorial: needle trauma, direct toxicity of the drug or vehicle, and infection. When severe, there may be overlying skin induration and contractures with replacement of muscle by connective tissue. Elevated serum CK and myopathic EMG are characteristic of these reactions. The muscle biopsy shows widespread or focal areas of necrosis. In conditions leading to rhabdomyolysis, patients need adequate hydration to reduce serum myoglobin and protect renal function. In all of these conditions, counseling is essential to limit drug abuse.

DRUG-INDUCED AUTOIMMUNE MYOPATHIES The most consistent drug-related inflammatory or antibody-mediated myopathy is caused by D-penicillamine. This drug chelates copper and is used in the treatment of Wilson’s disease. It is also used to treat other disorders including scleroderma, rheumatoid arthritis, and primary biliary cirrhosis. Adverse events include drug-induced polymyositis indistinguishable from the spontaneous disease. The incidence of this inflammatory muscle disease is about 1%. Myasthenia gravis is also induced by D-penicillamine, with a higher incidence estimated at 7%. These disorders resolve with drug withdrawal, although immunosuppressive therapy may be warranted in severe cases.
The inflammatory myopathies represent the largest group of acquired and potentially treatable causes of skeletal muscle weakness. They are classified into three major groups: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM).

**CLINICAL FEATURES** The prevalence of the inflammatory myopathies is estimated at 1 in 100,000. PM as a stand-alone entity is a rare disease affecting adults. DM affects both children and adults, and women more often than men. IBM is three times more frequent in men than in women, more common in Caucasians than blacks, and is most likely to affect persons >50 years of age.

These disorders present as progressive and often symmetric muscle weakness. Patients usually report increasing difficulty with everyday tasks requiring the use of proximal muscles, such as getting up from a chair, climbing steps, stepping onto a curb, lifting objects, or combing hair. Fine-motor movements that depend on the strength of distal muscles, such as buttoning a shirt, sewing, knitting, or writing, are affected only late in the course of PM and DM, but fairly early in IBM. Falling is common in IBM because of early involvement of the quadriceps muscle with buckling of the knees. Ocular muscles are spared, even in advanced, untreated cases; if these muscles are affected, the diagnosis of inflammatory myopathy should be questioned. Facial muscles are unaffected in PM and DM, but mild facial muscle weakness is common in patients with IBM. In all forms of inflammatory myopathy, pharyngeal and neck-flexor muscles are often involved, causing dysphagia or difficulty in holding up the head (head drop). In advanced and rarely in acute cases, respiratory muscles may also be affected. Severe weakness, if untreated, is almost always associated with muscle wasting. Sensation remains normal. The tendon reflexes are preserved but may be absent in severely weakened or atrophied muscles, especially in IBM where atrophy of the quadriceps and the distal muscles is common. Myalgia and muscle tenderness may occur in a small number of patients, usually early in the disease, and particularly in DM associated with connective tissue disorders. Weakness in PM and DM progresses subacutely over a period of weeks or months and rarely acutely; by contrast, IBM progresses very slowly, over years, simulating a late-life muscular dystrophy (Chap. 368) or slowly progressive motor neuron disorder (Chap. 353).

**SPECIFIC FEATURES** (Table 369-1)  

| TABLE 369-1  Features Associated with Inflammatory Myopathies |
|------------------|------------------|------------------|
| **Characteristic** | **Polymyositis** | **Dermatomyositis** | **Inclusion Body Myositis** |
| Age at onset | >18 yr | Adulthood and childhood | >50 yr |
| Familiar association | No | No | Yes, in some cases |
| Extramuscular manifestations | Yes | Yes | Yes |
| Connective tissue diseases | Yes | Scleroderma and mixed connective tissue disease (overlap syndromes) | Yes, in up to 20% of cases |
| Systemic autoimmune diseases† | Frequent | Infrequent | Infrequent |
| Malignancy | No | Yes, in up to 15% of cases | No |
| Viruses | Yes | Unproven | Yes‡ |
| Drugs‡ | Yes | Yes, rarely | No |
| Parasites and bacteria§ | Yes | No | No |

† Systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, mixed connective tissue disease.
‡ Crohn’s disease, vasculitis, sarcoidosis, primary biliary cirrhosis, adult celiac disease, chronic graft-versus-host disease, discoid lupus, ankylosing spondylitis, Behçet’s syndrome, myasthenia gravis, acne fulminans, dermatitis herpetiformis, psoriasis, Hashimoto’s disease, granulomatous diseases, agammaglobulinemia, monoclonal gammopathy, hyperesinophilic syndrome, Lyme disease, Kawasaki disease, autoimmune thrombocytopenia, hyperimmunglobulinemic purpura, hereditary complement deficiency, IgA deficiency.
§ HIV (human immunodeficiency virus) and HTLV-I (human T cell lymphotropic virus type I).

**OTHER DRUG-INDUCED MYOPATHIES** Certain drugs produce painless, largely proximal, muscle weakness. These drugs include the ampholytic cationic drugs (amiadone, chloroquine, hydroxychloroquine) and antimicrotubular drugs (colchicine). Muscle biopsy can be useful in the identification of toxicity since autophagic vacuoles are prominent pathologic features of these toxins.

**FURTHER READING**


---

**Table 369-1** Features Associated with Inflammatory Myopathies

- **Characteristic**
  - Age at onset
  - Familiar association
  - Extramuscular manifestations
  - Connective tissue diseases
  - Systemic autoimmune diseases
  - Malignancy
  - Viruses
  - Drugs
  - Parasites and bacteria

- **Polymyositis**
- **Dermatomyositis**
- **Inclusion Body Myositis**

- **Inclusion Body Myositis**
  - Yes, in up to 20% of cases

- **Inclusion Body Myositis**
  - Yes, in up to 15% of cases

- **Systemic autoimmune diseases**
  - Frequent
  - Infrequent

- **Malignancy**
  - Yes, rarely

- **Parasites and bacteria**
  - Yes

- **Other Drug-Induced Myopathies**

- **SPECIFIC FEATURES**

- **Polymyositis**

- **Dermatomyositis**

- **Inclusion Body Myositis**

- **PHARMACOLOGIC FEATURES**

- **SPECIFIC FEATURES**

- **OTHER DRUG-INDUCED MYOPATHIES**

- **FURTHER READING**

---

**Table 369-1** Features Associated with Inflammatory Myopathies

- **Characteristic**
  - Age at onset
  - Familiar association
  - Extramuscular manifestations
  - Connective tissue diseases
  - Systemic autoimmune diseases
  - Malignancy
  - Viruses
  - Drugs
  - Parasites and bacteria

- **Polymyositis**
- **Dermatomyositis**
- **Inclusion Body Myositis**

- **Inclusion Body Myositis**
  - Yes, in up to 20% of cases

- **Systemic autoimmune diseases**
  - Frequent
  - Infrequent

- **Malignancy**
  - Yes, rarely

- **Parasites and bacteria**
  - Yes

- **Other Drug-Induced Myopathies**

- **SPECIFIC FEATURES**

- **Polymyositis**

- **Dermatomyositis**

- **Inclusion Body Myositis**

- **PHARMACOLOGIC FEATURES**

- **SPECIFIC FEATURES**

- **OTHER DRUG-INDUCED MYOPATHIES**

- **FURTHER READING**
malleoli, neck and anterior chest (often in a V sign), or back and shoulders (shawl sign), and may worsen after sun exposure. In some patients the rash is pruritic, especially on the scalp, chest, and back. Dilated capillary loops at the base of the fingernails are also characteristic. The cuticles may be irregular, thickened, and distorted, and the lateral and palmar areas of the fingers may become rough and cracked, with irregular, “dirty” horizontal lines, resembling mechanic’s hands. The weakness can be mild, moderate, or severe enough to lead to quadriaparesis. At times, the muscle strength appears normal, hence the term dermatomyositis sine myositis. When muscle biopsy is performed in such cases, however, significant perivascular and perimysial inflammation is seen.

DM usually occurs alone but may overlap with scleroderma and mixed connective tissue disease. Fasciitis and thickening of the skin, similar to that seen in chronic cases of DM, have occurred in patients with the eosinophilia-myalgia syndrome associated with the ingestion of contaminated L-tryptophan.

**Inclusion Body Myositis** In patients ≥50 years of age, IBM is the most common of the inflammatory myopathies. It is often misdiagnosed as PM and suspected only later when a patient with presumed PM does not respond to therapy. Weakness and atrophy of the distal muscles, especially foot extensors and deep finger flexors, occur in almost all cases of IBM and may be a clue to early diagnosis. Some patients present with falls because of their knees collapse due to early quadriceps weakness. Others present with weakness in the small muscles of the hands, especially finger flexors, and complain of inability to hold objects such as golf clubs or perform tasks such as turning keys or tying knots. On occasion, the weakness and accompanying atrophy can be asymmetric and selectively involve the quadriceps, iliopsoas, triceps, biceps, and finger flexors, resembling a lower motor neuron disease. Dysphagia is common, occurring in up to 60% of IBM patients, and may lead to episodes of choking. Sensory examination is generally normal; some patients have mildly diminished vibratory sensation at the ankles that presumably is age-related. The pattern of distal weakness, which superficially resembles motor neuron or peripheral nerve disease, results from the myopathic process affecting distal muscles selectively. Disease progression is slow but steady, and most patients require an assistive device such as cane, walker, or wheelchair within several years of onset.

In at least 20% of cases, IBM is associated with systemic autoimmune or connective tissue diseases. Familial aggregation of typical IBM may occur; such cases have been designated as familial inflammatory IBM. This disorder is distinct from hereditary inclusion body myopathy (h-IBM), which describes a heterogeneous group of recessive, and less frequently dominant, inherited syndromes; the h-IBMs are noninflammatory myopathies. A subset of h-IBM that spares the quadriceps muscles has emerged as a distinct entity. This disorder, originally described in Iranian Jews and now seen in many ethnic groups, is linked to chromosome 9p1 and results from mutations in the GNE gene.

**ASSOCIATED CLINICAL FINDINGS**

- **Extramuscular Manifestations**
  These may be present to a varying degree in patients with PM or DM, including:

  1. **Systemic symptoms**, such as fever, malaise, weight loss, arthralgia, and Raynaud’s phenomenon, especially when inflammatory myopathy is associated with a connective tissue disorder.

  2. **Joint contractures**, mostly in DM and especially in children.

  3. **Dysphagia and gastrointestinal symptoms**, due to involvement of oropharyngeal striated muscles and upper esophagus, especially in DM and IBM.

  4. **Cardiac disturbances**, including atrioventricular conduction defects, tachyarrhythmias, dilated cardiomyopathy, and a low ejection fraction. Congestive heart failure and myocarditis may also occur, either from the disease itself or from hypertension associated with long-term use of glucocorticoids.

  5. **Pulmonary dysfunction**, due to weakness of the thoracic muscles, interstitial lung disease, or drug-induced pneumonitis (e.g., from methotrexate), which may cause dyspnea, nonproductive cough, and aspiration pneumonia. Interstitial lung disease may precede myopathy or occur early in the disease and develops in up to 10% of patients with PM or DM, most of whom have antibodies to t-RNA synthetases, as described below.


**Association with Malignancies** Although all the inflammatory myopathies can have a chance association with malignant lesions, especially in older age groups, the incidence of malignant conditions appears to be specifically increased only in patients with DM and not in PM or IBM. The most common tumors associated with DM are ovarian cancer, breast cancer, melanoma, colon cancer, and non-Hodgkin lymphoma. The extent of the search that should be conducted for an occult neoplasm in adults with DM depends on the clinical circumstances. Tumors in these patients are usually uncovered by abnormal findings in the medical history and physical examination and not through an extensive blind search. The weight of evidence argues against performing expensive, invasive, and nondirected tumor searches. A complete annual physical examination with pelvic, breast (mammogram, if indicated), and rectal examinations (with colonoscopy according to age and family history); urinalysis; complete blood count; blood chemistry tests; and a chest film should suffice in most cases. In Asians, nasopharyngeal cancer is common, and a careful examination of ears, nose, and throat is indicated.

**Overlap Syndromes** These describe the association of inflammatory myopathies with connective tissue diseases. A well-characterized overlap syndrome occurs in patients with DM who also have manifestations of systemic sclerosis or mixed connective tissue disease, such as sclerotic thickening of the dermis, contractures, esophageal hypomotility, microangiopathy, and calcium deposits (Table 369-1). By contrast, signs of rheumatoid arthritis, systemic lupus erythematosus, or Sjögren’s syndrome are very rare in patients with DM. Patients with the overlap syndrome of DM and systemic sclerosis may have a specific antinuclear antibody, the anti-PM/Scl, directed against a nucleolar protein complex.

**PATHOGENESIS** An autoimmune etiology of the inflammatory myopathies is indirectly supported by an association with other autoimmune or connective tissue diseases; the presence of various autoantibodies; an association with specific major histocompatibility complex (MHC) genes; demonstration of T cell–mediated myocytotoxicity or complement-mediated microangiopathy; and a response to immunotherapy.

**Autoantibodies and Immunogenetics** Various autoantibodies against nuclear antigens (antinuclear antibodies) and cytoplasmic antigens are found in up to 20% of patients with inflammatory myopathies. The antibodies to cytoplasmic antigens are directed against ribonucleoproteins involved in protein synthesis (anti-synthetases) or translational transport (anti-signal-recognition particles). The antibody directed against the histidyl-transfer RNA synthetase, called anti-Jo-1, accounts for 75% of all the anti-synthetases and is clinically useful because up to 80% of patients with anti-Jo-1 antibodies have interstitial lung disease. Some patients with the anti-Jo-1 antibody also have Raynaud’s phenomenon, nonerosive arthritis, and the MHC molecules DR3 and DRw52. DR3 (molecular designation DRB1*0301, DQB1*0201) occurs in up to 75% of patients with PM and IBM, whereas in juvenile DM there is an increased frequency of DQA1*0501 (Chap. 296).

**Immunopathologic Mechanisms** In DM, humoral immune mechanisms are implicated, resulting in a microangiopathy and muscle ischemia (Fig. 369-1). Endomyosial inflammatory infiltrates are composed of B cells located in proximity to CD4 T cells and macrophages; there is a relative absence of lymphocytic invasion of nonnecrotic muscle fibers. Activation of the complement C5b-9 membranolytic attack complex is thought to be a critical early event that triggers release of proinflam-
matory cytokines and chemokines, induces expression of vascular cell adhesion molecule (VCAM) 1 and intracellular adhesion molecule (ICAM) 1 on endothelial cells, and facilitates migration of activated lymphoid cells to the perimysial and endomysial spaces. Necrosis of the endothelial cells, reduced numbers of endomysial capillaries, ischemia, and muscle-fiber destruction resembling microinfarcts occur. The remaining capillaries often have dilated lumens in response to the ischemic process. Larger intramuscular blood vessels may also be affected in the same pattern. Residual perifascicular atrophy reflects the endofascicular hyperperfusion that is prominent in the periphery of the muscle fascicles.

By contrast, in PM and IBM a mechanism of T cell–mediated cytotoxicity is likely. CD8 T cells, along with macrophages, initially surround and eventually invade and destroy healthy, nonnecrotic muscle fibers that aberrantly express class I MHC molecules. MHC-I expression, absent from the sarcolemma of normal muscle fibers, is probably induced by cytokines secreted by activated T cells and macrophages. The CD8/MHC-I complex is characteristic of PM and IBM; its detection has now become necessary to confirm the histologic diagnosis of PM, as discussed later. The cytotoxic CD8 T cells contain perforin and granzyme granules directed towards the surface of the muscle fibers and capable of inducing myonecrosis. Analysis of T cell receptor molecules expressed by the infiltrating CD8 cells have revealed clonal expansion and conserved sequences in the antigen-binding region, both suggesting an antigen-driven T cell response. Whether the putative antigens are endogenous (e.g., muscle) or exogenous (e.g., viral) sequences is unknown. Viruses have not been identified within the muscle fibers. Key molecules involved in T cell–mediated cytotoxicity are depicted in Fig. 369-2.

**The Role of Nonimmune Factors in IBM** In IBM, the presence of vacuoles (almost always in fibers not invaded by T cells) together with β-amylloid deposits within the vacuolated muscle fibers and abnormal mitochondria with cytochrome oxidase–negative fibers suggest that, in addition to the autoimmune component, there is also a degenerative process. Similar to Alzheimer’s disease, the amyloid deposits in IBM are immunoreactive against amyloid precursor protein (APP), chymotrypsin, apolipoprotein E, and phosphorylated tau, but it is unclear whether these deposits are directly pathogenic or represent secondary phenomena. The same is true for the mitochondrial abnormalities, which may also be secondary to the effects of aging or a bystander effect of upregulated cytokines.

**Association with Viral Infections and the Role of Retroviruses** Several viruses, including coxsackieviruses, influenza, paramyxoviruses, mumps, cytomegalovirus, and Epstein-Barr virus, have been indirectly associated with myositis. For the coxsackieviruses, an autoimmune myositis triggered by molecular mimicry has been proposed because of structural homology between histidyl-transfer RNA synthetase that is the target of the Jo-1 antibody (see above) and genomic RNA of an animal picornavirus, the encephalomyocarditis virus. Sensitive polymerase chain reaction (PCR) studies, however, have repeatedly failed to confirm the presence of such viruses in muscle biopsies.

The best evidence of a viral connection in PM and IBM is with the retroviruses. Some individuals infected with HIV or with human T cell lymphotropic virus I (HTLV-I) develop PM or IBM; a similar disorder has been described in nonhuman primates infected with the simian immunodeficiency virus. The inflammatory myopathy may occur as the initial manifestation of a retroviral infection, or myositis may develop later in the disease course. Retroviral antigens have been detected only in occasional endomysial macrophages and not within the muscle fibers themselves, suggesting that persistent infection and viral replication within the muscle do not occur. Histologic findings are identical to retroviral-negative PM or IBM. This disorder should be distinguished from a toxic myopathy related to long-term therapy with AZT, characterized by fatigue, myalgia, mild muscle weakness, and mild elevation of creatine kinase (CK). AZT-induced myopathy, which generally improves when the drug is discontinued, is a mitochondrial disorder characterized histologically by "ragged-red" fibers. AZT inhibits γ-DNA polymerase, an enzyme found solely in the mitochondrial matrix.

**DIFFERENTIAL DIAGNOSIS** The clinical picture of the typical skin rash and proximal or diffuse muscle weakness has few causes other than DM. However, proximal muscle weakness without skin involvement can be due to many conditions other than PM or IBM.

**Subacute or Chronic Progressive Muscle Weakness** This may be due to denervating conditions such as the spinal muscular atrophies or amyotrophic lateral sclerosis (Chap. 353). In addition to the muscle weakness, upper motor neuron signs in the latter and signs of denervation detected by electromyography (EMG) aid in the diagnosis. The muscular dystrophies (Chap. 368) may be additional considerations; however, these disorders usually develop over years rather than weeks or months and rarely present after the age of 30. It may be difficult, even with a muscle biopsy, to distinguish chronic PM from a rapidly advancing muscular dystrophy. This is particularly true of facioscapulohumeral muscular dystrophy, dystrophin myopathy, and the dystrophinopathies where inflammatory cell infiltration is often found early in the disease. Such doubtful cases should always be given an adequate trial of glucocorticoid therapy and be screened for the respective genetic defect. Search for the MHC/CD8 lesion by immunocytochemistry is helpful to identify cases of PM as mentioned above. Some metabolic myopathies, including glycogen storage disease due to myophosphorylase or acid maltase deficiency, lipid storage myopathies due to carnitine deficiency, and mitochondrial diseases, produce weakness that is often associated with other characteristic clinical signs; diagnosis rests upon histochemical and biochemical studies of the muscle biopsy. The endocrine myopathies such as those due to hy-
pericorticosteroidism, hyper- and hypothyroidism, and hyper- and hypoparathyroidism require the appropriate laboratory investigations for diagnosis. Muscle wasting in patients with an underlying neoplasm may be due to disuse, cachexia, or rarely to a paraneoplastic neuromyopathy (Chap. 87).

Diseases of the neuromuscular junction, including myasthenia gravis or the Lambert-Eaton myasthenic syndrome, cause fatigueing weakness that also affects the eye and cranial muscles (Chap. 366). Repetitive nerve stimulation and single-fiber EMG studies aid in diagnosis.

**Acute Muscle Weakness** This may be caused by an acute neuropathy such as Guillain-Barré syndrome (Chap. 365), transverse myelitis (Chap. 356), a neurotoxin (Chap. 368), or a viral infection such as poliomyelitis or West Nile virus (Chap. 360). When acute weakness is associated with painful muscle cramps, rhabdomyolysis, and myoglobinuria, it may be due to metabolic disorders including a glyco- 

gen storage disease such as myophosphorylase deficiency or carnitine palmitoyltransferase deficiency (Chap. 368). Acute viral infections may cause a similar syndrome. Several animal parasites, such as protozoa (toxoplasma, trypanosoma), cestodes (cysticerci), and nemato 
dodes (trichinae), may produce a focal or diffuse inflammatory myopathy known as parasitic polymyositis. Staphylococcus au 

reus, Yersinia, Streptococcus, or other anaerobic bacteria may produce a suppurative myositis, known as tropical polymyositis, or pyomyositis. Pyomyositis, previously rare in the west, is now occasionally seen in AIDS patients. Other bacteria, such as Borrelia burgdorferi (Lyme disease) and Legionella pneumophila (Legionnaire’s disease) may infrequently cause myositis.

Patients with periodic paralysis develop episodes of recurrent painless acute muscle weakness, always beginning in childhood. Chronic alcoholics may develop painful myopathy with myoglobinuria after a bout of heavy drinking or present with a painless, acute hypokalemic myopathy, which is completely reversible with replacement therapy; other times they show an asymptomatic elevation of serum CK and myoglobin. Acute muscle weakness with myoglobinuria may occur with prolonged severe hypokalemia or with hypophosphatemia and hypomagnesemia, often seen in chronic alcoholics and in patients on nasogastric suction receiving parenteral hyperalimentation.

**Macrophagic Myofasciitis** This distinctive inflammatory muscle disorder presents as diffuse myalgias, fatigue, and mild muscle weakness. Muscle biopsy reveals pronounced infiltration of the connective tissue around the muscle by sheets of periodic acid–Schiff-positive macrophages and occasional CD8 T cells. The CK or erythrocyte sedimentation rate is variably elevated. Most patients respond to glucocorticoid therapy, and the overall prognosis seems favorable. Histologic involvement is focal and limited to sites of previous vaccinations, which may have been administered months or years earlier. This disorder, which to date has not been observed outside of France, has been linked to an aluminum-containing substrate used in vaccine preparation.

**Drug-Induced Myopathies** D-Penicillamine and procainamide may produce a true myositis resembling PM, and a DM-like illness had been associated with the contaminated preparations of L-tryptophan. As noted above, AZT causes a mitochondrial myopathy. Other drugs may elicit a toxic noninflammatory myopathy that is histologically different from DM, PM, or IBM. These include the cholesterol-lowering agents such as clofibrate, lovastatin, simvastatin, or pravastatin, especially when combined with cyclosporine or gemfibrozil. Rhabdomyolysis and myoglobinuria have been rarely associated with amphotericin B, e-aminoacaproic acid, fenfluramine, heroin, and phencyclidine. The use of amiodarone, chloroquine, colchicine, carbinamole, metemine, etet 
nate, ippecac syrup, chronic laxative or licorice use resulting in hypokalemia, and glucocorticoids or growth hormone administration have also been associated with myopathic muscle weakness. Some neuro 

muscular blocking agents such as pancuronium, in combination with glucocorticoids, may cause the acute critical illness myopathy. A care 

ful drug history is essential for diagnosis of these drug-induced myopathies, which do not require immunosuppressive therapy.

**Pain on Movement and Muscle Tenderness** A number of conditions including polymyalgia rheumatica (Chap. 306) and arthritic disorders of adjacent joints may enter into the differential diagnosis of inflammatory myopathy, even though they do not cause myositis. The muscle biopsy is either normal or discloses type II muscle fiber atrophy. Patients with fibrositis and fibromyalgia (Chap. 315) complain of focal or diffuse muscle tenderness, fatigue, and aching, which is sometimes poorly differentiated from joint pain. In other patients there may be suggestive signs of a collagen vascular disorder, such as an increased erythrocyte sedimentation rate, antinuclear antibody, or rheumatoid factor. Occasionally, there is slight but transient elevation of the serum CK. The muscle biopsy is usually normal and the prognosis favorable. Many such patients show some response to nonsteroidal anti-inflammatory agents, though most continue to have indolent complaints. Chronic fatigue syndrome, which may follow a viral infection, can present with debilitating fatigue, fever, sore throat, painful lymphad 

enopathy, myalgia, arthralgia, sleep disorder, and headache (Chap. 370). These patients do not have muscle weakness, and the muscle biopsy is normal.

**Diagnosis** The clinically suspected diagnosis of PM, DM, or IBM is confirmed by examining the serum muscle enzymes, EMG findings, and muscle biopsy (Table 369-2).

The most sensitive enzyme is CK, which in active disease can be
Myopathic muscle weakness, affecting proximal muscles more than distal ones and sparing eye and facial muscles, is characterized by a subacute onset (weeks to months) and rapid regression in patients who have no family history of neuromuscular disease, no endocrinopathy, no exposure to myotoxic drugs or toxins, and no biochemical muscle disease (excluded on the basis of muscle-biopsy findings).

In some cases with the typical rash, the muscle strength is seemingly normal (dermatomyositis sine myositis); these patients often have new onset of easy fatigue and reduced endurance. Careful muscle testing may reveal mild muscle weakness.

See text for details.

If the muscle biopsy does not contain vacuolated fibers but shows chronic myopathy with hypertrophic fibers, primary inflammation with the CD8/MHC-I complex and cytochrome oxygenase–negative fibers, the diagnosis is probable inclusion body myositis.

If rash is absent but muscle biopsy findings are characteristic of dermatomyositis, the diagnosis is probable DM.

However, it may guide the location of the muscle biopsy in certain clinical settings.

Muscle biopsy is the definitive test for establishing the diagnosis of inflammatory myopathy and for excluding other neuromuscular diseases. Inflammation is the histologic hallmark for these diseases; however, additional features are characteristic of each subtype.

In PM the inflammation is primary, a term used to indicate that T cell infiltrates, located primarily within the muscle fascicles (endomysially), surround individual, healthy muscle fibers and result in phagocytosis and necrosis. The MHC-I molecule is ubiquitously expressed on the sarcolemma, even in fibers not invaded by CD8+ cells. The CD8/MHC-I lesion is now fundamental for confirming or establishing the diagnosis and to exclude disorders with secondary, non-specific, inflammation. When the disease is chronic, connective tissue is increased and may react positively with alkaline phosphatase.

In DM the endomyosial inflammation is predominantly perivascular or in the interfascicular septae and around, rather than within, the muscle fascicles. The intramuscular blood vessels show endothelial hyalinization with tubuloreticular profiles, fibrin thrombi, and obliteration of capillaries. The muscle fibers undergo necrosis, degeneration, and phagocytosis, often in groups involving a portion of a muscle fasciculus in a wedge-like shape or at the periphery of the fascicle, due to microinfarcts within the muscle. This results in perifascicular atrophy, characterized by 2 to 10 layers of atrophic fibers at the periphery of the fascicles. The presence of perifascicular atrophy is diagnostic of DM, even in the absence of inflammation.

In IBM, there is endomyosial inflammation with T cells invading MHC-I–expressing nonvacuolated muscle fibers; basophilic granular deposits distributed around the edge of slittlike vacuoles (rimmed vacuoles); loss of fibers, replaced by fat and connective tissue, hypertrophic fibers, and angulated or round fibers; eosinophilic cytoplasmic inclusions; abnormal mitochondria characterized by the presence of ragged-red fibers or cytochrome oxidase–negative fibers; amyloid deposits within or next to the vacuoles; and filamentous inclusions seen by electron microscopy in the vicinity of the rimmed vacuoles.

TREATMENT

The goal of therapy is to improve muscle strength, thereby improving function in activities of daily living, and ameliorate the extramuscular manifestations (rash, dysphagia, dyspnea, fever). When strength improves, the serum CK falls concurrently; however, the reverse is not always true. Unfortunately, there is a common tendency to “chase” or treat the CK level instead of the disease is reached. The efficacy of prednisone is determined by an objective increase in muscle strength and activities of daily living, which almost always occur by the third month of therapy. A feeling of increased energy or a reduction of the CK level without a concomitant increase in muscle strength is not a reliable sign of improvement.

1. Glucocorticoids. Oral prednisone is the initial treatment of choice; the effectiveness and side effects of this therapy determine the future need for stronger immunosuppressive drugs. High-dose prednisone, at least 1 mg/kg per day, is initiated as early in the disease as possible. After 3 to 4 weeks, prednisone is tapered slowly over a period of 10 weeks to 1 mg/kg every other day. If there is evidence of efficacy and no serious side effects, the dosage is then further reduced by 5 or 10 mg every 3 to 4 weeks until the lowest possible dose that controls the disease is reached. The efficacy of prednisone is determined by an objective increase in muscle strength and activities of daily living, which almost always occur by the third month of therapy. A feeling of increased energy or a reduction of the CK level without a concomitant increase in muscle strength is not a reliable sign of improvement.

If prednisone provides no objective benefit after ~3 months of high-dose therapy, the disease is probably unresponsive to the drug and tapering should be accelerated while the next-in-line immunosuppressive drug is started. Although controlled trials have not been performed, almost all patients with true PM or DM respond to glucocorticoids to some degree and for some period of time; in general, DM responds better than PM. The long-term use of prednisone may cause increased weakness associated with a normal or unchanged CK level; this effect is referred to as steroid myopathy. In a patient who previously responded to high elevating 50-fold or normal

Polyomyositis |
| Myopathic muscle weakness | Yes | Yes | Yes | Yes, slow onset, early involvement of distal muscles, frequent falls |

Electromyographic findings |
| Muscle enzymes | Elevated (up to 50-fold) | Elevated (up to 50-fold) | Elevated (up to 50-fold) or normal |

Muscle biopsy findings |
| “Primary” inflammation with the CD8/MHC-I complex and no vacuoles | Ubiquitous MCH-I expression but minimal inflammation and no vacuoles |

Rash or calcinosis |
| Absent | Absent | Present | Absent |

Criteria for Diagnosis of Inflammatory Myopathies

| Myopathic muscle weakness | Yes | Yes | Yes |

Electromyographic findings |
| Muscle enzymes | Elevation up to 50-fold |

Muscle biopsy findings |
| “Primary” inflammation with the CD8/MHC-I complex and no vacuoles |

Rash or calcinosis |
| Absent | Absent | Present | Absent |

**TABLE 369-2 Criteria for Diagnosis of Inflammatory Myopathies**

| Myopathic muscle weakness | Yes | Yes | Yes |

Electromyographic findings |
| Muscle enzymes | Elevation up to 50-fold |

Muscle biopsy findings |
| “Primary” inflammation with the CD8/MHC-I complex and no vacuoles |

Rash or calcinosis |
| Absent | Absent | Present | Absent |

| Myopathic muscle weakness | Yes | Yes | Yes |

Electromyographic findings |
| Muscle enzymes | Elevation up to 50-fold |

Muscle biopsy findings |
| “Primary” inflammation with the CD8/MHC-I complex and no vacuoles |

Rash or calcinosis |
| Absent | Absent | Present | Absent |
doses of prednisone, the development of new weakness may be related to steroid myopathy or to disease activity that either will respond to a higher dose of glucocorticoids or has become glucocorticoid-resistant. In uncertain cases, the prednisone dosage can be adjusted arbitrarily: the cause of the weakness is usually evident in 2 to 8 weeks.

2. Other immunosuppressive drugs. Approximately 75% of patients ultimately require additional treatment. This occurs when a patient fails to respond adequately to glucocorticoids after a 3-month trial, the patient becomes glucocorticoid-resistant, glucocorticoid-related side effects appear, attempts to lower the prednisone dose repeatedly result in a new relapse, or rapidly progressive disease with evolving severe weakness and respiratory failure develops.

The following drugs are commonly used: (1) Azathioprine is well tolerated, has few side effects, and appears to be as effective for long-term therapy as other drugs. The dose is up to 3 mg/kg daily. (2) Methotrexate has a faster onset of action than azathioprine. It is given orally starting at 7.5 mg weekly for the first 3 weeks (2.5 mg every 12 h for 3 doses), with gradual dose escalation by 2.5 mg per week to a total of 25 mg weekly. A rare side effect is methotrexate pneumonitis, which can be difficult to distinguish from the interstitial lung disease of the primary myopathy associated with Jo-1 antibodies (described above). (3) Cyclophosphamide (0.5 to 1 g IV monthly for 6 months) has limited success and significant toxicity. (4) Chlorambucil has variable results. (5) Cyclosporine has inconsistent and mild benefit. (6) Mycophenolate mofetil has recently shown some effectiveness.

3. Immunomodulation. In a controlled trial of patients with refractory DM, intravenous immunoglobulin (IVIg) improved not only strength and rash but also the underlying immunopathology. The benefit is often short-lived (≤8 weeks); repeated infusions every 6 to 8 weeks are generally required to maintain improvement. A dose of 2 g/kg divided over 2 to 5 days per course is recommended. Uncontrolled observations suggest that IVIg may also be beneficial for patients with PM. Neither plasmapheresis nor leukapheresis appears to be effective in PM and DM.

The following sequential empirical approach to the treatment of PM and DM is suggested: Step 1: high-dose prednisone; step 2: azathioprine or methotrexate; step 3: IVIg; step 4: a trial, with guarded optimism, of one of the following agents, chosen according to the patient’s age, degree of disability, tolerance, experience with the drug, and the patient’s general health: cyclosporine, chlorambucil, cyclophosphamide, mycophenolate. Patients with interstitial lung disease may benefit from aggressive treatment with cyclophosphamide.

A patient with presumed PM who has not responded to any form of immunotherapy most likely has IBM or another disease, usually a metabolic myopathy, a muscular dystrophy, a drug-induced myopathy, or an endocrinopathy. In these cases, a repeat muscle biopsy and a new calcium deposit may be prevented if the primary disease responds to the available therapies. Diphosphonates, aluminum hydrox-

PROGNOSIS The 5-year survival rate for treated patients with PM and DM is ~95% and the 10-year survival 84%; death is usually due to pulmonary, cardiac, or other systemic complications. Patients severely affected at presentation or treated after long delays, those with severe dysphagia or respiratory difficulties, older patients, and those with associated cancer have a worse prognosis. DM responds more favorably to therapy than PM and thus has a better prognosis. Most patients improve with therapy, and many make a full functional recovery, which is often sustained with maintenance therapy. Up to 30% may be left with some residual muscle weakness. Relapses may occur at any time.

IBM has the least favorable prognosis of the inflammatory myopathies. Most patients will require the use of an assistive device such as a cane, walker, or wheelchair within 5 to 10 years of onset. In general, the older the age of onset in IBM, the more rapidly progressive is the course.

FURTHER READING

ASKANAS V, ENGEL WK: Inclusion body myopathies: Different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol 15:525, 2002


HILTON-JONES D: Inflammatory myopathies, Curr Opin Neurol 14:591, 2001


Section 4 Chronic Fatigue Syndrome

DEFINITION Chronic fatigue syndrome (CFS) is the current name for a disorder characterized by debilitating fatigue and several associated physical, constitutional, and neuropsychological complaints (Table 370-1). This syndrome is not new; in the past, patients diagnosed with conditions such as the vespers, neurasthenia, effort syndrome, chronic brucellosis, epidemic neuromyasthenia, myalgic encephalomyelitis, hypoglycemia, multiple chemical sensitivity syndrome, chronic can-
radically, but many clusters have also been reported. Famous outbreaks of CFS occurred in Los Angeles County Hospital in 1934; in Akureyri, Iceland, in 1948; in the Royal Free Hospital, London, in 1955; and in Incline Village, Nevada, in 1985. While these clustered cases suggest a common environmental or infectious cause, none has been identified.

Estimates of the prevalence of CFS have depended on the case definition used and the method of study. Chronic fatigue itself is a common symptom, occurring in as many as 20% of patients attending general medical clinics; CFS is far less common. Community-based studies find that 100 to 300 individuals per 100,000 population in the United States meet the current CDC case definition.

**PATHOGENESIS** The diverse names for the syndrome reflect the many and controversial hypotheses about its etiology. Several common themes underlie attempts to understand the disorder: It is often postinfectious, is associated with immunologic disturbances, and it is commonly accompanied or even precipitated by neuropsychological complaints, somatic preoccupation, and/or depression.

Many studies in the 1980s and 1990s attempted to link CFS to infection with Epstein-Barr virus, a retrovirus, or an enterovirus. In many patients with chronic fatigue, titers of antibodies to several viruses are elevated. Reports that viral antigens and nucleic acids could be specifically identified in patients with CFS have not been confirmed. One study from the United Kingdom failed to detect any association between acute infections and subsequent prolonged fatigue. Another study found that chronic fatigue did not develop after typical upper respiratory infections but did in some individuals after infectious mononucleosis. Thus, while antecedent viral infections are associated with CFS, a direct viral pathogenesis is unproven and unlikely.

Changes in numerous immune parameters of uncertain functional significance have been reported in CFS. Modest elevations in titers of antinuclear antibodies, reductions in immunoglobulin subclasses, deficiencies in mitogen-driven lymphocyte proliferation, reductions in natural killer cell activity, disturbances in cytokine production, and shifts in lymphocyte subsets have been described. None of the immune findings appears in all patients, nor do any correlate with the severity of CFS. Careful comparison of affected and unaffected monozygotic twins showed no substantive immunologic differences. In theory, symptoms of CFS could result from excessive production of a cytokine, such as interleukin 1, that induces asthenia and other flulike symptoms; however, compelling data in support of this long-held hypothesis are lacking.

In some studies, patients with CFS manifest unusual sensitivity to sustained upright tilting, resulting in hypotension and syncope, so as to suggest a form of dysautonomia. Disturbances in the hypothalamic-pituitary-adrenal function have been identified in several controlled studies of CFS, with some evidence for normalization in patients whose fatigue abates. These neuroendocrine abnormalities could contribute to the impaired energy and depressed mood of patients.

Mild to moderate depression is present in half to two-thirds of patients. Much of this depression may be reactive, but its prevalence exceeds that seen in other chronic medical illnesses. Some propose that CFS is fundamentally a psychiatric disorder and that the various neuroendocrine and immune disturbances arise secondarily.

**MANIFESTATIONS** Typically, CFS arises suddenly in a previously active individual. An otherwise unremarkable flulike illness or some other acute stress leaves unbearable exhaustion in its wake. Other symptoms, such as headache, sore throat, tender lymph nodes, muscle and joint aches, and frequent feverishness, lead to the belief that an infection persists, and medical attention is sought. Over several weeks, despite reassurances that nothing serious is wrong, the symptoms persist and other features of the syndrome become evident—disturbed sleep, difficulty in concentration, and depression (Table 370-1).

Depending on the dominant symptoms and the beliefs of the patient, additional consultations may be sought from allergists, rheumatologists, infectious disease specialists, psychiatrists, ecologic therapists, homeopaths, or other professionals, frequently with unsatisfactory results. Once the pattern of illness is established, the symptoms may fluctuate somewhat. Many patients report that diverse complaints are linked—that during periods of greatest fatigue they perceive the most pain and difficulty with concentration. Patients also commonly assert that excessive physical or emotional stress may exacerbate their symptoms.

Most patients remain capable of meeting family, work, or community obligations despite their symptoms; discretionary activities are abandoned first. Some feel unable to engage in any gainful employment. A minority of individuals require help with the activities of daily living.

Ultimately, isolation, frustration, and pathetic resignation can mark the protracted course of illness. Patients may become angry at physicians for failing to acknowledge or resolve their plight. Fortunately, CFS does not appear to progress. On the contrary, many patients experience gradual improvement, and a minority recover fully.

**DIAGNOSIS** A thorough history, physical examination, and judicious use of laboratory tests are required to exclude other causes of the patient’s symptoms. Prominent abnormalities argue strongly in favor of alternative diagnoses. No laboratory test, however, can diagnose this condition or measure its severity. In most cases, elaborate, expensive workups are not helpful. Early claims that magnetic resonance imaging or single photon emission computed tomography can identify

---

**TABLE 370-2 CDC Criteria for Diagnosis of Chronic Fatigue Syndrome**

A case of chronic fatigue syndrome is defined by the presence of:

1. Clinically evaluated, unexplained, persistent or relapsing fatigue that is of new or definite onset; is not the result of ongoing exertion; is not alleviated by rest; and results in substantial reduction of previous levels of occupational, educational, social, or personal activities; and

2. Four or more of the following symptoms that persist or recur during six or more consecutive months of illness and that do not predate the fatigue:
   - Sore throat
   - Tender cervical or axillary nodes
   - Muscle pain
   - Multijoint pain without redness or swelling
   - Headaches of a new pattern or severity
   - Unrefreshing sleep
   - Postexertional malaise lasting ≥24 h

**Source:** CDC, U.S. Centers for Disease Control and Prevention.

**Note:** CDC, U.S. Centers for Disease Control and Prevention.

**Source:** Adapted from K Fukuda et al: Ann Intern Med 121:953, 1994; with permission.

---

**TABLE 370-1 Specific Symptoms Reported by Patients with Chronic Fatigue Syndrome**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>100</td>
</tr>
<tr>
<td>Difficulty concentrating</td>
<td>90</td>
</tr>
<tr>
<td>Headache</td>
<td>90</td>
</tr>
<tr>
<td>Sore throat</td>
<td>85</td>
</tr>
<tr>
<td>Tender lymph nodes</td>
<td>80</td>
</tr>
<tr>
<td>Muscle aches</td>
<td>80</td>
</tr>
<tr>
<td>Joint aches</td>
<td>75</td>
</tr>
<tr>
<td>Feverishness</td>
<td>75</td>
</tr>
<tr>
<td>Difficulty sleeping</td>
<td>70</td>
</tr>
<tr>
<td>Psychiatric problems</td>
<td>65</td>
</tr>
<tr>
<td>Allergies</td>
<td>55</td>
</tr>
<tr>
<td>Abdominal cramps</td>
<td>40</td>
</tr>
<tr>
<td>Weight loss</td>
<td>20</td>
</tr>
<tr>
<td>Rash</td>
<td>10</td>
</tr>
<tr>
<td>Rapid pulse</td>
<td>10</td>
</tr>
<tr>
<td>Weight gain</td>
<td>5</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5</td>
</tr>
<tr>
<td>Night sweats</td>
<td>5</td>
</tr>
</tbody>
</table>

**Source:** From SE Straus: J Infect Diseases 157:405, 1988; with permission.
abnormalities in the brain of CFS patients have not withstood further study. The dilemma for patient and clinician alike is that CFS has no pathognomonic features and remains a constellation of symptoms and a diagnosis of exclusion. Often the patient presents with features that also meet criteria for other subjective disorders such as fibromyalgia and irritable bowel syndrome.

### Treatment

After other illnesses have been excluded, there are several points to address in the long-term care of a patient with chronic fatigue.

The patient should be informed about the illness and what is known of its pathogenesis; its potential impact on the physical, psychological, and social dimensions of life; and its prognosis. Patients are relieved when their complaints are taken seriously. Periodic reassessment is appropriate to identify a possible underlying process that is late in declaring itself and to address intercurrent symptoms that should not be simply dismissed as yet another subjective complaint.

Many symptoms of CFS respond to treatment. Non-steroidal anti-inflammatory drugs alleviate headache, diffuse pain, and feverishness. Allergic rhinitis and sinusitis are common; antihistamines or decongestants may be helpful. Although the patient may be averse to psychiatric diagnoses, depression and anxiety are often prominent and should be treated. Expert psychiatric assessment is sometimes advisable. Non-sedating antidepressants improve mood and disordered sleep and may attenuate the fatigue. Even modest improvements in symptoms can make an important difference in the patient’s degree of self-sufficiency and ability to appreciate life’s pleasures.

Practical advice should be given regarding life-style. Sleep disturbances are common; consumption of heavy meals with alcohol and caffeine at night can make sleep even more elusive, compounding fatigue. Total rest leads to further deconditioning and the self-image of being an invalid, whereas overexertion may worsen exhaustion and lead to total avoidance of exercise. A moderate, carefully graded regimen should be encouraged and has been proven to relieve symptoms and enhance exercise tolerance.

Controlled therapeutic trials have established that acyclovir, fluconazole, and intravenous immunoglobulin, among others, are of little or no value in CFS. Low doses of hydrocortisone provide modest benefit, but they may lead to adrenal suppression. Countless anecdotes circulate regarding other traditional and nontraditional therapies. It is important to guide patients away from those therapeutic modalities that are toxic, expensive, or unreasonable.

The physician should promote the patient’s efforts to recover. Controlled trials in the United Kingdom, in Australia, and in the Netherlands showed cognitive-behavioral therapy to be helpful. This approach aims to dispel misguided beliefs and fears about CFS that can contribute to inactivity and despair. For CFS, as for many other conditions, a comprehensive approach to physical, psychological, and social aspects of well-being is in order.

### Further Reading


---

### Mental Disorders

Mental disorders are common in medical practice and may present either as a primary disorder or as a comorbid condition. The prevalence of mental or substance use disorders in the United States is 18.5%, resulting in an annual cost of $148 billion dollars, only slightly less than the costs of cardiovascular diseases. Only 15% of these individuals are currently receiving treatment.

The revised 4th edition for use by primary care physicians of the Diagnostic and Statistical Manual (DSM-IV-PC) provides a useful synopsis of mental disorders most likely to be seen in primary care practice. The current system of classification is multiaxial and includes the presence or absence of a major mental disorder (axis I), any underlying personality disorder (axis II), general medical condition (axis III), psychosocial and environmental problems (axis IV), and overall rating of general psychosocial functioning (axis V).

Changes in health care delivery underscore the need for primary care physicians to assume responsibility for the initial diagnosis and treatment of the most common mental disorders. Prompt diagnosis is essential to ensure that patients have access to appropriate medical services and to maximize the clinical outcome. Validated patient-based questionnaires have been developed that systematically probe for signs and symptoms associated with the most prevalent psychiatric diagnoses and guide the clinician into targeted assessment. Prime MD (and a self-report form, the PHQ) and the Symptom-Driven Diagnostic System for Primary Care (SDDS-PC) are inventories that require only 10 min to complete and link patient responses to the formal diagnostic criteria of anxiety, mood, somatoform, and eating disorders and to alcohol abuse or dependence.

A physician who refers patients to a psychiatrist should know not only when doing so is appropriate but also how to refer, since societal misconceptions and the stigma of mental illness impede the process. Primary care physicians should base referrals to a psychiatrist on the presence of signs and symptoms of a mental disorder and not simply on the absence of a physical explanation for a patient’s complaint. The physician should discuss with the patient the reasons for requesting the referral or consultation and provide reassurance that he or she will continue to provide medical care and work collaboratively with the mental health professional. Consultation with a psychiatrist or transfer of care is appropriate when physicians encounter evidence of psychotic symptoms, mania, severe depression, or anxiety; symptoms of posttraumatic stress disorder (PTSD); suicidal or homicidal preoccupation; or a failure to respond to first-order treatment. Eating disorders are discussed in Chap. 65.

### Anxiety Disorders

Anxiety disorders, the most prevalent psychiatric illnesses in the general community, are present in 15 to 20% of medical clinic patients. Anxiety, defined as a subjective sense of unease, dread, or foreboding, can indicate a primary psychiatric condition or can be a component of, or reaction to, a primary medical disease. The primary anxiety disorders are classified according to their duration and course and the existence and nature of precipitants.

When evaluating the anxious patient, the clinician must first determine whether the anxiety antedates or postdates a medical illness or is due to a medication side effect. Approximately one-third of patients presenting with anxiety have a medical etiology for their psychiatric symptoms, but an anxiety disorder can also present with somatic symptoms in the absence of a diagnosable medical condition.

### Panic Disorder

Panic disorder is defined by the presence of recurrent and unpredictable panic attacks, which are distinct episodes of intense fear and discomfort associated with a variety of physical symptoms, including palpitations, sweating, trembling, shortness of breath, chest pain, dizziness, and a fear of impending...
situations in which a panic attack might recur. Results in a generalized fear and a progressive avoidance of places or the home, and onset is typically in late adolescence to early adulthood. In some individuals, anticipatory anxiety develops over time and results in a generalized fear and a progressive avoidance of places or situations in which a panic attack might recur. Agoraphobia, which occurs commonly in patients with panic disorder, is an acquired irrationai fear of being in places where one might feel trapped or unable to escape (Table 371-2). Typically, it leads the patient into a progressive restriction in lifestyle and, in a literal sense, in geography. Frequently, patients are embarrassed that they are housebound and dependent on the company of others to go out into the world and do not volunteer this information; thus physicians will fail to recognize the syndrome if direct questioning is not pursued.

**Differential Diagnosis** A diagnosis of panic disorder is made after a medical etiology for the panic attacks has been ruled out. A variety of cardiovascular, respiratory, endocrine, and neurologic conditions can present with anxiety as the chief complaint. Patients with true panic disorder will often focus on one specific feature to the exclusion of others. For example, 20% of patients who present with syncope as a primary medical complaint have a primary diagnosis of a mood, anxiety, or substance-abuse disorder, the most common being panic disorder. The differential diagnosis of panic disorder is complicated by a high rate of comorbidity with other psychiatric conditions, especially alcohol and benzodiazepine abuse, which patients initially use in an attempt at self-medication. Some 75% of panic disorder patients will also satisfy criteria for major depression at some point in their illness.

When the history is nonspecific, physical examination and focused laboratory testing must be used to rule out anxiety states resulting from medical disorders such as pheochromocytoma, thyrotoxicosis, or hypoglycemia. Electrocardiogram (ECG) and echocardiogram may detect some cardiovascular conditions associated with panic, such as paroxysmal atrial tachycardia and mitral valve prolapse. In two studies, panic disorder was the primary diagnosis in 43% of patients with chest pain who had normal coronary angiograms and was present in 9% of all outpatients referred for cardiac evaluation. Panic disorder has also been diagnosed in many patients referred for pulmonary function testing or with symptoms of irritable bowel syndrome.

**Etiology and Pathophysiology** The etiology of panic disorder is unknown but appears to involve a genetic predisposition, altered autonomic responsivity, and social learning. Panic disorder shows familial aggregation; the disorder is concordant in 30 to 45% of monozygotic twins, and genome-wide screens have identified suggestive risk loci on 1q, 7p15, 10q, 11p, and 13q. Acute panic attacks appear to be associated with increased noradrenergic discharges in the locus coeruleus. Intravenous infusion of sodium lactate evokes an attack in two-thirds of panic disorder patients, as do the α-adrenergic antagonist yohimbine, cholecystokinin tetrapeptide (CCK-4), and carbon dioxide inhalation. It is hypothesized that each of these stimuli activates a pathway involving noradrenergic neurons in the locus coeruleus and serotoninergic neurons in the dorsal raphe. Agents that block serotonin reuptake can prevent attacks. It is theorized that panic-disorder patients have a heightened sensitivity to somatic symptoms, which triggers increasing arousal, setting off the panic attack. Accordingly, therapeutic intervention involves altering the patient’s cognitive interpretation of anxiety-producing experiences as well as preventing the attack itself.

**Achievable goals of treatment are to decrease the frequency of panic attacks and to reduce their intensity.** The cornerstone of drug therapy is antidepressant medication (Tables 371-3, 371-4, and 371-5). The tricyclic antidepressants (TCAs) imipramine and clomipramine benefit 75 to 90% of panic disorder patients. Low doses (e.g., 10 to 25 mg/d) are given initially to avoid transient increased anxiety associated with heightened monoamine levels. Selective serotonin reuptake inhibitors (SSRIs) are equally effective and do not have the adverse effects of TCAs. SSRIs should be started at one-third to one-half of their usual antidepressant dose (e.g., 5 to 10 mg fluoxetine, 25 to 50 mg sertraline, 10 mg paroxetine). Monoamine oxidase inhibitors (MAOIs) are also effective and may specifically benefit patients who have comorbid features of atypical depression (i.e., hypsomminia and weight gain). Insomnia, orthostatic hypotension, and the need to maintain a low-tyramine diet (avoidance of cheese and wine) have limited their use, however. Antidepressants typically take 2 to 6 weeks to become effective, and doses may need to be adjusted based upon the clinical response.

Because of anticipatory anxiety and the need for immediate relief of panic symptoms, benzodiazepines are useful early in the course of treatment and sporadically thereafter (Table 371-6). For example, alprazolam, starting at 0.5 mg qid and increasing to 4 mg/d in divided doses, is effective, but patients must be monitored closely, as some develop dependence and begin to escalate the dose of this medication. Clonazepam, at a final maintenance dose of 2 to 4 mg/d, is also helpful; its longer half-life permits twice-daily dosing, and patients appear less likely to develop dependence on this agent.

Early psychotherapeutic intervention and education aimed at symp-

**TABLE 371-1 Diagnostic Criteria for Panic Attack**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palpitations, pounding heart, or accelerated heart rate</td>
<td>1.</td>
</tr>
<tr>
<td>Sweating</td>
<td>2.</td>
</tr>
<tr>
<td>Trembling or shaking</td>
<td>3.</td>
</tr>
<tr>
<td>Sensations of shortness of breath or smothering</td>
<td>1.</td>
</tr>
<tr>
<td>Feeling of choking</td>
<td>5.</td>
</tr>
<tr>
<td>Chest pain or discomfort</td>
<td>6.</td>
</tr>
<tr>
<td>Nausea or abdominal distress</td>
<td>7.</td>
</tr>
<tr>
<td>Feeling dizzy, unsteady, lightheaded, or faint</td>
<td>8.</td>
</tr>
<tr>
<td>Derealization (feelings of unreality) or depersonalization</td>
<td>9.</td>
</tr>
<tr>
<td>(being detached from oneself)</td>
<td>9.</td>
</tr>
<tr>
<td>Fear of losing control or going crazy</td>
<td>10.</td>
</tr>
<tr>
<td>Fear of dying</td>
<td>11.</td>
</tr>
<tr>
<td>Paresthesias (numbness or tingling sensations)</td>
<td>12.</td>
</tr>
<tr>
<td>Chills or hot flushes</td>
<td>13.</td>
</tr>
</tbody>
</table>

Source: Diagnostic and Statistical Manual of Mental Disorders, 4th ed.

**TABLE 371-2 Diagnostic Criteria for Agoraphobia**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety about being in places or situations from which escape might be</td>
<td>1.</td>
</tr>
<tr>
<td>difficult (or embarrassing) or in which help may not be available in</td>
<td></td>
</tr>
<tr>
<td>the event of having an unexpected or situationally predisposed panic</td>
<td></td>
</tr>
<tr>
<td>attack or panic-like symptoms. Agoraphobic fears typically involve</td>
<td></td>
</tr>
<tr>
<td>characteristic clusters of situations that include being outside the</td>
<td></td>
</tr>
<tr>
<td>home alone; being in a crowd or standing in a line; being on a bridge;</td>
<td></td>
</tr>
<tr>
<td>and traveling in a bus, train, or automobile.</td>
<td></td>
</tr>
<tr>
<td>The situations are avoided (e.g., travel is restricted) or else are</td>
<td>2.</td>
</tr>
<tr>
<td>endured with marked distress or with anxiety about having a panic attack</td>
<td></td>
</tr>
<tr>
<td>or panic-like symptoms, or require the presence of a companion.</td>
<td></td>
</tr>
<tr>
<td>The anxiety or phobic avoidance is not better accounted for by another</td>
<td>3.</td>
</tr>
<tr>
<td>mental disorder, such as social phobia (e.g., avoidance limited to</td>
<td></td>
</tr>
<tr>
<td>social situations because of fear of embarrassment), specific phobia</td>
<td></td>
</tr>
<tr>
<td>(e.g., avoidance limited to a single situation like elevators),</td>
<td></td>
</tr>
<tr>
<td>obsessive-compulsive disorder (e.g., avoidance of dirt in someone with</td>
<td></td>
</tr>
<tr>
<td>an obsession about contamination), posttraumatic stress disorder (e.g.,</td>
<td></td>
</tr>
<tr>
<td>avoidance of stimuli associated with a severe stressor), or separation</td>
<td></td>
</tr>
<tr>
<td>anxiety disorder (e.g., avoidance of leaving home or relatives).</td>
<td></td>
</tr>
</tbody>
</table>

Source: Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
tom control enhances the effectiveness of drug treatment. Patients can be taught breathing techniques, can be educated about physiologic changes that occur with panic, and can learn to expose themselves voluntarily to precipitating events in a treatment program spanning 12 to 15 sessions. Homework assignments and monitored compliance are important components of successful treatment. Once patients have achieved a satisfactory response, drug treatment should be maintained for 1 to 2 years to prevent relapse. Controlled trials indicate a success rate of 75 to 85%, although the likelihood of complete remission is somewhat lower.

**GENERALIZED ANXIETY DISORDER**

### Clinical Manifestations

Patients with generalized anxiety disorder (GAD) have persistent, excessive, and/or unrealistic worry associated with muscle tension, impaired concentration, autonomic arousal, feeling “on edge” or restless, and insomnia (Table 371-7). Onset is usually before age 20, and a history of childhood fears and social inhibition may be present. The lifetime prevalence of GAD is 5 to 6%; the risk is higher in first-degree relatives of patients with the diagnosis. Interestingly, family studies indicate that GAD and panic disorder segregate independently. Over 80% of patients with GAD also suffer from major depression, dysthymia, or social phobia. Comorbid substance abuse is common in these patients, particularly alcohol and/or sedative/hypnotic abuse. Patients with GAD worry excessively over minor matters, with life-disrupting effects; unlike in panic disorder, complaints of shortness of breath, palpitations, and tachycardia are relatively rare.

### Etiology and Pathophysiology

Experimental work suggests that anxiogenic agents share in common the property of altering the binding of benzodiazepines to the γ-aminobutyric acid (GABA) receptor/chloride ion channel complex. Benzodiazepines are thought to bind to two separate GABA<sub>A</sub> receptor sites: type I, which has a broad neuroanatomic distribution, and type II, which is concentrated in the hippocampus, striatum, and neocortex. The anxiolytic effects of the various benzodiazepines and side effects such as sedation and memory impairment are influenced by their relative binding to type I and type II receptor sites. Serotonin [5-hydroxytryptamine (5HT)] also appears to play a role in anxiety, and buspirone, a partial 5HT<sub>1A</sub> receptor agonist, and certain 5HT<sub>2A</sub> and 5HT<sub>2C</sub> receptor antagonists (e.g., nefazodone) may have beneficial effects.

### Treatment

A combination of pharmacologic and psychotherapeutic interventions is most effective in GAD, but complete symptomatic relief is rare. A short course of a benzodiazepine is usually indicated, preferably lorazepam, oxazepam, or temazepam. (The first two of these agents are metabolized via conjugation rather than oxidation and thus do not accumulate if hepatic function is altered.) Administration should be initiated at the lowest dose possible and prescribed on an as-needed basis as symptoms warrant. Benzodiazepines differ in their milligram per kilogram potency, half-life, lipid solubility, metabolic pathways, and presence of active metabolites. Agents that are absorbed rapidly and are lipid soluble, such as diazepam, have a rapid onset of action and a higher abuse potential. Benzodiazepines should generally not be prescribed for >4 to 6 weeks because of the development of tolerance and the risk of abuse and dependence. It is important to warn patients that concomitant use of alcohol or other sedating drugs may be neurotoxic and impair their ability to function. An optimistic approach that encourages the patient to clarify environmental precipitants, anticipate his or her reactions, and plan effective response strategies is an essential element of therapy.

### Adverse Effects

Adverse effects of benzodiazepines generally parallel their relative half-lives. Longer-acting agents, such as diazepam, chloridiazepoxide, flurazepam, and clonazepam, tend to accumulate active metabolites,

### TABLE 371-3 Antidepressants

<table>
<thead>
<tr>
<th>Name</th>
<th>Usual Daily Dose, mg</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRIs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine (Prozac)</td>
<td>10–80</td>
<td>Headache; nausea and other GI effects; jitteriness; insomnia; sexual dysfunction; can affect plasma levels of other meds (except sertraline); akathisia rare</td>
<td>Once daily dosing, usually in A.M.; fluoxetine has very long half-life; must not be combined with MAOIs</td>
</tr>
<tr>
<td>Sertraline (Zoloft)</td>
<td>50–200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paroxetine (Paxil)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluvoxamine (Luvox)</td>
<td>100–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citalopram (Celexa)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escitalopram (Lexapro)</td>
<td>10–30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCAs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline (Elavil)</td>
<td>150–300</td>
<td>Anticholinergic (dry mouth, tachycardia, constipation, urinary retention, blurred vision); sweating; tremor; postural hypotension; cardiac conduction delay; sedation; weight gain</td>
<td>Once daily dosing, usually qhs; blood levels of most TCAs available; can be lethal in O.D. (lethal dose = 2 g); nortriptyline best tolerated, especially by elderly</td>
</tr>
<tr>
<td>Nortriptyline (Pamelor)</td>
<td>50–200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imipramine (Tofranil)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desipramine (Norpramin)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxepin (Sinequan)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clomipramine (Anafranil)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed norepinephrine/serotonin reuptake inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venlafaxine (Effexor)</td>
<td>75–375</td>
<td>Nausea; dizziness; dry mouth; headaches; increased blood pressure; anxiety and insomnia</td>
<td>Bid-tid dosing (extended release available); lower potential for drug interactions than SSRIs; contraindicated with MAOIs</td>
</tr>
<tr>
<td>Mirtazapine (Remeron)</td>
<td>15–45</td>
<td>Somnolence; weight gain; neutropenia rare</td>
<td>Once daily dosing</td>
</tr>
<tr>
<td>Mixed-action drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupropion (Wellbutrin)</td>
<td>250–450</td>
<td>Jitteriness; flushing; seizures in at-risk patients; anorexia; tachycardia; psychosis</td>
<td>Tid dosing, but sustained release also available; fewer sexual side effects than SSRIs or TCAs; may be useful for adult ADD</td>
</tr>
<tr>
<td>Trazodone (Desyrel)</td>
<td>200–600</td>
<td>Sedation; dry mouth; ventricular irritability; postural hypotension; priapism rare</td>
<td>Useful in low doses for sleep because of sedating effects with no anticholinergic side effects</td>
</tr>
<tr>
<td>Nefazodone (Serzone)</td>
<td>300–600</td>
<td>Sedation; headache; dry mouth; nausea; constipation</td>
<td>Once daily dosing; no effect on REM sleep unlike other antidepressants</td>
</tr>
<tr>
<td>Amoxapine (Asendin)</td>
<td>200–600</td>
<td>Sexual dysfunction</td>
<td>Lethality in overdose; EPS possible</td>
</tr>
<tr>
<td>MAOIs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenelzine (Nardil)</td>
<td>45–90</td>
<td>Insomnia; hypotension; anorgasmia; weight gain; hypertensive crisis; tyramine cheese reaction; lethal reactions with SSRIs; serious reactions with narcotics</td>
<td>May be more effective in patients with atypical features or treatment-refractory depression</td>
</tr>
<tr>
<td>Tranylcypromine (Parnate)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isocarboxazid (Marplan)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** ADD, attention deficit disorder; MAOI, monoamine oxidase inhibitor; REM, rapid eye movement; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; EPS, extrapyramidal symptoms.
with resultant sedation, impairment of cognition, and poor psychomotor performance. Shorter-acting compounds, such as alprazolam and oxazepam, can produce daytime anxiety, early morning insomnia, and, with discontinuation, rebound anxiety and insomnia. Although patients develop tolerance to the sedative effects of benzodiazepines, they are less likely to habituate to the adverse psychomotor effects. Withdrawal from the longer half-life benzodiazepines can be accomplished through gradual, stepwise dose reduction (by 10% every 1 to 2 weeks) over 6 to 12 weeks. It is usually more difficult to taper patients off shorter-acting benzodiazepines. Physicians may need to switch the patient to a benzodiazepine with a longer half-life or use an adjunctive medication, such as a beta blocker or carbamazepine, before attempting to discontinue the benzodiazepine. Withdrawal reactions vary in severity and duration; they can include depression, anxiety, delirium, lethargy, diaphoresis, tinnitus, autonomic arousal, adventitious movements, and, rarely, seizures.

Buspirone is a nonbenzodiazepine anxiolytic agent. It is nontasing, does not produce tolerance or dependence, does not interact with benzodiazepine receptors or alcohol, and has no abuse or disinhibition potential. However, it requires several weeks to take effect and requires thrice-daily dosing. Patients who were previously responsive to a benzodiazepine are unlikely to rate buspirone as equally effective, but patients with head injury or dementia who have symptoms of anxiety and/or agitation may do well with this agent.

Administration of benzodiazepines to geriatric patients requires special care. Such patients have increased drug absorption; decreased hepatic metabolism, protein binding, and renal excretion; and an increased volume of distribution. These factors, together with the likely presence of comorbid medical illnesses and medication, dramatically increase the likelihood of toxicity. Iatrogenic psychomotor impairment can result in falls and fractures, confusional states, or motor vehicle accidents. If used, agents in this class should be started at the lowest possible dose, and effects should be monitored closely. Benzodiazepines are contraindicated during pregnancy and breast-feeding.

**PHOBIC DISORDERS**

**Clinical Manifestations**  The cardinal feature of phobic disorders is a marked and persistent fear of objects or situations, exposure to which results in an immediate anxiety reaction. The patient avoids the phobic stimulus, and this avoidance usually impairs occupational or social functioning. Panic attacks may be triggered by the phobic stimulus or may occur spontaneously. Unlike patients with other anxiety disorders, individuals with phobias usually experience anxiety only in specific situations. Common phobias include fear of closed spaces (claustrophobia), fear of blood, and fear of flying. Social phobia is distinguished by a specific fear of social or performance situations in which the individual is exposed to unfamiliar individuals or to possible examination and evaluation by others. Examples include having to converse at a party, use public restrooms, and meet strangers. In each case, the affected individual is aware that the experienced fear is excessive and unreasonable given the circumstance. The specific content of a phobia may vary across gender, ethnic, and cultural boundaries.

Phobic disorders are common, affecting ~10% of the population. Full criteria for diagnosis are usually satisfied first in early adulthood, but behavioral avoidance of unfamiliar people, situations, or objects dating from early childhood is common.

In one study of female twins, concordance rates for agoraphobia, social phobia, and animal phobia were found to be 23% for monoygotic twins and 15% for dizygotic twins. A twin study of fear conditioning, a model for the acquisition of phobias, demonstrated a heritability of 35 to 45%, and a genome-wide linkage scan has identified a risk locus on chromosome 14 in a region previously implicated in anxiety-related syndromes. Agents that selectively target GABA<sub>α</sub> receptor subtypes are currently under development; and it is hoped that these will lack the sedating, memory-impairing, and addicting properties of benzodiazepines.

### TABLE 371-4  Management of Antidepressant Side Effects

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Comments and Management Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td>Related to tolerance? Increase dose or drug holiday; add amantadine, 100 mg bid, buspirone, 10 mg tid, or pindolol, 2.5 mg bid</td>
</tr>
<tr>
<td>Nausea, loss of appetite</td>
<td>Consider temporary dose reduction or administration with food and antacids</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Famotidine, 20–40 mg/d</td>
</tr>
<tr>
<td>Constipation</td>
<td>Wait for tolerance; try diet change, stool softener, exercise; avoid laxatives</td>
</tr>
<tr>
<td>Sexual dysfunction</td>
<td>Consider dose reduction; drug holiday</td>
</tr>
<tr>
<td>Anorgasmia/impotence, impaired ejaculation</td>
<td>Bethanechol, 10–20 mg; 2 h before activity, or cyproheptadine, 4–8 mg 2 h before activity, or bupropion, 100 mg bid or amantadine, 100 mg bid/tid</td>
</tr>
<tr>
<td>Orthostasis</td>
<td>Tolerance unlikely; increase fluid intake, use caffeine/support hose; fludrocortisone, 0.025 mg/d</td>
</tr>
<tr>
<td>Anticholinergic</td>
<td>Wait for tolerance</td>
</tr>
<tr>
<td>Dry mouth, eyes</td>
<td>Maintain good oral hygiene; use artificial tears, sugar-free gum</td>
</tr>
<tr>
<td>Tremor/jitteriness</td>
<td>Antiparkinsonian drugs not effective; use dose reduction/slow increase; lorazepam, 0.5 mg bid, or propranolol, 10–20 mg bid</td>
</tr>
<tr>
<td>Insomnia</td>
<td>Schedule all doses for the morning; trazodone, 50–100 mg qhs</td>
</tr>
<tr>
<td>Sedation</td>
<td>Caffeine; schedule all dosing for bedtime; bupropion, 75–100 mg in afternoon</td>
</tr>
<tr>
<td>Headache</td>
<td>Evaluate diet, stress; other drugs; try dose reduction; amitriptyline, 50 mg/d</td>
</tr>
<tr>
<td>Weight gain</td>
<td>Decrease carbohydrates; exercise; consider fluoxetine</td>
</tr>
<tr>
<td>Loss of therapeutic benefit over time</td>
<td>Related to tolerance? Increase dose or drug holiday; add amantadine, 100 mg bid, buspirone, 10 mg tid, or pindolol, 2.5 mg bid</td>
</tr>
</tbody>
</table>

**Note:** SSRIs, selective serotonin reuptake inhibitor.

### TABLE 371-5  Possible Drug Interactions with Selective Serotonin Reuptake Inhibitors

<table>
<thead>
<tr>
<th>Agent</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td>Serotonin syndrome—absolute contraindication</td>
</tr>
<tr>
<td>Serotonergic agonists, e.g., tryptophan, fenfluramine</td>
<td>Potential serotonin syndrome</td>
</tr>
<tr>
<td>Drugs that are metabolized by P450 isoenzymes: tricyclics, other SSRI s, antipsychotics, beta blockers, codeine, terfenadine, astemizole, triazolobenzodiazepines, calcium channel blockers</td>
<td>Delayed metabolism resulting in increased blood levels and potential toxicity—possible fatality secondary to QT prolongation with terfenadine or astemizole</td>
</tr>
<tr>
<td>Drugs that are bound tightly to plasma proteins, e.g., warfarin</td>
<td>Increased bleeding secondary to displacement</td>
</tr>
<tr>
<td>Drugs that inhibit the metabolism of SSRIs by P450 isoenzymes, e.g., quinidine</td>
<td>Increased SSRI side effects</td>
</tr>
</tbody>
</table>

**Note:** SSRI, selective serotonin reuptake inhibitor.

**Beta blockers (e.g., propranolol, 20 to 40 mg orally 2 h before the event)** are particularly effective in the treatment of “performance anxiety” (but not general social phobia) and appear to work by blocking the peripheral manifestations of anxiety, such as perspiration, tachycardia, palpitations, and tremor. MAOIs alleviate social phobia independently of their antidepressant activity, and SSRIs appear to be ef-
Behavioral treatments. PTSD is highly correlated with peritraumatic dissociation and the development of an acute stress disorder at the time of the trauma. TCAs such as imipramine and amitriptyline, the MAOI phenelzine, and the SSRIs (fluoxetine, sertraline, citalopram, paroxetine) can all reduce anxiety, symptoms of intrusion, and avoidance behaviors, as can prazosin, an α1 antagonist. Trazodone, a sedating antidepressant, is frequently used at night to help with insomnia (50 to 150 mg qhs). Carbamazepine, valproic acid, or alprazolam have also independently produced improvement in uncontrolled trials. Psychotherapeutic strategies for PTSD help the patient overcome avoidance behaviors and demoralization and master fear of recurrence.

### TABLE 371-7 Diagnostic Criteria for Generalized Anxiety Disorder

| A. Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance). |
| B. The person finds it difficult to control the worry. |
| C. The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms present for more days than not for the past 6 months): (1) restlessness or feeling keyed up or on edge; (2) being easily fatigued; (3) difficulty concentrating or mind going blank; (4) irritability; (5) muscle tension; (6) sleep disturbance (difficulty falling or staying asleep, or restless unsatisfying sleep). |
| D. The focus of the anxiety and worry is not confined to features of an Axis I disorder, e.g., the anxiety or worry is not about having a panic attack (as in panic disorder), being embarrassed in public (as in social phobia), being contaminated (as in obsessive-compulsive disorder), being away from home or close relatives (as in separation anxiety disorder), gaining weight (as in anorexia nervosa), having multiple physical complaints (as in somatization disorder), or having a serious illness (as in hypochondriasis), and the anxiety and worry do not occur exclusively during posttraumatic stress disorder. |
| E. The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. |
| F. The disturbance is not due to the direct physiologic effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition (e.g., hyperthyroidism) and does not occur exclusively during a mood disorder, a psychotic disorder, or a pervasive developmental disorder. |

Source: Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
OBSESSIVE-COMPULSIVE DISORDER Clinical Manifestations

OBSESSIVE-COMPULSIVE DISORDER (OCD) is characterized by obsessive thoughts and compulsive behaviors that impair everyday functioning. Fears of contamination and germs are common, as are handwashing, counting behaviors, and having to check and recheck such actions as whether a door is locked. The degree to which the disorder is disruptive for the individual varies, but in all cases obsessive-compulsive activities take up >1 h/d and are undertaken to relieve the anxiety triggered by the core fear. Patients often conceal their symptoms, usually because they are embarrassed by the content of their thoughts or the nature of their actions. Physicians must ask specific questions regarding recurrent thoughts and behaviors, particularly if physical clues such as chafed and reddened hands or patchy hair loss (from repetitive hair pulling, or trichotillomania) are present. Comorbid conditions are common, the most frequent being depression, other anxiety disorders, eating disorders, and tics. OCD has a lifetime prevalence of 2 to 3% worldwide. Onset is usually gradual, beginning in early adulthood, but childhood onset is not rare. The disorder usually has a waxing and waning course, but some cases may show a steady deterioration in psychosocial functioning.

REFERENCES

TABLE 371-8 Diagnostic Criteria for Posttraumatic Stress Disorder

A. The person has been exposed to a traumatic event in which both of the following were present:

1. The person experienced, witnessed, or was confronted with an event or events that involved actual or threatened death or serious injury, or a threat to the physical integrity of self or others.

2. The person’s response involved intense fear, helplessness, or horror.

B. The traumatic event is persistently reexperienced in one (or more) of the following ways:

1. Recurrent and intrusive distressing recollections of the event, including images, thoughts, or perceptions.

2. Recurrent distressing dreams of the event.

3. Acting as if the traumatic event were recurring (includes a sense of reliving the experience, illusions, hallucinations, and dissociative flashback episodes, including those that occur on awakening or when intoxicated).

4. Intense psychological distress at exposure to internal or external cues that symbolize or resemble an aspect of the traumatic event.

5. Physiologic reactivity on exposure to internal or external cues that symbolize or resemble an aspect of the traumatic event.

C. Persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness (not present before the trauma), as indicated by three or more of the following:

1. Efforts to avoid thoughts, feelings, or conversations associated with the trauma.

2. Efforts to avoid activities, places, or people that arouse recollections of the trauma.

3. Inability to recall an important aspect of the trauma.

4. Markedly diminished interest or participation in significant activities.

5. Feeling of detachment or estrangement from others.

6. Restricted range of affect (e.g., unable to have loving feelings).

7. Sense of a foreshortened future (e.g., does not expect to have a career, marriage, children, or a normal life span).

D. Persistent symptoms of increased arousal (not present before the trauma), as indicated by two (or more) of the following:

1. Difficulty falling or staying asleep.

2. Irritability or outbursts of anger.

3. Difficulty concentrating.

4. Hyper vigilant.

5. Exaggerated startle response.

E. Duration of the disturbance (symptoms in criteria B, C, and D) is more than 1 month.

F. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Source: Diagnostic and Statistical Manual of Mental Disorders, 4th ed.

MOOD DISORDERS

Mood disorders are characterized by a disturbance in the regulation of mood, behavior, and affect. Mood disorders are subdivided into (1) depressive disorders, (2) bipolar disorders, and (3) depression in association with medical illness.

Clomipramine, fluoxetine, and fluvoxamine are approved for the treatment of OCD. Clomipramine is a TCA that is often tolerated poorly owing to anticholinergic and sedative side effects at the doses required to treat the illness (150 to 250 mg/d). Its efficacy in OCD is unrelated to its antidepressant activity. Fluoxetine (40 to 60 mg/d) and fluvoxamine (100 to 300 mg/d) are as effective as clomipramine and have a more benign side-effect profile. Only 50 to 60% of patients with OCD show adequate improvement with pharmacotherapy alone. In treatment-resistant cases, augmentation with other serotonergic agents, such as buspirone, or with a neuroleptic or benzodiazepine may be beneficial. When a therapeutic response is achieved, long-duration maintenance therapy is usually indicated.

For many individuals, particularly those with time-consuming compulsions, behavior therapy will result in as much improvement as that afforded by medication. Effective techniques include the gradual increase in exposure to stressful situations, maintenance of a diary to clarify stressors, and homework assignments that substitute new activities for compulsive behaviors.
ogy when self-reporting scales are used. Depressive symptoms following unstable angina, myocardial infarction, or heart transplant impairs rehabilitation and are associated with higher rates of mortality and medical morbidity. Depressed patients often show decreased variability in heart rate (an index of reduced parasympathetic nervous system activity), and this has been proposed as one mechanism by which depression may predispose individuals to ventricular arrhythmia and increased morbidity. Depression also appears to increase the risk of developing coronary heart disease; increased serotonin-induced platelet aggregation has been implicated as a possible cause. TCAs are contraindicated in patients with bundle branch block, and TCA-induced tachycardia is an additional concern in patients with congestive heart failure. Increased serotonin-induced platelet aggregation is sometimes required. Patients with subclinical hypothyroidism can also experience symptoms of depression and cognitive difficulty that respond to thyroid replacement.

In patients with cancer, the mean prevalence of depression is 25%, but depression occurs in 40 to 50% of patients with cancers of the pancreas or oropharynx. Extreme cachexia, common with some cancers, may be misinterpreted as part of the symptom complex of depression; the higher prevalence of depression in patients with pancreatic cancer nevertheless persists when compared to those with advanced gastric cancer. Initiation of antidepressant medication in cancer patients has been shown to improve quality of life as well as mood. Psychotherapeutic approaches, particularly group therapy, may have some effect on short-term depression, anxiety, and pain symptoms and, speculatively, on recurrence rates and long-term survival.

Depression occurs frequently in patients with neurologic disorders, particularly cerebrovascular disorders, Parkinson’s disease, dementia, multiple sclerosis, and traumatic brain injury. One in five patients with left-hemisphere stroke involving the dorsal lateral frontal cortex experiences major depression. Late-onset depression in otherwise cognitively normal individuals increases the risk of a subsequent diagnosis of Alzheimer’s disease. Both TCA and SSRI agents are effective against these depressions, as are stimulant compounds and, in some patients, MAOIs.

The reported prevalence of depression in patients with diabetes mellitus varies from 8 to 27%, with the severity of the mood state correlating with the level of hyperglycemia and the presence of diabetic complications. Treatment of depression may be complicated by effects of antidepressant agents on glycemic control. MAOIs can induce hypoglycemia and weight gain. TCAs can produce hyperglycemia and carbohydrate craving. SSRIs, like MAOIs, may reduce fasting plasma glucose, but they are easier to use and may also improve dietary and medication compliance.

Hypothyroidism is frequently associated with features of depression, most commonly depressed mood and memory impairment. Hyperthyroid states may also present in a similar fashion, usually in geriatric populations. Improvement in mood usually follows normalization of thyroid function, but adjunctive antidepressant medication is sometimes required. Patients with subclinical hypothyroidism can also experience symptoms of depression and cognitive difficulty that respond to thyroid replacement.

The lifetime prevalence of depression in HIV-positive individuals has been estimated at 22 to 45%. The relationship between depression and disease progression is multifactorial and likely to involve psychological and social factors, alterations in immune function, and central nervous system disease. Chronic hepatitis C infection is also associated with depression, which may worsen with interferon-α treatment. Some chronic disorders of uncertain etiology, such as chronic fatigue syndrome (Chap. 370) and fibromyalgia (Chap. 315), are strongly associated with depression and anxiety and may partially benefit from antidepressant treatment, usually at lower than normal dosing.

**DEPRESSIVE DISORDERS**

**Clinical Manifestations**

Major depression is defined as depressed mood on a daily basis for a minimum duration of 2 weeks (Table 371-9). An episode may be characterized by sadness, indifference, apathy, or irritability and is usually associated with changes in sleep patterns, appetite, and weight; motor agitation or retardation; fatigue; impaired concentration and decision-making; feelings of shame or guilt; and thoughts of death or dying. Patients with depression have a profound loss of pleasure in all enjoyable activities, exhibit early morning awakening, feel that the dysphoric mood state is qualitatively different from sadness, and often notice a diurnal variation in mood (worse in morning hours).

Approximately 15% of the population experiences a major depressive episode at some point in life, and 6 to 8% of all outpatients in primary care settings satisfy criteria for the disorder. Depression is often undiagnosed, and, even more frequently, it is treated inadequately. If a physician suspects the presence of a major depressive episode, the initial task is to determine whether it represents unipolar or bipolar depression or is one of the 10 to 15% of cases that are secondary to general medical illness or substance abuse. Physicians should also assess the risk of suicide by direct questioning, as patients are often reluctant to verbalize such thoughts without prompting. If specific plans are uncovered or if significant risk factors exist (e.g., a past history of suicide attempts, profound hopelessness, concurrent medical illness, substance abuse, or social isolation), the patient must be referred to a mental health specialist for immediate care. The physician should specifically probe each of these areas in an empathic and hopeful manner, being sensitive to denial and possible minimization of distress. The presence of anxiety, panic, or agitation significantly increases near-term suicidal risk. Approximately 4 to 5% of all de-

<table>
<thead>
<tr>
<th>TABLE 371-9 Criteria for Major Depressive Episode</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. <strong>Note:</strong> Do not include symptoms that are clearly due to a general medical condition, or mood-incongruent delusions or hallucinations.</td>
</tr>
<tr>
<td>1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful)</td>
</tr>
<tr>
<td>2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation made by others)</td>
</tr>
<tr>
<td>3. Significant weight loss when not dieting or weight gain (e.g., a change of &gt;5% of body weight in a month), or decrease or increase in appetite nearly every day</td>
</tr>
<tr>
<td>4. Insomnia or hypersomnia nearly every day</td>
</tr>
<tr>
<td>5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)</td>
</tr>
<tr>
<td>6. Fatigue or loss of energy nearly every day</td>
</tr>
<tr>
<td>7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)</td>
</tr>
<tr>
<td>8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)</td>
</tr>
<tr>
<td>9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide</td>
</tr>
</tbody>
</table>

| B. The symptoms do not meet criteria for a mixed episode |
| C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning |
| D. The symptoms are not due to the direct physiologic effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition (e.g., hypothyroidism) |
| E. The symptoms are not better accounted for by bereavement; i.e., after the loss of a loved one, the symptoms persist for >2 months or are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation |

**Source:** Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
pressed patients will commit suicide; most will have sought help from a physician within 1 month of their death.

In some depressed patients, the mood disorder does not appear to be episodic and is not clearly associated with either psychosocial dysfunction or change from the individual's usual experience in life. 

Dysthymic disorder consists of a pattern of chronic (at least 2 years), ongoing, mild depressive symptoms that are less severe and less disabling than those found in major depression; the two conditions are sometimes difficult to separate, however, and can occur together (“double depression”). Many patients who exhibit a profile of pessimism, disinterest, and low self-esteem respond to antidepressant treatment. Dysthymic disorder exists in ~5% of primary care patients. The term minor depression is used for individuals who experience at least two depressive symptoms for 2 weeks, but who do not meet the full criteria for major depression. Despite its name, minor depression is associated with significant morbidity and disability and also responds to pharmacologic treatment.

Depression is approximately twice as common in women as in men, and the incidence increases with age in both sexes. Twin studies indicate that the liability to major depression in adult women is largely genetic in origin. Negative life events can precipitate and contribute to depression, but genetic factors influence the sensitivity of individuals to these stressful events. In most cases, both biologic and psychosocial factors are involved in the precipitation and unfolding of depressive episodes. The most potent stressors appear to involve death of a relative, assault, or severe marital or relationship problems.

Unipolar depressive disorders usually begin in early adulthood and recur episodically over the course of a lifetime. The best predictor of future risk is the number of past episodes; 50 to 60% of patients who have a first episode have at least one or two recurrences. Some patients experience multiple episodes that become more severe and frequent over time. The duration of an untreated episode varies greatly, ranging from a few months to ≥1 year. The pattern of recurrence and clinical progression in a developing episode are also variable. Within an individual, the nature of attacks (e.g., specific presenting symptoms, frequency and duration of episodes) may be similar over time. In a minority of patients, a severe depressive episode may progress to a psychotic state; in elderly patients, depressive symptoms may be associated with cognitive deficits mimicking dementia (“pseudodementia”).

A seasonal pattern of depression, called seasonal affective disorder, may manifest with onset and remission of episodes at predictable times of the year. This disorder is more common in women, whose symptoms are anergy, fatigue, weight gain, hypersomnia, and episodic carbohydrate craving. The prevalence increases with distance from the equator, and improvement may occur by altering light exposure.

Etiology and Pathophysiology Although evidence for genetic transmission of unipolar depression is not as strong as in bipolar disorder, monozygotic twins have a higher concordance rate (46%) than dizygotic siblings (20%), with little evidence for any effect of a shared family environment. A recent study indicated that a functional polymorphism in the serotonin transporter (5-HTT) gene may interact with stressful life events to markedly increase risk of depression and suicide. Postmortem examination tomography (PET) studies show decreased metabolic activity in the caudate nuclei and frontal lobes in depressed patients that returns to normal with recovery. Single-photon emission computed tomography (SPECT) studies show comparable changes in blood flow.

Postmortem examination of brains of suicide victims indicate altered noradrenergic activity, including increased binding to α1- and α2-receptors and β-adrenergic receptors in the cerebral cortex and decreased numbers of noradrenergic neurons in the locus coeruleus. Involvement of the serotonin system is suggested by findings of antidepressant plasma tryptophan levels, a decreased cerebrospinal fluid level of 5-hydroxyindolacetic acid (the principal metabolite of serotonin in brain), and decreased platelet serotonergic transporter binding. An increase in brain serotonin receptors in suicide victims and decreased expression of the cyclic AMP response element-binding (CREB) protein are also reported. Depletion of blood tryptophan, the amino acid precursor of serotonin, rapidly reverses the antidepressant benefit in depressed patients who have been successfully treated. However, a decrement in mood after tryptophan reduction is considerably less robust in untreated patients, indicating that, if presynaptic serotonergic dysfunction occurs in depression, it likely plays a contributing rather than a causal role.

Neuroendocrine abnormalities that reflect the neurovegetative signs and symptoms of depression include (1) increased cortisol and corticotropin-releasing hormone (CRH) secretion, (2) an increase in adrenal size, (3) decreased postulated inhibitory response of glucocorticoids to dexamethasone, and (4) a blunted response of thyroid-stimulating hormone (TSH) level to infusion of thyroid-releasing hormone (TRH). Anti-depressant treatment leads to normalization of these pituitary-adrenal abnormalities. Major depression is also associated with an upregulation of proinflammatory cytokines, which normalizes with antidepressant treatment.

Diurnal variations in symptom severity and alterations in circadian rhythmicity of a number of neurochemical and neurohumoral factors suggest that biologic differences may be secondary to a primary defect in regulation of biologic rhythms. Patients with major depression show consistent findings of a decrease in rapid eye movement (REM) sleep onset (REM latency), an increase in REM density, and, in some subjects, a decrease in stage IV delta slow-wave sleep.

Although antidepressant drugs inhibit neurotransmitter uptake within hours, their therapeutic effects typically emerge over several weeks, implicating adaptive changes in second messenger systems and transcription factors as possible mechanisms of action. Antidepressant drugs have been shown to regulate neural plasticity and cell survival by increasing the expression of brain-derived neurotrophic factor (BDNF) through upregulation of the CREB protein and to alter stress responsivity through an increase in glucocorticoid receptor transcription. Secondary effects on activation of the mitogen-activated protein (MAP) kinase and phosphoinositide-3 kinase/AKT pathways and increased expression of the antiapoptotic protein, Bcl-2, are also thought to be critical to antidepressant actions.

**TREATMENT**

Treatment planning requires coordination of short-term symptom remission with longer term maintenance strategies designed to prevent recurrence. The most effective intervention for achieving remission and preventing relapse is medication, but combined treatment, incorporating psychotherapy to help the patient cope with decreased self-esteem and demoralization, improves outcome (Fig. 371-1). About 40% of primary care patients with depression drop out of treatment and discontinue medication if symptomatic improvement is not noted within a month, unless additional support is provided. Outcome improves with (1) increased intensity and frequency of visits during the first 4 to 6 weeks of treatment, (2) supplemental educational materials, and (3) psychiatric consultation as indicated. Despite the widespread use of SSRIs, there is no convincing evidence that this class of antidepressant is more efficacious than TCAs. Between 60 and 70% of all depressed patients respond to any drug chosen, if it is given in a sufficient dose for 6 to 8 weeks. There is no ideal antidepressant; no current compound combines rapid onset of action, moderate half-life, a meaningful relationship between dose and blood level, a low side-effect profile, minimal interaction with other drugs, and safety in overdose. A rational approach to selecting which antidepressant to use involves matching the patient’s preference and medical history with the metabolic and side effect profile of the drug (Tables 371-4 and 371-5). A previous response, or a family history of a positive response, to a specific antidepressant would suggest that that drug be tried first.

Before initiating antidepressant therapy, the physician should evaluate the possible contribution of comorbid illnesses and consider their spec-
specific treatment. In individuals with suicidal ideation, particular attention should be paid to choosing a drug with low toxicity if taken in overdose. The SSRIs and other newer antidepressants are distinctly safer in this regard; nevertheless, the advantages of TCAs have not been completely superseded. The existence of generic equivalents make TCAs relatively cheap, and for several tricyclics, particularly nortriptyline, imipramine, and desipramine, well-defined relationships among dose, plasma level, and therapeutic response exist. The steady-state plasma level achieved for a given drug dose can vary more than tenfold between individuals. Plasma levels may help in interpreting apparent resistance to treatment and/or unexpected drug toxicity. The principal side effects of TCAs are anticholinergic (sedation) and anticholinergic (constipation, dry mouth, urinary hesitancy, blurred vision). Cardiac toxicity due to conduction block or arrhythmias can also occur but is uncommon at therapeutic levels. TCAs are probably contraindicated in patients with serious cardiovascular risk factors. Overdoses of tricyclic agents can be lethal, with desipramine carrying the greatest risk. It is judicious to prescribe only a 10-day supply when suicide is a risk. Most patients require a daily dose of 150 to 200 mg of imipramine or amitriptyline or its equivalent to achieve a therapeutic blood level of 150 to 300 mg/mL and a satisfactory remission; some patients show a partial effect at lower doses. Geriatric patients may require a low starting dose and slow escalation. Ethnic differences in blood level of 150 to 300 ng/mL and a satisfactory remission; some patients show a partial effect at lower doses. Geriatric patients may require a low starting dose and slow escalation. Ethnic differences in function frequently result in noncompliance and should be asked about specifically. Sexual dysfunction can sometimes be ameliorated by lowering the dose, by instituting weekend drug holidays (two or three times a month), or by treatment with amantadine (100 mg tid), bethanechol (25 mg tid) buspirone (10 mg tid), or bupropion (100–150 mg/d). Paroxetine appears to be more anticholinergic than either fluoxetine or sertraline, and sertraline carries a lower risk of producing an adverse drug interaction than the other two. Rare side effects of SSRIs include angina due to vasoconstriction and prolongation of the prothrombin time. Escitalopram is the most specific of currently available SSRIs and appears to have no specific inhibitory effects on the P450 system.

Venlafaxine, like imipramine, blocks the reuptake of both norepinephrine and serotonin, but it produces relatively little in the way of traditional tricyclic side effects. Unlike the SSRIs, it has a relatively linear dose-response curve. Patients should be monitored for a possible increase in diastolic blood pressure, and multiple daily dosing is required because of the drug’s short half-life. An extended-release form is available and has a somewhat lower incidence of gastrointestinal side effects. Nefazodone is a selective 5HT1A receptor antagonist that also inhibits the presynaptic reuptake of serotonin and norepinephrine. Its side effects are similar to those of the SSRIs, and twice-daily dosing produces a steady state within 4 to 5 days. The drug is related structurally to trazodone, which is currently used more for its sedative than its antidepressant properties. Nefazodone appears to produce a lower incidence of sexual side effects than do the SSRIs. Mirtazapine is a tetracyclic antidepressant that has a unique spectrum of activity. It increases noradrenergic and serotonergic neurotransmission through a blockade of central α2-adrenergic receptors and postsynaptic 5HT1A and 5HT1 receptors. It is also strongly antihistaminic and, as such, may produce sedation.

With the exception of citalopram and escitalopram, each of the SSRIs, as well as nefazodone, may inhibit one or more cytochrome P450 enzymes. Depending on the specific isoenzyme involved, the metabolism of a number of concomitantly administered medications can be dramatically affected. Fluoxetine and paroxetine, for example, by inhibiting 2D6, can cause dramatic increases in the blood level of type 1C antiarrhythmics, while sertraline and nefazodone, by acting on 3A4, may alter blood levels of terfenadine, carbamazepine, and astemizole. Many of these compounds have a narrow therapeutic window and can cause iatrogenic ventricular arrhythmias at toxic levels; thus, the possibility of an adverse drug interaction should always be considered.

The MAOIs are highly effective, particularly in atypical depression, but the risk of hypertensive crisis following intake of tyramine-
Bipolar disorder is a serious mental illness that affects brain function. Patients experience alternating periods of mania (or hypomania), characterized by increased energy and activity, and depression, with its own symptoms and duration. This can be categorized into two main types: Bipolar I Disorder and Bipolar II Disorder. Bipolar I Disorder involves manic episodes that last for at least one week or result in hospitalization. The condition is lifelong and typically starts in late adolescence or early adulthood.

**Bipolar I Disorder**
- **Clinical Manifestations**
  - Patients experience marked increases in energy and activity, along with changes in mood, sleep, and behavior.
  - Symptoms may include irritability, increased activity, and hypersexual behavior.
- **Diagnosis**
  - Diagnosis is made based on the presence of manic or hypomanic episodes that last for at least one week or lead to hospitalization.
  - The condition is lifelong and typically starts in late adolescence or early adulthood.

**Bipolar II Disorder**
- **Clinical Manifestations**
  - Patients experience at least one hypomanic episode and at least one depressive episode.
  - Symptoms include irritability, increased activity, and hypersexual behavior.

**Etiology and Pathophysiology**
- **Etiology**
  - Bipolar disorder is thought to be caused by a combination of genetic and environmental factors.
  - Recent studies have linked the disorder to changes in brain function, including alterations in the brain's electrical activity and changes in the levels of certain neurotransmitters.

**Differential Diagnosis**
- Patients with bipolar disorder may be misdiagnosed with other conditions such as schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and substance use disorders.

**Treatment**
- Treatment options include medication, psychotherapy, and lifestyle modifications.
  - **Medication**
    - Mood stabilizers such as lithium, sodium valproate, and carbamazepine can be used to treat mood swings.
    - Antidepressants are often used in combination with mood stabilizers to treat depression.
  - **Psychotherapy**
    - Cognitive-behavioral therapy (CBT) and family-focused therapy are effective treatment options.

**Prognosis**
- The prognosis for bipolar disorder is generally good with proper treatment and management.

**Complications**
- Patients with bipolar disorder are at risk for developing other conditions such as substance use disorders, cardiovascular disease, and suicide.

**Prevention**
- Early identification and treatment can help reduce the risk of complications and improve outcomes for patients with bipolar disorder.

**References**

---

**Table 371-10: Criteria for a Manic Episode**

| A | A distinct period of abnormally and persistently elevated, expansive, or irritable mood, lasting at least 1 week (or any duration if hospitalization is necessary) |
| B | During the period of mood disturbance, three (or more) of the following symptoms have persisted (four if the mood is only irritable) |
|   | and have been present to a significant degree: |
|   | 1. Inflated self-esteem or grandiosity |
|   | 2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep) |
|   | 3. More talkative than usual or pressure to keep talking |
|   | 4. Flight of ideas or subjective experience that thoughts are racing |
|   | 5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant external stimuli) |
|   | 6. Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation |
|   | 7. Excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments) |

**Note:** Manic-like episodes that are clearly caused by somatic antidepressant treatment (e.g., medication, electroconvulsive therapy, light therapy) should not count toward a diagnosis of bipolar I disorder.

**Source:** Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
Lithium carbonate is the mainstay of treatment in bipolar disorder, although sodium valproate and olanzapine are equally effective in acute mania, as is lamotrigine in the depressed phase. The response rate to lithium carbonate is 70 to 80% in acute mania, with beneficial effects appearing in 1 to 2 weeks. Lithium also has a prophylactic effect in prevention of recurrent mania and, to a lesser extent, in the prevention of recurrent depression. A simple cation, lithium is rapidly absorbed from the gastrointestinal tract and remains unbound to plasma or tissue proteins. Some 95% of a given dose is excreted unchanged through the kidneys within 24 h.

Serious side effects from lithium administration are rare, but minor complaints such as gastrointestinal discomfort, nausea, diarrhea, polyuria, weight gain, skin rashes, alopecia, and edema are common. Over time, urine-concentrating ability may be decreased, but significant nephrotoxicity does not usually occur. Lithium exerts an antihyperoxic effect by interfering with the synthesis and release of thyroid hormones. More serious side effects include tremor, poor concentration and memory, ataxia, dysarthria, and incoordination. There is suggestive, but not conclusive, evidence that lithium is teratogenic, inducing cardiac malformations in the first trimester.

In the treatment of acute mania, lithium is initiated at 300 mg bid or tid, and the dose is then increased by 300 mg every 2 to 3 days to achieve blood levels of 0.8 to 1.2 meq/L. Because the therapeutic effect of lithium may not appear until after 7 to 10 days of treatment, adjunctive usage of lorazepam (1 to 2 mg every 4 h) or clonazepam (0.5 to 1 mg every 4 h) may be beneficial to control agitation. Antipsychotics are indicated in patients with severe agitation who respond only partially to benzodiazepines. Patients using lithium should be monitored closely, since the blood levels required to achieve a therapeutic benefit are close to those associated with toxicity.

Valproic acid is an alternative in patients who cannot tolerate lithium or respond poorly to it. Valproic acid may be better than lithium for patients who experience rapid cycling (i.e., more than four episodes a year) or who present with a mixed or dysphoric mania. Tremor and weight gain are the most common side effects; hepatotoxicity and pancreatitis are rare toxicities.

Carbamazepine and oxcarbazepine, although not formally approved by the U.S. Food and Drug Administration (FDA) for bipolar disorder, have clinical efficacy in the treatment of acute mania. Preliminary evidence also suggests that other anticonvulsant agents such as levetiracetam, zonisamide, and topiramate may possess some therapeutic benefit.

The recurrent nature of bipolar mood disorder necessitates maintenance treatment. A sustained blood lithium level of at least 0.8 mEq/L is important for optimal prophylaxis and has been shown to reduce risk of suicide, a finding not yet apparent for other mood stabilizers. Compliance is frequently an issue and often requires enlistment and education of concerned family members. Efforts to identify and modify psychosocial factors that may trigger episodes are important, as is an emphasis on lifestyle regularity. Antidepressant medications are sometimes required for the treatment of severe breakthrough depressions, but their use should generally be avoided during maintenance treatment because of the risk of precipitating mania or accelerating the cycle frequency. Loss of efficacy over time may be observed with any of the mood-stabilizing agents. In such situations, an alternative agent or combination therapy is usually helpful.

Consensus guidelines for the treatment of acute mania and bipolar depression are described in Table 371-12.

### SOMATOFORM DISORDERS

#### CLINICAL MANIFESTATIONS

Patients with multiple somatic complaints that cannot be explained by a known medical condition or by the effects of alcohol or of recreational or prescription drugs are commonly seen in primary care practice; one survey indicates a prevalence of such complaints of 5%. In somatization disorder, the patient presents with multiple physical complaints referable to different organ systems (Table 371-13). Onset is usually before age 30, and the disorder is persistent. Formal diagnostic criteria require the recording of at least four pain, two gastrointestinal, one sexual, and one pseudoneurologic symptom. Patients with somatization disorder often present with dramatic complaints, but the complaints are inconsistent. Symptoms of comorbid anxiety and mood disorder are common and may be the result of drug interactions due to regimens initiated independently by different physicians. Patients with somatization disorder may be impulsive and demanding and frequently qualify for a formal comorbid

<table>
<thead>
<tr>
<th>Condition</th>
<th>Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euphoric mania</td>
<td>Lithium</td>
</tr>
<tr>
<td>Mixed/dysphoric mania with psychosis</td>
<td>Valproic acid</td>
</tr>
<tr>
<td>Mania with psychosis</td>
<td>Valproic acid with olanzapine, conventional antipsychotic, or risperidone</td>
</tr>
<tr>
<td>Hypomania</td>
<td>Lithium, lamotrigine, or valproic acid alone</td>
</tr>
<tr>
<td>Severe depression with psychosis</td>
<td>Venlafaxine, bupropion, or paroxetine plus lithium plus olanzapine, or risperidone; consider ECT</td>
</tr>
<tr>
<td>Severe depression without psychosis</td>
<td>Bupropion, paroxetine, sertraline, venlafaxine, or citalopram plus lithium</td>
</tr>
<tr>
<td>Mild to moderate depression</td>
<td>Lithium or lamotrigine alone; add bupropion if needed</td>
</tr>
</tbody>
</table>

Note: ECT, electroconvulsive therapy.

### TABLE 371-11 Clinical Pharmacology of Mood Stabilizers

<table>
<thead>
<tr>
<th>Agent and Dosing</th>
<th>Side Effects and Other Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithium</td>
<td>Common side effects: Nausea/anorexia/ diarrhea, fine tremor, thirst, polyuria, fatigue, weight gain, acne, folliculitis, neutrophilia, hypothyroidism Blood level is increased by thiazides, tetracyclines, and NSAIDs Blood level is decreased by bronchodilators, verapamil, and carbonic anhydrase inhibitors Rare side effects: Neurotoxicity, renal toxicity, hypercalcaemia, ECG changes</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Starting dose: 250 mg tid Therapeutic blood level: 50–125 μg/mL Common side effects: Nausea/anorexia, weight gain, sedation, tremor, rash, alopecia Inhibits hepatic metabolism of other medications Rare side effects: Pancreatitis, hepatotoxicity, Stevens-Johnson syndrome</td>
</tr>
<tr>
<td>Carbamazepine/ oxcarbazepine</td>
<td>Starting dose: 200 mg bid for carbamazepine, 150 bid for oxcarbazepine Therapeutic blood level: 4–12 μg/mL, for carbamazepine Lamotrigine Starting dose: 25 mg/d Common side effects: Rash, dizziness, headache, tremor, sedation, nausea Rare side effects: Stevens-Johnson syndrome</td>
</tr>
<tr>
<td>Common side effects: Nausea/anorexia, sedation, rash, dizziness/ataxia Carbamazepine, but not oxcarbazepine, induces hepatic metabolism of other medications Rare side effects: Hyponatremia, agranulocytosis, Stevens-Johnson syndrome</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine, but not oxcarbazepine, induces hepatic metabolism of other medications</td>
<td></td>
</tr>
</tbody>
</table>

Note: NSAID, nonsteroidal anti-inflammatory drug; ECG, electrocardiogram.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euphoric mania</td>
<td>Lithium</td>
</tr>
<tr>
<td>Mixed/dysphoric mania</td>
<td>Valproic acid</td>
</tr>
<tr>
<td>Mania with psychosis</td>
<td>Valproic acid with olanzapine, conventional antipsychotic, or risperidone</td>
</tr>
<tr>
<td>Hypomania</td>
<td>Lithium, lamotrigine, or valproic acid alone</td>
</tr>
<tr>
<td>Severe depression</td>
<td>Venlafaxine, bupropion, or paroxetine plus lithium plus olanzapine, or risperidone; consider ECT</td>
</tr>
<tr>
<td>Severe depression</td>
<td>Bupropion, paroxetine, sertraline, venlafaxine, or citalopram plus lithium</td>
</tr>
<tr>
<td>Mild to moderate depression</td>
<td>Lithium or lamotrigine alone; add bupropion if needed</td>
</tr>
</tbody>
</table>

Note: ECT, electroconvulsive therapy.
not address the core issue. Successful treatment is best achieved through behavior modification, in which access to the physician is tightly regulated and adjusted to provide a sustained and predictable level of support that is less clearly contingent on the patient’s level of presenting distress. Visits can be brief and should not be associated with a need for a diagnostic or treatment action. Although the literature is limited, some patients with somatization disorder may benefit from antidepressant treatment. Fluoxetine and MAOIs have both been found to be useful in reducing obsessive ruminations, dysphoria, and anxious preoccupation in patients with multiple somatic complaints.

The treatment of factitious disorder is complicated in that any attempt to confront the patient usually only creates a sense of humiliation and causes the patient to abandon treatment from that caregiver. A better strategy is to introduce psychological causation as one of a number of possible explanations and to include factitious illness as an option in the differential diagnoses that are discussed. Without directly linking psychotherapeutic intervention to the diagnosis, the patient can be offered a face-saving means by which the pathologic relationship with the health care system can be examined and alternative approaches to life stressors developed.

**PERSONALITY DISORDERS**

**CLINICAL MANIFESTATIONS** Personality disorders are characteristic patterns of thinking, feeling, and interpersonal behavior that are relatively inflexible and cause significant functional impairment or subjective distress for the individual. The observed behaviors are not secondary to another mental disorder, nor are they precipitated by substance abuse or a general medical condition. This distinction is often difficult to make in clinical practice, as personality change may be the first sign of serious neurologic, endocrine, or other medical illness. Patients with frontal lobe tumors, for example, can present with changes in motivation and personality while the results of the neurologic examination remain within normal limits. Individuals with personality disorders are often regarded as “difficult patients” in clinical medical practice because they are seen as excessively demanding and/or unwilling to follow recommended treatment plans. Although DSM-IV portrays personality disorders as qualitatively distinct categories, there is an alternative perspective that personality characteristics vary as a continuum between normal functioning and formal mental disorder.

Personality disorders have been grouped into three overlapping clusters. Cluster A includes paranoid, schizoid, and schizotypal personality disorders. It includes individuals who are odd and eccentric and who maintain an emotional distance from others. Individuals have a restricted emotional range and remain socially isolated. Patients with schizotypal personality disorder frequently have unusual perceptual experiences and express magical beliefs about the external world. The essential feature of paranoid personality disorder is a pervasive mistrust and suspiciousness of others to an extent that is unjustified by available evidence. Cluster B disorders include antisocial, borderline, histrionic, and narcissistic types and describe individuals whose behavior is impulsive, excessively emotional, and erratic. Cluster C incorporates avoidant, dependent, and obsessive-compulsive personality types; enduring traits are anxiety and fear. The boundaries between cluster types are to some extent artificial, and many patients who meet criteria for one personality disorder also meet criteria for aspects of another. The risk of a comorbid major mental disorder is increased in patients who qualify for a diagnosis of personality disorder.

**TREATMENT**

Dialectical behavior therapy (DBT) is a cognitive-behavioral approach that focuses on behavioral change while providing acceptance, compassion, and validation of the patient. Several randomized trials have demonstrated the efficacy of DBT in the treatment of personality disorders. Antidepressant medications and low-dose antipsychotic drugs have some efficacy in cluster A personality disorders, while anticonvulsant mood-stabilizing agents and MAOIs may be considered for patients with cluster B diagnoses who show marked mood reactivity.

### TABLE 371-13 Diagnostic Criteria for Somatization Disorder

<table>
<thead>
<tr>
<th>A.</th>
<th>A history of many physical complaints beginning before age 30 years that occur over a period of several years and result in treatment being sought or significant impairment in social, occupational, or other important areas of functioning.</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.</td>
<td>Each of the following criteria must have been met, with individual symptoms occurring at any time during the course of the disturbance:</td>
</tr>
<tr>
<td>1. <strong>Four pain symptoms</strong>: a history of pain related to at least four different sites or functions (e.g., head, abdomen, back, joints, extremities, chest, rectum, during menstruation, during sexual intercourse, or during urination)</td>
<td></td>
</tr>
<tr>
<td>2. <strong>Two gastrointestinal symptoms</strong>: a history of at least two gastrointestinal symptoms other than pain (e.g., nausea, bloating, vomiting other than during pregnancy, diarrhea, or intolerance of several different foods)</td>
<td></td>
</tr>
<tr>
<td>3. <strong>One sexual symptom</strong>: a history of at least one sexual or reproductive symptom other than pain (e.g., sexual indifference, erectile or ejaculatory dysfunction, irregular menses, excessive menstrual bleeding, vomiting throughout pregnancy)</td>
<td></td>
</tr>
<tr>
<td>4. <strong>One pseudoneurologic symptom</strong>: a history of at least one symptom or deficit suggesting a neurologic condition not limited to pain (conversion symptoms such as impaired coordination or balance, paralysis or localized weakness, difficulty swallowing or lump in throat, aphony, urinary retention, hallucinations, loss of touch or pain sensation, double vision, blindness, deafness, seizures; dissociative symptoms such as amnesia; or loss of consciousness other than fainting)</td>
<td></td>
</tr>
<tr>
<td>C.</td>
<td>Either of the following:</td>
</tr>
<tr>
<td>1.</td>
<td>After appropriate investigation, each of the symptoms in criterion B cannot be fully explained by a known general medical condition or the direct effects of a substance (e.g., a drug of abuse, a medication)</td>
</tr>
<tr>
<td>2.</td>
<td>When there is a related general medical condition, the physical complaints or resulting social or occupational impairment are in excess of what would be expected from the history, physical examination, or laboratory findings</td>
</tr>
<tr>
<td>D.</td>
<td>The symptoms are not intentionally produced or feigned (as in factitious disorder or malingering).</td>
</tr>
</tbody>
</table>

Source: Diagnostic and Statistical Manual of Mental Disorders, 4th ed.

Psychiatric diagnosis. In conversion disorder, the symptoms focus on deficits that involve motor or sensory function and on psychological factors that initiate or exacerbate the medical presentation. Like somatization disorder, the deficit is not intentionally produced or simulated, as is the case in factitious disorder (malingering). In hypochondriasis, the essential feature is a belief of serious medical illness that persists despite reassurance and appropriate medical evaluation. As with somatization disorder, patients with hypochondriasis have a history of poor relationships with physicians stemming from their sense that they have been evaluated and treated inappropriately or inadequately. Hypochondriasis can be disabling in intensity and is persistent, with waxing and waning symptomatology.

In factitious illnesses, the patient consciously and voluntarily produces physical symptoms of illness. The term Munchausen’s syndrome is reserved for individuals with particularly dramatic, chronic, or severe factitious illness. In true factitious illness, the sick role itself is gratifying. A variety of signs, symptoms, and diseases have been either simulated or caused by factitious behavior, the most common including chronic diarrhea, fever of unknown origin, intestinal bleeding or hematuria, seizures, and hypoglycemia. Factitious disorder is usually not diagnosed until 5 to 10 years after its onset, and it can produce significant social and medical costs. In malingering, the fabrication derives from a desire for some external reward, such as a narcotic medication or disability reimbursement.

**TREATMENT**

Patients with somatization disorders are frequently subjected to multiple diagnostic testing and exploratory surgeries in an attempt to find their “real” illness. Such an approach is doomed to failure and does
behavioral discontrol, and/or rejection hypersensitivity. Anxious or fearful cluster C patients often respond to medications used for axis I anxiety disorders (see above). It is important that the physician and the patient have reasonable expectations vis-à-vis the possible benefit of any medication used and its side effects. Improvement may be subtle and observable only over time.

**SCHIZOPHRENIA**

**CLINICAL MANIFESTATIONS** Schizophrenia is a heterogeneous syndrome characterized by perturbations of language, perception, thinking, social activity, affect, and volition. There are no pathognomonic features. The syndrome commonly begins in late adolescence, has an insidious (and less commonly acute) onset, and, classically, a poor outcome, progressing from social withdrawal and perceptual distortions to a state of chronic delusions and hallucinations. Patients may present with positive symptoms (such as conceptual disorganization, delusions, or hallucinations) or negative symptoms (loss of function, anhedonia, decreased emotional expression, impaired concentration, and diminished social engagement) and must have at least two of these for a 1-month period and continuous signs for at least 6 months to meet formal diagnostic criteria. “Negative” symptoms predominate in one-third of the schizophrenic population and are associated with a poor long-term outcome and a poor response to drug treatment. However, marked variability in the cause and individual character of symptoms is typical.

The four main subtypes of schizophrenia are catatonic, paranoid, disorganized, and residual. Many individuals have symptoms of more than one type. *Catatonic-type* describes patients whose clinical presentation is dominated by profound changes in motor activity, negativism, and echolalia or echopraxia. *Paranoid-type* describes patients who have a prominent preoccupation with a specific delusional system and who otherwise do not qualify as having *disorganized-type* disease, in which disorganized speech and behavior are accompanied by a superficial or silly affect. In *residual-type* disease, negative symptomatology exists in the absence of delusions, hallucinations, or motor disturbance. The term *schizophreniform disorder* describes patients who meet the symptom requirements but not the duration requirements for schizophrenia, and *schizoaffective disorder* is used for those who manifest symptoms of schizophrenia and independent periods of mood disturbance. Prognosis depends not on symptom severity but on the response to antipsychotic medication. A permanent remission without recurrence does occasionally occur. About 10% of schizophrenic patients commit suicide.

Schizophrenia is present in 0.85% of individuals worldwide, with a lifetime prevalence of ~1 to 1.5%. An estimated 300,000 episodes of acute schizophrenia occur annually in the United States, resulting in direct and indirect costs estimated at >$33 billion.

**DIFFERENTIAL DIAGNOSIS** The diagnosis is principally one of exclusion, requiring the absence of significant associated mood symptoms, any relevant medical condition, and substance abuse. Drug reactions that cause hallucinations, paranoia, confusion, or bizarre behavior may be dose-related or idiosyncratic; β-adrenergic blockers, clonidine, cycloserine, and procaine derivatives are the most common prescription medications associated with these symptoms. Drug reactions should be ruled out in any case of newly emergent psychosis. The general neurologic examination in patients with schizophrenia is usually normal, but motor rigidity, tremor, and dyskinesias are noted in one-quarter of untreated patients.

**EPIDEMIOLOGY AND PATHOPHYSIOLOGY** Epidemiologic surveys identify several risk factors for schizophrenia including genetic susceptibility, early developmental insults, winter birth, and increasing parental age. Genetic factors are involved in at least a subset of individuals who develop schizophrenia. Schizophrenia is observed in ~6.6% of all first-degree relatives of an affected proband. If both parents are affected, the risk for offspring is 40%. The concordance rate for monozygotic twins is 50%, compared to 10% for dizygotic twins. Schizophrenia-prone families are also at risk for other psychiatric disorders, including schizoaffective disorder and schizotypal and schizoid personality disorders, the latter terms designating individuals who show a lifetime pattern of social and interpersonal deficits characterized by an inability to form close interpersonal relationships, eccentric behavior, and mild perceptual distortions.

Despite evidence for a genetic causation, the results of molecular genetic linkage studies in schizophrenia are inconclusive. Major gene effects appear unlikely. Possible susceptibility genes include: neuroregulin-1 at chromosome 8p21; dysbindin at 6p22.3, proline dehydrogenase at 22q11.1, and G72 at 13q34. Several of these may be involved in glutamatergic regulation, increasing interest in N-methyl-D-aspartate (NMDA)-mediated glutamate signaling as a possible therapeutic target for treatment. One group has reported risk variants in the α7 nicotinic acetylcholine receptor subunit gene and linked it to a specific auditory processing deficit.

Schizophrenia is also associated with gestational and perinatal complications, including Rh factor incompatibility, fetal hypoxia, perinatal exposure to influenza during the second trimester, and perinatal nutritional deficiency. Studies of monozygotic twins discordant for schizophrenia have reported neuroanatomic differences between affected and unaffected siblings, supporting a “two-strike” etiology involving both genetic susceptibility and an environmental insult. The latter might involve localized hypoxia during critical stages of brain development.

A number of structural and functional abnormalities have been identified in schizophrenia, including (1) cortical atrophy and ventricular enlargement; (2) specific volume losses in the amygdala, hippocampus, right prefrontal cortex, fusiform gyrus, and thalamus; (3) progressive reduction in cortical volume over time; (4) reduced metabolism in the thalamus and prefrontal cortex; (5) abnormalities of the planum temporale; and (6) changes in the size, orientation, and density of cells in the hippocampus and prefrontal cortex, and decreased numbers of cortical interneurons. These observations have suggested that schizophrenia may result from a disturbance in a cortical striatal–thalamic circuit resulting in abnormalities in sensory filtering and attention.

Schizophrenic individuals are highly distracible and demonstrate deficits in perceptual–motor speed, ability to shift attention, and filtering out of background stimuli. Event-related evoked potential studies of schizophrenia have defined a specific reduction in P300 amplitude to a novel stimulus, which implicates an impairment in cognitive processing. Impaired information processing is also found in unaffected family members.

The *dopamine hypothesis* of schizophrenia is based on the discovery that agents that diminish dopaminergic activity also reduce the acute symptoms and signs of psychosis, specifically agitation, anxiety, and hallucinations. Amelioration of delusions and social withdrawal is less dramatic. Thus far, however, evidence for increased dopaminergic activity in schizophrenia is indirect, although decreased D2 receptor occupancy by dopamine has recently been shown in drug-naïve patients. An increase in the activity of nigrostriatal and mesolimbic systems and a decrease in mesocortical tracts innervating the prefrontal cortex is hypothesized, although it is likely that other neurotransmitters, including serotonin, acetylcholine, glutamate, and GABA, also contribute to the pathophysiology of the illness. Possible involvement of excitatory amino acids is based on the genetic data cited above and finding that NMDA receptor antagonists and channel blockers, such as phencyclidine (PCP) and ketamine, produce characteristic signs of schizophrenia in normal individuals; cycloserine, an NMDA receptor agonist, can decrease the negative symptoms of psychosis.

**TREATMENT**

Antipsychotic agents (Table 371-14) are the cornerstone of acute and maintenance treatment of schizophrenia, and are effective in the treatment of hallucinations, delusions, and thought disorders, regardless of
etiology. The mechanism of action involves, at least in part, blockade of dopamine receptors in the limbic system and basal ganglia; the clinical potencies of traditional antipsychotic drugs parallel their affinities for the D₂ receptor, and even the newer “atypical” agents exert some degree of D₂ receptor blockade. All neuroleptics induce expression of the immediate-early gene c-fos and/ or altering the relationship between 5HT₂ and D₂ receptor activity, as fission of the immediate-early gene c-

<table>
<thead>
<tr>
<th>Table 371-14 Antipsychotic Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TYPICAL ANTIPSYCHOTICS</strong></td>
</tr>
<tr>
<td><strong>Name</strong></td>
</tr>
<tr>
<td>Low-potency</td>
</tr>
<tr>
<td>Chlorpromazine (Thorazine)</td>
</tr>
<tr>
<td>Thioridazine (Mellaril)</td>
</tr>
<tr>
<td>Mid-potency</td>
</tr>
<tr>
<td>Trifluoperazine (Stelazine)</td>
</tr>
<tr>
<td>Perphenazine (Trilafon)</td>
</tr>
<tr>
<td>Loxapine (Loxitane)</td>
</tr>
<tr>
<td>Molindone (Mohan)</td>
</tr>
<tr>
<td>High potency</td>
</tr>
<tr>
<td>Haloperidol (Haldol)</td>
</tr>
<tr>
<td>Fluphenazine (Prolixin)</td>
</tr>
<tr>
<td>Thiothixene (Navane)</td>
</tr>
</tbody>
</table>

**NOVEL ANTIPSYCHOTICS**

| **Name**                  | **Usual PO Daily Dose, mg** | **Side Effects** | **Sedation** | **Comments** |
| Clozapine (Clozaril)       | 200–600                    | Agranulocytosis (1%); weight gain; seizures; hydrocephalus/diabetes; neuroleptic dyskinesia | + + | Requires weekly WBC |
| Risperidone (Risperdal)    | 2–6                        | Orthostasis      | +            | Requires slow titration; EPSEs observed with doses >6 mg/d |
| Olanzapine (Zyprexa)       | 10–20                      | Weight gain      | + +          | Mild prolactin elevation |
| Quetiapine (Seroquel)      | 350–700                    | Sedation; weight gain; anxiety | + + + | Bid dosing |
| Ziprasidone (Geodon)       | 40–60                      | Orthostatic hypotension | +/+ + | Minimal weight gain; increases QT interval |
| Aripiprazole (Abilify)     | 10–30                      | Nausea, anxiety, insomnia | 0/+ | Mixed agonist/antagonist |

**Note:** EPSEs, extrapyramidal side effects; WBC, white blood cell count.

profile makes it most appropriate for treatment-resistant cases. Risperidone, a benzisoxazol derivative, is more potent at 5HT₂ than D₂ receptor sites, like clozapine, but it also exerts significant α₂ antagonism, a property that may contribute to its perceived ability to improve mood and increase motor activity. Risperidone is not as effective as clozapine in treatment-resistant cases but does not carry a risk of blood dyscrasias. Olanzapine is similar neurochemically to clozapine but has a significant risk of inducing weight gain. Quetiapine is distinct in having a weak D₂ effect but potent α₁ and histamine blockade. Ziprasidone causes minimal weight gain and is unlikely to increase prolactin, but may increase QT prolongation. Aripiprazole also has little risk of weight gain or prolactin increase but may increase anxiety, nausea, and insomnia as a result of its partial agonist properties.

Conventional antipsychotic agents are effective in 70% of patients presenting with a first episode. Improvement may be observed within hours or days, but full remission usually requires 6 to 8 weeks. The choice of agent depends principally on the side-effect profile and cost of treatment or on a past personal or family history of a favorable response to the drug in question. Atypical agents appear to be more effective in treating negative symptoms and improving cognitive function. An equivalent treatment response can usually be achieved with relatively low doses of any drug selected, i.e., 4 to 6 mg/d of haloperidol, 10 to 15 mg of olanzapine, or 4 to 6 mg/d of risperidone. Doses in this range result in >80% D₂ receptor blockade, and there is little evidence that higher doses increase either the rapidity or degree of response. Maintenance treatment requires careful attention to the possibility of relapse and monitoring for the development of a movement disorder. Intermittent drug treatment is less effective than regular dosing, but gradual dose reduction is likely to improve social functioning in many schizophrenic patients who have been maintained at high doses. If medications are completely discontinued, however, the relapse rate is 60% within 6 months. Long-acting injectable preparations are considered when noncompliance with oral therapy leads to relapses. In treatment-resistant patients, a transition to clozapine usually results in rapid improvement, but a prolonged delay in response in some cases necessitates a 6- to 9-month trial for maximal benefit to occur.

Antipsychotic medications can cause a broad range of side effects, including lethargy, weight gain, postural hypotension, constipation, and dry mouth. Extrapyramidal symptoms such as dystonia, akathisia, and akinesia are also frequent with traditional agents and may contribute to poor compliance if not specifically addressed. Anticholinergic and parkinsonian symptoms respond well to trihexyphenidyl, 2 antagonism, a property that may clinically. Conventional antipsychotics differ in their potency and side-effect profile. Older agents, such as chlorpromazine and thioridazine, are more sedating and anticholinergic and more likely to cause orthostatic hypotension, while higher potency antipsychotics, such as haloperidol, perphenazine, and thiothixene, are more likely to induce extrapyramidal side effects. The model atypical antipsychotic agent is clozapine, a dibenzodiazepine that has a greater potency in blocking the 5HT₂ than the D₂ receptor and a much higher affinity for the D₂ than the D₃ receptor. Its principal disadvantage is a risk of blood dyscrasias. Unlike other antipsychotics, clozapine does not cause a rise in prolactin level. Approximately 30% of patients have a better response to these agents than to traditional neuroleptics, suggesting that they will increasingly displace the older-generation drugs. Clozapine appears to be the most effective member of this class and has demonstrated superiority to other atypical agents in preventing suicide; however, its side-effect profile is complex and includes a significant rate of agranulocytosis, which has an incidence of 1%, and in 10%. Weekly white blood cell counts are required, particularly during the first 3 months of treatment.
The risk of type 2 diabetes mellitus appears to be increased in schizophrenia, and atypical agents as a group produce greater adverse effects on glucose regulation, independent of effects on obesity, than traditional agents. Clozapine, olanzapine, and quetiapine seem more likely to cause hyperglycemia, weight gain, and hypertriglyceridemia than other atypical antipsychotic drugs. Close monitoring of plasma glucose and lipid levels are indicated with the use of these agents.

A serious side effect of long-term use of the classic antipsychotic agents is tardive dyskinesia, characterized by repetitive, involuntary, and potentially irreversible movements of the tongue and lips (bucco-linguo-masticatory triad), and, in approximately half of cases, choreoathetosis (Chap. 21). Tardive dyskinesia has an incidence of 2 to 4% per year of exposure, and a prevalence of 20% in chronically treated patients. The prevalence increases with age, total dose, and duration of drug administration. The risk associated with the newer atypical agents appears to be much lower. The cause may involve formation of free radicals and perhaps mitochondrial energy failure. Vitamin E may reduce abnormal involuntary movements if given early in the syndrome.

Drug treatment of schizophrenia is by itself insufficient. Educational efforts directed toward families and relevant community resources have proved to be necessary to maintain stability and optimize outcome. A treatment model involving a multidisciplinary case-management team that seeks out and closely follows the patient in the community has proved particularly effective.

ASSESSMENT AND EVALUATION OF VIOLENCE

Primary care physicians may encounter situations in which family, domestic, or societal violence is discovered or suspected. Such an awareness can carry legal and moral obligations; many state laws mandate reporting of child, spousal, and elder abuse. Physicians are frequently the first point of contact for both victim and abuser. Between 1 and 2 million older Americans and 1.5 million U.S. children are thought to experience some form of physical maltreatment each year. Spousal abuse is thought to be even more prevalent. One survey of internal medicine practices found that 5.5% of all female patients had experienced domestic violence in the previous year, and that these individuals were more likely to suffer from depression, anxiety, somatization disorder, and substance abuse and have attempted suicide. When domestic violence is suspected, direct but nonjudgmental questioning should be pursued with each party separately—"Do you feel safe at home?" and "If there’s a disagreement or a conflict between the two of you, how is it worked out?" Individuals who are abused may have signs of obvious or suspected physical injury; in addition, abused individuals frequently express low self-esteem, vague somatic symptomatology, social isolation, and a passive feeling of loss of control. Although it is essential to treat these elements in the victim, the first obligation is to ensure that the perpetrator has taken responsibility for preventing any further violence. Substance abuse and/or dependence and serious mental illness in the abuser may contribute to the risk of harm and require direct intervention. Depending on the situation, law enforcement agencies, community resources such as support groups and shelters, and individual and family counseling can be appropriate components of a treatment plan. A safety plan should be formulated with the victim, in addition to providing information about abuse, its likelihood of recurrence, and its tendency to increase in severity and frequency. Antianxiety and antidepressant medications may sometimes be useful in treating the acute symptoms, but only if independent evidence for an appropriate psychiatric diagnosis exists. Antidepressants are generally not indicated when the diagnosis is linked to the social situation, such as an adjustment disorder with depressed mood. The most important element in treatment is the development of a supportive doctor–patient relationship that avoids further blame of the victim. In certain circumstances, a significant potential for societal violence may be discovered. Sympathetic, but direct, questioning about potential violent impulses, access to weapons, recreational drug use, and specific homicidal ideation is necessary and is sometimes therapeutic in its own right. The existence and possible contribution of such medical conditions as delirium and/or intoxication should be evaluated. Available disposition options for potentially violent patients include police custody, psychiatric hospitalization, and referral to home care, with involvement of family, friends, and caregivers. In deciding which treatment option is most appropriate, clinicians should endeavor to establish an empathic interaction with the patient, while avoiding interventions or stimuli that might precipitate or increase the risk of violent behavior.

MENTAL HEALTH PROBLEMS IN THE HOMELESS

There is a high prevalence of mental disorders and substance abuse among homeless and impoverished people. The total number of homeless individuals in the United States is estimated at 2 to 3 million, one-third of whom qualify as having a serious mental disorder. Poor hygiene and nutrition, substance abuse, psychiatric illness, physical trauma, and exposure to the elements combine to make the provision of medical care challenging. Only a minority of these individuals receive formal mental health care; the main points of contact are outpatient medical clinics and emergency departments. Primary care settings represent a critical site in which housing needs, treatment of substance dependence, and evaluation and treatment of psychiatric illness can most efficiently take place. Successful intervention is dependent on breaking down traditional administrative barriers to health care and recognizing the physical constraints and emotional costs imposed by homelessness. Simplifying health care instructions and follow-up, allowing frequent visits, and dispensing medications in limited amounts that require ongoing contact are possible techniques for establishing a successful therapeutic relationship.

FURTHER READING

ABLON JS, JONES EEJ: Validity of controlled clinical trials of psychotherapy: Findings from the NIMH treatment of depression collaborative research program. Am J Psychiatry 159:775, 2002


Alcohol, a drug, is consumed at some time by up to 80% of the population. At low doses alcohol can have some beneficial effects such as decreased rates of myocardial infarction, stroke, gallstones, and possibly vascular or Alzheimer’s dementias, but the consumption of more than two standard drinks per day increases the risk for health problems in many organ systems. Heavy repetitive drinking, as is seen in alcohol abuse and dependence, cuts short the life span by an estimated decade in both genders, all cultural groups, and all socioeconomic strata. Even low doses of alcohol have a significant effect on many organ systems, adversely affecting most preexisting disease states and altering the effectiveness or blood levels of most over-the-counter and prescribed medications.

PHARMACOLOGY AND NUTRITIONAL IMPACT OF ETHANOL  Ethanol is a weakly charged molecule that moves easily through cell membranes, rapidly equilibrating between blood and tissues. The level of alcohol in the blood is expressed as milligrams or grams of ethanol per deciliter (e.g., 100 mg/dL or 0.10 g/dL); a level of 0.02 to 0.03 results from the ingestion of one to two typical drinks. In round figures, 340 mL (12 oz) of beer, 115 mL (4 oz) of nonfortified wine, and 43 mL (1.5 oz) (a shot) of 80-proof beverage each contain ~10 to 15 g of ethanol; 0.5 L (1 pint) of 86-proof beverage contains ~160 g (about 16 standard drinks), and 1 L of wine contains ~80 g of ethanol. Congeners found in alcoholic beverages, including low-molecular-weight alcohols (e.g., methanol and butanol), aldehydes, esters, histamine, phenols, tannins, iron, lead, and cobalt, may contribute to the adverse health consequences associated with heavy drinking.

Ethanol is a central nervous system (CNS) depressant that decreases neuronal activity, although some behavioral stimulation is observed at low blood levels. This drug has cross-tolerance with other depressants, including benzodiazepines and barbiturates, and all produce similar behavioral alterations. Alcohol is absorbed from mucous membranes of the mouth and esophagus (in small amounts), from the stomach and large bowel (in modest amounts), and from the proximal portion of the small intestine (the major site). The rate of absorption is increased by rapid gastric emptying; by the absence of proteins, fats, or carbohydrates (which interfere with absorption); by the absence of congeners; by dilution to a modest percentage of ethanol (maximum at about 20% by volume); and by carboxylation (e.g., chamagne).

Between 2% (at low blood alcohol concentrations) and 10% (at high blood alcohol concentrations) of ethanol is excreted directly through the lungs, urine, or sweat, but the greater part is metabolized to acetaldehyde, primarily in the liver. The most important pathway occurs in the cell cytosol where alcohol dehydrogenase (ADH) produces acetaldehyde, which is then rapidly destroyed by aldehyde dehydrogenase (ALDH) in the cytosol and mitochondria (Fig. 372-1). A second pathway in the microsomes of the smooth endoplasmatic reticulum (the microsomal ethanol-oxidizing system, or MEOS), is responsible for ≥10% of ethanol oxidation at high blood alcohol concentrations.

While alcohol supplies calories (a drink contains ~300 kJ, or 70 to 100 kcal), these are devoid of nutrients such as minerals, proteins, and vitamins. Alcohol can also interfere with absorption of vitamins in the small intestine and decreases their storage in the liver with effects on folate (folacin or folic acid), pyridoxine (B6), thiamine (B1), nicotinic acid (niacin, B3), and vitamin A.

An ethanol load in a fasting, healthy individual is likely to produce transient hypoglycemia within 6 to 36 h, secondary to the acute actions of ethanol on gluconeogenesis. This can result in glucose intolerance until the alcoholic has abstained for 2 to 4 weeks. Alcohol ketoadosis, probably reflecting a decrease in fatty acid oxidation coupled with poor diet or recurrent vomiting, should not be misdiagnosed as diabetic ketosis. With the former, patients show an increase in serum ketones along with a mild increase in glucose but a large anion gap, a mild to moderate increase in serum lactate, and a β-hydroxybutyrate/lactate ratio of between 2:1 and 9:1 (with normal being 1:1).

BEHAVIORAL EFFECTS, TOLERANCE, AND DEPENDENCE  The effects of any drug depend on the dose, the rate of increase in plasma, the concomitant presence of other drugs, and the past experience with the agent. With alcohol, an additional factor is whether blood alcohol levels are rising or falling; the effects are more intense during the former period.

Even though “legal intoxication” requires a blood alcohol concentration of at least 80 to 100 mg/dL, behavioral, psychomotor, and cognitive changes are seen at levels as low as 20 to 30 mg/dL (i.e., after one to two drinks) (Table 372-1). Deep but disturbed sleep can be seen at twice the legal intoxication level, and death can occur with levels between 300 and 400 mg/dL. Beverage alcohol is probably responsible for more overdose deaths than any other drug.

The intoxicating effects of alcohol appear to be due to actions at a number of neurotransmitter receptors and transporters. Alcohol enhances γ-aminobutyric acid A (GABA A) receptors and inhibits N-methyl-D-aspartate (NMDA) receptors. In vitro studies suggest that additional effects involve inhibition of adenosine uptake and a translocation of the cyclic AMP–dependent protein kinase catalytic subunit from the cytoplasm to the nucleus. Neurons adapt quickly to these actions, and thus different effects may be present during chronic administration and withdrawal.

At least three types of compensatory changes develop after repeated exposure to the drug, producing tolerance of higher ethanol levels. First, after 1 to 2 weeks of daily drinking, metabolic or pharmacokinetic tolerance can be seen, with a 30% increase in the rate of hepatic

![FIGURE 372-1](The metabolism of alcohol.)

<table>
<thead>
<tr>
<th>TABLE 372-1</th>
<th>Effects of Blood Alcohol Levels in the Absence of Tolerance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Level, mg/dL</td>
<td>Usual Effect</td>
</tr>
<tr>
<td>20</td>
<td>Decreased inhibitions, a slight feeling of intoxication</td>
</tr>
<tr>
<td>80</td>
<td>Decrease in complex cognitive functions and motor performance</td>
</tr>
<tr>
<td>200</td>
<td>Obvious slurred speech, motor incoordination, irritability, and poor judgment</td>
</tr>
<tr>
<td>300</td>
<td>Light coma and depressed vital signs</td>
</tr>
<tr>
<td>400</td>
<td>Death</td>
</tr>
</tbody>
</table>

2562
ethanol metabolism. This alteration disappears almost as rapidly as it develops. Second, cellular or pharmacodynamic tolerance develops through neurochemical changes that may also contribute to physical dependence. Third, individuals can learn to adapt their behavior so that they can function better than expected under drug influence (behavioral tolerance).

The cellular changes caused by chronic ethanol exposure may not resolve for several weeks or longer following cessation of drinking. In the interim, the neurons require ethanol to function optimally, and the individual can be said to be physically dependent. This is distinct from psychological dependence, a concept indicating that the person is psychologically uncomfortable without the drug.

THE EFFECTS OF ETHANOL ON ORGAN SYSTEMS

Although one to two drinks per day in an otherwise healthy and non-pregnant individual can have some beneficial effects, at higher doses alcohol is toxic to most organ systems. Knowledge about the deleterious effects of alcohol helps the physician to identify alcoholic patients and provides information that can be used to help motivate them to abstain. The information offered here generally applies across ages and genders, with common sense differences (e.g., older persons carry higher health risks). It is important to remember that the typical white- or blue-collar alcoholic functions at a fairly high level for years, and that not everyone develops each problem.

CENTRAL NERVOUS SYSTEM

Approximately 35% of drinkers may experience a blackout, an episode of temporary anterograde amnesia, in which the person forgets all or part of what occurred during a drinking evening. Another common problem, one seen after as few as several drinks, is that alcohol causes alterations between sleep stages and a deficiency in rapid eye movement and deep sleep with resulting prominent and sometimes disturbing dreams later in the night. Finally, alcohol relieves muscles in the pharynx, which can cause snoring and exacerbate sleep apnea, with symptoms of the latter in 75% of alcoholic men over age 60. As a consequence of alcohol-related impairment in judgment and coordination, at least half of patients with physical trauma have evidence of substance-related impairment, a finding reflecting the fact that 40% of drinkers in the United States have at some time driven while intoxicated.

The effect of alcohol on the nervous system is even more pronounced among alcohol-dependent individuals. Chronic high doses cause peripheral neuropathy in 5 to 15% of alcoholics: patients experience bilateral limb numbness, tingling, and paresthesias, all of which are more pronounced distally. Wernicke’s syndrome (ophthalmoparesis, ataxia, and encephalopathy) and Korsakoff’s syndrome are seen in <10% of alcoholics as the result of thiamine deficiency, especially in persons with transketolase deficiency (Chap. 258). Approximately 1% of alcoholics develop cerebellar degeneration, a syndrome of progressive unsteady stance and gait often accompanied by mild nystagmus; neuroimaging studies reveal atrophy of the cerebellar vermis.

Alcoholics can manifest severe cognitive problems including impairment in recent and remote memory for weeks to months after an alcoholic binge. Increased size of the brain ventricles and cerebral sulci are seen in ≥50% of chronic alcoholics, but these changes are often reversible, returning toward normal within a year or so of abstinence. There is no single alcoholic dementia syndrome; rather, this label is used to describe patients who have apparently irreversible cognitive changes (possibly from diverse causes) and chronic alcoholism.

Finally, almost every psychiatric syndrome can be seen temporarily during heavy drinking or subsequent withdrawal. These include intense sadness lasting for days to weeks in the midst of heavy drinking in 40% of alcoholics, which is classified as an alcohol-induced mood disorder; temporary severe anxiety in 10 to 30% of alcoholics, often beginning during alcohol withdrawal, which can persist for many months after cessation of drinking (alcohol-induced anxiety disorder); and auditory hallucinations and/or paranoid delusions in a clear sensorium (alcohol-induced psychotic disorder) seen temporarily in 1 to 10% of alcoholics. Treatment of all forms of alcohol-induced psychopathology includes abstinence and supportive care, with the likelihood of full recovery within several days to 4 weeks. A history of alcohol intake is an important consideration in any patient with one of these psychiatric symptoms.

THE GASTROINTESTINAL SYSTEM

Acute alcohol intake can result in inflammation of the esophagus and stomach, causing epigastric distress and gastrointestinal bleeding. Chronic heavy drinking, if associated with violent vomiting, can produce a Mallory-Weiss lesion, a longitudinal tear in the mucosa at the gastroesophageal junction.

Pancreas and Liver

The incidence of acute pancreatitis (~25 per 1000 per year) is almost threefold higher than in the general population, accounting for an estimated 10% or more of the cases of this disorder (Chap. 294). Alcohol impairs gluconeogenesis in the liver with a resulting fall in the amount of glucose produced from glycogen; lactate production increases; and there is a decreased oxidation of fatty acids with an increase in fat accumulation in liver cells. In the healthy individual these changes are reversible, but with repeated exposure to ethanol, more severe changes can occur, including fatty accumulation, alcohol-induced hepatitis, perivenular sclerosis, and cirrhosis, with the latter observed in an estimated 15 to 20% of alcoholics (Chap. 288).

CANCER

Drinking as few as 1.5 drinks per day increases a woman’s risk of breast cancer 1.4-fold. For both genders, four drinks per day increases the risk for oral and esophageal cancers approximately threefold and rectal cancers by a factor of 1.5; seven to eight or more drinks per day enhances the risks for many cancers by a factor of five.

HEMATOPOIETIC SYSTEM

Ethanol causes an increase in red blood cell size [mean corpuscular volume, (MCV)], which reflects the effects on stem cells. If heavy drinking is accompanied by folic acid deficiency, there can also be hypersegmented neutrophils, reticulocytopenia, and a hyperplastic bone marrow; if malnutrition is present, sideroblastic changes can be observed. Chronic heavy drinking can decrease production of most white blood cells, decrease granulocyte mobility and adherence, and impair the delayed-hypersensitivity response to new antigens (with a possible false-negative tuberculin skin test). Finally, many alcoholics have mild thrombocytopenia, which usually resolves within a week of abstinence unless there is hepatic cirrhosis or congestive splenomegaly.

CARDIOVASCULAR SYSTEM

Acutely, ethanol decreases myocardial contractility and causes peripheral vasodilation, with a resulting mild decrease in blood pressure and a compensatory increase in cardiac output. Exercise-induced increases in cardiac oxygen consumption are higher after alcohol intake. These acute effects have little clinical significance for the average healthy drinker but can be problematic in men and women with cardiac disease.

The consumption of three or more drinks per day results in a dose-dependent increase in blood pressure, which returns to normal within weeks of abstinence. Heavy drinking is an important contributor to mild to moderate hypertension. Chronic heavy drinking can cause cardiomyopathy, with symptoms ranging from unexplained arrhythmias in the presence of left ventricular impairment to heart failure with dilation of all four heart chambers and hypocontractility of heart muscle. Perhaps one-third of cases of cardiomyopathy are alcohol-induced. Mural thrombi can form in the left atrium or ventricle, while heart enlargement ≥25% can cause mitral regurgitation. Atrial or ventricular arrhythmias, especially paroxysmal tachycardia, can also occur after a drinking binge in individuals showing no other evidence of heart disease—a syndrome known as the “holiday heart.”

Chronic intake of modest doses of alcohol can have some beneficial effects. A maximum of one to two drinks per day may decrease the risk for cardiovascular death, perhaps through an increase in high-density lipoprotein (HDL) cholesterol or changes in clotting mechanisms. In one large national study, cardiovascular mortality was re-
duced by 30 to 40% among individuals reporting one or more drinks daily compared to nondrinkers, with overall mortality lowest among those consuming approximately one drink per day. Recent data have also corroborated the decreased risk for ischemic, but not hemorrhagic, stroke associated with regular light drinking.

**GENITOURINARY SYSTEM CHANGES, SEXUAL FUNCTIONING, AND FETAL DEVELOPMENT**

Acute, modest ethanol doses (e.g., blood alcohol concentrations of ≤100 mg/dL) can both increase sexual drive and decrease erectile capacity in men. Even in the absence of liver impairment, a significant minority of chronic alcoholic men may show irreversible testicular atrophy with concomitant shrinkage of the seminiferous tubules, decreases in ejaculate volume, and a lower sperm count (Chap. 325).

The repeated ingestion of high doses of ethanol by women can result in amenorrhea, a decrease in ovarian size, and spontaneous abortions. Heavy drinking during pregnancy results in the rapid placental transfer of both ethanol and acetaldehyde, which may have serious consequences for fetal development. The **fetal alcohol syndrome** can include any of the following: facial changes with epicanthal eye folds, poorly formed concha, and small teeth with faulty enamel; cardiac atrial or ventricular septal defects; an aberrant palmar crease and limitation in joint movement; and microcephaly with mental retardation. The amount of ethanol and/or time of vulnerability during pregnancy have not been defined, making it advisable for pregnant women to abstain completely.

**OTHER EFFECTS OF ETHANOL**

Between one-half and two-thirds of alcoholics have skeletal muscle weakness caused by acute **alcoholic myopathy**, a condition that improves but which might not disappear with abstinence. Effects of repeated heavy drinking on the **skeletal system** include alterations in calcium metabolism, lower bone density, and less growth in the epiphyses, with an increased risk for fractures and osteonecrosis of the femoral head. **Hormonal changes** include an increase in cortisol levels, which can remain elevated during heavy drinking; inhibition of vasopressin secretion at rising blood alcohol concentrations and the opposite effect at falling blood alcohol concentrations (with the final result that most alcoholics are likely to be slightly overhydrated); a modest and reversible decrease in serum thyroxine (T₄); and a more marked decrease in serum triiodothyronine (T₃).

**ALCOHOLISM (ALCOHOL ABUSE OR DEPENDENCE)**

Because many drinkers occasionally imbibe to excess, temporary alcohol-related pathology is common in nonalcoholics, especially those in the late teens to the late twenties. When repeated problems in multiple life areas develop, the person is likely to meet criteria for alcohol abuse or dependence.

**DEFINITIONS AND EPIDEMIOLOGY**

**Alcohol dependence** is defined in the Fourth Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric Association as repeated alcohol-related difficulties in at least three of seven areas of functioning that cluster together over any 12-month period. A special emphasis is placed on tolerance and/or withdrawal, a condition referred to as “dependence with a physiological component,” which is associated with a more severe clinical course. Dependence occurs in both men and women and in individuals from all socioeconomic strata and of all racial backgrounds. The diagnosis predicts a course of recurrent problems with the use of alcohol and the consequent shortening of the life span by a decade or more. In the absence of alcohol dependence, an individual can be given a diagnosis of **alcohol abuse** if he or she demonstrates repetitive problems with alcohol in any one of four life areas that include social, interpersonal, legal, and occupational problems, or repeated use in hazardous situations such as driving.

The lifetime risk for alcohol dependence in most western countries is about 10 to 15% for men and 5 to 8% for women. When alcohol abuse is also considered, the rates are even higher. The typical alcoholic is a blue- or white-collar worker or homemaker and not the stereotypical homeless individual.

**GENETICS OF ALCOHOLISM**

**Alcoholism** is a complex genetically influenced disorder; genes explain about 60% of the risk. The importance of genetic influences is supported by a higher risk in the identical versus fraternal twin of an alcoholic and a fourfold increased risk in children of alcoholics even if adopted at birth and raised without knowledge of their biologic parents.

A variety of independent genetically influenced characteristics likely combine to explain the contribution of hereditary factors. For alcoholism and other substance dependencies, some families appear to carry an enhanced risk through high levels of impulsivity, as can be seen in the antisocial personality disorder. In other families the risk is associated with vulnerability for several independent psychiatric disorders such as schizophrenia and manic-depressive disease. A diminished alcoholism risk is seen in approximately half of Asian men and women; this is due to an inactive form of the enzyme ALDH, which results in higher levels of acetaldehyde following alcohol ingestion. A significant proportion of the vulnerability for alcoholism appears to relate to genes that affect the intensity of the response to alcohol. Most studies have shown that 40% of some subgroups at high risk for future alcoholism (e.g., offspring of alcoholics) require higher blood alcohol concentrations to produce the effects seen at lower blood levels in most other people. This relatively low response to alcohol predicts the risk for alcohol-related problems over the next decade, including alcohol use disorders.

**NATURAL HISTORY**

For the “average” alcoholic, the age of first drink and first problems (e.g., an alcoholic blackout) are similar to those in the general population. However, by the early to mid-twenties, most men and women moderate their drinking (perhaps learning from minor problems), whereas difficulties for alcoholics are likely to escalate, with the first major life problem from alcohol appearing in the mid-twenties. Once established, the course of alcoholism is likely to be one of exacerbations and remissions. As a rule, there is little difficulty in stopping alcohol use when problems develop, and this step is often followed by days to months of carefully controlled drinking. Unless abstinence is maintained, these periods almost inevitably give way to escalations in alcohol intake and subsequent problems. The course is not hopeless, because between half and two-thirds of alcoholics maintain abstinence for years, and often permanently after treatment. Even without formal treatment or self-help groups there is at least a 20% chance of long-term abstinence. However, should the alcoholic continue to drink, the life span is shortened by an average of 10 years, with the leading causes of death, in decreasing order, the result of heart disease, cancer, accidents, and suicide.

**IDENTIFICATION OF THE ALCOHOLIC AND INTERVENTION**

Physicians even in affluent areas should recognize that ~20% of patients have alcoholism. Therefore, it is important to pay attention to the alcohol-related symptoms and signs as well as laboratory tests that are likely to be abnormal in the context of regular consumption of 6 to 8 or more drinks per day. The two blood tests with between 70% and 80% sensitivity and specificity are γ-glutamyl transferase (GGT) (>30 U) and carbohydrate-deficient transferrin (CDT) (>20 U/L); the combination of the two is likely to be more accurate than either alone. Physicians should consider these tests when screening patients for high levels of alcohol intake. These serologic markers of heavy drinking can also be useful in monitoring abstinence as they are likely to return toward normal within several weeks of the cessation of drinking; thus, increases in values of as little as 10% are likely to indicate a resumption of heavy alcohol intake. Other blood tests that can be useful in identifying individuals consuming six or more standard drinks per day include high normal MCVs (>91 µm³) and serum uric acid (>416 mol/L, or 7 mg/dL). Physical signs and symptoms that can be useful in identifying alcoholism include mild and fluctuating hypertension (e.g., 140/95), repeated infections such as pneumonia, and otherwise unexplained cardiac arrhythmias. Other disorders suggestive of dependence include...
cancer of the head and neck, esophagus, or stomach as well as cirrhosis, unexplained hepatitis, pancreatitis, bilateral parotid gland swelling, and peripheral neuropathy.

The clinical diagnosis of alcohol abuse or dependence ultimately rests on the documentation of a pattern of difficulties associated with alcohol use; the definition is not based on the quantity and frequency of alcohol consumption. Thus, in screening it is important to probe for life problems and then attempt to tie in use of alcohol or another substance. Information regarding marital or job problems, legal difficulties, histories of accidents, medical problems, evidence of tolerance, etc., is important. While all physicians should be able to take the time needed to gather such information, some standardized questionnaires can be helpful, including the 10-item Alcohol Use Disorder Screening Test (AUDIT). However, these are only screening tools, and a careful face-to-face interview is still required for a meaningful diagnosis. Shorter questionnaires have limited usefulness.

After alcoholism is identified, the diagnosis must be shared with the patient as part of an intervention. The presenting complaint can be used as an entrée to the alcohol problem. For instance, the patient complaining of insomnia or hypertension could be told that these are clinically important symptoms and that physical findings and laboratory tests indicate that alcohol appears to have contributed to the complaints and is increasing the risk for further medical and psychological problems. The physician should share information about the course of alcoholism and explore possible avenues of addressing the problem. This process has been codified under the names of brief interventions and motivational interviewing. The former has been shown to be effective in decreasing alcohol use and problems when instituted as two 15-min sessions 1 month apart, along with a telephone follow-up reminder. Motivational interviewing uses the clinician’s level of concern and understanding of the need for patients to progress through their own stages of enhanced understanding of their problems to optimize their ability to alter their drinking behaviors.

The process of intervention is rarely accomplished in one session. For the person who refuses to stop drinking at the first intervention, a logical step is to “keep the door open,” establishing future meetings so that help is available as problems escalate. In the meantime the family may benefit from counseling or referral to self-help groups such as Al-Anon (the Alcoholics Anonymous group for family members) and Alateen (for teenage children of alcoholics).

**THE ALCOHOL WITHDRAWAL SYNDROME** Once the brain has been repeatedly exposed to high doses of alcohol, any sudden decrease in intake can produce withdrawal symptoms, many of which are the opposite of those produced by intoxication. Features include tremor of the hands (shakes or jitters); agitation and anxiety; autonomic nervous system overactivity including an increase in pulse, respiratory rate, and body temperature; insomnia, possibly accompanied by bad dreams; and gastrointestinal upset. These withdrawal symptoms generally begin within 5 to 10 h of decreasing ethanol intake, peak in intensity on day 2 or 3, and improve by day 4 or 5. Anxiety, insomnia, and mild levels of autonomic dysfunction may persist to some degree for ≥6 months as a protracted abstinence syndrome, which may contribute to the tendency to return to drinking.

At some point in their lives, between 2 and 5% of alcoholics experience withdrawal seizures, often within 48 h of stopping drinking. These rare events usually involve a single generalized seizure, and electroencephalographic abnormalities generally return to normal within several days.

The term *delirium tremens* (DTs) refers to delirium (mental confusion, agitation, and fluctuating levels of consciousness) associated with a tremor and autonomic overactivity (e.g., marked increases in pulse, blood pressure, and respirations). Fortunately, this serious and potentially life-threatening complication of alcohol withdrawal is seen in <5% of alcohol-dependent individuals, with the result that the chance of DTs during any single withdrawal is <1%. DTs are most likely to develop in patients with concomitant severe medical disorders and can usually be avoided by identifying and treating medical conditions.

**Acute Intoxication** The first priority is to be certain that the vital signs are relatively stable without evidence of respiratory depression, cardiac arrhythmia, or potentially dangerous changes in blood pressure. The possibility of intoxication with other drugs should be considered, and a blood or urine sample is indicated to screen for opioids or other CNS depressants such as benzodiazepines or barbiturates. Other medical conditions that must be evaluated include hypoglycemia, hepatic failure, or diabetic ketoacidosis.

Patients who are medically stable should be placed in a quiet environment and asked to lie on their side if fatigued in order to minimize the risk of aspiration. When the behavior indicates an increased likelihood of violence, hospital procedures should be followed, including planning for the possibility of a show of force with an intervention team. In the context of aggressiveness, patients should be clearly reminded in a nonthreatening way that it is the goal of the staff to help them to feel better and to avoid problems. If the aggressive behavior continues, relatively low doses of a short-acting benzodiazepine such as lorazepam (e.g., 1 mg orally) may be used and can be repeated as needed, but care must be taken so that the addition of this second CNS depressant does not destabilize vital signs or worsen confusion. An alternative approach is to use an antipsychotic medication (e.g., 5 mg of haloperidol), but this has the potential danger of lowering the seizure threshold. If aggression escalates, the patient might require a short-term admission to a locked ward, where medications can be used more safely and vital signs more closely monitored.

**Withdrawal** The first step is to perform a thorough physical examination in all alcoholics who are considering stopping drinking, including a search for evidence of liver failure, gastrointestinal bleeding, cardiac arrhythmia, and glucose or electrolyte imbalance.

The second step in treating withdrawal for even the typically well-nourished alcoholic is to offer adequate nutrition and rest. All patients should be given oral multiple B vitamins, including 50 to 100 mg of thiamine daily for a week or more. Most patients enter withdrawal with normal levels of body water or mild overhydration, and intravenous fluids should be avoided unless there is evidence of significant recent bleeding, vomiting, or diarrhea. Medications can usually be administered orally.

The third step in treatment is to recognize that most withdrawal symptoms are caused by the rapid removal of a CNS depressant. Patients can be weaned by administering any drug of this class and gradually decreasing the levels over 3 to 5 days. While many CNS depressants are effective, benzodiazepines have the highest margin of safety and lowest cost and are, therefore, the preferred class of drugs. Benzodiazepines with short half-lives (Chap. 371) are especially useful for patients with serious liver impairment or evidence of preexisting encephalopathy or brain damage, but result in rapidly changing drug blood levels and must be given every 4 h to avoid abrupt fluctuations in blood levels that may increase the risk for seizures. Therefore, most clinicians use drugs with longer half-lives, such as diazepam or chlor Diazepam, administering enough drug on day 1 to alleviate most of the symptoms of withdrawal (e.g., the tremor and elevated pulse) and then decreasing the dose by 20% on successive days over a period of 3 to 5 days. The approach is flexible; the dose is increased if signs of withdrawal escalate, and the medication is withheld if the patient is sleeping or shows signs of increasing or unstable hypotension. The average patient requires 25 to 50 mg of chlor Diazepam or 10 mg of diazepam given orally every 4 to 6 h on the first day.

Treatment of the patient with DTs can be difficult, and the condition is likely to run a course of 3 to 5 days regardless of the therapy employed. The focus of care is to identify medical problems and correct them and to control behavior and prevent injuries. Many clinicians recommend the use of high doses of a benzodiazepine (as much as 800 mg/d of chlor Diazepam have been reported), a treatment that
After completing alcoholic rehabilitation, and symptoms of withdrawal escalate. Family members are asked to return daily for a 2-day supply to be administered to the patient by a spouse or other family member four times a day. Patients are asked to return daily for evaluation of vital signs and to come to the emergency room if signs and symptoms of withdrawal escalate.

Rehabilitation of Alcoholics

After completing alcoholic rehabilitation, 60% or more of alcoholics maintain abstinence for at least a year, and many achieve lifetime abstinence. Considering the lack of evidence for the superiority of any specific treatment type, it is best to keep interventions simple.

Maneuvers in rehabilitation fall into several general categories, which are applied to all patients regardless of age or ethnic group. However, the manner in which the treatments are used should be sensitive to the practices and needs of specific populations. First are attempts to help the alcoholic achieve and maintain a high level of motivation toward abstinence. These include education about alcoholism and instructing family and/or friends to stop protecting the person from the problems caused by alcohol. The second step is to help the patient to readjust to life without alcohol and to reestablish a functional lifestyle through counseling, vocational rehabilitation, and self-help groups such as Alcoholics Anonymous. The third component, called relapse prevention, helps the person to identify situations in which a return to drinking is likely, formulate ways of managing these risks, and develop coping strategies that increase the chances of a return to abstinence if a slip occurs.

There is no convincing evidence that inpatient rehabilitation is always more effective than outpatient care. However, more intensive interventions work better than less intensive measures, and some alcoholics do not respond to outpatient approaches. The decision to hospitalize or place into residential care can be made if (1) the patient has medical problems that are difficult to treat outside a hospital; (2) depression, confusion, or psychosis interferes with outpatient care; (3) there is a severe life crisis that makes it difficult to work in an outpatient setting; (4) outpatient treatment has failed; or (5) the patient lives far from the treatment center. The best predictors of continued abstinence include evidence of higher levels of life stability (e.g., supportive family and friends) and higher levels of functioning (e.g., job skills, higher levels of education, and absence of crimes unrelated to alcohol).

Whether the treatment begins in an inpatient or an outpatient setting, subsequent outpatient contact should be maintained for a minimum of 6 months and preferably a full year after abstinence is achieved. Counseling with an individual physician or through groups focuses on day-to-day living—emphasizing areas of improved functioning in the absence of alcohol (i.e., why it is a good idea to continue to abstain) and helping the patient to manage free time without alcohol, develop a nondrinking peer group, and handle stresses on the job.

The physician serves an important role in identifying the alcoholic, treating associated medical or psychiatric syndromes, overseeing detoxification, referring the patient to rehabilitation programs, and providing counseling. The physician is also responsible for selecting which (if any) medication might be appropriate during alcoholism rehabilitation. Patients often complain of continuing sleep problems or anxiety when acute withdrawal treatment is over, problems that may be a component of protracted withdrawal. Unfortunately, there is no place for hypnotics or antianxiety drugs in the treatment of most alcoholics after acute withdrawal has been completed. Patients should be reassured that the trouble sleeping is normal after alcohol withdrawal and will improve over the subsequent weeks and months. Patients should follow a rigid bedtime and awakening schedule and avoid any naps or the use of caffeine in the evenings. The sleep pattern will improve rapidly. Anxiety can be addressed by helping the person to gain insight into the temporary nature of the symptoms and to develop strategies to achieve relaxation as well as by using forms of cognitive therapy.

While the mainstay of alcoholic rehabilitation involves counseling, education, and cognitive approaches, several medications might be useful. The first is the opioid-antagonist drug naltrexone, 50 to 150 mg/d, which has been reported in several small-scale, short-term studies to decrease the probability of a return to drinking and to shorten periods of relapse. However, at least one longer-term large-scale trial questioned the superiority of naltrexone to placebo, and more studies are required before the cost-effectiveness of this approach can be established. A second medication, acamprosate (Campral), 2 g/d, has been tested in >5000 patients in Europe, with results that appear similar to those reported for naltrexone. Several long-term trials of naltrexone and acamprosate, used individually and in combination, are in progress, and early results are promising. A third medication, which has historically been used in the treatment of alcoholism, is the ALDH inhibitor disulfiram. In doses of 250 mg/d this drug produces an unpleasant (and potentially dangerous) reaction in the presence of alcohol, a phenomenon related to rapidly rising blood levels of the first metabolite of alcohol, acetaldehyde. However, few adequate controlled trials have demonstrated the superiority of disulfiram over placebo. Disulfiram has many side effects, and the reaction with alcohol can be dangerous, especially for patients with heart disease, stroke, diabetes mellitus, and hypertension. Thus, most clinicians reserve this medication for patients who have a clear history of longer-term abstinence associated with prior use of disulfiram and for those who might take the drug under the supervision of another individual (such as a spouse), especially during discrete periods that they have identified as representing high-risk drinking situations for them (such as the Christmas holiday).

Additional support for alcoholics and their relatives and friends is available through self-help groups such as Alcoholics Anonymous (AA). These groups, which typically consist of recovering alcoholics, offer an effective model of abstinence, provide a sober peer group, and make crisis intervention available when the urge to drink escalates. This can help patients optimize their chances for recovery, especially when incorporated into a more structured treatment milieu.

Further Reading

It is difficult to imagine modern medical practice without the use of opioid analgesics. These drugs have been part of health care since 300 B.C. Opium and codeine were isolated in the early nineteenth century, opioid-like substances produced by the body were recognized in the 1970s, and the first endogenous opioid was isolated in 1995. As important as these substances are to modern medicine, opioid drugs have many disadvantages, including overdose and dependency; close to 1 million individuals in the United States are opioid-dependent. All opioid drugs are capable of producing a heroin-like intoxication, as well as tolerance and withdrawal.

PHARMACOLOGY  The prototypic opiates, morphine and codeine (3-methoxymorphine), are derived from the milky juice of the poppy Papaver somniferum. The semisynthetic drugs produced from the morphine or thebaine molecules include hydromorphone, diacetylmorphine (heroin), and oxycodone. The purely synthetic opioids and their cousins include meperidine, propoxyphene, diphenoxylate, fentanyl, buprenorphine, tramadol, methadone, and pentazocine.

Endogenous opioid peptides (i.e., enkephalins, endorphins, dynorphins, and others) have distinct distributions in the central nervous system (CNS) and appear to be natural ligands for opioid receptors. As summarized in Table 373-1, the receptors with which opioid peptides interact differentially produce analgesia, respiratory depression, constipation, euphoria, and other actions. Substances capable of antagonizing one or more of these actions include nalorphine, levallorphan, cyclazocine, butorphanol, buprenorphine, and pentazocine, each of which has mixed agonist and antagonist properties, as well as nalofoxone, nalmefene, and naltrexone, which are pure opiate antagonists. The availability of relatively specific antagonists has helped identify at least three different receptor subtypes, including μ receptors, which influence some of the more classic opioid actions such as pain control, reinforcement, constipation, hormone levels, and respiration; κ receptors, with possible similar functions along with sedation and effects on hormones; and δ receptors, thought to relate mostly to analgesia, mood, reinforcement, and breathing. A fourth possible receptor subtype, sensitive to another endogenous peptide, is sometimes called nociceptin or orphanin and may influence pain. The major features of tolerance, dependence, and withdrawal are thought to be mediated primarily by μ receptors, and these are affected by all prescription opioids.

The most rapid and pronounced effects of opioids occur following intravenous administration, with only slightly less efficient absorption after smoking or inhaling the vapor (“chasing the dragon”). The least intense effects occur after oral consumption. Most of the metabolism of opioids occurs in the liver, primarily through conjugation with glucuronic acid, and only small amounts are excreted directly in the urine or feces. The plasma half-lives of these drugs range from 2.5 to 3 h for morphine to more than 22 h for methadone and even longer for levomethadyl acetate (LAAM).

Street heroin is typically only 5 to 10% pure, mixed with sugars, quinine, powdered milk, phenacetin, caffeine, antipyrine, and strychnine. Unexpected increases in the purity of street drugs can cause unintentional lethal overdoses.

ACUTE AND CHRONIC EFFECTS OF OPIOIDS  With the exception of overdose and physical dependence, most opioid effects are rapidly reversible. A major danger, however, comes through the use of contaminated needles by intravenous users, which increases the risk of hepatitis B and C, bacterial endocarditis, and infection with HIV (Chap. 173).

Effects on Organ Systems  In addition to euphoria and rewarding effects of opioids due to stimulation of a dopaminergic pathway originating in the midbrain and terminating in the nucleus accumbens, CNS effects of opioid drugs include nausea and vomiting (medulla), decreased pain perception (spinal cord, thalamus, and periaqueductal gray region), and sedation (reticular activating system). The adulterants added to street drugs may contribute to nervous system damage, including peripheral neuropathy, amnestic myelopathy, and leukoencephalopathy. Acute opioid administration inhibits release of some hormones from the hypothalamus, including corticotropin-releasing factor (CRF) and luteinizing hormone, with a subsequent reduction in some sex hormones, actions that might contribute to the decreased sex drive and problems in handling stress. Other hormonal changes include a decrease in the release of thyrotropin and increases in prolactin and possibly growth hormone (Chap. 318).

Acute changes in the respiratory system include a CNS-mediated decrease in the cough reflex and respiratory depression, which result from a decreased response of the brainstem to carbon dioxide tension, a component of the drug overdose syndrome described below. At even low drug doses, this effect can be clinically significant for individuals with pulmonary disease. Aspiration pneumonia is an additional risk. The gastrointestinal effects of opioids can include nausea and decreased gut motility with resulting constipation and anorexia. Cardiovascular changes tend to be relatively mild, with no direct opioid effect on heart rhythm or myocardial contractility, but orthostatic hypotension can occur, probably secondary to histamine release and dilation of peripheral vessels. Bacterial endocarditis with septic emboli and stroke can occur from contaminated needles.

Opioid Toxicity and Overdose  High doses of opioids can result in a potentially lethal overdose, which may occur in >60% of opioid-dependent persons, especially with the more potent drugs such as fentanyl (80 to 100 times more powerful than morphine). The typical syndrome, which occurs immediately with intravenous overdose, includes shallow and slow respirations, pupillary miosis (with mydriasis once brain anoxia develops), bradycardia, hypothermia, and stupor or coma (Chap. 257). If not treated rapidly, respiratory depression, cardiorespiratory arrest, and death can ensue. Postmortem examination reveals few specific changes except for diffuse cerebral edema. An “allergic-like” reaction to intravenous heroin, perhaps in part related to adulterants, can also occur and is characterized by decreased alertness, frothy pulmonary edema, and an elevation in the blood eosinophil count.

The first step in managing overdose is to support vital signs, using intubation if needed. Definitive treatment is the administration of a narcotic antagonist such as 0.4 mg to 2 mg intravenous or intramuscular naloxone. A response should occur in 1 to 2 min; the dose should be repeated every 2 to 3 min up to 10 mg. Except with buprenorphine overdoses, no response after 10 mg makes an opioid toxic reaction unlikely. It is important to titrate the dose relative to the patient’s symptoms to ameliorate the respiratory depression but not provoke a severe withdrawal state; the latter cannot be aggressively treated until overdose-related vital signs are relatively stable. Because the effects of naloxone diminish within 2 to 3 h, the individual must be monitored.

### Table 373-1  Actions of Opioid Receptors

<table>
<thead>
<tr>
<th>Receptor Type</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mu (μ) (e.g., morphine)</td>
<td>Analgesia, reinforcement euphoria, cough and appetite suppression, decreased respirations, decreased GI motility, sedation, hormone changes, dopamine and acetylcholine release</td>
</tr>
<tr>
<td>Kappa (κ) (e.g., butorphanol)</td>
<td>Decreased dysphoria, decreased GI motility, decreased appetite, decreased respiration, psychotic symptoms, sedation, diuresis, analgesia</td>
</tr>
<tr>
<td>Delta (δ) (e.g., etorphine)</td>
<td>Hormone changes, appetite suppression, dopamine release</td>
</tr>
</tbody>
</table>

**Note:** GI, gastrointestinal.
for at least 24 h after a heroin overdose and 72 h after an overdose of a longer-acting drug such as methadone. For methadone overdose, the substitution of the longer acting naltrexone should be considered. If there is little response to an opioid antagonist, the possibility of a concomitant overdose with a benzodiazepine should be considered and a challenge with intravenous flumazenil, 0.2 mg/min up to a maximum of 3 mg in an hour, might be used.

Treatment of either the typical or the “allergic” type of opioid toxic reaction often requires continued respiratory support (often with oxygen supplementation and positive-pressure breathing for the “allergic” type of overdose), intravenous fluids, pressor agents when needed to support blood pressure, and gastric lavage to remove any remaining drug. Intubation is often required to prevent aspiration in the stuporous or comatose patient. Cardiac arrhythmias and/or seizures may also be part of the opioid toxic reaction, especially with codeine, propoxyphene, or meperidine.

**OPIOD ABUSE AND DEPENDENCE □ Definition and Epidemiology**

The Fourth Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric Association defines opioid dependence as repeated use of a drug of this class to the point of causing multiple problems. The definition requires evidence of three or more problems in the same year, including tolerance, withdrawal, use of greater amounts of opiates than intended, and use despite consequences. Patients who do not have dependence but demonstrate repeated opioid-related difficulties with the law, impaired ability to meet obligations, use in hazardous situations, or continued use despite problems can be labeled as having abuse.

The use of opioids for intoxication is less prevalent than the use of alcohol, marijuana, and several other drugs. A 2002 national survey of adolescents and young adults reported that 10% of 12th graders (high school seniors) had tried an opioid outside of a doctor’s prescription, including almost 2% who had used heroin. Figures for young adults and college students in 2001 were almost 12% and 2%, respectively. In all studies, prevalence rates were only slightly higher in males than females. None of the national surveys offered data regarding the prevalence of dependence, which is estimated as a lifetime risk of about 1%.

**Genetics**

One large study of >3000 male twin pairs reported that there are genetic influences that relate uniquely to heroin dependence and also noted additional genetic factors related to an overall vulnerability toward substance-related problems. The genetic influences operate in the context of additional environmental factors that are likely to relate both to the family of upbringing and the general environment. Genetic factors might influence personality characteristics such as impulsivity and sensation-seeking or susceptibility to develop antisocial personality disorder. Genes relating to the actions of the drug on specific neurochemical systems such as dopamine are also potential candidates for an enhanced vulnerability toward developing opioid dependence.

**Natural History**

While an opioid use disorder can develop in anyone, at least three groups are at increased risk for dependence or misuse. First, a minority of persons with chronic pain syndromes (e.g., back, joint, and muscle disorders) misuse their prescribed drugs. If physical dependence is established, any drop in opioid blood levels can then intensify the pain and promote continued drug intake. Physicians can avoid contributing to physical dependence by helping the patient to accept the goal of moderation rather than disappearance of the pain and to recognize that discomfort may not be completely eliminated (Chap. 11). Analgesic medication should be only one component of treatment and limited to the oral administration of the least potent analgesic that is able to “take the edge off” the pain (e.g., ibuprofen or, if needed, propoxyphene). Behavior-modification techniques, such as muscle relaxation and meditation, and carefully selected exercises should be used as appropriate to help increase function and decrease pain. Finally, nonmedicinal approaches, including electrical transcutaneous neurostimulation for muscle and joint disease, may be useful.

The second group at high risk are physicians, nurses, and pharmacists, primarily because of easy access to opioids. Physicians may begin use to help with sleep or to reduce stress or physical aches and pains, and then escalate doses as tolerance develops. Because of the growing awareness of these problems, programs have been developed to identify and aid substance-impaired physicians, providing peer support and education before problems escalate to the point of licensure revocation. All physicians are advised never to prescribe opioids for themselves or family members.

The third group are those who buy street drugs to get high. While some of these individuals have prior histories of severe antisocial problems, most have a relatively high level of premorbid functioning. The typical person begins using opioids occasionally, often after experimentation with tobacco, then alcohol, then marijuana, and then brain depressants or stimulants. Occasional opiate use, or “chipping,” might continue for some time, and some individuals never escalate their intake to the point of developing dependence.

Opioid-dependent individuals are likely to continue to have experience with other drugs. Alcohol may be used to moderate withdrawal problems, to enhance the opioid high, and to serve as a substitute when the opioid is not available, including during methadone and other treatments. Problematic drinking, including alcohol dependence, is seen in about half of opioid-dependent persons. Cocaine appears to be taken for many of the same reasons as alcohol, and is often administered intravenously with the opioid in a mixture known as a “speedball.” Another relevant class of drugs is the benzodiazepines, especially among people in methadone maintenance.

Once persistent opioid use is established, severe problems are likely to develop. At least 25% of habitual users die within 10 to 20 years (a mortality rate 15-fold higher than the general population) from suicide, homicide, accidents, or infectious diseases such as tuberculosis, hepatitis, or AIDS. The latter has become an epidemic among injection drug users, with an estimated 60% of these men and women carrying HIV (Chap. 173). Although the majority of opioid-dependent persons experience frequent exacerbations and remissions, it is important to remember that even without treatment ~35% achieve long-term, often permanent, abstinence, especially after the age of 40. As is true with most drugs of abuse, a favorable prognosis is associated with a prior history of marital and employment stability and fewer prior criminal activities unrelated to drugs.

**TREATMENT**

One key to diagnosis is to discard the erroneous stereotype that opioid-dependent individuals are always unemployed and homeless. Abuse or dependence is possible in any patient who demonstrates symptoms of what might be opioid withdrawal; anyone who has a chronic pain syndrome; physicians, nurses, and pharmacists or others with easy access to opioids; and all patients who repeatedly seek out prescription analgesics. Therefore, before prescribing an opioid analgesic, it is important to gather a complete history that elucidates patterns of life problems and any history of opioid use. If a problem with opioids is suspected, gathering further data from a relative or close friend can be helpful. Additionally, clinicians should search for physical stigmata of misuse (e.g., needle marks) and, when appropriate, screen blood or urine for opioids.

After identifying opioid dependence, the next step is intervention as described for alcoholism in Chap. 372. The need for continuing treatment even after the patient achieves abstinence can be presented, and the availability of help in establishing a drug-free life-style can be emphasized.

**Symptoms of Withdrawal**

Withdrawal symptoms, generally the opposite of the acute effects of the drug, include nausea and diarrhea, coughing, lacrimation, mydriasis, rhinorrhea, profuse sweating, twitching of muscles, and piloerection (or “goose bumps”) as well as mild elevations in body temperature, respiratory rate, and blood pressure. In addition, diffuse body pain, insomnia, and yawning occur, along with intense drug craving. Drugs with shorter half-lives, such as morphine...
or heroin, usually cause symptoms within 8 to 16 h of the last dose; intensity peaks within 36 to 72 h after discontinuation of the drug; and the acute syndrome disappears within 5 to 8 days. A protracted abstinence phase of mild moodiness, autonomic dysfunction, and changes in pain threshold and sleep patterns may persist for ≥6 months and probably contributes to relapse.

**Treatment of the Withdrawal Syndrome** A thorough physical examination, including an assessment of neurologic function and a search for focal and systemic infections, especially abscesses, is mandatory. Laboratory testing includes assessment of liver function and, in intravenous users, HIV and hepatitis B and C status. Proper nutrition and rest must be initiated as soon as possible.

One treatment of withdrawal requires administration of any opioid (e.g., 10 to 25 mg of methadone bid) on day 1 to decrease symptoms. After several days of a stabilized drug dose, the opioid is then decreased by 10 to 20% of the original day’s dose each day. However, detoxification with opioids is proscribed or limited in most states. Thus, pharmacologic treatments often center on relief of symptoms of diarrhea with loperamide, or “sniffles” with decongestants, and pain with nonopioid analgesics (e.g., ibuprofen). Comfort can be enhanced with administration of the α2-adrenergic agonist clonidine in doses up to 0.3 mg given two to four times a day to decrease sympathetic nervous system overactivity. Blood pressure must be closely monitored. Some clinicians augment this regimen with low to moderate doses of benzodiazepines for 2 to 5 days to decrease agitation. An ultra-rapid detoxification procedure using deep sedation and withdrawal precipitated by naltrexone has been proposed, but has many inherent dangers and little evidence of efficacy.

A special case of opioid withdrawal is seen in the newborn made passively dependent through the mother’s drug abuse during pregnancy; withdrawal consists of irritability, crying, a tremor, increased reflexes, increased respiratory rate, diarrhea, vomiting, and sneezing/yawning/hiccuping. Treatment follows the same general steps used in the treatment of the physically dependent adult but using paregoric (0.2 mL orally every 3 to 4 h), methadone (0.1 to 0.5 mg/kg per day), phenobarbital (8 mg/kg per day), or diazepam (1 to 2 mg/kg every 8 h) in decreasing dosages for 10 to 20 days. Dependent infants of mothers on methadone maintenance also benefit by breast feeding while the mother continues to take methadone.

**Rehabilitation** Despite some differences in demographics, the same general rules for rehabilitation apply to opioid-dependent persons as to alcoholics. The basic strategy includes detoxification and establishment of realistic goals, along with counseling and education to increase motivation toward abstinence. A long-term commitment by the patient to rebuilding a life-style without the substance is essential for preventing relapse.

In most programs, patients are educated about their responsibility for improving their lives, and motivation for abstinence is increased by providing information about the medical and psychological problems that can be expected if dependence continues. Patients and families are encouraged to establish an opioid-free life-style by learning to cope with chronic pain and develop realistic vocational planning (e.g., for pharmacists, physicians, and nurses). The dependent person is also advised to establish a drug-free peer group and to participate in self-help groups such as Narcotics Anonymous. Another important treatment component is relapse prevention aimed at identifying triggers for a return to drugs and developing appropriate coping strategies.

Much of this advice and counseling can be given by the physician or by referring the patients to formal drug programs, including methadone maintenance clinics, programs using narcotic antagonists, and therapeutic communities. Long-term follow-up of treated patients indicates that approximately one-third are completely drug free, and 60% no longer use opioids.

**Opioid Maintenance** Maintenance programs with methadone and the longer-acting LAAM should be used only in combination with education and counseling. The goal is to provide a substitute drug that is legally accessible, safer, can be taken orally, and has a long half-life so that it can be taken once a day. This can help persons who have repeatedly failed in drug-free programs to improve functioning within the family and job, to decrease legal problems, and to improve health. Individuals who stay in methadone maintenance are likely to show improvement in antisocial behavior and employment status.

Methadone is a long-acting opioid optimally dosed at 80 to 120 mg/d (a goal met through slow, careful increases over time). This level is optimally effective in blocking heroin-induced euphoria, decreasing craving, and maintaining abstinence from illegal opioids. Over three-quarters of patients in well-supervised methadone clinics are likely to remain heroin-free for ≥6 months. Methadone is administered as an oral liquid given once a day at the program, with weekend doses taken at home. The longer-acting analogues, such as LAAM, can be given in doses up to 80 mg two or three times a week. After a period of maintenance (usually 6 months to ≥1 year), the clinician can work to slowly decrease the dose by about 5% per week.

An additional medication that has been used for maintenance treatment involves the μ opioid agonist and κ antagonist buprenorphine. Administered either as a sublingual liquid or tablet, doses of 8 to 12 mg per day (up to 32 mg in some patients) are usually given between 3 and 7 days per week. This drug has several advantages including low overdose danger, easier detoxification than is seen with methadone, and a probable ceiling effect in which higher doses do not increase euphoria. While many studies report equal effectiveness of buprenorphine and methadone, others suggest higher dropout rates or concomitant drug use with buprenorphine. As with all opioids, there is still a danger of misuse.

In the past, the British have used heroin maintenance with goals and guidelines similar to those of current methadone programs. There is no evidence that heroin maintenance has any advantages over methadone maintenance, but the heroin approach increases the risk that the drug will be sold on the streets.

**Opioid Antagonists** The opiate antagonists (e.g., naltrexone) compete with heroin and other opioids at receptors, reducing the effects of the opioid agonists. Administered over long periods with the intention of blocking the opioid “high,” these drugs can be useful as part of an overall treatment approach that includes counseling and support. Naltrexone doses of 50 mg/d antagonize 15 mg of heroin for 24 h, and the possibly more effective higher doses (125 to 150 mg) block the effects of 25 mg of intravenous heroin for up to 3 days. To avoid precipitating a withdrawal syndrome, patients must be free of opioids for a minimum of 5 days before beginning treatment with naltrexone and should first be challenged with 0.4 or 0.8 mg of the shorter-acting agent nalozone to be certain they can tolerate the long-acting antagonist. A test dose of 10 mg of naltrexone is then given, which can produce withdrawal symptoms in 0.5 to 2 h. If none appear, the patient can begin with the usual dose of 40 to 150 mg three times per week.

**Drug-Free Programs** Most opioid-dependent individuals enter treatment programs based primarily on the cognitive behavioral approaches of enhancing commitment to abstinence, helping individuals to rebuild their lives without substances, and preventing relapse. Whether carried out in inpatient or outpatient settings, patients do not receive medications.

A variation of this approach can be used for persons who are having problems maintaining a drug-free state. Here, the basic elements of treatment are incorporated into long-term (often a year or more) residence in a therapeutic community. The person begins with almost full immersion in the environment in which other individuals at various stages of recovery become the primary support group, offering advice and a drug-free atmosphere in which the opioid-dependent person progresses through ever-increasing levels of independence, including assuming a job outside the therapeutic atmosphere.

As is true for treatments of all substance-use disorders, it is likely that counseling, behavioral treatments, and relatively simple approaches to psychotherapy add significantly to a positive outcome.
Most programs focus on teaching participants to cope with stress, enhancing their understanding of personality attributes, teaching better cognitive styles, and, through the process of relapse prevention, addressing issues that might contribute to increased craving, easy access to drugs, or periods of decreased motivation. A combination of these therapies with the approaches described above appears to give the best results.

Finally, it is important to discuss prevention. Except for the terminally ill, physicians should carefully monitor opioid drug use in their patients, keeping doses as low as is practical and administering them over as short a period as the level of pain would warrant in the average person. Physicians must be vigilant regarding their own risk for opioid abuse and dependence, never prescribing these drugs for themselves. For the nonmedical intravenous drug–dependent person, all possible efforts must be made to prevent AIDS, hepatitis, bacterial endocarditis, and other consequences of contaminated needles both through methadone maintenance and by considering needle-exchange programs.

FURTHER READING


374 COCAINE AND OTHER COMMONLY ABUSED DRUGS

Jack H. Mendelson, Nancy K. Mello

Cocaine and other psychostimulant drug abuse remains a major public health problem in the United States and throughout the world; its prevalence appears to be increasing in some metropolitan areas for both college students and adults ages 19 to 40. Drug abuse by women continues to parallel abuse of cocaine and other psychostimulant drugs by men: psychostimulant abuse among youth in the United States is a special concern.

The initiation and persistence of drug abuse are determined by a complex interaction of the pharmacologic properties and relative availability of each drug, the personality and expectations of the user, and the environmental context in which the drug is used. Polydrug abuse, the concurrent use of several drugs with different pharmacologic effects, is increasingly common among individuals from all socioeconomic strata. Particularly dangerous forms of polydrug abuse, such as the combined use of heroin and cocaine intravenously, remain a major problem in hospital emergency room settings. Drug abusers may attempt to attenuate one drug effect with another, as when heroin or alcohol is used to modulate the cocaine high. Sometimes one drug is used to enhance the effects of another, as with benzodiazepines and methadone, or cocaine plus heroin in methadone-maintained patients.

Chronic cocaine and psychostimulant abuse may cause a number of adverse health consequences, ranging from pulmonary disease to reproductive dysfunction. Preexisting disorders such as hypertension and cardiac disease may be exacerbated by drug abuse, and the combined use of two or more drugs may accentuate medical complications associated with abuse of one of them.

Drug abuse increases the risk of exposure to HIV. Cocaine and psychostimulant abuse contribute to the risk for HIV infection in part by suppression of immune function. In addition, concurrent use of cocaine and opiates (the “speedball”) is frequently associated with needle-sharing by intravenous drug users. Intravenous drug abusers continue to represent the largest single group of persons with HIV infection in several major metropolitan areas in the United States as well as in urban areas in Scotland, Italy, Spain, Thailand, and China.

COCAINE Cocaine is a stimulant and local anesthetic with potent vasoconstrictor properties. The leaves of the coca plant (Erythroxylon coca) contain ~0.5 to 1% cocaine. The drug produces physiologic and behavioral effects when administered orally, intranasally, intravenously, or via inhalation following pyrolysis (smoking). Cocaine increases synaptic concentrations of the monoamine neurotransmitters dopamine, norepinephrine, and serotonin by binding to transporter proteins in presynaptic neurons and blocking reuptake. The reinforcing effects of cocaine appear to be related to effects on dopaminergic neurons in the mesolimbic system.

Prevalence of Use Cocaine is widely available throughout the United States, and cocaine abuse occurs in virtually all social and economic strata of society. The prevalence of cocaine abuse in the general population has been accompanied by an increase in cocaine abuse by heroin-dependent persons, including those in methadone maintenance programs. Intravenous cocaine is often used concurrently with intravenous heroin. This combination purportedly attenuates the postcocaine “crash” and substitutes a cocaine “high” for the heroin “high” blocked by methadone.

Acute and Chronic Intoxication There has been an increase in both intravenous administration and inhalation of pyrolyzed cocaine via smoking. Following intranasal administration, changes in mood and sensation are perceived within 3 to 5 min, and peak effects occur at 10 to 20 min. The effects rarely last more than 1 h. Inhalation of pyrolyzed materials includes inhaling crack/cocaine or smoking coca paste, a product made by extracting cocaine preparations with flammable solvents, and cocaine free-base smoking. Free-base cocaine, including the free base prepared with sodium bicarbonate (crack), has become increasingly popular because of the relative high potency of the compound and its rapid onset of action (8 to 10 s following smoking).

Cocaine produces a brief, dose-related stimulation and enhancement of mood and an increase in cardiac rate and blood pressure. Body temperature usually increases following cocaine administration, and high doses of cocaine may induce lethal pyrexia or hypertension. Because cocaine inhibits reuptake of catecholamines at adrenergic nerve endings, the drug potentiates sympathetic nervous system activity. Cocaine has a short plasma half-life of ~45 to 60 min. Cocaine is metabolized by plasma esterases, and cocaine metabolites are excreted in urine. The very short duration of the euphorogenic effects of cocaine observed in chronic abusers is probably due to both acute and chronic tolerance. Frequent self-administration of the drug (two to three times per hour) is often reported by chronic cocaine abusers. Alcohol is used to modulate both the cocaine high and the dysphoria associated with the abrupt disappearance of cocaine’s effects. A metabolite of cocaine, cocaethylene, has been detected in blood and urine of persons who concurrently abuse alcohol and cocaine. Cocaethylene induces changes in cardiovascular function similar to those of cocaine alone, and the pathophysiologic consequences of alcohol abuse plus cocaine abuse may be additive when both are used together.

The prevalent assumption that cocaine inhalation or intravenous administration is relatively safe is contradicted by reports of death from respiratory depression, cardiac arrhythmias, and convulsions associated with cocaine use. In addition to generalized seizures, neurologic complications may include headache, ischemic or hemorrhagic stroke, or subarachnoid hemorrhage. Disorders of cerebral blood flow...
Concentration varies between 10 and 40 mg, concentrations of resin of cigarette have been detected. Hashish is prepared from concentrated 12% percent by weight. "Hash oil," a lipid-soluble plant extract, may be at higher risk for later polydrug and alcohol abuse problems.

As with abuse of cocaine, opioids, and alcohol, chronic marijuana abusers may lose interest in common socially desirable goals and steadily devote more time to drug acquisition and use. However, THC does not cause a specific and unique "amotivational syndrome." The range of symptoms sometimes attributed to marijuana use is difficult to distinguish from mild to moderate depression and the maturational dysfunctions often associated with protracted adolescence. Chronic marijuana use has also been reported to increase the risk of psychotic symptoms in individuals with a past history of schizophrenia. Persons who initiate marijuana smoking before the age of 17 may subsequently develop severe cognitive and neuropsychological disorders, and may be at higher risk for later polydrug and alcohol abuse problems.

Physical Effects Conjunctional injection and tachycardia are the most frequent immediate physical concomitants of smoking marijuana. Tolerance for marijuana-induced tachycardia develops rapidly among regular users. However, marijuana smoking may precipitate angina in persons with a history of coronary insufficiency. Exercise-induced angina may be increased after marijuana use to a greater extent than after tobacco cigarette smoking. Patients with cardiac disease should be strongly advised not to smoke marijuana or use cannabis compounds.

Significant decrements in pulmonary vital capacity have been found in the cerebral cortex, basal ganglia, and hippocampus. B lymphocytes also appear to have cannabinoid receptors. A naturally occurring THC-like ligand has been identified in the nervous system, where it is widely distributed.

Prevalence of Use Marijuana is the most commonly used illegal drug in the United States. Use is particularly prevalent among adolescents; studies suggest that ~37% of high school students in the United States have used marijuana. Marijuana is relatively inexpensive and is often considered to be less hazardous than other controlled drugs and substances. Very potent forms of marijuana (sinsemilla) are now available in many communities, and concurrent use of marijuana with crack/cocaine and phencyclidine is increasing. Marijuana abuse by individuals from all social strata has been increasing.

Acute and Chronic Intoxication Acute intoxication from marijuana and cannabis compounds is related to both the dose of THC and the route of administration. THC is absorbed more rapidly from marijuana smoking than from orally ingested cannabis compounds. Acute marijuana intoxication usually consists of a subjective perception of relaxation and mild euphoria resembling mild to moderate alcohol intoxication. This condition is usually accompanied by some impairment in thinking, concentration, and perceptual and psychomotor function. Higher doses of cannabis may produce behavioral effects analogous to severe alcohol intoxication. Although the effects of acute marijuana intoxication are relatively benign in normal users, the drug can precipitate severe emotional disorders in individuals who have antecedent psychotic or neurotic problems. As with other psychoactive compounds, both set (user’s expectations) and setting (environmental context) are important determinants of the type and severity of behavioral intoxication.

With abuse of cocaine, opioids, and alcohol, chronic marijuana abusers may lose interest in common socially desirable goals and steadily devote more time to drug acquisition and use. However, THC does not cause a specific and unique “amotivational syndrome.” The range of symptoms sometimes attributed to marijuana use is difficult to distinguish from mild to moderate depression and the maturational dysfunctions often associated with protracted adolescence. Chronic marijuana use has also been reported to increase the risk of psychotic symptoms in individuals with a past history of schizophrenia. Persons who initiate marijuana smoking before the age of 17 may subsequently develop severe cognitive and neuropsychological disorders, and may be at higher risk for later polydrug and alcohol abuse problems.

Physical Effects Conjunctival injection and tachycardia are the most frequent immediate physical concomitants of smoking marijuana. Tolerance for marijuana-induced tachycardia develops rapidly among regular users. However, marijuana smoking may precipitate angina in persons with a history of coronary insufficiency. Exercise-induced angina may be increased after marijuana use to a greater extent than after tobacco cigarette smoking. Patients with cardiac disease should be strongly advised not to smoke marijuana or use cannabis compounds.

Significant decrements in pulmonary vital capacity have been found in the cerebral cortex, basal ganglia, and hippocampus. B lymphocytes also appear to have cannabinoid receptors. A naturally occurring THC-like ligand has been identified in the nervous system, where it is widely distributed.

Prevalence of Use Marijuana is the most commonly used illegal drug in the United States. Use is particularly prevalent among adolescents; studies suggest that ~37% of high school students in the United States have used marijuana. Marijuana is relatively inexpensive and is often considered to be less hazardous than other controlled drugs and substances. Very potent forms of marijuana (sinsemilla) are now available in many communities, and concurrent use of marijuana with crack/cocaine and phencyclidine is increasing. Marijuana abuse by individuals from all social strata has been increasing.

Acute and Chronic Intoxication Acute intoxication from marijuana and cannabis compounds is related to both the dose of THC and the route of administration. THC is absorbed more rapidly from marijuana smoking than from orally ingested cannabis compounds. Acute marijuana intoxication usually consists of a subjective perception of relaxation and mild euphoria resembling mild to moderate alcohol intoxication. This condition is usually accompanied by some impairment in thinking, concentration, and perceptual and psychomotor function. Higher doses of cannabis may produce behavioral effects analogous to severe alcohol intoxication. Although the effects of acute marijuana intoxication are relatively benign in normal users, the drug can precipitate severe emotional disorders in individuals who have antecedent psychotic or neurotic problems. As with other psychoactive compounds, both set (user’s expectations) and setting (environmental context) are important determinants of the type and severity of behavioral intoxication.

With abuse of cocaine, opioids, and alcohol, chronic marijuana abusers may lose interest in common socially desirable goals and steadily devote more time to drug acquisition and use. However, THC does not cause a specific and unique “amotivational syndrome.” The range of symptoms sometimes attributed to marijuana use is difficult to distinguish from mild to moderate depression and the maturational dysfunctions often associated with protracted adolescence. Chronic marijuana use has also been reported to increase the risk of psychotic symptoms in individuals with a past history of schizophrenia. Persons who initiate marijuana smoking before the age of 17 may subsequently develop severe cognitive and neuropsychological disorders, and may be at higher risk for later polydrug and alcohol abuse problems.

Physical Effects Conjunctival injection and tachycardia are the most frequent immediate physical concomitants of smoking marijuana. Tolerance for marijuana-induced tachycardia develops rapidly among regular users. However, marijuana smoking may precipitate angina in persons with a history of coronary insufficiency. Exercise-induced angina may be increased after marijuana use to a greater extent than after tobacco cigarette smoking. Patients with cardiac disease should be strongly advised not to smoke marijuana or use cannabis compounds.

Significant decrements in pulmonary vital capacity have been found in the cerebral cortex, basal ganglia, and hippocampus. B lymphocytes also appear to have cannabinoid receptors. A naturally occurring THC-like ligand has been identified in the nervous system, where it is widely distributed.

Prevalence of Use Marijuana is the most commonly used illegal drug in the United States. Use is particularly prevalent among adolescents; studies suggest that ~37% of high school students in the United States have used marijuana. Marijuana is relatively inexpensive and is often considered to be less hazardous than other controlled drugs and substances. Very potent forms of marijuana (sinsemilla) are now available in many communities, and concurrent use of marijuana with crack/cocaine and phencyclidine is increasing. Marijuana abuse by individuals from all social strata has been increasing.

Acute and Chronic Intoxication Acute intoxication from marijuana and cannabis compounds is related to both the dose of THC and the route of administration. THC is absorbed more rapidly from marijuana smoking than from orally ingested cannabis compounds. Acute marijuana intoxication usually consists of a subjective perception of relaxation and mild euphoria resembling mild to moderate alcohol intoxication. This condition is usually accompanied by some impairment in thinking, concentration, and perceptual and psychomotor function. Higher doses of cannabis may produce behavioral effects analogous to severe alcohol intoxication. Although the effects of acute marijuana intoxication are relatively benign in normal users, the drug can precipitate severe emotional disorders in individuals who have antecedent psychotic or neurotic problems. As with other psychoactive compounds, both set (user’s expectations) and setting (environmental context) are important determinants of the type and severity of behavioral intoxication.

With abuse of cocaine, opioids, and alcohol, chronic marijuana abusers may lose interest in common socially desirable goals and steadily devote more time to drug acquisition and use. However, THC does not cause a specific and unique “amotivational syndrome.” The range of symptoms sometimes attributed to marijuana use is difficult to distinguish from mild to moderate depression and the maturational dysfunctions often associated with protracted adolescence. Chronic marijuana use has also been reported to increase the risk of psychotic symptoms in individuals with a past history of schizophrenia. Persons who initiate marijuana smoking before the age of 17 may subsequently develop severe cognitive and neuropsychological disorders, and may be at higher risk for later polydrug and alcohol abuse problems.

Physical Effects Conjunctival injection and tachycardia are the most frequent immediate physical concomitants of smoking marijuana. Tolerance for marijuana-induced tachycardia develops rapidly among regular users. However, marijuana smoking may precipitate angina in persons with a history of coronary insufficiency. Exercise-induced angina may be increased after marijuana use to a greater extent than after tobacco cigarette smoking. Patients with cardiac disease should be strongly advised not to smoke marijuana or use cannabis compounds.

Significant decrements in pulmonary vital capacity have been found in the cerebral cortex, basal ganglia, and hippocampus. B lymphocytes also appear to have cannabinoid receptors. A naturally occurring THC-like ligand has been identified in the nervous system, where it is widely distributed.
found in regular daily marijuana smokers. Because marijuana smoking typically involves deep inhalation and prolonged retention of marijuana smoke, marijuana smokers may develop chronic bronchial irritation. Impairment of single-breath carbon monoxide diffusion capacity (DL CO ) is greater in persons who smoke both marijuana and tobacco than in tobacco smokers.

Although marijuana has also been associated with adverse effects on a number of other systems, many of these studies await replication and confirmation. A reported correlation between chronic marijuana use and decreased testosterone levels in males has not been confirmed. Decreased sperm count and sperm motility and morphologic abnormalities of spermatocytes following marijuana use have also been reported. Prospective studies demonstrated a correlation between impaired fetal growth and development and heavy marijuana use during pregnancy. Marijuana has also been implicated in derangements of the immune system; in chromosomal abnormalities; and in inhibition of DNA, RNA, and protein synthesis; however, these findings have not been confirmed or related to any specific physiologic effect in humans.

Tolerance and Physical Dependence Habitual marijuana users rapidly develop tolerance to the psychoactive effects of marijuana and often smoke more frequently and try to secure more potent cannabis compounds. Tolerance for the physiologic effects of marijuana develops at different rates; e.g., tolerance develops rapidly for marijuana-induced tachycardia but more slowly for marijuana-induced conjunctival injection. Tolerance to both behavioral and physiologic effects of marijuana decreases rapidly upon cessation of marijuana use.

Withdrawal signs and symptoms have been reported in chronic cannabis users, with the severity of symptoms related to dosage and duration of use. These include tremor, nystagmus, sweating, nausea, vomiting, diarrhea, irritability, anorexia, and sleep disturbances. Withdrawal signs and symptoms observed in chronic marijuana users are usually relatively mild in comparison to those observed in heavy opiate or alcohol users and rarely require medical or pharmacologic intervention. More severe and protracted abstinence syndromes may occur after sustained use of high-potency cannabis compounds.

Therapeutic Use Marijuana, administered as cigarettes or as a synthetic oral cannabinoid (dronabinol), has been proposed to have a number of properties that may be clinically useful in some situations. These include antiemetic effects in chemotherapy recipients, appetite-promoting effects in AIDS, reduction of intraocular pressure in glaucoma, and reduction of spasticity in multiple sclerosis and other neurologic disorders. With the possible exception of AIDS-related cachexia, none of these attributes of marijuana compounds is clearly superior to other readily available therapies.

Methamphetamine The abuse of methamphetamine, also referred to as "meth," "speed," "crank," "chuck," "ice," "glass," or "crystal," has been declining in many metropolitan areas and communities throughout the United States. This decrease is attributed in part to drug seizure and the closures of clandestine laboratories that produce methamphetamine illegally. Prevention programs focusing upon methamphetamine abuse have also increased.

Most persons who abuse methamphetamine self-administer the drug orally, although there have been reports of methamphetamine administration by inhalation and intravenous injection. Individuals who abuse or become dependent upon methamphetamine state that use of this drug induces feelings of euphoria and decreases fatigue associated with difficult life situations. Adverse physiologic effects observed as a consequence of methamphetamine abuse include headache, difficulty concentrating, diminished appetite, abdominal pain, vomiting or diarrhea, disordered sleep, paranoid or aggressive behavior, and psychosis. Severe, life-threatening toxicity may present as hypertension, cardiac arrhythmia or failure, subarachnoid hemorrhage, ischemic stroke, intracerebral hemorrhage, convulsions, or coma. Methamphetamine increase the release of monoamine neurotransmitters (dopamine, norepinephrine, and serotonin) from presynaptic neurons. It is thought that the euphoric and reinforcing effects of this class of drugs are mediated through dopamine and the mesolimbic system, whereas the cardiovascular effects are related to norepinephrine. MRS studies suggest that chronic abuse may injure the frontal areas and basal ganglia of the brain.

Therapy of acute methamphetamine overdose is largely symptomatic. Ammonium chloride may be useful to acidify the urine and enhance clearance of the drug. Hypertension may respond to sodium nitroprusside or α-adrenergic antagonists. Sedatives may reduce agitation and other signs of central nervous system hyperactivity. Treatment of chronic methamphetamine dependence may be accomplished in either an inpatient or outpatient setting using strategies similar to those described above for cocaine abuse.

MDMA (3,4-methylenedioxymethamphetamine), or Ecstasy, is a derivative of methamphetamine. Ecstasy is usually taken orally but may be injected or inhaled. In addition to amphetamine-like effects, MDMA can induce hyperthermia and vivid hallucinations and other perceptual distortions.

During the past decade, an eighteenfold increase in DMAA-related emergency room incidents has been reported in the United States. Recent studies have revealed that MDMA induces both brain dopaminergic and serotonergic neurotoxicity. Thus, use of recreational use of MDMA by young persons may significantly increase the risk for subsequent occurrence of severe neuropsychiatric disorders.

Lysergic Acid Diethylamide (LSD) The discovery of the psychedelic effects of LSD in 1947 led to an epidemic of LSD abuse during the 1960s. Imposition of stringent constraints on the manufacture and distribution of LSD (classified as a Schedule I substance by the U.S. Food and Drug Administration), as well as public recognition that psychedelic experiences induced by LSD were a health hazard, have resulted in a reduction in LSD abuse. The drug still retains some popularity among adolescents and young adults, however, and there are indications that LSD use among young persons has been increasing in some communities in the United States.

LSD is a very potent drug; oral doses as low as 20 μg may induce profound psychological and physiologic effects. Tachycardia, hypertension, pupillary dilation, tremor, and hyperpyrexia occur within minutes following oral administration of 0.5 to 2 μg/kg. A variety of bizarre and often conflicting perceptual and mood changes, including visual illusions, synesthesias, and extreme lability of mood, usually occur within 30 min after LSD intake. These effects of LSD may persist for 12 to 18 h, even though the half-life of the drug is only 3 h.

Tolerance develops rapidly for LSD-induced changes in psychological function when the drug is used one or more times per day for >4 days. Abrupt abstinence following continued use does not produce withdrawal signs or symptoms. There have been no clinical reports of death caused by the direct effects of LSD.

The most frequent acute medical emergency associated with LSD use is panic episode (the "bad trip"), which may persist up to 24 h. Management of this problem is best accomplished by supportive reassurance ("talking down") and, if necessary, administration of small doses of anxiolytic drugs. Adverse consequences of chronic LSD use include enhanced risk for schizophreniform psychosis and derangements in memory function, problem solving, and abstract thinking. Treatment of these disorders is best carried out in specialized psychiatric facilities.

Phencyclidine Phencyclidine (PCP), a cyclohexylamine derivative, is widely used in veterinary medicine to briefly immobilize large animals and is sometimes described as a dissociative anesthetic. PCP binds to ionotropic n-methyl-d-aspartate (NMDA) receptors in the nervous system, blocking ion current through these channels. PCP is easily synthesized; its abusers are primarily young people and polydrug users. It is used orally, by smoking, or by intravenous injection. It is also used as an adulterant in THC, LSD, amphetamine, or cocaine. The most common street preparation, angel dust, is a white granular pow-
The use of tobacco leaf to create and satisfy nicotine addiction was introduced to Columbus by Native Americans and spread rapidly to Europe. The use of tobacco as cigarettes, however, is predominantly a twentieth century phenomenon, as is the epidemic of disease caused by this form of tobacco.

Nicotine is the principal constituent of tobacco responsible for its addictive character. Addicted smokers regulate their nicotine intake by this form of tobacco. Addiction to nicotine is a twentieth century phenomenon, as is the epidemic of disease caused by this form of tobacco.

Unburned cured tobacco contains nicotine, carcinogens, and other toxins capable of causing gum disease and oral cancer. When tobacco is burned, the resultant smoke contains, in addition to nicotine, carbon monoxide and 4000 other compounds that result from volatilization, pyrolysis, and pyrosynthesis of tobacco and various chemical additives used in making different tobacco products. The smoke is composed of a fine aerosol, with a particle size distribution predominantly in the range to deposit in the airways and alveolar surfaces of the lungs, and a vapor phase. The bulk of the toxicity and carcinogenicity of the smoke resides in the aerosolized particulate phase, which contains a large number of toxic constituents and carcinogetic compounds. The aggregate of particulate matter, after subtracting nicotine and moisture, is referred to as tar. The vapor phase contains carbon monoxide, respiratory irritants, and ciliotoxins as well as many of the volatile compounds responsible for the distinctive smell of cigarette smoke.

The alkaline pH of smoke from blends of tobacco utilized for pipes and cigars allows sufficient absorption of nicotine across the oral mucosa to satisfy the smoker’s need for this drug. Therefore, smokers of pipes and cigars tend not to inhale the smoke into the lung, confining the toxic and carcinogetic exposure (and the increased rates of disease) largely to the upper airway for most users of these products. The acidic pH of smoke generated by the tobacco used in cigarettes dramatically reduces absorption of nicotine in the mouth, necessitating inhalation of the smoke into the larger surface of the lungs in order to absorb

The diagnosis of PCP overdose is difficult because the patient’s initial symptoms may suggest an acute schizophrenic reaction. Confirmation of PCP use is possible by determination of PCP levels in serum or urine. PCP assays are available at most toxicologic centers. PCP remains in urine for 1 to 5 days following high-dose intake. Chronic PCP use has been shown to induce insomnia, anorexia, severe social and behavioral changes, and, in some cases, chronic schizophrenia.

**POLYDRUG ABUSE** Although drug abusers often report a preference for a particular drug, such as alcohol or opiates, the concurrent use of other drugs is common. Multiple drug use often involves substances that may have different pharmacologic effects from the preferred drug. Concurrent use of such dissimilar compounds as stimulants and opiates or stimulants and alcohol is not unusual. The diversity of reported drug use combinations suggests that achieving some perceptible change in state, rather than any particular direction of change (stimulation or depression), may be the primary reinforcer in polydrug use and abuse. There is also evidence that intoxication with alcohol or opiates is as (sedation), may be the primary reinforcer in polydrug use and abuse. Therefore, the combined use of cocaine, heroin, and alcohol increases the risk for toxic effects and adverse medical consequences over risks associated with use of a single drug. One determinant of polydrug use patterns is the relative availability and cost of the drugs. There are many examples of situational determined drug use patterns. For example, alcohol abuse, with its attendant medical complications, is one of the most serious problems encountered in former heroin addicts participating in methadone maintenance programs.

The physician must recognize that perpetuation of polydrug abuse and drug dependence is not necessarily a symptom of an underlying emotional disorder. Neither alleviation of anxiety nor reduction of depression accounts for initiation and perpetuation of polydrug abuse. Severe depression and anxiety are as frequently the consequences of polydrug abuse as they are the antecedents. There is also evidence that some of the most adverse consequences of drug use may be reinforcing and contribute to the continuation of polydrug abuse.
quantities of nicotine sufficient to satisfy the smoker’s addiction. The shift to using tobacco as cigarettes, with resultant increased deposition of smoke in the lung, has created the epidemic of heart disease, lung disease, and lung cancer that dominates the current disease manifestations of tobacco use.

**GENETIC CONSIDERATIONS** Several genes have been associated with nicotine addiction. Some reduce the clearance of nicotine, and others have been associated with an increased likelihood of becoming dependent on tobacco and other drugs as well as a higher incidence of depression. It is unlikely that genetic factors are the principal determinants of addiction. Rates of smoking initiation among males, and corresponding rates of nicotine addiction, have dropped by almost 50% since the mid-1950s, suggesting that factors other than genetics are important. It is more likely that genetic susceptibility influences the probability that experimentation with tobacco as an adolescent will lead to addiction as an adult.

**DISEASE MANIFESTATIONS OF CIGARETTE SMOKING**

Over 400,000 individuals die prematurely each year in the United States from cigarette use; this represents approximately one out of every five deaths in the United States. Approximately 40% of cigarette smokers will die prematurely due to cigarette smoking unless they are able to quit.

The major diseases caused by cigarette smoking are listed in Table 375-1. The incidence of smoking-related diseases is proportionately greater in younger than in older smokers, particularly for coronary artery disease and stroke. At older ages, the background rate of disease in nonsmokers decreases, diminishing the fractional contribution of disease mortality found in smokers compared to nonsmokers increase with increasing age. The organ damage caused by smoking and the number of smokers who die from smoking are both greater among the elderly, as one would expect from a process of cumulative injury.

**CARDIOVASCULAR DISEASES** Cigarette smokers are more likely than non-smokers to develop large-vessel atherosclerosis as well as small-vessel disease. Approximately 90% of peripheral vascular disease in the non-diabetic population can be attributed to cigarette smoking, as can ~50% of aortic aneurysms. In contrast, 20 to 30% of coronary artery disease and ~10% of occlusive cerebrovascular disease are caused by cigarette smoking. There is a multiplicative interaction between cigarette smoking and other cardiac risk factors such that the increment in risk produced by smoking among individuals with hypertension or elevated serum lipids is substantially greater than the increment in risk produced by smoking for individuals without these risk factors.

In addition to its role in promoting atherosclerosis, cigarette smoking also increases the likelihood of myocardial infarction and sudden cardiac death by promoting platelet aggregation and vascular occlusion. Reversal of these effects may explain the rapid benefit of smoking cessation for a new coronary event demonstrable among those who have survived a first myocardial infarction. This effect may also explain the substantially higher rates of graft occlusion among continuing smokers following vascular bypass surgery for cardiac or peripheral vascular disease, as well as the high failure rate of angioplasty procedures among continuing smokers.

Cessation of cigarette smoking reduces the risk of a second coronary event within 6 to 12 months; rates of first myocardial infarction or death from coronary heart disease also decline within the first few years following cessation. After 15 years of cessation, the risk of a new myocardial infarction or death from coronary heart disease is similar to that for those who have never smoked.

**CANCER** Tobacco smoking causes cancer of the lung, oral cavity, naso-, oro-, and hypopharynx, nasal cavity and paranasal sinuses, larynx, esophagus, stomach, pancreas, liver, kidney (body and pelvis), ureter, urinary bladder, and uterine cervix and also causes myeloid leukemia. There is evidence suggesting that cigarette smoking may play a role in increasing the risk of colorectal and possibly breast cancer. There does not appear to be a causal link between cigarette smoking and cancer of the endometrium, and there is a lower risk of uterine cancer among postmenopausal women who smoke. The risks of cancer increase with the increasing number of cigarettes smoked per day and with increasing duration of smoking, and there are synergistic interactions between cigarette smoking and alcohol use for cancer of the oral cavity, esophagus, and possibly lung. Several occupational exposures also synergistically increase lung cancer risk among cigarette smokers, most notably occupational asbestos and radon exposure.

Cessation of cigarette smoking reduces the risk of developing cancer relative to continuing smoking, but even 20 years after cessation there is a modest persistent increased risk of developing lung cancer.

**RESPIRATORY DISEASE** Cigarette smoking is responsible for 90% of chronic obstructive pulmonary disease. Within 1 to 2 years of beginning to smoke regularly, many young smokers will develop inflammatory changes in their small airways, although lung function measures of these changes do not predict development of chronic airway obstruction. After 20 years of smoking, pathophysiologic changes in the lungs develop and progress proportional to smoking intensity and duration. Chronic mucous hyperplasia of the larger airways results in chronic productive cough in as many as 80% of smokers over age 60. Chronic inflammation and narrowing of the small airways and/or enzymatic digestion of alveolar walls resulting in pulmonary emphysema can result in reduced expiratory airflow sufficient to produce clinical symptoms of respiratory limitation in ~15% of smokers.

Changes in the small airways of young smokers will reverse after 1 to 2 years of cessation. There may also be a small increase in measures of expiratory airflow among individuals who have developed chronic airflow obstruction, but the major change following cessation is a slowing of the rate of decline in lung function with advancing age rather than a return of lung function toward normal.

**PREGNANCY** Cigarette smoking is associated with several maternal complications of pregnancy: premature rupture of membranes, abruptio placenta, and placenta previa; there is also a small increase in the risk of spontaneous abortion among smokers. Infants of smoking mothers are more likely to experience preterm delivery, have a higher perinatal mortality, are small for their gestational age, have higher rates of infant respiratory distress syndrome, are more likely to die of sudden infant death syndrome, and appear to have a developmental lag for at least the first several years of life.

---

**TABLE 375-1 Relative Risks for Current Smokers of Cigarettes**

<table>
<thead>
<tr>
<th>Disease or Condition</th>
<th>Current Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td></td>
</tr>
<tr>
<td>Age 35–64</td>
<td>2.8</td>
</tr>
<tr>
<td>Age ≥65</td>
<td>1.5</td>
</tr>
<tr>
<td>Cerebrovascular lesions</td>
<td></td>
</tr>
<tr>
<td>Age 35–64</td>
<td>3.3</td>
</tr>
<tr>
<td>Age ≥65</td>
<td>1.6</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>6.2</td>
</tr>
<tr>
<td>Chronic airways obstruction</td>
<td>10.6</td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td>Lip, oral cavity, pharynx</td>
<td>10.9</td>
</tr>
<tr>
<td>Esophagus</td>
<td>6.8</td>
</tr>
<tr>
<td>Stomach</td>
<td>2</td>
</tr>
<tr>
<td>Pancreas</td>
<td>2.3</td>
</tr>
<tr>
<td>Larynx</td>
<td>14.6</td>
</tr>
<tr>
<td>Lung</td>
<td>23.3</td>
</tr>
<tr>
<td>Cervix</td>
<td>1.6</td>
</tr>
<tr>
<td>Kidney</td>
<td>2.7</td>
</tr>
<tr>
<td>Bladder, other urinary organs</td>
<td>3.3</td>
</tr>
<tr>
<td>Sudden Infant Death syndrome</td>
<td>2.3</td>
</tr>
<tr>
<td>Infant respiratory distress syndrome</td>
<td>1.3</td>
</tr>
<tr>
<td>Low birth weight at delivery</td>
<td>1.8</td>
</tr>
</tbody>
</table>
PHYSICIAN INTERVENTION (Table 375-3)

All patients should be asked whether they smoke, their past experience with quitting, and whether they are currently interested in quitting. Those who are not interested in quitting should be encouraged and motivated to quit; provided a clear, strong, and personalized physician message that smoking is an important health concern; and offered assistance if they become interested in quitting in the future. There is a relationship between the amount of assistance a patient is willing to receive and the success of their quitting attempts.

TABLE 375-3 Clinical Practice Guidelines

**Physician actions**

- Ask: Systematically identify all tobacco users at every visit
- Advise: Strongly urge all smokers to quit
- Identify smokers willing to quit
- Assist the patient in quitting
- Arrange follow-up contact

**Pharmacologic interventions—first-line therapies**

- Nicotine gum (1.5)
  - Nicotine 24-h patch: 21-mg patch for 4 weeks, 14-mg patch for 2 weeks, and 7-mg patch for 2 weeks (1.9)
  - Nicotine nasal inhaler: one spray to each nostril 1–2 times/h for 3–6 months (2.7)
  - Nicotine oral inhaler: 6–16 puffs per day for up to 6 months (2.5)
  - Bupropion: 150 mg/d PO for 3 days followed by 150 mg bid for 7–12 weeks (2.1)

**Pharmacologic interventions—second-line therapies**

- Clonidine: Initial dose 0.1 mg bid PO, or 0.1-mg transdermal patch, increasing to 0.15–0.75 mg/d PO or 0.2-mg patch for 3–10 weeks (2.1)
- Nortriptyline: Initial dose 25 mg/d PO, increasing to 75–100 mg/d for 12 weeks (3.2)

**Other interventions**

- Physician or other medical personnel counseling, 10 minutes (1.3)
- Intensive smoking cessation program (2.3)
- Clinic-based smoking status identification system (3.1)
- Counseling by nonclinicians and social support by family and friends
- Telephone counseling (1.2)

Note: Numerical value in parentheses is the multiple for cessation success compared to no intervention.

a At least four to seven sessions of 20- to 30-min duration, lasting at least 2 weeks, preferably 8 weeks.
accept and the success of the cessation attempt. A quit date should be negotiated, usually not the day of the visit but within the next few weeks, and a follow-up contact by office staff around the time of the quit date should be provided.

There are a variety of nicotine-replacement products, including over-the-counter nicotine patch and gum, as well as nicotine nasal and oral inhalers available by prescription. Recently, antidepressants such as bupropion have also been shown to be effective; some evidence supports the combined use of nicotine-replacement therapy and antidepressants. Nicotine-replacement therapy is provided in different dosages. Clonidine or nortriptyline may be useful for patients who have failed on first-line pharmacologic treatment, or who are unable to use other therapies. Antidepressants are more effective in those with a history of depression symptoms.

Current recommendations are to offer pharmacologic treatment, usually with nicotine replacement therapy and bupropion, to all who will accept it and to provide counseling and other support as a part of the cessation attempt. Cessation advice alone by a physician or his or her staff is likely to increase success compared with no intervention; a more comprehensive approach with advice, pharmacologic assistance, and counseling can increase cessation success by almost threefold.

In order for physicians to incorporate cessation assistance into their practice successfully, it is essential to change the infrastructure in which the physician practices. The following are simple changes: (1) including questions on smoking and interest in cessation on patient-intake questionnaires, (2) asking patients whether they smoke as part of the initial vital sign measurements made by office staff, (3) listing smoking as a problem in the medical record, and (4) automating follow-up contact with the patient on the quit date. These changes are essential to institutionalizing smoking intervention within the practice setting; without this institutionalization, the best intentions of physicians to intervene with their patients who smoke are often lost in the time crush of a busy practice.

**PREVENTION**

Approximately 90% of individuals who will become cigarette smokers initiate the behavior during adolescence. Factors that promote adolescent initiation are parental or older generation cigarette smoking, tobacco advertising and promotional activities, the availability of cigarettes, and the social acceptability of smoking. The need for an enhanced self-image and to imitate adult behavior is greatest for those adolescents who have the least external validation of their self-worth, which may explain in part the enormous differences in adolescent smoking prevalence by socioeconomic and school performance strata.

Prevention of smoking initiation must begin early, preferably in the elementary school years. Physicians who treat adolescents should be sensitive to the prevalence of this problem. Physicians should ask all adolescents whether they have experimented with tobacco or currently use tobacco, reinforce the facts that most adolescents and adults do not smoke, and explain that all forms of tobacco are both addictive and harmful.

**FURTHER READING**

